PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chow, LSN; Lam, CW; Chan, SYY; Tsao, SW; To, KF; Tong, SF; Hung, WK; Dammann, R; Huang, DP; Lo, KW				Chow, LSN; Lam, CW; Chan, SYY; Tsao, SW; To, KF; Tong, SF; Hung, WK; Dammann, R; Huang, DP; Lo, KW			Identification of RASSF1A modulated genes in nasopharyngeal carcinoma	ONCOGENE			English	Article						RASSF1A; Id2; microarray; tumor suppressor; nasopharyngeal carcinoma	TUMOR-SUPPRESSOR RASSF1A; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; EPITHELIAL-CELLS; PROTEIN; 3P21.3; LUNG; EXPRESSION; APOPTOSIS; INTERACTS	RASSF1A is a tumor suppressor gene on 3p21.3 frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma (NPC). To identify RASSF1A target genes in NPC, we have investigated the expression pro. le of the stable RASSF1A transfectants and controls by high-density oligonucleotide array. A total of 57 genes showed differential expression in the RASSF1A-expressing cells. These RASSF1A target genes were involved in multiple cellular regulatory processes such as transcription, signal transduction, cell adhesion and RNA processing. The RASSF1A-modulated expression of eight selected genes with the highest fold changes (ATF5, TCRB, RGS1, activin beta E, HNRPH1, HNRPD, Id2 and CKS2) by RASSF1A was confirmed in both stable and transient transfectants. Compared with the RASSF1A transfectants, an inverse expression pattern of activin bE, Id2 and ATF5 was shown in the immortalized nasopharyngeal epithelial cells treated with siRNA against RASSF1A. The findings imply that the expression of activin bE, Id2 and ATF5 was tightly regulated by RASSF1A and may associate with its tumor suppressor function. Strikingly, overexpression of Id2 is common in NPC and RASSF1A-induced repression of Id2 was mediated by the overexpression of activin bE. The results suggest a novel RASSF1A pathway in which both activin bE and Id2 are involved.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle An Der Saale, Germany	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Hong Kong; Martin Luther University Halle Wittenberg	Lo, KW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.	kwlo@cuhk.edu.hk						Agathanggelou A, 2003, CANCER RES, V63, P5344; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chabicovsky M, 2003, ENDOCRINOLOGY, V144, P3497, DOI 10.1210/en.2003-0388; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; Coppe JP, 2003, EXP CELL RES, V285, P131, DOI 10.1016/S0014-4827(03)00014-4; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kwong J, 2002, CLIN CANCER RES, V8, P131; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu WJ, 2004, BIOCHEM BIOPH RES CO, V321, P954, DOI 10.1016/j.bbrc.2004.07.053; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2001, CANCER RES, V61, P3877; Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tommasi S, 2005, CANCER RES, V65, P92; TSAO SW, 2002, BIOCHIM BIOPHYS ACTA, V12, P158; TSAO SW, 2002, BIOCHIM BIOPHYS ACTA, V12, P1590; Vejda S, 2003, CARCINOGENESIS, V24, P1801, DOI 10.1093/carcin/bgg154; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	27	46	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					310	316		10.1038/sj.onc.1209001	http://dx.doi.org/10.1038/sj.onc.1209001			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116475				2022-12-25	WOS:000234583600016
J	Zhang, W; Fletcher, L; Muschel, RJ				Zhang, W; Fletcher, L; Muschel, RJ			The role of polo-like kinase 1 in the inhibition of centrosome separation after ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; NEK2 PROTEIN-KINASE; NIMA-RELATED KINASE; MITOSIS; ATM; PHOSPHATASE; PHOSPHORYLATION; LOCALIZATION	Activation of the G(2)/M cell cycle checkpoint by DNA damage prevents cells from entering mitosis. Centrosome separation is initiated in G(2) phase and completed in M phase. This critical process for cell division is targeted by G(2)/M checkpoint. Here we show that Plk1 signaling plays an important role in regulation of centrosome separation after DNA damage. Constitutively active Plk1 overrides the inhibition of centrosome separation induced by DNA damage. This inhibition is dependent on ATM, but not on Chk2 or Chk1. Nek2 is a key regulator of centrosome separation and is a target of Plk1 in blocking centrosome separation. We found that Plk1 can phosphorylate Nek2 in vitro and interacts with Nek2 in vivo. Downregulation of Plk1 with RNA interference prevents Nek2-induced centrosome splitting. DNA damage is known to inhibit Plk1 activity. We propose that the DNA damage-induced inhibition of Plk1 leads to inhibition of Nek2 activity and thus prevents centrosome separation.	Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Muschel, RJ (corresponding author), John Radcliffe Hosp, 4A122 Acad Block, Oxford OX3 9DU, England.	ruth.muschel@rob.ox.ac.uk			NCI NIH HHS [CA09677, CA 75138] Funding Source: Medline; NIGMS NIH HHS [GM47439] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009677, P01CA075138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Donaldson MM, 2001, J CELL SCI, V114, P2357; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fletcher L, 2004, RADIAT RES, V162, P128, DOI 10.1667/RR3211; Fletcher L, 2003, RADIAT RES, V159, P604, DOI 10.1667/0033-7587(2003)159[0604:DDIHCI]2.0.CO;2; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hutchins JRA, 2004, CELL CYCLE, V3, P41; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meraldi P, 2001, J CELL SCI, V114, P3749; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schnackenberg BJ, 1999, BIOL CELL, V91, P429, DOI 10.1016/S0248-4900(99)80084-7; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uzbekov R, 2002, BIOL CELL, V94, P275, DOI 10.1016/S0248-4900(02)01202-9; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	29	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42994	42999		10.1074/jbc.M505450200	http://dx.doi.org/10.1074/jbc.M505450200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16157594	hybrid			2022-12-25	WOS:000234200800063
J	Piechulek, T; Rehlen, T; Walliser, C; Vatter, P; Moepps, B; Gierschik, P				Piechulek, T; Rehlen, T; Walliser, C; Vatter, P; Moepps, B; Gierschik, P			Isozyme-specific stimulation of phospholipase C-gamma(2) by Rac GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; VAV-FAMILY PROTEINS; RBL-2H3 MAST-CELLS; BETA-GAMMA DIMERS; B-CELL; C-GAMMA; SIGNAL-TRANSDUCTION; RHO GTPASES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE-PHOSPHORYLATION	The regulation of the two isoforms of phospholipase C-gamma, PLC gamma(1) and PLC gamma(2), by cell surface receptors involves protein tyrosine phosphorylation as well as interaction with adapter proteins and phosphatidylinositol 3,4,5-trisphosphate (PtdInsP(3)) generated by inositol phospholipid 3-kinases (PI3Ks). All three processes may lead to recruitment of the PLC gamma isozymes to the plasmamembrane and/or stimulation of their catalytic activity. Recent evidence suggests that PLC gamma may also be regulated by Rho GTPases. In this study, PLC gamma(1) and PLC gamma(2) were reconstituted in intact cells and in a cell-free system with Rho GTPases to examine their influence on PLC gamma activity. PLC gamma(2), but not PLC gamma(1), was markedly activated in intact cells by constitutively active Rac1(G12V), Rac2(G12V), and Rac3(G12V) but not by Cdc42(G12V) and RhoA(G14V). The mechanism of PLC gamma(2) activation was apparently independent of phosphorylation of tyrosine residues known to be modified by PLC gamma(2)-activating protein-tyrosine kinases. Activation of PLC gamma(2) by Rac2(G12V) in intact cells coincided with a translocation of PLC gamma(2) from the soluble to the particulate fraction. PLC gamma isozyme- specific activation of PLC gamma(2) by Rac GTPases (Rac1 approximate to Rac2 > Rac3), but not by Cdc42 or RhoA, was also observed in a cell-free system. Herein, activation of wild-type Rac GTPases with guanosine 5'-(3-O-thio)triphosphate caused a marked stimulation of PLC gamma(2) but had no effect on the activity of PLC gamma(1). PLC gamma(1) and PLC gamma(2) have previously been shown to be indiscriminately activated by PtdInsP(3) in vitro. Thus, the results suggest a novel mechanism of PLC gamma(2) activation by Rac GTPases involving neither protein tyrosine phosphorylation nor PI3K-mediated generation of PtdInsP(3).	Univ Ulm, Dept Pharmacol & Toxicol, D-89081 Ulm, Germany	Ulm University	Gierschik, P (corresponding author), Univ Ulm, Dept Pharmacol & Toxicol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	peter.gierschik@uni-ulm.de						Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Berridge MJ, 2005, ANNU REV PHYSIOL, V67, P1, DOI 10.1146/annurev.physiol.67.040103.152647; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1990, BIOCHEM J, V271, P743, DOI 10.1042/bj2710743; Cancelas JA, 2005, NAT MED, V11, P886, DOI 10.1038/nm1274; Caprini M, 2003, EMBO J, V22, P3004, DOI 10.1093/emboj/cdg294; CAROZZI AJ, 1992, EUR J BIOCHEM, V210, P521, DOI 10.1111/j.1432-1033.1992.tb17450.x; Carrasco YR, 2004, IMMUNITY, V20, P589, DOI 10.1016/S1074-7613(04)00105-0; Carstanjen D, 2005, J IMMUNOL, V174, P4613, DOI 10.4049/jimmunol.174.8.4613; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Croker BA, 2002, IMMUNOL CELL BIOL, V80, P231, DOI 10.1046/j.1440-1711.2002.01077.x; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; Djouder N, 2000, J BIOL CHEM, V275, P18732, DOI 10.1074/jbc.M001425200; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gu Y, 2002, MOL CELL BIOL, V22, P7645, DOI 10.1128/MCB.22.21.7645-7657.2002; Guan JL, 2004, SCIENCE, V303, P773, DOI 10.1126/science.1094376; Guo YJ, 2005, J BIOL CHEM, V280, P1438, DOI 10.1074/jbc.M407593200; Haeusler LC, 2003, FEBS LETT, V555, P556, DOI 10.1016/S0014-5793(03)01351-6; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hong-Geller E, 2001, P NATL ACAD SCI USA, V98, P1154, DOI 10.1073/pnas.98.3.1154; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Humphries LA, 2004, J BIOL CHEM, V279, P37651, DOI 10.1074/jbc.M311985200; Hwang JI, 2005, BIOCHEM J, V389, P181, DOI 10.1042/BJ20041677; Illenberger D, 2000, METHOD ENZYMOL, V325, P167; Illenberger D, 2003, J BIOL CHEM, V278, P8645, DOI 10.1074/jbc.M211971200; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Inabe K, 2002, FEBS LETT, V514, P260, DOI 10.1016/S0014-5793(02)02375-X; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P586, DOI 10.1038/nrm1152; Katan M, 2003, ADV ENZYME REGUL, V43, P77, DOI 10.1016/S0065-2571(02)00027-4; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kim YJ, 2004, MOL CELL BIOL, V24, P9986, DOI 10.1128/MCB.24.22.9986-9999.2004; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Nakahara M, 2005, J BIOL CHEM, V280, P29128, DOI 10.1074/jbc.M503817200; Nishida M, 2003, EMBO J, V22, P4677, DOI 10.1093/emboj/cdg457; Nishizuka Y, 2003, J BIOCHEM, V133, P155, DOI 10.1093/jb/mvg035; Ochocka AM, 2003, ACTA BIOCHIM POL, V50, P1097; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; PENNOCK GD, 1984, MOL CELL BIOL, V4, P399, DOI 10.1128/MCB.4.3.399; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Prepens U, 1996, J BIOL CHEM, V271, P7324, DOI 10.1074/jbc.271.13.7324; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rodriguez R, 2001, J BIOL CHEM, V276, P47982, DOI 10.1074/jbc.M107577200; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Sidhu RS, 2005, J BIOL CHEM, V280, P21933, DOI 10.1074/jbc.M412966200; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Suh BC, 2005, CURR OPIN NEUROBIOL, V15, P370, DOI 10.1016/j.conb.2005.05.005; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Watanabe D, 2001, J BIOL CHEM, V276, P38595, DOI 10.1074/jbc.M103675200; Wen RR, 2002, J IMMUNOL, V169, P6743, DOI 10.4049/jimmunol.169.12.6743; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Wing Michele R, 2003, Mol Interv, V3, P273, DOI 10.1124/mi.3.5.273; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	79	66	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38923	38931		10.1074/jbc.M509396200	http://dx.doi.org/10.1074/jbc.M509396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16172125	hybrid			2022-12-25	WOS:000233362200005
J	Mao, JH; Li, JZ; Jiang, T; Li, Q; Wu, D; Perez-Losada, J; DelRosario, R; Peterson, L; Balmain, A; Cai, WW				Mao, JH; Li, JZ; Jiang, T; Li, Q; Wu, D; Perez-Losada, J; DelRosario, R; Peterson, L; Balmain, A; Cai, WW			Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice	ONCOGENE			English	Article						p53; genomic instability; radiation; thymic lymphoma	IONIZING-RADIATION; CHROMOSOMAL INSTABILITY; P53-DEFICIENT MICE; ARRAY CGH; CANCER; TUMORIGENESIS; GENE; TRANSFORMATION; AMPLIFICATION; IRRADIATION	Although radiation can directly induce DNA damage and is a known human and animal carcinogen, the number of genetic changes in radiation-induced tumors, and the pathways responsible for generating them, are unknown. We have used high-density BAC arrays covering > 95% of the mouse genome for analysis of genomic patterns of aberrations in spontaneous and radiation-induced mouse lymphomas. The majority of radiation-induced tumors exhibit one of three 'signatures' based on gene copy number changes. Some exhibit extensive scrambling of the genome, with very high numbers of recurrent gains and losses. Two other signatures are characterized by excess gains but relatively few losses, or vice versa. Changes in spontaneous tumors often involve whole chromosomes, whereas radiation-induced tumors exhibit a high frequency of localized deletion/amplification events. The number of copy number abnormalities does not correlate with the latency or pathology of the tumors. We propose that specific early events following radiation exposure induce changes in 'caretaker' genes that control specific downstream pathways involved in DNA damage repair. The nature of these early events may determine the overall genomic signature observed in the resulting tumor.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of California System; University of California San Francisco; Baylor College of Medicine; Baylor College of Medicine	Cai, WW (corresponding author), Univ Calif San Francisco, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu; wcai@bcm.tmc.edu	Pérez-Losada, Jesús/A-5883-2019; Mao, Jian-Hua/EIZ-8595-2022	Pérez-Losada, Jesús/0000-0003-2400-624X; Mao, Jian-Hua/0000-0001-9320-6021; Peterson, Leif/0000-0002-1187-0883	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; Azzam EI, 2003, ONCOGENE, V22, P7050, DOI 10.1038/sj.onc.1206961; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gregory SG, 2002, NATURE, V418, P743, DOI 10.1038/nature00957; Hande MP, 2003, AM J HUM GENET, V72, P1162, DOI 10.1086/375041; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KENNEDY AR, 1984, RADIAT RES, V99, P228, DOI 10.2307/3576368; KENNEDY AR, 1984, NATURE, V307, P85, DOI 10.1038/307085a0; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kinzler KW, 1997, NATURE, V386, P763; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; LOEB LA, 1974, CANCER RES, V34, P2311; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2003, ONCOGENE, V22, P8379, DOI 10.1038/sj.onc.1207083; Marx J, 2002, SCIENCE, V297, P544, DOI 10.1126/science.297.5581.544; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mitelman F, 2005, MITELMAN DATABASE CH; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Peterson LE, 2002, COMPUT METH PROG BIO, V69, P179, DOI 10.1016/S0169-2607(01)00189-4; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sigurdson AJ, 2003, ONCOGENE, V22, P7018, DOI 10.1038/sj.onc.1206989; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UNO M, 1987, INT J CANCER, V40, P540, DOI 10.1002/ijc.2910400418; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824	38	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7924	7934		10.1038/sj.onc.1208926	http://dx.doi.org/10.1038/sj.onc.1208926			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116484				2022-12-25	WOS:000233463000011
J	Li, JSS; Cu, LW; Rock, DL; Li, JY				Li, JSS; Cu, LW; Rock, DL; Li, JY			Novel glycosidic linkage in aedes Aegypti chorion peroxidase N-mannosyl tryptophan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN C-MANNOSYLATION; FAST-ATOM-BOMBARDMENT; MASS-SPECTROMETRY; LINKED OLIGOSACCHARIDES; O-FUCOSYLATION; RNASE 2; GLYCOSYLATION; COMPLEMENT; FLAVONOIDS	Aedes aegypti chorion peroxidase (CPO) plays a crucial role in chorion hardening by catalyzing chorion protein cross-linking through dityrosine formation. The enzyme is extremely resistant to denaturing conditions, which seem intimately related to its posttranslational modifications, including disulfide bond formation and glycosylation. In this report, we have provided data that describe a new type of glycosylation in CPO, where a mannose is linked to the N-1 atom of the indole ring of Trp residue. Through liquid chromatography/electrospray ionization/tandem mass spectrometry and de novo sequencing of CPO tryptic peptides, we determined that three of the seven available Trp residues in mature CPO are partially ( 40 - 50%) or completely mannosylated. This conclusion is based on the following properties of the electrospray ionization/ tandem mass spectrometry spectra and the enzymatic reaction of these peptides: 1) the presence of a 162-Da substituent in each Trp residue; 2) the presence of abundant fragments of m/z 163 ([ Hex + H]) and [M + H - 162] (typical for N-glycosides); 3) the absence of a loss of 120 Da ( this loss is typical for aromatic C-glycosides); and 4) the cleavage of the glycosidic linkage by PNGase A or F ( typical for N-glycans). These results establish that a C - N bond is formed between the anomeric carbon of amannose residue and the N-1 atom of the indole ring of Trp. This is the first report that provides definitive evidence for N-mannosylation of Trp residues in a protein. In addition, our data demonstrate that PNGase can hydrolyze Trp N-linked mannose in peptides, which is unusual because no typical beta-amide bond is present in the Trp-mannosyl moiety. Results of this study should stimulate research toward a comprehensive understanding of physiology and biochemistry of Trp N-mannosylation in proteins and the overall biochemical mechanisms of PNGase-catalyzed reactions.	Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA; Penn State Univ, Dept Entomol, University Pk, PA 16802 USA	University of Illinois System; University of Illinois Urbana-Champaign; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Li, JY (corresponding author), Univ Illinois, Dept Pathobiol, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	jli2@uiuc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037789, R29AI037789] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37789] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECCHI M, 1989, BIOMED ENVIRON MASS, V18, P122, DOI 10.1002/bms.1200180207; de Beer T., 1995, BIOCHEMISTRY-US, V34; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Diem S, 2000, J AGR FOOD CHEM, V48, P4913, DOI 10.1021/jf0003146; Doucey MA, 1999, GLYCOBIOLOGY, V9, P435, DOI 10.1093/glycob/9.5.435; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; Ervin LA, 2005, INVEST OPHTH VIS SCI, V46, P627, DOI 10.1167/iovs.04-0894; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; GADE G, 1992, BIOCHEM BIOPH RES CO, V189, P1303, DOI 10.1016/0006-291X(92)90215-7; Gutsche B, 1999, BIOCHEM J, V343, P11, DOI 10.1042/0264-6021:3430011; Han Q, 2000, ARCH BIOCHEM BIOPHYS, V378, P107, DOI 10.1006/abbi.2000.1821; Hartmann S, 2000, J BIOL CHEM, V275, P28569, DOI 10.1074/jbc.M001732200; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hofsteenge J, 1999, J BIOL CHEM, V274, P32786, DOI 10.1074/jbc.274.46.32786; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Ihara Y, 2005, GLYCOBIOLOGY, V15, P383, DOI 10.1093/glycob/cwi012; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Krieg J, 1997, J BIOL CHEM, V272, P26687, DOI 10.1074/jbc.272.42.26687; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Li JS, 2004, INSECT BIOCHEM MOLEC, V34, P1195, DOI 10.1016/j.ibmb.2004.08.001; Li JSS, 2005, PROTEIN SCI, V14, P2370, DOI 10.1110/ps.051419105; Li JY, 1996, INSECT BIOCHEM MOLEC, V26, P309, DOI 10.1016/0965-1748(95)00099-2; LI QM, 1992, BIOL MASS SPECTROM, V21, P213, DOI 10.1002/bms.1200210406; Loffler A, 1996, BIOCHEMISTRY-US, V35, P12005, DOI 10.1021/bi9610515; Perez-Vilar J, 2004, GLYCOBIOLOGY, V14, P325, DOI 10.1093/glycob/cwh041; PROX A, 1968, TETRAHEDRON, V24, P3697, DOI 10.1016/S0040-4020(01)92002-2; VARKI A, 1999, ESSENTIALS GLYCOBIOL, P85	28	14	16	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38513	38521		10.1074/jbc.M508449200	http://dx.doi.org/10.1074/jbc.M508449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16150691	hybrid			2022-12-25	WOS:000233239800049
J	Thevenet, L; Albrecht, KH; Malki, S; Berta, P; Boizet-Bonhoure, B; Poulat, F				Thevenet, L; Albrecht, KH; Malki, S; Berta, P; Boizet-Bonhoure, B; Poulat, F			NHERF2/SIP-1 interacts with mouse SRY via a different mechanism than human SRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-DETERMINING FACTOR; SEX-REVERSING MUTATIONS; DNA-BINDING ACTIVITY; HMG BOX; GONADAL-DYSGENESIS; DETERMINING REGION; DETERMINING GENE; PDZ-DOMAIN; PROTEIN; EBP50	In mammals, male sex determination is controlled by the SRY protein, which drives differentiation of the bipotential embryonic gonads into testes by activating the Sertoli cell differentiation program. The morphological effects of SRY are well documented; however, its molecular mechanism of action remains unknown. Moreover, SRY proteins display high sequence variability among mammalian species, which makes protein motifs difficult to delineate. We previously isolated SIP-1/NHERF2 as a human SRY-interacting protein. SIP-1/NHERF2, a PDZ protein, interacts with the C-terminal extremity of the human SRY protein. Here we showed that the interaction of SIP-1/NHERF2 and SRY via the SIP-1/NHERF2 PDZ1 domain is conserved in mice. However, the interaction occurs via a domain that is internal to the mouse SRY protein and involves a different recognition mechanism than human SRY. Furthermore, we show that mouse and human SRY induce nuclear accumulation of the SIP-1/NHERF2 protein in cultured cells. Finally, a transgenic mouse line expressing green fluorescent protein under the control of the mouse Sry promoter allowed us to show that SRY and SIP-1/NHERF2 are co-expressed in the nucleus of pre-Sertoli cells during testis determination. Taken together, our results suggested that the function of SIP-1/NHERF2 as an SRY cofactor during testis determination is conserved between human and mouse.	CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier, France; Boston Univ, Sch Med, Dept Med, Genet Program, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Univ Nimes, F-30021 Nimes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Boston University; Boston University; Universite de Nimes	Poulat, F (corresponding author), CNRS, UPR 1142, Inst Genet Humaine, 141 Rue Cardonille, F-34396 Montpellier, France.	francis@igh.cnrs.fr	POULAT, FRANCIS/AAV-2170-2020	POULAT, FRANCIS/0000-0003-2070-1296; Albrecht, Kenneth/0000-0002-9769-3362				Albrecht KH, 2001, DEV BIOL, V240, P92, DOI 10.1006/dbio.2001.0438; Albrecht KH, 1997, GENETICS, V147, P1267; Assumpcao JG, 2002, J MOL MED, V80, P782, DOI 10.1007/s00109-002-0376-9; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Brennan J, 2004, NAT REV GENET, V5, P509, DOI 10.1038/nrg1381; COWARD P, 1994, NAT GENET, V6, P245, DOI 10.1038/ng0394-245; Domenice S, 2004, BRAZ J MED BIOL RES, V37, P145, DOI 10.1590/S0100-879X2004000100020; Gasca S, 2002, P NATL ACAD SCI USA, V99, P11199, DOI 10.1073/pnas.172383099; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HACKER A, 1995, DEVELOPMENT, V121, P1603; Harley VR, 2003, P NATL ACAD SCI USA, V100, P7045, DOI 10.1073/pnas.1137864100; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Knower KC, 2003, CYTOGENET GENOME RES, V101, P185, DOI 10.1159/000074336; Lovell-Badge R, 2002, NOVART FDN SYMP, V244, P4; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Oh H, 2005, BIOL REPROD, V72, P407, DOI 10.1095/biolreprod.104.034447; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Shahid M, 2005, J CLIN ENDOCR METAB, V90, P2429, DOI 10.1210/jc.2004-1110; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TAJIMA T, 1994, HUM MOL GENET, V3, P1187, DOI 10.1093/hmg/3.7.1187; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0	29	25	28	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38625	38630		10.1074/jbc.M504127200	http://dx.doi.org/10.1074/jbc.M504127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166090	Green Published, hybrid			2022-12-25	WOS:000233239800063
J	Hemming, ML; Selkoe, DJ				Hemming, ML; Selkoe, DJ			Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION-DELETION POLYMORPHISM; 2 HOMOLOGOUS DOMAINS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; A-BETA; ENDOTHELIAL-CELLS; MICE; INSULIN; DEMENTIA; CLEAVAGE	Human genetic data have associated angiotensin-converting enzyme ( ACE) with Alzheimer disease ( AD), and purified ACE has been reported to cleave synthetic amyloid beta-protein (A beta) in vitro. Whether deficiency in ACE activity, arising from genetic alteration or pharmacological inhibition, can decrease A beta degradation and allow A beta accumulation in intact cells is unknown. We cloned ACE from human neuroblastoma cells and showed that it had posttranslational processing and enzymatic activity typical of the endogenous protease. Cellular expression of ACE promoted degradation of naturally secreted A beta 40 and A beta 42, leading to significant clearance of both species. Using site-directed mutagenesis, we determined that both active sites within ACE contribute to A beta clearance, and an ACE construct bearing mutations in each catalytic domain had no effect on A beta levels. Pharmacological inhibition of ACE with a widely prescribed drug, captopril, promoted the accumulation of cell-derived A beta in the media of beta-amyloid precursor-protein expressing cells. Together, these results show that ACE can lower the levels of secreted A beta in living cells and that this effect is blocked by inhibiting the protease's activity with an ACE inhibitor. This work, combined with the genetic studies, supports the hypothesis that ACE may modulate the susceptibility to and progression of AD via degradation of A beta. Our data encourage further analyses of the ACE gene for disease association and raise the question of whether currently prescribed ACE inhibitors could elevate cerebral A beta levels in humans.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Selkoe, DJ (corresponding author), Harvard Inst Med 730, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	dselkoe@rics.bwh.harvard.edu		Hemming, Mathew/0000-0003-4674-7778	NIA NIH HHS [R01 AG012749-10, AG12749, R01 AG012749] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012749] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARREGUI A, 1982, J NEUROCHEM, V38, P1490, DOI 10.1111/j.1471-4159.1982.tb07930.x; Balyasnikova IV, 2002, BIOCHEM J, V362, P585, DOI 10.1042/0264-6021:3620585; BARNES NM, 1991, EUR J PHARMACOL, V200, P289, DOI 10.1016/0014-2999(91)90584-D; BELDENT V, 1993, J BIOL CHEM, V268, P26428; Binevski PV, 2003, FEBS LETT, V550, P84, DOI 10.1016/S0014-5793(03)00825-1; Birkenhager WH, 2004, CURR OPIN NEPHROL HY, V13, P225, DOI 10.1097/01.mnh.0000119534.79618.7d; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Coates D, 2003, INT J BIOCHEM CELL B, V35, P769, DOI 10.1016/S1357-2725(02)00309-6; Cole J, 2002, CIRC RES, V90, P87, DOI 10.1161/hh0102.102360; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Elkins JS, 2004, NEUROLOGY, V62, P363, DOI 10.1212/01.WNL.0000106823.72493.FF; Farris W, 2005, BIOCHEMISTRY-US, V44, P6513, DOI 10.1021/bi0476578; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fuchs S, 2004, J BIOL CHEM, V279, P15946, DOI 10.1074/jbc.M400149200; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Herrmann N, 2004, NEUROLOGY, V63, P200, DOI 10.1212/01.WNL.0000134774.19232.09; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Katzov H, 2004, HUM MOL GENET, V13, P2647, DOI 10.1093/hmg/ddh286; Kehoe PG, 1999, NAT GENET, V21, P71, DOI 10.1038/5009; Kohlstedt K, 2005, HYPERTENSION, V45, P126, DOI 10.1161/01.HYP.0000150159.48992.11; Kohlstedt K, 2004, CIRC RES, V94, P60, DOI 10.1161/01.RES.0000107195.13573.E4; Kolsch H, 2005, NEUROSCI LETT, V377, P37, DOI 10.1016/j.neulet.2004.11.062; Lehmann DJ, 2005, AM J EPIDEMIOL, V162, P305, DOI 10.1093/aje/kwi202; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081; Lendon CL, 2002, NEUROSCI LETT, V328, P314, DOI 10.1016/S0304-3940(02)00553-0; Michaud A, 1997, MOL PHARMACOL, V51, P1070, DOI 10.1124/mol.51.6.1070; Oba R, 2005, EUR J NEUROSCI, V21, P733, DOI 10.1111/j.1460-9568.2005.03912.x; Ohrui T, 2004, NEUROLOGY, V63, P1324, DOI 10.1212/01.WNL.0000140705.23869.E9; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SANTOS RAS, 1985, HYPERTENSION, V7, P244, DOI 10.1161/01.HYP.7.2.244; Savaskan E, 2001, NEUROBIOL AGING, V22, P541, DOI 10.1016/S0197-4580(00)00259-1; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; SKIDGEL RA, 1987, CLIN EXP HYPERTENS A, V9, P243, DOI 10.3109/10641968709164184; Sleegers K, 2005, NEUROBIOL AGING, V26, P1153, DOI 10.1016/j.neurobiolaging.2004.09.011; Tucker HM, 2004, NEUROSCI LETT, V368, P285, DOI 10.1016/j.neulet.2004.07.011; Tucker HM, 2000, J NEUROSCI, V20, P3937; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711	46	244	260	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37644	37650		10.1074/jbc.M508460200	http://dx.doi.org/10.1074/jbc.M508460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154999	Green Accepted, hybrid			2022-12-25	WOS:000233044500041
J	Sneck, M; Kovanen, PT; Oorni, K				Sneck, M; Kovanen, PT; Oorni, K			Decrease in pH strongly enhances binding of native, proteolyzed, lipolyzed, and oxidized low density lipoprotein particles to human aortic proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMERICAN-HEART-ASSOCIATION; HUMAN ATHEROSCLEROTIC LESIONS; TO-RETENTION HYPOTHESIS; CHOLESTEROL-FED RABBITS; APO-B LIPOPROTEINS; VASCULAR-LESIONS; ATHEROGENIC LIPOPROTEINS; EXTRACELLULAR-MATRIX; PLASMA-LIPOPROTEINS; HUMAN MACROPHAGES	Binding of low density lipoprotein (LDL) to proteoglycans and modification of LDL are key processes in atherogenesis. Recently, it has been demonstrated that during atherogenesis the extracellular pH of atherosclerotic lesions decreases. We have examined the effect of the decreased pH on the binding of LDL to human aortic proteoglycans. The binding of native, oxidized, proteolyzed (alpha-chymotrypsintreated), or lipolyzed (sphingomyelinase- or phospholipase A(2)-treated) LDL particles to proteoglycans were measured in microtiter well assays at pH 5.5 - 7.5. We found that the lower the pH, the higher the amount of binding of LDL to proteoglycans. At the lowest pH tested ( pH 5.5), the amounts of proteoglycan-bound native, proteolyzed, sphingomyelinase-, and phospholipase A(2)-treated LDL were 20-, 23-, 30-, and 37-fold higher, respectively, than at pH 7.5. Interestingly, although oxidized LDL failed to bind to proteoglycans at neutral pH, there was significant binding at acidic pH. Binding of native and modified LDL to proteoglycans at pH 5.5 was blocked by 1 M NaCl, indicating that at neutral pH LDL binds to proteoglycans via ionic interactions. Inhibition of this binding by acetylation and cyclohexanedione treatment of LDL showed that the positively charged amino acids of apolipoprotein B-100, lysine, and arginine, respectively, mediated the ionic interaction. Taken together, our results suggest that in areas of atherosclerotic arterial intima where the extracellular pH decreases, retention of LDL by proteoglycans is enhanced, leading to extracellular accumulation of LDL and progression of the disease.	Wihuri Res Inst, FIN-00140 Helsinki, Finland	Wihuri Research Institute	Oorni, K (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.	kati.oorni@wri.fi	Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				Asatryan L, 2005, J LIPID RES, V46, P115, DOI 10.1194/jlr.M400306-JLR200; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; Boren J, 2000, CURR OPIN LIPIDOL, V11, P451, DOI 10.1097/00041433-200010000-00002; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; De Vries HE, 1998, FASEB J, V12, P111, DOI 10.1096/fasebj.12.1.111; Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; Hakala JK, 2003, ARTERIOSCL THROM VAS, V23, P1430, DOI 10.1161/01.ATV.0000077207.49221.06; Hakala JK, 2001, ARTERIOSCL THROM VAS, V21, P1053, DOI 10.1161/01.ATV.21.6.1053; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; KAMAT BR, 1987, HUM PATHOL, V18, P1036, DOI 10.1016/S0046-8177(87)80220-4; KLEINMAN Y, 1988, J LIPID RES, V29, P729; Leake DS, 1997, ATHEROSCLEROSIS, V129, P149, DOI 10.1016/S0021-9150(96)06035-2; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; Naghavi M, 2002, ATHEROSCLEROSIS, V164, P27, DOI 10.1016/S0021-9150(02)00018-7; NEWSHOLME P, 1987, BIOCHEM J, V242, P631, DOI 10.1042/bj2420631; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 2004, J BIOL CHEM, V279, P34776, DOI 10.1074/jbc.M310814200; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; Pentikainen MO, 2001, ARTERIOSCL THROM VAS, V21, P1902, DOI 10.1161/hq1201.099423; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; SRINIVASAN SR, 1986, ATHEROSCLEROSIS, V62, P201, DOI 10.1016/0021-9150(86)90094-8; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; STARY HC, 1992, ARTERIOSCLER THROMB, V12, P120, DOI 10.1161/01.ATV.12.1.120; Stefanadis C, 1999, CIRCULATION, V99, P1965, DOI 10.1161/01.CIR.99.15.1965; Tozer EC, 1997, CIRC RES, V80, P208, DOI 10.1161/01.RES.80.2.208; WIGHT TN, 1995, CURR OPIN LIPIDOL, V6, P326, DOI 10.1097/00041433-199510000-00013; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; Wooton-Kee CR, 2004, ARTERIOSCL THROM VAS, V24, P762, DOI 10.1161/01.ATV.0000122363.02961.c1	47	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37449	37454		10.1074/jbc.M508565200	http://dx.doi.org/10.1074/jbc.M508565200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147996	hybrid			2022-12-25	WOS:000233044500020
J	Tarrega, C; Rios, P; Cejudo-Marin, R; Blanco-Aparicio, C; van den Berk, L; Schepens, J; Hendriks, W; Tabernero, L; Pulido, R				Tarrega, C; Rios, P; Cejudo-Marin, R; Blanco-Aparicio, C; van den Berk, L; Schepens, J; Hendriks, W; Tabernero, L; Pulido, R			ERK2 shows a restrictive and locally selective mechanism of recognition by its tyrosine phosphatase inactivators not shared by its activator MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; SIGNAL-REGULATED KINASES; OF-FUNCTION MUTATION; PROTEIN-KINASE; PTP-SL; FEEDBACK PHOSPHORYLATION; SUBSTRATE RECOGNITION; CATALYTIC ACTIVATION; BIOLOGICAL FUNCTIONS; MASS-SPECTROMETRY	The two regulatory residues that control the enzymatic activity of the mitogen-activated protein (MAP) kinase ERK2 are phosphorylated by the unique MAP kinase kinases MEK1/2 and dephosphorylated by several tyrosine-specific and dual specificity protein phosphatases. Selective docking interactions facilitate these phosphorylation and dephosphorylation events, controlling the specificity and duration of the MAP kinase activation-inactivation cycles. We have analyzed the contribution of specific residues of ERK2 in the physical and functional interaction with the ERK2 phosphatase inactivators PTP-SL and MKP-3 and with its activator MEK1. Single mutations in ERK2 that abrogated the dephosphorylation by endogenous tyrosine phosphatases from HEK293 cells still allowed efficient phosphorylation by endogenous MEK1/2. Discrete ERK2 mutations at the ERK2 docking groove differentially affected binding and inactivation by PTP-SL and MKP-3. Remarkably, the cytosolic retention of ERK2 by its activator MEK1 was not affected by any of the analyzed ERK2 single amino acid substitutions. A chimeric MEK1 protein, containing the kinase interaction motif of PTP-SL, bound tightly to ERK2 through its docking groove and behaved as a gain-of-function MAP kinase kinase that hyperactivated ERK2. Our results provide evidence that the ERK2 docking groove is more restrictive and selective for its tyrosine phosphatase inactivators than for MEK1/2 and indicate that distinct ERK2 residues modulate the docking interactions with activating and inactivating effectors.	Ctr Invest Principe Felipe, Valencia 46013, Spain; Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6525 GA Nijmegen, Netherlands; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	Prince Felipe Research Center; Radboud University Nijmegen; University of Manchester	Pulido, R (corresponding author), Ctr Invest Principe Felipe, Avda Autopista Saler 16-3, Valencia 46013, Spain.	rpulido@cipf.es	Blanco-Aparicio, Carmen/I-3162-2015; Tabernero, Lydia/F-3795-2018; Cejudo, Rocio/I-2794-2015; Hendriks, Wiljan J.A.J./A-5214-2013; Hendriks, Wiljan/Q-4325-2019	Blanco-Aparicio, Carmen/0000-0002-3249-6595; Tabernero, Lydia/0000-0001-8867-455X; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Hendriks, Wiljan/0000-0001-9481-8281; Pulido, Rafael/0000-0001-9100-248X; Cejudo Marin, Rocio/0000-0001-5389-7200				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bellon S, 1999, STRUCTURE, V7, P1057, DOI 10.1016/S0969-2126(99)80173-7; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Buschbeck M, 2002, J BIOL CHEM, V277, P29503, DOI 10.1074/jbc.M202149200; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Cha H, 2001, J BIOL CHEM, V276, P48494, DOI 10.1074/jbc.M107601200; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Dilaver G, 2003, HISTOCHEM CELL BIOL, V119, P1, DOI 10.1007/s00418-002-0489-9; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HENDRIKS W, 1995, BIOCHEM J, V305, P499, DOI 10.1042/bj3050499; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Huang ZH, 2004, J BIOL CHEM, V279, P52150, DOI 10.1074/jbc.M407820200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lim YM, 1999, GENETICS, V153, P763; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Munoz JJ, 2003, BIOCHEM J, V372, P193, DOI 10.1042/BJ20021941; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1992, J BIOL CHEM, V267, P25628; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Tarrega C, 2002, J BIOL CHEM, V277, P2629, DOI 10.1074/jbc.M108874200; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200; Zhan XL, 2001, CHEM REV, V101, P2477, DOI 10.1021/cr000245u; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	77	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37885	37894		10.1074/jbc.M504366200	http://dx.doi.org/10.1074/jbc.M504366200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148006	Green Published, hybrid			2022-12-25	WOS:000233044500069
J	Blachon, S; Bellanger, S; Demeret, C; Thierry, G				Blachon, S; Bellanger, S; Demeret, C; Thierry, G			Nucleo-cytoplasmic shuttling of high risk human Papillomavirus E2 proteins induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E6 PROMOTER; TRANSACTIVATION DOMAIN; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; VIRAL-DNA; TYPE-16; REPRESSOR; COMPLEX; PATHWAY; BINDING	Human Papillomavirus (HPV) E2 proteins are the major viral regulators of transcription and replication during the viral life cycle. In addition to these conserved functions, we show that E2 proteins from high risk HPV types 16 and 18, which are associated with cervical cancer, can induce apoptosis. In contrast, E2 proteins from low risk HPV types 6 and 11, which are associated with benign lesions, do not cause cell death. We show that the ability to induce apoptosis is linked to the intracellular localization of the respective E2 proteins rather than to inherent properties of the proteins. Although low risk HPV E2 proteins remain strictly nuclear, high risk HPV E2 proteins are present in both the nucleus and the cytoplasm of expressing cells due to exportin-1 receptor (CRM1)-dependent nucleo-cytoplasmic shuttling. Induction of apoptosis is caused by accumulation of E2 in the cytoplasm and involves caspase 8 activation. We speculate that disruption of the E2 gene during viral genome integration in cervical carcinoma provides a means to avoid E2-induced apoptosis and allow initiation of carcinogenesis.	Inst Pasteur, Unite Express Genet & Malad, CNRS, FRE 2850, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thierry, G (corresponding author), Inst Pasteur, Unite Express Genet & Malad, CNRS, FRE 2850, 25 Rue Dr Roux, F-75724 Paris, France.	fthierry@pasteur.fr		Demeret, caroline/0000-0002-1103-6805				Abbate EA, 2004, GENE DEV, V18, P1981, DOI 10.1101/gad.1220104; Ameisen JC, 2003, CELL DEATH DIFFER, V10, pS3, DOI 10.1038/sj.cdd.4401117; Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; BELLANGER S, 2005, IN PRESS CELL CYCLE, V4; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Boya P, 2004, BBA-BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007; CHIN MT, 1988, J VIROL, V62, P2994, DOI 10.1128/JVI.62.8.2994-3002.1988; Crouzet J, 1997, P NATL ACAD SCI USA, V94, P1414, DOI 10.1073/pnas.94.4.1414; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Hwang ES, 1996, ONCOGENE, V12, P795; Irusta PM, 2003, CURR OPIN CELL BIOL, V15, P700, DOI 10.1016/j.ceb.2003.10.007; Kassis R, 2004, J VIROL, V78, P6543, DOI 10.1128/JVI.78.12.6543-6555.2004; Kim KH, 2003, EMBO J, V22, P2104, DOI 10.1093/emboj/cdg210; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Prikhod'ko EA, 2004, VIROLOGY, V329, P53, DOI 10.1016/j.virol.2004.08.012; Raj K, 2004, J VIROL, V78, P7199, DOI 10.1128/JVI.78.13.7199-7207.2004; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Skiadopoulos MH, 1996, J VIROL, V70, P1117, DOI 10.1128/JVI.70.2.1117-1124.1996; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; Teodoro JG, 2004, GENE DEV, V18, P1952, DOI 10.1101/gad.1198404; THIERRY F, 1991, NEW BIOL, V3, P90; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Van Tine BA, 2004, P NATL ACAD SCI USA, V101, P4030, DOI 10.1073/pnas.0306848101; Wang Y, 2004, J BIOL CHEM, V279, P6976, DOI 10.1074/jbc.M311376200; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7; Zou NX, 2000, J VIROL, V74, P3761, DOI 10.1128/JVI.74.8.3761-3770.2000	49	63	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36088	36098		10.1074/jbc.M505138200	http://dx.doi.org/10.1074/jbc.M505138200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16135518	hybrid			2022-12-25	WOS:000232726900039
J	Khan, AN; Lewis, PN				Khan, AN; Lewis, PN			Unstructured conformations are a substrate requirement for the Sir2 family of NAD-dependent protein deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; DISORDER; PEPTIDE; ACETYLATION; PREDICTION; RESOLUTION; COMPLEX	The regulation of protein function is often achieved through post-translational modifications including phosphorylation, methylation, ubiquitination, and acetylation. The role of acetylation has been most extensively studied in the context of histones, but it is becoming increasingly evident that this modification now includes other proteins. The Sir2 family of NAD-dependent deacetylases was initially recognized as mediating gene silencing through histone deacetylation, but several family members display non-nuclear subcellular localization and deacetylate non-histone protein substrates. Although many structural and enzymatic studies of Sir2 proteins have been reported, how substrate recognition is achieved by this family of enzymes is unknown. Here we use in vitro deacetylase assays and a variety of potential substrates to examine the substrate specificity of yeast homologue Hst2. We show that Hst2 is specific for acetyl-lysine within proteins; it does not deacetylate small polycations such as acetyl-spermine or acetylated amino termini of proteins. Furthermore we have found that Hst2 displays conformational rather than sequence specificity, preferentially deacetylating acetyl-lysine within unstructured regions of proteins. Our results suggest that this conformational requirement may be a general feature for substrate recognition in the Sir2 family.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Lewis, PN (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.	peter.lewis@utoronto.ca						Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Banci L, 1997, BIOCHEMISTRY-US, V36, P9867, DOI 10.1021/bi970724w; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Blander G, 2005, J BIOL CHEM, V280, P9780, DOI 10.1074/jbc.M414080200; Cuperus G, 2000, EMBO J, V19, P2641, DOI 10.1093/emboj/19.11.2641; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; GU W, 2004, NOVART FDN SYMP, V259, P223; Gu Wei, 2004, Novartis Found Symp, V259, P197; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LEONIDAS DD, 1997, BIOCHEMISTRY-US, V36, P5578; LEWIS PN, 1988, EUR J BIOCHEM, V172, P135, DOI 10.1111/j.1432-1033.1988.tb13865.x; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Liu BS, 2005, J BIOL CHEM, V280, P16659, DOI 10.1074/jbc.M414008200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Thomson R, 2004, LECT NOTES COMPUT SC, V3177, P108; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Zhao KH, 2003, STRUCTURE, V11, P1403, DOI 10.1016/j.str.2003.09.016	29	37	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36073	36078		10.1074/jbc.M508247200	http://dx.doi.org/10.1074/jbc.M508247200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131486	hybrid			2022-12-25	WOS:000232726900037
J	Reppel, M; Sasse, P; Piekorz, R; Tang, M; Roell, W; Duan, YQ; Kletke, A; Hescheler, J; Nurnberg, B; Fleischmann, BK				Reppel, M; Sasse, P; Piekorz, R; Tang, M; Roell, W; Duan, YQ; Kletke, A; Hescheler, J; Nurnberg, B; Fleischmann, BK			S100A1 enhances the L-type Ca2+ current in embryonic mouse and neonatal rat ventricular cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEIN S100A1; CALCIUM-BINDING PROTEINS; MYOCARDIAL-INFARCTION; CARDIAC CONTRACTILITY; GUINEA-PIG; CYCLIC-AMP; TROPONIN-T; KINASE-A; HEART; EXPRESSION	S100A1 is an EF-hand type Ca2+-binding protein with a muscle-specific expression pattern. The highest S100A1 protein levels are found in cardiomyocytes, and it is expressed already at day 8 in the heart during embryonic development. Since S100A1 is known to be involved in the regulation of Ca2+ homeostasis, we tested whether extracellular S100A1 plays a role in regulating the L-type Ca2+ current (I-Ca) in ventricular cardiomyocytes. Murine embryonic ( day 16.5 postcoitum) ventricular cardiomyocytes were incubated with S100A1 (0.001 - 10 mu M) for different time periods ( 20 min to 48 h). ICa density was found to be significantly increased as early as 20 min ( from - 10.8 +/- 1 pA/pF, n = 18, to - 22.9 +/- 1.4 pA/pF; + 112.5 +/- 13%, n = 9, p< 0.001) after the addition of S100A1 ( 1 mu M). S100A1 also enhanced I-Ca current density in neonatal rat cardiomyocytes. Fluorescence and capacitance measurements evidenced a fast translocation of rhodamine-coupled S100A1 from the extracellular space into cardiomyocytes. S100A1 treatment did not affect cAMP levels. However, protein kinase inhibitor, a blocker of cAMP-dependent protein kinase A (PKA), abolished the S100A1-induced enhancement of I-Ca. Accordingly, measurements of PKA activity yielded a significant increase in S100A1-treated cardiomyocytes. In vitro reconstitution assays further demonstrated that S100A1 enhanced PKA activity. We conclude that the Ca2+-binding protein S100A1 augments transsarcolemmal Ca2+ influx via an increase of PKA activity in ventricular cardiomyocytes and hence represents an important regulator of cardiac function.	Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Univ Bonn, Inst Physiol 1, D-53105 Bonn, Germany; Univ Bonn, Dept Cardiothorac Surg, D-53105 Bonn, Germany; Univ Dusseldorf, Dept Biochem & Mol Biol 2, D-40225 Dusseldorf, Germany; Tongji Med Coll, Dept Physiol, Wuhan 430030, Peoples R China	University of Cologne; University of Bonn; University of Bonn; Heinrich Heine University Dusseldorf; Huazhong University of Science & Technology	Reppel, M (corresponding author), Univ Cologne, Inst Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	michael.reppel@uni-koeln.de; bernd.fleischmann@uni-bonn.de	Sasse, Philipp/G-9866-2013	Sasse, Philipp/0000-0002-8502-9472; Nurnberg, Bernd/0000-0002-5995-6555; Roell, Wilhelm/0000-0002-2213-5024				ARGEL MI, 1980, J MOL CELL CARDIOL, V12, P939, DOI 10.1016/0022-2828(80)90023-1; BLONDEL B, 1971, EXPERIENTIA, V27, P356, DOI 10.1007/BF02138197; Brett W, 2001, BIOCHEM BIOPH RES CO, V284, P698, DOI 10.1006/bbrc.2001.4996; DANIELS CK, 1994, J PHARMACOL TOXICOL, V31, P41, DOI 10.1016/1056-8719(94)90027-2; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Ehlermann P, 2000, J CHROMATOGR B, V737, P39, DOI 10.1016/S0378-4347(99)00366-7; Ehlermann P, 2000, BBA-MOL BASIS DIS, V1500, P249, DOI 10.1016/S0925-4439(99)00106-4; Findlay I, 2002, J PHYSIOL-LONDON, V545, P375, DOI 10.1113/jphysiol.2002.028605; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; Gupta IR, 1999, J BIOL CHEM, V274, P26305, DOI 10.1074/jbc.274.37.26305; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Horackova M, 1997, EXP CELL RES, V237, P158, DOI 10.1006/excr.1997.3775; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; Kennergren C, 1999, CARDIOLOGY, V92, P162, DOI 10.1159/000006966; Kiewitz R, 2000, BIOCHEM BIOPH RES CO, V274, P865, DOI 10.1006/bbrc.2000.3229; Kiewitz R, 2003, BIOCHEM BIOPH RES CO, V306, P550, DOI 10.1016/S0006-291X(03)00987-2; Kiewitz R, 2000, BBA-MOL CELL RES, V1498, P207, DOI 10.1016/S0167-4889(00)00097-5; Kosuge S, 2001, J BIOCHEM, V129, P403, DOI 10.1093/oxfordjournals.jbchem.a002871; KUO WN, 1986, CYTOBIOS, V46, P139; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; Mason HS, 2002, MOL PHARMACOL, V61, P285, DOI 10.1124/mol.61.2.285; Matsushita T, 1999, CIRCULATION, V100, P262; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Most P, 2005, J CELL SCI, V118, P421, DOI 10.1242/jcs.01614; Most P, 2003, J BIOL CHEM, V278, P33809, DOI 10.1074/jbc.M301788200; Most P, 2001, P NATL ACAD SCI USA, V98, P13889, DOI 10.1073/pnas.241393598; Podlowski S, 1998, CIRCULATION, V98, P2470, DOI 10.1161/01.CIR.98.22.2470; Remppis A, 1996, BBA-MOL CELL RES, V1313, P253, DOI 10.1016/0167-4889(96)00097-3; Remppis A, 2002, BASIC RES CARDIOL S1, V97, P56; Sako H, 1998, PFLUG ARCH EUR J PHY, V435, P749, DOI 10.1007/s004240050579; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; Wang W, 2004, CIRC RES, V95, P798, DOI 10.1161/01.RES.0000145361.50017.aa; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	38	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36019	36028		10.1074/jbc.M504750200	http://dx.doi.org/10.1074/jbc.M504750200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129693	hybrid			2022-12-25	WOS:000232726900031
J	Bandhuvula, P; Tam, YY; Oskouian, B; Saba, JD				Bandhuvula, P; Tam, YY; Oskouian, B; Saba, JD			The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; LYMPH-NODES; T-CELLS; EXPRESSION; PHOSPHORYLATION; IMMUNOMODULATOR; TRANSPLANTATION; TRAFFICKING; IMPAIRS; S1P(1)	FTY720 is a novel immunomodulatory agent that inhibits lymphocyte trafficking and prevents allograft rejection. FTY720 is phosphorylated in vivo, and the phosphorylated drug acts as agonist for a family of G protein- coupled receptors that recognize sphingosine 1- phosphate. Evidence suggests that FTY720- phosphate- induced activation of S1P(1) is responsible for its mechanism of action. FTY720 was rationally designed by modification of myriocin, a naturally occurring sphingoid base analog that causes immunosuppression by interrupting sphingolipid metabolism. In this study, we examined interactions between FTY720, FTY720- phosphate, and sphingosine- 1- phosphate lyase, the enzyme responsible for irreversible sphingosine 1- phosphate degradation. FTY720- phosphate was stable in the presence of active sphingosine1- phosphate lyase, demonstrating that the lyase does not contribute to FTY720 catabolism. Conversely, FTY720 inhibited sphingosine- 1- phosphate lyase activity in vitro. Treatment of mice with FTY720 inhibited tissue sphingosine1- phosphate lyase activity within 12 h, whereas lyase gene and protein expression were not significantly affected. Tissue sphingosine 1- phosphate levels remained stable or increased throughout treatment. These studies raise the possibility that disruption of sphingosine 1- phosphate metabolism may account for some effects of FTY720 on immune function and that sphingosine1- phosphate lyase may be a potential target for immunomodulatory therapy.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Saba, JD (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther Jr Way, Oakland, CA 94609 USA.	jsaba@chori.org			NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER; NCI NIH HHS [CA77528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2004, YONSEI MED J, V45, P991, DOI 10.3349/ymj.2004.45.6.991; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073; Caligan TB, 2000, ANAL BIOCHEM, V281, P36, DOI 10.1006/abio.2000.4555; CAMPBELL RA, 1991, LIFE SCI, V48, P225, DOI 10.1016/0024-3205(91)90349-G; Chiba K, 1998, J IMMUNOL, V160, P5037; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; Fyrst H, 2004, J LIPID RES, V45, P54, DOI 10.1194/jlr.M300005-JLR200; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Halin C, 2005, BLOOD, V106, P1314, DOI 10.1182/blood-2004-09-3687; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Jiang Q, 2004, P NATL ACAD SCI USA, V101, P17825, DOI 10.1073/pnas.0408340102; Kimura T, 2004, BLOOD, V103, P4478, DOI 10.1182/blood-2003-03-0875; Li GC, 2001, DEVELOPMENT, V128, P3473; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; Oskouian B, 2005, J BIOL CHEM, V280, P18403, DOI 10.1074/jbc.M410928200; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; SCOUNTZOU J, 1989, IMMUNOPHARM IMMUNOT, V11, P657, DOI 10.3109/08923978909005393; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VORA K, 2005, J LEUKOCYTE BIOL, V78, P1; Xie JH, 2003, J IMMUNOL, V170, P3662, DOI 10.4049/jimmunol.170.7.3662	30	120	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33697	33700		10.1074/jbc.C500294200	http://dx.doi.org/10.1074/jbc.C500294200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16118221	hybrid			2022-12-25	WOS:000232229700003
J	Cowan, KN; Leung, WCY; Mar, C; Bhattacharjee, R; Zhu, YH; Rabinovitch, M				Cowan, KN; Leung, WCY; Mar, C; Bhattacharjee, R; Zhu, YH; Rabinovitch, M			Caspases from apoptotic myocytes degrade extracellular matrix: a novel remodeling paradigm	FASEB JOURNAL			English	Article						apoptosis; smooth muscle; elastin	PROGRAMMED CELL-DEATH; TENASCIN-C; INHIBITORS; REGRESSION; ELASTASE; MICE; SUPPRESSION; MECHANISM; SURVIVAL; INTEGRIN	Induction of smooth muscle cell apoptosis is critical to the reversal of severe structural remodeling in hypertensive pulmonary arteries during disease regression (1, 2). This process involves coordinated resorption of pathologically deposited extracellular matrix, including elastin, and occurs in the presence of serine elastase and matrix metalloproteinase inhibitors (2). Here, we show that apoptotic smooth muscle cells exhibit extensive degradation of elastin coincident with cell surface immunolocalization and release of caspases. We further document that recombinant caspase-2, -3, and -7 are potently elastolytic. These enzymes are present in an active form on apoptotic cell surfaces and caspase inhibitors attenuate their elastolytic activity. Our results reveal a previously undescribed function for apoptotic cells and a novel paradigm whereby removal of cells is coordinated with degradation of excess extracellular matrix during remodeling in development and disease.	Stanford Univ, Sch Med, Wall Ctr Pulm Vasc Dis, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Univ Toronto, Hosp Sick Children, Div Cardiovasc Res, Dept Pediat,Lab Med & Pathobiol & Med, Toronto, ON, Canada	Stanford University; Stanford University; Stanford University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rabinovitch, M (corresponding author), Stanford Univ, Sch Med, Wall Ctr Pulm Vasc Dis, CCSR-Room 2245B,269 Campus Dr, Stanford, CA 94305 USA.	marlener@stanford.edu	Bhattacharjee, Rakesh/ABC-8810-2021	Cowan, Kyle/0000-0003-0109-7716				AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Brooks Dennis E., 1999, Veterinary Ophthalmology, V2, P3; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Cowan KN, 2000, NAT MED, V6, P698, DOI 10.1038/76282; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Edwards PD, 1997, J MED CHEM, V40, P1876, DOI 10.1021/jm960819g; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; TAKADA T, 1996, CEREBROVASC DIS, V2, P32; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841	20	28	31	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1848	+		10.1096/fj.05-3706fje	http://dx.doi.org/10.1096/fj.05-3706fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16123172				2022-12-25	WOS:000231843700005
J	Anderson, CJ; Hoare, SF; Ashcroft, M; Bilsland, AE; Keith, WN				Anderson, CJ; Hoare, SF; Ashcroft, M; Bilsland, AE; Keith, WN			Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms	ONCOGENE			English	Article						telomerase; hTR; hTERT; hypoxia; RNA splicing; chromatin	STRESS-INDUCED APOPTOSIS; HUMAN CANCER-CELLS; INDUCIBLE FACTOR-1-ALPHA; BACTERIAL NITROREDUCTASE; REVERSE-TRANSCRIPTASE; TUMOR-GROWTH; LIFE-SPAN; IN-VIVO; ACTIVATION; HTERT	Basal telomerase activity is dependent on expression of the hTERT and hTR genes and upregulation of telomerase gene expression is associated with tumour development. It is therefore possible that signal transduction pathways involved in tumour development and features of the tumour environment itself may influence telomerase gene regulation. The majority of solid tumours contain regions of hypoxia and it has recently been demonstrated that hypoxia can increase telomerase activity by mechanisms that are still poorly defined. Here, we show that hypoxia induces the transcriptional activity of both hTR and hTERT gene promoters. While endogenous hTR expression is regulated at the transcriptional level, hTERT is subject to regulation by alternative splicing under hypoxic conditions, which involves a switch in the splice pattern in favour of the active variant. Furthermore, analysis of the chromatin landscape of the telomerase promoters reveals dynamic recruitment of a transcriptional complex involving the hypoxia- inducible factor-1 transcription factor, p300, RNA polymerase II and TFIIB, to both promoters during hypoxia, which traffics along and remains associated with the hTERT gene as transcription proceeds. These studies show that hTERT and hTR are subject to similar controls under hypoxia and highlight the rapid and dynamic regulation of the telomerase genes in vivo.	Univ Glasgow, Canc Res UK, Beatson Labs, Ctr Oncol & Appl Pharmacol, Glasgow G61 1BD, Lanark, Scotland; Inst Canc Res, Canc Res UK, Ctr Canc Therapeut, Sutton, Surrey, England	Beatson Institute; Cancer Research UK; University of Glasgow; Cancer Research UK; University of London; Institute of Cancer Research - UK	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK, Beatson Labs, Ctr Oncol & Appl Pharmacol, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.	n.keith@beatson.gla.ac.uk	Cairney, Claire/H-6989-2012; Bilsland, Alan/G-2629-2010; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Bilsland, Alan/0000-0003-0957-3908; Cairney, Claire/0000-0001-6531-245X				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; ASHCROFT M, 2004, BIOESSAYS, V26, P262; ATKINSON SP, 2005, IN PRESS CANC RES; Bilsland AE, 2003, ONCOGENE, V22, P370, DOI 10.1038/sj.onc.1206168; Blasco MA, 2003, TRENDS CELL BIOL, V13, P289, DOI 10.1016/S0962-8924(03)00085-0; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; Elsby LM, 2004, BIOCHEM SOC T, V32, P1098, DOI 10.1042/BST0321098; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; GRAVEN KK, 1994, J BIOL CHEM, V269, P24446; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Munch C, 2003, J NEUROSCI RES, V71, P819, DOI 10.1002/jnr.10536; Nishi H, 2004, MOL CELL BIOL, V24, P6076, DOI 10.1128/MCB.24.13.6076-6083.2004; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Reynolds TY, 1996, CANCER RES, V56, P5754; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Ulaner GA, 1998, CANCER RES, V58, P4168; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Zaffaroni N, 2002, J PATHOL, V198, P37, DOI 10.1002/path.1178; Zhang C, 2003, J BIOL CHEM, V278, P35325, DOI 10.1074/jbc.M305191200; Zhang LQ, 2003, CANCER RES, V63, P4552	34	76	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					61	69		10.1038/sj.onc.1209011	http://dx.doi.org/10.1038/sj.onc.1209011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170363				2022-12-25	WOS:000234406400007
J	Wei, X; Hao, L; Ni, S; Liu, QP; Xu, J; Correll, PH				Wei, X; Hao, L; Ni, S; Liu, QP; Xu, J; Correll, PH			Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; MACROPHAGE-STIMULATING PROTEIN; BINDING-SITE; TUMOR-FORMATION; MURINE MODEL; IFN-GAMMA; C-MET; ACTIVATION; GROWTH; STK	Alternative splicing of signaling proteins can contribute to the complexity of signaling networks. We find that expression of mouse RON, but not human RON, results in constitutive receptor autophosphorylation, ligand-independent activation of the mitogen-activated protein kinase pathway, and association of the receptor with c-Src. Using chimeric receptors, we mapped the region for this difference in signaling capacity of mouse and human RON to the juxtamembrane domain. Expression of these receptors in primary erythroid progenitor cells also demonstrated a functional difference in the ability of mouse and human RON to support erythropoietin-independent colony formation that mapped to the juxtamembrane domain. Splicing of the mouse RON receptor tyrosine kinase transcript results in the constitutive deletion of an exon used by all other known RON orthologs that encodes part of the juxtamembrane domain of the receptor. Mutational analysis indicated that the two tyrosines present in this region in human RON, one of which has been previously shown to be a c-Cbl binding site, are not responsible for this difference. However, deletion of this region in the context of human RON enhanced receptor phosphorylation, activation of mitogen-activated protein kinase, and association of c-Src at levels comparable with those observed with mouse RON. These data provide direct evidence that the divergence of exon usage among different species can generate a protein with novel activity and subsequently add to the complexity of cellular signaling regulation.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Grd Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Integrat Biosci Grad Program, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Correll, PH (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu	wei, xin/C-1395-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066471] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66471] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chan EL, 2005, ONCOGENE, V24, P479, DOI 10.1038/sj.onc.1208231; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch A, 1999, J LEUKOCYTE BIOL, V65, P345, DOI 10.1002/jlb.65.3.345; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Danilkovitch-Miagkova A, 2001, HISTOL HISTOPATHOL, V16, P623, DOI 10.14670/HH-16.623; De Maria R, 2002, ONCOGENE, V21, P1785, DOI 10.1038/sj.onc.1205221; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Go M., 1985, Advances in Biophysics, V19, P91; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hubbard SR, 2004, NAT REV MOL CELL BIO, V5, P464, DOI 10.1038/nrm1399; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; LEE S, 2005, J IMMUNOL, V173, P6864; Liu QP, 1999, J IMMUNOL, V163, P6606; Ma PC, 2003, CANCER RES, V63, P6272; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Nakaigawa N, 2000, ONCOGENE, V19, P2996, DOI 10.1038/sj.onc.1203628; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Santoro MM, 2000, ONCOGENE, V19, P5208, DOI 10.1038/sj.onc.1203819; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; van den Akker E, 2004, BLOOD, V103, P4457, DOI 10.1182/blood-2003-08-2713; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; WEI X, 2005, J BIOL CHEM	41	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40241	40251		10.1074/jbc.M506806200	http://dx.doi.org/10.1074/jbc.M506806200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16166096	hybrid			2022-12-25	WOS:000233461300066
J	Niida, H; Tsuge, S; Katsuno, Y; Konishi, A; Takeda, N; Nakanishi, M				Niida, H; Tsuge, S; Katsuno, Y; Konishi, A; Takeda, N; Nakanishi, M			Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; CHROMOSOMAL REARRANGEMENTS; SACCHAROMYCES-CEREVISIAE; CHECKPOINT FUNCTION; TUMOR-SUPPRESSOR; CELL-DEATH; CYCLIN B1; KINASE; APOPTOSIS; REPLICATION	Mitotic catastrophe occurs as a result of the uncoupling of the onset of mitosis from the completion of DNA replication, but precisely how the ensuing lethality is regulated or what signals are involved is largely unknown. We demonstrate here the essential role of the ATM/ATR-p53 pathway in mitotic catastrophe from premature mitosis. Chk1 deficiency resulted in a premature onset of mitosis because of abnormal activation of cyclin B-Cdc2 and led to the activation of caspases 3 and 9 triggered by cytoplasmic release of cytochrome c. This deficiency was associated with foci formation by the phosphorylated histone, H2AX (gamma H2AX), specifically at S phase. Ectopic expression of Cdc2AF, a mutant that cannot be phosphorylated at inhibitory sites, also induced premature mitosis and foci formation by gamma H2AX at S phase in both embryonic stem cells and HCT116 cells. Depletion of ATM and ATR protected against cell death from premature mitosis. p53-deficient cells were highly resistant to lethality from premature mitosis as well. Our results therefore suggest that ATM/ATR-p53 is required for mitotic catastrophe that eliminates cells escaping Chk1-dependent mitotic regulation. Loss of this function might be important in mammalian tumorigenesis.	Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan	Nagoya City University; Nagoya City University; Kumamoto University	Nakanishi, M (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	mkt-naka@med.nagoya-cu.ac.jp	Konishi, Akimitsu/J-4024-2019	Konishi, Akimitsu/0000-0002-3291-0821				AYSCOUGH K, 1992, MOL GEN GENET, V232, P344, DOI 10.1007/BF00266236; Brown EJ, 2000, GENE DEV, V14, P397; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Liu QH, 2000, GENE DEV, V14, P1448; Lock RB, 1996, CANCER RES, V56, P4006; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; MOLZ L, 1989, GENETICS, V122, P773; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORGAN DO, 1998, CANC J SCI AM S1, V4, P77; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nakanishi M, 2000, GENES CELLS, V5, P839, DOI 10.1046/j.1365-2443.2000.00367.x; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohashi A, 2001, BIOL REPROD, V65, P1195, DOI 10.1095/biolreprod65.4.1195; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ruth AC, 2000, CANCER RES, V60, P2576; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Takai H, 2000, GENE DEV, V14, P1439; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607	36	104	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39246	39252		10.1074/jbc.M505009200	http://dx.doi.org/10.1074/jbc.M505009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16159883	hybrid			2022-12-25	WOS:000233362200041
J	Oldham, ML; Brash, AR; Newcomer, ME				Oldham, ML; Brash, AR; Newcomer, ME			Insights from the X-ray crystal structure of coral 8R-lipoxygenase - Calcium activation via a C2-like domain and a structural basis of product chirality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; SOYBEAN LIPOXYGENASE-1; DETERMINANTS; BINDING; 5-LIPOXYGENASE; PROTEIN; 15-LIPOXYGENASE; IDENTIFICATION; PEROXIDASE; SURFACE	Lipoxygenases (LOXs) catalyze the regio- and stereospecific dioxygenation of polyunsaturated membrane-embedded fatty acids. We report here the 3.2 angstrom resolution structure of 8R-LOX from the Caribbean sea whip coral Plexaura homomalla, a LOX isozyme with calcium dependence and the uncommon R chiral stereospecificity. Structural and spectroscopic analyses demonstrated calcium binding in a C2-like membrane-binding domain, illuminating the function of similar amino acids in calcium-activated mammalian 5-LOX, the key enzyme in the pathway to the pro-inflammatory leukotrienes. Mutation of Ca2+ ligating amino acids in 8R-LOX resulted not only in a diminished capacity to bind membranes, as monitored by fluorescence resonance energy transfer, but also in an associated loss of Ca2+-regulated enzyme activity. Moreover, a structural basis for R chiral specificity is also revealed; creation of a small oxygen pocket next to Gly(428) ( Ala in all S-LOX isozymes) promoted C-8 oxygenation with R chirality on the activated fatty acid substrate.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Louisiana State University System; Louisiana State University; Vanderbilt University; Vanderbilt University	Newcomer, ME (corresponding author), Louisiana State Univ, Dept Biol Sci, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.	newcomer@lsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055420, R01GM053638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55420, GM53638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boutaud O, 1999, J BIOL CHEM, V274, P33764, DOI 10.1074/jbc.274.47.33764; BOYINGTON JC, 1990, J BIOL CHEM, V265, P12771; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Coffa G, 2004, P NATL ACAD SCI USA, V101, P15579, DOI 10.1073/pnas.0406727101; Di Venere A, 2003, J BIOL CHEM, V278, P18281, DOI 10.1074/jbc.M212122200; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hornung E, 2000, BIOCHEM SOC T, V28, P825; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; Naylor CE, 1999, J MOL BIOL, V294, P757, DOI 10.1006/jmbi.1999.3279; Naylor CE, 1998, NAT STRUCT BIOL, V5, P738, DOI 10.1038/1447; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pande AH, 2005, BIOPHYS J, V88, P4084, DOI 10.1529/biophysj.104.056788; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Skrzypczak-Jankun E, 2001, J AM CHEM SOC, V123, P10814, DOI 10.1021/ja011759t; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; Walther M, 2004, J BIOL CHEM, V279, P3717, DOI 10.1074/jbc.M309564200; Walther M, 2002, J BIOL CHEM, V277, P27360, DOI 10.1074/jbc.M203234200; ZHANG YY, 1994, ANAL BIOCHEM, V220, P28, DOI 10.1006/abio.1994.1294	32	82	85	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39545	39552		10.1074/jbc.M506675200	http://dx.doi.org/10.1074/jbc.M506675200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16162493	hybrid			2022-12-25	WOS:000233362200077
J	Clerici, M; Mantiero, D; Lucchini, G; Longhese, MP				Clerici, M; Mantiero, D; Lucchini, G; Longhese, MP			The Saccharomyces cerevisiae Sae2 protein promotes resection and bridging of double strand break ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; MRE11 COMPLEX; HOMOLOGOUS RECOMBINATION; NUCLEASE ACTIVITY; ESCHERICHIA-COLI; GENE CONVERSION; BUDDING YEAST; REPAIR; CHECKPOINT; MEIOSIS	When eukaryotic chromosomes undergo double strand breaks (DSBs), several evolutionarily conserved proteins, among which the MRX complex, are recruited to the break site, leading to checkpoint activation and DNA repair. The function of the Saccharomyces cerevisiae Sae2 protein, which is known to work together with the MRX complex in meiotic DSB processing and in specific mitotic DSB repair events, is only beginning to be elucidated. Here we provide new insights into the role of Sae2 in mitotic DSB repair. We show that repair by single strand annealing of a single DSB, which is generated by the HO endonuclease between direct repeats, is defective both in the absence of Sae2 and in the presence of the hypomorphic rad50s allele altering the Rad50 subunit of MRX. Moreover, SAE2 overexpression partially suppresses the rad50s single strand annealing repair defects, suggesting that the latter might arise from defective MRX-Sae2 interactions. Finally, SAE2 deletion slows down resection of an HO-induced DSB and impairs DSB end bridging. Thus, Sae2 participates in DSB single strand annealing repair by ensuring both resection and intrachromosomal association of the broken ends.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy	University of Milano-Bicocca	Longhese, MP (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy.	mariapia.longhese@unimib.it	Clerici, Michela/AAK-2807-2020; Pia, Maria/AAK-2693-2020	Longhese, Maria Pia/0000-0003-1726-2034				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Baroni E, 2004, MOL CELL BIOL, V24, P4151, DOI 10.1128/MCB.24.10.4151-4165.2004; Borde V, 2004, MOL CELL, V13, P389, DOI 10.1016/S1097-2765(04)00034-6; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Clerici M, 2004, MOL CELL BIOL, V24, P10126, DOI 10.1128/MCB.24.23.10126-10144.2004; Colaiacovo MP, 1999, GENETICS, V151, P1409; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Ivanov EL, 1996, GENETICS, V142, P693; Kaye JA, 2004, CURR BIOL, V14, P2096, DOI 10.1016/j.cub.2004.10.051; KEENEY S, 1995, P NATL ACAD SCI USA, V92, P11274, DOI 10.1073/pnas.92.24.11274; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lewis LK, 2004, GENETICS, V166, P1701, DOI 10.1534/genetics.166.4.1701; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; Lobachev K, 2004, CURR BIOL, V14, P2107, DOI 10.1016/j.cub.2004.11.051; Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1; McKee AHZ, 1997, GENETICS, V146, P797; Moreau S, 1999, MOL CELL BIOL, V19, P556; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Prinz S, 1997, GENETICS, V146, P781; Rattray AJ, 2005, GENE DEV, V19, P1390, DOI 10.1101/gad.1315805; Rattray AJ, 2001, GENETICS, V158, P109; Rose MD., 1990, METHODS YEAST GENETI; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Warren CD, 2004, MOL BIOL CELL, V15, P1724, DOI 10.1091/mbc.E03-09-0637; Wiltzius JJW, 2005, NAT STRUCT MOL BIOL, V12, P403, DOI 10.1038/nsmb928	46	155	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38631	38638		10.1074/jbc.M508339200	http://dx.doi.org/10.1074/jbc.M508339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16162495	hybrid			2022-12-25	WOS:000233239800064
J	Itou, H; Okada, U; Suzuki, H; Yao, M; Wachi, M; Watanabe, N; Tanaka, I				Itou, H; Okada, U; Suzuki, H; Yao, M; Wachi, M; Watanabe, N; Tanaka, I			The CGL2612 protein from Corynebacterium glutamicum is a drug resistance-related transcriptional repressor - Structural and functional analysis of a newly identified transcription factor from genomic DNA analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMP; TET REPRESSOR; STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURE; PROTEIN; BINDING; QACR; MECHANISMS; EXPRESSION; DATABASE	The emergence of antibiotic-resistant bacteria often causes serious clinical problems. The TetR family is one of the major transcription factor families that regulate expression of genes involved in bacterial antimicrobial resistance systems. CGL2612 protein is a transcription factor newly identified by genomic DNA analysis on Corynebacterium glutamicum, which belongs to the mycolic acid-containing Actinomycetales, including the well known pathogens Corynebacterium diphtheriae and Mycobacterium tuberculosis. Crystal structure analysis showed that the CGL2612 protein exhibits significant structural similarity to the multidrug resistance (MDR)-related transcription factor QacR from Staphylococcus aureus, despite poor amino acid sequence similarity between these proteins. Binding DNA sequence analysis of CGL2612 protein using the systematic evolution of ligands by the exponential enrichment ( systematic evolution of ligands by exponential enrichment, or SELEX) method revealed that this protein is a new member of the TetR family, which regulates expression of the immediately upstream gene, cgl2611, probably encoding a major facilitator superfamily permease. Subsequent functional analyses confirmed a function of the CGL2612 as a transcriptional repressor responsible for the antimicrobial resistance system in C. glutamicum. The strategy used in the present study is one of the most convenient and powerful methods to analyze functionally unknown transcription factors, and the results obtained here will contribute to our understanding of the drug resistance mechanism not only in C. glutamicum but also in the related bacteria, C. diphtheriae and M. tuberculosis.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Tokyo Inst Technol, Dept Bioengn, Yokohama, Kanagawa 2268501, Japan	Hokkaido University; Tokyo Institute of Technology	Tanaka, I (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	tanaka@castor.sci.hokudai.ac.jp	Watanabe, Nobuhisa/B-1187-2008; Wachi, Masaaki/D-1220-2015; yao, min/F-5287-2011; Okada, Ui/B-9821-2015	Watanabe, Nobuhisa/0000-0002-0118-5815; Wachi, Masaaki/0000-0002-3655-4035; yao, min/0000-0003-1687-5904; Okada, Ui/0000-0001-7633-9308				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dover LG, 2004, J MOL BIOL, V340, P1095, DOI 10.1016/j.jmb.2004.06.003; Frenois F, 2004, MOL CELL, V16, P301, DOI 10.1016/j.molcel.2004.09.020; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Itou H, 2004, ACTA CRYSTALLOGR D, V60, P1094, DOI 10.1107/S0907444904008522; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawabata T, 2002, NUCLEIC ACIDS RES, V30, P294, DOI 10.1093/nar/30.1.294; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchell BA, 1998, ANTIMICROB AGENTS CH, V42, P475; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Natsume R, 2004, J MOL BIOL, V336, P409, DOI 10.1016/j.jmb.2003.12.040; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072	31	29	32	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38711	38719		10.1074/jbc.M505999200	http://dx.doi.org/10.1074/jbc.M505999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166084	hybrid			2022-12-25	WOS:000233239800073
J	Petrosky, KY; Ou, HD; Lohr, F; Dotsch, V; Lim, WA				Petrosky, KY; Ou, HD; Lohr, F; Dotsch, V; Lim, WA			A general model for preferential hetero-oligomerization of LIN-2/7 domains - Mechanism underlying directed assembly of supramolecular signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL POLARITY COMPLEXES; L27 DOMAIN; DISCS-LARGE; DROSOPHILA STARDUST; EPITHELIAL-CELLS; PROTEIN COMPLEX; TIGHT JUNCTION; PDZ DOMAINS; T-CELLS; NMR	LIN-2/7 (L27) domains are protein interaction modules that preferentially hetero-oligomerize, a property critical for their function in directing specific assembly of supramolecular signaling complexes at synapses and other polarized cell-cell junctions. We have solved the solution structure of the heterodimer composed of the L27 domains from LIN-2 and LIN-7. Comparison of this structure with other L27 domain structures has allowed us to formulate a general model for why most L27 domains form an obligate heterodimer complex. L27 domains can be divided in two types ( A and B), with each heterodimer comprising an A/B pair. We have identified two keystone positions that play a central role in discrimination. The residues at these positions are energetically acceptable in the context of an A/B heterodimer, but would lead to packing defects or electrostatic repulsion in the context of A/A and B/B homodimers. As predicted by the model, mutations of keystone residues stabilize normally strongly disfavored homodimers. Thus, L27 domains are specifically optimized to avoid homodimeric interactions.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Biophys Grad Program, San Francisco, CA 94143 USA; Univ Frankfurt, Inst Biophys Chem, D-60439 Frankfurt, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Goethe University Frankfurt	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 600 16th St, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu	Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X				Bachmann A, 2004, J CELL SCI, V117, P1899, DOI 10.1242/jcs.01029; Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Feng W, 2005, P NATL ACAD SCI USA, V102, P6861, DOI 10.1073/pnas.0409346102; Feng W, 2004, NAT STRUCT MOL BIOL, V11, P475, DOI 10.1038/nsmb751; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Harris BZ, 2001, J CELL SCI, V114, P3219; Havranek JJ, 2003, NAT STRUCT BIOL, V10, P45, DOI 10.1038/nsb877; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kortemme T, 2004, NAT STRUCT MOL BIOL, V11, P371, DOI 10.1038/nsmb749; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Li YH, 2004, EMBO J, V23, P2723, DOI 10.1038/sj.emboj.7600294; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Ralston KJ, 2004, J BIOL CHEM, V279, P33816, DOI 10.1074/jbc.M401040200; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Rongo C, 2001, CYTOKINE GROWTH F R, V12, P349, DOI 10.1016/S1359-6101(01)00011-9; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Zarrinpar A, 2003, NATURE, V426, P676, DOI 10.1038/nature02178	46	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38528	38536		10.1074/jbc.M506536200	http://dx.doi.org/10.1074/jbc.M506536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16147993	hybrid			2022-12-25	WOS:000233239800051
J	Yamada, RX; Matsuki, N; Ikegaya, Y				Yamada, RX; Matsuki, N; Ikegaya, Y			cAMP differentially regulates axonal and dendritic development of dentate granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOSSY FIBER DEVELOPMENT; LONG-TERM POTENTIATION; ADENYLYL-CYCLASE; SEMAPHORIN 3A; GROWTH CONES; GLUTAMATE RECEPTORS; ADULT HIPPOCAMPUS; PERFORANT PATH; IN-VITRO	Neurite polarity is a morphological characteristic of dentate gyrus granule cells, which extend axons to the hilar region and dendrites in the opposite direction, i.e. to the molecular layer. This remarkable polarity must require a differential system for axon and dendrite guidance. Here, we report that the axon and dendrites of a granule cell are differentially responsive to cAMP. In developing cultures of dispersed granule cells, dendritic growth cones were increased in number after pharmacological activation of cAMP signaling and decreased after blockade of cAMP signaling. Activation of cAMP signaling antagonized dendritic collapse induced by the potent repellents Sema3F and glutamate. In contrast to dendrites, axons were protected from Sema3F-induced collapse when cAMP signaling was inhibited. Axonal and dendritic growth cones both expressed type 1 adenylyl cyclase, but only axons showed a cAMP increase in response to Sema3F, and the elevated cAMP was sufficient to collapse axonal growth cones. Thus, the axons and dendrites of dentate granule cells differ in the regulation of cAMP levels as well as responsiveness to cAMP. cAMP may be crucial for shaping the information flow polarity in the dentate gyrus circuit.	Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Ikegaya, Y (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ikegaya@mol.f.u-tokyo.ac.jp		Ikegaya, Yuji/0000-0003-2260-8191				ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Baba A, 2003, J NEUROSCI, V23, P7737; Baba A, 2002, J NEUROCYTOL, V31, P41, DOI 10.1023/A:1022519632041; Bagri A, 2003, CELL, V113, P285, DOI 10.1016/S0092-8674(03)00267-8; Barnes G, 2003, HIPPOCAMPUS, V13, P1, DOI 10.1002/hipo.10041; BEKENSTEIN JW, 1990, BRAIN RES, V514, P334, DOI 10.1016/0006-8993(90)91429-K; Butler CD, 2004, J NEUROSCI, V24, P462, DOI 10.1523/JNEUROSCI.3040-03.2004; Campbell DS, 2001, J NEUROSCI, V21, P8538, DOI 10.1523/JNEUROSCI.21-21-08538.2001; Chang S, 2001, NAT NEUROSCI, V4, P787, DOI 10.1038/90489; Chedotal A, 1998, DEVELOPMENT, V125, P4313; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; CLAIBORNE BJ, 1990, J COMP NEUROL, V302, P206, DOI 10.1002/cne.903020203; CONNERKERR TA, 1993, J NEUROCHEM, V61, P627; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; DESMOND NL, 1982, J COMP NEUROL, V212, P131, DOI 10.1002/cne.902120204; Dontchev VD, 2002, J NEUROSCI, V22, P6659; Fabbri E, 1991, J Enzyme Inhib, V5, P87, DOI 10.3109/14756369109069062; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Fujioka T, 2004, J NEUROSCI, V24, P319, DOI 10.1523/JNEUROSCI.1065.03.2004; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Grimpe B, 2002, J NEUROSCI, V22, P3144, DOI 10.1523/JNEUROSCI.22-08-03144.2002; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; HEI YJ, 1991, MOL PHARMACOL, V39, P233; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Huang YY, 2000, J NEUROSCI, V20, P6317, DOI 10.1523/JNEUROSCI.20-17-06317.2000; JONES RSG, 1994, HIPPOCAMPUS, V4, P335, DOI 10.1002/hipo.450040317; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kim JA, 2004, CEREB CORTEX, V14, P1358, DOI 10.1093/cercor/bhh096; Koyama R, 2004, CURR NEUROVASC RES, V1, P3, DOI 10.2174/1567202043480242; Koyama R, 2004, DEV BIOL, V267, P29, DOI 10.1016/j.ydbio.2003.11.008; Koyama R, 2002, J PHYSIOL-LONDON, V539, P157, DOI 10.1113/jphysiol.2001.013505; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; Lamoureux P, 2002, J CELL BIOL, V159, P499, DOI 10.1083/jcb.200207174; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; METZGER H, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1248; Mizuhashi S, 2001, J NEUROSCI, V21, P6181, DOI 10.1523/JNEUROSCI.21-16-06181.2001; Mons N, 2003, NEUROBIOL LEARN MEM, V79, P226, DOI 10.1016/S1074-7427(03)00005-4; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Polleux F, 1998, SCIENCE, V282, P1904, DOI 10.1126/science.282.5395.1904; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Sahay A, 2003, J NEUROSCI, V23, P6671; SANDLER R, 1991, J COMP NEUROL, V303, P177, DOI 10.1002/cne.903030202; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Schaefer ML, 2000, J NEUROSCI, V20, P4809; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Storm-Mathisen J, 1981, Adv Biochem Psychopharmacol, V27, P43; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tashiro A, 2003, NEURON, V38, P773, DOI 10.1016/S0896-6273(03)00299-X; Terman JR, 2004, SCIENCE, V303, P1204, DOI 10.1126/science.1092121; TERRIAN DM, 1990, NEUROCHEM RES, V15, P1, DOI 10.1007/BF00969176; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trousse F, 2001, DEVELOPMENT, V128, P3927; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Villacres EC, 1998, J NEUROSCI, V18, P3186; Wong WT, 2000, CURR OPIN NEUROBIOL, V10, P118, DOI 10.1016/S0959-4388(99)00059-8; Yamaguchi N, 2004, FEBS LETT, V566, P71, DOI 10.1016/j.febslet.2004.04.009; Zheng JQ, 1996, J NEUROSCI, V16, P1140	66	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38020	38028		10.1074/jbc.M503800200	http://dx.doi.org/10.1074/jbc.M503800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155295	hybrid			2022-12-25	WOS:000233044500085
J	Orth, JHC; Lang, S; Taniguchi, M; Aktories, K				Orth, JHC; Lang, S; Taniguchi, M; Aktories, K			Pasteurella multocida toxin-induced activation of RhoA is mediated via two families of G alpha proteins, G alpha(q) and G alpha(12/13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; HETEROTRIMERIC G-PROTEINS; SERUM RESPONSE FACTOR; C-TERMINAL FRAGMENT; TYROSINE PHOSPHORYLATION; P115 RHOGEF; RECEPTOR; INVOLVEMENT; CELLS; PATHWAYS	Pasteurella multocida toxin (PMT) is a potent mitogen, which is known to activate phospholipase C beta by stimulating the alpha-subunit of the heterotrimeric G protein G(q). PMT also activates RhoA and RhoA-dependent pathways. Using YM-254890, a specific inhibitor of G(q/11), we studied whether activation of RhoA involves G proteins other than G(q/11). YM-254890 inhibited PMT or muscarinic M3-receptor-mediated stimulation of phospholipase C beta at similar concentrations in HEK293m3 cells. In these cells, PMT-induced RhoA activation and enhancement of RhoA-dependent luciferase activity were partially inhibited by YM-254890. In G alpha(q/11)-deficient fibroblasts, PMT induced activation of RhoA, increase in RhoA-dependent luciferase activity, and increase in ERK phosphorylation. None of these effects were influenced by YM-254890. However, RhoA activation by PMT was inhibited by RGS2, RGS16, lscRGS, and dominant negative G(13)(GA), indicating involvement of G alpha(12/13) in the PMT effect on RhoA. In G alpha(12/13) gene-deficient cells, PMT-induced stimulation of RhoA, luciferase activity, and ERK phosphorylation were blocked by YM-254890, indicating the involvement of G(q). Infection with a virus harboring the gene of G alpha(13) reconstituted the increase in RhoA-dependent luciferase activity by PMT even in the presence of YM-254890. The data show that YM-254890 is able to block PMT activation of G alpha(q) and indicate that, in addition to G alpha(q), the G alpha(12/13) G proteins are targets of PMT.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Astellas Pharma Inc, Inst Drug Discovery Res, Tsakuba, Ibaraki 3088585, Japan	University of Freiburg; Astellas Pharmaceuticals	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628-3634.2001; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Dudet LI, 1996, J CELL PHYSIOL, V168, P173; Essler M, 1998, J IMMUNOL, V161, P5640; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Ingi T, 1998, J NEUROSCI, V18, P7178; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; Lax AJ, 2004, INT J MED MICROBIOL, V293, P505, DOI 10.1078/1438-4221-00287; LEE E, 1992, J BIOL CHEM, V267, P1212; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Orth JHC, 2004, J BIOL CHEM, V279, P34150, DOI 10.1074/jbc.M405353200; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Sleight S, 2002, BIOCHEM BIOPH RES CO, V295, P561, DOI 10.1016/S0006-291X(02)00701-5; STADDON JM, 1991, J BIOL CHEM, V266, P4840; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Wilson BA, 2005, REV PHYSIOL BIOCH P, V152, P93, DOI 10.1007/s10254-004-0032-6; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	45	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36701	36707		10.1074/jbc.M507203200	http://dx.doi.org/10.1074/jbc.M507203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141214	hybrid			2022-12-25	WOS:000232901800022
J	Zhang, Z; Wang, H; Li, M; Rayburn, ER; Agrawal, S; Zhang, RW				Zhang, Z; Wang, H; Li, M; Rayburn, ER; Agrawal, S; Zhang, RW			Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway	ONCOGENE			English	Article						MDM2; E2F1; ubiquitination; protein-protein interaction	IN-VIVO ACTIVITIES; ANTISENSE ANTI-MDM2 OLIGONUCLEOTIDES; MIXED-BACKBONE OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR E2F-1; HUMAN CANCER; PROSTATE-CANCER; BREAST-CANCER; CELL-GROWTH; P53; EXPRESSION	Although previous studies suggested that the tumorigenicity of mouse double minute 2 (MDM2) was due to its negative regulation of p53, the p53-independent interactions may be equally as important. During recent studies utilizing MDM2 inhibitors, we noted that E2F transcription factor 1 (E2F1) was downregulated upon inhibition of MDM2, regardless of the p53 status of the cancer. The present study investigated the mechanisms responsible for the MDM2-mediated increase in E2F1 expression. MDM2 prolongs the half-life of the E2F1 protein by inhibiting its ubiquitination. MDM2 displaces SCFSKP2, the E2F1 E3 ligase. Direct binding between MDM2 and E2F1 is necessary for the negative effects of MDM2 on E2F1 ubiquitination, and deletion of the MDM2 nuclear localization signal does not result in loss of the ability to increase the E2F1 protein level. The downregulation of E2F1 upon MDM2 inhibition was not due to either pRB or p14(Arf). In addition, E2F1 was responsible for at least part of the inhibition of cell proliferation induced by MDM2 knockdown. In conclusion, the present study provides evidence that stabilization of the E2F1 protein is likely another p53-independent component of MDM2-mediated tumorigenesis. More knowledge about the MDM2-E2F1 interaction may be helpful in developing novel anticancer therapies.	Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Div Clin Pharmacol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Hybridon Inc, Cambridge, MA 02139 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhang, RW (corresponding author), Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Pharmacol & Toxicol, VH 113,1670 Univ Blvd, Birmingham, AL 35294 USA.	ruiwen.zhang@ccc.uab.edu		Agrawal, Sudhir/0000-0003-4275-2510	NCI NIH HHS [CA 112029, CA80698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arakawa Y, 2004, BIOCHEM BIOPH RES CO, V322, P297, DOI 10.1016/j.bbrc.2004.04.208; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Bartel F, 2004, MOL CANCER RES, V2, P29; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; Deb SP, 2003, MOL CANCER RES, V1, P1009; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Imai MA, 2004, J CANCER RES CLIN, V130, P320, DOI 10.1007/s00432-003-0538-3; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liang HL, 2004, GENE, V338, P217, DOI 10.1016/j.gene.2004.05.015; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin WC, 2001, GENE DEV, V15, P1833; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Meek DW, 2003, MOL CANCER RES, V1, P1017; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Onda M, 2004, J HUM GENET, V49, P312, DOI 10.1007/s10038-004-0146-3; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Stanelle J, 2005, CELL DEATH DIFFER, V12, P347, DOI 10.1038/sj.cdd.4401532; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Wang H, 2003, ANN NY ACAD SCI, V1002, P217, DOI 10.1196/annals.1281.025; Wang H, 1999, INT J ONCOL, V15, P653; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; Wang H, 2001, CLIN CANCER RES, V7, P3613; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Yamazaki K, 2003, PATHOL RES PRACT, V199, P23, DOI 10.1078/0344-0338-00348; Zhang RW, 2005, CURR CANCER DRUG TAR, V5, P43, DOI 10.2174/1568009053332663; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhang Z, 2004, CLIN CANCER RES, V10, P1263, DOI 10.1158/1078-0432.CCR-0245-03; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618	58	101	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7238	7247		10.1038/sj.onc.1208814	http://dx.doi.org/10.1038/sj.onc.1208814			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170383				2022-12-25	WOS:000232990100012
J	Lora, JM; Zhang, DM; Liao, SM; Burwell, T; King, AM; Barker, PA; Singh, L; Keaveney, M; Morgenstern, J; Gutierrez-Ramos, JC; Coyle, AJ; Fraser, CC				Lora, JM; Zhang, DM; Liao, SM; Burwell, T; King, AM; Barker, PA; Singh, L; Keaveney, M; Morgenstern, J; Gutierrez-Ramos, JC; Coyle, AJ; Fraser, CC			Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an I kappa B kinase beta-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUC5AC MUCIN TRANSCRIPTION; GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; ACTIVATION; PATHWAY; INFLAMMATION; POLYMORPHISM; SYSTEM; CELLS; TNF	Excessive mucus production by airway epithelium is a major characteristic of a number of respiratory diseases, including asthma, chronic bronchitis, and cystic fibrosis. However, the signal transduction pathways leading to mucus production are poorly understood. Here we examined the potential role of I kappa B kinase beta (IKK beta) in mucus synthesis in vitro and in vivo. Tumor necrosis factor-alpha ( TNF-alpha) or transforming growth factor-alpha stimulation of human epithelial cells resulted in mucus secretion as measured by MUC5AC mRNA and protein. TNF-alpha stimulation induced IKK beta-dependent p65 nuclear translocation, mucus synthesis, and production of cytokines from epithelial cells. TNF-alpha, but not transforming growth factor-alpha, induced mucus production dependent on IKK beta-mediated NF-kappa B activation. In vivo, TNF-alpha induced NF-kappa B as determined by whole mouse body bioluminescence. This activation was localized to the epithelium as revealed by LacZ staining in NF-kappa B-LacZ transgenic mice. TNF-alpha-induced mucus production in vivo could also be inhibited by administration into the epithelium of an IKK beta dominant negative adenovirus. Taken together, our results demonstrated the important role of IKK beta in TNF-alpha-mediated mucus production in airway epithelium in vitro and in vivo.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; McGill University	Fraser, CC (corresponding author), Millennium Pharmaceut Inc, 35 Landsdowne St, Cambridge, MA 02139 USA.	chris.fraser@mpi.com						Adler KB, 2001, AM J RESP CELL MOL, V25, P397, DOI 10.1165/ajrcmb.25.4.f214; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253, DOI 10.1165/ajrcmb.22.3.3768; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bhakar AL, 2002, J NEUROSCI, V22, P8466; Brouillard F, 2001, J BIOL CHEM, V276, P9486, DOI 10.1074/jbc.M006636200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Chung KF, 2001, EUR RESPIR J, V18, p50S, DOI 10.1183/09031936.01.00229701; Churg A, 2002, AM J RESP CRIT CARE, V166, P849, DOI 10.1164/rccm.200202-097OC; DAIZONG L, 1998, J BIOL CHEM, V273, P6812; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Desmet C, 2004, J IMMUNOL, V173, P5766, DOI 10.4049/jimmunol.173.9.5766; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Donovan CE, 1999, J IMMUNOL, V163, P6827; Escande F, 2001, BIOCHEM J, V358, P763, DOI 10.1042/0264-6021:3580763; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; Jackson AD, 2001, TRENDS PHARMACOL SCI, V22, P39, DOI 10.1016/S0165-6147(00)01600-X; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Kaycan MKC, 2002, RESP RES, V3; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Nadel JA, 2001, RESP RES, V2, P85, DOI 10.1186/rr43; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Poynter ME, 2004, J IMMUNOL, V173, P7003, DOI 10.4049/jimmunol.173.11.7003; Poynter ME, 2002, AM J PATHOL, V160, P1325, DOI 10.1016/S0002-9440(10)62559-X; ROSE MC, 1997, AIRWAY MUCUS BASIC M, P41; Sakao S, 2001, AM J RESP CRIT CARE, V163, P420, DOI 10.1164/ajrccm.163.2.2006031; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Smirnova MG, 2000, CYTOKINE, V12, P1732, DOI 10.1006/cyto.2000.0763; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; THORNTON DJ, 1997, AIRWAY MUCUS BASIC M, P19; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wu WD, 2002, AM J PHYSIOL-LUNG C, V282, pL1040, DOI 10.1152/ajplung.00390.2001	41	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36510	36517		10.1074/jbc.M507977200	http://dx.doi.org/10.1074/jbc.M507977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123045	hybrid			2022-12-25	WOS:000232726900085
J	Metzner, L; Kottra, G; Neubert, K; Daniel, H; Brandsch, M				Metzner, L; Kottra, G; Neubert, K; Daniel, H; Brandsch, M			Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1	FASEB JOURNAL			English	Article						membrane transport; proton gradient; nontransported inhibitors; Xenopus laevis oocytes; Caco-2 cells	CACO-2 CELL MONOLAYERS; LINE CACO-2; ABSORPTION; IDENTIFICATION; IMINO; PEPT1; HPAT1	The proton-coupled amino acid transporter PAT1, cloned recently from brain and intestine, mediates the uphill transport of L- and D-proline, L-alanine, glycine, taurine, D-serine, GABA, and many other related compounds and drugs. Here we describe the novel finding that L-tryptophan and its derivatives tryptamine, 5-hydroxy-L-tryptophan, serotonin, and indole-3-propionic acid strongly inhibit H+-dependent L-[H-3] proline uptake into Caco-2 cells with inhibition constants (K-i) of 0.9 to 6.1 mM. Uptake of L-[H-3] tryptophan into Caco-2 cells on the other hand was not inhibited by L-proline. Whereas PAT1 substrates produced significant changes in a membrane potential assay for electrogenic transport in Caco-2 cells, L-tryptophan, tryptamine, and 5-hydroxy-L-tryptophan failed to alter membrane voltage. When PAT1 was expressed in Xenopus laevis oocytes and analyzed by the two-electrode voltage clamp technique, glycine elicited high inward currents that were dependent on membrane potential but no currents were observed with L-tryptophan, tryptamine, 5-hydroxy-L-tryptophan, or serotonin. Although not transported electrogenically by PAT1, L-tryptophan and its derivatives inhibited glycine-evoked currents dose-dependently. We conclude that serotonin, L-tryptophan, and tryptamine bind to PAT1 with potencies similar to the prototype substrates, inhibit transport function but are not transported by this carrier protein. They may be considered as the carriers' naturally occurring inhibitors that may alter the transport function of PAT1.	Univ Halle Wittenberg, Biozentrum, Membrane Transport Grp, D-06120 Halle Saale, Germany; Tech Univ Munich, Ctr Life & Food Sci, Mol Nutr Unit, D-8050 Freising Weihenstephan, Germany; Univ Halle Wittenberg, Dept Biochem Biotechnol, Inst Biochem, Halle Saale, Germany	Martin Luther University Halle Wittenberg; Technical University of Munich; Martin Luther University Halle Wittenberg	Brandsch, M (corresponding author), Univ Halle Wittenberg, Biozentrum, Membrane Transport Grp, Weinbergweg 22, D-06120 Halle Saale, Germany.	brandsch@biozentrum.uni-halle.de	Daniel, Hannelore/B-8982-2009					Anderson CMH, 2004, GASTROENTEROLOGY, V127, P1410, DOI 10.1053/j.gastro.2004.08.017; Birdsall T C, 1998, Altern Med Rev, V3, P271; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Boll M, 2003, MOL MEMBR BIOL, V20, P261, DOI 10.1080/0968768031000100759; Boll M, 2003, GENOMICS, V82, P47, DOI 10.1016/S0888-7543(03)00099-5; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; Brandsch M, 1998, J BIOL CHEM, V273, P3861, DOI 10.1074/jbc.273.7.3861; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Faria TN, 2004, MOL PHARMACEUT, V1, P67, DOI 10.1021/mp034001k; Foltz M, 2004, FASEB J, V18, P1758, DOI 10.1096/fj.03-1387fje; Knutter I, 2001, BIOCHEMISTRY-US, V40, P4454, DOI 10.1021/bi0026371; Metzner L, 2004, J PHARMACOL EXP THER, V309, P28, DOI 10.1124/jpet.103.059014; RANALDI G, 1994, ANTIMICROB AGENTS CH, V38, P1239, DOI 10.1128/AAC.38.6.1239; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Takanaga H, 2005, J BIOL CHEM, V280, P8974, DOI 10.1074/jbc.M413027200; Theis S, 2002, J BIOL CHEM, V277, P7287, DOI 10.1074/jbc.M105028200; THWAITES DT, 1993, J BIOL CHEM, V268, P18438; THWAITES DT, 1993, FEBS LETT, V333, P78, DOI 10.1016/0014-5793(93)80378-8; Thwaites DT, 2000, BRIT J PHARMACOL, V129, P457, DOI 10.1038/sj.bjp.0703069; THWAITES DT, 1995, J MEMBRANE BIOL, V145, P245	20	49	52	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1468	1473		10.1096/fj.05-3683com	http://dx.doi.org/10.1096/fj.05-3683com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126914				2022-12-25	WOS:000232315700040
J	Niesen, MI; Osborne, AR; Yang, H; Rastogi, S; Chellappan, S; Cheng, JQ; Boss, JM; Blanck, G				Niesen, MI; Osborne, AR; Yang, H; Rastogi, S; Chellappan, S; Cheng, JQ; Boss, JM; Blanck, G			Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARE LYMPHOCYTE SYNDROME; CLASS-II DEFICIENCY; REGULATORY FACTOR-X; HLA-DRA PROMOTER; NF-Y; HISTONE DEACETYLASE; CHROMATIN-STRUCTURE; CARCINOMA CELLS; CLASS-SWITCH; LYSINE 9	The roles of eukaryotic DNA methylation in the repression of mRNA transcription and in the formation of heterochromatin have been extensively elucidated over the past several years. However, the role of DNA methylation in transcriptional activation remains a mystery. In particular, it is not known whether the transcriptional activation of methylated DNA is promoter-specific, depends directly on sequence-specific DNA-binding proteins, or is facilitated by the methylation. Here we report that the sequence-specific DNA-binding protein, RFX, previously shown to mediate the transition from an inactive to an active chromatin structure, activates a methylated promoter. RFX is capable of mediating enhanceosome formation on a methylated promoter, thereby mediating a transition from amethylation-dependent repression of the promoter to a methylation-dependent activation of the promoter. These results indicate novel roles for DNA methylation and sequence-specific DNA-binding proteins in transcriptional activation.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Emory University	Blanck, G (corresponding author), 12901 Bruce B Downs,MDC 7, Tampa, FL 33612 USA.	gblanck@hsc.usf.edu	Niesen, Melissa I/J-5453-2013; Rastogi, Shipra/L-1209-2015; Blanck, George/A-5365-2012; Rastogi, Shipra/F-5109-2012	Niesen, Melissa I/0000-0001-8020-0958; Rastogi, Shipra/0000-0003-3296-4405; 	NCI NIH HHS [R01 CA63136, R01 CA81497, R01 CA089242] Funding Source: Medline; NIAID NIH HHS [R01 AI34000] Funding Source: Medline; NIGMS NIH HHS [R01 GM47310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063136, R01CA089242, R01CA081497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; Caretti G, 2000, J MOL BIOL, V302, P539, DOI 10.1006/jmbi.2000.4028; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; De Larco JE, 2003, P NATL ACAD SCI USA, V100, P13988, DOI 10.1073/pnas.2335921100; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; GONCZY P, 1989, MOL CELL BIOL, V9, P296; Horvath GC, 2004, BIOL REPROD, V71, P1551, DOI 10.1095/biolreprod.104.032268; ITOHLINDSTROM Y, 1995, MOL CELL BIOL, V15, P282, DOI 10.1128/MCB.15.1.282; Jabrane-Ferrat N, 2003, INT IMMUNOL, V15, P467, DOI 10.1093/intimm/dxg048; Jabrane-Ferrat N, 2002, MOL CELL BIOL, V22, P5616, DOI 10.1128/MCB.22.15.5616-5625.2002; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lembo F, 2003, MOL CELL BIOL, V23, P1656, DOI 10.1128/MCB.23.5.1656-1665.2003; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lin JH, 1999, J BIOL CHEM, V274, P14706, DOI 10.1074/jbc.274.21.14706; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Lu YM, 1996, J IMMUNOL, V156, P2495; Masternak K, 2002, EMBO J, V21, P1379, DOI 10.1093/emboj/21.6.1379; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Mudhasani R, 2005, MOL IMMUNOL, V42, P673, DOI 10.1016/j.molimm.2004.09.021; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Osborne AR, 2004, J BIOL CHEM, V279, P28911, DOI 10.1074/jbc.M403118200; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Samac S, 1998, BIOL CHEM, V379, P541; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Unoki M, 2003, FEBS LETT, V554, P67, DOI 10.1016/S0014-5793(03)01092-5; Vandaele C, 2001, MECH DEVELOP, V103, P159, DOI 10.1016/S0925-4773(01)00340-9; Vandel L, 2001, EMBO REP, V2, P21, DOI 10.1093/embo-reports/kve002; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Villard J, 2000, MOL CELL BIOL, V20, P3364, DOI 10.1128/MCB.20.10.3364-3376.2000; Wang CL, 2004, J IMMUNOL, V172, P5815, DOI 10.4049/jimmunol.172.10.5815; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635; Zhang HQ, 1999, CELL GROWTH DIFFER, V10, P457; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000	50	29	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38914	38922		10.1074/jbc.M504633200	http://dx.doi.org/10.1074/jbc.M504633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16166088	hybrid			2022-12-25	WOS:000233362200004
J	Bosl, B; Grimminger, V; Walter, S				Bosl, B; Grimminger, V; Walter, S			Substrate binding to the molecular chaperone Hsp104 and its regulation by nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; ATP-BINDING; PROTEIN DISAGGREGATION; ESCHERICHIA-COLI; ACID-RESIDUES; CLPB; MECHANISM; COMMUNICATION; RECOGNITION; HYDROLYSIS	The Hsp104 protein from Saccharomyces cerevisiae is a member of the Hsp100/Clp family of molecular chaperones. It mediates the solubilization of aggregated proteins in an ATP-dependent process assisted by the Hsp70/40 system. Although the principal function of Hsp104 is well established, the mechanistic details of this catalyzed disaggregation are poorly understood. In this work, we have investigated the interaction of Hsp104 with reduced, carboxymethylated alpha-lactalbumin (RCMLa), a permanently unfolded model substrate. Our results demonstrate that the affinity of Hsp104 toward polypeptides is regulated by nucleotides. In the presence of ATP or adenosine-5'-O-(3-thiotriphosphate), the chaperone formed complexes with RCMLa, whereas no binding was observed in the presence of ADP. In particular, the occupation of the N-terminally located nucleotide-binding domain with ATP seems to be crucial for substrate interaction. When ATP binding to this domain was impaired by mutation, Hsp104 lost its ability to interact with RCMLa. Our results also indicate that upon association with a polypeptide, a conformational change occurs within Hsp104 that strongly reduces the dynamics of nucleotide exchange and commits the bound polypeptide to ATP hydrolysis.	Tech Univ Munich, Dept Chem, D-85747 Garching, Germany	Technical University of Munich	Walter, S (corresponding author), Tech Univ Munich, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	stefan.walter@ch.tum.de						Barnett ME, 2005, J BIOL CHEM, V280, P34940, DOI 10.1074/jbc.M505653200; Barnett ME, 2002, BIOCHEMISTRY-US, V41, P11277, DOI 10.1021/bi026161s; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Bolon DN, 2004, MOL CELL, V16, P343, DOI 10.1016/j.molcel.2004.10.001; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Grimminger V, 2004, J BIOL CHEM, V279, P7378, DOI 10.1074/jbc.M312403200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Liu ZH, 2002, J MOL BIOL, V321, P111, DOI 10.1016/S0022-2836(02)00591-0; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Watanabe Y, 2005, J BIOL CHEM, V280, P24562, DOI 10.1074/jbc.M414623200; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	44	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38170	38176		10.1074/jbc.M506149200	http://dx.doi.org/10.1074/jbc.M506149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16135516	hybrid			2022-12-25	WOS:000233239800009
J	McLaughlin, LA; Paine, MJI; Kemp, CA; Marechal, JD; Flanagan, JU; Ward, CJ; Sutcliffe, MJ; Roberts, GCK; Wolf, CR				McLaughlin, LA; Paine, MJI; Kemp, CA; Marechal, JD; Flanagan, JU; Ward, CJ; Sutcliffe, MJ; Roberts, GCK; Wolf, CR			Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER CYTOCHROME-P-450; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; GENETIC ALGORITHM; OXIDATION; REGIOSPECIFICITY; DETERMINANTS; VALIDATION; MICROSOMES; RESOLUTION	We have previously shown that Phe(120), Glu(216), and Asp(301) in the active site of cytochrome P450 2D6 (CYP2D6) play a key role in substrate recognition by this important drug-metabolizing enzyme (Paine, M. J., McLaughlin, L. A., Flanagan, J. U., Kemp, C. A., Sutcliffe, M. J., Roberts, G. C., and Wolf, C. R. (2003) J. Biol. Chem. 278, 4021-4027 and Flanagan, J. U., Marechal, J.-D., Ward, R., Kemp, C. A., McLaughlin, L. A., Sutcliffe, M. J., Roberts, G. C., Paine, M. J., and Wolf, C. R. (2004) Biochem. J. 380, 353-360). We have now examined the effect of mutations of these residues on interactions of the enzyme with the prototypical CYP2D6 inhibitor, quinidine. Abolition of the negative charge at either or both residues 216 and 301 decreased quinidine inhibition of bufuralol 1'-hydroxylation and dextromethorphan O-demethylation by at least 100-fold. The apparent dissociation constants (K-d) for quinidine binding to the wild-type enzyme and the E216D and D301E mutants were 0.25-0.50 mu M. The amide substitution of Glu216 or Asp301 resulted in 30-64-fold increases in the Kd for quinidine. The double mutant E216Q/D301Q showed the largest decrease in quinidine affinity, with a Kd of 65 mu M. Alanine substitution of Phe(120), Phe(481), or Phe(483) had only a minor effect on the inhibition of bufuralol 1'-hydroxylation and dextromethorphan O-demethylation and on binding. In contrast to the wild-type enzyme, a number of the mutants studied were found to be able to metabolize quinidine. E216F produced O-demethylated quinidine, and F120A and E216Q/D301Q produced both O-demethylated quinidine and 3-hydroxyquinidine metabolites. Homology modeling and molecular docking were used to predict the modes of quinidine binding to the wild-type and mutant enzymes; these were able to rationalize the experimental observations.	Univ Dundee, Ninewells Hosp & Med Sch, Canc Res UK Mol Pharmacol Unit, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	University of Dundee; University of Leicester; University of Leicester	Roberts, GCK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Canc Res UK Mol Pharmacol Unit, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	gcr@le.ac.uk; Roland.Wolf@cancer.org.uk	Maréchal, Jean-Didier P/A-8936-2012; Paine, Mark John Ingraham/O-7450-2019	Maréchal, Jean-Didier P/0000-0002-8344-9043; Paine, Mark John Ingraham/0000-0003-2061-7713; Sutcliffe, Mike/0000-0003-0414-1700; Roberts, Gordon/0000-0001-6200-1373				Branch RA, 2000, CLIN PHARMACOL THER, V68, P401, DOI 10.1067/mcp.2000.110561; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; Daly AK, 1996, PHARMACOGENETICS, V6, P193, DOI 10.1097/00008571-199606000-00001; EICHELBAUM M, 1979, EUR J CLIN PHARMACOL, V16, P183, DOI 10.1007/BF00562059; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; ELLIS SW, 1995, J BIOL CHEM, V270, P29055, DOI 10.1074/jbc.270.49.29055; Flanagan JU, 2004, BIOCHEM J, V380, P353, DOI 10.1042/BJ20040062; Guengerich FP, 2003, BIOCHEMISTRY-US, V42, P1245, DOI 10.1021/bi027085w; Guengerich FP, 2002, J BIOL CHEM, V277, P33711, DOI 10.1074/jbc.M205146200; GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; Hayhurst GP, 2001, BIOCHEM J, V355, P373, DOI 10.1042/0264-6021:3550373; Hutzler JM, 2003, CHEM RES TOXICOL, V16, P450, DOI 10.1021/tx025674x; Jones BC, 1997, XENOBIOTICA, V27, P1025, DOI 10.1080/004982597240000; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Keizers PHJ, 2004, BIOCHEM PHARMACOL, V68, P2263, DOI 10.1016/j.bcp.2004.08.013; Kirton SB, 2002, PROTEINS, V49, P216, DOI 10.1002/prot.10192; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; MODI S, 1995, BIOCHEMISTRY-US, V34, P8982, DOI 10.1021/bi00028a006; Nielsen TL, 1999, J PHARMACOL EXP THER, V289, P31; OTTON SV, 1988, DRUG METAB DISPOS, V16, P15; Paine MJI, 2003, J BIOL CHEM, V278, P4021, DOI 10.1074/jbc.M209519200; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHENKMAN JB, 1981, PHARMACOL THERAPEUT, V12, P43, DOI 10.1016/0163-7258(81)90075-9; Smith G, 1998, BIOCHEM J, V331, P783, DOI 10.1042/bj3310783; STROBL GR, 1993, J MED CHEM, V36, P1136, DOI 10.1021/jm00061a004; Venhorst J, 2003, J MED CHEM, V46, P74, DOI 10.1021/jm0209578; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; VONBAHR C, 1985, BIOCHEM PHARMACOL, V34, P2501, DOI 10.1016/0006-2952(85)90533-7; Williams PA, 2000, J INORG BIOCHEM, V81, P183, DOI 10.1016/S0162-0134(00)00102-1	36	64	67	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38617	38624		10.1074/jbc.M505974200	http://dx.doi.org/10.1074/jbc.M505974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16162505	hybrid			2022-12-25	WOS:000233239800062
J	Sirinian, MI; Belleudi, F; Campagna, F; Ceridono, M; Garofalo, T; Quagliarini, F; Verna, R; Calandra, S; Bertolini, S; Sorice, M; Torrisi, MR; Arca, M				Sirinian, MI; Belleudi, F; Campagna, F; Ceridono, M; Garofalo, T; Quagliarini, F; Verna, R; Calandra, S; Bertolini, S; Sorice, M; Torrisi, MR; Arca, M			Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein (LDL) binding and modulates endocytosis of the LDL/LDL receptor complex in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; MOLECULAR-MECHANISMS; CLATHRIN; INTERNALIZATION; MUTATIONS; DUPLEXES; RNAS; RAB4	ARH is a newly discovered adaptor protein required for the efficient activity of low density lipoprotein receptor ( LDLR) in selected tissues. Individuals lacking ARH have severe hypercholesterolemia due to an impaired hepatic clearance of LDL. It has been demonstrated that ARH is required for the efficient internalization of the LDL-LDLR complex and to stabilize the association of the receptor with LDL in Epstein-Barr virus-immortalized B lymphocytes. However, little information is available on the role of ARH in liver cells. Here we provide evidence that ARH is codistributed with LDLR on the basolateral area in confluent HepG2-polarized cells. This distribution is not modified by the overexpression of LDLR. Conversely, the activation of the LDLR-mediated endocytosis, but not the binding of LDL to LDLR, promotes a significant colocalization of ARH with LDL-LDLR complex that peaked at 2 min at 37 degrees C. To further assess the role of ARH in LDL-LDLR complex internalization, we depleted ARH protein using the RNA interference technique. Twenty-four hours after transfection with ARH-specific RNA interference, ARH protein was depleted in HepG2 cells by more than 70%. Quantitative immunofluorescence analysis revealed that the depletion of ARH caused about 80% reduction in LDL internalization. Moreover, our findings indicate that ARH is associated with other proteins of the endocytic machinery. We suggest that ARH is an endocytic sorting adaptor that actively participates in the internalization of the LDL-LDLR complex, possibly enhancing the efficiency of its packaging into the endocytic vesicles.	Univ Roma La Sapienza, Dept Clin & Appl Med Therapy, Policlin Umberto I, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ Roma La Sapienza, Azienda Osped SantAndrea, I-00161 Rome, Italy; Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy; Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; Sapienza University Rome; Universita di Modena e Reggio Emilia; University of Genoa	Arca, M (corresponding author), Univ Roma La Sapienza, Dept Clin & Appl Med Therapy, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.	marcelloarca@libero.it	ARCA, Marcello/AAC-3883-2022; Sorice, Maurizio/Q-5079-2019; Sousa, Maria/HCI-9642-2022; /V-4899-2019	ARCA, Marcello/0000-0003-3786-0883; Garofalo, Tina/0000-0003-0645-2510; Quagliarini, Fabiana/0000-0002-1384-4857; VERNA, Roberto/0000-0002-1869-3912; Sorice, Maurizio/0000-0003-3534-1502	Telethon [GGP02149] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Arca M, 2002, LANCET, V359, P841, DOI 10.1016/S0140-6736(02)07955-2; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; Carbone R, 1997, CANCER RES, V57, P5498; CARPENTIER JL, 1979, EXP CELL RES, V121, P135, DOI 10.1016/0014-4827(79)90453-1; Cohen JC, 2003, CURR OPIN LIPIDOL, V14, P121, DOI 10.1097/00041433-200304000-00002; Deneka M, 2003, EMBO J, V22, P2645, DOI 10.1093/emboj/cdg257; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fouraux MA, 2004, MOL BIOL CELL, V15, P611, DOI 10.1091/mbc.E03-05-0343; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; Harada-Shiba M, 2004, CIRC RES, V95, P945, DOI 10.1161/01.RES.0000146946.78540.46; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Heinonen JE, 2002, FEBS LETT, V527, P274, DOI 10.1016/S0014-5793(02)03206-4; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Lian WN, 1999, HEPATOLOGY, V30, P748, DOI 10.1002/hep.510300302; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Van Dam AM, 2000, NEUROSCI LETT, V285, P169, DOI 10.1016/S0304-3940(00)01031-4; vanIjzendoorn SCD, 1997, J CELL BIOL, V137, P347, DOI 10.1083/jcb.137.2.347; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802	32	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38416	38423		10.1074/jbc.M504343200	http://dx.doi.org/10.1074/jbc.M504343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16129683	hybrid			2022-12-25	WOS:000233239800038
J	Darie, CC; Biniossek, ML; Gawinowicz, MA; Milgrom, Y; Thumfart, JO; Jovine, L; Litscher, ES; Wassarman, PM				Darie, CC; Biniossek, ML; Gawinowicz, MA; Milgrom, Y; Thumfart, JO; Jovine, L; Litscher, ES; Wassarman, PM			Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONA-PELLUCIDA GLYCOPROTEINS; FURIN CLEAVAGE-SITE; BASS DICENTRARCHUS-LABRAX; GILTHEAD SEA BREAM; ONCORHYNCHUS-MYKISS; STRUCTURAL-ANALYSIS; ORYZIAS-LATIPES; PRECURSOR PROTEINS; MOLECULAR-CLONING; DOMAIN PROTEINS	The rainbow trout egg vitelline envelope (VE) is constructed of three proteins, called VE alpha, VE beta, and VE gamma, that are synthesized and secreted by the liver and transported in the bloodstream to the ovary, the site of VE assembly around eggs. All three proteins possess an N-terminal signal peptide, a zona pellucida domain, a consensus furin-like cleavage site (CFLCS) close to the C terminus, and a short propeptide downstream of the CFLCS. Proteolytic processing at the CFLCS results in loss of the short C-terminal propeptide from precursor proteins and enables incorporation of mature proteins into the VE. Here mass spectrometry (matrix-assisted laser desorption ionization time-of-flight-mass spectrometry and liquid chromatography-mass spectrometry with amicromass-quadrupole TOF hybrid mass and a QSTAR Pulsar i mass spectrometer) was employed with VE proteins isolated from rainbow trout eggs in a peptidomics-based approach to determine the following: 1) the C-terminal amino acid of mature, proteolytically processed VE proteins; 2) the cellular site of proteolytic processing at the CFLCS of VE precursor proteins; and 3) the relationship between proteolytic processing and limited covalent cross-linking of VE proteins. Peptides derived from the C-terminal region were found for all three VE proteins isolated from eggs, indicating that processing at the CFLCS occurs after the arrival of VE precursor proteins at the egg. Consistent with this conclusion, peptides containing an intact CFLCS were also found for all three VE proteins isolated from eggs. Furthermore, peptides derived from the C-terminal propeptides of VE protein heterodimers VE alpha- VE gamma and VE beta-VE gamma were found, suggesting that a small amount of VE protein can be covalently cross-linked on eggs prior to proteolytic processing at the CFLCS. Collectively, these results provide important evidence about the process of VE formation in rainbow trout and other non-cyprinoid fish and allow comparisons to be made with the process of zona pellucida formation in mammals.	Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA; Univ Freiburg, Inst Mol Med & Zellforsch Physiol 2, D-79104 Freiburg, Germany; Columbia Univ Coll Phys & Surg, Prot Core Facil, New York, NY 10032 USA	Icahn School of Medicine at Mount Sinai; University of Freiburg; Columbia University	Wassarman, PM (corresponding author), Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	paul.wassarman@mssm.edu	Jovine, Luca/J-3563-2019; Darie, Costel/F-1274-2011; Thumfart, Joerg O/F-9741-2013; Jovine, Luca/E-8170-2010	Jovine, Luca/0000-0002-2679-6946; Thumfart, Joerg O/0000-0001-7647-9888; Jovine, Luca/0000-0002-2679-6946; Darie, Costel C./0000-0001-6402-2311	NICHD NIH HHS [HD-35105] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035105] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; BLEIL JD, 1980, P NATL ACAD SCI-BIOL, V77, P1029, DOI 10.1073/pnas.77.2.1029; Boja ES, 2003, J BIOL CHEM, V278, P34189, DOI 10.1074/jbc.M304026200; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BRIVIO MF, 1991, MOL REPROD DEV, V28, P85, DOI 10.1002/mrd.1080280114; CARR MD, 1994, P NATL ACAD SCI USA, V91, P2206, DOI 10.1073/pnas.91.6.2206; Chang YS, 1997, MOL REPROD DEV, V46, P258, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;258::AID-MRD4&gt;3.0.CO;2-O; Chang YS, 1996, MOL REPROD DEV, V44, P295, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;295::AID-MRD3&gt;3.0.CO;2-H; CRIMMINS DL, 1995, ANAL BIOCHEM, V226, P355, DOI 10.1006/abio.1995.1236; Darie CC, 2004, BIOCHEMISTRY-US, V43, P7459, DOI 10.1021/bi0495937; DelGiacco L, 1998, MOL REPROD DEV, V49, P58, DOI 10.1002/(SICI)1098-2795(199801)49:1&lt;58::AID-MRD7&gt;3.0.CO;2-N; Dumont J N, 1985, Dev Biol (N Y 1985), V1, P235; Fujita T, 2002, COMP BIOCHEM PHYS B, V132, P599, DOI 10.1016/S1096-4959(02)00075-1; Fukuoka SI, 2001, BIOCHEM BIOPH RES CO, V289, P1044, DOI 10.1006/bbrc.2001.6112; HAMAZAKI TS, 1989, DEV BIOL, V133, P101, DOI 10.1016/0012-1606(89)90301-1; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HYLLNER SJ, 1991, J ENDOCRINOL, V131, P229, DOI 10.1677/joe.0.1310229; HYLLNER SJ, 1992, J ENDOCRINOL, V135, P303, DOI 10.1677/joe.0.1350303; HYLLNER SJ, 1995, MOL REPROD DEV, V41, P339, DOI 10.1002/mrd.1080410309; Hyllner SJ, 2001, BIOL REPROD, V64, P805, DOI 10.1095/biolreprod64.3.805; HYLLNER SJ, 1991, VITELLINE ENVELOPE P; Jovine L, 2005, ANNU REV BIOCHEM, V74, P83, DOI 10.1146/annurev.biochem.74.082803.133039; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; Jovine L, 2004, P NATL ACAD SCI USA, V101, P5922, DOI 10.1073/pnas.0401600101; Jovine L., 2002, Gene expression at the beginning of animal development, P31; Kiefer SM, 2002, BIOL REPROD, V66, P407, DOI 10.1095/biolreprod66.2.407; Kubo H, 1997, DEV GROWTH DIFFER, V39, P405; Kubo H, 1999, DEV GENET, V25, P123, DOI 10.1002/(SICI)1520-6408(1999)25:2<123::AID-DVG6>3.3.CO;2-V; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Kuster B, 1998, CURR OPIN STRUC BIOL, V8, P393, DOI 10.1016/S0959-440X(98)80075-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Litscher ES, 1999, BIOCHEMISTRY-US, V38, P12280, DOI 10.1021/bi991154y; LYONS CE, 1993, J BIOL CHEM, V268, P21351; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Mold DE, 2001, MOL REPROD DEV, V58, P4, DOI 10.1002/1098-2795(200101)58:1&lt;4::AID-MRD2&gt;3.0.CO;2-P; MURATA K, 1995, DEV BIOL, V167, P9, DOI 10.1006/dbio.1995.1002; Murata K, 1997, P NATL ACAD SCI USA, V94, P2050, DOI 10.1073/pnas.94.5.2050; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nesvizhskii AI, 2004, DRUG DISCOV TODAY, V9, P173, DOI 10.1016/S1359-6446(03)02978-7; OPPENBERNTSEN DO, 1990, DEV BIOL, V137, P258, DOI 10.1016/0012-1606(90)90252-E; OPPENBERNTSEN DO, 1992, J ENDOCRINOL, V135, P293, DOI 10.1677/joe.0.1350293; Qi HY, 2002, MOL BIOL CELL, V13, P530, DOI 10.1091/mbc.01-09-0440; Sasaki K, 2002, CANCER RES, V62, P4894; Sasanami T, 2003, BIOL REPROD, V68, P1613, DOI 10.1095/biolreprod.102.011841; Sasanami T, 2002, EUR J BIOCHEM, V269, P2223, DOI 10.1046/j.1432-1033.2002.02880.x; Scapigliati G, 1999, BIOL REPROD, V60, P783, DOI 10.1095/biolreprod60.4.783; Schneider WJ, 1996, INT REV CYTOL, V166, P103, DOI 10.1016/S0074-7696(08)62507-3; Shevchenko A, 1996, BIOCHEM SOC T, V24, P893, DOI 10.1042/bst0240893; Siegfried G, 2003, CANCER RES, V63, P1458; Sugiyama H, 1999, J BIOCHEM-TOKYO, V125, P469, DOI 10.1093/oxfordjournals.jbchem.a022310; Sugiyama Hitoshi, 2000, Recent Research Developments in Comparative Biochemistry & Physiology, V1, P139; WALLACE RA, 1985, DEV BIOL, P127; Wang H, 1999, BBA-GENE STRUCT EXPR, V1446, P156, DOI 10.1016/S0167-4781(99)00066-4; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Williams Z, 2001, BIOCHEMISTRY-US, V40, P929, DOI 10.1021/bi002275x; Yang JC, 1997, DEV GROWTH DIFFER, V39, P457; Yonezawa N, 2003, BIOCHEM BIOPH RES CO, V307, P877, DOI 10.1016/S0006-291X(03)01297-X; Zhao M, 2004, BIOCHEMISTRY-US, V43, P12090, DOI 10.1021/bi048958k; Zhao M, 2002, MOL CELL BIOL, V22, P3111, DOI 10.1128/MCB.22.9.3111-3120.2002	62	48	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37585	37598		10.1074/jbc.M506709200	http://dx.doi.org/10.1074/jbc.M506709200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157586	hybrid			2022-12-25	WOS:000233044500035
J	Herrmann, F; Lee, J; Bedford, MT; Fackelmayer, FO				Herrmann, F; Lee, J; Bedford, MT; Fackelmayer, FO			Dynamics of human protein arginine methyltransferase 1 (PRMT1) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; N-METHYLTRANSFERASE; SUBSTRATE-SPECIFICITY; SYMMETRIC DIMETHYLARGININE; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; HISTONE H4; METHYLATION; CELLS; RECEPTOR	Arginine methylation is a posttranslational protein modification catalyzed by a family of protein arginine methyltransferases (PRMT), the predominant member of which is PRMT1. Despite its major role in arginine methylation of nuclear proteins, surprisingly little is known about the subcellular localization and dynamics of PRMT1. We show here that only a fraction of PRMT1 is located in the nucleus, but the protein is predominantly cytoplasmic. Fluorescence recovery after photobleaching experiments reveal that PRMT1 is highly mobile both in the cytoplasm and the nucleus. However, inhibition of methylation leads to a significant nuclear accumulation of PRMT1, concomitant with the appearance of an immobile fraction of the protein in the nucleus, but not the cytoplasm. Both the accumulation and immobility of PRMT1 is reversed when re-methylation is allowed, suggesting a mechanism where PRMT1 is trapped by unmethylated substrates such as core histones and heterogeneous nuclear ribonucleoprotein proteins until it has executed the methylation reaction.	Heinrich Pette Inst, Dept Mol Cell Biol, D-20251 Hamburg, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA	Heinrich Pette Institute; University of Texas System; UTMD Anderson Cancer Center	Fackelmayer, FO (corresponding author), Heinrich Pette Inst, Dept Mol Cell Biol, Martinistr 52, D-20251 Hamburg, Germany.	frank@fackelmayer.de	Bedford, Mark T/E-7856-2011		NIDDK NIH HHS [DK62248] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062248, R01DK062248] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Altschuler L, 1999, J INTERF CYTOK RES, V19, P189, DOI 10.1089/107999099314333; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Berthet C, 2002, GENES CELLS, V7, P29, DOI 10.1046/j.1356-9597.2001.00497.x; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Fackelmayer FO, 2005, J BIOL CHEM, V280, P1720, DOI 10.1074/jbc.C400531200; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Herrmann F, 2004, J BIOL CHEM, V279, P48774, DOI 10.1074/jbc.M407332200; Kimura H, 2005, DNA REPAIR, V4, P939, DOI 10.1016/j.dnarep.2005.04.012; LEE DY, 2004, ENDOCR REV; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; Lim Y, 2005, BBA-GEN SUBJECTS, V1723, P240, DOI 10.1016/j.bbagen.2005.02.015; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pawlak MR, 2002, J CELL BIOCHEM, V87, P394, DOI 10.1002/jcb.10307; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Smith WA, 2004, J BIOL CHEM, V279, P22795, DOI 10.1074/jbc.C300512200; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6	37	87	91	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38005	38010		10.1074/jbc.M502458200	http://dx.doi.org/10.1074/jbc.M502458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16159886	hybrid			2022-12-25	WOS:000233044500083
J	Kimura, Y; Mizusawa, N; Ishii, A; Nakazawa, S; Ono, T				Kimura, Y; Mizusawa, N; Ishii, A; Nakazawa, S; Ono, T			Changes in structural and functional properties of oxygen-evolving complex induced by replacement of D1-glutamate 189 with glutamine in photosystem II - Ligation of glutamate 189 carboxylate to the manganese cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; TYROSINE Y-Z; FTIR DIFFERENCE SPECTROSCOPY; D1 POLYPEPTIDE LIGATE; CRYSTAL-STRUCTURE; MN CLUSTER; REDOX PROPERTIES; WATER-OXIDATION; C-TERMINUS; DONOR SIDE	A carboxylate group of D1-Glu-189 in photosystem II has been proposed to serve as a direct ligand for the manganese cluster. Here we constructed a mutant that eliminates the carboxylate by replacing D1-Glu-189 with Gln in the cyanobacterium Synechocystis sp. PCC 6803, and we examined the resulting effects on the structural and functional properties of the oxygen-evolving complex (OEC) in photosystem II. The E189Q mutant grew photoautotrophically, and isolated photosystem II core particles evolved oxygen at similar to 70% of the rate of control wild-type particles. The E189Q OEC showed typical S-2 state electron spin resonance signals, and the spin center distance between the S-2 state manganese cluster and the Y-D (D2-Tyr- 160), detected by electron-electron double resonance spectroscopy, was not affected by this mutation. However, the redox potential of the E189Q OEC was considerably lower than that of the control OEC, as revealed by the elevated peak temperature of the S2 state thermoluminescence bands. The mutation resulted in specific changes to bands ascribed to the putative carboxylate ligands for the manganese cluster and to a few carbonyl bands in mid-frequency (1800 to 1100 cm(-1)) S-2/S-1 Fourier transform infrared difference spectrum. Notably, the low frequency (650 to 350 cm(-1)) S-2/S-1 Fourier transform infrared difference spectrum was also uniquely changed by this mutation in the frequencies for the manganese cluster core vibrations. These results suggested that the carboxylate group of D1-Glu-189 ligates the manganese ion, which is influenced by the redox change of the oxidizable manganese ion upon the S-1 to S-2 transition.	Inst Phys & Chem Res, RIKEN Photodynam Res Ctr, Lab Photobiol 1, Aoba Ku, Sendai, Miyagi 9800845, Japan	RIKEN	Kimura, Y (corresponding author), Inst Phys & Chem Res, RIKEN Photodynam Res Ctr, Lab Photobiol 1, Aoba Ku, 519-1399 Aoba, Sendai, Miyagi 9800845, Japan.	ykimura@riken.jp; takaaki@riken.jp						Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Chu HA, 2000, BIOCHEMISTRY-US, V39, P14371, DOI 10.1021/bi001751g; Chu HA, 2004, BIOCHEMISTRY-US, V43, P3152, DOI 10.1021/bi035915f; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; Chu HA, 2001, BIOCHEMISTRY-US, V40, P2312, DOI 10.1021/bi0022994; Clausen J, 2001, BBA-BIOENERGETICS, V1506, P224, DOI 10.1016/S0005-2728(01)00217-1; DEACON GB, 1980, COORDIN CHEM REV, V33, P227, DOI 10.1016/S0010-8545(00)80455-5; Debus RJ, 2000, BIOCHEMISTRY-US, V39, P470, DOI 10.1021/bi9917737; Debus RJ, 2000, BIOCHEMISTRY-US, V39, P6275, DOI 10.1021/bi992749w; Debus RJ, 2005, BIOCHEMISTRY-US, V44, P1367, DOI 10.1021/bi047558u; Debus RJ, 2003, BIOCHEMISTRY-US, V42, P10600, DOI 10.1021/bi034859f; Debus RJ, 2001, BIOCHEMISTRY-US, V40, P3690, DOI 10.1021/bi002394c; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Glatzel P, 2004, J AM CHEM SOC, V126, P9946, DOI 10.1021/ja038579z; Hara H, 1996, BBA-BIOENERGETICS, V1276, P140, DOI 10.1016/0005-2728(96)00071-0; Hienerwadel R, 1997, BIOCHEMISTRY-US, V36, P14712, DOI 10.1021/bi971521a; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kimura Y, 2005, PHOTOSYNTH RES, V84, P245, DOI 10.1007/s11120-005-0412-z; Kimura Y, 2005, BIOCHEMISTRY-US, V44, P7613, DOI 10.1021/bi048203d; Kimura Y, 2005, J BIOL CHEM, V280, P2078, DOI 10.1074/jbc.M410627200; Kimura Y, 2003, BIOCHEMISTRY-US, V42, P13170, DOI 10.1021/bi035420q; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Mizusawa N, 2004, BIOCHEMISTRY-US, V43, P14644, DOI 10.1021/bi0486076; Mizusawa N, 2004, J BIOL CHEM, V279, P29622, DOI 10.1074/jbc.M402397200; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1994, BIOCHEM SOC T, V22, P338, DOI 10.1042/bst0220338; Noguchi T, 1999, BIOCHEMISTRY-US, V38, P10187, DOI 10.1021/bi990631+; Noguchi T, 2002, BIOCHEMISTRY-US, V41, P15706, DOI 10.1021/bi020603i; NOGUCHI T, 1995, BBA-BIOENERGETICS, V1232, P59, DOI 10.1016/0005-2728(95)00111-3; Noguchi T, 1997, BIOCHEMISTRY-US, V36, P14705, DOI 10.1021/bi971760y; Strickler MA, 2005, BIOCHEMISTRY-US, V44, P8571, DOI 10.1021/bi050653y; TANG XS, 1994, P NATL ACAD SCI USA, V91, P704, DOI 10.1073/pnas.91.2.704; Tommos C, 1998, ACCOUNTS CHEM RES, V31, P18, DOI 10.1021/ar9600188; Tommos C, 2000, BBA-BIOENERGETICS, V1458, P199, DOI 10.1016/S0005-2728(00)00069-4; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	43	38	39	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37895	37900		10.1074/jbc.M505887200	http://dx.doi.org/10.1074/jbc.M505887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157592	hybrid			2022-12-25	WOS:000233044500070
J	Okumura, K; Ohno, A; Nishida, M; Hayashi, K; Ikeda, K; Inoue, S				Okumura, K; Ohno, A; Nishida, M; Hayashi, K; Ikeda, K; Inoue, S			Mapping the region of the alpha-type phospholipase A(2) inhibitor responsible for its inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; AGKISTRODON-BLOMHOFFII-SINITICUS; HELICAL COILED-COIL; MANNOSE-BINDING PROTEIN; AMINO-ACID-SEQUENCE; TRIMERESURUS-FLAVOVIRIDIS; BLOOD-PLASMA; CARBOHYDRATE-RECOGNITION; CRYSTAL-STRUCTURE; MOLECULAR-CLONING	alpha-Type phospholipase A(2) inhibitory protein (PLI alpha) from the serum of the venomous snake Gloydius brevicaudus, GbPLI alpha, is one of the protective endogenous proteins that neutralizes its own venom phospholipase A(2) (PLA(2)), and it is a homotrimer of subunits having a C-type lectin-like domain. The nonvenomous snake Elaphe quadrivirgata has a homologous serum protein, EqPLI alpha-LP, that does not show any inhibitory activity against various snake venom PLA(2)s (Okumura, K., Inoue, S., Ikeda, K., and Hayashi, K. ( 2003) IUBMB Life 55, 539 - 545). By constructing GbPLI alpha-EqPLI alpha-LP chimeric proteins, we have mapped the residues important in conferring GbPLI alpha inhibitory activity on region 13 - 36 in the primary structure of GbPLI alpha. Noninhibitory EqPLI alpha-LP showed comparable inhibitory activity only when this region was replaced with that of GbPLI alpha. Further, mutational analysis of the candidate residues revealed that the individual GbPLI alpha to EqPLI alpha-LP residue substitutions N26K, K28E, D29N, and Y144S each produced a mutant GbPLI alpha protein with reduced inhibitory activity, with the single N26K substitution having the most significant effect. Residues 13 - 36 were suspected to be located in the helical neck region of the GbPLI alpha trimer. Therefore, the region of GbPLI alpha responsible for PLA(2) inhibition was distinct from the carbohydrate-binding site of the homologous C-type lectin.	Osaka Univ Pharmaceut Sci, Dept Biochem, Osaka 5691094, Japan	Osaka University of Pharmaceutical Sciences	Inoue, S (corresponding author), Osaka Univ Pharmaceut Sci, Dept Biochem, 4-20-1 Nasahara, Osaka 5691094, Japan.	inoue@gly.oups.ac.jp	Inoue, Seiji/E-5128-2010	Inoue, Seiji/0000-0003-0760-1047				Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Chabot S, 2003, J IMMUNOL, V171, P995, DOI 10.4049/jimmunol.171.2.995; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Dunn RD, 2001, BBA-MOL CELL BIOL L, V1533, P29, DOI 10.1016/S1388-1981(01)00138-X; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; Higashino K, 2002, J BIOL CHEM, V277, P13583, DOI 10.1074/jbc.M108752200; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; Inoue S, 1997, BIOCHEM MOL BIOL INT, V41, P529; INOUE S, 1991, J BIOL CHEM, V266, P1001; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Kini RM, 2003, TOXICON, V42, P827, DOI 10.1016/j.toxicon.2003.11.002; KOGAKI H, 1989, J BIOCHEM-TOKYO, V106, P966, DOI 10.1093/oxfordjournals.jbchem.a122983; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Lizano S, 1997, BIOCHEM J, V326, P853, DOI 10.1042/bj3260853; Lizano S, 2000, BIOCHEM J, V346, P631, DOI 10.1042/0264-6021:3460631; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; Nobuhisa I, 1998, FEBS LETT, V429, P385, DOI 10.1016/S0014-5793(98)00602-4; OHKURA N, 1993, J BIOCHEM-TOKYO, V113, P413, DOI 10.1093/oxfordjournals.jbchem.a124060; Ohkura N, 1997, BIOCHEM J, V325, P527, DOI 10.1042/bj3250527; Okumura K, 2003, IUBMB LIFE, V55, P539, DOI 10.1080/15216540310001620995; Okumura K, 1999, BBA-MOL CELL BIOL L, V1441, P51, DOI 10.1016/S1388-1981(99)00141-9; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	31	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37651	37659		10.1074/jbc.M507250200	http://dx.doi.org/10.1074/jbc.M507250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150695	hybrid			2022-12-25	WOS:000233044500042
J	Parra, JL; Buxade, M; Proud, CG				Parra, JL; Buxade, M; Proud, CG			Features of the catalytic domains and C termini of the MAPK signal-integrating kinases Mnk1 and Mnk2 determine their differing activities and regulatory properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; RIBOSOMAL S6 KINASE; TRANSLATION INITIATION; N-TERMINI; IN-VIVO; PHOSPHORYLATION; DOCKING; EIF4E; IDENTIFICATION	The MAPK signal-integrating kinases Mnk1 and Mnk2 are closely related but show marked differences in their basal activities and regulation. Both possess, within their C termini, motifs for binding to MAPKs, although these differ between Mnk1 and Mnk2. Mnk2 shows much higher activity in unstimulated cells than Mnk1, whose activity is greatly increased, e. g. by stimulation of the MEK/ ERK pathway. Such increases are sensitive to blockade of that pathway, whereas the activation state of Mnk2 is relatively insensitive to inhibition of upstream signaling. Here we have studied the roles of features in their catalytic domains and C termini in determining their regulatory properties and basal activities. Mnk2 can bind to phosphorylated, active ERK, whereas Mnk1 cannot. Such binding apparently protects ERK against dephosphorylation and inactivation. The high basal activity of Mnk2 and its binding to ( phospho) ERK requires features both of the catalytic domain and of the C terminus. For example, within the catalytic region an aspartate in Mnk2 plays a key role. Mutation to alanine inactivates Mnk2. In the C terminus, features within the MAPK-binding motif and to either side of it, including potential phosphorylation sites, affect MAPK binding and activity. The association of Mnks with the scaffold protein eukaryotic initiation factor 4G is negatively modulated by Mnk activity. These data indicate that multiple features determine the activities of the Mnks and thus impact on their ability to phosphorylate physiological substrates such as eukaryotic initiation factor 4E.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of Dundee; University of British Columbia	Proud, CG (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Dow St, Dundee DD1 5EH, Scotland.	cgpr@interchange.ubc.ca	Buxade, Maria/F-7870-2014	Buxade, Maria/0000-0002-3020-8393; Proud, Christopher/0000-0003-0704-6442				Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Mahalingam M, 2001, PROG MOLEC, V27, P131; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; O'Loghlen A, 2004, EXP CELL RES, V299, P343, DOI 10.1016/j.yexcr.2004.06.006; Orton KC, 2004, J BIOL CHEM, V279, P38649, DOI 10.1074/jbc.M407337200; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Slentz-Kesler K, 2000, GENOMICS, V69, P63, DOI 10.1006/geno.2000.6299; Smith JK, 2000, J BIOL CHEM, V275, P31588, DOI 10.1074/jbc.M005892200; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200	24	51	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37623	37633		10.1074/jbc.M508356200	http://dx.doi.org/10.1074/jbc.M508356200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16162500	hybrid			2022-12-25	WOS:000233044500039
J	Auerbach, SD; Johnson, KA				Auerbach, SD; Johnson, KA			Alternating site ATPase pathway of rat conventional kinesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAND-OVER-HAND; T7 RNA-POLYMERASE; DIMERIC KINESIN; MOTOR DOMAIN; ACTOMYOSIN SUBFRAGMENT-1; KINETIC MECHANISM; ESCHERICHIA-COLI; CLONED GENES; HEAD DOMAINS; MICROTUBULE	The pathway of ATP hydrolysis by rat kinesin was established by pre-steady-state kinetic methods. A 406-residue long N-terminal fragment was shown by sedimentation equilibrium analysis to form a dimer with a K-d of 46 nM. The pathway of ATP hydrolysis follows the Gilbert-Johnson pathway determined previously for a similar-sized N-terminal fragment of Drosophila conventional kinesin. However, the rates of ADP release were at least 3-fold faster, and ATP hydrolysis was similar to 5-fold faster. Paralleling our previous mechanistic data, these results support an alternating site ATPase pathway, including a captive head state as an intermediate in the kinesin ATPase cycle. The kinetic data presented in this report once again point to the importance of the captive head state and argue against a pathway that short-circuits this key intermediate. In addition, several unique aspects of the rat kinesin kinetics reveal new aspects of the ATPase-coupling mechanism. These studies provide a baseline set of kinetic parameters against which future studies of rat kinesin mutants may be evaluated and directly correlated with the structure of the dimeric kinesin.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, MBB 3-122,2500 Speedway A4800, Austin, TX 78735 USA.	kajohnson@mail.utexas.edu			NIGMS NIH HHS [GM-26726-25] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; Auerbach SD, 2005, J BIOL CHEM, V280, P37061, DOI 10.1074/jbc.M502985200; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BORISY GG, 1974, FED PROC, V33, P167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braman J, 1996, Methods Mol Biol, V57, P31; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Cheng JQ, 1998, BIOCHEMISTRY-US, V37, P5288, DOI 10.1021/bi972742j; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; Cross RA, 2000, PHILOS T ROY SOC B, V355, P459, DOI 10.1098/rstb.2000.0587; Endow SA, 1999, EUR J BIOCHEM, V262, P12, DOI 10.1046/j.1432-1327.1999.00339.x; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hunter AW, 2000, J CELL SCI, V113, P4379; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kaseda K, 2003, NAT CELL BIOL, V5, P1079, DOI 10.1038/ncb1067; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Mandelkow E, 1999, CURR OPIN CELL BIOL, V11, P34, DOI 10.1016/S0955-0674(99)80005-2; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Morfini G, 2001, DEV NEUROSCI-BASEL, V23, P364, DOI 10.1159/000048720; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Naber N, 2003, BIOPHYS J, V84, P3190, DOI 10.1016/S0006-3495(03)70043-5; OMOTO CK, 1986, BIOCHEMISTRY-US, V25, P419, DOI 10.1021/bi00350a022; Peterman EJG, 2004, ANNU REV PHYS CHEM, V55, P79, DOI 10.1146/annurev.physchem.55.091602.094340; Peterman EJG, 2001, BIOPHYS J, V81, P2851, DOI 10.1016/S0006-3495(01)75926-7; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schief WR, 2004, P NATL ACAD SCI USA, V101, P1183, DOI 10.1073/pnas.0304369101; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	59	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37048	37060		10.1074/jbc.M502984200	http://dx.doi.org/10.1074/jbc.M502984200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118218	hybrid			2022-12-25	WOS:000232901800063
J	Shen, CL; Ye, Y; Robertson, SE; Lau, AW; Mak, DOD; Chou, MM				Shen, CL; Ye, Y; Robertson, SE; Lau, AW; Mak, DOD; Chou, MM			Calcium/calmodulin regulates ubiquitination of the ubiquitin-specific protease TRE17/USP6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANEURYSMAL BONE-CYST; DEUBIQUITINATING ENZYMES; CALMODULIN; ACTIVATION; ONCOGENE; PROTEINS; PATHWAY; USP6; MONOUBIQUITINATION	The TRE17 (USP6/TRE-2) oncogene induces tumorigenesis in both humans and mice. However, little is known regarding its regulation or mechanism of transformation. TRE17 encodes a TBC (Tre-2/Bub2/Cdc16)/Rab GTPase-activating protein homology domain at its N terminus and a ubiquitin-specific protease at its C terminus. In the current study, we identified the ubiquitous calcium (Ca2+)-binding protein calmodulin (CaM) as a novel binding partner for TRE17. CaM bound directly to TRE17 in a Ca2+-dependent manner both in vitro and in vivo. The CaM-binding site was mapped to two hydrophobic motifs near the C terminus of the TBC domain. Point mutations within these motifs significantly reduced the interaction of TRE17 with CaM. We further found that TRE17 is monoubiquitinated and promotes its own deubiquitination in vivo. CaM binding-deficient mutants of TRE17 exhibited significantly reduced monoubiquitination, suggesting that binding of Ca2+/CaM to TRE17 promotes this modification. Consistent with this notion, treatment of cells with the CaM inhibitor W7 reduced levels of TRE17 monoubiquitination. Interestingly, the calcium ionophore A23187 induced accumulation of a polyubiquitinated TRE17 species. The effect of A23187 was attenuated in CaM binding-deficient mutants of TRE17. Taken together, these studies indicate a role for Ca2+/CaM in regulating ubiquitination through direct interaction with TRE17.	Univ Penn, Sch Med, Dept Cell & Dev Biol, BRBII, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Chou, MM (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, BRBII, Rm 1011,421 Curie Blvd, Philadelphia, PA 19104 USA.	mmc@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER; NCI NIH HHS [CA-81415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; Bootman MD, 2001, J CELL SCI, V114, P2213; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Ingvarsdottir K, 2005, MOL CELL BIOL, V25, P1162, DOI 10.1128/MCB.25.3.1162-1172.2005; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li QW, 2004, BIOCHEM BIOPH RES CO, V317, P787, DOI 10.1016/j.bbrc.2004.03.119; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; NAKAMURA T, 1992, ONCOGENE, V7, P733; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8	34	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35967	35973		10.1074/jbc.M505220200	http://dx.doi.org/10.1074/jbc.M505220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16127172	hybrid			2022-12-25	WOS:000232726900024
J	Clarke, CAL; Bennett, LN; Clarke, PR				Clarke, CAL; Bennett, LN; Clarke, PR			Cleavage of claspin by caspase-7 during apoptosis inhibits the Chk1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DNA-DAMAGE CHECKPOINT; EARLY EMBRYONIC LETHALITY; XENOPUS EGG EXTRACTS; CELL-FREE SYSTEM; POLY(ADP-RIBOSE) POLYMERASE; RADIOSENSITIZING AGENT; CATALYTIC SUBUNIT; TUMOR SUPPRESSION; ATR	Claspin is required for the phosphorylation and activation of the Chk1 protein kinase by ATR during DNA replication and in response to DNA damage. This checkpoint pathway plays a critical role in the resistance of cells to genotoxic stress. Here, we show that human Claspin is cleaved by caspase- 7 during the initiation of apoptosis. In cells, induction of DNA damage by etoposide at first produced rapid phosphorylation of Chk1 at a site targeted by ATR. Subsequently, etoposide caused activation of caspase- 7, cleavage of Claspin, and dephosphorylation of Chk1. In apoptotic cell extracts, Claspin was cleaved by caspase- 7 at a single aspartate residue into a large N- terminal fragment and a smaller C- terminal fragment that contain different functional domains. The large N- terminal fragment was heavily phosphorylated in a human cell- free system in response to double- stranded DNA oligonucleotides, and this fragment retained Chk1 binding activity. In contrast, the smaller C- terminal fragment did not bind Chk1, but did associate with DNA and inhibited the DNA- dependent phosphorylation of Chk1 associated with its activation. These results indicate that cleavage of Claspin by caspase- 7 inactivates the Chk1 signaling pathway. This mechanism may regulate the balance between cell cycle arrest and induction of apoptosis during the response to genotoxic stress.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Clarke, PR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Level 5, Dundee DD1 9SY, Scotland.	paul.clarke@cancer.org.uk	Clarke, Paul/B-1684-2009; Clarke, Paul R./AAA-6803-2020	Clarke, Paul/0000-0003-3525-2622; 				Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Brown EJ, 2000, GENE DEV, V14, P397; Busby EC, 2000, CANCER RES, V60, P2108; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Korfali N, 2004, J BIOL CHEM, V279, P1030, DOI 10.1074/jbc.M306277200; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; LeRomancer M, 1996, J CELL SCI, V109, P3121; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Takai H, 2000, GENE DEV, V14, P1439; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Yaoita Y, 2002, BIOCHEM BIOPH RES CO, V291, P79, DOI 10.1006/bbrc.2002.6408; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao H, 2004, J BIOL CHEM, V279, P53023, DOI 10.1074/jbc.M410449200; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	56	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35337	35345		10.1074/jbc.M506460200	http://dx.doi.org/10.1074/jbc.M506460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123041	hybrid			2022-12-25	WOS:000232561200032
J	Spath, B; Kirchner, S; Vogel, A; Schubert, S; Meinlschmidt, P; Aymanns, S; Nezzar, J; Marchfelder, A				Spath, B; Kirchner, S; Vogel, A; Schubert, S; Meinlschmidt, P; Aymanns, S; Nezzar, J; Marchfelder, A			Analysis of the functional modules of the tRNA 3 ' endonuclease (tRNase Z)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLO-BETA-LACTAMASE; BINUCLEAR ZINC PHOSPHODIESTERASE; CANCER SUSCEPTIBILITY GENE; RNASE-Z; SUBSTRATE RECOGNITION; END MATURATION; GLYOXALASE-II; IN-VIVO; BINDING; FAMILY	tRNA 3 ' processing is one of the essential steps during tRNA maturation. The tRNA 3 '- processing endonuclease tRNase Z was only recently isolated, and its functional domains have not been identified so far. We performed an extensive mutational study to identify amino acids and regions involved in dimerization, tRNA binding, and catalytic activity. 29 deletion and point variants of the tRNase Z enzyme were generated. According to the results obtained, variants can be sorted into five different classes. The first class still had wild type activity in all three respects. Members of the second and third class still formed dimers and bound tRNAs but had reduced catalytic activity ( class two) or no catalytic activity ( class three). The fourth class still formed dimers but did not bind the tRNA and did not process precursors. Since this class still formed dimers, it seems that the amino acids mutated in these variants are important for RNA binding. The fifth class did not have any activity anymore. Several conserved amino acids could be mutated without or with little loss of activity.	Univ Ulm, D-89069 Ulm, Germany; Max Planck Inst Kohlenforsch, D-45470 Mulheim, Germany	Ulm University; Max Planck Society	Marchfelder, A (corresponding author), Univ Ulm, Albert Einstein Allee 11, D-89069 Ulm, Germany.	anita.marchfelder@uni-ulm.de		Marchfelder, Anita/0000-0002-1382-1794				Aravind L, 1999, In Silico Biol, V1, P69; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; Deutscher Murray P., 1995, P51; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; ISHII R, 2005, J BIOL CHEM; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; Mayer M, 2000, BIOCHEMISTRY-US, V39, P2096, DOI 10.1021/bi992253e; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schilling O, 2005, J BIOL CHEM, V280, P17857, DOI 10.1074/jbc.M500591200; Schilling O, 2005, BIOCHEM J, V385, P145, DOI 10.1042/BJ20040773; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Vogel A, 2004, BIOCHEMISTRY-US, V43, P10379, DOI 10.1021/bi049703+; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wolter R, 1996, MOL GEN GENET, V250, P162, DOI 10.1007/s004380050063; Zareen N, 2005, J MOL BIOL, V350, P189, DOI 10.1016/j.jmb.2005.04.073	31	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35440	35447		10.1074/jbc.M506418200	http://dx.doi.org/10.1074/jbc.M506418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118225	hybrid			2022-12-25	WOS:000232561200044
J	D'Costa, AM; Robinson, JK; Maududi, T; Chaturvedi, V; Nickoloff, BJ; Denning, MF				D'Costa, AM; Robinson, JK; Maududi, T; Chaturvedi, V; Nickoloff, BJ; Denning, MF			The proapoptotic tumor suppressor protein kinase C-delta is lost in human squamous cell carcinomas	ONCOGENE			English	Article						protein kinase C-delta; skin cancer; squamous cell carcinoma; tumor suppressor gene	GROWTH-FACTOR RECEPTOR; RADIATION-INDUCED APOPTOSIS; INDUCED CUTANEOUS DAMAGE; PKC-DELTA; HUMAN KERATINOCYTES; TRANSGENIC MICE; RAS ONCOGENE; TYROSINE PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; PHORBOL ESTER	Protein kinase C (PKC)-delta is proapoptotic in human keratinocytes, and is downregulated or inactivated in keratinocytes expressing the activated Ha-ras oncogene, making it a candidate tumor suppressor gene for squamous cell carcinoma (SCC). We evaluated the significance of PKC-delta loss in transformed human keratinocytes using tumorigenic HaCaT Ras II-4 cells that have significantly reduced PKC-delta levels. Re-expression of PKC-delta by retro virus transduction caused an increase in apoptosis and growth inhibition in culture. The growth inhibition induced by PKC-delta could be partially reversed by Bcl-(xL) expression, indicating that apoptosis was in part responsible for PKC-delta-induced growth inhibition. PKC-delta re-expression suppressed the tumor-igenicity of HaCaT Ras II-4 cells in nude mice (P < 0.05), and the small tumors that did form contained elevated levels of activated caspase-3, indicating increased apoptosis. In addition, we found that 29% (12/42) of human Bowen's disease ( squamous carcinoma in situ) or SCC cases had absent or reduced PKC-delta when compared to the surrounding normal epidermis. These results indicate that PKC-delta inhibits transformed keratinocyte growth by inducing apoptosis, and that PKC-delta may function as a tumor suppressor in human SCCs where its loss in cells harboring activated ras could provide a growth advantage by conferring resistance to apoptosis.	Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Skin Canc Res Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Skin Canc Res Program, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Denning, MF (corresponding author), Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, 2160 S 1st Ave,Room 304, Maywood, IL 60153 USA.	mdennin@lumc.edu			NCI NIH HHS [CA83784] Funding Source: Medline; NIAMS NIH HHS [AR47814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashton KJ, 2003, ARCH DERMATOL, V139, P876, DOI 10.1001/archderm.139.7.876; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BOUKAMP P, 1990, CANCER RES, V50, P2840; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURNS FJ, 1976, CANCER RES, V36, P1422; Cataldi A, 2002, J CELL BIOCHEM, V86, P553, DOI 10.1002/jcb.10251; Chida K, 2003, CANCER RES, V63, P2404; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; Dlugosz AA, 1997, CANCER RES, V57, P3180; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; Dobler M, 1999, INT J ONCOL, V14, P571; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Einspahr Janine G., 1999, Neoplasia (New York), V1, P468, DOI 10.1038/sj.neo.7900061; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; Frey MR, 2001, BIOCHEM PHARMACOL, V61, P1093, DOI 10.1016/S0006-2952(01)00596-2; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; Hansen LA, 2000, CANCER RES, V60, P3328; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Jansen AP, 2001, CANCER RES, V61, P808; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LEE E, 1992, CARCINOGENESIS, V13, P2367, DOI 10.1093/carcin/13.12.2367; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu JH, 2003, CANCER RES, V63, P1153; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; Papp H, 2004, CELL MOL LIFE SCI, V61, P1095, DOI 10.1007/s00018-004-4014-2; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wheeler DL, 2005, PHOTOCHEM PHOTOBIOL, V81, P9, DOI 10.1562/2004-08-12-RA-271.1; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881; Wheeler DL, 2003, CANCER RES, V63, P6547; Wheeler DL, 2002, ONCOGENE, V21, P3620, DOI 10.1038/sj.onc.1205451; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	64	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					378	386		10.1038/sj.onc.1209065	http://dx.doi.org/10.1038/sj.onc.1209065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158048				2022-12-25	WOS:000234714100006
J	Lu, Z; Luo, RZ; Peng, H; Huang, M; Nishmoto, A; Hunt, KK; Helin, K; Liao, WSL; Yu, Y				Lu, Z; Luo, RZ; Peng, H; Huang, M; Nishmoto, A; Hunt, KK; Helin, K; Liao, WSL; Yu, Y			E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer	ONCOGENE			English	Article						ARHI; tumor suppressor gene; transcriptional regulation; E2F; HDAC; breast cancer	CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTORS; HISTONE H3; IN-VIVO; E2F; EXPRESSION; CARCINOGENESIS; REPLICATION; METHYLATION; REPRESSION	ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor - trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F - HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.	UT MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA; European Inst Oncol, Dept Expt Oncol, Milan, Italy; Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; IRCCS European Institute of Oncology (IEO); University of Copenhagen; University of Texas System; UTMD Anderson Cancer Center	Yu, Y (corresponding author), UT MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 354, Houston, TX 77030 USA.	yyu@mdanderson.org	Lu, Zhen/E-5221-2015; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097	NCI NIH HHS [CA 64602, CA 80957] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; Hisatomi H, 2002, ONCOLOGY-BASEL, V62, P136, DOI 10.1159/000048259; Lu Z H, 2001, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V23, P324; Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; Shi Zonggao, 2002, Zhonghua Zhongliu Zazhi, V24, P475; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang L, 2003, CLIN CANCER RES, V9, P3660; Weber F, 2005, J CLIN ENDOCR METAB, V90, P1149, DOI 10.1210/jc.2004-1447; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Yuan JH, 2003, CANCER RES, V63, P4174; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	27	51	51	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					230	239		10.1038/sj.onc.1209025	http://dx.doi.org/10.1038/sj.onc.1209025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158053				2022-12-25	WOS:000234583600007
J	McCracken, S; Longman, D; Marcon, E; Moens, P; Downey, M; Nickerson, JA; Jessberger, R; Wilde, A; Caceres, JF; Emili, A; Blencowe, BJ				McCracken, S; Longman, D; Marcon, E; Moens, P; Downey, M; Nickerson, JA; Jessberger, R; Wilde, A; Caceres, JF; Emili, A; Blencowe, BJ			Proteomic analysis of SRm160-containing complexes reveals a conserved association with cohesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SISTER-CHROMATID COHESION; SRM160/300 SPLICING COACTIVATOR; EXON JUNCTION COMPLEX; SYNAPTONEMAL COMPLEXES; CAENORHABDITIS-ELEGANS; HISTONE DEACETYLASE; CHROMOSOME DYNAMICS; NUCLEAR-MATRIX; REMODELING COMPLEX	In this study, we describe a rapid immunoaffinity purification procedure for gel-free tandem mass spectrometry-based analysis of endogenous protein complexes and apply it to the characterization of complexes containing the SRm160 (serine/arginine repeat-related nuclear matrix protein of 160 kDa) splicing coactivator. In addition to promoting splicing, SRm160 stimulates 3'-end processing via its N-terminal PWI nucleic acid-binding domain and is found in a post-splicing exon junction complex that has been implicated in coupling splicing with mRNA turnover, export, and translation. Consistent with these known functional associations, we found that the majority of proteins identified in SRm160-containing complexes are associated with pre-mRNA processing. Interestingly, SRm160 is also associated with factors involved in chromatin regulation and sister chromatid cohesion, specifically the cohesin subunits SMC1 alpha, SMC3, RAD21, and SA2. Gradient fractionation suggested that there are two predominant SRm160-containing complexes, one enriched in splicing components and the other enriched in cohesin subunits. Co-immunoprecipitation and co-localization experiments, as well as combinatorial RNA interference in Caenorhabditis elegans, support the existence of conserved and functional interactions between SRm160 and cohesin.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada; MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Tech Univ Dresden, Med Theoret Zentrum, Sch Med, Inst Physiol Chem, D-01307 Dresden, Germany	University of Toronto; University of Toronto; University of Edinburgh; York University - Canada; University of Massachusetts System; University of Massachusetts Worcester; Technische Universitat Dresden	Blencowe, BJ (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Rm 410,112 Coll St, Toronto, ON M5G 1L6, Canada.	b.blencowe@utoronto.ca	Caceres, Javier F/D-5260-2013	Caceres, Javier F/0000-0001-8025-6169; Wilde, Andrew/0000-0002-9812-3847	MRC [MC_U127584479] Funding Source: UKRI; Medical Research Council [MC_U127584479] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Blencowe BJ, 2000, RNA, V6, P111, DOI 10.1017/S1355838200991982; BLENCOWE BJ, 1995, RNA, V1, P852; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Dowhan DH, 2005, MOL CELL, V17, P429, DOI 10.1016/j.molcel.2004.12.025; Eijpe M, 2000, J CELL SCI, V113, P673; Eijpe M, 2003, J CELL BIOL, V160, P657, DOI 10.1083/jcb.200212080; Eldridge AG, 1999, P NATL ACAD SCI USA, V96, P6125, DOI 10.1073/pnas.96.11.6125; Emili A, 2002, RNA, V8, P1102, DOI 10.1017/S1355838202025037; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; He LS, 2000, NUCLEIC ACIDS RES, V28, P4558, DOI 10.1093/nar/28.22.4558; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Li Y, 1999, J BIOL CHEM, V274, P35074, DOI 10.1074/jbc.274.49.35074; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Longman D, 2001, CURR BIOL, V11, P1923, DOI 10.1016/S0960-9822(01)00589-9; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441; Makarova OV, 2004, EMBO J, V23, P2381, DOI 10.1038/sj.emboj.7600241; McCracken S, 2003, J BIOL CHEM, V278, P44153, DOI 10.1074/jbc.M306856200; McCracken S, 2002, MOL CELL BIOL, V22, P148, DOI 10.1128/MCB.22.1.148-160.2002; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Pasierbek P, 2003, EXP CELL RES, V289, P245, DOI 10.1016/S0014-4827(03)00266-0; Pasierbek P, 2001, GENE DEV, V15, P1349, DOI 10.1101/gad.192701; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Revenkova E, 2004, NAT CELL BIOL, V6, P555, DOI 10.1038/ncb1135; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Sauve FD, 2001, MOL CELL BIOL, V21, P343, DOI 10.1128/MCB.21.1.343-353.2001; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Stursberg S, 1999, GENE, V228, P1, DOI 10.1016/S0378-1119(99)00021-9; Szymczyna BR, 2003, GENE DEV, V17, P461, DOI 10.1101/gad.1060403; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; WAN KM, 1994, P NATL ACAD SCI USA, V91, P594, DOI 10.1073/pnas.91.2.594; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yates JR, 2004, ANNU REV BIOPH BIOM, V33, P297, DOI 10.1146/annurev.biophys.33.111502.082538; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	63	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42227	42236		10.1074/jbc.M507410200	http://dx.doi.org/10.1074/jbc.M507410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16159877	hybrid			2022-12-25	WOS:000233992700051
J	Song, SM; Lippman, SM; Zou, YY; Ye, XF; Ajani, JA; Xu, XC				Song, SM; Lippman, SM; Zou, YY; Ye, XF; Ajani, JA; Xu, XC			Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta(2) expression	ONCOGENE			English	Article						RAR-beta(2); COX-2; Erk1/2; AP-1; BPDE; esophageal cancer	ACID RECEPTOR-BETA; RETINOIC ACID; UP-REGULATION; LUNG-CANCER; RAR-BETA; PROMOTER HYPERMETHYLATION; DIFFERENTIAL EXPRESSION; BRONCHIAL EPITHELIUM; 13-CIS-RETINOIC ACID; CELL-PROLIFERATION	Benzo[a] pyrene diol epoxide (BPDE, a carcinogen present in tobacco smoke and environmental pollution) has been shown to suppress retinoic acid receptor-beta2 (RAR-beta(2)) and induce cyclooxygenase-2 (COX-2) expression. Restoration of RAR-beta 2 inhibited growth and colony formation of esophageal cancer cells, which was correlated with COX-2 suppression. In this study, we investigated the molecular mechanisms for RAR-beta(2)-mediated suppression of COX-2 expression using BPDE as a tool. We found that BPDE-induced COX-2 expression was through inhibition of RAR-beta 2 and consequently, induction of epidermal growth factor receptor (EGFR), extracellular signal-regulated protein kinases 1/2 (Erk1/2) phosphorylation, and c-Jun expression. Esophageal cancer cells that do not express RAR-beta 2 did not respond to BPDE for induction of COX-2. BPDE was also unable to induce COX-2 expression after RAR-beta 2 expression was manipulated in these esophageal cancer cells. Furthermore, BPDE induced time-dependent methylation of RAR-beta 2 gene promoter in esophageal cancer cells. Transfection of RAR-beta 2 expression vector into esophageal cancer cells suppressed expression of EGFR, Erk1/2 phosphorylation, c-Jun, and COX-2. In addition, co-treatment of RAR-beta 2-positive cells with BPDE and the MEK1/2 inhibitor U0126 caused little change in c-Jun and COX-2 expression. This study demonstrated that BPDE-suppressed expression of RAR-beta 2 results in COX-2 induction and restoration of RAR-beta 2 expression reduces COX-2 protein in esophageal cancer cells, thereby further supporting our previous finding that RAR-beta 2 plays an important role in suppressing esophageal carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10461 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med Oncol GI, Unit 1360, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Xu, XC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xxu@mdanderson.org						Alberts D, 2004, CLIN CANCER RES, V10, P1875, DOI 10.1158/1078-0432.CCR-03-0188; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Berg WJ, 1999, CLIN CANCER RES, V5, P1671; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; DeVita VT, 1997, CANC PRINCIPLES PRAC; Dragnev KH, 2003, CANCER BIOL THER, V2, pS150; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; GEBERT JF, 1991, ONCOGENE, V6, P1859; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Khuri FR, 2001, CLIN CANCER RES, V7, P861; Kim YT, 2005, ANN THORAC SURG, V79, P1180, DOI 10.1016/j.athoracsur.2004.09.060; Koch Timothy R, 2003, Curr Gastroenterol Rep, V5, P187, DOI 10.1007/s11894-003-0018-6; Kong G, 2005, CANCER RES, V65, P3462, DOI 10.1158/0008-5472.CAN-03-2912; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Kurie JM, 2000, CLIN CANCER RES, V6, P2973; Kuroki T, 2003, CANCER RES, V63, P3724; Lam S, 2003, INT J ONCOL, V23, P1607; Lango M, 2003, CLIN CANCER RES, V9, P4205; Li M, 2002, ONCOGENE, V21, P411, DOI 10.1038/sj.onc.1205106; Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000; Lin F, 2000, CANCER RES, V60, P3271; Liu ZM, 2004, WORLD J GASTROENTERO, V10, P771; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116; Mayne ST, 2002, J NUTR, V132, p3467S, DOI 10.1093/jn/132.11.3467S; McCann J, 1999, J NATL CANCER I, V91, P497, DOI 10.1093/jnci/91.6.497; McGregor F, 2002, CANCER RES, V62, P4757; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; POSNER MC, 2002, CANC UPPER GASTROINT; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; Qiu HM, 2000, GENE CHROMOSOME CANC, V28, P196, DOI 10.1002/(SICI)1098-2264(200006)28:2<196::AID-GCC8>3.0.CO;2-L; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Su H, 2003, CANCER RES, V63, P3872; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wang XD, 1999, J NATL CANCER I, V91, P60, DOI 10.1093/jnci/91.1.60; Wang YM, 2003, CLIN CANCER RES, V9, P5257; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Xu M, 2002, WORLD J GASTROENTERO, V8, P200; Xu X.-C., 1999, HANDB EXP PHARM, P323; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1999, J NATL CANCER I, V91, P1317, DOI 10.1093/jnci/91.15.1317; Xu XC, 2002, CANCER EPIDEM BIOMAR, V11, p1148S; Xu XC, 2002, ANTI-CANCER DRUG, V13, P127, DOI 10.1097/00001813-200202000-00003; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang W, 2001, J CANCER RES CLIN, V127, P237, DOI 10.1007/s004320000183; Zhuang Y, 2003, MOL CANCER RES, V1, P619; 2004, US SURG GEN REPORT	56	45	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8268	8276		10.1038/sj.onc.1208992	http://dx.doi.org/10.1038/sj.onc.1208992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170369				2022-12-25	WOS:000233956500006
J	D'Alessio, C; Caramelo, JJ; Parodi, AJ				D'Alessio, C; Caramelo, JJ; Parodi, AJ			Absence of nucleoside diphosphatase activities in the yeast secretory pathway does not abolish nucleotide sugar-dependent protein glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GUANOSINE DIPHOSPHATASE; SCHIZOSACCHAROMYCES-POMBE; GOLGI VESICLES; MANNOSYLPHOSPHATE TRANSFER; LINKED GLYCOSYLATION; O-GLYCOSYLATION; GDP-MANNOSE; RAT-LIVER	It is accepted that glycosyltransferase-generated nucleoside diphosphates are converted to monophosphates in the secretory pathway by nucleoside diphosphatases (NDPases) to provide substrates for antiport transport systems by which entrance of nucleotide sugars from the cytosol into the lumen is coupled to exit of nucleoside monophosphates. Working with Saccharomyces cerevisiae mutants affected in anterograde and/or retrograde endoplasmic reticulum (ER)-Golgi vesicular traffic and/or defective in one or both secretory pathway (Golgi) NDPases, we show that UDP-Glc: glycoprotein glucosyltransferase-mediated glucosylation is not dependent on the presence of NDPases or on ER-Golgi vesicular traffic and that GDP-Man-dependent N- and O-mannosylations are reduced but not abolished in the absence of NDPases in the secretory pathway. Further, the absence of the main Man-1-P transferase (a Golgi GMP-generating enzyme) does not modify the limited mannosylation observed in the absence of NDPases. Based on these results and on available additional information, we suggest that in the absence of NDPases, the already characterized nucleotide sugar transporters allow entrance of nucleotide sugars into the luminal compartments and that resulting nucleoside diphosphates exit to the cytosol by a still unknown mechanism. Further, an unexpected side result suggests that formation of Ser/Thr-Man(2) may occur in the ER and not exclusively in the Golgi.	Fdn Inst Leloir, Lab Glycobiol, Buenos Aires, DF, Argentina	Leloir Institute	Parodi, AJ (corresponding author), Fdn Inst Leloir, Lab Glycobiol, Avda Patricias Argentinas 435,C1405BWE, Buenos Aires, DF, Argentina.	aparodi@leloir.org.ar		D'Alessio, Cecilia/0000-0001-7371-5080	NIGMS NIH HHS [GM44500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Bossuyt X, 1997, BIOCHEM J, V323, P645, DOI 10.1042/bj3230645; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; Chiaramonte M, 2001, BIOCHEMISTRY-US, V40, P14260, DOI 10.1021/bi011262w; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; ENGEL JC, 1985, J BIOL CHEM, V260, P105; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; Jigami Y, 1999, BBA-GEN SUBJECTS, V1426, P335, DOI 10.1016/S0304-4165(98)00134-2; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Segawa H, 2005, J BIOL CHEM, V280, P2028, DOI 10.1074/jbc.M404915200; Shahinian S, 1998, GENETICS, V149, P843; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Todorow Z, 2000, P NATL ACAD SCI USA, V97, P13643, DOI 10.1073/pnas.250472397; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; TROMBETTA ES, 1992, THESIS U BUENOS AIRE; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704	37	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40417	40427		10.1074/jbc.M503149200	http://dx.doi.org/10.1074/jbc.M503149200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16172132	Green Published, hybrid			2022-12-25	WOS:000233666600006
J	Korolchuk, VI; Cozier, G; Banting, G				Korolchuk, VI; Cozier, G; Banting, G			Regulation of CK2 activity by phosphatidylinositol phosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; COATED VESICLES; CLATHRIN; PHOSPHORYLATION; DOMAIN; PURIFICATION; SUBUNIT; BINDING; AP180	The process of clathrin-coated vesicle (CCV) formation/disassembly involves numerous proteins that act cooperatively. Phosphorylation is an important regulatory mechanism governing protein interactions in CCVs, and many of the core and accessory proteins of the CCV machinery are reversibly phosphorylated in vivo. CK2 is highly enriched in CCVs and is capable of phosphorylating a number of peripheral membrane proteins involved in the process of clathrin-mediated endocytosis. At least some of these phosphorylation events have been shown to be inhibitory for CCV assembly, and CK2 has been shown to be inactive when associated with intact CCVs. Here we show that CCV membranes inhibit CK2 activity even after incubation in trypsin, indicating that a component of the lipid bilayer may be the inhibitory factor. Consistent with this, we showed that liposomes containing phosphatidylinositol phosphates inhibit the activity of CK2 and that CK2 binds to those liposomes. Notably, liposomes containing phosphatidylinositol 4,5-bisphosphate (PtdIns( 4,5) P-2), a component of CCVs, bind CK2 and inhibit its activity. Furthermore, we showed that the binding of CK2 to PtdIns( 4,5) P-2-containing liposomes is via the active site of CK2, thus providing a molecular explanation for the inhibition of CK2 activity when it is bound to PtdIns( 4,5) P-2-containing liposomes. Thus CK2 is inactive in CCVs because of the fact that it is bound to the CCV membrane via an interaction between PtdIns( 4,5) P2 in the CCV membrane and the active site in CK2.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Banting, G (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	banting@bris.ac.uk	Cozier, Gyles/A-5891-2009	Cozier, Gyles/0000-0003-2851-0902; Banting, George/0000-0001-8249-1621; Korolchuk, Viktor/0000-0002-4071-592X				BARZVI D, 1988, J BIOL CHEM, V263, P4408; BARZVI D, 1986, J BIOL CHEM, V261, P9614; Benetti PH, 1998, PROTEIN EXPRES PURIF, V13, P283, DOI 10.1006/prep.1998.0905; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Cotlin LF, 1999, J BIOL CHEM, V274, P30550, DOI 10.1074/jbc.274.43.30550; Cozier GE, 2000, J BIOL CHEM, V275, P28261; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GEORGIEVAHANSON V, 1988, J NEUROCHEM, V50, P307, DOI 10.1111/j.1471-4159.1988.tb13265.x; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Hilfiker S, 1999, J NEUROCHEM, V73, P921, DOI 10.1046/j.1471-4159.1999.0730921.x; Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600-0854.2002.30606.x; Krehan A, 1996, BIOCHEMISTRY-US, V35, P4966, DOI 10.1021/bi951989i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leroy D, 1999, MOL CELL BIOCHEM, V191, P43, DOI 10.1023/A:1006832312169; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sarrouilhe D, 1998, BBA-MOL CELL RES, V1403, P199, DOI 10.1016/S0167-4889(98)00038-X; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZANDOMENI R, 1988, FEBS LETT, V235, P247, DOI 10.1016/0014-5793(88)81272-9	29	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40796	40801		10.1074/jbc.M508988200	http://dx.doi.org/10.1074/jbc.M508988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16157582	hybrid			2022-12-25	WOS:000233666600050
J	Ramboarina, S; Fernandes, PJ; Daniell, S; Islam, S; Simpson, P; Frankel, G; Booy, F; Donnenberg, MS; Matthews, S				Ramboarina, S; Fernandes, PJ; Daniell, S; Islam, S; Simpson, P; Frankel, G; Booy, F; Donnenberg, MS; Matthews, S			Structure of the bundle-forming pilus from enteropathogenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA PAK PILIN; PSEUDOMONAS-AERUGINOSA; IV PILUS; VIBRIO-CHOLERAE; TWITCHING MOTILITY; PROCESSING SYSTEM; EPITHELIAL-CELLS; BIOGENESIS; ADHERENCE; GENE	Bundle-forming pili (BFP) are essential for the full virulence of enteropathogenic Escherichia coli (EPEC) because they are required for localized adherence to epithelial cells and auto-aggregation. We report the high resolution structure of bundlin, the monomer of BFP, solved by NMR. The structure reveals a new variation in the topology of type IVb pilins with significant differences in the composition and relative orientation of elements of secondary structure. In addition, the structural parameters of native BFP filaments were determined by electron microscopy after negative staining. The solution structure of bundlin was assembled according to these helical parameters to provide a plausible atomic resolution model for the BFP filament. We show that EPEC and Vibrio-cholerae type IVb pili display distinct differences in their monomer subunits consistent with data showing that bundlin and TcpA cannot complement each other, but assemble into filaments with similar helical organization.	Univ Maryland, Div Infect Dis, Sch Med, Baltimore, MD 21201 USA; Univ London Imperial Coll Sci & Technol, Dept Biol Sci, Wolfson Lab, London SW7 2AZ, England; Univ London Imperial Coll Sci & Technol, Ctr Struct Biol, London SW7 2AZ, England	University System of Maryland; University of Maryland Baltimore; Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK	Donnenberg, MS (corresponding author), Univ Maryland, Div Infect Dis, Sch Med, Baltimore, MD 21201 USA.	mdonnenb@umaryland.edu; s.j.matthews@imperial.ac.uk		Simpson, Pete/0000-0002-2679-9303; Matthews, Steve/0000-0003-0676-0927; Donnenberg, Michael/0000-0002-8818-3184	Medical Research Council [MC_U117533887] Funding Source: Medline; NIAID NIH HHS [R01 AI037606] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037606] Funding Source: NIH RePORTER; MRC [MC_U117533887] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anantha TP, 2000, J BACTERIOL, V182, P2498, DOI 10.1128/JB.182.9.2498-2506.2000; Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; Blank TE, 2003, EMERG INFECT DIS, V9, P113, DOI 10.3201/eid0901.020072; Blank TE, 2000, INFECT IMMUN, V68, P7028, DOI 10.1128/IAI.68.12.7028-7038.2000; BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen I, 2003, FRONT BIOSCI, V8, pS544; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Craig L, 2004, NAT REV MICROBIOL, V2, P363, DOI 10.1038/nrmicro885; Craig L, 2003, MOL CELL, V11, P1139, DOI 10.1016/S1097-2765(03)00170-9; CROWTHER LJ, 2005, IN PRESS J BIOL CHEM; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOIG P, 1990, INFECT IMMUN, V58, P124, DOI 10.1128/IAI.58.1.124-130.1990; DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x; Donnenberg MS, 1996, CURR TOP MICROBIOL, V209, P79; FARINHA MA, 1994, INFECT IMMUN, V62, P4118, DOI 10.1128/IAI.62.10.4118-4123.1994; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hazes B, 2000, J MOL BIOL, V299, P1005, DOI 10.1006/jmbi.2000.3801; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hwang JW, 2003, J BACTERIOL, V185, P6695, DOI 10.1128/JB.185.22.6695-6701.2003; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Keizer DW, 2001, J BIOL CHEM, V276, P24186, DOI 10.1074/jbc.M100659200; Kirn TJ, 2000, MOL MICROBIOL, V35, P896, DOI 10.1046/j.1365-2958.2000.01764.x; Kohler R, 2004, MOL MICROBIOL, V54, P647, DOI 10.1111/j.1365-2958.2004.04307.x; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; McNamara BP, 2000, MICROBIOL-UK, V146, P719, DOI 10.1099/00221287-146-3-719; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Park HSM, 2001, MOL MICROBIOL, V42, P293, DOI 10.1046/j.1365-2958.2001.02629.x; Ramboarina S, 2004, J BIOMOL NMR, V29, P427, DOI 10.1023/B:JNMR.0000032511.89525.64; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schreiber W, 2002, MICROBIOL-SGM, V148, P2507, DOI 10.1099/00221287-148-8-2507; SEIFERT HS, 1988, NATURE, V336, P392, DOI 10.1038/336392a0; Stone BJ, 1998, INFECT IMMUN, V66, P1768, DOI 10.1128/IAI.66.4.1768-1775.1998; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Xu XF, 2004, J BIOL CHEM, V279, P31599, DOI 10.1074/jbc.M404727200; Yoshida T, 1998, J BACTERIOL, V180, P2842, DOI 10.1128/JB.180.11.2842-2848.1998; ZHANG HZ, 1994, J BACTERIOL, V176, P6885, DOI 10.1128/JB.176.22.6885-6891.1994; Zhang HZ, 1996, MOL MICROBIOL, V21, P787, DOI 10.1046/j.1365-2958.1996.431403.x; Zhang XL, 2000, INFECT IMMUN, V68, P3067, DOI 10.1128/IAI.68.6.3067-3073.2000	45	52	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40252	40260		10.1074/jbc.M508099200	http://dx.doi.org/10.1074/jbc.M508099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16172128	hybrid			2022-12-25	WOS:000233461300067
J	Ozawa, T; Araki, N; Yunoue, S; Tokuo, H; Feng, LP; Patrakitkomjorn, S; Hara, T; Ichikawa, Y; Matsumoto, K; Fujii, K; Saya, H				Ozawa, T; Araki, N; Yunoue, S; Tokuo, H; Feng, LP; Patrakitkomjorn, S; Hara, T; Ichikawa, Y; Matsumoto, K; Fujii, K; Saya, H			The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; BINDING PROTEIN RHO; LIM-KINASE; COFILIN PHOSPHORYLATION; MAST-CELLS; NEURONAL DIFFERENTIATION; CYTOSKELETAL DYNAMICS; TUMOR ENVIRONMENT; RNA INTERFERENCE; FOCAL ADHESIONS	Neurofibromin is a neurofibromatosis type 1 (NF1) tumor suppressor gene product with a domain that acts as a GTPase-activating protein and functions, in part, as a negative regulator of Ras. Loss of neurofibromin expression in NF1 patients is associated with elevated Ras activity and increased cell proliferation, predisposing to a variety of tumors of the peripheral and central nervous systems. We show here, using the small interfering RNA ( siRNA) technique, that neurofibromin dynamically regulates actin cytoskeletal reorganization, followed by enhanced cell motility and gross cell aggregation in Matrigel matrix. NF1 siRNA induces characteristic morphological changes, such as excessive actin stress fiber formation, with elevated negative phosphorylation levels of cofilin, which regulates actin cytoskeletal reorganization by depolymerizing and severing actin filaments. Wefound that the elevated phosphorylation of cofilin in neurofibromin-depleted cells is promoted by activation of a Rho-ROCK-LIMK2 pathway, which requires Ras activation but is not transduced through three major Ras-mediated downstream pathways via Raf, phosphatidylinositol 3-kinase, and RalGEF. In addition, the exogenous expression of the NF1-GTPase-activating protein-related domain suppressed the NF1 siRNA-induced phenotypes. Neurofibromin was demonstrated to play a significant role in the machinery regulating cell proliferation and in actin cytoskeletal reorganization, which affects cell motility and adhesion. These findings may explain, in part, the mechanism of multiple neurofibroma formation in NF1 patients.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kitasato Univ, Fac Med, Dept Neurosurg, Kanagawa 2288555, Japan; Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, Suita, Osaka 5650871, Japan	Kumamoto University; Kitasato University; Osaka University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482; Tokuo, Hiroshi/0000-0002-7614-7805				Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Corral T, 2003, J CELL PHYSIOL, V197, P214, DOI 10.1002/jcp.10349; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; Hsueh YP, 2001, J NEUROSCI, V21, P3764, DOI 10.1523/JNEUROSCI.21-11-03764.2001; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; McLaughlin ME, 2002, CANCER CELL, V1, P408, DOI 10.1016/S1535-6108(02)00078-8; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nebl G, 2004, CELL SIGNAL, V16, P235, DOI 10.1016/S0898-6568(03)00133-5; NISHI T, 1991, ONCOGENE, V6, P1555; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; North K, 2000, AM J MED GENET, V97, P119, DOI 10.1002/1096-8628(200022)97:2<119::AID-AJMG3>3.0.CO;2-3; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; STEPHENS K, 1987, Genomics, V1, P353, DOI 10.1016/0888-7543(87)90037-1; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P23092, DOI 10.1074/jbc.C100196200; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Suyama E, 2004, J GENE MED, V6, P357, DOI 10.1002/jgm.491; Toshima J, 2001, J BIOL CHEM, V276, P31449, DOI 10.1074/jbc.M102988200; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Viskochil DH, 2003, J CLIN INVEST, V112, P1791, DOI 10.1172/JCI200320503; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yunoue S, 2003, J BIOL CHEM, V278, P26958, DOI 10.1074/jbc.M209413200; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	50	55	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39524	39533		10.1074/jbc.M503707200	http://dx.doi.org/10.1074/jbc.M503707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16169856	hybrid			2022-12-25	WOS:000233362200075
J	Banci, L; Bertini, I; Cantini, F; Chasapis, CT; Hadjiliadis, N; Rosato, A				Banci, L; Bertini, I; Cantini, F; Chasapis, CT; Hadjiliadis, N; Rosato, A			A NMR study of the interaction of a three-domain construct of ATP7A with copper(I) and copper(I)-HAH1 - The interplay of domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSON-DISEASE PROTEIN; N-TERMINAL DOMAIN; BINDING DOMAIN; MENKES PROTEIN; CHAPERONE; METALLOCHAPERONES; TRAFFICKING; TRANSPORT; SITES	ATP7A is a P-type ATPase involved in copper(I) homeostasis in humans. It possesses a long N-terminal tail protruding into the cytosol and containing six copper(I)-binding domains, which are individually folded and capable of binding one copper(I) ion. ATP7A receives copper from a soluble protein, the metallochaperone HAH1. The exact role and interplay of the six soluble domains is still quite unclear, as it has been extensively demonstrated that they are strongly redundant with respect to copper(I) transport in vivo. In the present work, a three-domain (fourth to sixth, MNK456) construct has been investigated in solution by NMR, in the absence and presence of copper(I). In addition, the interaction of MNK456 with copper(I)-HAH1 has been studied. It is proposed that the fourth domain is the preferential site for the initial interaction with the partner. A significant dependence of the overall domain dynamics on the metallation state and on the presence of HAH1 is observed. This dependence could constitute the molecular mechanism to trigger copper(I) translocation and/or ATP7A relocalization from the trans-Golgi network to the plasmatic membrane.	Univ Florence, Magnet Resonance Ctr CERM, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; Univ Ioannina, Dept Chem, Sect Inorgan & Analyt Chem, GR-45110 Ioannina, Greece	University of Florence; University of Florence; University of Ioannina	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr CERM, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Chasapis, Christos/ABD-3272-2020; Hadjikakou, Sotiris K./I-2909-2019; Cantini, Francesca/O-1220-2015; Rosato, Antonio/M-3250-2019; Rosato, Antonio/D-8548-2011	Chasapis, Christos/0000-0002-8728-6245; Hadjikakou, Sotiris K./0000-0001-9556-6266; Cantini, Francesca/0000-0003-0526-6732; Rosato, Antonio/0000-0001-6172-0368; Rosato, Antonio/0000-0001-6172-0368; BANCI, LUCIA/0000-0003-0562-5774				Anastassopoulou I, 2004, BIOCHEMISTRY-US, V43, P13046, DOI 10.1021/bi0487591; Arnesano F, 2004, STRUCTURE, V12, P669, DOI 10.1016/j.str.2004.03.006; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Banci L, 2005, FEBS J, V272, P865, DOI 10.1111/j.1742-4658.2004.04526.x; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; Linder M, 1991, BIOCH COPPER; MENKES JH, 1962, PEDIATRICS, V29, P764; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; van Dongen EMWM, 2004, BIOCHEM BIOPH RES CO, V323, P789, DOI 10.1016/j.bbrc.2004.08.160; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; Walker JM, 2004, J BIOL CHEM, V279, P15376, DOI 10.1074/jbc.M400053200; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Wishart DS, 2001, METHOD ENZYMOL, V338, P3	26	57	57	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38259	38263		10.1074/jbc.M506219200	http://dx.doi.org/10.1074/jbc.M506219200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172131	hybrid			2022-12-25	WOS:000233239800020
J	Campbell, GR; Watkins, JD; Esquieu, D; Pasquier, E; Loret, EP; Spector, SA				Campbell, GR; Watkins, JD; Esquieu, D; Pasquier, E; Loret, EP; Spector, SA			The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 TRANSACTIVATION; 2ND CODING EXON; BLOOD-LYMPHOCYTES; IN-VITRO; PROTEIN; DEATH; AIDS; ACTIVATION; INFECTION; CD4(+)	HIV infection and the progression to AIDS are characterized by the depletion of CD4(+) T cells through apoptosis of the uninfected bystander cells and the direct killing of HIV-infected cells. This is mediated in part by the human immunodeficiency virus, type 1 Tat protein, which is secreted by virally infected cells and taken up by uninfected cells and CD178 gene expression, which is critically involved in T cell apoptosis. The differing ability of HIV strains to induce death of infected and uninfected cells may play a role in the clinical and biological differences displayed by HIV strains. We chemically synthesized the 86-residue truncated short variant of Tat and its full-length form. We show that the trans-activation ability of Tat at the long terminal repeat does not correlate with T cell apoptosis but that the ability of Tat to up-regulate CD178 mRNA expression and induce apoptosis in T cells is critically dependent on the C terminus of Tat. Moreover, the greater 86-residue Tat-induced apoptosis is via the extrinsic pathway of CD95-CD178.	Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA; Univ Mediterranee, Fac Pharm, CNRS, Format Rech Evolut 2737, F-13385 Marseille, France; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr AIDS Res, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of California System; University of California San Diego; University of California System; University of California San Diego	Spector, SA (corresponding author), Univ Calif San Diego, Dept Pediat, Div Infect Dis, 9500 Gilman Dr, La Jolla, CA 92093 USA.	saspector@ucsd.edu	Campbell, Grant/C-9018-2011; Pasquier, Eddy/A-8112-2018	Campbell, Grant/0000-0003-3927-1994; Pasquier, Eddy/0000-0003-2824-5002	NIAID NIH HHS [AI-27563, AI-39004, AI-36214] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, U01AI027563, R01AI039004] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alimonti JB, 2003, J GEN VIROL, V84, P1649, DOI 10.1099/vir.0.19110-0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; Aries SP, 1995, J MOL MED-JMM, V73, P591; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999; Baumler CB, 1996, BLOOD, V88, P1741; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Campbell GR, 2004, J BIOL CHEM, V279, P48197, DOI 10.1074/jbc.M406195200; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Conti L, 1998, J EXP MED, V187, P403, DOI 10.1084/jem.187.3.403; Contreras X, 2004, MICROBES INFECT, V6, P1182, DOI 10.1016/j.micinf.2004.06.008; de Mareuil J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-5; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Epie N, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-6; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gatignol A, 2000, Adv Pharmacol, V48, P209; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gulow K, 2005, J IMMUNOL, V174, P5249, DOI 10.4049/jimmunol.174.9.5249; Huigen MCDG, 2004, EUR J CLIN INVEST, V34, P57, DOI 10.1111/j.1365-2362.2004.01282.x; JEANG KT, 1996, HUMAN RETROVIRUSES A; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaleebu P, 2001, AIDS, V15, P293, DOI 10.1097/00002030-200102160-00001; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Moretti S, 2000, CLIN EXP IMMUNOL, V122, P364, DOI 10.1046/j.1365-2249.2000.01375.x; NARDELLI B, 1995, P NATL ACAD SCI USA, V92, P7312, DOI 10.1073/pnas.92.16.7312; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; Noraz N, 1997, AIDS, V11, P1671, DOI 10.1097/00002030-199714000-00003; Opi S, 2002, J BIOL CHEM, V277, P35915, DOI 10.1074/jbc.M204393200; Opi S, 2004, VACCINE, V22, P3105, DOI 10.1016/j.vaccine.2004.01.057; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Patki AH, 1996, CELL IMMUNOL, V169, P40, DOI 10.1006/cimm.1996.0088; Peloponese JM, 1999, J BIOL CHEM, V274, P11473, DOI 10.1074/jbc.274.17.11473; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Senkaali D, 2004, AIDS RES HUM RETROV, V20, P932, DOI 10.1089/aid.2004.20.932; Silvestris F, 1996, AIDS, V10, P131, DOI 10.1097/00002030-199602000-00002; Smith SM, 2003, J BIOL CHEM, V278, P44816, DOI 10.1074/jbc.M307546200; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636; VIVES E, 1994, J VIROL, V68, P3343, DOI 10.1128/JVI.68.5.3343-3353.1994; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Xiao H, 1998, BIOCHEM BIOPH RES CO, V244, P384, DOI 10.1006/bbrc.1998.8274; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466	60	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38376	38382		10.1074/jbc.M506630200	http://dx.doi.org/10.1074/jbc.M506630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16155003	hybrid			2022-12-25	WOS:000233239800033
J	Dantsker, D; Roche, C; Samuni, U; Blouin, G; Olson, JS; Friedman, JM				Dantsker, D; Roche, C; Samuni, U; Blouin, G; Olson, JS; Friedman, JM			The position 68(E11) side chain in myoglobin regulates ligand capture, bond formation with heme iron, and internal movement into the xenon cavities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE MYOGLOBIN; NITRIC-OXIDE RECOMBINATION; SITE-DIRECTED MUTAGENESIS; STRUCTURAL DYNAMICS; CO BINDING; CONFORMATIONAL RELAXATION; CARBONMONOXY MYOGLOBIN; PROTEIN DYNAMICS; GEMINATE RECOMBINATION; MOLECULAR-DYNAMICS	After photodissociation, ligand rebinding to myoglobin exhibits complex kinetic patterns associated with multiple first-order geminate recombination processes occurring within the protein and a simpler bimolecular phase representing second-order ligand rebinding from the solvent. A smooth transition from cryogenic-like to solution phase properties can be obtained by using a combination of sol-gel encapsulation, addition of glycerol as a bathing medium, and temperature tuning (- 15 --> 65 degrees C). This approach was applied to a series of double mutants, myoglobin CO ( H64L/ V68X, where X = Ala, Val, Leu, Asn, and Phe), which were designed to examine the contributions of the position 68( E11) side chain to the appearance and disappearance of internal rebinding phases in the absence of steric and polar interactions with the distal histidine. Based on the effects of viscosity, temperature, and the stereochemistry of the E11 side chain, the three major phases, B --> A, C --> A, and D-->A, can be assigned, respectively, to ligand rebinding from the following: (i) the distal heme pocket, (ii) the xenon cavities prior to large amplitude side chain conformational relaxation, and (iii) the xenon cavities after significant conformational relaxation of the position 68( E11) side chain. The relative amplitudes of the B --> A and C-->A phases depend markedly on the size and shape of the E11 side chain, which regulates sterically both ligand return to the heme iron atom and ligand migration to the xenon cavities. The internal xenon cavities provide a transient docking site that allows side chain relaxations and the entry of water into the vacated distal pocket, which in turn slows ligand recombination markedly.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Yeshiva University; Albert Einstein College of Medicine; Rice University; Rice University	Friedman, JM (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu		Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, P01GM058890, R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIBIB NIH HHS [R01 EB00296] Funding Source: Medline; NIGMS NIH HHS [P01 GM58890, GM35649, T32 GM008280, GM08280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGMON N, 1988, BIOCHEMISTRY-US, V27, P3507, DOI 10.1021/bi00409a057; Agmon N, 1996, CHEM PHYS, V212, P207, DOI 10.1016/S0301-0104(96)00179-6; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1994, BIOPHYS J, V66, P1612, DOI 10.1016/S0006-3495(94)80953-1; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; Antonini E, 1971, HEMOGLOBINS MYOGLOBI; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; AUSTIN RH, 1973, SCIENCE, V181, P541, DOI 10.1126/science.181.4099.541; BALASUBRAMANIAN S, 1993, BIOCHEMISTRY-US, V32, P2202, DOI 10.1021/bi00060a011; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; Bossa C, 2004, BIOPHYS J, V86, P3855, DOI 10.1529/biophysj.103.037432; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; CAMPBELL BF, 1987, SCIENCE, V238, P373, DOI 10.1126/science.3659921; Cao WX, 2001, BIOCHEMISTRY-US, V40, P5728, DOI 10.1021/bi010067e; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHU K, 1995, PHYS REV LETT, V74, P2607, DOI 10.1103/PhysRevLett.74.2607; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Dantsker D, 2005, BBA-PROTEINS PROTEOM, V1749, P234, DOI 10.1016/j.bbapap.2005.04.002; Dantsker D, 2002, J MOL BIOL, V315, P239, DOI 10.1006/jmbi.2001.5218; Doster W., 1993, PROTEIN SOLVENT INTE, P375; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; FRAUENFELDER H, 1995, NAT STRUCT BIOL, V2, P821, DOI 10.1038/nsb1095-821; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; Huang J, 1997, BIOCHEMISTRY-US, V36, P14353, DOI 10.1021/bi9700274; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Ishikawa H, 2001, BIOPHYS J, V80, P1507, DOI 10.1016/S0006-3495(01)76123-1; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; Kleinert T, 1998, BIOCHEMISTRY-US, V37, P717, DOI 10.1021/bi971508q; Kriegl JM, 2003, P NATL ACAD SCI USA, V100, P7069, DOI 10.1073/pnas.1231856100; Krzywda S, 1998, BIOCHEMISTRY-US, V37, P15896, DOI 10.1021/bi9812470; Lamb DC, 2004, BIOPHYS CHEM, V109, P41, DOI 10.1016/j.bpc.2003.10.002; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; Librizzi F, 2002, J CHEM PHYS, V116, P1193, DOI 10.1063/1.1426409; McNaughton L, 2003, J AM CHEM SOC, V125, P3813, DOI 10.1021/ja028064s; Nienhaus K, 2005, J AM CHEM SOC, V127, P40, DOI 10.1021/ja0466917; Nienhaus K, 2004, MICRON, V35, P67, DOI 10.1016/j.micron.2003.10.014; Nienhaus K, 2003, J BIOL CHEM, V278, P42532, DOI 10.1074/jbc.M306888200; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9633, DOI 10.1021/bi034787s; Nutt DR, 2004, P NATL ACAD SCI USA, V101, P5998, DOI 10.1073/pnas.0306712101; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Radding W, 2004, BIOESSAYS, V26, P422, DOI 10.1002/bies.20010; Samuni U, 2003, J BIOL CHEM, V278, P27241, DOI 10.1074/jbc.M212634200; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; Sastry GM, 1997, BIOCHEMISTRY-US, V36, P7097, DOI 10.1021/bi9626057; Schlichting I, 2000, CURR OPIN STRUC BIOL, V10, P744, DOI 10.1016/S0959-440X(00)00158-5; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; SIEMIARCZUK A, 1990, J PHYS CHEM-US, V94, P1661, DOI 10.1021/j100367a080; SIEMIARCZUK A, 1989, J PHYS CHEM-US, V93, P7609, DOI 10.1021/j100359a017; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; Teeter MM, 2004, PROTEIN SCI, V13, P313, DOI 10.1110/ps.03334304; Tetreau C, 2004, BIOPHYS J, V86, P435, DOI 10.1016/S0006-3495(04)74120-X; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029	76	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38740	38755		10.1074/jbc.M506333200	http://dx.doi.org/10.1074/jbc.M506333200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16155005	hybrid			2022-12-25	WOS:000233239800076
J	Feinberg, MW; Cao, ZX; Wara, AK; Lebedeva, MA; SenBanerjee, S; Jain, MK				Feinberg, MW; Cao, ZX; Wara, AK; Lebedeva, MA; SenBanerjee, S; Jain, MK			Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; INDUCED TRANSCRIPTIONAL ACTIVATION; TRANSPLANTED MOUSE HEARTS; CREB-BINDING PROTEIN; KRUPPEL-LIKE FACTORS; INTERFERON-GAMMA; TGF-BETA; COACTIVATORS CBP/P300; NUCLEAR INTEGRATION	Activation of macrophages is important in chronic inflammatory disease states such as atherosclerosis. Proinflammatory cytokines such as interferon-gamma (IFN-gamma), lipopolysaccharide (LPS), or tumor necrosis factor-alpha can promote macrophage activation. Conversely, anti-inflammatory factors such as transforming growth factor-beta 1 (TGF-beta 1) can decrease proinflammatory activation. The molecular mediators regulating the balance of these opposing effectors remain incompletely understood. Herein, we identify Kruppel-like factor 4 (KLF4) as being markedly induced in response to IFN-gamma, LPS, or tumor necrosis factor-alpha and decreased by TGF-beta 1 in macrophages. Overexpression of KLF4 in J774a macrophages induced the macrophage activation marker inducible nitric-oxide synthase and inhibited the TGF-beta 1 and Smad3 target gene plasminogen activator inhibitor-1 (PAI-1). Conversely, KLF4 knockdown markedly attenuated the ability of IFN-gamma, LPS, or IFN-gamma plus LPS to induce the iNOS promoter, whereas it augmented macrophage responsiveness to TGF-beta 1 and Smad3 signaling. The KLF4 induction of the iNOS promoter is mediated by two KLF DNA-binding sites at -95 and -212 bp, and mutation of these sites diminished induction by IFN-gamma and LPS. We further provide evidence that KLF4 interacts with the NF-kappa B family member p65 (RelA) to cooperatively induce the iNOS promoter. In contrast, KLF4 inhibited the TGF-beta 1/Smad3 induction of the PAI-1 promoter independent of KLF4 DNA binding through a novel antagonistic competition with Smad3 for the C terminus of the coactivator p300/CBP. These findings support an important role for KLF4 as a regulator of key signaling pathways that control macrophage activation.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc,Program Cardiovasc Transcript Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Feinberg, MW (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc,Program Cardiovasc Transcript Biol, 75 Francis St, Boston, MA 02115 USA.	mfeinberg@rics.bwh.harvard.edu		Feinberg, Mark/0000-0001-9523-3859	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069477, R01HL076754, R01HL075427, R01HL072952, K08HL067755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-75427, HL-67755, HL-76754, HL-69477, HL-72952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bitzer M, 2000, GENE DEV, V14, P187; Buono C, 2003, ARTERIOSCL THROM VAS, V23, P454, DOI 10.1161/01.ATV.0000059419.11002.6E; Chen ZY, 2002, EXP CELL RES, V281, P19, DOI 10.1006/excr.2002.5633; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; DYSON N, 1992, CANCER SURV, V12, P161; Feinberg MW, 2004, CIRC RES, V94, P601, DOI 10.1161/01.RES.0000119170.70818.4F; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Katz JP, 2002, DEVELOPMENT, V129, P2619; Koh KP, 2004, J CLIN INVEST, V114, P846, DOI 10.1172/JCI200421767; Kolios G, 2004, IMMUNOLOGY, V113, P427, DOI 10.1111/j.1365-2567.2004.01984.x; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Noti JD, 2005, J BIOL CHEM, V280, P3449, DOI 10.1074/jbc.M412627200; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Raisanen-Sokolowski A, 1998, AM J PATHOL, V152, P359; Ranganath S, 1998, J IMMUNOL, V161, P3822; Rao CV, 2004, MUTAT RES-FUND MOL M, V555, P107, DOI 10.1016/j.mrfmmm.2004.05.022; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUSSELL PS, 1994, TRANSPLANTATION, V57, P1367, DOI 10.1097/00007890-199405150-00014; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Ueland T, 2003, AM J CARDIOL, V92, P715, DOI 10.1016/S0002-9149(03)00836-1; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Whitman SC, 2000, AM J PATHOL, V157, P1819, DOI 10.1016/S0002-9440(10)64820-1; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Zhang N, 2003, J IMMUNOL, V170, P6307, DOI 10.4049/jimmunol.170.12.6307	77	222	239	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38247	38258		10.1074/jbc.M509378200	http://dx.doi.org/10.1074/jbc.M509378200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169848	hybrid			2022-12-25	WOS:000233239800019
J	Ximenes, VF; Silva, SO; Rodrigues, MR; Catalani, LH; Maghzal, GJ; Kettle, AJ; Campa, A				Ximenes, VF; Silva, SO; Rodrigues, MR; Catalani, LH; Maghzal, GJ; Kettle, AJ; Campa, A			Superoxide-dependent oxidation of melatonin by myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; INDOLEAMINE 2,3-DIOXYGENASE; HORSERADISH-PEROXIDASE; HUMAN-NEUTROPHILS; COMPOUND-III; TRYPTOPHAN; ACID; HYDROXYLATION; MECHANISM; HYDROQUINONE	Myeloperoxidase uses hydrogen peroxide to oxidize numerous substrates to hypohalous acids or reactive free radicals. Here we show that neutrophils oxidize melatonin to N-1-acetyl-N-2-formyl-5-methoxykynuramine (AFMK) in a reaction that is catalyzed by myeloperoxidase. Production of AFMK was highly dependent on superoxide but not hydrogen peroxide. It did not require hypochlorous acid, singlet oxygen, or hydroxyl radical. Purified myeloperoxidase and a superoxide-generating system oxidized melatonin to AFMK and a dimer. The dimer would result from coupling of melatonin radicals. Oxidation of melatonin was partially inhibited by catalase or superoxide dismutase. Formation of AFMK was almost completely eliminated by superoxide dismutase but weakly inhibited by catalase. In contrast, production of melatonin dimer was enhanced by superoxide dismutase and blocked by catalase. We propose that myeloperoxidase uses superoxide to oxidize melatonin by two distinct pathways. One pathway involves the classical peroxidation mechanism in which hydrogen peroxide is used to oxidize melatonin to radicals. Superoxide adds to these radicals to form an unstable peroxide that decays to AFMK. In the other pathway, myeloperoxidase uses superoxide to insert dioxygen into melatonin to form AFMK. This novel activity expands the types of oxidative reactions myeloperoxidase can catalyze. It should be relevant to the way neutrophils use superoxide to kill bacteria and how they metabolize xenobiotics.	Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand; Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Sao Paulo, Brazil	University of Otago; Universidade de Sao Paulo; Universidade de Sao Paulo	Kettle, AJ (corresponding author), Christchurch Sch Med & Hlth Sci, Dept Pathol, POB 4345, Christchurch, New Zealand.	tony.kettle@chmeds.ac.nz	Rodrigues, Maria Rita/ABE-1097-2020; Catalani, Luiz Henrique/E-2841-2010; Campa, Ana/D-4669-2012; maghzal, ghassan/A-9692-2015; Kettle, Anthony J/A-8520-2008; Lautenschlager, Sueli OS/P-2164-2017; Ximenes, Valdecir/A-5323-2008	Catalani, Luiz Henrique/0000-0003-3689-1792; Campa, Ana/0000-0002-6183-3378; Kettle, Anthony J/0000-0002-8218-7766; Lautenschlager, Sueli OS/0000-0001-9303-0804; Ximenes, Valdecir/0000-0003-2636-3080				Allegra M, 2001, BIOCHEM BIOPH RES CO, V282, P380, DOI 10.1006/bbrc.2001.4582; BEERS RF, 1952, J BIOL CHEM, V195, P133; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Cuzzocrea S, 1999, FASEB J, V13, P1930, DOI 10.1096/fasebj.13.14.1930; d'Alessandro N, 2000, J CHEM SOC PERK T 2, P1862, DOI 10.1039/b003346o; DAVIS WB, 1989, BIOCHEM PHARMACOL, V38, P4013; de Almeida EA, 2003, J PINEAL RES, V35, P131; de Oliveira Silva Sueli, 2000, Biochemical and Biophysical Research Communications, V279, P657, DOI 10.1006/bbrc.2000.3993; Dunford HB, 1999, BIOCHEM CELL BIOL, V77, P449, DOI 10.1139/bcb-77-5-449; Fang XW, 1998, J CHEM SOC PERK T 2, P259, DOI 10.1039/a706979k; Ferry G, 2005, BIOCHEM J, V388, P205, DOI 10.1042/BJ20042075; Fridovich I, 1985, CRC HDB METHODS OXYG, P213; Gitto E, 2001, PEDIATR RES, V50, P756, DOI 10.1203/00006450-200112000-00021; Green PS, 2004, J NEUROCHEM, V90, P724, DOI 10.1111/j.1471-4159.2004.02527.x; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HOOGLAND H, 1987, BIOCHIM BIOPHYS ACTA, V916, P76, DOI 10.1016/0167-4838(87)90212-3; KALYANARAMAN B, 1993, J AM CHEM SOC, V115, P4007, DOI 10.1021/ja00063a021; Kettle AJ, 1999, METHOD ENZYMOL, V300, P111; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KETTLE AJ, 1992, J BIOL CHEM, V267, P8319; KETTLE AJ, 1989, BIOCHEM J, V263, P823, DOI 10.1042/bj2630823; Kettle AJ, 2000, REDOX REP, V5, P179, DOI 10.1179/135100000101535726; KETTLE AJ, 1994, J BIOL CHEM, V269, P17146; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 2001, BIOCHEMISTRY-US, V40, P10204, DOI 10.1021/bi010940b; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; KLEBANOFF SJ, 1968, J BACTERIOL, V95, P2131, DOI 10.1128/JB.95.6.2131-2138.1968; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MARQUEZ LA, 1993, ARCH BIOCHEM BIOPHYS, V305, P414, DOI 10.1006/abbi.1993.1440; MARQUEZ LA, 1990, J BIOL CHEM, V265, P6074; Nagra RM, 1997, J NEUROIMMUNOL, V78, P97, DOI 10.1016/S0165-5728(97)00089-1; Newcomb M, 2003, ARCH BIOCHEM BIOPHYS, V409, P72, DOI 10.1016/S0003-9861(02)00445-9; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; Reiter RJ, 2002, J PHARM PHARMACOL, V54, P1299, DOI 10.1211/002235702760345374; Rodrigues MR, 2003, J PINEAL RES, V34, P69, DOI 10.1034/j.1600-079X.2003.02944.x; Rodrigues MR, 2002, BIOCHEM BIOPH RES CO, V292, P869, DOI 10.1006/bbrc.2002.6724; SAKIYAMA F, 1978, CHEM LETT, P893, DOI 10.1246/cl.1978.893; SANTUS R, 1995, FREE RADICAL BIO MED, V19, P837, DOI 10.1016/0891-5849(95)00055-3; Silva SO, 2004, J NEUROIMMUNOL, V156, P146, DOI 10.1016/j.jneuroim.2004.07.015; Silva SO, 2004, J PINEAL RES, V37, P171, DOI 10.1111/j.1600-079X.2004.00149.x; SUBRAHMANYAM VV, 1991, FREE RADICAL RES COM, V15, P285, DOI 10.3109/10715769109105224; Tafazoli S, 2005, DRUG DISCOV TODAY, V10, P617, DOI 10.1016/S1359-6446(05)03394-5; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 1999, BBA-GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304-4165(99)00125-7; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; UETRECHT JP, 1992, DRUG METAB REV, V24, P299, DOI 10.3109/03602539208996297; Winterbourn CC, 1997, ARCH BIOCHEM BIOPHYS, V338, P15, DOI 10.1006/abbi.1996.9773; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583; Ximenes VF, 2001, BIOCHEM BIOPH RES CO, V287, P130, DOI 10.1006/bbrc.2001.5557; Ximenes VF, 2001, ARCH BIOCHEM BIOPHYS, V387, P173, DOI 10.1006/abbi.2000.2228; YOKOTA K, 1965, BIOCHEM BIOPH RES CO, V18, P48, DOI 10.1016/0006-291X(65)90880-6	59	64	65	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38160	38169		10.1074/jbc.M506384200	http://dx.doi.org/10.1074/jbc.M506384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16148002	hybrid			2022-12-25	WOS:000233239800008
J	Hausmann, S; Koiwa, H; Krishnamurthy, S; Hampsey, M; Shuman, S				Hausmann, S; Koiwa, H; Krishnamurthy, S; Hampsey, M; Shuman, S			Different strategies for carboxyl-terminal domain (CTD) recognition by serine 5-specific CTD phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ACTIVE-SITE; POLYMERASE; SSU72; TRANSCRIPTION; YEAST; PHOSPHORYLATION; MECHANISM; PROTEIN; FCP1	The phosphorylated carboxyl-terminal domain (CTD) of RNA polymerase II, consisting of ((YSPTSPS7)-Y-1)(n) heptad repeats, encodes information about the state of the transcriptional apparatus that can be conveyed to factors that regulate mRNA synthesis and processing. Here we describe how the CTD code is read by two classes of protein phosphatases, plant CPLs and yeast Ssu72, that specifically dephosphorylate Ser(5) in vitro. The CPLs and Ssu72 recognize entirely different positional cues in the CTD primary structure. Whereas the CPLs rely on Tyr(1) and Pro(3) located on the upstream side of the Ser(5)- PO4 target site, Ssu72 recognizes Thr(4) and Pro(6) flanking the target Ser(5)- PO4 plus the downstream Tyr(1) residue of the adjacent heptad. We surmise that the reading of the CTD code does not obey uniform rules with respect to the location and phasing of specificity determinants. Thus, CTD code, like the CTD structure, is plastic.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Texas A&M Univ, Dept Hort Sci, College Stn, TX 77843 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Memorial Sloan Kettering Cancer Center; Texas A&M University System; Texas A&M University College Station; Rutgers State University New Brunswick; Rutgers State University Medical Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Koiwa, Hisashi/AAA-8182-2019; Koiwa, Hisashi/AAO-6512-2020	Koiwa, Hisashi/0000-0002-7421-340X	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Ganem C, 2003, EMBO J, V22, P1588, DOI 10.1093/emboj/cdg141; Hausmann S, 2004, BIOCHEMISTRY-US, V43, P7111, DOI 10.1021/bi0499617; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hausmann S, 2003, J BIOL CHEM, V278, P13627, DOI 10.1074/jbc.M213191200; Hausmann S, 2004, J BIOL CHEM, V279, P10892, DOI 10.1074/jbc.M312513200; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Kamenski T, 2004, MOL CELL, V15, P399, DOI 10.1016/j.molcel.2004.06.035; Koiwa H, 2004, P NATL ACAD SCI USA, V101, P14539, DOI 10.1073/pnas.0403174101; Koiwa H, 2002, P NATL ACAD SCI USA, V99, P10893, DOI 10.1073/pnas.112276199; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Meinhart A, 2003, J BIOL CHEM, V278, P15917, DOI 10.1074/jbc.M301643200; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Nedea E, 2003, J BIOL CHEM, V278, P33000, DOI 10.1074/jbc.M304454200; Noble CG, 2005, NAT STRUCT MOL BIOL, V12, P144, DOI 10.1038/nsmb887; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Steinmetz EJ, 2003, MOL CELL BIOL, V23, P6339, DOI 10.1128/MCB.23.18.6339-6349.2003; Stiller JW, 2004, EUKARYOT CELL, V3, P735, DOI 10.1128/EC.3.3.735-740.2004; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200	26	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37681	37688		10.1074/jbc.M505292200	http://dx.doi.org/10.1074/jbc.M505292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148005	hybrid			2022-12-25	WOS:000233044500045
J	Li, J; Stern, DF				Li, J; Stern, DF			DNA damage regulates Chk2 association with chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; CHECKPOINT KINASE ATR; DOUBLE-STRAND BREAKS; CELL-CYCLE; PHOSPHORYLATION EVENTS; PROTEIN-KINASE; REPLICATION; RECRUITMENT; ACTIVATION; SITES	DNA damage triggers cellular signaling pathways that control the cell cycle and DNA repair. Chk2 is a critical mediator of diverse responses to DNA damage. Chk2 transmits signals from upstream phosphatidylinositol 3'-kinase-like kinases to effector substrates including p53, Brca1, Cdc25A, and Cdc25C. Using chromatin fractionation as well as immunostaining combined with detergent pre-extraction, we have found that a small pool of Chk2 is associated with chromatin prior to DNA damage. Recovery of chromatin-bound Chk2 is reduced in an ATM-dependent manner by exposure to ionizing radiation. Camptothecin and adriamycin also reduce the amount of chromatin-associated Chk2. The Thr(68)-phosphorylated forms of Chk2 induced by DNA damage are found in soluble fractions, but not in the chromatin-enriched fraction. Functional serine/threonine glutamine cluster domain, forkhead-associated domain, and kinase activity are all required for efficient reduction of chromatin-bound Chk2 in response to DNA damage. Artificial induction of Chk2 oligomerization concomitant with exposure to low dose ionizing radiation reduces chromatin-bound Chk2. When Chk2 is incubated with chromatin-enriched fractions in vitro in the presence of ATP, hyperphosphorylated forms of Chk2 bind more weakly to chromatin than hypophosphorylated forms. Taken together, our data suggest that DNA damage induces activation of chromatin-bound Chk2 by a chromatin-derived signal, and that this results in dissociation of activated Chk2 from chromatin, facilitating further signal amplification and transmission to soluble substrates.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University	Stern, DF (corresponding author), 310 Cedar ST,BML342, New Haven, CT 06510 USA.	Df.stern@yale.edu			NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Emili A, 2001, MOL CELL, V7, P13, DOI 10.1016/S1097-2765(01)00150-2; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Frei C, 2000, GENE DEV, V14, P81; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li J, 2005, J BIOL CHEM, V280, P12041, DOI 10.1074/jbc.M412445200; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Longhese MP, 2000, GENETICS, V155, P1577; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo JA, 2001, GENE DEV, V15, P2809; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	57	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37948	37956		10.1074/jbc.M509299200	http://dx.doi.org/10.1074/jbc.M509299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150728	hybrid			2022-12-25	WOS:000233044500077
J	Sarrazin, S; Bonnaffe, D; Lubineau, A; Lortat-Jacob, H				Sarrazin, S; Bonnaffe, D; Lubineau, A; Lortat-Jacob, H			Heparan sulfate mimicry - A synthetic glycoconjugate that recognizes the heparin binding domain of interferon-gamma inhibits the cytokine activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; IFN-GAMMA; RECEPTOR; COMPLEX; DIVERSITY; SEQUENCE; PROTEOGLYCANS; PURIFICATION; ANTIBODIES	Cell-associated heparan sulfate (HS) is endowed with the remarkable ability to bind numerous proteins. As such, it represents a unique system that integrates signaling from circulating ligands with cellular receptors. This polysaccharide is extraordinary complex, and examples that define the structure-function relationship of HS are limited. In particular, it remains difficult to understand the structures by which HS interact with proteins. Among them, interferon-gamma(IFN gamma), a dimeric cytokine, binds to a complex oligosaccharide motif encompassing a N-acetylated glucosamine-rich domain and two highly sulfated sequences, each of which binds to one IFN gamma monomer. Based on this template, we have synthesized a set of glycoconjugate mimetics and evaluated their ability to interact with IFN gamma. One of these molecules, composed of two authentic N-sulfated octasaccharides linked to each other through a 50-angstrom-long spacer termed 2O(10), displays high affinity for the cytokine and inhibits IFN gamma-HS binding with an IC50 of 35 - 40 nM. Interestingly, this molecule also inhibits the binding of IFN gamma to its cellular receptor. Thus, in addition to its ability to delocalize the cytokine from cell surface-associated HS, this compound has direct anti-IFN gamma activity. Altogether, our results represent the first synthetic HS-like molecule that targets a cytokine, strongly validating the HS structural determinants for IFN gamma recognition, providing a new strategy to inhibit IFN gamma in a number of diseases in which the cytokine has been identified as a target, and reinforcing the view that it is possible to create "tailor-made" sequences based on the HS template to isolate therapeutic activities.	Univ Grenoble 1, Inst Biol Struct, Comm Energie Atom, CNRS,Unite Mixte Rech 5075, F-38027 Grenoble, France; Univ Paris 11, CNRS, Unite Mixte Rech 8614, Lab Chim Organ Multifonct, F-91405 Orsay, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lortat-Jacob, H (corresponding author), Univ Grenoble 1, Inst Biol Struct, Comm Energie Atom, CNRS,Unite Mixte Rech 5075, 41 Ave Horowitz, F-38027 Grenoble, France.	Hugues.Lortat-Jacob@ibs.fr						BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Coombe DR, 2005, CELL MOL LIFE SCI, V62, P410, DOI 10.1007/s00018-004-4293-7; Dilhas A, 2004, TETRAHEDRON LETT, V45, P3643, DOI 10.1016/j.tetlet.2004.03.046; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Fernandez-Botran R, 2002, TRANSPLANTATION, V74, P623, DOI 10.1097/00007890-200209150-00007; Froyen G, 1997, BIOTHERAPY, V10, P49, DOI 10.1007/BF02678217; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gavard O, 2003, EUR J ORG CHEM, V2003, P3603, DOI 10.1002/ejoc.200300254; GIBSON UEM, 1989, J IMMUNOL METHODS, V125, P105, DOI 10.1016/0022-1759(89)90083-5; Haelewyn J, 1995, BIOCHEM MOL BIOL INT, V37, P1163; Hidalgo LG, 2002, CRIT REV IMMUNOL, V22, P317; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; Lim Wee-Chian, 2004, Rev Gastroenterol Disord, V4, P66; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lubineau A, 2004, CHEM-EUR J, V10, P4265, DOI 10.1002/chem.200306063; Lubineau A, 1997, TETRAHEDRON LETT, V38, P4087, DOI 10.1016/S0040-4039(97)00830-7; LUNDELL DJ, 1994, PHARMACOL THERAPEUT, V64, P1, DOI 10.1016/0163-7258(94)90031-0; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Nicoletti F, 1996, ENDOCRINOLOGY, V137, P5567, DOI 10.1210/en.137.12.5567; OLTVOORT JJ, 1981, SYNTHESIS-STUTTGART, P305; OZMEN L, 1995, EUR J IMMUNOL, V25, P6, DOI 10.1002/eji.1830250103; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Petitou M, 2004, ANGEW CHEM INT EDIT, V43, P3118, DOI 10.1002/anie.200300640; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Raman R, 2005, CHEM BIOL, V12, P267, DOI 10.1016/j.chembiol.2004.11.020; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Skurkovich B, 2003, CURR OPIN MOL THER, V5, P52; TROST BM, 1981, TETRAHEDRON LETT, V22, P1287, DOI 10.1016/S0040-4039(01)90298-9; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Vives RR, 2001, BIOCHEM J, V354, P141, DOI 10.1042/0264-6021:3540141; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Yamada M, 2004, AM J PHYSIOL-LUNG C, V287, pL1042, DOI 10.1152/ajplung.00155.2004	46	44	45	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37558	37564		10.1074/jbc.M507729200	http://dx.doi.org/10.1074/jbc.M507729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155294	hybrid			2022-12-25	WOS:000233044500032
J	Takino, T; Nakada, M; Miyamori, H; Watanabe, Y; Sato, T; Gantulga, D; Yoshioka, K; Yamada, KM; Sato, H				Takino, T; Nakada, M; Miyamori, H; Watanabe, Y; Sato, T; Gantulga, D; Yoshioka, K; Yamada, KM; Sato, H			JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c-Jun N-terminal kinase and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JNK SIGNALING PATHWAY; SCAFFOLD PROTEIN; TYROSINE PHOSPHORYLATION; MATRIX ADHESION; INVASION; FAK; SRC; MICROTUBULES; P130(CAS)	c-Jun N-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1) ( also termed JNK-interacting protein 3; JIP3) is a member of a family of scaffold factors for the mitogen-activated protein kinase ( MAPK) cascades, and it also forms a complex with focal adhesion kinase (FAK). Here we demonstrate that JSAP1 serves as a cooperative scaffold for activation of JNK and regulation of cell migration in response to fibronectin (FN) stimulation. JSAP1 mediated an association between FAK and JNK, which was induced by either co-expression of Src or attachment of cells to FN. Complex formation of FAK with JSAP1 and p130 Crk-associated substrate (p130(Cas)) resulted in augmentation of FAK activity and phosphorylation of both JSAP1 and p130(Cas), which required p130(Cas) hyperphosphorylation and was abolished by inhibition of Src. JNK activation by FN was enhanced by JSAP1, which was suppressed by disrupting the FAK/p130(Cas) pathway by expression of a dominant-negative form of p130(Cas) or by inhibiting Src. We also documented the co-localization of JSAP1 with JNK and phosphorylated FAK at the leading edge and stimulation of cell migration by JSAP1 expression, which depended on its JNK binding domain and was suppressed by inhibition of JNK. The level of JSAP1 mRNA correlated with advanced malignancy in brain tumors, unlike other JIPs. We propose that the JSAP1 center dot FAK complex functions cooperatively as a scaffold for the JNK signaling pathway and regulator of cell migration on FN, and we suggest that JSAP1 is also associated with malignancy in brain tumors.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Dept Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Neurosurg, Div Neurosci, Kanazawa, Ishikawa 9200934, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Kanazawa University; Kanazawa University; Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Takino, T (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan.	ttakino@kenroku.kanazawa-u.ac.jp	Pillay, Nischalan/F-9536-2012; Nakada, Mitsutoshi/B-2790-2012; TAKINO, Takahisa/D-8460-2015; SATO, Hiroshi/D-8454-2015	Nakada, Mitsutoshi/0000-0001-9419-6101; Yamada, Kenneth/0000-0003-1512-6805; Davaakhuu, Gantulga/0000-0003-3792-7101	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Dunty JM, 2004, MOL CELL BIOL, V24, P5353, DOI 10.1128/MCB.24.12.5353-5368.2004; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Ha HY, 2005, DEV BIOL, V277, P184, DOI 10.1016/j.ydbio.2004.09.019; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Im JY, 2003, J NEUROSCI RES, V74, P326, DOI 10.1002/jnr.10761; Ito M, 1999, MOL CELL BIOL, V19, P7539; Iwahara T, 2004, P NATL ACAD SCI USA, V101, P17693, DOI 10.1073/pnas.0408413102; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kleihues P, 1993, HISTOLOGICAL TYPING; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Mariani L, 2001, CANCER RES, V61, P4190; Martin-Blanco E, 2000, P NATL ACAD SCI USA, V97, P7888, DOI 10.1073/pnas.97.14.7888; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OWENS LV, 1995, CANCER RES, V55, P2752; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Sato S, 2004, GENE, V329, P51, DOI 10.1016/j.gene.2003.12.034; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Takino T, 2003, J CELL SCI, V116, P3145, DOI 10.1242/jcs.00632; Takino T, 2003, CANCER RES, V63, P2335; Takino T, 2002, ONCOGENE, V21, P6488, DOI 10.1038/sj.onc.1205840; Tamura M, 1999, CANCER RES, V59, P442; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Wittmann T, 2001, J CELL SCI, V114, P3795; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 2003, J BIOL CHEM, V278, P3846, DOI 10.1074/jbc.M206087200	42	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37772	37781		10.1074/jbc.M505241200	http://dx.doi.org/10.1074/jbc.M505241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141199	hybrid			2022-12-25	WOS:000233044500056
J	Enkvetchakul, D; Jeliazkova, I; Nichols, CG				Enkvetchakul, D; Jeliazkova, I; Nichols, CG			Direct modulation of Kir channel gating by membrane phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; ANIONIC PHOSPHOLIPIDS; PIP2 REGULATION; ATP CHANNELS; BINDING-SITE; ACTIVATION; DOMAIN; INHIBITION; DETERMINANTS	Multiple ion channels have now been shown to be regulated by phosphatidylinositol 4,5-bisphosphate (PIP2) at the cytoplasmic face of the membrane. However, direct evidence for a specific interaction between phosphoinositides and ion channels is critically lacking. We reconstituted pure KirBac1.1 and KcsA protein into liposomes of defined composition ( 3: 1 phosphatidylethanolamine: phosphatidylglycerol) and examined channel activity using a Rb-86(+) uptake assay. We demonstrate direct modulation by PIP2 of KirBac1.1 but not KcsA activity. In marked contrast to activation of eukaryotic Kir channels by PIP2, KirBac1.1 is inhibited by PIP2 incorporated in the membrane (K-1/2 = 0.3 mol %). The dependence of inhibition on the number of phosphate groups and requirement for a lipid tail matches that for activation of eukaryotic Kir channels, suggesting a fundamentally similar interaction mechanism. The data exclude the possibility of indirect modulation via cytoskeletal or other intermediary elements and establish a direct interaction of the channel with PIP2 in the membrane.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Renal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	cnichols@cellbio.wustl.edu	Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54171] Funding Source: Medline; NIDDK NIH HHS [DK60086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antcliff JF, 2005, EMBO J, V24, P229, DOI 10.1038/sj.emboj.7600487; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Bian JS, 2004, AM J PHYSIOL-HEART C, V287, pH2154, DOI 10.1152/ajpheart.00120.2004; Chemin J, 2005, EMBO J, V24, P44, DOI 10.1038/sj.emboj.7600494; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; Enkvetchakul D, 2004, J BIOL CHEM, V279, P47076, DOI 10.1074/jbc.C400417200; Enkvetchakul D, 2003, J GEN PHYSIOL, V122, P471, DOI 10.1085/jgp.200308878; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Haider S, 2005, BIOPHYS J, V88, P3310, DOI 10.1529/biophysj.104.052019; Harvey J, 2000, J PHYSIOL-LONDON, V527, P95, DOI 10.1111/j.1469-7793.2000.00095.x; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 2004, SCIENCE, V304, P223, DOI 10.1126/science.1097439; Himmel B, 2004, EMBO REP, V5, P85, DOI 10.1038/sj.embor.7400034; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Lopes CMB, 2005, J PHYSIOL-LONDON, V564, P117, DOI 10.1113/jphysiol.2004.081935; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Ptak CP, 2005, BIOCHEMISTRY-US, V44, P62, DOI 10.1021/bi048390f; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Rohacs T, 2002, METHOD ENZYMOL, V345, P71; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Suh BC, 2005, CURR OPIN NEUROBIOL, V15, P370, DOI 10.1016/j.conb.2005.05.005; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	42	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35785	35788		10.1074/jbc.C500355200	http://dx.doi.org/10.1074/jbc.C500355200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16144841	hybrid			2022-12-25	WOS:000232726900002
J	Guo, J; Sheng, G; Warner, BW				Guo, J; Sheng, G; Warner, BW			Epidermal growth factor-induced rapid retinoblastoma phosphorylation at Ser(780) and Ser(795) is mediated by ERK1/2 in small intestine epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-BOWEL RESECTION; CYCLIN D1; DEPENDENT KINASE; PROTEIN; ACTIVATION; EXPRESSION; RB; ADAPTATION; MECHANISMS; RECEPTOR	The retinoblastoma protein Rb is critical for the regulation of mammalian cell cycle entry. Hypophosphorylated Rb is considered to be the active form and directs G(1) arrest, while hyperphosphorylated Rb permits the transition from G(1) to S phase for cell proliferation. Upon stimulation by various growth factors, Rb appears to be phosphorylated by a cascade of phosphorylation events mediated mainly by kinases associated with cyclins D and E. Here we report that in prototype small intestine crypt stem cells (RIEC-6), stimulation with either epidermal growth factor or fetal bovine serum results in an unexpected rapid and sustained Rb phosphorylation at sites Ser(780), Ser(795), and Thr(821) which precedes cyclin D1 expression, cyclin D1/cdk4 complex formation, and cdk4 kinase activity. Rb phosphorylation at Ser(780) and Ser(795) is prevented by MEK, but not phosphatidylinositol 3-kinase, inhibitors. In vitro, Rb is directly phosphorylated by active ERK1/2 as shown by [gamma-P-32] ATP labeling. The phosphorylation sites are further directed to Ser(780) and Ser(795) by kinase assays using recombined active ERK1/2 or immunoprecipitated phospho-ERK1/2 from mitogen stimulated cells. Pull-down assays revealed that Rb interacts with active ERK1/2 but not their inactive unphosphorylated forms. Upon EGF stimulation, phosphorylated ERK1/2 co-immunoprecipitates together with phosphorylated Rb. Collectively, these results demonstrate a novel rapid Rb phosphorylation at specific sites induced by mitogen stimulation in epithelial cells of the small intestine. These data specifically identify ERK1/2 as the kinase responsible for Rb phosphorylation targeted to sites Ser(780) and Ser(795). It appears that ERK1/2 could be an important link between a mitogenic signal directly to Rb, thereby providing a rapid response mechanism between mitogen stimulation and cell cycle machinery.	Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Surg,Div Pediat Gen & Thorac Surg, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Warner, BW (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Surg,Div Pediat Gen & Thorac Surg, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	brad.warner@cchmc.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053234, T32DK064581] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK064581, R0-1 DK53234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adegbola O, 2005, J BIOL CHEM, V280, P15497, DOI 10.1074/jbc.M411382200; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Buckley CT, 2004, J BIOL CHEM, V279, P41807, DOI 10.1074/jbc.M407851200; CHAET MS, 1994, J PEDIATR SURG, V29, P1035, DOI 10.1016/0022-3468(94)90274-7; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Crossin KL, 2002, ANN NY ACAD SCI, V961, P159, DOI 10.1111/j.1749-6632.2002.tb03072.x; D'Abaco GM, 2002, J CELL SCI, V115, P4607, DOI 10.1242/jcs.00161; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; DYSON N, 1994, J CELL SCI, P81; Erwin CR, 1999, AM J PHYSIOL-GASTR L, V277, pG533, DOI 10.1152/ajpgi.1999.277.3.G533; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Garnovskaya MN, 2004, J BIOL CHEM, V279, P24899, DOI 10.1074/jbc.M311622200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helmrath MA, 1997, J SURG RES, V69, P76, DOI 10.1006/jsre.1997.5033; Helmrath MA, 1998, J PEDIATR SURG, V33, P229, DOI 10.1016/S0022-3468(98)90437-7; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; O'Brien D P, 2001, Semin Pediatr Surg, V10, P56, DOI 10.1053/spsu.2001.22383; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	39	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35992	35998		10.1074/jbc.M504583200	http://dx.doi.org/10.1074/jbc.M504583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126730	hybrid			2022-12-25	WOS:000232726900027
J	Redon, E; Loubiere, P; Cocaign-Bousquet, M				Redon, E; Loubiere, P; Cocaign-Bousquet, M			Role of mRNA stability during genome-wide adaptation of Lactococcus lactis to carbon starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; POSTTRANSCRIPTIONAL CONTROL; STREPTOCOCCUS-CREMORIS; METABOLIC-REGULATION; HALF-LIVES; E-CLEAVAGE; DECAY; DEGRADATION; BACTERIA	The stability of mRNA was investigated for the first time at the genomic scale during carbon starvation adaptation of Lactococcus lactis IL1403. In exponential phase, mRNA half-lives were correlated positively to open reading frame length. A polypurine sequence, AGGAG, was identified as a putative 5'-stabilizer and inverted repeated sequences as a 3'-destabilizer. These original findings suggested that multiple pathways of mRNA degradation should coexist: internal cleavage, endonuclease cleavage initiated at the 5'-end, and exonuclease attack at the 3'-end. During carbon starvation adaptation, mRNA stability globally increased, but specific mechanisms allowing a wide range of stabilization factors between genes and differential kinetic evolution were involved. A formal method allowing the quantification of the relative influences of transcription and degradation on the mRNA pool control was developed and applied in L. lactis. Gene expression was mostly controlled by altered transcription prior to carbon source exhaustion, while the influence of mRNA stability increased during the starvation phase. This study highlighted that stability modulation in response to adverse growth conditions can govern gene regulation to the same extent as transcription in bacteria.	CNRS, Unite Mixte Rech 5504, Lab Biotechnol Bioproc, F-31077 Toulouse, France; Inst Natl Sci Appl, INRA, Unite Mixte Rech 792, F-31077 Toulouse, France	Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse	Cocaign-Bousquet, M (corresponding author), CNRS, Unite Mixte Rech 5504, Lab Biotechnol Bioproc, 135 Ave Rangueil, F-31077 Toulouse, France.	cocaign@insa-toulouse.fr						Agaisse H, 1996, MOL MICROBIOL, V20, P633, DOI 10.1046/j.1365-2958.1996.5401046.x; ALBERTSON NH, 1990, J GEN MICROBIOL, V136, P2195; ALBERTSON NH, 1994, FEMS MICROBIOL LETT, V117, P181, DOI 10.1111/j.1574-6968.1994.tb06762.x; Amblar M, 2004, BIOCHEM BIOPH RES CO, V323, P884, DOI 10.1016/j.bbrc.2004.08.167; BELASCO JG, 1986, CELL, V46, P245, DOI 10.1016/0092-8674(86)90741-5; Bernhardt J, 2003, GENOME RES, V13, P224, DOI 10.1101/gr.905003; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Braun F, 1998, EMBO J, V17, P4790, DOI 10.1093/emboj/17.16.4790; Calin-Jageman I, 2003, NUCLEIC ACIDS RES, V31, P2381, DOI 10.1093/nar/gkg329; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; COCAIGNBOUSQUET M, 1995, J APPL BACTERIOL, V79, P108, DOI 10.1111/j.1365-2672.1995.tb03131.x; Condon C, 2003, MICROBIOL MOL BIOL R, V67, P157, DOI 10.1128/MMBR.67.2.157-174.2003; DIMARI JF, 1993, MOL MICROBIOL, V7, P705; DREYFUS M, 2002, TRANSLATION MECH; Drider D, 2002, PLASMID, V47, P246, DOI 10.1016/S0147-619X(02)00010-0; Drider D, 2002, MOL MICROBIOL, V43, P1319, DOI 10.1046/j.1365-2958.2002.02830.x; Even S, 2005, NUCLEIC ACIDS RES, V33, P2141, DOI 10.1093/nar/gki505; Even S, 2002, MOL MICROBIOL, V45, P1143, DOI 10.1046/j.1365-2958.2002.03086.x; Even S, 2003, MICROBIOL-SGM, V149, P1935, DOI 10.1099/mic.0.26146-0; Farr GA, 1999, J BACTERIOL, V181, P7323, DOI 10.1128/JB.181.23.7323-7330.1999; Fontaine L, 2001, ANAL BIOCHEM, V298, P246, DOI 10.1006/abio.2001.5390; Grigull J, 2004, MOL CELL BIOL, V24, P5534, DOI 10.1128/MCB.24.12.5534-5547.2004; Gualerzi CO, 2003, J MOL BIOL, V331, P527, DOI 10.1016/S0022-2836(03)00732-0; Hambraeus G, 2003, MOL GENET GENOMICS, V269, P706, DOI 10.1007/s00438-003-0883-6; Hambraeus G, 2002, MICROBIOL-SGM, V148, P1795, DOI 10.1099/00221287-148-6-1795; HUE KK, 1995, J BACTERIOL, V177, P3465, DOI 10.1128/jb.177.12.3465-3471.1995; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; Meyer BJ, 1996, GENE, V179, P263, DOI 10.1016/S0378-1119(96)00377-0; Nickel M, 2004, MOL GENET GENOMICS, V272, P98, DOI 10.1007/s00438-004-1038-0; Nierlich DP, 1996, PROG NUCLEIC ACID RE, V52, P153, DOI 10.1016/S0079-6603(08)60967-8; OTTO R, 1983, FEMS MICROBIOL LETT, V16, P69, DOI 10.1111/j.1574-6968.1983.tb00261.x; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; Redon E, 2005, J BACTERIOL, V187, P3589, DOI 10.1128/JB.187.10.3589-3592.2005; Regnier P, 2000, BIOESSAYS, V22, P235; Selinger DW, 2003, GENOME RES, V13, P216, DOI 10.1101/gr.912603; Sharp JS, 2003, J BACTERIOL, V185, P5372, DOI 10.1128/JB.185.18.5372-5379.2003; Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015; Takayama K, 2000, ENVIRON MICROBIOL, V2, P355, DOI 10.1046/j.1462-2920.2000.00119.x; ter Kuile BH, 2001, FEBS LETT, V500, P169, DOI 10.1016/S0014-5793(01)02613-8; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wassarman KM, 2002, CELL, V109, P141, DOI 10.1016/S0092-8674(02)00717-1; WONG HC, 1986, P NATL ACAD SCI USA, V83, P3233, DOI 10.1073/pnas.83.10.3233	46	61	63	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36380	36385		10.1074/jbc.M506006200	http://dx.doi.org/10.1074/jbc.M506006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131490	Green Published, hybrid			2022-12-25	WOS:000232726900072
J	Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG				Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG			Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTR	ONCOGENE			English	Article						telomerase; hTR; ribbon antisense; DPL transfection	CATALYTIC SUBUNIT; IN-VITRO; MAMMALIAN TELOMERASE; INDUCED APOPTOSIS; RNA COMPONENT; INHIBITION; EXPRESSION; CANCER; OLIGONUCLEOTIDES; GENE	Ribbon antisense (RiAS) to the hTR RNA, a component of the telomerase complex, was employed to inhibit telomerase activity and cancer cell growth. The antisense molecule, hTR-RiAS, combined with enhanced cellular uptake was shown to effectively inhibit telomerase activity and cause rapid cell death in various cancer cell lines. When cancer cells were treated with hTR-RiAS, the level of hTR RNA was reduced by more than 90% accompanied with reduction in telomerase activity. When checked for cancer cell viability, cancer cell lines treated with hTR-RiAS using DNA+Peptide+Lipid complex showed 70-80% growth inhibition in 3 days. The reduced cell viability was due to apoptosis as the percentage of cells exhibiting the sub-G(0) arrest and DNA fragmentation increased after antisense treatment. Further, when subcutaneous tumors of a colon cancer cell line (SW480) were treated intratumorally with hTR-RiAS, tumor growth was markedly suppressed with almost total ablation of hTR RNA in the tumor tissue. Cells in the tumor tissue were also found to undergo apoptosis after hTR-RiAS treatment. These results suggest that hTR-RiAS is an effective anticancer reagent, with a potential for broad efficacy to diverse malignant tumors.	Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, Joongu, Daegu, South Korea; WelGENE Inc 71B4L, Dalseogu 704230, Daegu, South Korea; Keimyung Univ, Sch Med, Chron Dis Res Ctr, Taegu, South Korea; Keimyung Univ, Sch Med, Inst Med Sci, Taegu, South Korea	Keimyung University; Keimyung University; Keimyung University	Park, JG (corresponding author), Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, 194 Dongsadong, Joongu, Daegu, South Korea.	jonggu@kmu.ac.kr						Avilion AA, 1996, CANCER RES, V56, P645; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Ishikawa T, 1999, CANCER LETT, V141, P187, DOI 10.1016/S0304-3835(99)00103-2; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 2000, ONCOGENE, V19, P2205, DOI 10.1038/sj.onc.1203538; Kosciolek BA, 2003, MOL CANCER THER, V2, P209; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Moon IJ, 2000, BIOCHEM J, V346, P295, DOI 10.1042/0264-6021:3460295; Moon IJ, 2000, J BIOL CHEM, V275, P4647, DOI 10.1074/jbc.275.7.4647; Mukai S, 2000, CANCER RES, V60, P4461; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x	34	7	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6492	6501		10.1038/sj.onc.1208731	http://dx.doi.org/10.1038/sj.onc.1208731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16170384				2022-12-25	WOS:000232204100003
J	Tschope, C; Walther, T; Escher, F; Spillmann, F; Du, J; Altmann, C; Schimke, I; Bader, M; Sanchez-Ferrer, CF; Schultheiss, HP; Noutsias, M				Tschope, C; Walther, T; Escher, F; Spillmann, F; Du, J; Altmann, C; Schimke, I; Bader, M; Sanchez-Ferrer, CF; Schultheiss, HP; Noutsias, M			Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy	FASEB JOURNAL			English	Article						adhesion molecules; immune system; thiobarbituric acid reactive substances; transgenic animal	ADHESION MOLECULES; DILATED CARDIOMYOPATHY; HEART-FAILURE; BRADYKININ; EXPRESSION; RATS; RECEPTOR; HYPERGLYCEMIA; ANGIOTENSIN; METABOLISM	The mechanisms contributing to diabetic cardiomyopathy, as well as the protective pathways of the kallikrein-kinin-system (KKS), are incompletely understood. In a kallikrein-overexpressing rat model of streptozotocin (STZ)-induced diabetic cardiomyopathy, we investigated the involvement of inflammatory pathways, endothelial dysfunction, and oxidative stress. Six weeks after STZ injection, impairment of left ventricular (LV) function parameters measured by a Millar-tip catheter (peak LV systolic pressure; dP/dt(max); dP/dt(min)) was accompanied by a significant increment of ICAM-1 and VCAM-1 (CAMs) expression, as well as of beta(2)-leukocyteintegrins(+) (CD18(+), CD11a(+), CD11b(+)) and cytokine (TNF-alpha and IL-1 beta)-expressing infiltrates in male Sprague-Dawley (SD-STZ) rats compared with normoglycemic littermates. Furthermore, SD-STZ rats demonstrated a significant impairment of endothelium-dependent relaxation evoked by acetylcholine and significantly increased plasma TBARS (plasma thiobarbituric acid reactive substances) levels as a measure of oxidative stress. These diabetic cardiomyopathy-associated alterations were significantly attenuated (P<0.05) in diabetic transgenic rats expressing the human kallikrein 1 (hKLK1) gene with STZ-induced diabetes. CAMs expression, beta(2)-leukocyte-integrins(+), and cytokine-expressing infiltrates correlated significantly with all evaluated LV function parameters. The multiple protective effects of the KKS in experimental diabetic cardiomyopathy comprise the inhibition of intramyocardial inflammation (CAMs expression, beta(2)-leukocyte-integrins(+) infiltration and cytokine expression), an improvement of endothelium-dependent relaxation and the attenuation of oxidative stress. These insights might have therapeutic implications also for human diabetic cardiomyopathy.	Univ Med Berlin, Charite, Benjamin Franklin Dept Cardiol & Pneumonol, D-12220 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Autonoma Madrid, Fac Med, Dept Pharmacol & Therapeut, Madrid, Spain	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Autonomous University of Madrid	Tschope, C (corresponding author), Univ Med Berlin, Charite, Benjamin Franklin Dept Cardiol & Pneumonol, Hindenburgdamm 30, D-12220 Berlin, Germany.	cstchoepe@yahoo.com	Noutsias, Michel/AAM-4006-2021; Bader, Michael/K-2124-2013	Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164; Escher, Felicitas/0000-0003-0678-5681; Spillmann, Frank/0000-0003-0002-5745; Noutsias, Michel/0000-0002-9066-5262				Adamopoulos Stamatis, 2002, Eur J Intern Med, V13, P233, DOI 10.1016/S0953-6205(02)00033-X; Bauters C, 2003, CARDIOVASC DIABETOL, V2, DOI 10.1186/1475-2840-2-1; Cai L, 2001, Cardiovasc Toxicol, V1, P181, DOI 10.1385/CT:1:3:181; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Emanueli C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8; Emanueli C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Fiordaliso F, 2000, LAB INVEST, V80, P513, DOI 10.1038/labinvest.3780057; Gohlke P, 1997, ADV EXP MED BIOL, V432, P159; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Marfella R, 2000, CIRCULATION, V101, P2247, DOI 10.1161/01.CIR.101.19.2247; Mikrut K, 2001, DIABETES RES CLIN PR, V51, P79, DOI 10.1016/S0168-8227(00)00222-9; MODRAK J, 1980, DIABETES, V29, P547, DOI 10.2337/diabetes.29.7.547; Monkemann H, 2002, AMINO ACIDS, V23, P331, DOI 10.1007/s00726-001-0146-y; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; Noutsias M, 1999, CIRCULATION, V99, P2124, DOI 10.1161/01.CIR.99.16.2124; Noutsias M, 2002, EUR HEART J SUPPL, V4, pI54, DOI 10.1016/S1520-765X(02)90112-4; Noutsias M, 2003, EUR J HEART FAIL, V5, P469, DOI 10.1016/S1388-9842(03)00037-0; Noutsias M, 2001, CIRCULATION, V104, P275; Noutsias M, 2002, MED SCI MONITOR, V8, pMT59; Pinto YM, 2000, FASEB J, V14, P1861; Rett K, 1997, AM J CARDIOL, V80, pA143, DOI 10.1016/S0002-9149(97)00470-0; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Rodriguez-Manas L, 2003, DIABETOLOGIA, V46, P556, DOI 10.1007/s00125-003-1056-1; Rodriguez-Manas L, 1998, BRIT J PHARMACOL, V123, P1495, DOI 10.1038/sj.bjp.0701749; ROSEN P, 1983, H-S Z PHYSIOL CHEM, V364, P1431, DOI 10.1515/bchm2.1983.364.2.1431; Scholz D, 1996, CELL TISSUE RES, V284, P415, DOI 10.1007/s004410050602; Shiuchi T, 2002, HYPERTENSION, V40, P329, DOI 10.1161/01.HYP.0000028979.98877.0C; Silva JA, 2000, FASEB J, V14, P1858; Spillmann F, 2002, INT IMMUNOPHARMACOL, V2, P1823, DOI 10.1016/S1567-5769(02)00174-1; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; TAKEDA K, 1984, CRIT CARE MED, V12, P957, DOI 10.1097/00003246-198411000-00007; Tschope C, 1999, AM J PHYSIOL-HEART C, V277, pH2333, DOI 10.1152/ajpheart.1999.277.6.H2333; Tschope C, 2002, J CARDIOVASC PHARM, V39, P478, DOI 10.1097/00005344-200204000-00003; Tschope C, 2004, FASEB J, V18, P1967, DOI 10.1096/fj.04-1614fje; Tschope C, 2004, FASEB J, V18, P828, DOI 10.1096/fj.03-0736com; Tschope C, 2004, CARDIOVASC RES, V61, P559, DOI 10.1016/j.cardiores.2003.10.018; Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P35, DOI 10.1016/S0162-3109(99)00109-5; Vallbracht KB, 2002, J AM COLL CARDIOL, V40, P515, DOI 10.1016/S0735-1097(02)01990-3; ZARICH SW, 1989, AM HEART J, V118, P1000, DOI 10.1016/0002-8703(89)90236-6; Zhang LF, 2003, CIRCULATION, V108, P472, DOI 10.1161/01.CIR.0000080378.96063.23	42	96	102	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					2057	+		10.1096/fj.05-4095fje	http://dx.doi.org/10.1096/fj.05-4095fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129698				2022-12-25	WOS:000231843700003
J	Hara, T; Abe, M; Inoue, H; Yu, LR; Veenstra, TD; Kang, YH; Lee, KS; Miki, T				Hara, T; Abe, M; Inoue, H; Yu, LR; Veenstra, TD; Kang, YH; Lee, KS; Miki, T			Cytokinesis regulator ECT2 changes its conformation through phosphorylation at Thr-341 in G2/M phase	ONCOGENE			English	Article						exchange factor; Rho GTPases; Cdk1; interacting proteins; cell division	EXCHANGE FACTOR ECT2; RHOA; SPINDLE; MIDBODY; DOMAINS; GTPASES; CDK1; CDC2	The Rho activator ECT2 functions as a key regulator in cytokinesis. ECT2 is phosphorylated during G2/M phase, but the physiological significance of this event is not well known. In this study, we show that phosphorylation of ECT2 at threonine-341 (T341) affects the autoregulatory mechanism of ECT2. In G2/M phase, ECT2 was phosphorylated at T341 most likely by Cyclin B/Cyclindependent kinase 1 (Cdk1), and then dephosphorylated before cytokinesis. Depletion of ECT2 by RNA interference (RNAi) efficiently induced multinucleate cells. Expression of the phospho-deficient mutant of ECT2 at T341 suppressed the multinucleation induced by RNAi to ECT2, indicating that ECT2 is biologically active even when it is not phosphorylated at T341. However, the phospho-mimic mutation at T341 weakly stimulates the catalytic activity of ECT2 as detected by serum response element reporter gene assays. As T341 is located at the hinge region of the N-terminal regulatory domain and C-terminal catalytic domain, phosphorylation of T341 may help accessing downstream signaling molecules to further activate ECT2. We found that the phospho-mimic mutation T341D increases binding with itself or the N-terminal half of ECT2. These results suggest a conformational change of ECT2 upon phosphorylation at T341. Therefore, ECT2 activity might be regulated by the phosphorylation status of T341. We propose that T341 phosphorylation by Cyclin B/Cdk1 could be a trigger for further activation of ECT2.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, Bethesda, MD 20892 USA; NCI, Lab Prote & Analyt Technol, SAIC Frederick Inc, Frederick, MD 21701 USA; NCI, Lab Metab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, Bldg 37,Room 2144,37 Convent Dr MSC 4256, Bethesda, MD 20892 USA.	toru@helix.nih.gov	Abe, Mitsuhiro/C-3602-2017	Yu, Li-Rong/0000-0001-6084-991X	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Echard A, 2003, CURR BIOL, V13, P373, DOI 10.1016/S0960-9822(03)00127-1; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; James P, 1996, GENETICS, V144, P1425; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Lowery DM, 2004, CELL CYCLE, V3, P128; Matuliene J, 2004, MOL BIOL CELL, V15, P3083, DOI 10.1091/mbc.E03-12-0888; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; O'Keefe L, 2001, CELL STRUCT FUNCT, V26, P619, DOI 10.1247/csf.26.619; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Sakata H, 2000, HEPATOLOGY, V32, P193, DOI 10.1053/jhep.2000.8271; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Yoshizaki H, 2004, J BIOL CHEM, V279, P44756, DOI 10.1074/jbc.M402292200	26	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					566	578		10.1038/sj.onc.1209078	http://dx.doi.org/10.1038/sj.onc.1209078			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170345				2022-12-25	WOS:000234897400008
J	Joshi, S; Guleria, R; Pan, J; DiPette, D; Singh, US				Joshi, S; Guleria, R; Pan, J; DiPette, D; Singh, US			Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells	ONCOGENE			English	Article						neuroblastoma; SH-SY5Y; IMR-32; retinoic acid; RAR; RXR; tissue-transglutaminase	CENTRAL-NERVOUS-SYSTEM; GROWTH IN-VIVO; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; UP-REGULATION; TUMOR-GROWTH; MATRIX-METALLOPROTEINASE-9 EXPRESSION; MATRIX-METALLOPROTEINASE; KINASE PATHWAYS; ACTIVATION	Long-term treatment with all trans-retinoic acid ( RA) induces neuronal differentiation and apoptosis. However, the effect of short-term RA treatment on cell proliferation, migration and invasion of neuroblastoma cell lines (SH-SY5Y and IMR-32) remains unclear. RA induces expression of tissue-transglutaminase ( TGase) and promotes migration and invasion after 24 h of treatment in SH-SY5Y cells, but not in IMR-32 cells. RA receptor (RAR) agonist (4-(E-2-[5,6,7,8-tetrahydro-5,5,8,8-tetramethy-2- naphthalenyl]-1-propenyl) benzoic acid) and RAR/retinoid X receptor (RXR) agonist (9-cis-RA) promote expression of TGase, migration and invasion of SH-SY5Y cells, while RXR agonist has no significant effect. RAR antagonist blocks RA effect on migration and invasion, indicating that RAR receptors are required. Retinoid receptors are expressed and activated by RA in both cell lines. However, only transient activation of RAR is observed in IMR-32 cells. These findings suggest that different responses observed in SH-SY5Y and IMR-32 cells could be due to differential activation of retinoid receptors. Overexpression of TGase has no effect on migration or invasion, while overexpression of antisense TGase blocks RA-induced migration and invasion, indicating that other molecules along with TGase mediate RA effects. In addition to the long-term effects of RA that are coupled with cell differentiation, short-term effects involve migration and invasion of neuroblastoma SH-SY5Y cells.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Dept Internal Med,Coll Med, Temple, TX 76504 USA; Scott & White Mem Hosp & Clin, Temple, TX USA; Cent Texas Vet Hlth Care Syst, Temple, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center	Singh, US (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Dept Internal Med,Coll Med, Bldg 205,1901 S 1st St, Temple, TX 76504 USA.	Usingh@medicine.tamhsc.edu						Abel EL, 2001, J PEDIATR-US, V138, P295, DOI 10.1067/mpd.2001.107612; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Arvidsson Y, 2001, CELL DEATH DIFFER, V8, P1029, DOI 10.1038/sj.cdd.4400922; Biedler J L, 1988, Prog Clin Biol Res, V271, P265; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; CICCARONE V, 1989, CANCER RES, V49, P219; DAVIES PJA, 1992, RETINOIDS NORMAL DEV; DENNING MF, 1991, BIOCHEM BIOPH RES CO, V175, P344, DOI 10.1016/S0006-291X(05)81241-0; Eggert A, 2002, CANCER RES, V62, P1802; Emionite L, 2003, ANTICANCER RES, V23, P13; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Farina AR, 2002, CELL GROWTH DIFFER, V13, P343; FESTUCCIA C, 1996, INT J CANC PRED ONCO, V69, P1; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; JULIANO R, 1994, CANCER METAST REV, V13, P25, DOI 10.1007/BF00690416; Kang SK, 2004, J BIOL CHEM, V279, P36593, DOI 10.1074/jbc.M402084200; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Klaassen I, 2001, INT J CANCER, V92, P661, DOI 10.1002/1097-0215(20010601)92:5<661::AID-IJC1251>3.0.CO;2-O; Leelawat K, 2005, CANCER LETT, V224, P303, DOI 10.1016/j.canlet.2004.10.016; Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116; MACKAY AR, 1992, INVAS METAST, V12, P168; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mohan K, 2003, J IMMUNOL, V171, P3179, DOI 10.4049/jimmunol.171.6.3179; NILES RM, 2004, MUTAT RES, V55, P97; Palm-Leis A, 2004, J BIOL CHEM, V279, P54905, DOI 10.1074/jbc.M407383200; PAN J, 2005, J NEUROCHEM, V10, P1; Phuangsab A, 2001, CANCER LETT, V172, P27, DOI 10.1016/S0304-3835(01)00617-6; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; Ponthan F, 2001, MED PEDIATR ONCOL, V36, P127, DOI 10.1002/1096-911X(20010101)36:1<127::AID-MPO1030>3.0.CO;2-B; Ponthan F, 2003, INT J CANCER, V104, P418, DOI 10.1002/ijc.10954; PRAISE L, 2000, SEMIN CANCER BIOL, V10, P407; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; QUI H, 1999, AM J PATHOL, V155, P1519; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; SATO H, 1992, ONCOGENE, V7, P77; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Soprano KJ, 2002, J NUTR, V132, p3809S, DOI 10.1093/jn/132.12.3809S; SPORN MB, 1994, RETINOIDS BIOL MED; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Sugiura Y, 1998, CANCER RES, V58, P2209; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Voigt A, 2003, MED PEDIATR ONCOL, V40, P205, DOI 10.1002/mpo.10250; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; XU C, 1997, CANCER RES, V57, P4992; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; XU XC, 1994, CANCER RES, V54, P3580; YAO M, 1995, J NEUROSCI RES, V41, P792, DOI 10.1002/jnr.490410610; Zang CB, 2000, J CANCER RES CLIN, V126, P33, DOI 10.1007/PL00008462; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	71	64	70	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					240	247		10.1038/sj.onc.1209027	http://dx.doi.org/10.1038/sj.onc.1209027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158052				2022-12-25	WOS:000234583600008
J	Li, X; Deng, W; Nail, CD; Bailey, SK; Kraus, MH; Ruppert, JM; Lobo-Ruppert, SM				Li, X; Deng, W; Nail, CD; Bailey, SK; Kraus, MH; Ruppert, JM; Lobo-Ruppert, SM			Snail induction is an early response to Gli1 that determines the effciency of epithelial transformation	ONCOGENE			English	Article						basal cell carcinoma; hedgehog; Snail; Gli1; epithelial cell; E-cadherin	BASAL-CELL CARCINOMAS; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; HAIR FOLLICLE MORPHOGENESIS; HEDGEHOG SIGNALING PATHWAY; SONIC-HEDGEHOG; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; TUMOR-SUPPRESSOR; REPRESSOR SNAIL	Gli family members mediate constitutive Hedgehog signaling in the common skin cancer, basal cell carcinoma (BCC). Snail/Snai1 is rapidly induced by Gli1 in vitro, and is coexpressed with Gli1 in human hair follicles and skin tumors. In the current study, we generated a dominant-negative allele of Snail, SnaZFD, composed of the zinc-finger domain and flanking sequence. In promoter -reporter assays, SnaZFD blocked the activity of wildtype Snail on the E-cadherin promoter. Snail loss-of-function mediated by SnaZFD or by one of several short hairpin RNAs inhibited transformation of RK3E epithelial cells by Gli1. Conversely, enforced expression of Snail promoted transformation in vitro by Gli1, but not by other genes that were tested, including Notch1, ErbB2, and N-Ras. As observed for Gli1, wild-type Snail repressed E-cadherin in RK3E cells and induced blebbing of the cytoplasmic membrane. Induction of a conditional Gli1 transgene in the basal keratinocytes of mouse skin led to rapid upregulation of Snail transcripts and to cell proliferation in the interfollicular epidermis. Established Gli1-induced skin lesions exhibited molecular similarities to BCC, including loss of E-cadherin. The results identify Snail as a Gli1-inducible effector of transformation in vitro, and an early Gli1-responsive gene in the skin.	Univ Alabama, Sch Med, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lobo-Ruppert, SM (corresponding author), Univ Alabama, Sch Med, Dept Med, Room 570 WTI, Birmingham, AL 35294 USA.	sruppert@uab.edu		Kammerud, Sarah/0000-0002-4808-1618	NCI NIH HHS [R01 CA065686, P50 CA097247, CA65686, P50CA097247, P30CA13148, CA094030, P30 CA013148, P50 CA089019, R29 CA065686, CA89019, R01 CA094030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097247, P30CA013148, R29CA065686, R01CA094030, R01CA065686, P50CA089019] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Cunningham CC, 1997, J CELL BIOL, V136, P845, DOI 10.1083/jcb.136.4.845; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DEFIORE PP, 1987, SCIENCE, V237, P178; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Hay ED, 1995, ACTA ANAT, V154, P8; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Jamora C, 2005, PLOS BIOL, V3, P131, DOI 10.1371/journal.pbio.0030011; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Ling G, 2001, ONCOGENE, V20, P7770, DOI 10.1038/sj.onc.1204946; Louro ID, 2002, CANCER RES, V62, P5867; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Miller SJ, 1995, CLIN DERMATOL, V13, P527, DOI 10.1016/0738-081X(95)00062-K; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; PIZARRO A, 1994, BRIT J CANCER, V69, P157, DOI 10.1038/bjc.1994.26; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	67	153	160	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					609	621		10.1038/sj.onc.1209077	http://dx.doi.org/10.1038/sj.onc.1209077			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158046	Green Accepted			2022-12-25	WOS:000234897400012
J	Nagano, K; Itagaki, C; Izumi, T; Nunomura, K; Soda, Y; Tani, K; Takahashi, N; Takenawa, T; Isobe, T				Nagano, K; Itagaki, C; Izumi, T; Nunomura, K; Soda, Y; Tani, K; Takahashi, N; Takenawa, T; Isobe, T			Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase	ONCOGENE			English	Article						Rb; Abl; tyrosine phosphorylation; chronic myelogenous leukemia; apoptosis	RETINOBLASTOMA PROTEIN; C-ABL; HISTONE DEACETYLASE; SUPPRESSOR; E2F; INHIBITION; MECHANISMS; APOPTOSIS; PEPTIDE; BINDING	The retinoblastoma (Rb) gene product is a tumor suppressor that is mutated or inactivated in many types of human cancers. Although Rb is known to be an upstream negative regulator of Abl protein tyrosine kinase, we propose here that Rb also functions as a downstream effector of Abl that plays a positive role in survival of Abl-dependent human tumor cells, including Bcr/Abl-positive chronic myelogenous leukemia (CML). We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the C-terminal domain of the molecule. We also show that ectopic expression of Rb induces apoptosis in Abl-dependent tumor cells by inhibiting the Abl tyrosine kinase activity, and that Rb-induced apoptosis is compromised by Abl-catalysed phosphorylation of Rb at Y805. Furthermore, the silencing of endogenous Rb by RNA interference induced apoptosis in Abl-dependent tumor cells. Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML.	Univ Tokyo, Inst Med Sci, Div Prote Res, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Div Mol Therapy, Adv Clin Res Ctr, Minato Ku, Tokyo 1088639, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Adv Mol & Cell Therapy, Higashi Ku, Fukuoka 812, Japan; Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Fuchu, Tokyo 183, Japan; Univ Tokyo, Inst Med Sci, Div Biochem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; Kyushu University; Tokyo University of Agriculture & Technology; University of Tokyo	Isobe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Prote Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	isobe-toshiaki@c.metro-u.ac.jp	TAKAHASHI, Nobuhiro/G-1129-2013					BALTIMORE D, 1995, ANN NY ACAD SCI, V758, P339, DOI 10.1111/j.1749-6632.1995.tb24839.x; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Cujec TP, 2002, CHEM BIOL, V9, P253, DOI 10.1016/S1074-5521(02)00098-4; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Guo XYD, 1999, ONCOGENE, V18, P1589, DOI 10.1038/sj.onc.1202479; Harata M, 2004, BLOOD, V104, P1442, DOI 10.1182/blood-2004-02-0588; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318	35	18	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					493	502		10.1038/sj.onc.1208996	http://dx.doi.org/10.1038/sj.onc.1208996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158058				2022-12-25	WOS:000234897400001
J	Ren, J; Bharti, A; Raina, D; Chen, W; Ahmad, R; Kufe, D				Ren, J; Bharti, A; Raina, D; Chen, W; Ahmad, R; Kufe, D			MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90	ONCOGENE			English	Article						MUC1; heregulin; c-Src; HSP70; HSP90; mitochondria	CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; BREAST-CARCINOMA; MONOCLONAL-ANTIBODY; GENE-TRANSCRIPTION; CYTOPLASMIC TAIL; TYROSINE KINASE; PROTEIN IMPORT; MAMMARY-GLAND	The MUC1 heterodimeric transmembrane glycoprotein is aberrantly overexpressed by most human carcinomas. The MUC1 C-terminal subunit localizes to mitochondria and blocks stress-induced activation of the intrinsic apoptotic pathway. How MUC1 is delivered to mitochondria is not known. The present studies demonstrate that MUC1 forms intracellular complexes with HSP70 and HSP90. We show that the MUC1 cytoplasmic domain binds directly to HSP70 in vitro. By contrast, binding of MUC1 to HSP90 in vitro is induced by c-Src-mediated phosphorylation of the MUC1 cytoplasmic domain. c-Src also increases binding of MUC1 to HSP90 in cells. In concert with these results, we show that heregulin (HRG), a ligand for ErbB receptors, activates c-Src and, in turn, stimulates binding of MUC1 to HSP90. We also show that inhibitors of c-Src or HSP90 block HRG-induced targeting of MUC1 to mitochondria and integration of MUC1 into the mitochondrial outer membrane. These findings indicate that MUC1 is delivered to mitochondria by a mechanism involving activation of the ErbB receptor-c-Src pathway and transport by the molecular chaperone HSP70/HSP90 complex.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA97098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Huang L, 2003, CANCER BIOL THER, V2, P702; Kharbanda S, 1996, CANCER RES, V56, P3617; Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LEVITAN F, 2005, IN PRESS J BIOL CHEM; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; MERLO GR, 1989, CANCER RES, V49, P6966; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Park SJ, 2005, EMBO J, V24, P1557, DOI 10.1038/sj.emboj.7600586; PEREY L, 1992, CANCER RES, V52, P2563; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	43	106	114	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					20	31		10.1038/sj.onc.1209012	http://dx.doi.org/10.1038/sj.onc.1209012			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16158055				2022-12-25	WOS:000234406400003
J	Sugimoto, H; Okamura, K; Sugimoto, S; Satou, M; Hattori, T; Vance, DE; Izumi, T				Sugimoto, H; Okamura, K; Sugimoto, S; Satou, M; Hattori, T; Vance, DE; Izumi, T			Sp1 is a co-activator with Ets-1, and net is an important repressor of the transcription of CTP : Phosphocholine cytidylyltransferase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CELL-CYCLE; RAT-LIVER; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; BINDING PROTEINS; POINTED DOMAIN; FACTORS ELK-1; S-PHASE; GENE; EXPRESSION	Phosphatidylcholine biosynthesis via the CDP-choline pathway is primarily regulated by CTP:phosphocholine cytidylyltransferase (CT) encoded by the Pcyt1a and Pcyt1b genes. Previously, we identified an Ets-1-binding site located at -49/-47 in the promoter of Pcyt1a as an important transcriptional element involved in basal CT alpha transcription (Sugimoto, H., Sugimoto, S., Tatei, K., Obinata, H., Bakovic, M., Izumi, T., and Vance, D. E. (2003) J. Biol. Chem. 278, 19716-19722). In this study, we determined whether or not there were other important elements and binding proteins for basal CT alpha transcription in the Pcyt1a promoter, and if other Ets family proteins bind to the Ets-1-binding site. The results indicate the formation of a ternary complex with Ets-1 binding at -49/-47 and Sp1 binding at -58/-54 of the Pcyt1a promoter that is important for activating CT alpha transcription. When nuclear extracts of COS-7 cells expressing various Ets family repressors were incubated with DNA probes, binding of Net to the probes was observed. Net dose-dependently depressed the promoter-luciferase activity by 98%, even when co-expressed with Ets-1. RNA interference targeting Net caused an increase of endogenous CT alpha mRNA. After synchronizing the cell cycle in NIH3T3 cells, CT alpha mRNA increased at the S-M phase corresponding to an increase of Ets-1 mRNA and a decrease of Net mRNA. These results indicated that Net is an important endogenous repressor for CT alpha transcription.	Gunma Univ, Grad Sch Med, Dept Mol Biochem, Maebashi, Gumma 3718511, Japan; Dokkyo Univ, Sch Med, Dept Biochem, Mibu, Tochigi 3210293, Japan; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	Gunma University; Dokkyo Medical University; University of Alberta; University of Alberta	Vance, DE (corresponding author), Gunma Univ, Grad Sch Med, Dept Mol Biochem, Maebashi, Gumma 3718511, Japan.	dennis.vance@ualberta.ca; takizumi@med.gunma-u.ac.jp						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Chen YH, 2003, J BIOL CHEM, V278, P39572, DOI 10.1074/jbc.M308179200; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Ducret C, 1999, MOL CELL BIOL, V19, P7076; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Hadri L, 2002, J BIOL CHEM, V277, P36471, DOI 10.1074/jbc.M204731200; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; Kast HR, 2001, J LIPID RES, V42, P1266; KAURMA MM, 2002, J BIOL CHEM, V277, P36244; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Ridgway ND, 2003, BIOCHEM J, V372, P811, DOI 10.1042/BJ20030252; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Sugimoto H, 2003, J BIOL CHEM, V278, P19716, DOI 10.1074/jbc.M301590200; Sugimoto H, 2001, J BIOL CHEM, V276, P12338, DOI 10.1074/jbc.M100090200; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Tseu I, 2002, AM J RESP CELL MOL, V26, P506, DOI 10.1165/ajrcmb.26.4.4702; UTAL AK, 1991, J BIOL CHEM, V266, P24084; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Wieprecht M, 1996, J BIOL CHEM, V271, P9955, DOI 10.1074/jbc.271.17.9955; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297; Yamazaki Y, 2003, J BIOL CHEM, V278, P30642, DOI 10.1074/jbc.M212242200; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	60	20	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40857	40866		10.1074/jbc.M503578200	http://dx.doi.org/10.1074/jbc.M503578200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16157598	hybrid			2022-12-25	WOS:000233666600057
J	Bernacchi, S; Ennifar, E; Toth, K; Walter, P; Langowski, J; Dumas, P				Bernacchi, S; Ennifar, E; Toth, K; Walter, P; Langowski, J; Dumas, P			Mechanism of hairpin-duplex conversion for the HIV-1 dimerization initiation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RNA INTERNAL LOOPS; CRYSTAL-STRUCTURE; GENOMIC RNA; NUCLEOCAPSID PROTEIN; KISSING COMPLEX; EXTENDED-DUPLEX; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; STABLE DIMER	We have used the dimerization initiation site of HIV-1 genomic RNA as a model to investigate hairpin-duplex interconversion with a combination of fluorescence, UV melting, gel electrophoresis, and x-ray crystallographic techniques. Fluorescence studies with molecular beacons and crystallization experiments with 23-nucleotide dimerization initiation site fragments showed that the ratio of hairpin to duplex formed after annealing in water essentially depends on RNA concentration and not on cooling kinetics. With natural sequences allowing to form the most stable duplex, and thus also the loop-loop complex ( or "kissing complex"), concentrations as low as 3 mu M in strands are necessary to obtain a majority of the hairpin form. With a mutated sequence preventing kissing complex formation, a majority of hairpins was even obtained at 80 mu M in strands. However, this did not prevent an efficient conversion from hairpin to duplex in the presence of salts. Kinetic considerations are in favor of duplex formation from intermediates involving hairpins engaged in cruciform dimers rather than from free strands. The very first step of formation of such a cruciform intermediate could be trapped in a crystal structure. This mechanism might be significant for the dynamics of small RNAs beyond the strict field of HIV-1.	Univ Louis Pasteur Strasbourg 1, CNRS Convent, UPR 9002, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; German Canc Res Ctr, Div Biophys & Macromol, D-69120 Heidelberg, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; German Cancer Research Center (DKFZ)	Dumas, P (corresponding author), Univ Louis Pasteur Strasbourg 1, CNRS Convent, UPR 9002, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France.	p.dumas@ibmc.u-strasbg.fr	Toth, Katalin/AAC-2064-2020; Langowski, Jorg/A-1843-2011	Toth, Katalin/0000-0002-0081-4720; Langowski, Jorg/0000-0001-8600-0666; bernacchi, serena/0000-0003-2824-8326				ABOULELA F, 1994, FEBS LETT, V347, P261, DOI 10.1016/0014-5793(94)00564-8; AVIZONIS DZ, 1995, BIOPOLYMERS, V35, P187, DOI 10.1002/bip.360350207; Baba S, 2003, J BIOCHEM, V134, P637, DOI 10.1093/jb/mvg200; BABA S, 2001, NUCL ACIDS RES S, V1, P155; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; BORER PN, 1995, BIOCHEMISTRY-US, V34, P6488, DOI 10.1021/bi00019a030; Cabello-Villegas J, 2000, Nucleic Acids Res, V28, pE74, DOI 10.1093/nar/28.15.e74; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3, P1109; Correll CC, 1999, J MOL BIOL, V292, P275, DOI 10.1006/jmbi.1999.3072; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; Ennifar E, 2000, J MOL BIOL, V304, P35, DOI 10.1006/jmbi.2000.4204; Ennifar E, 1999, STRUCTURE, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7; Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727; Haddrick M, 1996, J MOL BIOL, V259, P58, DOI 10.1006/jmbi.1996.0301; HALD M, 1995, NUCLEIC ACIDS RES, V23, P4576, DOI 10.1093/nar/23.22.4576; Jovine L, 2000, STRUCTURE, V8, P527, DOI 10.1016/S0969-2126(00)00137-4; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kirchner R, 1998, ANTISENSE NUCLEIC A, V8, P507, DOI 10.1089/oli.1.1998.8.507; Klosterman PS, 1999, BIOCHEMISTRY-US, V38, P14784, DOI 10.1021/bi9912793; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; MARKY LA, 1983, BIOPOLYMERS, V22, P1247, DOI 10.1002/bip.360220416; Mihailescu MR, 2004, P NATL ACAD SCI USA, V101, P1189, DOI 10.1073/pnas.0307966100; Mujeeb A, 1998, NAT STRUCT BIOL, V5, P432, DOI 10.1038/nsb0698-432; Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686; Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s; Narberhaus F, 2002, ARCH MICROBIOL, V178, P404, DOI 10.1007/s00203-002-0481-8; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Paillart JC, 1996, BIOCHIMIE, V78, P639, DOI 10.1016/S0300-9084(96)80010-1; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; Rist MJ, 2002, BIOCHEMISTRY-US, V41, P14762, DOI 10.1021/bi0267240; SANTALUCIA J, 1990, BIOCHEMISTRY-US, V29, P8813, DOI 10.1021/bi00489a044; SCHEFFLE.IE, 1968, J MOL BIOL, V36, P291, DOI 10.1016/0022-2836(68)90156-3; Schroeder S, 1996, BIOCHEMISTRY-US, V35, P16105, DOI 10.1021/bi961789m; Shah SA, 1999, J MOL BIOL, V285, P1577, DOI 10.1006/jmbi.1998.2385; St Louis DC, 1998, J VIROL, V72, P3991; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P681, DOI 10.1093/oxfordjournals.jbchem.a022657; Takahashi K, 2001, J BIOL CHEM, V276, P31274, DOI 10.1074/jbc.M104577200; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; Theilleux-Delalande V, 2000, EUR J BIOCHEM, V267, P2711, DOI 10.1046/j.1432-1327.2000.01292.x; Tishchenko S, 2001, J MOL BIOL, V311, P311, DOI 10.1006/jmbi.2001.4877; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Turner D. H, 2000, NUCL ACIDS STRUCTURE, P259; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; WEMMER DE, 1985, NUCLEIC ACIDS RES, V13, P3755, DOI 10.1093/nar/13.10.3755; Wild K, 1999, STRUCTURE, V7, P1345, DOI 10.1016/S0969-2126(00)80024-6; Wild K, 2001, SCIENCE, V294, P598, DOI 10.1126/science.1063839; Windbichler N, 2003, NUCLEIC ACIDS RES, V31, P6419, DOI 10.1093/nar/gkg873; XODO LE, 1989, J MOL BIOL, V205, P777, DOI 10.1016/0022-2836(89)90322-7; Yakubovskaya MG, 2001, EUR J BIOCHEM, V268, P7, DOI 10.1046/j.1432-1327.2001.01861.x; Yusupov M, 1999, ACTA CRYSTALLOGR D, V55, P281, DOI 10.1107/S0907444998008506	55	42	42	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40112	40121		10.1074/jbc.M503230200	http://dx.doi.org/10.1074/jbc.M503230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16169845	hybrid			2022-12-25	WOS:000233461300050
J	Ravi, D; Muniyappa, H; Das, KC				Ravi, D; Muniyappa, H; Das, KC			Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER REACTIONS; BIOCHEMICAL SYSTEMS; REDUCTIVE CLEAVAGE; OXIDATIVE STRESS; P53; ROLES; DRUG; DOXORUBICIN; SENSITIVITY; ACTIVATION	Apoptosis is a major mechanism of cancer cell destruction by chemotherapy and radiotherapy. The anthracycline class of antitumor drugs undergoes redox cycling in living cells producing increased amounts of reactive oxygen species and semiquinone radical, both of which can cause DNA damage, and consequently trigger apoptotic death of cancer cells. We show here that MCF-7 cells overexpressing thioredoxin ( Trx) were more apoptotic in response to daunomycin. Trx overexpression in MCF-7 cells increased the generation of superoxide anion ( O-2(.-)) in anthracycline-treated cell extracts. Enhanced generation of O-2(.-) in response to daunomycin in Trx-overexpressing MCF-7 cells was inhibited by diphenyleneiodonium chloride, a general NADPH reductase inhibitor, demonstrating that Trx provides reducing equivalents to a bioreductive enzyme for redox cycling of daunomycin. Additionally Trx increased p53-DNA binding and expression in response to anthracyclines. MCF-7 cells expressing mutant redox-inactive Trx showed decreased superoxide generation, apoptosis, and p53 protein and DNA binding. In addition, down-regulation of endogenous Trx expression by small interfering RNA resulted in decreased expression of caspase-7 and cleaved poly( ADP-ribose) polymerase expression in response to daunomycin. These results suggest that endogenous Trx is required for anthracycline-mediated apoptosis of breast cancer cells. Taken together, our data demonstrate a novel pro-oxidant and proapoptotic role of Trx in anthracycline- mediated apoptosis in anthracycline chemotherapy.	Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Canc Res Ctr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Das, KC (corresponding author), Univ Arkansas Med Sci, Dept Pathol, 4301 W Markham,Slot 845, Little Rock, AR 72205 USA.	kdas@uams.edu	Dashnamoorthy, Ravi/B-8540-2013	Dashnamoorthy, Ravi/0000-0002-6108-2076	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071558] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL071558] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; Barham HM, 1996, BIOCHEM PHARMACOL, V51, P829, DOI 10.1016/0006-2952(95)02257-0; Berggren MI, 2001, ARCH BIOCHEM BIOPHYS, V392, P103, DOI 10.1006/abbi.2001.2435; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; Cho Y, 1999, Hokkaido Igaku Zasshi, V74, P239; Das KC, 1998, J IMMUNOL METHODS, V211, P9, DOI 10.1016/S0022-1759(97)00163-4; Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809; Das KC, 2000, BIOCHEM BIOPH RES CO, V277, P443, DOI 10.1006/bbrc.2000.3689; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Gallegos A, 1996, CANCER RES, V56, P5765; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Gardner PR, 1996, ARCH BIOCHEM BIOPHYS, V325, P20, DOI 10.1006/abbi.1996.0003; Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200; Gutierrez PL, 2000, FRONT BIOSCI-LANDMRK, V5, pD629, DOI 10.2741/gutier; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Heusler P, 2004, BRAIN RES, V1024, P104, DOI 10.1016/j.brainres.2004.07.047; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HRDNA R, 2000, ACTA MED, V43, P75; Islam MM, 2002, CANCER CHEMOTH PHARM, V49, P111, DOI 10.1007/s00280-001-0397-z; IYANAGI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P370, DOI 10.1016/0005-2728(69)90133-9; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KOMIYAMA T, 1985, BIOCHEM PHARMACOL, V34, P977, DOI 10.1016/0006-2952(85)90599-4; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; Mordente A, 2001, IUBMB LIFE, V52, P83; Munshi A, 2005, METH MOLEC MED, V110, P21; Ngo EO, 1998, CHEM RES TOXICOL, V11, P360, DOI 10.1021/tx9701945; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; PAN SS, 1980, MOL PHARMACOL, V17, P95; PAN SS, 1981, MOL PHARMACOL, V19, P184; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Ravi D, 2004, CANCER CHEMOTH PHARM, V54, P449, DOI 10.1007/s00280-004-0833-y; SAASIVAM S, 2005, ONCOGENE, V24, P627; Sadji-Ouatas Z, 2002, BIOCHEM J, V364, P881, DOI 10.1042/BJ20020349; Sasada T, 1999, FREE RADICAL BIO MED, V27, P504, DOI 10.1016/S0891-5849(99)00101-X; Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Wang JX, 1997, BLOOD, V89, P2480, DOI 10.1182/blood.V89.7.2480; Waxman DJ, 2003, CANCER RES, V63, P8563; YOKOMIZO A, 1995, CANCER RES, V55, P4293	52	54	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40084	40096		10.1074/jbc.M507192200	http://dx.doi.org/10.1074/jbc.M507192200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16159878	hybrid			2022-12-25	WOS:000233461300047
J	Novoselov, SV; Calvisi, DF; Labunskyy, VM; Factor, VM; Carlson, BA; Fomenko, DE; Moustafa, ME; Hatfield, DL; Gladyshev, VN				Novoselov, SV; Calvisi, DF; Labunskyy, VM; Factor, VM; Carlson, BA; Fomenko, DE; Moustafa, ME; Hatfield, DL; Gladyshev, VN			Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice	ONCOGENE			English	Article						selenoprotein; selenocysteine; selenium; cancer prevention; redox regulation	GROWTH-FACTOR-ALPHA; CANCER PREVENTION; THIOREDOXIN REDUCTASE; MOUSE MODEL; ACCELERATED HEPATOCARCINOGENESIS; GLUTATHIONE PEROXIDASE-1; PROSTATE-CANCER; LIVER-CANCER; C-MYC; SELENOCYSTEINE	The micronutrient element selenium ( Se) has been shown to be effective in reducing the incidence of cancer in animal models and human clinical trials. Selenoproteins and low molecular weight Se compounds were implicated in the chemopreventive effect, but specific mechanisms are not clear. We examined the role of Se and selenoproteins in liver tumor formation in TGF alpha/c-Myc transgenic mice, which are characterized by disrupted redox homeostasis and develop liver cancer by 6 months of age. In these mice, both Se deficiency and high levels of Se compounds suppressed hepatocarcinogenesis. In addition, both treatments induced expression of detoxification genes, increased apoptosis and inhibited cell proliferation. Within low-to-optimal levels of dietary Se, tumor formation correlated with expression of most selenoproteins. These data suggest that changes in selenoprotein expression may either suppress or promote tumorigenesis depending on cell type and genotype. Since dietary Se may have opposing effects on cancer, it is important to identify the subjects who will benefit from Se supplementation as well as those who will not.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; NCI, Expt Carcinogenesis Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, N 151 Beadle Ctr,1901 Vine St, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Labunskyy, Vyacheslav/AAC-8489-2020; Gladyshev, Vadim N/A-9894-2013; Moustafa, Mohamed E/E-9002-2018; Gladyshev, Vadim N/J-6187-2013; Moustafa, Mohamed/AAM-2211-2021	Moustafa, Mohamed/0000-0003-1308-6221; Labunskyy, Vyacheslav/0000-0001-9317-1076; Novoselov, Sergey/0000-0003-0104-6492; Gladyshev, Vadim/0000-0002-0372-7016	NCI NIH HHS [CA080946] Funding Source: Medline; NIA NIH HHS [AG021518] Funding Source: Medline; NIGMS NIH HHS [GM061603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005317, ZIABC005317, R01CA080946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bock A, 2000, Biofactors, V11, P77; Burk Raymond F, 2002, Nutr Clin Care, V5, P75, DOI 10.1046/j.1523-5408.2002.00006.x; BURK RF, 1983, FUND APPL TOXICOL, V3, P218, DOI 10.1016/S0272-0590(83)80129-8; Calvisi DF, 2004, GASTROENTEROLOGY, V126, P1374, DOI 10.1053/j.gastro.2004.02.014; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; El-Bayoumy K, 2004, MUTAT RES-FUND MOL M, V551, P181, DOI 10.1016/j.mrfmmm.2004.02.023; Factor VM, 2000, P NATL ACAD SCI USA, V97, P2196, DOI 10.1073/pnas.040428797; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; Felix K, 2004, CANCER RES, V64, P2910, DOI 10.1158/0008-5472.CAN-03-2672; Fu YX, 2001, J BIOL CHEM, V276, P43004, DOI 10.1074/jbc.M106946200; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gouaze V, 2002, J BIOL CHEM, V277, P42867, DOI 10.1074/jbc.M203067200; Hatfield D. L., 2001, SELENIUM ITS MOL BIO; HILL KE, 1984, TOXICOL APPL PHARM, V72, P32, DOI 10.1016/0041-008X(84)90246-1; Hironaka K, 2003, LAB INVEST, V83, P643, DOI 10.1097/01.LAB.0000067483.89649.11; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; Ip C, 1998, ANTICANCER RES, V18, P9; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; Klein EA, 2000, PROSTATE CANCER P D, V3, P145, DOI 10.1038/sj.pcan.4500412; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Milner JA, 2001, NUTR CANCER, V41, P1, DOI 10.1207/S15327914NC41-1&amp;2_1; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; REITER R, 1984, BIOCHEM PHARMACOL, V33, P1923, DOI 10.1016/0006-2952(84)90548-3; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sunde R. A., 1994, Selenium in biology and human health., P45; Whanger PD, 2004, BRIT J NUTR, V91, P11, DOI 10.1079/BJN20031015; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Yu SY, 1997, BIOL TRACE ELEM RES, V56, P117, DOI 10.1007/BF02778987; Zhao HJ, 2004, MOL BIOL CELL, V15, P506, DOI 10.1091/mbc.E03-07-0501	36	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8003	8011		10.1038/sj.onc.1208940	http://dx.doi.org/10.1038/sj.onc.1208940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170372	hybrid			2022-12-25	WOS:000233656600007
J	Compaan, DM; Gonzalez, LC; Tom, I; Loyet, KM; Eaton, D; Hymowitz, SG				Compaan, DM; Gonzalez, LC; Tom, I; Loyet, KM; Eaton, D; Hymowitz, SG			Attenuating lymphocyte activity - The crystal structure of the BTLA-HVEM complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS ENTRY MEDIATOR; NERVE GROWTH-FACTOR; T-CELL-ACTIVATION; GLYCOPROTEIN-D; B-LYMPHOCYTE; RECEPTOR FAMILY; BINDING; VIRUS; SUPERFAMILY; RESPONSES	Five CD28-like proteins exert positive or negative effects on immune cells. Only four of these five receptors interact with members of the B7 family. The exception is BTLA ( B and T lymphocyte attenuator), which instead interacts with the tumor necrosis factor receptor superfamily member HVEM( herpes virus entry mediator). To better understand this interaction, we determined the 2.8-angstrom crystal structure of the BTLA-HVEM complex. This structure shows that BTLA binds the N-terminal cysteine-rich domain of HVEM and employs a unique binding surface compared with other CD28-like receptors. Moreover, the structure shows that BTLA recognizes the same surface on HVEM as gD ( herpes virus glycoprotein D) and utilizes a similar binding motif. Light scattering analysis demonstrates that the extracellular domain of BTLA is monomeric and that BTLA and HVEM form a 1:1 complex. Alanine-scanning mutagenesis of HVEM was used to further define critical binding residues. Finally, BTLA adopts an immunoglobulin I-set fold. Despite structural similarities to other CD28-like members, BTLA represents a unique co-receptor.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Hymowitz, SG (corresponding author), 1 DNA Way, San Francisco, CA 94080 USA.	hymowitz@gene.com	Gonzalez, Lino/E-4102-2012; Loyet, Kelly/AAD-7544-2021	Gonzalez, Lino/0000-0003-3817-6450; 				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Cheung TC, 2005, P NATL ACAD SCI USA, V102, P13218, DOI 10.1073/pnas.0506172102; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Connolly SA, 2003, J VIROL, V77, P8127, DOI 10.1128/JVI.77.14.8127-8140.2003; Connolly SA, 2002, J VIROL, V76, P10894, DOI 10.1128/JVI.76.21.10894-10904.2002; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Evans EJ, 2005, NAT IMMUNOL, V6, P271, DOI 10.1038/ni1170; Gonzalez LC, 2005, P NATL ACAD SCI USA, V102, P1116, DOI 10.1073/pnas.0409071102; Granger SW, 2003, CYTOKINE GROWTH F R, V14, P289, DOI 10.1016/S1359-6101(03)00031-5; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Hurchla MA, 2005, J IMMUNOL, V174, P3377, DOI 10.4049/jimmunol.174.6.3377; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200; Metzler WJ, 1997, NAT STRUCT BIOL, V4, P527, DOI 10.1038/nsb0797-527; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Shimojima M, 2004, SCIENCE, V303, P1192, DOI 10.1126/science.1092124; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Wang Y, 2005, J CLIN INVEST, V115, P711, DOI 10.1172/JCI200522982; Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Wiesmann C, 2001, CELL MOL LIFE SCI, V58, P748, DOI 10.1007/PL00000898; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Zhang XW, 2004, IMMUNITY, V20, P337, DOI 10.1016/S1074-7613(04)00051-2	35	118	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39553	39561		10.1074/jbc.M507629200	http://dx.doi.org/10.1074/jbc.M507629200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16169851	hybrid			2022-12-25	WOS:000233362200078
J	Sun, CJ; Waite, JH				Sun, CJ; Waite, JH			Mapping chemical gradients within and along a fibrous structural tissue, mussel byssal threads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYTILUS-EDULIS; ADHESIVE PROTEIN; ACCUMULATION; DECAPEPTIDE; SOLUBILITY; RESISTANCE; HYDROXIDE; SURFACES; REPEATS; YIELD	The byssal thread of a mussel is an extraorganismic connective tissue that exhibits a striking end-to-end gradient in mechanical properties and thus provides a unique opportunity for studying how gradients are made. Mfp-1 ( Mytilus foot protein-1) is a conspicuous component of the protective outer cuticle of byssal threads given its high 3,4-dihydroxyphenylalanine ( Dopa) content at 10-15 mol%. Amino acid analysis of mfp-1 extracted from successive foot sections of Mytilus galloprovincialis reveals a post-translationally mediated gradient with highest Dopa levels present in mfp-1 from the accessory gland near the tip of the foot decreasing gradually toward the base. The Dopa content of successive segments of byssal threads decreases from the distal to the proximal end and thus reflects the trend of mfp-1 in the foot. Inductively coupled plasma analysis indicates that certain metal ions including iron follow the trend in Dopa along the thread. Energy-dispersive x-ray spectrometry showed that iron, when present, was concentrated in the cuticle of the threads but sparse in the core. The axial iron gradient appears most closely correlated with the Dopa gradient. The direct incubation of mussels and byssal threads in Fe3+ supplemented seawater showed that byssal threads are unable to sequester iron from the seawater. Instead, particulate/soluble iron is actively taken up by mussels during filter feeding and incorporated into byssal threads during their secretion. Our results suggest that mussels may exploit the interplay between Dopa and metals to tailor the different parts of threads for specific mechanical properties.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Sun, CJ (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	sun@lifesci.ucsb.edu			NIDCR NIH HHS [R01 DE015415] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015415] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson KE, 2000, J EXP BIOL, V203, P3065; Bell EC, 1996, J EXP BIOL, V199, P1005; BENEDICT CV, 1986, J MORPHOL, V189, P171, DOI 10.1002/jmor.1051890207; COOMBS TL, 1981, AQUAT TOXICOL, V1, P291, DOI 10.1016/0166-445X(81)90023-0; COULON J, 1987, ANN I OCEANOGR PARIS, V63, P89; Coyne KJ, 2000, J EXP BIOL, V203, P1425; Dalsin JL, 2005, LANGMUIR, V21, P640, DOI 10.1021/la048626g; Dalsin JL, 2003, J AM CHEM SOC, V125, P4253, DOI 10.1021/ja0284963; Frank BP, 2002, BIOTECHNOL PROGR, V18, P580, DOI 10.1021/bp010140s; GEORGE SG, 1976, J EXP MAR BIOL ECOL, V23, P71, DOI 10.1016/0022-0981(76)90086-1; Hassenkam T, 2004, BIOMACROMOLECULES, V5, P1351, DOI 10.1021/bm049899t; Holten-Andersen N, 2005, MATER RES SOC SYMP P, V844, P155; INOUE K, 1994, BIOL BULL, V186, P349, DOI 10.2307/1542281; KOIDE M, 1982, ESTUAR COAST SHELF S, V15, P679, DOI 10.1016/0272-7714(82)90079-8; Kuma K, 1998, DEEP-SEA RES PT I, V45, P91, DOI 10.1016/S0967-0637(97)00067-8; Liu XW, 2002, MAR CHEM, V77, P43, DOI 10.1016/S0304-4203(01)00074-3; QIN XX, 1995, J EXP BIOL, V198, P633; Qin XX, 1998, P NATL ACAD SCI USA, V95, P10517, DOI 10.1073/pnas.95.18.10517; Robinson MW, 2001, PARASITOLOGY, V123, P509, DOI 10.1017/S0031182001008630; Sever MJ, 2004, ANGEW CHEM INT EDIT, V43, P448, DOI 10.1002/anie.200352759; Sun CJ, 2002, BIOMACROMOLECULES, V3, P1240, DOI 10.1021/bm0255903; Suresh S, 2001, SCIENCE, V292, P2447, DOI 10.1126/science.1059716; TATEDA Y, 1986, B JPN SOC SCI FISH, V52, P2019; TAYLOR SW, 1994, INORG CHEM, V33, P5819, DOI 10.1021/ic00103a032; Taylor SW, 1996, INORG CHEM, V35, P7572, DOI 10.1021/ic960514s; Vaccaro E, 2001, BIOMACROMOLECULES, V2, P906, DOI 10.1021/bm0100514; Vitellaro-Zuccarello L., 1981, TISSUE CELL, V13, P701, DOI [10.1016/S0040- 8166(81) 80007-9, DOI 10.1016/S0040-8166(81)80007-9]; WAITE JH, 1990, INT J BIOL MACROMOL, V12, P139, DOI 10.1016/0141-8130(90)90065-I; Waite JH, 1998, MATRIX BIOL, V17, P93, DOI 10.1016/S0945-053X(98)90023-3; WAITE JH, 1985, BIOCHEMISTRY-US, V24, P5010, DOI 10.1021/bi00340a008; Waite JH, 2002, PHILOS T R SOC B, V357, P143, DOI 10.1098/rstb.2001.1025; WAITE JH, 1983, J BIOL CHEM, V258, P2911; WAITE JH, 1992, BIOPOLYMERS, V19, P27	33	90	97	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39332	39336		10.1074/jbc.M508674200	http://dx.doi.org/10.1074/jbc.M508674200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16166079	hybrid			2022-12-25	WOS:000233362200053
J	Tiso, M; Konas, DW; Panda, K; Garcin, ED; Sharma, M; Getzoff, ED; Stuehr, DJ				Tiso, M; Konas, DW; Panda, K; Garcin, ED; Sharma, M; Getzoff, ED; Stuehr, DJ			C-terminal tail residue Arg(1400) enables NADPH to regulate electron transfer in neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME-P450 REDUCTASE; AUTOINHIBITORY CONTROL ELEMENT; NO COMPLEX-FORMATION; FLAVIN DOMAIN; FERREDOXIN-NADP(+) REDUCTASE; COENZYME SPECIFICITY; CALMODULIN-BINDING; ENZYME ACTIVATION; STRUCTURAL BASIS; CALCIUM-BINDING	The neuronal nitric-oxide synthase (nNOS) flavoprotein domain (nNOSr) contains regulatory elements that repress its electron flux in the absence of bound calmodulin (CaM). The repression also requires bound NADP(H), but the mechanism is unclear. The crystal structure of a CaM-free nNOSr revealed an ionic interaction between Arg(1400) in the C-terminal tail regulatory element and the 2'-phosphate group of bound NADP( H). We tested the role of this interaction by substituting Ser and Glu for Arg1400 in nNOSr and in the full-length nNOS enzyme. The CaM-free nNOSr mutants had cytochrome c reductase activities that were less repressed than in wild-type, and this effect could be mimicked in wild-type by using NADH instead of NADPH. The nNOSr mutants also had faster flavin reduction rates, greater apparent Km for NADPH, and greater rates of flavin auto-oxidation. Single-turnover cytochrome c reduction data linked these properties to an inability of NADP(H) to cause shielding of the FMN module in the CaM-free nNOSr mutants. The full-length nNOS mutants had no NO synthesis in the CaM-free state and had lower steady-state NO synthesis activities in the CaM-bound state compared with wild-type. However, the mutants had faster rates of ferric heme reduction and ferrous heme-NO complex formation. Slowing down heme reduction in R1400E nNOS with CaM analogues brought its NO synthesis activity back up to normal level. Our studies indicate that the Arg(1400)-2'-phosphate interaction is a means by which bound NADP(H) represses electron transfer into and out of CaM-free nNOSr. This interaction enables the C-terminal tail to regulate a conformational equilibrium of the FMN module that controls its electron transfer reactions in both the CaM-free and CaM-bound forms of nNOS.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Scripps Research Institute; Scripps Research Institute	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, 9500 Euclid Ave,NB-30, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Garcin, Elsa D/C-1556-2013; Panda, Koustubh/E-5273-2017	Garcin, Elsa D/0000-0003-0501-8421; Panda, Koustubh/0000-0002-4783-2221	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL005883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL5883] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Aoyagi M, 2003, EMBO J, V22, P766, DOI 10.1093/emboj/cdg078; BATIE CJ, 1984, J BIOL CHEM, V259, P8832; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Daff S, 2001, BIOCHEM SOC T, V29, P147, DOI 10.1042/0300-5127:0290147; de Montellano PRO, 1998, DRUG METAB DISPOS, V26, P1185; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dunford AJ, 2004, EUR J BIOCHEM, V271, P2548, DOI 10.1111/j.1432-1033.2004.04185.x; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Garnaud PE, 2004, BIOCHEMISTRY-US, V43, P11035, DOI 10.1021/bi049312v; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Guan ZW, 2003, J BIOL CHEM, V278, P30859, DOI 10.1074/jbc.M301929200; Guan ZW, 2003, ARCH BIOCHEM BIOPHYS, V412, P65, DOI 10.1016/S0003-9861(03)00009-2; Gutierrez A, 2003, EUR J BIOCHEM, V270, P2612, DOI 10.1046/j.1432-1033.2003.03633.x; Gutierrez A, 2001, BIOCHEMISTRY-US, V40, P1964, DOI 10.1021/bi001719m; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Ignarro Louis J, 2005, Curr Diab Rep, V5, P17, DOI 10.1007/s11892-005-0062-8; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; Kondo R, 1999, J BIOL CHEM, V274, P36213, DOI 10.1074/jbc.274.51.36213; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Martinez-Julvez M, 2005, BIOPHYS CHEM, V115, P219, DOI 10.1016/j.bpc.2004.12.034; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MIZE RR, 1998, NITRIX OXIDE BRAIN D; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Murataliev MB, 2004, BBA-PROTEINS PROTEOM, V1698, P1, DOI 10.1016/j.bbapap.2003.10.003; Neeli R, 2005, J BIOL CHEM, V280, P17634, DOI 10.1074/jbc.M413826200; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Nogues I, 2004, BIOCHEMISTRY-US, V43, P6127, DOI 10.1021/bi049858h; Panda K, 2004, J BIOL CHEM, V279, P18323, DOI 10.1074/jbc.M310391200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Tejero J, 2003, J BIOL CHEM, V278, P49203, DOI 10.1074/jbc.M307934200; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	77	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39208	39219		10.1074/jbc.M507775200	http://dx.doi.org/10.1074/jbc.M507775200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16150731	hybrid			2022-12-25	WOS:000233362200037
J	Fernandez-Murray, JP; McMaster, CR				Fernandez-Murray, JP; McMaster, CR			Glycerophosphocholine catabolism as a new route for choline formation for phosphatidylcholine synthesis by the Kennedy pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPATHY TARGET ESTERASE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID-METABOLISM; MEMBRANE-PROTEINS; YEAST; PHOSPHODIESTERASE; GLYCEROPHOSPHOINOSITOL; GENE; LYSOPHOSPHOLIPASE; PHOSPHOINOSITIDES	In eukaryotes, neuropathy target esterase (Nte1p in yeast) deacylates phosphatidylcholine derived exclusively from the CDP-choline pathway to produce glycerophosphocholine (GroPCho) and release two fatty acids. The metabolic fate of GroPCho in eukaryotic cells is currently not known. Saccharomyces cerevisiae contains two open reading frames predicted to contain glycerophosphodiester phosphodiesterase domains, YPL110c and YPL206c. Pulse-chase experiments were conducted to monitor GroPCho metabolic fate under conditions known to alter CDP-choline pathway flux and consequently produce different rates of formation of GroPCho. From this analysis, it was revealed that GroPCho was metabolized to choline, with this choline serving as substrate for renewed synthesis of phosphatidylcholine. YPL110c played the major role in this metabolic pathway. To extend and confirm the metabolic studies, the ability of the ypl110c Delta and ypl206c Delta strains to utilize exogenous GroPCho or glycerophosphoinositol as the sole source of phosphate was analyzed. Consistent with our metabolic profiling, the ypl206c Delta strain grew on both substrates with a similar rate to wild type, whereas the ypl110c Delta strain grew very poorly on GroPCho and with moderately reduced growth on glycerophosphoinositol.	Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, 5849 Univ Ave,Rm C302, Halifax, NS B3H 4H7, Canada.	Christopher.mcmaster@dal.ca		McMaster, Christopher/0000-0003-0822-5776				Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; AMES BN, 1960, J BIOL CHEM, V235, P769; Beilharz T, 2003, J BIOL CHEM, V278, P8219, DOI 10.1074/jbc.M212725200; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Hama H, 2000, METHODS, V20, P465, DOI 10.1006/meth.2000.0959; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Huang SD, 2001, MOL CELL BIOL, V21, P6695, DOI 10.1128/MCB.21.19.6695-6705.2001; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kaiser C., 1994, METHODS YEAST GENETI; LARSON TJ, 1983, J BIOL CHEM, V258, P5428; LEE KS, 1994, J BIOL CHEM, V269, P19725; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McMaster CR, 2004, TOP CURR GENET, V6, P5; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Muhlig-Versen M, 2005, J NEUROSCI, V25, P2865, DOI 10.1523/JNEUROSCI.5097-04.2005; MUNSON RS, 1993, J BACTERIOL, V175, P4569, DOI 10.1128/JB.175.14.4569-4571.1993; MURRAY JPF, 2005, J BIOL CHEM, V280, P8544; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; Patton-Vogt JL, 1998, GENETICS, V149, P1707; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Sakagami H, 2005, J BIOL CHEM, V280, P23084, DOI 10.1074/jbc.M413438200; Sciorra VA, 2002, J CELL BIOL, V159, P1039, DOI 10.1083/jcb.200205056; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; van der Rest B, 2004, BIOCHEM J, V379, P601, DOI 10.1042/BJ20031489; Winrow CJ, 2003, NAT GENET, V33, P477, DOI 10.1038/ng1131; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100	32	60	66	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38290	38296		10.1074/jbc.M507700200	http://dx.doi.org/10.1074/jbc.M507700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172116	hybrid			2022-12-25	WOS:000233239800024
J	Gao, ZH; Shao, YF; Jiang, XJ				Gao, ZH; Shao, YF; Jiang, XJ			Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER MITOCHONDRIAL-MEMBRANE; CYTOCHROME-C; ACTIVATION; CLEAVAGE; MEMBERS; LIFE; BAX	Caspase-2 is an initiating caspase required for stress-induced apoptosis in various human cancer cells. Recent studies suggest that it can mediate the death function of tumor suppressor p53 and is activated by a multimeric protein complex, PIDDosome. However, it is not clear how caspase-2 exerts its apoptotic function in cells and whether its enzymatic activity is required for the apoptotic function. In this study, we used both in vitro mitochondrial cytochrome c release assays and cell culture apoptosis analyses to investigate the mechanism by which caspase-2 induces apoptosis. We show that active caspase-2, but neither a catalytically mutated caspase-2 nor active caspase-2 with its inhibitor, can cause cytochrome c release. Caspase-2 failed to induce cytochrome c release from mitochondria with Bid(-/-) background, and the release could be restored by addition of the wild-type Bid protein, but not by Bid with the caspase-2 cleavage site mutated. Caspase-2 was not able to induce cytochrome c release from Bax(-/-)Bak(-/-) mitochondria either. In cultured cells, gene deletion of Bax/Bak or Bid abrogated apoptosis induced by overexpression of caspase-2. Collectively, these results indicate that proteolytic activation of Bid and the subsequent induction of the mitochondrial apoptotic pathway through Bax/Bak is essential for apoptosis triggered by caspase-2.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Jiang, XJ (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 522, New York, NY 10021 USA.	jiangx@mskcc.org						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Fesik SW, 2001, SCIENCE, V294, P1477, DOI 10.1126/science.1062236; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Horvitz HR, 1999, CANCER RES, V59, p1701S; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	30	59	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38271	38275		10.1074/jbc.M506488200	http://dx.doi.org/10.1074/jbc.M506488200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172118	hybrid			2022-12-25	WOS:000233239800022
J	Han, S; Kim, TD; Ha, DC; Kim, KT				Han, S; Kim, TD; Ha, DC; Kim, KT			Rhythmic expression of adenylyl cyclase VI contributes to the differential regulation of serotonin N-acetyltransferase by bradykinin in rat pineal glands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELATONIN SYNTHESIS; TISSUE KALLIKREIN; RECEPTORS; CELLS; RELEASE; NEURONS; BRAIN; CAMP; INHIBITION; ASSAY	The rhythmic nocturnal production of melatonin in pineal glands is controlled by the periodic release of norepinephrine from the superior cervical ganglion. Norepinephrine binds to the beta-adrenergic receptor and stimulates an increase in intracellular cAMP levels, leading to the transcriptional activation of serotonin N-acetyltransferase, which in turn promotes melatonin production. In the present study, we report that bradykinin inhibits basal- and forskolin-stimulated adenylyl cyclase activity, norepinephrine-induced cAMP generation, and N-acetyltransferase expression in a calcium-dependent manner. These effects were blocked by pretreatment with U73122 (a selective phospholipase C inhibitor), and 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (a Ca2+ chelator), but not pertussis toxin. The calcium ionophore, ionomycin, inhibited isoproterenol-mediated cAMP generation, similar to bradykinin. Interestingly, the inhibitory effect of bradykinin was evident only during the daytime. At midday, bradykinin inhibited the cAMP level by similar to 50% but markedly stimulated cAMP production (by similar to 50%) at night. Northern blotting and immunoblotting data disclosed circadian expression of calcium-inhibitable adenylyl cyclase type 6. Expression of adenylyl cyclase type 6 was maximal at Zeitgeber Time (ZT) 01 and very low at ZT 13. Our results suggest that bradykinin-induced calcium inhibits melatonin synthesis through the mediation of adenylyl cyclase type 6 expression.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Syst Biodynam NCRC, Pohang 790784, South Korea; LG Life Sci Ltd, Drug Discovery Grp, Taejon 305380, South Korea	Pohang University of Science & Technology (POSTECH); LG Life Sciences Ltd	Kim, KT (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Syst Biodynam NCRC, San 31, Pohang 790784, South Korea.	ktk@postech.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627; Kim, Tae-Don/0000-0002-5910-4264				ALTIOK N, 1993, CELL SIGNAL, V5, P279, DOI 10.1016/0898-6568(93)90018-H; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Boehm S, 1997, BRIT J PHARMACOL, V122, P455, DOI 10.1038/sj.bjp.0701404; Borlongan CV, 2003, BRAIN RES BULL, V60, P297, DOI 10.1016/S0361-9230(03)00043-1; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; Chae HD, 1999, NEUROCHEM INT, V35, P447, DOI 10.1016/S0197-0186(99)00086-8; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; Chan GCK, 2001, EUR J NEUROSCI, V13, P2054, DOI 10.1046/j.0953-816x.2001.01578.x; CHAO J, 1987, ENDOCRINOLOGY, V120, P475, DOI 10.1210/endo-120-2-475; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; Choi BH, 2004, J NEUROCHEM, V90, P442, DOI 10.1111/j.1471-4159.2004.02495.x; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; Drijfhout WJ, 1996, J NEUROCHEM, V66, P748; Emala CW, 1998, BIOL REPROD, V59, P169, DOI 10.1095/biolreprod59.1.169; FUJIEDA H, 1993, J PINEAL RES, V14, P84, DOI 10.1111/j.1600-079X.1993.tb00490.x; Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004; Ganguly S, 2002, CELL TISSUE RES, V309, P127, DOI 10.1007/s00441-002-0579-y; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Hur EM, 2005, J CELL BIOL, V169, P657, DOI 10.1083/jcb.200411034; Kim TD, 2005, MOL CELL BIOL, V25, P3232, DOI 10.1128/MCB.25.8.3232-3246.2005; KIZUKI K, 1994, BRAIN RES, V634, P305, DOI 10.1016/0006-8993(94)91934-8; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; Kudo M, 1998, BRAIN RES, V797, P287, DOI 10.1016/S0006-8993(98)00174-7; Lee H, 2003, J NEUROCHEM, V85, P1043, DOI 10.1046/j.1471-4159.2003.01761.x; MANOLOPOULOS VG, 1995, BIOCHEM BIOPH RES CO, V208, P323, DOI 10.1006/bbrc.1995.1341; Marin A, 1996, J PINEAL RES, V21, P15, DOI 10.1111/j.1600-079X.1996.tb00266.x; Ongali B, 2003, J COMP NEUROL, V461, P506, DOI 10.1002/cne.10706; PERRY DC, 1984, J NEUROCHEM, V43, P1072, DOI 10.1111/j.1471-4159.1984.tb12846.x; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Shi B, 1999, ENDOCRINOLOGY, V140, P4669, DOI 10.1210/en.140.10.4669; Simonneaux V, 2003, PHARMACOL REV, V55, P325, DOI 10.1124/pr.55.2.2; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; SUGDEN AL, 1986, J BIOL CHEM, V261, P1608; SUGDEN D, 1988, J NEUROCHEM, V50, P149, DOI 10.1111/j.1471-4159.1988.tb13242.x; TAKAHASHI JS, 1993, NATURE, V365, P299, DOI 10.1038/365299a0; TAKAHASHI JS, 1980, P NATL ACAD SCI-BIOL, V77, P2319, DOI 10.1073/pnas.77.4.2319; Trendelenburg AU, 2000, BRIT J PHARMACOL, V130, P321, DOI 10.1038/sj.bjp.0703305; Tzavara ET, 1996, P NATL ACAD SCI USA, V93, P11208, DOI 10.1073/pnas.93.20.11208; Wicht H, 1999, J HISTOCHEM CYTOCHEM, V47, P411, DOI 10.1177/002215549904700315; Yamada H, 1996, J PINEAL RES, V21, P165, DOI 10.1111/j.1600-079X.1996.tb00284.x; Yamada H, 1998, J NEUROSCI, V18, P2056; YU L, 1993, J NEUROCHEM, V60, P1436, DOI 10.1111/j.1471-4159.1993.tb03306.x	49	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38228	38234		10.1074/jbc.M508130200	http://dx.doi.org/10.1074/jbc.M508130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166080	hybrid			2022-12-25	WOS:000233239800016
J	Hansen, M; Wind, T; Blouse, GE; Christensen, A; Petersen, HH; Kjelgaard, S; Mathiasen, L; Holtet, TL; Andreasen, PA				Hansen, M; Wind, T; Blouse, GE; Christensen, A; Petersen, HH; Kjelgaard, S; Mathiasen, L; Holtet, TL; Andreasen, PA			A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P-2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE INHIBITORS; ONCOGENIC VIRUS; MOUSE CELLS; MECHANISM; SERINE; SPECIFICITY; MUTAGENESIS; TRANSITION; TRYPSIN; POTENT	To find new principles for inhibiting serine proteases, we screened phage-displayed random peptide repertoires with urokinase-type plasminogen activator (uPA) as the target. The most frequent of the isolated phage clones contained the disulfide bridge-constrained sequence CSWRGLENHRMC, which we designated upain-1. When expressed recombinantly with a protein fusion partner, upain-1 inhibited the enzymatic activity of uPA competitively with a temperature and pH-dependent K-i, which at 25 degrees C and pH 7.4 was similar to 500 nM. At the same conditions, the equilibrium dissociation constant K-D, monitored by displacement of p-aminobenzamidine from the specificity pocket of uPA, was similar to 400 nM. By an inhibitory screen against other serine proteases, including trypsin, upain-1 was found to be highly selective for uPA. The cyclical structure of upain-1 was indispensable for uPA binding. Alanine-scanning mutagenesis identified Arg(4) of upain-1 as the P-1 residue and indicated an extended binding interaction including the specificity pocket and the 37-, 60-, and 97-loops of uPA and the P-1, P-2, P-3', P-4', and the P-5' residues of upain-1. Substitution with alanine of the P-2 residue, Trp(3), converted upain-1 into a distinct, although poor, uPA substrate. Upain-1 represents a new type of uPA inhibitor that achieves selectivity by targeting uPA-specific surface loops. Most likely, the inhibitory activity depends on its cyclical structure and the unusual P2 residue preventing the scissile bond from assuming a tetrahedral geometry and thus from undergoing hydrolysis. Peptide-derived inhibitors such as upain-1 may provide novel mechanistic information about enzyme-inhibitor interactions and alternative methodologies for designing effective protease inhibitors.	Aarhus Univ, Dept Mol Biol, Lab Cellular Prot Sci, DK-8000 Aarhus, Denmark	Aarhus University	Andreasen, PA (corresponding author), Aarhus Univ, Dept Mol Biol, Lab Cellular Prot Sci, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	pa@mb.au.dk						Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P177; Blouse GE, 2002, BIOCHEMISTRY-US, V41, P11997, DOI 10.1021/bi025967p; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P231; Christensen L, 1996, INT J CANCER, V66, P441; Coombs GS, 1998, J BIOL CHEM, V273, P4323, DOI 10.1074/jbc.273.8.4323; Coombs GS, 1996, J BIOL CHEM, V271, P4461; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DANO K, 1980, BIOCHIM BIOPHYS ACTA, V613, P542, DOI 10.1016/0005-2744(80)90110-2; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1980, BIOCHIM BIOPHYS ACTA, V630, P146, DOI 10.1016/0304-4165(80)90146-4; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Holtet TL, 1997, PROTEIN SCI, V6, P1511, DOI 10.1002/pro.5560060715; Jensen CM, 2005, J ORG CHEM, V70, P7512, DOI 10.1021/jo0505775; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; KALTOFT K, 1982, P NATL ACAD SCI-BIOL, V79, P3720, DOI 10.1073/pnas.79.12.3720; Katz BA, 2004, J MOL BIOL, V344, P527, DOI 10.1016/j.jmb.2004.09.032; Katz BA, 2003, J MOL BIOL, V329, P93, DOI 10.1016/S0022-2836(03)00399-1; Katz BA, 2001, CHEM BIOL, V8, P1107, DOI 10.1016/S1074-5521(01)00084-9; Klinghofer V, 2001, BIOCHEMISTRY-US, V40, P9125, DOI 10.1021/bi010186u; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; Krook M, 1998, MOL DIVERS, V3, P149; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Laboissiere MCA, 2002, J BIOL CHEM, V277, P26623, DOI 10.1074/jbc.M203076200; Leinonen J, 2000, SCAND J CLIN LAB INV, V60, P59, DOI 10.1080/00365510050217726; LUND LR, 1988, MOL CELL ENDOCRINOL, V60, P43, DOI 10.1016/0303-7207(88)90118-9; Mackman RL, 2001, J MED CHEM, V44, P3856, DOI 10.1021/jm010244+; OLSON ST, 1995, J BIOL CHEM, V270, P30007; Petersen HH, 2001, EUR J BIOCHEM, V268, P4430, DOI 10.1046/j.1432-1327.2001.02365.x; Renatus M, 1998, J MED CHEM, V41, P5445, DOI 10.1021/jm981068g; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Salvesen, 1986, PROTEINASE INHIBITOR, P23; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Spencer JR, 2002, BIOORG MED CHEM LETT, V12, P2023, DOI 10.1016/S0960-894X(02)00312-8; Sperl S, 2000, P NATL ACAD SCI USA, V97, P5113, DOI 10.1073/pnas.97.10.5113; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; THOGERSEN HC, 1994, Patent No. 9418227; Wendt MD, 2004, J MED CHEM, V47, P303, DOI 10.1021/jm0300072; Wind T, 2003, EUR J BIOCHEM, V270, P1680, DOI 10.1046/j.1432-1033.2003.03524.x; Wu P, 2000, EUR J BIOCHEM, V267, P6212, DOI 10.1046/j.1432-1327.2000.01696.x; Zeslawska E, 2000, J MOL BIOL, V301, P465, DOI 10.1006/jmbi.2000.3966; Zeslawska E, 2003, J MOL BIOL, V328, P109, DOI 10.1016/S0022-2836(03)00267-5	46	48	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38424	38437		10.1074/jbc.M505933200	http://dx.doi.org/10.1074/jbc.M505933200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16141208	hybrid			2022-12-25	WOS:000233239800039
J	Kaur, S; Wang, F; Venkatraman, M; Arsura, M				Kaur, S; Wang, F; Venkatraman, M; Arsura, M			X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta 1 (TGF-beta 1) through ubiquitin-mediated proteosomal degradation of the TGF-beta 1-activated kinase 1 (TAK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TGF-BETA; HEPATOCELLULAR CARCINOMAS; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; LIVER DEVELOPMENT; KINASE COMPLEX; PROTEIN; ALPHA; GROWTH-FACTOR-BETA-1	Active NF-kappa B renders malignant hepatocytes refractory to the growth inhibitory and pro-apoptotic properties of transforming growth factor beta 1 (TGF-beta 1). NF-kappa B counteracts TGF-beta 1-induced apoptosis through up-regulation of downstream target genes, such as XIAP and Bcl-X-L, which in turn inhibit the intrinsic pathway of apoptosis. In addition, induction of NF-kappa B by TGF-beta 1 inhibits JNK signaling, thereby attenuating TGF-beta 1-induced cell death of normal hepatocytes. However, the mechanism involved in the negative cross-talk between the NF-kappa B and JNK pathways during TGF-beta 1 signaling has not been determined. In this study, we have identified the XIAP gene as one of the critical mediators of NF-kappa B-mediated suppression of JNK signaling. We show that NF-kappa B plays a role in the up-regulation of XIAP gene expression in response to TGF-beta 1 treatment and forms a TGF-beta 1-inducible complex with TAK1. Furthermore, we show that the RING domain of XIAP mediates TAK1 polyubiquitination, which then targets this molecule for proteosomal degradation. Down-regulation of TAK1 protein expression inhibits TGF-beta 1-mediated activation of JNK and apoptosis. Conversely, silencing of XIAP promotes persistent JNK activation and potentiates TGF-beta 1-induced apoptosis. Collectively, our findings identify a novel mechanism for the regulation of JNK activity by NF-kappa B during TGF-beta 1 signaling and raise the possibility that pharmacologic inhibition of the NF-kappa B/XIAP signaling pathway might selectively abolish the pro-oncogenic activity of TGF-beta 1 in advanced hepatocellular carcinomas (HCCs) without affecting the proapoptotic effects of TGF-beta 1 involved in normal liver homeostasis.	Univ Tennessee, Coll Med, Dept Pharmacol, Hlth Sci Ctr,Canc Inst, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Arsura, M (corresponding author), Univ Tennessee, Coll Med, Dept Pharmacol, Hlth Sci Ctr,Canc Inst, 874 Union Ave, Memphis, TN 38163 USA.	marsura@utmem.edu			NATIONAL CANCER INSTITUTE [R01CA078616] Funding Source: NIH RePORTER; NCI NIH HHS [CA78616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Attisano L., 2001, GENOME BIOL, V2, p3010.3011, DOI [DOI 10.1186/GB-2001-2-8-REVIEWS3010, 10.1186/gb-2001-2-8-reviews3010]; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Carter BZ, 2005, BLOOD, V105, P4043, DOI 10.1182/blood-2004-08-3168; Cavin LG, 2004, CANCER RES, V64, P7030, DOI 10.1158/0008-5472.CAN-04-1647; Cavin LG, 2003, HEPATOLOGY, V38, P1540, DOI 10.1016/j.hep.2003.09.019; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; FAUSTO N, 1990, ANN NY ACAD SCI, V593, P231, DOI 10.1111/j.1749-6632.1990.tb16115.x; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAGY P, 1989, MOL CARCINOGEN, V2, P345, DOI 10.1002/mc.2940020609; NAGY P, 1988, CANCER RES, V48, P5522; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Park JM, 2004, GENE DEV, V18, P584, DOI 10.1101/gad.1168104; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 2002, J BIOL CHEM, V277, P30454, DOI 10.1074/jbc.M203312200; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; WU JC, 1994, CANCER RES, V54, P5964; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361	67	75	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38599	38608		10.1074/jbc.M505671200	http://dx.doi.org/10.1074/jbc.M505671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16157589	hybrid			2022-12-25	WOS:000233239800060
J	Stankiewicz, AR; Lachapelle, G; Foo, CPZ; Radicioni, SM; Mosser, DD				Stankiewicz, AR; Lachapelle, G; Foo, CPZ; Radicioni, SM; Mosser, DD			Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; MOLECULAR CHAPERONES; CELL-DEATH; BCL-2 FAMILY; MEMBRANE PERMEABILIZATION; SUBCELLULAR LOCATION; DEPENDENT APOPTOSIS; SIGNAL-TRANSDUCTION; APAF-1 APOPTOSOME	Hsp70 overexpression can protect cells from stress-induced apoptosis. Our previous observation that Hsp70 inhibits cytochrome c release in heat-stressed cells led us to examine events occurring upstream of mitochondrial disruption. In this study we examined the effects of heat shock on the proapoptotic Bcl-2 family member Bax because of its central role in regulating cytochrome c release in stressed cells. We found that heat shock caused a conformational change in Bax that leads to its translocation to mitochondria, stable membrane association, and oligomerization. All of these events were inhibited in cells that had elevated levels of Hsp70. Hsp70 did not physically interact with Bax in control or heat-shocked cells, indicating that Hsp70 acts to suppress signals leading to Bax activation. Hsp70 inhibited stress-induced JNK activation and inhibition of JNK with SP600125 or by expression of a dominant negative mutant of JNK-blocked Bax translocation as effectively as Hsp70 overexpression. Hsp70 did not protect cells expressing a mutant form of Bax that has constitutive membrane insertion capability or cells treated with a small molecule activator of apoptosome formation, indicating that it is unable to prevent cell death after mitochondrial disruption and caspase activation have occurred. These results indicate that Hsp70 blocks heat-induced apoptosis primarily by inhibiting Bax activation and thereby preventing the release of proapoptotic factors from mitochondria. Hsp70, therefore, inhibits events leading up to mitochondrial membrane permeabilization in heat-stressed cells and thereby controls the decision to die but does not interfere with cell death after this event has occurred.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Mosser, DD (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	rmosser@uoguelph.ca	Mosser, Dick D/A-7391-2008	Mosser, Richard/0000-0002-9183-2288				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Gabai VL, 2005, ONCOGENE, V24, P3328, DOI 10.1038/sj.onc.1208495; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GERNER EW, 1975, NATURE, V256, P500, DOI 10.1038/256500a0; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lee KH, 2005, J BIOL CHEM, V280, P13179, DOI 10.1074/jbc.M410059200; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Nollen EAA, 2002, J CELL SCI, V115, P2809; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	67	328	362	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38729	38739		10.1074/jbc.M509497200	http://dx.doi.org/10.1074/jbc.M509497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172114	hybrid			2022-12-25	WOS:000233239800075
J	Wolfe, CL; Warrington, JA; Treadwell, L; Norcum, MT				Wolfe, CL; Warrington, JA; Treadwell, L; Norcum, MT			A three-dimensional working model of the multienzyme complex of aminoacyl-tRNA synthetases based on electron microscopic placements of tRNA and proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONYL-TRANSFER-RNA; EUKARYOTIC MULTISYNTHETASE COMPLEX; STRUCTURAL-ANALYSIS; MACROMOLECULAR ASSEMBLAGE; FUNCTIONAL IMPLICATIONS; P43 COMPONENT; CYTOKINE; ARC1P; IDENTIFICATION; LOCALIZATION	It has become evident that the process of protein synthesis is performed by many cellular polypeptides acting in concert within the structural confines of protein complexes. In multicellular eukaryotes, one of these assemblies is amultienzyme complex composed of eight proteins that have aminoacyl-tRNA synthetase activities as well as three non-synthetase proteins (p43, p38, and p18) with diverse functions. This study uses electron microscopy and three-dimensional reconstruction to explore the arrangement of proteins and tRNA substrates within this "core" multisynthetase complex. Binding of unfractionated tRNA establishes that these molecules are widely distributed on the exterior of the structure. Binding of gold-labeled tRNA(Leu) places leucyl-tRNA synthetase and the bifunctional glutamyl-/prolyl-tRNA synthetase at the base of this asymmetric "V"-shaped particle. Astable cell line has been produced that incorporates hexahistidine-labeled p43 into the multisynthetase complex. Using a gold-labeled nickel-nitrilotriacetic acid probe, the polypeptides of the p43 dimer have been located along one face of the particle. The results of this and previous studies are combined into an initial three-dimensional working model of the multisynthetase complex. This is the first conceptualization of how the protein constituents and tRNA substrates are arrayed within the structural confines of this multiprotein assembly.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Tougaloo Coll, Dept Biol, Tougaloo, MS 39174 USA	University of Mississippi; University of Mississippi Medical Center; Tougaloo College	Norcum, MT (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.	mnorcum@biochem.umsmed.edu						Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; Golinelli-Cohen MP, 2004, J MOL BIOL, V340, P15, DOI 10.1016/j.jmb.2004.04.040; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; Guigou L, 2004, BIOCHEMISTRY-US, V43, P4592, DOI 10.1021/bi036150e; Hainfeld JF, 2000, J HISTOCHEM CYTOCHEM, V48, P471, DOI 10.1177/002215540004800404; Han JM, 2003, BIOCHEM BIOPH RES CO, V303, P985, DOI 10.1016/S0006-291X(03)00485-6; HOUNTONDJI C, 1979, EUR J BIOCHEM, V102, P247, DOI 10.1111/j.1432-1033.1979.tb06286.x; Jeong EJ, 2000, BIOCHEMISTRY-US, V39, P15775, DOI 10.1021/bi001393h; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim Y, 2000, J BIOL CHEM, V275, P27062; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD M, 1987, J BIOL CHEM, V262, P3982; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; MIRANDE M, 1983, EUR J BIOCHEM, V131, P163, DOI 10.1111/j.1432-1033.1983.tb07244.x; Norcum MT, 1999, J BIOL CHEM, V274, P12205, DOI 10.1074/jbc.274.18.12205; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; NORCUM MT, 1991, J BIOL CHEM, V266, P15398; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Renault L, 2001, EMBO J, V20, P570, DOI 10.1093/emboj/20.3.570; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; RYAZANOV AG, 1987, BIOSYSTEMS, V20, P275, DOI 10.1016/0303-2647(87)90035-9; SANG LJ, 2002, BIOCHEM BIOPH RES CO, V291, P158; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; Shalak V, 2001, J BIOL CHEM, V276, P23769, DOI 10.1074/jbc.M100489200; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Sorzano COS, 2001, J STRUCT BIOL, V133, P108, DOI 10.1006/jsbi.2001.4338; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wolfe CL, 2003, PROTEIN SCI, V12, P2282, DOI 10.1110/ps.03147903; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	36	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38870	38878		10.1074/jbc.M502759200	http://dx.doi.org/10.1074/jbc.M502759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169847	hybrid			2022-12-25	WOS:000233239800089
J	Barbour, LA; Rahman, SM; Gurevich, I; Leitner, JW; Fischer, SJ; Roper, MD; Knotts, TA; Vo, Y; McCurdy, CE; Yakar, S; LeRoith, D; Kahn, CR; Cantley, LC; Friedman, JE; Draznin, B				Barbour, LA; Rahman, SM; Gurevich, I; Leitner, JW; Fischer, SJ; Roper, MD; Knotts, TA; Vo, Y; McCurdy, CE; Yakar, S; LeRoith, D; Kahn, CR; Cantley, LC; Friedman, JE; Draznin, B			Increased p85 alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TRANSGENIC MICE; P85 ALPHA; SUBUNIT; SENSITIVITY; EXPRESSION; INHIBITION; LACKING	Insulin resistance is a cardinal feature of normal pregnancy and excess growth hormone (GH) states, but its underlying mechanism remains enigmatic. We previously found a significant increase in the p85 regulatory subunit of phosphatidylinositol kinase ( PI3-kinase) and striking decrease in IRS-1-associated PI 3-kinase activity in the skeletal muscle of transgenic animals overexpressing human placental growth hormone. Herein, using transgenic mice bearing deletions in p85 alpha, p85 beta, or insulin-like growth factor-1, we provide novel evidence suggesting that overexpression of p85 alpha is a primary mechanism for skeletal muscle insulin resistance in response to GH. We found that the excess in total p85 was entirely accounted for by an increase in the free p85 alpha-specific isoform. In mice with a liver-specific deletion in insulin-like growth factor-1, excess GH caused insulin resistance and an increase in skeletal muscle p85 alpha, which was completely reversible using a GH-releasing hormone antagonist. To understand the role of p85 alpha in GH-induced insulin resistance, we used mice bearing deletions of the genes coding for p85 alpha or p85 beta, respectively (p85 alpha(+/-) and p85 beta(-/-)). Wild type and p85 beta(-/-) mice developed in vivo insulin resistance and demonstrated overexpression of p85 alpha and reduced insulin-stimulated PI 3-kinase activity in skeletal muscle in response to GH. In contrast, p85 alpha(+/-) mice retained global insulin sensitivity and PI 3-kinase activity associated with reduced p85 alpha expression. These findings demonstrated the importance of increased p85 alpha in mediating skeletal muscle insulin resistance in response to GH and suggested a potential role for reducing p85 alpha as a therapeutic strategy for enhancing insulin sensitivity in skeletal muscle.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Obstet & Gynecol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Vet Affairs Res Serv, Denver, CO 80220 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Childrens Hosp, Joslin Diabet Ctr,Res Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Boston Children's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Friedman, JE (corresponding author), Univ Colorado, Hlth Sci Ctr, Mail Stop 8106,POB 6511, Aurora, CO 80045 USA.	Jed.Friedman@uchsc.edu	Rahman, Shaikh Mizanoor/GLN-7518-2022; Kahn, Ronald/AAY-2435-2021; Cantley, Lewis C/D-1800-2014	Rahman, Shaikh Mizanoor/0000-0002-4879-2663; Kahn, Ronald/0000-0002-7583-9228; Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK062155] Funding Source: Medline; NIGMS NIH HHS [GM41890, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAK JF, 1991, AM J PHYSIOL, V260, pE736, DOI 10.1152/ajpendo.1991.260.5.E736; Barbour LA, 2005, DIABETES, V54, pA39; Barbour LA, 2004, ENDOCRINOLOGY, V145, P1144, DOI 10.1210/en.2003-1297; Barbour LA, 2002, AM J OBSTET GYNECOL, V186, P512, DOI 10.1067/mob.2002.121256; DELRINCON JP, 2005, END SOC 87 ANN M SAN; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dominici FP, 1999, AM J PHYSIOL-ENDOC M, V277, pE447, DOI 10.1152/ajpendo.1999.277.3.E447; Friedman JE, 1999, DIABETES, V48, P1807, DOI 10.2337/diabetes.48.9.1807; Giorgino F, 1997, J BIOL CHEM, V272, P7455, DOI 10.1074/jbc.272.11.7455; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Kim JK, 1999, AM J PHYSIOL-ENDOC M, V277, pE742, DOI 10.1152/ajpendo.1999.277.4.E742; Kirwan JP, 2004, J CLIN ENDOCR METAB, V89, P4678, DOI 10.1210/jc.2004-0749; Lamia KA, 2004, MOL CELL BIOL, V24, P5080, DOI 10.1128/MCB.24.11.5080-5087.2004; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Smith TR, 1997, AM J PHYSIOL-ENDOC M, V272, pE1071, DOI 10.1152/ajpendo.1997.272.6.E1071; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Thirone ACP, 1998, FEBS LETT, V421, P191, DOI 10.1016/S0014-5793(97)01560-3; Thirone ACP, 1997, MOL CELL ENDOCRINOL, V130, P33, DOI 10.1016/S0303-7207(97)00071-3; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Yakar S, 2004, J CLIN INVEST, V113, P96, DOI 10.1172/JCI200417763; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110	26	104	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37489	37494		10.1074/jbc.M506967200	http://dx.doi.org/10.1074/jbc.M506967200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16166093	hybrid			2022-12-25	WOS:000233044500025
J	Chen, YR; Chen, CL; Zhang, LW; Green-Church, KB; Zweier, JL				Chen, YR; Chen, CL; Zhang, LW; Green-Church, KB; Zweier, JL			Superoxide generation from mitochondrial NADH dehydrogenase induces self-inactivation with specific protein radical formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; BOVINE HEART-MITOCHONDRIA; OXIDOREDUCTASE COMPLEX-I; CYTOCHROME C REDUCTASE; OXYGEN-FREE RADICALS; UBIQUINONE OXIDOREDUCTASE; QUINONE OXIDOREDUCTASE; PARKINSONS-DISEASE; ELECTRON-TRANSPORT; MASS-SPECTROMETRY	Mitochondrial superoxide (O-2(radical anion).) production is an important mediator of oxidative cellular injury. While NADH dehydrogenase (NDH) is a critical site of this O-2(radical anion) production; its mechanism of O-2(radical anion) generation is not known. Therefore, the catalytic function of NDH in the mediation of O-2(radical anion) generation was investigated by EPR spin-trapping. In the presence of NADH, O-2(radical anion) generation from NDH was observed and was inhibited by diphenyleneiodinium chloride (DPI), indicating involvement of the FMN-binding site of NDH. Addition of FMN increased O-2(radical anion) production. Destruction of the cysteine ligands of iron-sulfur clusters decreased O-2(radical anion) generation, suggesting a secondary role of this site. This inhibitory effect was reversed by addition of FMN. However, FMN addition could not reverse the inhibition of NDH by either DPI or heat denaturation, demonstrating involvement of both FMN and its FMN-binding protein moiety in the catalysis of O-2(radical anion) generation. O-2(radical anion) production by NDH also induced self-inactivation. Immunospin-trapping with anti-DMPO antibody and subsequent mass spectrometry was used to define the sites of oxidative damage of NDH. A DMPO adduct was detected on the 51-kDa subunit and was O-2(radical anion)-dependent. Alkylation of the cysteine residues of NDH significantly inhibited NDH-DMPO spin adduct formation, indicating involvement of protein thiyl radicals. LC/MS/MS analysis of a tryptic digest of the 51-kDa polypeptide revealed that cysteine (Cys(206)) and tyrosine (Tyr(177)) were specific sites of NDH-derived protein radical formation. Thus, two domains of the 51-kDa subunit, Gly(200-) Ala-Gly-Ala-Tyr-Ile-Cys(206)- Gly-Glu-Glu- Thr-Ala-Leu-Ile-Glu-Ser-Ile-Glu-Gly-Lys(219) and Ala(176)-Tyr(177)- Glu-Ala-Gly-Leu-Ile-Gly-Lys(184), were demonstrated to be susceptible to oxidative attack, and their oxidative modification results in decreased electron transfer activity.	Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, Div Cardiovasc Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Campus Chem Instrument Ctr, Proteom & Mass Spectrometry Facil, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chen, YR (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst 607, 473 W 12th Ave, Columbus, OH 43210 USA.	yeong-renn.chen@osumc.edu	Zhang, Liwen/P-1111-2016; Green, Kari B/H-3541-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083237, R29HL038324, P01HL065608, R01HL038324, R01HL063744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES011031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL65608, HL63744, R01 HL083237] Funding Source: Medline; NIEHS NIH HHS [K22 ES011031, ES11031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ANDERSON RF, 1995, INT J RADIAT BIOL, V68, P535, DOI 10.1080/09553009514551521; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cardounel AJ, 2005, J BIOL CHEM, V280, P7540, DOI 10.1074/jbc.M410241200; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Chen YR, 2004, FREE RADICAL BIO MED, V37, P1591, DOI 10.1016/j.freeradbiomed.2004.07.013; Chen YR, 2000, BIOCHEMISTRY-US, V39, P4415, DOI 10.1021/bi992652+; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; Deterding LJ, 2004, J BIOL CHEM, V279, P11600, DOI 10.1074/jbc.M310704200; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; Feldkamp T, 2004, AM J PHYSIOL-RENAL, V286, pF749, DOI 10.1152/ajprenal.00276.2003; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Galkin A, 2005, J BIOL CHEM, V280, P30129, DOI 10.1074/jbc.M504709200; Hatefi Y, 1978, Methods Enzymol, V53, P11; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lee C, 2000, J BIOL CHEM, V275, P38965, DOI 10.1074/jbc.M006341200; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mason RP, 2004, FREE RADICAL BIO MED, V36, P1214, DOI 10.1016/j.freeradbiomed.2004.02.077; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Ohnishi ST, 2005, J BIOENERG BIOMEMBR, V37, P1, DOI 10.1007/s10863-005-4117-y; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Prutz W A, 1986, Free Radic Res Commun, V2, P69, DOI 10.3109/10715768609088056; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; REDFEARN ER, 1966, BIOCHIM BIOPHYS ACTA, V118, P413, DOI 10.1016/S0926-6593(66)80050-4; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Song Y, 2002, BIOCHEMISTRY-US, V41, P10616, DOI 10.1021/bi026060u; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vinogradov A D, 1979, Methods Enzymol, V55, P118; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; Yano T, 2005, BIOCHEMISTRY-US, V44, P1744, DOI 10.1021/bi048132i; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zhang Z, 1998, FREE RADICAL RES, V28, P151, DOI 10.3109/10715769809065801; Zhao X, 2005, CIRCULATION, V111, P2966, DOI 10.1161/CIRCULATIONAHA.104.527226; ZHU J, 2004, THESIS OKLAHOMA STAT; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	60	108	111	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37339	37348		10.1074/jbc.M503936200	http://dx.doi.org/10.1074/jbc.M503936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150735	hybrid			2022-12-25	WOS:000233044500007
J	Desire, L; Bourdin, J; Loiseau, N; Peillon, H; Picard, V; De Oliveira, C; Bachelot, F; Leblond, B; Taverne, T; Beausoleil, E; Lacombe, S; Drouin, D; Schweighoffer, F				Desire, L; Bourdin, J; Loiseau, N; Peillon, H; Picard, V; De Oliveira, C; Bachelot, F; Leblond, B; Taverne, T; Beausoleil, E; Lacombe, S; Drouin, D; Schweighoffer, F			RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases A beta production in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; LIPID RAFTS; MEDIATED CLEAVAGE; ACTIVATION; CELLS; PRESENILIN-1; MICE; RHO; GENERATION; DOMAIN	beta-Amyloid peptides (A beta) that form the senile plaques of Alzheimer disease consist mainly of 40- and 42-amino acid (A beta 40 and A beta 42) peptides generated from the cleavage of the amyloid precursor protein (APP). Generation of A beta involves beta-secretase and gamma-secretase activities and is regulated by membrane trafficking of the proteins involved in A beta production. Here we describe a new small molecule, EHT1864, which blocks the Rac1 signaling pathways. In vitro, EHT 1864 blocks A beta 40 and A beta 42 production but does not impact sAPP alpha levels and does not inhibit beta-secretase. Rather, EHT 1864 modulates APP processing at the level of gamma-secretase to prevent A beta 40 and A beta 42 generation. This effect does not result from a direct inhibition of the gamma-secretase activity and is specific for APP cleavage, since EHT 1864 does not affect Notch cleavage. In vivo, EHT 1864 significantly reduces A beta 40 and A beta 42 levels in guinea pig brains at a threshold that is compatible with delaying plaque accumulation and/or clearing the existing plaque in brain. EHT 1864 is the first derivative of a new chemical series that consists of candidates for inhibiting A beta formation in the brain of AD patients. Our findings represent the first pharmacological validation of Rac1 signaling as a target for developing novel therapies for Alzheimer disease.	Exonhit Therapeut, F-75013 Paris, France		Desire, L (corresponding author), Exonhit Therapeut, 63 Bd Massena, F-75013 Paris, France.	laurent.desire@exonhit.com	Leblond, Bertrand/A-3076-2015	Leblond, Bertrand/0000-0003-2585-9834				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andrau D, 2003, J BIOL CHEM, V278, P25859, DOI 10.1074/jbc.M302622200; Beck M, 2003, NEUROCHEM RES, V28, P637, DOI 10.1023/A:1022850113083; Blasko I, 1999, FASEB J, V13, P63, DOI 10.1096/fasebj.13.1.63; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Chevallier N, 1997, BRIT J PHARMACOL, V121, P556, DOI 10.1038/sj.bjp.0701151; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Field KA, 2000, MOL BIOL CELL, V11, P3661, DOI 10.1091/mbc.11.10.3661; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Jaksits S, 2004, J IMMUNOL, V173, P1628, DOI 10.4049/jimmunol.173.3.1628; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kumanogoh H, 2001, NEUROSCI RES, V39, P189, DOI 10.1016/S0168-0102(00)00211-X; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; LEBLOND B, Patent No. 2004076445; Lee M, 2002, BIOCHEM J, V366, P937, DOI 10.1042/BJ20020453; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; O'Kane EM, 2004, NEUROPHARMACOLOGY, V46, P879, DOI 10.1016/j.neuropharm.2003.11.020; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Zambrano N, 2004, J BIOL CHEM, V279, P16161, DOI 10.1074/jbc.M311027200; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154; Zhu XW, 2000, INT J DEV NEUROSCI, V18, P433, DOI 10.1016/S0736-5748(00)00010-1	55	102	115	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37516	37525		10.1074/jbc.M507913200	http://dx.doi.org/10.1074/jbc.M507913200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150730	hybrid			2022-12-25	WOS:000233044500028
J	San Miguel, SM; Namdar-Attar, M; Noh, T; Frenkel, B; Bab, I				San Miguel, SM; Namdar-Attar, M; Noh, T; Frenkel, B; Bab, I			ERK1/2-activated de novo Mapkapk2 synthesis is essential for osteogenic growth peptide mitogenic signaling in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; C-TERMINAL PENTAPEPTIDE; TRANSCRIPTION FACTOR; MAP KINASE; PARATHYROID-HORMONE; MECHANICAL STRAIN; IN-VITRO; PROLIFERATION; DIFFERENTIATION	In osteoblasts, the mitogen-activated protein kinases ERK1/2 and p38 as well as the cAMP-response element-binding protein ( CREB) have been implicated in the regulation of proliferation and differentiation. The osteogenic growth peptide (OGP) is a 14-mer bone cell mitogen that increases bone formation and trabecular bone density and stimulates fracture healing. OGP-(10-14) is the physiologically active form of OGP. Using gene array analysis, real-time reverse transcription-PCR, and immunoblot and DNA synthesis assays we show here that in MC3T3E1 and newborn mouse calvarial osteoblastic cultures the OGP-( 10 - 14) mitogenic signaling is critically dependent on de novo synthesis of mitogen-activated protein kinase-activated protein kinase 2 (Mapkapk2) mRNA and protein. The increase in Mapkapk2 occurs following short term ( 5 - 60 min) stimulation of ERK1/2 activity by OGP-( 10 - 14); phosphorylation of p38 remains unaffected. Downstream of Mapkapk2, CREB is phosphorylated on Ser133 leading to its enhanced transcriptional activity. That these events are critical for the OGP-( 10 - 14) mitogenic signaling is demonstrated by blocking the effects of OGP( 10 - 14) on the ERK1/2 pathway, Mapkapk2, CREB, and DNA synthesis using the MEK inhibitor PD098059. The OGP-( 10 - 14) stimulation of CREB transcriptional activity and DNA synthesis is also blocked by Mapkapk2 siRNA. These data define a novel mitogenic signaling pathway in osteoblasts whereby ERK1/2 stimulation of CREB phosphorylation and transcriptional activity as well as DNA synthesis are critically dependent on de novo Mapkapk2 synthesis.	Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthoped Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Hebrew University of Jerusalem; University of Southern California; University of Southern California	Bab, I (corresponding author), Hebrew Univ Jerusalem, Bone Lab, POB 12272, IL-91120 Jerusalem, Israel.	babi@cc.huji.ac.il						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bab I, 2002, BIOPOLYMERS, V66, P33, DOI 10.1002/bip.10202; Bab I, 1999, J PEPT RES, V54, P408, DOI 10.1034/j.1399-3011.1999.00135.x; BAB I, 1992, EMBO J, V11, P1867, DOI 10.1002/j.1460-2075.1992.tb05238.x; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bond CT, 1999, ANN NY ACAD SCI, V868, P370, DOI 10.1111/j.1749-6632.1999.tb11298.x; Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200; Chen YC, 2002, J MED CHEM, V45, P1624, DOI 10.1021/jm010479l; Cheng TJ, 1998, J CELL BIOCHEM, V71, P169; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gabarin N, 2001, J CELL BIOCHEM, V81, P594, DOI 10.1002/jcb.1083; Gabet Y, 2004, BONE, V35, P65, DOI 10.1016/j.bone.2004.03.025; Gavish H, 1997, BIOCHEMISTRY-US, V36, P14883, DOI 10.1021/bi971670t; Ghayor C, 2005, BONE, V36, P93, DOI 10.1016/j.bone.2004.10.007; GREENBERG Z, 1993, BIOCHIM BIOPHYS ACTA, V1178, P273, DOI 10.1016/0167-4889(93)90204-3; Greenberg Z, 1997, J CELL BIOCHEM, V65, P359, DOI 10.1002/(SICI)1097-4644(19970601)65:3<359::AID-JCB6>3.0.CO;2-R; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Gurevitch O, 1996, BLOOD, V88, P4719, DOI 10.1182/blood.V88.12.4719.bloodjournal88124719; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045; Kato C, 2005, BIOCHEM BIOPH RES CO, V326, P147, DOI 10.1016/j.bbrc.2004.11.010; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Mattii L, 2004, J CELL BIOCHEM, V93, P1231, DOI 10.1002/jcb.20248; Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; ROBINSON D, 1995, J BONE MINER RES, V10, P690; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200; Smith E, 2005, NUCLEIC ACIDS RES, V33, P1298, DOI 10.1093/nar/gki248; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; ter Haar E, 2003, STRUCTURE, V11, P611, DOI 10.1016/S0969-2126(03)00104-7; Vician LJ, 2004, J NEUROSCI RES, V78, P315, DOI 10.1002/jnr.20251; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8	51	38	44	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37495	37502		10.1074/jbc.M503861200	http://dx.doi.org/10.1074/jbc.M503861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150701	hybrid			2022-12-25	WOS:000233044500026
J	Zhao, GJ; Cui, MZ; Mao, GZ; Dong, YZ; Tan, JX; Sun, LS; Xu, XM				Zhao, GJ; Cui, MZ; Mao, GZ; Dong, YZ; Tan, JX; Sun, LS; Xu, XM			gamma-cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL FRAGMENT-GAMMA; TRANS-GOLGI NETWORK; SECRETASE ACTIVITY; BETA-PROTEIN; INTRAMEMBRANE CLEAVAGE; ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; PRESENILIN-1; SITE; INHIBITORS	beta-Amyloid precursor protein apparently undergoes at least three major cleavages, gamma-, epsilon-, and the newly identified zeta-cleavage, within its transmembrane domain to produce secreted beta-amyloid protein (A beta). However, the roles of epsilon- and zeta-cleavages in the formation of secreted A beta and the relationship among these three cleavages, namely epsilon-,zeta-, and gamma-cleavages, remain elusive. We investigated these issues by attempting to determine the formation and turnover of the intermediate products generated by these cleavages, in the presence or absence of known gamma-secretase inhibitors. By using a differential inhibition strategy, our data demonstrate that A beta(46) is an intermediate precursor of secreted A beta. Our co-immunoprecipitation data also reveal that, as an intermediate, A beta(46) is tightly associated with presenilin in intact cells. Furthermore, we identified a long A beta species that is most likely the long sought after intermediate product, A beta(49), generated by epsilon-cleavage, and this A beta(49) is further processed by zeta- and gamma-cleavages to generate A beta(46) and ultimately the secreted A beta(40/42). More interestingly, our data demonstrate that gamma-cleavage not only occurs last but also depends on zeta-cleavage occurring prior to it, indicating that zeta-cleavage is crucial for the formation of secreted A beta. Thus, we conclude that the C terminus of secreted A beta is most likely generated by a series of sequential cleavages, namely first epsilon-cleavage which is then followed by epsilon- and gamma-cleavages, and that A beta(46) produced by zeta-cleavage is the precursor of secreted A beta(40/42).	Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Xu, XM (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathobiol, 2407 River Dr, Knoxville, TN 37996 USA.	xmx@utk.edu		xu, xuemin/0000-0002-7426-272X; Cui, Mei-Zhen/0000-0003-4745-6999	NINDS NIH HHS [NS42314] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2003, J NEUROSCI RES, V74, P353, DOI 10.1002/jnr.10736; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Pitsi D, 2004, J BIOL CHEM, V279, P25333, DOI 10.1074/jbc.M312710200; Qi-Takahara Y, 2005, J NEUROSCI, V25, P436, DOI 10.1523/JNEUROSCI.1575-04.2005; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhao GJ, 2004, J BIOL CHEM, V279, P50647, DOI 10.1074/jbc.C400473200	27	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37689	37697		10.1074/jbc.M507993200	http://dx.doi.org/10.1074/jbc.M507993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157587	hybrid			2022-12-25	WOS:000233044500046
J	Bose, A; Guilherme, A; Huang, SH; Hubbard, AC; Lane, CR; Soriano, NA; Czech, MP				Bose, A; Guilherme, A; Huang, SH; Hubbard, AC; Lane, CR; Soriano, NA; Czech, MP			The v-SNARE Vti1a regulates insulin-stimulated glucose transport and Acrp30 secretion in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4-CONTAINING VESICLES; GLUT4 VESICLES; GOLGI NETWORK; COMPARTMENTS; TRAFFICKING; TRANSLOCATION; LOCALIZATION; SYNTAXIN-6; ENDOSOMES; MEMBRANE	Regulated exocytosis in adipocytes mediates key functions, exemplified by insulin-stimulated secretion of peptides such as adiponectin and recycling of intracellular membranes containing GLUT4 glucose transporters to the cell surface. Using a proteomics approach, the v-SNARE Vti1a (vps10p tail interacting 1a) was identified by mass spectrometry in purified GLUT4-containing membranes. Insulin treatment of 3T3-L1 adipocytes decreased the amounts of both Vti1a and GLUT4 in these membranes, confirming that Vti1a is a component of insulin-sensitive GLUT4-containing vesicles. In the basal state, endogenous Vti1a colocalizes exclusively with perinuclear GLUT4. Although Vti1a has previously been reported to be a v-SNARE localized in the trans-Golgi network, treatment with brefeldin A failed to significantly modify Vti1a or GLUT4 localization while completely dispersing Golgi and trans-Golgi network marker proteins. Furthermore, depletion of Vti1a protein in cultured adipocytes through small interfering RNA-based gene silencing significantly inhibited both adiponectin secretion and insulin-stimulated deoxyglucose uptake. Taken together, these results suggest that the v-SNARE Vti1a may regulate a step common to both GLUT4 and Acrp30 trafficking in 3T3-L1 adipocytes.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, P30DK032520, R01DK060837, R01DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32520, DK30898, DK60837] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kreykenbohm V, 2002, EUR J CELL BIOL, V81, P273, DOI 10.1078/0171-9335-00247; Kupriyanova TA, 2000, J BIOL CHEM, V275, P36263, DOI 10.1074/jbc.M002797200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Martin S, 2000, J CELL SCI, V113, P3427; Martin S, 2000, TRAFFIC, V1, P652, DOI 10.1034/j.1600-0854.2000.010809.x; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Xu Y, 1998, J BIOL CHEM, V273, P21783, DOI 10.1074/jbc.273.34.21783; Xu Z, 2002, J BIOL CHEM, V277, P47972, DOI 10.1074/jbc.C200486200; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071	27	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36946	36951		10.1074/jbc.M508317200	http://dx.doi.org/10.1074/jbc.M508317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131485	hybrid			2022-12-25	WOS:000232901800051
J	Rubi, B; Ljubicic, S; Pournourmohammadi, S; Carobbio, S; Armanet, M; Bartley, C; Maechler, P				Rubi, B; Ljubicic, S; Pournourmohammadi, S; Carobbio, S; Armanet, M; Bartley, C; Maechler, P			Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; L-DOPA; POTASSIUM CHANNELS; DIABETES-MELLITUS; HORMONE-SECRETION; CA2+ CURRENTS; B-CELLS; GLUCOSE; PROTEIN; D2	Dopamine signaling is mediated by five cloned receptors, grouped into D1-like (D1 and D5) and D2-like (D2, D3 and D4) families. We identified by reverse transcription-PCR the presence of dopamine receptors from both families in INS-1E insulin-secreting cells as well as in rodent and human isolated islets. D2 receptor expression was confirmed by immunodetection revealing localization on insulin secretory granules of INS-1E and primary rodent and human beta cells. We then tested potential effects mediated by the identified receptors on beta cell function. Dopamine ( 10 mu M) and the D2-like receptor agonist quinpirole ( 5 mu M) inhibited glucose-stimulated insulin secretion tested in several models, i.e. INS-1E beta cells, fluorescence-activated cell-sorted primary rat beta cells, and pancreatic islets of rat, mouse, and human origin. Insulin exocytosis is controlled by metabolism coupled to cytosolic calcium changes. Measurements of glucose-induced mitochondrial hyperpolarization and ATP generation showed that dopamine and D2-like agonists did not inhibit glucose metabolism. On the other hand, dopamine decreased cell membrane depolarization as well as cytosolic calcium increases evoked by glucose stimulation in INS-1E beta cells. These results show for the first time that dopamine receptors are expressed in pancreatic beta cells. Dopamine inhibited glucose-stimulated insulin secretion, an effect that could be ascribed to D2-like receptors. Regarding the molecular mechanisms implicated in dopamine-mediated inhibition of insulin release, our results point to distal steps in metabolism-secretion coupling. Thus, the role played by dopamine in glucose homeostasis might involve dopamine receptors, expressed in pancreatic beta cells, modulating insulin release.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Surg, Cell Isolat & Transplantat Ctr, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Rubi, B (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	rubiweiss@yahoo.com	carobbio, stefania/E-7095-2018	Maechler, Pierre/0000-0002-2005-1433				Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; AHREN B, 1985, PHARMACOLOGY, V30, P71, DOI 10.1159/000138053; Ananth Jambur, 2004, Ann Clin Psychiatry, V16, P75, DOI 10.1080/10401230490453293; ARNERIC SP, 1984, DIABETES, V33, P888, DOI 10.2337/diabetes.33.9.888; Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; Binda AV, 2002, MOL PHARMACOL, V62, P507, DOI 10.1124/mol.62.3.507; Borelli MI, 1997, DIABETES METAB, V23, P161; BOUNDY VA, 1993, MOL PHARMACOL, V43, P666; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Budman CL, 2001, AM J PSYCHIAT, V158, P500, DOI 10.1176/appi.ajp.158.3.500-a; Callier S, 2003, BIOL CELL, V95, P489, DOI 10.1016/S0248-4900(03)00089-3; Citrome LL, 2004, DRUG TODAY, V40, P445, DOI 10.1358/dot.2004.40.5.850492; DEBUYSER A, 1991, PFLUG ARCH EUR J PHY, V419, P131, DOI 10.1007/BF00372998; Derouiche A, 1999, EUR J NEUROSCI, V11, P1391, DOI 10.1046/j.1460-9568.1999.00557.x; ERICSON LE, 1977, DIABETOLOGIA, V13, P117, DOI 10.1007/BF00745138; FERRER J, 1995, J BIOL CHEM, V270, P26086, DOI 10.1074/jbc.270.44.26086; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; HAVRANKOVA J, 1981, DIABETOLOGIA, V20, P268, DOI 10.1007/BF00254492; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hernandez-Lopez S, 2000, J NEUROSCI, V20, P8987; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Kuzhikandathil EV, 1998, MOL CELL NEUROSCI, V12, P390, DOI 10.1006/mcne.1998.0722; LACEY MG, 1987, J PHYSIOL-LONDON, V392, P397, DOI 10.1113/jphysiol.1987.sp016787; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Marder SR, 2004, AM J PSYCHIAT, V161, P1334, DOI 10.1176/appi.ajp.161.8.1334; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MEMO M, 1982, P NATL ACAD SCI-BIOL, V79, P4456, DOI 10.1073/pnas.79.14.4456; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Mezey E, 1996, P NATL ACAD SCI USA, V93, P10377, DOI 10.1073/pnas.93.19.10377; Nowicki S, 2000, AM J PHYSIOL-CELL PH, V279, pC1812, DOI 10.1152/ajpcell.2000.279.6.C1812; Okada Y, 2003, BRAIN RES, V968, P248, DOI 10.1016/S0006-8993(03)02267-4; OOMURA Y, 1981, DIABETOLOGIA, V20, P290, DOI 10.1007/BF00254495; Pijl H, 2003, EUR J PHARMACOL, V480, P125, DOI 10.1016/j.ejphar.2003.08.100; Prou D, 2001, J CELL SCI, V114, P3517; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; ROSATI G, 1976, EUR NEUROL, V14, P229, DOI 10.1159/000114744; Rubi B, 2004, J BIOL CHEM, V279, P55659, DOI 10.1074/jbc.M409303200; Salamone JD, 2003, J PHARMACOL EXP THER, V305, P1, DOI 10.1124/jpet.102.035063; Sandyk R, 1993, Int J Neurosci, V69, P125; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; Sieg A, 2004, AM J PHYSIOL-ENDOC M, V286, pE463, DOI 10.1152/ajpendo.00365.2003; Sowell MO, 2002, J CLIN ENDOCR METAB, V87, P2918, DOI 10.1210/jc.87.6.2918; STRICKER EM, 1975, SCIENCE, V189, P895, DOI 10.1126/science.1154028; Strowski MZ, 2003, MOL ENDOCRINOL, V17, P93, DOI 10.1210/me.2001-0035; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Takayanagi M, 1996, TISSUE CELL, V28, P17, DOI 10.1016/S0040-8166(96)80040-1; Takeuchi Y, 2003, J NEUROCHEM, V85, P1064, DOI 10.1046/j.1471-4159.2003.01763.x; Uchida S, 2000, NEUROPHARMACOLOGY, V39, P191, DOI 10.1016/S0028-3908(99)00111-2; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; VANWOERT MH, 1971, CLIN PHARMACOL THER, V12, P360; Vaughn J, 2000, BIOCHEM BIOPH RES CO, V274, P302, DOI 10.1006/bbrc.2000.3136; ZERN RT, 1980, DIABETOLOGIA, V18, P341	63	177	187	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36824	36832		10.1074/jbc.M505560200	http://dx.doi.org/10.1074/jbc.M505560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129680	hybrid			2022-12-25	WOS:000232901800037
J	Tani, M; Igarashi, Y; Ito, M				Tani, M; Igarashi, Y; Ito, M			Involvement of neutral ceramidase in ceramide metabolism at the plasma membrane and in extracellular milieu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR-CLONING; SPHINGOSINE 1-PHOSPHATE; SECRETORY SPHINGOMYELINASE; ALKALINE CERAMIDASE; FUNCTIONAL-ANALYSIS; ACTIVATION; EXPRESSION; APOPTOSIS; RECEPTOR	Neutral ceramidase is a type II integral membrane protein, which is occasionally secreted into the extracellular milieu after the processing of its N-terminal anchor (Tani, M., Iida, H., and Ito, M. ( 2003) J. Biol. Chem. 278, 10523 - 10530). We found that when overexpressed in CHOP cells, neutral ceramidase hydrolyzed cell surface ceramide, which increased in amount after the treatment of cells with bacterial sphingomyelinase, leading to an increase in the cellular level of sphingosine and sphingosine 1-phosphate. On the other hand, knockdown of the endogenous enzyme by siRNA decreased the cellular level of both sphingolipid metabolites. The treatment of cells with bovine serum albumin significantly reduced the cellular level of sphingosine, but not sphingosine 1-phosphate, generated by overexpression of the enzyme. The cellular level of sphingosine 1-phosphate increased with overexpression of the cytosolic sphingosine kinase. These results suggest that sphingosine 1-phosphate is mainly produced inside of the cell after the incorporation of sphingosine generated on the plasma membranes. The enzyme also seems to participate in the hydrolysis of serum-derived ceramide in the vascular system. Significant amounts of sphingosine as well as sphingosine 1-phosphate were generated in the cell-free conditioned medium of ceramidase transfectants, compared with mock transfectants. No increase in these metabolites was observed if serum or bacterial sphingomyelinase was omitted from the conditioned medium, suggesting that the major source of ceramide is the serum-derived sphingomyelin. A sphingosine 1-phosphate receptor, S1P(1), was internalized much faster by the treatment of S1P(1)-overexpressing cells with conditioned medium of ceramidase transfectants than that of mock transfectants. Collectively, these results clearly indicate that the enzyme is involved in the metabolism of ceramide at the plasma membrane and in the extracellular milieu, which could regulate sphingosine 1-phosphate-mediated signaling through the generation of sphingosine.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Kyushu University; Hokkaido University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				Acharya U, 2004, P NATL ACAD SCI USA, V101, P1922, DOI 10.1073/pnas.0308693100; Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Arakaki N, 2003, MOL CANCER RES, V1, P931; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Di Bartolomeo S, 2000, J NEUROCHEM, V75, P532, DOI 10.1046/j.1471-4159.2000.0750532.x; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Hwang YH, 2005, BIOCHEM BIOPH RES CO, V331, P37, DOI 10.1016/j.bbrc.2005.03.134; ITO M, 2003, CERAMIDE SIGNALING, P41; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kohno T, 2002, FASEB J, V16, P983, DOI 10.1096/fj.01-0809com; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang KS, 2004, CELL DEATH DIFFER, V11, P231, DOI 10.1038/sj.cdd.4401311; Lightle S, 2003, ARCH BIOCHEM BIOPHYS, V419, P120, DOI 10.1016/j.abb.2003.08.031; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Min JK, 2002, ANAL BIOCHEM, V303, P167, DOI 10.1006/abio.2002.5579; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Monjusho H, 2003, BIOCHEM J, V376, P473, DOI 10.1042/BJ20030652; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ochi S, 2004, J BIOL CHEM, V279, P12181, DOI 10.1074/jbc.M307046200; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SEGERS RPAM, 1990, INFECT IMMUN, V58, P2177, DOI 10.1128/IAI.58.7.2177-2185.1990; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; Tseng HJ, 2004, BIOCHEM BIOPH RES CO, V314, P513, DOI 10.1016/j.bbrc.2003.12.125; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; Yoshimura Y, 2004, J BIOL CHEM, V279, P44012, DOI 10.1074/jbc.M405598200; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215	61	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36592	36600		10.1074/jbc.M506827200	http://dx.doi.org/10.1074/jbc.M506827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16126722	hybrid			2022-12-25	WOS:000232901800009
J	Travassos, LH; Carneiro, LAM; Girardin, SE; Boneca, IG; Lemos, R; Bozza, MT; Domingues, RCP; Coyle, AJ; Bertin, J; Philpott, DJ; Plotkowski, MC				Travassos, LH; Carneiro, LAM; Girardin, SE; Boneca, IG; Lemos, R; Bozza, MT; Domingues, RCP; Coyle, AJ; Bertin, J; Philpott, DJ; Plotkowski, MC			Nod1 participates in the innate immune response to Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; TOLL-LIKE RECEPTOR-5; NF-KAPPA-B; PEPTIDOGLYCAN RECOGNITION; HOST RESPONSE; EXOTOXIN-A; INFLAMMATION; ACTIVATION; FLAGELLIN; LIPOPOLYSACCHARIDE	The mammalian innate immune system recognizes pathogen-associated molecular patterns through pathogen recognition receptors. Nod1 has been described recently as a cytosolic receptor that detects specifically diaminopimelate-containing muropeptides from Gram-negative bacteria peptidoglycan. In the present study we investigated the potential role of Nod1 in the innate immune response against the opportunistic pathogen Pseudomonas aeruginosa. We demonstrate that Nod1 detects the P. aeruginosa peptidoglycan leading to NF-kappa B activation and that this activity is diminished in epithelial cells expressing a dominant-negative Nod1 construct or in mouse embryonic fibroblasts from Nod1 knock-out mice infected with P. aeruginosa. Finally, we demonstrate that the cytokine secretion kinetics and bacterial killing are altered in Nod1-deficient cells infected with P. aeruginosa in the early stages of infection.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, BR-21941590 Rio De Janeiro, Brazil; Univ Estado Rio de Janeiro, Fac Ciencias Med, BR-20551030 Rio De Janeiro, Brazil; Inst Pasteur, Unite Pathogenie Microbienne Mol, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris, France; Inst Pasteur, Grp Immun Innee & Signalisat, F-75724 Paris, France; Millenium Pharmaceut, Cambridge, MA 02139 USA	Universidade Federal do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Travassos, LH (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, Bloco 1,Prof Paulo de Goes Ctr Cidade Univ,Ilha F, BR-21941590 Rio De Janeiro, Brazil.	lhtravassos@ufrj.br	Carneiro, Leticia/T-8978-2019; Travassos, Leonardo/G-1925-2012; Boneca, Ivo G/H-1677-2014; Domingues, Regina/V-3046-2019	Carneiro, Leticia/0000-0001-5870-8288; Travassos, Leonardo/0000-0003-1323-3797; Boneca, Ivo G/0000-0001-8122-509X; Bozza, Marcelo/0000-0003-3683-7550				Agramonte-Hevia J, 2002, FEMS IMMUNOL MED MIC, V34, P255, DOI 10.1016/S0928-8244(02)00408-X; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; CRIPPS AW, 1995, IMMUNOL CELL BIOL, V73, P418, DOI 10.1038/icb.1995.65; deBentzmann S, 1996, AM J RESP CRIT CARE, V154, pS155, DOI 10.1164/ajrccm/154.4_Pt_2.S155; Endlich B, 2002, J IMMUNOL, V168, P3586, DOI 10.4049/jimmunol.168.7.3586; Fritz JH, 2005, EUR J IMMUNOL, V35, P2459, DOI 10.1002/eji.200526286; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Girardin SE, 2003, EMBO REP, V4, P932, DOI 10.1038/sj.embor.embor940; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Greene CM, 2005, J IMMUNOL, V174, P1638, DOI 10.4049/jimmunol.174.3.1638; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; JOHNSON DA, 1982, AM REV RESPIR DIS, V126, P1070; Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kooguchi K, 1998, INFECT IMMUN, V66, P3164, DOI 10.1128/IAI.66.7.3164-3169.1998; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Plotkowski MC, 2002, AM J RESP CELL MOL, V26, P617, DOI 10.1165/ajrcmb.26.5.4489; Plotkowski MC, 1999, AM J RESP CELL MOL, V20, P880, DOI 10.1165/ajrcmb.20.5.3408; Power MR, 2004, J BIOL CHEM, V279, P49315, DOI 10.1074/jbc.M402111200; Sato H, 2004, MOL MICROBIOL, V53, P1279, DOI 10.1111/j.1365-2958.2004.04194.x; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Tsai WC, 2000, INFECT IMMUN, V68, P4289, DOI 10.1128/IAI.68.7.4289-4296.2000; van Heel DA, 2005, EUR J IMMUNOL, V35, P2471, DOI 10.1002/eji.200526296; VANHEIJENOORT J, 1975, EUR J BIOCHEM, V58, P611; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wieland CW, 2002, INFECT IMMUN, V70, P1352, DOI 10.1128/IAI.70.3.1352-1358.2002; Zhang J, 2003, INVEST OPHTH VIS SCI, V44, P4247, DOI 10.1167/iovs.03-0219	36	118	124	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36714	36718		10.1074/jbc.M501649200	http://dx.doi.org/10.1074/jbc.M501649200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150702	hybrid			2022-12-25	WOS:000232901800024
J	Beringer, M; Bruell, C; Xiong, LQ; Pfister, P; Bieling, P; Katunin, VI; Mankin, AS; Bottger, EC; Rodnina, MV				Beringer, M; Bruell, C; Xiong, LQ; Pfister, P; Bieling, P; Katunin, VI; Mankin, AS; Bottger, EC; Rodnina, MV			Essential mechanisms in the catalysis of peptide bond formation on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLTRANSFERASE ACTIVE-SITE; ELONGATION-FACTOR TU; TRANSFERASE CENTER; AMINOGLYCOSIDE RESISTANCE; STRUCTURAL BASIS; BASE-PAIR; RNA; MUTATIONS; SUBUNIT; ROLES	Peptide bond formation is the main catalytic function of the ribosome. The mechanism of catalysis is presumed to be highly conserved in all organisms. We tested the conservation by comparing mechanistic features of the peptidyl transfer reaction on ribosomes from Escherichia coli and the Gram-positive bacterium Mycobacterium smegmatis. In both cases, the major contribution to catalysis was the lowering of the activation entropy. The rate of peptide bond formation was pH independent with the natural substrate, amino-acyl-tRNA, but was slowed down 200-fold with decreasing pH when puromycin was used as a substrate analog. Mutation of the conserved base A2451 of 23 SrRNA to U did not abolish the pH dependence of the reaction with puromycin in M. smegmatis, suggesting that A2451 did not confer the pH dependence. However, the A2451U mutation alters the structure of the peptidyl transferase center and changes the pattern of pH-dependent rearrangements, as probed by chemical modification of 23 S rRNA. A2451 seems to function as a pivot point in ordering the structure of the peptidyl transferase center rather than taking part in chemical catalysis.	Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany; Univ Zurich, Inst Med Microbiol, CH-8006 Zurich, Switzerland; Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA; Russian Acad Sci, Petersburg Nucl Phys Inst, Gatchina 188350, Russia	Witten Herdecke University; University of Zurich; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Russian Academy of Sciences	Rodnina, MV (corresponding author), Univ Witten Herdecke, Inst Phys Biochem, Stockumer Str 10, D-58448 Witten, Germany.	rodnina@uni-wh.de	Beringer, Malte/N-3766-2015; Rodnina, Marina V./AAD-4667-2019; Beringer, Malte/AAC-5734-2020; Böttger, Erik C./F-6175-2011	Beringer, Malte/0000-0003-1958-9786; Rodnina, Marina V./0000-0003-0105-3879; Bieling, Peter/0000-0002-7458-4358	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059028] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59028] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BARTA A, 1996, RIBOSOMAL RNA GROUP, P35; Bashan A, 2003, MOL CELL, V11, P91, DOI 10.1016/S1097-2765(03)00009-1; Bayfield MA, 2004, NUCLEIC ACIDS RES, V32, P5512, DOI 10.1093/nar/gkh888; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; Beringer M, 2003, RNA, V9, P919, DOI 10.1261/rna.5600503; Bevilacqua PC, 2004, BIOPOLYMERS, V73, P90, DOI 10.1002/bip.10519; Erlacher MD, 2005, NUCLEIC ACIDS RES, V33, P1618, DOI 10.1093/nar/gki308; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; Hansen JL, 2002, P NATL ACAD SCI USA, V99, P11670, DOI 10.1073/pnas.172404099; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Hesslein AE, 2004, NUCLEIC ACIDS RES, V32, P3760, DOI 10.1093/nar/gkh672; Katunin VI, 2002, MOL CELL, V10, P339, DOI 10.1016/S1097-2765(02)00566-X; KEARSEY SE, 1981, NATURE, V290, P607, DOI 10.1038/290607a0; LIEBERMAN KR, 1995, PROG NUCLEIC ACID RE, V50, P1, DOI 10.1016/S0079-6603(08)60809-0; MADEN BEH, 1968, EUR J BIOCHEM, V6, P309, DOI 10.1111/j.1432-1033.1968.tb00450.x; Merryman C, 1998, PRACT APPROACH SER, V192, P237; MISKIN R, 1968, BIOCHEM BIOPH RES CO, V33, P551, DOI 10.1016/0006-291X(68)90330-6; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Muth GW, 2001, RNA, V7, P1403; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Parnell KM, 2002, P NATL ACAD SCI USA, V99, P11658, DOI 10.1073/pnas.182210099; Pfister P, 2005, J MOL BIOL, V346, P467, DOI 10.1016/j.jmb.2004.11.073; Pfister P, 2003, CHEMBIOCHEM, V4, P1078, DOI 10.1002/cbic.200300657; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; Prammananan T, 1999, ANTIMICROB AGENTS CH, V43, P447, DOI 10.1128/AAC.43.3.447; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Sander P, 2002, MOL MICROBIOL, V46, P1295, DOI 10.1046/j.1365-2958.2002.03242.x; Sander P, 1996, MOL MICROBIOL, V22, P841, DOI 10.1046/j.1365-2958.1996.01532.x; Sievers A, 2004, P NATL ACAD SCI USA, V101, P7897, DOI 10.1073/pnas.0402488101; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Weinger JS, 2004, NAT STRUCT MOL BIOL, V11, P1101, DOI 10.1038/nsmb841; WOLFENDEN R, 1963, BIOCHEMISTRY-US, V2, P1090, DOI 10.1021/bi00905a031; Xiong LQ, 2001, RNA, V7, P1365; Youngman EM, 2004, CELL, V117, P589, DOI 10.1016/S0092-8674(04)00411-8; [No title captured]	40	74	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36065	36072		10.1074/jbc.M507961200	http://dx.doi.org/10.1074/jbc.M507961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129670	Green Published, hybrid			2022-12-25	WOS:000232726900036
J	David-Dufilho, M; Millanvoye-Ban Brussel, E; Topal, G; Walch, L; Brunet, A; Rendu, F				David-Dufilho, M; Millanvoye-Ban Brussel, E; Topal, G; Walch, L; Brunet, A; Rendu, F			Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; NO SYNTHASE ACTIVITY; SRC FAMILY KINASES; SOLUBLE THROMBOMODULIN; REGULATED KINASE; THROMBIN; PHOSPHORYLATION; HISTAMINE; MECHANISMS; CELLS	Endothelial membrane-bound thrombomodulin is a high affinity receptor for thrombin to inhibit coagulation. We previously demonstrated that the thrombin-thrombomodulin complex restrains cell proliferation mediated through protease-activated receptor (PAR)-1. We have now tested the hypothesis that thrombomodulin transduces a signal to activate the endothelial nitric-oxide synthase (NOS3) and to modulate G protein-coupled receptor signaling. Cultured human umbilical vein endothelial cells were stimulated with thrombin or a mutant of thrombin that binds to thrombomodulin and has no catalytic activity on PAR-1. Thrombin and its mutant dose dependently activated NO release at cell surface. Pretreatment with anti-thrombomodulin antibody suppressed NO response to the mutant and to low thrombin concentration and reduced by half response to high concentration. Thrombin receptor-activating peptide that only activates PAR-1 and high thrombin concentration induced marked biphasic Ca2+ signals with rapid phosphorylation of PLC beta 3 and NOS3 at both serine 1177 and threonine 495. The mutant thrombin evoked a Ca2+ spark and progressive phosphorylation of Src family kinases at tyrosine 416 and NOS3 only at threonine 495. It activated rapid phosphatidylinositol-3 kinase-dependent NO synthesis and phosphorylation of epidermal growth factor receptor and calmodulin kinase II. Complete epidermal growth factor receptor inhibition only partly reduced the activation of phospholipase C gamma(1) and NOS3. Prestimulation of thrombomodulin did not affect NO release but reduced Ca2+ responses to thrombin and histamine, suggesting cross-talks between thrombomodulin and G protein-coupled receptors. This is the first demonstration of an outside-in signal mediated by the cell surface thrombomodulin receptor to activate NOS3 through tyrosine kinase-dependent pathway. This signaling may contribute to thrombomodulin function in thrombosis, inflammation, and atherosclerosis.	Univ Paris 06, Dept Signalisat Cellulaire & Atherosclerose Preco, CNRS, UMR 7131, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	David-Dufilho, M (corresponding author), Univ Paris 06, Dept Signalisat Cellulaire & Atherosclerose Preco, CNRS, UMR 7131, 102 Rue Didot, F-75014 Paris, France.	monique.dufilho@brs.aphp.fr		DAVID-DUFILHO, Monique/0000-0002-7479-075X				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhattacharya A, 2000, J PHARMACOL EXP THER, V295, P284; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Cha MS, 2001, BIOCHEM BIOPH RES CO, V282, P1061, DOI 10.1006/bbrc.2001.4682; Drew BG, 2004, P NATL ACAD SCI USA, V101, P6999, DOI 10.1073/pnas.0306266101; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Hanafy K A, 2001, Med Sci Monit, V7, P801; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; IOUZALEN L, 1995, EUR J PHARM-MOLEC PH, V289, P189, DOI 10.1016/0922-4106(95)90094-2; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Lafay M, 1998, THROMB HAEMOSTASIS, V79, P848, DOI 10.1055/s-0037-1615076; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANTOINE F, 1995, J ELECTROANAL CHEM, V392, P85, DOI 10.1016/0022-0728(95)04042-M; Lantoine F, 1998, BIOCHEM J, V330, P695, DOI 10.1042/bj3300695; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P132, DOI 10.1016/S1089-8603(02)00127-1; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Lohi O, 2004, CURR BIOL, V14, P236, DOI 10.1016/j.cub.2004.01.025; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McLaughlin JN, 2005, J BIOL CHEM, V280, P25048, DOI 10.1074/jbc.M414090200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Millanvoye-Van Brussel E, 2004, BIOCHEM J, V380, P533, DOI 10.1042/BJ20040069; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Nesheim M, 2003, CHEST, V124, p33S, DOI 10.1378/chest.124.3_suppl.33S; Olivot JM, 2001, CIRC RES, V88, P681, DOI 10.1161/hh0701.088769; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Sadler JE, 1997, THROMB HAEMOSTASIS, V78, P392; Salomaa V, 1999, LANCET, V353, P1729, DOI 10.1016/S0140-6736(98)09057-6; Schaeffer P, 1997, BIOCHEM PHARMACOL, V53, P487, DOI 10.1016/S0006-2952(96)00735-6; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shi CS, 2005, CIRCULATION, V111, P1627, DOI 10.1161/01.CIR.0000160364.05405.B5; Stephens LR, 2001, J BIOL CHEM, V276, P42767, DOI 10.1074/jbc.M107194200; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Thors B, 2004, FEBS LETT, V573, P175, DOI 10.1016/j.febslet.2004.07.078; Thors B, 2003, ATHEROSCLEROSIS, V168, P245, DOI 10.1016/S0021-9150(03)00127-8; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Topal G, 2004, FREE RADICAL BIO MED, V36, P1532, DOI 10.1016/j.freeradbiomed.2004.03.019; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; Van de Wouwer M, 2004, ARTERIOSCL THROM VAS, V24, P1374, DOI 10.1161/01.ATV.0000134298.25489.92; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Wu KK, 2003, CIRCULATION, V107, P1729, DOI 10.1161/01.CIR.0000064894.97094.4F; YE J, 1992, J BIOL CHEM, V267, P11023; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	51	22	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35999	36006		10.1074/jbc.M506374200	http://dx.doi.org/10.1074/jbc.M506374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126727	hybrid, Green Published			2022-12-25	WOS:000232726900028
J	Gordon, SM; Alon, N; Buchwald, M				Gordon, SM; Alon, N; Buchwald, M			FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-COMPLEX; PROTEIN INTERACTIONS; UBIQUITIN LIGASE; YEAST 2-HYBRID; GENE; COMPLEMENTATION; ACCUMULATION; LOCALIZATION; SELECTION; INTERACT	Fanconi anemia ( FA) is a genetically heterogeneous disorder characterized by bone marrow failure, cancer predisposition, and increased cellular sensitivity to DNA-cross-linking agents. The products of seven of the nine identified FA genes participate in a protein complex required for monoubiquitination of the FANCD2 protein. Direct interaction of the FANCE protein with both fellow FA complex component FANCC and the downstream FANCD2 protein has been observed in the yeast two-hybrid system. Here, we demonstrate the ability of FANCE to mediate the interaction between FANCC and FANCD2 in the yeast three-hybrid system and confirm the FANCE-mediated association of FANCC with FANCD2 in human cells. A yeast two-hybrid system-based screen was devised to identify randomly mutagenized FANCE proteins capable of interaction with FANCC but not with FANCD2. Exogenous expression of these mutants in an FA-E cell line and subsequent evaluation of FANCD2 monoubiquitination and DNA crosslinker sensitivity indicated a critical role for the FANCE/FANCD2 interaction in maintaining FA pathway integrity. Three-hybrid experiments also demonstrated the ability of FANCE to mediate the interaction between FA core complex components FANCC and FANCF, indicating an additional role for FANCE in complex assembly. Thus, FANCE is shown to be a key mediator of protein interactions both in the architecture of the FA protein complex and in the connection of complex components to the putative downstream targets of complex activity.	Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Gordon, SM (corresponding author), Hosp Sick Children, Res Inst, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	susan.gordon@utoronto.ca						Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GAVISH H, 1993, HUM MOL GENET, V2, P123, DOI 10.1093/hmg/2.2.123; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; James P, 1996, GENETICS, V144, P1425; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Leveille F, 2004, J BIOL CHEM, V279, P39421, DOI 10.1074/jbc.M407034200; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Lightfoot J, 1999, HUM MOL GENET, V8, P1007, DOI 10.1093/hmg/8.6.1007; LO TF, 1996, NAT GENET, V14, P320; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Thomashevski A, 2004, J BIOL CHEM, V279, P26201, DOI 10.1074/jbc.M400091200; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975	33	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36118	36125		10.1074/jbc.M507758200	http://dx.doi.org/10.1074/jbc.M507758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16127171	hybrid			2022-12-25	WOS:000232726900042
J	Kandel, S; Morant, M; Benveniste, I; Blee, E; Werck-Reichhart, D; Pinot, F				Kandel, S; Morant, M; Benveniste, I; Blee, E; Werck-Reichhart, D; Pinot, F			Cloning, functional expression, and characterization of CYP709C1, the first sub-terminal hydroxylase of long chain fatty acid in plants - Induction by chemicals and methyl jasmonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPOXIDE HYDROLASE ACTIVITIES; LAURIC-ACID; OMEGA-HYDROXYLATION; CUTIN MONOMERS; MICROSOMAL CYTOCHROME-P450; IN-VITRO; YEAST; METABOLISM; WHEAT; MONOOXYGENASE	We cloned and characterized CYP709C1, a new plant cytochrome P450 belonging to the P450 family, that so far has no identified function except for clustering with a fatty acid metabolizing clade of P450 enzymes. We showed here that CYP709C1 is capable of hydroxylating fatty acids at the omega-1 and omega-2 positions. This work was performed after recoding and heterologous expression of a full-length cDNA isolated from a wheat cDNA library in an engineered yeast strain. Investigation on substrate specificity indicates that CYP709C1 metabolizes different fatty acids varying in their chain length (C12 to C18) and unsaturation. CYP709C1 is the first identified plant cytochrome P450 that can catalyze sub-terminal hydroxylation of C18 fatty acids. cis-9,10-Epoxystearic acid is metabolized with the highest efficiency, i.e. K-m(app) of 8 mu M and V-max(app) of 328 nmol/min/nmol P450. This, together with the fact that wheat possesses amicrosomal peroxygenase able to synthesize this compound from oleic acid, strongly suggests that it is a physiological substrate. Hydroxylated fatty acids are implicated in plant defense events. We postulated that CYP709C1 could be involved in plant defense by producing such compounds. This receives support from the observation that (i) sub-terminal hydroxylation of 9,10-epoxystearic acid is induced (15-fold after 3 h) in microsomes of wheat seedlings treated with the stress hormone methyl jasmonate and (ii) CYP709C1 is enhanced at the transcriptional level by this treatment. CYP709C1 transcript also accumulated after treatment with a combination of the safener naphthalic acid anhydride and phenobarbital. This indicates a possible detoxifying function for CYP709C1 that we discussed.	IBMP, CNRS,UPR 2357, Inst Bot, Dept Response Metab Environm Biot, F-67083 Strasbourg, France; Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg, Denmark	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Copenhagen	Pinot, F (corresponding author), IBMP, CNRS,UPR 2357, Inst Bot, Dept Response Metab Environm Biot, 28 Rue Goethe, F-67083 Strasbourg, France.	franck.pinot@bota-ulp.u-strasbg.fr	WERCK-REICHHART, Danièle/U-3713-2019	WERCK-REICHHART, Danièle/0000-0003-2869-4262; Kandel, Sylvie/0000-0002-8059-8035				Afitlhile MM, 2004, PHYTOCHEMISTRY, V65, P2679, DOI 10.1016/j.phytochem.2004.08.028; Benveniste I, 1998, BIOCHEM BIOPH RES CO, V243, P688, DOI 10.1006/bbrc.1998.8156; BENVENISTE I, 1982, PLANT PHYSIOL, V70, P122, DOI 10.1104/pp.70.1.122; BLEE E, 1990, J BIOL CHEM, V265, P12887; Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Cabello-Hurtado F, 1998, J BIOL CHEM, V273, P7260, DOI 10.1074/jbc.273.13.7260; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; Capdevila JH, 2002, CELL MOL LIFE SCI, V59, P780, DOI 10.1007/s00018-002-8466-y; Carroll MA, 1996, AM J PHYSIOL-REG I, V271, pR863, DOI 10.1152/ajpregu.1996.271.4.R863; Chuang SS, 2004, J BIOL CHEM, V279, P6305, DOI 10.1074/jbc.M311830200; Corcos L, 2001, PHARMACOL TOXICOL, V89, P113, DOI 10.1034/j.1600-0773.2001.d01-144.x; CROSS JW, 1992, PESTIC BIOCHEM PHYS, V44, P28, DOI 10.1016/0048-3575(92)90006-L; Durst Francis, 1995, Drug Metabolism and Drug Interactions, V12, P189; EGLINTON G, 1968, ORG MASS SPECTROM, V1, P593, DOI 10.1002/oms.1210010413; Fauth M, 1998, PLANT PHYSIOL, V117, P1373, DOI 10.1104/pp.117.4.1373; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GIBSON GG, 1989, XENOBIOTICA, V19, P1123; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; Hehn A, 2002, METHOD ENZYMOL, V357, P343; Helvig C, 2004, BIOCHEM BIOPH RES CO, V325, P1495, DOI 10.1016/j.bbrc.2004.10.194; Holloway P. J., 1982, The plant cuticle, P45; Kahn RA, 2001, ARCH BIOCHEM BIOPHYS, V391, P180, DOI 10.1006/abbi.2001.2415; KATO T, 1985, TETRAHEDRON LETT, V26, P2357, DOI 10.1016/S0040-4039(00)95098-6; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; KOLATTUKUDY PE, 1980, SCIENCE, V208, P990, DOI 10.1126/science.208.4447.990; Kong L, 2005, GENOME, V48, P29, DOI 10.1139/G04-097; Lait CG, 2003, P NATL ACAD SCI USA, V100, P7027, DOI 10.1073/pnas.1232474100; Le Bouquin R, 2001, EUR J BIOCHEM, V268, P3083, DOI 10.1046/j.1432-1327.2001.02207.x; Maitra S, 1996, GENE, V180, P165, DOI 10.1016/S0378-1119(96)00446-5; MASUI H, 1989, PHYTOCHEMISTRY, V28, P2613, DOI 10.1016/S0031-9422(00)98051-8; MCFADDEN JJ, 1990, BIOCHEM BIOPH RES CO, V168, P206, DOI 10.1016/0006-291X(90)91695-O; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; MEIJER AH, 1993, PLANT MOL BIOL, V22, P379, DOI 10.1007/BF00014944; MEYER A, 1989, PHYTOCHEMISTRY, V28, P1007, DOI 10.1016/0031-9422(89)80173-6; Morant Marc, 2002, BMC Plant Biol, V2, P7, DOI 10.1186/1471-2229-2-7; Noverr MC, 2003, CLIN MICROBIOL REV, V16, P517, DOI 10.1128/CMR.16.3.517-533.2003; OHTA H, 1991, PLANT PHYSIOL, V97, P94, DOI 10.1104/pp.97.1.94; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pare PW, 1998, P NATL ACAD SCI USA, V95, P13971, DOI 10.1073/pnas.95.23.13971; Pinot F, 1997, PLANT PHYSIOL BIOCH, V35, P103; Pinot F, 1998, PLANT PHYSIOL, V118, P1481, DOI 10.1104/pp.118.4.1481; PINOT F, 1994, BIOCHEM BIOPH RES CO, V198, P795, DOI 10.1006/bbrc.1994.1114; Pinot F, 1999, BIOCHEM J, V342, P27, DOI 10.1042/0264-6021:3420027; PINOT F, 1992, BIOCHEM BIOPH RES CO, V184, P183, DOI 10.1016/0006-291X(92)91176-Q; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; SALAUN JP, 1978, EUR J BIOCHEM, V90, P155, DOI 10.1111/j.1432-1033.1978.tb12586.x; SALAUN JP, 1982, PHYSIOL VEG, V20, P613; SALAUN JP, 1986, LIPIDS, V21, P776, DOI 10.1007/BF02535411; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; Schweizer P, 1996, PHYSIOL MOL PLANT P, V49, P103, DOI 10.1006/pmpp.1996.0043; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Spector AA, 2004, PROG LIPID RES, V43, P55, DOI 10.1016/S0163-7827(03)00049-3; Summerer S, 2002, BIOCHEM J, V366, P471, DOI 10.1042/BJ20011778; Theodoulou F. L., 1999, Plant Physiology, V119, P1567, DOI 10.1104/pp.119.4.1567; Tijet N, 1998, BIOCHEM J, V332, P583, DOI 10.1042/bj3320583; Werck-Reichhart D, 2000, GENOME BIOL, V6, P1, DOI [10.1186/GB-2000-1-6-REVIEWS3003, DOI 10.1186/GB-2000-1-6-REVIEWS3003]; ZIMMERLIN A, 1992, PLANT PHYSIOL, V100, P874, DOI 10.1104/pp.100.2.874	58	46	66	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35881	35889		10.1074/jbc.M500918200	http://dx.doi.org/10.1074/jbc.M500918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120613	hybrid			2022-12-25	WOS:000232726900014
J	Lange, Y; Ye, J; Steck, TL				Lange, Y; Ye, J; Steck, TL			Activation of membrane cholesterol by displacement from phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; LIPID-BILAYERS; MAXIMUM SOLUBILITY; HUMAN-FIBROBLASTS; STEROL STRUCTURE; SPHINGOMYELIN; MOVEMENT; MODEL; CYCLODEXTRIN; CALORIMETRY	We tested the hypothesis that certain membrane-intercalating agents increase the chemical activity of cholesterol by displacing it from its low activity association with phospholipids. Octanol, 1,2-dioctanoyl-sn- glycerol ( a diglyceride), and N-hexanoyl-D-erythrosphingosine ( a ceramide) were shown to increase both the rate of transfer and the extent of equilibrium partition of human red blood cell cholesterol to methyl-beta-cyclodextrin. These agents also promoted the interaction of the sterol with two cholesterol-specific probes, cholesterol oxidase and saponin. Expanding the pool of bilayer phospholipids with lysophosphatides countered these effects. The three intercalators also protected the red cells against lysis by cholesterol depletion as if substituting for the extracted sterol. As is the case for excess plasmamembrane cholesterol, treating human fibroblasts with octanol, diglyceride, or ceramide stimulated the rapid inactivation of their hydroxymethylglutaryl-CoA reductase, presumably through an increase in the pool of endoplasmic reticulum cholesterol. These data supported the stated hypothesis and point to competition between cholesterol and endogenous and exogenous intercalators for association with membrane phospholipids. We also describe simple screens using red cells in a microtiter well format to identify intercalating agents that increase or decrease the activity of membrane cholesterol.	Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Rush University; University of Chicago	Lange, Y (corresponding author), Rush Univ, Med Ctr, Dept Pathol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	ylange@rush.edu	Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL028448, R01HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beattie ME, 2005, BIOPHYS J, V89, P1760, DOI 10.1529/biophysj.104.049635; BLOOM M, 1991, Q REV BIOPHYS, V24, P293, DOI 10.1017/S0033583500003735; Chen XY, 2000, BIOCHEMISTRY-US, V39, P13383, DOI 10.1021/bi001407j; Chiu SW, 2002, BIOPHYS J, V83, P1842, DOI 10.1016/S0006-3495(02)73949-0; COOPER RA, 1978, J SUPRAMOL STR CELL, V8, P413, DOI 10.1002/jss.400080404; Francis G, 2002, BRIT J NUTR, V88, P587, DOI 10.1079/BJN2002725; GUPTA AK, 1991, J LIPID RES, V32, P125; Holopainen JM, 2004, BIOPHYS J, V86, P1510, DOI 10.1016/S0006-3495(04)74219-8; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Huang JY, 1999, BBA-BIOMEMBRANES, V1417, P89, DOI 10.1016/S0005-2736(98)00260-0; Khelashvili GA, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1943412; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 2004, P NATL ACAD SCI USA, V101, P11664, DOI 10.1073/pnas.0404766101; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1984, BIOCHIM BIOPHYS ACTA, V769, P551, DOI 10.1016/0005-2736(84)90053-1; LANGE Y, 1980, J BIOL CHEM, V255, P9331; Lange Y, 1999, J LIPID RES, V40, P2264; LANGE Y, 1989, J BIOL CHEM, V264, P3786; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Mannock DA, 2003, BIOPHYS J, V84, P1038, DOI 10.1016/S0006-3495(03)74920-0; McConnell HM, 2003, BBA-BIOMEMBRANES, V1610, P159, DOI 10.1016/S0005-2736(03)00015-4; NISHIKAWA M, 1984, J BIOCHEM-TOKYO, V96, P1231, DOI 10.1093/oxfordjournals.jbchem.a134941; OHNOIWASHITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1109, P81, DOI 10.1016/0005-2736(92)90190-W; Radhakrishnan A, 2000, BIOCHEMISTRY-US, V39, P8119, DOI 10.1021/bi0005097; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P39, DOI 10.1016/0005-2760(95)00009-2; Rowe ES, 1998, BIOCHEMISTRY-US, V37, P2430, DOI 10.1021/bi9721602; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Steck T L, 1974, Methods Enzymol, V31, P172; Steck TL, 2002, BIOPHYS J, V83, P2118, DOI 10.1016/S0006-3495(02)73972-6; Tsamaloukas A, 2005, BIOPHYS J, V89, P1109, DOI 10.1529/biophysj.105.061846; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; Zitzer A, 2001, J BIOL CHEM, V276, P14628, DOI 10.1074/jbc.M100241200	38	69	69	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36126	36131		10.1074/jbc.M507149200	http://dx.doi.org/10.1074/jbc.M507149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129675	hybrid			2022-12-25	WOS:000232726900043
J	Lievremont, JP; Numaga, T; Vazquez, G; Lemonnier, L; Hara, Y; Mori, E; Trebak, M; Moss, SE; Bird, GS; Mori, Y; Putney, JW				Lievremont, JP; Numaga, T; Vazquez, G; Lemonnier, L; Hara, Y; Mori, E; Trebak, M; Moss, SE; Bird, GS; Mori, Y; Putney, JW			The role of canonical transient receptor potential 7 in B-cell receptor-activated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; TRANSIENT RECEPTOR; CATION ENTRY; ENDOPLASMIC-RETICULUM; CALCIUM CURRENT; TRPC3 CHANNELS; RELEASE; EXPRESSION; PROTEIN; MOBILIZATION	Phospholipase C signaling stimulates Ca2+ entry across the plasma membrane through multiple mechanisms. Ca2+ store depletion stimulates store- operated Ca2+- selective channels, or alternatively, other phospholipase C- dependent events activate Ca2+- permeable non- selective cation channels. Transient receptor potential 7 ( TRPC7) is a non- selective cation channel that can be activated by both mechanisms when ectopically expressed, but the regulation of native TRPC7 channels is not known. We knocked out TRPC7 in DT40 B- cells, which expresses both forms of Ca2+ entry. No difference in the store- operated current I-crac was detected between TRPC7 (-/-) and wild- type cells. Wild- type cells demonstrated non-store-operated cation entry and currents in response to activation of the B- cell receptor or protease- activated receptor 2, intracellular dialysis with GTP gamma S, or application of the synthetic diacylglycerol oleyl- acetyl- glycerol. These responses were absent in TRPC7 (-/-) cells but could be restored by transfection with human TRPC7. In conclusion, in B- lymphocytes, TRPC7 appeared to participate in the formation of ion channels that could be activated by phospholipase C- linked receptors. This represents the first demonstration of a physiological function for endogenous TRPC7 channels.	NIEHS, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA; Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Mol Biol Lab, Kyoto 6158510, Japan; UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kyoto University; University of London; University College London	Putney, JW (corresponding author), NIEHS, Dept Hlth & Human Serv, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Bird, Gary/AAI-8186-2021; Lemonnier, Loic/L-7289-2018; Putney, James W/F-7247-2019; Trebak, Mohamed/E-7405-2014	Bird, Gary/0000-0003-1389-8748; Lemonnier, Loic/0000-0001-6200-5382; Putney, James W/0000-0002-3379-4789; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Broad LM, 1996, BIOCHEM J, V316, P759, DOI 10.1042/bj3160759; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BYRON KL, 1995, J PHYSIOL-LONDON, V485, P455, DOI 10.1113/jphysiol.1995.sp020742; Grafton G, 2001, IMMUNOLOGY, V104, P119, DOI 10.1046/j.0019-2805.2001.01321.x; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; KWAN CY, 1990, J BIOL CHEM, V265, P678; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Morita T, 2004, BIOCHEM J, V382, P793, DOI 10.1042/BJ20031970; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wisnoskey BJ, 2003, BIOCHEM J, V372, P517, DOI 10.1042/BJ20021574	31	44	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35346	35351		10.1074/jbc.M507606200	http://dx.doi.org/10.1074/jbc.M507606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123040	hybrid			2022-12-25	WOS:000232561200033
J	Fischer, DF; van Dijk, R; Sluijs, JA; Nair, SM; Racchi, M; Levelt, CN; van Leeuwen, FW; Hol, EM				Fischer, DF; van Dijk, R; Sluijs, JA; Nair, SM; Racchi, M; Levelt, CN; van Leeuwen, FW; Hol, EM			Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP	FASEB JOURNAL			English	Article						Alzheimer disease; gamma-secretase complex; beta APP; Notch intracellular domain	AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; GENE-EXPRESSION; FE65; PRESENILIN; CLEAVAGE; RELEASE; CELLS	Down syndrome (DS) patients suffer from mental retardation, but also display enhanced beta-APP production and develop cortical amyloid plaques at an early age. As beta-APP and Notch are both processed by beta-secretase, we analyzed expression of the Notch signaling pathway in the adult DS brain and in a model system for DS, human trisomy 21 fibroblasts by quantitative PCR. In adult DS cortex we found that Notch1, Dll1 and Hes1 expression is up-regulated. Moreover, DS fibroblasts and Alzheimer disease cortex also show overexpression of Notch1 and Dll1, indicating that enhanced beta-APP processing found in both DS and AD could be instrumental in these changes. Using pull-down studies we could demonstrate interaction of APP with Notch1, suggesting that these transmembrane proteins form heterodimers, but independent of beta-secretase. We could demonstrate binding of the intracellular domain of Notch1 to the APP adaptor protein Fe65. Furthermore, activated Notch1 can trans-activate an APP target gene, Kai1, and vice versa, activated APP can trans-activate the classical Notch target gene Hes1. These data suggest that Notch expression is activated in Down syndrome, possibly through cross-talk with APP signaling. This interaction might affect brain development, since the Notch pathway plays a pivotal role in neuron-glia differentiation.	Vrije Univ Amsterdam, CNCR, Dept Funct Genom, NL-1081 HV Amsterdam, Netherlands; Netherlands Inst Brain Res, Amsterdam, Netherlands; Univ Pavia, Dept Expt & Appl Pharmacol, I-27100 Pavia, Italy; Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Pavia; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Fischer, DF (corresponding author), Vrije Univ Amsterdam, CNCR, Dept Funct Genom, Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	david@cncr.vu.nl	Racchi, Marco/G-6104-2018; Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019	Racchi, Marco/0000-0002-7185-7808; Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; Fischer, David/0000-0002-6690-0197				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CHENG SV, 1988, P NATL ACAD SCI USA, V85, P6032, DOI 10.1073/pnas.85.16.6032; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Delatour B, 2001, AM J PATHOL, V158, P1585, DOI 10.1016/S0002-9440(10)64113-2; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Lleo A, 2003, J BIOL CHEM, V278, P47370, DOI 10.1074/jbc.M308480200; MANN DMA, 1989, J NEUROL SCI, V89, P169, DOI 10.1016/0022-510X(89)90019-1; Mao R, 2003, GENOMICS, V81, P457, DOI 10.1016/S0888-7543(03)00035-1; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MONNING U, 1992, J BIOL CHEM, V267, P23950; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; NYE JS, 1994, DEVELOPMENT, V120, P2421; OH S, 2004, ANN M SOC NEUR; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Racchi M, 1999, BIOCHEM J, V338, P777, DOI 10.1042/0264-6021:3380777; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; van Dijk R, 2004, J NEUROCHEM, V90, P712, DOI 10.1111/j.1471-4159.2004.02528.x; WISNIEWSKI KE, 1990, AM J MED GENET, P274	46	81	85	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1451	1458		10.1096/fj.04-3395.com	http://dx.doi.org/10.1096/fj.04-3395.com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126912				2022-12-25	WOS:000232315700038
J	Funasaka, T; Yanagawa, T; Hogan, V; Raz, A				Funasaka, T; Yanagawa, T; Hogan, V; Raz, A			Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia	FASEB JOURNAL			English	Article						hypoxia-inducible factor-1; phosphoglucose isomerase; VEGF	NUCLEAR-LOCALIZATION SEQUENCE; FIBROBLAST GROWTH-FACTOR; TUMOR-CELLS; INDUCIBLE FACTOR-1; GLYCOLYTIC-ENZYMES; HEMOLYTIC-ANEMIA; CANCER-CELLS; ISOMERASE; NEUROLEUKIN; SECRETION	Phosphoglucose isomerase (PGI; EC 5.3.1.9) is a housekeeping cytosolic enzyme of the sugar metabolism pathways that plays a key role in glycolysis and gluconeogenesis. PGI is a multifunctional dimeric protein that extracellularly acts as a cytokine with properties that include autocrine motility factor (AMF) eliciting mitogenic, motogenic, differentiation functions and has been implicated in tumor progression and metastasis. Since metastasis is regulated in part by hypoxia, which induces the transcription of metastasis-associated genes and anaerobic glycolic metabolism, we questioned whether hypoxia also regulates the expression level of tumor cells' PGI/AMF. We establish here that in the human breast carcinoma BT-549 cells hypoxia enhanced expression of the transcription factor hypoxia-inducible factor (HIF)-1, which in turn led to the up-regulation of PGI/AMF expression and was specifically inhibited by inhibitors of the phosphatidylinositol 3'-kinase signaling pathway. In addition, the hypoxia induction of PGI/AMF expression was suppressed by inhibitors of vascular endothelial growth factor ( VEGF) or VEGF receptors, suggesting that hypoxia-inducible VEGF regulates the PGI/AMF expression. Hypoxia also enhanced cancer cell motility, and these effects were strongly inhibited by the PGI/AMF, VEGF, or VEGF receptor inhibitors. The results presented here suggest that under hypoxic conditions the expression of PGI/AMF is regulated in part by the HIF pathway, which in turn increases the flow of the glycolytic cascade leading to an increased anaerobic energy generation; thus, inhibition of PGI/AMF expression and activities may provide a new therapeutic modality for treatment of hypoxic tumors.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Tumor Progress & Metastasis Program, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Raz, A (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Tumor Progress & Metastasis Program, 110 E Warren Ave, Detroit, MI 48201 USA.	raza@karmanos.org			NCI NIH HHS [CA 51714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P402, DOI 10.1006/bcmd.1997.0157; Blancher C, 2001, CANCER RES, V61, P7349; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cao MJ, 2000, BIOCHEM BIOPH RES CO, V272, P485, DOI 10.1006/bbrc.2000.2803; Daly EB, 2004, BBA-MOL CELL RES, V1691, P17, DOI 10.1016/j.bbamcr.2003.11.004; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; FILELLA X, 1991, TUMOR BIOL, V12, P360, DOI 10.1159/000217737; Funasaka T, 2002, INT J CANCER, V101, P217, DOI 10.1002/ijc.10617; Galle J, 1999, BRIT J PHARMACOL, V127, P195, DOI 10.1038/sj.bjp.0702495; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOMM SA, 1988, BRIT J CANCER, V58, P797, DOI 10.1038/bjc.1988.312; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; Haga A, 2000, BBA-PROTEIN STRUCT M, V1480, P235, DOI 10.1016/S0167-4838(00)00075-3; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; Komi A, 2003, EXP CELL RES, V283, P91, DOI 10.1016/S0014-4827(02)00029-0; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; Niinaka Y, 1998, CANCER RES, V58, P2667; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; SCHROTER W, 1985, EUR J PEDIATR, V144, P301, DOI 10.1007/BF00441768; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHWEIKI D, 1992, NATURE, V359, P845; SIVITZ WI, 1992, AM J PHYSIOL, V263, pE562, DOI 10.1152/ajpendo.1992.263.3.E562; Tsutsumi S, 2003, CANCER RES, V63, P242; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; Watanabe H, 1996, CANCER RES, V56, P2960; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yakirevich E, 2000, BIOL REPROD, V62, P1016, DOI 10.1095/biolreprod62.4.1016; Yanagawa T, 2004, LAB INVEST, V84, P513, DOI 10.1038/labinvest.3700057; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867	46	79	85	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1422	1430		10.1096/fj.05-3699com	http://dx.doi.org/10.1096/fj.05-3699com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126909				2022-12-25	WOS:000232315700035
J	Nikolova, T; Czyz, J; Rolletschek, A; Blyszczuk, P; Fuchs, J; Jovtchev, G; Schuderer, J; Kuster, N; Wobus, AM				Nikolova, T; Czyz, J; Rolletschek, A; Blyszczuk, P; Fuchs, J; Jovtchev, G; Schuderer, J; Kuster, N; Wobus, AM			Electromagnetic fields affect transcript levels of apoptosis-related genes in embryonic stem cell-derived neural progenitor cells	FASEB JOURNAL			English	Article						mouse embryonic stem cells; neuronal differentiation; GADD45; bcl-2; bax	CENTRAL-NERVOUS-SYSTEM; DNA STRAND BREAKS; MAGNETIC-FIELD; HUMAN-LYMPHOCYTES; TYROSINE KINASES; TRANSGENIC MICE; MHZ MICROWAVES; MESSENGER-RNA; BRAIN-CELLS; EXPOSURE	Mouse embryonic stem (ES) cells were used as an experimental model to study the effects of electromagnetic fields (EMF). ES-derived nestin-positive neural progenitor cells were exposed to extremely low frequency EMF simulating power line magnetic fields at 50 Hz (ELF-EMF) and to radiofrequency EMF simulating the Global System for Mobile Communication (GSM) signals at 1.71 GHz (RF-EMF). Following EMF exposure, cells were analyzed for transcript levels of cell cycle regulatory, apoptosis-related, and neural-specific genes and proteins; changes in proliferation; apoptosis; and cytogenetic effects. Quantitative RT-PCR analysis revealed that ELF-EMF exposure to ES-derived neural cells significantly affected transcript levels of the apoptosis-related bcl-2, bax, and cell cycle regulatory "growth arrest DNA damage inducible" GADD45 genes, whereas mRNA levels of neural-specific genes were not affected. RF-EMF exposure of neural progenitor cells resulted in down-regulation of neural-specific Nurr1 and in up-regulation of bax and GADD45 mRNA levels. Short-term RF-EMF exposure for 6 h, but not for 48 h, resulted in a low and transient increase of DNA double-strand breaks. No effects of ELF- and RF-EMF on mitochondrial function, nuclear apoptosis, cell proliferation, and chromosomal alterations were observed. We may conclude that EMF exposure of ES-derived neural progenitor cells transiently affects the transcript level of genes related to apoptosis and cell cycle control. However, these responses are not associated with detectable changes of cell physiology, suggesting compensatory mechanisms at the translational and posttranslational level.	Inst Plant Genet & Crop Plant Res, In Vitro Differentiat Grp, D-06466 Gatersleben, Germany; Fdn Res Informat Technol Soc, CH-8004 Zurich, Switzerland	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Wobus, AM (corresponding author), Inst Plant Genet & Crop Plant Res, In Vitro Differentiat Grp, Corrensstr 3, D-06466 Gatersleben, Germany.	wobusam@ipk-gatersleben.de	Blyszczuk, Przemyslaw/J-2153-2019; Kuster, Niels/B-9706-2008	Blyszczuk, Przemyslaw/0000-0003-2521-3232; Czyz, Jaroslaw/0000-0001-6779-7630; Kuster, Niels/0000-0002-5827-3728; Jovtchev, Gabriele/0000-0002-0170-4718; Fuchs, Joerg/0000-0003-4171-5371				Adey WR, 2000, CANCER RES, V60, P1857; ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X; *APPL BIOS FCU, 2003, US B APPL BIOS FCU, V2; Auvinen A, 2002, EPIDEMIOLOGY, V13, P356, DOI 10.1097/00001648-200205000-00018; Bethwaite P, 2001, CANCER CAUSE CONTROL, V12, P683, DOI 10.1023/A:1011297803849; Chan WY, 2002, ANAT RECORD, V267, P261, DOI 10.1002/ar.10100; Chung HK, 2003, J BIOL CHEM, V278, P28079, DOI 10.1074/jbc.M212835200; Czyz J, 2004, BIOELECTROMAGNETICS, V25, P296, DOI 10.1002/bem.10199; Czyz J, 2003, BIOL CHEM, V384, P1391, DOI 10.1515/BC.2003.155; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; Di Carlo A, 2002, J CELL BIOCHEM, V84, P447, DOI 10.1002/jcb.10036.abs; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Fassler R, 1996, J CELL SCI, V109, P2989; Feychting M, 1997, EPIDEMIOLOGY, V8, P384, DOI 10.1097/00001648-199707000-00006; Grassi C, 2004, CELL CALCIUM, V35, P307, DOI 10.1016/j.ceca.2003.09.001; Harry GJ, 2000, RADIAT RES, V153, P642; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; *IEC, 1995, EL COMP EMC; Ivancsits S, 2002, MUTAT RES-GEN TOX EN, V519, P1, DOI 10.1016/S1383-5718(02)00109-2; Jin M, 2000, J CELL BIOCHEM, V78, P371, DOI 10.1002/1097-4644(20000901)78:3<371::AID-JCB3>3.0.CO;2-M; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim JY, 2003, J NEUROCHEM, V85, P1443, DOI 10.1046/j.1471-4159.2003.01780.x; Kuster N, 2000, BIOELECTROMAGNETICS, V21, P508, DOI 10.1002/1521-186X(200010)21:7<508::AID-BEM4>3.0.CO;2-F; KUSTER NN, 1997, MOBILE COMMUNICATION; Lagroye I, 2004, INT J RADIAT BIOL, V80, P11, DOI 10.1080/09553000310001642911; Lai H, 2004, ENVIRON HEALTH PERSP, V112, P687, DOI 10.1289/ehp.6355; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Leszczynski D, 2002, DIFFERENTIATION, V70, P120, DOI 10.1046/j.1432-0436.2002.700207.x; Li Yi, 2002, Space Med Med Eng (Beijing), V15, P374; LIBURDY RP, 1992, FEBS LETT, V301, P53, DOI 10.1016/0014-5793(92)80209-Y; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; Liu Yun, 2003, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V21, P339; Lonn S, 2004, INT J CANCER, V108, P450, DOI 10.1002/ijc.11578; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; McFarlane EH, 2000, BIOELECTROCHEMISTRY, V52, P23, DOI 10.1016/S0302-4598(00)00078-7; Mostafapour SP, 2002, J NEUROSCI, V22, P4670, DOI 10.1523/JNEUROSCI.22-11-04670.2002; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Narita K, 1997, IN VIVO, V11, P329; Oldenburg O, 2004, AM J PHYSIOL-HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003; Pacini S, 1999, NEUROSCI LETT, V267, P185, DOI 10.1016/S0304-3940(99)00362-6; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; Pipkin JL, 1999, BIOELECTROMAGNETICS, V20, P347, DOI 10.1002/(SICI)1521-186X(199909)20:6<347::AID-BEM3>3.0.CO;2-I; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Ratajczak MZ, 2004, LEUKEMIA, V18, P29, DOI 10.1038/sj.leu.2403184; Repacholi MH, 1997, RADIAT RES, V147, P631, DOI 10.2307/3579630; Rohwedel J, 2001, TOXICOL IN VITRO, V15, P741, DOI 10.1016/S0887-2333(01)00074-1; Rolletschek A, 2004, TOXICOL LETT, V149, P361, DOI 10.1016/j.toxlet.2003.12.064; Rolletschek A, 2001, MECH DEVELOP, V105, P93, DOI 10.1016/S0925-4773(01)00385-9; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Salford LG, 2003, ENVIRON HEALTH PERSP, V111, P881, DOI 10.1289/ehp.6039; Sarkar SA, 2002, CELL STRUCT FUNCT, V27, P99, DOI 10.1247/csf.27.99; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Saunders RD, 2002, HEALTH PHYS, V83, P366, DOI 10.1097/00004032-200209000-00006; Schonborn F, 2000, BIOELECTROMAGNETICS, V21, P372, DOI 10.1002/1521-186X(200007)21:5<372::AID-BEM6>3.0.CO;2-S; Schuderer J, 2004, BIOELECTROMAGNETICS, V25, P582, DOI 10.1002/bem.20037; SINGH NP, 1991, MUTAT RES, V252, P289, DOI 10.1016/0165-1161(91)90008-V; SISKEN BF, 1995, J NEUROSCI RES, V42, P692, DOI 10.1002/jnr.490420512; Sommer AM, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-77; Stang A, 2001, EPIDEMIOLOGY, V12, P7, DOI 10.1097/00001648-200101000-00003; Suliman Y, 2001, CANCER RES, V61, P6467; SZMIGIELSKI S, 1982, BIOELECTROMAGNETICS, V3, P179, DOI 10.1002/bem.2250030202; TENFORDE TS, 1992, ANNU REV PUBL HEALTH, V13, P173, DOI 10.1146/annurev.publhealth.13.1.173; Utteridge TD, 2002, RADIAT RES, V158, P357, DOI 10.1667/0033-7587(2002)158[0357:LTEOEP]2.0.CO;2; Ventura C, 2004, FASEB J, V18, P155, DOI 10.1096/fj.04-2695fje; Wallace OB, 1999, ADV AMIN AC MIM PEPT, V2, P1, DOI 10.1016/S1874-5113(99)80003-3; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wetzel B J, 2001, Biomed Sci Instrum, V37, P203; Wilkinson BL, 2002, MOL BRAIN RES, V99, P67, DOI 10.1016/S0169-328X(02)00113-4; Winter C, 2002, MOL BRAIN RES, V104, P194, DOI 10.1016/S0169-328X(02)00378-9; Wobus A M, 2002, Methods Mol Biol, V185, P127; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Woods M, 2000, FASEB J, V14, P2284, DOI 10.1096/fj.00-0164com; WU RY, 1994, BIOELECTROMAGNETICS, V15, P531, DOI 10.1002/bem.2250150606; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	75	131	145	0	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1686	+		10.1096/fj.04-3549fje	http://dx.doi.org/10.1096/fj.04-3549fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16116041				2022-12-25	WOS:000231843700009
J	Poole, KES; van Bezooijen, RL; Loveridge, N; Hamersma, H; Papapoulos, SE; Lowik, CW; Reeve, J				Poole, KES; van Bezooijen, RL; Loveridge, N; Hamersma, H; Papapoulos, SE; Lowik, CW; Reeve, J			Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation	FASEB JOURNAL			English	Article						bone remodeling; immunohistochemistry; sclerosteosis	INTRACAPSULAR HIP FRACTURE; BMP ANTAGONIST; LINING CELLS; FEMORAL-NECK; PROTEIN; OSTEOCLASTS; APOPTOSIS; ESTROGEN; HORMONE; DENSITY	Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte-derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.	Univ Cambridge, Addenbrookes Hosp, Bone Res Grp, Dept Med, Cambridge CB2 2QQ, England; Leiden Univ, Ctr Med, Dept Endocrinol & Metab Dis, Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Mol Cell Biol, Leiden, Netherlands	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Poole, KES (corresponding author), Univ Cambridge, Dept Med, MRC Clin Res Training Fellow Bone Res Grp, Box 157,Level 5, Cambridge CB2 2QQ, England.	kesp2@cam.ac.uk	Reeve, Jonathan/C-7551-2012	Reeve, Jonathan/0000-0002-4364-2682; Loveridge, Nigel/0000-0002-5550-7584				Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; BEIGHTON P, 1976, ANN INTERN MED, V84, P393, DOI 10.7326/0003-4819-84-4-393; BEIGHTON P, 1977, CLIN GENET, V11, P1; BEIGHTON P, 1979, S AFR MED J, V55, P783; Bell KL, 1997, J BONE MINER RES, V12, P1231, DOI 10.1359/jbmr.1997.12.8.1231; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Chow JWM, 1998, J BONE MINER RES, V13, P1760, DOI 10.1359/jbmr.1998.13.11.1760; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Gross TS, 2005, J BONE MINER RES, V20, P250, DOI 10.1359/JBMR.041004; Gross TS, 2001, J APPL PHYSIOL, V90, P2514, DOI 10.1152/jappl.2001.90.6.2514; Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399-0004.2003.00036.x; Kaptoge S, 2003, OSTEOPOROSIS INT, V14, P941, DOI 10.1007/s00198-003-1484-2; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Loveridge N, 2002, BONE, V30, P866, DOI 10.1016/S8756-3282(02)00732-9; Marotti G, 1996, Ital J Anat Embryol, V101, P25; MAROTTI G, 1992, BONE, V13, P363, DOI 10.1016/8756-3282(92)90452-3; Martin RB, 2000, BONE, V26, P1, DOI 10.1016/S8756-3282(99)00241-0; Martin RB, 2000, BONE, V26, P71, DOI 10.1016/S8756-3282(99)00242-2; Metz LN, 2003, BONE, V33, P753, DOI 10.1016/S8756-3282(03)00245-X; Noble BS, 2003, AM J PHYSIOL-CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002; Parfitt AM., 1983, BONE HISTOMORPHOMETR, V1983, P143; Power J, 2003, OSTEOPOROSIS INT, V14, P141, DOI 10.1007/s00198-002-1333-8; STEIN SA, 1983, NEUROLOGY, V33, P267, DOI 10.1212/WNL.33.3.267; Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023; Tate MLK, 2004, INT J BIOCHEM CELL B, V36, P1, DOI 10.1016/S1357-2725(03)00241-3; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60; WARMINGTON K, 2004, J BACK MUSCULOSKE S1, V19, P56; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599	33	657	710	0	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1842	+		10.1096/fj.05-4221fje	http://dx.doi.org/10.1096/fj.05-4221fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16123173				2022-12-25	WOS:000231843700007
J	Ko, MJ; Murata, K; Hwang, DS; Parvin, JD				Ko, MJ; Murata, K; Hwang, DS; Parvin, JD			Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle	ONCOGENE			English	Article						BRCA1; centrosome; cell cycle; breast cancer	AMPLIFICATION; INSTABILITY; CHECKPOINT; NUMBER; CANCER	BRCA1-dependent ubiquitination activity regulates centrosome number in several tissue culture cell lines derived from breast cells. In these experiments, we asked how BRCA1 inhibits centrosome amplification. In general, supernumerary centrosomes can accumulate by three mechanisms: (1) failed cytokinesis and the accumulation of centrosomes by duplication in a repeated S-phase of the cell cycle, (2) disruption of the licensing of centrosome doubling such that they duplicate at inappropriate times in the cell cycle, or (3) fragmentation of the centrosomes. In this study, we found that inhibition of BRCA1 caused premature separation of centrioles and reduplication. By blocking cells in early S-phase before centrosome amplification secondary to BRCA1 inhibition could occur and then releasing, we found that inhibition of BRCA1 caused centrosome amplification between late S-phase and G2/M before the cell divided. These results suggest that normal BRCA1 function is critical in these cell lines to prevent centriole separation and centrosome reduplication before mitosis.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul, South Korea; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Seoul National University (SNU); Harvard University; Harvard Medical School	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, NRB 630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER; NCI NIH HHS [CA90281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Hsu LC, 2001, CANCER RES, V61, P7713; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pihan GA, 2003, CANCER RES, V63, P1398; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Suto K, 1999, MOL BIOL CELL, V10, P3331, DOI 10.1091/mbc.10.10.3331; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Wyllie FS, 1996, ONCOGENE, V12, P1077; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	16	40	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					298	303		10.1038/sj.onc.1209028	http://dx.doi.org/10.1038/sj.onc.1209028			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170356				2022-12-25	WOS:000234583600014
J	Mai, RT; Yeh, TS; Kao, CF; Sun, SK; Huang, HH; Lee, YHW				Mai, RT; Yeh, TS; Kao, CF; Sun, SK; Huang, HH; Lee, YHW			Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression	ONCOGENE			English	Article						HCV core protein; B23; YY1; p300; B23 promoter	HISTONE ACETYLTRANSFERASE ACTIVITY; HEPATOCELLULAR-CARCINOMA; ADENOVIRUS E1A; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; DNA-DAMAGE; NON-A; P53; ACTIVATION; NUCLEOPHOSMIN/B23	Hepatitis C virus (HCV) core has a pleiotropic effect on various promoters. In this study, we found that the expression of nucleolar phosphoprotein B23 was enhanced in HCV core-expressing cells and, moreover, HCV core interacts directly with the C-terminal end of B23. Using sucrose gradient centrifugation analysis and immunoprecipitation assays, HCV core was found in a large complex containing B23 and its interacting partner transcription factor YY1. Both B23 and HCV core associated with YY1 in the central GA/GK-rich and C-terminal zinc finger domain. These physical interactions between core, B23, and YY1 led to ternary complex formation that was bound to the YY1 response element. In a transient cotransfection experiment, relief of the transsuppression activity of YY1 on the YY1-response element-driven reporter by core and B23 was found. This is also true when examining the effects of these three constructs on the B23 promoter-driven reporter. Additionally, chromatin immunoprecipitation assays indicated that a transcriptional activation complex consisting of core, together with B23, p300, and YY1, was recruited to the YY1 response element of B23 promoter, and this probably occurred through complex formation between core and these three cellular transcription regulators. This is different from the situation in the absence of core, where YY1 and histone deacetylase 1, but not B23 and p300, were associated on the YY1 element as the transcription repression complex. Together, our results indicate that HCV core can recruit B23 and p300 to relieve the repression effect of YY1 on B23 promoter activity, a property that requires the intrinsic histone acetyltransferase activity of p300. Thus, because these three core-associated cellular transcription regulators have a multitude of cellular interacting proteins and are involved in a versatility of cellular processes, the complex formation described here may partially account for the pleiotropic effects of core protein on gene expression and cellular function in HCV-infected cells.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155 Li Nog St Sect 2,Shih Pai, Taipei 112, Taiwan.	yhwulee@ym.edu.tw		Mai, Ru-Tsun/0000-0002-9935-4268; Lee Wu, Yan-Hwa/0000-0001-7299-7354				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brockmann D, 2001, GENE, V277, P111, DOI 10.1016/S0378-1119(01)00703-X; BRUIX J, 1989, LANCET, V2, P1004; Chan HM, 2001, J CELL SCI, V114, P2363; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Gomez-Gonzalo M, 2004, VIROLOGY, V328, P120, DOI 10.1016/j.virol.2004.06.044; Goodman RH, 2000, GENE DEV, V14, P1553; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; HSIEH CL, 1995, BIOCHEM BIOPH RES CO, V214, P910, DOI 10.1006/bbrc.1995.2373; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Kao CF, 2004, J BIOMED SCI, V11, P72, DOI 10.1159/000075291; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Krippner-Heidenreich A, 2005, MOL CELL BIOL, V25, P3704, DOI 10.1128/MCB.25.9.3704-3714.2005; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Machida K, 2004, J VIROL, V78, P8835, DOI 10.1128/JVI.78.16.8835-8843.2004; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sun HJ, 2004, MOL IMMUNOL, V41, P1241, DOI 10.1016/j.molimm.2004.05.013; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Takemura M, 2002, EXP CELL RES, V276, P233, DOI 10.1006/excr.2002.5523; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; van Pelt JF, 2004, CANCER LETT, V209, P197, DOI 10.1016/j.canlet.2003.11.035; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Watashi K, 2003, CANCER SCI, V94, P937, DOI 10.1111/j.1349-7006.2003.tb01381.x; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	67	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					448	462		10.1038/sj.onc.1209052	http://dx.doi.org/10.1038/sj.onc.1209052			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170350				2022-12-25	WOS:000234714100013
J	Glascock, MC; Ballou, DP; Dawson, JH				Glascock, MC; Ballou, DP; Dawson, JH			Direct observation of a novel perturbed oxyferrous catalytic intermediate during reduced putidaredoxin-initiated turnover of cytochrome P-450-CAM - Probing the effector role of putidaredoxin in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; HEME-CONTAINING OXYGENASES; COMPOUND-I FORMATION; ELECTRON-TRANSFER; THIOLATE LIGATION; MECHANISTIC IMPLICATIONS; KINETIC CHARACTERIZATION; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; COMPLEX-FORMATION	The single turnover of ( 1R)(+)-camphor-bound oxyferrous cytochrome P450-CAM with one equivalent of dithionite-reduced putidaredoxin ( Pdx) was monitored for the appearance of transient intermediates at 3 degrees C by double mixing rapid scanning stopped-flow spectroscopy. With excess camphor, three successive species were observed after generating oxyferrous P450-CAM and reacting versus reduced Pdx: a perturbed oxyferrous derivative, as species that was a mixture of high and low spin Fe( III), and high spin ferric camphor-bound enzyme. The rates of the first two steps, similar to 140 and similar to 85 s(-1), were assigned to formation of the perturbed oxyferrous intermediate and to electron transfer from reduced Pdx, respectively. In the presence of stoichiometric substrate, three phases with similar rates were seen even though the final state is low spin ferric P450-CAM. This is consistent with substrate being hydroxylated during the reaction. The single turnover reaction initiated by adding dioxygen to a preformed reduced P450-CAM center dot Pdx complex with excess camphor also led to phases with similar rates. It is proposed that formation of the perturbed oxyferrous intermediate reflects alteration of H-bonding to the proximal Cys, increasing the reduction potential of the oxyferrous state and triggering electron transfer from reduced Pdx. This species may be a direct spectral signature of the effector role of Pdx on P450-CAM reactivity ( i.e. during catalysis). The substrate-free oxyferrous enzyme also reacted readily with reduced Pdx, showing that the inability of substrate-free P450-CAM to accept electrons from reduced Pdx and function as an NADH oxidase is completely due to the incapacity of reduced Pdx to deliver the first but not the second electron.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Columbia, SC 29208 USA	University of Michigan System; University of Michigan; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Ballou, DP (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dballou@umich.edu; dawson@sc.edu	dballou@umich.edu, David P/A-1298-2007; Dawson, John/HDM-6702-2022	Dawson, John H/0000-0002-4902-4295	NIGMS NIH HHS [GM 20877, GM 26730] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026730, R37GM020877, R01GM020877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Brazeau BJ, 2003, BIOCHEM BIOPH RES CO, V312, P143, DOI 10.1016/j.bbrc.2003.09.242; BREWER CB, 1988, J BIOL CHEM, V263, P791; Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Dawson JH, 2002, BIOPOLYMERS, V67, P200, DOI 10.1002/bip.10087; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DAWSON JH, 1976, J AM CHEM SOC, V98, P3707, DOI 10.1021/ja00428a054; EBLE KS, 1984, J BIOL CHEM, V259, P4389; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HITCHMAN ML, 1978, MEASUREMENT DISSOLVE, P7; Hoa G H, 1978, Biochemistry, V17, P2835; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; LI HY, 1995, J AM CHEM SOC, V117, P6297, DOI 10.1021/ja00128a019; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; Mouro C, 1999, FEBS LETT, V455, P302, DOI 10.1016/S0014-5793(99)00898-4; Nagano S, 2003, BIOCHEMISTRY-US, V42, P14507, DOI 10.1021/bi035410p; Nagano S, 2004, J BIOL CHEM, V279, P42844, DOI 10.1074/jbc.M404217200; Ogliaro F, 2000, J AM CHEM SOC, V122, P12892, DOI 10.1021/ja005619f; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; PEDERSON TC, 1977, MICROSOMES DRUG OXID, P275; Pochapsky SS, 2003, BIOCHEMISTRY-US, V42, P5649, DOI 10.1021/bi034263s; Purdy MM, 2004, BIOCHEMISTRY-US, V43, P271, DOI 10.1021/bi0356045; Roach MP, 1999, J AM CHEM SOC, V121, P12088, DOI 10.1021/ja9915504; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; Shimada H, 2001, J INORG BIOCHEM, V83, P255, DOI 10.1016/S0162-0134(00)00173-2; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; SONO M, 1985, J BIOL CHEM, V260, P5530; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Spolitak T, 2005, J BIOL CHEM, V280, P20300, DOI 10.1074/jbc.M501761200; Suzuki N, 1999, J AM CHEM SOC, V121, P11571, DOI 10.1021/ja992511v; Tosha T, 2002, BIOCHEMISTRY-US, V41, P13883, DOI 10.1021/bi0261037; Tosha T, 2003, J BIOL CHEM, V278, P39809, DOI 10.1074/jbc.M304265200; Tosha T, 2004, J BIOL CHEM, V279, P42836, DOI 10.1074/jbc.M404216200; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 2002, J BIOL CHEM, V277, P2547, DOI 10.1074/jbc.M108917200; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; Yoshioka S, 2002, J AM CHEM SOC, V124, P14571, DOI 10.1021/ja0265409; Yoshioka S, 2000, J INORG BIOCHEM, V81, P141, DOI 10.1016/S0162-0134(00)00097-0; Zhang HM, 2003, BIOCHEMISTRY-US, V42, P11594, DOI 10.1021/bi034968u	50	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42134	42141		10.1074/jbc.M505426200	http://dx.doi.org/10.1074/jbc.M505426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16115886	hybrid			2022-12-25	WOS:000233992700040
J	Janiszewski, M; Lopes, LR; Carmo, AO; Pedro, MA; Brandes, RP; Santos, CXC; Laurindo, FRM				Janiszewski, M; Lopes, LR; Carmo, AO; Pedro, MA; Brandes, RP; Santos, CXC; Laurindo, FRM			Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; NADPH OXIDASE; SUPEROXIDE GENERATION; CELLULAR GLUTATHIONE; PHENYLARSINE OXIDE; PLASMA-MEMBRANE; ACTIVATION; IDENTIFICATION; SUBUNIT; THIOREDOXIN	NAD( P) H oxidase, the main source of reactive oxygen species in vascular cells, is known to be regulated by redox processes and thiols. However, the nature of thiol-dependent regulation has not been established. Protein disulfide isomerase (PDI) is a dithiol/disulfide oxidoreductase chaperone of the thioredoxin superfamily involved in protein processing and translocation. We postulated that PDI regulates NAD( P) H oxidase activity of rabbit aortic smooth muscle cells ( VSMCs). Western blotting confirmed robust PDI expression and shift to membrane fraction after incubation with angiotensin II (AII, 100 nM, 6 h). In VSMC membrane fraction, PDI antagonism with bacitracin, scrambled RNase, or neutralizing antibody led to 26 - 83% inhibition (p < 0.05) of oxidase activity. AII incubation led to significant increase in oxidase activity, accompanied by a 6-fold increase in PDI refolding isomerase activity. AII-induced NAD( P) H oxidase activation was inhibited by 57 - 71% with antisense oligonucleotide against PDI ( PDIasODN). Dihydroethidium fluorescence showed decreased superoxide generation due to PDIasODN. Confocal microscopy showed co-localization between PDI and the oxidase subunits p22phox, Nox1, and Nox4. Co-immunoprecipitation assays supported spatial association between PDI and oxidase subunits p22phox, Nox1, and Nox4 in VSMCs. Moreover, in HEK293 cells transfected with green fluorescent protein constructs for Nox1, Nox2, and Nox4, each of these subunits co- immunoprecipitated with PDI. Akt phosphorylation, a known downstream pathway of AII- driven oxidase activation, was significantly reduced by PDIasODN. These results suggest that PDI closely associates with NAD( P) H oxidase and acts as a novel redoxsensitive regulatory protein of such enzyme complex, potentially affecting subunit traffic/assembling.	Univ Sao Paulo, Sch Med, Vasc Biol Lab, Heart Inst,Inst Coracao, BR-05403000 Sao Paulo, Brazil; Goethe Univ Frankfurt, Inst Kardiovaskulare Physiol, D-60596 Frankfurt, Germany; Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, BR-05508900 Sao Paulo, Brazil; Hosp Israelita Albert Einstein, BR-05651901 Sao Paulo, Brazil	Universidade de Sao Paulo; Goethe University Frankfurt; Universidade de Sao Paulo; Hospital Israelita Albert Einstein	Laurindo, FRM (corresponding author), Univ Sao Paulo, Sch Med, Vasc Biol Lab, Heart Inst,Inst Coracao, Av Eneas Carvalho Aguiar,44 Subsolo, BR-05403000 Sao Paulo, Brazil.	expfrancisco@incor.usp.br	Lopes, Lucia R/B-9063-2012; Brandes, Ralf P/L-3058-2017; Laurindo, Francisco R/J-6575-2015	Lopes, Lucia R/0000-0003-0530-7805; Brandes, Ralf P/0000-0002-8035-0048; 				Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; Brandes RP, 2005, CARDIOVASC RES, V65, P16, DOI 10.1016/j.cardiores.2004.08.007; BUONASSISI V, 1976, P NATL ACAD SCI USA, V73, P1612, DOI 10.1073/pnas.73.5.1612; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Clissold PM, 2003, BIOESSAYS, V25, P603, DOI 10.1002/bies.10287; Colston JT, 2005, FEBS LETT, V579, P2533, DOI 10.1016/j.febslet.2005.03.057; Delom F, 2001, J BIOL CHEM, V276, P21337, DOI 10.1074/jbc.M101086200; Djordjevic T, 2005, FREE RADICAL BIO MED, V38, P616, DOI 10.1016/j.freeradbiomed.2004.09.036; Doussiere J, 1998, EUR J BIOCHEM, V251, P649, DOI 10.1046/j.1432-1327.1998.2510649.x; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gallina A, 2002, J BIOL CHEM, V277, P50579, DOI 10.1074/jbc.M204547200; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; Inanami O, 1998, ARCH BIOCHEM BIOPHYS, V350, P36, DOI 10.1006/abbi.1997.0484; Janiszewski M, 2000, FREE RADICAL BIO MED, V29, P889, DOI 10.1016/S0891-5849(00)00393-2; Janiszewski M, 2002, FREE RADICAL BIO MED, V32, P446, DOI 10.1016/S0891-5849(01)00828-0; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kimura T, 2005, BIOCHEM BIOPH RES CO, V331, P224, DOI 10.1016/j.bbrc.2005.03.147; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Kobayashi T, 1998, J CELL SCI, V111, P81; Lahav J, 2003, BLOOD, V102, P2085, DOI 10.1182/blood-2002-06-1646; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Laurindo FRM, 2002, METHOD ENZYMOL, V352, P432; Li JM, 2003, J BIOL CHEM, V278, P12094, DOI 10.1074/jbc.M209793200; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; MURPHY JK, 1995, FREE RADICAL BIO MED, V18, P37, DOI 10.1016/0891-5849(94)00101-O; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Souza HP, 2002, AM J PHYSIOL-HEART C, V282, pH466, DOI 10.1152/ajpheart.00482.2001; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Wang DT, 2005, J BIOL CHEM, V280, P3096, DOI 10.1074/jbc.M407709200; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Xiao RY, 2005, J BIOL CHEM, V280, P21099, DOI 10.1074/jbc.M411476200; Yamawaki H, 2003, CIRC RES, V93, P1029, DOI 10.1161/01.RES.0000102869.39150.23; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890	53	168	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40813	40819		10.1074/jbc.M509255200	http://dx.doi.org/10.1074/jbc.M509255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16150729	hybrid			2022-12-25	WOS:000233666600052
J	Hajishengallis, G; Ratti, P; Harokopakis, E				Hajishengallis, G; Ratti, P; Harokopakis, E			Peptide mapping of bacterial fimbrial epitopes interacting with pattern recognition receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; PORPHYROMONAS-GINGIVALIS INVASION; HEAT-LABILE ENTEROTOXINS; MAC-1 CD11B/CD18; EPITHELIAL-CELLS; BINDING; INNATE; CD14; ACTIVATION; LIPOPOLYSACCHARIDE	The fimbriae of the oral pathogen Porphyromonas gingivalis induce Toll-like receptor 2 (TLR2)-dependent macrophage activation upon their recognition by CD14 and the beta 2 integrin CD11b/CD18. To map functional epitopes of fimbriae that interact with these pattern recognition receptors (PRRs), we examined 20 synthetic peptides covering the entire length of the 41-kDa fimbrillin subunit. Using direct or competitive inhibition assays for receptor binding or cell activation, the CD14 binding activity of fimbriae was localized to residues 69 - 90 and was essential for TLR2-dependent cytokine induction. The CD11b/CD18 binding activity of fimbriae was localized to two neighboring epitopes defined by residues 166-185 and 206-225. Unlike epitope 69-90 that constitutively bound CD14, the CD11b/CD18 binding activity of epitopes 166-185 and 206-225 was inducible by integrin activators. The CD11b/CD18 binding activity played a contributory role to TLR2-dependent induction of tumor necrosis factor-alpha by fimbriae but was involved in specific down-regulation of interleukin-12. Cell activation by a combination of fimbrillin peptides corresponding to the CD14 and CD11b/CD18 binding activities resulted in higher tumor necrosis factor-alpha responses than would be expected from a simply additive effect, attributable to CD14-dependent inside-out signaling leading to enhanced binding interactions with CD11b/CD18. These data suggest that P. gingivalis fimbriae display a modular structure that interacts through discrete epitopes and in a regulated mode with distinct PRRs, which in turn differentially modulate the state of cell activation. Elucidation of pathogen interactions with PRRs at the molecular level may glean insight into host defense mechanisms as well as into microbial strategies that subvert innate immunity.	Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, New Orleans, LA 70119 USA; Louisiana State Univ, Hlth Sci Ctr, Ctr Excellence Oral & Craniofacial Biol, New Orleans, LA 70119 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Hajishengallis, G (corresponding author), Univ Louisville, Sch Dent, Oral Hlth & Syst Dis Res Ctr, Dept Periodont & Endodont, Rm 206,501 S Preston St, Louisville, KY 40202 USA.	g0haji01@louisville.edu	Hajishengallis, George N./K-1117-2019	Hajishengallis, George N./0000-0001-7392-8852	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015254] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE015254] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Amano A, 1996, INFECT IMMUN, V64, P1631, DOI 10.1128/IAI.64.5.1631-1637.1996; Chun YHP, 2005, J PERIODONTAL RES, V40, P87, DOI 10.1111/j.1600-0765.2004.00771.x; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Cunningham MD, 1996, INFECT IMMUN, V64, P3601, DOI 10.1128/IAI.64.9.3601-3608.1996; Delima AJ, 2003, PERIODONTOL 2000, V31, P55, DOI 10.1034/j.1600-0757.2003.03105.x; Deshpande RG, 1998, INFECT IMMUN, V66, P5337, DOI 10.1128/IAI.66.11.5337-5343.1998; Desvarieux M, 2005, CIRCULATION, V111, P576, DOI 10.1161/01.CIR.0000154582.37101.15; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DICKINSON DP, 1988, J BACTERIOL, V170, P1658, DOI 10.1128/jb.170.4.1658-1665.1988; Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998; Gibson FC, 2004, CIRCULATION, V109, P2801, DOI 10.1161/01.CIR.0000129769.17895.F0; GLACONA MB, 2004, FEMS MICROBIOL LETT, V241, P95; Hajishengallis G, 2005, INFECT IMMUN, V73, P1343, DOI 10.1128/IAI.73.3.1343-1349.2005; Hajishengallis G, 2004, INFECT IMMUN, V72, P6351, DOI 10.1128/IAI.72.11.6351-6358.2004; Hajishengallis G, 2004, INFECT IMMUN, V72, P1188, DOI 10.1128/IAI.72.2.1188-1191.2004; Hajishengallis G, 2002, INFECT IMMUN, V70, P6658, DOI 10.1128/IAI.70.12.6658-6664.2002; Hajishengallis G, 2002, CLIN DIAGN LAB IMMUN, V9, P403, DOI 10.1128/CDLI.9.2.403-411.2002; Hajishengallis George, 2002, Ann Periodontol, V7, P72, DOI 10.1902/annals.2002.7.1.72; Haraszthy VI, 2000, J PERIODONTOL, V71, P1554, DOI 10.1902/jop.2000.71.10.1554; Harokopakis E, 2005, EUR J IMMUNOL, V35, P1201, DOI 10.1002/eji.200425883; Jotwani R, 2004, INFECT IMMUN, V72, P1725, DOI 10.1128/IAI.72.3.1725-1732.2004; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; LAMONT RJ, 1995, INFECT IMMUN, V63, P3878, DOI 10.1128/IAI.63.10.3878-3885.1995; LEE JY, 1995, PROTEIN EXPRES PURIF, V6, P496, DOI 10.1006/prep.1995.1066; Levitz SM, 1997, INFECT IMMUN, V65, P931, DOI 10.1128/IAI.65.3.931-935.1997; MALEK R, 1994, J BACTERIOL, V176, P1052, DOI 10.1128/JB.176.4.1052-1059.1994; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Muthukuru M, 2005, INFECT IMMUN, V73, P687, DOI 10.1128/IAI.73.2.687-694.2005; NAITO Y, 1993, ORAL MICROBIOL IMMUN, V8, P195, DOI 10.1111/j.1399-302X.1993.tb00559.x; Ogawa T, 2002, EUR J IMMUNOL, V32, P2543, DOI 10.1002/1521-4141(200209)32:9<2543::AID-IMMU2543>3.0.CO;2-2; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; SOJAR HT, 1995, BIOCHEM BIOPH RES CO, V216, P785, DOI 10.1006/bbrc.1995.2690; STOCKL J, 1995, J IMMUNOL, V154, P5452; Triantafilou M, 2002, CRIT REV IMMUNOL, V22, P251; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; WATANABE K, 1992, ORAL MICROBIOL IMMUN, V7, P357, DOI 10.1111/j.1399-302X.1992.tb00636.x; Weinberg A, 1997, INFECT IMMUN, V65, P313, DOI 10.1128/IAI.65.1.313-316.1997; Wooten RM, 2002, J IMMUNOL, V168, P348, DOI 10.4049/jimmunol.168.1.348; Yilmaz O, 2002, CELL MICROBIOL, V4, P305, DOI 10.1046/j.1462-5822.2002.00192.x; ZAMBON JJ, 1994, MOLECULAR PATHOGENESIS OF PERIODONTAL DISEASE, P3; Zhou Q, 2005, INFECT IMMUN, V73, P935, DOI 10.1128/IAI.73.2.935-943.2005	48	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38902	38913		10.1074/jbc.M507326200	http://dx.doi.org/10.1074/jbc.M507326200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16129673	hybrid			2022-12-25	WOS:000233362200003
J	Mok, MTS; Edwards, MR				Mok, MTS; Edwards, MR			Kinetic and physical characterization of the inducible UDP-N-acetylglucosamine pyrophosphorylase from Giardia intestinalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GLUCOSAMINE; ESCHERICHIA-COLI; N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE; CRYSTAL-STRUCTURES; ENCYSTING GIARDIA; ACTIVE-SITES; PROTEIN; BINDING; IDENTIFICATION; LAMBLIA	The UDP-N-acetylglucosamine pyrophosphorylase in Giardia intestinalis ( GiUAP) is one of the five inducible enzymes to synthesize UDP-GalNAc, which is an important precursor for cyst wall synthesis. The recombinant UDP-N-acetylglucosamine pyrophosphorylase ( rGiUAP) and its mutants G(108)A and G(210)A were expressed and identified by SDS-PAGE, size-exclusion chromatography, Western hybridization, and MALDI mass spectrometry. Sequence comparison with other eukaryotic UAPs has identified three specific motifs. Within these motifs alanine substitution for Gly(108) or Gly(210) dramatically reduced the pyrophosphate synthesis, suggesting these amino acids are catalytic residues. Besides, the rGiUAP was found to have relaxed binding to other uridine-based nucleotides, suggesting the substrate binding pocket is specific to uridine rather than phosphate group( s). Moreover, thermal denaturation analysis showed a significant increase in T-m for the rGiUAP and G(108)A upon binding of the substrate Mg-UTP. In contrast, G(210)A showed a decreased Tm upon binding of Mg-UTP. These results showed that binding of Mg-UTP increases protein stability of the rGiUAP, and the catalytic residue Gly(210) plays a significant role in stabilizing the protein structure. Such stabilization effect induced by substrate binding might be physiologically important as it favors the production of UDP-GlcNAc and hence the downstream GalNAc, which is crucial to survival of Giardia. These results help to define the essential amino acids for catalysis in the GiUAP and reveal the role of Mg-UTP binding in regulation of protein stability.	Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Mok, MTS (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia.	mythmok@mythmok.com	Mok, Myth/M-2958-2013	Mok, Myth/0000-0003-3156-4944				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulik DA, 1998, MOL BIOCHEM PARASIT, V95, P135, DOI 10.1016/S0166-6851(98)00076-0; Bulik DA, 2000, J BIOL CHEM, V275, P14722, DOI 10.1074/jbc.275.19.14722; Chakrabarti A, 2001, BIOCHEM BIOPH RES CO, V282, P1189, DOI 10.1006/bbrc.2001.4715; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; Gerwig GJ, 2002, GLYCOBIOLOGY, V12, P499, DOI 10.1093/glycob/cwf059; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang JY, 2001, NUCLEIC ACIDS RES, V29, P202, DOI 10.1093/nar/29.1.202; JARROLL EL, 1989, MOL BIOCHEM PARASIT, V32, P121, DOI 10.1016/0166-6851(89)90063-7; JARROLL EL, 1995, FOLIA PARASIT, V42, P81; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; Kostrewa D, 2001, J MOL BIOL, V305, P279, DOI 10.1006/jmbi.2000.4296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz R, 1983, PRINCIPLES FLUORESCE; Lloyd D, 2002, MICROBIOL-SGM, V148, P1349, DOI 10.1099/00221287-148-5-1349; Lopez  AB, 2003, MOL BIOCHEM PARASIT, V128, P51, DOI 10.1016/S0166-6851(03)00049-5; MACECHKO PT, 1992, MOL BIOCHEM PARASIT, V56, P301, DOI 10.1016/0166-6851(92)90179-N; MANNING P, 1992, J PROTOZOOL, V39, P290, DOI 10.1111/j.1550-7408.1992.tb01317.x; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; Minotto L, 1999, MOL BIOCHEM PARASIT, V98, P43, DOI 10.1016/S0166-6851(98)00141-8; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Mok MTS, 2005, GENE, V357, P73, DOI 10.1016/j.gene.2005.05.010; Mok MTS, 2005, ANAL BIOCHEM, V343, P341, DOI 10.1016/j.ab.2005.05.023; Nevill-Manning CG, 1998, P NATL ACAD SCI USA, V95, P5865, DOI 10.1073/pnas.95.11.5865; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; ORTEGABARRIA E, 1990, MOL BIOCHEM PARASIT, V43, P151, DOI 10.1016/0166-6851(90)90141-8; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Stoitsova SR, 2003, BBA-GEN SUBJECTS, V1619, P213, DOI 10.1016/S0304-4165(02)00496-8; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; Szumilo T, 1996, J BIOL CHEM, V271, P13147, DOI 10.1074/jbc.271.22.13147; VAARA M, 1992, FEMS MICROBIOL LETT, V97, P249, DOI 10.1016/0378-1097(92)90344-N; Wang-Gillam A, 1998, J BIOL CHEM, V273, P27055, DOI 10.1074/jbc.273.42.27055; Wang-Gillam A, 2000, J BIOL CHEM, V275, P1433, DOI 10.1074/jbc.275.2.1433; WARD HD, 1988, J EXP MED, V167, P73, DOI 10.1084/jem.167.1.73; WARD HD, 1985, INFECT IMMUN, V49, P629, DOI 10.1128/IAI.49.3.629-634.1985; WIECZOREK Z, 1995, J PHOTOCH PHOTOBIO B, V28, P57, DOI 10.1016/1011-1344(94)07098-9; WIECZOREK Z, 1993, BIOPHYS CHEM, V47, P233, DOI 10.1016/0301-4622(93)80048-N; Wieczorek Z, 1998, J PHOTOCH PHOTOBIO B, V43, P158, DOI 10.1016/S1011-1344(98)00100-6; YAMAMOTO K, 1976, AGR BIOL CHEM TOKYO, V40, P2275, DOI 10.1080/00021369.1976.10862393; YAMAMOTO K, 1979, CAN J MICROBIOL, V25, P1381, DOI 10.1139/m79-216	47	10	10	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39363	39372		10.1074/jbc.M509209200	http://dx.doi.org/10.1074/jbc.M509209200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16169849	hybrid			2022-12-25	WOS:000233362200057
J	Kodvawala, A; Ghering, AB; Davidson, WS; Hui, DY				Kodvawala, A; Ghering, AB; Davidson, WS; Hui, DY			Carboxyl ester lipase expression in macrophages increases cholesteryl ester accumulation and promotes atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT-STIMULATED LIPASE; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E; DEPENDENT LIPASE; DEFICIENT MICE; CHO-CELLS; IN-VITRO; CERAMIDE; LYSOPHOSPHATIDYLCHOLINE; SECRETION	Carboxyl ester lipase (CEL, also called cholesterol esterase or bile salt-dependent lipase) is a lipolytic enzyme capable of hydrolyzing cholesteryl esters, triacylglycerols, and phospholipids in a trihydroxy bile salt-dependent manner but hydrolyzes ceramides and lysophospholipids via bile salt-independent mechanisms. Although CEL is synthesized predominantly in the pancreas, a low level of CEL expression was reported in human macrophages. This study used transgenic mice with macrophage CEL expression at levels comparable with that observed in human macrophages to explore the functional role and physiological significance of macrophage CEL expression. Peritoneal macrophages from CEL transgenic mice displayed a 4-fold increase in [H-3]oleate incorporation into cholesteryl [H-3]oleate compared with CEL-negative macrophages when the cells were incubated under basal conditions in vitro. When challenged with acetylated low density lipoprotein, cholesteryl ester accumulation was 2.5-fold higher in macrophages expressing the CEL transgene. The differences in cholesteryl ester accumulation were attributed to the lower levels of ceramide and lysophosphatidylcholine in CEL-expressing cells than in CEL-negative cells. CEL transgenic mice bred to an atherosclerosis susceptible apoE(-/-) background displayed an approximate 4-fold higher atherosclerotic lesion area than apoE(-/-) mice without the CEL transgene when both were fed a high fat/cholesterol diet. Plasma level of the atherogenic lysophosphatidylcholine was lower in the CEL transgenic mice, but plasma cholesterol level and lipoprotein profile were similar between the two groups. These studies documented that CEL expression in macrophages is pro-atherogenic and that the mechanism is because of its hydrolysis of ceramide and lysophosphatidylcholine in promoting cholesterol esterification and decreasing cholesterol efflux.	Univ Cincinnati, Coll Med, Genome Res Inst, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), ML 0507,2120 E Galbraith Rd, Cincinnati, OH 45237 USA.	huidy@email.uc.edu		Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan D, 2000, BIOCHEM J, V345, P603, DOI 10.1042/0264-6021:3450603; Auge N, 2003, CIRCULATION, V108, P86, DOI 10.1161/01.CIR.0000079101.69806.47; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bodennec J, 2002, FASEB J, V16, P1814, DOI 10.1096/fj.02-0149fje; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; DESILVA HV, 1994, J LIPID RES, V35, P1297; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; Du H, 2001, J LIPID RES, V42, P489; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hara S, 1997, ARTERIOSCL THROM VAS, V17, P1258, DOI 10.1161/01.ATV.17.7.1258; Hopkins PCR, 2002, J LIPID RES, V43, P1881, DOI 10.1194/jlr.M200172-JLR200; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; HUI DY, 1993, BIOCHEM J, V291, P65, DOI 10.1042/bj2910065; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; Innerarity T L, 1986, Methods Enzymol, V129, P542; JACOBSON PW, 1990, J BIOL CHEM, V265, P515; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; KYGER EM, 1990, BIOCHEMISTRY-US, V29, P3853, DOI 10.1021/bi00468a008; Lange Y, 2004, P NATL ACAD SCI USA, V101, P11664, DOI 10.1073/pnas.0404766101; Le Petit-Thevenin J, 1998, BBA-LIPID LIPID MET, V1393, P307, DOI 10.1016/S0005-2760(98)00085-X; Li F, 1998, BIOCHEM J, V329, P675, DOI 10.1042/bj3290675; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; Nyberg L, 1998, J PEDIATR GASTR NUTR, V27, P560, DOI 10.1097/00005176-199811000-00013; OKWU AK, 1994, J LIPID RES, V35, P644; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Ramos B, 2002, MOL PHARMACOL, V62, P1068, DOI 10.1124/mol.62.5.1068; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P39, DOI 10.1016/0005-2760(95)00009-2; Rudd E.A., 1984, P185; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; Schreyer SA, 2003, ATHEROSCLEROSIS, V171, P49, DOI 10.1016/j.atherosclerosis.2003.07.010; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; Turunen P, 2004, J LIPID RES, V45, P1633, DOI 10.1194/jlr.M400176-JLR200; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; ZOLFAGHARI R, 1993, J BIOL CHEM, V268, P13532	40	33	36	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38592	38598		10.1074/jbc.M502266200	http://dx.doi.org/10.1074/jbc.M502266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166077	hybrid			2022-12-25	WOS:000233239800059
J	Misra, UK; Pizzo, SV				Misra, UK; Pizzo, SV			Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling - Effects of silencing CREB gene expression on Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RECOGNIZED FORMS; NF-KAPPA-B; CYCLIC-AMP; TRANSCRIPTION FACTOR; BCL-2 EXPRESSION; CROSS-TALK; CAMP; RAP1; SURVIVAL; PHOSPHORYLATION	In this study, we have examined the role of two cAMP downstream effectors protein kinase A (PKA) and Epac, in forskolin-induced macrophage proliferation. Treatment of macrophages with forskolin enhanced [H-3]thymidine uptake and increased cell number, and both were profoundly reduced by prior treatment of cells with H-89, a specific PKA inhibitor. Incubation of macrophages with forskolin triggered the activation of Akt, predominantly by phosphorylation of Ser-473, as measured by Western blotting and assay of its kinase activity. Akt activation was significantly inhibited by LY294002 and wortmannin, specific inhibitors of phosphatidylinositol 3-kinase, but not by H-89. Incubation of macrophages with forskolin also increased Epac1 and Rap1.GTP. Immunoprecipitation of Epac1 in forskolin-stimulated cells co-immunoprecipitated Rap1, p-Akt(Thr-308), and p-Akt(Ser-473). Silencing of CREB gene expression by RNA interference prior to forskolin treatment not only decreased CREB protein and its phosphorylation at Ser-133, but also phosphorylation of Akt at Ser-473, and Thr-308. Concomitantly, this treatment inhibited [H-3]thymidine uptake and reduced forskolin-induced proliferation of macrophages. Forskolin treatment also inhibited activation of the apoptotic mechanism while promoting up-regulation of the anti-apoptotic pathway. We conclude that forskolin mediates cellular proliferation via cAMP-dependent activation of both PKA and Epac.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	pizzo001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cullen KA, 2004, AM J PHYSIOL-GASTR L, V287, pG334, DOI 10.1152/ajpgi.00517.2003; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2002, METHOD ENZYMOL, V345, P448; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Komalavilas P, 2001, J APPL PHYSIOL, V91, P1819, DOI 10.1152/jappl.2001.91.4.1819; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Martin MC, 2005, J BIOL CHEM, V280, P15449, DOI 10.1074/jbc.M414325200; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Misra UK, 1997, J BIOL CHEM, V272, P497; Misra UK, 2004, J CELL BIOCHEM, V93, P1020, DOI 10.1002/jcb.20233; Misra UK, 2002, J BIOL CHEM, V277, P4069, DOI 10.1074/jbc.M109764200; Misra UK, 2002, J BIOL CHEM, V277, P36509, DOI 10.1074/jbc.M203543200; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Morisco C, 2005, CIRC RES, V96, P180, DOI 10.1161/01.RES.0000152968.71868.c3; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Robinson-White A, 2002, ANN NY ACAD SCI, V968, P256, DOI 10.1111/j.1749-6632.2002.tb04340.x; Rudolph JA, 2004, J BIOL CHEM, V279, P14828, DOI 10.1074/jbc.M310289200; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Xaus J, 1999, J IMMUNOL, V163, P4140; Zhang CY, 2002, J BIOL CHEM, V277, P48359, DOI 10.1074/jbc.M209329200; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	76	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38276	38289		10.1074/jbc.M507332200	http://dx.doi.org/10.1074/jbc.M507332200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172130	hybrid			2022-12-25	WOS:000233239800023
J	Roy, H; Ling, JQ; Alfonzo, J; Ibba, M				Roy, H; Ling, JQ; Alfonzo, J; Ibba, M			Loss of editing activity during the evolution of mitochondrial phenylalanyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; GENETIC-CODE; IN-VIVO; YEAST; DISCRIMINATION; DOMAIN; EXPRESSION; SEQUENCE; AMINOACYLATION; CYS-TRNA(PRO)	Accurate selection of amino acids is essential for faithful translation of the genetic code. Errors during amino acid selection are usually corrected by the editing activity of aminoacyl-tRNA synthetases such as phenylalanyl-tRNA synthetases (PheRS), which edit misactivated tyrosine. Comparison of cytosolic and mitochondrial PheRS from the yeast Saccharomyces cerevisiae suggested that the organellar protein might lack the editing activity. Yeast cytosolic PheRS was found to contain an editing site, which upon disruption abolished both cis and trans editing of Tyr-tRNA(Phe). Wild-type mitochondrial PheRS lacked cis and trans editing and could synthesize Tyr-tRNA(Phe), an activity enhanced in active site variants with improved tyrosine recognition. Possible trans editing was investigated in isolated mitochondrial extracts, but no such activity was detected. These data indicate that the mitochondrial protein synthesis machinery lacks the tyrosine proofreading activity characteristic of cytosolic translation. This difference between the mitochondria and the cytosol suggests that either organellar protein synthesis quality control is focused on another step or that translation in this compartment is inherently less accurate than in the cytosol.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ibba, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.	ibba.1@osu.edu	Ling, Jiqiang/AAU-1097-2021; Ling, Jiqiang/B-2885-2009	Ling, Jiqiang/0000-0003-4466-8304; Ling, Jiqiang/0000-0003-4466-8304				Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; An S, 2005, J BIOL CHEM, V280, P34465, DOI 10.1074/jbc.M507550200; An SG, 2004, J BIOL CHEM, V279, P42359, DOI 10.1074/jbc.C400304200; Ataide SF, 2005, EMBO REP, V6, P742, DOI 10.1038/sj.embor.7400474; Augustin S, 2005, J BIOL CHEM, V280, P2691, DOI 10.1074/jbc.M410609200; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2004, P NATL ACAD SCI USA, V101, P5958, DOI 10.1073/pnas.0401530101; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Brown JR, 2001, SYST BIOL, V50, P497, DOI 10.1080/10635150117729; Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708; COSTANTINO P, 1973, P NATL ACAD SCI USA, V70, P1490, DOI 10.1073/pnas.70.5.1490; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; Datta D, 2002, J AM CHEM SOC, V124, P5652, DOI 10.1021/ja0177096; DAUM G, 1982, J BIOL CHEM, V257, P3028; de Pouplana LR, 2001, TRENDS BIOCHEM SCI, V26, P591, DOI 10.1016/S0968-0004(01)01932-6; de Pouplana LR, 2001, CELL, V104, P191, DOI 10.1016/S0092-8674(01)00204-5; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Dou XW, 2001, J MOL BIOL, V305, P451, DOI 10.1006/jmbi.2000.4312; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FERSHT AR, 1980, BIOCHEMISTRY-US, V19, P5520, DOI 10.1021/bi00565a009; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; GABIUS HJ, 1983, BIOCHEMISTRY-US, V22, P5306, DOI 10.1021/bi00292a009; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hauenstein S, 2004, NAT STRUCT MOL BIOL, V11, P1134, DOI 10.1038/nsmb849; Hendrickson TL, 2003, MOL B INT U, P34; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; IGLOI GL, 1978, BIOCHEMISTRY-US, V17, P3459, DOI 10.1021/bi00610a006; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 2004, AMINOACYL TRNA SYNTH, P384; KAST P, 1991, J MOL BIOL, V222, P99, DOI 10.1016/0022-2836(91)90740-W; Korencic D, 2004, P NATL ACAD SCI USA, V101, P10260, DOI 10.1073/pnas.0403926101; Lechler A, 1997, FEBS LETT, V420, P139, DOI 10.1016/S0014-5793(97)01504-4; Lin J, 2003, ACTA BIOCH BIOPH SIN, V35, P1061; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LIN SX, 1984, BIOCHEMISTRY-US, V23, P4109, DOI 10.1021/bi00313a015; LIN SX, 1983, BIOCHEMISTRY-US, V22, P681, DOI 10.1021/bi00272a024; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; Lue SW, 2005, BIOCHEMISTRY-US, V44, P3010, DOI 10.1021/bi047901v; McClain WH, 1998, P NATL ACAD SCI USA, V95, P460, DOI 10.1073/pnas.95.2.460; Newberry KJ, 2002, EMBO J, V21, P2778, DOI 10.1093/emboj/21.11.2778; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Rinehart J, 2005, GENE DEV, V19, P583, DOI 10.1101/gad.1269305; Roy H, 2004, EMBO J, V23, P4639, DOI 10.1038/sj.emboj.7600474; Ruan BF, 2005, J BIOL CHEM, V280, P25887, DOI 10.1074/jbc.M502174200; Saks ME, 1998, SCIENCE, V279, P1665, DOI 10.1126/science.279.5357.1665; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SANNI A, 1991, P NATL ACAD SCI USA, V88, P8387, DOI 10.1073/pnas.88.19.8387; Sauerwald A, 2005, SCIENCE, V307, P1969, DOI 10.1126/science.1108329; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; Wong FC, 2003, J BIOL CHEM, V278, P52857, DOI 10.1074/jbc.M309627200; Zhao MW, 2005, EMBO J, V24, P1430, DOI 10.1038/sj.emboj.7600618	59	89	91	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38186	38192		10.1074/jbc.M508281200	http://dx.doi.org/10.1074/jbc.M508281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16162501	Green Published, hybrid			2022-12-25	WOS:000233239800011
J	Labunskyy, VM; Ferguson, AD; Fomenko, DE; Chelliah, Y; Hatfield, DL; Gladyshev, VN				Labunskyy, VM; Ferguson, AD; Fomenko, DE; Chelliah, Y; Hatfield, DL; Gladyshev, VN			A novel cysteine-rich domain of Sep15 mediates the interaction with UDP-glucose : glycoprotein glucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALRETICULIN P-DOMAIN; ENDOPLASMIC-RETICULUM; 15-KDA SELENOPROTEIN; QUALITY-CONTROL; RIBONUCLEASE B; PROTEIN; CALNEXIN; SELENIUM; EXPRESSION; CHAPERONE	Selenium is an essential trace element with potent cancer prevention activity in mammals. The 15-kDa selenoprotein (Sep15) has been implicated in the chemopreventive effect of dietary selenium. Although the precise function of Sep15 remains elusive, Sep15 co-purifies with UDP-glucose: glycoprotein glucosyltransferase (GT), an essential regulator of quality control mechanisms within the endoplasmic reticulum. Recent studies identified two GT and two Sep15 homologues in mammals. We characterize interactions between these protein families in this report. Sep15 and GT form a tight 1: 1 complex, and these interactions are conserved between mammals and fruit flies. In mammalian cells, Sep15 co-immunoprecipitates with both GT isozymes. In contrast, a Sep15 homologue, designated selenoprotein M(SelM), does not form a complex with GT. Sequence analysis of members of the Sep15 family identified a novel N-terminal cysteine-rich domain in Sep15 that is absent in SelM. This domain contains six conserved cysteine residues that form two CxxC motifs that do not coordinate metal ions. If this domain is deleted or the cysteines are mutated, Sep15 no longer forms a complex with GT. Conversely, if the cysteine-rich domain of Sep15 is fused to the N-terminus of SelM, the resulting chimera is capable of binding GT. These data indicate that the cysteine-rich domain of Sep15 exclusively mediates protein-protein interactions with GT.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; NCI, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013; Labunskyy, Vyacheslav/AAC-8489-2020	Gladyshev, Vadim/0000-0002-0372-7016; Labunskyy, Vyacheslav/0000-0001-9317-1076	NCI NIH HHS [CA080946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005317, R01CA080946, Z01BC005317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Apostolou S, 1999, CELL, V97, P684, DOI 10.1016/S0092-8674(02)09765-9; Arac D, 2003, BIOCHEMISTRY-US, V42, P2774, DOI 10.1021/bi0272050; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Arnold SM, 2003, J BIOL CHEM, V278, P43320, DOI 10.1074/jbc.M305800200; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Cheung TH, 1999, CANCER-AM CANCER SOC, V86, P1294, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1294::AID-CNCR26>3.3.CO;2-F; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hu YJ, 2001, CANCER RES, V61, P2307; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; Kapoor M, 2003, J BIOL CHEM, V278, P6194, DOI 10.1074/jbc.M209132200; Keith N, 2005, J BIOL CHEM, V280, P18138, DOI 10.1074/jbc.M501710200; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2000, J BIOL CHEM, V275, P35540, DOI 10.1074/jbc.M004014200; Kumaraswamy E, 2002, METHOD ENZYMOL, V347, P187; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Pelletier MF, 2000, GLYCOBIOLOGY, V10, P815, DOI 10.1093/glycob/10.8.815; Ritter C, 2005, EMBO J, V24, P1730, DOI 10.1038/sj.emboj.7600645; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Taylor SC, 2004, NAT STRUCT MOL BIOL, V11, P128, DOI 10.1038/nsmb715; Taylor SC, 2003, EMBO REP, V4, P405, DOI 10.1038/sj.embor.embor797; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang ZH, 1997, BIOL TRACE ELEM RES, V57, P147, DOI 10.1007/BF02778198	40	64	66	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37839	37845		10.1074/jbc.M508685200	http://dx.doi.org/10.1074/jbc.M508685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129668	hybrid, Green Submitted			2022-12-25	WOS:000233044500064
J	Sato, H; Shiiya, A; Kimata, M; Maebara, K; Tamba, M; Sakakura, Y; Makino, N; Sugiyama, F; Yagami, K; Moriguchi, T; Takahashi, S; Bannai, S				Sato, H; Shiiya, A; Kimata, M; Maebara, K; Tamba, M; Sakakura, Y; Makino, N; Sugiyama, F; Yagami, K; Moriguchi, T; Takahashi, S; Bannai, S			Redox imbalance in cystine/glutamate transporter-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; HUMAN PLASMA; EXCHANGE TRANSPORTER; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN-FIBROBLASTS; CYSTINE; GLUTATHIONE; CYSTEINE; INDUCTION; STATE	Cystine/glutamate transporter, designated as system x(c)(-), mediates cystine entry in exchange for intracellular glutamate in mammalian cells. This transporter consists of two protein components, xCT and 4F2 heavy chain, and the former is predicted to mediate the transport activity. This transporter plays a pivotal role for maintaining the intracellular GSH levels and extracellular cystine/ cysteine redox balance in cultured cells. To clarify the physiological roles of this transporter in vivo, we generated and characterized mice lacking xCT. The xCT(-/-) mice were healthy in appearance and fertile. However, cystine concentration in plasma was significantly higher in these mice, compared with that in the littermate xCT(-/-) mice, while there was no significant difference in plasma cysteine concentration. Plasma GSH level in xCT(-/-) mice was lower than that in the xCT(+/+) mice. The embryonic fibroblasts derived from xCT(-/-) mice failed to survive in routine culture medium, and 2-mercaptoethanol was required for survival and growth. When 2-mercaptoethanol was removed from the culture medium, cysteine and GSH in these cells dramatically decreased, and cells started to die within 24 h. N-Acetyl cysteine also rescued xCT(-/-)- derived cells and permitted growth. These results demonstrate that system x(c)(-) contributes to maintaining the plasma redox balance in vivo but is dispensable in mammalian development, although it is vitally important to cells in vitro.	Yamagata Univ, Fac Agr, Dept Bioresource Engn, Yamagata 9978555, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Anat & Dev, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058575, Japan; Ibaraki Prefectural Univ Hlth Sci, Ctr Humanity & Sci, Ami, Ibaraki 3000394, Japan	Yamagata University; University of Tsukuba; University of Tsukuba; University of Tsukuba	Sato, H (corresponding author), Yamagata Univ, Fac Agr, Dept Bioresource Engn, Yamagata 9978555, Japan.	shideyo@tds1.tr.yamagata-u.ac.jp						BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1991, BIOCHIM BIOPHYS ACTA, V1092, P175, DOI 10.1016/0167-4889(91)90153-O; BANNAI S, 1989, J BIOL CHEM, V264, P18480; BANNAI S, 1984, J BIOL CHEM, V259, P2435; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Hack V, 1997, FASEB J, V11, P84, DOI 10.1096/fasebj.11.1.9034170; Hack V, 1998, BLOOD, V92, P59, DOI 10.1182/blood.V92.1.59.413a05_59_67; Hildebrandt W, 2002, MECH AGEING DEV, V123, P1269, DOI 10.1016/S0047-6374(02)00013-1; Hildebrandt W, 2002, BLOOD, V99, P1552, DOI 10.1182/blood.V99.5.1552; ISHII T, 1981, J BIOL CHEM, V256, P2387; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006; SAGARA J, 1993, J NEUROCHEM, V61, P1667, DOI 10.1111/j.1471-4159.1993.tb09801.x; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2004, BIOCHEM BIOPH RES CO, V325, P109, DOI 10.1016/j.bbrc.2004.10.009; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628; WILCKEN DEL, 1980, CLIN SCI, V58, P427, DOI 10.1042/cs0580427; Wlodek PJ, 2001, CLIN CHIM ACTA, V304, P9, DOI 10.1016/S0009-8981(00)00369-7	29	277	296	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37423	37429		10.1074/jbc.M506439200	http://dx.doi.org/10.1074/jbc.M506439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144837	hybrid			2022-12-25	WOS:000233044500017
J	Chou, WK; Dick, S; Wakarchuk, WW; Tanner, ME				Chou, WK; Dick, S; Wakarchuk, WW; Tanner, ME			Identification and characterization of NeuB3 from Campylobacter jejuni as a pseudaminic acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; PNEUMOPHILA SEROGROUP-1 LIPOPOLYSACCHARIDE; PSEUDOMONAS-AERUGINOSA; HELICOBACTER-PYLORI; SIALIC ACIDS; NEISSERIA-MENINGITIDIS; BISUBSTRATE INHIBITOR; ESCHERICHIA-COLI; SOMATIC ANTIGENS; KDO8P SYNTHASE	Campylobacter jejuni and Campylobacter coli are the main causes of bacterial diarrhea worldwide, and Helicobacter pylori is known to cause duodenal ulcers. In all of these pathogenic organisms, the flagellin proteins are heavily glycosylated with a 2-keto-3-deoxy acid, pseudaminic acid (5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L- manno-nonulosonic acid). The presence of pseudaminic acid is required for the proper development of the flagella and is thereby necessary for motility in, and invasion of, the host. In this study we report the first characterization of NeuB3 from C. jejuni as a pseudaminic acid synthase; the enzyme directly responsible for the biosynthesis of pseudaminic acid. Pseudaminic acid synthase catalyzes the condensation of phosphoenolpyruvate ( PEP) with the hexose, 2,4-diacetamido-2,4,6- trideoxy-L-altrose (6-deoxy-AltdiNAc), to form pseudaminic acid and phosphate. The enzymatic activity was monitored using H-1 and P-31 NMR spectroscopy, and the product was isolated and characterized. Kinetic analysis reveals that pseudaminic acid synthase requires the presence of a divalent metal ion for catalysis and that optimal catalysis occurs at pH 7.0. A coupled enzymatic assay gave the values for k(cat) of 0.65 +/- 0.01 s(-1), KmPEP of 6.5 +/- 0.4 mu M, and K(m)6-deoxy- AltdiNAc of 9.5 +/- 0.7 mu M. A mechanistic study on pseudaminic acid synthase, using[2-O-18] PEP, shows that catalysis proceeds through a C-O bond cleavage mechanism similar to other PEP condensing synthases such as sialic acid synthase.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of British Columbia; National Research Council Canada	Tanner, ME (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	mtanner@chem.ubc.ca	Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679				Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Asojo O, 2001, BIOCHEMISTRY-US, V40, P6326, DOI 10.1021/bi010339d; BARTLETT PA, 1983, J ORG CHEM, V48, P3854, DOI 10.1021/jo00169a064; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; BLACKLOW RS, 1962, J BIOL CHEM, V237, P3520; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTZLER JP, 1979, CLIN GASTROENTEROL, V8, P737; CALDWELL MB, 1985, INFECT IMMUN, V50, P941, DOI 10.1128/IAI.50.3.941-943.1985; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; *ER SOFTW LTD, 2003, GRAFIT; FLOWERS HM, 1967, CARBOHYD RES, P189; Furdui C, 2004, J BIOL CHEM, V279, P45618, DOI 10.1074/jbc.M404753200; GORE MP, 1990, J ORG CHEM, V55, P758, DOI 10.1021/jo00289a063; Gunawan J, 2005, J BIOL CHEM, V280, P3555, DOI 10.1074/jbc.M411942200; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; HOLBEIN BE, 1983, J BACTERIOL, P728; JOSENHANS C, 1995, J BACTERIOL, V177, P3010, DOI 10.1128/jb.177.11.3010-3020.1995; Kaustov L, 2003, J AM CHEM SOC, V125, P4662, DOI 10.1021/ja028688y; Kenne L, 1988, CARBOHYD RES, V180, P285, DOI 10.1016/0008-6215(88)80085-5; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P627, DOI 10.1111/j.1432-1033.1987.tb10912.x; KNIREL YA, 1984, CARBOHYD RES, V133, pC5, DOI 10.1016/0008-6215(84)85213-1; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Knirel YA, 1997, CARBOHYD RES, V304, P77, DOI 10.1016/S0008-6215(97)00211-5; Kondakova AN, 2001, CARBOHYD RES, V333, P241, DOI 10.1016/S0008-6215(01)00145-8; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; LIAV AL, 1973, CARBOHYD RES, V30, P109, DOI 10.1016/S0008-6215(00)82178-3; Linton D, 2000, MOL MICROBIOL, V35, P1120, DOI 10.1046/j.1365-2958.2000.01780.x; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Matte A, 1997, J BIOL CHEM, V272, P8105, DOI 10.1074/jbc.272.13.8105; MOROOKA T, 1985, J GEN MICROBIOL, V131, P1973; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; SEEHOLZER SH, 1991, BIOCHEMISTRY-US, V30, P727, DOI 10.1021/bi00217a022; Shulami S, 2004, J BIOL CHEM, V279, P45110, DOI 10.1074/jbc.M404561200; Sundaram AK, 2004, BIOCHEM J, V383, P83, DOI 10.1042/BJ20040218; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Tsvetkov YE, 2001, CARBOHYD RES, V331, P233, DOI 10.1016/S0008-6215(01)00041-6; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Wang J, 2001, BIOCHEMISTRY-US, V40, P15676, DOI 10.1021/bi015568e; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884	43	62	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35922	35928		10.1074/jbc.M507483200	http://dx.doi.org/10.1074/jbc.M507483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120604	hybrid			2022-12-25	WOS:000232726900019
J	Deng, Q; Sun, JJ; Barbieri, JT				Deng, Q; Sun, JJ; Barbieri, JT			Uncoupling Crk signal transduction by Pseudomonas exoenzyme T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; FAMILY ADAPTER PROTEINS; GROWTH-FACTOR RECEPTOR; C-ABL KINASE; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; MAMMALIAN-CELLS; AERUGINOSA EXOT; IN-VIVO; EPITHELIAL-CELLS	Exoenzyme T (ExoT) is a bifunctional type III cytotoxin of Pseudomonas aeruginosa that possesses both Rho GTPase-activating protein and ADP-ribosyltransferase activities. The ADP-ribosyltransferase activity of ExoT stimulated depolymerization of the actin cytoskeleton independent of Rho GTPase-activating protein function, and ExoT was subsequently shown to ADP-ribosylate Crk (CT10 regulator of kinase)-I and Crk-II. Crk proteins are eukaryotic adaptor proteins comprising SH2 and SH3 domains that are components of the integrin signaling pathway leading to Rac1 and Rap1 functions. Mass spectroscopic analysis identified Arg(20) as the site of ADP-ribosylation by ExoT. Arg(20) is a conserved residue located within the SH2 domain that is required for interactions with upstream signaling molecules such as paxillin and p130(cas). Glutathione S-transferase pull-down and far Western assays showed that ADP-ribosylated Crk-I or Crk-I(R20K) failed to bind p130cas or paxillin. This indicates that ADP-ribosylation inhibited the direct interaction of Crk with these focal adhesion proteins. Overexpression of wild-type Crk-I reduced cell rounding by ExoT, whereas expression of dominant-active Rac1 interfered with the ability of ExoT to round cells. Thus, the ADP-ribosylation of Crk uncouples integrin signaling by direct inhibition of the binding of Crk to focal adhesion proteins.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu	Deng, Qing/AAC-1123-2020; Deng, Qing/G-3923-2011	Deng, Qing/0000-0002-9254-9951; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI30162] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Barbieri JT, 2005, REV PHYSIOL BIOCH P, V152, P79, DOI 10.1007/s10254-004-0031-7; Black DS, 2000, CELL MICROBIOL, V2, P401, DOI 10.1046/j.1462-5822.2000.00061.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; CARY LA, 1999, FRONT BIOSCI, V4, P102; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, J BIOL CHEM, V266, P6438; Donaldson LW, 2002, P NATL ACAD SCI USA, V99, P14053, DOI 10.1073/pnas.212518799; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Evans DJ, 2002, MICROB PATHOGENESIS, V33, P135, DOI 10.1006/mpat.2002.0521; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feltman H, 2001, MICROBIOL-SGM, V147, P2659, DOI 10.1099/00221287-147-10-2659; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Garrity-Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100-7113.2000; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kazmierczak BI, 2002, INFECT IMMUN, V70, P2198, DOI 10.1128/IAI.70.4.2198-2205.2002; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; Koval AP, 1998, BIOCHEM J, V330, P923; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Krall R, 2004, J BIOL CHEM, V279, P2747, DOI 10.1074/jbc.M301963200; Krall R, 2002, INFECT IMMUN, V70, P360, DOI 10.1128/IAI.70.1.360-367.2002; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Ling P, 1999, MOL CELL BIOL, V19, P1359; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Maresso AW, 2004, J BIOL CHEM, V279, P38402, DOI 10.1074/jbc.M405707200; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nakashima K, 1999, J BIOL CHEM, V274, P27786, DOI 10.1074/jbc.274.39.27786; Nasertorabi F, 2004, BIOCHEM BIOPH RES CO, V324, P993, DOI 10.1016/j.bbrc.2004.09.148; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sato H, 2003, EMBO J, V22, P2959, DOI 10.1093/emboj/cdg290; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sun JJ, 2003, J BIOL CHEM, V278, P32794, DOI 10.1074/jbc.M304290200; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Van Delden C, 1998, EMERG INFECT DIS, V4, P551, DOI 10.3201/eid0404.980405; Weidow CL, 2000, CELL MICROBIOL, V2, P549, DOI 10.1046/j.1462-5822.2000.00079.x; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yang LT, 2002, J BIOL CHEM, V277, P17406, DOI 10.1074/jbc.M111902200; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Zamir E, 2001, J CELL SCI, V114, P3583; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	68	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35953	35960		10.1074/jbc.M504901200	http://dx.doi.org/10.1074/jbc.M504901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123042	hybrid			2022-12-25	WOS:000232726900022
J	Huang, LQ; Cao, J; Wang, H; Vo, LA; Brand, JG				Huang, LQ; Cao, J; Wang, H; Vo, LA; Brand, JG			Identification and functional characterization of a voltage-gated chloride channel and its novel splice variant in taste bud cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-CELLS; BITTER TASTE; SWEET TASTE; ALPHA-GUSTDUCIN; MESSENGER-RNA; SOUR TASTE; SYNAPTIC VESICLES; ACTION-POTENTIALS; EXPRESSION LEVELS; MUS-SPRETUS	Taste bud cells are epithelial cells with neuronal properties. Voltage-dependent ion channels have been physiologically described in these cells. Here, we report the molecular identification and functional characterization of a voltage-gated chloride channel (ClC-4) and its novel splice variant (ClC-4A) from taste bud cells. ClC-4A skipped an exon near its 5'-end, incurring the loss of 60 amino acids at the N terminus. In situ hybridization and immunohistochemistry localized these two channels' transcripts and proteins to a subset of taste bud cells. Electrophysiological recordings of the heterologously expressed channels in Xenopus oocytes showed that ClC-4 and ClC-4A have opposite sensitivity to pH and unique ion selectivity. The chloride channel blockers niflumic acid and 5-nitro-2-(3-phenylpropylamino) benzoic acid had a slight or no inhibitory effect on the conductance of ClC-4, but both blockers inhibited ClC-4A, suggesting that ClC-4A is a candidate channel for an acid-induced 5-nitro-2-( 3-phenylpropylamino) benzoic acid-sensitive current. Furthermore, these two channels may play a role in bitter-, sweet-, and umami-mediated taste transmission by regulating transmitter uptake into synaptic vesicles.	Monell Chem Senses Ctr, Philadelphia, PA 19104 USA; Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem, Philadelphia, PA 19104 USA	Monell Chemical Senses Center; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania	Huang, LQ (corresponding author), Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA.	lhuang@monell.org		Huang, Liquan/0000-0003-3400-0685; Wang, Hong/0000-0003-4130-8741	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC005154] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; AVENET P, 1991, J MEMBRANE BIOL, V124, P33, DOI 10.1007/BF01871362; Bachmanov AA, 2001, CHEM SENSES, V26, P925, DOI 10.1093/chemse/26.7.925; BEHE P, 1990, J GEN PHYSIOL, V96, P1061, DOI 10.1085/jgp.96.5.1061; Behrens M, 2004, BIOCHEM BIOPH RES CO, V319, P479, DOI 10.1016/j.bbrc.2004.05.019; Bufe B, 2002, NAT GENET, V32, P397, DOI 10.1038/ng1014; Caicedo A, 2003, J NEUROSCI, V23, P9947; Campos-Xavier AB, 2003, HUM GENET, V112, P186, DOI 10.1007/s00439-002-0861-9; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Chaudhari N, 1998, ANN NY ACAD SCI, V855, P398, DOI 10.1111/j.1749-6632.1998.tb10598.x; Chen L, 2004, MUSCLE NERVE, V29, P670, DOI 10.1002/mus.20005; Chen YH, 1997, PFLUG ARCH EUR J PHY, V434, P215, DOI 10.1007/s004240050388; Chen YS, 1996, J NEUROPHYSIOL, V75, P820, DOI 10.1152/jn.1996.75.2.820; Chu SJ, 1996, NUCLEIC ACIDS RES, V24, P3453, DOI 10.1093/nar/24.17.3453; Chu SJ, 1997, NUCLEIC ACIDS RES, V25, P4153, DOI 10.1093/nar/25.20.4153; Clapp TR, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-6; CUMMINGS TA, 1993, J NEUROPHYSIOL, V70, P2326, DOI 10.1152/jn.1993.70.6.2326; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Eggermont J, 1997, BIOCHEM J, V325, P269, DOI 10.1042/bj3250269; Forino M, 2004, J HUM GENET, V49, P53, DOI 10.1007/s10038-003-0108-1; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Ghiaroni V, 2003, CHEM SENSES, V28, P827, DOI 10.1093/chemse/bjg076; GILBERTSON TA, 1992, J GEN PHYSIOL, V100, P803, DOI 10.1085/jgp.100.5.803; Gilbertson TA, 2000, CURR OPIN NEUROBIOL, V10, P519, DOI 10.1016/S0959-4388(00)00118-5; Gilbertson TA, 2002, CHEM SENSES, V27, P383, DOI 10.1093/chemse/27.4.383; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Hara-Chikuma M, 2005, BIOCHEM BIOPH RES CO, V329, P941, DOI 10.1016/j.bbrc.2005.02.060; Herness MS, 1999, J NEUROPHYSIOL, V82, P260, DOI 10.1152/jn.1999.82.1.260; HERNESS MS, 1995, J MEMBRANE BIOL, V146, P73; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; KASHIWAYANAGI M, 1983, AM J PHYSIOL, V244, pC82, DOI 10.1152/ajpcell.1983.244.1.C82; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; Kitagawa M, 2001, BIOCHEM BIOPH RES CO, V283, P236, DOI 10.1006/bbrc.2001.4760; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Lin WH, 2002, J NEUROPHYSIOL, V88, P133, DOI 10.1152/jn.2002.88.1.133; Lin WH, 1999, J COMP NEUROL, V405, P406, DOI 10.1002/(SICI)1096-9861(19990315)405:3<406::AID-CNE10>3.0.CO;2-F; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Liu LJ, 2001, BRAIN RES, V923, P58, DOI 10.1016/S0006-8993(01)03190-0; Loewen ME, 2000, BBA-GENE STRUCT EXPR, V1493, P284, DOI 10.1016/S0167-4781(00)00181-0; Lyall V, 2002, J NEUROPHYSIOL, V87, P399, DOI 10.1152/jn.00331.2001; Lyall V, 2001, AM J PHYSIOL-CELL PH, V281, pC1005, DOI 10.1152/ajpcell.2001.281.3.C1005; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; MCLAUGHLIN SK, 1994, PHYSIOL BEHAV, V56, P1157, DOI 10.1016/0031-9384(94)90360-3; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Miyamoto T, 1998, J NEUROPHYSIOL, V80, P1852, DOI 10.1152/jn.1998.80.4.1852; Mohammad-Panah R, 2003, J BIOL CHEM, V278, P29267, DOI 10.1074/jbc.M304357200; Mohammad-Panah R, 2002, J BIOL CHEM, V277, P566, DOI 10.1074/jbc.M106968200; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Robinson NC, 2004, J PHYSIOL-LONDON, V556, P353, DOI 10.1113/jphysiol.2003.058032; ROPER S, 1983, SCIENCE, V220, P1311, DOI 10.1126/science.6857254; Rossler P, 2000, CHEM SENSES, V25, P413, DOI 10.1093/chemse/25.4.413; Rossler P, 1998, EUR J CELL BIOL, V77, P253; RUGARLI EI, 1995, NAT GENET, V10, P466, DOI 10.1038/ng0895-466; Ruiz CJ, 2003, CHEM SENSES, V28, P573, DOI 10.1093/chemse/bjg049; Sainz E, 2001, J NEUROCHEM, V77, P896, DOI 10.1046/j.1471-4159.2001.00292.x; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Stevens DR, 2001, NATURE, V413, P631, DOI 10.1038/35098087; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Sun XD, 1996, AM J PHYSIOL-CELL PH, V271, pC1221, DOI 10.1152/ajpcell.1996.271.4.C1221; Ugawa S, 1998, NATURE, V395, P555, DOI 10.1038/26882; Van der Kloot W, 2003, BRAIN RES, V961, P287, DOI 10.1016/S0006-8993(02)03954-9; Vanoye CG, 2002, J PHYSIOL-LONDON, V539, P373, DOI 10.1113/jphysiol.2001.013115; Varkevisser B, 2001, CHEM SENSES, V26, P499, DOI 10.1093/chemse/26.5.499; Wladkowski SL, 1998, J MEMBRANE BIOL, V164, P91, DOI 10.1007/s002329900396; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0; Yan WT, 2001, AM J PHYSIOL-CELL PH, V280, pC742, DOI 10.1152/ajpcell.2001.280.4.C742; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0	82	18	20	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36150	36157		10.1074/jbc.M507706200	http://dx.doi.org/10.1074/jbc.M507706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129671	Green Accepted, hybrid			2022-12-25	WOS:000232726900046
J	Chen, CL; Deutscher, MP				Chen, CL; Deutscher, MP			Elevation of RNase R in response to multiple stress conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI POLYNUCLEOTIDE PHOSPHORYLASE; ESCHERICHIA-COLI; QUALITY-CONTROL; DEGRADATION; DEGRADOSOME; INDUCTION; HELICASE; DECAY; SHOCK	Cells respond to adverse environmental conditions by synthesizing new proteins or elevating the levels of pre-existing ones that are needed to cope with the particular stress situation. We show here that Escherichia coli RNase R, a processive 3'- to 5'-exoribonuclease, is dramatically increased in response to a variety of different stress conditions. Elevation of RNase R activity by as much as 10-fold was observed in response to entry into stationary phase, starvation, and cold shock, and a similar to 3-fold increase was seen during growth in minimal medium compared with rich medium. The elevation in RNase R activity was associated primarily with an increase in RNase R protein. RNase R was previously implicated in quality control of rRNA and tRNA and in the decay of mRNAs with extensive secondary structure. Its dramatic increase under multiple stress conditions suggests extensive remodeling of structured RNA in response to the altered environment.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	mdeutsch@med.miami.edu			NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beran RK, 2001, MOL MICROBIOL, V39, P112, DOI 10.1046/j.1365-2958.2001.02216.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bremer H, 1996, ESCHERICHIA COLI SAL; Cairrao F, 2003, MOL MICROBIOL, V50, P1349, DOI 10.1046/j.1365-2958.2003.03766.x; Cheng ZF, 2005, MOL CELL, V17, P313, DOI 10.1016/j.molcel.2004.11.048; Cheng ZF, 2003, P NATL ACAD SCI USA, V100, P6388, DOI 10.1073/pnas.1231041100; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Coburn GA, 1999, GENE DEV, V13, P2594, DOI 10.1101/gad.13.19.2594; Deutscher MP, 2003, J BIOL CHEM, V278, P45041, DOI 10.1074/jbc.R300031200; Hong SJ, 2005, MOL MICROBIOL, V57, P565, DOI 10.1111/j.1365-2958.2005.04709.x; Khemici V, 2004, MOL MICROBIOL, V51, P777, DOI 10.1046/j.1365-2958.2003.03862.x; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Mathy N, 2001, J BACTERIOL, V183, P3848, DOI 10.1128/JB.183.13.3848-3854.2001; Purusharth RI, 2005, J BIOL CHEM, V280, P14572, DOI 10.1074/jbc.M413507200; Takayama K, 2000, ENVIRON MICROBIOL, V2, P355, DOI 10.1046/j.1462-2920.2000.00119.x; Thieringer HA, 1998, BIOESSAYS, V20, P49; Yamanaka Kunitoshi, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P193; Zangrossi S, 2000, MOL MICROBIOL, V36, P1470, DOI 10.1046/j.1365-2958.2000.01971.x	19	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34393	34396		10.1074/jbc.C500333200	http://dx.doi.org/10.1074/jbc.C500333200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16135521	hybrid			2022-12-25	WOS:000232403900004
J	Brantley-Sieders, DM; Fang, WB; Hicks, DJ; Zhuang, GL; Yu, S; Chen, J				Brantley-Sieders, DM; Fang, WB; Hicks, DJ; Zhuang, GL; Yu, S; Chen, J			Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression	FASEB JOURNAL			English	Article						mouse model; adenocarcinoma; metastasis; receptor tyrosine kinases	RECEPTOR TYROSINE KINASE; BREAST-CANCER; SIGNALING PATHWAYS; CELL INTERACTIONS; EPH RECEPTORS; KIT RECEPTOR; GROWTH; CARCINOGENESIS; TUMORIGENESIS; NEOVASCULARIZATION	EphA2 belongs to a unique family of receptor tyrosine kinases that play critical roles in development and disease. Since EphA2 is required for ephrin-A1 ligand-induced vascular remodeling and is overexpressed in a variety of vascularized human adenocarcinomas, we assessed tumor angiogenesis and metastatic progression in EphA2-deficient host animals. 4T1 metastatic mammary adenocarcinoma cells transplanted subcutaneously and orthotopically into EphA2-deficient female mice displayed decreased tumor volume, tumor cell survival, microvascular density, and lung metastasis relative to tumor-bearing littermate controls. To determine if the phenotype in EphA2-deficient mice was endothelial cell intrinsic, we also analyzed endothelial cells isolated from EphA2-deficient animals for their ability to incorporate into tumor vessels in vivo, as well as to migrate in response to tumor-derived signals in vitro. EphA2-deficient endothelial cells displayed impaired survival and failed to incorporate into tumor microvessels in vivo, and displayed impaired tumor-mediated migration in vitro relative to controls. These data suggest that host EphA2 receptor tyrosine kinase function is required in the tumor microenvironment for tumor angiogenesis and metastatic progression.	Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu	Zhuang, Guanglei/K-6097-2013	Chen, Jin/0000-0002-5557-2079; Zhuang, Guanglei/0000-0001-8141-5096	NCI NIH HHS [CA95004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5; Leek RD, 2001, ANTICANCER RES, V21, P4325; Liu W, 2004, BRIT J CANCER, V90, P1620, DOI 10.1038/sj.bjc.6601723; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Patan S, 2004, CANC TREAT, V117, P3; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; Rossant J, 2002, ANNU REV CELL DEV BI, V18, P541, DOI 10.1146/annurev.cellbio.18.012502.105825; Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Tsutsui Shinichi, 2003, Breast Cancer, V10, P312, DOI 10.1007/BF02967651; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zantek ND, 2001, CLIN CANCER RES, V7, P3640; Zelinski DP, 2001, CANCER RES, V61, P2301	40	103	124	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1884	+		10.1096/fj.05-4038fje	http://dx.doi.org/10.1096/fj.05-4038fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16166198				2022-12-25	WOS:000232315700012
J	Stenina, OI; Ustinov, V; Krukovets, I; Marinic, T; Topol, EJ; Plow, EF				Stenina, OI; Ustinov, V; Krukovets, I; Marinic, T; Topol, EJ; Plow, EF			Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites	FASEB JOURNAL			English	Article						coronary artery disease; single nucleotide polymorphism; Ca2+ binding; TSP	OLIGOMERIC MATRIX PROTEIN; CORONARY-ARTERY-DISEASE; MULTIPLE EPIPHYSEAL DYSPLASIA; ION LUMINESCENCE PROBES; GROWTH-FACTOR; CA2+ BINDING; CATION-BINDING; MYOCARDIAL-INFARCTION; LIGAND-BINDING; DISULFIDE BOND	Recent genetic studies have associated members of the thrombospondin (TSP) gene family with premature cardiovascular disease. The disease-associated polymorphisms lead to single amino acid changes in TSP-4 (A387P) and TSP-1 (N700S). These substitutions reside in adjacent domains of these highly homologous proteins. Secondary structural predictive programs and the homology of the domains harboring these amino acid substitutions to those in other proteins pointed to potential alterations of putative Ca2+ binding sites that reside in close proximity to the polymorphic amino acids. Since Ca2+ binding is critical for the structure and function of TSP family members, direct evidence for differences in Ca2+ binding by the polymorphic forms was sought. Using synthetic peptides and purified recombinant variant fragments bearing the amino acid substitutions, we measured differences in Tb3+ luminescence as an index of Ca2+ binding. The Tb3+ binding constants placed the TSP-1 region affected by N700S polymorphism among other high-affinity Ca2+ binding sites. The affinity of Ca2+ binding was lower for peptides (3.5-fold) and recombinant fragments (10-fold) containing the S700 vs. the N700 form. In TSP-4, the P387 form acquired an additional Ca2+ binding site absent in the A387 form. The results of our study suggest that both substitutions (A387P in TSP-4 and N700S in TSP-1) alter Ca2+ binding properties. Since these substitutions exert the opposite effects on Ca2+ binding, a decrease in TSP-1 and an increase in TSP-4, the two TSP variants are likely to influence cardiovascular functions in distinct but yet pathogenic ways.	Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Stenina, OI (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	stenino@ccf.org	Ustinov, Valentin/J-6301-2018	, Olga/0000-0002-1256-0545; Topol, Eric/0000-0002-1478-4729	NHLBI NIH HHS [P50HL077107-01] Funding Source: Medline; NIDDK NIH HHS [K01DK62128] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062128] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BJORNHOLM B, 1993, BIOCHEMISTRY-US, V32, P2954; Boeke JD, 2002, MOBILE DNA, P24; BORIN G, 1989, BIOPOLYMERS, V28, P353, DOI 10.1002/bip.360280134; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; BURROUGHS SE, 1992, BIOPHYS CHEM, V42, P249; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; Cierniewska-Cieslak A, 2002, J BIOL CHEM, V277, P11126, DOI 10.1074/jbc.M112388200; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Dukhanina EA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P530; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Hannah BLA, 2004, J BIOL CHEM, V279, P51915, DOI 10.1074/jbc.M409632200; Hanney Stephen R., 2003, HEALTH RES POLICY SY, V1, P1, DOI DOI 10.1186/1478-4505-1-2; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HIGHSMITH SR, 1983, J BIOL CHEM, V258, P6858; Hogg PJ, 1997, BIOCHEM J, V326, P709, DOI 10.1042/bj3260709; Horrocks W.D. Jr., 1983, PROG INORG CHEM, V31, P1; HORROCKS WD, 1981, ACCOUNTS CHEM RES, V14, P384, DOI 10.1021/ar00072a004; Hou J, 2000, CELL CALCIUM, V27, P309, DOI 10.1054/ceca.2000.0125; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; Kato T, 2003, CIRCULATION, V108, P712; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; KUZMIC P, 1992, ANAL BIOCHEM, V205, P65, DOI 10.1016/0003-2697(92)90579-V; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; KWOK F, 1994, ARCH BIOCHEM BIOPHYS, V313, P274, DOI 10.1006/abbi.1994.1388; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LENKINSKI RE, 1978, BIOINORG CHEM, V8, P363, DOI 10.1016/S0006-3061(00)80169-6; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; Manoharan HT, 1997, GENE, V193, P229, DOI 10.1016/S0378-1119(97)00126-1; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Narizhneva NV, 2004, J BIOL CHEM, V279, P21651, DOI 10.1074/jbc.M311090200; Narouz-Ott L, 2000, J BIOL CHEM, V275, P37110, DOI 10.1074/jbc.M007223200; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; Peyvandi F, 2003, BLOOD, V102, p314A; REUKEN J, 1977, CALCIUM BINDING PROT; SNYDER AP, 1981, BIOCHEMISTRY-US, V20, P3334, DOI 10.1021/bi00515a003; SPEZIALE MV, 1991, ARCH BIOCHEM BIOPHYS, V286, P546, DOI 10.1016/0003-9861(91)90077-V; Stenberg Y, 1997, J BIOL CHEM, V272, P23255, DOI 10.1074/jbc.272.37.23255; STENFLO J, 1991, BLOOD, V78, P1637; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Stenina OI, 2004, INT J BIOCHEM CELL B, V36, P1013, DOI 10.1016/j.biocel.2004.01.005; Stenina OI, 2003, CIRCULATION, V108, P1514, DOI 10.1161/01.CIR.0000089085.76320.4E; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; VANSCHARRENBURG GJM, 1985, BIOCHEMISTRY-US, V24, P334, DOI 10.1021/bi00323a015; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; Walton B, 2003, CIRCULATION, V108, P771; WARD LD, 1985, METHOD ENZYMOL, V117, P400; Wessel J, 2003, CIRCULATION, V108, P767; Wessel J, 2004, AM HEART J, V147, P905, DOI 10.1016/j.ahj.2003.12.013; Wu XC, 1997, BIOCHEMISTRY-US, V36, P8649, DOI 10.1021/bi970278c; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445	65	33	34	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1893	+		10.1096/fj.05-3712fje	http://dx.doi.org/10.1096/fj.05-3712fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148025				2022-12-25	WOS:000232315700025
J	Froy, O; Chapnik, N; Miskin, R				Froy, O; Chapnik, N; Miskin, R			Mouse intestinal cryptdins exhibit circadian oscillation	FASEB JOURNAL			English	Article						circadian rhythms, biological clock; defensins; FVB/N; C57BL/6	SUPRACHIASMATIC NUCLEUS; INNATE IMMUNITY; HELICOBACTER-FELIS; TRANSGENIC MICE; ALPHA-DEFENSINS; CROHNS-DISEASE; PANETH CELLS; CLOCK; GENE; EXPRESSION	The innate immunity utilizes a plethora of antibacterial polypeptides, known as defensins, to combat ingested bacteria. Mouse enteric defensins (cryptdins) are produced and secreted constitutively but are overexpressed in instances of infection and/or inflammation. Our objective was to determine whether the biological clock plays a role in cryptdin expression under healthy conditions. Analysis of cryptdin 1 and cryptdin 4 expression in the ileum and jejunum of the small intestine of FVB/N mice around the circadian cycle revealed oscillation that peaked at the end of the dark phase. To eliminate the possibility that cryptdin oscillation stems from food intake, we analyzed cryptdin expression under fasting conditions and found oscillation but with a 3 h phase-shift. Comparison of cryptdin expression in two mouse strains (C57BL/6 vs. FVB/N) revealed higher levels in C57BL/6, a mouse strain that is highly susceptible to enteric infection, due, most likely, to impaired cryptdin maturation. The results of this study indicate the involvement of the biological clock in regulating cryptdin expression in the small intestine and reinforce the capacity of food to act as a zeitgeber (synchronizer). With the assumption of similar control in humans, our results may imply that defensin expression peaks during the day.	Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Froy, O (corresponding author), Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel.	froy@agri.huji.ac.il	Froy, Oren/C-3550-2009					Aarbiou J, 2002, ANN MED, V34, P96, DOI 10.1080/07853890252953482; Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Boivin DB, 2003, BLOOD, V102, P4143, DOI 10.1182/blood-2003-03-0779; Cassone VM, 2002, NUTRITION, V18, P814, DOI 10.1016/S0899-9007(02)00937-1; Challet E, 2003, BIOL CHEM, V384, P711, DOI 10.1515/BC.2003.079; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Cunliffe RN, 2001, GUT, V48, P176, DOI 10.1136/gut.48.2.176; Cunliffe RN, 2003, MOL IMMUNOL, V40, P463, DOI 10.1016/S0161-5890(03)00157-3; Fellermann K, 2003, EUR J GASTROEN HEPAT, V15, P627, DOI 10.1097/00042737-200306000-00008; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; Froy O, 2005, IUBMB LIFE, V57, P41, DOI 10.1080/15216540500088912; Froy O, 2003, TRENDS GENET, V19, P684, DOI 10.1016/j.tig.2003.10.010; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Froy O, 2003, SCIENCE, V300, P1303, DOI 10.1126/science.1084874; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hastings M H, 1999, J Neurosci, V19, pRC11; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Lin PW, 2004, J BIOL CHEM, V279, P19902, DOI 10.1074/jbc.M311821200; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Lucas RJ, 2001, BEHAV BRAIN RES, V125, P97, DOI 10.1016/S0166-4328(01)00274-1; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Mohammadi M, 1996, INFECT IMMUN, V64, P238, DOI 10.1128/IAI.64.1.238-245.1996; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 2004, BEST PRACT RES CL GA, V18, P405, DOI 10.1016/j.bpg.2003.10.010; PLANT J, 1974, NATURE, V248, P345, DOI 10.1038/248345a0; Pugh PL, 2004, BEHAV BRAIN RES, V155, P283, DOI 10.1016/j.bbr.2004.04.021; Raj PA, 2002, FEMS MICROBIOL LETT, V206, P9, DOI 10.1111/j.1574-6968.2002.tb10979.x; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; ROBSON HG, 1972, J INFECT DIS, V126, P378, DOI 10.1093/infdis/126.4.378; Sakagami T, 1996, GUT, V39, P639, DOI 10.1136/gut.39.5.639; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	45	30	30	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1920	+		10.1096/fj.05-4216fje	http://dx.doi.org/10.1096/fj.05-4216fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129697				2022-12-25	WOS:000231843700002
J	Bossi, G; Lapi, E; Strano, S; Rinaldo, C; Blandino, G; Sacchi, A				Bossi, G; Lapi, E; Strano, S; Rinaldo, C; Blandino, G; Sacchi, A			Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression	ONCOGENE			English	Article						mutant p53; gain of function; human cancer cells; RNA interference	GENE-EXPRESSION; WILD-TYPE; MUTATIONS; DOXORUBICIN; RESISTANCE; SUPPRESSOR; REQUIRES	Mutations in the TP53 tumor suppressor gene are the most frequent genetic alteration in human cancers. These alterations are mostly missense point mutations that cluster in the DNA binding domain. There is growing evidence that many of these mutations generate mutant p53 proteins that have acquired new biochemical and biological properties. Through this gain of function activity, mutant p53 is believed to contribute to tumor malignancy. The purpose of our study was to explore mutant p53 as a target for novel anticancer treatments. To this aim, we inhibited mutant p53 expression by RNA interference in three different cancer cell lines endogenously expressing mutant p53 proteins, and evaluated the effects on the biological activities through which mutant p53 exerts gain of function. We found that depletion of mutant p53 reduces cell proliferation, in vitro and in vivo tumorigenicity, and resistance to anticancer drugs. Our results demonstrate that mutant p53 knocking down weakens the aggressiveness of human cancer cells, and provides further insight into the comprehension of mutant p53 gain of function activity in human tumor.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Sacchi, A (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	bossi@ifo.it; sacchi@ifo.it	Blandino, Giovanni/B-1137-2013; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/ABH-6846-2020; Strano, Sabrina/K-9654-2016; Rinaldo, Cinzia/A-4252-2015; Lapi, Eleonora/ABF-9748-2021; strano, sabrina/B-6743-2013; Bossi, Gianluca/B-9394-2017	Blandino, Giovanni/0000-0002-6970-2241; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Rinaldo, Cinzia/0000-0001-6124-762X; Lapi, Eleonora/0000-0003-4052-0361; strano, sabrina/0000-0002-6341-4230; Bossi, Gianluca/0000-0002-2947-1063				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Care A, 2001, CANCER RES, V61, P6532; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sigal A, 2000, CANCER RES, V60, P6788; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tsang WP, 2005, INT J CANCER, V114, P331, DOI 10.1002/ijc.20818; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wang LH, 1998, ANTICANCER RES, V18, P321; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	24	168	173	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					304	309		10.1038/sj.onc.1209026	http://dx.doi.org/10.1038/sj.onc.1209026			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170357				2022-12-25	WOS:000234583600015
J	Chen, Y; Shiue, SJ; Huang, CW; Chang, JL; Chien, YL; Hu, NT; Chan, NL				Chen, Y; Shiue, SJ; Huang, CW; Chang, JL; Chien, YL; Hu, NT; Chan, NL			Structure and function of the XpsE N-terminal domain, an essential component of the Xanthomonas campestris type II secretion system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR PROTEIN SECRETION; PV. CAMPESTRIS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; VIBRIO-CHOLERAE; CYTOPLASMIC MEMBRANE; MAJOR PSEUDOPILIN; ESCHERICHIA-COLI; PILUS BIOGENESIS; OUTER-MEMBRANE	Secretion of fully folded extracellular proteins across the outer membrane of Gram-negative bacteria is mainly assisted by the ATP-dependent type II secretion system (T2SS). Depending on species, 12-15 proteins are usually required for the function of T2SS by forming a trans-envelope multiprotein secretion complex. Here we report crystal structures of an essential component of the Xanthomonas campestris T2SS, the 21-kDaN-terminal domain of cytosolic secretion ATPase XpsE (XpsE(N)), in two conformational states. By mediating interaction between XpsE and the cytoplasmic membrane protein XpsL, XpsE(N) anchors XpsE to the membrane-associated secretion complex to allow the coupling between ATP utilization and exoprotein secretion. The structure of XpsEN observed in crystal form P4(3)2(1)2 is composed of a 90-residue alpha/beta sandwich core domain capped by a 62-residue N-terminal helical region. The core domain exhibits structural similarity with the NifU-like domain, suggesting that XpsE(N) may be involved in the regulation of XpsE ATPase activity. Surprisingly, although a similar core domain structure was observed in crystal form I4(1)22, the N-terminal 36 residues of the helical region undergo a large structural rearrangement. Deletion analysis indicates that these residues are required for exoprotein secretion by mediating the XpsE/XpsL interaction. Site-directed mutagenesis study further suggests the more compact conformation observed in the P4(3)2(1)2 crystal likely represents the XpsL binding-competent state. Based on these findings, we speculate that XpsE might function in T2SS by cycling between two conformational states. As a closely related protein to XpsE, secretion ATPase PilB may function similarly in the type IV pilus assembly.	Natl Chung Hsing Univ, Inst Biochem, Coll Life Sci, Taichung 402, Taiwan	National Chung Hsing University	Hu, NT (corresponding author), Natl Chung Hsing Univ, Inst Biochem, Coll Life Sci, Taichung 402, Taiwan.	nthu@nchu.edu.tw; nlchan@dragon.nchu.edu.tw		CHAN, NEI-LI/0000-0003-0139-6513				Abendroth J, 2005, J MOL BIOL, V348, P845, DOI 10.1016/j.jmb.2005.02.061; Alder NN, 2003, TRENDS BIOCHEM SCI, V28, P442, DOI 10.1016/S0968-0004(03)00167-1; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Bleves S, 1998, MOL MICROBIOL, V27, P31, DOI 10.1046/j.1365-2958.1998.00653.x; Camberg JL, 2005, J BACTERIOL, V187, P249, DOI 10.1128/JB.187.1.249-256.2005; Chen Y, 2004, ACTA CRYSTALLOGR D, V60, P129, DOI 10.1107/S0907444903022625; *COLL COMP PROJ, 1994, ACTA CRYSTALLOGR D, V50, P764; Crowther LJ, 2004, MOL MICROBIOL, V52, P67, DOI 10.1111/j.1365-2958.2003.03963.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Filloux A, 2004, BBA-MOL CELL RES, V1694, P163, DOI 10.1016/j.bbamcr.2004.05.003; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HU NT, 1992, J BACTERIOL, V174, P2679, DOI 10.1128/jb.174.8.2679-2687.1992; Hu NT, 2002, BIOCHEM J, V365, P205, DOI 10.1042/BJ20020194; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Lee HM, 2004, J BACTERIOL, V186, P2946, DOI 10.1128/JB.186.10.2946-2955.2004; Lee HM, 2000, J BACTERIOL, V182, P1549, DOI 10.1128/JB.182.6.1549-1557.2000; Lee MS, 2005, J BIOL CHEM, V280, P4585, DOI 10.1074/jbc.M409362200; Lory S, 1998, CURR OPIN MICROBIOL, V1, P27, DOI 10.1016/S1369-5274(98)80139-2; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; MARTIN PR, 1995, MOL MICROBIOL, V16, P497, DOI 10.1111/j.1365-2958.1995.tb02414.x; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Nunn D, 1999, TRENDS CELL BIOL, V9, P402, DOI 10.1016/S0962-8924(99)01634-7; NUNN DN, 1993, J BACTERIOL, V175, P4375, DOI 10.1128/JB.175.14.4375-4382.1993; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Planet PJ, 2001, P NATL ACAD SCI USA, V98, P2503, DOI 10.1073/pnas.051436598; POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x; Py B, 1999, J MOL BIOL, V289, P659, DOI 10.1006/jmbi.1999.2803; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Robien MA, 2003, J MOL BIOL, V333, P657, DOI 10.1016/j.jmb.2003.07.015; Russel M, 1998, J MOL BIOL, V279, P485, DOI 10.1006/jmbi.1998.1791; SANDKVIST M, 1995, EMBO J, V14, P1664, DOI 10.1002/j.1460-2075.1995.tb07155.x; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsai RT, 2002, BIOCHEM J, V367, P865, DOI 10.1042/BJ20020909; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Yeo HJ, 2000, MOL CELL, V6, P1461, DOI 10.1016/S1097-2765(00)00142-8	44	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					42356	42363		10.1074/jbc.M506843200	http://dx.doi.org/10.1074/jbc.M506843200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	16162504	hybrid			2022-12-25	WOS:000233992700065
J	Cegelski, L; Schaefer, J				Cegelski, L; Schaefer, J			Glycine metabolism in intact leaves by in vivo C-13 and N-15 labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE ASSIMILATION; NMR DETERMINATION; CHEMICAL-SHIFTS; TERNARY COMPLEX; PHOTOSYNTHESIS; PHOTORESPIRATION; PROTEIN	Solid-state C-13 NMR measurements of intact soybean leaves labeled by (CO2)-C-13 ( at subambient concentrations) show that excess glycine from the photorespiratory C-2 cycle (i.e. glycine not part of the production of glycerate in support of photosynthesis) is either fully decarboxylated or inserted as C-13-labeled glycyl residues in proteins. This 13C incorporation in leaf protein, which is uniformly N-15 labeled by (NH4)-N-15 (NO3)-N-15, occurs as soon as 2 min after the start of (CO2)-C-13 labeling. In those leaves with lower levels of available nitrogen (as measured by leaf nitrate and glutamine-glutamate concentrations), the excess glycine is used primarily as glycyl residues in protein.	Washington Univ, Dept Chem, St Louis, MO 63130 USA	Washington University (WUSTL)	Schaefer, J (corresponding author), Washington Univ, Dept Chem, 1 Brookings Dr, St Louis, MO 63130 USA.	jschaefer@wustl.edu						BORK V, 1988, J MAGN RESON, V78, P348, DOI 10.1016/0022-2364(88)90281-8; Bunce JA, 1998, PLANT CELL ENVIRON, V21, P115, DOI 10.1046/j.1365-3040.1998.00253.x; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; CEGELSKI L, 2006, IN PRESS J MAGN RESO; Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1; Drake BG, 1997, ANNU REV PLANT PHYS, V48, P609, DOI 10.1146/annurev.arplant.48.1.609; Farage PK, 1998, PLANT PHYSIOL, V118, P573, DOI 10.1104/pp.118.2.573; Griffin RG, 1998, NAT STRUCT BIOL, V5, P508, DOI 10.1038/749; GULLION T, 1990, J MAGN RESON, V89, P479, DOI 10.1016/0022-2364(90)90331-3; GULLION T, 1989, ADV MAGN RESON, V13, P57; Laws DD, 2001, P NATL ACAD SCI USA, V98, P11686, DOI 10.1073/pnas.201404298; McDowell LM, 2004, J BIOMOL NMR, V28, P11, DOI 10.1023/B:JNMR.0000012864.70184.48; McDowell LM, 1996, J MOL BIOL, V256, P160, DOI 10.1006/jmbi.1996.0074; Mesnard F, 2005, PHOTOSYNTH RES, V83, P163, DOI 10.1007/s11120-004-2081-8; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; Noctor G, 1998, J EXP BOT, V49, P1895, DOI 10.1093/jexbot/49.329.1895; OGREN WL, 1984, ANNU REV PLANT PHYS, V35, P415, DOI 10.1146/annurev.pp.35.060184.002215; Prentice IC, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P183; Rachmilevitch S, 2004, P NATL ACAD SCI USA, V101, P11506, DOI 10.1073/pnas.0404388101; Ringli C, 2001, CELL MOL LIFE SCI, V58, P1430, DOI 10.1007/PL00000786; Rogers A, 2004, PLANT CELL ENVIRON, V27, P449, DOI 10.1111/j.1365-3040.2004.01163.x; SAITO H, 1986, MAGN RESON CHEM, V24, P835, DOI 10.1002/mrc.1260241002; SCHAEFER J, 1979, BIOCHEM BIOPH RES CO, V88, P274, DOI 10.1016/0006-291X(79)91726-1; SCHAEFER J, 1999, Patent No. 5861748; SHARKEY TD, 1988, PHYSIOL PLANTARUM, V73, P147, DOI 10.1111/j.1399-3054.1988.tb09205.x; SKOKUT TA, 1985, PLANT PHYSIOL, V79, P579, DOI 10.1104/pp.79.3.579; SKOKUT TA, 1982, PLANT PHYSIOL, V69, P308, DOI 10.1104/pp.69.2.308; WISHART DS, 1994, METHOD ENZYMOL, V239, P363	28	39	39	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39238	39245		10.1074/jbc.M507053200	http://dx.doi.org/10.1074/jbc.M507053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16159873	hybrid			2022-12-25	WOS:000233362200040
J	Chami, M; Guilvout, I; Gregorini, M; Remigy, HW; Muller, SA; Valerio, M; Engel, A; Pugsley, AP; Bayan, N				Chami, M; Guilvout, I; Gregorini, M; Remigy, HW; Muller, SA; Valerio, M; Engel, A; Pugsley, AP; Bayan, N			Structural insights into the secretin PulD and its trypsin-resistant core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; PHAGE PIV MULTIMER; C-TERMINAL DOMAIN; ESCHERICHIA-COLI; NEISSERIA-MENINGITIDIS; PILQ SECRETIN; FUNCTIONAL-CHARACTERIZATION; PULLULANASE SECRETION; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE	Limited proteolysis, secondary structure and biochemical analyses, mass spectrometry, and mass measurements by scanning transmission electron microscopy were combined with cryo-electron microscopy to generate a three-dimensional model of the homomultimeric complex formed by the outer membrane secretin PulD, an essential channel-forming component of the type II secretion system from Klebsiella oxytoca. The complex is a dodecameric structure composed of two rings that sandwich a closed disc. The two rings form chambers on either side of a central plug that is part of the middle disc. The PulD polypeptide comprises two major, structurally quite distinct domains; an N domain, which forms the walls of one of the chambers, and a trypsin-resistant C domain, which contributes to the outer chamber, the central disc, and the plug. The C domain contains a lower proportion of potentially transmembrane beta-structure than classical outer membrane proteins, suggesting that only a small part of it is embedded within the outer membrane. Indeed, the C domain probably extends well beyond the confines of the outer membrane bilayer, forming a centrally plugged channel that penetrates both the peptidoglycan on the periplasmic side and the lipopolysaccharide and capsule layers on the cell surface. The inner chamber is proposed to constitute a docking site for the secreted exoprotein pullulanase, whereas the outer chamber could allow displacement of the plug to open the channel and permit the exoprotein to escape.	Inst Pasteur, CNRS, URA 2175, Mol Genet Unit, F-75724 Paris, France; Univ Basel, Biozentrum, ME Muller Inst, CH-4056 Basel, Switzerland; Univ Paris 11, Lab Modelisat & Ingn Prot, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Basel; UDICE-French Research Universities; Universite Paris Saclay	Pugsley, AP (corresponding author), Inst Pasteur, CNRS, URA 2175, Mol Genet Unit, 25 Rue Dr Roux, F-75724 Paris, France.	max@pasteur.fr	Bayan, Nicolas/AAI-5034-2020	Bayan, Nicolas/0000-0001-7760-0811				BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Beis K, 2004, J BIOL CHEM, V279, P28227, DOI 10.1074/jbc.M402913200; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bleves S, 1999, J BACTERIOL, V181, P4012, DOI 10.1128/JB.181.13.4012-4019.1999; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Brok R, 1999, J MOL BIOL, V294, P1169, DOI 10.1006/jmbi.1999.3340; Burghout P, 2004, J BACTERIOL, V186, P4645, DOI 10.1128/JB.186.14.4645-4654.2004; Chen CJ, 2004, J BACTERIOL, V186, P730, DOI 10.1128/JB.186.3.730-739.2004; Collins RF, 2005, J BIOL CHEM, V280, P18923, DOI 10.1074/jbc.M411603200; Collins RF, 2004, J BIOL CHEM, V279, P39750, DOI 10.1074/jbc.M405971200; Collins RF, 2003, J BACTERIOL, V185, P2611, DOI 10.1128/JB.185.8.2611-2617.2003; Collins RF, 2001, J BACTERIOL, V183, P3825, DOI 10.1128/JB.183.13.3825-3832.2001; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Daefler S, 1997, MOL MICROBIOL, V24, P465, DOI 10.1046/j.1365-2958.1997.3531727.x; Daefler S, 1997, J MOL BIOL, V266, P978, DOI 10.1006/jmbi.1996.0866; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; Faller M, 2004, SCIENCE, V303, P1189, DOI 10.1126/science.1094114; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Guilvout I, 1999, J BACTERIOL, V181, P7212, DOI 10.1128/JB.181.23.7212-7220.1999; Hardie KR, 1996, MOL MICROBIOL, V22, P967, DOI 10.1046/j.1365-2958.1996.01539.x; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Kohler R, 2004, MOL MICROBIOL, V54, P647, DOI 10.1111/j.1365-2958.2004.04307.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koster M, 1997, MOL MICROBIOL, V26, P789, DOI 10.1046/j.1365-2958.1997.6141981.x; Lario PI, 2005, EMBO J, V24, P1111, DOI 10.1038/sj.emboj.7600610; Lee MS, 2005, J BIOL CHEM, V280, P4585, DOI 10.1074/jbc.M409362200; Letellier L, 1997, J BIOL CHEM, V272, P11109; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; Linderoth NA, 1996, J BACTERIOL, V178, P1962, DOI 10.1128/jb.178.7.1962-1970.1996; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; Marciano DK, 2001, P NATL ACAD SCI USA, V98, P9359, DOI 10.1073/pnas.161170398; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; MICHAELIS S, 1985, J BACTERIOL, V164, P633, DOI 10.1128/JB.164.2.633-638.1985; MILLER JH, 1992, SHORT COURSE BACTERI, P437; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Possot OM, 1997, MOL MICROBIOL, V24, P457, DOI 10.1046/j.1365-2958.1997.3451726.x; Possot OM, 2000, J BACTERIOL, V182, P2142, DOI 10.1128/JB.182.8.2142-2152.2000; Possot OM, 1999, J BACTERIOL, V181, P4004, DOI 10.1128/JB.181.13.4004-4011.1999; Pugsley AP, 2001, J BACTERIOL, V183, P1312, DOI 10.1128/JB.183.4.1312-1319.2001; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P343, DOI 10.1111/j.1365-2958.1991.tb02115.x; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; Shevchik VE, 1998, MICROBIOL-UK, V144, P3219, DOI 10.1099/00221287-144-11-3219; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; Vignon G, 2003, J BACTERIOL, V185, P3416, DOI 10.1128/JB.185.11.3416-3428.2003; Voulhoux R, 2001, EMBO J, V20, P6735, DOI 10.1093/emboj/20.23.6735; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Zhao SQ, 2005, MOL MICROBIOL, V57, P1238, DOI 10.1111/j.1365-2958.2005.04752.x	61	115	119	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37732	37741		10.1074/jbc.M504463200	http://dx.doi.org/10.1074/jbc.M504463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129681	hybrid			2022-12-25	WOS:000233044500051
J	Daujat, S; Zeissler, U; Waldmann, T; Happel, N; Schneider, R				Daujat, S; Zeissler, U; Waldmann, T; Happel, N; Schneider, R			HP1 binds specifically to Lys(26)-methylated histone H1.4, whereas simultaneous Ser(27) phosphorylation blocks HP1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE 9; H3; CHROMATIN; METHYLATION; EXPRESSION; PROTEINS; DEPHOSPHORYLATION; RECRUITMENT; MAINTENANCE; NUCLEOSOME	Histone lysine methylation can have positive or negative effects on transcription, depending on the precise methylation site. According to the "histone code" hypothesis these methylation marks can be read by proteins that bind them specifically and then regulate downstream events. Hetero-chromatin protein 1 (HP1), an essential component of heterochromatin, binds specifically to methylated Lys(9) of histone H3 (K9/H3). The linker histone H1.4 is methylated on Lys(26) (K26/H1.4), but the role of this methylation in downstream events remains unknown. Here we identify HP1 as a protein specifically recognizing and binding to methylated K26/ H1.4. We demonstrate that the Chromo domain of HP1 is mediating this binding and that phosphorylation of Ser(27) on H1.4 (S27/ H1.4) prevents HP1 from binding. We suggest that methylation of K26/ H1.4 could have a role in tethering HP1 to chromatin and that this could also explain how HP1 is targeted to those regions of chromatin where it does not colocalize with methylated K9/H3. Our results provide the first experimental evidence for a "phospho switch" model in which neighboring phosphorylation reverts the effect of histone lysine methylation.	Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Univ Gottingen, Inst Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	Max Planck Society; University of Gottingen	Schneider, R (corresponding author), Max Planck Inst Immunbiol, D-79108 Freiburg, Germany.	schneiderr@immunbio.mpg.de	Waldmann, Tanja/A-5145-2010; Daujat, Sylvain/A-6070-2017	Waldmann, Tanja/0000-0001-9276-1592; Daujat, Sylvain/0000-0001-5107-119X				Albig W, 1998, FEBS LETT, V435, P245, DOI 10.1016/S0014-5793(98)01084-9; Alexandrow MG, 2005, J CELL BIOL, V168, P875, DOI 10.1083/jcb.200409055; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Dou YL, 2000, MOL CELL, V6, P225, DOI 10.1016/S1097-2765(00)00024-1; Dou YL, 2002, J CELL BIOL, V158, P1161, DOI 10.1083/jcb.200202131; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Garcia BA, 2004, J PROTEOME RES, V3, P1219, DOI 10.1021/pr0498887; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; Kratzmeier M, 2000, J BIOL CHEM, V275, P30478, DOI 10.1074/jbc.M003956200; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Meergans T, 1997, DNA CELL BIOL, V16, P1041, DOI 10.1089/dna.1997.16.1041; Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Van Holde KE, 1988, SPRINGER SERIES MOL; Yamamoto K, 2004, J BIOL CHEM, V279, P401, DOI 10.1074/jbc.M307344200	29	185	187	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38090	38095		10.1074/jbc.C500229200	http://dx.doi.org/10.1074/jbc.C500229200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16127177	hybrid			2022-12-25	WOS:000233044500092
J	Dumont, L; Gautier, T; de Barros, JPP; Laplanche, H; Blache, D; Ducoroy, P; Fruchart, J; Fruchart, JC; Gambert, P; Masson, D; Lagrost, L				Dumont, L; Gautier, T; de Barros, JPP; Laplanche, H; Blache, D; Ducoroy, P; Fruchart, J; Fruchart, JC; Gambert, P; Masson, D; Lagrost, L			Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; LIPID TRANSFER PROTEINS; CORONARY-HEART-DISEASE; TRANSGENIC MICE; CETP ACTIVITY; A-I; ATHEROSCLEROSIS; RECEPTOR; HDL	Genetically engineered mice demonstrated that apolipoprotein (apo) CI is a potent, physiological inhibitor of plasma cholesteryl ester transfer protein ( CETP) activity. The goal of this study was to determine the molecular mechanism of the apoCI-mediated blockade of CETP activity. Kinetic analyses revealed that the inhibitory property of apoCI is independent of the amount of active CETP, but it is tightly dependent on the amount of high density lipoproteins (HDL) in the incubation mixtures. The electrostatic charge of HDL, i.e. the main carrier of apoCI in human plasma, is gradually modified with increasing amounts of apoCI, and the neutralization of apoCI lysine residues by acetylation produces a marked reduction in its inhibitory potential. The inhibitory property of full-length apoCI is shared by its C-terminal alpha-helix with significant electrostratic properties, whereas its N-terminal alpha-helix with no CETP inhibitory property has no effect on HDL electronegativity. Finally, binding experiments demonstrated that apoCI and to a lower extent its C-terminal alpha-helix are able to disrupt CETP-lipoprotein complexes in a concentration-dependent manner. It was concluded that the inhibition of CETP activity by apoCI is in direct link with its specific electrostatic properties, and the apoCI-mediated reduction in the binding properties of lipoproteins results in weaker CETP-HDL interactions and fewer cholesteryl ester transfers.	Fac Med, INSERM, U498, Lab Biochim Lipoprot, F-21079 Dijon, France; Fac Med, Inst Federat Rech 100, F-21079 Dijon, France; Inst Pasteur, INSERM, U545, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Masson, D (corresponding author), Fac Med, INSERM, U498, Lab Biochim Lipoprot, BP87900, F-21079 Dijon, France.	david.masson@chu-dijon.fr; laurent.lagrost@u-bourgogne.fr	Gautier, Thomas/Q-5371-2018; MASSON, David/AAC-8896-2022; Masson, David/R-6633-2019; MASSON, David/R-4557-2017	Gautier, Thomas/0000-0003-1119-7382; MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; PAIS DE BARROS, Jean-Paul/0000-0002-5124-2283				Barter PJ, 2003, ARTERIOSCL THROM VAS, V23, P160, DOI 10.1161/01.ATV.0000054658.91146.64; BARTER PJ, 1980, J LIPID RES, V21, P238; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Boekholdt SM, 2004, CIRCULATION, V110, P1418, DOI 10.1161/01.CIR.0000141730.65972.95; Brousseau ME, 2004, NEW ENGL J MED, V350, P1505, DOI 10.1056/NEJMoa031766; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; Cho KH, 1998, BBA-LIPID LIPID MET, V1391, P133, DOI 10.1016/S0005-2760(97)00197-5; Clark RW, 2004, ARTERIOSCL THROM VAS, V24, P490, DOI 10.1161/01.ATV.0000118278.21719.17; Connolly DT, 1996, BBA-LIPID LIPID MET, V1304, P145, DOI 10.1016/S0005-2760(96)00115-4; Curb JD, 2004, J LIPID RES, V45, P948, DOI 10.1194/jlr.M300520-JLR200; de Grooth GJ, 2002, CIRCULATION, V105, P2159, DOI 10.1161/01.CIR.0000015857.31889.7B; Desrumaux C, 1998, J LIPID RES, V39, P131; EPPS DE, 1995, BIOCHEMISTRY-US, V34, P12560, DOI 10.1021/bi00039a010; Gautier T, 2005, BIOCHEM J, V385, P189, DOI 10.1042/BJ20041149; Gautier T, 2002, J BIOL CHEM, V277, P31354, DOI 10.1074/jbc.M203151200; Gautier T, 2000, J BIOL CHEM, V275, P37504, DOI 10.1074/jbc.M007210200; GUYARDDANGREMONT V, 1994, J LIPID RES, V35, P982; GUYARDDANGREMONT V, 1994, CLIN CHIM ACTA, V231, P147, DOI 10.1016/0009-8981(94)90199-6; HAVEL RJ, 1973, BIOCHEMISTRY-US, V12, P1828, DOI 10.1021/bi00733a026; Herrera VLM, 1999, NAT MED, V5, P1383, DOI 10.1038/70956; Hirano K, 2000, CURR OPIN LIPIDOL, V11, P589, DOI 10.1097/00041433-200012000-00004; Hope HR, 2000, J LIPID RES, V41, P1604; IHM J, 1982, J LIPID RES, V23, P1328; Jong MC, 1999, BIOCHEM J, V338, P281, DOI 10.1042/0264-6021:3380281; KUSHWAHA RS, 1993, J LIPID RES, V34, P1285; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LAGROST L, 1994, J LIPID RES, V35, P825; MALMENDIER CL, 1986, ATHEROSCLEROSIS, V62, P167, DOI 10.1016/0021-9150(86)90063-8; Masson D, 1996, J LIPID RES, V37, P1579; Masson D, 1997, J BIOL CHEM, V272, P24287, DOI 10.1074/jbc.272.39.24287; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; Rittershaus CW, 2000, ARTERIOSCL THROM VAS, V20, P2106, DOI 10.1161/01.ATV.20.9.2106; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SPARKS DL, 1992, J LIPID RES, V33, P123; Sugano M, 1998, J BIOL CHEM, V273, P5033, DOI 10.1074/jbc.273.9.5033; SWANEY JB, 1994, J LIPID RES, V35, P134; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TALL AR, 1986, J LIPID RES, V27, P361; TOURNIER JF, 1984, BIOCHIM BIOPHYS ACTA, V804, P216, DOI 10.1016/0167-4889(84)90152-6; van der Steeg WA, 2004, CURR OPIN LIPIDOL, V15, P631, DOI 10.1097/00041433-200412000-00002; Wang XX, 1999, J BIOL CHEM, V274, P1814, DOI 10.1074/jbc.274.3.1814; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453	45	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38108	38116		10.1074/jbc.M504678200	http://dx.doi.org/10.1074/jbc.M504678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16159884	hybrid			2022-12-25	WOS:000233044500095
J	Katsanakis, KD; Pillay, TS				Katsanakis, KD; Pillay, TS			Cross-talk between the two divergent insulin signaling pathways is revealed by the protein kinase B (Akt)-mediated phosphorylation of adapter protein APS on serine 588	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; C-CBL; GLUCOSE-TRANSPORT; RECEPTOR; RECRUITMENT; ADIPOCYTES; SUBSTRATE; CELLS; IDENTIFICATION; DEGUELIN	The APS adapter protein is recruited to the autophosphorylated kinase domain of the insulin receptor and initiates the phosphatidylinositol 3-kinase (PI3K)-independent pathway of insulin-stimulated glucose transport by recruiting CAP and c-Cbl. In this study, we have identified APS as a novel substrate for protein kinase B/Akt using an antibody that exhibits insulin-dependent immunoreactivity with a phosphospecific antibody raised against the protein kinase B substrate consensus sequence RXRXX(pS/pT) and a phosphospecific antibody that recognizes serine 21/9 of glycogen synthase kinase-3 alpha/beta. This phosphorylation of APS is observed in both 3T3-L1 adipocytes and transfected cells. The insulin-stimulated serine phosphorylation of APS was inhibited by a PI3-kinase inhibitor, LY290004, a specific protein kinase B (PKB) inhibitor, deguelin, and knockdown of Akt. Serine 588 of APS is contained in a protein kinase B consensus sequence for phosphorylation conserved in APS across multiple species but not found in other members of this family, including SH2-B and Lnk. Mutation of serine 588 to alanine abolished the insulin-stimulated serine phosphorylation of APS and prevented the localization of APS to membrane ruffles. A glutathione S-transferase fusion protein containing amino acids 534 - 621 of APS was phosphorylated by purified PKB in vitro, and mutation of serine 588 abolished the PKB-mediated phosphorylation of APS in vitro. Taken together, this study identifies APS as a novel physiological substrate for PKB and the first serine phosphorylation site on APS. These data therefore reveal the molecular cross-talk between the insulin-activated PI3-kinase-dependent and - independent pathways previously thought to be distinct and divergent.	Univ Nottingham, Sch Med, Inst Cell Signaling, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Pillay, TS (corresponding author), Univ Nottingham, Sch Med, Inst Cell Signaling, Nottingham NG7 2UH, England.	tpillay@nottingham.ac.uk		pillay, tahir/0000-0002-9982-9710	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Ahn MY, 2004, J BIOL CHEM, V279, P21526, DOI 10.1074/jbc.M307740200; Berwick DC, 2004, TRENDS BIOCHEM SCI, V29, P227, DOI 10.1016/j.tibs.2004.03.004; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bortul R, 2005, BRIT J HAEMATOL, V129, P677, DOI 10.1111/j.1365-2141.2005.05504.x; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chiang SH, 2003, EMBO J, V22, P2679, DOI 10.1093/emboj/cdg262; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CHIANG SH, 2002, J BIOL CHEM, V30, P30; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Welsh GL, 2005, BIOCHEM SOC T, V33, P346, DOI 10.1042/BST0330346; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wilcox A, 2004, J BIOL CHEM, V279, P38881, DOI 10.1074/jbc.M406101200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	25	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37827	37832		10.1074/jbc.M505959200	http://dx.doi.org/10.1074/jbc.M505959200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141217	hybrid			2022-12-25	WOS:000233044500062
J	Odell, AF; Scott, JL; Van Helden, DF				Odell, AF; Scott, JL; Van Helden, DF			Epidermal growth factor induces tyrosine phosphorylation, membrane insertion, and activation of transient receptor potential channel 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; OPERATED CA2+ ENTRY; SURFACE EXPRESSION; PLASMA-MEMBRANE; CATION CHANNELS; TRPC6 CHANNEL; CALCIUM-ENTRY; PDZ-DOMAIN; PROTEIN; CELLS	Various members of the canonical family of transient receptor potential channels (TRPCs) exhibit increased cation influx following receptor stimulation or Ca2+ store depletion. Tyrosine phosphorylation of TRP family members also results in increased channel activity; however, the link between the two events is unclear. We report that two tyrosine residues in the C terminus of human TRPC4 (hTRPC4), Tyr-959 and Tyr-972, are phosphorylated following epidermal growth factor (EGF) receptor stimulation of COS-7 cells. This phosphorylation was mediated by Src family tyrosine kinases (STKs), with Fyn appearing to be the dominant kinase. In addition, EGF receptor stimulation induced the exocytotic insertion of hTRPC4 into the plasma membrane dependent on the activity of STKs and was accompanied by a phosphorylation-dependent increase in the association of hTRPC4 with Na+/H+ exchanger regulatory factor. Furthermore, this translocation and association was defective upon mutation of Tyr-959 and Tyr-972 to phenylalanine. Significantly, inhibition of STKs was concomitant with a reduction in Ca2+ influx in both native COS-7 cells and hTRPC4-expressing HEK293 cells, with cells expressing the Y959F/Y972F mutant exhibiting a reduced EGF response. These findings represent the first demonstration of a mechanism for phosphorylation to modulate TRPC channel function.	Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia	University of Newcastle	Odell, AF (corresponding author), Univ Newcastle, Sch Biomed Sci, Level 5 MSB,Univ Dr, Callaghan, NSW 2308, Australia.	adam.odell@newcastle.edu.au	Odell, Adam/J-1386-2012					Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Babnigg G, 1997, J BIOL CHEM, V272, P29434, DOI 10.1074/jbc.272.47.29434; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Berridge MJ, 2004, BBA-MOL CELL RES, V1742, P3, DOI 10.1016/j.bbamcr.2004.08.012; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Boels K, 2001, J CELL SCI, V114, P3599; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; FLOCKERZI V, 2005, IN PRESS PFLUGERS AR; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hildreth KL, 2004, J BIOL CHEM, V279, P41775, DOI 10.1074/jbc.M403274200; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Itagaki K, 2004, J IMMUNOL, V172, P601, DOI 10.4049/jimmunol.172.1.601; Jiang XP, 2003, J BIOL CHEM, V278, P42867, DOI 10.1074/jbc.M304487200; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Mery L, 2002, J CELL SCI, V115, P3497; Misonou H, 2004, CRIT REV BIOCHEM MOL, V39, P125, DOI 10.1080/10409230490475417; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Obukhov AG, 2004, J CELL PHYSIOL, V201, P227, DOI 10.1002/jcp.20057; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Redondo PC, 2003, BIOCHEM J, V370, P255, DOI 10.1042/BJ20021505; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Saavedra FR, 2004, ARCH BIOCHEM BIOPHYS, V432, P261, DOI 10.1016/j.abb.2004.09.034; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker RL, 2002, AM J PHYSIOL-CELL PH, V283, pC1637, DOI 10.1152/ajpcell.00266.2002; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Yang H, 2005, J BIOL CHEM, V280, P32230, DOI 10.1074/jbc.M504553200; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391	49	89	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37974	37987		10.1074/jbc.M503646200	http://dx.doi.org/10.1074/jbc.M503646200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144838	hybrid			2022-12-25	WOS:000233044500080
J	Shi, GX; Han, JH; Andres, DA				Shi, GX; Han, JH; Andres, DA			Rin GTPase couples nerve growth factor signaling to p38 and b-Raf/ERK pathways to promote neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N1E-115 NEUROBLASTOMA-CELLS; PC12 CELLS; NEURITE OUTGROWTH; REGULATED KINASE; SYNAPTIC PLASTICITY; PC-12 CELLS; RAS; PHOSPHORYLATION; MAPK	In neuronal precursor cells, the magnitude and longevity of mitogen-activated protein ( MAP) kinase cascade activation contribute to the nature of the cellular response, differentiation, or proliferation. However, the mechanisms by which neurotrophins promote prolonged MAP kinase signaling are not well understood. Here we defined the Rin GTPase as a novel component of the regulatory machinery contributing to the selective integration of MAP kinase signaling and neuronal development. Rin is expressed exclusively in neurons and is activated by neurotrophin signaling, and loss-of-function analysis demonstrates that Rin makes an essential contribution to nerve growth factor (NGF)-mediated neuronal differentiation. Most surprisingly, although Rin was unable to stimulate MAP kinase activity in NIH 3T3 cells, it potently activated isoform-specific p38 alpha MAP kinase signaling and weakly stimulated ERK signaling in pheochromocytoma (PC6) cells. This cell-type specificity is explained in part by the finding that Rin binds and stimulates b-Raf but does not activate c-Raf. Accordingly, selective down-regulation of Rin in PC6 cells suppressed neurotrophin-elicited activation of b-Raf and p38, without obvious effects on NGF-induced ERK activation. Moreover, the ability of NGF to promote neurite outgrowth was inhibited by Rin knockdown. Together, these observations establish Rin as a neuronal specific regulator of neurotrophin signaling, required to couple NGF stimulation to sustain activation of p38 MAP kinase and b-Raf signaling cascades required for neuronal development.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Kentucky; Scripps Research Institute	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 741 S Limestone St, Lexington, KY 40536 USA.	dandres@pop.uky.edu	Shi, Geng-Xian/AAK-6061-2021; Han, J/G-4671-2010		NCRR NIH HHS [P20RR20171] Funding Source: Medline; NINDS NIH HHS [NS045103, R01 NS045103, R01 NS045103-03] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045103, R56NS045103] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bolshakov VY, 2000, NAT NEUROSCI, V3, P1107, DOI 10.1038/80624; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guan ZH, 2003, J NEUROSCI, V23, P7317; Hansen TVO, 2000, J NEUROCHEM, V75, P1870, DOI 10.1046/j.1471-4159.2000.0751870.x; Hoshino M, 2003, J CELL BIOL, V163, P1067, DOI 10.1083/jcb.200308070; Hoshino M, 2002, BIOCHEM BIOPH RES CO, V295, P651, DOI 10.1016/S0006-291X(02)00731-3; Huang C, 2004, J CELL BIOL, V164, P593, DOI 10.1083/jcb.200307081; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Hynds DL, 2003, J CELL SCI, V116, P1925, DOI 10.1242/jcs.00401; Ishii T, 2001, J BIOL CHEM, V276, P42994, DOI 10.1074/jbc.M105198200; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kimmelman AC, 2002, MOL CELL BIOL, V22, P5946, DOI 10.1128/MCB.22.16.5946-5961.2002; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee CHJ, 1996, J NEUROSCI, V16, P6784; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakata K, 2005, CELL, V120, P407, DOI 10.1016/j.cell.2004.12.017; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shi GX, 2005, MOL CELL BIOL, V25, P830, DOI 10.1128/MCB.25.2.830-846.2005; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Spencer ML, 2002, J BIOL CHEM, V277, P20160, DOI 10.1074/jbc.M201092200; Spencer ML, 2002, J BIOL CHEM, V277, P17605, DOI 10.1074/jbc.M111400200; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takeda K, 2002, GENES CELLS, V7, P1099, DOI 10.1046/j.1365-2443.2002.00591.x; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Yang LT, 2002, J BIOL CHEM, V277, P17406, DOI 10.1074/jbc.M111902200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	53	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37599	37609		10.1074/jbc.M507364200	http://dx.doi.org/10.1074/jbc.M507364200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157584	hybrid			2022-12-25	WOS:000233044500036
J	Blau, CA; Barbas, CF; Bomhoff, AL; Neades, R; Yan, J; Navas, PA; Peterson, KR				Blau, CA; Barbas, CF; Bomhoff, AL; Neades, R; Yan, J; Navas, PA; Peterson, KR			gamma-globin gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established from human beta-globin locus yeast artificial chromosome (beta-YAC) transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-HEMOGLOBIN; THALASSEMIA; INDUCTION; NF-E4	Identification of trans-acting factors or drugs capable of reactivating gamma-globin gene expression is complicated by the lack of suitable cell lines. Human K562 cells co-express epsilon- and gamma-globin but not beta-globin; transgenic mouse erythroleukemia 585 cells express predominantly human beta-globin but also gamma-globin; and transgenic murine GM979 cells co-express human gamma- and beta-globin. Human beta-globin locus yeast artificial chromosome transgenic mice display correct developmental regulation of beta-like globin gene expression. We rationalized that cells established from the adult bone marrow of these mice might express exclusively beta-globin and therefore could be employed to select or screen inducers of gamma-globin expression. A thrombopoietin receptor derivative that brings the proliferative status of primary mouse bone marrow cells under control of a chemical inducer of dimerization was employed to institute and maintain these cell populations. Human beta-globin was expressed, but gamma-globin was not; a similar expression pattern was observed in cells derived from fetal liver. gamma-Globin expression was induced upon exposure to 5-azacytidine, in cells derived from - 117 Greek hereditary persistence of fetal hemoglobin human beta-globin locus yeast artificial chromosome (beta-YAC) mice, showing that the hereditary persistence of fetal hemoglobin (HPFH) phenotype was maintained in these cells or was reactivated by an artificial zinc finger-gamma-globin transcription factor and the previously identified fetal globin transactivators fetal Kruppel-like factor ( FKLF) and fetal globin-increasing factor (FGIF). These cells may be useful for identifying transcription factors that reactivate gamma-globin synthesis or screening gamma-globin inducers for the treatment of sickle cell disease or beta-thalassemia.	Univ Washington, Med Ctr, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66213 USA; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66213 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Scripps Research Institute; Scripps Research Institute; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Peterson, KR (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, MS 3030,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	kpeterson@kumc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL067336, P01HL053750, R01HL067336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052997, R01DK061804, R01DK061803] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53750, HL67336] Funding Source: Medline; NIDDK NIH HHS [DK61803, DK61804, DK52997, DK53510] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano H, 1999, MOL CELL BIOL, V19, P3571; Asano H, 2000, BLOOD, V95, P3578, DOI 10.1182/blood.V95.11.3578.011k48_3578_3584; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; CONSTANTOULAKIS P, 1989, BLOOD, V74, P1963; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; FIBACH E, 1993, BLOOD, V82, P2203, DOI 10.1182/blood.V82.7.2203.bloodjournal8272203; Graslund T, 2005, J BIOL CHEM, V280, P3707, DOI 10.1074/jbc.M406809200; Harju S, 2001, BIOTECHNIQUES, V30, P1198, DOI 10.2144/01306bm02; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Neff T, 2001, BLOOD, V97, P2535, DOI 10.1182/blood.V97.9.2535; Papayannopoulou T, 2000, BLOOD, V95, P1274, DOI 10.1182/blood.V95.4.1274.004k45_1274_1282; PAPAYANNOPOULOU T, 1986, CELL, V46, P469, DOI 10.1016/0092-8674(86)90667-7; Peterson K R, 1997, Genet Eng (N Y), V19, P235; Peterson KR, 2004, GENESIS, V39, P1, DOI 10.1002/gene.20020; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Peterson KR, 1998, HUM MOL GENET, V7, P2079, DOI 10.1093/hmg/7.13.2079; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P11207, DOI 10.1073/pnas.90.23.11207; Skarpidi E, 1998, BLOOD, V92, P3416, DOI 10.1182/blood.V92.9.3416.421k16_3416_3421; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Stamatoyannopoulos G., 2001, MOL BASIS BLOOD DIS, Vthird, P135; Swank RA, 1998, CURR OPIN GENET DEV, V8, P366, DOI 10.1016/S0959-437X(98)80095-6; Vassilopoulos G, 1999, BLOOD, V93, P703, DOI 10.1182/blood.V93.2.703.402k07_703_712; Yang Y, 2001, BLOOD CELL MOL DIS, V27, P1, DOI 10.1006/bcmd.2000.0344; Zeng H, 2001, BLOOD, V98, P328, DOI 10.1182/blood.V98.2.328; Zhou WL, 2004, J BIOL CHEM, V279, P26227, DOI 10.1074/jbc.M402191200; Zhou WL, 2000, MOL CELL BIOL, V20, P7662, DOI 10.1128/MCB.20.20.7662-7672.2000	29	22	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36642	36647		10.1074/jbc.M504402200	http://dx.doi.org/10.1074/jbc.M504402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131492	hybrid			2022-12-25	WOS:000232901800015
J	Santoso, S; Orlova, VV; Song, KM; Sachs, UJ; Andrei-Selmer, CL; Chavakis, T				Santoso, S; Orlova, VV; Song, KM; Sachs, UJ; Andrei-Selmer, CL; Chavakis, T			The homophilic binding of junctional adhesion molecule-C mediates tumor cell-endothelial cell interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; JAM FAMILY; TRANSENDOTHELIAL MIGRATION; HUMAN PLATELETS; LIGAND; COUNTERRECEPTOR; EXPRESSION; INTEGRINS; RECEPTOR; MEMBER	The junctional adhesion molecule C(JAM-C) was recently shown to undergo a heterophilic interaction with the leukocyte beta 2 integrin Mac-1, thereby mediating interactions between vascular cells in inflammatory cell recruitment. Here, the homophilic interaction of JAM-C is presented and functionally characterized to mediate tumor cell-endothelial cell interactions. Recombinant soluble JAM-C in fluid phase bound to immobilized JAM-C as assessed in a purified system; moreover, JAM-C-transfected Chinese hamster ovary (CHO) cells adhered to immobilized JAM-C. The homophilic interaction of JAM-C was mediated by the isolated amino-terminal Ig domain (D1), but not the carboxyl-terminal Ig domain (D2), of the molecule. Dimerization of JAM-A is dependent on the sequence RVE in the amino-terminal Ig domain. This motif is conserved in JAM-C (Arg(64)-Ile(65)-Glu(66)), and a single amino acid mutation in this motif (E66R) abolished the homophilic interaction of JAM-C. The lung carcinoma cell line NCI-H522 was found to express JAM-C. NCI-H522 cells adhered to immobilized JAM-C, as well as to JAM-C-transfected CHO cells, but not to mock-transfected CHO cells or to CHO cells transfected with the JAM-Cmutant ( E66R). Adhesion of NCI-H522 cells to JAM-C protein or JAM-C-transfected CHO cells was abolished in the presence of soluble JAM-C or the isolated D1. Furthermore, the adhesion of NCI-H522 cells to endothelial cells was significantly blocked by soluble JAM-C or the isolated D1. Thus, JAM-C undergoes a homophilic interaction via the Arg(64)Ile(65)-Glu(66) motif on the membrane-distal Ig domain of the molecule. The homophilic interaction of JAM-C can mediate tumor cell-endothelial cell interactions and may thereby be involved in the process of tumor cell metastasis.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Justus Liebig University Giessen	Chavakis, T (corresponding author), NCI, Expt Immunol Branch, NIH, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Orlova, Valeria V/C-6065-2014; Sachs, Ulrich/GSI-7824-2022; Chavakis, Triantafyllos/ABE-8845-2020	Orlova, Valeria V/0000-0002-1169-2802; 				Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2003, CURR OPIN CELL BIOL, V15, P525, DOI 10.1016/S0955-0674(03)00104-2; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Engers R, 2000, J CANCER RES CLIN, V126, P682, DOI 10.1007/s004320000148; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Keiper T, 2005, HISTOL HISTOPATHOL, V20, P197, DOI 10.14670/HH-20.197; KORNECKI E, 1990, J BIOL CHEM, V265, P10042; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Liu Y, 2000, J CELL SCI, V113, P2363; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; Roschke AV, 2003, CANCER RES, V63, P8634; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Sobocka MB, 2000, BLOOD, V95, P2600; Yoshimasu T, 2004, CANCER SCI, V95, P142, DOI 10.1111/j.1349-7006.2004.tb03195.x; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	29	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36326	36333		10.1074/jbc.M505059200	http://dx.doi.org/10.1074/jbc.M505059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118203	hybrid			2022-12-25	WOS:000232726900066
J	Inuzuka, M; Hayakawa, M; Ingi, T				Inuzuka, M; Hayakawa, M; Ingi, T			Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EXPRESSION; RAFTS; GENE; IDENTIFICATION; PURIFICATION; PLASTICITY; SEQUENCE; BRAIN; RGS2	Cell membranes contain various transporter proteins, some of which are responsible for transferring amino acids across membrane. In this study, we report another class of carrier proteins, termed Serinc1 - 5, that incorporates a polar amino acid serine into membranes and facilitates the synthesis of two serine- derived lipids, phosphatidylserine and sphingolipids. Serinc is a unique protein family that shows no amino acid homology to other proteins but is highly conserved among eukaryotes. The members contain 11 transmembrane domains, and rat Serinc1 protein co- localizes with lipid biosynthetic enzymes in endoplasmic reticulum membranes. A Serinc protein forms an intracellular complex with key enzymes involved in serine and sphingolipid biosyntheses, and both functions, serine synthesis and membrane incorporation, are linked to each other. In the rat brain, expression of Serinc1 and Serinc2 mRNA was rapidly up- regulated by kainate- induced seizures in neuronal cell layers of the hippocampus. In contrast, myelin throughout the brain is enriched with Serinc5, which was down-regulated in the hippocampus by seizures. These results indicate a novel mechanism linking neural activity and lipid biosynthesis.	Niigata Univ, Brain Res Inst, Dept Neurophysiol, Niigata 9518585, Japan	Niigata University	Ingi, T (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurophysiol, 1 Asahi Machi, Niigata 9518585, Japan.	tingi@bri.niigata-u.ac.jp						BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; Cagney G, 2000, METHOD ENZYMOL, V328, P3, DOI 10.1016/S0076-6879(00)28386-9; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; De Hertogh Benoit, 2002, Funct Integr Genomics, V2, P154; DESTRUELLE M, 1994, MOL CELL BIOL, V14, P2740, DOI 10.1128/MCB.14.4.2740; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; DOWHAN W, 1992, METHOD ENZYMOL, V209, P287; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; Grossman TR, 2000, J EXP BIOL, V203, P447; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Ingi T, 2002, EUR J NEUROSCI, V15, P929, DOI 10.1046/j.1460-9568.2002.01925.x; Ingi T, 2001, EUR J NEUROSCI, V13, P1459, DOI 10.1046/j.0953-816x.2001.01529.x; Ingi T, 1998, J NEUROSCI, V18, P7178; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; KANFER JN, 1992, METHOD ENZYMOL, V209, P341; Krueger WHH, 1997, J NEUROCHEM, V69, P1343; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; LEBEL M, 1994, DNA SEQUENCE, V5, P31, DOI 10.3109/10425179409039702; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9	28	121	129	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35776	35783		10.1074/jbc.M505712200	http://dx.doi.org/10.1074/jbc.M505712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120614	hybrid			2022-12-25	WOS:000232561200081
J	Dluzniewska, J; Sarnowska, A; Beresewicz, M; Johnson, I; Srai, SKS; Ramesh, B; Goldspink, G; Gorecki, DC; Zablocka, B				Dluzniewska, J; Sarnowska, A; Beresewicz, M; Johnson, I; Srai, SKS; Ramesh, B; Goldspink, G; Gorecki, DC; Zablocka, B			A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia	FASEB JOURNAL			English	Article						hippocampus; stroke; insulin-like growth factor 1; mechano-growth factor	GROWTH-FACTOR-I; CEREBRAL-ARTERY OCCLUSION; SKELETAL-MUSCLE; SPLICE VARIANTS; NEURONAL DEATH; GERBIL HIPPOCAMPUS; FOREBRAIN ISCHEMIA; HYPOXIA-ISCHEMIA; CELL-DEATH; EXPRESSION	The ischemic stroke is the third leading cause of death in developed countries. The C-terminal peptide of mechano-growth factor (MGF), an alternatively spliced variant of insulin-like growth factor 1 (IGF-1), was found to function independently from the rest of the molecule and showed a neuroprotective effect in vivo and in vitro. In vivo, in a gerbil model of transient brain ischemia, treatment with the synthetic MGF C-terminal peptide provided very significant protection to the vulnerable neurons. In the same model, ischemia evoked increased expression of endogenous MGF in the ischemia-resistant hippocampal neurons, suggesting that the endogenous MGF might have an important neuroprotective function. In an in vitro organotypic hippocampal culture model of neurodegeneration, the synthetic peptide was as potent as the full-length IGF-1 while its effect lasted significantly longer than that of recombinant IGF-1. While two peptides showed an additive effect, the neuroprotective action of the C-terminal MGF was independent from the IGF-1 receptor, indicating a new mode of action for this molecule. Although MGF is known for its regenerative capability in skeletal muscle, our findings demonstrate for the first time a neuroprotective role against ischemia for this specific IGF-1 isoform. Therefore, the C-terminal MGF peptide has a potential to be developed into a therapeutic modality for the prevention of neuronal damage.	Univ Portsmouth, Sch Pharm & Biomed Sci, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England; Polish Acad Sci, Med Res Ctr, Mol Biol Unit, PL-02106 Warsaw, Poland; Polish Acad Sci, Med Res Ctr, Dept Neurorepair, PL-02106 Warsaw, Poland; UCL Royal Free & Univ Coll Med Sch, Dept Anat, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Surg, Mol Tissue Repair Unit, London, England	University of Portsmouth; Polish Academy of Sciences; Polish Academy of Sciences; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Gorecki, DC (corresponding author), Univ Portsmouth, Sch Pharm & Biomed Sci, Inst Biomed & Biomol Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.	darek.gorecki@port.ac.uk; zablocka@cmdik.pan.pl	Srai, Surjit K/C-5575-2009; Beresewicz Haller, Malgorzata/AAG-2147-2020; Srai, Kaila/AAE-7039-2021	Beresewicz Haller, Malgorzata/0000-0002-2204-5184; Johnson, Ian/0000-0001-5951-6990; Zablocka, Barbara/0000-0003-3116-7295	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aperghis M, 2004, BRAIN RES, V1009, P213, DOI 10.1016/j.brainres.2004.02.049; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Cheng CM, 2003, J NEUROSCI RES, V73, P1, DOI 10.1002/jnr.10634; DELBARRE G, 1991, J OCUL PHARMACOL, V7, P147, DOI 10.1089/jop.1991.7.147; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Fukudome Y, 2003, EUR J NEUROSCI, V17, P2006, DOI 10.1046/j.1460-9568.2003.02640.x; Garnier P, 2004, EUR J NEUROSCI, V20, P937, DOI 10.1111/j.1460-9568.2004.03551.x; Gleichmann M, 2000, NEUROSCI LETT, V282, P69, DOI 10.1016/S0304-3940(00)00857-0; Gorecki DC, 1999, MOL CELL NEUROSCI, V13, P218, DOI 10.1006/mcne.1999.0740; Guan J, 2000, J CEREBR BLOOD F MET, V20, P513, DOI 10.1097/00004647-200003000-00010; Guan J, 2001, NEUROSCIENCE, V105, P299, DOI 10.1016/S0306-4522(01)00145-2; Hameed M, 2003, J PHYSIOL-LONDON, V547, P247, DOI 10.1113/jphysiol.2002.032136; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; Hwang IK, 2004, NEUROCHEM INT, V45, P149, DOI 10.1016/j.neuint.2003.10.006; Ito Y, 2003, BRAIN RES, V985, P98, DOI 10.1016/S0006-8993(03)03173-1; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Kawano T, 2001, J CEREBR BLOOD F MET, V21, P1268, DOI 10.1097/00004647-200111000-00003; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; LIPTON P, 1995, J NEUROSCI METH, V59, P151, DOI 10.1016/0165-0270(94)00205-U; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; McKoy G, 1999, J PHYSIOL-LONDON, V516, P583, DOI 10.1111/j.1469-7793.1999.0583v.x; Owino V, 2001, FEBS LETT, V505, P259, DOI 10.1016/S0014-5793(01)02825-3; PAHLMARK K, 1993, STROKE, V24, P731, DOI 10.1161/01.STR.24.5.731; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Rytter A, 2003, J CEREBR BLOOD F MET, V23, P23, DOI 10.1097/01.WCB.0000034361.37277.1B; Sarnowska A, 2002, FOLIA NEUROPATHOL, V40, P101; Schabitz WR, 2001, STROKE, V32, P1226, DOI 10.1161/01.STR.32.5.1226; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Vicario-Abejon C, 2003, J NEUROSCI, V23, P895; Vincent AM, 2004, NEUROBIOL DIS, V16, P407, DOI 10.1016/j.nbd.2004.03.001; Wang JM, 2000, BRAIN RES, V859, P381, DOI 10.1016/S0006-8993(00)02008-4; Winn N, 2002, COLD SPRING HARB SYM, V67, P507, DOI 10.1101/sqb.2002.67.507; Yang HY, 2001, J MATER SCI TECHNOL, V17, P495; Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014-5793(02)02918-6; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	41	105	129	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1896	+		10.1096/fj.05-3786fje	http://dx.doi.org/10.1096/fj.05-3786fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16144956				2022-12-25	WOS:000232315700029
J	Paintlia, AS; Paintlia, MK; Khan, M; Vollmer, T; Singh, AK; Singh, I				Paintlia, AS; Paintlia, MK; Khan, M; Vollmer, T; Singh, AK; Singh, I			HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis	FASEB JOURNAL			English	Article						lovastatin; oligodendrocyte progenitors; spinal cord; encephalomyelitis; multiple sclerosis; remyelination	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DEMYELINATING DISEASES; CNS REMYELINATION; NITRIC-OXIDE; GLIAL-CELLS; RHO; ACTIVATION; EXPRESSION; LOVASTATIN	Impaired remyelination due to degeneration of both postmitotic oligodendrocytes and oligodendrocyte progenitors (OPs) is the major hallmark of inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE). Here, we have demonstrated the potential of lovastatin, a HMG-CoA reductase inhibitor, for the restoration of impaired remyelination mediated through enhanced survival and differentiation of OPs in the spinal cord of treated EAE animals. Lovastatin treatment significantly increased the level of myelin lipids in the spinal cord of treated EAE animals, coinciding with the attenuation of disease severity and inflammatory demyelination as compared with untreated EAE animals. The increased expression of myelin proteins and transcription factors associated with differentiating oligodendrocytes along with the increase in number of NG2(+)/BrdU(-) and NG2(+)/BrdU(+) cells, and the expression of proliferating OP-specific proteins, demonstrated the restoration of remyelination in the spinal cord of lovastatin-treated EAE animals. Corresponding to this, in vitro studies further corroborated the increased survival and differentiation of OPs in lovastatin-treated activated mixed glial cells suggesting that lovastatin protects against the degeneration of OPs and enhances their differentiation through induction of a pro-remyelinating environment in the spinal cord of treated EAE animals. Together, these data demonstrate that lovastatin has the potential to augment remyelination in MS lesions and other neuroinflammatory diseases.	Med Univ S Carolina, Children Res Inst, Dept Pediat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA; Barrow Neurol Inst, Phoenix, AZ 85013 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Barrow Neurological Institute	Singh, I (corresponding author), Med Univ S Carolina, Children Res Inst, Dept Pediat, 173 Ashley Ave,509 CRI,POB 250515, Charleston, SC 29425 USA.	singhi@musc.edu	Singh, Ashok/HGF-2506-2022	Paintlia, Ajaib/0000-0003-4525-5333	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037766, R01NS034741, R01NS040144, R01NS022576, R37NS022576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-40144, NS-22576, NS-37766, NS-34741] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Althaus HH, 2004, PROG BRAIN RES, V146, P415; Asakura K, 1998, J NEUROSCI, V18, P7700; Back SA, 2001, J NEUROSCI, V21, P1302; Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; Bolot G, 2003, BIOCHIMIE, V85, P409, DOI 10.1016/S0300-9084(03)00044-0; Bruck W, 2003, J NEUROL SCI, V206, P181, DOI 10.1016/s0022-510x(02)00191-0; Brundin L, 2003, BRAIN PATHOL, V13, P322; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Cimini A, 2003, GLIA, V41, P3, DOI 10.1002/glia.10143; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Dyer CA, 2000, J NEUROSCI RES, V60, P412, DOI 10.1002/(SICI)1097-4547(20000501)60:3<412::AID-JNR16>3.3.CO;2-5; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Giovannoni G, 1998, MULT SCLER J, V4, P212, DOI 10.1177/135245859800400323; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Jurevics H, 2001, J NEUROCHEM, V77, P1067, DOI 10.1046/j.1471-4159.2001.00310.x; Khan M, 2000, J ENDOTOXIN RES, V6, P41, DOI 10.1177/09680519000060010601; Khan M, 1998, J NEUROCHEM, V71, P78; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lassmann H, 2001, CURR OPIN NEUROL, V14, P253, DOI 10.1097/00019052-200106000-00001; Laufs U, 2000, TRENDS CARDIOVAS MED, V10, P143, DOI 10.1016/S1050-1738(00)00044-X; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Marcus J, 2002, BBA-GEN SUBJECTS, V1573, P406, DOI 10.1016/S0304-4165(02)00410-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mews I, 1998, MULT SCLER, V4, P55, DOI 10.1191/135245898678919582; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Paintlia AS, 2004, J NEUROSCI RES, V77, P63, DOI 10.1002/jnr.20130; Paintlia AS, 2003, NEUROBIOL DIS, V14, P425, DOI 10.1016/j.nbd.2003.08.013; Paintlia MK, 2004, J NEUROSCI RES, V78, P347, DOI 10.1002/jnr.20261; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PITKANEN ASL, 1986, J NEUROL SCI, V74, P45, DOI 10.1016/0022-510X(86)90190-5; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; Ruffini F, 2001, GENE THER, V8, P1207, DOI 10.1038/sj.gt.3301523; Saluja I, 2001, GLIA, V33, P191, DOI 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; Sorensen PS, 2003, J NEUROL SCI, V206, P123, DOI 10.1016/S0022-510X(02)00343-X; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Tang Y, 1999, MOL CELL BIOL, V19, P1881; TSUJI S, 1985, J NEUROL SCI, V68, P175, DOI 10.1016/0022-510X(85)90098-X; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	48	81	88	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1407	1421		10.1096/fj.05-3861com	http://dx.doi.org/10.1096/fj.05-3861com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126908				2022-12-25	WOS:000232315700034
J	Bhonde, MR; Hanski, ML; Notter, M; Gillissen, BF; Daniel, PT; Zeitz, M; Hanski, C				Bhonde, MR; Hanski, ML; Notter, M; Gillissen, BF; Daniel, PT; Zeitz, M; Hanski, C			Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth	ONCOGENE			English	Article						colon carcinoma; chemotherapy; irinotecan; apoptosis; cell cycle arrest	COLORECTAL-CANCER CELLS; POLY(ADP-RIBOSE) POLYMERASE CLEAVAGE; HUMAN GLIOBLASTOMA CELLS; P53 WILD-TYPE; G(2) ARREST; MITOTIC CATASTROPHE; IRINOTECAN CPT-11; IN-VITRO; SENESCENCE; LINES	Knowledge of the type of biological reaction to chemotherapy is a prerequisite for its rational enhancement. We previously showed that irinotecan-induced DNA damage triggers in the HCT116p53(wt) colon carcinoma cell line a long-term cell cycle arrest and in HCT116p53(-/-) cells apoptosis (Magrini et al., 2002). To compare the contribution of long-term cell cycle arrest and that of apoptosis to inhibition of cell proliferation after irinotecan-induced DNA damage, we used this isogenic system as well as the cell lines LS174T (p53(wt)) and HT-29 (p53(mut)). Both p53wt cell lines responded to damage by undergoing a long-term tetraploid G1 arrest, whereas the p53mut cell lines underwent apoptosis. Cell cycle arrest as well as apoptosis caused a similar delay in cell proliferation. Irinotecan treatment also induced in mouse tumours derived from the p53wt cell lines a tetraploid G1 arrest and in those derived from the p53-deficient cell lines a transient G2/M arrest and apoptosis. The delay of tumour growth was in the same range in both groups, that is, arrest-and apoptosis-mediated tumour growth inhibition was comparable. In conclusion, cell cycle arrest as well as apoptosis may be equipotent mechanisms mediating the chemotherapeutic effects of irinotecan.	Charite Univ Med Berlin, Dept Gastroenterol, D-12200 Berlin, Germany; Charite Univ Med Berlin, Dept Hematol, Berlin, Germany; Charite, Dept Clin & Mol Oncol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hanski, ML (corresponding author), Charite Univ Med Berlin, Dept Gastroenterol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christoph.hanski@charite.de		Gillissen, Bernhard/0000-0002-1815-2091				Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299; Andreassen PR, 2001, CANCER RES, V61, P7660; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bartussek C, 1999, EXP CELL RES, V253, P432, DOI 10.1006/excr.1999.4654; Bhonde MR, 2005, ONCOGENE, V24, P148, DOI 10.1038/sj.onc.1207842; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Brown JM, 1999, CANCER RES, V59, P1391; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Clifford B, 2003, CANCER RES, V63, P4074; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Cusack JC, 2001, CANCER RES, V61, P3535; Ducreux M, 2003, ANN ONCOL, V14, P17, DOI 10.1093/annonc/mdg724; Goldwasser F, 1996, CANCER RES, V56, P4430; Gunasekar P, 2001, TOXICOL SCI, V64, P83, DOI 10.1093/toxsci/64.1.83; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hirose Y, 2001, CANCER RES, V61, P1957; Jacob S, 2001, CANCER RES, V61, P6555; Jansen WJM, 1997, INT J CANCER, V70, P335, DOI 10.1002/(SICI)1097-0215(19970127)70:3<335::AID-IJC15>3.0.CO;2-E; Koike M, 2004, CANCER SCI, V95, P541, DOI 10.1111/j.1349-7006.2004.tb03246.x; Koizumi F, 2004, INT J CANCER, V108, P464, DOI 10.1002/ijc.11539; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Paradis V, 2001, HUM PATHOL, V32, P327, DOI 10.1053/hupa.2001.22747; Pavillard V, 2002, CANCER CHEMOTH PHARM, V49, P329, DOI 10.1007/s00280-001-0416-0; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Roninson IB, 2003, CANCER RES, V63, P2705; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2001, DRUG RESIST UPDATE, V4, P132, DOI 10.1054/drup.2001.0188; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; te Poele RH, 2002, CANCER RES, V62, P1876; te Poele RH, 1999, BRIT J CANCER, V81, P1285; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; Waxman DJ, 2003, CANCER RES, V63, P8563; Whitacre CM, 1999, CLIN CANCER RES, V5, P665; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	52	40	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					165	175		10.1038/sj.onc.1209017	http://dx.doi.org/10.1038/sj.onc.1209017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170360				2022-12-25	WOS:000234583600001
J	Cezar-de-Mello, PFT; Nascimento-Silva, V; Villela, CG; Fierro, IM				Cezar-de-Mello, PFT; Nascimento-Silva, V; Villela, CG; Fierro, IM			Aspirin-triggered Lipoxin A(4) inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly	ONCOGENE			English	Article						lipoxins; angiogenesis; cytoskeleton; FAK; p38	15-EPI-LIPOXIN A(4); EICOSANOID REGULATION; PHOSPHORYLATION; ACTIVATION; KINASE; ANGIOGENESIS; CYCLOOXYGENASE-2; PROLIFERATION; RECRUITMENT; LEUKOTRIENE	Angiogenesis, the growth of new capillaries from preexisting ones, occurs through dynamic functions of the endothelial cells (EC), including migration, which is essential to achieve an organized formation of the vessel sprout. We demonstrated previously that an aspirintriggered lipoxin analog, 15-epi-16-(para-fluoro)- phenoxylipoxin A4 (ATL-1), inhibits vascular endothelial growth factor (VEGF)- induced EC migration. In the present study, we investigated the effects of ATL-1 in the actin cytoskeleton reorganization of EC stimulated with VEGF. Pretreatment of EC with ATL-1 caused a reduction in VEGF-induced stress. bers and therefore reduced the intracellular content of lamentous actin. A concomitant impairment in stress-activated protein kinase (SAPK2/p38) phosphorylation suggests that ATL inhibition of VEGF- stimulated actin polymerization involves the SAPK2 p38 pathway. Moreover, ATL-1 treatment inhibited focal adhesion clustering due to inhibition of focal adhesion kinase (FAK) phosphorylation and the subsequent association of FAK with the actin cytoskeleton. This final event, which ultimately allows cell migration, was reverted by an LX receptor antagonist, but not by a cys-LT1R antagonist, indicating an effect via the Gproteinlinked LXA4 receptor. Together our results provide evidence that ATL-1 inhibits EC migration via the concerted inhibition of actin polymerization and proper assembly of focal adhesions, supporting a role for these novel lipid mediators as angiogenesis modulators.	Univ Estado Rio de Janeiro, Dept Farmacol & Psicobiol, Inst Biol Roberto Alcantara Gomes, BR-20551030 Rio De Janeiro, Brazil	Universidade do Estado do Rio de Janeiro	Fierro, IM (corresponding author), Univ Estado Rio de Janeiro, Dept Farmacol & Psicobiol, Inst Biol Roberto Alcantara Gomes, Av 28 Setembro 87 Fundos,5o Andar,Sala 2,Vila Isa, BR-20551030 Rio De Janeiro, Brazil.	iolanda@uerj.br	Fierro, Iolanda/AAJ-2705-2021	Fernandes Tavares Cezar de Mello, Paula/0000-0002-9293-9773				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ARENBERG AD, 1999, GALLIN JI SNYDERMAN, P851; Ashton AW, 2004, CIRC RES, V95, P372, DOI 10.1161/01.RES.0000138300.41642.15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fierro IM, 2002, J PHARMACOL EXP THER, V300, P385, DOI 10.1124/jpet.300.2.385; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; GRANESS A, 2000, BIOCHEM J, V15, P441; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Lynch KR, 1999, NATURE, V399, P789; Maderna P, 2000, AM J PHYSIOL-CELL PH, V279, pC945, DOI 10.1152/ajpcell.2000.279.4.C945; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nie DT, 2004, SEMIN THROMB HEMOST, V30, P119; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Ohira T, 2004, J IMMUNOL, V173, P2091, DOI 10.4049/jimmunol.173.3.2091; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SERHAN CN, 1999, INFLAMMATION BASIC P, P373; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Shtivelband MI, 2003, J THROMB HAEMOST, V1, P2225, DOI 10.1046/j.1538-7836.2003.00446.x; Strieter RM, 2004, SEMIN CANCER BIOL, V14, P195, DOI 10.1016/j.semcancer.2003.10.006; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Vane J, 2000, THORAX, V55, pS3, DOI 10.1136/thorax.55.suppl_2.S3; Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008; Zachary I, 2003, BIOCHEM SOC T, V31, P1171	39	72	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					122	129		10.1038/sj.onc.1209002	http://dx.doi.org/10.1038/sj.onc.1209002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16132039				2022-12-25	WOS:000234406400013
J	DeAngelis, T; Chen, J; Wu, A; Prisco, M; Baserga, R				DeAngelis, T; Chen, J; Wu, A; Prisco, M; Baserga, R			Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling	ONCOGENE			English	Article						T antigen; growth factor signaling; transformation	GROWTH-FACTOR-I; BREAST-CANCER CELLS; RIBOSOMAL GENE-TRANSCRIPTION; MOUSE EMBRYO FIBROBLASTS; LARGE TUMOR-ANTIGEN; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; HEMATOPOIETIC-CELLS; SIMIAN VIRUS-40	Previous work has shown that the Simian Virus 40 T antigen (T antigen) cannot transform mouse embryo. fibroblasts (MEFs) that do not express the type 1 insulin-like growth factor receptor (IGF-IR). We have now investigated the mechanism(s) by which the transforming activity of T antigen is affected by IGF-IR signaling. We demonstrate that transformation by T antigen of MEFs and several other cell lines requires an insulin receptor substrate-1 (IRS-1) phosphorylated on tyrosines. If IRS-1 is not expressed, or is serine phosphorylated or otherwise inactive, T antigen fails to transform cells in culture. For instance, while T antigen cannot transform 32D myeloid cells (that do not express IRS-1), its transforming activity is restored by the expression of a wild-type IRS-1, but not of an IRS-1 mutated at the PI3K binding sites. The importance of IRS-1 activation of PI3K in T-antigen transformation is supported by the. finding that a constitutively activated p110 subunit of PI3K, a target of IRS-1, overcomes the inability of T antigen to transform MEFs with a serine phosphorylated IRS-1. Taken together, these results indicate that the IRS-1/PI3K signaling is one of the mechanisms regulating transformation by the SV40 T antigen. We propose that the requirement for a tyrosyl-phosphorylated IRS-1 provides a mechanism to explain the failure of T antigen to transform MEFs with deleted IGF- IR genes.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	b_lupo@mail.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020956] Funding Source: NIH RePORTER; NCI NIH HHS [CA89640] Funding Source: Medline; NIA NIH HHS [AG 20956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Baserga Renato, 2004, VVolume 42, P235; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; CASTLES CG, 1993, CANCER RES, V53, P5934; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LIEBERMAN I, 1963, J BIOL CHEM, V238, P2141; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 2001, ONCOGENE, V20, P4842, DOI 10.1038/sj.onc.1204649; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SANTOS M, 1982, J CELL BIOCHEM, V19, P127, DOI 10.1002/jcb.240190204; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SOPRANO KJ, 1979, P NATL ACAD SCI USA, V76, P3885, DOI 10.1073/pnas.76.8.3885; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; VALENTINIS B, 1994, ONCOGENE, V9, P825; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White Robert J., 2004, VVolume 42, P371; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	61	50	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					32	42		10.1038/sj.onc.1209013	http://dx.doi.org/10.1038/sj.onc.1209013			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170362				2022-12-25	WOS:000234406400004
J	Maeno, K; Masuda, A; Yanagisawa, K; Konishi, H; Osada, H; Saito, T; Ueda, R; Takahashi, T				Maeno, K; Masuda, A; Yanagisawa, K; Konishi, H; Osada, H; Saito, T; Ueda, R; Takahashi, T			Altered regulation of c-jun and its involvement in anchorage-independent growth of human lung cancers	ONCOGENE			English	Article						c-jun; lung cancer; anchorage; independent growth; K-ras	BRONCHIAL EPITHELIAL-CELLS; NEOPLASTIC TRANSFORMATION; EMBRYO FIBROBLASTS; RAT-1A CELLS; TARGET GENE; RAT1A CELLS; EXPRESSION; APOPTOSIS; RAS; TRANSACTIVATION	The c-jun oncogene is frequently overexpressed in non-small-cell lung cancers (NSCLC), but its functional involvement in lung cancer development has not been clearly elucidated. In this study, we found that among the immediate-early serum responsible genes, exemplified by c-jun, c-fos and c-myc, induction of c-jun in a human bronchial epithelial cell line, BEAS-2B, was dependent on anchorage, in contrast to clear induction of c-fos and c-myc under both anchorage-dependent and - independent conditions. In fact, forced expression of c-jun in BEAS-2B cells significantly increased cell viability and colony formation in soft agar. Furthermore, we also found that such anchorage-dependent regulation of c-jun was lost in a significant fraction of human lung cancer cell lines. Interestingly, suppressed anchorage-independent but not anchorage-dependent growth was noted by constitutive expression of a dominant-negative c-jun mutant in a lung cancer cell line showing dysregulated and sustained c-jun expression in the absence of anchorage. These findings suggest that dysregulated c-jun expression may be involved in the acquisition of anchorage independence in the process of human lung carcinogenesis.	Nagoya Univ, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Grad Sch Med,Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med, Nagoya, Aichi, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Sci, Nagoya, Aichi, Japan	Nagoya University; Aichi Cancer Center; Nagoya City University; Nagoya City University	Takahashi, T (corresponding author), Nagoya Univ, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				AMSTAD P, 1988, MOL CARCINOGEN, V1, P151, DOI 10.1002/mc.2940010303; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; BENEZRA JM, 1994, AM J PATHOL, V145, P1036; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; FUJITA M, 1995, ONCOGENE, V11, P15; HIDA T, 1989, CANCER RES, V49, P4785; Hommura F, 2004, MOL CANCER RES, V2, P305; IKEGAKI N, 1994, CANCER RES, V54, P6; Katabami M, 2005, J BIOL CHEM, V280, P16728, DOI 10.1074/jbc.M413892200; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; Lu AP, 2002, J BIOL CHEM, V277, P31364, DOI 10.1074/jbc.M201060200; Masuda A, 1997, CANCER RES, V57, P4898; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Reddel R R, 1988, Oncogene Res, V3, P401; REDDEL RR, 1995, INT J CANCER, V61, P199; REDDEL RR, 1988, CANCER RES, V48, P1904; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Szabo E, 1996, CANCER RES, V56, P305; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	36	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					271	277		10.1038/sj.onc.1209018	http://dx.doi.org/10.1038/sj.onc.1209018			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158054				2022-12-25	WOS:000234583600011
J	Kerr, FK; O'Brien, G; Quinsey, NS; Whisstock, JC; Boyd, S; de la Banda, MG; Kaiserman, D; Matthews, AY; Bird, PI; Pike, RN				Kerr, FK; O'Brien, G; Quinsey, NS; Whisstock, JC; Boyd, S; de la Banda, MG; Kaiserman, D; Matthews, AY; Bird, PI; Pike, RN			Elucidation of the substrate specificity of the C1s protease of the classical complement pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID-ARTHRITIS; SERINE-PROTEASE; CLASS-I; RECOGNITION; ACTIVATION; COMPONENT; MECHANISM; CLEAVAGE; SITE	The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the first complement component, the C1 complex, initiates the pathway. In this study we have elucidated the full specificity of the enzyme for the first time using a randomized phage display library. It was found that, aside from the crucial P-1 position, the S-3 and S-2 subsites ( in that order) played the greatest role in determining specificity. C1s prefers Leu or Val at P-3 and Gly or Ala residues at P-2. Apart from the S-2' position, which showed specificity for Leu, prime subsites did not greatly affect specificity. It was evident, however, that together they significantly contributed to the efficiency of cleavage of a peptide. A peptide substrate based on the top sequence obtained in the phage display validated these results and produced the best kinetics of any C1s substrate to date. The results allow an understanding of the active site specificity of the C1s protease for the first time and provide a basis for the development of specific inhibitors aimed at controlling inflammation associated with complement activation in adverse pathological situations.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Cooperat Res Ctr Vaccine Technol, Clayton, Vic 3800, Australia; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Monash Univ, ARC Ctr Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia; Monash Univ, Sch Comp Sci & Software Engn, Clayton, Vic 3800, Australia	Monash University; Monash University; Monash University; Monash University; Monash University	Pike, RN (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.	rob.pike@med.monash.edu.au	Boyd, Sarah E/I-9047-2012	Garcia de la Banda, Maria/0000-0002-6666-514X; Whisstock, James/0000-0003-4200-5611; Bird, Phillip/0000-0002-6695-606X; Boyd, Sarah/0000-0002-7264-8602; Pike, Robert/0000-0002-2083-0269				ARLAUD GJ, 1993, METHOD ENZYMOL, V223, P61; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; Boyd Sarah E., 2005, Journal of Bioinformatics and Computational Biology, V3, P551, DOI 10.1142/S021972000500117X; Busby WH, 2000, J BIOL CHEM, V275, P37638, DOI 10.1074/jbc.M006107200; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Eriksson H, 1996, IMMUNOTECHNOLOGY, V2, P163, DOI 10.1016/S1380-2933(96)00050-4; ERIKSSON H, 1990, BIOCHIM BIOPHYS ACTA, V1037, P209, DOI 10.1016/0167-4838(90)90169-G; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; Janeway C. A., 2001, IMMUNOBIOLOGY IMMUNE, P43; Kochi Y, 2005, NAT GENET, V37, P478, DOI 10.1038/ng1540; MCRAE BJ, 1981, J BIOL CHEM, V256, P2362; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Nakagawa K, 1999, ANN RHEUM DIS, V58, P175, DOI 10.1136/ard.58.3.175; O'Brien G, 2003, BIOCHEMISTRY-US, V42, P14939, DOI 10.1021/bi035507b; OBRIEN G, 2003, BIOCH MOL BIOL, P240; PORTER RR, 1978, NATURE, V275, P699, DOI 10.1038/275699a0; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Riedemann NC, 2003, AM J PATHOL, V162, P363, DOI 10.1016/S0002-9440(10)63830-8; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; YAMAGUCHI K, 1990, FEBS LETT, V268, P206, DOI 10.1016/0014-5793(90)81009-D	22	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39510	39514		10.1074/jbc.M506131200	http://dx.doi.org/10.1074/jbc.M506131200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16169853	hybrid			2022-12-25	WOS:000233362200073
J	Hammel, M; Fierober, HP; Czjzek, M; Kurkal, V; Smith, JC; Bayer, EA; Finet, S; Receveur-Brechot, V				Hammel, M; Fierober, HP; Czjzek, M; Kurkal, V; Smith, JC; Bayer, EA; Finet, S; Receveur-Brechot, V			Structural basis of cellulosome efficiency explored by small angle X-ray scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-THERMOCELLUM CELLULOSOME; ANALYTICAL ULTRACENTRIFUGATION; CONFORMATIONAL FLEXIBILITY; DOCKERIN DOMAIN; PROTEIN; COMPLEX; CELLULOLYTICUM; MECHANISM; BINDING; SYSTEM	Cellulose, the main structural component of plant cell walls, is the most abundant carbohydrate polymer in nature. To break down plant cell walls, anaerobic microorganisms have evolved a large extracellular enzyme complex termed cellulosome. This megadalton catalytic machinery organizes an enzymatic assembly, tenaciously bound to a scaffolding protein via specialized intermodular "cohesin-dockerin" interactions that serve to enhance synergistic activity among the different catalytic subunits. Here, we report the solution structure properties of cellulosome-like assemblies analyzed by small angle x-ray scattering and molecular dynamics. The atomic models, generated by our strategy for the free chimeric scaffoldin and for binary and ternary complexes, reveal the existence of various conformations due to intrinsic structural flexibility with no, or only coincidental, inter-cohesin interactions. These results provide primary evidence concerning the mechanisms by which these protein assemblies attain their remarkable synergy. The data suggest that the motional freedom of the scaffoldin allows precise positioning of the complexed enzymes according to the topography of the substrate, whereas short-scale motions permitted by residual flexibility of the enzyme linkers allow "fine-tuning" of individual catalytic domains.	CNRS, Unite Mixte Rech 6098, F-13288 Marseille, France; Univ Aix Marseille 1, F-13288 Marseille, France; Univ Aix Marseille 2, F-13288 Marseille, France; Austrian Acad Sci, Inst Biophys & Xray Struct Res, A-8042 Graz, Austria; CNRS, UPR 9036, F-13402 Marseille, France; Univ Heidelberg, IWR, D-69120 Heidelberg, Germany; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Austrian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Ruprecht Karls University Heidelberg; Weizmann Institute of Science; European Synchrotron Radiation Facility (ESRF)	Receveur-Brechot, V (corresponding author), CNRS, Unite Mixte Rech 6098, 163 Ave Luminy,Case 932, F-13288 Marseille, France.	veronique.brechot@afmb.univ-mrs.fr	smith, jeremy c/B-7287-2012	smith, jeremy c/0000-0002-2978-3227; Hammel, Michal/0000-0002-5610-9289; Receveur-Brechot, Veronique/0000-0002-7464-6192				Aslam M, 2003, J MOL BIOL, V329, P525, DOI 10.1016/S0022-2836(03)00492-3; Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; BAYER EA, 1983, J BACTERIOL, V156, P818, DOI 10.1128/JB.156.2.818-827.1983; Bergmann A, 2000, J APPL CRYSTALLOGR, V33, P1212, DOI 10.1107/S0021889800008372; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Engh RA, 2002, PHARMACOL THERAPEUT, V93, P99, DOI 10.1016/S0163-7258(02)00180-8; Fierobe HP, 2005, J BIOL CHEM, V280, P16325, DOI 10.1074/jbc.M414449200; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; Fierobe HP, 2002, J BIOL CHEM, V277, P49621, DOI 10.1074/jbc.M207672200; Fierobe HP, 2001, J BIOL CHEM, V276, P21257, DOI 10.1074/jbc.M102082200; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Gal L, 1997, J BACTERIOL, V179, P6595, DOI 10.1128/jb.179.21.6595-6601.1997; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; Graille M, 2005, J BIOL CHEM, V280, P14780, DOI 10.1074/jbc.M414642200; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hammel M, 2004, J BIOL CHEM, V279, P55985, DOI 10.1074/jbc.M408979200; Hammel M, 2004, J MOL BIOL, V343, P917, DOI 10.1016/j.jmb.2004.08.076; Hammel M, 2002, J MOL BIOL, V321, P85, DOI 10.1016/S0022-2836(02)00621-6; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; LEACH AR, 2001, MOL MODELLING PRINCI, P457; Leibovitz E, 1996, J BACTERIOL, V178, P3077, DOI 10.1128/jb.178.11.3077-3084.1996; Longhi S, 2003, J BIOL CHEM, V278, P18638, DOI 10.1074/jbc.M300518200; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MAYER F, 1987, APPL ENVIRON MICROB, V53, P2785, DOI 10.1128/AEM.53.12.2785-2792.1987; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Petoukhov MV, 2002, BIOPHYS J, V83, P3113, DOI 10.1016/S0006-3495(02)75315-0; POHLSCHRODER M, 1995, J BACTERIOL, V177, P6625, DOI 10.1128/jb.177.22.6625-6629.1995; Receveur V, 2002, J BIOL CHEM, V277, P40887, DOI 10.1074/jbc.M205404200; Rincon MT, 2003, J BACTERIOL, V185, P703, DOI 10.1128/JB.185.3.703-713.2003; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Xu Q, 2003, J BACTERIOL, V185, P4548, DOI 10.1128/JB.185.15.4548-4557.2003; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J; Yuzawa S, 2001, J MOL BIOL, V306, P527, DOI 10.1006/jmbi.2000.4396	42	84	89	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38562	38568		10.1074/jbc.M503168200	http://dx.doi.org/10.1074/jbc.M503168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16157599	hybrid			2022-12-25	WOS:000233239800055
J	Tong, A; Nguyen, J; Lynch, KW				Tong, A; Nguyen, J; Lynch, KW			Differential expression of CD45 isoforms is controlled by the combined activity of basal and inducible splicing-regulatory elements in each of the variable exons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PRE-MESSENGER-RNA; LYMPHOCYTE-ACTIVATION; MULTIPLE-SCLEROSIS; POINT MUTATION; T-CELLS; ANTIGEN; PTPRC; GENE; DIVERSITY	The human CD45 gene encodes five isoforms of a transmembrane tyrosine phosphatase that differ in their extracellular domains as a result of alternative splicing of exons 4-6. Expression of the CD45 isoforms is tightly regulated in peripheral T cells such that resting cells predominantly express the larger CD45 isoforms, encoded by mRNAs containing two or three variable exons. In contrast, activated T cells express CD45 isoforms encoded by mRNAs lacking most or all of the variable exons. We have previously identified the sequences within CD45 variable exon 4 that control its level of inclusion into spliced mRNAs. Here we map the splicing-regulatory sequences within CD45 variable exons 5 and 6. We show that, like exon 4, exons 5 and 6 each contain an exonic splicing silencer (ESS) and an exonic splicing enhancer (ESE), which together determine the level of exon inclusion in naive cells. We further demonstrate that the primary activation-responsive silencing motif in exons 5 and 6 is homologous to that in exon 4 and, as in exon 4, binds specifically to the protein heterogeneous nuclear ribonucleoprotein L. Together these studies reveal common themes in the regulation of the CD45 variable exons and provide a mechanistic explanation for the observed physiological expression of CD45 isoforms.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lynch, KW (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	klynch@biochem.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067719] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM067719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Boxall S, 2004, HUM MOL GENET, V13, P2377, DOI 10.1093/hmg/ddh276; Cale CM, 1997, ARCH DIS CHILD, V76, P163, DOI 10.1136/adc.76.2.163; Dornan S, 2002, J BIOL CHEM, V277, P1912, DOI 10.1074/jbc.M108386200; Fu XD, 2004, CELL, V119, P736, DOI 10.1016/j.cell.2004.11.039; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; Jacobsen M, 2002, IMMUNOGENETICS, V54, P158, DOI 10.1007/s00251-002-0455-7; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Kung C, 2000, NAT MED, V6, P343; Lynch KW, 2000, MOL CELL BIOL, V20, P70, DOI 10.1128/MCB.20.1.70-80.2000; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; Rothrock C, 2003, MOL CELL, V12, P1317, DOI 10.1016/S1097-2765(03)00434-9; Rothrock CR, 2005, EMBO J, V24, P2792, DOI 10.1038/sj.emboj.7600745; Schaal TD, 1999, MOL CELL BIOL, V19, P261; Schwinzer R, 2003, GENES IMMUN, V4, P168, DOI 10.1038/sj.gene.6363894; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; Tchilian EZ, 2001, AIDS, V15, P1892, DOI 10.1097/00002030-200109280-00024; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Vogel A, 2003, GENES IMMUN, V4, P79, DOI 10.1038/sj.gene.6363918; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822	24	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38297	38304		10.1074/jbc.M508123200	http://dx.doi.org/10.1074/jbc.M508123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172127	hybrid			2022-12-25	WOS:000233239800025
J	Duncan, MJ; Mann, EL; Cohen, MS; Ofek, I; Sharon, N; Abraham, SN				Duncan, MJ; Mann, EL; Cohen, MS; Ofek, I; Sharon, N; Abraham, SN			The distinct binding specificities exhibited by enterobacterial type 1 fimbriae are determined by their fimbrial shafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIMH ADHESIN; SALMONELLA-TYPHIMURIUM; KLEBSIELLA-PNEUMONIAE; RECOMBINANT PLASMIDS; NUCLEOTIDE-SEQUENCE; FAMILY ENTEROBACTERIACEAE; CARBOHYDRATE SPECIFICITY; MONOCLONAL-ANTIBODIES; EPITHELIAL-CELLS	Type 1 fimbriae of enterobacteria are heteropolymeric organelles of adhesion composed of FimH, a mannose-binding lectin, and a shaft composed primarily of FimA. We compared the binding activities of recombinant clones expressing type 1 fimbriae from Escherichia coli, Klebsiella pneumoniae, and Salmonella typhimurium for gut and uroepithelial cells and for various soluble mannosylated proteins. Each fimbria was characterized by its capacity to bind particular epithelial cells and to aggregate mannoproteins. However, when each respective FimH subunit was cloned and expressed in the absence of its shaft as a fusion protein with MalE, each FimH bound a wide range of mannose-containing compounds. In addition, we found that expression of FimH on a heterologous fimbrial shaft, e. g. K. pneumoniae FimH on the E. coli fimbrial shaft or vice versa, altered the binding specificity of FimH such that it closely resembled that of the native heterologous type 1 fimbriae. Furthermore, attachment to and invasion of bladder epithelial cells, which were mediated much better by native E. coli type 1 fimbriae compared with native K. pneumoniae type 1 fimbriae, were found to be dependent on the background of the fimbrial shaft ( E. coli versus K. pneumoniae) rather than the background of the FimH expressed. Thus, the distinct binding specificities of different enterobacterial type 1 fimbriae cannot be ascribed solely to the primary structure of their respective FimH subunits, but are also modulated by the fimbrial shaft on which each FimH subunit is presented, possibly through conformational constraints imposed on FimH by the fimbrial shaft. The capacity of type 1 fimbrial shafts to modulate the tissue tropism of different enterobacterial species represents a novel function for these highly organized structures.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Duke University; Duke University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science	Abraham, SN (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Campus Box 3020, Durham, NC 27710 USA.	soman.abraham@duke.edu	Ofek, Itzhak/L-4616-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050814, R01DK050814] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 056101, AI150021] Funding Source: Medline; NIDDK NIH HHS [DK050814] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; ADEGBOLA RA, 1987, J MED MICROBIOL, V24, P21, DOI 10.1099/00222615-24-1-21; BIRK HW, 1987, ANAL BIOCHEM, V164, P12, DOI 10.1016/0003-2697(87)90360-5; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; Chandra NR, 1999, J MOL BIOL, V285, P1157, DOI 10.1006/jmbi.1998.2353; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; CLEGG S, 1987, J BACTERIOL, V169, P934, DOI 10.1128/jb.169.3.934-938.1987; CLEGG S, 1985, INFECT IMMUN, V48, P275, DOI 10.1128/IAI.48.2.275-279.1985; DODD DC, 1982, INFECT IMMUN, V38, P764, DOI 10.1128/IAI.38.2.764-773.1982; Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200; EDEN CS, 1984, INFECT IMMUN, V44, P672; FEUTRIER J, 1986, J BACTERIOL, V168, P221, DOI 10.1128/jb.168.1.221-227.1986; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; FIRON N, 1984, INFECT IMMUN, V43, P1088, DOI 10.1128/IAI.43.3.1088-1090.1984; GERLACH GF, 1989, J BACTERIOL, V171, P1262, DOI 10.1128/jb.171.3.1262-1270.1989; GERLACH GF, 1989, INFECT IMMUN, V57, P764, DOI 10.1128/IAI.57.3.764-770.1989; GHOSH S, 1994, FEMS MICROBIOL LETT, V115, P229; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HANSON MS, 1983, THESIS U PITTSBURGH; Harris SL, 2001, J BACTERIOL, V183, P4099, DOI 10.1128/JB.183.13.4099-4102.2001; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KLEMM P, 1984, EUR J BIOCHEM, V143, P395, DOI 10.1111/j.1432-1033.1984.tb08386.x; KROGFELT KA, 1988, MICROB PATHOGENESIS, V4, P231, DOI 10.1016/0882-4010(88)90073-3; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; MADISON B, 1994, INFECT IMMUN, V62, P843, DOI 10.1128/IAI.62.3.843-848.1994; Marc D, 1996, J MED MICROBIOL, V44, P444, DOI 10.1099/00222615-44-6-444; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MAY AK, 1993, INFECT IMMUN, V61, P1667, DOI 10.1128/IAI.61.5.1667-1673.1993; MINION FC, 1986, J BACTERIOL, V165, P1033, DOI 10.1128/jb.165.3.1033-1036.1986; MULLER KH, 1991, J BACTERIOL, V173, P4765; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Muro MD, 1996, J INVEST ALLERG CLIN, V6, P166; MUSCAS P, 1994, MICROBIOL IMMUNOL, V38, P353, DOI 10.1111/j.1348-0421.1994.tb01790.x; NICHOLS WA, 1990, MOL MICROBIOL, V4, P2119, DOI 10.1111/j.1365-2958.1990.tb00573.x; OFEK I, 1977, NATURE, V265, P623, DOI 10.1038/265623a0; Ofek I, 2000, ADV EXP MED BIOL, V485, P183; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; ORNDORFF PE, 1985, J BACTERIOL, V162, P454, DOI 10.1128/JB.162.1.454-457.1985; PONNIAH S, 1991, J BACTERIOL, V173, P4195, DOI 10.1128/jb.173.13.4195-4202.1991; PURCELL BK, 1983, INFECT IMMUN, V39, P1122, DOI 10.1128/IAI.39.3.1122-1127.1983; ROSENBAUM LC, 1989, ANAL BIOCHEM, V183, P250, DOI 10.1016/0003-2697(89)90475-2; SALIT IE, 1977, J EXP MED, V146, P1169, DOI 10.1084/jem.146.5.1169; Schembri MA, 2000, INFECT IMMUN, V68, P2638, DOI 10.1128/IAI.68.5.2638-2646.2000; Schembri MA, 1996, FEMS MICROBIOL LETT, V137, P257, DOI 10.1016/0378-1097(96)00067-5; Schembri MA, 2001, J INFECT DIS, V183, pS28, DOI 10.1086/318847; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; SOKURENKO EV, 1995, J BACTERIOL, V177, P3680, DOI 10.1128/jb.177.13.3680-3686.1995; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; Sokurenko EV, 2001, MOL MICROBIOL, V41, P675, DOI 10.1046/j.1365-2958.2001.02545.x; Sukupolvi S, 1997, INFECT IMMUN, V65, P5320, DOI 10.1128/IAI.65.12.5320-5325.1997; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TEWARI R, 1993, J BIOL CHEM, V268, P3009; Thankavel K, 1999, J BIOL CHEM, V274, P5797, DOI 10.1074/jbc.274.9.5797; Thankavel K, 1997, J CLIN INVEST, V100, P1123, DOI 10.1172/JCI119623	58	62	68	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37707	37716		10.1074/jbc.M501249200	http://dx.doi.org/10.1074/jbc.M501249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16118220	hybrid			2022-12-25	WOS:000233044500048
J	Li, JQ; Dai, ZP; Jana, D; Callaway, DJE; Bu, ZM				Li, JQ; Dai, ZP; Jana, D; Callaway, DJE; Bu, ZM			Ezrin controls the macromolecular complexes formed between an adapter protein Na+/H+ exchanger regulatory factor and the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-MEDIATED INTERACTION; CARBOXYL-TERMINAL REGION; X-RAY-SCATTERING; PDZ-DOMAIN; ERM PROTEINS; BETA(2)-ADRENERGIC RECEPTOR; BIOLOGICAL MACROMOLECULES; PARATHYROID-HORMONE; ION-TRANSPORT; BINDING-SITE	Na+/H+ exchanger regulatory factor ( NHERF) is an adapter protein that is responsible for organizing a number of cell receptors and channels. NHERF contains two amino-terminal PDZ ( postsynaptic density 95/disk-large/zonula occluden-1) domains that bind to the cytoplasmic domains of a number of membrane channels or receptors. The carboxyl terminus of NHERF interacts with the FERM domain ( a domain shared by protein 4.1, ezrin, radixin, and moesin) of a family of actin-binding proteins, ezrin-radixin-moesin. NHERF was shown previously to be capable of enhancing the channel activities of cystic fibrosis transmembrane conductance regulator ( CFTR). Here we show that binding of the FERM domain of ezrin to NHERF regulates the cooperative binding of NHERF to bring two cytoplasmic tails of CFTR into spatial proximity to each other. We find that ezrin binding activates the second PDZ domain of NHERF to interact with the cytoplasmic tails of CFTR (C-CFTR), so as to form a specific 2: 1: 1 (CCFTR)(2) center dot NHERF center dot ezrin ternary complex. Without ezrin binding, the cytoplasmic tail of CFTR only interacts strongly with the first amino-terminal PDZ domain to form a 1: 1 C-CFTR center dot NHERF complex. Immunoprecipitation and immunoblotting confirm the specific interactions of NHERF with the full-length CFTR and with ezrin in vivo. Because of the concentrated distribution of ezrin and NHERF in the apical membrane regions of epithelial cells and the diverse binding partners for the NHERF PDZ domains, the regulation of NHERF by ezrin may be employed as a general mechanism to assemble channels and receptors in the membrane cytoskeleton.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Bu, ZM (corresponding author), Fox Chase Canc Ctr, Reimann 414,333 Cottman Ave, Philadelphia, PA 19111 USA.	Zimei.Bu@fccc.edu			NCI NIH HHS [CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Benharouga M, 2003, J BIOL CHEM, V278, P22079, DOI 10.1074/jbc.M301030200; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brone B, 2005, AM J PHYSIOL-CELL PH, V288, pC20, DOI 10.1152/ajpcell.00368.2004; Bu ZM, 1999, BIOPHYS J, V77, P1064, DOI 10.1016/S0006-3495(99)76956-0; Bu ZM, 1998, J APPL CRYSTALLOGR, V31, P533, DOI 10.1107/S0021889897015422; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Finnerty CM, 2004, J CELL SCI, V117, P1547, DOI 10.1242/jcs.01038; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P15; Guggino WB, 2004, AM J RESP CRIT CARE, V170, P815, DOI 10.1164/rccm.200403-381WS; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Ho DL, 2004, J BIOL CHEM, V279, P39146, DOI 10.1074/jbc.M404565200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Karthikeyan S, 2002, J BIOL CHEM, V277, P18973, DOI 10.1074/jbc.M201507200; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Ladias JAA, 2003, J MEMBRANE BIOL, V192, P79, DOI 10.1007/s00232-002-1065-x; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mahon MJ, 2004, J BIOL CHEM, V279, P23550, DOI 10.1074/jbc.M313229200; Masters Shane C, 2004, Methods Mol Biol, V261, P337; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; VANHOLDE KE, 1998, PRINCIPLES PHYS BIOC, P325; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; WEINMAN EJ, 1993, J CLIN INVEST, V91, P2097, DOI 10.1172/JCI116433; Wriggers W, 2001, J APPL CRYSTALLOGR, V34, P773, DOI 10.1107/S0021889801012869; Yoo D, 2004, J BIOL CHEM, V279, P6863, DOI 10.1074/jbc.M311599200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	65	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37634	37643		10.1074/jbc.M502305200	http://dx.doi.org/10.1074/jbc.M502305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129695	hybrid			2022-12-25	WOS:000233044500040
J	Nakashima, A; Katagiri, T; Tamura, M				Nakashima, A; Katagiri, T; Tamura, M			Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; BETA-CATENIN; OSTEOBLAST DIFFERENTIATION; MESSENGER-RNA; DNA-BINDING; GENE; EXPRESSION; IDENTIFICATION; MOUSE; ACTIVATION	Loss of function of the Wnt co-receptor, lipoprotein receptor-related protein 5, decreases bone formation, and a point mutation in this gene results in high bone mass, indicating the importance of this signaling pathway in bone formation. However, the exact mechanism is currently unknown. We examined a potential role for Wnt signaling and functional cross-talk of bone morphogenetic protein 2 (BMP-2) in osteoblast differentiation. To assess the contribution of Wnt, we generated C2C12 cells over-expressing Wnt3a or Wnt5a and treated these with BMP-2. We showed that expression of matrix extracellular phosphoglycoprotein was induced by BMP-2 in Wnt3a over-expressing C2C12 cells but not in Wnt5a over-expressing C2C12 cells. Over-expression of Wnt3a blocked BMP-2-induced inhibition of myotube formation in C2C12 cells when switched to low mitogen medium. In these cultures, expression of inhibitor of DNA binding/differentiation ( Id) 1, a helix-loop-helix protein induced by BMP-2, decreased in stable Wnt3a- but not in Wnt5a-expressing cells. This suppression is mediated by a GC-rich region of the BMP-2-responsive element of the Id1 gene promoter, and interaction between Smad1/4 and beta-catenin is crucial for Wnt-mediated suppression of the BMP-2 response in C2C12 cells. Overexpression of the inhibitor of canonical Wnt signaling, Dickkopf, inhibits this suppression. In contrast, BMP-2 or Smad1/4 up-regulated Wnt3a or activated beta-catenin-induced lymphoid-enhancing factor 1/T cell factor-dependent transcriptional activity. These findings identify functional cross-talk of Id1 expression between Wnt and BMP signaling and demonstrate a novel mechanism for Wnt regulation of the BMP-2 response, linking Id1 expression to Wnt/beta-catenin signaling.	Hokkaido Univ, Grad Sch Dent Med, Dept Biochem & Mol Biol, Sapporo, Hokkaido 0608586, Japan; Saitama Med Sch, Res Ctr Genom Med, Div Pathophysiol, Hidaka 3501241, Japan	Hokkaido University; Saitama Medical University	Tamura, M (corresponding author), Hokkaido Univ, Grad Sch Dent Med, Dept Biochem & Mol Biol, N 13,W 7, Sapporo, Hokkaido 0608586, Japan.	mtamura@den.hokudai.ac.jp	tamura, masato/B-7304-2009	tamura, masato/0000-0003-3700-5203				Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gowen LC, 2003, J BIOL CHEM, V278, P1998, DOI 10.1074/jbc.M203250200; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200; Haegele L, 2003, MOL CELL NEUROSCI, V24, P696, DOI 10.1016/S1044-7431(03)00232-X; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Norton JD, 2000, J CELL SCI, V113, P3897; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Obama H, 1997, J BIOL CHEM, V272, P11017; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; Vinals F, 2004, EMBO J, V23, P3527, DOI 10.1038/sj.emboj.7600360; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zhang GX, 2004, ENDOCRINE, V24, P15, DOI 10.1385/ENDO:24:1:015; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	55	117	141	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37660	37668		10.1074/jbc.M504612200	http://dx.doi.org/10.1074/jbc.M504612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150699	Green Submitted, hybrid			2022-12-25	WOS:000233044500043
J	Anthony, AC; Ushkaryov, YA				Anthony, AC; Ushkaryov, YA			Properties of synaptic vesicle pools in mature central nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							READILY RELEASABLE POOL; FROG NEUROMUSCULAR-JUNCTION; PROTEIN-KINASE-C; HIPPOCAMPAL SYNAPSES; TRANSMITTER RELEASE; ALPHA-LATROTOXIN; MEDIATED ENDOCYTOSIS; EXOCYTOSIS; NEURONS; CA2+	Readily releasable and reserve pools of synaptic vesicles play different roles in neurotransmission, and it is important to understand their recycling and interchange in mature central synapses. Using adult rat cerebrocortical synaptosomes, we have shown that 100 mosM hypertonic sucrose caused complete exocytosis of only the readily releasable pool (RRP) of synaptic vesicles containing glutamate or gamma-aminobutyric acid. Repetitive hypertonic stimulations revealed that this pool recycled (and reloaded the neurotransmitter from the cytosol) fully in <30 s and did so independently of the reserve pool. Multiple rounds of exocytosis could occur in the constant absence of extracellular Ca2+. However, although each vesicle cycle includes a Ca2+-independent exocytotic step, some other stage(s) critically require an elevation of cytosolic [Ca2+], and this is supplied by intracellular stores. Repetitive recycling also requires energy, but not the activity of phosphatidylinositol 4-kinase, which maintains the normal level of phosphoinositides. By varying the length of hypertonic stimulations, we found that similar to 70% of the RRP vesicles fused completely with the plasmalemma during exocytosis and could then enter silent pools, probably outside active zones. The rest of the RRP vesicles underwent very fast local recycling (possibly by kiss-and-run) and did not leave active zones. Forcing the fully fused RRP vesicles into the silent pool enabled us to measure the transfer of reserve vesicles to the RRP and to show that this process requires intact phosphatidylinositol 4-kinase and actin microfilaments. Our findings also demonstrate that respective vesicle pools have similar characteristics and requirements in excitatory and inhibitory nerve terminals.	Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Dept Biol Sci, London SW7 2AZ, England; Univ Cent Lancashire, Dept Biol Sci, Preston PR1 2HE, Lancs, England	Imperial College London; University of Central Lancashire	Ushkaryov, YA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Dept Biol Sci, London SW7 2AZ, England.	y.ushkaryov@imperial.ac.uk	Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297	Biotechnology and Biological Sciences Research Council [BB/D523078/1] Funding Source: Medline; Wellcome Trust [074359] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; Ashton AC, 2000, J NEUROCHEM, V74, P1979, DOI 10.1046/j.1471-4159.2000.0741979.x; Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; BRADFORD HF, 1986, CHEM NEUROBIOLOGY; BROSIUS DC, 1992, J NEUROPHYSIOL, V68, P1229, DOI 10.1152/jn.1992.68.4.1229; Bykhovskaia M, 2001, J PHYSIOL-LONDON, V537, P179, DOI 10.1111/j.1469-7793.2001.0179k.x; Capogna M, 2003, J NEUROSCI, V23, P4044; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Chawla S, 2001, J PHYSIOL-LONDON, V536, P351, DOI 10.1111/j.1469-7793.2001.0351c.xd; Cole JC, 2000, J PHYSIOL-LONDON, V525, P579, DOI 10.1111/j.1469-7793.2000.t01-2-00579.x; Cousin MA, 2000, J NEUROCHEM, V75, P1645, DOI 10.1046/j.1471-4159.2000.0751645.x; Cremona O, 2001, J CELL SCI, V114, P1041; Cseresnyes Z, 1997, NEURON, V19, P403, DOI 10.1016/S0896-6273(00)80949-6; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; ELMQVIST D, 1965, J PHYSIOL-LONDON, V178, P505, DOI 10.1113/jphysiol.1965.sp007639; Gad H, 1998, NEURON, V21, P607, DOI 10.1016/S0896-6273(00)80570-X; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; GIBSON AE, 1989, AM J PHYSIOL, V257, pC182, DOI 10.1152/ajpcell.1989.257.2.C182; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANO T, 1989, HYPERTENSION, V13, P250, DOI 10.1161/01.HYP.13.3.250; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; Khvotchev M, 2000, NEUROSCIENCE, V101, P793, DOI 10.1016/S0306-4522(00)00378-X; Kuromi H, 2002, NEURON, V35, P333, DOI 10.1016/S0896-6273(02)00777-8; Lee MC, 2002, SYNAPSE, V43, P102, DOI 10.1002/syn.10014; Leenders AGM, 2002, NEUROSCIENCE, V109, P195, DOI 10.1016/S0306-4522(01)00450-X; Lonart G, 2000, J BIOL CHEM, V275, P27703; Moskowitz HS, 2003, MOL BIOL CELL, V14, P4437, DOI 10.1091/mbc.e03-04-0230; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; OJA SS, 1988, NEUROCHEM RES, V13, P923, DOI 10.1007/BF00970763; Olsen HL, 2003, P NATL ACAD SCI USA, V100, P5187, DOI 10.1073/pnas.0931282100; Otsu Y, 2004, J NEUROSCI, V24, P9076, DOI 10.1523/JNEUROSCI.2060-04.2004; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pyle JL, 2000, NEURON, V28, P221, DOI 10.1016/S0896-6273(00)00098-2; Richards DA, 2005, J CELL BIOL, V168, P929, DOI 10.1083/jcb.200407148; Richards DA, 2004, J PHYSIOL-LONDON, V557, P77, DOI 10.1113/jphysiol.2004.062158; Richards DA, 2003, NEURON, V39, P529, DOI 10.1016/S0896-6273(03)00405-7; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Rosenmund C, 1997, J NEUROSCI METH, V76, P1, DOI 10.1016/S0165-0270(97)00061-7; Sakaba T, 2003, J NEUROSCI, V23, P837; Sara Y, 2002, J NEUROSCI, V22, P1608, DOI 10.1523/JNEUROSCI.22-05-01608.2002; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Smith SM, 2004, NEURON, V41, P243, DOI 10.1016/S0896-6273(03)00837-7; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; Stevens CF, 1999, NEURON, V24, P1017, DOI 10.1016/S0896-6273(00)81047-8; Stevens CF, 1998, NEURON, V21, P415, DOI 10.1016/S0896-6273(00)80550-4; Suzuki K, 2002, J PHYSIOL-LONDON, V538, P103, DOI 10.1113/jphysiol.2001.012901; Troyer KP, 2002, J BIOL CHEM, V277, P29101, DOI 10.1074/jbc.M202856200; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; WHITTAKER VP, 1993, J NEUROCYTOL, V22, P735, DOI 10.1007/BF01181319; WILKINSON RJ, 1989, NEUROCHEM INT, V15, P191, DOI 10.1016/0197-0186(89)90100-9; Wu XS, 2001, J NEUROSCI, V21, P7928, DOI 10.1523/JNEUROSCI.21-20-07928.2001; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	57	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37278	37288		10.1074/jbc.M504137200	http://dx.doi.org/10.1074/jbc.M504137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16148008	hybrid			2022-12-25	WOS:000232901800086
J	Hiriart, E; Gruffat, H; Buisson, M; Mikaelian, I; Keppler, S; Meresse, P; Mercher, T; Bernard, OA; Sergeant, A; Manet, E				Hiriart, E; Gruffat, H; Buisson, M; Mikaelian, I; Keppler, S; Meresse, P; Mercher, T; Bernard, OA; Sergeant, A; Manet, E			Interaction of the Epstein-Barr virus mRNA export factor EB2 with human spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links spen proteins with splicing regulation and mRNA export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; IN-VIVO; SIGNALING PATHWAY; BINDING-PROTEIN; GENE-EXPRESSION; SPLIT-ENDS; SM PROTEIN; J-KAPPA; TRANSCRIPTION; RECEPTOR	The Epstein-Barr virus early protein EB2 ( also called BMLF1, Mta, or SM), a protein absolutely required for the production of infectious virions, shares properties with mRNA export factors. By using a yeast two-hybrid screen, we have identified the human protein OTT3 as an EB2-interacting factor. OTT3 is a new member of the Spen ( split end) family of proteins (huSHARP, huOTT1, DmSpen, and muMINT), which are characterized by several N-terminal RNA recognition motifs and a highly conserved C-terminal SPOC ( Spen Paralog and Ortholog C-terminal) domain that, in the case of SHARP, has been shown to interact with SMRT/NCoR co-repressors. OTT3 is ubiquitously expressed as a 120-kDa protein. Transfected OTT3 is a nonshuttling nuclear protein that co-localizes with co-transfected EB2. We also showed that EB2 interacts with the SPOC domains of both OTT1 and SHARP proteins. Although the OTT3 interaction domain maps within the 40 N-terminal amino acids of EB2, OTT1 and SHARP interact within the C-terminal half of the protein. Furthermore, we demonstrated that the capacity of the OTT3 and OTT1 SPOC domains to interact with SMRT and repress transcription is far weaker than that of SHARP. Thus there is no evidence for a role of OTT3 in transcriptional regulation. Most interestingly, however, we have found that OTT3 has a role in splicing regulation; OTT3 represses accumulation of the alternatively spliced beta-thalassemia mRNAs, but it has no effect on the beta-globin constitutively spliced mRNA. Thus our results suggested a new function for Spen proteins related to mRNA export and splicing.	Ecole Normale Super Lyon, INSERM, U412, IFR Biosci Lyon Gerland 128,Lab Virol Humaine, F-69364 Lyon, France; UJR Lab Virol Mol & Struct, CNRS, FRE 2854, F-38706 La Tronche, France; Hop Necker Enfants Malad, INSERM E0210, F-75743 Paris, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Manet, E (corresponding author), Ecole Normale Super Lyon, INSERM, U412, IFR Biosci Lyon Gerland 128,Lab Virol Humaine, 46 Allee Italie, F-69364 Lyon, France.	evelyne.manet@ens-lyon.fr	MANET, Evelyne/G-5644-2019; Mercher, Thomas/J-2446-2014; Bernard, Olivier A./E-5721-2016; Gruffat, Henri/I-2407-2016	MANET, Evelyne/0000-0001-7619-9982; Mercher, Thomas/0000-0003-1552-087X; Gruffat, Henri/0000-0002-4735-6894; Keppler, Selina Jessica/0000-0002-9010-8044; Bernard, Olivier/0000-0002-0463-9747				Ariyoshi M, 2003, GENE DEV, V17, P1909, DOI 10.1101/gad.266203; Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Boyle SM, 1999, J VIROL, V73, P6872, DOI 10.1128/JVI.73.8.6872-6881.1999; Buisson M, 1999, J VIROL, V73, P4090, DOI 10.1128/JVI.73.5.4090-4100.1999; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Farago M, 2003, MOL BIOL CELL, V14, P2744, DOI 10.1091/mbc.E02-11-0740; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; Gruffat H, 2002, J VIROL, V76, P9635, DOI 10.1128/JVI.76.19.9635-9644.2002; HIKADA M, 1988, EMBO J, V7, P519; Hiriart E, 2003, J BIOL CHEM, V278, P37790, DOI 10.1074/jbc.M305925200; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; Kuang B, 2000, DEVELOPMENT, V127, P1517; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lei EP, 2002, GENE DEV, V16, P2761, DOI 10.1101/gad.1032902; Lin HV, 2003, DEVELOPMENT, V130, P3125, DOI 10.1242/dev.00527; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Raijmakers R, 2004, EUR J CELL BIOL, V83, P175, DOI 10.1078/0171-9335-00385; Rebay I, 2000, GENETICS, V154, P695; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Ruvolo V, 2001, J VIROL, V75, P6033, DOI 10.1128/JVI.75.13.6033-6041.2001; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Semmes OJ, 1998, J VIROL, V72, P9526, DOI 10.1128/JVI.72.12.9526-9534.1998; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; Sokolowski M, 2003, J BIOL CHEM, V278, P33540, DOI 10.1074/jbc.M302063200; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200	55	58	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36935	36945		10.1074/jbc.M501725200	http://dx.doi.org/10.1074/jbc.M501725200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129689	Green Published, hybrid			2022-12-25	WOS:000232901800050
J	Muenster, U; Harrison, CA; Donaldson, C; Vale, W; Fischer, WH				Muenster, U; Harrison, CA; Donaldson, C; Vale, W; Fischer, WH			An activin-A/C chimera exhibits activin and myostatin antagonistic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTORS; BETA-C; BINDING; COMPLEX; CELLS; GROWTH; BMP-2; DIFFERENTIATION; BETA(C)-SUBUNIT; HETERODIMERS	Activins are involved in many physiological and pathological processes and, like other members of the transforming growth factor-beta superfamily, signal via type II and I receptor serine kinases. Ligand residues involved in type II receptor binding are located in the two anti-parallel beta strands of the TGF-beta proteins, also known as the fingers. Activin-A mutants able to bind ActRII but unable to bind the activin type I receptor ALK4 define ligand residues involved in ALK4 binding and could potentially act as antagonists. Therefore, a series of FLAG-tagged activin-A/C chimeras were constructed, in each of which eight residues in the wrist loop and helix region (A/C 46 - 53, 54 - 61, 62 - 69, and 70 - 78) were replaced. Additionally, a chimera was generated in which the entire wrist region ( A/ C 46 - 78) was changed from activin-A to activin-C. The chimeras were assessed for ActRII binding, activin bioactivity, as well as antagonistic properties. All five chimeras retained high affinity for mouse ActRII. Of these, only A/ C 46 - 78 was devoid of significant activin bioactivity in an A3 Lux reporter assay in 293T cells at concentrations up to 40 nM. A/C 46 - 53, 54 - 61, 62 - 69, and 70 - 78 showed activity comparable with wild type activin- A. When tested for the ability to antagonize ligands that signal via activin type II receptors, such as activin- A and myostatin, only the A/ C 46 - 78 chimera showed antagonism (IC50, 1 - 10 nM). Additionally, A/ C 46 - 78 decreased follicle-stimulating hormone release from the L beta T2 cell line and rat anterior pituitary cells in primary culture in a concentration-dependent manner. These data indicate that activin residues in the wrist are involved in ALK4-mediated signaling. The activin antagonist A/ C 46 - 78 may be useful for the study and modulation of activin- dependent processes.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Monash Med Ctr, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Salk Institute; Monash University; Prince Henry's Institute of Medical Research	Fischer, WH (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fischer@salk.edu		Harrison, Craig/0000-0003-1059-3682	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-13527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Attisano L, 1996, MOL CELL BIOL, V16, P1066; Butler CM, 2005, CYTOKINE GROWTH F R, V16, P377, DOI 10.1016/j.cytogfr.2005.04.005; Chabicovsky M, 2003, ENDOCRINOLOGY, V144, P3497, DOI 10.1210/en.2003-0388; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Fischer WH, 2003, J ENDOCRINOL, V176, P61, DOI 10.1677/joe.0.1760061; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Knaus P, 2001, BIOL CHEM, V382, P1189, DOI 10.1515/BC.2001.149; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lau AL, 2000, MOL CELL BIOL, V20, P6127, DOI 10.1128/MCB.20.16.6127-6137.2000; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mellor SL, 2000, J CLIN ENDOCR METAB, V85, P4851, DOI 10.1210/jc.85.12.4851; Mellor SL, 2003, ENDOCRINOLOGY, V144, P4410, DOI 10.1210/en.2003-0225; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Risbridger GP, 2001, ENDOCR REV, V22, P836, DOI 10.1210/er.22.6.836; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; VALE W, 1983, METHOD ENZYMOL, V103, P565; Vejda S, 2002, J MOL ENDOCRINOL, V28, P137, DOI 10.1677/jme.0.0280137; Vejda S, 2003, CARCINOGENESIS, V24, P1801, DOI 10.1093/carcin/bgg154; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; Wada W, 2004, AM J PHYSIOL-ENDOC M, V287, pE247, DOI 10.1152/ajpendo.00390.2003; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821	34	17	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36626	36632		10.1074/jbc.M507236200	http://dx.doi.org/10.1074/jbc.M507236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129674	hybrid			2022-12-25	WOS:000232901800013
J	Newcomb, DC; Sajjan, U; Nanua, S; Jia, Y; Goldsmith, AM; Bentley, JK; Hershenson, MB				Newcomb, DC; Sajjan, U; Nanua, S; Jia, Y; Goldsmith, AM; Bentley, JK; Hershenson, MB			Phosphatidylinositol 3-kinase is required for rhinovirusinduced airway epithelial cell interleukin-8 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; PHOSPHOINOSITIDE 3-KINASE; RESPIRATORY VIRUSES; ASTHMATIC SUBJECTS; IN-VIVO; INFLAMMATORY MARKERS; ACUTE EXACERBATIONS	Rhinovirus (RV) is a common cause of asthma exacerbations. The signaling mechanisms regulating RV-induced airway epithelial cell responses have not been well studied. We examined the role of phosphatidylinositol ( PI) 3-kinase in RV-induced interleukin (IL)-8 expression. Infection of 16HBE14o - human bronchial epithelial cells with RV39 induced rapid activation of PI 3-kinase and phosphorylation of Akt, a downstream effector of PI 3-kinase. RV39 also colocalized with cit-Akt-PH, a citrogen-tagged fluorescent fusion protein encoding the pleckstrin homology domain of Akt, indicating that 3-phosphorylated PI accumulates at the site of RV infection. Inhibition of PI 3-kinase and Akt attenuated RV39-induced NF-kappa B transactivation and IL-8 expression. Inhibition of PI 3-kinase also blocked internalization of labeled RV39 into 16HBE14o - cells, suggesting that the requirement of PI 3-kinase for RV39-induced IL-8 expression, at least in part, relates to its role in viral endocytosis.	Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Univ Michigan, Dept Pediat & Communicable Dis, 1150 W Med Ctr Dr,Rm 3570,MSRBII,Box 0688, Ann Arbor, MI 48109 USA.	mhershen@umich.edu		Bentley, John Kelley/0000-0001-8865-7979	NHLBI NIH HHS [HL56399, HL82550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399, R01HL082550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaron SD, 2001, AM J RESP CRIT CARE, V163, P349, DOI 10.1164/ajrccm.163.2.2003122; Baravalle G, 2004, J VIROL, V78, P2729, DOI 10.1128/JVI.78.6.2729-2737.2004; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Denning GM, 1998, INFECT IMMUN, V66, P5777, DOI 10.1128/IAI.66.12.5777-5784.1998; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Funkhouser AW, 2004, PEDIATR RES, V55, P13, DOI 10.1203/01.PDR.0000099801.06360.AB; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Gompertz S, 2001, EUR RESPIR J, V17, P1112, DOI 10.1183/09031936.01.99114901; Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Grunert HP, 1997, MED MICROBIOL IMMUN, V186, P1, DOI 10.1007/s004300050039; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Huber M, 2001, TRAFFIC, V2, P727, DOI 10.1034/j.1600-0854.2001.21007.x; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Li EG, 1998, J VIROL, V72, P2055, DOI 10.1128/JVI.72.3.2055-2061.1998; Li J, 2003, AM J PHYSIOL-LUNG C, V284, pL307, DOI 10.1152/ajplung.00086.2002; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Qiu YS, 2003, AM J RESP CRIT CARE, V168, P968, DOI 10.1164/rccm.200208-794OC; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Sajjan U, 2004, INFECT IMMUN, V72, P4188, DOI 10.1128/IAI.72.7.4188-4199.2004; Sanlioglu S, 2000, J VIROL, V74, P9184, DOI 10.1128/JVI.74.19.9184-9196.2000; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Suzuki T, 2001, AM J PHYSIOL-LUNG C, V280, pL1115, DOI 10.1152/ajplung.2001.280.6.L1115; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200; Vojtek AB, 2003, MOL CELL BIOL, V23, P4417, DOI 10.1128/MCB.23.13.4417-4427.2003; Wang Q, 2003, J BIOL CHEM, V278, P47731, DOI 10.1074/jbc.M308466200; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yamaya M, 1999, AM J PHYSIOL-LUNG C, V277, pL362, DOI 10.1152/ajplung.1999.277.2.L362; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	57	79	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36952	36961		10.1074/jbc.M502449200	http://dx.doi.org/10.1074/jbc.M502449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16120607	hybrid			2022-12-25	WOS:000232901800052
J	Hamelin, E; Theriault, C; Laroche, G; Parent, JL				Hamelin, E; Theriault, C; Laroche, G; Parent, JL			The intracellular trafficking of the G protein-coupled receptor TP beta depends on a direct interaction with Rab11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE A(2) RECEPTOR; ENDOCYTIC RECYCLING SIGNAL; HUMAN LUTROPIN RECEPTOR; MEMBRANE TRAFFICKING; MYOSIN VB; MEDIATED ENDOCYTOSIS; EFFECTOR PROTEIN; GTP-BINDING; GTPASES; IDENTIFICATION	Intracellular trafficking pathways of cell surface receptors following their internalization are the subject of intense research efforts. However, the mechanisms by which they recycle back to the cell surface are still poorly defined. We have recently demonstrated that the small Rab11 GTPase protein is a determinant factor in controlling the recycling to the cell surface of the beta-isoform of the thromboxane A(2) receptor (TP beta) following its internalization. Here, we demonstrate with co-immunoprecipitation studies in HEK293 cells that there is a Rab11-TP beta association occurring in the absence of agonist, which is not modulated by stimulation of TP beta. We show with purified TP beta intracellular domains fused to GST and HIS-Rab11 proteins that Rab11 interacts directly with the first intracellular loop and the C-tail of TP beta. Amino acids 335 - 344 of the TP beta C-tail were determined to be essential for the interaction of Rab11 with this receptor domain. This identified sequence appears to be important in directing the intracellular trafficking of the receptor from the Rab5-positive intracellular compartment to the perinuclear recycling endosome. Interestingly, our data indicate that TP beta interacts with the GDP-bound form, and not the GTP-bound form, of Rab11 which is necessary for recycling of the receptor back to the cell surface. To our knowledge, this is the first demonstration of a direct interaction between Rab11 and a transmembrane receptor.	Univ Sherbrooke, Fac Med, Serv Rhumatol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, CHUS, Ctr Rech Clin, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Parent, JL (corresponding author), Univ Sherbrooke, Fac Med, Serv Rhumatol, 3001 12E Ave Nord, Fleurimont, PQ J1H 5N4, Canada.	jean-luc.parent@USherbrooke.ca						Bartz R, 2003, BIOCHEM BIOPH RES CO, V312, P663, DOI 10.1016/j.bbrc.2003.10.172; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; Fan GH, 2004, MOL BIOL CELL, V15, P2456, DOI 10.1091/mbc.E03-09-0706; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; Fischer D, 1999, PROTEINS, P209; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; Galet C, 2004, MOL ENDOCRINOL, V18, P434, DOI 10.1210/me.2003-0293; Galet C, 2003, MOL ENDOCRINOL, V17, P411, DOI 10.1210/me.2002-0161; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Huang JS, 2004, CELL SIGNAL, V16, P521, DOI 10.1016/j.cellsig.2003.10.008; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KELLEY LA, 1999, RECOMB 99 P 3 ANN C, P218; Kinsella BT, 2001, BIOCHEM SOC T, V29, P641, DOI 10.1042/BST0290641; Kreuzer OJ, 2001, J NEUROENDOCRINOL, V13, P279, DOI 10.1046/j.1365-2826.2001.00630.x; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Miggin SM, 2002, MOL PHARMACOL, V61, P817, DOI 10.1124/mol.61.4.817; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; MORINELLI TA, 1991, ADV PROSTAG THROMB L, V21, P331; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; OGLETREE ML, 1987, FED PROC, V46, P133; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Prekeris Rytis, 2003, ScientificWorldJournal, V3, P870; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rochdi MD, 2004, J BIOL CHEM, V279, P18981, DOI 10.1074/jbc.M312621200; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Spurney RF, 2001, J PHARMACOL EXP THER, V296, P592; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Wallace DME, 2002, BIOCHEM BIOPH RES CO, V299, P770, DOI 10.1016/S0006-291X(02)02720-1; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; Ward ES, 2005, MOL BIOL CELL, V16, P2028, DOI 10.1091/mbc.E04-08-0735; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	62	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36195	36205		10.1074/jbc.M503438200	http://dx.doi.org/10.1074/jbc.M503438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126723	hybrid			2022-12-25	WOS:000232726900051
J	Asmis, R; Wang, YM; Xu, L; Kisgati, M; Begley, JG; Mieyal, JJ				Asmis, R; Wang, YM; Xu, L; Kisgati, M; Begley, JG; Mieyal, JJ			A novel thiol oxidation-based mechanism for adriamycin-induced cell injury in human macrophages	FASEB JOURNAL			English	Article						cell death; oxidative stress; glutathione; glutathione reductase; glutaredoxin	MONOCYTE-DERIVED MACROPHAGES; LOW-DENSITY-LIPOPROTEIN; GLUTATHIONE-REDUCTASE; S-GLUTATHIONYLATION; ANTICANCER AGENTS; CARDIAC TOXICITY; REDOX; INHIBITION; MOUSE; ACID	Adriamycin is a widely used antitumor antibiotic, but its use has been limited by its cytotoxicity in both cardiomyocytes and non-cardiac tissues. While adriamycin's ability to redox cycle via one-electron transfer reactions and generate ROS is thought to promote cardiotoxicity, the mechanisms involved in non-cardiac tissue injury are not clear. Here we show that prolonged exposure ( 48 h) of human monocyte-derived macrophages to adriamycin at concentrations as low as 1 mu M promotes caspase-independent cell death. Treatment of cells with scavengers of superoxide and peroxyl radicals blocked adriamycin-induced oxidation of dichlorodihydrofluorescein ( DCFH) but did not prevent macrophage injury. Macrophages treated with either adriamycin or the thiol oxidant diamide showed elevated levels of glutathione disulfide and increased protein-S-glutathionylation prior to cell injury, indicating that thiol oxidation is involved in adriamycin-induced macrophage death. Furthermore, inhibition of glutathione reductase (GR) with 1,3-bis[2-chloroethyl]-1-nitrosourea or transfection of macrophages with small inhibitory RNA ( siRNA) directed against GR or glutaredoxin (Grx) potentiated adriamycin-induced macrophage injury. Thus, both GR and Grx appear to play a crucial role in protecting macrophages from adriamycin-induced cell injury. These findings suggest a new mechanism for adriamycin-induced tissue injury whereby thiol oxidation, rather than one-electron redox cycling and ROS generation, mediates adriamycin-induced cell damage.	Univ Kentucky, Div Cardiovasc Med, Lexington, KY 40506 USA; Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40506 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	University of Kentucky; University of Kentucky; Case Western Reserve University	Asmis, R (corresponding author), Univ Texas, Hlth Sci Ctr, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	asmis@uthscsa.edu			NHLBI NIH HHS [HL-70963] Funding Source: Medline; NIA NIH HHS [2 PO1 AG-15885, 1 R01 AG-024413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885, R01AG024413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asmis R, 1998, EUR J BIOCHEM, V255, P147, DOI 10.1046/j.1432-1327.1998.2550147.x; Asmis R, 2003, CIRC RES, V92, pE20, DOI 10.1161/01.RES.0000051886.43510.90; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BEELEN RHJ, 1989, HUMAN MONOCYTES, P7; Birtle AJ, 2000, CLIN ONCOL-UK, V12, P146, DOI 10.1053/clon.2000.9141; BLAND KI, 1984, ANN SURG, V199, P782, DOI 10.1097/00000658-198406000-00017; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; Chaudiere J, 1999, FOOD CHEM TOXICOL, V37, P949, DOI 10.1016/S0278-6915(99)00090-3; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CROMACK DT, 1990, J TRAUMA, V30, pS129; DENEKE SM, 1989, AM J PHYSIOL, V257, P163; DEVEREUX DF, 1979, CANCER, V43, P932, DOI 10.1002/1097-0142(197903)43:3<932::AID-CNCR2820430322>3.0.CO;2-A; DiPietro LA, 1998, J CLIN INVEST, V101, P1693, DOI 10.1172/JCI1020; DIPIETRO LA, 1995, SHOCK, V4, P233, DOI 10.1097/00024382-199510000-00001; DOROSHOW JH, 1981, J CLIN INVEST, V68, P1053, DOI 10.1172/JCI110328; EHRKE MJ, 1989, SEMIN ONCOL, V16, P230; Fernberg JO, 2001, MED ONCOL, V18, P231, DOI 10.1385/mo:18:3:231; FINLEY KT, 1974, CHEM QUINOID COMPO 2, P878; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; Garner AP, 1999, CANCER RES, V59, P1929; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Groves R W, 2000, Adv Skin Wound Care, V13, P107; HARRISON LE, 1995, J SURG RES, V58, P646; Horenstein MS, 2000, MOL GENET METAB, V71, P436, DOI 10.1006/mgme.2000.3043; Jung K, 2001, ADV DRUG DELIVER REV, V49, P87, DOI 10.1016/S0169-409X(01)00128-4; Kang YJ, 2002, CHEM RES TOXICOL, V15, P1, DOI 10.1021/tx015532n; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Lothstein L, 2001, DRUG RESIST UPDATE, V4, P169, DOI 10.1054/drup.2001.0201; Low QEH, 2001, AM J PATHOL, V159, P457, DOI 10.1016/S0002-9440(10)61717-8; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Miura T, 2000, BIOCHEM PHARMACOL, V60, P95, DOI 10.1016/S0006-2952(00)00303-8; Morrissette Naomi, 1999, Trends in Cell Biology, V9, P199, DOI 10.1016/S0962-8924(99)01540-8; PARONI R, 1995, CLIN CHEM, V41, P448; POWELL SR, 1995, FREE RADICAL BIO MED, V18, P159, DOI 10.1016/0891-5849(94)00109-W; REID VC, 1993, ATHEROSCLEROSIS, V98, P17, DOI 10.1016/0021-9150(93)90219-K; Reszka KJ, 2001, BIOCHEMISTRY-US, V40, P15349, DOI 10.1021/bi011869c; Savvides SN, 2002, J BIOL CHEM, V277, P2779, DOI 10.1074/jbc.M108190200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; Ueda-Kawamitsu H, 2002, BIOCHEM PHARMACOL, V63, P1209, DOI 10.1016/S0006-2952(02)00878-X; UNTUCHTGRAU R, 1981, EUR J BIOCHEM, V120, P407, DOI 10.1111/j.1432-1033.1981.tb05718.x; VILE G, 1990, BIOCHEM PHARMACOL, V39, P769, DOI 10.1016/0006-2952(90)90157-G; WELLS WW, 1995, FREE RADICAL BIO MED, V18, P699, DOI 10.1016/0891-5849(94)00188-P; Wintergerst ES, 1998, HISTOCHEM CELL BIOL, V110, P231, DOI 10.1007/s004180050285; Wu LC, 1997, J SURG RES, V72, P162, DOI 10.1006/jsre.1997.5178; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; Yin XH, 1998, BIOCHEM PHARMACOL, V56, P87, DOI 10.1016/S0006-2952(98)00099-9	50	31	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1866	+		10.1096/fj.04-2991fje	http://dx.doi.org/10.1096/fj.04-2991fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16160061				2022-12-25	WOS:000232315700015
J	Lanone, S; Bloc, S; Foresti, R; Almolki, A; Taille, C; Callebert, J; Conti, M; Goven, D; Aubier, M; Dureuil, B; El-Benna, J; Motterlini, R; Boczkowski, J				Lanone, S; Bloc, S; Foresti, R; Almolki, A; Taille, C; Callebert, J; Conti, M; Goven, D; Aubier, M; Dureuil, B; El-Benna, J; Motterlini, R; Boczkowski, J			Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats	FASEB JOURNAL			English	Article						oxygen free radicals; nitric oxide	HEME OXYGENASE-1; SERUM BILIRUBIN; SYNTHASE EXPRESSION; OXIDATIVE STRESS; IN-VIVO; ANTIOXIDANT; SUPEROXIDE; BILIVERDIN; ACTIVATION; INDUCTION	We investigated a possible beneficial role for bilirubin, one of the products of heme degradation by the cytoprotective enzyme heme oxygenase-1 in counteracting Escherichia coli endotoxin-mediated toxicity. Homozygous jaundice Gunn rats, which display high plasma bilirubin levels due to deficiency of glucuronyl transferase activity, and Sprague-Dawley rats subjected to sustained exogenous bilirubin administration were more resistant to endotoxin (LPS)-induced hypotension and death compared with nonhyperbilirubinemic rats. LPS-stimulated production of nitric oxide ( NO) was significantly decreased in hyperbilirubinemic rats compared with normal animals; this effect was associated with reduction of inducible NO synthase (NOS2) expression in renal, myocardial, and aortic tissues. Furthermore, NOS2 protein expression and activity were reduced in murine macrophages stimulated with LPS and preincubated with bilirubin at concentrations similar to that found in the serum of hyperbilirubinemic animals. This effect was secondary to inhibition of NAD(P)H oxidase since 1) inhibition of NAD(P) H oxidase attenuated NOS2 induction by LPS, 2) bilirubin decreased NAD(P) H oxidase activity in vivo and in vitro, and 3) down-regulation of NOS2 by bilirubin was reversed by addition of NAD(P) H. These findings indicate that bilirubin can act as an effective agent to reduce mortality and counteract hypotension elicited by endotoxin through mechanisms involving a decreased NOS2 induction secondary to inhibition of NAD(P)H oxidase.	INSERM, U700, Fac 10, F-75870 Paris, France; Univ Paris 07, Fac Med Xavier Bichat, U683, Paris, France; Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow, Middx, England; Univ Paris 07, Hop Lariboisiere, Serv Biochim, Paris, France; Univ Paris 11, Hop Kremlin Bicetre, Serv Biochim, Paris, France; Hop Charles Nicole, Dept Anesthesie Reanimat, Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; CHU de Rouen	Boczkowski, J (corresponding author), INSERM, U700, Fac 10, Bichat BP416, F-75870 Paris, France.	jbb2@bichat.inserm.fr	Motterlini, Roberto/G-2489-2013; Boczkowski, Jorge/S-7474-2018; Motterlini, Roberto/Q-1890-2019; Lanone, Sophie/I-4042-2016; Taille, Camille/J-3751-2017; callebert, jacques/L-4569-2017	Motterlini, Roberto/0000-0003-2684-2612; Boczkowski, Jorge/0000-0001-6619-5785; Motterlini, Roberto/0000-0003-2684-2612; Lanone, Sophie/0000-0003-2509-8799; foresti, roberta/0000-0002-0836-7937				Adin CA, 2005, AM J PHYSIOL-RENAL, V288, pF778, DOI 10.1152/ajprenal.00215.2004; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BENARON DA, 1991, LANCET, V338, P78, DOI 10.1016/0140-6736(91)90074-Y; Boczkowski J, 1996, J CLIN INVEST, V98, P1550, DOI 10.1172/JCI118948; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Chen CC, 1999, MOL PHARMACOL, V55, P481; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; CONTI M, 1991, CLIN CHEM, V37, P1273; DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S; Dore S, 1999, ANN NY ACAD SCI, V890, P167, DOI 10.1111/j.1749-6632.1999.tb07991.x; Elzi DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC350; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Giovannoni G, 1997, ANN CLIN BIOCHEM, V34, P193, DOI 10.1177/000456329703400212; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; Kato Y, 2003, HEPATOLOGY, V38, P364, DOI 10.1053/jhep.2003.50300; Kaur H, 2003, FEBS LETT, V543, P113, DOI 10.1016/S0014-5793(03)00420-4; Knowles RG, 1998, METH MOL B, V100, P67; Kranc KR, 2000, EUR J BIOCHEM, V267, P7094, DOI 10.1046/j.1432-1327.2000.01812.x; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Macarthur H, 2000, P NATL ACAD SCI USA, V97, P9753, DOI 10.1073/pnas.97.17.9753; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; O'Brien A, 2001, AM J RESP CRIT CARE, V164, P365, DOI 10.1164/ajrccm.164.3.2002052; O'Dowd Y, 2004, BIOCHEM PHARMACOL, V68, P2003, DOI 10.1016/j.bcp.2004.06.023; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Piao YJ, 2005, FREE RADICAL BIO MED, V38, P989, DOI 10.1016/j.freeradbiomed.2004.11.011; Polytarchou C, 2004, FREE RADICAL RES, V38, P501, DOI 10.1080/10715760410001684621; Ritter C, 2004, CRIT CARE MED, V32, P342, DOI 10.1097/01.CCM.0000109454.13145.CA; Samb A, 2002, AM J PHYSIOL-LUNG C, V283, pL596, DOI 10.1152/ajplung.00446.2001; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; TANAKA Y, 1992, NEUROSURGERY, V30, P195, DOI 10.1227/00006123-199202000-00008; Temme EHM, 2001, CANCER CAUSE CONTROL, V12, P887, DOI 10.1023/A:1013794407325; Wang WZW, 2004, HEPATOLOGY, V40, P424, DOI 10.1002/hep.20334; YAMAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V214, P11, DOI 10.1006/bbrc.1995.2250; Zhou J, 1999, PHARMACOL RES, V39, P363, DOI 10.1006/phrs.1998.0450	44	206	211	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1890	+		10.1096/fj.04-2368fje	http://dx.doi.org/10.1096/fj.04-2368fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129699				2022-12-25	WOS:000231843700004
J	Horvath, AJ; Irving, JA; Rossjohn, J; Law, RH; Bottomley, SP; Quinsey, NS; Pike, RN; Coughlin, PB; Whisstock, JC				Horvath, AJ; Irving, JA; Rossjohn, J; Law, RH; Bottomley, SP; Quinsey, NS; Pike, RN; Coughlin, PB; Whisstock, JC			The murine orthologue of human antichymotrypsin - A structural paradigm for CLADE A3 serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTICHYMOTRYPSIN; PROTEASE INHIBITOR; REACTIVE LOOP; DNA-BINDING; CATHEPSIN-G; ALPHA(1)-ANTICHYMOTRYPSIN; IDENTIFICATION; ANTITHROMBIN; ASSOCIATION; MECHANISM	Antichymotrypsin (SERPINA3) is a widely expressed member of the serpin superfamily, required for the regulation of leukocyte proteases released during an inflammatory response and with a permissive role in the development of amyloid encephalopathy. Despite its biological significance, there is at present no available structure of this serpin in its native, inhibitory state. We present here the first fully refined structure of a murine antichymotrypsin orthologue to 2.1 angstrom, which we propose as a template for other antichymotrypsin-like serpins. A most unexpected feature of the structure of murine serpina3n is that it reveals the reactive center loop (RCL) to be partially inserted into the A beta-sheet, a structural motif associated with ligand-dependent activation in other serpins. The RCL is, in addition, stabilized by salt bridges, and its plane is oriented at 90 to the RCL of antitrypsin. A biochemical and biophysical analysis of this serpin demonstrates that it is a fast and efficient inhibitor of human leukocyte elastase (k(a):4 +/- 0.9 x 10(6) M-1 s(-1)) and cathepsin G (ka: 7.9 +/- 0.9 x 10(5) M-1 s(-1)) giving a spectrum of activity intermediate between that of human antichymotrypsin and human antitrypsin. An evolutionary analysis reveals that residues subject to positive selection and that have contributed to the diversity of sequences in this sub-branch (A3) of the serpin superfamily are essentially restricted to the P-4 - P-6' region of the RCL, the distal hinge, and the loop between strands 4B and 5B.	Monash Univ, Australian Ctr Blood Dis, Alfred Med Res Precinct, Prahran, Vic 3181, Australia; Monash Univ, Prot Crystallog Unit, Monash Ctr Synchrotron Sci, Clayton, Vic 3800, Australia; Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Clayton, Vic 3800, Australia; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Monash Univ, Australian Res Council Ctr Struct & Funct Microbi, Clayton, Vic 3800, Australia	Monash University; Monash University; Monash University; Monash University; Monash University	Coughlin, PB (corresponding author), Monash Univ, Australian Ctr Blood Dis, Alfred Med Res Precinct, Commercial Rd,6th Floor,Macfarlane Burnet Bldg, Prahran, Vic 3181, Australia.	Paul.Coughlin@med.monash.edu.au; James.Whisstock@med.monash.edu.au	Irving, James/P-3860-2019; Irving, James A/I-8467-2015; Rossjohn, Jamie/F-9032-2013	Irving, James/0000-0003-3204-6356; Rossjohn, Jamie/0000-0002-2020-7522; law, ruby/0000-0001-5432-5781; Whisstock, James/0000-0003-4200-5611; Pike, Robert/0000-0002-2083-0269	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham CR, 2001, NEUROBIOL AGING, V22, P931, DOI 10.1016/S0197-4580(01)00302-5; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Adachi J., 1996, MOLPHY PROGRAMS MOL; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbour KW, 2002, GENOMICS, V80, P515, DOI [10.1016/S0888-7543(02)96864-3, 10.1006/geno.2002.6864]; Barbour KW, 2002, MOL BIOL EVOL, V19, P718, DOI 10.1093/oxfordjournals.molbev.a004130; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEATTY K, 1980, J BIOL CHEM, V255, P3931; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaillan-Huntington CE, 1998, J BIOL CHEM, V273, P4569, DOI 10.1074/jbc.273.8.4569; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; Chang WSW, 1997, PROTEIN SCI, V6, P89; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; DICKSON I, 1974, CLIN CHIM ACTA, V54, P381, DOI 10.1016/0009-8981(74)90257-5; Dunstone MA, 2000, PROTEIN SCI, V9, P417; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FABER JP, 1993, J HEPATOL, V18, P313, DOI 10.1016/S0168-8278(05)80275-2; Forsyth S, 2003, GENOMICS, V81, P336, DOI 10.1016/S0888-7543(02)00041-1; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Horvath AJ, 2004, J MOL EVOL, V59, P488, DOI 10.1007/s00239-004-2640-9; Hwang SR, 1999, J BIOL CHEM, V274, P1821, DOI 10.1074/jbc.274.3.1821; INGLIS JD, 1991, EMBO J, V10, P255, DOI 10.1002/j.1460-2075.1991.tb07945.x; Irving JA, 2004, METHODS, V32, P73, DOI 10.1016/S1046-2023(03)00200-7; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kaiserman D, 2002, GENOMICS, V79, P349, DOI 10.1006/geno.2002.6716; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LOMAS DA, 1995, J BIOL CHEM, V270, P23437, DOI 10.1074/jbc.270.40.23437; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen R, 1998, GENETICS, V148, P929; O'Keeffe D, 2004, J BIOL CHEM, V279, P50267, DOI 10.1074/jbc.M408774200; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plotnick MI, 1997, BIOCHEMISTRY-US, V36, P14601, DOI 10.1021/bi971530j; POLLER W, 1993, GENOMICS, V17, P740, DOI 10.1006/geno.1993.1396; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SIDDIQUI AA, 1980, BIOCHEM BIOPH RES CO, V95, P1737, DOI 10.1016/S0006-291X(80)80099-4; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Yamada M, 1998, ANN NEUROL, V44, P129, DOI 10.1002/ana.410440120; Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957	67	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43168	43178		10.1074/jbc.M505598200	http://dx.doi.org/10.1074/jbc.M505598200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16141197	hybrid			2022-12-25	WOS:000234200800083
J	Ulmer, TS; Bax, A				Ulmer, TS; Bax, A			Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE DETERMINATION; MOLECULAR FRAGMENT REPLACEMENT; RESIDUAL DIPOLAR COUPLINGS; MODEL-FREE APPROACH; BIOLOGICAL MACROMOLECULES; SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; BACKBONE DYNAMICS; GLOBULAR-PROTEINS; FIBRIL FORMATION	Three point mutations (A30P, E46K, and A53T) as well as gene triplication genetically link the 140-residue protein alpha-synuclein (aS) to the development of Parkinson disease. Here, the structure and dynamics of micelle-bound aS( A30P) and aS( A53T) are described and compared with wild-type aS, in addition to describing the aS-micelle interaction. A53T is sensed only by directly adjacent residues and leaves the backbone structure and dynamics indistinguishable from the wild type. A30P interrupts one helix turn (Val(26)-Ala(29)) and destabilizes the preceding one. A shift in helix register following A30P disturbs the canonical succession of polar and hydrophobic residues for at least two turns. The shortened helix-N adopts a slightly higher helical content and is less bent, indicating that strain was present in the micelle-bound helix. In the vicinity of the A30P-induced perturbations, the underlying micelle environment has rearranged, but nevertheless all aS variants maintain similar interrelationships with the micelle. Moreover, aS-micelle immersion correlates well with fast and slow aS backbone dynamics, allowing a rare insight into protein-micelle interplay.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bax, A (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Room B1-31,5 Mem Dr, Bethesda, MD 20892 USA.	tulmer@usc.edu; bax@nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029020] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Anderson CAF, 2002, STRUCTURE, V10, P175, DOI 10.1016/S0969-2126(02)00700-1; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bisaglia M, 2005, BIOCHEMISTRY-US, V44, P329, DOI 10.1021/bi048448q; Bouvignies G, 2005, J MAGN RESON, V173, P328, DOI 10.1016/j.jmr.2005.01.001; BRITO RMM, 1986, ANAL BIOCHEM, V152, P250, DOI 10.1016/0003-2697(86)90406-9; Bussell R, 2005, PROTEIN SCI, V14, P862, DOI 10.1110/ps.041255905; Bussell R, 2004, BIOCHEMISTRY-US, V43, P4810, DOI 10.1021/bi036135+; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Cole NB, 2005, J BIOL CHEM, V280, P9678, DOI 10.1074/jbc.M409946200; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; Cornilescu G, 2000, J AM CHEM SOC, V122, P10143, DOI 10.1021/ja0016194; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Delaglio F, 2000, J AM CHEM SOC, V122, P2142, DOI 10.1021/ja993603n; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deschamps M, 2005, J MAGN RESON, V172, P118, DOI 10.1016/j.jmr.2004.09.023; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Garg G, 2005, J PHYS CHEM B, V109, P1340, DOI 10.1021/jp0472663; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jaroniec CP, 2004, J BIOMOL NMR, V30, P181, DOI 10.1023/B:JNMR.0000048946.71249.2f; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Karplus PA, 1996, PROTEIN SCI, V5, P1406, DOI 10.1002/pro.5560050719; Kontaxis G, 2005, METHOD ENZYMOL, V394, P42, DOI 10.1016/S0076-6879(05)94003-2; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kumar S, 1998, BIOPHYS J, V75, P1935, DOI 10.1016/S0006-3495(98)77634-9; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Meiler J, 2001, J AM CHEM SOC, V123, P6098, DOI 10.1021/ja010002z; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Montserret R, 2000, BIOCHEMISTRY-US, V39, P8362, DOI 10.1021/bi000208x; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Norris EH, 2004, CURR TOP DEV BIOL, V60, P17; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prieto J, 1997, J MOL BIOL, V274, P276, DOI 10.1006/jmbi.1997.1322; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Sambrook J, 2001, MOL CLONING LAB MANU; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y; Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Ulmer TS, 2004, J MAGN RESON, V166, P190, DOI 10.1016/j.jmr.2003.10.012; Ulmer TS, 2003, J AM CHEM SOC, V125, P9179, DOI 10.1021/ja0350684; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022	78	127	134	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					43179	43187		10.1074/jbc.M507624200	http://dx.doi.org/10.1074/jbc.M507624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16166095	hybrid			2022-12-25	WOS:000234200800084
J	de Parseval, A; Bobardt, MD; Chatterji, A; Chatterji, U; Elder, JH; David, G; Zolla-Pazner, S; Farzan, M; Lee, TH; Gallay, PA				de Parseval, A; Bobardt, MD; Chatterji, A; Chatterji, U; Elder, JH; David, G; Zolla-Pazner, S; Farzan, M; Lee, TH; Gallay, PA			A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; CELL-SURFACE HEPARANS; ENVELOPE GLYCOPROTEIN; GLYCOSAMINOGLYCAN BINDING; PRIMARY LYMPHOCYTES; PRIMARY MACROPHAGES; TYROSINE SULFATION; TYPE-1 ATTACHMENT; IN-VIVO	HIV-1 has maximized its utilization of syndecans. It uses them as in cis receptors to infect macrophages and as in trans receptors to infect T-lymphocytes. In this study, we investigated at a molecular level the mechanisms that control HIV-1-syndecan interactions. We found that a single conserved arginine (Arg-298) in the V3 region of gp120 governs HIV-1 binding to syndecans. We found that an amine group on the side chain of this residue is necessary for syndecan utilization by HIV-1. Furthermore, we showed that HIV-1 binds syndecans via a 6-O sulfation, demonstrating that this binding is not the result of random interactions between basic residues and negative charges, but the result of specific contacts between gp120 and a well defined sulfation in syndecans. Surprisingly, we found that Arg-298, which mediates HIV-1 binding to syndecans, also mediates HIV-1 binding to CCR5. We postulated that HIV-1 recognizes similar motifs on syndecans and CCR5. Supporting this hypothesis, we obtained several lines of evidence that suggest that the 6-O sulfation recognized by HIV-1 on syndecans mimics the sulfated tyrosines recognized by HIV-1 in the N terminus of CCR5. Our finding that CCR5 and syndecans are exploited by HIV-1 via a single determinant echoes the mechanisms by which chemokines utilize these two disparate receptors and suggests that the gp120/ chemokine mimicry may represent a common strategy in microbial pathogenesis.	Scripps Res Inst, Dept Immunol IMM 9, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; NYU, Sch Med, Dept Pathol, Inst Environm Med, New York, NY 10016 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Scripps Research Institute; Scripps Research Institute; KU Leuven; New York University; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Gallay, PA (corresponding author), Scripps Res Inst, Dept Immunol IMM 9, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gallay@scripps.edu	Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666; Farzan, Michael/0000-0002-2990-5319	NIAID NIH HHS [AI054196] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054196] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI SA, 1995, BIOTECHNIQUES, V18, P746; Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003; Blanpain C, 2002, RECEPTOR CHANNEL, V8, P19, DOI 10.1080/10606820212135; Bobardt MD, 2004, VIROLOGY, V325, P389, DOI 10.1016/j.virol.2004.05.011; Bobardt MD, 2004, J VIROL, V78, P6567, DOI 10.1128/JVI.78.12.6567-6584.2004; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Cao J, 1997, J VIROL, V71, P9808, DOI 10.1128/JVI.71.12.9808-9812.1997; Cavacini L, 2003, AIDS, V17, P685, DOI 10.1097/00002030-200303280-00006; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; de Parseval A, 2001, J VIROL, V75, P4528, DOI 10.1128/JVI.75.10.4528-4539.2001; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P40397, DOI 10.1074/jbc.M206784200; GORNY MK, 1993, J IMMUNOL, V150, P635; GORNY MK, 1991, P NATL ACAD SCI USA, V88, P3238, DOI 10.1073/pnas.88.8.3238; Hamon M, 2004, GLYCOBIOLOGY, V14, P311, DOI 10.1093/glycob/cwh038; Ibrahim J, 1999, VIRUS RES, V60, P159, DOI 10.1016/S0168-1702(99)00018-0; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moulard M, 2002, P NATL ACAD SCI USA, V99, P6913, DOI 10.1073/pnas.102562599; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; Pesenti E, 1999, AIDS RES HUM RETROV, V15, P983, DOI 10.1089/088922299310494; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Proost Paul, 1996, Methods (Orlando), V10, P82, DOI 10.1006/meth.1996.0082; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Sharon M, 2003, STRUCTURE, V11, P225, DOI 10.1016/S0969-2126(03)00011-X; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Slimani H, 2003, BBA-BIOMEMBRANES, V1617, P80, DOI 10.1016/j.bbamem.2003.09.006; Slimani H, 2003, GLYCOBIOLOGY, V13, P623, DOI 10.1093/glycob/cwg083; Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Wang WK, 1998, P NATL ACAD SCI USA, V95, P5740, DOI 10.1073/pnas.95.10.5740; WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yarovinsky F, 2004, J BIOL CHEM, V279, P53635, DOI 10.1074/jbc.M410550200; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002; Zhou J, 2001, J VIROL, V75, P5851, DOI 10.1128/JVI.75.13.5851-5859.2001	54	67	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39493	39504		10.1074/jbc.M504233200	http://dx.doi.org/10.1074/jbc.M504233200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16157597	hybrid			2022-12-25	WOS:000233362200071
J	Vesce, S; Jekabsons, MB; Johnson-Cadwell, LI; Nicholls, DG				Vesce, S; Jekabsons, MB; Johnson-Cadwell, LI; Nicholls, DG			Acute glutathione depletion restricts mitochondrial ATP export in cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; PLASMA-MEMBRANE DEPOLARIZATION; ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOCHROME-C RELEASE; PARKINSONS-DISEASE; OXIDATIVE STRESS; CELL-DEATH; GLUTAMATE EXCITOTOXICITY; CALCIUM DEREGULATION; TRANSPORT ACTIVITY	Decreases in GSH pools detected during ischemia sensitize neurons to excitotoxic damage. Thermodynamic analysis predicts that partial GSH depletion will cause an oxidative shift in the thiol redox potential. To investigate the acute bioenergetic consequences, neurons were exposed to monochlorobimane (mBCl), which depletes GSH by forming a fluorescent conjugate. Neurons transfected with redox-sensitive green fluorescent protein showed a positive shift in thiol redox potential synchronous with the formation of the conjugate. Mitochondria within neurons treated with mBCl for 1 h failed to hyperpolarize upon addition of oligomycin to inhibit their ATP synthesis. A decreased ATP turnover was confirmed by monitoring neuronal oxygen consumption in parallel with mitochondrial membrane potential (Delta psi(m)) and GSH-mBCl formation. mBCl progressively decreased cell respiration, with no effect on mitochondrial proton leak or maximal respiratory capacity, suggesting adequate glycolysis and a functional electron transport chain. This approach to "state 4" could be mimicked by the adenine nucleotide translocator inhibitor bongkrekic acid, which did not further decrease respiration when administered after mBCl. The cellular ATP/ADP ratio was decreased by mBCl, and consistent with mitochondrial ATP export failure, respiration could not respond to an increased cytoplasmic ATP demand by plasma membrane Na+ cycling; instead, mitochondria depolarized. More prolonged mBCl exposure induced mitochondrial failure, with Delta psi(m) collapse followed by cytoplasmic Ca2+ deregulation. The initial bioenergetic consequence of neuronal GSH depletion in this model is thus an inhibition of ATP export, which precedes other forms of mitochondrial dysfunction.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Vesce, S (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	svesce@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041908] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS4-1908] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Anderson MF, 2004, NEUROSCI LETT, V354, P163, DOI 10.1016/j.neulet.2003.09.067; Anderson MF, 2002, J NEUROCHEM, V81, P541, DOI 10.1046/j.1471-4159.2002.00836.x; Armstrong JS, 2004, J BIOL CHEM, V279, P50420, DOI 10.1074/jbc.M408882200; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BARHOUMI R, 1995, CYTOMETRY, V19, P226, DOI 10.1002/cyto.990190306; Berman FW, 1999, J PHARMACOL EXP THER, V290, P439; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Canals S, 2001, J NEUROCHEM, V79, P1183, DOI 10.1046/j.1471-4159.2001.00635.x; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; Dalby B, 2004, METHODS, V33, P95, DOI 10.1016/j.ymeth.2003.11.023; Dooley CT, 2004, J BIOL CHEM, V279, P22284, DOI 10.1074/jbc.M312847200; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; HOEK JB, 1988, BIOCHEM J, V254, P1; Hsu M, 2005, J NEUROCHEM, V92, P1091, DOI 10.1111/j.1471-4159.2004.02929.x; Jekabsons MB, 2004, J BIOL CHEM, V279, P32989, DOI 10.1074/jbc.M401540200; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kamencic H, 2000, ANAL BIOCHEM, V286, P35, DOI 10.1006/abio.2000.4765; Keelan J, 2001, J NEUROSCI RES, V66, P873, DOI 10.1002/jnr.10085; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Klaidman LK, 2001, BBA-GEN SUBJECTS, V1525, P136, DOI 10.1016/S0304-4165(00)00181-1; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Koshkin V, 2004, J BIOL CHEM, V279, P41368, DOI 10.1074/jbc.M406914200; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; MAJIMA E, 1994, BIOCHEMISTRY-US, V33, P9530, DOI 10.1021/bi00198a019; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; MANUEL MA, 1976, J PHARMACOL EXP THER, V198, P209; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; Muyderman H, 2004, J NEUROSCI, V24, P8019, DOI 10.1523/JNEUROSCI.1103-04.2004; Nicholls D., 2002, BIOENERGETICS, V3; Nicholls DG, 2004, J BIOENERG BIOMEMBR, V36, P277, DOI 10.1023/B:JOBB.0000041753.52832.f3; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; Ostergaard H, 2004, J CELL BIOL, V166, P337, DOI 10.1083/jcb.200402120; Raza H, 2002, BIOCHEM J, V366, P45, DOI 10.1042/BJ20020533; Rego AC, 2001, J NEUROSCI, V21, P1893, DOI 10.1523/JNEUROSCI.21-06-01893.2001; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Sebastia J, 2003, CYTOM PART A, V51A, P16, DOI 10.1002/cyto.a.10003; Seyfried J, 1999, NEUROSCI LETT, V264, P1, DOI 10.1016/S0304-3940(99)00107-X; Stevenson D, 2002, TOXICOL IN VITRO, V16, P609, DOI 10.1016/S0887-2333(02)00042-5; Toninello A, 2004, FREE RADICAL BIO MED, V37, P1073, DOI 10.1016/j.freeradbiomed.2004.06.044; Vesce S, 2004, J NEUROCHEM, V90, P683, DOI 10.1111/j.1471-4159.2004.02516.x; Ward MW, 2000, J NEUROSCI, V20, P7208; Wullner U, 1999, BRAIN RES, V826, P53, DOI 10.1016/S0006-8993(99)01228-7	60	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38720	38728		10.1074/jbc.M506575200	http://dx.doi.org/10.1074/jbc.M506575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172117	hybrid			2022-12-25	WOS:000233239800074
J	Karamyshev, AL; Johnson, AE				Karamyshev, AL; Johnson, AE			Selective SecA association with signal sequences in ribosome-bound nascent chains - A potential role for SecA in ribosome targeting to the bacterial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PARTICLE BINDS; ESCHERICHIA-COLI; TRIGGER FACTOR; PROTEIN-TRANSLOCATION; PLASMA-MEMBRANE; ATPASE ACTIVITY; INNER MEMBRANE; ER MEMBRANE; INTEGRATION; PEPTIDE	The role of SecA in selecting bacterial proteins for export was examined using a heterologous system that lacks endogenous SecA and other bacterial proteins. This approach allowed us to assess the interaction of SecA with ribosome-bound photoreactive nascent chains in the absence of trigger factor, SecB, Ffh ( the bacterial protein component of the signal recognition particle), and the SecYEG translocon in the bacterial plasma membrane. In the absence of membranes, SecA photocross-linked efficiently to nascent translocation substrate OmpA in ribosome-nascent chain (RNC) complexes in an interaction that was independent of both ATP and SecB. However, no photocross-linking to a nascent membrane protein that is normally targeted by a signal recognition particle was observed. Modification of the signal sequence revealed that its affinity for SecA and Ffh varied inversely. Gel filtration showed that SecA binds tightly to both translating and non-translating ribosomes. When purified SecA center dot RNC complexes containing nascent OmpA were exposed to inner membrane vesicles lacking functional SecA, the nascent chains were successfully targeted to SecYEG translocons. However, purified RNCs lacking SecA were unable to target to the same membranes. Taken together, these data strongly suggest that cytosolic SecA participates in the selection of proteins for export by co-translationally binding to the signal sequences of non-membrane proteins and directing those nascent chains to the translocon.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Johnson, AE (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Dept Med Biochem & Genet, TAMU 1114,116 Reynolds Med Bldg, College Stn, TX 77843 USA.	ajohnson@medicine.tamhsc.edu	Johnson, Arthur E/G-3457-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1986, EUR J BIOCHEM, V159, P263, DOI 10.1111/j.1432-1033.1986.tb09862.x; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; Chou YT, 2005, J BIOL CHEM, V280, P32753, DOI 10.1074/jbc.M507532200; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; Kebir MO, 2002, BIOCHEMISTRY-US, V41, P5573, DOI 10.1021/bi015798t; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Peluso P, 2001, BIOCHEMISTRY-US, V40, P15224, DOI 10.1021/bi011639y; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; Randall LL, 2005, J MOL BIOL, V348, P479, DOI 10.1016/j.jmb.2005.02.036; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; TAI PC, 1991, METHOD CELL BIOL, V34, P167; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	57	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37930	37940		10.1074/jbc.M509100200	http://dx.doi.org/10.1074/jbc.M509100200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16120599	hybrid			2022-12-25	WOS:000233044500075
J	Kim, IM; Zhou, Y; Ramakrishna, S; Hughes, DE; Solway, J; Costa, RH; Kalinichenko, VV				Kim, IM; Zhou, Y; Ramakrishna, S; Hughes, DE; Solway, J; Costa, RH; Kalinichenko, VV			Functional characterization of evolutionarily conserved DNA regions in Forkhead Box f1 gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINGED HELIX PROTEINS; NUCLEAR FACTOR 3-BETA; TRANSCRIPTION FACTOR; PULMONARY VASCULATURE; EMBRYONIC-DEVELOPMENT; LIVER-REGENERATION; SONIC HEDGEHOG; MOUSE EMBRYOS; EXPRESSION; LUNG	The Forkhead Box f1 (Foxf1) transcription factor ( previously known as HFH-8 or Freac-1) is expressed in the septum transversum and splanchnic ( visceral) mesoderm and is required for proper development of gut-derived organs. Sequence comparisons of mouse and human Foxf1 genes have revealed highly conserved DNA sequences located within the -5.3-kb Foxf1 promoter region and the 400-nucleotide regulatory element located 1 kb 3' to the Foxf1 gene (3'RE). To examine their transcriptional activity during mouse embryonic development, we generated transgenic mice in which the expression of the beta-galactosidase transgene was controlled by the - 2.7- kb Foxf1 promoter region, the - 5.3-kb Foxf1 promoter region, or the - 5.3-kb Foxf1 promoter region fused to the 3' RE. The - 5.3-kb Foxf1 promoter sequences induced appropriate transgene expression in the midgut and developing intestine, whereas the - 2.7-kb Foxf1 promoter region was transcriptionally inactive. Addition of 3' RE to the - 5.3-kb Foxf1 promoter restored proper transgene expression in the foregut, liver, and lung mesenchyme and prevented ectopic transgene expression in the developing nervous system. Cotransfection studies demonstrated that FoxA2 protein bound to the 3' RE region (+ 4506/+4529 bp) and was sufficient to inhibit expression of the -5.3-kb Foxf1 promoter. Furthermore, C/EBP beta and HNF-6 proteins bound to the 3' RE region (+ 4647/ + 4694 bp) and provided synergistic transcriptional activation of the - 5.3-kb Foxf1 promoter in cotransfection assays. These studies demonstrated that the conserved Foxf1 3' RE region is essential for proper tissue-specific regulation of the Foxf1 promoter region during mouse embryogenesis.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalinichenko, VV (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.	vkalin@medicine.bsd.uchicago.edu	Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530; Kim, Il-man/0000-0002-9268-8337; Ramakrishna, Sneha/0000-0001-7445-3190	NHLBI NIH HHS [HL 62446] Funding Source: Medline; NIDDK NIH HHS [DK 54687-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Baxter RM, 2002, J INVEST DERMATOL, V118, P303, DOI 10.1046/j.0022-202x.2001.01662.x; Beck F, 2002, GUT, V51, P450, DOI 10.1136/gut.51.3.450; Chang VWH, 2001, GENE, V267, P201, DOI 10.1016/S0378-1119(01)00400-0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Duncan SA, 2003, MECH DEVELOP, V120, P19, DOI 10.1016/S0925-4773(02)00328-3; Garry DJ, 1997, DEV BIOL, V188, P280, DOI 10.1006/dbio.1997.8657; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kalinichenko VV, 2002, AM J PHYSIOL-LUNG C, V282, pL1253, DOI 10.1152/ajplung.00463.2001; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Kunath M, 2002, MECH DEVELOP, V119, pS117, DOI 10.1016/S0925-4773(03)00103-5; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lim L, 2002, AM J PHYSIOL-LUNG C, V282, pL1012, DOI 10.1152/ajplung.00371.2001; Mahlapuu M, 1998, DEV BIOL, V202, P183, DOI 10.1006/dbio.1998.9010; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nervi C, 2001, CANCER RES, V61, P1247; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tan YJ, 2001, GENE EXPRESSION, V9, P237, DOI 10.3727/000000001783992542; Tremblay JJ, 2002, ENDOCRINOLOGY, V143, P3935, DOI 10.1210/en.2002-220413; Tseng HT, 2004, DEVELOPMENT, V131, P3637, DOI 10.1242/dev.01234; Vogt PK, 1997, VIROLOGY, V238, P1, DOI 10.1006/viro.1997.8846; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	46	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37908	37916		10.1074/jbc.M506531200	http://dx.doi.org/10.1074/jbc.M506531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144835	hybrid			2022-12-25	WOS:000233044500072
J	Kumar, A; Mohan, S; Newton, J; Rehage, M; Tran, K; Baylink, DJ; Qin, XZ				Kumar, A; Mohan, S; Newton, J; Rehage, M; Tran, K; Baylink, DJ; Qin, XZ			Pregnancy-associated plasma protein-A regulates myoblast proliferation and differentiation through an insulin-like growth factor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEINS; IGF-I; MYOGENIC DIFFERENTIATION; PAPP-A; PROTEOLYTIC ACTIVITY; GENE-EXPRESSION; SERUM; (IGFBP)-4; MICE; IDENTIFICATION	Pregnancy-associated plasma protein-A (PAPP-A), a member of the metalloproteinase superfamily, is an important regulator of mammalian growth and development. However, the role of PAPP-A and its mechanism of action in various cellular processes remain unknown. In this study, we have investigated the role of PAPP-A in skeletal myogenesis using C2C12 myoblasts. Recombinant PAPP-A was purified from the conditioned medium of HT1080 cells overexpressing PAPP-A. Treatment of C2C12 myoblasts with PAPP-A increased their proliferation in a dose- and time-dependent manner. Addition of exogenous PAPP-A also increased the myotube formation and the activity of creatine kinase in C2C12 cultures. Transient overexpression of the full-length PAPP-A-( 1 - 1547), but not truncated protease-inactive N-terminal PAPP-A-( 1 - 920) or C-terminal PAPP-A-( 1100 - 1547), significantly enhanced the proliferation of C2C12 myoblasts. In vitro and in situ experiments demonstrated that PAPP-A cleaves insulin-like growth factor-binding protein ( IGFBP)- 2, but not IGFBP-3, in the conditioned medium of C2C12 myoblasts. Overexpression of PAPP-A led to degradation of the IGFBP-2 produced by C2C12 myoblasts and increased free IGF-I concentrations without affecting total IGF-I concentrations. Addition of protease-resistant IGFBP-4 completely abolished the PAPP-A- induced proliferation of C2C12 myoblasts. Our results demonstrate that 1) PAPP-A increases the proliferation and differentiation of myoblasts, 2) the stimulatory effect of PAPP-A on myogenesis is governed by its proteolytic activity, and 3) PAPP-A promotes skeletal myogenesis by increasing the amount of free IGFs via specific degradation of IGFBP-2 produced by myoblasts.	JL Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Physiol, Loma Linda, CA 92357 USA	Loma Linda University; Loma Linda University; Loma Linda University	Qin, XZ (corresponding author), JL Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, 151,11201 Benton St, Loma Linda, CA 92357 USA.	Xuezhong.Qin@med.va.gov		Kumar, Ashok/0000-0001-8571-2848	NIAMS NIH HHS [R01 AR45210, R01 AR031062, R01 AR045210, R01 AR031062-21, R01 AR31062] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045210, R01AR031062] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amin S, 2004, J BONE MINER RES, V19, P1075, DOI 10.1359/JBMR.040301; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Byun DW, 2001, J CLIN ENDOCR METAB, V86, P847, DOI 10.1210/jc.86.2.847; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Damon SE, 1998, J CELL PHYSIOL, V175, P109, DOI 10.1002/(SICI)1097-4652(199804)175:1<109::AID-JCP12>3.0.CO;2-6; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; ERNST CW, 1992, ENDOCRINOLOGY, V130, P607, DOI 10.1210/en.130.2.607; Ernst CW, 1996, J ENDOCRINOL, V149, P417, DOI 10.1677/joe.0.1490417; Ernst CW, 1996, DIFFERENTIATION, V61, P25, DOI 10.1046/j.1432-0436.1996.6110025.x; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FUNSTON RN, 1995, ENDOCRINOLOGY, V136, P62, DOI 10.1210/en.136.1.62; Gustafsson T, 1999, J ENDOCRINOL, V161, P245, DOI 10.1677/joe.0.1610245; Haugk KL, 2000, ENDOCRINOLOGY, V141, P100, DOI 10.1210/en.141.1.100; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J CLIN ENDOCR METAB, V80, P2638, DOI 10.1210/jc.80.9.2638; Monget P, 2003, BIOL REPROD, V68, P77, DOI 10.1095/biolreprod.102.007609; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; ORLOWSKI CC, 1990, ENDOCRINOLOGY, V126, P644, DOI 10.1210/endo-126-1-644; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Qin XZ, 1999, J BONE MINER RES, V14, P2079, DOI 10.1359/jbmr.1999.14.12.2079; Qin XZ, 2000, ARCH BIOCHEM BIOPHYS, V379, P209, DOI 10.1006/abbi.2000.1872; Qin XZ, 2002, GROWTH HORM IGF RES, V12, P359, DOI 10.1016/S1096-6374(02)00046-1; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; ROSEN CJ, 1994, P SOC EXP BIOL MED, V206, P83; Salih DAM, 2004, P NATL ACAD SCI USA, V101, P4314, DOI 10.1073/pnas.0400230101; Sivanandam AS, 2004, BIOCHEM J, V379, P57, DOI 10.1042/BJ20030937; Sivanandam AS, 2004, ARCH BIOCHEM BIOPHYS, V423, P343, DOI 10.1016/j.abb.2004.01.005; SKAAR TC, 1994, J ANIM SCI, V72, P421, DOI 10.2527/1994.722421x; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Tomczak KK, 2003, FASEB J, V17, P403, DOI 10.1096/f.03-0568fje; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; van den Beld AW, 2003, EUR J ENDOCRINOL, V148, P627, DOI 10.1530/eje.0.1480627; Xi G, 2004, J CELL PHYSIOL, V200, P387, DOI 10.1002/jcp.20068; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	53	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37782	37789		10.1074/jbc.M505278200	http://dx.doi.org/10.1074/jbc.M505278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16115888	hybrid, Green Accepted			2022-12-25	WOS:000233044500057
J	Seales, EC; Shaikh, FM; Woodard-Grice, AV; Aggarwal, P; McBrayer, AC; Hennessy, KM; Bellis, SL				Seales, EC; Shaikh, FM; Woodard-Grice, AV; Aggarwal, P; McBrayer, AC; Hennessy, KM; Bellis, SL			A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronectin receptors by altering beta 1 integrin sialylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; RAS ONCOGENE; MONOCYTIC DIFFERENTIATION; CELL-DIFFERENTIATION; LEUKEMIA CELLS; HA-RAS; INTEGRIN; EXPRESSION; MANUMYCIN; INHIBITOR	Here we report that myeloid cells differentiating along the monocyte/ macrophage lineage down-regulate the ST6Gal-I sialyltransferase via a protein kinase C/Ras/ERK signaling cascade. In consequence, the beta 1 integrin subunit becomes hyposialylated, which stimulates the ligand binding activity of alpha 5 beta 1 fibronectin receptors. Pharmacologic inhibitors of protein kinase C, Ras, and MEK, but not phosphoinositide 3-kinase, block ST6Gal-I down-regulation, integrin hyposialylation, and fibronectin binding. In contrast, constitutively active MEK stimulates these same events, indicating that ERK is both a necessary and sufficient activator of hyposialylation-dependent integrin activation. Consistent with the enhanced activity of hyposialylated cell surface integrins, purified alpha 5 beta 1 receptors bind fibronectin more strongly upon enzymatic desialylation, an effect completely reversed by resialylation of these integrins with recombinant ST6Gal-I. Finally, we have mapped the N-glycosylation sites on the beta 1 integrin to better understand the potential effects of differential sialylation on integrin structure/function. Notably, there are three N-glycosylated sites within the beta 1 I-like domain, a region that plays a crucial role in ligand binding. Our collective results suggest that variant sialylation, induced by a specific signaling cascade, mediates the sustained increase in cell adhesiveness associated with monocytic differentiation.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bellis, SL (corresponding author), Univ Alabama, Dept Physiol & Biophys, 982A MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.	bellis@physiology.uab.edu			NATIONAL CANCER INSTITUTE [R01CA084248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007450, P60AR020614] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA84248] Funding Source: Medline; NIAMS NIH HHS [2 T32 AR07450, 5 P60 AR20614-23] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Appenheimer MM, 2003, GLYCOBIOLOGY, V13, P591, DOI 10.1093/glycob/cwg066; Bellis SL, 2004, BBA-BIOMEMBRANES, V1663, P52, DOI 10.1016/j.bbamem.2004.03.012; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; Boles BK, 2000, AM J PHYSIOL-LUNG C, V278, pL703, DOI 10.1152/ajplung.2000.278.4.L703; Brown JR, 2003, J BIOL CHEM, V278, P23352, DOI 10.1074/jbc.M303093200; Dalziel M, 2004, EUR J BIOCHEM, V271, P3623, DOI 10.1111/j.1432-1033.2004.04284.x; Di Paolo A, 2000, BRIT J CANCER, V82, P905; EASTON EW, 1991, J BIOL CHEM, V266, P21674; FERREIRA OC, 1991, EXP CELL RES, V193, P20, DOI 10.1016/0014-4827(91)90533-Z; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; He HC, 1999, CELL GROWTH DIFFER, V10, P307; HEINO J, 1989, J BIOL CHEM, V264, P380; HIBI S, 1993, BLOOD, V81, P1841; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; JASPERS M, 1988, FEBS LETT, V231, P402, DOI 10.1016/0014-5793(88)80859-7; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; Kouchi H, 1999, BIOCHEM BIOPH RES CO, V264, P915, DOI 10.1006/bbrc.1999.1546; Laouar A, 1999, J IMMUNOL, V162, P407; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LENTER M, 1994, J BIOL CHEM, V269, P12263; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834; Semel AC, 2002, J BIOL CHEM, V277, P32830, DOI 10.1074/jbc.M202493200; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Taniguchi A, 1998, FEBS LETT, V441, P191, DOI 10.1016/S0014-5793(98)01548-8; VANDAMME V, 1992, BIOCHIMIE, V74, P89, DOI 10.1016/0300-9084(92)90188-K; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	31	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37610	37615		10.1074/jbc.M508476200	http://dx.doi.org/10.1074/jbc.M508476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157583	hybrid			2022-12-25	WOS:000233044500037
J	Weigert, C; Hennige, AM; Brischmann, T; Beck, A; Moeschel, K; Schauble, M; Brodbeck, K; Haring, HU; Schleicher, ED; Lehmann, R				Weigert, C; Hennige, AM; Brischmann, T; Beck, A; Moeschel, K; Schauble, M; Brodbeck, K; Haring, HU; Schleicher, ED; Lehmann, R			The phosphorylation of Ser(318) of insulin receptor substrate 1 is not per se inhibitory in skeletal muscle cells but is necessary to trigger the attenuation of the insulin-stimulated signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUCOSE-TRANSPORT; PKC-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY ROLE; IRS-1; ACTIVATION; ALPHA; PROLIFERATION; PATHOGENESIS	The Ser/Thr phosphorylation of insulin receptor substrate 1 (IRS) is one key mechanism to stimulate and/or attenuate insulin signal transduction. Using a phospho-specific polyclonal antibody directed against phosphorylated Ser(318) of IRS-1, we found a rapid and transient insulin-stimulated phosphorylation of Ser(318) in human and rodent skeletal muscle cell models and in muscle tissue of insulin-treated mice. None of the investigated insulin resistance-associated factors ( e. g. high glucose, tumor necrosis factor-alpha, adrenaline) stimulated the phosphorylation of Ser(318). Studying the function of this phosphorylation, we found that replacing Ser(318) by alanine completely prevented both the attenuation of insulin-stimulated Akt/protein kinase B Ser(473) phosphorylation and glucose uptake after 60 min of insulin stimulation. Unexpectedly, after acute insulin stimulation, we observed that phosphorylation of Ser(318) is not inhibitory but rather enhances insulin signal transduction because introduction of Ala(318) led to a reduction of the insulin-stimulated Akt/protein kinase B phosphorylation. Furthermore, replacing Ser(318) by glutamate, i.e. mimicking phosphorylation, improved glucose uptake after acute insulin stimulation. These data suggest that phosphorylation of Ser(318) is not per se inhibitory but is necessary to trigger the attenuation of the insulin-stimulated signal in skeletal muscle cells. Investigating the molecular mechanism of insulin-stimulated Ser(318) phosphorylation, we found that phosphatidylinositol 3-kinase-mediated activation of atypical protein kinase C-zeta and recruitment of protein kinase C-zeta to IRS-1 was responsible for this phosphorylation. We conclude that Ser(318) phosphorylation of IRS-1 is an early physiological event in insulin-stimulated signal transduction, which attenuates the continuing action of insulin.	Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Lehmann, R (corresponding author), Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, Otfried Muller Str 10, D-72076 Tubingen, Germany.	rainer.lehmann@med.uni-tuebingen.de	Lehmann, Rainer/AAF-4281-2019	Lehmann, Rainer/0000-0003-1218-6810				Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFronzo RA, 2004, MED CLIN N AM, V88, P787, DOI 10.1016/j.mcna.2004.04.013; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; Krutzfeldt J, 2000, DIABETES, V49, P992, DOI 10.2337/diabetes.49.6.992; LEHMANN R, 2002, SIGN TRANSDUCT, V1, P40; Liu YF, 2004, MOL CELL BIOL, V24, P9668, DOI 10.1128/MCB.24.21.9668-9681.2004; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Olefsky JM, 1999, J BIOL CHEM, V274, P1863, DOI 10.1074/jbc.274.4.1863; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Petersen KF, 2002, AM J CARDIOL, V90, p11G; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Standaert ML, 2001, BIOCHEMISTRY-US, V40, P249, DOI 10.1021/bi0018234; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; WALKER PS, 1989, J BIOL CHEM, V264, P6587; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; ZHANG B, 1991, J BIOL CHEM, V266, P990; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zick Y, 2004, BIOCHEM SOC T, V32, P812, DOI 10.1042/BST0320812	41	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37393	37399		10.1074/jbc.M506134200	http://dx.doi.org/10.1074/jbc.M506134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129678	hybrid			2022-12-25	WOS:000233044500013
J	Goto, M; Miyahara, I; Hirotsu, K; Conway, M; Islam, MM; Hutson, SM				Goto, M; Miyahara, I; Hirotsu, K; Conway, M; Islam, MM; Hutson, SM			Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; COLI ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; HUMAN MITOCHONDRIAL; NEUROTRANSMITTER METABOLISM; 3-DIMENSIONAL STRUCTURE; SUBSTRATE RECOGNITION; GLUTAMATE SYNTHESIS; CRYSTAL-STRUCTURES; RAT-TISSUES	This study presents the first three-dimensional structures of human cytosolic branched-chain aminotransferase (hBCATc) isozyme complexed with the neuroactive drug gabapentin, the hBCATc Michaelis complex with the substrate analog, 4-methylvalerate, and the mitochondrial isozyme (hBCATm) complexed with gabapentin. The branched-chain aminotransferases (BCAT) reversibly catalyze transamination of the essential branched-chain amino acids (leucine, isoleucine, valine) to alpha-ketoglutarate to form the respective branched-chain alpha-keto acids and glutamate. The cytosolic isozyme is the predominant BCAT found in the nervous system, and only hBCATc is inhibited by gabapentin. Pre-steady state kinetics show that 1.3 mM gabapentin can completely inhibit the binding of leucine to reduced hBCATc, whereas 65.4 mM gabapentin is required to inhibit leucine binding to hBCATm. Structural analysis shows that the bulky gabapentin is enclosed in the active-site cavity by the shift of a flexible loop that enlarges the active-site cavity. The specificity of gabapentin for the cytosolic isozyme is ascribed at least in part to the location of the interdomain loop and the relative orientation between the small and large domain which is different from these relationships in the mitochondrial isozyme. Both isozymes contain a CXXC center and form a disulfide bond under oxidizing conditions. The structure of reduced hBCATc was obtained by soaking the oxidized hBCATc crystals with dithiothreitol. The close similarity in active-site structures between cytosolic enzyme complexes in the oxidized and reduced states is consistent with the small effect of oxidation on pre-steady state kinetics of the hBCATc first half-reaction. However, these kinetic data do not explain the inactivation of hBCATm by oxidation of the CXXC center. The structural data suggest that there is a larger effect of oxidation on the interdomain loop and residues surrounding the CXXC center in hBCATm than in hBCATc.	Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem & Mol Biol, Winston Salem, NC 27157 USA; Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab, University Pk, PA 16802 USA	Osaka Metropolitan University; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hirotsu, K (corresponding author), Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan.	hirotsu@sci.osaka-cu.ac.jp			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK034738, R01DK034738] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34738] Funding Source: Medline; NINDS NIH HHS [NS3864] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS J, 1990, LANCET, V335, P1114; Bergey GK, 1997, NEUROLOGY, V49, P739, DOI 10.1212/WNL.49.3.739; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTEN P, 1985, TRANSAMINASES, V2, P430; Conway ME, 2000, METHOD ENZYMOL, V324, P355; Conway ME, 2004, BIOCHEMISTRY-US, V43, P7356, DOI 10.1021/bi0498050; Conway ME, 2002, BIOCHEMISTRY-US, V41, P9070, DOI 10.1021/bi020200i; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; DeLano WL, 2002, PYMOL USERS MANUAL; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; GOTO M, 1977, GANN, V68, P663; Goto M, 2003, BIOCHEMISTRY-US, V42, P3725, DOI 10.1021/bi026722f; HALL TR, 1993, J BIOL CHEM, V268, P3092; Hutson S, 2001, PROG NUCLEIC ACID RE, V70, P175, DOI 10.1016/S0079-6603(01)70017-7; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1988, J BIOL CHEM, V263, P3618; HUTSON SM, 1988, J NUTR, V118, P1475, DOI 10.1093/jn/118.12.1475; Hutson SM, 1998, J NEUROCHEM, V71, P863; ICHIHARA A, 1966, J BIOCHEM-TOKYO, V59, P160, DOI 10.1093/oxfordjournals.jbchem.a128277; ICHIHARA A, 1985, TRANSAMINASES, V2, P430; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; Jhee KH, 2000, J BIOCHEM-TOKYO, V128, P679, DOI 10.1093/oxfordjournals.jbchem.a022801; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMITORI S, 1989, J BIOCHEM-TOKYO, V105, P671, DOI 10.1093/oxfordjournals.jbchem.a122723; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LaNoue KF, 2001, J NEUROSCI RES, V66, P914, DOI 10.1002/jnr.10064; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lieth E, 2001, J NEUROCHEM, V76, P1712, DOI 10.1046/j.1471-4159.2001.00156.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCLEAN MJ, 1997, NEUROLOGY, V43, P2292; Nakai T, 2000, J BIOCHEM, V128, P29, DOI 10.1093/oxfordjournals.jbchem.a022727; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okada K, 2001, BIOCHEMISTRY-US, V40, P7453, DOI 10.1021/bi010384l; Okada K, 1997, J BIOCHEM-TOKYO, V121, P637; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; Rogawski MA, 2004, NAT MED, V10, P685, DOI 10.1038/nm1074; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Sweatt AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE64, DOI 10.1152/ajpendo.00276.2003; TAYLOR RT, 1966, J BIOL CHEM, V241, P4396; WELTY DF, 1995, ANN PHARMACOTHER, V29, P1164, DOI 10.1177/106002809502901118; YANO T, 1992, BIOCHEMISTRY-US, V31, P5878, DOI 10.1021/bi00140a025; YANO T, 1993, J MOL BIOL, V234, P1218, DOI 10.1006/jmbi.1993.1672; Yennawar N, 2001, ACTA CRYSTALLOGR D, V57, P506, DOI 10.1107/S0907444901001925; Yennawar NH, 2002, BIOCHEMISTRY-US, V41, P11592, DOI 10.1021/bi020221c; YOSHIMURA T, 1993, J AM CHEM SOC, V115, P3897, DOI 10.1021/ja00063a007	51	60	65	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37246	37256		10.1074/jbc.M506486200	http://dx.doi.org/10.1074/jbc.M506486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141215	hybrid			2022-12-25	WOS:000232901800083
J	Liu, ML; Tarsio, M; Charsky, CMH; Kane, PM				Liu, ML; Tarsio, M; Charsky, CMH; Kane, PM			Structural and functional separation of the N- and C-terminal domains of the yeast V-ATPase subunit H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CROSS-LINKING; COLI F1F0-ATP SYNTHASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; VACUOLAR-ATPASE; 3-DIMENSIONAL STRUCTURE; TRANSLOCATING ATPASE; CRYSTAL-STRUCTURE; MANDUCA-SEXTA; BINDING-SITE	The H subunit of the yeast V-ATPase is an extended structure with two relatively independent domains, an N-terminal domain consisting of amino acids 1 - 348 and a C-terminal domain consisting of amino acids 352 - 478 (Sagermann, M., Stevens, T. H., and Matthews, B. W. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7134 7139). We have expressed these two domains independently and together in a yeast strain lacking the H subunit (vma13 Delta mutant). The N-terminal domain partially complements the growth defects of the mutant and supports similar to 25% of the wild-type Mg2+-dependent ATPase activity in isolated vacuolar vesicles, but surprisingly, this activity is both largely concanamycin-insensitive and uncoupled from proton transport. The C-terminal domain does not complement the growth defects, and supports no ATP hydrolysis or proton transport, even though it is recruited to the vacuolar membrane. Expression of both domains in a vma13 Delta strain gives better complementation than either fragment alone and results in higher concanamycin-sensitive ATPase activity and ATP-driven proton pumping than the N-terminal domain alone. Thus, the two domains make complementary contributions to structural and functional coupling of the peripheral V-1 and membrane V-o sectors of the V-ATPase, but this coupling does not require that they be joined covalently. The N-terminal domain alone is sufficient for activation of ATP hydrolysis in V-1, but the C-terminal domain is essential for proper communication between the V-1 and V-o sectors.	SUNy Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNy Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NIGMS NIH HHS [1R01GM50322, R01 GM050322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Chaban YL, 2004, J BIOL CHEM, V279, P47866, DOI 10.1074/jbc.M408460200; Crider BP, 2003, J BIOL CHEM, V278, P44281, DOI 10.1074/jbc.M307372200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; CURTIS KK, 2001, J BIOL CHEM, V20, P20; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1994, J BIOL CHEM, V269, P13224; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; HAZARD AL, 1994, J BIOL CHEM, V269, P418; HAZARD AL, 1994, J BIOL CHEM, V269, P427; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P18286; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHYA Y, 1994, GENETICS, V138, P1041; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sagermann M, 2001, P NATL ACAD SCI USA, V98, P7134, DOI 10.1073/pnas.131192798; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; Sherman F., 1982, METHODS YEAST GENETI; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200	51	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36978	36985		10.1074/jbc.M505296200	http://dx.doi.org/10.1074/jbc.M505296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141210	Green Accepted, hybrid			2022-12-25	WOS:000232901800055
J	Ma, B; Lau, LH; Palcic, MM; Hazes, B; Taylor, DE				Ma, B; Lau, LH; Palcic, MM; Hazes, B; Taylor, DE			A single aromatic amino acid at the carboxyl terminus of Helicobacter pylori alpha 1,3/4 fucosyltransferase determines substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SIALYL-LEWIS-X; PHASE VARIATION; MOLECULAR-CLONING; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; ACCEPTOR SPECIFICITY; GASTRIC EPITHELIUM; EXPRESSION; OLIGOSACCHARIDES; ENZYME	Fucosyltransferases ( FucT) from different Helicobacter pylori strains display distinct Type I (Gal beta 1,3GlcNAc) or Type II (Gal beta 1,4GlcNAc) substrate specificity. FucT from strain UA948 can transfer fucose to the OH-3 of Type II acceptors as well as to the OH-4 of Type I acceptors on the GlcNAc moiety, so it has both alpha 1,3 and alpha 1,4 activities. In contrast, FucT from strain NCTC11639 has exclusive alpha 1,3 activity. Our domain swapping study (Ma, B., Wang, G., Palcic, M. M., Hazes, B., and Taylor, D. E. ( 2003) J. Biol. Chem. 278, 21893 - 21900) demonstrated that exchange of the hypervariable loops, (DNPFIFC353)-D-347 in 11639FucT and (345)CNDAHYSALH(354) in UA948FucT, were sufficient to either confer or abolish alpha 1,4 activity. Here we performed alanine scanning site-directed mutagenesis to identify which amino acids within (345)CNDAHYSALH(354) of UA948FucT confer Type I substrate specificity. The Tyr(350) --> Ala mutation dramatically reduced alpha 1,4 activity without lowering alpha 1,3 activity. None of the other alanine substitutions selectively eliminated alpha 1,4 activity. To elucidate how Tyr(350) determines alpha 1,4 specificity, mutants Tyr(350) --> Phe, Tyr(350) --> Trp, and Tyr(350) --> Gly were constructed in UA948FucT. These mutations did not decrease alpha 1,3 activity but reduced the alpha 1,4 activity to 61.8%, 78.5%, and 4.7% of wild type level, respectively. Apparently the aromatic nature, but not the hydroxyl group of Tyr(350), is essential for alpha 1,4 activity. Our data demonstrate that a single amino acid ( Tyr350) in the C-terminal hypervariable region of UA948FucT determines Type I acceptor specificity. Notably, a single aromatic residue ( Trp) has also been implicated in controlling Type I acceptor preference for human FucT III, but it is located in an N-terminal hypervariable stem domain.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Alberta; University of Alberta	Taylor, DE (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 1-63 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	diane.taylor@ualberta.ca						Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Appelmelk BJ, 2000, INFECT IMMUN, V68, P5928, DOI 10.1128/IAI.68.10.5928-5932.2000; Appelmelk BJ, 1999, INFECT IMMUN, V67, P5361, DOI 10.1128/IAI.67.10.5361-5366.1999; Azurmendi HF, 2002, BIOPOLYMERS, V63, P89, DOI 10.1002/bip.10015; BISWAS M, 1980, BIOPOLYMERS, V19, P1555, DOI 10.1002/bip.1980.360190811; BOURNE Y, 1992, J BIOL CHEM, V267, P197; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Dupuy F, 2004, GLYCOBIOLOGY, V14, P347, DOI 10.1093/glycob/cwh053; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Edwards NJ, 2000, MOL MICROBIOL, V35, P1530, DOI 10.1046/j.1365-2958.2000.01823.x; Endo T, 2000, CURR OPIN STRUC BIOL, V10, P536, DOI 10.1016/S0959-440X(00)00127-5; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Gosselin S, 1996, BIOORGAN MED CHEM, V4, P2023, DOI 10.1016/S0968-0896(97)81455-1; Guo ZM, 1997, APPL BIOCHEM BIOTECH, V68, P1, DOI 10.1007/BF02785977; HOMANS SW, 1993, GLYCOBIOLOGY, V3, P551, DOI 10.1093/glycob/3.6.551; Johnson KF, 1999, GLYCOCONJUGATE J, V16, P141, DOI 10.1023/A:1026440509859; KHARE DP, 1985, CARBOHYD RES, V136, P285, DOI 10.1016/0008-6215(85)85204-6; Krylov SN, 2000, ANAL BIOCHEM, V283, P133, DOI 10.1006/abio.2000.4648; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; Lozniewski A, 2003, INFECT IMMUN, V71, P2902, DOI 10.1128/IAI.71.5.2902-2906.2003; Ma B, 2003, J BIOL CHEM, V278, P21893, DOI 10.1074/jbc.M301704200; Mahdavi J, 2003, INFECT IMMUN, V71, P2876, DOI 10.1128/IAI.71.5.2876-2880.2003; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Moran AP, 2002, J BIOL CHEM, V277, P5785, DOI 10.1074/jbc.M108574200; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Qiao L, 1996, J AM CHEM SOC, V118, P7653, DOI 10.1021/ja960274f; RABBANI S, 2005, IN PRESS GLYCOBIOLOG; Rasko DA, 2000, EUR J BIOCHEM, V267, P6059, DOI 10.1046/j.1432-1327.2000.01683.x; Rasko DA, 2000, J BIOL CHEM, V275, P4988, DOI 10.1074/jbc.275.7.4988; RASKO DA, 2000, THESIS U ALBERTA EDM, P220; Suresh MR, 2000, J PHARM PHARM SCI, V3, P259; Takata T, 2002, INFECT IMMUN, V70, P3073, DOI 10.1128/IAI.70.6.3073-3079.2002; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wang G, 1999, MICROBIOL-SGM, V145, P3245, DOI 10.1099/00221287-145-11-3245; Wang G, 1999, MOL MICROBIOL, V31, P1265, DOI 10.1046/j.1365-2958.1999.01268.x; Wang G, 2000, MOL MICROBIOL, V36, P1187, DOI 10.1046/j.1365-2958.2000.01934.x; Watt GM, 1997, CURR OPIN STRUC BIOL, V7, P652, DOI 10.1016/S0959-440X(97)80074-7; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; ZHANG YN, 1995, ANAL BIOCHEM, V227, P368, DOI 10.1006/abio.1995.1293	53	13	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36848	36856		10.1074/jbc.M504415200	http://dx.doi.org/10.1074/jbc.M504415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150700	hybrid			2022-12-25	WOS:000232901800040
J	Martinez-Arca, S; Bech-Serra, JJ; Hurtado-Kuttner, M; Borroto, A; Arribas, J				Martinez-Arca, S; Bech-Serra, JJ; Hurtado-Kuttner, M; Borroto, A; Arribas, J			Recycling of cell surface pro-transforming growth factor-alpha regulates epidermal growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; TGF-ALPHA; PROTEIN; MEMBRANE; PRECURSOR; TRANSPORT; PATHWAY	Impairments in signal transduction, leading to the regulation of cell proliferation, differentiation, or migration are frequently the cause of cancer. Since the accurate spatial and temporal location of their components is crucial to ensure the correct regulation of these signaling pathways, it could be anticipated that defects in intracellular trafficking are at the base of certain neoplasias. However, the trafficking of many components of pathways frequently up-regulated in cancers, such as the epidermal growth factor receptor ( EGFR) pathway, are largely unknown. Here, we show that the protransforming growth factor-alpha (pro-TGF-alpha), a prototypical EGFR ligand, is endocytosed from the cell surface via a clathrin-dependent pathway. Internalized pro-TGF-alpha does not progress to the lysosome; instead, it is delivered to the cell surface via recycling endosomes. To analyze the functional meaning of the internalization of pro-TGF-alpha, we used a deletion construct that is normally transported to the cell surface but is deficiently endocytosed. Due to this impairment, the levels of this construct at the cell surface are dramatically augmented. Consequently, the deletion construct displays a higher EGFR-activating ability, revealing a link between the trafficking of pro-TGF-alpha and the signaling by the EGFR and opening the possibility that defects in the trafficking of the growth factor may contribute to the development of tumors.	Vall dHebron Res Inst Univ Hosp, Med Oncol Res Program, Barcelona 08035, Spain		Arribas, J (corresponding author), Vall dHebron Res Inst Univ Hosp, Med Oncol Res Program, 119-129 Psg Vall dHebron, Barcelona 08035, Spain.	jarribas@vhebron.net	Bech-Serra, Joan Josep/AAA-2330-2020; Arribas, Joaquin/M-4482-2014	Bech-Serra, Joan Josep/0000-0003-3486-781X; Arribas, Joaquin/0000-0002-0504-0664				Aridor M, 2002, TRAFFIC, V3, P537, DOI 10.1034/j.1600-0854.2002.30804.x; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Dempsey PJ, 2003, EXP CELL RES, V285, P159, DOI 10.1016/S0014-4827(03)00035-1; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Martinez-Arca S, 2003, J CELL SCI, V116, P2805, DOI 10.1242/jcs.00467; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Szymkiewicz I, 2004, BIOCHEM J, V383, P1, DOI 10.1042/BJ20040913; Urena JM, 1999, J CELL SCI, V112, P773; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	33	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36970	36977		10.1074/jbc.M504425200	http://dx.doi.org/10.1074/jbc.M504425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129682	hybrid			2022-12-25	WOS:000232901800054
J	Berger, F; Lau, C; Dahlmann, M; Ziegler, M				Berger, F; Lau, C; Dahlmann, M; Ziegler, M			Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMN ADENYLYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASE; NAD BIOSYNTHESIS; NUCLEAR ENZYME; LIFE-SPAN; IDENTIFICATION; EXPRESSION; PROTEIN; CLONING; PURIFICATION	Nicotinamide mononucleotide adenylyltransferase (NMNAT) is the central enzyme of the NAD biosynthetic pathway. Three human NMNAT isoforms have recently been identified, but isoform-specific functions are presently unknown, although a tissue-specific role has been suggested. Analyses of the subcellular localization confirmed NMNAT1 to be a nuclear protein, whereas NMNAT2 and -3 were localized to the Golgi complex and the mitochondria, respectively. This differential subcellular localization points to an organelle-specific, nonredundant function of each of the three proteins. Comparison of the kinetic properties showed that particularly NMNAT3 exhibits a high tolerance toward substrate modifications. Moreover, as opposed to preferred NAD(+) synthesis by NMNAT1, the other two isoforms could also form NADH directly from the reduced nicotinamide mononucleotide, supporting a hitherto unknown pathway of NAD generation. A variety of physiological intermediates was tested and exerted only minor influence on the catalytic activities of the NMNATs. However, gallotannin was found to be a potent inhibitor, thereby compromising its use as a specific inhibitor of poly-ADP-ribose glycohydrolase. The presence of substrate-specific and independent nuclear, mitochondrial, and Golgi-specific NAD biosynthetic pathways is opposed to the assumption of a general cellular NAD pool. Their existence appears to be consistent with important compartment-specific functions rather than to reflect simple functional redundance.	Univ Bergen, Inst Mol Biol, N-5020 Bergen, Norway; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	University of Bergen; Free University of Berlin	Ziegler, M (corresponding author), Univ Bergen, Inst Mol Biol, Thormohlensgt 55, N-5020 Bergen, Norway.	Mathias.Ziegler@mbi.uib.no		Lau, Corinna/0000-0003-1750-8065; Dahlmann, Mathias/0000-0002-0036-5283; Ziegler, Mathias/0000-0001-6961-2396				Abdelraheim SR, 2003, BIOCHEM J, V374, P329, DOI 10.1042/BJ20030441; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; AOKI K, 1993, BIOCHIM BIOPHYS ACTA, V1158, P251, DOI 10.1016/0304-4165(93)90022-Z; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bakondi E, 2004, EXP DERMATOL, V13, P170, DOI 10.1111/j.0906-6705.2004.0150.x; Barile M, 1996, BIOCHEM MOL BIOL INT, V38, P297; Bedalov A, 2004, SCIENCE, V305, P954, DOI 10.1126/science.1102497; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; Fernando FS, 2002, GENE, V284, P23, DOI 10.1016/S0378-1119(02)00394-3; Galione A, 2000, Sci STKE, V2000, ppe1; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Guse AH, 2004, CURR MED CHEM, V11, P847, DOI 10.2174/0929867043455602; HOGEBOOM GH, 1952, NATURE, V170, P374, DOI 10.1038/170374a0; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Keil C, 2004, ARCH BIOCHEM BIOPHYS, V425, P115, DOI 10.1016/j.abb.2004.02.024; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Magni G, 1997, METHOD ENZYMOL, V280, P241; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; PREISS J, 1957, J BIOL CHEM, V225, P759; Raffaelli N, 2002, BIOCHEM BIOPH RES CO, V297, P835, DOI 10.1016/S0006-291X(02)02285-4; Raffaelli N, 1999, MOL CELL BIOCHEM, V193, P99, DOI 10.1023/A:1006968328186; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; Raffaelli N, 2001, METHOD ENZYMOL, V331, P292; Raffaelli N, 2001, METHOD ENZYMOL, V331, P281; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TSAI YJ, 1992, J BIOL CHEM, V267, P14436; Turner WL, 2004, PLANT PHYSIOL, V135, P1243, DOI 10.1104/pp.104.040428; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Werner E, 2002, FEBS LETT, V516, P239, DOI 10.1016/S0014-5793(02)02556-5; Yalowitz JA, 2004, BIOCHEM J, V377, P317, DOI 10.1042/BJ20030518; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Zhang XJ, 2003, J BIOL CHEM, V278, P13503, DOI 10.1074/jbc.M300073200; Zhou TJ, 2002, J BIOL CHEM, V277, P13148, DOI 10.1074/jbc.M111469200	51	354	367	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36334	36341		10.1074/jbc.M508660200	http://dx.doi.org/10.1074/jbc.M508660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118205	hybrid			2022-12-25	WOS:000232726900067
J	Grimm, SL; Contreras, A; Barcellos-Hoff, MH; Rosen, JM				Grimm, SL; Contreras, A; Barcellos-Hoff, MH; Rosen, JM			Cell cycle defects contribute to a block in hormone-induced mammary gland proliferation in CCAAT/enhancer-binding protein (C/EBP beta)-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; HUMAN BREAST-CANCER; C/EBP-BETA; PROGESTERONE-RECEPTOR; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; TGF-BETA-1 EXPRESSION; DUCTAL MORPHOGENESIS; PARTIAL-HEPATECTOMY	In contrast to hormone-dependent breast cancer, steroid hormone-induced proliferation in the normal mammary gland does not occur in the steroid-receptor positive cells but rather in adjacent cells via paracrine signaling involving several local growth factors. To help elucidate the mechanisms involved in the block in proliferation in hormone-receptor positive cells, we have utilized a CCAAT/enhancer binding protein (C/EBP beta)-null mouse model. Loss of this transcription factor results in increased steroid and prolactin receptor expression concomitant with a 10-fold decrease in proliferation in response to pregnancy hormones. To determine the basis for this decrease, several markers of cell cycle progression were analyzed in wild type and C/EBP beta-null mammary epithelial cells (MECs). These studies indicated that cell cycle progression in C/EBP beta-null MECs is blocked at the G(1)/S transition. C/EBP beta-null mammary glands display substantially increased levels of the activated form of transforming growth factor beta, a potent inhibitor of epithelial cell proliferation, as well as increased downstream Smad2 expression and signaling. While cyclin D1 levels were equivalent, cyclin E expression was markedly reduced in C/EBP beta-null as compared with wildtype MECs. In addition, increased p27 stability and retention in the nucleus and decreased levels of the cdc25a phosphatase contributed to a significant loss of cdk2 kinase activity. Collectively, these changes prevent C/EBP beta-null mammary epithelial cells from responding to hormone-induced proliferative signals.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94710 USA	Baylor College of Medicine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	jrosen@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Berger C, 2005, CELL CYCLE, V4, P422, DOI 10.4161/cc.4.3.1524; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; Clarke RB, 1997, CANCER RES, V57, P4987; Clarysse W, 2000, STUD HELLENIST, V36, P29; Contreras A, 2003, MOL CELL BIOL, V23, P8626, DOI 10.1128/MCB.23.23.8626-8636.2003; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Ewan KBR, 2005, AM J PATHOL, V167, P409, DOI 10.1016/S0002-9440(10)62985-9; GERDES J, 1984, J IMMUNOL, V133, P1710; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; KEYOMARSI K, 1994, CANCER RES, V54, P380; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Loffler H, 2003, ONCOGENE, V22, P8063, DOI 10.1038/sj.onc.1206976; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nakano K, 2001, BIOCHEM BIOPH RES CO, V280, P640, DOI 10.1006/bbrc.2000.4185; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Polesello C, 2004, TRENDS CELL BIOL, V14, P294, DOI 10.1016/j.tcb.2004.04.003; Pullan Shirley E., 1996, P97; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Ray D, 2005, MOL CELL BIOL, V25, P3338, DOI 10.1128/MCB.25.8.3338-3347.2005; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; Talasz H, 1996, BIOCHEMISTRY-US, V35, P1761, DOI 10.1021/bi951914e; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Zahnow CA, 2001, CANCER RES, V61, P261; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	53	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36301	36309		10.1074/jbc.M508167200	http://dx.doi.org/10.1074/jbc.M508167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120603	hybrid			2022-12-25	WOS:000232726900063
J	Ryer, EJ; Sakakibara, K; Wang, C; Sarkar, D; Fisher, PB; Faries, PL; Kent, KC; Liu, B				Ryer, EJ; Sakakibara, K; Wang, C; Sarkar, D; Fisher, PB; Faries, PL; Kent, KC; Liu, B			Protein kinase C delta induces apoptosis of vascular smooth muscle cells through induction of the tumor suppressor p53 by both p38-dependent and p38-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 GENE-TRANSFER; DNA-DAMAGE; KAPPA-B; MAP KINASES; PKC-DELTA; PROLIFERATION; ACTIVATION; EXPRESSION; ATHEROSCLEROSIS; VEIN	Apoptotic death of vascular smooth muscle cells ( SMCs) is a prominent feature of blood vessel remodeling. In the present study, we examined the novel PKC isoform protein kinase C delta ( PKC delta) and its role in vascular SMC apoptosis. In A10 SMCs, overexpression of PKC delta was sufficient to induce apoptosis, whereas inhibition of PKC delta diminished H2O2- induced apoptosis. Moreover, evidence is provided that the tumor suppressor p53 is an essential mediator of PKC delta- induced apoptosis in SMCs. Activation of PKC delta led to accumulation as well as phosphorylation of p53 in SMCs; this induction correlated with apoptosis. Furthermore, blocking p53 induction with small interference RNA or targeted gene deletion prevented PKC delta- induced apoptosis, whereas restoring p53 expression rescued the ability of PKC delta to induce apoptosis in p53 null SMCs. We also establish that PKC delta regulates p53 at both transcriptional and post- translational levels. Specifically, the transcriptional regulation required p38 MAPK, whereas the post- translational modification, at least for serine 46, did not involve MAPK. Additionally, PKC delta, p38 MAPK, and p53 co- associate in cells under conditions favoring apoptosis. Together, our data suggest that SMC apoptosis proceeds through a pathway that involves PKC delta, the intermediary p38 MAPK, and the downstream target tumor suppressor p53.	New York Presbyterian Hosp, Dept Surg, Div Vasc Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA	NewYork-Presbyterian Hospital; Cornell University; Columbia University; Columbia University; Columbia University	Liu, B (corresponding author), New York Presbyterian Hosp, Dept Surg, Div Vasc Surg, 525 E 68th St,Payson 707, New York, NY 10021 USA.	bol2001@med.cornell.edu			NATIONAL CANCER INSTITUTE [T32CA068971] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068673] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA68971-07] Funding Source: Medline; NHLBI NIH HHS [HL-68673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Bauriedel G, 1998, ARTERIOSCL THROM VAS, V18, P1132, DOI 10.1161/01.ATV.18.7.1132; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BODHATONPIALLAT M, 1995, AM J PATHOL, V146, P1059; CLOWES MM, 1994, J CLIN INVEST, V93, P644, DOI 10.1172/JCI117016; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Durland-Busbice S, 2002, LEUKEMIA, V16, P2165, DOI 10.1038/sj.leu.2402647; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GENG YJ, 1995, AM J PATHOL, V147, P251; George SJ, 2001, GENE THER, V8, P668, DOI 10.1038/sj.gt.3301431; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HAN DKM, 1995, AM J PATHOL, V147, P267; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hollenbeck ST, 2004, BIOCHEM BIOPH RES CO, V325, P328, DOI 10.1016/j.bbrc.2004.10.031; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Itoh H, 2001, AM J PHYSIOL-HEART C, V281, pH359, DOI 10.1152/ajpheart.2001.281.1.H359; Johnson CL, 2002, MOL CANCER THER, V1, P861; Jorgensen K, 2005, BIOCHEM BIOPH RES CO, V329, P266, DOI 10.1016/j.bbrc.2005.01.143; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kubota K, 2003, J SURG RES, V109, P43, DOI 10.1016/S0022-4804(02)00037-9; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Leirdal M, 1999, BRIT J CANCER, V80, P1558, DOI 10.1038/sj.bjc.6690560; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Newby AC, 1996, CURR OPIN CARDIOL, V11, P574, DOI 10.1097/00001573-199611000-00004; Niwa K, 2002, FREE RADICAL RES, V36, P1147, DOI 10.1080/1071576021000016409; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Reisman D, 1996, GENOMICS, V38, P364, DOI 10.1006/geno.1996.0639; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakakibara K, 2005, J BIOL CHEM, V280, P25470, DOI 10.1074/jbc.M502320200; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Scheinman M, 1999, J VASC SURG, V29, P360, DOI 10.1016/S0741-5214(99)70389-7; Scheinman M, 1999, SURGERY, V126, P863, DOI 10.1016/S0039-6060(99)70027-9; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wada T, 2001, AM J KIDNEY DIS, V38, P1169, DOI 10.1053/ajkd.2001.29206; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu QB, 2000, TRENDS CARDIOVAS MED, V10, P35, DOI 10.1016/S1050-1738(00)00042-6; Yonemitsu Y, 1998, CIRC RES, V82, P147; Zhao TC, 2003, AM J PHYSIOL-HEART C, V285, pH434, DOI 10.1152/ajpheart.00095.2003	64	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35310	35317		10.1074/jbc.M507187200	http://dx.doi.org/10.1074/jbc.M507187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118209	hybrid			2022-12-25	WOS:000232561200029
J	O'Malley, D; Irving, AJ; Harvey, J				O'Malley, D; Irving, AJ; Harvey, J			Leptin-induced dynamic changes in the actin cytoskeleton mediate the activation and synaptic clustering of BK channels	FASEB JOURNAL			English	Article						PI 3-kinase; actin cytoskeleton; PtdIns(3,4,5)P-3	CA2+-ACTIVATED K+ CHANNELS; RAT HIPPOCAMPAL-NEURONS; LARGE-CONDUCTANCE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POTASSIUM CHANNEL; CALCIUM-CHANNEL; RHO-GTPASES; EXCITOTOXICITY; REPOLARIZATION	Phosphoinositide 3-kinase (PI3-kinase) has been shown to link leptin receptor activation to stimulation of large conductance Ca2+-activated K+ (BK) channels and subsequent inhibition of hippocampal epileptiform-like activity. However, the downstream targets of PI3-kinase in this action of leptin are unknown. Here we show that BK channel activation by leptin is dependent on the actin cytoskeleton, as it is prevented by actin filament stabilization and mimicked by actin disruption. Fluorescent labeling of polymerized actin filaments revealed that leptin promotes the rapid rearrangement of actin filaments via activation of PI 3-kinase; an action paralleled by discrete increases in PtdIns( 3,4,5) P-3 immunoreactivity in close proximity to BK channels. After leptin exposure, there was also an actin-dependent increase in the association of BK channel immunoreactivity with synaptic markers. These data are consistent with the notion that leptin activates BK channels via PI 3-kinase-dependent reorganization of actin filaments and subsequent clustering of BK channels at synapses.	Univ Dundee, Ninewells Hosp & Med Sch, Inst Neurosci, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland	University of Dundee	Harvey, J (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Inst Neurosci, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	j.z.harvey@dundee.ac.uk		Harvey, Jenni/0000-0002-9858-001X; O'Malley, Dervla/0000-0002-7031-4879	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABELE AE, 1990, NEURON, V4, P413, DOI 10.1016/0896-6273(90)90053-I; Allison DW, 1998, J NEUROSCI, V18, P2423; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Cheng HL, 2000, J BIOL CHEM, V275, P27197; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Coussen F, 2002, J NEUROSCI, V22, P6426, DOI 10.1523/jneurosci.22-15-06426.2002; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; FURUKAWA K, 1995, EXP NEUROL, V133, P153, DOI 10.1006/exnr.1995.1018; Furukawa K, 1997, J NEUROSCI, V17, P8178, DOI 10.1523/jneurosci.17-21-08178.1997; Golding NL, 1999, J NEUROSCI, V19, P8789, DOI 10.1523/JNEUROSCI.19-20-08789.1999; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm-Alvarez SF, 1998, PHYSIOL REV, V78, P1109, DOI 10.1152/physrev.1998.78.4.1109; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Harvey J, 2000, J PHYSIOL-LONDON, V527, P95, DOI 10.1111/j.1469-7793.2000.00095.x; Hilpela P, 2004, CURR TOP MICROBIOL, V282, P117; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Huang H, 2002, NEUROSCI LETT, V332, P141, DOI 10.1016/S0304-3940(02)00836-4; Kraft R, 2000, J MEMBRANE BIOL, V175, P25, DOI 10.1007/s002320001052; Lesage F, 2004, P NATL ACAD SCI USA, V101, P671, DOI 10.1073/pnas.0307681100; Maguire G, 1998, NEUROREPORT, V9, P665, DOI 10.1097/00001756-199803090-00019; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Niswender KD, 2003, J HISTOCHEM CYTOCHEM, V51, P275, DOI 10.1177/002215540305100302; Oheim M, 2000, EUR BIOPHYS J BIOPHY, V29, P67, DOI 10.1007/s002490050253; Petrecca K, 2000, J NEUROSCI, V20, P8736; Piao L, 2003, PFLUG ARCH EUR J PHY, V446, P523, DOI 10.1007/s00424-003-1079-y; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Shanley LJ, 2002, J PHYSIOL-LONDON, V545, P933, DOI 10.1113/jphysiol.2002.029488; Shanley LJ, 2002, NAT NEUROSCI, V5, P299, DOI 10.1038/nn824; Shanley LJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0001.2001; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; Terzic A, 1996, J PHYSIOL-LONDON, V492, P395, DOI 10.1113/jphysiol.1996.sp021316; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Unno T, 1999, BRIT J PHARMACOL, V127, P1703, DOI 10.1038/sj.bjp.0702711; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wang ZR, 2004, AM J PHYSIOL-HEART C, V286, pH749, DOI 10.1152/ajpheart.00398.2003; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798	49	50	52	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1917	+		10.1096/fj.05-4166fje	http://dx.doi.org/10.1096/fj.05-4166fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16166199				2022-12-25	WOS:000232315700013
J	Rui, T; Kvietys, PR				Rui, T; Kvietys, PR			NF-kappa B and AP-1 differentially contribute to the induction of Mn-SOD and eNOS during the development of oxidant tolerance	FASEB JOURNAL			English	Article						anoxia/reoxygenation; oxidant stress; PMN transendothelial migration	MANGANESE SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; MYOCARDIAL-ISCHEMIA; MONOCLONAL-ANTIBODY; TRANSCRIPTIONAL INDUCTION; REPERFUSION INJURY; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; P-SELECTIN	Exposure of cardiac myocytes to anoxia/reoxygenation (A/R) increases myocyte oxidant stress and converts the myocytes to a proinflammatory phenotype. These oxidant-induced effects are prevented by pretreatment of the myocytes with an oxidant stress (A/R or H2O2) 24 h earlier ( oxidant tolerance). Although NF-kappa B and AP-1 ( nuclear signaling) and Mn-SOD and eNOS ( effector enzymes) have been implicated in the development oxidant tolerance, the precise relationship between the nuclear transcription factors and the effector enzymes in the development of oxidant tolerance has not been defined. Herein, we show that an initial A/R challenge results in nuclear accumulation of both NF-kappa B and AP-1 ( EMSA). In addition, blockade of nuclear translocation of NF-kappa B (SN50) or AP-1 ( decoy oligonucleotide) prevents the development of oxidant tolerance, i.e., the second A/R challenge produces the same quantitative effects as the initial A/R challenge. In this model, nuclear translocation of both NF-kappa B and AP-1 is required for induction of Mn-SOD, while nuclear translocation of AP-1, but not NF-kappa B, is a prerequisite for induction of eNOS. Collectively, our findings indicate that NF-kappa B and AP-1 work in concert to ensure the induction eNOS and Mn-SOD, which in turn are important for the development of oxidant tolerance.	Univ Western Ontario, Vasc Cell Biol Lab, Ctr Crit Illness Res, Lawson Hlth Res Inst, London, ON N6A 4G5, Canada; Univ Western Ontario, Dept Med Biophys, London, England	Western University (University of Western Ontario); Western University (University of Western Ontario)	Kvietys, PR (corresponding author), Univ Western Ontario, Vasc Cell Biol Lab, Ctr Crit Illness Res, Lawson Hlth Res Inst, 800 Commissioners Rd,VRL 6th FL, London, ON N6A 4G5, Canada.	pkvietys@uwo.ca	Rui, Tao/H-7044-2016					Bell RM, 2002, CARDIOVASC RES, V53, P405, DOI 10.1016/S0008-6363(01)00472-2; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Cepinskas G, 1999, CIRC RES, V84, P103; Cepinskas G, 2001, ACTA PHYSIOL SCAND, V173, P23, DOI 10.1046/j.1365-201X.2001.00881.x; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; Dana A, 2000, CIRCULATION, V101, P2841, DOI 10.1161/01.CIR.101.24.2841; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf; Fisslthaler B, 2003, NITRIC OXIDE-BIOL CH, V8, P253, DOI 10.1016/S1089-8603(03)00042-9; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; Guo Z, 2003, J BIOL CHEM, V278, P23570, DOI 10.1074/jbc.M303431200; HARTMAN JC, 1995, CARDIOVASC RES, V30, P47, DOI 10.1016/0008-6363(95)00015-1; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kaneko M, 2004, BIOL PHARM BULL, V27, P1202, DOI 10.1248/bpb.27.1202; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Lacza Z, 2004, J NEUROCHEM, V90, P942, DOI 10.1111/j.1471-4159.2004.02553.x; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; LEFER DJ, 1993, CIRCULATION, V88, P1779, DOI 10.1161/01.CIR.88.4.1779; LEPIC E, 2001, CAN J CARDIOL, V17, P388; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH1865, DOI 10.1152/ajpheart.1998.275.5.H1865; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH2300, DOI 10.1152/ajpheart.1998.275.6.H2300; Peakman MC, 2003, BRAIN RES, V970, P73, DOI 10.1016/S0006-8993(03)02230-3; Peng TQ, 2003, J BIOL CHEM, V278, P8099, DOI 10.1074/jbc.M207288200; Rui T, 2005, CARDIOVASC RES, V65, P719, DOI 10.1016/j.cardiores.2004.11.019; Rui T, 2003, CARDIOVASC RES, V59, P901, DOI 10.1016/S0008-6363(03)00502-9; Rui T, 2001, AM J PHYSIOL-HEART C, V281, pH440, DOI 10.1152/ajpheart.2001.281.1.H440; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SMITH EF, 1988, AM J PHYSIOL, V255, pH1060, DOI 10.1152/ajpheart.1988.255.5.H1060; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Tay YMS, 2004, FREE RADICAL RES, V38, P591, DOI 10.1080/10715760410001694008; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Vulin AI, 2004, J BIOL CHEM, V279, P25172, DOI 10.1074/jbc.M403184200; Wang D, 1999, AM J HYPERTENS, V12, P174, DOI 10.1016/S0895-7061(98)00235-0; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wilson SH, 2000, ATHEROSCLEROSIS, V148, P23, DOI 10.1016/S0021-9150(99)00211-7; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xuan YT, 1999, CIRC RES, V84, P1095, DOI 10.1161/01.RES.84.9.1095; YAMASHITA N, 1994, J CLIN INVEST, V94, P2193, DOI 10.1172/JCI117580; Yeh CH, 2005, J SURG RES, V125, P109, DOI 10.1016/j.jss.2004.11.009; Yellon DM, 1998, CARDIOVASC RES, V37, P21, DOI 10.1016/S0008-6363(97)00214-9	54	24	28	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1908	+		10.1096/fj.05-4028fje	http://dx.doi.org/10.1096/fj.05-4028fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16157693				2022-12-25	WOS:000232315700019
J	Tscharntke, M; Pofahl, R; Krieg, T; Haase, I				Tscharntke, M; Pofahl, R; Krieg, T; Haase, I			Ras-induced spreading and wound closure in human epidermal keratinocytes	FASEB JOURNAL			English	Article						wound epithelialization; cell spreading; Rac1; epidermis; wound healing	GROWTH-FACTOR; ACTIVATION; MIGRATION; MICE; DIFFERENTIATION; PROLIFERATION; EXPRESSION; SAFE	Although it is known that growth factor signaling cascades are active during epithelial wound healing, signals that regulate reepithelialization after wounding are not very well characterized. The small GTP binding protein Ras is a molecular switch involved in the regulation of signals originating from different growth factor receptors. We have investigated consequences of its activation in primary human keratinocytes. We provide evidence that activation of Ras can lead to shape changes of keratinocytes caused by rearrangements of the actin cytoskeleton that result in membrane protrusion and ruffling. Similar shape changes were found in the migrating tip of newly formed epithelium in mouse wounds. These cytoskeletal changes occur independently of keratinocyte terminal differentiation, and they can determine the speed of wound epithelialization in vitro. Using various mutant constructs and specific pharmacological inhibitors, we found that the effects of activated Ras on the cytoskeleton of keratinocytes are mediated by a phosphatidylinositol 3 kinase-independent activation of Rac. Our results suggest that growth factor-induced, Ras-mediated changes of keratinocyte shape may be an important mechanism that determines the speed of wound epithelialization.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Cologne, CMMC, Ctr Mol Med, D-50924 Cologne, Germany	University of Cologne; University of Cologne	Haase, I (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	Ingo.Haase@uni-koeln.de						ANDO Y, 1993, J INVEST DERMATOL, V100, P633, DOI 10.1111/1523-1747.ep12472297; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; Chaturvedi V, 2003, AM J PATHOL, V162, P161, DOI 10.1016/S0002-9440(10)63807-2; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckes B, 2000, J CELL SCI, V113, P2455; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Haase I, 2003, J CELL SCI, V116, P3227, DOI 10.1242/jcs.00610; Haase I, 2002, J INVEST DERMATOL, V118, P891, DOI 10.1046/j.1523-1747.2002.17631.x; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Jenzora A, 2005, FEBS LETT, V579, P455, DOI 10.1016/j.febslet.2004.10.110; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Nanney LB, 1996, MOL CELLULAR BIOL WO, P171; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Schoff CK, 2004, JCT COATINGSTECH, V1, P64; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; Watt FM, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P113; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhu AJ, 1996, J CELL SCI, V109, P3013	25	15	16	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1836	+		10.1096/fj.04-3327fje	http://dx.doi.org/10.1096/fj.04-3327fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16170018				2022-12-25	WOS:000232315700011
J	Gorin, Y; Block, K; Hernandez, J; Bhandari, B; Wagner, B; Barnes, JL; Abboud, HE				Gorin, Y; Block, K; Hernandez, J; Bhandari, B; Wagner, B; Barnes, JL; Abboud, HE			Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT/PROTEIN KINASE-B; OXIDATIVE STRESS; ANGIOTENSIN-II; NADPH OXIDASE; HIGH-GLUCOSE; MESANGIAL CELLS; EXTRACELLULAR-MATRIX; PROTEIN-SYNTHESIS; GENE-EXPRESSION; DNA-DAMAGE	Renal hypertrophy and extracellular matrix accumulation are early features of diabetic nephropathy. We investigated the role of the NAD(P) H oxidase Nox4 in generation of reactive oxygen species (ROS), hypertrophy, and fibronectin expression in a rat model of type 1 diabetes induced by streptozotocin. Phosphorothioated antisense (AS) or sense oligonucleotides for Nox4 were administered for 2 weeks with an osmotic minipump 72 h after streptozotocin treatment. Nox4 protein expression was increased in diabetic kidney cortex compared with non-diabetic controls and was down-regulated in AS-treated animals. AS oligonucleotides inhibited NADPH-dependent ROS generation in renal cortical and glomerular homogenates. ROS generation by intact isolated glomeruli from diabetic animals was increased compared with glomeruli isolated from AS-treated animals. AS treatment reduced whole kidney and glomerular hypertrophy. Moreover, the increased expression of fibronectin protein was markedly reduced in renal cortex including glomeruli of AS-treated diabetic rats. Akt/protein kinase B and ERK1/2, two protein kinases critical for cell growth and hypertrophy, were activated in diabetes, and AS treatment almost abolished their activation. In cultured mesangial cells, high glucose increased NADPH oxidase activity and fibronectin expression, effects that were prevented in cells transfected with AS oligonucleotides. These data establish a role for Nox4 as the major source of ROS in the kidneys during early stages of diabetes and establish that Nox4-derived ROS mediate renal hypertrophy and increased fibronectin expression.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Abboud, HE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	abboud@uthsca.edu	Wagner, Brent/AAA-8291-2020	Wagner, Brent/0000-0002-7063-0142; Gorin, Yves/0000-0003-4048-6925	NIDDK NIH HHS [DK43988, DK33665] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033665, R37DK033665, R01DK043988] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOUD HE, 1982, J CLIN INVEST, V69, P327, DOI 10.1172/JCI110456; Abboud HE, 1997, KIDNEY INT, pS3; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Carey RM, 2003, TRENDS ENDOCRIN MET, V14, P274, DOI 10.1016/S1043-2760(03)00111-5; Chen HC, 2000, J LAB CLIN MED, V135, P309, DOI 10.1067/mlc.2000.105616; Chen K, 2004, J BIOL CHEM, V279, P35079, DOI 10.1074/jbc.M404859200; Choudhury GG, 2004, CELL SIGNAL, V16, P31, DOI 10.1016/S0898-6568(03)00094-9; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DeRubertis FR, 2004, DIABETES, V53, P762, DOI 10.2337/diabetes.53.3.762; Etoh T, 2003, DIABETOLOGIA, V46, P1428, DOI 10.1007/s00125-003-1205-6; Forbes JM, 2002, DIABETES, V51, P3274, DOI 10.2337/diabetes.51.11.3274; Fujita H, 2004, AM J PHYSIOL-RENAL, V286, pF120, DOI 10.1152/ajprenal.00351.2002; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorin Y, 2004, BIOCHEM J, V381, P231, DOI 10.1042/BJ20031614; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; HA HJ, 1994, FREE RADICAL BIO MED, V16, P271, DOI 10.1016/0891-5849(94)90152-X; Haneda M, 2003, J AM SOC NEPHROL, V14, P1374, DOI 10.1097/01.ASN.0000064500.89551.76; Hink U, 2001, CIRC RES, V88, pE14; Hinokio Y, 1999, DIABETOLOGIA, V42, P995, DOI 10.1007/s001250051258; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hua H, 2003, J BIOL CHEM, V278, P33951, DOI 10.1074/jbc.M302823200; Inoguchi T, 2003, J AM SOC NEPHROL, V14, pS227, DOI 10.1097/01.ASN.0000077407.90309.65; Isono M, 2000, J AM SOC NEPHROL, V11, P2222, DOI 10.1681/ASN.V11122222; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Kim IJ, 2003, DIABETES RES CLIN PR, V60, P11, DOI 10.1016/S0168-8227(02)00278-4; Kimura S, 2005, HYPERTENSION, V45, P860, DOI 10.1161/01.HYP.0000163462.98381.7f; Kiritoshi S, 2003, DIABETES, V52, P2570, DOI 10.2337/diabetes.52.10.2570; Kitada M, 2003, DIABETES, V52, P2603, DOI 10.2337/diabetes.52.10.2603; Koya D, 2003, J AM SOC NEPHROL, V14, pS250, DOI 10.1097/01.ASN.0000077412.07578.44; Kuroki T, 2003, J AM SOC NEPHROL, V14, pS216, DOI 10.1097/01.ASN.0000077405.07888.07; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Lee HB, 2003, J AM SOC NEPHROL, V14, pS241, DOI 10.1097/01.ASN.0000077410.66390.0F; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Onozato ML, 2002, KIDNEY INT, V61, P186, DOI 10.1046/j.1523-1755.2002.00123.x; Petermann AT, 2005, KIDNEY INT, V67, P157, DOI 10.1111/j.1523-1755.2005.00066.x; Phillips Aled O, 2003, Curr Diab Rep, V3, P491, DOI 10.1007/s11892-003-0013-1; RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205; Sano T, 1998, DIABETOLOGIA, V41, P1355, DOI 10.1007/s001250051076; Schafer M, 2003, CIRC RES, V92, P1010, DOI 10.1161/01.RES.0000070882.81508.FC; Schnackenberg CG, 2002, CURR OPIN PHARMACOL, V2, P121, DOI 10.1016/S1471-4892(02)00133-9; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Sheu ML, 2004, MOL PHARMACOL, V66, P187, DOI 10.1124/mol.66.1.187; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Wolf G, 2004, HYPERTENSION, V43, P693, DOI 10.1161/01.HYP.0000120963.09029.ca; Wolf Gunter, 2003, Curr Diab Rep, V3, P485, DOI 10.1007/s11892-003-0012-2; Yamagishi S, 2001, DIABETES, V50, P1491, DOI 10.2337/diabetes.50.6.1491; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	62	421	444	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39616	39626		10.1074/jbc.M502412200	http://dx.doi.org/10.1074/jbc.M502412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16135519	hybrid			2022-12-25	WOS:000233362200085
J	Hakuno, D; Takahashi, T; Lammerding, J; Lee, RT				Hakuno, D; Takahashi, T; Lammerding, J; Lee, RT			Focal adhesion kinase signaling regulates cardiogenesis of embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; CARDIAC DIFFERENTIATION; ENDOGENOUS INHIBITOR; GENE-EXPRESSION; MOUSE EMBRYOS; SELF-RENEWAL; SRC FAMILY; MUSCLE; PROLIFERATION; INTEGRINS	The signaling steps that induce cardiac differentiation in embryonic stem (ES) cells are incompletely understood. We examined the effect of adhesion signaling including Src and focal adhesion kinase (FAK) on cardiogenesis in mouse ES cells using alpha-myosin heavy chain promoter-driven enhanced green fluorescent protein or luciferase as reporters. Cardiac transcription factors including Nkx2.5 and Tbx5 mRNA were first expressed at day 4 in hanging drop embryoid bodies, and adhesion of embryoid bodies to surfaces at or before that day strongly inhibited differentiation of ES cells to cardiomyocytes. Since adhesion signaling could suppress cardiogenesis through Src kinases, embryoid bodies were exposed to the small molecule PP2, known as a Src family kinase inhibitor. PP2 during embryoid body adhesion dramatically increased cardiomyocyte differentiation and decreased mRNA expression of neuronal cellular adhesion molecule and alpha-fetoprotein, neuroectodermal, and endodermal markers, respectively. Surprisingly, although there was an interaction between Src and FAK in cardiogenesis, the procardiogenic effect of PP2 appeared incompletely explained by Src kinase inhibition, since another Src family kinase inhibitor, SU6656, failed to induce cardiogenesis. Instead, PP2 specifically inhibited adhesion-induced FAK phosphorylation. In ES cells stably expressing FAK-related nonkinase, which functions as a dominant negative FAK, cell migration from embryoid bodies was inhibited, whereas alpha-myosin heavy chain expression and myosin-stained cardiomyocytes were increased, suggesting that reducing cell motility may contribute to cardiogenesis. These data indicate that FAK is a key regulator of cardiogenesis in mouse ES cells and that FAK signaling within embryoid bodies can direct stem cell lineage commitment.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital	Lee, RT (corresponding author), Partners Res Facil, Rm 279,65 Landsdowne St, Cambridge, MA 02139 USA.	rlee@rics.bwh.harvard.edu	Lammerding, Jan/A-9498-2016	Lammerding, Jan/0000-0003-4335-8611	NHLBI NIH HHS [HL081404] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anneren C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200; Aplin AE, 1998, PHARMACOL REV, V50, P197; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Ching YH, 2005, NAT GENET, V37, P423, DOI 10.1038/ng1526; Choi SC, 2004, EXP MOL MED, V36, P515, DOI 10.1038/emm.2004.66; Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x; Dallabrida SM, 2005, CIRC RES, V96, DOI 10.1161/01.RES.0000158285.57191.60; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gepstein L, 2002, CIRC RES, V91, P866, DOI 10.1161/01.RES.0000041435.95082.84; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goh KL, 1997, DEVELOPMENT, V124, P4309; Hamazaki T, 2004, J CELL SCI, V117, P5681, DOI 10.1242/jcs.01489; Hatcher CJ, 2001, DEV BIOL, V230, P177, DOI 10.1006/dbio.2000.0134; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Heidkamp MC, 2002, CIRC RES, V90, P1282, DOI 10.1161/01.RES.0000023201.41774.EA; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; Kanno S, 2004, P NATL ACAD SCI USA, V101, P12277, DOI 10.1073/pnas.0401557101; Karni R, 2003, FEBS LETT, V537, P47, DOI 10.1016/S0014-5793(03)00069-3; Kehat I, 2004, NAT BIOTECHNOL, V22, P1282, DOI 10.1038/nbt1014; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klees RF, 2005, MOL BIOL CELL, V16, P881, DOI 10.1091/mbc.e04-08-0695; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Lunn JA, 2004, J BIOL CHEM, V279, P45266, DOI 10.1074/jbc.M314132200; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Naito AT, 2005, CIRC RES, V97, P144, DOI 10.1161/01.RES.0000175241.92285.f8; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; Park HB, 2004, BIOCHEM J, V378, P559, DOI 10.1042/BJ20031392; Parsons MJ, 2002, DEVELOPMENT, V129, P3137; Prudhomme W, 2004, P NATL ACAD SCI USA, V101, P2900, DOI 10.1073/pnas.0308768101; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ross RS, 2001, CIRC RES, V88, P1112, DOI 10.1161/hh1101.091862; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Solloway MJ, 2003, CARDIOVASC RES, V58, P264, DOI 10.1016/S0008-6363(03)00286-4; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Takahashi T, 2003, CIRCULATION, V107, P1912, DOI 10.1161/01.CIR.0000064899.53876.A3; Takito J, 2004, J CELL BIOL, V166, P1093, DOI 10.1083/jcb.200405159; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Torsoni AS, 2003, CIRC RES, V93, P140, DOI 10.1161/01.RES.0000081595.25297.1B; Ventura C, 2000, CIRC RES, V87, P189, DOI 10.1161/01.RES.87.3.189; Vinarsky V, 2005, DEV BIOL, V279, P86, DOI 10.1016/j.ydbio.2004.12.003; Walker HA, 2003, MOL BIOL CELL, V14, P1941, DOI 10.1091/mbc.E02-08-0508; Waltenberger J, 1999, CIRC RES, V85, P12; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91	63	63	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39534	39544		10.1074/jbc.M505575200	http://dx.doi.org/10.1074/jbc.M505575200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16157602	hybrid			2022-12-25	WOS:000233362200076
J	Girardin, SE; Jehanno, M; Mengin-Lecreulx, D; Sansonetti, PJ; Alzari, PM; Philpott, DJ				Girardin, SE; Jehanno, M; Mengin-Lecreulx, D; Sansonetti, PJ; Alzari, PM; Philpott, DJ			Identification of the critical residues involved in peptidoglycan detection by Nod1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HOST RECOGNITION; INNATE; TOLL; SUSCEPTIBILITY; ASSOCIATION; PROTEINS; CATERPILLER; BACTERIA; MUTATION	Nod1 is an intracellular pattern recognition molecule activated following bacterial infection, which senses a specific muropeptide (L-Ala-D-Glu-meso-DAP (diaminopimelic acid); "Tri(DAP)") from peptidoglycan. Here we investigated the molecular basis of Tri(DAP) sensing by human (h) Nod1. Our results identified the domain responsible for Tri(DAP) detection in the center of the concave surface of hNod1 leucine-rich repeat domain. Amino acid residues critical for sensing define a contiguous surface patch that is largely conserved in Nod1 proteins from different species. Accordingly, the distinct specificities of human versus murine Nod1 toward muropeptide detection were also found to lie in this central cleft. Several splicing variants of Nod1 lacking repeats 7-9 have been characterized recently, the relative balance of which is thought to correlate with the onset of asthma or inflammatory bowel disease. We demonstrated that these isoforms failed to transduce NF-kappa B activation upon muropeptide stimulation. This study provided insights into the molecular mechanisms responsible for the detection of bacterial peptidoglycan by Nod1 and suggested that defects in Nod1-dependent peptidoglycan sensing may contribute to elicit certain inflammatory disorders.	Inst Pasteur, Grp Inserm Avenir Peptidoglycan & Innate Immun, F-75724 Paris, France; Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris, France; Inst Pasteur, Grp Immunite Innee & Signalisat, F-75724 Paris, France; Inst Pasteur, Unite Biochim Struct, F-75724 Paris, France; Univ Paris 11, CNRS, UMR 8619, IBBMC, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Girardin, SE (corresponding author), Inst Pasteur, 28 Rue Dr Roux, F-75724 Paris, France.	girardin@pasteur.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275; Alzari, Pedro/0000-0002-4233-1903				Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Chamaillard M, 2004, TRENDS MICROBIOL, V12, P529, DOI 10.1016/j.tim.2004.10.001; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Magalhaes JG, 2005, EMBO REP, V6, P1201, DOI 10.1038/sj.embor.7400552; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Opitz B, 2005, CIRC RES, V96, P319, DOI 10.1161/01.RES.0000155721.83594.2c; Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200; Rose CD, 2005, J RHEUMATOL, V32, P373; Schubert WD, 2002, CELL, V111, P825, DOI 10.1016/S0092-8674(02)01136-4; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Steiner H, 2004, IMMUNOL REV, V198, P83, DOI 10.1111/j.0105-2896.2004.0120.x; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Ting JPY, 2005, CLIN IMMUNOL, V115, P33, DOI 10.1016/j.clim.2005.02.007; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Travassos LH, 2005, J BIOL CHEM, V280, P36714, DOI 10.1074/jbc.M501649200; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034	34	99	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38648	38656		10.1074/jbc.M509537200	http://dx.doi.org/10.1074/jbc.M509537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172124	hybrid, Green Published			2022-12-25	WOS:000233239800066
J	Duy, C; Fitter, J				Duy, C; Fitter, J			Thermostability of irreversible unfolding alpha-amylases analyzed by unfolding kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; PYRROLIDONE CARBOXYL PEPTIDASE; THERMAL-DENATURATION; THERMODYNAMIC STABILITY; TAKA-AMYLASE; MECHANISM; PROTEIN; HYPERTHERMOPHILE; COLD; STABILIZATION	For most multidomain proteins the thermal unfolding transitions are accompanied by an irreversible step, often related to aggregation at elevated temperatures. As a consequence the analysis of thermostabilities in terms of equilibrium thermodynamics is not applicable, at least not if the irreversible process is fast with respect the structural unfolding transition. In a comparative study we investigated aggregation effects and unfolding kinetics for five homologous alpha-amylases, all from mesophilic sources but with rather different thermostabilities. The results indicate that for all enzymes the irreversible process is fast and the precedent unfolding transition is the rate-limiting step. In this case the kinetic barrier toward unfolding, as measured by unfolding rates as function of temperature, is the key feature in thermostability. The investigated enzymes exhibit activation energies (E-a) between 208 and 364 kJ mol(-1) and pronounced differences in the corresponding unfolding rates. The most thermostable alpha-amylase from Bacillus licheniformis ( apparent transition temperature, T-1/2 similar to 100 degrees C) shows an unfolding rate which is four orders of magnitude smaller as compared with the alpha-amylase from pig pancreas (T-1/2 similar to 65 degrees C). Even with respect to two other alpha-amylases from Bacillus species (T-1/2 similar to 86 degrees C) the difference in unfolding rates is still two orders of magnitude.	Forschungszentrum Julich, Biol Strukturforsch, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Fitter, J (corresponding author), Forschungszentrum Julich, Biol Strukturforsch, IBI-2, D-52425 Julich, Germany.	j.fitter@fz-juelich.de	Duy, Cihangir/AAD-7735-2022; Fitter, Joerg/J-3294-2013	Duy, Cihangir/0000-0001-9150-9379; Fitter, Joerg/0000-0002-4503-2079				Bachmann A, 2005, PROTEIN FOLDING HANDBOOK, P379; Cavagnero S, 1998, BIOCHEMISTRY-US, V37, P3369, DOI 10.1021/bi9721795; Cavagnero S, 1998, BIOCHEMISTRY-US, V37, P3377, DOI 10.1021/bi9721804; Collins T, 2003, J MOL BIOL, V328, P419, DOI 10.1016/S0022-2836(03)00287-0; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; Declerck N, 1997, PROTEIN ENG, V10, P541, DOI 10.1093/protein/10.5.541; del Pino IMP, 2000, PROTEINS, V40, P58, DOI 10.1002/(SICI)1097-0134(20000701)40:1<58::AID-PROT80>3.0.CO;2-M; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Fitter J, 2005, CELL MOL LIFE SCI, V62, P1925, DOI 10.1007/s00018-005-5079-2; Fitter J, 2004, BIOCHEMISTRY-US, V43, P9589, DOI 10.1021/bi0493362; Fitter J, 2001, BIOCHEMISTRY-US, V40, P10723, DOI 10.1021/bi010808b; FUKADA H, 1987, BIOCHEMISTRY-US, V26, P4063, DOI 10.1021/bi00387a048; GALISTEO ML, 1991, BIOCHEMISTRY-US, V30, P2061, DOI 10.1021/bi00222a009; Georlette D, 2004, FEMS MICROBIOL REV, V28, P25, DOI 10.1016/j.femsre.2003.07.003; Hollien J, 2002, J MOL BIOL, V316, P327, DOI 10.1006/jmbi.2001.5346; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kaushik JK, 2002, J MOL BIOL, V316, P991, DOI 10.1006/jmbi.2001.5355; Kawata Y, 1998, PROTEIN ENG, V11, P1293, DOI 10.1093/protein/11.12.1293; Khajeh K, 2001, BBA-PROTEIN STRUCT M, V1548, P229, DOI 10.1016/S0167-4838(01)00236-9; LADERMAN KA, 1993, J BIOL CHEM, V268, P24394; LASKIN AI, 1988, CRC HDB MICROBIOLOGY, P325; LEPOCK JR, 1992, BIOCHEMISTRY-US, V31, P12706, DOI 10.1021/bi00165a023; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; Machius M, 2003, J BIOL CHEM, V278, P11546, DOI 10.1074/jbc.M212618200; Mukaiyama A, 2004, BIOCHEMISTRY-US, V43, P13859, DOI 10.1021/bi0487645; Nielsen AD, 2003, BBA-PROTEINS PROTEOM, V1652, P52, DOI 10.1016/j.bbapap.2003.08.002; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P5939, DOI 10.1021/bi973172q; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Rosengarth A, 1999, EUR J BIOCHEM, V264, P989, DOI 10.1046/j.1432-1327.1999.00712.x; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; Shin I, 2002, PROTEIN SCI, V11, P2022, DOI 10.1110/ps.0205102; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; Tanaka A, 2002, BIOCHEM J, V364, P635, DOI 10.1042/BJ20011436; TELLOSOLIS SR, 1995, BIOCHEM J, V311, P969, DOI 10.1042/bj3110969; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665; Vogl T, 1997, BIOCHEMISTRY-US, V36, P1657, DOI 10.1021/bi962163z; Wittung-Stafshede P, 2004, BBA-PROTEINS PROTEOM, V1700, P1, DOI 10.1016/j.bbapap.2004.04.002; Yazdanparast R, 2005, INT J BIOL MACROMOL, V35, P257, DOI 10.1016/j.ijbiomac.2005.02.007	44	74	74	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37360	37365		10.1074/jbc.M507530200	http://dx.doi.org/10.1074/jbc.M507530200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150692	hybrid			2022-12-25	WOS:000233044500009
J	Verlinden, L; Eelen, G; Beullens, I; Van Camp, M; Van Hummelen, P; Engelen, K; Van Hellemont, R; Marchal, K; De Moor, B; Foijer, F; Riele, HT; Beullens, M; Bollen, M; Mathieu, C; Bouillon, R; Verstuyf, A				Verlinden, L; Eelen, G; Beullens, I; Van Camp, M; Van Hummelen, P; Engelen, K; Van Hellemont, R; Marchal, K; De Moor, B; Foijer, F; Riele, HT; Beullens, M; Bollen, M; Mathieu, C; Bouillon, R; Verstuyf, A			Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target genes down-regulated by 1,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; IN-VIVO; DNA-REPLICATION; FAMILY-MEMBER; EXPRESSION; TRANSCRIPTION; COMPLEX; PROFILES; PROLIFERATION; PROGRESSION	1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) has potent antiproliferative effects characterized by a hampered G(1)/S transition. cDNA microarrays were used to monitor expression of 21,492 genes in MC3T3-E1 mouse osteoblasts at 1, 6, 12, 24, and 36 h after treatment with 1,25(OH)(2)D-3. Statistical analysis revealed a cluster of genes that were strongly down-regulated by 1,25(OH)(2)D-3 and which not only function in cell cycle regulation and DNA replication but also mediate checkpoint control, DNA repair, chromosome modifications, and mitosis. Because many of these genes were shown earlier to be regulated by the transcriptional repressor E2F4, the intergenic regions of these 1,25(OH)(2)D-3-down-regulated genes were searched for the presence of E2F binding sites. This led to the characterization of two novel E2F target genes, chromosome condensation-related SMC-associated protein 1 (Cnap1) and maternal embryonic leucine zipper kinase ( Melk). Transfection studies and site-directed mutagenesis confirmed Cnap1 and Melk to be bona fide E2F targets. Repression of Cnap1 and Melk by 1,25(OH)(2)D-3 was confirmed not only in MC3T3-E1 cells but also in several other bone-unrelated cell types. This down-regulation as well as the antiproliferative effect of 1,25( OH)(2)D-3 depended on the pocket proteins p107 and p130 because 1,25(OH)(2)D-3 failed to repress these E2F target genes and lost its antiproliferative action in p107(-/-); p130(-/-) cells but not in pRb(-/-) cells.	Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium; Vlaams Interuniv Inst Biotechnol, Microarray Facil, B-3000 Louvain, Belgium; Katholieke Univ Leuven, ESAT SCD, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Afdeling Biochem, Louvain, Belgium; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	KU Leuven; KU Leuven; KU Leuven; Netherlands Cancer Institute	Bouillon, R (corresponding author), Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium.	Roger.Bouillon@med.kuleuven.be	Verlinden, Lieve/E-6517-2011; Marchal, Kathleen/O-7936-2017; Marchal, Kathleen/B-5001-2013; mathieu, chantal/ABD-5505-2021	Marchal, Kathleen/0000-0002-2169-4588; Marchal, Kathleen/0000-0002-2169-4588; mathieu, chantal/0000-0002-4055-5233; Foijer, Floris/0000-0003-0989-3127; van hummelen, paul/0000-0002-4801-8600; Verlinden, Lieve/0000-0002-9621-3662; Engelen, Kristof/0000-0001-6215-1689; Verstuyf, Annemieke/0000-0003-3193-2698				Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Audo I, 2003, INVEST OPHTH VIS SCI, V44, P4192, DOI 10.1167/iovs.02-1198; Ball AR, 2002, MOL CELL BIOL, V22, P5769, DOI 10.1128/MCB.22.16.5769-5781.2002; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; De Smet F, 2002, BIOINFORMATICS, V18, P735, DOI 10.1093/bioinformatics/18.5.735; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Engelen K, 2003, BIOINFORMATICS, V19, P893, DOI 10.1093/bioinformatics/btg085; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heyer BS, 1999, DEV DYNAM, V215, P344; Hofman K, 2001, BIOCHEM BIOPH RES CO, V283, P97, DOI 10.1006/bbrc.2001.4738; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; Kasprzyk A, 2004, GENOME RES, V14, P160, DOI 10.1101/gr.1645104; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lenhard B, 2002, BIOINFORMATICS, V18, P1135, DOI 10.1093/bioinformatics/18.8.1135; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Thijs G, 2002, BIOINFORMATICS, V18, P331, DOI 10.1093/bioinformatics/18.2.331; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vaisanen S, 2004, J STEROID BIOCHEM, V89-90, P277, DOI 10.1016/j.jsbmb.2004.03.075; Verlinden L, 2000, CANCER RES, V60, P2673; Vulsteke V, 2004, J BIOL CHEM, V279, P8642, DOI 10.1074/jbc.M311466200; Wang QM, 1997, CANCER RES, V57, P2851; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488	39	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37319	37330		10.1074/jbc.M503587200	http://dx.doi.org/10.1074/jbc.M503587200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144839	hybrid, Green Published			2022-12-25	WOS:000233044500005
J	O'Gorman, W; Thomas, B; Kwek, KY; Furger, A; Akoulitchev, A				O'Gorman, W; Thomas, B; Kwek, KY; Furger, A; Akoulitchev, A			Analysis of U1 small nuclear RNA interaction with cyclin H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; POLYMERASE-II TRANSCRIPTION; CARBOXYL-TERMINAL DOMAIN; P-TEFB; HIV-1 TAT; SUBSTRATE-SPECIFICITY; MASS-SPECTROMETRY; CROSS-LINKING; SMN COMPLEX; DNA-REPAIR	TFIIH is a general transcription and repair factor implicated in RNA polymerase II transcription, nucleotide excision repair, and transcription-coupled repair. Genetic defects in TFIIH lead to three distinct inheritable diseases: xeroderma pigmentosa, Cockayne syndrome, and trichothiodystrophy, with xeroderma pigmentosa patients being highly susceptible to skin cancer. Earlier data revealed that the cyclin H subunit of TFIIH associates with U1 small nuclear RNA, a core-splicing component. In addition to its role in RNA processing U1 small nuclear RNA also regulates diverse stages of transcription by RNA polymerase II both in vivo and in vitro, including abortive initiation and re-initiation. Here we identify structural components of U1 and cyclin H implicated in the direct interaction and show how they affect function. Because of unique features of cyclin H we have developed a new methodology for mapping RNA interaction with the full-length cyclin H polypeptide based on electrospray ionization tandem mass spectrometry. We also demonstrate the importance of U1 stem-loops 1 and 2 for the interaction with cyclin H. Functional assays implicate the identified interaction with U1 in regulation of the activity of the cyclin H associated kinase CDK7.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Akoulitchev, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	alexandre.akoulitchev@pathology.ox.ac.uk			Medical Research Council [G0200452] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0200452] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Ashe MP, 2000, RNA, V6, P170, DOI 10.1017/S1355838200991957; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Gubitz AK, 2004, EXP CELL RES, V296, P51, DOI 10.1016/j.yexcr.2004.03.022; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; O'Sullivan JM, 2004, NAT GENET, V36, P1014, DOI 10.1038/ng1411; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reese JC, 2003, CURR OPIN GENET DEV, V13, P114, DOI 10.1016/S0959-437X(03)00013-3; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Rusconi F, 2002, MASS SPECTROM REV, V21, P305, DOI 10.1002/mas.10036; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Steen H, 2002, MASS SPECTROM REV, V21, P163, DOI 10.1002/mas.10024; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	51	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36920	36925		10.1074/jbc.M505791200	http://dx.doi.org/10.1074/jbc.M505791200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115885	hybrid			2022-12-25	WOS:000232901800048
J	Predescu, SA; Predescu, DN; Shimizu, K; Klein, IK; Malik, AB				Predescu, SA; Predescu, DN; Shimizu, K; Klein, IK; Malik, AB			Cholesterol-dependent syntaxin-4 and SNAP-23 clustering regulates caveolar fusion with the endothelial plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCYTOSIS; TRANSPORT; VESICLES; CELLS; MACHINERY; ENDOCYTOSIS; COMPLEXES; FISSION; DOCKING; SNARES	We determined the organization of target (t) SNARE proteins on the basolateral endothelial plasmamembrane ( PM) and their role in the mechanism of caveolar fusion. Studies were performed in a cell-free system involving endothelial PM sheets and isolated biotin-labeled caveolae. We monitored the fusion of caveolae with the PM by the detection of biotin-streptavidin complexes using correlative high resolution fluorescence microscopy and gold labeling electron microscopy on ultrathin sections of PM sheets. Imaging of PM sheets demonstrated and biochemical findings showed that the t-SNARE proteins present in endothelial cells (SNAP-23 and syntaxin-4) formed cholesterol-dependent clusters in discrete areas of the PM. Upon fusion of caveolae with the target PM, 50% of the caveolae co-localized with the t-SNARE clusters, indicating that these caveolae were at the peak of the fusion reaction. Fluorescent streptavidin staining of PM sheets correlated with the ultrastructure in the same area. These findings demonstrate that t-SNARE clusters in the endothelial target PM serve as the fusion sites for caveolae during exocytosis.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Malik, AB (corresponding author), Univ Illinois, Dept Pharmacol MC868, 835 S Wolcott Ave, Chicago, IL 60612 USA.	abmalik@uic.edu		Malik, Asrar/0000-0002-8205-7128; Predescu, Sanda/0000-0002-9386-6756	NHLBI NIH HHS [P01 HL60678] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avery J, 2000, J CELL BIOL, V148, P317, DOI 10.1083/jcb.148.2.317; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Heuser J, 2000, TRAFFIC, V1, P545, DOI 10.1034/j.1600-0854.2000.010704.x; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Niles WD, 1999, J MEMBRANE BIOL, V167, P85, DOI 10.1007/s002329900474; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1979, ACTA PHYSIOL SCAND, P11; PREDESCU AS, 1997, AM J PHYSIOL, V272, pH937; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; Predescu SA, 2003, MOL BIOL CELL, V14, P4997, DOI 10.1091/mbc.e03-01-0041; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Rothman JE, 2002, NAT MED, V8, P1059, DOI 10.1038/nm770; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SIMIONESCU N, 1983, J CELL BIOL, V97, P1592, DOI 10.1083/jcb.97.5.1592; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500	21	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37130	37138		10.1074/jbc.M505659200	http://dx.doi.org/10.1074/jbc.M505659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118213	hybrid			2022-12-25	WOS:000232901800071
J	Kao, KC; Tran, LM; Liao, JC				Kao, KC; Tran, LM; Liao, JC			A global regulatory role of gluconeogenic genes in Escherichia coli revealed by transcriptome network analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA SYNTHETASE; PHOSPHORYLATION STATE; ACETATE OPERON; RNA-POLYMERASE; IN-VIVO; EXPRESSION; PROTEIN; SIGMA(S); GROWTH; IDENTIFICATION	In bacterial adaptation to the dynamic environment, metabolic genes are typically thought to be the executors, whereas global transcription regulators are regarded as the decision makers. Although the feedback from metabolic consequence is believed to be important, much less is understood. This work demonstrates that the gluconeogenic genes in Escherichia coli, ppsA, sfcA, and maeB, provide a feedback loop to the global regulator, cAMP receptor protein (CRP), in carbon source transition. Disruption of one of the gluconeogenic pathways has no phenotype in balanced growth, but causes a significant delay in the diauxic transition from glucose to acetate. To investigate the underlying mechanism, we measured the transcriptome profiles during the transition using DNA microarray, and network component analysis was employed to obtain the transcription factor activities. Results showed that one of the global regulators, CRP, was insufficiently activated during the transition in the ppsA deletion mutant. Indeed, addition of cAMP partially rescued the delay in transition. These results suggest that the gluconeogenic flux to phosphoenolpyruvate is important for full activation of adenylate cyclase through the phosphorylated enzyme IIA(glu) of the phosphotransferase system. Reduction of this flux causes insufficient activation of CRP and a global metabolic deficiency, which exemplifies a significant feedback interaction from metabolism to the a global regulatory system.	Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Liao, JC (corresponding author), Univ Calif Los Angeles, Dept Chem & Biomol Engn, 420 Westwood Plaza, Los Angeles, CA 90095 USA.	liaoj@ucla.edu		Kao, Katy/0000-0002-1184-276X; Liao, James/0000-0002-4580-7276				Almeida Jonas S, 2003, Genome Inform, V14, P114; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Beatty CM, 2003, J BACTERIOL, V185, P5148, DOI 10.1128/JB.185.17.5148-5157.2003; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; Cozzone AJ, 1998, ANNU REV MICROBIOL, V52, P127, DOI 10.1146/annurev.micro.52.1.127; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; ELMANSI EMT, 1986, J GEN MICROBIOL, V132, P797; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; Gimenez R, 2003, J BACTERIOL, V185, P6448, DOI 10.1128/JB.185.21.6448-6455.2003; Hogema BM, 1998, MOL MICROBIOL, V30, P487, DOI 10.1046/j.1365-2958.1998.01053.x; Holms H, 1996, FEMS MICROBIOL REV, V19, P85, DOI 10.1111/j.1574-6976.1996.tb00255.x; Hyduke Daniel R., 2003, OMICS A Journal of Integrative Biology, V7, P227, DOI 10.1089/153623103322452369; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; Kao KC, 2004, P NATL ACAD SCI USA, V101, P641, DOI 10.1073/pnas.0305287101; Kumari S, 2000, J BACTERIOL, V182, P4173, DOI 10.1128/JB.182.15.4173-4179.2000; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; Liao JC, 1996, BIOTECHNOL BIOENG, V52, P129, DOI 10.1002/(SICI)1097-0290(19961005)52:1<129::AID-BIT13>3.0.CO;2-J; Liao JC, 2003, P NATL ACAD SCI USA, V100, P15522, DOI 10.1073/pnas.2136632100; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Murray HD, 2003, MOL CELL, V12, P125, DOI 10.1016/S1097-2765(03)00266-1; Nair S, 2004, J BACTERIOL, V186, P4192, DOI 10.1128/JB.186.13.4192-4198.2004; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; PARK SJ, 1995, J BACTERIOL, V177, P6652, DOI 10.1128/jb.177.22.6652-6656.1995; PATNAIK R, 1992, J BACTERIOL, V174, P7527, DOI 10.1128/JB.174.23.7527-7532.1992; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; Resnik E, 1996, J BACTERIOL, V178, P2715, DOI 10.1128/jb.178.9.2715-2717.1996; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; Savageau M, 1976, BIOCH SYSTEMS ANAL S; Shin S, 1997, FEMS MICROBIOL LETT, V146, P103, DOI 10.1111/j.1574-6968.1997.tb10178.x; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Teich A, 1999, BIOTECHNOL PROGR, V15, P123, DOI 10.1021/bp980102h; Tran LM, 2005, METAB ENG, V7, P128, DOI 10.1016/j.ymben.2004.12.001; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Wolfe AJ, 2005, MICROBIOL MOL BIOL R, V69, P12, DOI 10.1128/MMBR.69.1.12-50.2005; Yamamoto K, 2003, MOL MICROBIOL, V47, P183, DOI 10.1046/j.1365-2958.2003.03287.x; Zheng DL, 2004, NUCLEIC ACIDS RES, V32, P5874, DOI 10.1093/nar/gkh908	44	67	71	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36079	36087		10.1074/jbc.M508202200	http://dx.doi.org/10.1074/jbc.M508202200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141204	hybrid, Green Published			2022-12-25	WOS:000232726900038
J	Tabner, BJ; El-Agnaf, OMA; Turnbull, S; German, MJ; Paleologou, KE; Hayashi, Y; Cooper, LJ; Fullwood, NJ; Allsop, D				Tabner, BJ; El-Agnaf, OMA; Turnbull, S; German, MJ; Paleologou, KE; Hayashi, Y; Cooper, LJ; Fullwood, NJ; Allsop, D			Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; OXIDATIVE STRESS; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; CELL-DEATH; NEURODEGENERATIVE DISEASES; ABRI PEPTIDE; PROTEIN; REDUCTION; OLIGOMERS	Alzheimer disease and familial British dementia are neurodegenerative diseases that are characterized by the presence of numerous amyloid plaques in the brain. These lesions contain fibrillar deposits of the beta-amyloid peptide (A beta) and the British dementia peptide (ABri), respectively. Both peptides are toxic to cells in culture, and there is increasing evidence that early "soluble oligomers" are the toxic entity rather than mature amyloid fibrils. The molecular mechanisms responsible for this toxicity are not clear, but in the case of A beta, one prominent hypothesis is that the peptide can induce oxidative damage via the formation of hydrogen peroxide. We have developed a reliable method, employing electron spin resonance spectroscopy in conjunction with the spin-trapping technique, to detect any hydrogen peroxide generated during the incubation of A beta and other amyloidogenic peptides. Here, we monitored levels of hydrogen peroxide accumulation during different stages of aggregation of A beta-(1 - 40) and ABri and found that in both cases it was generated as a short "burst" early on in the aggregation process. Ultrastructural studies with both peptides revealed that structures resembling "soluble oligomers" or "protofibrils" were present during this early phase of hydrogen peroxide formation. Mature amyloid fibrils derived from A beta-( 1 - 40) did not generate hydrogen peroxide. We conclude that hydrogen peroxide formation during the early stages of protein aggregation may be a common mechanism of cell death in these ( and possibly other) neurodegenerative diseases.	Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Lancaster, Dept Phys, Lancaster LA1 4YQ, England; Univ Lancaster, Magnet Resonance Lab, Lancaster LA1 4YQ, England; United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates	Lancaster University; Lancaster University; Lancaster University; United Arab Emirates University	Allsop, D (corresponding author), Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England.	d.allsop@lancaster.ac.uk	German, Matt/R-5269-2018; Allsop, David/B-9725-2008	German, Matt/0000-0002-3910-6377; Allsop, David/0000-0002-0513-5575; Fullwood, Nigel James/0000-0002-9405-8515	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Antunes F, 2001, FREE RADICAL BIO MED, V30, P1008, DOI 10.1016/S0891-5849(01)00493-2; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Barnham KJ, 2004, FASEB J, V18, P1427, DOI 10.1096/fj.04-1890fje; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bitan G, 2003, J BIOL CHEM, V278, P34882, DOI 10.1074/jbc.M300825200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Dikalov SI, 2004, FREE RADICAL BIO MED, V36, P340, DOI 10.1016/j.freeradbiomed.2003.11.004; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; El-Agnaf OMA, 2001, BIOCHEMISTRY-US, V40, P3449, DOI 10.1021/bi002287i; HARPER JD, 1997, ANNU REV BIOCHEM, V66, P387; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; Moore SA, 2004, BIOCHEMISTRY-US, V43, P819, DOI 10.1021/bi035728h; Nelson TJ, 2005, J BIOL CHEM, V280, P7377, DOI 10.1074/jbc.M409071200; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; Srinivasan R, 2003, J MOL BIOL, V333, P1003, DOI 10.1016/j.jmb.2003.09.001; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Tabner Brian J., 2003, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V3, P299, DOI 10.2174/1568013033483249; Tabner Brian J., 2001, Current Topics in Medicinal Chemistry, V1, P507, DOI 10.2174/1568026013394822; Turnbull S, 2003, NEUROSCI LETT, V336, P159, DOI 10.1016/S0304-3940(02)01254-5; Turnbull S, 2003, BIOCHEMISTRY-US, V42, P7675, DOI 10.1021/bi030036e; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200	39	191	193	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35789	35792		10.1074/jbc.C500238200	http://dx.doi.org/10.1074/jbc.C500238200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141213	hybrid			2022-12-25	WOS:000232726900003
J	Amiry-Moghaddam, M; Lindland, H; Zelenin, S; Roberg, BA; Gundersen, BB; Petersen, P; Rinvik, E; Torgner, IA; Ottersen, OP				Amiry-Moghaddam, M; Lindland, H; Zelenin, S; Roberg, BA; Gundersen, BB; Petersen, P; Rinvik, E; Torgner, IA; Ottersen, OP			Brain mitochondria contain aquaporin water channels: evidence for the expression of a short AQP9 isoform in the inner mitochondrial membrane	FASEB JOURNAL			English	Article						water channels; mitochondria; Parkinson's disease; astrocytes; substantia nigra	PHOSPHATE-ACTIVATED GLUTAMINASE; NEUTRAL SOLUTE CHANNEL; RAT-BRAIN; ISCHEMIC BRAIN; MOLECULAR CHARACTERIZATION; ASTROCYTE MITOCHONDRIA; GLYCEROL FACILITATOR; ENERGY-METABOLISM; ESCHERICHIA-COLI; HYPOXIA-ISCHEMIA	Aquaporins are a family of water channels found in animals, plants, and microorganisms. A subfamily of aquaporins, the aquaglyceroporins, are permeable for water as well as certain solutes such as glycerol, lactate, and urea. Here we show that the brain contains two isoforms of AQP9 - an aquaglyceroporin with a particularly broad substrate specificity - and that the more prevalent of these isoforms is expressed in brain mitochondria. The mitochondrial AQP9 isoform is detected as an similar to 25 kDa band in immunoblots. This isoform is likely to correspond to a new AQP9 mRNA that is obtained by alternative splicing and has a shorter ORF than the liver isoform. Subfractionation experiments and high-resolution immunogold analyses revealed that this novel AQP9 isoform is enriched in mitochondrial inner membranes. AQP9 immunopositive mitochondria occurred in astrocytes throughout the brain and in a subpopulation of neurons in the substantia nigra, ventral tegmental area, and arcuate nucleus. In the latter structures, the AQP9 immunopositive mitochondria were located in neurons that were also immunopositive for tyrosine hydroxylase, as demonstrated by double labeling immunogold electron microscopy. Our findings suggest that mitochondrial AQP9 is a hallmark of astrocytes and midbrain dopaminergic neurons. In physiological conditions, the flux of lactate and other metabolites through AQP9 may confer an advantage by allowing the mitochondria to adjust to the metabolic status of the extramitochondrial cytoplasm. We hypothesize that the complement of mitochondrial AQP9 in dopaminergic neurons may relate to the vulnerability of these neurons in Parkinson's disease.	Univ Oslo, Ctr Mol Biol & Neurosci, N-0317 Oslo, Norway; Univ Oslo, Nord Ctr Water Imbalance Related Disorders, N-0317 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Biochem, N-0317 Oslo, Norway; Karolinska Inst, Dept Woman & Child Hlth, Stockholm, Sweden	University of Oslo; University of Oslo; University of Oslo; Karolinska Institutet	Amiry-Moghaddam, M (corresponding author), Univ Oslo, Ctr Mol Biol & Neurosci, POB 1105 Blindern, N-0317 Oslo, Norway.	mahmo@medisin.uio.no	, PeturHenry/H-1506-2011; Roberg, Bjørg/B-4589-2013	Amiry-Moghaddam, Mahmood/0000-0003-1071-1247; Gundersen, Brigitta/0000-0002-7801-9348				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Badaut J, 2004, NEUROSCIENCE, V128, P27, DOI 10.1016/j.neuroscience.2004.05.042; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; BRANDT RB, 1987, ARCH BIOCHEM BIOPHYS, V259, P412, DOI 10.1016/0003-9861(87)90507-8; Cancherini DV, 2003, AM J PHYSIOL-RENAL, V285, pF1291, DOI 10.1152/ajprenal.00103.2003; Carbrey JM, 2003, P NATL ACAD SCI USA, V100, P2945, DOI 10.1073/pnas.0437994100; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; Dijkhuizen RM, 1998, STROKE, V29, P695, DOI 10.1161/01.STR.29.3.695; Dugan LL, 2004, J BIOENERG BIOMEMBR, V36, P317, DOI 10.1023/B:JOBB.0000041761.61554.44; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; GO KG, 1988, METAB BRAIN DIS, V3, P257, DOI 10.1007/BF00999535; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Jensen MO, 2002, P NATL ACAD SCI USA, V99, P6731, DOI 10.1073/pnas.102649299; Kitano T, 2002, LIFE SCI, V72, P557, DOI 10.1016/S0024-3205(02)02251-8; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Laake JH, 1999, NEUROSCIENCE, V88, P1137, DOI 10.1016/S0306-4522(98)00298-X; Lee WK, 2005, AM J PHYSIOL-RENAL, V288, pF27, DOI 10.1152/ajprenal.00224.2004; Liu ZH, 2002, J ENHANC HEAT TRANSF, V9, P99, DOI 10.1080/10655130214158; MAUREL C, 1994, J BIOL CHEM, V269, P11869; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; Nicchia GP, 2001, J HISTOCHEM CYTOCHEM, V49, P1547, DOI 10.1177/002215540104901208; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; Nihei K, 2001, ARCH HISTOL CYTOL, V64, P81, DOI 10.1679/aohc.64.81; Oshio K, 2003, ACT NEUR S, V86, P525; Phillis JW, 1999, NEUROSCI LETT, V272, P195, DOI 10.1016/S0304-3940(99)00584-4; Roberg B, 2000, AM J PHYSIOL-CELL PH, V279, pC648, DOI 10.1152/ajpcell.2000.279.3.C648; Roberg B, 1999, NEUROCHEM RES, V24, P383, DOI 10.1023/A:1020985600422; ROBERG B, 1995, NEUROCHEM INT, V27, P367, DOI 10.1016/0197-0186(95)00018-4; Schipper HM, 1998, EXP NEUROL, V152, P188, DOI 10.1006/exnr.1998.6854; Schurr A, 2002, INT J MOL MED, V10, P131, DOI 10.3892/ijmm.10.2.131; Sheline CT, 2004, ANN NEUROL, V55, P645, DOI 10.1002/ana.20047; Starkov AA, 1997, BIOSCIENCE REP, V17, P273, DOI 10.1023/A:1027380527769; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; Veech RL, 2001, IUBMB LIFE, V51, P241; VONZGLINICKI T, 1987, J THEOR BIOL, V127, P127, DOI 10.1016/S0022-5193(87)80123-6; Zardoya R, 2001, J MOL EVOL, V52, P391, DOI 10.1007/s002390010169; Zelenina M, 2004, J BIOL CHEM, V279, P51939, DOI 10.1074/jbc.M407645200	47	103	109	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1459	1467		10.1096/fj.04-3515com	http://dx.doi.org/10.1096/fj.04-3515com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126913				2022-12-25	WOS:000232315700039
J	Madeira, A; Pommet, JM; Prochiantz, A; Allinquant, B				Madeira, A; Pommet, JM; Prochiantz, A; Allinquant, B			SET protein (TAF1 beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain	FASEB JOURNAL			English	Article						Alzheimer's disease; cell death; antisense strategy; subcellular localization	CASPASE-CLEAVAGE; GAMMA-SECRETASE; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; TERMINAL FRAGMENT; IN-VITRO; TAU; APP; DOMAIN; SUPPRESSOR	When overexpressed, a short cytoplasmic domain of the amyloid precursor protein (APP), normally unmasked in the brain of Alzheimer's disease patients, activates caspase-3 and induces neuronal death. Death induction by this "Jcasp" domain is lost when tyrosine 653 is changed into an aspartate, suggesting specific interactions with unknown partners. To identify these putative partners and start to elucidate the mechanisms involved in Jcasp-induced cell death, we internalized a biotinylated version of the peptide into primary neurons and analyzed intracellular interacting proteins by pull-down and mass spectrometry. We find that SET protein, also called template-activating factor (TAF1 beta) or phosphatase 2A inhibitor 2 (I-2(PP2A)), specifically binds Jcasp early after internalization and that SET and Jcasp interact directly in vitro. Downregulation of SET reduces Jcasp-induced cell death, confirming a role of this protein in Jcasp-induced apoptosis. Conversely, SET gain of function increases cell death, which suggests that SET level is crucial for neuronal survival/ death. Taken together, these results suggest that SET is part of a neuronal apoptotic pathway related to Alzheimer's disease and provides a new entry in the analysis of this pathology.	Ctr Paul Broca, INSERM, U573, F-75014 Paris, France; ENS, CNRS, UMR 8542, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Allinquant, B (corresponding author), Ctr Paul Broca, INSERM, U573, 2 Ter Rue Alesia, F-75014 Paris, France.	Bernadette.Allinquant@broca.inserm.fr						ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; Bertrand E, 2001, MOL CELL NEUROSCI, V18, P503, DOI 10.1006/mcne.2001.1030; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Compagnone NA, 2000, MOL ENDOCRINOL, V14, P875, DOI 10.1210/me.14.6.875; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Guo HS, 2004, AM J PATHOL, V165, P523, DOI 10.1016/S0002-9440(10)63317-2; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kroenke CD, 1997, BIOCHEMISTRY-US, V36, P8145, DOI 10.1021/bi9705669; LAFONT F, 1992, DEVELOPMENT, V114, P17; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Li SP, 2004, J PINEAL RES, V36, P186, DOI 10.1111/j.1600-079X.2004.00116.x; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lu DC, 2003, ANN NEUROL, V54, P781, DOI 10.1002/ana.10761; Mbebi C, 2002, J BIOL CHEM, V277, P20979, DOI 10.1074/jbc.M107948200; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Rohn TT, 2000, J NEUROCHEM, V74, P2331, DOI 10.1046/j.1471-4159.2000.0742331.x; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Sudo H, 2000, MOL CELL NEUROSCI, V16, P708, DOI 10.1006/mcne.2000.0910; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; VON LM, 1992, MOL CELL BIOL, V12, P3346; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wen CH, 2000, P NATL ACAD SCI USA, V97, P14524, DOI 10.1073/pnas.011446498; Yang FS, 1998, AM J PATHOL, V152, P379; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	51	95	102	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1905	+		10.1096/fj.05-3839fje	http://dx.doi.org/10.1096/fj.05-3839fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16162853				2022-12-25	WOS:000232315700014
J	Zhang, JS; Krassilnikova, S; Gharaei, AA; Fassaei, HR; Esmailzadeh, L; Asadi, A; Edwards, DS; Harris, TD; Azure, M; Tellides, G; Sinusas, AJ; Zaret, BL; Bender, JR; Sadeghi, MM				Zhang, JS; Krassilnikova, S; Gharaei, AA; Fassaei, HR; Esmailzadeh, L; Asadi, A; Edwards, DS; Harris, TD; Azure, M; Tellides, G; Sinusas, AJ; Zaret, BL; Bender, JR; Sadeghi, MM			alpha v beta 3-Targeted detection of arteriopathy in transplanted human coronary arteries: an autoradiographic study	FASEB JOURNAL			English	Article						vitronectin receptor; imaging; transplant vasculopathy	VITRONECTIN RECEPTOR; HEART-TRANSPLANTATION; ENDOTHELIAL-CELLS; ALPHA(V)BETA(3); VASCULOPATHY; REJECTION; INJURY; ARTERIOSCLEROSIS; TRANSDUCTION; PATHOGENESIS	Graft arteriopathy (GA), characterized by diffuse concentric narrowing of coronary arteries, is the major cause of late graft failure in cardiac transplantation. alpha v beta 3 Integrin is up-regulated in proliferating vascular cells and may constitute an appropriate target for imaging GA. We used a human/mouse chimeric model of GA, in which segments of human coronary artery were transplanted to severe combined immunodeficiency mice, followed by reconstitution with allogeneic human peripheral blood mononuclear cells (PBMC). This led to vascular remodeling characterized by neointima formation over a period of 4 wk. alpha v beta 3 expression in the graft was minimal in animals without PBMC, considerably increased by 2 wk, and decreased toward baseline by 4 wk after PBMC reconstitution. Cell proliferation was maximal at 2 wk, correlating with peak alpha v beta 3 expression. RP748, an In-111-labeled alpha v beta 3 ( active conformation)- targeted radiotracer was injected into groups of 5 recipients at 0, 2, and 4 wk after PBMC reconstitution. Relative uptakes, defined as autoradiographic intensity in the graft/native aortas closely tracked the proliferative process. Specificity of uptake was demonstrated using excess nonlabeled tracer. In conclusion, alpha v beta 3 integrin is transiently up-regulated ( and activated) in GA and may be targeted by RP748 for detection of the proliferative process in early GA.	VA Connecticut Healthcare Syst, West Haven, CT 06516 USA; Yale Univ, Sch Med, Raymond & Beverly Sackler Cardiovasc Mol Imaging, Sect Cardiovasc Med, New Haven, CT USA; Yale Univ, Sch Med, Sect Cardiothorac Surg, New Haven, CT USA; Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT USA; Bristol Myers Squibb Med Imaging, N Billerica, MA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University; Yale University; Bristol-Myers Squibb	Sadeghi, MM (corresponding author), VA Connecticut Healthcare Syst, 950 Campbell Ave,111B, West Haven, CT 06516 USA.	mehran.sadeghi@yale.edu	Sinusas, Albert J/A-7235-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL-70295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bishop GG, 2001, CIRCULATION, V103, P1906, DOI 10.1161/01.cir.103.14.1906; Di Filippo S, 2003, J HEART LUNG TRANSPL, V22, P876, DOI 10.1016/S1053-2498(02)00664-2; Elhendy A, 2002, AM J CARDIOL, V89, P964, DOI 10.1016/S0002-9149(02)02247-6; EVERETT JP, 1992, J HEART LUNG TRANS S, V11, P133; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Harris TD, 2003, CANCER BIOTHER RADIO, V18, P627, DOI 10.1089/108497803322287727; Haubner R, 1999, J NUCL MED, V40, P1061; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Kapadia SR, 1999, CURR OPIN CARDIOL, V14, P140, DOI 10.1097/00001573-199903000-00011; Koh KP, 2004, J CLIN INVEST, V114, P846, DOI 10.1172/JCI200421767; Lenihan DJ, 1999, AM HEART J, V137, P942, DOI 10.1016/S0002-8703(99)70420-5; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Lorber MI, 1999, TRANSPLANTATION, V67, P897, DOI 10.1097/00007890-199903270-00018; Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352; Mitchell RN, 2004, CARDIOVASC PATHOL, V13, P33, DOI 10.1016/S1054-8807(03)00108-X; Moiseeva EP, 2001, CARDIOVASC RES, V52, P372, DOI 10.1016/S0008-6363(01)00399-6; Pober JS, 2002, AM J TRANSPLANT, V2, P201, DOI 10.1034/j.1600-6143.2002.20302.x; RICKENBACHER PR, 1995, CIRCULATION, V92, P3445, DOI 10.1161/01.CIR.92.12.3445; Sadeghi MM, 2004, CIRCULATION, V110, P84, DOI 10.1161/01.CIR.0000133319.84326.70; SALOMON RN, 1991, AM J PATHOL, V138, P791; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Slepian MJ, 1998, CIRCULATION, V97, P1818, DOI 10.1161/01.CIR.97.18.1818; SMART FW, 1991, AM J CARDIOL, V67, P243, DOI 10.1016/0002-9149(91)90553-W; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Tilney NL, 1997, TRANSPLANTATION, V64, P945, DOI 10.1097/00007890-199710150-00001; Wang YN, 2004, FASEB J, V18, P606, DOI 10.1096/fj.03-0840fje; Yamani MH, 2002, J AM COLL CARDIOL, V39, P804, DOI 10.1016/S0735-1097(01)01823-X; Yamani MH, 2002, CIRCULATION, V105, P1955, DOI 10.1161/01.CIR.0000014971.09169.BC	31	15	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1857	+		10.1096/fj.05-4130fje	http://dx.doi.org/10.1096/fj.05-4130fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150802				2022-12-25	WOS:000232315700020
J	Angelastro, JM; Canoll, PD; Kuo, J; Weicker, M; Costa, A; Bruce, JN; Greene, LA				Angelastro, JM; Canoll, PD; Kuo, J; Weicker, M; Costa, A; Bruce, JN; Greene, LA			Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5	ONCOGENE			English	Article						ATF5; astrocytes; glioma; apoptosis; brain tumor	NEURAL PROGENITOR CELLS; MALIGNANT GLIOMA; DIFFERENTIATION; TRANSCRIPTION; CHECKPOINT; FAMILY; GROWTH; LINE; P53	Glioblastoma multifome is the most common and most aggressive primary brain tumor with no current curative therapy. We found expression of the bZip transcription factor ATF5 in all 29 human glioblastomas and eight human and rat glioma cell lines assessed. ATF5 is not detectably expressed by mature brain neurons and astrocytes, but is expressed by reactive astrocytes. Interference with ATF5 function or expression in all glioma cell lines tested causes marked apoptotic cell death. In contrast, such manipulations do not affect survival of ATF5-expressing cultured astrocytes or of several other cell types that express this protein. In a proof-of-principle experiment, retroviral delivery of a function-blocking mutant form of ATF5 into a rat glioma model evokes death of the infected tumor cells, but not of infected brain cells outside the tumors. The widespread expression of ATF5 in glioblastomas and the selective effect of interference with ATF5 function/expression on their survival suggest that ATF5 may be an attractive target for therapeutic intervention in such tumors.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY USA	Columbia University; Columbia University; Columbia University	Angelastro, JM (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 2165 Haring Hall,1 Shields Ave, Davis, CA 95616 USA.	jmangelastro@ucdavis.edu	Kuo, John S/D-3561-2013; Bruce, Jeffrey N/AAC-5307-2022	Kuo, John S/0000-0001-6809-4806; 				AIELLO L, 1979, VIROLOGY, V94, P460, DOI 10.1016/0042-6822(79)90476-8; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Angelastro JM, 2005, J NEUROSCI, V25, P3889, DOI 10.1523/JNEUROSCI.3447-04.2005; Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Badie B, 1999, CANCER GENE THER, V6, P155, DOI 10.1038/sj.cgt.7700009; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Collins V P, 2004, J Neurol Neurosurg Psychiatry, V75 Suppl 2, pii2, DOI 10.1136/jnnp.2004.040337; Dai CK, 2001, BBA-REV CANCER, V1551, pM19, DOI 10.1016/S0304-419X(01)00027-0; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Hansen MB, 2002, GENOMICS, V80, P344, DOI 10.1006/geno.2002.6838; Hirose Y, 2001, CANCER RES, V61, P5843; JENSEN AM, 1991, J NEUROSCI, V11, P1674; KLEIHUES P, 1993, HISTOLOGY TYPING TUM; KO L, 1980, ACTA NEUROPATHOL, V51, P23, DOI 10.1007/BF00688846; KRUSE CA, 1992, IN VITRO CELL DEV-AN, V28A, P609; LEVISON SW, 1991, ASTROGLIA CULTURE, P309; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mason JL, 2005, MOL CELL NEUROSCI, V29, P372, DOI 10.1016/j.mcn.2005.03.004; MCLENDON RE, 1998, RUSSELL RUBINSTEINS, P307; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Pati D, 1999, MOL CELL BIOL, V19, P5001; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; PINKERTON H, 1976, P SOC EXP BIOL MED, V151, P532; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; Qi YP, 1997, J NEUROSCI, V17, P1217; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonoda Y, 2001, CANCER RES, V61, P4956; Vogelbaum MA, 1999, J NEUROSURG, V91, P483, DOI 10.3171/jns.1999.91.3.0483; Yamagishi N, 1995, J RADIAT RES, V36, P239, DOI 10.1269/jrr.36.239	33	71	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					907	916		10.1038/sj.onc.1209116	http://dx.doi.org/10.1038/sj.onc.1209116			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170340	Bronze			2022-12-25	WOS:000235212700010
J	Khanzada, UK; Pardo, OE; Meier, C; Downward, J; Seckl, MJ; Arcaro, A				Khanzada, UK; Pardo, OE; Meier, C; Downward, J; Seckl, MJ; Arcaro, A			Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling	ONCOGENE			English	Article						lung cancer; statins; ras; protein kinase B; receptor tyrosine kinase	PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; CARCINOMA-CELLS; PATHWAY; STATINS; PROLIFERATION; SUPPRESSION; PROGRESSION; LINES; MEK	The impact of the 3-hydroxy-3methylglutaryl CoA reductase inhibitor simvastatin on human small-cell lung cancer (SCLC) cell growth and survival was investigated. Simvastatin profoundly impaired basal and growth factor-stimulated SCLC cell growth in vitro and induced apoptosis. SCLC cells treated with simvastatin were sensitized to the effects of the chemotherapeutic agent etoposide. Moreover, SCLC tumour growth in vivo was inhibited by simvastatin. These responses correlated with the inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. Constitutive activation of the Erk pathway was sufficient to rescue SCLC cell from the effects of simvastatin. The drug did not directly affect activation of c-Kit or its localization to lipid rafts, but in addition to its ability to block Ras membrane localization, it selectively downregulated H-Ras protein levels at the post-translational level. Downregulation of either H- or K-Ras by RNA interference (RNAi) did not impair Erk activation by growth factors, whereas an RNAi specific for N-Ras inhibited activation of Erk, PKB and SCLC cell growth. Together our data demonstrate that inhibiting Ras signalling with simvastatin potently disrupts growth and survival in human SCLC cells.	Univ Childrens Hosp Zurich, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, Div Med,Lung Canc Biol Grp, London, England; CRUK London Res Inst, London, England	University Children's Hospital Zurich; Imperial College London; Cancer Research UK	Arcaro, A (corresponding author), Univ Childrens Hosp Zurich, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	Alexandre.Arcaro@kispi.unizh.ch	Arcaro, Alexandre/G-1711-2010; Pardo, Oliver/AEM-2071-2022; Downward, Julian/A-3251-2012	Arcaro, Alexandre/0000-0001-9107-2947; Pardo, Oliver/0000-0003-2223-1435; Downward, Julian/0000-0002-2331-4729				Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Chan KKW, 2003, CLIN CANCER RES, V9, P10; Chun KH, 2003, CANCER RES, V63, P4796; Furst J, 2002, CELL PHYSIOL BIOCHEM, V12, P19, DOI 10.1159/000047823; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hirai A, 1997, J BIOL CHEM, V272, P13; Hiwasa T, 1998, BIOCHEM BIOPH RES CO, V250, P741, DOI 10.1006/bbrc.1998.9386; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Johnson BE, 2004, CLIN CANCER RES, V10, p4254S, DOI 10.1158/1078-0432.CCR-040016; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kusama T, 2001, CANCER RES, V61, P4885; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Moore SM, 1998, CANCER RES, V58, P5239; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Tsao H, 2000, CANCER RES, V60, P1800; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200	24	93	99	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					877	887		10.1038/sj.onc.1209117	http://dx.doi.org/10.1038/sj.onc.1209117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170339				2022-12-25	WOS:000235212700007
J	Ware, MD; DeSilva, D; Sinilnikova, OM; Stoppa-Lyonnet, D; Tavtigian, SV; Mazoyer, S				Ware, MD; DeSilva, D; Sinilnikova, OM; Stoppa-Lyonnet, D; Tavtigian, SV; Mazoyer, S			Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene?	ONCOGENE			English	Article						BRCA2; ovarian cancer cluster region; nonsense-mediated mRNA decay; genotype-phenotype correlation	PREMATURE TERMINATION CODONS; DNA-REPAIR; PROTEIN; TRANSCRIPTS; BREAST; SUSCEPTIBILITY; RECOMBINATION; TRANSLATION; EXPRESSION; MUTATIONS	BRCA2 (BReast CAncer susceptibility gene 2) germline mutation carriers are at increased risk for breast and ovarian cancers. Mutations occurring in the ovarian cancer cluster region (OCCR) are linked to higher ovarian cancer and/or lower breast cancer risk(s) than mutations occurring elsewhere in BRCA2. Most BRCA2 germline mutations introduce premature termination codons (PTCs), making their mRNAs likely targets of nonsense-mediated mRNA decay (NMD), a mechanism that eliminates PTC-bearing transcripts to prevent expression of truncated proteins. Contradictory evidence exists regarding whether NMD can be triggered by PTCs located far upstream of the nearest exon-exon junction (EEJ). Since the OCCR comprises a major portion of the 4.9 kb exon 11 of BRCA2, we investigated if transcripts bearing PTCs in this large exon are unable to trigger NMD, and if this might contribute to the phenotypic difference associated with the OCCR. We examined cDNA from 18 carriers of PTC-introducing germline mutations located throughout BRCA2, and found that PTC-bearing transcripts were 1.4-3.3-fold less prevalent than their nonmutated counterparts irregardless of PTC position. We conclude that NMD can recognize PTCs up to 4.5 kb upstream of the nearest EEJ, demonstrating that a general inability of NMD to recognize PTCs in exon 11 is unlikely to explain the genotype-phenotype correlation associated with the OCCR.	Univ Lyon 1, CNRS, UMR 5201, Fac Med Rockefeller,Lab Genet Mol Signalisat & Ca, F-69373 Lyon 08, France; Int Agcy Res Canc, F-69372 Lyon, France; Hosp Civils Lyon, Ctr Leon Berard, Plate Forme Mixte Genet Constitut Canc Frequents, Lyon, France; Inst Curie, Serv Genet Oncol, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mazoyer, S (corresponding author), Univ Lyon 1, CNRS, UMR 5201, Fac Med Rockefeller,Lab Genet Mol Signalisat & Ca, 8 Ave Rockefeller, F-69373 Lyon 08, France.	sylvie.mazoyer@sante.univ-lyon1.fr	Mazoyer, Sylvie/N-7559-2017	Mazoyer, Sylvie/0000-0002-2135-0160				Chatr-aryamontri A, 2004, HUM MUTAT, V24, P526, DOI 10.1002/humu.20117; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Gismondi V, 1998, GENE CHROMOSOME CANC, V22, P278, DOI 10.1002/(SICI)1098-2264(199808)22:4<278::AID-GCC3>3.3.CO;2-Q; Harries LW, 2004, DIABETES, V53, P500, DOI 10.2337/diabetes.53.2.500; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Lubinski Jan, 2004, Fam Cancer, V3, P1; Maquat LE, 2001, RNA, V7, P445, DOI 10.1017/S1355838201002229; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Neu-Yilik G, 2001, EMBO J, V20, P532, DOI 10.1093/emboj/20.3.532; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Rodningen OK, 1999, HUM MUTAT, V13, P186, DOI 10.1002/(SICI)1098-1004(1999)13:3<186::AID-HUMU2>3.0.CO;2-K; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Tournier I, 2004, HUM MUTAT, V23, P379, DOI 10.1002/humu.20008; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	25	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					323	328		10.1038/sj.onc.1209033	http://dx.doi.org/10.1038/sj.onc.1209033			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170354				2022-12-25	WOS:000234583600018
J	Sansom, OJ; Griffiths, DFR; Reed, KR; Winton, DJ; Clarke, AR				Sansom, OJ; Griffiths, DFR; Reed, KR; Winton, DJ; Clarke, AR			Apc deficiency predisposes to renal carcinoma in the mouse	ONCOGENE			English	Article						Apc; kidney; Wnt; Cre; renal cancer	BETA-CATENIN GENE; WILMS-TUMORS; EMBRYONIC LETHALITY; CELL CARCINOMAS; TSC2 MUTATION; P53 GENE; EXPRESSION; MICE; CARCINOGENESIS; INACTIVATION	Deregulation of Wnt signalling has recently been implicated in human renal cancer. Here, we directly test this association by using a Cre-LoxP strategy to inactivate the Adenomatous Polyposis Coli (Apc) gene in the murine renal epithelium. Mice homozygous for a conditional Apc allele were intercrossed with mice transgenic for Cre recombinase under control of the Cyp1A promoter, which delivers constitutive recombination within a proportion of cells in the renal epithelium. Inactivation of Apc leads to the accumulation of nuclear beta-catenin and the rapid development of multiple dysplastic foci. Renal carcinoma was observed with an earliest onset of 4 months. This predisposition was accelerated by p53 deficiency, reducing the earliest onset to 2 months. Compared to other murine models of kidney neoplasia, this represents particularly rapid onset of disease, and so implicates an important role for Apc in suppressing renal carcinoma.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales; Univ Wales Coll Cardiff, Coll Med, Dept Pathol, Cardiff CF10 3US, Wales; Cambridge Inst Med Res, Canc Res UK, Dept Oncol, Cambridge CB2 2XY, England	Cardiff University; Cardiff University; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales.	clarkear@cf.ac.uk	Reed, Karen/B-8813-2011; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Reed, Karen/0000-0002-7467-1718; Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilim V, 2000, CLIN CANCER RES, V6, P460; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Guo LM, 2001, ONCOL REP, V8, P521; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kleymenova E, 2004, CARCINOGENESIS, V25, P309, DOI 10.1093/carcin/bgh017; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Kusafuka T, 2002, INT J MOL MED, V10, P395; Menke AL, 2002, CANCER RES, V62, P6615; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pecina-Slaus N, 1999, J MOL MED-JMM, V77, P446, DOI 10.1007/s001090050375; Qian CN, 2005, J BIOL CHEM, V280, P3938, DOI 10.1074/jbc.M410697200; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Zang T, 2001, CHINESE MED J-PEKING, V114, P152; Zhu XD, 2000, PATHOL INT, V50, P945, DOI 10.1046/j.1440-1827.2000.01139.x	26	55	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8205	8210		10.1038/sj.onc.1208956	http://dx.doi.org/10.1038/sj.onc.1208956			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16116480				2022-12-25	WOS:000233809400012
J	Pearson, K; Tubb, MR; Tanaka, M; Zhang, XQ; Tso, P; Weinberg, RB; Davidson, WS				Pearson, K; Tubb, MR; Tanaka, M; Zhang, XQ; Tso, P; Weinberg, RB; Davidson, WS			Specific sequences in the N and C termini of apolipoprotein A-IV modulate its conformation and lipid association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA APOLIPOPROTEINS; INTERFACIAL PROPERTIES; DOMAIN-STRUCTURE; BINDING; RAT; MODEL; GENE; POLYMORPHISMS; TRANSPORTER; EXPRESSION	Apolipoprotein (apoA-IV) is a 376-residue exchangeable apolipoprotein that may play a number of important roles in lipid metabolism, including chylomicron assembly, reverse cholesterol transport, and appetite regulation. In vivo, apoA-IV exists in both lipid-poor and lipid-associated forms, and the balance between these states may determine its function. We examined the structural elements that modulate apoA-IV lipid binding by producing a series of deletion mutants and determining their ability to interact with phospholipid liposomes. We found that the deletion of residues 333-343 strongly increased the lipid association rate versus native apoA-IV. Additional mutagenesis revealed that two phenylalanine residues at positions 334 and 335 mediated this lipid binding inhibitory effect. We also observed that residues 11-20 in the N terminus were required for the enhanced lipid affinity induced by deletion of the C-terminal sequence. We propose a structural model in which these sequences can modulate the conformation and lipid affinity of apoA-IV.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Wake Forest University; Wake Forest University	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 2120 Galbraith Rd, Cincinnati, OH 45237 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989; Tubb, Matthew/0000-0002-4543-2742	NHLBI NIH HHS [HL67093, R01 HL030897, HL30897, HL62542, R01 HL030897-23] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062542, R01HL067093, R23HL030897, R01HL030897] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; BOGUSKI MS, 1985, P NATL ACAD SCI USA, V82, P992, DOI 10.1073/pnas.82.4.992; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; FUJIMOTO K, 1992, AM J PHYSIOL, V262, pG1002, DOI 10.1152/ajpgi.1992.262.6.G1002; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; Hockey KJ, 2001, J LIPID RES, V42, P211; KALOGERIS TJ, 1997, J NUTR S, V127, P537; KARATHANASIS SK, 1986, P NATL ACAD SCI USA, V83, P8457, DOI 10.1073/pnas.83.22.8457; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MCLEAN LR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P289, DOI 10.1016/0005-2760(93)90231-W; Navarro MA, 2004, GENE, V325, P157, DOI 10.1016/j.gene.2003.10.007; Ostos MA, 2001, ARTERIOSCL THROM VAS, V21, P1023, DOI 10.1161/01.ATV.21.6.1023; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Pearson K, 2005, PROTEIN EXPRES PURIF, V41, P447, DOI 10.1016/j.pep.2005.02.011; Pearson K, 2004, BIOCHEMISTRY-US, V43, P10719, DOI 10.1021/bi048978m; Qin XF, 1998, AM J PHYSIOL-HEART C, V274, pH1836, DOI 10.1152/ajpheart.1998.274.5.H1836; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; ROHEIM PS, 1976, P NATL ACAD SCI USA, V73, P1757, DOI 10.1073/pnas.73.5.1757; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Weers PMM, 2003, BIOPHYS CHEM, V100, P481, DOI 10.1016/S0301-4622(02)00300-9; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WEINBERG RB, 1985, J LIPID RES, V26, P26; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; Weinberg RB, 2002, CURR OPIN LIPIDOL, V13, P125, DOI 10.1097/00041433-200204000-00003; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; WEINBERG RB, 1994, J LIPID RES, V35, P2212; WEINBERG RB, 1987, BIOCHIM BIOPHYS ACTA, V918, P299, DOI 10.1016/0005-2760(87)90234-7; WEINBERG RB, 1988, BIOCHEMISTRY-US, V27, P1515, DOI 10.1021/bi00405a018; Weinberg RB, 2000, J LIPID RES, V41, P1410; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	40	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38576	38582		10.1074/jbc.M506802200	http://dx.doi.org/10.1074/jbc.M506802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159879				2022-12-25	WOS:000233239800057
J	Kim, YC; Russell, WK; Ranjith-Kumar, CT; Thomson, M; Russell, DH; Kao, CC				Kim, YC; Russell, WK; Ranjith-Kumar, CT; Thomson, M; Russell, DH; Kao, CC			Functional analysis of RNA binding by the hepatitis C virus RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; CRYSTAL-STRUCTURE; IDENTIFICATION; MECHANISM; PROTEIN; CONFORMATIONS; REQUIREMENTS; MUTATIONS; REVEALS; COMPLEX	Protein-RNA interaction plays a critical role in regulating RNA synthesis by the hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp). RNAs of 7 nucleotides (nt) or longer had affinities 5-fold better than an RNA of 5 nt, suggesting aminimal length required for binding. To identify RNA contact sites on the HCV RdRp, a biotinylated 7-nt RNA capable of directing de novo initiation was used in a process that coupled reversible formaldehyde cross-linking, RNA affinity chromatography, and mass spectrometry. By this process, we identified 18 peptides cross-linked to the 7-nt RNA. When these identified peptides were overlaid on the three-dimensional structures of NS5B, most mapped to the fingers subdomain, connecting loops between fingers and thumb subdomains and in the putative RNA binding channel. Two of the identified peptides resided in the active site cavity of the RdRp. Recombinant HCV RdRp with single residue changes in likely RNA contact sites were generated and characterized for effects on HCV RdRp activity. Mutant proteins had significant effects on cross-linking to 7-nt RNA and reduced RNA synthesis in vitro by 2- to 20-fold compared with wild type protein. When the mutations were tested for the replication of HCV RNA in the context of the cells transfected with the HCV subgenomic replicon, all except one prevented colony formation, indicating a defect in HCV RNA replication. These biochemical and functional analyses identified a number of residues in the HCV RdRp that are important for HCV RNA synthesis.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Lab Biol Mass Spectrometry, College Stn, TX 77843 USA; GlaxoSmithKline Inc, Dept Virol, Metab & Viral Dis Ctr Excellence & Drug Discovery, Res Triangle Pk, NC 27709 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; GlaxoSmithKline	Kao, CC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	ckao@tamu.edu	Russell, David H/C-3618-2015; Kumar CT, Ranjith/J-5701-2016	Russell, David H/0000-0003-0830-3914; 	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR019587] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR019587] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8; Adkins S, 1998, RNA, V4, P455; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Beckman MTL, 1998, J BIOL CHEM, V273, P6724, DOI 10.1074/jbc.273.12.6724; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Biswal BK, 2005, J BIOL CHEM, V280, P18202, DOI 10.1074/jbc.M413410200; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; HOUGHTON M, 1996, FIELDS VIROLOGY; Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; Labonte P, 2002, J BIOL CHEM, V277, P38838, DOI 10.1074/jbc.M204657200; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Metz B, 2004, J BIOL CHEM, V279, P6235, DOI 10.1074/jbc.M310752200; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Ranjith-Kumar CT, 2004, J VIROL, V78, P12207, DOI 10.1128/JVI.78.22.12207-12217.2004; Ranjith-Kumar CT, 2003, J MOL BIOL, V330, P675, DOI 10.1016/S0022-2836(03)00613-2; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; SARSTRY SS, 1996, BIOCHEMISTRY-US, V35, P13519; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; *WHO, 1998, LANCET, V351, P1415; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	40	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38011	38019		10.1074/jbc.M508145200	http://dx.doi.org/10.1074/jbc.M508145200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16166071	hybrid			2022-12-25	WOS:000233044500084
J	Korenaga, M; Wang, T; Li, YC; Showalter, LA; Chan, TS; Sun, JR; Weinman, SA				Korenaga, M; Wang, T; Li, YC; Showalter, LA; Chan, TS; Sun, JR; Weinman, SA			Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE REDUCTASE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; SUPEROXIDE ANION; PLUS RIBAVIRIN; COMPLEX-I; ER STRESS; LIVER; APOPTOSIS	Hepatitis C infection causes a state of chronic oxidative stress, which may contribute to fibrosis and carcinogenesis in the liver. Previous studies have shown that expression of the HCV core protein in hepatoma cells depolarized mitochondria and increased reactive oxygen species (ROS) production, but the mechanisms of these effects are unknown. In this study we examined the properties of liver mitochondria from transgenic mice expressing HCV core protein, and from normal liver mitochondria incubated with recombinant core protein. Liver mitochondria from transgenic mice expressing the HCV proteins core, E1 and E2 demonstrated oxidation of the glutathione pool and a decrease in NADPH content. In addition, there was reduced activity of electron transport complex I, and increased ROS production from complex I substrates. There were no abnormalities observed in complex II or complex III function. Incubation of control mitochondria in vitro with recombinant core protein also caused glutathione oxidation, selective complex I inhibition, and increased ROS production. Proteinase K digestion of either transgenic mitochondria or control mitochondria incubated with core protein showed that core protein associates strongly with mitochondria, remains associated with the outer membrane, and is not taken up across the outer membrane. Core protein also increased Ca2+ uptake into isolated mitochondria. These results suggest that interaction of core protein with mitochondria and subsequent oxidation of the glutathione pool and complex I inhibition may be an important cause of the oxidative stress seen in chronic hepatitis C.	Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Ctr Hepatitis Res, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Yamaguchi Univ, Sch Med, Dept Gastroenterol & Hepatol, Yamaguchi 7558505, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Yamaguchi University	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	sweinman@utmb.edu	Korenaga, Masaaki/AAE-7479-2020; Weinman, Steven/E-7012-2011		NIAAA NIH HHS [AA12863] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012863] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432; Anderson M. E., 1989, GLUTATHIONE CHEM BIO, VA, P339; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Barbaro G, 1999, AM J GASTROENTEROL, V94, P2198, DOI 10.1111/j.1572-0241.1999.01294.x; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673; Bianchi K, 2004, BBA-MOL CELL RES, V1742, P119, DOI 10.1016/j.bbamcr.2004.09.015; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cerny A, 1999, HEPATOLOGY, V30, P595, DOI 10.1002/hep.510300312; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Davis GL, 2000, GASTROENTEROLOGY, V118, pS104, DOI 10.1016/S0016-5085(00)70009-6; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; HANUKOGLU I, 1995, ENDOCR RES, V21, P231, DOI 10.3109/07435809509030439; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Houglum K, 1997, GASTROENTEROLOGY, V113, P1069, DOI 10.1053/gast.1997.v113.pm9322499; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0; JOHONSON D, 1967, METHOD ENZYMOL, V10, P94; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kumar D, 2002, HEPATOLOGY, V36, P1266, DOI 10.1053/jhep.2002.36370; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lau JYN, 1996, J HEPATOL, V24, P43; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Li YB, 1999, BIOCHEM BIOPH RES CO, V262, P80, DOI 10.1006/bbrc.1999.1174; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; Loguercio C, 2003, FREE RADICAL BIO MED, V34, P1, DOI 10.1016/S0891-5849(02)01167-X; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Martin EJ, 2003, J PHARMACOL EXP THER, V304, P121, DOI 10.1124/jpet.102.041392; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Moriya K, 2001, CANCER RES, V61, P4365; OKUDA M, 1992, ACTA PHYSIOL SCAND, V145, P159, DOI 10.1111/j.1748-1716.1992.tb09351.x; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; OLAFSDOTTIR K, 1988, ARCH BIOCHEM BIOPHYS, V263, P226, DOI 10.1016/0003-9861(88)90631-5; Otani K, 2005, GASTROENTEROLOGY, V128, P96, DOI 10.1053/j.gastro.2004.10.045; Otsuka M, 2002, VIROLOGY, V296, P84, DOI 10.1006/viro.2002.1371; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Rolo AP, 2002, TOXICOL APPL PHARM, V182, P20, DOI 10.1006/taap.2002.9434; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Suzuki R, 2005, J VIROL, V79, P1271, DOI 10.1128/JVI.79.2.1271-1281.2005; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; Tardif KD, 2005, TRENDS MICROBIOL, V13, P159, DOI 10.1016/j.tim.2005.02.004; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Valgimigli M, 2002, FREE RADICAL RES, V36, P939, DOI 10.1080/107156021000006653; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Watashi K, 2003, CANCER SCI, V94, P937, DOI 10.1111/j.1349-7006.2003.tb01381.x; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wen F, 2004, J MED VIROL, V72, P230, DOI 10.1002/jmv.10567; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	63	313	324	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37481	37488		10.1074/jbc.M506412200	http://dx.doi.org/10.1074/jbc.M506412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150732	hybrid			2022-12-25	WOS:000233044500024
J	Singh, M; Krajewski, M; Mikolajka, A; Holak, TA				Singh, M; Krajewski, M; Mikolajka, A; Holak, TA			Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; CELL-CYCLE CONTROL; ONCOGENIC POINT MUTATIONS; TUMOR-SUPPRESSOR PROTEIN; HISTONE DEACETYLASE; RB FAMILY; FUNCTIONAL INTERACTIONS; REPRESS TRANSCRIPTION; VIRAL ONCOPROTEINS; STRUCTURAL BASIS	The retinoblastoma tumor suppressor protein (pRb) is a key negative regulator of cell proliferation that is frequently disregulated in human cancer. Many viral oncoproteins ( for example, HPV E7 and E1A) are known to bind to the pRb pocket domain via a LXCXE binding motif. There are also some 20 cellular proteins that contain a LXCXE motif and have been reported to associate with the pocket domain of pRb. Using NMR spectroscopy and isothermal calorimetry titration, we show that LXCXE peptides of viral oncoproteins bind strongly to the pocket domain of pRb. Additionally, we show that LXCXE-like peptides of HDAC1 bind to the same site on pRb with a weak ( micromolar) and transient association. Systematic substitution of residues other than conserved Leu, Cys, and Glu show that the residues flanking the LXCXE are important for the binding, whereas positively charged amino acids in the XLXCX-EXXX sequence significantly weaken the interaction.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Holak, TA (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.	holak@biochem.mpg.de						Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown VD, 2002, MOL CELL BIOL, V22, P1390, DOI 10.1128/MCB.22.5.1390-1401.2002; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kennedy BK, 2001, P NATL ACAD SCI USA, V98, P8720, DOI 10.1073/pnas.151240898; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; Laj A, 1999, MOL CELL BIOL, V19, P6632; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee C, 2002, REV MED VIROL, V12, P81, DOI 10.1002/rmv.340; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; Pellecchia M, 2002, NAT REV DRUG DISCOV, V1, P211, DOI 10.1038/nrd748; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Rehm T, 2002, STRUCTURE, V10, P1613, DOI 10.1016/S0969-2126(02)00894-8; Sambrook J., 2001, MOL CLONING; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P28; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	57	61	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37868	37876		10.1074/jbc.M504877200	http://dx.doi.org/10.1074/jbc.M504877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16118215	hybrid			2022-12-25	WOS:000233044500067
J	Walter, KU; Vamvaca, K; Hilvert, D				Walter, KU; Vamvaca, K; Hilvert, D			An active enzyme constructed from a 9-amino acid alphabet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOFUNCTIONAL CHORISMATE MUTASE; NOVO PROTEIN DESIGN; COMBINATORIAL MUTAGENESIS; COMPUTATIONAL DESIGN; MOLTEN GLOBULE; CATALYSIS; SELECTION; STATE; EVOLUTION; FOLD	Nature employs a set of 20 amino acids to produce a repertoire of protein structures endowed with sophisticated functions. Here, we combined design and selection to create an enzyme composed entirely from a set of only 9 amino acids that can rescue auxotrophic cells lacking chorismate mutase. The simplified protein captures key structural features of its natural counterpart but appears to be somewhat less stable and more flexible. The potential of a dramatically reduced amino acid alphabet to produce an active catalyst supports the notion that primordial enzymes may have possessed low amino acid diversity and suggests that combinatorial engineering strategies, such as the one used here, may be generally applied to create enzymes with novel structures and functions.	ETH Honggerberg, Swiss Fed Inst Technol, Organ Chem Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Hilvert, D (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Organ Chem Lab, CH-8093 Zurich, Switzerland.	hilvert@org.chem.ethz.ch						Akanuma S, 2002, P NATL ACAD SCI USA, V99, P13549, DOI 10.1073/pnas.222243999; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P171; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DAVIDSON AR, 1995, NAT STRUCT BIOL, V2, P856, DOI 10.1038/nsb1095-856; Davis BK, 2002, PROG BIOPHYS MOL BIO, V79, P77, DOI 10.1016/S0079-6107(02)00012-3; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Firth AE, 2005, BIOINFORMATICS, V21, P3314, DOI 10.1093/bioinformatics/bti516; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; MacBeath G, 1998, BIOTECHNIQUES, V24, P789, DOI 10.2144/98245st02; MacBeath G, 1998, BIOCHEMISTRY-US, V37, P10062, DOI 10.1021/bi980449t; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Riddle DS, 1997, NAT STRUCT BIOL, V4, P805, DOI 10.1038/nsb1097-805; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; Silverman JA, 2001, P NATL ACAD SCI USA, V98, P3092, DOI 10.1073/pnas.041613598; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; Taylor SV, 2001, ANGEW CHEM INT EDIT, V40, P3310, DOI 10.1002/1521-3773(20010917)40:18<3310::AID-ANIE3310>3.0.CO;2-P; Taylor SV, 2001, P NATL ACAD SCI USA, V98, P10596, DOI 10.1073/pnas.191159298; Vamvaca K, 2004, P NATL ACAD SCI USA, V101, P12860, DOI 10.1073/pnas.0404109101; Wang J, 1999, NAT STRUCT BIOL, V6, P1033; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5	32	76	79	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37742	37746		10.1074/jbc.M507210200	http://dx.doi.org/10.1074/jbc.M507210200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144843	hybrid			2022-12-25	WOS:000233044500052
J	Zaremberg, V; Gajate, C; Cacharro, LM; Mollinedo, F; McMaster, CR				Zaremberg, V; Gajate, C; Cacharro, LM; Mollinedo, F; McMaster, CR			Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; SPHINGOID BASE SYNTHESIS; LIVING YEAST-CELLS; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE SYNTHESIS; ET-18-OCH3 EDELFOSINE; DOMAINS RAFTS; CERAMIDE; APOPTOSIS	Edelfosine is a prototypical member of the alkylphosphocholine class of antitumor drugs. Saccharomyces cerevisiae was used to screen for genes that modulate edelfosine cytotoxicity and identified sterol and sphingolipid pathways as relevant regulators. Edelfosine addition to yeast resulted in the selective partitioning of the essential plasma membrane protein Pma1p out of lipid rafts. Microscopic analysis revealed that Pma1p moved from the plasma membrane to intracellular punctate regions and finally localized to the vacuole. Consistent with altered sterol and sphingolipid synthesis resulting in increased edelfosine sensitivity, mislocalization of Pma1p was preceded by the movement of sterols out of the plasma membrane. Cells with enfeebled endocytosis and vacuolar protease activities prevented edelfosine-mediated (i) mobilization of sterols, (ii) loss of Pma1p from lipid rafts, and (iii) cell death. The activities of proteins and signaling processes are meaningfully altered by changes in lipid raft biophysical properties. This study points to a novel mode of action for an anti-cancer drug through modification of plasma membrane lipid composition resulting in the displacement of an essential protein from lipid rafts.	Dalhousie Univ, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Univ Salamanca, Consejo Super Invest Cient, Inst Biol Mol & Celular Canc, Ctr Invest Canc, E-37007 Salamanca, Spain	Dalhousie University; Dalhousie University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	McMaster, CR (corresponding author), 5849 Univ Ave,Rm C302, Halifax, NS B3H 4H7, Canada.	Christopher.mcmaster@dal.ca		McMaster, Christopher/0000-0003-0822-5776; Gajate, Consuelo/0000-0003-0604-6459				AMES BN, 1960, J BIOL CHEM, V235, P769; Arthur G, 1998, BBA-LIPID LIPID MET, V1390, P85, DOI 10.1016/S0005-2760(97)00163-X; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Balguerie A, 2002, EUKARYOT CELL, V1, P1021, DOI 10.1128/EC.1.6.1021-1031.2002; Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Beh CT, 2004, J CELL SCI, V117, P2983, DOI 10.1242/jcs.01157; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Eisenkolb M, 2002, MOL BIOL CELL, V13, P4414, DOI 10.1091/mbc.E02-02-0116; Ferreira T, 2002, J BIOL CHEM, V277, P21027, DOI 10.1074/jbc.M112281200; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Gaigg B, 2005, J BIOL CHEM, V280, P22515, DOI 10.1074/jbc.M413472200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; Howe AG, 2001, BBA-MOL CELL BIOL L, V1534, P65, DOI 10.1016/S1388-1981(01)00181-0; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; Lee MCS, 2002, J BIOL CHEM, V277, P22395, DOI 10.1074/jbc.M200450200; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malinska K, 2003, MOL BIOL CELL, V14, P4427, DOI 10.1091/mbc.E03-04-0221; Mollinedo F, 1997, CANCER RES, V57, P1320; Pichler H, 2004, BBA-BIOMEMBRANES, V1666, P51, DOI 10.1016/j.bbamem.2004.05.011; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Swain E, 2002, J BIOL CHEM, V277, P26177, DOI 10.1074/jbc.M204115200; Takeda T, 2004, NAT CELL BIOL, V6, P1142, DOI 10.1038/ncb1189; Tatchell K, 2002, METHOD ENZYMOL, V351, P661; Van der Luit AH, 2003, BIOCHEM J, V374, P747, DOI 10.1042/BJ20030179; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zink S, 2005, EUKARYOT CELL, V4, P879, DOI 10.1128/EC.4.5.879-889.2005; Zurzolo C, 2003, EMBO REP, V4, P1117, DOI 10.1038/sj.embor.7400032	49	71	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38047	38058		10.1074/jbc.M502849200	http://dx.doi.org/10.1074/jbc.M502849200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155007	hybrid			2022-12-25	WOS:000233044500088
J	McKane, M; Wen, KK; Boldogh, IR; Ramcharan, S; Pon, LA; Rubenstein, PA				McKane, M; Wen, KK; Boldogh, IR; Ramcharan, S; Pon, LA; Rubenstein, PA			A mammalian actin substitution in yeast actin (H372R) causes a suppressible mitochondria/vacuole phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; F-ACTIN; BETA-ACTIN; CRYSTAL-STRUCTURE; ARP2/3 COMPLEX; CELL-DIVISION; BUDDING YEAST; BINDING SITE; MYOSIN; PROFILIN	To determine the reason for the inviability of Saccharomyces cerevisiae with skeletal muscle actin, we introduced into yeast actin the first variant muscle residue from the C-terminal end, H372R. Arg is also found at this position in non-yeast nonmuscle actins. The substitution caused retarded growth on glucose and an inability to use glycerol as a sole carbon source. The mitochondria were clumped and had lost their DNA, the vacuole appeared hypervesiculated, and the actin cytoskeleton became somewhat depolarized. Introduction of the second muscle actin-specific substitution, S365A, rescued these defects. Suppression was also achieved by introducing the four acidic N-terminal residues of muscle actin in place of the two found in yeast actin. The H372R substitution results in an increase in polymerization-dependent fluorescence of Cys-374 pyrene-labeled actin. H372R actin polymerizes slightly faster than wild-type (WT) actin. Yeast actin-related proteins 2 and 3 (Arp2/3) accelerates the polymerization of H372R actin to a much greater extent than WT actin. The two suppressors did not affect the rate of H372R actin polymerization in the absence of an Arp2/3 complex. In contrast, the S365A substitution dampened the rate of Arp2/3 complex-stimulated H372R actin polymerization, and the addition of the four acidic N-terminal residues caused this rate to decrease below that observed with WT actin in the presence of Arp2/3. Structural analysis of the mutations suggests the presence of stringent steric and ionic requirements for the bottom of actin subdomain 1 and also suggests that there is allosteric communication through subdomain 1 within the actin monomer between the N and C termini.	Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	University of Iowa; Columbia University	Rubenstein, PA (corresponding author), Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045735, R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 66037, GM33689, GM45735] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASPENSTROM P, 1993, FEBS LETT, V329, P163, DOI 10.1016/0014-5793(93)80215-G; ASPENSTROM P, 1992, FEBS LETT, V303, P59, DOI 10.1016/0014-5793(92)80477-X; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Blondin L, 2001, EUR J BIOCHEM, V268, P6426, DOI 10.1046/j.0014-2956.2001.02592.x; Boldogh IR, 2004, MOL BIOL CELL, V15, P3994, DOI 10.1091/mbc.E04-01-0053; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CROSBIE RH, 1994, BIOPHYS J, V67, P1957, DOI 10.1016/S0006-3495(94)80678-2; DASGUPTA G, 1991, BIOCHEMISTRY-US, V30, P9961, DOI 10.1021/bi00105a021; Dickinson RB, 2004, BIOPHYS J, V87, P2838, DOI 10.1529/biophysj.104.045211; Dickinson RB, 2002, BIOPHYS J, V82, P605, DOI 10.1016/S0006-3495(02)75425-8; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Eads JC, 1998, BIOCHEMISTRY-US, V37, P11171, DOI 10.1021/bi9720033; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; Fehrenbacher KL, 2004, CURR BIOL, V14, P1996, DOI 10.1016/j.cub.2004.11.004; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; Head JF, 2002, BIOCHEMISTRY-US, V41, P9015, DOI 10.1021/bi026054y; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; HOLMES KC, 1993, ADV EXP MED BIOL, V332, P15; Ishikawa K, 2003, J CELL BIOL, V160, P887, DOI 10.1083/jcb.200210139; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kim E, 2000, J MOL BIOL, V299, P421, DOI 10.1006/jmbi.2000.3727; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; Okamoto K, 2001, METHOD CELL BIOL, V65, P277, DOI 10.1016/S0091-679X(01)65017-9; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon VR, 1997, CELL MOTIL CYTOSKEL, V37, P199, DOI 10.1002/(SICI)1097-0169(1997)37:3<199::AID-CM2>3.0.CO;2-2; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; Tang FS, 2003, NATURE, V422, P87, DOI 10.1038/nature01453; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; VANDEKERCKHOVE J, 1978, NATURE, V276, P720, DOI 10.1038/276720a0; Vorobiev S, 2003, P NATL ACAD SCI USA, V100, P5760, DOI 10.1073/pnas.0832273100; Wen KK, 2005, J BIOL CHEM, V280, P24168, DOI 10.1074/jbc.M502024200; WOOD, 2002, NATURE, V415, P671; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yang HC, 2001, METHOD CELL BIOL, V65, P333, DOI 10.1016/S0091-679X(01)65020-9; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	59	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36494	36501		10.1074/jbc.M506970200	http://dx.doi.org/10.1074/jbc.M506970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118223	hybrid			2022-12-25	WOS:000232726900083
J	Samudio, I; Konopleva, M; Hail, N; Shi, YX; McQueen, T; Hsu, T; Evans, R; Honda, T; Gribble, GW; Sporn, M; Gilbert, HF; Safe, S; Andreeff, M				Samudio, I; Konopleva, M; Hail, N; Shi, YX; McQueen, T; Hsu, T; Evans, R; Honda, T; Gribble, GW; Sporn, M; Gilbert, HF; Safe, S; Andreeff, M			2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PERMEABILITY TRANSITION PORE; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-NECROSIS-FACTOR; TRITERPENOID CDDO; 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID; MEDIATED APOPTOSIS; BIOLOGICAL EVALUATION; ADENOCARCINOMA CELLS; REDOX REGULATION	Surgical resection is the only curative strategy for pancreatic cancer ( PC). Unfortunately, > 80% of pancreatic cancer patients bear inoperable, locally advanced, chemoresistant tumors demonstrating the urgent need for development of novel therapeutic approaches to treat this disease. Here we report that the synthetic triterpenoid 2-cyano-3,12 dioxooleana-1,9dien-28-imidazolide (CDDO-Im) antagonizes PC cell growth by inducing apoptosis at submicromolar concentrations. Notably, we demonstrate for the first time that the cytotoxicity of CDDO-Im is accompanied by the rapid and selective depletion of mitochondrial glutathione that results in accumulation of reactive oxygen species, oxidation of the cellular glutathione pool, loss of mitochondrial membrane potential, and phosphatidylserine externalization. The parent compound CDDO as well as the methyl ester of CDDO also depleted mitochondrial glutathione, demonstrating that this effect is mediated by the triterpenoid nucleus of these agents. Cotreatment with sulfhydryl nucleophiles completely prevented apoptosis and loss of viability induced by CDDO-Im, whereas alkylation of intracellular thiols by diethylmaleate or cotreatment with dithiothreitol decreased the accumulation of a biotinylated derivative of CDDO, TP-301, in PC cells, suggesting that intracellular reduced thiols are functional targets of the electrophilic triterpenoid nucleus of CDDO and its derivatives. In conclusion, our report is the first to identify mitochondrial glutathione as a target of CDDO and its derivatives and demonstrates that depletion of this antioxidant in the mitochondria is an effective strategy to induce cell death in PC cells. These results suggest that CDDO and its derivatives may offer a clinical benefit for the treatment of PC.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, Houston, TX 77030 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA	University of Texas System; UTMD Anderson Cancer Center; Dartmouth College; Dartmouth College; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Andreeff, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, 1400 Holcombe Blvd,Unit 448, Houston, TX 77030 USA.	mandreef@mdanderson.org	Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NCI NIH HHS [CA16672, R01 CA089346, P01 CA55164] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, R01CA089346, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbruzzese James L, 2003, Int J Gastrointest Cancer, V33, P1, DOI 10.1385/IJGC:33:1:1; Abbruzzese JL, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.37382; Anderson KM, 1998, ANTICANCER RES, V18, P791; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Colell A, 2001, HEPATOLOGY, V34, P964, DOI 10.1053/jhep.2001.28510; Coll O, 2003, HEPATOLOGY, V38, P692, DOI 10.1053/jhep.2003.50351; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DHANBHOORA CM, 1992, ARCH BIOCHEM BIOPHYS, V293, P130, DOI 10.1016/0003-9861(92)90375-7; Dinkova-Kostova AT, 2005, P NATL ACAD SCI USA, V102, P4584, DOI 10.1073/pnas.0500815102; Dragovich PS, 1998, J MED CHEM, V41, P2806, DOI 10.1021/jm980068d; Duxbury MS, 2004, SURGERY, V136, P261, DOI 10.1016/j.surg.2004.04.029; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; Fernandez-Checa JC, 2003, BIOCHEM BIOPH RES CO, V304, P471, DOI 10.1016/S0006-291X(03)00619-3; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Filomeni G, 2002, FASEB J, V16, P64, DOI 10.1096/fj.02-0105fje; Hail N, 2004, J BIOL CHEM, V279, P11179, DOI 10.1074/jbc.M312758200; Hancock JT, 2003, ANN NY ACAD SCI, V1010, P446, DOI 10.1196/annals.1299.081; Herzig MCS, 2002, BREAST CANCER RES TR, V71, P133, DOI 10.1023/A:1013855615712; Honda T, 2004, J MED CHEM, V47, P4923, DOI 10.1021/jm049727e; Honda T, 2002, BIOORG MED CHEM LETT, V12, P1027, DOI 10.1016/S0960-894X(02)00105-1; Ikeda T, 2004, MOL CANCER THER, V3, P39, DOI 10.2463/mrms.3.39; Ikeda T, 2003, CANCER RES, V63, P5551; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Inoue S, 2004, LEUKEMIA, V18, P948, DOI 10.1038/sj.leu.2403328; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; Kim KB, 2002, MOL CANCER THER, V1, P177; Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402; Konopleva M, 2002, BLOOD, V99, P326, DOI 10.1182/blood.V99.1.326; Lapillonne H, 2003, CANCER RES, V63, P5926; Latham P, 2001, GUT, V49, P97, DOI 10.1136/gut.49.1.97; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Melichar B, 2004, GYNECOL ONCOL, V93, P149, DOI 10.1016/j.ygyno.2004.01.008; Minns LA, 2004, GASTROENTEROLOGY, V127, P119, DOI 10.1053/j.gastro.2004.03.053; Myers AG, 2003, J AM CHEM SOC, V125, P12080, DOI 10.1021/ja0372006; *NAT CANC I, 2002, SURV EP END RES FAST; Place AE, 2003, CLIN CANCER RES, V9, P2798; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Rizzardini M, 2003, J NEUROL SCI, V207, P51, DOI 10.1016/S0022-510X(02)00357-X; Saeki K, 2002, BIOCHEM J, V368, P705, DOI 10.1042/BJ20020101; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Suh NJ, 1999, CANCER RES, V59, P336; Suh WS, 2003, LEUKEMIA, V17, P2122, DOI 10.1038/sj.leu.2403112; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Woynarowska BA, 2002, BBA-MOL BASIS DIS, V1587, P309, DOI 10.1016/S0925-4439(02)00094-7; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	52	93	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36273	36282		10.1074/jbc.M507518200	http://dx.doi.org/10.1074/jbc.M507518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118208	hybrid			2022-12-25	WOS:000232726900060
J	Serban, G; Kouchi, Z; Baki, L; Georgakopoulos, A; Litterst, CM; Shioi, J; Robakis, NK				Serban, G; Kouchi, Z; Baki, L; Georgakopoulos, A; Litterst, CM; Shioi, J; Robakis, NK			Cadherins mediate both the association between PS1 and beta-catenin and the effects of PS1 on beta-catenin stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL REGION; ADHERENS JUNCTIONS; CYTOPLASMIC DOMAIN; ADHESION ACTIVITY; PRESENILIN-1; PROTEIN; COMPLEX; MUTATIONS; ARMADILLO; PHOSPHORYLATION	Presenilin1 (PS1), a protein involved in cellular development, forms functional complexes with beta-catenin, a regulator of Wnt signaling and cell-cell adhesion. In addition, both proteins have been shown to play important roles in disease including cancer and Alzheimer disease. Although PS1 and beta-catenin are found in the same complexes, it is not clear whether they bind directly to each other or a third complex component, like cadherin, may mediate their interactions. Here we show that PS1 and beta-catenin form no detectable complexes in cells that express no cadherin. In contrast, these complexes are readily found in E-cadherin containing cells. Furthermore, binding of both PS1 and beta-catenin to E-cadherin is necessary for the formation of PS1/beta-catenin complexes. Importantly, our data show that binding of PS1 to cadherin mediates the effects of PS1 on the phosphorylation, ubiquitination, and destabilization of beta-catenin. Thus, cadherins mediate both the association of PS1 and beta-catenin and the effects of PS1 on the cellular levels of beta-catenin.	NYU, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Robakis, NK (corresponding author), NYU, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.	nikos.robakis@mssm.edu	Robakis, Nikolaos/AAA-1838-2021; Serban, Geo/AAO-8819-2020	Serban, Geo/0000-0002-4985-7035; Georgakopoulos, Anastasios/0000-0001-8241-6306	NATIONAL INSTITUTE ON AGING [R01AG008200, R37AG017926, R01AG017926] Funding Source: NIH RePORTER; NIA NIH HHS [AG-17926, R01 AG008200, R37 AG017926, R01 AG017926, AG-08200] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Killick R, 2001, J BIOL CHEM, V276, P48554, DOI 10.1074/jbc.M108332200; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Onishi M, 1996, EXP HEMATOL, V24, P324; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Polakis P, 2000, GENE DEV, V14, P1837; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Simcha I, 2001, MOL BIOL CELL, V12, P1177, DOI 10.1091/mbc.12.4.1177; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	32	30	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36007	36012		10.1074/jbc.M507503200	http://dx.doi.org/10.1074/jbc.M507503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126725	Green Published, hybrid			2022-12-25	WOS:000232726900029
J	Theiss, AL; Simmons, JG; Jobin, C; Lund, PK				Theiss, AL; Simmons, JG; Jobin, C; Lund, PK			Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; FACTOR-ALPHA; IGF-I; TISSUE INHIBITOR; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; TRANSGENIC MICE; CROHNS-DISEASE	Intestinal fibrosis is an incurable complication of Crohn's disease involving increased numbers of collagen-producing myofibroblasts. Tumor necrosis factor (TNF) alpha has defined proinflammatory roles in Crohn's disease but its role in fibrosis is unclear. We tested the hypothesis that TNF alpha increases collagen accumulation and proliferation in intestinal myofibroblasts and has additive effects in combination with insulin-like growth factor (IGF) I. The mechanisms, TNF receptor isoform, and downstream signaling pathways were examined. Intestinal myofibroblasts from wild-type (WT) mice or mice homozygous for disruption of genes encoding TNFR1 ( TNFR1(-/-)), TNFR2 ( TNFR2(-/-)), or both (TNFR1/2(-/-)), were treated with TNF alpha, IGF-I, or both. In WT cells, TNF alpha and IGF- I stimulated type I collagen accumulation and DNA synthesis in an additive manner. IGF- I, but not TNF alpha, stimulated type I collagen gene activation. TNF alpha, but not IGF- I, induced tissue inhibitor of metalloproteinase-1 (TIMP-1) expression and reduced matrix metalloproteinases-2 activity and collagen degradation. TNF alpha also activated ERK1/2. These responses to TNF alpha were absent in TNFR2(-/-) and TNFR1/2(-/-) myofibroblasts, whereas TNFR1(-/-) cells showed similar responses to WT. Inhibition of ERK1/2 diminished TNF alpha-induced DNA synthesis in WT and TNFR1(-/-) cells. Differences in TNF alpha-induced STAT3/DNA binding activity and not NF kappa B and AP-1 transcriptional activation correlated with impaired collagen accumulation/TIMP-1 induction in TNFR2(-/-) cells. Constitutively active STAT3 rescued TIMP-1 expression in TNFR2(-/-) cells. We conclude that TNF alpha and IGF- I may additively contribute to fibrosis during intestinal inflammation. TNFR2 is a primary mediator of fibrogenic actions of TNF alpha acting through ERK1/2 to stimulate proliferation and through STAT3 to stimulate TIMP-1 and inhibit collagen degradation.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lund, PK (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA.	empk@med.unc.edu		Theiss, Arianne/0000-0003-2862-0933	NCI NIH HHS [CA 16086] Funding Source: Medline; NIDDK NIH HHS [R01-DK-40247, P30-DK-34987, R01-DK-47769] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047769, P30DK034987, R01DK040247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Fruchtman S, 2005, AM J PHYSIOL-GASTR L, V289, pG342, DOI 10.1152/ajpgi.00413.2004; Guo DQ, 1998, J IMMUNOL, V160, P2742; Guo GJ, 2001, AM J PHYSIOL-RENAL, V280, pF777, DOI 10.1152/ajprenal.2001.280.5.F777; Haas E, 1999, J BIOL CHEM, V274, P18107, DOI 10.1074/jbc.274.25.18107; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Helm KA, 2005, NEUROPHARMACOLOGY, V48, P956, DOI 10.1016/j.neuropharm.2005.01.019; Hernandez I, 2000, DNA CELL BIOL, V19, P341, DOI 10.1089/10445490050043317; HernandezMunoz I, 1997, GASTROENTEROLOGY, V113, P625, DOI 10.1053/gast.1997.v113.pm9247485; Holtmann MH, 2002, EUR J IMMUNOL, V32, P3142, DOI 10.1002/1521-4141(200211)32:11<3142::AID-IMMU3142>3.0.CO;2-4; Holtmann MH, 2004, CURR MOL MED, V4, P439, DOI 10.2174/1566524043360636; Houglum K, 1998, AM J PHYSIOL-GASTR L, V274, pG840, DOI 10.1152/ajpgi.1998.274.5.G840; Jijon HB, 2005, EUR J IMMUNOL, V35, P718, DOI 10.1002/eji.200425688; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Krempen K, 1999, GENE EXPRESSION, V8, P151; Lawrance IC, 2003, GASTROENTEROLOGY, V125, P1750, DOI 10.1053/j.gastro.2003.08.027; Lawrance IC, 2001, INFLAMM BOWEL DIS, V7, P16, DOI 10.1097/00054725-200102000-00003; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Louis E, 2000, CLIN EXP IMMUNOL, V120, P241, DOI 10.1046/j.1365-2249.2000.01227.x; MATTHES H, 1992, GASTROENTEROLOGY, V102, P431, DOI 10.1016/0016-5085(92)90087-F; MCCRAY PB, 1995, J CLIN INVEST, V95, P2620, DOI 10.1172/JCI117964; McKaig BC, 2003, AM J PATHOL, V162, P1355, DOI 10.1016/S0002-9440(10)63931-4; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; Mizoguchi E, 2002, GASTROENTEROLOGY, V122, P134, DOI 10.1053/gast.2002.30347; Ohneda K, 1997, GASTROENTEROLOGY, V112, P444, DOI 10.1053/gast.1997.v112.pm9024298; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; PETERKOFSKY B, 1995, EXTRACELLULAR MATRIX, P33; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG1307, DOI 10.1152/ajpgi.2000.279.6.G1307; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Savendahl L, 1997, ENDOCRINOLOGY, V138, P734, DOI 10.1210/en.138.2.734; Simmons JG, 2002, AM J PHYSIOL-GASTR L, V283, pG809, DOI 10.1152/ajpgi.00057.2002; Simmons JG, 1999, AM J PHYSIOL-GASTR L, V276, pG817, DOI 10.1152/ajpgi.1999.276.4.G817; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; Taylor PC, 2004, CURR OPIN BIOTECH, V15, P557, DOI 10.1016/j.copbio.2004.09.005; van Tol EAF, 1999, AM J PHYSIOL-GASTR L, V277, pG245, DOI 10.1152/ajpgi.1999.277.1.G245; von Lampe B, 2000, GUT, V47, P63, DOI 10.1136/gut.47.1.63; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Williams KL, 2002, AM J PHYSIOL-GASTR L, V283, pG875, DOI 10.1152/ajpgi.00089.2002; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; Wu Q, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-26; Zeeh JM, 1998, J RECEPT SIGNAL TR R, V18, P265, DOI 10.3109/10799899809047747; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; ZIMMERMANN E, 2004, KIRSNERS INFLAMMATOR, P219; ZIMMERMANN EM, 1993, GASTROENTEROLOGY, V105, P399, DOI 10.1016/0016-5085(93)90713-M; Zimmermann EM, 1997, AM J PHYSIOL-GASTR L, V273, pG875, DOI 10.1152/ajpgi.1997.273.4.G875	52	163	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36099	36109		10.1074/jbc.M505291200	http://dx.doi.org/10.1074/jbc.M505291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141211	hybrid, Green Published			2022-12-25	WOS:000232726900040
J	Ueda, T; Kato, A; Kuramitsu, S; Terasawa, H; Shimada, I				Ueda, T; Kato, A; Kuramitsu, S; Terasawa, H; Shimada, I			Identification and characterization of a second chromophore of DNA photolyase from Thermus thermophilus HB27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SUBSTRATE COMPLEX; ABSOLUTE ACTION SPECTRUM; ESCHERICHIA-COLI; ANACYSTIS-NIDULANS; CRYSTAL-STRUCTURE; PHOTOREACTIVATING ENZYME; PURIFICATION; MECHANISM; REPAIR; BINDING	Cyclobutane pyrimidine dimer (CPD) photolyases use light to repair CPDs. For efficient light absorption, CPD photolyases use a second chromophore. We purified Thermus thermophilus CPD photolyase with its second chromophore. UV-visible absorption spectra, reverse-phase HPLC, and NMR analyses of the chromophores revealed that the second chromophore of the enzyme is flavin mononucleotide (FMN). To clarify the role of FMN in the CPD repair reaction, the enzyme without FMN (Enz-FMN(-) and that with a stoichiometric amount of FMN ( Enz-FMN(+)) were both successfully obtained. The CPD repair activity of Enz-FMN(+) was higher than that of Enz-FMN(-), and the CPD repair activity ratio of Enz-FMN(+) and Enz-FMN(-) was dependent on the wavelength of light. These results suggest that FMN increases the light absorption efficiency of the enzyme. NMR analyses of Enz-FMN(+) and Enz-FMN(-) revealed that the binding mode of FMN is similar to that of 7,8-didemethyl-8-hydroxy-5-deazariboflavin in Anacystis nidulans CPD photolyase, and thus a direct electron transfer between FMN and CPD is not likely to occur. Based on these results, we concluded that FMN acts as a highly efficient light harvester that gathers light and transfers the energy to FAD.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp						BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; Carell T, 2001, CURR OPIN CHEM BIOL, V5, P491, DOI 10.1016/S1367-5931(00)00239-8; EKER APM, 1975, BIOCHIM BIOPHYS ACTA, V378, P54, DOI 10.1016/0005-2787(75)90136-7; EKER APM, 1990, J BIOL CHEM, V265, P8009; Graham DE, 2003, ARCH MICROBIOL, V180, P455, DOI 10.1007/s00203-003-0614-8; HAUSINGER RP, 1986, METHOD ENZYMOL, V122, P199; IWATSUKI N, 1980, BIOCHEMISTRY-US, V19, P1172, DOI 10.1021/bi00547a021; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; Kobayashi H, 1998, J BIOCHEM-TOKYO, V123, P182; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Kort R, 2004, ACTA CRYSTALLOGR D, V60, P1205, DOI 10.1107/S0907444904009321; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; RUPERT CS, 1962, J GEN PHYSIOL, V45, P725, DOI 10.1085/jgp.45.4.725; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR A, 1984, J MOL BIOL, V172, P223, DOI 10.1016/S0022-2836(84)80040-6; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SUBRAMANIAN S, 1984, CRC CR REV BIOCH MOL, V16, P169, DOI 10.3109/10409238409102302; Takeda M, 2003, J BIOL CHEM, V278, P43550, DOI 10.1074/jbc.M308199200; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Torizawa T, 2004, J BIOL CHEM, V279, P32950, DOI 10.1074/jbc.M404536200; Torizawa T, 1998, FEBS LETT, V429, P157, DOI 10.1016/S0014-5793(98)00582-1; Ueda T, 2004, J BIOL CHEM, V279, P52574, DOI 10.1074/jbc.M409942200; WALSH C, 1986, ACCOUNTS CHEM RES, V19, P216, DOI 10.1021/ar00127a004; WARD JM, 1991, ANAL CHIM ACTA, V249, P195, DOI 10.1016/0003-2670(91)87022-Y; YAGI T, 1988, BIOCHEMISTRY-US, V27, P2008, DOI 10.1021/bi00406a030; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	36	41	41	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36237	36243		10.1074/jbc.M507972200	http://dx.doi.org/10.1074/jbc.M507972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118222	hybrid			2022-12-25	WOS:000232726900056
J	Watt, NT; Taylor, DR; Gillott, A; Thomas, DA; Perera, WSS; Hooper, NM				Watt, NT; Taylor, DR; Gillott, A; Thomas, DA; Perera, WSS; Hooper, NM			Reactive oxygen species-mediated beta-cleavage of the prion protein in the cellular response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; BINDING-SITES; AMINO-TERMINUS; SCRAPIE AGENT; IN-VIVO; DISEASE; MICE; PRP; BRAIN; ENDOCYTOSIS	The cellular prion protein (PrPC) is critical for the development of prion diseases. However, the physiological role of PrPC is less clear, although a role in the cellular resistance to oxidative stress has been proposed. PrPC is cleaved at the end of the copper-binding octapeptide repeats through the action of reactive oxygen species (ROS), a process termed beta-cleavage. Here we show that ROS-mediated beta-cleavage of cell surface PrPC occurs within minutes and was inhibited by the hydroxyl radical quencher dimethyl sulfoxide and by an antibody against the octapeptide repeats. A construct of PrP lacking the octapeptide repeats, PrP Delta oct, failed to undergo ROS-mediated beta-cleavage, as did two mutant forms of PrP, PG14 and A116V, associated with human prion diseases. As compared with cells expressing wild type PrP, when challenged with H2O2 and Cu2+, cells expressing PrP Delta oct, PG14, or A116V had reduced viability and glutathione peroxidase activity and increased intracellular free radicals. Thus, lack of ROS-mediated beta-cleavage of PrP correlated with the sensitivity of the cells to oxidative stress. These data indicate that the beta-cleavage of PrPC is an early and critical event in the mechanism by which PrP protects cells against oxidative stress.	Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Hooper, NM (corresponding author), Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.	n.m.hooper@leeds.ac.uk		Thomas, Daniel/0000-0002-5177-1900; Hooper, Nigel/0000-0002-5811-3484	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Atarashi R, 2003, J BIOL CHEM, V278, P28944, DOI 10.1074/jbc.M303655200; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 2003, J NEUROCHEM, V87, P377, DOI 10.1046/j.1471-4159.2003.02046.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Choi SI, 1998, ACTA NEUROPATHOL, V96, P279, DOI 10.1007/s004010050895; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; Guentchev M, 2000, NEUROBIOL DIS, V7, P270, DOI 10.1006/nbdi.2000.0290; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hetz C, 2003, TRENDS MOL MED, V9, P237, DOI 10.1016/S1471-4914(03)00069-8; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Inouye H, 2000, J MOL BIOL, V300, P1283, DOI 10.1006/jmbi.2000.3926; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; KIM K, 1985, J BIOL CHEM, V260, P5394; Krasemann S, 1995, Brain Res Mol Brain Res, V34, P173; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lee DW, 1999, FREE RADICAL RES, V30, P499, DOI 10.1080/10715769900300541; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Mange A, 2004, BIOL CELL, V96, P125, DOI 10.1016/j.biolcel.2003.11.007; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Vincent B, 2001, J BIOL CHEM, V276, P37743; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Yadavalli R, 2004, J BIOL CHEM, V279, P21948, DOI 10.1074/jbc.M400793200; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; Zeng FN, 2003, J NEUROCHEM, V84, P480, DOI 10.1046/j.1471-4159.2003.01529.x	47	130	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35914	35921		10.1074/jbc.M507327200	http://dx.doi.org/10.1074/jbc.M507327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120605	hybrid			2022-12-25	WOS:000232726900018
J	Zhou, AF; Li, J				Zhou, AF; Li, J			Arabidopsis BRS1 is a secreted and active serine carboxypeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE GROWTH-FACTOR; SECONDARY METABOLISM; PROTEIN-KINASE; GENE FAMILY; EXPRESSION; PRECURSOR; BRI1; ACYLTRANSFERASE; POLYPEPTIDE; PHYTOSULFOKINE	The Arabidopsis BRS1 gene encodes a serine carboxypeptidase II-like protein. Its biological role in the brassinosteroid signaling pathway was first established by its capability to specifically suppress a weak brassinosteroid insensitive 1 (bri1) allele, bri1-5, when overexpressed. To gain additional insights into the molecular mechanisms of BRS1 function, the subcellular localization and the biochemical characteristics of BRS1 were determined by using transgenic plants harboring a 35S-BRS1-GFP construct and fusion proteins purified from 35S-BRS1-FLAG transgenic plants. The BRS1-GFP protein was mainly secreted and accumulated in the extracellular space. Immunological data suggest that BRS1 is proteolytically processed by an unknown endoproteinase in planta. Affinity-purified BRS1-FLAG from transgenic plants show strong hydrolytic activity with a broad P1 substrate preference including basic and hydrophobic groups on either side of the scissile bond. The hydrolytic activity of BRS1 can be strongly inhibited by a serine protease inhibitor, phenylmethylsulfonyl fluoride. The pH and temperature optima for the hydrolytic activity of BRS1 are pH 5.5 and 50 C, respectively. These data demonstrate that BRS1 is a secreted and active serine carboxypeptidase, consistent with the hypothesis suggested by our previous genetic evidence that BRS1 may process a protein involved in an early event in the BRI1 signaling pathway.	Univ Oklahoma, Dept Bot & Microbiol, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Li, J (corresponding author), Univ Oklahoma, Dept Bot & Microbiol, 770 Van Vleet Oval, Norman, OK 73019 USA.	lij@ou.edu						BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Becraft PW, 2002, DEVELOPMENT, V129, P5217; Berger D, 2000, GENE DEV, V14, P1119; BREDDAM K, 1987, CARLSBERG RES COMMUN, V52, P297, DOI 10.1007/BF02907172; Cercos M, 2003, PLANT MOL BIOL, V51, P165, DOI 10.1023/A:1021142403856; DOAN NP, 1988, J BIOL CHEM, V263, P11106; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Dominguez F, 1999, PLANT PHYSIOL, V119, P81, DOI 10.1104/pp.119.1.81; Fan XM, 2002, J HISTOCHEM CYTOCHEM, V50, P1509, DOI 10.1177/002215540205001111; Fraser CM, 2005, PLANT PHYSIOL, V138, P1136, DOI 10.1104/pp.104.057950; Friedrichsen DM, 2000, PLANT PHYSIOL, V123, P1247, DOI 10.1104/pp.123.4.1247; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; LATCHINIANSADEK L, 1993, J BIOL CHEM, V268, P534; Lehfeldt C, 2000, PLANT CELL, V12, P1295, DOI 10.1105/tpc.12.8.1295; Li AX, 2000, P NATL ACAD SCI USA, V97, P6902, DOI 10.1073/pnas.110154197; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li J, 2001, P NATL ACAD SCI USA, V98, P5916, DOI 10.1073/pnas.091065998; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Lid SE, 2002, P NATL ACAD SCI USA, V99, P5460, DOI 10.1073/pnas.042098799; Matsubayashi Y, 2003, J CELL SCI, V116, P3863, DOI 10.1242/jcs.00733; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; RAMINGTON SJ, 1993, CURR OPIN BIOTECH, V4, P462; Robatzek S, 2001, PLANT J, V28, P123, DOI 10.1046/j.1365-313X.2001.01131.x; Schaller A, 2004, PLANTA, V220, P183, DOI 10.1007/s00425-004-1407-2; SCHALLER A, 1994, P NATL ACAD SCI USA, V91, P11802, DOI 10.1073/pnas.91.25.11802; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; Shirley AM, 2003, J BIOL CHEM, V278, P19870, DOI 10.1074/jbc.M302362200; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Steffens J C, 2000, Plant Cell, V12, P1253; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758; Wei SW, 2003, LIFE SCI, V73, P655, DOI 10.1016/S0024-3205(03)00386-2; Yang HP, 1999, P NATL ACAD SCI USA, V96, P13560, DOI 10.1073/pnas.96.23.13560; Yang HP, 2001, PLANT PHYSIOL, V127, P842, DOI 10.1104/pp.010452; Zhou A, 2004, PLANT J, V40, P399, DOI 10.1111/j.1365-313X.2004.02214.x	40	40	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35554	35561		10.1074/jbc.M503299200	http://dx.doi.org/10.1074/jbc.M503299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123046	hybrid			2022-12-25	WOS:000232561200057
J	Fujiwara, Y; Sardar, V; Tokumura, A; Baker, D; Murakami-Murofushi, K; Parrill, A; Tigyi, G				Fujiwara, Y; Sardar, V; Tokumura, A; Baker, D; Murakami-Murofushi, K; Parrill, A; Tigyi, G			Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; LPA RECEPTORS; EMERGING ROLE; EDG-FAMILY; ACTIVATION; SUBTYPE; ANALOGS; HETERODIMERIZATION; HOMODIMERIZATION	The endothelial differentiation gene family encodes three highly homologous G protein-coupled receptors for lysophosphatidic acid (LPA). Based on baculoviral overexpression studies, differences have been proposed in the structure-activity relationship (SAR) of these receptors. We have compared the SAR of the individual receptors either overexpressed transiently at high or at lower levels following stable transfection in LPA-nonresponsive RH7777 cells. The SAR in transfected RH7777 cells was markedly different from that described in insect cells. The LPA(3) receptor has been proposed to be selectively activated by unsaturated LPA species and shows a strong preference for sn-2 versus the sn-1 acyl-LPA regioisomer. Because of the short half-life of sn-2 LPA due to acyl migration under some conditions, we have synthesized acyl migration-resistant analogs using an acetyl group in place of the free hydroxyl group in order to evaluate LPA receptor SAR. Only LPA(1) and LPA(2) showed regioisomeric preference and only for the 18: 2 fatty acyl-stabilized LPA sn-1 regioisomer. To identify residues involved in ligand recognition of LPA(3), we developed and validated computational models of LPA(3) complexes with the analogs studied. The models revealed that Arg-3.28 and Gln-3.29 conserved within the LPA-selective endothelial differentiation gene receptors and the more variable Lys-7.35 and Arg-5.38 of LPA(3) form critical interactions with the polar head-group of LPA. The models identified Leu-2.60 and Val-7.39 of LPA(3) underlying the regioisomer-selective interaction with the acetyl group of the stabilized regioisomers. Mutation of Leu-2.60 to alanine selectively increased the EC50 of the sn-2 acetyl-LPA regioisomers, whereas alanine replacement of Val-7.39 profoundly affected both regioisomers.	Univ Tennessee, Inst Canc, Hlth Sci Ctr, Memphis, TN 38152 USA; Univ Tennessee, Dept Chem, Memphis, TN 38152 USA; Univ Tennessee, Computat Res Mat Inst, Memphis, TN 38152 USA; Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan; Ochanomizu Univ, Dept Biol, Bunkyo Ku, Tokyo 112, Japan	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Tokushima University; Ochanomizu University	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu		Parrill, Abby/0000-0003-1658-8497; Baker, Daniel/0000-0003-1482-0416	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER; NCI NIH HHS [CA92160] Funding Source: Medline; NHLBI NIH HHS [HL61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; *CHEM COMP GROUP, 2003, MOE; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Hama K, 2002, FEBS LETT, V523, P187, DOI 10.1016/S0014-5793(02)02976-9; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Holdsworth Gill, 2004, BMC Biochemistry, V5, P1, DOI 10.1186/1471-2091-5-12; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; INAGAKI Y, 2005, IN PRESS BIOCH J; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; JALINK K, 1990, J BIOL CHEM, V265, P12232; KOBAYASHI S, 1993, TETRAHEDRON LETT, V34, P4047, DOI 10.1016/S0040-4039(00)60612-3; Liliom K, 1998, J BIOL CHEM, V273, P13461, DOI 10.1074/jbc.273.22.13461; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tokumura A, 2002, BIOCHEM J, V365, P617, DOI 10.1042/BJ20020348; Van Brocklyn JR, 2002, BBA-MOL CELL BIOL L, V1582, P89, DOI 10.1016/S1388-1981(02)00141-5; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619; ZHU BT, 1993, J PHARMACOL TOXICOL, V29, P85, DOI 10.1016/1056-8719(93)90055-J	42	70	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35038	35050		10.1074/jbc.M504351200	http://dx.doi.org/10.1074/jbc.M504351200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16115890	hybrid			2022-12-25	WOS:000232403900077
J	Corti, S; Locatelli, F; Papadimitriou, D; Donadoni, C; Del Bo, R; Fortunato, F; Strazzer, S; Salani, S; Bresolin, N; Comi, GP				Corti, S; Locatelli, F; Papadimitriou, D; Donadoni, C; Del Bo, R; Fortunato, F; Strazzer, S; Salani, S; Bresolin, N; Comi, GP			Multipotentiality, homing properties, and pyramidal neurogenesis of CNS-derived LeX(ssea-1)(+)/CXCR4(+) stem cells	FASEB JOURNAL			English	Article						neural stem cells; transplantation; neurodegenerative diseases	NEURAL STEM; PROGENITOR CELLS; HEMATOPOIETIC STEM; INTRAVENOUS TRANSPLANTATION; CHOLINERGIC NEURONS; DIRECTED MIGRATION; ADULT RATS; MOUSE; MUSCLE; DIFFERENTIATION	Achieving efficient distribution of neural stem cells throughout the central nervous system (CNS) and robust generation of specific neurons is a major challenge for the development of cell-mediated therapy for neurodegenerative diseases. We isolated a primitive neural stem cell subset, double positive for LeX(Le) and CXCR4(CX) antigens that possesses CNS homing potential and extensive neuronal repopulating capacity. Le(+)CX(+) cells are multipotential and can generate neurons as well as myogenic and endothelial cells. In vivo Le(+)CX(+) cells displayed widespread incorporation and differentiated into cortical and hippocampal pyramidal neurons. Since intravenous delivery could be a less invasive route of transplantation, we investigated whether Le(+)CX(+) cells could migrate across endothelial monolayers. Intracerebral coadministration of SDF enabled migration of intravenously injected Le(+) CX+ cells into the CNS and a small, yet significant, number of donor cells differentiated into neurons. The isolation of a specific neural stem cell population could offer major advantages to neuronal replacement strategies.	Univ Milan, IRCCS Fdn Osped Maggiore Policlin Mangiagalli & R, Dept Neurol Sci, Dino Ferrari Ctr, I-20122 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, Milan, Italy; IRCCS Eugenio Medea, Lecce, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; IRCCS Eugenio Medea	Comi, GP (corresponding author), Univ Milan, IRCCS Fdn Osped Maggiore Policlin Mangiagalli & R, Dept Neurol Sci, Dino Ferrari Ctr, Padiglione Ponti,Via Francesco Sforza 35, I-20122 Milan, Italy.	giacomo.comi@unimi.it	Comi, Giacomo P/K-5702-2016; FEDERICA, LOCATELLI/AAA-5601-2020; Corti, Stefania/K-6034-2016; strazzer, sandra/AAH-5712-2019	Comi, Giacomo P/0000-0002-1383-5248; FEDERICA, LOCATELLI/0000-0002-8243-5483; Corti, Stefania/0000-0001-5425-969X; strazzer, sandra/0000-0001-8414-6565; Bresolin, Nereo/0000-0001-6694-3595				Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5; Corti S, 2004, BRAIN, V127, P2518, DOI 10.1093/brain/awh273; Corti S, 2002, EXP CELL RES, V277, P74, DOI 10.1006/excr.2002.5543; Corti S, 2001, EXP CELL RES, V268, P36, DOI 10.1006/excr.2001.5267; Donadoni C, 2004, J HISTOCHEM CYTOCHEM, V52, P1333, DOI 10.1369/jhc.4A6320.2004; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gao J, 2005, NEUROSCIENCE, V131, P257, DOI 10.1016/j.neuroscience.2004.10.033; Gocht A, 1996, HISTOL HISTOPATHOL, V11, P1007; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin KL, 2005, NEUROBIOL DIS, V18, P366, DOI 10.1016/j.nbd.2004.10.010; Kim M, 2003, J NEUROSCI, V23, P10703; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; Szabo PE, 2002, MECH DEVELOP, V115, P157, DOI 10.1016/S0925-4773(02)00087-4; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Wernig M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	39	57	65	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1860	+		10.1096/fj.05-4170fje	http://dx.doi.org/10.1096/fj.05-4170fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150803				2022-12-25	WOS:000232315700022
J	Woltjer, RL; Cimino, PJ; Boutte, AM; Schantz, AM; Montine, KS; Larson, EB; Bird, T; Quinn, JF; Zhang, J; Montine, TJ				Woltjer, RL; Cimino, PJ; Boutte, AM; Schantz, AM; Montine, KS; Larson, EB; Bird, T; Quinn, JF; Zhang, J; Montine, TJ			Proteomic determination of widespread detergent insolubility, including A beta but not tau, early in the pathogenesis of Alzheimer's disease	FASEB JOURNAL			English	Article						prodromal; dementia; sarkosyl; presenilin	MILD COGNITIVE IMPAIRMENT; AMYLOID PLAQUES; NEUROFIBRILLARY TANGLES; GENETIC-VARIATION; APOLIPOPROTEIN-D; ALPHA-SYNUCLEIN; FATAL ATTRACTIONS; TRANSGENIC MICE; PROTEINS; BRAIN	Biochemical characterization of the major detergent-insoluble proteins that comprise hallmark histopathologic lesions initiated the molecular era of Alzheimer's disease (AD) research. Here, we reinvestigated detergent-insoluble proteins in AD using modern proteomic techniques. Using liquid chromatography (LC)-mass spectrometry (MS)-MS-based proteomics, we robustly identified 125 proteins in the detergent-insoluble fraction of late-onset AD (LOAD) temporal cortex that included several proteins critical to A beta production, components of synaptic scaffolding, and products of genes linked to an increased risk of LOAD; we verified 15 of 15 of these proteins by Western blot. Following multiple analyses, we estimated that these represent similar to 80% of detergent-insoluble proteins in LOAD detectable by our method. A beta, tau, and 7 of 8 other newly identified detergent-insoluble proteins were disproportionately increased in temporal cortex from patients with LOAD and AD derived from mutations in PSEN1 and PSEN2; all of these except tau were elevated in individuals with prodromal dementia, while none except A beta were elevated in aged APPswe mice. These results are consistent with the amyloid hypothesis of AD and extend it to include widespread protein insolubility, not exclusively A beta insolubility, early in AD pathogenesis even before the onset of clinical dementia.	Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Univ Washington, Div Neuropathol, Dept Pathol, Seattle, WA 98104 USA; Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oregon Health & Science University	Montine, TJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, Box 359791, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Montine, Kathleen/0000-0003-2110-8363; Cimino, P.J./0000-0003-0441-4502	NIA NIH HHS [AG24011, AG22040, AG23801, AG05136, AG06781] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K01AG022040, R01AG024011, U01AG006781, P50AG005136, R01AG023801] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett DA, 2005, NEUROLOGY, V64, P834, DOI 10.1212/01.WNL.0000152982.47274.9E; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Boyd-Kimball D, 2005, NEUROSCIENCE, V132, P313, DOI 10.1016/j.neuroscience.2004.12.022; Busciglio J, 1997, J NEUROSCI, V17, P5101, DOI 10.1523/jneurosci.17-13-05101.1997; CARLIER MF, 1984, BIOCHIMIE, V66, P305, DOI 10.1016/0300-9084(84)90007-5; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; David S, 1998, MOL BRAIN RES, V54, P276, DOI 10.1016/S0169-328X(97)00343-4; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; deLeon MJ, 1997, NEUROBIOL AGING, V18, P1, DOI 10.1016/S0197-4580(96)00213-8; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Desai PP, 2003, AM J MED GENET B, V116B, P98, DOI 10.1002/ajmg.b.10798; Donahue JE, 1999, P NATL ACAD SCI USA, V96, P6468, DOI 10.1073/pnas.96.11.6468; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Gan L, 2004, J BIOL CHEM, V279, P5565, DOI 10.1074/jbc.M306183200; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.3.CO;2-1; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Helisalmi S, 2004, J NEUROL, V251, P951, DOI 10.1007/s00415-004-0470-8; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P1009, DOI 10.1097/00005072-199709000-00006; Jing Z, 2005, NEUROBIOL AGING, V26, P207, DOI 10.1016/j.neurobiolaging.2004.03.012; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; Keller JN, 2005, NEUROLOGY, V64, P1152, DOI 10.1212/01.WNL.0000156156.13641.BA; KOWALL NW, 1991, ANN NEUROL, V29, P162, DOI 10.1002/ana.410290208; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7; Li Y, 2004, P NATL ACAD SCI USA, V101, P15688, DOI 10.1073/pnas.0403535101; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; Mitchell TW, 2002, ANN NEUROL, V51, P182, DOI 10.1002/ana.10086; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Morris JC, 2001, J MOL NEUROSCI, V17, P101, DOI 10.1385/JMN:17:2:101; Nagy JI, 1996, BRAIN RES, V717, P173, DOI 10.1016/0006-8993(95)01526-4; Navarro A, 2003, EXP NEUROL, V184, P697, DOI 10.1016/S0014-4886(03)00315-7; Ntais C, 2004, AM J EPIDEMIOL, V159, P527, DOI 10.1093/aje/kwh069; Parkin ET, 1999, J NEUROCHEM, V72, P1534, DOI 10.1046/j.1471-4159.1999.721534.x; Petrovitch H, 2005, ANN NEUROL, V57, P98, DOI 10.1002/ana.20318; Riley KP, 2002, ANN NEUROL, V51, P567, DOI 10.1002/ana.10161; Roses AD, 1996, ANN NY ACAD SCI, V777, P146, DOI 10.1111/j.1749-6632.1996.tb34413.x; Shiozaki A, 2004, J ALZHEIMERS DIS, V6, P257; Smillie KJ, 2005, BIOCHEM SOC SYMP, V72, P87, DOI 10.1042/bss0720087; Soderberg L, 2005, J BIOL CHEM, V280, P1007, DOI 10.1074/jbc.M403628200; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Stoltzner SE, 2000, AM J PATHOL, V156, P489, DOI 10.1016/S0002-9440(10)64753-0; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Trojanowski JQ, 2001, J ALZHEIMERS DIS, V3, P117, DOI 10.3233/JAD-2001-3116; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Trojanowski JQ, 2000, ANN NY ACAD SCI, V924, P62; Tsuang DW, 2002, MED CLIN N AM, V86, P591, DOI 10.1016/S0025-7125(02)00003-2; Umahara T, 2004, ACTA NEUROPATHOL, V108, P279, DOI 10.1007/s00401-004-0885-4; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085; Wang Q, 2005, FASEB J, V19, P869, DOI 10.1096/fj.04-3210fje; WHALLEY L, 2002, DEMENTIA; White L, 2002, ANN NY ACAD SCI, V977, P9, DOI 10.1111/j.1749-6632.2002.tb04794.x; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMADA T, 1990, NEUROSCI LETT, V120, P163, DOI 10.1016/0304-3940(90)90028-8; Yao PJ, 2004, TRENDS NEUROSCI, V27, P24, DOI 10.1016/j.tins.2003.10.012; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200	71	47	47	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1923	+		10.1096/fj.05-4263fje	http://dx.doi.org/10.1096/fj.05-4263fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129700				2022-12-25	WOS:000231843700001
J	Kristiansen, M; Messenger, MJ; Klohn, PC; Brandner, S; Wadsworth, JDF; Collinge, J; Tabrizi, SJ				Kristiansen, M; Messenger, MJ; Klohn, PC; Brandner, S; Wadsworth, JDF; Collinge, J; Tabrizi, SJ			Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; CREUTZFELDT-JAKOB-DISEASE; INCLUSION-BODY FORMATION; FATAL FAMILIAL INSOMNIA; ENDOPLASMIC-RETICULUM; SCRAPIE PRIONS; PRP; DEGRADATION; MICE; NEUROTOXICITY	The molecular basis for neuronal death in prion disease is not established, but putative pathogenic roles for both disease-related prion protein (PrPSc) and accumulated cytosolic PrPC have been proposed. Here we report that only prion-infected neuronal cells become apoptotic after mild inhibition of the proteasome, and this is strictly dependent upon sustained propagation of PrPSc. Whereas cells overexpressing PrPC developed cytosolic PrPC aggregates, this did not cause cell death. In contrast, only in prion- infected cells, mild proteasome impairment resulted in the formation of large cytosolic perinuclear aggresomes that contained PrPSc, heat shock chaperone 70, ubiquitin, proteasome subunits, and vimentin. Similar structures were found in the brains of prion- infected mice. PrPSc aggresome formation was directly associated with activation of caspase 3 and 8, resulting in apoptosis. These data suggest that neuronal propagation of prions invokes a neurotoxic mechanism involving intracellular formation of PrPSc aggresomes. This, in turn, triggers caspase-dependent apoptosis and further implicates proteasome dysfunction in the pathogenesis of prion diseases.	UCL, Inst Neurol, MRC, Prion Unit, London WC1N 3BG, England; UCL, Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Tabrizi, SJ (corresponding author), UCL, Inst Neurol, MRC, Prion Unit, Queen Sq, London WC1N 3BG, England.	sarah.tabrizi@prion.ucl.ac.uk	Brandner, Sebastian/J-4562-2014; Kloehn, Peter/AAS-3719-2021	Brandner, Sebastian/0000-0002-9821-0342; Wadsworth, Jonathan/0000-0002-4797-2259; Tabrizi, Sarah/0000-0003-2716-2045	MRC [MC_U123160655] Funding Source: UKRI; Medical Research Council [MC_U123160655] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Campana V, 2005, TRENDS CELL BIOL, V15, P102, DOI 10.1016/j.tcb.2004.12.002; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cohen E, 2003, EMBO J, V22, P404, DOI 10.1093/emboj/cdg045; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; Cronier S, 2004, P NATL ACAD SCI USA, V101, P12271, DOI 10.1073/pnas.0402725101; Ding QX, 2003, J NEUROCHEM, V86, P489, DOI 10.1046/j.1471-4159.2003.01885.x; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fioriti L, 2005, J BIOL CHEM, V280, P11320, DOI 10.1074/jbc.M412441200; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Fraser JR, 2002, NEUROPATH APPL NEURO, V28, P1, DOI 10.1046/j.1365-2990.2002.00376.x; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hetz C, 2003, CELL MOL LIFE SCI, V60, P133, DOI 10.1007/s000180300009; Hill AF, 2003, TRENDS MICROBIOL, V11, P578, DOI 10.1016/j.tim.2003.10.007; Jamieson E, 2001, NEUROREPORT, V12, P3567, DOI 10.1097/00001756-200111160-00039; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kang SC, 2004, J PATHOL, V203, P603, DOI 10.1002/path.1555; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kovacs GG, 2005, AM J PATHOL, V166, P287, DOI 10.1016/S0002-9440(10)62252-3; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lu DC, 2003, ANN NEUROL, V54, P781, DOI 10.1002/ana.10761; Luhr KM, 2004, NEUROREPORT, V15, P1663, DOI 10.1097/01.wnr.0000134931.81690.34; Luhr KM, 2004, J VIROL, V78, P4776, DOI 10.1128/JVI.78.9.4776-4782.2004; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mallucci G, 2005, NAT REV NEUROSCI, V6, P23, DOI 10.1038/nrn1584; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MEDORI R, 1992, NEUROLOGY, V42, P669, DOI 10.1212/WNL.42.3.669; Mishra RS, 2003, J ALZHEIMERS DIS, V5, P15, DOI 10.3233/JAD-2003-5103; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Sathasivam K, 2001, HUM MOL GENET, V10, P2425, DOI 10.1093/hmg/10.21.2425; Schatzl HM, 1997, J VIROL, V71, P8821; Siso S, 2002, ACTA NEUROPATHOL, V103, P615, DOI 10.1007/s00401-001-0512-6; Solassol J, 2003, BRIT MED BULL, V66, P87, DOI 10.1093/bmb/66.1.87; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Wang XH, 2005, J BIOL CHEM, V280, P317, DOI 10.1074/jbc.M410649200; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	66	105	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38851	38861		10.1074/jbc.M506600200	http://dx.doi.org/10.1074/jbc.M506600200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16157591	hybrid			2022-12-25	WOS:000233239800087
J	Lebrun, P; Montminy, MR; Van Obberghen, E				Lebrun, P; Montminy, MR; Van Obberghen, E			Regulation of the pancreatic duodenal homeobox-1 protein by DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; ISLET CELLS; BETA-CELLS; V(D)J RECOMBINATION; FACTOR STF-1; KU ANTIGEN; FACTOR-I; C-JUN; HOMEODOMAIN; PHOSPHORYLATION	The transcription factor PDX-1 plays a crucial role during pancreatic development and in the function of insulin-producing beta cells. Disruption of the pdx-1 gene in these cells induces overt diabetes in mice, and this gene is modified in several type 2 diabetic families. It is thus crucial to determine the molecular mechanisms involved in the regulation of PDX-1 expression and/or activation. We identified new proteins associated with PDX-1 by mass spectrometry. These proteins, Ku70 and Ku80, are regulatory subunits of DNA-dependent protein kinase (DNA-PK). We determined that the interaction between PDX-1 and Ku70 or Ku80 is dependent on the homeodomain of PDX-1. Most interestingly, we demonstrated in vitro that the DNA-PK phosphorylates PDX-1 on threonine 11. Although this residue is located in the transactivation domain, this phosphorylation does not seem to be implicated in the transcriptional activation of PDX-1. However, in response to radiation, which activates DNA-PK, a second form of the PDX-1 protein appears rapidly. This form is phosphorylated on threonine and seems to drive PDX-1 degradation by the proteosome. In correlation with this degradation, we observed a subsequent reduction in the activation of the insulin promoter and a decrease in PDX-1-mediated gene expression, i.e. glut2 and glucokinase. Our study demonstrates that radiation, through the activation of DNA-PK, may regulate PDX-1 protein expression.	Fac Med Nice, INSERM, U145, IFR50, Nice, France; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Salk Institute	Lebrun, P (corresponding author), Fac Med Nice, INSERM, U145, IFR50, Nice, France.	plebrun@unice.fr; vanobbeg@unice.fr	LEBRUN, Patricia/O-5765-2016					Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; GUZ Y, 1995, DEVELOPMENT, V121, P11; Henkels KM, 1999, CANCER RES, V59, P3077; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; MATTSON G, 1993, MOL BIOL REP, V17, P167, DOI 10.1007/BF00986726; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Melloul D, 2002, DIABETES, V51, pS320, DOI 10.2337/diabetes.51.2007.S320; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Sharma A, 1999, DIABETES, V48, P507, DOI 10.2337/diabetes.48.3.507; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Song JY, 2003, J BIOL CHEM, V278, P36676, DOI 10.1074/jbc.M303692200; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; UM JH, 2004, EXP MOL MED, V36, P233; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	45	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38203	38210		10.1074/jbc.M504842200	http://dx.doi.org/10.1074/jbc.M504842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166097	hybrid			2022-12-25	WOS:000233239800013
J	Huttenrach, F; Pollok-Kopp, B; Oppermann, M				Huttenrach, F; Pollok-Kopp, B; Oppermann, M			G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C5A ANAPHYLATOXIN RECEPTOR; CHEMOKINE RECEPTOR; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; HIV-1 INFECTION; DOWN-REGULATION; IN-VIVO; DESENSITIZATION; DIMERIZATION; BINDING	Expression levels of the chemokine receptor, CC chemokine receptor 5 (CCR5), at the cell surface determine cell susceptibility to HIV entry and infection. Cellular activation by CCR5 itself, but also by unrelated receptors leads to cross-phosphorylation and cross-internalization of CCR5. This study addresses the underlying molecular mechanisms of homologous and heterologous CCR5 regulation. As shown by bioluminescence resonance energy transfer experiments, CCR5 formed constitutive homo- as well as heterooligomeric complexes together with C5aR but not with the unrelated AT(1a)R in living cells. Stimulation with CCL5 of RBL cells, which co-expressed CCR5 together with an N-terminally truncated CCR5-Delta NT mutant, resulted in both protein kinase C(PKC)- and G protein-coupled receptor (GPCR) kinase (GRK)-mediated cross-phosphorylation of the mutant unligated receptor, as determined by phosphosite-specific monoclonal antibody. Similarly, both PKC and GRK cross-phosphorylated CCR5 in a heterologous manner after C5a stimulation of RBL-CCR5/ C5aR cells, whereas AT(1a)R stimulation resulted only in classical PKC-mediated CCR5 phosphorylation. Co-expression of CCR5-Delta NT together with a phosphorylation-deficient CCR5 mutant that neither binds beta-arrestin nor undergoes internalization partially restored the CCL5-induced association of beta-arrestin with the homo- oligomeric receptor complex and augmented cellular uptake of I-125-CCL5. Co-expression of C5aR, but not of AT1aR, promoted CCR5 co-internalization upon agonist stimulation by a mechanism independent of CCR5 phosphorylation. Co-internalization of phosphorylated CCR5 was also observed in C5a-stimulated macrophages. Finally, co-expression of a constitutively internalized C5aR-US28(CT) mutant led to intracellular accumulation of CCR5 in the absence of ligand stimulation. These results show that GRKs and beta-arrestin are involved in heterologous receptor regulation by cross-phosphorylating and co-internalizing unligated receptors within homo- or hetero-oligomeric protein complexes.	Univ Gottingen, Dept Cellular & Mol Immunol, D-37073 Gottingen, Germany	University of Gottingen	Oppermann, M (corresponding author), Univ Gottingen, Dept Cellular & Mol Immunol, Humboldtallee 34, D-37073 Gottingen, Germany.	mopperm@gwdg.de						AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; ALI H, 1993, J BIOL CHEM, V268, P24247; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Ayoub M, 2001, N-S ARCH PHARMACOL, V363, pR53; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chelli M, 2002, J BIOL CHEM, V277, P39388, DOI 10.1074/jbc.M205394200; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; El-Asmar L, 2005, MOL PHARMACOL, V67, P460, DOI 10.1124/mol.104.003624; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hansen JL, 2004, J BIOL CHEM, V279, P24108, DOI 10.1074/jbc.M400092200; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Lagane B, 2005, MOL PHARMACOL, V67, P1966, DOI 10.1124/mol.104.009779; Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521-4141(199909)29:09<3035::AID-IMMU3035>3.0.CO;2-Z; Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; Lemay J, 2005, NAT IMMUNOL, V6, P535, DOI 10.1038/ni0605-535a; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mesnier D, 2004, J BIOL CHEM, V279, P49664, DOI 10.1074/jbc.M404941200; MONTZ H, 1990, CELL IMMUNOL, V127, P337, DOI 10.1016/0008-8749(90)90137-G; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Novi F, 2004, J BIOL CHEM, V279, P7476, DOI 10.1074/jbc.M306818200; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; Park PSH, 2004, J NEUROCHEM, V90, P537, DOI 10.1111/j.1471-4159.2004.02536.x; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pfeiffer M, 2003, J BIOL CHEM, V278, P51630, DOI 10.1074/jbc.M307095200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; Richardson RM, 2003, J BIOL CHEM, V278, P15867, DOI 10.1074/jbc.M211745200; Rothermel E, 1997, BBA-GENE STRUCT EXPR, V1351, P9, DOI 10.1016/S0167-4781(97)00006-7; Shen WP, 2000, BLOOD, V96, P2887, DOI 10.1182/blood.V96.8.2887.h8002887_2887_2894; Signoret N, 1998, J CELL SCI, V111, P2819; Szabo I, 2003, J LEUKOCYTE BIOL, V74, P1074, DOI 10.1189/jlb.0203067; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200	57	64	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37503	37515		10.1074/jbc.M500535200	http://dx.doi.org/10.1074/jbc.M500535200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144840	hybrid			2022-12-25	WOS:000233044500027
J	Song, LN; Gelmann, EP				Song, LN; Gelmann, EP			Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; CRYSTAL-STRUCTURE; MUTATIONS; COMPLEX; GENE; COACTIVATORS; CELLS; RECOGNITION; PROGRESSION; INHIBITION	The multifunctional oncoprotein beta-catenin interacts with the activation function-2 domain of androgen receptor (AR) to stimulate androgen receptor transcriptional activity, increase sensitivity, and broaden specificity of ligand interactions. beta-Catenin interacts with androgen receptor in close proximity to the binding groove for P160 coactivators such as transcriptional intermediary factor-2 (TIF2)/glucocorticoid receptor interacting protein-1 (GRIP1). beta-Catenin can also bind directly to TIF2/GRIP1. Both N- and C-terminal regions of beta-catenin are needed for optimal interaction with TIF2/GRIP1. We show that distinct residues of beta-catenin are responsible for both binding and functional interactions with androgen receptor and with TCF4, thus allowing the introduction of missense mutations that selectively affect these interactions. beta-Catenin and TIF2/GRIP1 are each able to mediate binding between the other and androgen receptor in functional interactions that enhance ligand-dependent transcription. The data strongly imply that AR, beta-catenin, and TIF2/GRIP1 bind in a three-way interaction that mediates transcription. Lastly, we observed that a beta-catenin C-terminal peptide containing 229 amino acids can bind TIF2/GRIP1 and AR but has a profound dominant inhibitory effect on ligand-dependent transcription. We propose that beta-catenin may play an integral role in formation of the androgen-receptor transcriptional complex.	Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med, Washington, DC 20007 USA	Georgetown University; Georgetown University	Gelmann, EP (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	Gelmanne@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA096854] Funding Source: NIH RePORTER; NCI NIH HHS [CA96854] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Horvath LG, 2005, INT J CANCER, V113, P415, DOI 10.1002/ijc.20599; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Lehrer S, 2000, CANCER GENET CYTOGEN, V122, P131, DOI 10.1016/S0165-4608(00)00291-0; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Rios-Doria J, 2004, CANCER RES, V64, P7237, DOI 10.1158/0008-5472.CAN-04-1048; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tago K, 2000, GENE DEV, V14, P1741; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Truica CI, 2000, CANCER RES, V60, P4709; Tyrrell CJ, 1998, EUR UROL, V33, P447, DOI 10.1159/000019634; Umar A, 2005, J CLIN ENDOCR METAB, V90, P507, DOI 10.1210/jc.2004-0057; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voeller HJ, 1998, CANCER RES, V58, P2520; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200	37	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37853	37867		10.1074/jbc.M503850200	http://dx.doi.org/10.1074/jbc.M503850200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141201	hybrid			2022-12-25	WOS:000233044500066
J	Beeser, A; Jaffer, ZM; Hofmann, C; Chernoff, J				Beeser, A; Jaffer, ZM; Hofmann, C; Chernoff, J			Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; SERINE-338 PHOSPHORYLATION; DEPENDENT ACTIVATION; PROTEIN-KINASES; RAF ACTIVATION; B-RAF; PAK; ERK; TRANSFORMATION; FIBROBLASTS	The canonical extracellular-regulated kinase (ERK) signaling cascade, consisting of the Ras-Raf-Mek-ERK module, is critically important to many cellular functions. Although the general mechanism of activation of the ERK cascade is well established, additional noncanonical components greatly influence the activity of this pathway. Here, we focus on the group A p21-activated kinases (Paks), which have previously been implicated in regulating both c-Raf and Mek1 activity, by phosphorylating these proteins at Ser(338) and Ser(298), respectively. In NIH-3T3 cells, expression of an inhibitor of all three group A Paks reduced activation of ERK in response to platelet-derived growth factor ( PDGF) but not to epidermal growth factor (EGF). Similar results were obtained in HeLa cells using small interference RNA-mediated simultaneous knockdown of both Pak1 and Pak2 to reduce group A Pak function. Inhibition of Pak kinase activity dramatically decreased phosphorylation of Mek1 at Ser(298) in response to either PDGF or EGF, but this inhibition did not prevent Mek1 activation by EGF, suggesting that although Pak can phosphorylate Mek1 at Ser(298), this event is not required for Mek1 activation by growth factors. Inhibition of Pak reduced the Ser(338) phosphorylation of c-Raf in response to both PDGF and EGF; however, in the case of EGF, the reduction in Ser(338) phosphorylation was not accompanied by a significant decrease in c-Raf activity. These findings suggest that Paks are required for the phosphorylation of c-Raf at Ser(338) in response to either growth factor, but that the mechanisms by which EGF and PDGF activate c-Raf are fundamentally different.	Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Tumor Cell Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	J_Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM54168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOKOCH GM, 2003, ANN REV BIOCH; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DING JB, 1993, J BIOL CHEM, V268, P17326; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Edin ML, 2005, MOL CELL BIOL, V25, P4466, DOI 10.1128/MCB.25.11.4466-4475.2005; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; LU W, 1997, CURR BIOL, V7, P88; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Muller J, 2002, METHOD ENZYMOL, V345, P490; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Oehrl W, 2003, J BIOL CHEM, V278, P17819, DOI 10.1074/jbc.M209951200; Pullikuth A, 2005, MOL CELL BIOL, V25, P5119, DOI 10.1128/MCB.25.12.5119-5133.2005; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tilbrook PA, 2001, ARCH BIOCHEM BIOPHYS, V396, P128, DOI 10.1006/abbi.2001.2577; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	38	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36609	36615		10.1074/jbc.M502306200	http://dx.doi.org/10.1074/jbc.M502306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129686	hybrid			2022-12-25	WOS:000232901800011
J	Sano, T; Kihara, A; Kurotsu, F; Iwaki, S; Igarashi, Y				Sano, T; Kihara, A; Kurotsu, F; Iwaki, S; Igarashi, Y			Regulation of the sphingoid long-chain base kinase Lcb4p by ergosterol and heme - Studies in phytosphingosine-resistant mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTOPORPHYRINOGEN OXIDASE; KEY REGULATOR; YEAST-CELLS; HEAT-STRESS; GENE; PROTEIN; 1-PHOSPHATE; IDENTIFICATION; BIOSYNTHESIS	Sphingoid long-chain base 1-phosphates (LCBPs) are widely conserved, bioactive lipid molecules. In yeast, LCBPs are known to be involved in several cellular responses such as heat shock resistance and Ca2+ mobilization, although their target molecules and signaling pathways remain unclear. To identify genes involved in LCBP signaling and in regulation of LCBP synthesis, we performed transposon mutagenesis in cells lacking the LCBP lyase DPL1 and LCBP phosphatase LCB3 genes and screened for phytosphingosine-resistant clones. Further isolation and identification revealed eight genes (PBP1, HEM14, UFD4, HMG1, TPS1, KES1, WHI2, and ERG5), in addition to the previously characterized LCB4 and PDR5 genes, that are involved in phytosphingosine resistance. Of these eight, four are ergosterol-related genes ( HEM14, HMG1, KES1, and ERG5). We also demonstrated that protein expression of the long-chain base kinase Lcb4p was reduced in Delta hem14 and Delta hmg1 cells, likely as a consequence of decreased activity of the heme-dependent transcription factor Hap1p. In addition, phosphorylation of Lcb4p was decreased in all the ergosterol-related mutants isolated and other ergosterol mutants constructed (Delta erg2, Delta erg3, and Delta erg6). Finally, plasma membrane localization of Lcb4p was found to be reduced in Delta erg6 cells. These results suggest that changes in sterol composition affect the phosphorylation of Lcb4p because of the altered localization. The other genes isolated ( PBP1, UFD4, TPS1, and WHI2) may be involved in LCBP signaling.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012; Sano, Takamitsu/F-9410-2012	KIHARA, AKIO/0000-0001-5889-0788; 				ARGUELLES JC, 1994, FEBS LETT, V350, P266, DOI 10.1016/0014-5793(94)00786-1; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; Beh CT, 2001, GENETICS, V157, P1117; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Camadro JM, 1996, J BIOL CHEM, V271, P9120, DOI 10.1074/jbc.271.15.9120; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Emter R, 2002, FEBS LETT, V521, P57, DOI 10.1016/S0014-5793(02)02818-1; Fukuda Y, 2004, BBA-MOL CELL BIOL L, V1636, P12, DOI 10.1016/j.bbalip.2003.11.006; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Glerum DM, 1996, YEAST, V12, P1421; Grabinska K, 2002, FEMS YEAST RES, V2, P259, DOI 10.1016/S1567-1356(02)00110-1; Hait NC, 2002, FEBS LETT, V532, P97, DOI 10.1016/S0014-5793(02)03636-0; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Heese-Peck A, 2002, MOL BIOL CELL, V13, P2664, DOI 10.1091/mbc.E02-04-0186; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Iwaki S, 2005, J BIOL CHEM, V280, P6520, DOI 10.1074/jbc.M410908200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kaida D, 2002, GENES CELLS, V7, P543, DOI 10.1046/j.1365-2443.2002.00538.x; Kaiser C., 1994, METHODS YEAST GENETI; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; Kihara A, 2004, MOL BIOL CELL, V15, P4949, DOI 10.1091/mbc.E04-06-0458; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; KIHARA A, 2005, IN PRESS MOL CELL BI; Kim S, 2000, GENETICS, V156, P1519; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Moraes CT, 2004, BBA-BIOENERGETICS, V1659, P153, DOI 10.1016/j.bbabio.2004.09.002; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Skaggs BA, 1996, GENE, V169, P105, DOI 10.1016/0378-1119(95)00770-9; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Swain E, 2002, J BIOL CHEM, V277, P36152, DOI 10.1074/jbc.M206624200; Swain E, 2002, J BIOL CHEM, V277, P26177, DOI 10.1074/jbc.M204115200; THORSNESS M, 1989, MOL CELL BIOL, V9, P5702, DOI 10.1128/MCB.9.12.5702; TURI TG, 1992, J BIOL CHEM, V267, P2046; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yatomi Y, 2000, BLOOD, V96, P3431; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	49	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36674	36682		10.1074/jbc.M503147200	http://dx.doi.org/10.1074/jbc.M503147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16141212	hybrid			2022-12-25	WOS:000232901800019
J	Linnerth, NM; Baldwin, M; Campbell, C; Brown, M; McGowan, H; Moorehead, RA				Linnerth, NM; Baldwin, M; Campbell, C; Brown, M; McGowan, H; Moorehead, RA			IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells	ONCOGENE			English	Article						IGF-II; CREB; lung cancer; transformation	GROWTH-FACTOR-I; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR CREB; HUMAN-MELANOMA CELLS; GENE-EXPRESSION; BREAST-CANCER; FACTOR FAMILY; FACTOR RECEPTOR; TUMOR-GROWTH; MICE	We have previously shown that lung tumors arising in MMTV-IGF-II transgenic mice displayed elevated levels of phospho rylated cAMP response element binding protein (CREB). To investigate the role that insulin-like growth factor II (IGF-II) and CREB play in human lung tumorigenesis, A549 and NCI-H358 cells were examined. In these cell lines, IGF-II administration enhances human tumor cell survival and CREB phosphorylation. Further, the effects of IGF-II on cell survival and CREB phosphorylation appeared to be mediated, at least in part, by activation of the Erk pathways, as inhibition of these signaling pathways reduced tumor cell survival and CREB phosphorylation. Specifi. cally, Erk5 appeared as the predominant mediator of CRE B phosporylation. To further verify the importance of CREB in human lung tumorigenesis, A549 and NCI-H358 cells were stably transfected with a vector containing a dominant negative CREB construct (KCREB). KCREB transfection significantly inhibited the soft agar growth of both human tumor cell lines. In contrast, overexpression of wild-type CREB in the normal human bronchial epithelial cell line, HBE135, enhanced soft agar growth. Therefore, our results indicate that CREB and its associated proteins play a significant role in lung adenocarcinoma and IGF-II induces CREB phosphorylation, at least in part, via the Erk5 signaling pathway.	Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada	University of Guelph	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Alvarez-Lopez C, 2004, NEUROSCI LETT, V357, P223, DOI 10.1016/j.neulet.2003.12.099; Arteaga CL, 1996, CANCER RES, V56, P1098; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Fowden AL, 2003, PLACENTA, V24, P803, DOI 10.1016/S0143-4004(03)00080-8; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Grothey A, 1999, J CANCER RES CLIN, V125, P166, DOI 10.1007/s004320050259; HABENER JF, 1989, HORM RES, V32, P61, DOI 10.1159/000181246; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Jean D, 2000, MOL CELL BIOCHEM, V212, P19, DOI 10.1023/A:1007128101751; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Luciani P, 2003, EUR J ENDOCRINOL, V148, P579, DOI 10.1530/eje.0.1480579; MALKINSON AM, 1991, ENVIRON HEALTH PERSP, V93, P149, DOI 10.2307/3431183; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; OFIR R, 1991, GENE EXPRESSION, V1, P55; Pavelic J, 2002, MOL MED, V8, P149, DOI 10.1007/BF03402007; Pavelic K, 1999, J PATHOL, V188, P69; Peri A, 2002, EUR J ENDOCRINOL, V146, P759, DOI 10.1530/eje.0.1460759; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Rabelo FLA, 2003, BIOCHEM BIOPH RES CO, V303, P968, DOI 10.1016/S0006-291X(03)00454-6; Reddy SPM, 2002, AM J RESP CELL MOL, V27, P64, DOI 10.1165/ajrcmb.27.1.20020003oc; REEVE JG, 1993, CANCER RES, V53, P4680; REEVE JG, 1992, J NATL CANCER I, V84, P628, DOI 10.1093/jnci/84.8.628; REHM S, 1991, EXP LUNG RES, V17, P181, DOI 10.3109/01902149109064410; Rosenberg D, 2002, ENDOCR RES, V28, P765, DOI 10.1081/ERC-120017071; Rosenberg D, 2002, ANN NY ACAD SCI, V968, P65, DOI 10.1111/j.1749-6632.2002.tb04327.x; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; RUBIN R, 1995, LAB INVEST, V73, P311; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; Saeki K, 2001, LEUKEMIA, V15, P238, DOI 10.1038/sj.leu.2402014; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Scapoli L, 2004, ONCOGENE, V23, P805, DOI 10.1038/sj.onc.1207163; Shankar DB, 2004, LEUKEMIA LYMPHOMA, V45, P265, DOI 10.1080/1042819031000151095; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Takanami I, 1996, J SURG ONCOL, V61, P205, DOI 10.1002/(SICI)1096-9098(199603)61:3<205::AID-JSO8>3.0.CO;2-F; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Yan SF, 2000, J CLIN INVEST, V105, P553, DOI 10.1172/JCI9513; YOSHIDA K, 1995, J NEUROCHEM, V65, P1499	58	44	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7310	7319		10.1038/sj.onc.1208882	http://dx.doi.org/10.1038/sj.onc.1208882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16158061				2022-12-25	WOS:000233142100007
J	Arnoult, D; Grodet, A; Lee, YJ; Estaquier, J; Blackstone, C				Arnoult, D; Grodet, A; Lee, YJ; Estaquier, J; Blackstone, C			Release of OPA1 during apoptosis participates in the rapid and complete release of cytochrome c and subsequent mitochondrial fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; FUSION; FISSION; BAX; ASSOCIATION; DYSFUNCTION; DYNAMICS; DRP1	Mitochondria are important participants in apoptosis, releasing cytochrome c into the cytoplasm and undergoing extensive fragmentation. However, mechanisms underlying these processes remain unclear. Here, we demonstrate that cytochrome c release during apoptosis precedes mitochondrial fragmentation. Unexpectedly, OPA1, a dynamin- like GTPase of the mitochondrial intermembrane space important for maintaining cristae structure, is co-released with cytochrome c. To mimic the loss of OPA1 occurring after its release, we knocked down OPA1 expression using RNA interference. This triggered structural changes in the mitochondrial cristae and caused increased fragmentation by blocking mitochondrial fusion. Because cytochrome c is mostly sequestered within cristae folds but released rapidly and completely during apoptosis, we examined the effect of OPA1 loss on cytochrome c release, demonstrating that it is accelerated. Thus, our results suggest that an initial mitochondrial leak of OPA1 leads to cristae structural alterations and exposure of previously sequestered protein pools, permitting continued release in a feed- forward manner to completion. Moreover, our findings indicate that the resulting OPA1 depletion causes a block in mitochondrial fusion, providing a compelling mechanism for the prominent increase in mitochondrial fragmentation seen during apoptosis.	NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA; NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Inst Pasteur, Unite Physiopathol Infect Lentivirales, F-75724 Paris, France; Univ Paris 07, INSERM, U327, F-75018 Paris, France	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Blackstone, C (corresponding author), NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA.	blackstc@ninds.nih.gov	Arnoult, Damien/R-2032-2018; , ESTAQUIER/AAR-7799-2020	, ESTAQUIER/0000-0002-9432-8044	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002992, ZIANS002992] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission)		BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Esseiva AC, 2004, EMBO REP, V5, P268, DOI 10.1038/sj.embor.7400095; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gao WH, 2001, J CELL SCI, V114, P2855; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Hengartner M, 2005, NATURE, V433, P692, DOI 10.1038/433692a; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Zhu PP, 2003, J BIOL CHEM, V278, P49063, DOI 10.1074/jbc.M306702200	27	216	221	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35742	35750		10.1074/jbc.M505970200	http://dx.doi.org/10.1074/jbc.M505970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115883	hybrid			2022-12-25	WOS:000232561200077
J	Eckhart, L; Ballaun, C; Uthman, A; Kittel, C; Stichenwirth, M; Buchberger, M; Fischer, H; Sipos, W; Tschachler, E				Eckhart, L; Ballaun, C; Uthman, A; Kittel, C; Stichenwirth, M; Buchberger, M; Fischer, H; Sipos, W; Tschachler, E			Identification and characterization of a novel mammalian caspase with proapoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIN DOMAIN; ACTIVATION; APOPTOSIS; ASC; DIFFERENTIATION; OLIGOMERIZATION; SPECIFICITY; PROTEIN	Caspases are essential proteases in programmed cell death and inflammation. Studies in murine and human cells have led to the characterization of 14 members of this enzyme family. Here we report the identification of caspase-15, a novel caspase that is expressed in various mammalian species including pig, dog, and cattle. The caspase-15 protein contains a catalytic domain with all amino acid residues critical for caspase activity and a prodomain that is predicted to fold into a pyrin domain structure, which is a unique feature among mammalian caspases. Recombinant porcine caspase-15 underwent autocatalytic processing into its subunits and cleaved both tetrapeptide caspase substrates and the apoptosis regulator protein Bid in vitro. Overexpression of caspase-15 in mammalian cells induced proenzyme maturation, cleavage of Bid, activation of caspase-3, and eventually cell death. Both the proteolytic and the pro-apoptotic activity of caspase-15 were abolished by mutation of the active site cysteine. Since a homolog of caspase-15 is absent in the human and the mouse genome, our results reveal an unexpected variability in the molecular apoptotic machinery of mammals.	Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; Univ Vet Med Vienna, Clin Dept Farm Anim & Herd Management, A-1210 Vienna, Austria	Medical University of Vienna; University of Veterinary Medicine Vienna	Tschachler, E (corresponding author), Med Univ Vienna, Dept Dermatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	erwin.tschachler@meduniwien.ac.at	Fischer, Heinz/AAD-9950-2020; Sipos, Wolfgang/AGH-1464-2022	Eckhart, Leopold/0000-0002-5645-2036; Tschachler, Erwin/0000-0002-0248-1798; Fischer, Heinz/0000-0003-1280-0200				Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Hiller S, 2003, STRUCTURE, V11, P1199, DOI 10.1016/j.str.2003.08.009; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Koenig U, 2001, BIOCHEM BIOPH RES CO, V285, P1150, DOI 10.1006/bbrc.2001.5315; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 2003, J BIOL CHEM, V278, P4268, DOI 10.1074/jbc.M203944200; Moriya M, 2005, BIOCHEMISTRY-US, V44, P575, DOI 10.1021/bi048374i; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976	22	40	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35077	35080		10.1074/jbc.C500282200	http://dx.doi.org/10.1074/jbc.C500282200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120609	hybrid			2022-12-25	WOS:000232561200002
J	Monje, P; Hernandez-Losa, J; Lyons, RJ; Castellone, MD; Gutkind, JS				Monje, P; Hernandez-Losa, J; Lyons, RJ; Castellone, MD; Gutkind, JS			Regulation of the transcriptional activity of c-Fos by ERK: A novel role for the prolyl isomerase Pin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; CELLULAR-TRANSFORMATION; GROWTH-FACTOR; JUN PROMOTER; PHOSPHORYLATION; AP-1; DOMAINS	The activation of the activating protein-1 (AP-1) family of transcription factors, including c-Fos and c-Jun family members, is one of the earliest nuclear events induced by growth factors that stimulate extracellular signal-regulated kinases (ERKs). In the case of c-Fos, the activation of ERK leads to an increased expression of c-fos mRNA. In turn, we have recently shown that ERK phosphorylates multiple residues within the carboxyl-terminal transactivation domain (TAD) of c-Fos, thus resulting in its increased transcriptional activity. However, how ERK-dependent phosphorylation regulates c-Fos function is still poorly understood. In this regard, it has been recently observed that the prolyl isomerase Pin1 can interact with proteins phosphorylated on serine or threonine residues that precede prolines (pS/T-P), such as the transcription factors p53 and c-Jun, thereby controlling their activity by promoting the cis-trans isomerization of these pS/T-P bonds. Here, we found that Pin1 binds c-Fos through specific pS/T-P sites within the c-Fos TAD, and that this interaction results in an enhanced transcriptional response of c-Fos to polypeptide growth factors that stimulate ERK. Our findings suggest that c-Fos represents a novel target for the isomerizing activity of Pin1 and support a role for Pin1 in the mechanism by which c-Jun and c-Fos can cooperate to regulate AP-1-dependent gene transcription upon phosphorylation by mitogen-activated kinase (MAPK) family members.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, DHHS, 30 Convent Dr,Bldg 30,Rm 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Javier, Hernandez Losa/C-1173-2008; Gutkind, J. Silvio/J-1201-2016; Monje, Paula/AAB-9099-2020	Javier, Hernandez Losa/0000-0003-1526-3201; Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	17	214	219	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35081	35084		10.1074/jbc.C500353200	http://dx.doi.org/10.1074/jbc.C500353200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16123044	hybrid			2022-12-25	WOS:000232561200003
J	Sun, XJ; Wei, J; Wu, XY; Hu, M; Wang, L; Wang, HH; Zhang, QH; Chen, SJ; Huang, QH; Chen, Z				Sun, XJ; Wei, J; Wu, XY; Hu, M; Wang, L; Wang, HH; Zhang, QH; Chen, SJ; Huang, QH; Chen, Z			Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAINS; ACUTE MYELOID-LEUKEMIA; SET-DOMAIN; STEM/PROGENITOR CELLS; TERMINAL DOMAIN; SOTOS-SYNDROME; METHYLATION; PROTEINS; GENE	Histone methylation plays an important role in eukaryotic transcriptional regulation. A number of histone methyltransferases (HMTases) with distinct functions have been identified. The HSPC069/HYPB gene was originally isolated from the human hematopoietic stem/progenitor cells (HSPCs), and it was also identified as a huntingtin interacting protein, implicated in the pathogenesis of Huntington disease (HD). However, its biochemical function is poorly understood. Here we report the structural and functional characterization of the huntingtin interacting protein B (HYPB). 1) The triplicate AWS-SET-PostSET domains mediate a histone H3 lysine 36 specific HMTase activity. 2) A low charged region that is rich in glutamine and proline has been characterized as a novel transcriptional activation domain. The structural features of this region are evolutionarily conserved in vertebrates. 3) Coimmunoprecipitation assays indicate that HYPB protein associates with hyperphosphorylated RNA polymerase II (RNAPII) but not the unphosphorylated form. Furthermore, the RNAPII-association region of HYPB protein has been identified to encompass the C-terminal 142 amino acids. Thus, our results suggest that HYPB HMTase may coordinate histone methylation and transcriptional regulation in mammals and open perspective for the further study of the potential roles of HYPB protein in hematopoiesis and pathogenesis of HD.	Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Beijing 100864, Peoples R China; Shanghai Med Univ 2, Shanghai, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences	Chen, Z (corresponding author), Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom, 197 Ruijin Rd 2, Shanghai 200025, Peoples R China.	qiuhua_huang@etang.com; zchen@stn.sh.cn	Sun, Xiao-Jian/D-1560-2011	Sun, Xiao-Jian/0000-0001-8826-4614				Aagaard L, 2000, J CELL SCI, V113, P817; Abedi M, 2001, BMC Mol Biol, V2, P10, DOI 10.1186/1471-2199-2-10; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baujat G, 2004, AM J HUM GENET, V74, P715, DOI 10.1086/383093; Blau J, 1996, MOL CELL BIOL, V16, P2044; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Fang J, 2004, METHOD ENZYMOL, V377, P213; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kim KC, 2003, CANCER RES, V63, P7619; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krajewski WA, 2005, MOL CELL BIOL, V25, P1891, DOI 10.1128/MCB.25.5.1891-1899.2005; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Mao M, 1998, P NATL ACAD SCI USA, V95, P8175, DOI 10.1073/pnas.95.14.8175; Miller W, 2004, ANNU REV GENOM HUM G, V5, P15, DOI 10.1146/annurev.genom.5.061903.180057; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Passani LA, 2000, HUM MOL GENET, V9, P2175, DOI 10.1093/hmg/9.14.2175; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rega S, 2001, MOL CELL NEUROSCI, V18, P68, DOI 10.1006/mcne.2001.1004; Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857; Sambrook J, 2001, MOL CLONING LAB MANU; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Song HD, 2004, P NATL ACAD SCI USA, V101, P16240, DOI 10.1073/pnas.0407241101; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	66	174	184	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35261	35271		10.1074/jbc.M504012200	http://dx.doi.org/10.1074/jbc.M504012200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118227	hybrid			2022-12-25	WOS:000232561200024
J	Fieger, CB; Huang, MC; Van Brocklyn, JR; Goetzl, EJ				Fieger, CB; Huang, MC; Van Brocklyn, JR; Goetzl, EJ			Type 1 sphingosine 1-phosphate G protein-coupled receptor signaling of lymphocyte functions requires sulfation of its extracellular amino-terminal tyrosines	FASEB JOURNAL			English	Article						T cell receptors; lipid mediators; chemotaxis; cytokines	TYROSYLPROTEIN SULFOTRANSFERASE; EXPRESSION	The type 1 sphingosine 1-phosphate (S1P) G protein-coupled receptor (S1P1) transduces signals from S1P that mediate thymocyte emigration, T cell transmigration of lymph nodes, and T cell chemotaxis in tissues. Alterations in expression of functional S1P1 receptors by lymphocytes are the major mechanisms controlling their responses to S1P and were thought to be solely a consequence of the balance between surface down-regulation and insertion. However, results now show that lack of sulfation of tyrosines 19 and 22 of the extracellular N terminus of S1P1 diminishes high-affinity S1P binding and decreases S1P signaling of T cell migration and other functions. Non-sulfatable mutant (Y19,22F) S1P1 endows T cells with lower-affinity binding of [P-32]S1P than wild-type S1P1 and transduces lesser effects of S1P on chemotaxis, chemokine-elicited chemotaxis, and T cell receptor-mediated proliferation and cytokine generation. Inhibition of S1P1 tyrosine sulfation or sulfatase removal of S1P1 sulfate in mouse CD4 T cells suppresses immune functional effects of S1P. Tyrosine sulfation of S1P1 may be a major controller of S1P effects on T cell traffic.	Univ Calif San Francisco, Dept Med Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Ohio; Ohio State University	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med Microbiol & Immunol, Room UB8B,UC Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Van Brocklyn, Jim/A-9733-2010		NHLBI NIH HHS [R01-HL-31809, R01 HL031809, R01 HL031809-22A2, P0-HL68738, P01 HL068738] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068738, R01HL031809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Goetzl EJ, 2004, J CLIN INVEST, V114, P1531, DOI 10.1172/JCI200423704; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Grahler MH, 2005, J IMMUNOL, V174, P1997; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEE RWH, 1983, J BIOL CHEM, V258, P1326; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Moore BCJ, 2003, OTOL NEUROTOL, V24, P243, DOI 10.1097/00129492-200303000-00019; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Tigyi G, 2002, BBA-MOL CELL BIOL L, V1582, pVII, DOI 10.1016/S1388-1981(02)00130-0; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229	18	17	25	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1926	+		10.1096/fj.05-4476fje	http://dx.doi.org/10.1096/fj.05-4476fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148028	Green Accepted			2022-12-25	WOS:000232315700024
J	Linggi, B; Cheng, QC; Rao, AR; Carpenter, G				Linggi, B; Cheng, QC; Rao, AR; Carpenter, G			The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase	ONCOGENE			English	Article						ErbB-4; tyrosine kinase; growth factor	GROWTH-FACTOR RECEPTOR; NUCLEAR EXPRESSION; CELL CARCINOMA; MAMMARY-GLAND; EGF RECEPTOR; CLEAVAGE; ACTIVATION; DIFFERENTIATION; IDENTIFICATION; ASSOCIATION	The ErbB-4 receptor tyrosine kinase homo- and heterodimerizes following heregulin binding, which provokes increased levels of tyrosine autophosphorylation. Unique to the ErbB family, ErbB-4 is then proteolytically cleaved by alpha- and gamma-secretase to produce an 80 kDa intracellular domain (s80 ICD) fragment. This fragment is found in both the cytoplasm and nucleus of many normal and cancer cells and can interact with transcription factors in the cytoplasm and nucleus. Since the s80 ICD lacks ectodomain sequences known to play a major role in dimerization of ErbB family members, we asked whether the s80 ICD is an active tyrosine kinase. Here, we demonstrate that the s80 ICD is a constitutively active tyrosine kinase and can form homodimers. The s80 ICD is autophosphorylated in cells and can phosphorylate an exogenous substrate in vitro. Also, the s80 ICD can coassociate and dimers are detected by chemical cross-linking. This is the first example of constitutive kinase activation and dimerization totally within the cytoplasmic domain of an ErbB receptor and suggests that the s80 ICD may function to phosphorylate substrates in the cytoplasm or nucleus.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu			NCI NIH HHS [P30 CA6845, T32 CA009582, CA97456] Funding Source: Medline; NIDDK NIH HHS [P30 DK20593, P30 DK020593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097456, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aifa S, 2005, EXP CELL RES, V302, P108, DOI 10.1016/j.yexcr.2004.08.032; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Bei R, 2004, J PATHOL, V204, P317, DOI 10.1002/path.1642; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Srinivasan R, 2000, CANCER RES, V60, P1483; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	33	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					160	163		10.1038/sj.onc.1209003	http://dx.doi.org/10.1038/sj.onc.1209003			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170367				2022-12-25	WOS:000234406400018
J	Robison, AJ; Bartlett, RK; Bass, MA; Colbran, RJ				Robison, AJ; Bartlett, RK; Bass, MA; Colbran, RJ			Differential modulation of Ca2+/calmodulin-dependent protein kinase II activity by regulated interactions with N-methyl-D-aspartate receptor NR2B subunits and alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTORS; CALCIUM/CALMODULIN; CALMODULIN; CAMKII; AUTOPHOSPHORYLATION; TRANSLOCATION; LOCALIZATION; DENSIN-180; PLASTICITY; MECHANISM	Neuronal Ca2+/calmodulin-dependent protein kinase II (CaMKII) interacts with several prominent dendritic spine proteins, which have been termed CaMKII-associated proteins. The NR2B subunit of N-methyl-D-aspartate (NMDA)-type glutamate receptor, densin-180, and alpha-actinin bind comparable, approximately stoichiometric amounts of Thr(286)-autophosphorylated CaMKII alpha, forming a ternary complex (Robison, A. J., Bass, M. A., Jiao, Y., Macmillan, L. B., Carmody, L. C., Bartlett, R. K., and Colbran, R. J. (2005) J. Biol. Chem. 280, 35329-35336), but their impacts on CaMKII function are poorly understood. Here we show that these interactions are differentially regulated and exert distinct effects on CaMKII activity. Nonphosphorylated and Thr(286)-autophosphorylated CaMKII bind to alpha-actinin with similar efficacy, but autophosphorylation at Thr(305/306) or Ca2+/calmodulin binding significantly reduce this binding. Moreover, alpha-actinin antagonizes CaMKII activation by Ca2+/calmodulin, as assessed by autophosphorylation and phosphorylation of a peptide substrate. CaMKII binding to densin (1247-1542) is partially independent of Thr(286) autophosphorylation and is unaffected by Ca2+-independent autophosphorylation or Ca2+/calmodulin. In addition, the CaMKII binding domain of densin-180 has little effect on CaMKII activity. In contrast, the interaction of CaMKII alpha with NR2B requires either Thr286 autophosphorylation or the binding of both Ca2+/calmodulin and adenine nucleotides. NR2B inhibits both the Ca2+/calmodulin-dependent and autonomous activities of CaMKII by a mechanism that is competitive with autocamtide-2 substrate, non-competitive with syntide-2 substrate, and uncompetitive with respect to ATP. In combination, these data suggest that dynamically regulated interactions with CaMKII-associated proteins could play pleiotropic roles in fine-tuning CaMKII signaling in defined subcellular compartments.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys,Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys,Ctr Mol Neurosci, Rm 724 RRB, Nashville, TN 37232 USA.	roger.colbran@vanderbilt.edu	Robison, Alfred J/P-8521-2018; Colbran, Roger/AAU-7708-2021	Robison, Alfred J/0000-0002-4150-9570; Colbran, Roger/0000-0001-7401-8244	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH068129, R01MH063232] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32-DK07563] Funding Source: Medline; NIMH NIH HHS [F32-MH068129, MH63232, R01 MH063232-05, R01 MH063232] Funding Source: Medline; NINDS NIH HHS [NS44082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apperson ML, 1996, J NEUROSCI, V16, P6839; Bartlett RK, 2003, BIOCHEMISTRY-US, V42, P3231, DOI 10.1021/bi026956z; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Bradshaw JM, 2002, J BIOL CHEM, V277, P20991, DOI 10.1074/jbc.M202154200; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; Dhavan R, 2002, J NEUROSCI, V22, P7879; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Fong DK, 2002, J NEUROSCI, V22, P2153, DOI 10.1523/JNEUROSCI.22-06-02153.2002; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GOMPERTS BD, 1992, METHOD ENZYMOL, V219, P178; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Griffith LC, 2004, J NEUROSCI, V24, P8394, DOI 10.1523/JNEUROSCI.3604-04.2004; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; Kamphuis PJGH, 2003, FASEB J, V17, P911, DOI 10.1096/fj.02-0333fje; Lengyel I, 2004, EUR J NEUROSCI, V20, P3063, DOI 10.1111/j.1460-9568.2004.03748.x; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li WD, 2001, J BIOL CHEM, V276, P21417, DOI 10.1074/jbc.M010744200; Lu CS, 2003, NEURON, V40, P1185, DOI 10.1016/S0896-6273(03)00786-4; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Quitsch A, 2005, J NEUROSCI, V25, P479, DOI 10.1523/JNEUROSCI.2699-04.2005; Robison AJ, 2005, J BIOL CHEM, V280, P35329, DOI 10.1074/jbc.M502191200; Sessoms-Sikes S, 2005, MOL CELL NEUROSCI, V29, P139, DOI 10.1016/j.mcn.2005.01.006; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Strack S, 2000, J BIOL CHEM, V275, P25061, DOI 10.1074/jbc.C000319200; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Tsui J, 2005, J BIOL CHEM, V280, P9210, DOI 10.1074/jbc.M407653200; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Weeber EJ, 2003, J NEUROSCI, V23, P2634; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199	49	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39316	39323		10.1074/jbc.M508189200	http://dx.doi.org/10.1074/jbc.M508189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16172120	hybrid			2022-12-25	WOS:000233362200051
J	Larance, M; Ramm, G; Stockli, J; van Dam, EM; Winata, S; Wasinger, V; Simpson, F; Graham, M; Junutula, JR; Guilhaus, M; James, DE				Larance, M; Ramm, G; Stockli, J; van Dam, EM; Winata, S; Wasinger, V; Simpson, F; Graham, M; Junutula, JR; Guilhaus, M; James, DE			Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; PLASMA-MEMBRANE; 3T3-L1 ADIPOCYTES; GOLGI NETWORK; CELL-SURFACE; TRANSFERRIN RECEPTORS; SYNAPTIC VESICLES; STORAGE-VESICLES; MAJOR PROTEIN; TRANSLOCATION	Insulin stimulates the translocation of the glucose transporter GLUT4 from intracellular vesicles to the plasma membrane. In the present study we have conducted a comprehensive proteomic analysis of affinity-purified GLUT4 vesicles from 3T3-L1 adipocytes to discover potential regulators of GLUT4 trafficking. In addition to previously identified components of GLUT4 storage vesicles including the insulin-regulated aminopeptidase insulin-regulated aminopeptidase and the vesicle soluble N-ethylmaleimide factor attachment protein (v-SNARE) VAMP2, we have identified three new Rab proteins, Rab10, Rab11, and Rab14, on GLUT4 vesicles. We have also found that the putative Rab GTPase-activating protein AS160 (Akt substrate of 160 kDa) is associated with GLUT4 vesicles in the basal state and dissociates in response to insulin. This association is likely to be mediated by the cytosolic tail of insulin-regulated aminopeptidase, which interacted both in vitro and in vivo with AS160. Consistent with an inhibitory role of AS160 in the basal state, reduced expression of AS160 in adipocytes using short hairpin RNA increased plasma membrane levels of GLUT4 in an insulin-independent manner. These findings support an important role for AS160 in the insulin regulated trafficking of GLUT4.	Garvan Inst Med Res, Diabet & Obes Program, Sydney, NSW 2010, Australia; Univ New S Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW 2052, Australia; Univ Queensland, Inst Mol Biol, Brisbane, Qld 4072, Australia; Benitec Inc, Mountain View, CA 94043 USA; Genentech Inc, San Francisco, CA 94080 USA	Garvan Institute of Medical Research; University of New South Wales Sydney; University of Queensland; Roche Holding; Genentech	James, DE (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Diabet & Obes Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	d.james@garvan.org.au	Larance, Mark/AAG-8613-2019; Stoeckli, Jacqueline/Z-4443-2019; Wasinger, Valerie/AAC-5004-2021; Stoeckli, Jacqueline/D-7053-2016; Simpson, Fiona/ABE-1276-2020; Junutula, Jagath Reddy/ABD-4753-2020; Simpson, Fiona/J-2721-2012	Stoeckli, Jacqueline/0000-0002-6446-7350; Wasinger, Valerie/0000-0001-5338-0869; Stoeckli, Jacqueline/0000-0002-6446-7350; Simpson, Fiona/0000-0002-0271-781X; Junutula, Jagath Reddy/0000-0002-5942-4428; Simpson, Fiona/0000-0002-0271-781X; Ramm, Georg/0000-0003-3596-2288; James, David/0000-0001-5946-5257; Larance, Mark/0000-0002-8579-2267				Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Bock JB, 1997, MOL BIOL CELL, V8, P2461; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHANEY LK, 1983, J BIOL CHEM, V258, P62; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cormont M, 1996, ENDOCRINOLOGY, V137, P3408, DOI 10.1210/en.137.8.3408; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Davey KAB, 2004, J MOL CELL CARDIOL, V37, P264; Fernandez-Chacon R, 2000, J NEUROSCI, V20, P7941; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; HANPETER D, 1995, MOL MEMBR BIOL, V12, P263, DOI 10.3109/09687689509072426; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Junutula JR, 2004, MOL BIOL CELL, V15, P2218, DOI 10.1091/mbc.E03-10-0777; Kalinina EV, 2003, J BIOL CHEM, V278, P9244, DOI 10.1074/jbc.M209379200; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Keller SR, 2002, J BIOL CHEM, V277, P17677, DOI 10.1074/jbc.M202037200; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Lee SM, 2004, BIOCHEM BIOPH RES CO, V324, P768, DOI 10.1016/j.bbrc.2004.09.118; Li L, 2001, J BIOL CHEM, V276, P5265, DOI 10.1074/jbc.M003883200; Ligos JM, 1998, BIOCHEM BIOPH RES CO, V249, P380, DOI 10.1006/bbrc.1998.9163; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Malide D, 2000, J CELL SCI, V113, P4203; Martin S, 2000, J CELL SCI, V113, P3427; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Mastick CC, 1997, ENDOCRINOLOGY, V138, P2391, DOI 10.1210/en.138.6.2391; Mesa R, 2005, EXP CELL RES, V304, P339, DOI 10.1016/j.yexcr.2004.11.017; Miinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Morel N, 2003, J CELL SCI, V116, P4751, DOI 10.1242/jcs.00791; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Ralston E, 1996, J CELL SCI, V109, P2967; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rice RR, 2005, METHOD ENZYMOL, V392, P405, DOI 10.1016/S0076-6879(04)92024-1; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Tellam JT, 1997, J BIOL CHEM, V272, P6187, DOI 10.1074/jbc.272.10.6187; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Trischler M, 1999, J CELL SCI, V112, P4773; van Dam EM, 2005, MOL ENDOCRINOL, V19, P1067, DOI 10.1210/me.2004-0413; Varadi A, 2004, J CELL SCI, V117, P4389, DOI 10.1242/jcs.01299; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	83	300	309	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37803	37813		10.1074/jbc.M503897200	http://dx.doi.org/10.1074/jbc.M503897200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154996	hybrid			2022-12-25	WOS:000233044500060
J	Fulton, D; Church, JE; Ruan, L; Li, CY; Sood, SG; Kemp, BE; Jennings, IG; Venema, RC				Fulton, D; Church, JE; Ruan, L; Li, CY; Sood, SG; Kemp, BE; Jennings, IG; Venema, RC			Src kinase activates endothelial nitric-oxide synthase by phosphorylating Tyr-83	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; AKT-DEPENDENT PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; HYDROGEN-PEROXIDE; GROWTH-FACTOR; C-SRC; CELLS; IDENTIFICATION; DEPHOSPHORYLATION	The endothelial nitric-oxide synthase ( eNOS) is regulated in part by serine/threonine phosphorylation, but eNOS tyrosine phosphorylation is less well understood. In the present study we have examined the tyrosine phosphorylation of eNOS in bovine aortic endothelial cells (BAECs) exposed to oxidant stress. Hydrogen peroxide and pervanadate (PV) treatment stimulates eNOS tyrosine phosphorylation in BAECs. Phosphorylation is blocked by the Src kinase family inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[ 3,4-d] pyrimidine (PP2). Moreover, eNOS and c-Src can be coimmunoprecipitated from BAEC lysates by antibodies directed against either protein. Domain mapping and site-directed mutagenesis studies in COS-7 cells transfected with either eNOS alone and then treated with PV or cotransfected with eNOS and constitutively active v-Src identified Tyr-83 ( bovine sequence) as the major eNOS tyrosine phosphorylation site. Tyr-83 phosphorylation is associated with a 3-fold increase in basal NO release from cotransfected cells. Furthermore, the Y83F eNOS mutation attenuated thapsigargin-stimulated NO production. Taken together, these data indicate that Src-mediated tyrosine phosphorylation of eNOS at Tyr-83 modulates eNOS activity in endothelial cells.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol, Augusta, GA 30912 USA; St Vincents Inst, Fitzroy, Vic 3065, Australia; CSIRO Mol & Hlth Technol, Fitzroy, Vic 3065, Australia	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; St. Vincent's Institute of Medical Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Fulton, D (corresponding author), Med Coll Georgia, Vasc Biol Ctr, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	dfulton@mcg.edu; rvenema@mcg.edu	Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Jennings, Ian/0000-0002-4781-9465; Church, Jarrod/0000-0001-8266-4043	NHLBI NIH HHS [HL74279, HL72768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072768, R01HL074279] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Boo YC, 2003, AM J PHYSIOL-CELL PH, V285, pC499, DOI 10.1152/ajpcell.00122.2003; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Cai H, 2003, MOL PHARMACOL, V63, P325, DOI 10.1124/mol.63.2.325; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Papapetropoulos A, 2004, MOL PHARMACOL, V65, P407, DOI 10.1124/mol.65.2.407; Takenouchi Y, 2004, ONCOL REP, V11, P1059; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574	33	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35943	35952		10.1074/jbc.M504606200	http://dx.doi.org/10.1074/jbc.M504606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123043	hybrid			2022-12-25	WOS:000232726900021
J	Niiya, F; Xie, XZ; Lee, KS; Inoue, H; Miki, T				Niiya, F; Xie, XZ; Lee, KS; Inoue, H; Miki, T			Inhibition of cyclin-dependent kinase 1 induces cytokinesis without chromosome segregation in an ECT2 and MgcRacGAP-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; LIGHT-CHAIN; CLEAVAGE FURROW; CITRON KINASE; CELL-DIVISION; MYOSIN-II; RHO; PHOSPHORYLATION; SPINDLE; COMPLEX	Cleavage furrow formation marks the onset of cell division during early anaphase. The small GTPase RhoA and its regulators ECT2 and MgcRacGAP have been implicated in furrow ingression in mammalian cells, but the signaling upstream of these molecules remains unclear. We now show that the inhibition of cyclin-dependent kinase (Cdk) 1 is sufficient to initiate cytokinesis. When mitotically synchronized cells were treated with the Cdk-specific inhibitor BMI-1026, the initiation of cytokinesis was induced precociously before chromosomal separation. Cytokinesis was also induced by the Cdk1-specific inhibitor purvalanol A but not by Cdk2/Cdk5- or Cdk4-specific inhibitors. Consistent with initiation of precocious cytokinesis by Cdk1 inhibition, introduction of anti-Cdk1 monoclonal antibody resulted in cells with aberrant nuclei. Depolymerization of mitotic spindles by nocodazole inhibited BMI-1026-induced precocious cytokinesis. However, in the presence of a low concentration of nocodazole, BMI-1026 induced excessive membrane blebbing, which appeared to be caused by formation of ectopic cleavage furrows. Depletion of ECT2 or MgcRacGAP by RNA interference abolished both of the phenotypes ( precocious furrowing after nocodazole release and excessive blebbing in the presence of nocodazole). RNA interference of RhoA or expression of dominant-negative RhoA efficiently reduced both phenotypes. RhoA was localized at the cleavage furrow or at the necks of blebs. We propose that Cdk1 inactivation is sufficient to activate a signaling pathway leading to cytokinesis, which emanates from mitotic spindles and is regulated by ECT2, MgcRacGAP, and RhoA. Chemical induction of cytokinesis will be a valuable tool to study the initiation mechanism of cytokinesis.	NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Cell Biol Lab, NIH, Bldg 37,Rm 2144,37 Convent Dr, Bethesda, MD 20892 USA.	toru@helix.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Echard A, 2003, CURR BIOL, V13, P373, DOI 10.1016/S0960-9822(03)00127-1; Glotzer M, 2004, J CELL BIOL, V164, P347, DOI 10.1083/jcb.200310112; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lee JS, 2004, EXP CELL RES, V293, P275, DOI 10.1016/j.yexcr.2003.10.015; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maddox AS, 2003, MOL CELL, V11, P846, DOI 10.1016/S1097-2765(03)00151-5; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Seong YS, 2003, CANCER RES, V63, P7384; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van de Putte T, 2001, MECH DEVELOP, V102, P33, DOI 10.1016/S0925-4773(01)00279-9; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Wong K, 2000, CELL MOTIL CYTOSKEL, V45, P121, DOI 10.1002/(SICI)1097-0169(200002)45:2<121::AID-CM4>3.3.CO;2-R; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427	34	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36502	36509		10.1074/jbc.M508007200	http://dx.doi.org/10.1074/jbc.M508007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118207	hybrid			2022-12-25	WOS:000232726900084
J	Tefsen, B; Bos, MP; Beckers, F; Tommassen, J; de Cock, H				Tefsen, B; Bos, MP; Beckers, F; Tommassen, J; de Cock, H			MsbA is not required for phospholipid transport in Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI K-12; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; NULL MUTATIONS; HTRB GENE; LIPOPOLYSACCHARIDE; MUTANT; LIPIDS; TRANSLOCATION	The outer membrane of Gram-negative bacteria contains phospholipids and lipopolysaccharide (LPS) in the inner and outer leaflet, respectively. Little is known about the transport of the phospholipids from their site of synthesis to the outer membrane. The inner membrane protein MsbA of Escherichia coli, which is involved in the transport of LPS across the inner membrane, has been reported to be involved in phospholipid transport as well. Here, we have reported the construction and the characterization of a Neisseria meningitidis msbA mutant. The mutant was viable, and it showed a retarded growth phenotype and contained very low amounts of LPS. However, it produced an outer membrane, demonstrating that phospholipid transport was not affected by the mutation. Notably, higher amounts of phospholipids were produced in the msbA mutant than in its isogenic parental strain, provided that capsular biosynthesis was also disrupted. Although these results confirmed that MsbA functions in LPS transport, they also demonstrated that it is not required for phospholipid transport, at least not in N. meningitidis.	Univ Utrecht, Dept Mol Microbiol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	Tommassen, J (corresponding author), Univ Utrecht, Dept Mol Microbiol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	J.P.M.Tommassen@bio.uu.nl	Tommassen, Jan/I-1690-2016; de Cock, Hans/B-7790-2011; Tefsen, Boris/J-1503-2012	Tommassen, Jan/0000-0001-7633-4945; de Cock, Hans/0000-0002-8420-6764; Tefsen, Boris/0000-0001-6668-217X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bos MP, 2005, INFECT IMMUN, V73, P6194, DOI 10.1128/IAI.73.9.6194-6197.2005; Bos MP, 2004, P NATL ACAD SCI USA, V101, P9417, DOI 10.1073/pnas.0402340101; Braun M, 2002, MOL MICROBIOL, V45, P1289, DOI 10.1046/j.1365-2958.2002.03091.x; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Gajic O, 2003, J BIOL CHEM, V278, P34291, DOI 10.1074/jbc.M211100200; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; Kloser A, 1998, MOL MICROBIOL, V27, P1003, DOI 10.1046/j.1365-2958.1998.00746.x; Kol MA, 2004, BIOCHEMISTRY-US, V43, P2673, DOI 10.1021/bi036200f; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahman MM, 2000, MICROBIOL-UK, V146, P1901, DOI 10.1099/00221287-146-8-1901; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Seifert HS, 1997, GENE, V188, P215, DOI 10.1016/S0378-1119(96)00810-4; Seigneuret M, 2003, J BIOL CHEM, V278, P30115, DOI 10.1074/jbc.M302443200; Steeghs L, 2001, EMBO J, V20, P6937, DOI 10.1093/emboj/20.24.6937; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; Steinfels E, 2004, BIOCHEMISTRY-US, V43, P7491, DOI 10.1021/bi0362018; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VANALPHEN L, 1978, J BACTERIOL, V134, P1089, DOI 10.1128/JB.134.3.1089-1098.1978; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VOORHOUT WF, 1986, J MICROSC-OXFORD, V141, P303, DOI 10.1111/j.1365-2818.1986.tb02724.x; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	38	45	46	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35961	35966		10.1074/jbc.M509026200	http://dx.doi.org/10.1074/jbc.M509026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123038	Green Published, hybrid			2022-12-25	WOS:000232726900023
J	Robison, AJ; Bass, MA; Jiao, YX; MacMillan, LB; Carmody, LC; Bartlett, RK; Colbran, RJ				Robison, AJ; Bass, MA; Jiao, YX; MacMillan, LB; Carmody, LC; Bartlett, RK; Colbran, RJ			Multivalent interactions of calcium/calmodulin-dependent protein kinase II with the postsynaptic density proteins NR2B, densin-180, and alpha-actinin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; D-ASPARTATE RECEPTOR; NMDA RECEPTOR; ALPHA-ACTININ; RAT-BRAIN; SIGNALING COMPLEXES; SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; DENDRITIC SPINES; CALMODULIN	Dendritic calcium/ calmodulin- dependent protein kinase II ( CaMKII) is dynamically targeted to the synapse. We show that CaMKII alpha is associated with the CaMKII- binding proteins densin-180, the N- methyl- D- aspartate receptor NR2B subunit, and alpha- actinin in postsynaptic density- enriched rat brain fractions. Residues 819 - 894 within the C- terminal domain of alpha- actinin- 2 constitute the minimal CaMKII- binding domain. Similar amounts of Thr(286)-autophosphorylated CaMKII alpha holoenzyme [ P- T-286] CaMKII bind to alpha- actinin- 2 as bind to NR2B ( residues 1260 - 1339) or to densin-180 ( residues 1247 - 1495) in glutathione- agarose cosedimentation assays, even though the CaMKII- binding domains share no amino acid sequence similarity. Like NR2B, alpha- actinin- 2 binds to representative splice variants of each CaMKII gene ( alpha, beta, gamma, and delta), whereas densin- 180 binds selectively to CaMKII alpha. In addition, C- terminal truncated CaMKII alpha monomers can interact with NR2B and alpha- actinin- 2, but not with densin- 180. Soluble alpha- actinin- 2 does not compete for [ P- T-286] CaMKII binding to immobilized densin-180 or NR2B. However, soluble densin- 180, but not soluble NR2B, increases CaMKII binding to immobilized alpha- actinin- 2 by approximate to 10- fold in a PDZ domain- dependent manner. A His(6)- tagged NR2B fragment associates with GST- densin or GST- actinin but only in the presence of [ P- T-286] CaMKII. Similarly, His6- tagged densin- 180 or alpha- actinin fragments associate with GST- NR2B in a[ P-T-286] CaMKII-dependent manner. In addition, GST- NR2B and His(6)- tagged alpha- actinin can bind simultaneously to monomeric CaMKII subunits. In combination, these data support a model in which [ P-T-286] CaMKII alpha can simultaneously interact with multiple dendritic spine proteins, possibly stabilizing the synaptic localization of CaMKII and/ or nucleating a multiprotein synaptic signaling complex.	Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Ctr Mol Neurosci, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Ctr Mol Neurosci, Dept Mol Physiol & Biophys, 702 Light Hall, Nashville, TN 37232 USA.	roger.colbran@vanderbilt.edu	Robison, Alfred J/P-8521-2018; Colbran, Roger/AAU-7708-2021; Jiao, Yuxia/H-3300-2019	Robison, Alfred J/0000-0002-4150-9570; Colbran, Roger/0000-0001-7401-8244; Jiao, Yuxia/0000-0002-8633-7047; Carmody, Leigh/0000-0001-7941-2961	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063232, F31MH068129] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32-DK07563] Funding Source: Medline; NIMH NIH HHS [R01 MH063232, F32-MH068129, R01-MH63232, R01 MH063232-05] Funding Source: Medline; NINDS NIH HHS [R01-NS44282] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; Apperson ML, 1996, J NEUROSCI, V16, P6839; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Chen XB, 2005, P NATL ACAD SCI USA, V102, P11551, DOI 10.1073/pnas.0505359102; Colbran RJ, 2004, BIOCHEM J, V378, P1, DOI 10.1042/BJ20031547; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Dhavan R, 2002, J NEUROSCI, V22, P7879; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Fong DK, 2002, J NEUROSCI, V22, P2153, DOI 10.1523/JNEUROSCI.22-06-02153.2002; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Griffith LC, 2004, J NEUROSCI, V24, P8391, DOI 10.1523/JNEUROSCI.2888-04.2004; Griffith LC, 2004, J NEUROSCI, V24, P8394, DOI 10.1523/JNEUROSCI.3604-04.2004; HARTWIG JH, 1995, PROTEIN PROFILE, V2, P703; Hata Y, 1996, J NEUROSCI, V16, P2488; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Jourdain P, 2003, J NEUROSCI, V23, P10645; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li WD, 2001, J BIOL CHEM, V276, P21417, DOI 10.1074/jbc.M010744200; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Muller D, 2000, HIPPOCAMPUS, V10, P596, DOI 10.1002/1098-1063(2000)10:5<596::AID-HIPO10>3.3.CO;2-P; Ohtakara K, 2002, GENES CELLS, V7, P1149, DOI 10.1046/j.1365-2443.2002.00589.x; Petersen JD, 2003, J NEUROSCI, V23, P11270; SAHYOUN N, 1985, J BIOL CHEM, V260, P1230; Schulman H, 2004, J NEUROSCI, V24, P8399, DOI 10.1523/JNEUROSCI.3606-04.2004; Sessoms-Sikes S, 2005, MOL CELL NEUROSCI, V29, P139, DOI 10.1016/j.mcn.2005.01.006; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2001, J CELL SCI, V114, P1251; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Strack S, 2000, J BIOL CHEM, V275, P25061, DOI 10.1074/jbc.C000319200; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	55	100	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35329	35336		10.1074/jbc.M502191200	http://dx.doi.org/10.1074/jbc.M502191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120608	hybrid			2022-12-25	WOS:000232561200031
J	Korn, T; Magnus, T; Jung, S				Korn, T; Magnus, T; Jung, S			Autoantigen specific T cells inhibit glutamate uptake in astrocytes by decreasing expression of astrocytic glutamate transporter GLAST: a mechanism mediated by tumor necrosis factor-alpha	FASEB JOURNAL			English	Article						central nervous system; TNF-alpha; myelin basic protein	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; RAT-BRAIN; DIFFERENTIAL EXPRESSION; ASPARTATE TRANSPORTER; SURFACE EXPRESSION; ARACHIDONIC-ACID; NMDA RECEPTOR; AXONAL DAMAGE; UP-REGULATION	Glutamate excitotoxicity is increasingly being recognized as a pathogenic mechanism in autoimmune inflammatory disorders of the central nervous system (CNS). Astrocytes are the predominant players in clearing the extracellular space from glutamate and normally have extensive spare capacities in terms of glutamate uptake. We asked what might be the basis of glutamate accumulation in T cell triggered autoimmune inflammation. In vitro, coculture of primary rat astrocytes with activated myelin basic protein (MBP)-specific T cells resulted in a decrease of astrocytic glutamate uptake rates (V-max). In parallel, the amount of the Na+-dependent glutamate transporter GLAST was reduced within 48-60 h. Significant decreases of GLAST protein were observed in astrocytes harvested after incubation with T cells activated by MBP during coculture or after incubation with T cell blasts preactivated in the presence of splenocytes beforehand. Since exposure of astrocytes to cell-free supernatant of MBP-activated T cells also resulted in reduced expression of GLAST, a humoral factor appeared to be the driving agent. In blocking experiments using neutralizing antibodies and by incubation of astrocytes with recombinant cytokines, tumor necrosis factor-alpha (TNF-alpha) was identified as being responsible for the down-modulation of GLAST. GLAST was also down-regulated in the CNS of autoimmune encephalomyelitic rats but not in animals suffering from systemic inflammation. Since the loss of GLAST was not confined to inflammatory infiltrates, here too, a humoral factor seemed to be causative. In conclusion, T cell derived TNF-alpha impairs glutamate clearance capacity of astrocytes in vitro and probably also in vivo providing a pathogenic link to glutamate excitotoxicity that may contribute to early axonal dysfunction remote from active autoimmune inflammatory demyelination.	Univ Saarland, Dept Neurol, Homburg, Germany	Saarland University	Korn, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Inst Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	tkorn@rics.bwh.harvard.edu	Korn, Thomas/AAE-6960-2019	Korn, Thomas/0000-0002-3633-0955				BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Bozzali M, 2002, AM J NEURORADIOL, V23, P985; CENDES F, 1995, ANN NEUROL, V37, P123, DOI 10.1002/ana.410370125; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; Davis KE, 1998, J NEUROSCI, V18, P2475; De Stefano N, 2001, ARCH NEUROL-CHICAGO, V58, P65, DOI 10.1001/archneur.58.1.65; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Duan SM, 1999, J NEUROSCI, V19, P10193; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Fu L, 1998, BRAIN, V121, P103, DOI 10.1093/brain/121.1.103; Gegelashvili G, 1996, NEUROREPORT, V8, P261, DOI 10.1097/00001756-199612200-00052; Gold R, 1996, BRAIN, V119, P651, DOI 10.1093/brain/119.2.651; HARTUNG HP, 1995, NEUROLOGY, V45, pS22, DOI 10.1212/WNL.45.6_Suppl_6.S22; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; JUNG S, 1991, J NEUROIMMUNOL, V35, P1, DOI 10.1016/0165-5728(91)90156-2; JUNG S, 1995, EUR J IMMUNOL, V25, P1391, DOI 10.1002/eji.1830250538; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kassiotis G, 1999, EUR J IMMUNOL, V29, P774, DOI 10.1002/(SICI)1521-4141(199903)29:03<774::AID-IMMU774>3.0.CO;2-T; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; Kim SY, 2003, J NEUROCHEM, V87, P1485, DOI 10.1046/j.1471-4159.2003.02128.x; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; Korn T, 2005, GLIA, V49, P73, DOI 10.1002/glia.20101; Korner H, 1996, IMMUNOL CELL BIOL, V74, P465, DOI 10.1038/icb.1996.77; Ledeboer A, 2002, EUR J NEUROSCI, V16, P1175, DOI 10.1046/j.1460-9568.2002.02200.x; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Lopez-Bayghen E, 2004, J NEUROCHEM, V91, P200, DOI 10.1111/j.1471-4159.2004.02706.x; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Magnus T, 2002, J NEUROPATH EXP NEUR, V61, P760, DOI 10.1093/jnen/61.9.760; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MARTIN R, 1992, J IMMUNOL, V148, P1359; Matsuura S, 2002, GLIA, V37, P178, DOI 10.1002/glia.10020; Matute C, 2002, EUR J PHARMACOL, V447, P239, DOI 10.1016/S0014-2999(02)01847-2; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Muraro PA, 1997, J CLIN INVEST, V100, P339, DOI 10.1172/JCI119539; NOKTA MA, 1995, VIROLOGY, V208, P590, DOI 10.1006/viro.1995.1190; Ohgoh M, 2002, J NEUROIMMUNOL, V125, P170, DOI 10.1016/S0165-5728(02)00029-2; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; Pahan K, 2000, J NEUROCHEM, V75, P576, DOI 10.1046/j.1471-4159.2000.0750576.x; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Pitt D, 2003, NEUROLOGY, V61, P1113, DOI 10.1212/01.WNL.0000090564.88719.37; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Probert L, 2000, BRAIN, V123, P2005, DOI 10.1093/brain/123.10.2005; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 1996, CLIN NEUROSCI, V3, P348; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Susarla BTS, 2004, J NEUROCHEM, V91, P1151, DOI 10.1111/j.1471-4159.2004.02791.x; Suzuki K, 2001, J CELL SCI, V114, P3717; Swanson RA, 1997, J NEUROSCI, V17, P932; Szymocha R, 2000, J VIROL, V74, P6433, DOI 10.1128/JVI.74.14.6433-6441.2000; Takahashi JL, 2003, ANN NEUROL, V53, P588, DOI 10.1002/ana.10519; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Taupin VR, 1997, EUR J IMMUNOL, V27, P905, DOI 10.1002/eji.1830270416; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Wang GW, 2003, EDUC ASIA-PACIFIC, V2, P1; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Weishaupt A, 2000, J IMMUNOL, V165, P7157, DOI 10.4049/jimmunol.165.12.7157; Zelenaia OA, 2000, J NEUROCHEM, V75, P2252, DOI 10.1046/j.1471-4159.2000.0752252.x; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	88	98	102	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1878	+		10.1096/fj.05-3748fje	http://dx.doi.org/10.1096/fj.05-3748fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16123171				2022-12-25	WOS:000231843700006
J	Kim, YH; Girard, L; Giacomini, CP; Wang, P; Hernandez-Boussard, T; Tibshirani, R; Minna, JD; Pollack, JR				Kim, YH; Girard, L; Giacomini, CP; Wang, P; Hernandez-Boussard, T; Tibshirani, R; Minna, JD; Pollack, JR			Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification	ONCOGENE			English	Article						small cell lung cancer; array CGH; expression profiling; DNA amplification; MYC	COMPARATIVE GENOMIC HYBRIDIZATION; DNA-BINDING; N-MYC; C-MYC; IDENTIFICATION; COMPLEX; PROTEIN; DEATH; MECHANISMS; DATABASE	DNA amplifications and deletions frequently contribute to the development and progression of lung cancer. To identify such novel alterations in small cell lung cancer (SCLC), we performed comparative genomic hybridization on a set of 24 SCLC cell lines, using cDNA microarrays representing similar to 22 000 human genes (providing an average mapping resolution of < 70 kb). We identified localized DNA amplifi. cations corresponding to oncogenes known to be amplified in SCLC, including MYC (8q24), MYCN (2p24) and MYCL1 (1p34). Additional highly localized DNA amplifi. cations suggested candidate oncogenes not previously identified as amplifified in SCLC, including the antiapoptotic genes TNFRSF4 (1p36), DAD1 (14q11), BCL2L1 (20q11) and BCL2L2 (14q11). Likewise, newly discovered PCR-validated homozygous deletions suggested candidate tumor-suppressor genes, including the proapoptotic genes MAPK10 (4q21) and TNFRSF6 (10q23). To characterize the effect of DNA amplifi. cation on gene expression patterns, we performed expression pro. ling using the same microarray platform. Among our findings, we identified sets of genes whose expression correlated with MYC, MYCN or MYCL1 amplification, with surprisingly little overlap among gene sets. While both MYC and MYCN ampli. cation were associated with increased and decreased expression of known MYC upregulated and downregulated targets, respectively, MYCL1 amplification was associated only with the latter. Our. findings support a role of altered apoptotic balance in the pathogenesis of SCLC, and suggest that MYC family genes might affect oncogenesis through distinct sets of targets, in particular implicating the importance of transcriptional repression.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University; Stanford University; Stanford University	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 269 Campus Dr,CCSR 3245A, Stanford, CA 94305 USA.	pollack1@stanford.edu		Wang, Pei/0000-0002-6890-6453	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bednarek AK, 2001, CANCER RES, V61, P8068; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARNEY DN, 1985, CANCER RES, V45, P2913; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cory S, 1999, CANCER RES, V59, p1685S; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; MA A, 1993, ONCOGENE, V8, P1093; Malynn BA, 2000, GENE DEV, V14, P1390; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; PERLAKY L, 1992, CANCER RES, V52, P428; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Raetz EA, 2003, CANCER, V98, P841, DOI 10.1002/cncr.11584; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang P, 2005, BIOSTATISTICS, V6, P45, DOI 10.1093/biostatistics/kxh017; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	46	145	151	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					130	138		10.1038/sj.onc.1208997	http://dx.doi.org/10.1038/sj.onc.1208997			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16116477				2022-12-25	WOS:000234406400014
J	Buchanan, KT; Ames, JB; Asfaw, SH; Wingard, JN; Olson, CL; Campana, PT; Araujo, APU; Engman, DM				Buchanan, KT; Ames, JB; Asfaw, SH; Wingard, JN; Olson, CL; Campana, PT; Araujo, APU; Engman, DM			A flagellum-specific calcium sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR GUANYLYL CYCLASE; TRYPANOSOMA-CRUZI; BINDING-PROTEINS; CA-2+-BINDING PROTEIN; CA2+-BINDING SITES; RHODOPSIN KINASE; FREEZE-FRACTURE; DNA-BINDING; RECOVERIN; MEMBRANE	The flagellar calcium-binding protein ( FCaBP) of the flagellated protozoan Trypanosoma cruzi associates with the flagellar membrane via its N-terminal myristate and palmitate moieties in a calcium-modulated, conformation-dependent manner. This mechanism of localization is similar to that described for neuronal calcium sensors, which undergo calcium-dependent changes in conformation, which modulate the availability of the acyl groups for membrane interaction and partner association. To test whether FCaBP undergoes a calcium-dependent conformational change and to explore the role of such a change in flagellar targeting, we first introduced point mutations into each of the two EF-hand calcium-binding sites of FCaBP to define their affinities. Analysis of recombinant EF-3 mutant ( E151Q), EF-4 mutant ( E188Q), and double mutant proteins showed EF-3 to be the high affinity site ( K-d similar to 9 mu M) and EF-4 the low affinity site ( K-d similar to 120 mu M). These assignments also correlated with partial ( E188Q), nearly complete ( E151Q), and complete ( E151Q, E188Q) disruption of calcium-induced conformational changes determined by NMR spectrometry. We next expressed the FCaBP E151Q mutant and the double mutant in T. cruzi epimastigotes. These transproteins localized to the flagellum, suggesting the existence of a calcium-dependent interaction of FCaBP that is independent of its intrinsic calcium binding capacity. Several proteins were identified by FCaBP affinity chromatography that interact with FCaBP in a calcium-dependent manner, but with differential dependence on calcium-binding by FCaBP. These findings may have broader implications for the calcium acyl switch mechanism of protein regulation.	Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; Inst Fis Sao Carlos, Dept Fis & Informat, Sao Carlos, SP, Brazil; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	Northwestern University; Northwestern University; Feinberg School of Medicine; University System of Maryland; University of Maryland Baltimore	Engman, DM (corresponding author), Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA.	d-engman@northwestern.edu	Campana, Patricia T/C-5703-2012; Campana, Patricia/GLS-1060-2022; Araujo, Ana Paula U/I-6664-2012; Engman, David/T-6747-2018	Campana, Patricia T/0000-0002-2337-6372; Campana, Patricia/0000-0002-2337-6372; Araujo, Ana Paula U/0000-0001-5455-084X; Engman, David/0000-0001-5869-9844	NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046781] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46781] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alekseev AM, 1998, FEBS LETT, V440, P116, DOI 10.1016/S0014-5793(98)01426-4; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHEN CK, 1995, J BIOL CHEM, V270, P18066; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; ENGMAN DM, 1989, J BIOL CHEM, V264, P18627; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; Felleisen RSJ, 2001, PARASITOLOGY, V122, P125, DOI 10.1017/S0031182001007168; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; GORODOVIKOVA EN, 1993, FEBS LETT, V335, P277, DOI 10.1016/0014-5793(93)80746-H; KIRCHHOFF LV, 1985, JAMA-J AM MED ASSOC, V254, P3058, DOI 10.1001/jama.254.21.3058; LEE MG, 1990, NUCLEIC ACIDS RES, V18, P4252, DOI 10.1093/nar/18.14.4252; Maldonado RA, 1999, MOL BIOCHEM PARASIT, V101, P61, DOI 10.1016/S0166-6851(99)00055-9; Maldonado RA, 1997, EXP PARASITOL, V86, P200, DOI 10.1006/expr.1997.4159; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; Osawa M, 2005, J BIOL CHEM, V280, P18008, DOI 10.1074/jbc.M500338200; Osawa M, 2001, J BIOL CHEM, V276, P41005, DOI 10.1074/jbc.M105842200; Permyakov SE, 2000, PROTEIN ENG, V13, P783, DOI 10.1093/protein/13.11.783; Pinto APA, 2003, BBA-PROTEINS PROTEOM, V1652, P107, DOI 10.1016/j.bbapap.2003.08.008; Porcel BM, 1996, EXP PARASITOL, V84, P387, DOI 10.1006/expr.1996.0127; Ridgley E, 2000, MOL BIOCHEM PARASIT, V109, P195, DOI 10.1016/S0166-6851(00)00246-2; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sanada K, 1996, FEBS LETT, V384, P227, DOI 10.1016/0014-5793(96)00318-3; Senin II, 2004, J BIOL CHEM, V279, P48647, DOI 10.1074/jbc.M402516200; Senin II, 2002, J BIOL CHEM, V277, P50365, DOI 10.1074/jbc.M204338200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOUTOPADRON T, 1983, J PARASITOL, V69, P129, DOI 10.2307/3281287; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TETLEY L, 1986, ACTA TROP, V43, P307; TIBBETTS RS, 1995, EXP PARASITOL, V80, P572, DOI 10.1006/expr.1995.1071; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tull D, 2004, MOL BIOL CELL, V15, P4775, DOI 10.1091/mbc.E04-06-0457; WU YM, 1994, BIOCHEM J, V304, P833, DOI 10.1042/bj3040833; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					40104	40111		10.1074/jbc.M505777200	http://dx.doi.org/10.1074/jbc.M505777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16148003	hybrid			2022-12-25	WOS:000233461300049
J	Egler, RA; Fernandes, E; Rothermund, K; Sereika, S; de Souza-Pinto, N; Jaruga, P; Dizdaroglu, M; Prochownik, EV				Egler, RA; Fernandes, E; Rothermund, K; Sereika, S; de Souza-Pinto, N; Jaruga, P; Dizdaroglu, M; Prochownik, EV			Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1	ONCOGENE			English	Article						peroxiredoxin 1; c-Myc; c-Abl; reactive oxygen species; DNA damage; Ras; Omnibank (R)	CHROMATOGRAPHY-MASS SPECTROMETRY; REPRESSES TRANSCRIPTION; CELL-PROLIFERATION; HYDROGEN-PEROXIDE; TUMOR-SUPPRESSOR; REPAIR PATHWAY; GROWTH-FACTORS; TARGET GENE; LIFE-SPAN; EXPRESSION	Overexpression of c-Myc results in transformation and multiple other phenotypes, and is accompanied by the deregulation of a large number of target genes. We previously demonstrated that peroxiredoxin 1 (Prdx1), a scavenger of reactive oxygen species (ROS), interacts with a region of the c-Myc transcriptional regulatory domain that is essential for transformation. This results either in the suppression or enhancement of some c-Myc functions and in the altered expression of select target genes. Most notably, c-Myc-mediated transformation is inhibited, implying a tumor suppressor role for Prdx1. Consistent with this, prdx1 -/- mice develop age-dependent hemolytic anemias and/or malignancies. We now show that erythrocytes and embryonic fibroblasts from these animals contain higher levels of ROS, and that the latter cells show evidence of c-Myc activation, including the ability to be transformed by a ras oncogene alone. In contrast, other primary cells from prdx1 -/- mice do not have elevated ROS, but nonetheless show increased oxidative DNA damage. This apparent paradox can be explained by the fact that ROS localize primarily to the cytoplasm of prdx1 -/- cells, whereas in prdx1 -/- cells, much higher levels of nuclear ROS are seen. We suggest that increased DNA damage and tumor susceptibility in prdx1 -/- animals results from this shift in intracellular ROS. prdx1 -/- mice should be useful in studying the role of oxidative DNA damage in the causation of cancer and its prevention by antioxidants. They should also help in studying the relationship between oncogenes such as c-Myc and DNA damage.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA; NIH, Lab Mol Gerontol, Baltimore, MD 21224 USA; Univ Maryland, Dept Chem & Biochem Engn, Baltimore, MD 21250 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Dept Pediat, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu	Jaruga, Pawel/M-4378-2015; Souza-Pinto, Nadja/T-3050-2019; Souza-Pinto, Nadja C./C-3462-2013	Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; Jaruga, Pawel/0000-0001-9192-6084	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD042987] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000727, ZIAAG000727] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline; NICHD NIH HHS [T32 HD042987] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barker N, 2000, ADV CANCER RES, V77, P1; Birincioglu M, 2003, J AM CHEM SOC, V125, P11607, DOI 10.1021/ja0352146; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Bubendorf L, 1999, CANCER RES, V59, P803; Bubendorf L, 1999, CANCER RES, V59, P1388; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Dizdaroglu M, 2001, FREE RADICAL BIO MED, V30, P774, DOI 10.1016/S0891-5849(01)00464-6; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisen JA, 2000, GENOME BIOL, V1; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hironaka K, 2003, LAB INVEST, V83, P643, DOI 10.1097/01.LAB.0000067483.89649.11; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Iritani BM, 2002, EMBO J, V21, P4820, DOI 10.1093/emboj/cdf492; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Jaruga P, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh087; Jaruga P, 2002, BIOCHEMISTRY-US, V41, P3703, DOI 10.1021/bi016004d; Jaruga PW, 2001, FREE RADICAL BIO MED, V31, P336, DOI 10.1016/S0891-5849(01)00594-9; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Kuraoka I, 2001, J BIOL CHEM, V276, P49283, DOI 10.1074/jbc.M107779200; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Marietta C, 2002, DNA REPAIR, V1, P967, DOI 10.1016/S1568-7864(02)00148-9; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Naidu R, 2002, INT J MOL MED, V9, P189; Nakahara H, 1998, FREE RADICAL BIO MED, V24, P85, DOI 10.1016/S0891-5849(97)00164-0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Obaya AJ, 2002, J BIOL CHEM, V277, P31263, DOI 10.1074/jbc.M202528200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PARADA LF, 1985, PROG MED VIROL, V32, P115; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PIETILAINEN T, 1995, ANTICANCER RES, V15, P959; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Senturker S, 1999, FREE RADICAL BIO MED, V27, P370, DOI 10.1016/S0891-5849(99)00069-6; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Smith DR, 1996, CLIN CANCER RES, V2, P1049; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thorgeirsson SS, 2000, TOXICOL LETT, V112, P553, DOI 10.1016/S0378-4274(99)00224-6; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; Trzeciak AR, 2004, CARCINOGENESIS, V25, P1359, DOI 10.1093/carcin/bgh144; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; YUAN L, 1993, EXP CELL RES, V209, P375, DOI 10.1006/excr.1993.1323	99	183	191	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8038	8050		10.1038/sj.onc.1208821	http://dx.doi.org/10.1038/sj.onc.1208821			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170382				2022-12-25	WOS:000233656600010
J	Reichman, C; Singh, K; Liu, Y; Singh, S; Li, H; Fajardo, JE; Fiser, A; Birge, RB				Reichman, C; Singh, K; Liu, Y; Singh, S; Li, H; Fajardo, JE; Fiser, A; Birge, RB			Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain	ONCOGENE			English	Article						Crk; Abl; SH3 domain; atypical; covariation; protein modeling; kinase activation	TERMINAL SH3 DOMAIN; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAIN; C-ABL; TYROSINE KINASE; STRUCTURAL BASIS; HIGH-AFFINITY; ACTIVATION; RECOGNITION; BINDING	To gain a better understanding of how Crk II regulates the function of the Abl tyrosine kinase, we explored the function of the C-terminal linker and SH3 domain, a region of Crk II that is still poorly understood. Molecular modeling, tryptophan. fluorescence, and covariation sequence alignment indicate that the Crk-SH3-C has a unique binding groove and RT loop not observed in typical SH3 domains. Based on these models, we made a series of mutations in the linker and in residues predicted to destabilize the putative binding pocket and RT loop. In Abl transactivation assays, Y222F and P225A mutations in the linker resulted in strong transactivation of Abl by Crk II. However, mutations predicted to be at the surface of the Crk SH3-C were not activators of Abl. Interestingly, combinations of activating mutations of Crk II with mutations in the highly conserved PNAY sequence in the SH3-C inactivated the activating mutations, suggesting that the SH3-C is necessary for activation. Our data provide insight into the role of highly conserved residues in the Crk-SH3-C, suggesting a mechanism for how the linker and the Crk-SH3-C function in the transactivation of the Abl tyrosine kinase.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; Albert Einstein College of Medicine	Birge, RB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	birgera@umdnj.edu		Li, Hong/0000-0001-5731-5335; Singh, Sukhwinder/0000-0002-7061-0096	NIGMS NIH HHS [GMS55760] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kurakin A, 2002, J BIOMOL STRUCT DYN, V19, P1015, DOI 10.1080/07391102.2002.10506805; Kurakin AV, 2003, J BIOL CHEM, V278, P34102, DOI 10.1074/jbc.M305264200; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lewitzky M, 2004, J BIOL CHEM, V279, P28724, DOI 10.1074/jbc.M402745200; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; OGAWA S, 1994, ONCOGENE, V9, P1669; Pires JR, 2003, J MOL BIOL, V326, P1427, DOI 10.1016/S0022-2836(03)00039-1; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith KM, 2001, J BIOL CHEM, V276, P24372, DOI 10.1074/jbc.M100786200; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvara A, 2001, ONCOGENE, V20, P951, DOI 10.1038/sj.onc.1204173	54	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8187	8199		10.1038/sj.onc.1208988	http://dx.doi.org/10.1038/sj.onc.1208988			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16158059				2022-12-25	WOS:000233809400010
J	Warner, FJ; Lew, RA; Smith, IA; Lambert, DW; Hooper, NM; Turner, AJ				Warner, FJ; Lew, RA; Smith, IA; Lambert, DW; Hooper, NM; Turner, AJ			Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ULTRASTRUCTURAL-LOCALIZATION; FUNCTIONAL RECEPTOR; MEMBRANE PEPTIDASES; SARS CORONAVIRUS; MESSENGER-RNA; UP-REGULATION; HUMAN HEART; IN-VIVO; EXPRESSION	Angiotensin-converting enzyme-2 ( ACE2) is a homologue of angiotensin-I converting enzyme ( ACE), the central enzyme of the renin-angiotensin system ( RAS). ACE2 is abundant in human kidney and heart and has been implicated in renal and cardiac function through its ability to hydrolyze Angiotensin II. Although ACE2 and ACE are both type I integral membrane proteins and share 61% protein sequence similarity, they display distinct modes of enzyme action and tissue distribution. This study characterized ACE2 at the plasma membrane of non-polarized Chinese hamster ovary ( CHO) cells and polarized Madin-Darby canine kidney ( MDCKII) epithelial cells and compared its cellular localization to its related enzyme, ACE, using indirect immunofluorescence, cell-surface biotinylation, Western analysis, and enzyme activity assays. This study shows ACE2 and ACE are both cell-surface proteins distributed evenly to detergent-soluble regions of the plasma membrane in CHO cells. However, in polarized MDCKII cells under steady-state conditions the two enzymes are differentially expressed. ACE2 is localized predominantly to the apical surface ( similar to 92%) where it is proteolytically cleaved within its ectodomain to release a soluble form. Comparatively, ACE is present on both the apical ( similar to 55%) and basolateral membranes ( similar to 45%) where it is also secreted but differentially; the ectodomain cleavage of ACE is 2.5-fold greater from the apical surface than the basolateral surface. These studies suggest that both ACE2 and ACE are ectoenzymes that have distinct localization and secretion patterns that determine their role on the cell surface in kidney epithelium and in urine.	Univ Leeds, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England; Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	University of Leeds; Monash University	Turner, AJ (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.	a.j.turner@leeds.ac.uk	Lew, Rebecca A/C-5454-2008	Hooper, Nigel/0000-0002-5811-3484; Smith, Ian/0000-0002-4143-2892	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acharya KR, 2003, NAT REV DRUG DISCOV, V2, P891, DOI 10.1038/nrd1227; ALHENCGELAS F, 1989, J HYPERTENS, V7, pS9, DOI 10.1097/00004872-198909007-00003; Allen AM, 2000, AM J HYPERTENS, V13, p31S, DOI 10.1016/S0895-7061(99)00249-6; Barnes K, 1998, HYPERTENSION, V31, P3, DOI 10.1161/01.HYP.31.1.3; BARNES K, 1991, NEUROSCIENCE, V44, P245, DOI 10.1016/0306-4522(91)90265-P; Barton M, 2000, HYPERTENSION, V35, P329, DOI 10.1161/01.HYP.35.1.329; Brosnihan KB, 2003, HYPERTENSION, V42, P749, DOI 10.1161/01.HYP.0000085220.53285.11; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226; DANILOV SM, 1987, HISTOCHEMISTRY, V87, P487, DOI 10.1007/BF00496822; DEFENDINI R, 1983, NEUROENDOCRINOLOGY, V37, P32, DOI 10.1159/000123512; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Donoghue M, 2003, J MOL CELL CARDIOL, V35, P1043, DOI 10.1016/S0022-2828(03)00177-9; Douglas GC, 2004, ENDOCRINOLOGY, V145, P4703, DOI 10.1210/en.2004-0443; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Ferrario CM, 2002, AM J HYPERTENS, V15, P557, DOI 10.1016/S0895-7061(02)02268-9; Flavia FJ, 2002, J AM SOC NEPHROL, V13, p146A; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Gembardt F, 2005, PEPTIDES, V26, P1270, DOI 10.1016/j.peptides.2005.01.009; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; Guy JL, 2003, BIOCHEMISTRY-US, V42, P13185, DOI 10.1021/bi035268s; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; HOWELL S, 1993, FEBS LETT, V317, P109, DOI 10.1016/0014-5793(93)81502-Q; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a; Kohlstedt K, 2002, CIRC RES, V91, P749, DOI 10.1161/01.RES.0000038114.17939.C8; KOKUBU T, 1987, CLIN EXP HYPERTENS A, V9, P481; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200; LANCTOT C, 1995, BIOCHEM J, V305, P165, DOI 10.1042/bj3050165; Levy DE, 1998, J MED CHEM, V41, P199, DOI 10.1021/jm970494j; Li DY, 2003, CARDIOVASC RES, V57, P238, DOI 10.1016/S0008-6363(02)00674-0; Li NJ, 2005, AM J PHYSIOL-RENAL, V288, pF353, DOI 10.1152/ajprenal.00144.2004; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; Parkin ET, 2003, J CELL SCI, V116, P3079, DOI 10.1242/jcs.00626; Parvathy S, 1997, BIOCHEM J, V327, P37, DOI 10.1042/bj3270037; Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Sadhukhan R, 1996, J BIOL CHEM, V271, P6429, DOI 10.1074/jbc.271.11.6429; Santos RAS, 2000, REGUL PEPTIDES, V91, P45, DOI 10.1016/S0167-0115(00)00138-5; SCHULZ WW, 1988, LAB INVEST, V59, P789; Skidgel R A, 1985, Prog Clin Biol Res, V192, P371; Takeda T, 2003, AM J PHYSIOL-CELL PH, V284, pC1105, DOI 10.1152/ajpcell.00514.2002; Tikellis C, 2003, HYPERTENSION, V41, P392, DOI 10.1161/01.HYP.0000060689.38912.CB; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; WOLLNER DA, 1992, J CELL SCI, V102, P185; Ye MH, 2004, HYPERTENSION, V43, P1120, DOI 10.1161/01.HYP.0000126192.27644.76; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Zisman LS, 2003, CIRCULATION, V108, P1679, DOI 10.1161/01.CIR.0000094733.61689.D4; Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99	58	128	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39353	39362		10.1074/jbc.M508914200	http://dx.doi.org/10.1074/jbc.M508914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16166094	hybrid			2022-12-25	WOS:000233362200056
J	Llorian, M; Beullens, M; Lesage, B; Nicolaescu, E; Landuyt, W; Ortiz, JM; Bollen, M				Llorian, M; Beullens, M; Lesage, B; Nicolaescu, E; Landuyt, W; Ortiz, JM; Bollen, M			Nucleocytoplasmic shuttling of the splicing factor SIPP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYGLUTAMINE TRACT-BINDING; MESSENGER-RNA; PROTEOMIC ANALYSIS; WW DOMAIN; PROTEIN; TRANSCRIPTION; PQBP-1; MUTATIONS; INTERACTOR; NPW38	SIPP1 ( splicing factor that interacts with PQBP1 and PP1) is a widely expressed protein of 70 kDa that has been implicated in pre-mRNA splicing. It interacts with protein Ser/Thr phosphatase-1 (PP1) and with the polyglutamine-tract-binding protein 1 ( PQBP1), which contributes to the pathogenesis of X-linked mental retardation and neurodegenerative diseases caused by polyglutamine tract expansions. We show here that SIPP1 is a nucleocytoplasmic shuttling protein. Under basal circumstances SIPP1 was largely nuclear, but it accumulated in the cytoplasm following UV- or X-radiation. Nuclear import was mediated by two nuclear localization signals. In addition, SIPP1 could be piggy-back transported to the nucleus with its ligand PQBP1. In the nucleus SIPP1 and PQBP1 formed inclusion bodies similar to those detected in polyglutamine diseases. SIPP1 did not function as a nuclear targeting subunit of PP1 but re-localized nuclear PP1 to storage sites for splicing factors. The C-terminal residues of SIPP1, which do not conform to a classic nuclear export signal, were required for its nuclear export via the CMR-1 pathway. Finally, SIPP1 activated pre-mRNA splicing in intact cells, and the extent of splicing activation correlated with the nuclear concentration of SIPP1. We conclude that SIPP1 is a positive regulator of pre-mRNA splicing that is regulated by nucleocytoplasmic shuttling. These findings also have potential implications for a better understanding of the pathogenesis of X-linked mental retardation and polyglutamine-linked neurodegenerative disorders.	Katholieke Univ Leuven, Fac Geneeskunde, Afdelingen Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Geneeskunde, Gezwelziekten Expt Radiotherapie, B-3000 Louvain, Belgium; Univ Cantabria, Fac Med, Dept Biol Mol, Asociada Ctr Invest Biol,Consejo Super Invest Cie, Santander 39011, Spain	KU Leuven; KU Leuven; Universidad de Cantabria	Bollen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdelingen Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.be						Benzeno S, 2004, J BIOL CHEM, V279, P56061, DOI 10.1074/jbc.M411910200; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Craggs G, 2001, J BIOL CHEM, V276, P30552, DOI 10.1074/jbc.M103142200; Enokido Y, 2002, BIOCHEM BIOPH RES CO, V294, P268, DOI 10.1016/S0006-291X(02)00477-1; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Kalscheuer VM, 2003, NAT GENET, V35, P313, DOI 10.1038/ng1264; Kleefstra T, 2004, CLIN GENET, V66, P318, DOI 10.1111/j.1399-0004.2004.00308.x; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Lenski C, 2004, AM J HUM GENET, V74, P777, DOI 10.1086/383205; Lesage B, 2004, J BIOL CHEM, V279, P55978, DOI 10.1074/jbc.M411911200; Llorian M, 2004, BIOCHEM J, V378, P229, DOI 10.1042/BJ20030950; Makarova OV, 2004, EMBO J, V23, P2381, DOI 10.1038/sj.emboj.7600241; Nasim MT, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf108; Okazawa H, 2001, BRAIN RES BULL, V56, P273, DOI 10.1016/S0361-9230(01)00579-2; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; Okuda T, 2003, HUM MOL GENET, V12, P711, DOI 10.1093/hmg/ddg084; Pearson A, 2004, J VIROL, V78, P23, DOI 10.1128/JVI.78.1.23-32.2004; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Stoilov P, 2004, HUM MOL GENET, V13, P509, DOI 10.1093/hmg/ddh051; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Zhang YZ, 2000, GENE, V257, P33, DOI 10.1016/S0378-1119(00)00372-3; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	25	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38862	38869		10.1074/jbc.M509185200	http://dx.doi.org/10.1074/jbc.M509185200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16162498	hybrid			2022-12-25	WOS:000233239800088
J	Tang, ZS; El Far, O; Betz, H; Scheschonka, A				Tang, ZS; El Far, O; Betz, H; Scheschonka, A			Pias1 interaction and sumoylation of metabotropic glutamate receptor 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PRESYNAPTIC LOCALIZATION; C-TERMINUS; FILAMIN-A; SUMO; UBIQUITIN; PROTEINS; BINDING; RAT; CALMODULIN	Group III presynaptic metabotropic glutamate receptors (mGluRs) play a central role in regulating presynaptic activity through G-protein effects on ion channels and signal transducing enzymes. Like all Class C G-protein-coupled receptors, mGluR8 has an extended intracellular C-terminal domain (CTD) presumed to allow for modulation of downstream signaling. In a yeast two-hybrid screen of an adult rat brain cDNA library with the CTDs of mGluR8a and 8b (mGluR8-C) as baits, we identified sumo1 and four different components of the sumoylation cascade (ube2a, Pias1, Pias gamma, Piasx beta) as interacting proteins. Binding assays using recombinant GST fusion proteins confirmed that Pias1 interacts not only with mGluR8-C but also with all group III mGluR CTDs. Pias1 binding to mGluR8-C required a region N-terminal to a consensus sumoylation motif and was not affected by arginine substitution of the conserved lysine 882 within this motif. Co-transfection of fluorescently tagged mGluR8a-C, sumo1, and enzymes of the sumoylation cascade into HEK293 cells showed that mGluR8a-C can be sumoylated in vivo. Arginine substitution of lysine 882 within the consensus sumoylation motif, but not other conserved lysines within the CTD, abolished in vivo sumoylation. Our results are consistent with post-translational sumoylation providing a novel mechanism of group III mGluR regulation.	MPI Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany		Betz, H (corresponding author), MPI Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de; scheschonka@mpih-frankfurt.mpg.de	Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345				Airas JM, 2001, FEBS LETT, V494, P60, DOI 10.1016/S0014-5793(01)02311-0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Corti C, 1998, EUR J NEUROSCI, V10, P3629, DOI 10.1046/j.1460-9568.1998.00371.x; Dev KK, 2001, TRENDS PHARMACOL SCI, V22, P355, DOI 10.1016/S0165-6147(00)01684-9; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Enz R, 2003, BIOCHEM J, V372, P183, DOI 10.1042/BJ20021750; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; Gerlai R, 2002, NEUROPHARMACOLOGY, V43, P235, DOI 10.1016/S0028-3908(02)00078-3; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Iacovelli L, 2004, MOL PHARMACOL, V65, P1103, DOI 10.1124/mol.65.5.1103; Ishikawa K, 1999, GENES CELLS, V4, P381, DOI 10.1046/j.1365-2443.1999.00269.x; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kammermeier PJ, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-15; Kinoshita A, 1996, NEUROSCI LETT, V207, P61, DOI 10.1016/0304-3940(96)12489-7; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; Linden AM, 2002, NEUROPHARMACOLOGY, V43, P251, DOI 10.1016/S0028-3908(02)00079-5; Marchese Adriano, 2004, Methods Mol Biol, V259, P299; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200; Moriyoshi K, 2004, P NATL ACAD SCI USA, V101, P8614, DOI 10.1073/pnas.0403042101; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAKANISHI S, 1994, EXS, V71, P71; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Saugstad JA, 1997, MOL PHARMACOL, V51, P119, DOI 10.1124/mol.51.1.119; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200	46	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38153	38159		10.1074/jbc.M508168200	http://dx.doi.org/10.1074/jbc.M508168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144832	hybrid			2022-12-25	WOS:000233239800007
J	Athenstaedt, K; Daum, G				Athenstaedt, K; Daum, G			Tgl4p and Tgl5p, two triacylglycerol lipases of the yeast Saccharomyces cerevisiae are localized to lipid particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; CELLS; PROTEINS; ESTERS; GENE; STEROIDOGENESIS; IDENTIFICATION; LIPOPROTEINS; METABOLISM; HYDROLASE	Triacylglycerol ( TAG) lipases are required for mobilization of TAG stored in lipid particles. Recently, Tgl3p was identified as a major TAG lipase of the yeast Saccharomyces cerevisiae ( Athenstaedt, K., and Daum, G. ( 2003) J. Biol. Chem. 278, 23317 - 23323). Here, we report the identification of Tgl4p and Tgl5p as additional TAG lipases of the yeast. Both polypeptides, encoded by open reading frames YKR089c/TGL4 and YOR081c/TGL5, share 30 and 26% homology, respectively, to Tgl3p. Cell fractionation experiments and microscopic inspection of strains bearing Tgl4p-GFP and Tgl5p-GFP hybrids demonstrated that both proteins are localized to lipid particles similar to Tgl3p. A 1.7-fold increased amount of TAG enriched in myristic and palmitic acids and the reduced mobilization rate of TAG from tgl4 Delta in the presence of the fatty acid synthesis inhibitor cerulenin demonstrated the lipolytic function of Tgl4p in vivo. In contrast, neither the total amount of TAG nor the TAG mobilization rate after addition of cerulenin was affected in tgl5 Delta cells. However, the enrichment of C26: 0 esterified to TAG of tgl5 Delta, an additional increase of TAG in the tgl4 Delta tgl5 Delta double deletion mutant compared with tgl4 Delta, and the impairment of TAG mobilization in the tgl4 Delta tgl5 Delta strain in the presence of cerulenin suggested that also Tgl5p functions as a TAG lipase in vivo. Most importantly, the purified His(6)-tagged Tgl4p and Tgl5p hybrids exhibited TAG lipase activity demonstrating their function in vitro. In summary, our data obtained by biochemical, molecular, and cell biological analyses unambiguously identified Tgl4p and Tgl5p as novel TAG lipases of yeast lipid particles with certain enzymatic specificities.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at		Athenstaedt, Karin/0000-0001-7198-3989				Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BISGAIER CL, 1985, J STEROID BIOCHEM, V23, P967, DOI 10.1016/0022-4731(85)90054-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; GIETZ RD, 1995, METHODS MOL CELL BIO, V43, P177; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; HAID A, 1983, METHOD ENZYMOL, V96, P192; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; Jandrositz A, 2005, BBA-MOL CELL BIOL L, V1735, P50, DOI 10.1016/j.bbalip.2005.04.005; Koffel R, 2005, MOL CELL BIOL, V25, P1655, DOI 10.1128/MCB.25.5.1655-1668.2005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lee GC, 2002, BIOCHEM J, V366, P603, DOI 10.1042/BJ20020404; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON WR, 1964, J LIPID RES, V5, P600; MURPHY DJ, 1990, PROG LIPID RES, V29, P299; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; PICKERS P, 2005, FUNGAL GENET BIOL, V42, P264; Schmitt J, 2002, PROTEIN ENG, V15, P595, DOI 10.1093/protein/15.7.595; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Spalinger JH, 1998, BBA-LIPID LIPID MET, V1393, P119, DOI 10.1016/S0005-2760(98)00068-X; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; TAKETANI S, 1978, BIOCHIM BIOPHYS ACTA, V525, P87, DOI 10.1016/0005-2744(78)90202-4; WELLER PF, 1994, J ALLERGY CLIN IMMUN, V94, P1151, DOI 10.1016/0091-6749(94)90325-5; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1995, J LIPID RES, V36, P125; Zhang Q, 2003, J BIOL CHEM, V278, P47145, DOI 10.1074/jbc.M306998200; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	39	152	161	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37301	37309		10.1074/jbc.M507261200	http://dx.doi.org/10.1074/jbc.M507261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16135509	hybrid			2022-12-25	WOS:000233044500003
J	Cargnin, F; Flora, A; Di Lascio, S; Battaglioli, E; Longhi, R; Clementi, F; Fornasari, D				Cargnin, F; Flora, A; Di Lascio, S; Battaglioli, E; Longhi, R; Clementi, F; Fornasari, D			PHOX2B regulates its own expression by a transcriptional auto-regulatory mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-HYPOVENTILATION-SYNDROME; BONE MORPHOGENETIC PROTEINS; NICOTINIC RECEPTOR SUBUNIT; HOMEOBOX GENE PHOX2B; SYMPATHETIC NEURON DEVELOPMENT; FUNCTIONAL-CHARACTERIZATION; POLYALANINE EXPANSIONS; FRAMESHIFT MUTATIONS; SIGNAL-TRANSDUCTION; AUTONOMIC NEURONS	The specification of neuronal identity is a result of interactions between the following two distinct classes of determinants: extrinsic factors that include secreted or cell membrane-associated signals in the local environment, and intrinsic factors that generally consist of ordered cascades of transcription factors. Little is known about the molecular mechanisms underlying the interplay between these extrinsic and intrinsic factors and the transcriptional processes that establish and maintain a given neuronal phenotype. Phox2b is a vertebrate homeodomain transcription factor and a well established intrinsic factor in developing autonomic ganglia, where its expression is triggered by the bone morphogenic proteins secreted by the dorsal aorta. In this study we characterized its proximal 5'-regulatory region and found that it contained five putative DNA sites that potentially bind homeodomain proteins, including PHOX2B itself. Chromatin immunoprecipitation assays showed that PHOX2B could bind its own promoter in vivo, and electromobility gel shift assays confirmed that four of the five sites could be involved in PHOX2B binding. Functional experiments demonstrated that 65% of the transcriptional activity of the PHOX2B promoter in neuroblastoma cells depends on this auto-regulatory mechanism and that all four sites were required for full self-transactivation. Our data provide a possible molecular explanation for the maintenance of PHOX2B expression in developing ganglia, in which initially its expression is triggered by bone morphogenic proteins, but may become independent of external stimuli when it reaches a certain nuclear concentration and sustains its own transcription.	Univ Milan, Sch Med, Dept Pharmacol, I-20129 Milan, Italy; CNR, Inst Neurosci, I-20129 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20129 Milan, Italy; Univ Milan, Dept Biol & Genet Med Sci, I-20129 Milan, Italy; CNR, Inst Chem & Mol Recognit, I-20129 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Fornasari, D (corresponding author), Univ Milan, Sch Med, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	diego.fornasari@unimi.it	Flora, Adriano/A-9663-2008; battaglioli, elena/H-9350-2017	Battaglioli, Elena/0000-0001-9168-7212; DI LASCIO, SIMONA/0000-0002-5971-1515; Fornasari, Diego/0000-0002-9668-3103				Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Bachetti T, 2005, HUM MOL GENET, V14, P1815, DOI 10.1093/hmg/ddi188; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; Chen D, 2004, FRONT BIOSCI-LANDMRK, V9, P349, DOI 10.2741/1090; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; Dubreuil W, 2002, DEVELOPMENT, V129, P5241; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; FIELDS C G, 1991, Peptide Research, V4, P95; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; Flora A, 2001, J NEUROSCI, V21, P7037, DOI 10.1523/JNEUROSCI.21-18-07037.2001; Gaultier C, 2003, RESP PHYSIOL NEUROBI, V136, P105, DOI 10.1016/S1569-9048(03)00075-2; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hong SJ, 2004, MOL BRAIN RES, V125, P29, DOI 10.1016/j.molbrainres.2004.02.023; Hong SJ, 2001, J NEUROCHEM, V79, P1225, DOI 10.1046/j.1471-4159.2001.00672.x; Howard MJ, 2005, DEV BIOL, V277, P271, DOI 10.1016/j.ydbio.2004.09.034; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; Pattyn A, 2000, MOL CELL NEUROSCI, V15, P235, DOI 10.1006/mcne.1999.0826; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Rohrer H, 2003, DRUG NEWS PERSPECT, V16, P589, DOI 10.1358/dnp.2003.16.9.829341; Samad OA, 2004, DEVELOPMENT, V131, P4071, DOI 10.1242/dev.01282; Stanke M, 2004, MOL CELL NEUROSCI, V25, P374, DOI 10.1016/j.mcn.2003.10.021; ten Dijke P, 2003, J BONE JOINT SURG AM, V85A, P34; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200	32	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37439	37448		10.1074/jbc.M508368200	http://dx.doi.org/10.1074/jbc.M508368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144830	hybrid			2022-12-25	WOS:000233044500019
J	Holmes, WF; Braastad, CD; Mitra, P; Hampe, C; Doenecke, D; Albig, W; Stein, JL; van Wijnen, AJ; Stein, GS				Holmes, WF; Braastad, CD; Mitra, P; Hampe, C; Doenecke, D; Albig, W; Stein, JL; van Wijnen, AJ; Stein, GS			Coordinate control and selective expression of the full complement of replication-dependent histone H4 genes in normal and cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS H4TF-1; PROTEIN-DNA INTERACTIONS; FACTOR HINF-D; CYCLE TRANSITION; MESSENGER-RNA; FACTOR IRF-2; G1/S PHASE; S-PHASE; PROMOTER; DIFFERENTIATION	The replication of eukaryotic genomes necessitates the coordination of histone biosynthesis with DNA replication at the onset of S phase. The multiple histone H4 genes encode identical proteins, but their regulatory sequences differ. The contributions of these individual genes to histone H4 mRNA expression have not been described. We have determined, by real-time quantitative PCR and RNase protection, that the human histone H4 genes are not equally expressed and that a subset contributes disproportionately to the total pool of H4 mRNA. Differences in histone H4 gene expression can be attributed to observed unequal activities of the H4 gene promoters, which exhibit variations in gene regulatory elements. The overall expression pattern of the histone H4 gene complement is similar in normal and cancer cells. However, H4 genes that are moderately expressed in normal cells are sporadically silenced in tumor cells with compensation of expression by other H4 gene copies. Chromatin immunoprecipitation analyses and in vitro DNA binding assays indicated that 11 of the 15 histone H4 genes interact with the cell cycle regulatory histone nuclear factor P, which forms a complex with the cyclin E/CDK2-responsive co-regulator p220(NPAT). These 11 H4 genes account for 95% of the histone H4 mRNA pool. We conclude that the cyclin E/CDK2/p220(NPAT)/ histone nuclear factor P signaling pathway is the principal regulator of histone H4 biosynthesis.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Univ Gottingen, Inst Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Gottingen	Stein, GS (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	gary.stein@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032010] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM032010, GM32010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; Aziz F, 1998, J CELL PHYSIOL, V177, P453, DOI 10.1002/(SICI)1097-4652(199812)177:3<453::AID-JCP8>3.0.CO;2-F; Braastad CD, 2004, GENE, V342, P35, DOI 10.1016/j.gene.2004.07.036; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DAILEY L, 1987, MOL CELL BIOL, V7, P4582, DOI 10.1128/MCB.7.12.4582; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; HOLTHUIS J, 1990, SCIENCE, V247, P1454, DOI 10.1126/science.2321007; Hovhannisyan H, 2003, MOL CELL BIOL, V23, P1460, DOI 10.1128/MCB.23.4.1460-1469.2003; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Koessler H, 2003, DNA CELL BIOL, V22, P233, DOI 10.1089/104454903321908629; LICHTLER AC, 1980, P NATL ACAD SCI-BIOL, V77, P1942, DOI 10.1073/pnas.77.4.1942; LICHTLER AC, 1982, NATURE, V298, P195, DOI 10.1038/298195a0; Liss B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf088; Miele A, 2005, MOL CELL BIOL, V25, P6140, DOI 10.1128/MCB.25.14.6140-6153.2005; Mitra P, 2003, MOL CELL BIOL, V23, P8110, DOI 10.1128/MCB.23.22.8110-8123.2003; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P7927, DOI 10.1093/nar/11.22.7927; RAMSEYEWING A, 1994, P NATL ACAD SCI USA, V91, P4475, DOI 10.1073/pnas.91.10.4475; Stein GS, 1996, CELL BIOL INT, V20, P41, DOI 10.1006/cbir.1996.0007; Stein GS, 1984, HISTONE GENES; van der Meijden CMJ, 1998, BBA-GENE STRUCT EXPR, V1442, P82, DOI 10.1016/S0167-4781(98)00147-X; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V46, P174, DOI 10.1002/jcb.240460211; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194	27	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37400	37407		10.1074/jbc.M506995200	http://dx.doi.org/10.1074/jbc.M506995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16131487	hybrid			2022-12-25	WOS:000233044500014
J	Napierala, M; Bacolla, A; Wells, RD				Napierala, M; Bacolla, A; Wells, RD			Increased negative superhelical density in vivo enhances the genetic instability of triplet repeat sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; NUCLEOTIDE EXCISION-REPAIR; INTRAMOLECULAR DNA TRIPLEXES; ORIENTATION-DEPENDENT MANNER; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEATS; FRIEDREICHS-ATAXIA; MYOTONIC-DYSTROPHY; DYNAMIC MUTATIONS; TOPOISOMERASE-I	The influence of negative superhelical density on the genetic instabilities of long GAA center dot TTC, CGG center dot CCG, and CTG center dot CAG repeat sequences was studied in vivo in topologically constrained plasmids in Escherichia coli. These repeat tracts are involved in the etiologies of Friedreich ataxia, fragile X syndrome, and myotonic dystrophy type 1, respectively. The capacity of these DNA tracts to undergo deletions-expansions was explored with three genetic-biochemical approaches including first, the utilization of topoisomerase I and/or DNA gyrase mutants, second, the specific inhibition of DNA gyrase by novobiocin, and third, the genetic removal of the HU protein, thus lowering the negative supercoil density (-sigma). All three strategies revealed that higher -sigma in vivo enhanced the formation of deleted repeat sequences. The effects were most pronounced for the Friedreich ataxia and the fragile X triplet repeat sequences. Higher levels of -sigma stabilize non-B DNA conformations (i.e. triplexes, sticky DNA, flexible and writhed DNA, slipped structures) at appropriate repeat tracts; also, numerous prior genetic instability investigations invoke a role for these structures in promoting the slippage of the DNA complementary strands. Thus, we propose that the in vivo modulation of the DNA structure, localized to the repeat tracts, is responsible for these behaviors. Presuming that these interrelationships are also found in humans, dynamic alterations in the chromosomal nuclear matrix may modulate the -sigma of certain DNA regions and, thus, stabilize/destabilize certain non-B conformations which regulate the genetic expansions-deletions responsible for the diseases.	Texas A&M Univ Syst Hlth Sci Ctr, Ctr Genome Res, Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wells, RD (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamhsc.edu	Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES11347] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 2004, J BIOL CHEM, V279, P47411, DOI 10.1074/jbc.R400028200; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; Bensaid A, 1996, J MOL BIOL, V256, P292, DOI 10.1006/jmbi.1996.0086; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Chen CR, 1996, J MOL BIOL, V258, P627, DOI 10.1006/jmbi.1996.0274; CHIANG CS, 1988, PLASMID, V20, P207, DOI 10.1016/0147-619X(88)90027-3; Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837; Cleary JD, 2005, TRENDS GENET, V21, P272, DOI 10.1016/j.tig.2005.03.008; Cleary JD, 2002, NAT GENET, V31, P37, DOI 10.1038/ng870; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; Dai X, 1997, P NATL ACAD SCI USA, V94, P2174, DOI 10.1073/pnas.94.6.2174; Dame RT, 2005, MOL MICROBIOL, V56, P858, DOI 10.1111/j.1365-2958.2005.04598.x; Davie JR, 1995, INT REV CYTOL, V162A, P191; Demeret C, 2001, ONCOGENE, V20, P3086, DOI 10.1038/sj.onc.1204333; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FRANKAMENETSKII MD, 1990, DNA TOPOLOGY ITS BIO; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GECZ J, 2003, NUCLEOTIDE PROTEIN E; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Gorbunova V, 2004, HUM MOL GENET, V13, P2979, DOI 10.1093/hmg/ddh317; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; Hardy CD, 2003, ANTIMICROB AGENTS CH, V47, P941, DOI 10.1128/AAC.47.3.941-947.2003; Heng HHQ, 2001, CYTOGENET CELL GENET, V93, P155, DOI 10.1159/000056977; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; Janin N, 2000, ADV CANCER RES, V77, P189; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Krasilnikova MM, 2004, MOL CELL BIOL, V24, P2286, DOI 10.1128/MCB.24.6.2286-2295.2004; LeProust EM, 2000, J MOL BIOL, V302, P1063, DOI 10.1006/jmbi.2000.4073; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Malik M, 1996, J MOL BIOL, V256, P66, DOI 10.1006/jmbi.1996.0068; Mariappan SVS, 1999, J MOL BIOL, V285, P2035, DOI 10.1006/jmbi.1998.2435; Menzel R, 1994, Adv Pharmacol, V29A, P39; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Mochmann LH, 2004, NUCLEIC ACIDS RES, V32, P4469, DOI 10.1093/nar/gkh787; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Nichol K, 2002, GENOME RES, V12, P1246, DOI 10.1101/gr.74502; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Oussatcheva EA, 2001, J BIOL CHEM, V276, P30878, DOI 10.1074/jbc.M104697200; Panigrahi GB, 2005, NAT STRUCT MOL BIOL, V12, P654, DOI 10.1038/nsmb959; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; PEARSON CE, 1996, AM J HUM GENET, V59, P244; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Potaman VN, 2004, NUCLEIC ACIDS RES, V32, P1224, DOI 10.1093/nar/gkh274; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Razin SV, 1995, INT REV CYTOL, V162B, P405; Razin SV, 1996, CRIT REV EUKAR GENE, V6, P247, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.70; Richards RI, 2001, HUM MOL GENET, V10, P2187, DOI 10.1093/hmg/10.20.2187; Rolfsmeier ML, 2000, MOL CELL BIOL, V20, P173, DOI 10.1128/MCB.20.1.173-180.2000; Rolfsmeier ML, 2001, GENETICS, V157, P1569; Rolfsmeier ML, 2000, MOL CELL, V6, P1501, DOI 10.1016/S1097-2765(00)00146-5; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sinden RR, 1998, ADV GENOM B, V5, P1; Sinden RR, 2002, J BIOSCIENCES, V27, P53, DOI 10.1007/BF02703683; SINDEN RR, 1984, J BIOL CHEM, V259, P6593; Sinden RR, 1999, AM J HUM GENET, V64, P346, DOI 10.1086/302271; Sobczak K, 2004, HUM MUTAT, V24, P236, DOI 10.1002/humu.20075; Subramanian S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r13; Subramanian S, 2003, BIOINFORMATICS, V19, P549, DOI 10.1093/bioinformatics/btg029; TANAKA H, 1995, MOL GEN GENET, V248, P518, DOI 10.1007/BF02423446; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tsai FTF, 1997, PROTEINS, V28, P41; Vasquez KM, 2002, P NATL ACAD SCI USA, V99, P5848, DOI 10.1073/pnas.082193799; Vassetzky Y, 2000, CRIT REV EUKAR GENE, V10, P31; Vassetzky YS, 2000, J CELL BIOCHEM, P54; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; Wanner G, 2000, J STRUCT BIOL, V132, P147, DOI 10.1006/jsbi.2000.4310; WARD WS, 1989, CHROMOSOMA, V98, P153, DOI 10.1007/BF00329678; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 2005, NUCLEIC ACIDS RES, V33, P3785, DOI 10.1093/nar/gki697; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 2006, IN PRESS GENETIC INS; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	100	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37366	37376		10.1074/jbc.M508065200	http://dx.doi.org/10.1074/jbc.M508065200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16166072	hybrid			2022-12-25	WOS:000233044500010
J	Fay, N; Redeker, V; Savistchenko, J; Dubois, S; Bousset, L; Melki, R				Fay, N; Redeker, V; Savistchenko, J; Dubois, S; Bousset, L; Melki, R			Structure of the prion Ure2p in protein fibrils assembled in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GLUTATHIONE; FILAMENTS; DOMAIN; CONFORMATION; REGIONS; FORM	The Ure2 protein from the yeast Saccharomyces cerevisiae has prion properties. In vitro and at neutral pH, soluble Ure2p spontaneously forms long, straight, insoluble protein fibrils. Two models have been proposed to account for the assembly of Ure2p into protein fibrils. The "amyloid backbone" model postulates that a segment ranging from 40 to 70 amino acids in the flexible N-terminal domain from different Ure2p molecules forms a parallel superpleated beta-structure running along the fibrils ( Kajava, A. V., Baxa, U., Wickner, R. B., and Steven, A. C. ( 2004) Proc. Natl. Acad. Sci. U. S. A. 101, 7885 - 7890). The second model hypothesizes that assembly of full-length Ure2p is driven by limited conformational rearrangements and non-native inter- and/or intramolecular interactions between Ure2p monomers (Bousset, L., Thomson, N. H., Radford, S. E., and Melki, R. ( 2002) EMBO J. 21, 2903 - 2911). Here, we performed a cysteine scan on residues located in the N- and C-terminal parts of Ure2p to determine whether these domains interact. Amino acid sequences centered around residue 6 in the N- terminal domain of Ure2p and residue 137 in the C-terminal moiety interacted at least transiently via intramolecular interactions. We documented the assembly properties of a Ure2p variant in which a disulfide bond was established between the N- and C-terminal domains and showed that it possesses assembly properties indistinguishable from those of wild-type Ure2p. We probed the structure of Ure2pC6C137 within the fibrils and demonstrate that the polypeptide is in a conformation similar to that of its soluble assembly-competent state. Our results constitute the first structural characterization of the N- terminal domain of Ure2p in both its soluble assembly-competent and fibrillar forms. Our data indicate that the flexibility of the N- terminal domain and conformational changes within this domain are essential for fibril formation and provide new insight into the conformational rearrangements that lead to the assembly of Ure2p into fibrils and the propagation of the [URE3] phenotype in yeast.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Redeker, V (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrassee, F-91198 Gif Sur Yvette, France.	redeker@lebs.cnrs-gif.fr	Savistchenko, Jimmy/A-6448-2011; Redeker, Virginie/L-8929-2018	Redeker, Virginie/0000-0003-2694-8388; bousset, luc/0000-0002-0433-4337				*APPL BIOS, 1993, US B APPL BIOS, V58; Bai M, 2004, J BIOL CHEM, V279, P50025, DOI 10.1074/jbc.M406612200; Baxa U, 2005, J STRUCT BIOL, V150, P170, DOI 10.1016/j.jsb.2005.02.007; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2004, BIOCHEMISTRY-US, V43, P5022, DOI 10.1021/bi049828e; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Fay N, 2003, J BIOL CHEM, V278, P30199, DOI 10.1074/jbc.M303000200; Fernandez-Bellot E, 2000, EMBO J, V19, P3215, DOI 10.1093/emboj/19.13.3215; Fernandez-Bellot E, 1999, BIOCHEM J, V338, P403, DOI 10.1042/0264-6021:3380403; Jiang Y, 2004, J BIOL CHEM, V279, P3361, DOI 10.1074/jbc.M310494200; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2758, DOI 10.1128/MCB.4.12.2758; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Pierce MM, 2005, BIOCHEMISTRY-US, V44, P321, DOI 10.1021/bi047964d; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Xu SH, 2001, BIOPHYS J, V81, P446, DOI 10.1016/S0006-3495(01)75712-8	30	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37149	37158		10.1074/jbc.M506917200	http://dx.doi.org/10.1074/jbc.M506917200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131495	hybrid			2022-12-25	WOS:000232901800073
J	Freche, B; Guillaumot, P; Charmetant, J; Pelletier, L; Luquain, C; Christiansen, D; Billaud, M; Manie, SN				Freche, B; Guillaumot, P; Charmetant, J; Pelletier, L; Luquain, C; Christiansen, D; Billaud, M; Manie, SN			Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; LIPID RAFTS; CELL-LINE; C-RET; AUTOPHOSPHORYLATION SITES; NEUROTROPHIC FACTOR; NEURONAL SURVIVAL; ACTIVATION; MEMBRANE; MUTATIONS	Dominant-activating mutations in the RET ( rearranged during transfection) proto-oncogene, a receptor tyrosine kinase, are causally associated with the development of multiple endocrine neoplasia type 2A (MEN2A) syndrome. Such oncogenic RET mutations induce its ligand-independent constitutive activation, but whether it spreads identical signaling to ligand-induced signaling is uncertain. To address this question, we designed a cellular model in which RET can be activated either by its natural ligand, or alternatively, by controlled dimerization of the protein that mimics MEN2A dimerization. We have shown that controlled dimerization leaves proximal RET signaling intact but impacts substantially on the tuning of the distal AKT kinase activation ( delayed and sustained). In marked contrast, distal activation of ERK remained unaffected. We further demonstrated that specific temporal adjustment of ligand-induced AKT activation is dependent upon a lipid-based cholesterol-sensitive environment, and this control step is bypassed by MEN2A RET mutants. Therefore, these studies revealed that MEN2A mutations propagate previously unappreciated subtle differences in signaling pathways and unravel a role for lipid rafts in the temporal regulation of AKT activation.	Fac Med, UMR 5201, Lab Genet Mol Signalisat & Canc, F-69373 Lyon, France; Univ Lyon 1, UMR 754, Lab Retrovirus & Pathol Comparee, F-69366 Lyon, France; Austin Hlth, Austin Res Inst, Heidelberg, Vic 3084, Australia	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Manie, SN (corresponding author), Fac Med, UMR 5201, Lab Genet Mol Signalisat & Canc, 8 Ave Rockefeller, F-69373 Lyon, France.	manie@sante.univ-lyon1.fr	Billaud, Marc N/M-6954-2013; Manie, Serge/ABC-8331-2021	manie, serge/0000-0002-9168-1977				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; DI FP, 1987, CELL, V51, P1063; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Heerklotz H, 2003, J MOL BIOL, V329, P793, DOI 10.1016/S0022-2836(03)00504-7; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Incoronato M, 2004, CELL SIGNAL, V16, P847, DOI 10.1016/j.cellsig.2004.01.002; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Kusumi A, 2004, TRAFFIC, V5, P213, DOI 10.1111/j.1600-0854.2004.0178.x; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Mograbi B, 2001, MOL CELL BIOL, V21, P6719, DOI 10.1128/MCB.21.20.6719-6730.2001; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4	46	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36584	36591		10.1074/jbc.M505707200	http://dx.doi.org/10.1074/jbc.M505707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16123037	hybrid			2022-12-25	WOS:000232901800008
J	Hung, JJ; Wu, CY; Liao, PC; Chang, WC				Hung, JJ; Wu, CY; Liao, PC; Chang, WC			Hsp90 alpha recruited by Sp1 is important for transcription of 12(S)-lipoxygenase in A431 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; O-GLYCOSYLATION; GENE-EXPRESSION; DNA-BINDING; HSP90-BINDING IMMUNOPHILINS; MOLECULAR CHAPERONES; PROMOTER ACTIVATION; ARACHIDONIC-ACID; HSP90; PROTEIN	Sp1 is a basic transcriptional factor that binds to the GC-rich region in the promoter of the target gene. It is involved in transcription of numerous genes by recruiting transcriptional factors to the promoters of target genes. In this study, we found in vivo and in vitro that Hsp90 alpha was recruited to the GC-rich region of the 12(S)-lipoxygenase promoter through interaction with Sp1 in A431 cells by employing DNA affinity immunoprecipitation assay and chromatin immunoprecipitation assay. When Hsp90 alpha was inhibited by geldanamycin ( GA, a specific inhibitor of the Hsp90 family) or by siRNA of Hsp90 alpha ( to block its activity or to knockdown protein levels), respectively, luciferase activity ( driven by the 12( S)-lipoxygenase promoter) and both mRNA and protein levels of 12( S)- lipoxygenase were reduced significantly in cells. In addition, the effect of GA was abolished when the Sp1 binding sites of 12( S)lipoxygenase were mutated in A431 cells. Interestingly, binding of Sp1 to the 12( S)- lipoxygenase promoter was also decreased upon GA treatment in cells. In conclusion, our results indicate that Sp1 interacts with Hsp90 alpha to recruit it to the promoter of 12( S)- lipoxygenase and then to regulate gene transcription by modulating the binding ability of Sp1 to promoters.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Occupat Hlth, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University	Chang, WC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.	wcchang@mail.ncku.edu.tw	HUNG, Jan-Jong/G-7872-2011					Alekseev OM, 2005, J BIOL CHEM, V280, P2904, DOI 10.1074/jbc.M410397200; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bedin M, 2004, INT J CANCER, V109, P643, DOI 10.1002/ijc.20010; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Brasse-Lagnel C, 2003, J BIOL CHEM, V278, P52504, DOI 10.1074/jbc.M306752200; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Chang WC, 2003, PROSTAG OTH LIPID M, V71, P277, DOI 10.1016/S1098-8823(03)00048-0; CHANG WC, 1993, J BIOL CHEM, V268, P18734; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Citri A, 2004, CELL CYCLE, V3, P51; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; FOJAS DB, 2001, EMBO J, V20, P5737; Gale M, 2002, BIOCHEMISTRY-US, V41, P11878, DOI 10.1021/bi020397e; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Garfinkel Mark D, 2004, Methods Mol Biol, V287, P151; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; Gerges NZ, 2004, J NEUROSCI, V24, P4758, DOI 10.1523/JNEUROSCI.0594-04.2004; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Grammatikakis N, 2002, J BIOL CHEM, V277, P8312, DOI 10.1074/jbc.M109200200; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hu YZ, 2003, J BIOL CHEM, V278, P17299, DOI 10.1074/jbc.M300788200; Huang YC, 2004, ONCOGENE, V23, P4856, DOI 10.1038/sj.onc.1207621; Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547; IWAMOTO I, 1990, NEUROPEPTIDES, V16, P103, DOI 10.1016/0143-4179(90)90119-J; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; Jez JM, 2003, CHEM BIOL, V10, P361, DOI 10.1016/S1074-5521(03)00075-9; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; Kimmins S, 2000, CELL STRESS CHAPERON, V5, P76, DOI 10.1379/1466-1268(2000)005<0076:MOSRAE>2.0.CO;2; Liang P, 1997, J CELL SCI, V110, P1431; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Muramatsu T, 1996, J PROTEIN CHEM, V15, P709, DOI 10.1007/BF01887144; Murphy PJM, 2004, J BIOL CHEM, V279, P30195, DOI 10.1074/jbc.M403539200; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Piatelli MJ, 2002, J BIOL CHEM, V277, P12144, DOI 10.1074/jbc.M200102200; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; Sugawara T, 2004, J ENDOCRINOL INVEST, V27, P133, DOI 10.1007/BF03346258; Sumanasekera WK, 2003, BIOCHEMISTRY-US, V42, P10726, DOI 10.1021/bi0347353; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; SZPIRER J, 1991, GENOMICS, V11, P168, DOI 10.1016/0888-7543(91)90114-T; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Tago K, 2004, MOL CELL ENDOCRINOL, V213, P131, DOI 10.1016/j.mce.2003.10.057; Tyan YC, 2005, PROTEOMICS, V5, P1062, DOI 10.1002/pmic.200401041; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhang YB, 2004, GENE, V325, P43, DOI 10.1016/j.gene.2003.09.039	69	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36283	36292		10.1074/jbc.M504904200	http://dx.doi.org/10.1074/jbc.M504904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118214	hybrid			2022-12-25	WOS:000232726900061
J	Danielsson, A; Ost, A; Nystrom, FH; Stralfors, P				Danielsson, A; Ost, A; Nystrom, FH; Stralfors, P			Attenuation of insulin-stimulated insulin receptor substrate-1 serine 307 phosphorylation in insulin resistance of type 2 diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; AMINO-ACID POLYMORPHISM; GLUCOSE-TRANSPORT; HUMAN ADIPOCYTES; SKELETAL-MUSCLE; OKADAIC ACID; SERINE/THREONINE PHOSPHORYLATION; KINASE-ACTIVITY; IRS-1; ACTIVATION	Insulin resistance is a primary characteristic of type 2 diabetes and likely causally related to the pathogenesis of the disease. It is a result of defects in signal transduction from the cell surface receptor of insulin to target effects. We found that insulin-stimulated phosphorylation of serine 307 ( corresponding to serine 302 in the murine sequence) in the immediate downstream mediator protein of the insulin receptor, insulin receptor substrate-1 (IRS1), is required for efficient insulin signaling and that this phosphorylation is attenuated in adipocytes from patients with type 2 diabetes. Inhibition of serine 307 phosphorylation by rapamycin mimicked type 2 diabetes and reduced the sensitivity of IRS1 tyrosine phosphorylation in response to insulin, while stimulation of the phosphorylation by okadaic acid, in cells from patients with type 2 diabetes, rescued cells from insulin resistance. EC50 for insulin-stimulated phosphorylation of serine 307 was about 0.2 nM with a t(1/2) of about 2 min. The amount of IRS1 was similar in cells from non-diabetic and diabetic subjects. These findings identify a molecular mechanism for insulin resistance in non-selected patients with type 2 diabetes.	Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Diabet Res Ctr, SE-58185 Linkoping, Sweden	Linkoping University; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden.	peter.stralfors@ibk.liu.se		Stralfors, Peter/0000-0002-1196-1806; Nystrom, Fredrik/0000-0002-1680-1000				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; Birnbaum MJ, 2001, J CLIN INVEST, V108, P655, DOI 10.1172/JCI200113714; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Danielsson A, 2005, FEBS J, V272, P141, DOI 10.1111/j.1432-1033.2004.04396.x; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Esposito DL, 2003, J CLIN ENDOCR METAB, V88, P1468, DOI 10.1210/jc.2002-020933; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Hribal ML, 2000, J CLIN ENDOCR METAB, V85, P2004, DOI 10.1210/jc.85.5.2004; Imai Y, 1997, J CLIN ENDOCR METAB, V82, P4201, DOI 10.1210/jc.82.12.4201; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Rondinone CM, 1999, DIABETOLOGIA, V42, P819, DOI 10.1007/s001250051232; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tremblay F, 2005, ENDOCRINOLOGY, V146, P1328, DOI 10.1210/en.2004-0777; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; Yoshimura R, 1997, DIABETES, V46, P929, DOI 10.2337/diabetes.46.6.929; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	36	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34389	34392		10.1074/jbc.C500230200	http://dx.doi.org/10.1074/jbc.C500230200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16129690	hybrid			2022-12-25	WOS:000232403900003
J	Bose, S; Morgan, LJ; Booth, DR; Goudie, DR; Ferguson-Smith, MA; Richards, FM				Bose, S; Morgan, LJ; Booth, DR; Goudie, DR; Ferguson-Smith, MA; Richards, FM			The elusive multiple self-healing squamous epithelioma (MSSE) gene: further mapping, analysis of candidates, and loss of heterozygosity	ONCOGENE			English	Article						skin cancer; tumour suppressor gene; chromosome 9q22.3; CDC14B; MSSE	ANEMIA GROUP-C; CELL CARCINOMA; HUMAN GENOME; CHROMOSOMAL LOCALIZATION; HUMAN HOMOLOG; HUMAN CDNA; REGION; 9Q22.3; CANCER; MAPS	The MSSE gene predisposes to multiple invasive but self-healing skin tumours ( multiple self-healing epitheliomata). MSSE was previously mapped to chromosome 9q22-q31 and a shared haplotype in affected families suggested a founder mutation. We have refined the MSSE critical region (< 1 cM, < 1 Mb) between the zinc-finger gene ZNF169 and the Fanconi anaemia gene FANCC. By genetic mapping we have excluded ZNF169 and FANCC as well as PTCH (PATCHED) and TGFBR1 ( transforming growth factor beta receptor type-1) genes. The CDC14B cell cycle phosphatase gene also lies in the region but screening of the complete coding region revealed no mutation in MSSE patients. Somatic cell hybrids created by haploid conversion of an MSSE patient's cells enabled screening of the MSSE chromosome 9 and showed no CDC14B deletion or mutation that abrogates CDC14B mRNA expression. Thus, CDC14B is unlikely to be the MSSE gene. We also report the first molecular analysis of MSSE tumours showing loss of heterozygosity of the MSSE region, with loss of the normal allele, providing the first evidence that MSSE is a tumour suppressor gene.	Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham, W Midlands, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Ninewells Hosp & Med Sch, Dept Pathol, Dundee, Scotland; Univ Cambridge, Dept Vet Clin Med, Cambridge, England	University of Birmingham; University of Cambridge; University of Dundee; University of Cambridge	Richards, FM (corresponding author), Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	fran.richards@daniolabs.com		Booth, Daniel/0000-0001-6231-5911				Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Byrom J, 2004, INT J ONCOL, V24, P1271; Chadwick BP, 1998, GENOMICS, V47, P58, DOI 10.1006/geno.1997.5084; Chadwick BP, 1997, GENOMICS, V41, P390, DOI 10.1006/geno.1997.4692; Chatterjee TK, 1997, GENOMICS, V45, P429, DOI 10.1006/geno.1997.4929; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P250, DOI 10.1159/000134349; Eichler EE, 2004, NAT REV GENET, V5, P345, DOI 10.1038/nrg1322; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gong YQ, 1999, AM J HUM GENET, V64, P570, DOI 10.1086/302249; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; Jorgenson E, 2005, AM J HUM GENET, V76, P276, DOI 10.1086/427926; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405; Levanat S, 1997, CYTOGENET CELL GENET, V76, P208, DOI 10.1159/000134551; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Martignetti JA, 2000, GENE CHROMOSOME CANC, V27, P191, DOI 10.1002/(SICI)1098-2264(200002)27:2<191::AID-GCC11>3.0.CO;2-L; Nishiu J, 1998, GENOMICS, V52, P378, DOI 10.1006/geno.1998.5455; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Richards FM, 1997, HUM GENET, V101, P317, DOI 10.1007/s004390050635; Savoia A, 1996, MOL CELL PROBE, V10, P213, DOI 10.1006/mcpr.1996.0029; SLAUGENHAUPT SA, 1995, GENOMICS, V25, P730, DOI 10.1016/0888-7543(95)80019-I; Suzuki M, 1999, J HUM GENET, V44, P300, DOI 10.1007/s100380050164; WICKING C, 1995, CYTOGENET CELL GENET, V68, P119, DOI 10.1159/000133904; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	31	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					806	812		10.1038/sj.onc.1209092	http://dx.doi.org/10.1038/sj.onc.1209092			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16170343				2022-12-25	WOS:000235068800015
J	Chen, A; Xu, J; Johnson, AC				Chen, A; Xu, J; Johnson, AC			Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1	ONCOGENE			English	Article						colon cancer; receptors; phyto-chemical; gene expression; chemo-prevention	NF-KAPPA-B; SERUM RESPONSE ELEMENTS; TERNARY COMPLEX FACTORS; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION; MALIGNANCIES; CONTRIBUTES; INDUCTION; APOPTOSIS	High expression of epidermal growth factor receptor (EGFR) is found in a variety of solid tumors, including colorectal cancer. EGFR has been identified as a rational target for anticancer therapy. Curcumin, the yellow pigment of turmeric in curry, has received attention as a promising dietary supplement for cancer prevention and treatment. We recently reported that curcumin inhibited the growth of human colon cancer-derived Moser cells by suppressing gene expression of cyclinD1 and EGFR. The aim of the present study was to explore the molecular mechanisms underlying curcumin inhibition of gene expression of EGFR in colon cancer cells. The generality of the inhibitory effect of curcumin on gene expression of EGFR was verified in other human colon cancer-derived cell lines, including Caco-2 and HT-29 cells. Promoter deletion assays and site-directed mutageneses identified a binding site for the transcription factor early growth response-1 (Egr-1) in egfr promoter as a putative curcumin response element in regulating the promoter activity of the gene in Moser cells. Electrophoretic mobility shift assays demonstrated that curcumin significantly reduced the DNA-binding activity of the transcription factor Egr-1 to the curcumin response element. In addition, curcumin reduced the trans-activation activity of Egr-1 by suppressing egr-1 gene expression, which required interruption of the ERK signal pathway and reduction of the level of phosphorylation of Elk-1 and its activity. Taken together, our results demonstrated that curcumin inhibited human colon cancer cell growth by suppressing gene expression of EGFR through reducing the trans-activation activity of Egr-1. These results provided novel insights into the mechanisms of curcumin inhibition of colon cancer cell growth and potential therapeutic strategies for treatment of colon cancer.	Louisiana State Univ, HSC, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA USA; NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chen, A (corresponding author), Louisiana State Univ, HSC, Dept Pathol, BRI F8-20,1501 Kings Hwy, Shreveport, LA 71130 USA.	achen@lsuhsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047995] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47995] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Andrade AA, 2004, BIOCHEM J, V381, P437, DOI 10.1042/BJ20031375; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Baselga J, 2000, ANN ONCOL, V11, P187, DOI 10.1023/A:1011144502974; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chauhan DP, 2002, CURR PHARM DESIGN, V8, P1695, DOI 10.2174/1381612023394016; Chen AP, 2002, BIOCHEM J, V368, P695, DOI 10.1042/BJ20020894; Chen AP, 2005, AM J PHYSIOL-GASTR L, V288, pG447, DOI 10.1152/ajpgi.00209.2004; Chen AP, 2002, AM J PHYSIOL-GASTR L, V283, pG864, DOI 10.1152/ajpgi.00524.2001; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Chen CC, 2004, J CELL BIOCHEM, V93, P1063, DOI 10.1002/jcb.20257; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Giri RK, 2004, J NEUROCHEM, V91, P1199, DOI 10.1111/j.1471-4159.2004.02800.x; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Harja E, 2004, CIRC RES, V94, P333, DOI 10.1161/01.RES.0000112405.61577.95; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jobin C, 1999, J IMMUNOL, V163, P3474; Kamimura M, 2004, HYPERTENSION, V44, P944, DOI 10.1161/01.HYP.0000146908.75091.99; LEVINE AE, 1985, CANCER RES, V45, P2248; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Mohandas K M, 1999, Indian J Gastroenterol, V18, P118; Nishi H, 2002, CANCER RES, V62, P827; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; Pendurthi UR, 2000, THROMB RES, V97, P179, DOI 10.1016/S0049-3848(99)00148-6; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rowinsky E, 2000, DRUGS, V60, P41; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schaefer A, 2004, CELL SIGNAL, V16, P223, DOI 10.1016/j.cellsig.2003.07.001; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Xu JY, 2003, AM J PHYSIOL-GASTR L, V285, pG20, DOI 10.1152/ajpgi.00474.2002; Zheng Liduan, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P55	48	217	231	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					278	287		10.1038/sj.onc.1209019	http://dx.doi.org/10.1038/sj.onc.1209019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170359				2022-12-25	WOS:000234583600012
J	Yemelyanov, A; Gasparian, A; Lindholm, P; Dang, L; Pierce, JW; Kisseljov, F; Karseladze, A; Budunova, I				Yemelyanov, A; Gasparian, A; Lindholm, P; Dang, L; Pierce, JW; Kisseljov, F; Karseladze, A; Budunova, I			Effects of IKK inhibitor PS1145 on NF-kappa B function, proliferation, apoptosis and invasion activity in prostate carcinoma cells	ONCOGENE			English	Article						prostate carcinoma; NF-kappa B; IKK; apoptosis; invasion	NECROSIS-FACTOR-ALPHA; CANCER CELLS; CONSTITUTIVE ACTIVATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; THERAPEUTIC TARGET; BINDING-SITES; TNF-ALPHA; IN-VITRO; KINASE	A key antiapoptotic transcription factor, nuclear factor kappa-B (NF-kappa B), is known to be critically important for tumor cell growth, angiogenesis and development of metastatic lesions. We and others showed previously that NF-kappa B transcription factor was constitutively activated in androgen- independent prostate carcinoma (PC) cell lines due to the upregulated activity of inhibitor of NF-kappa B kinases (IKK). In this work, using luciferase assay, electrophoretic mobility shift assay and Northern blot analysis of expression of endogenous kappa B-responsive genes, we demonstrate that a novel highly specific small-molecule IKK inhibitor, PS1145, efficiently inhibited both basal and induced NF-kappa B activity in PC cells. We found that PS1145 induced caspase 3/7-dependent apoptosis in PC cells and significantly sensitized PC cells to apoptosis induced by tumor necrosis factor alpha. We also showed that PS1145 inhibited PC cell proliferation. Effects of PS1145 on proliferation and apoptosis correlated with inhibition of interleukin (IL)- 6, cyclin D1, D2, inhibitor of apoptosis (IAP)-1 and IAP-2 gene expression and decreased IL-6 protein level. In addition, we found that incubation with PS1145 inhibited the invasion activity of highly invasive PC3-S cells in invasion chamber assay in a dose-dependent manner. Overall, this study provides the framework for development of a novel therapeutic approach targeting NF-kappa B transcription factor to treat advanced PC.	Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; NN Nlokhin Russian Canc Res Ctr, Moscow, Russia; Millennium Pharmaceut Inc, Cambridge, MA USA	Northwestern University; Feinberg School of Medicine; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Budunova, I (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i-budunova@northwestern.edu						Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Castro AC, 2003, BIOORG MED CHEM LETT, V13, P2419, DOI 10.1016/S0960-894X(03)00408-6; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Figueroa B, 2004, BIOTECHNOL BIOENG, V85, P589, DOI 10.1002/bit.10913; Gasparian AV, 2002, J CELL SCI, V115, P141; GASPARIAN AV, 2003, P AACR, V44, P1451; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, ANN RHEUM DIS, V63, P62, DOI 10.1136/ard.2004.028274; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lam LT, 2005, CLIN CANCER RES, V11, P28; Li L, 2005, PROSTATE CANCER P D, V8, P108, DOI 10.1038/sj.pcan.4500776; Lindholm PF, 2001, CLIN EXP METASTAS, V18, P471, DOI 10.1023/A:1011845725394; Lyakh LA, 2000, J IMMUNOL, V165, P3647, DOI 10.4049/jimmunol.165.7.3647; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Murata T, 2004, BIOORG MED CHEM LETT, V14, P4013, DOI 10.1016/j.bmcl.2004.05.040; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Peter Marcus E, 2004, Biochem J, V382, pe1; Rapp UR, 2004, BBA-MOL CELL RES, V1644, P149, DOI 10.1016/j.bbamcr.2003.10.015; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROSENBERG IM, 1996, BENCHTOP TECHNIQUES; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yasui H, 2003, ANN NY ACAD SCI, V1010, P273, DOI 10.1196/annals.1299.047; Zerbini LF, 2003, CANCER RES, V63, P2206; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	57	98	102	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					387	398		10.1038/sj.onc.1209066	http://dx.doi.org/10.1038/sj.onc.1209066			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170348				2022-12-25	WOS:000234714100007
J	Raulo, E; Tumova, S; Pavlov, I; Pekkanen, M; Hienola, A; Klankki, E; Kalkkinen, N; Taira, T; Kilpelainen, I; Rauvala, H				Raulo, E; Tumova, S; Pavlov, I; Pekkanen, M; Hienola, A; Klankki, E; Kalkkinen, N; Taira, T; Kilpelainen, I; Rauvala, H			The two thrombospondin type I repeat domains of the heparin-binding growth-associated molecule bind to heparin/heparan sulfate and regulate neurite extension and plasticity in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE ZETA/RPTP-BETA; LONG-TERM POTENTIATION; HB-GAM; N-SYNDECAN; CELL-SURFACE; BRAIN NEURONS; PROTEIN; OUTGROWTH; LTP; EXPRESSION	HB-GAM (heparin-binding growth-associated molecule, also designated as pleiotrophin) and midkine form a two-member family of extracellular matrix proteins that bind tightly to sulfated carbohydrate structures such as heparan sulfate. These proteins are used by developing neurons as extracellular cues in axonal growth and guidance. HB-GAM was recently reported to enhance differentiation of neural stem cells. Based on the solution structure of HB-GAM, we have recently shown that HB-GAM consists of two beta-sheet domains flanked by flexible lysine-rich N- and C-terminal tails with no apparent structure. These domains are homologous to thrombospondin type I repeats present in numerous extracellular proteins that interact with the cell surface. Our findings showed that the two beta-sheet domains fold independently. We showed that the domains (but not the lysine-rich tails) in HB-GAM are required and sufficient for interaction with hippocampal neurons. The individual domains bind heparan sulfate weakly and fail to produce significant biological effects in neurite outgrowth and long term potentiation assays. The amino acids in the linker region joining the two domains may be replaced with glycines with no effect on protein function. These results suggest a co-operative action of the two beta-sheet domains in the biologically relevant interaction with neuron surface heparan sulfate.	Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Chem, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Raulo, E (corresponding author), Univ Helsinki, Ctr Neurosci, Viikinkaari 4,POB 56, FIN-00014 Helsinki, Finland.	erkki.raulo@helsinki.fi; heikki.rauvala@helsinki.fi	Kalkkinen, Nisse EJ/B-3923-2010; Pavlov, Ivan/GVT-5113-2022; Tumova, Sarka/AAD-6353-2019; Pavlov, Ivan/B-5939-2008	Tumova, Sarka/0000-0003-2044-4998; Pavlov, Ivan/0000-0002-9559-4600; Pekkanen-Mattila, Mari/0000-0002-8621-4303; Ahonen-Bishopp, Anni/0000-0002-4215-6228; Raulo, Erkki/0000-0001-9113-3770; Pavlov, Ivan/0000-0003-1266-6988; Rauvala, Heikki/0000-0001-7809-9811				Adams JC, 2000, DEV DYNAM, V218, P280; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CAVANAGH J, PROTEIN NMR SPECTROS, P478; Fath M, 1999, FEBS LETT, V454, P105, DOI 10.1016/S0014-5793(99)00785-1; Hienola A, 2004, MOL CELL NEUROSCI, V26, P75, DOI 10.1016/j.mcn.2004.01.018; Imai S, 1998, J CELL BIOL, V143, P1113, DOI 10.1083/jcb.143.4.1113; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kaksonen M, 2002, MOL CELL NEUROSCI, V21, P158, DOI 10.1006/mcne.2002.1167; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; Kinnunen A, 1998, EUR J NEUROSCI, V10, P635, DOI 10.1046/j.1460-9568.1998.00082.x; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; Lauri SE, 1996, NEUROREPORT, V7, P1670, DOI 10.1097/00001756-199607080-00029; Lauri SE, 1999, J NEUROSCI, V19, P1226; Lauri SE, 1998, EUR J NEUROSCI, V10, P188; Lethias C, 2001, J BIOL CHEM, V276, P16432, DOI 10.1074/jbc.M010210200; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Munoz EM, 2004, ARTERIOSCL THROM VAS, V24, P1549, DOI 10.1161/01.ATV.0000137189.22999.3f; Pavlov I, 2002, MOL CELL NEUROSCI, V20, P330, DOI 10.1006/mcne.2002.1104; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; SIMMONS DL, 1993, CELLULAR INTERACTION, P93	33	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41576	41583		10.1074/jbc.M506457200	http://dx.doi.org/10.1074/jbc.M506457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	16155004	hybrid			2022-12-25	WOS:000233866900058
J	Syed, V; Zhang, X; Lau, KM; Cheng, R; Mukherjee, K; Ho, SM				Syed, V; Zhang, X; Lau, KM; Cheng, R; Mukherjee, K; Ho, SM			Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells	ONCOGENE			English	Article						erythrocyte adducin alpha subunit clone; 5.1 RNA-binding protein S1; nuclear protein SkiP; Rap-2 plexin A3; sex gene	HORMONE REPLACEMENT THERAPY; SUPPRESSES TUMOR-FORMATION; SKI-INTERACTING PROTEIN; MESSENGER-RNA; BREAST-CANCER; IN-VITRO; INDUCED APOPTOSIS; KINASE-C; RECEPTOR; GROWTH	Estrogens regulate normal ovarian surface epithelium (OSE) cell functions but also affect epithelial ovarian cancer (OCa) development. Little is known about how estrogens play such opposing roles. Transcriptional pro. ling using a cDNA microarray containing 2400 named genes identified 155 genes whose expression was altered by estradiol-17 beta (E2) in three immortalized normal human ovarian surface epithelial (HOSE) cell lines and 315 genes whose expression was affected by the hormone in three established OCa (OVCA) cell lines. All but 19 of the genes in these two sets were different. Among the 19 overlapping genes, five were found to show discordant responses between HOSE and OVCA cell lines. The five genes are those that encode clone 5.1 RNA-binding protein (RNPS1), erythrocyte adducin a subunit (ADD1), plexin A3 (PLXNA3 or the SEX gene), nuclear protein SkiP (SKIIP), and Rap-2 (rap-2). RNPS1, ADD1, rap-2, and SKIIP were upregulated by E2 in HOSE cells but downregulated by estrogen in OVCA cells, whereas PLXNA3 showed the reverse pattern of regulation. The estrogen effects was observed within 6 18 h of treatment. In silicon analyses revealed presence of estrogen response elements in the proximal promoters of all five genes. RNPS1, ADD1, and PLXNA3 were underexpressed in OVCA cell lines compared to HOSE cell lines, while the opposite was true for rap-2 and SKIIP. Functional studies showed that RNPS1 and ADD1 exerted multiple antitumor actions in OVCA cells, while PLXNA3 only inhibited cell invasiveness. In contrast, rap-2 was found to cause significant oncogenic effects in OVCA cells, while SKIIP promotes only anchorage-independent growth. In sum, gene pro. ling data reveal that (1) E2 exerts different actions on HOSE cells than on OVCA cells by affecting two distinct transcriptomes with few overlapping genes and (2) among the overlapping genes, a set of putative oncogenes/tumor suppressors have been identified due to their differential responses to E2 between the two cell types. These findings may explain the paradoxical roles of estrogens in regulating normal and malignant OSE cell functions.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Room 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-Mei.Ho@umassmed.edu	Zhang, Xiang/D-3632-2009; Cheng, Robert/E-9799-2013	Cheng, Robert/0000-0003-0287-6439; Lau, Kin-Mang/0000-0001-5888-1937	NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA94221, CA091250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AACR, 2005, STAT; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Badolato J, 1995, GENE, V166, P323, DOI 10.1016/0378-1119(95)00571-4; Bai WL, 2000, IN VITRO CELL DEV-AN, V36, P657; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Bardin A, 2004, CANCER RES, V64, P5861, DOI 10.1158/0008-5472.CAN-04-0552; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Birkenmeier CS, 2004, J PATHOL, V204, P450, DOI 10.1002/path.1636; Bowen SL, 2003, J PATHOL, V201, P119, DOI 10.1002/path.1389; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Folk P, 1996, GENE, V181, P229, DOI 10.1016/S0378-1119(96)00483-0; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; Gorringe KL, 2005, CARCINOGENESIS, V26, P923, DOI 10.1093/carcin/bgi032; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; Hough CD, 2001, CANCER RES, V61, P3869; JANOUEIXLEROSEY I, 1992, BIOCHEM BIOPH RES CO, V189, P455, DOI 10.1016/0006-291X(92)91580-J; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kim K, 2005, MOL ENDOCRINOL, V19, P843, DOI 10.1210/me.2004-0326; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; LANGDON SP, 1990, BRIT J CANCER, V62, P213, DOI 10.1038/bjc.1990.263; LANGDON SP, 1993, INT J CANCER, V55, P459, DOI 10.1002/ijc.2910550323; LANGDON SP, 1994, EUR J CANCER, V30A, P682, DOI 10.1016/0959-8049(94)90545-2; Lassus H, 2003, GYNECOL ONCOL, V91, P504, DOI 10.1016/j.ygyno.2003.08.034; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lau KM, 2003, LAB INVEST, V83, P743, DOI 10.1097/01.LAB.0000069519.06988.24; Lee BC, 2004, INT J ONCOL, V24, P847; Leong GM, 2004, BIOCHEM BIOPH RES CO, V315, P1070, DOI 10.1016/j.bbrc.2004.02.004; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NASH JD, 1989, OBSTET GYNECOL, V73, P1009; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Okamura H, 2003, MOL CELL ENDOCRINOL, V202, P37, DOI 10.1016/S0303-7207(03)00060-1; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Prathapam T, 2002, NUCLEIC ACIDS RES, V30, P5261, DOI 10.1093/nar/gkf658; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Riman T, 2004, ACTA OBSTET GYN SCAN, V83, P783, DOI 10.1111/j.0001-6349.2004.00550.x; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Roche J, 2001, Clin Lung Cancer, V3, P145, DOI 10.3816/CLC.2001.n.026; RUNGE HM, 1986, EUR J CANCER CLIN ON, V22, P691, DOI 10.1016/0277-5379(86)90167-7; RUNGE HM, 1986, CANCER CHEMOTH PHARM, V16, P58; Sakamoto M, 2001, Hum Cell, V14, P305; Santin AD, 2004, BRIT J CANCER, V90, P1814, DOI 10.1038/sj.bjc.6601791; Simpson BJB, 1998, J STEROID BIOCHEM, V64, P137, DOI 10.1016/S0960-0760(97)00159-3; Sit ASY, 2002, GYNECOL ONCOL, V86, P118, DOI 10.1006/gyno.2002.6746; Song J, 2005, CANCER LETT, V220, P57, DOI 10.1016/j.canlet.2004.04.024; Stopper H, 2003, MUTAGENESIS, V18, P243, DOI 10.1093/mutage/18.3.243; Sugimura M, 2004, ONCOLOGY-BASEL, V66, P53, DOI 10.1159/000076335; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Taube M, 2002, INT J ONCOL, V20, P589; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tse C, 2002, CANCER RES, V62, P542; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Xiang RH, 2002, CANCER RES, V62, P2637; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	88	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8128	8143		10.1038/sj.onc.1208959	http://dx.doi.org/10.1038/sj.onc.1208959			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16116479				2022-12-25	WOS:000233809400005
J	Lee, DH; Jin, SG; Cai, S; Chen, Y; Pfeifer, GP; O'Connor, TR				Lee, DH; Jin, SG; Cai, S; Chen, Y; Pfeifer, GP; O'Connor, TR			Repair of methylation damage in DNA and RNA by mammalian AlkB homologues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALKYLATION DAMAGE; OXIDATIVE DEMETHYLATION; MOLECULAR-CLONING; ABASIC SITES; ENZYME ALKB; PROTEIN; GLYCOSYLASE; DIOXYGENASE; BACTERIAL	Human and Escherichia coli derivatives of AlkB enzymes remove methyl groups from 1-methyladenine and 3-methylcytosine in nucleic acids via an oxidative mechanism that releases the methyl group as formaldehyde. In this report, we demonstrate that the mouse homologues of the alpha-ketoglutarate Fe( II) oxygen-dependent enzymes mAbh2 and Abh3 have activities comparable to those of their human counterparts. The mAbh2 and mAbh3 release modified bases from both DNA and RNA. Comparison of the activities of the homogenous ABH2 and ABH3 enzymes demonstrate that these activities are shared by both sets of enzymes. An assay for the detection of alpha-ketoglutarate Fe( II) dioxygenase activity using an oligode-oxyribonucleotide with a unique modification shows activity for all four enzymes studied and a loss of activity for eight mutant proteins. Steady-state kinetics for removal of methyl groups from DNA substrates indicates that the reactions of the proteins are close to the diffusion limit. Moreover, mAbh2 or mAbh3 activity increases survival in a strain defective in alkB. The mRNAs of AHB2 and ABH3 are expressed most in testis for ABH2 and ABH3, whereas expression of the homologous mouse genes is different. The mAbh3 is strongly expressed in testis, whereas highest expression of mAbh2 is in heart. Other purified human AlkB homologue proteins ABH4, ABH6, and ABH7 do not manifest activity. The demonstration of mAbh2 and mAbh3 activities and their distributions provide data on these mammalian homologues of AlkB that can be used in animal studies.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	O'Connor, TR (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	toconnor@coh.org		O'Connor, Timothy/0000-0001-5848-3592; Jin, Seung-Gi/0000-0001-5041-0559				Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; ARAVIND L, 2001, GENOME BIOL, V2, DOI DOI 10.1186/gb-2001-2-3-research0007; Begley TJ, 2003, TRENDS BIOCHEM SCI, V28, P2, DOI 10.1016/S0968-0004(02)00010-5; Bellacosa A, 2003, CURR BIOL, V13, pR482, DOI 10.1016/S0960-9822(03)00408-1; Castaing B, 1999, NUCLEIC ACIDS RES, V27, P608, DOI 10.1093/nar/27.2.608; CHEN BRJ, 1994, J BACTERIOL, V176, P6255, DOI 10.1128/jb.176.20.6255-6261.1994; Delaney JC, 2004, P NATL ACAD SCI USA, V101, P14051, DOI 10.1073/pnas.0403489101; Dinglay S, 1998, MUTAT RES-DNA REPAIR, V407, P109, DOI 10.1016/S0921-8777(97)00065-7; Dinglay S, 2000, GENE DEV, V14, P2097; Drablos F, 2004, DNA REPAIR, V3, P1389, DOI 10.1016/j.dnarep.2004.05.004; Duncan T, 2002, P NATL ACAD SCI USA, V99, P16660, DOI 10.1073/pnas.262589799; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Falnes PO, 2004, NUCLEIC ACIDS RES, V32, P3456, DOI 10.1093/nar/gkh655; Henshaw TF, 2004, J INORG BIOCHEM, V98, P856, DOI 10.1016/j.jinorgbio.2003.10.021; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; KATAOKA H, 1985, MOL GEN GENET, V198, P263, DOI 10.1007/BF00383004; KLEIN S, 1992, ANAL BIOCHEM, V205, P294, DOI 10.1016/0003-2697(92)90438-D; Koivisto P, 2004, J BIOL CHEM, V279, P40470, DOI 10.1074/jbc.M407960200; Koivisto P, 2003, J BIOL CHEM, V278, P44348, DOI 10.1074/jbc.M307361200; KONDO H, 1986, J BIOL CHEM, V261, P5772; Kreklau EL, 2001, NUCLEIC ACIDS RES, V29, P2558, DOI 10.1093/nar/29.12.2558; Kurowski MA, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-48; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LAWLEY PD, 1971, BIOCHEM J, V122, pP22, DOI 10.1042/bj1220022Pb; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; Margison G, 2002, DNA REPAIR, V1, P1057, DOI 10.1016/S1568-7864(02)00169-6; MARGISON GP, 1979, CHEM CARCINOGENESIS, V1; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; Mishina Y, 2004, NUCLEIC ACIDS RES, V32, P1548, DOI 10.1093/nar/gkh319; Muller I, 2005, J BIOL CHEM, V280, P5716, DOI 10.1074/jbc.M410840200; Ougland R, 2004, MOL CELL, V16, P107, DOI 10.1016/j.molcel.2004.09.002; Pope MA, 2005, DNA REPAIR, V4, P91, DOI 10.1016/j.dnarep.2004.08.004; Ryle MJ, 2003, P NATL ACAD SCI USA, V100, P3790, DOI 10.1073/pnas.0636740100; Ryle MJ, 2003, BIOCHEMISTRY-US, V42, P1854, DOI 10.1021/bi026832m; SAMSON L, 1986, P NATL ACAD SCI USA, V83, P5607, DOI 10.1073/pnas.83.15.5607; Sedgwick B, 2002, ONCOGENE, V21, P8886, DOI 10.1038/sj.onc.1205998; SHOOTER KV, 1977, CHEM-BIOL INTERACT, V19, P353, DOI 10.1016/0009-2797(77)90057-6; Singer B., 1983, MOL BIOL MUTAGENS CA; Steinacher R, 2005, CURR BIOL, V15, P616, DOI 10.1016/j.cub.2005.02.054; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; VOLKERT MR, 1989, J BACTERIOL, V171, P1196, DOI 10.1128/jb.171.2.1196-1198.1989; VOLKERT MR, 1988, ENVIRON MOL MUTAGEN, V11, P241, DOI 10.1002/em.2850110210; VOLKERT MR, 1989, MUTAT RES, V217, P109, DOI 10.1016/0921-8777(89)90062-1; Wei YF, 1996, NUCLEIC ACIDS RES, V24, P931, DOI 10.1093/nar/24.5.931; Welford RWD, 2003, J BIOL CHEM, V278, P10157, DOI 10.1074/jbc.M211058200; WILSON BD, 1994, CARCINOGENESIS, V15, P2143, DOI 10.1093/carcin/15.10.2143; Zharkov DO, 2002, DNA REPAIR, V1, P661, DOI 10.1016/S1568-7864(02)00074-5	47	109	117	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39448	39459		10.1074/jbc.M509881200	http://dx.doi.org/10.1074/jbc.M509881200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16174769	hybrid			2022-12-25	WOS:000233362200066
J	Lee, BH; Williams, IR; Anastasiadou, E; Boulton, CL; Joseph, SW; Amaral, SM; Curley, DP; Duclos, N; Huntly, BJP; Fabbro, D; Griffin, JD; Gilliland, DG				Lee, BH; Williams, IR; Anastasiadou, E; Boulton, CL; Joseph, SW; Amaral, SM; Curley, DP; Duclos, N; Huntly, BJP; Fabbro, D; Griffin, JD; Gilliland, DG			FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model	ONCOGENE			English	Article						FLT3 tyrosine kinase; transgenic; mouse; leukemia	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; HEMATOPOIETIC-CELLS; CONSTITUTIVE ACTIVATION; EXPRESSION; GENE; TRANSFORMATION; COMPARTMENT; PKC412; LIGAND	Activating FMS-like tyrosine kinase 3 (FLT3) mutations have been identified in similar to 30% of patients with acute myelogenous leukemia (AML), and recently in a smaller subset of patients with acute lymphoblastic leukemia (ALL). To explore the in vivo consequences of an activating FLT3 internal tandem duplication mutation (FLT3-ITD), we created a transgenic mouse model in which FLT3-ITD was expressed under the control of the vav hematopoietic promoter. Five independent lines of vavFLT3-ITD transgenic mice developed a myeloproliferative disease with high penetrance and a disease latency of 6-12 months. The phenotype was characterized by splenomegaly, megakaryocytic hyperplasia, and marked thrombocythemia, but without leukocytosis, polycythemia, or marrow fibrosis, displaying features reminiscent of the human disease essential thrombocythemia (ET). Clonal immature B- or T-lymphoid disease was observed in two additional founder mice, respectively, that could be secondarily transplanted to recipient mice that rapidly developed lymphoid disease. Treatment of these mice with the FLT3 tyrosine kinase inhibitor, PKC412, resulted in suppression of disease and a statistically significant prolongation of survival. These results demonstrate that FLT3-ITD is capable of inducing myeloproliferative as well as lymphoid disease, and indicate that small-molecule tyrosine kinase inhibitors may be an effective treatment for lymphoid malignancies in humans that are associated with activating mutations in FLT3.	Brigham & Womens Hosp, Div Hematol, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Novartis Pharma AG, Basel, Switzerland; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Emory University; Novartis; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Div Hematol, Dept Med, Childrens Hosp Res Bldg,1 Blackfan Circle,5th Flo, Boston, MA 02115 USA.	ggilliland@rics.bwh.harvard.edu	huntly, brian JP/E-6725-2014; Williams, Ifor R/D-3648-2011	huntly, brian JP/0000-0003-0312-161X; Williams, Ifor R/0000-0002-8810-2911	NCI NIH HHS [CA66996] Funding Source: Medline; NHLBI NIH HHS [5T32HL 07627-16] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P1076, DOI 10.1046/j.1365-2141.2001.02821.x; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; BRASEL K, 1995, LEUKEMIA, V9, P1212; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; DASILVA N, 1994, LEUKEMIA, V8, P885; DELAPEYRIERE O, 1995, DIFFERENTIATION, V58, P351, DOI 10.1046/j.1432-0436.1995.5850351.x; Drexler HG, 1996, LEUKEMIA, V10, P588; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Griffin JD, 2001, BLOOD, V97, P2193; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Ishii E, 1999, PEDIATR HEMAT ONCOL, V16, P437, DOI 10.1080/088800199276994; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MAROC N, 1993, ONCOGENE, V8, P909; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nakao M, 1996, LEUKEMIA, V10, P1911; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; Rosnet O, 1996, LEUKEMIA, V10, P238; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Turner AM, 1996, BLOOD, V88, P3383, DOI 10.1182/blood.V88.9.3383.bloodjournal8893383; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434	33	59	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7882	7892		10.1038/sj.onc.1208933	http://dx.doi.org/10.1038/sj.onc.1208933			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116483				2022-12-25	WOS:000233463000007
J	Bohl, CE; Miller, DD; Chen, JY; Bell, CE; Dalton, JT				Bohl, CE; Miller, DD; Chen, JY; Bell, CE; Dalton, JT			Structural basis for accommodation of nonsteroidal ligands in the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; PROSTATE-CANCER; WITHDRAWAL SYNDROME; NUCLEAR RECEPTOR; GENE-MUTATIONS; LNCAP CELLS; ANTAGONISM; BICALUTAMIDE; RECOGNITION; ACTIVATION	The mechanism by which the androgen receptor (AR) distinguishes between agonist and antagonist ligands is poorly understood. AR antagonists are currently used to treat prostate cancer. However, mutations commonly develop in patients that convert these compounds to agonists. Recently, our laboratory discovered selective androgen receptor modulators, which structurally resemble the nonsteroidal AR antagonists bicalutamide and hydroxyflutamide but act as agonists for the androgen receptor in a tissue-selective manner. To investigate why subtle structural changes to both the ligand and the receptor (i.e. mutations) result in drastic changes in activity, we studied structure-activity relationships for nonsteroidal AR ligands through crystallography and site-directed mutagenesis, comparing bound conformations of R-bicalutamide, hydroxyflutamide, and two previously reported nonsteroidal androgens, S-1 and R-3. These studies provide the first crystallographic evidence of the mechanism by which nonsteroidal ligands interact with the wild type AR. We have shown that changes induced to the positions of Trp-741, Thr-877, and Met-895 allow for ligand accommodation within the AR binding pocket and that a water-mediated hydrogen bond to the backbone oxygen of Leu-873 and the ketone of hydroxyflutamide is present when bound to the T877A AR variant. Additionally, we demonstrated that R-bicalutamide stimulates transcriptional activation in AR harboring the M895T point mutation. As a whole, these studies provide critical new insight for receptor-based drug design of nonsteroidal AR agonists and antagonists.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA; Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center	Bell, CE (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	bell.489@osu.edu; dalton.1@osu.edu		Dalton, James T/0000-0002-3915-7326	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065227, R01DK059800] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK059800-06, R01 DK065227, R01 DK59800, R01 DK059800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balog A, 2004, BIOORG MED CHEM LETT, V14, P6107, DOI 10.1016/j.bmcl.2004.09.049; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Bohl CE, 2004, J MED CHEM, V47, P3765, DOI 10.1021/jm0499007; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Dalton JT, 1998, BIOCHEM BIOPH RES CO, V244, P1, DOI 10.1006/bbrc.1998.8209; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Gao WQ, 2004, ENDOCRINOLOGY, V145, P5420, DOI 10.1210/en.2004-0627; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hara T, 2003, CANCER RES, V63, P149; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Marhefka CA, 2004, J MED CHEM, V47, P993, DOI 10.1021/jm030336u; Marhefka CA, 2001, J MED CHEM, V44, P1729, DOI 10.1021/jm0005353; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; Negro-Vilar A, 1999, J CLIN ENDOCR METAB, V84, P3459, DOI 10.1210/jc.84.10.3459; Poujol N, 2000, J BIOL CHEM, V275, P24022, DOI 10.1074/jbc.M001999200; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Soderholm AA, 2005, J MED CHEM, V48, P917, DOI 10.1021/jm0495879; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Suzuki H, 1996, PROSTATE, V29, P153, DOI 10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Yin DH, 2003, MOL PHARMACOL, V63, P211, DOI 10.1124/mol.63.1.211	32	160	182	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37747	37754		10.1074/jbc.M507464200	http://dx.doi.org/10.1074/jbc.M507464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129672	Green Accepted, hybrid			2022-12-25	WOS:000233044500053
J	Gallagher, MJ; Shen, WZ; Song, LY; Macdonald, RL				Gallagher, MJ; Shen, WZ; Song, LY; Macdonald, RL			Endoplasmic reticulum retention and associated degradation of a GABA(A) receptor epilepsy mutation that inserts an aspartate in the M3 transmembrane segment of the alpha 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CELL-SURFACE EXPRESSION; INTERSUBUNIT CONTACTS; ALPHA-SUBUNITS; IDENTIFICATION; CURRENTS; RESIDUES; POSITION; MEDIATE; NEURONS	A GABA(A) receptor alpha 1 subunit epilepsy mutation (alpha 1(A322D)) introduces a negatively charged aspartate residue into the hydrophobic M3 transmembrane domain of the alpha 1 subunit. We reported previously that heterologous expression of alpha 1(A322D) beta 2 gamma 2 receptors in mammalian cells resulted in reduced total and surface alpha 1 subunit protein. Here we demonstrate the mechanism of this reduction. Total alpha 1(A322D) subunit protein was reduced relative to wild type protein by a similar amount when expressed alone ( 86 +/- 6%) or when coexpressed with beta 2 and gamma 2S subunits (78 +/- 6%), indicating an expression reduction prior to subunit oligomerization. In alpha 1 beta 2 gamma 2S receptors, endoglycosidase H deglycosylated only 26 +/- 5% of alpha 1 subunits, consistent with substantial protein maturation, but in alpha 1(A322D) beta 2 gamma 2S receptors, endoglycosidase H deglycosylated 91 +/- 4% of alpha 1(A322D) subunits, consistent with failure of protein maturation. To determine the cellular localization of wild type and mutant subunits, the alpha 1 subunit was tagged with yellow (alpha 1-YFP) or cyan (alpha 1-CFP) fluorescent protein. Confocal microscopic imaging demonstrated that 36 +/- 4% of alpha 1-YFP beta 2 gamma 2 but only 5 +/- 1% alpha 1(A322D)- YFP beta 2 gamma 2 colocalized with the plasma membrane, whereas the majority of the remaining receptors colocalized with the endoplasmic reticulum (55 +/- 4% alpha 1-YFP beta 2 gamma 2S, 86 +/- 3% alpha 1(A322D)-YFP). Heterozygous expression of alpha 1-CFP beta 2 gamma 2S and alpha 1(A322D)-YFP beta 2 gamma 2S or alpha 1-YFP beta 2 gamma 2S and alpha 1(A322D)CFP beta 2 gamma 2S receptors showed that membrane GABA(A) receptors contained primarily wild type alpha 1 subunits. These data demonstrate that the A322D mutation reduces alpha 1 subunit expression after translation, but before assembly, resulting in endoplasmic reticulum-associated degradation and membrane alpha 1 subunits that are almost exclusively wild type subunits.	Vanderbilt Univ, Dept Neurol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Gallagher, MJ (corresponding author), Vanderbilt Univ, Dept Neurol, 6140 Med Res Bldg 3,465 21st Ave S, Nashville, TN 37232 USA.	Martin.Gallagher@Vanderbilt.edu		Gallagher, Martin/0000-0002-3537-4200	NINDS NIH HHS [NS39479, NS33300, K08NS44257-01, K08 NS044257] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039479, R01NS033300, K08NS044257] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amaral MD, 2004, J MOL NEUROSCI, V23, P41, DOI 10.1385/JMN:23:1-2:041; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Bianchi MT, 2002, J NEUROSCI, V22, P5321; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Bolte S, 2004, J CELL SCI, V117, P943, DOI 10.1242/jcs.00920; BULLER AL, 1994, MOL PHARMACOL, V46, P858; Caputo GA, 2004, BIOCHEMISTRY-US, V43, P8794, DOI 10.1021/bi049696p; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connor JX, 1998, J BIOL CHEM, V273, P28906, DOI 10.1074/jbc.273.44.28906; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Dibbens LM, 2004, HUM MOL GENET, V13, P1315, DOI 10.1093/hmg/ddh146; Fisher JL, 2004, NEUROPHARMACOLOGY, V46, P629, DOI 10.1016/j.neuropharm.2003.11.015; Gallagher MJ, 2004, J NEUROSCI, V24, P5570, DOI 10.1523/JNEUROSCI.1301-04.2004; Genton P, 2001, ARCH NEUROL-CHICAGO, V58, P1487, DOI 10.1001/archneur.58.9.1487; Gorrie GH, 1997, J NEUROSCI, V17, P6587; Greenfield LJ, 1997, NEUROPHARMACOLOGY, V36, P63, DOI 10.1016/S0028-3908(96)00150-5; Gregersen N, 2000, J INHERIT METAB DIS, V23, P441, DOI 10.1023/A:1005663728291; Hales TG, 2005, MOL CELL NEUROSCI, V29, P120, DOI 10.1016/j.mcn.2005.01.002; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hinkle DJ, 2003, BIOTECHNIQUES, V35, P472; Hirsch C, 2004, BBA-MOL CELL RES, V1695, P215, DOI 10.1016/j.bbamcr.2004.10.006; Kang JQ, 2004, J NEUROSCI, V24, P8672, DOI 10.1523/JNEUROSCI.2717-04.2004; Kittler JT, 2000, MOL CELL NEUROSCI, V16, P440, DOI 10.1006/mcne.2000.0882; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; Kralic JE, 2002, J PHARMACOL EXP THER, V302, P1037, DOI 10.1124/jpet.102.036665; Kralic JE, 2002, NEUROPHARMACOLOGY, V43, P685, DOI 10.1016/S0028-3908(02)00174-0; Krampfl K, 2005, EUR J NEUROSCI, V22, P10, DOI 10.1111/j.1460-9568.2005.04168.x; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Matsuda S, 2004, EUR J NEUROSCI, V19, P1683, DOI 10.1111/j.1460-9568.2004.03307.x; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Sancar F, 2004, J BIOL CHEM, V279, P47034, DOI 10.1074/jbc.M403388200; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Tretter V, 1997, J NEUROSCI, V17, P2728; Vicini S, 2001, J NEUROSCI, V21, P3009, DOI 10.1523/JNEUROSCI.21-09-03009.2001	42	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37995	38004		10.1074/jbc.M508305200	http://dx.doi.org/10.1074/jbc.M508305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16123039	hybrid			2022-12-25	WOS:000233044500082
J	Noguchi, T; Takeda, K; Matsuzawa, A; Saegusa, K; Nakano, H; Gohda, J; Inoue, J; Ichijo, H				Noguchi, T; Takeda, K; Matsuzawa, A; Saegusa, K; Nakano, H; Gohda, J; Inoue, J; Ichijo, H			Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IKK ACTIVATION; DEFECTIVE INTERLEUKIN-1; INFLAMMATORY CASPASES; INTERACTING PROTEIN; HUMAN TRAF2; ASK1; COMPLEX; CD40; BETA	Apoptosis signal-regulating kinase 1 (ASK1) plays a pivotal role in oxidative stress-induced cell death. Reactive oxygen species disrupt the interaction of ASK1 with its cellular inhibitor thioredoxin and thereby activates ASK1. However, the precise mechanism by which ASK1 freed from thioredoxin undergoes oligomerization-dependent activation has not been fully elucidated. Here we show that endogenous ASK1 constitutively forms a high molecular mass complex including Trx ( similar to 1,500 - 2,000 kDa), which we designate ASK1 signalosome. Upon H2O2 treatment, the ASK1 signalosome forms a higher molecular mass complex at least in part because of the recruitment of tumor necrosis factor receptor-associated factor 2 (TRAF2) and TRAF6. Consistent with our previous findings that TRAF2 and TRAF6 activate ASK1, H2O2-induced ASK1 activation and cell death were strongly reduced in the cells derived from Traf2-/- and Traf6-/- mice. A novel signaling complex including TRAF2, TRAF6, and ASK1 may thus be the key component in oxidative stress-induced cell death.	Univ Tokyo, Japan Sci & Technol Corp,CREST, Grad Sch Pharmaceut Sci,Lab Cell Signalling, Bunkyo Ku, Tokyo 1130033, Japan; Ctr Excellence Program, Bunkyo Ku, Tokyo 1130033, Japan; Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Juntendo University; University of Tokyo	Ichijo, H (corresponding author), Univ Tokyo, Japan Sci & Technol Corp,CREST, Grad Sch Pharmaceut Sci,Lab Cell Signalling, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ichijo@mol.f.u-tokyo.ac.jp	Matsuzawa, Atsushi/GLU-1387-2022; Noguchi, Takuya/T-6767-2019	Noguchi, Takuya/0000-0001-6187-6645; Takeda, Kohsuke/0000-0002-8359-8399; Matsuzawa, Atsushi/0000-0001-8303-3905; Ichijo, Hidenori/0000-0002-5005-6438; Nakano, Hiroyasu/0000-0003-4843-1427				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chung JY, 2002, J CELL SCI, V115, P679; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gohda J, 2004, J IMMUNOL, V173, P2913, DOI 10.4049/jimmunol.173.5.2913; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	58	170	180	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37033	37040		10.1074/jbc.M506771200	http://dx.doi.org/10.1074/jbc.M506771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129676	hybrid			2022-12-25	WOS:000232901800061
J	Karginov, FV; Caruthers, JM; Hu, YX; McKay, DB; Uhlenbeck, OC				Karginov, FV; Caruthers, JM; Hu, YX; McKay, DB; Uhlenbeck, OC			YxiN is a modular protein combining a DEx(D)/(H) core and a specific RNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI DBPA; TERMINAL DOMAIN; BOX PROTEINS; HELICASE; RECOGNITION; INITIATION; MECHANISM; PRP16	DEx(D)/(H) proteins, typically described as RNA helicases, participate in rearrangement of RNA- RNA and possibly RNA- protein complexes in the cell. Aside from the conserved DEx(D)/(H) core, members of this protein family often contain N- and C- terminal extensions that are responsible for additional functions. The Bacillus subtilis DEx(D)/ (H)- box protein YxiN and its Escherichia coli ortholog DbpA contain an similar to 80 amino acid C- terminal extension that has been proposed to specifically interact with a region of 23 S ribosomal RNA including hairpin 92. In this study, the DEx(D)/(H)- box core and the C- terminal domain of YxiN were expressed and characterized as separate proteins. The isolated DEx(D)/(H)- box core, YxCat, had weak, nonspecific RNA binding activity and showed RNA- stimulated ATPase activity with a K-m( ATP) that resembled several nonspecific DEx(D)/(H) proteins. The isolated C- terminal domain, YxRBD, bound RNA with the high affinity and specificity seen with full-length YxiN. Thus, YxiN is a modular protein combining the activities of the YxCat and YxRBD domains. Footprinting of YxiN and YxRBD on a 172- nucleotide fragment of 23 S rRNA was used to identify the sites of interaction of the C- terminal and helicase domains with the RNA.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Northwestern University; Stanford University	Uhlenbeck, OC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	o-uhlenbeck@northwestern.edu						Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bizebard T, 2004, BIOCHEMISTRY-US, V43, P7857, DOI 10.1021/bi049852s; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Charollais J, 2004, NUCLEIC ACIDS RES, V32, P2751, DOI 10.1093/nar/gkh603; Diges CM, 2005, BIOCHEMISTRY-US, V44, P7903, DOI 10.1021/bi050033x; Diges CM, 2001, EMBO J, V20, P5503, DOI 10.1093/emboj/20.19.5503; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Karginov FV, 2004, NUCLEIC ACIDS RES, V32, P3028, DOI 10.1093/nar/gkh640; Kawaoka J, 2004, NAT STRUCT MOL BIOL, V11, P526, DOI 10.1038/nsmb771; Kossen K, 2002, J MOL BIOL, V324, P625, DOI 10.1016/S0022-2836(02)01140-3; Kossen K, 1999, NUCLEIC ACIDS RES, V27, P3811, DOI 10.1093/nar/27.19.3811; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; NICOL SM, 1995, P NATL ACAD SCI USA, V92, P11681, DOI 10.1073/pnas.92.25.11681; Paolini C, 2000, J GEN VIROL, V81, P1335, DOI 10.1099/0022-1317-81-5-1335; Polach KJ, 2002, BIOCHEMISTRY-US, V41, P3693, DOI 10.1021/bi012062n; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Tsu CA, 1998, BIOCHEMISTRY-US, V37, P16989, DOI 10.1021/bi981837y; Tsu CA, 2001, RNA, V7, P702, DOI 10.1017/S1355838201010135; Wang Y, 1998, RNA, V4, P1216, DOI 10.1017/S1355838298980992; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003	29	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35499	35505		10.1074/jbc.M506815200	http://dx.doi.org/10.1074/jbc.M506815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118224	hybrid			2022-12-25	WOS:000232561200050
J	Maul, B; Krause, W; Pankow, K; Becker, M; Gembardt, F; Alenina, N; Walther, T; Bader, M; Siems, WE				Maul, B; Krause, W; Pankow, K; Becker, M; Gembardt, F; Alenina, N; Walther, T; Bader, M; Siems, WE			Central angiotensin II controls alcohol consumption via its AT1 receptor	FASEB JOURNAL			English	Article						angiotensin; dopamine; alcohol; knockout mice; transgenic rats	BLOOD-PRESSURE; TRANSGENIC RATS; C57/BL10 MICE; BRAIN; GENE; PREFERENCE; ADDICTION; DOPAMINE; INJECTIONS; INHIBITORS	Pharmacological and genetic manipulations of the renin-angiotensin system (RAS) have been found to alter the voluntary consumption of alcohol. Here we characterize the role of central angiotensin II (Ang II) in alcohol intake first by using transgenic rats that express an antisense RNA against angiotensinogen and consequently have reduced Ang II levels exclusively in the central nervous system [TGR(ASrAOGEN)680]. These rats consumed markedly less alcohol in comparison to their wild-type controls. Second, Spirapril, an inhibitor of the angiotensin-converting enzyme ( ACE), which passes the blood-brain barrier, did not influence the alcohol consumption in the TGR(ASrAOGEN) 680, but it significantly reduced alcohol intake in wild-type rats. Studies in knockout mice indicated that the central effect of Ang II on alcohol consumption is mediated by the angiotensin receptor AT1 whereas the AT2 receptor and the bradykinin B2 receptor are not involved. Furthermore, the dopamine concentration in the ventral tegmental area (VTA) is markedly reduced in rats with low central Ang II, strengthening our hypothesis of a role of dopaminergic transmission in Ang II-controlled alcohol preference. Our results indicate that a distinct drug-mediated control of the central RAS could be a promising therapy for alcohol disease.	Inst Mol Pharmacol, Berlin, Germany; Erasmus MC, Dept Pharmacol, Rotterdam, Netherlands; Charite, Dept Cardiol, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Erasmus University Rotterdam; Erasmus MC; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Siems, WE (corresponding author), FMP, Robert Rossle Str 10, D-13125 Berlin, Germany.	siems@fmp-berlin.de	Gembardt, Florian/H-2360-2011; Bader, Michael/K-2124-2013	Gembardt, Florian/0000-0003-2739-345X; Becker, Matthias/0000-0001-9965-6648; Bader, Michael/0000-0003-4780-4164				Baltatu O, 2004, ACTA PHYSIOL SCAND, V181, P579, DOI 10.1111/j.1365-201X.2004.01333.x; Baltatu O, 2000, HYPERTENSION, V35, P409, DOI 10.1161/01.HYP.35.1.409; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; FITTS DA, 1993, PHARMACOL BIOCHEM BE, V45, P35, DOI 10.1016/0091-3057(93)90082-5; GRUPP LA, 1988, PHARMACOL BIOCHEM BE, V29, P479, DOI 10.1016/0091-3057(88)90007-X; GRUPP LA, 1993, NIAAA RES MONOGRAPH, V23, P37; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; Jenkins TA, 1996, ADV EXP MED BIOL, V396, P93; Kakinuma Y, 1997, NEUROSCI LETT, V232, P167, DOI 10.1016/S0304-3940(97)00605-8; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Little HJ, 1999, PSYCHOPHARMACOLOGY, V147, P182, DOI 10.1007/s002130051159; Maul J, 2001, FASEB J, V15, P1640, DOI 10.1096/fj.00-097fje; MENDELSOHN FAO, 1993, BRAIN RES, V613, P221; Monti J, 2001, AM J PHYSIOL-REG I, V280, pR233, DOI 10.1152/ajpregu.2001.280.1.R233; O'Callaghan MJ, 2002, PSYCHOPHARMACOLOGY, V160, P206, DOI 10.1007/s00213-001-0968-z; O'Callaghan MJ, 2002, PHARMACOL BIOCHEM BE, V72, P475, DOI 10.1016/S0091-3057(02)00717-7; Ogier M, 2003, HYPERTENSION, V42, P978, DOI 10.1161/01.HYP.0000094982.97568.65; Phillips TJ, 1998, NAT NEUROSCI, V1, P610, DOI 10.1038/2843; POPOV N, 1973, ACTA BIOL MED GER, V31, P51; Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002; ROBERTSON JM, 1993, PHARMACOL BIOCHEM BE, V46, P751, DOI 10.1016/0091-3057(93)90197-2; Schinke M, 1999, P NATL ACAD SCI USA, V96, P3975, DOI 10.1073/pnas.96.7.3975; Spanagel R, 2003, BEST PRACT RES CL GA, V17, P507, DOI 10.1016/S1521-6918(03)00031-3; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; SYBERTZ E J, 1987, Journal of Cardiovascular Pharmacology, V10, pS105; Takai S, 1996, LIFE SCI, V59, pPL331, DOI 10.1016/0024-3205(96)00527-9; Thorsell A, 2002, NEUROPEPTIDES, V36, P182, DOI 10.1054/npep.2002.0897; Tom B, 2002, BRIT J PHARMACOL, V137, P276, DOI 10.1038/sj.bjp.0704862; Tracy HA, 1997, ALCOHOL, V14, P511, DOI 10.1016/S0741-8329(97)00041-4; Vervoort VS, 2002, SCIENCE, V296, P2401; von Bohlen und Halbach O, 2001, REGUL PEPTIDES, V99, P209, DOI 10.1016/S0167-0115(01)00258-0; Walther T, 1999, BEHAV BRAIN RES, V100, P1, DOI 10.1016/S0166-4328(98)00078-3; Weisinger RS, 1999, PHYSIOL BEHAV, V67, P369, DOI 10.1016/S0031-9384(99)00085-2; Winkler A, 1998, BBA-MOL BASIS DIS, V1406, P219, DOI 10.1016/S0925-4439(97)00041-0; Wyss JM, 2003, CLIN EXP HYPERTENS, V25, P455, DOI 10.1081/CEH-120024988	40	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1474	1481		10.1096/fj.05-3742com	http://dx.doi.org/10.1096/fj.05-3742com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126915				2022-12-25	WOS:000232315700041
J	Weksler, BB; Subileau, EA; Perriere, N; Charneau, P; Holloway, K; Leveque, M; Tricoire-Leignel, H; Nicotra, A; Bourdoulous, S; Turowski, P; Male, DK; Roux, F; Greenwood, J; Romero, IA; Couraud, PO				Weksler, BB; Subileau, EA; Perriere, N; Charneau, P; Holloway, K; Leveque, M; Tricoire-Leignel, H; Nicotra, A; Bourdoulous, S; Turowski, P; Male, DK; Roux, F; Greenwood, J; Romero, IA; Couraud, PO			Blood-brain barrier-specific properties of a human adult brain endothelial cell line	FASEB JOURNAL			English	Article						drug permeability; cellular junctions; multidrug resistance; in vitro model	IN-VITRO MODEL; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; TIGHT JUNCTIONS; T-LYMPHOCYTES; EXPRESSION; TRANSPORT; PROTEIN; PERMEABILITY; MONOLAYERS	Establishment of a human model of the blood-brain barrier has proven to be a difficult goal. To accomplish this, normal human brain endothelial cells were transduced by lentiviral vectors incorporating human telomerase or SV40 T antigen. Among the many stable immortalized clones obtained by sequential limiting dilution cloning of the transduced cells, one was selected for expression of normal endothelial markers, including CD31, VE cadherin, and von Willebrand factor. This cell line, termed hCMEC/D3, showed a stable normal karyotype, maintained contact-inhibited monolayers in tissue culture, exhibited robust proliferation in response to endothelial growth factors, and formed capillary tubes in matrix but no colonies in soft agar. hCMEC/D3 cells expressed telomerase and grew indefinitely without phenotypic dedifferentiation. These cells expressed chemokine receptors, up-regulated adhesion molecules in response to inflammatory cytokines, and demonstrated blood-brain barrier characteristics, including tight junctional proteins and the capacity to actively exclude drugs. hCMEC/D3 are excellent candidates for studies of blood-brain barrier function, the responses of brain endothelium to inflammatory and infectious stimuli, and the interaction of brain endothelium with lymphocytes or tumor cells. Thus, hCMEC/D3 represents the first stable, fully characterized, well-differentiated human brain endothelial cell line and should serve as a widely usable research tool.	Univ Paris 05, INSERM, Inst Cochin, CNRS,UMR 8104, Paris, France; Open Univ, Dept Biol Sci, Milton Keynes, Bucks, England; Hop Fernand Widal, INSERM, Paris, France; UCL, Inst Ophthalmol, Div Cellular Therapy, London, England; Inst Pasteur, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Open University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Weksler, BB (corresponding author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.	babette@mail.med.cornell.edu; couraud@cochin.inserm.fr	Romero, Ignacio/A-7381-2008; Tricoire-Leignel, Hélène/ABG-2320-2020; CHARNEAU, Pierre/M-1565-2017	Tricoire-Leignel, Hélène/0000-0002-2881-2962; CHARNEAU, Pierre/0000-0003-1184-5773; Male, David/0000-0002-1242-3137; Leveque, Mathilde/0000-0003-1253-3798; Greenwood, John/0000-0003-4496-2984; Romero, Ignacio/0000-0002-0322-9180; Holloway, Courtney Jean/0000-0003-3661-1957	Multiple Sclerosis Society [675, 630] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society); Wellcome Trust(Wellcome TrustEuropean Commission)		Abbott NJ, 1995, NEW CONCEPTS OF A BLOOD-BRAIN BARRIER, P239; ABBOTT NJ, 1992, J CELL SCI, V103, P23; Allen JD, 2002, MOL CANCER THER, V1, P417; Andjelkovic AV, 2000, J NEUROCHEM, V75, P1898, DOI 10.1046/j.1471-4159.2000.0751898.x; Begley DJ, 2004, CURR PHARM DESIGN, V10, P1295, DOI 10.2174/1381612043384844; Berezowski V, 2004, BRAIN RES, V1018, P1, DOI 10.1016/j.brainres.2004.05.092; Berger O, 1999, MOL MED, V5, P795, DOI 10.1007/BF03401992; Bo L, 1996, J NEUROPATH EXP NEUR, V55, P1060, DOI 10.1097/00005072-199655100-00006; Callahan MK, 2004, J NEUROIMMUNOL, V153, P150, DOI 10.1016/j.jneuroim.2004.05.004; Cecchelli R, 1999, ADV DRUG DELIVER REV, V36, P165, DOI 10.1016/S0169-409X(98)00083-0; Cisternino S, 2004, PHARM RES-DORDR, V21, P1382, DOI 10.1023/B:PHAM.0000036911.49191.da; Cisternino S, 2003, PHARMACEUT RES, V20, P1607, DOI 10.1023/A:1026187301648; DEHOUCK MP, 1992, J NEUROCHEM, V58, P1790, DOI 10.1111/j.1471-4159.1992.tb10055.x; DOROVINIZIS K, 1991, LAB INVEST, V64, P425; Eisenblatter T, 2003, BRAIN RES, V971, P221, DOI 10.1016/S0006-8993(03)02401-6; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; FELLER N, 1995, BRIT J CANCER, V72, P543, DOI 10.1038/bjc.1995.371; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; Golden PL, 1999, BRAIN RES, V819, P143, DOI 10.1016/S0006-8993(98)01305-5; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Gu XL, 2003, INVEST OPHTH VIS SCI, V44, P3219, DOI 10.1167/ivos.02-0852; Gutmann H, 1999, DRUG METAB DISPOS, V27, P937; Hoheisel D, 1998, BIOCHEM BIOPH RES CO, V244, P312, DOI 10.1006/bbrc.1997.8051; JOO F, 1993, NEUROCHEM INT, V23, P499, DOI 10.1016/0197-0186(93)90098-P; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Omari KM, 2003, J NEUROIMMUNOL, V134, P166, DOI 10.1016/S0165-5728(02)00423-X; Perriere N, 2005, J NEUROCHEM, V93, P279, DOI 10.1111/j.1471-4159.2004.03020.x; Prieto P, 2004, ATLA-ALTERN LAB ANIM, V32, P37, DOI 10.1177/026119290403200107; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; Regina A, 1998, J NEUROCHEM, V71, P705; Rist RJ, 1997, BRAIN RES, V768, P10, DOI 10.1016/S0006-8993(97)00586-6; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Romero IA, 1997, BRAIN RES, V756, P133, DOI 10.1016/S0006-8993(97)00127-3; Romero IA, 2003, NEUROSCI LETT, V344, P112, DOI 10.1016/S0304-3940(03)00348-3; ROUX F, 1994, J CELL PHYSIOL, V159, P101, DOI 10.1002/jcp.1041590114; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4; Seetharaman S, 1998, J NEUROCHEM, V70, P1151, DOI 10.1046/j.1471-4159.1998.70031151.x; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; VANBREE JBMM, 1988, J PHARMACOL EXP THER, V247, P1233; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Wong D, 1999, J NEUROPATH EXP NEUR, V58, P138, DOI 10.1097/00005072-199902000-00004; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje	52	961	1005	5	107	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1872	+		10.1096/fj.04-3458fje	http://dx.doi.org/10.1096/fj.04-3458fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16141364	Bronze			2022-12-25	WOS:000232315700043
J	Duong, V; Licznar, A; Margueron, R; Boulle, N; Busson, M; Lacroix, M; Katzenellenbogen, BS; Cavailles, V; Lazennec, G				Duong, V; Licznar, A; Margueron, R; Boulle, N; Busson, M; Lacroix, M; Katzenellenbogen, BS; Cavailles, V; Lazennec, G			ER alpha and ER beta expression and transcriptional activity are differentially regulated by HDAC inhibitors	ONCOGENE			English	Article						estrogen receptor; histone deacetylase; breast cancer; transcription; proliferation	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITION; ANDROGEN RECEPTOR; CARCINOMA-CELLS; TRICHOSTATIN-A; PROLIFERATION; ACETYLATION; TRANSACTIVATION; ACTIVATION	The proliferative action of ER alpha largely accounts for the carcinogenic activity of estrogens. By contrast, recent data show that ER beta displays tumor-suppressor properties, thus supporting the interest to identify compounds that could increase its activity. Here, we show that histone deacetylase inhibitors (HDI) upregulated ER beta protein levels, whereas it decreased ER alpha expression. Part of this regulation took place at the mRNA level through a mechanism independent of de novo protein synthesis. In addition, we found that, in various cancer cells, the treatment with different HDI enhanced the ligand-dependent activity of ER beta more strongly than that of ER alpha. On the other hand, in MDA-MB231 and HeLa cells, the expression of ERs modified the transcriptional response to HDI. The use of deletion mutants of both receptors demonstrated that AF1 domain of the receptors was required. Finally, we show that ER beta expression led to a dramatic increased in the antiproliferative activity of HDI, which correlated with a modi. cation of the transcription of genes involved in cell cycle control by HDI. Altogether, these data demonstrate that the interference of ER beta and HDAC on the control of transcription and cell proliferation constitute a promising approach for cancer therapy.	INSERM, U540, F-34090 Montpellier, France; Hop Arnaud Villeneuve, Lab Biol Cellulaire & Hormonale, Montpellier, France; INRA, UMR 866, F-34060 Montpellier, France; Univ Illinois, Coll Med, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; INRAE; Universite de Montpellier; University of Illinois System; University of Illinois Urbana-Champaign	Cavailles, V (corresponding author), INSERM, U540, 60,Rue Navacelles, F-34090 Montpellier, France.	v.cavailles@montp.inserm.fr; lazennec@montp.inserm.fr	Cavailles, Vincent/Y-5379-2019; Lacroix, Matthieu/O-1928-2018; Margueron, Raphael F/B-9996-2015; cavailles, vincent/C-6277-2017	Cavailles, Vincent/0000-0002-7160-3074; Lacroix, Matthieu/0000-0002-1268-9058; Margueron, Raphael F/0000-0002-9093-7977; Lazennec, Gwendal/0000-0002-8522-1763	NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA018119, CA18119] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campbell-Thompson M, 2001, CANCER RES, V61, P632; Cheng J, 2004, FEBS LETT, V566, P169, DOI 10.1016/j.febslet.2004.04.025; Cheung E, 2003, EMBO J, V22, P600, DOI 10.1093/emboj/cdg037; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; de Cremoux P, 2002, BIOCHEM PHARMACOL, V64, P507, DOI 10.1016/S0006-2952(02)01187-5; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fajas L, 2003, ONCOGENE, V22, P4186, DOI 10.1038/sj.onc.1206530; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENDERSON BE, 1988, CANCER RES, V48, P246; Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031; Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Pujol P, 1998, CANCER RES, V58, P5367; Roger P, 2001, CANCER RES, V61, P2537; Ruh MF, 1999, ENDOCRINE, V11, P157, DOI 10.1385/ENDO:11:2:157; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; STANLEY F, 1984, J BIOL CHEM, V259, P9768; STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Yang XW, 2000, CANCER RES, V60, P6890	36	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1799	1806		10.1038/sj.onc.1209102	http://dx.doi.org/10.1038/sj.onc.1209102			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16158045	Green Submitted, Green Accepted			2022-12-25	WOS:000236013700011
J	Krystyniak, A; Garcia-Echeverria, C; Prigent, C; Ferrari, S				Krystyniak, A; Garcia-Echeverria, C; Prigent, C; Ferrari, S			Inhibition of Aurora A in response to DNA damage	ONCOGENE			English	Article						AurA; CDK1; DNA damage; mitosis; phosphorylation	ANAPHASE-PROMOTING COMPLEX; TUMOR AMPLIFIED KINASE; PROTEIN-KINASE; CENTROSOME AMPLIFICATION; MAMMALIAN-CELLS; PHOSPHORYLATION; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; CHECKPOINT	Mitotic kinases are the ultimate target of pathways sensing genotoxic damage and impinging on the cell cycle machinery. Here, we provide evidence that Aurora A (AurA) was inhibited upon generation of double-strand breaks in DNA. We demonstrate that AurA was not downstream of CDK1 and that inhibition of AurA and CDK1 by DNA damage occurred independently. Using a cell line functionally deficient in Chk2, a selective Chk1 inhibitor and siRNA to Chk1, we show that DNA-damage signals were delivered to AurA through a Chk1-dependent pathway. With regard to the molecular mechanism of AurA inhibition, we found that the point mutation Ser342 > Ala rendered AurA resistant to inhibition by DNA damage. By means of two distinct approaches we examined the impact of reconstitution of AurA activity in DNA-damaged cells: (i) transient expression of wild-type and Ser342 > Ala mutant, but not kinase-dead, AurA led to bypass of the DNA damage block; (ii) direct transduction of highly active wt-AurA into G2 arrested cells precisely after induction of DNA damage resulted in mitotic entry. We show that the mechanism through which AurA allowed entry into mitosis was reactivation of CDK1, thus indicating that AurA plays a key role upstream of CDK1. A model depicting the possible role of AurA at the onset of mitosis and upon DNA damage is presented.	Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; Novartis Pharmaceut, Dept Oncol, Basel, Switzerland; Univ Rennes 1, CNRS, UMR6061, Cell Cycle Grp, Rennes, France	University of Zurich; Novartis; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Ferrari, S (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	sferrari@imcr.unizh.ch	Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Maton G, 2003, J BIOL CHEM, V278, P21439, DOI 10.1074/jbc.M300811200; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	42	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					338	348		10.1038/sj.onc.1209056	http://dx.doi.org/10.1038/sj.onc.1209056			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158051				2022-12-25	WOS:000234714100002
J	Quaranta, MT; Spinello, I; Testa, U; Mariani, G; Diverio, D; Foa, R; Peschle, C; Labbaye, C				Quaranta, MT; Spinello, I; Testa, U; Mariani, G; Diverio, D; Foa, R; Peschle, C; Labbaye, C			PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells	ONCOGENE			English	Article						PLZF; VLA-4; mobilization; acute myeloid leukemia	ZINC-FINGER; HEMATOPOIETIC PROGENITORS; STEM-CELLS; PROTEIN; MOBILIZATION; DIFFERENTIATION; GENE; PROLIFERATION; FIBRONECTIN; INTERACTS	The promyelocytic leukemia zinc-finger protein (PLZF) is a transcriptional repressor. To investigate the role of PLZF in the regulation of cytoadhesion molecules involved in the mobilization of hemopoietic cells, we have analysed PLZF and very late antigen 4 ( VLA-4) expression in normal and leukemic cells. In hematopoiesis, we found a negative correlation between PLZF and VLA4 expression, except for the megakaryocytic lineage. In contrast, we observed a positive correlation between PLZF and VLA-4 expression in a panel of acute myeloid leukemia (AML) samples. In K562 cells expressing PLZF (K562-PLZF), we found that the expression of VLA-4 and c-kit was downmodulated. We have investigated the possibility for VLA-4 or the c-kit receptor to be direct target genes of PLZF in K562-PLZF cells and identified a PLZF DNA-binding site within the VLA-4 promoter. Furthermore, decrease in VLA-4 expression was associated with loss of adhesion on. bronectin-coated plates, which promotes drug-induced apoptosis of K562-PLZF cells. Our findings indicate that VLA-4 is a potential target gene of PLZF. However, in primary AMLs the control of PLZF on VLA-4 expression is lost. Altogether, we suggest that VLA-4 modulation by PLZF may represent an important step in the control of normal and leukemic cell mobilization.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	clabbaye@iss.it	SPINELLO, ISABELLA/J-8779-2016; Quaranta, Maria Teresa/AAC-2134-2019; Testa, Ugo/J-6472-2016; Labbaye, Catherine/J-9930-2016	Quaranta, Maria Teresa/0000-0002-5886-507X; Testa, Ugo/0000-0001-7900-8942; Labbaye, Catherine/0000-0003-1255-4396				Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chauchereau A, 2004, ONCOGENE, V23, P8777, DOI 10.1038/sj.onc.1208128; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Craddock CF, 1997, BLOOD, V90, P4779, DOI 10.1182/blood.V90.12.4779.4779_4779_4788; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gazitt Y, 2004, STEM CELLS, V22, P65, DOI 10.1634/stemcells.22-1-65; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; GUERRIERO R, 1995, BLOOD, V86, P3725, DOI 10.1182/blood.V86.10.3725.bloodjournal86103725; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mossuz P, 1997, BRIT J HAEMATOL, V98, P819, DOI 10.1046/j.1365-2141.1997.3013118.x; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Yuan Q, 1997, J EXP MED, V186, P313, DOI 10.1084/jem.186.2.313	31	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					399	408		10.1038/sj.onc.1209060	http://dx.doi.org/10.1038/sj.onc.1209060			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158049				2022-12-25	WOS:000234714100008
J	Bonner, ER; Cahoon, RE; Knapke, SM; Jez, JM				Bonner, ER; Cahoon, RE; Knapke, SM; Jez, JM			Molecular basis of cysteine biosynthesis in plants - Structural and functional analysis of O-acetylserine sulfhydrylase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CYTOSOLIC O-ACETYLSERINE(THIOL)LYASE GENE; SERINE ACETYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; CONFORMATIONAL-CHANGE; THREONINE SYNTHASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; THIOL LYASE; 3-DIMENSIONAL STRUCTURE	In plants, cysteine biosynthesis plays a central role in fixing inorganic sulfur from the environment and provides the only metabolic sulfide donor for the generation of methionine, glutathione, phytochelatins, iron-sulfur clusters, vitamin cofactors, and multiple secondary metabolites. O-Acetylserine sulfhydrylase (OASS) catalyzes the final step of cysteine biosynthesis, the pyridoxal 5'-phosphate (PLP)-dependent conversion of O-acetylserine into cysteine. Here we describe the 2.2 angstrom resolution crystal structure of OASS from Arabidopsis thaliana (AtOASS) and the 2.7 angstrom resolution structure of the AtOASS K46A mutant with PLP and methionine covalently linked as an external aldimine in the active site. Although the plant and bacterial OASS share a conserved set of amino acids for PLP binding, the structure of AtOASS reveals a difference from the bacterial enzyme in the positioning of an active site loop formed by residues 74 - 78 when methionine is bound. Site-directed mutagenesis, kinetic analysis, and ligand binding titrations probed the functional roles of active site residues. These experiments indicate that Asn(77) and Gln(147) are key amino acids for O-acetylserine binding and that Thr(74) and Ser(75) are involved in sulfur incorporation into cysteine. In addition, examination of the AtOASS structure and nearly 300 plant and bacterial OASS sequences suggest that the highly conserved beta 8A-beta 9A surface loop may be important for interaction with serine acetyltransferase, the other enzyme in cysteine biosynthesis. Initial protein-protein interaction experiments using AtOASS mutants targeted to this loop support this hypothesis.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Jez, JM (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jjez@danforthcenter.org						BARROSO C, 1995, FEBS LETT, V363, P1, DOI 10.1016/0014-5793(95)00255-8; Berkowitz O, 2002, J BIOL CHEM, V277, P30629, DOI 10.1074/jbc.M111632200; Bogdanova N, 1997, PLANT J, V11, P251, DOI 10.1046/j.1365-313X.1997.11020251.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Claus MT, 2005, BIOCHEMISTRY-US, V44, P8620, DOI 10.1021/bi050485+; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1977, ARCH BIOCHEM BIOPHYS, V178, P293, DOI 10.1016/0003-9861(77)90194-1; Daum S, 2003, BIOCHEMISTRY-US, V42, P106, DOI 10.1021/bi0268044; Dominguez-Solis JR, 2001, J BIOL CHEM, V276, P9297, DOI 10.1074/jbc.M009574200; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Garrido-Franco M, 2002, J BIOL CHEM, V277, P12396, DOI 10.1074/jbc.M108734200; HELL R, 1994, FEBS LETT, V351, P257, DOI 10.1016/0014-5793(94)00872-8; Hell R, 2001, CURR OPIN BIOTECH, V12, P161, DOI 10.1016/S0958-1669(00)00193-2; HRAZDINA G, 1992, ANNU REV PLANT PHYS, V43, P241, DOI 10.1146/annurev.pp.43.060192.001325; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; Huang B, 2005, J BACTERIOL, V187, P3201, DOI 10.1128/JB.187.9.3201-3205.2005; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1993, ACTA CRYSTALLOGR D, V49, P148; Jost R, 2000, GENE, V253, P237, DOI 10.1016/S0378-1119(00)00261-4; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; Leustek T, 2000, ANNU REV PLANT PHYS, V51, P141, DOI 10.1146/annurev.arplant.51.1.141; Leustek T, 1999, PLANT PHYSIOL, V120, P637, DOI 10.1104/pp.120.3.637; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; Mino K, 2000, BIOSCI BIOTECH BIOCH, V64, P1874, DOI 10.1271/bbb.64.1874; Noji M, 2001, PLANT PHYSIOL, V126, P973, DOI 10.1104/pp.126.3.973; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Omi R, 2003, J BIOL CHEM, V278, P46035, DOI 10.1074/jbc.M308065200; Rabeh WM, 2005, BIOCHEMISTRY-US, V44, P5541, DOI 10.1021/bi047479i; Rabeh WM, 2004, J BIOL CHEM, V279, P26803, DOI 10.1074/jbc.R400001200; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; Rolland N, 1996, EUR J BIOCHEM, V236, P272, DOI 10.1111/j.1432-1033.1996.00272.x; ROLLAND N, 1993, ARCH BIOCHEM BIOPHYS, V300, P213, DOI 10.1006/abbi.1993.1030; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; SAITO K, 1995, J BIOL CHEM, V270, P16321, DOI 10.1074/jbc.270.27.16321; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.104.046755; SAITO K, 1994, PLANT PHYSIOL, V106, P887, DOI 10.1104/pp.106.3.887; SAITO K, 1994, J BIOL CHEM, V269, P28187; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; Tai CH, 2001, ACCOUNTS CHEM RES, V34, P49, DOI 10.1021/ar990169l; Takahashi H, 1996, PLANT PHYSIOL, V112, P273, DOI 10.1104/pp.112.1.273; Thomazeau K, 2001, PROTEIN SCI, V10, P638, DOI 10.1110/ps.44301; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; Wirtz M, 2004, J EXP BOT, V55, P1785, DOI 10.1093/jxb/erh201; Wirtz M, 2001, EUR J BIOCHEM, V268, P686, DOI 10.1046/j.1432-1327.2001.01920.x; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o; Yamada T, 2003, BIOCHEMISTRY-US, V42, P12854, DOI 10.1021/bi035324p; Yao M, 2000, J BIOL CHEM, V275, P34557, DOI 10.1074/jbc.M004681200; Youssefian S, 2001, PLANT PHYSIOL, V126, P1001, DOI 10.1104/pp.126.3.1001	55	134	146	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38803	38813		10.1074/jbc.M505313200	http://dx.doi.org/10.1074/jbc.M505313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166087	hybrid			2022-12-25	WOS:000233239800082
J	Cheng, B; Shukla, S; Vasunilashorn, S; Mukhopadhyay, S; Tse-Dinh, YC				Cheng, B; Shukla, S; Vasunilashorn, S; Mukhopadhyay, S; Tse-Dinh, YC			Bacterial cell killing mediated by topoisomerase I DNA cleavage activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACILLI; P-BAD PROMOTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; STAPHYLOCOCCUS-AUREUS; TOPRIM DOMAIN; EXPRESSION; RESISTANCE; BINDING; MECHANISMS	DNA topoisomerases are important clinical targets for antibacterial and anticancer therapy. At least one type IA DNA topoisomerase can be found in every bacterium, making it a logical target for antibacterial agents that can convert the enzyme into poison by trapping its covalent complex with DNA. However, it has not been possible previously to observe the consequence of having such a stabilized covalent complex of bacterial topoisomerase I in vivo. We isolated a mutant of recombinant Yersinia pestis topoisomerase I that forms a stabilized covalent complex with DNA by screening for the ability to induce the SOS response in Escherichia coli. Overexpression of this mutant topoisomerase I resulted in bacterial cell death. From sequence analysis and site-directed mutagenesis, it was determined that a single amino acid substitution in the TOPRIM domain changing a strictly conserved glycine residue to serine in either the Y. pestis or E. coli topoisomerase I can result in a mutant enzyme that has the SOS-inducing and cell-killing properties. Analysis of the purified mutant enzymes showed that they have no relaxation activity but retain the ability to cleave DNA and form a covalent complex. These results demonstrate that perturbation of the active site region of bacterial topoisomerase I can result in stabilization of the covalent intermediate, with the in vivo consequence of bacterial cell death. Small molecules that induce similar perturbation in the enzyme-DNA complex should be candidates as leads for novel antibacterial agents.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Tse-Dinh, YC (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	yuk-ching_tse-dinh@nymc.edu		Mukhopadhyay, Somshuvra/0000-0002-3420-7830	NIGMS NIH HHS [R01 GM054226, R01 GM54226] Funding Source: Medline; NINDS NIH HHS [R03 NS050782] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS050782] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allemand F, 2005, NUCLEIC ACIDS RES, V33, P4368, DOI 10.1093/nar/gki752; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; BHRIAIN NN, 1993, MOL MICROBIOL, V7, P351; Canton R, 2003, CURR OPIN INFECT DIS, V16, P315, DOI 10.1097/00001432-200308000-00003; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng B, 2004, J BIOL CHEM, V279, P39207, DOI 10.1074/jbc.M405891200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; DEPEW RE, 1978, J BIOL CHEM, V253, P511; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; Gari E, 1996, MOL MICROBIOL, V21, P111, DOI 10.1046/j.1365-2958.1996.6221338.x; GUPTA M, 1994, J BIOL CHEM, V269, P573; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; Khlebnikov A, 2001, MICROBIOL-SGM, V147, P3241, DOI 10.1099/00221287-147-12-3241; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1979, J BIOL CHEM, V254, P1082; LIU TK, 2001, ANN REV PHARM TOXICO, V41, P53; Mathijssen RHJ, 2002, CURR CANCER DRUG TAR, V2, P103, DOI 10.2174/1568009023333890; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Nagaraja V, 2002, CURR PHARM DESIGN, V8, P1995, DOI 10.2174/1381612023393567; Neuhauser MM, 2003, JAMA-J AM MED ASSOC, V289, P885, DOI 10.1001/jama.289.7.885; Nitiss John L, 2002, Curr Opin Investig Drugs, V3, P1512; Noble CG, 2002, J MOL BIOL, V318, P361, DOI 10.1016/S0022-2836(02)00049-9; Podobnik M, 2000, J MOL BIOL, V300, P353, DOI 10.1006/jmbi.2000.3844; Qi HY, 1999, FEMS MICROBIOL LETT, V178, P141, DOI 10.1111/j.1574-6968.1999.tb13770.x; QIU L, 1999, P NATL ACAD SCI USA, V96, P881; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; Stevens DL, 2003, CURR OPIN INFECT DIS, V16, P189, DOI 10.1097/00001432-200306000-00001; Stewart N, 2005, MICROBIOL-SGM, V151, P2783, DOI 10.1099/mic.0.28022-0; Stupina VA, 2005, J BIOL CHEM, V280, P355, DOI 10.1074/jbc.M411924200; Takei M, 2001, ANTIMICROB AGENTS CH, V45, P3544, DOI 10.1128/AAC.45.12.3544-3547.2001; Tse-Dinh YC, 2000, J BACTERIOL, V182, P829, DOI 10.1128/JB.182.3.829-832.2000; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Zhu CX, 1997, J BIOL CHEM, V272, P16206, DOI 10.1074/jbc.272.26.16206; Zhu CX, 2000, J BIOL CHEM, V275, P5318, DOI 10.1074/jbc.275.8.5318; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898	38	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38489	38495		10.1074/jbc.M509722200	http://dx.doi.org/10.1074/jbc.M509722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159875	Green Accepted, hybrid			2022-12-25	WOS:000233239800046
J	Chi, SW; Lee, SH; Kim, DH; Ahn, MJ; Kim, JS; Woo, JY; Torizawa, T; Kainosho, M; Han, KH				Chi, SW; Lee, SH; Kim, DH; Ahn, MJ; Kim, JS; Woo, JY; Torizawa, T; Kainosho, M; Han, KH			Structural details on mdm2-p53 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TUMOR-SUPPRESSOR; INTRINSICALLY UNSTRUCTURED PROTEINS; TRANSACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATOR; UNFOLDED PROTEINS; CRYSTAL-STRUCTURE; DNA-DAMAGE; PHOSPHORYLATION; BINDING; RECOGNITION	Mdm2 is a cellular antagonist of p53 that keeps a balanced cellular level of p53. The two proteins are linked by a negative regulatory feedback loop and physically bind to each other via a putative helix formed by residues 18 - 26 of p53 transactivation domain (TAD) and its binding pocket located within the N-terminal 100-residue domain of mdm2 (Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. ( 1996) Science 274, 948 - 953). In a previous report we demonstrated that p53 TAD in the mdm2-freee state is mostly unstructured but contains two nascent turns in addition to a "preformed" helix that is the same as the putative helix mediating p53-mdm2 binding. Here, using heteronuclear multidimensional NMR methods, we show that the two nascent turn motifs in p53 TAD, turn I ( residues 40 - 45) and turn II ( residues 49 - 54), are also capable of binding to mdm2. In particular, the turn II motif has a higher mdm2 binding affinity ( similar to 20 mu M) than the turn I and targets the same site in mdm2 as the helix. Upon mdm2 binding this motif becomes a well defined full helix turn whose hydrophobic face formed by the side chains of Ile-50, Trp-53, and Phe-54 inserts deeply into the helix binding pocket. Our results suggest that p53-mdm2 binding is subtler than previously thought and involves global contacts such as multiple "non-contiguous" minimally structured motifs instead of being localized to one small helix mini-domain in p53 TAD.	Korea Res Inst Biosci & Biotechnol, Div Drug Discovery, Prot Anal & Design Lab, Taejon 305600, South Korea; Tokyo Metropolitan Univ, JST, CREST, Tokyo 1920397, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Tokyo 1920397, Japan	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Japan Science & Technology Agency (JST); Tokyo Metropolitan University; Tokyo Metropolitan University	Han, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Div Drug Discovery, Prot Anal & Design Lab, Yusong POB 115, Taejon 305600, South Korea.	khhan600@kribb.re.kr						Acevedo ML, 2004, MOL CELL, V13, P725, DOI 10.1016/S1097-2765(04)00121-2; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Dafforn TR, 2004, EMBO REP, V5, P1046, DOI 10.1038/sj.embor.7400276; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; Dunker A K, 2000, Genome Inform Ser Workshop Genome Inform, V11, P161; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dyson HJ, 2002, ADV PROTEIN CHEM, V62, P311; Fuxreiter M, 2004, J MOL BIOL, V338, P1015, DOI 10.1016/j.jmb.2004.03.017; Garcia-Echeverria C, 2000, J MED CHEM, V43, P3205, DOI 10.1021/jm990966p; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Jabbur JR, 2002, ONCOGENE, V21, P7100, DOI 10.1038/sj.onc.1205856; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kumar R, 2003, MOL ENDOCRINOL, V17, P1, DOI 10.1210/me.2002-0258; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Martin K, 1995, J CELL SCI, P91; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Mucsi Z, 2003, PROTEIN SCI, V12, P2327, DOI 10.1110/ps.03138803; PAKER D, 1999, MOL CELL BIOL, V19, P5601; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Schon O, 2004, J MOL BIOL, V336, P197, DOI 10.1016/j.jmb.2003.11.051; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stoll R, 2001, BIOCHEMISTRY-US, V40, P336, DOI 10.1021/bi000930v; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vise PD, 2005, NUCLEIC ACIDS RES, V33, P2061, DOI 10.1093/nar/gki336; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Zitzewitz JA, 2000, J MOL BIOL, V296, P1105, DOI 10.1006/jmbi.2000.3507	44	118	120	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38795	38802		10.1074/jbc.M508578200	http://dx.doi.org/10.1074/jbc.M508578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159876	hybrid			2022-12-25	WOS:000233239800081
J	Leger-Silvestre, I; Caffrey, JM; Dawaliby, R; Alvarez-Arias, DA; Gas, N; Bertolone, SJ; Gleizes, PE; Ellis, SR				Leger-Silvestre, I; Caffrey, JM; Dawaliby, R; Alvarez-Arias, DA; Gas, N; Bertolone, SJ; Gleizes, PE; Ellis, SR			Specific role for yeast homologs of the diamond blackfan anemia-associated Rps19 protein in ribosome synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P40/LAMININ RECEPTOR PRECURSOR; SACCHAROMYCES-CEREVISIAE; PRE-RIBOSOMES; S19 GENE; RNA; MUTATIONS; MATURATION; SUBUNIT; PRERIBOSOMES; U3	Approximately 25% of cases of Diamond Blackfan anemia, a severe hypoplastic anemia, are linked to heterozygous mutations in the gene encoding ribosomal protein S19 that result in haploinsufficiency for this protein. Here we show that deletion of either of the two genes encoding Rps19 in yeast severely affects the production of 40 S ribosomal subunits. Rps19 is an essential protein that is strictly required for maturation of the 3'-end of 18 S rRNA. Depletion of Rps19 results in the accumulation of aberrant pre-40 S particles retained in the nucleus that fail to associate with pre-ribosomal factors involved in late maturation steps, including Enp1, Tsr1, and Rio2. When introduced in yeast Rps19, amino acid substitutions found in Diamond Blackfan anemia patients induce defects in the processing of the pre-rRNA similar to those observed in cells under-expressing Rps19. These results uncover a pivotal role of Rps19 in the assembly and maturation of the pre-40 S particles and demonstrate for the first time the effect of Diamond Blackfan anemia-associated mutations on the function of Rps19, strongly connecting the pathology to ribosome biogenesis.	CNRS, Lab Biol Mol Eucaryotes, UMR5099, F-31062 Toulouse, France; CNRS, Inst Explorat Fonct Genomes, IFR109, F-31062 Toulouse, France; Univ Toulouse 3, F-31062 Toulouse, France; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Chem, Louisville, KY 40292 USA; Univ Louisville, Dept Pediat, Louisville, KY 40292 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Louisville; University of Louisville; University of Louisville	Gleizes, PE (corresponding author), CNRS, Lab Biol Mol Eucaryotes, UMR5099, 118 Route Narbonne, F-31062 Toulouse, France.	gleizes@ibcg.biotoul.fr; srellis@louisville.edu	LEGER-SILVESTRE, Isabelle/C-8982-2013; Gleizes, Pierre-Emmanuel/ABB-9653-2021; Gleizes, Pierre-Emmanuel/H-3821-2014	Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Dawaliby, Rosie/0000-0001-7476-0350				BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BaudinBaillieu A, 1997, MOL CELL BIOL, V17, P5023, DOI 10.1128/MCB.17.9.5023; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; Chen WD, 2003, NUCLEIC ACIDS RES, V31, P690, DOI 10.1093/nar/gkg145; Demianova M, 1996, J BIOL CHEM, V271, P11383, DOI 10.1074/jbc.271.19.11383; Dez C, 2002, MOL CELL BIOL, V22, P7053, DOI 10.1128/MCB.22.20.7053-7065.2002; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Ford CL, 1999, CANCER RES, V59, P704; Freedman MH, 2000, BEST PRACT RES CL HA, V13, P391, DOI 10.1053/beha.2000.0084; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Gazda HT, 2004, BRIT J HAEMATOL, V127, P105, DOI 10.1111/j.1365-2141.2004.05152.x; Gleizes PE, 2001, J CELL BIOL, V155, P923, DOI 10.1083/jcb.200108142; Jakovljevic J, 2004, MOL CELL, V14, P331, DOI 10.1016/S1097-2765(04)00215-1; Leger-Silvestre I, 2004, EMBO J, V23, P2336, DOI 10.1038/sj.emboj.7600252; Matsson H, 2004, MOL CELL BIOL, V24, P4032, DOI 10.1128/MCB.24.9.4032-4037.2004; Milkereit P, 2003, NUCLEIC ACIDS RES, V31, P799, DOI 10.1093/nar/gkg165; Mochizuki Y, 2004, P NATL ACAD SCI USA, V101, P10756, DOI 10.1073/pnas.0402560101; NOMURA M, 1990, RIBOSOME, P3; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Roberts P, 2003, MOL BIOL CELL, V14, P129, DOI 10.1091/mbc.E02-08-0483; Rothbaum R, 2002, J PEDIATR-US, V141, P266, DOI 10.1067/mpd.2002.125850; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHERMAN F, 1991, METHOD ENZYMOL, V194, P1; Tabb-Massey A, 2003, NUCLEIC ACIDS RES, V31, P6798, DOI 10.1093/nar/gkg899; Torchet C, 2000, RNA, V6, P1498, DOI 10.1017/S1355838200000558; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Valdez BC, 2004, P NATL ACAD SCI USA, V101, P10709, DOI 10.1073/pnas.0402492101; Vanrobays E, 2003, MOL CELL BIOL, V23, P2083, DOI 10.1128/MCB.23.6.2083-2095.2003; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Vos HR, 2004, NUCLEIC ACIDS RES, V32, P5827, DOI 10.1093/nar/gkh904; Willig TN, 1999, BLOOD, V94, P4294; Willig TN, 2000, CURR OPIN HEMATOL, V7, P85, DOI 10.1097/00062752-200003000-00003	35	102	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38177	38185		10.1074/jbc.M506916200	http://dx.doi.org/10.1074/jbc.M506916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159874	hybrid			2022-12-25	WOS:000233239800010
J	Oria-Hernandez, J; Cabrera, N; Perez-Montfort, R; Ramirez-Silva, L				Oria-Hernandez, J; Cabrera, N; Perez-Montfort, R; Ramirez-Silva, L			Pyruvate kinase revisited - The activating effect of K+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE MONOPHOSPHATE DEHYDROGENASE; NUCLEAR MAGNETIC-RESONANCE; RABBIT MUSCLE; ESCHERICHIA-COLI; REGULATORY PROPERTIES; ANGSTROM RESOLUTION; MONOVALENT CATIONS; UNIVALENT CATIONS; DIVALENT-CATIONS; ION-BINDING	For more than 50 years, it has been known that K+ is an essential activator of pyruvate kinase (Kachmar, J. F., and Boyer, P. D. ( 1953) J. Biol. Chem. 200, 669 - 683). However, the role of K+ in the catalysis by pyruvate kinase has not been totally understood. Previous studies without K+ showed that the affinity of ADP-Mg2+ depends on the concentration of phosphoenolpyruvate, although the kinetics of the enzyme at saturating K+ concentrations show independence in the binding of substrates (Reynard, A. M., Hass, L. F., Jacobsen, D. D. & Boyer, P. D. ( 1961) J. Biol. Chem. 236, 2277 - 2283). Here, we explored the kinetics of the enzyme with and without K+. The results show that without K+, the kinetic mechanism of pyruvate kinase changes from random to ordered with phosphoenolpyruvate as first substrate. V-max with K+ was about 400 higher than without K+. In the presence of K+, the affinities for phosphoenolpyruvate, ADP-Mg2+, oxalate, and ADP-Cr2+ were 2 - 6-fold higher than in the absence of K+. This as well as fluorescence data also indicate that K+ is involved in the acquisition of the active conformation of the enzyme, allowing either phosphoenolpyruvate or ADP to bind independently ( random mechanism). In the absence of K+, ADP cannot bind to the enzyme until phosphoenolpyruvate forms a competent active site ( ordered mechanism). We propose that K+ induces the closure of the active site and the arrangement of the residues involved in the binding of the nucleotide.	Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Bioquim, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Ramirez-Silva, L (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Apartado Postal 70-159, Mexico City 04510, DF, Mexico.	lramirez@bq.unam.mx		Oria-Hernandez, Jesus/0000-0001-7147-1879; Cabrera Gonzalez, Elizabeth Nallely/0000-0001-8766-6996; Perez-Montfort, Ruy/0000-0003-0810-1159				AINSWORTH S, 1973, BIOCHEM J, V131, P223, DOI 10.1042/bj1310223; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; BUSTO F, 1988, BIOCHEM CELL BIOL, V66, P148, DOI 10.1139/o88-020; Cleland W. W, 1970, ENZYMES, V2, P1; DEPAMPHILIS ML, 1973, BIOCHEMISTRY-US, V12, P3714, DOI 10.1021/bi00743a022; Di Cera E, 2004, CR BIOL, V327, P1065, DOI 10.1016/j.crvi.2004.07.011; GUPTA RK, 1978, J BIOL CHEM, V253, P8878; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P645, DOI 10.1016/0005-2744(76)90314-4; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P661, DOI 10.1016/0005-2744(76)90315-6; JETTEN MSM, 1994, APPL ENVIRON MICROB, V60, P2501, DOI 10.1128/AEM.60.7.2501-2507.1994; Johnsen U, 2003, J BIOL CHEM, V278, P25417, DOI 10.1074/jbc.M210288200; KACHMAR JF, 1953, J BIOL CHEM, V200, P669; KAYNE FJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P232, DOI 10.1016/0003-9861(71)90204-9; KAYNE FJ, 1965, J AM CHEM SOC, V87, P897, DOI 10.1021/ja01082a035; KAYNE FJ, 1970, J AM CHEM SOC, V92, P220, DOI 10.1021/ja00704a048; KAYNE FJ, 1968, BIOCHEMISTRY-US, V7, P1678, DOI 10.1021/bi00845a009; Kerr KM, 2000, ARCH BIOCHEM BIOPHYS, V375, P131, DOI 10.1006/abbi.1999.1644; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; Larsen TM, 2001, HANDBOOK ON METALLOPROTEINS, P9; Larsen TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P199, DOI 10.1006/abbi.1997.0257; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; Laughlin LT, 1997, ARCH BIOCHEM BIOPHYS, V348, P262, DOI 10.1006/abbi.1997.0448; MALCOVATI M, 1982, METHOD ENZYMOL, V90, P170; Markham GD, 1999, BIOCHEMISTRY-US, V38, P4433, DOI 10.1021/bi9829579; MILDVAN AS, 1966, J BIOL CHEM, V241, P1178; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; NOWAK T, 1972, BIOCHEMISTRY-US, V11, P2819, DOI 10.1021/bi00765a014; NOWAK T, 1981, MOL CELL BIOCHEM, V35, P65, DOI 10.1007/BF02354821; PONCE E, 1995, J BACTERIOL, V177, P5719, DOI 10.1128/jb.177.19.5719-5722.1995; Prosise GL, 2002, J BIOL CHEM, V277, P50654, DOI 10.1074/jbc.M208330200; Ramirez-Silva L, 2003, EUR J BIOCHEM, V270, P2377, DOI 10.1046/j.1432-1033.2003.03605.x; Ramirez-Silva L, 2001, EUR J BIOCHEM, V268, P3267, DOI 10.1046/j.1432-1327.2001.02222.x; RAMIREZSILVA L, 1993, BIOCHEMISTRY-US, V32, P5332, DOI 10.1021/bi00071a008; RamirezSilva L, 1997, EUR J BIOCHEM, V250, P583, DOI 10.1111/j.1432-1033.1997.0583a.x; REED GH, 1973, J BIOL CHEM, V248, P6436; REED GH, 1974, BIOCHEMISTRY-US, V13, P3537, DOI 10.1021/bi00714a020; REUBEN J, 1971, J BIOL CHEM, V246, P6227; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; SORGER GJ, 1965, P NATL ACAD SCI USA, V54, P1614, DOI 10.1073/pnas.54.6.1614; Steiner P, 1998, GENE, V220, P31, DOI 10.1016/S0378-1119(98)00418-1; SUELTER CH, 1966, BIOCHEMISTRY-US, V5, P131, DOI 10.1021/bi00865a017; SUELTER CH, 1967, BIOCHEMISTRY-US, V6, P418, DOI 10.1021/bi00854a008; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; WILDES RA, 1971, BIOCHIM BIOPHYS ACTA, V229, P850, DOI 10.1016/0005-2795(71)90305-9; WILSON RH, 1967, J BIOL CHEM, V242, P3825	48	38	39	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37924	37929		10.1074/jbc.M508490200	http://dx.doi.org/10.1074/jbc.M508490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147999	hybrid			2022-12-25	WOS:000233044500074
J	Silve, C; Petrel, C; Leroy, C; Bruel, H; Mallet, E; Rognan, D; Ruat, M				Silve, C; Petrel, C; Leroy, C; Bruel, H; Mallet, E; Rognan, D; Ruat, M			Delineating a Ca2+ binding pocket within the Venus flytrap module of the human calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; EXTRACELLULAR CA2+-SENSING RECEPTOR; 7-TRANSMEMBRANE DOMAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; STRUCTURAL BASIS; TASTE RECEPTORS; MUTATIONS; PROTEIN; CATION	The Ca2+-sensing receptor (CaSR) belongs to the class III G-protein-coupled receptors (GPCRs), which include receptors for pheromones, amino acids, sweeteners, and the neurotransmitters glutamate and gamma-aminobutyric acid (GABA). These receptors are characterized by a long extracellular amino-terminal domain called a Venus flytrap module (VFTM) containing the ligand binding pocket. To elucidate the molecular determinants implicated in Ca2+ recognition by the CaSR VFTM, we developed a homology model of the human CaSR VFTM from the x-ray structure of the metabotropic glutamate receptor type 1 (mGluR1), and a phylogenetic analysis of 14 class III GPCR VFTMs. We identified critical amino acids delineating a Ca2+ binding pocket predicted to be adjacent to, but distinct from, a cavity reminiscent of the binding site described for amino acids in mGluRs, GABA-B receptor, and GPRC6a. Most interestingly, these Ca2+-contacting residues are well conserved within class III GPCR VFTMs. Our model was validated by mutational and functional analysis, including the characterization of activating and inactivating mutations affecting a single amino acid, Glu-297, located within the proposed Ca2+ binding pocket of the CaSR and associated with autosomal dominant hypocalcemia and familial hypocalciuric hypercalcemia, respectively, genetic diseases characterized by perturbations in Ca2+ homeostasis. Altogether, these data define a Ca2+ binding pocket within the CaSR VFTM that may be conserved in several other class III GPCRs, thereby providing a molecular basis for extracellular Ca2+ sensing by these receptors.	Inst Neurobiol Alfred Fessard, CNRS, IFR 2118, UPR9040, F-91198 Gif Sur Yvette, France; Univ Paris 07, INSERM, U426, F-75870 Paris, France; IFR02, F-75870 Paris, France; Univ Paris 07, F-75221 Paris, France; Grp Hosp Havre, Serv Med Neonatale, F-76083 Le Havre, France; Hop Charles Nicolle, Dept Pediat, F-76031 Rouen, France; Lab Pharmacochim Commun Cellulaire, CNRS, UMR7081, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU de Rouen; Centre National de la Recherche Scientifique (CNRS)	Ruat, M (corresponding author), Inst Neurobiol Alfred Fessard, CNRS, IFR 2118, UPR9040, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	ruat@nbcm.cnrs-gif.fr	Ruat, Martial/E-5544-2016; Centeno, Patricia Pacios/O-8368-2016; Rognan, Didier/B-9939-2014					Abe H, 2003, FEBS LETT, V545, P233, DOI 10.1016/S0014-5793(03)00569-6; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Cetani F, 2003, CLIN ENDOCRINOL, V58, P199, DOI 10.1046/j.1365-2265.2003.01696.x; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209; Dyer J, 2005, BIOCHEM SOC T, V33, P302, DOI 10.1042/BST0330302; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hu JX, 2005, J BIOL CHEM, V280, P5113, DOI 10.1074/jbc.M413403200; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Hu JX, 2002, J BONE MINER RES, V17, P1461, DOI 10.1359/jbmr.2002.17.8.1461; Kuang DH, 2005, J NEUROCHEM, V93, P383, DOI 10.1111/j.1471-4159.2005.03025.x; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Nemeth EF, 2002, CURR PHARM DESIGN, V8, P2077, DOI 10.2174/1381612023393387; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pi M, 2004, J BONE MINER RES, V19, P862, DOI 10.1359/JBMR.040114; Pi M, 2000, J BIOL CHEM, V275, P3256, DOI 10.1074/jbc.275.5.3256; Pin JP, 2004, BIOL CELL, V96, P335, DOI 10.1016/j.biolcel.2004.03.005; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Prie D, 2002, NEW ENGL J MED, V347, P983, DOI 10.1056/NEJMoa020028; PUMAIN R, 1987, CAN J PHYSIOL PHARM, V65, P1067, DOI 10.1139/y87-168; PUMAIN R, 1983, SCIENCE, V222, P177, DOI 10.1126/science.6623066; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Reyes-Cruz G, 2001, J BIOL CHEM, V276, P32145, DOI 10.1074/jbc.M102977200; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Wellendorph P, 2005, MOL PHARMACOL, V67, P589, DOI 10.1124/mol.104.007559; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.0404384101; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200	54	107	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37917	37923		10.1074/jbc.M506263200	http://dx.doi.org/10.1074/jbc.M506263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147994	hybrid			2022-12-25	WOS:000233044500073
J	Jain, N; Gupta, S; Sudhakar, C; Radha, V; Swarup, G				Jain, N; Gupta, S; Sudhakar, C; Radha, V; Swarup, G			Role of p73 in regulating human caspase-1 gene transcription induced by interferon-gamma and cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; INDUCED APOPTOSIS; SPLICE VARIANTS; CELL-DEATH; P53; EXPRESSION; PATHWAY; IDENTIFICATION; P63; ACTIVATION	Caspase-1, a cysteine protease is primarily involved in proteolytic activation of proinflammatory cytokines such as interleukin-1 beta. It is also involved in some forms of apoptosis. Here we have analyzed the role of p73, a homolog of tumor suppressor p53, in regulating human caspase-1 gene transcription. The caspase-1 promoter was strongly activated by p73 alpha and p73 beta primarily through a p53/p73 responsive site. Overexpression of p73 by transient transfection increased the caspase-1 mRNA level. Treatment of cells with cisplatin ( which increases p73 protein level) resulted in increased caspase-1 promoter activity and its mRNA level. Blocking of p73 function by a dominant negative mutant reduced basal as well as cisplatin-induced caspase-1 promoter activity. Mutation of the p73 responsive site abolished cisplatin-induced activation of the promoter. Interferon-gamma induced caspase-1 promoter activity and this was reduced by p73-directed small hairpin RNA and also by a dominant negative mutant of p73. Abrogation of the p73 responsive site partially inhibited interferon-gamma-induced activation of the caspase-1 promoter. Treatment of HeLa cells with interferon-gamma resulted in an increase in p73 protein as well as its activity. Mutation of the IRF-1 binding site abolished interferon-gamma-induced caspase-1 promoter activity but p73-induced activation was only marginally reduced. IRF-1 cooperated with p73 and cisplatin cooperated with interferon-gamma in the activation of the caspase-1 promoter. Our results show that p73 is a regulator of caspase-1 gene transcription, and is required for optimal activation of the caspase-1 promoter by interferon-gamma.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Swarup, G (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	gshyam@ccmb.res.in	Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008	Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853; Swarup, Ghanshyam/0000-0002-8098-0509				CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Fu XY, 1999, CELL DEATH DIFFER, V6, P1201, DOI 10.1038/sj.cdd.4400613; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gong JG, 1999, NATURE, V399, P806; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Innocente SA, 2005, BIOCHEM BIOPH RES CO, V329, P713, DOI 10.1016/j.bbrc.2005.02.028; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LEVERO M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shinbo J, 2002, BIOCHEM BIOPH RES CO, V295, P501, DOI 10.1016/S0006-291X(02)00707-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Wang J, 2000, J CELL SCI, V113, P753; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhu JH, 1998, CANCER RES, V58, P5061	45	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36664	36673		10.1074/jbc.M413261200	http://dx.doi.org/10.1074/jbc.M413261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135520	hybrid			2022-12-25	WOS:000232901800018
J	Lee, JK; Simurdiak, M; Zhao, HM				Lee, JK; Simurdiak, M; Zhao, HM			Reconstitution and characterization of aminopyrrolnitrin oxygenase, a Rieske N-oxygenase that catalyzes unusual arylamine oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; NADH-QUINONE OXIDOREDUCTASE; SITE-DIRECTED MUTAGENESIS; PSEUDOMONAS-ARVILLA C-1; NAPHTHALENE 1,2-DIOXYGENASE; DIOXYGEN ACTIVATION; CYTOCHROME-BC(1) COMPLEX; PARACOCCUS-DENITRIFICANS; PYRROLNITRIN PRODUCTION; SUBSTRATE-SPECIFICITY	Rieske oxygenases catalyze a wide variety of important oxidation reactions. Here we report the characterization of a novel Rieske N-oxygenase, aminopyrrolnitrin oxygenase (PrnD) that catalyzes the unusual oxidation of an arylamine to an arylnitro group. PrnD from Pseudomonas fluorescens Pf5 was functionally expressed in Escherichia coli, and the activity of the purified PrnD was reconstituted, which required in vitro assembly of the Rieske iron-sulfur cluster into the protein and the presence of NADPH, FMN, and an E. coli flavin reductase SsuE. Biochemical and bioinformatics studies indicated that the reconstituted PrnD contains a Rieske iron-sulfur cluster and a mononuclear iron center that are formed by residues Cys(69), Cys(88), His(71), His(91), Asp(323), His(186), and His(191), respectively. The enzyme showed a limited range of substrate specificity and catalyzed the conversion of aminopyrrolnitrin into pyrrolnitrin with K-m = 191 mu M and k(cat) = 6.8 min(-1). Isotope labeling experiments with O-18(2) and (H2O)-O-18 suggested that the oxygen atoms in the pyrrolnitrin product are derived exclusively from molecular oxygen. In addition, it was found that the oxygenation of the arylamine substrates catalyzed by PrnD occurs at the enzyme active site and does not involve free radical chain reactions. By analogy to known examples of arylamine oxidation, a catalytic mechanism for the bioconversion of amino pyrrolnitrin into pyrrolnitrin was proposed. Our results should facilitate further mechanistic and crystallographic studies of this arylamine oxygenase and may provide a new enzymatic route for the synthesis of aromatic nitro compounds from their corresponding aromatic amines.	Univ Illinois, Inst Genom Biol, Ctr Biophys & Computat Biol, Dept Chem & Biomol Engn, Urbana, IL 61801 USA; Univ Illinois, Inst Genom Biol, Ctr Biophys & Computat Biol, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Zhao, HM (corresponding author), Univ Illinois, Inst Genom Biol, Ctr Biophys & Computat Biol, Dept Chem & Biomol Engn, 600 S Mathews Ave, Urbana, IL 61801 USA.	zhao5@uiuc.edu						ARIMA K, 1965, J ANTIBIOT, V18, P201; BALDWIN JE, 1993, TETRAHEDRON, V49, P7499, DOI 10.1016/S0040-4020(01)87226-4; Bassan A, 2004, J BIOL INORG CHEM, V9, P439, DOI 10.1007/s00775-004-0537-0; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; Bertini I, 1996, COORDIN CHEM REV, V151, P145, DOI 10.1016/S0010-8545(96)90203-9; BURKHEAD KD, 1994, APPL ENVIRON MICROB, V60, P2031, DOI 10.1128/AEM.60.6.2031-2039.1994; CAMMACK R, 1984, CHARGE FIELD EFFECTS, P41; CEDERBAUM AI, 1978, BIOCHEMISTRY-US, V17, P3058, DOI 10.1021/bi00608a018; CHENG H, 1995, ARCH BIOCHEM BIOPHYS, V316, P619, DOI 10.1006/abbi.1995.1082; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; CRUTCHER SE, 1979, BIOCHEM J, V177, P393, DOI 10.1042/bj1770393; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; De Montellano P, 2005, CYTOCHROME P 450 STR; DOERGE DR, 1991, CHEM RES TOXICOL, V4, P556, DOI 10.1021/tx00023a011; FEE JA, 1984, J BIOL CHEM, V259, P124; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GEARY PJ, 1990, METHOD ENZYMOL, V188, P52; Gong XM, 2003, ANAL BIOCHEM, V321, P259, DOI 10.1016/S0003-2697(03)00456-1; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; Hammer PE, 1997, APPL ENVIRON MICROB, V63, P2147, DOI 10.1128/AEM.63.6.2147-2154.1997; He J, 2004, J AM CHEM SOC, V126, P3694, DOI 10.1021/ja039328t; Holton B, 1996, BIOCHEMISTRY-US, V35, P15485, DOI 10.1021/bi961367c; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JESPERS ABK, 1995, PESTIC SCI, V44, P167, DOI 10.1002/ps.2780440210; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Keller S, 2000, ANGEW CHEM INT EDIT, V39, P2300, DOI 10.1002/1521-3773(20000703)39:13<2300::AID-ANIE2300>3.0.CO;2-I; KERSCHER L, 1976, EUR J BIOCHEM, V71, P101, DOI 10.1111/j.1432-1033.1976.tb11094.x; KIM IC, 1992, J BIOL CHEM, V267, P22108; Kim YW, 2003, APPL ENVIRON MICROB, V69, P4866, DOI 10.1128/AEM.69.8.4866-4874.2003; King RR, 1998, PHYTOCHEMISTRY, V49, P1265, DOI 10.1016/S0031-9422(98)00137-X; Kirner S, 1996, MICROBIOL-UK, V142, P2129, DOI 10.1099/13500872-142-8-2129; Kirner S, 1998, J BACTERIOL, V180, P1939, DOI 10.1128/JB.180.7.1939-1943.1998; KIRNER S, 1994, ANGEW CHEM INT EDIT, V33, P352, DOI 10.1002/anie.199403521; KUILA D, 1986, J BIOL CHEM, V261, P2768; LAMBERT B, 1987, APPL ENVIRON MICROB, V53, P1866, DOI 10.1128/AEM.53.8.1866-1871.1987; LAMBOWITZ AM, 1972, J BACTERIOL, V112, P1020, DOI 10.1128/JB.112.2.1020-1022.1972; LANCINI GC, 1966, BIOCHIM BIOPHYS ACTA, V130, P37, DOI 10.1016/0304-4165(66)90006-7; Lessner DJ, 2002, APPL ENVIRON MICROB, V68, P634, DOI 10.1128/AEM.68.2.634-641.2002; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; MALKIN R, 1975, BIOCHEM BIOPH RES CO, V63, P1157, DOI 10.1016/0006-291X(75)90690-7; MALKIN R, 1973, IRON SULFUR PROTEINS, P1; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; McKay DB, 2003, J BACTERIOL, V185, P2944, DOI 10.1128/JB.185.9.2944-2951.2003; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; MORRIS MP, 1954, SCIENCE, V119, P322, DOI 10.1126/science.119.3088.322; MURRAY RW, 1986, TETRAHEDRON LETT, V27, P2335, DOI 10.1016/S0040-4039(00)84522-0; NISHIDA M, 1965, J ANTIBIOT, V18, P211; Parales JV, 1998, J BACTERIOL, V180, P1194, DOI 10.1128/JB.180.5.1194-1199.1998; PFENDER WF, 1993, PHYTOPATHOLOGY, V83, P1223, DOI 10.1094/Phyto-83-1223; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; REBSTOCK MC, 1949, J AM CHEM SOC, V71, P2458, DOI 10.1021/ja01175a065; Resnick SM, 1996, J IND MICROBIOL BIOT, V17, P438, DOI 10.1007/BF01574775; Riedel A, 1995, J BIOL CHEM, V270, P30869, DOI 10.1074/jbc.270.52.30869; RIESKE JS, 1964, J BIOL CHEM, V239, P3017; SALCHER O, 1978, TETRAHEDRON LETT, P3097; Sambrook J., 1989, MOL CLONING LAB MANU, V2; van Pee KH, 2000, NAT PROD REP, V17, P157, DOI 10.1039/a902138h; VANPEE KH, 1980, ANGEW CHEM INT EDIT, V19, P828, DOI 10.1002/anie.198008281; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Winkler R, 2005, ANGEW CHEM INT EDIT, V44, P4083, DOI 10.1002/anie.200500365; Wolfe MD, 2001, J BIOL CHEM, V276, P1945, DOI 10.1074/jbc.M007795200; YAMAGUCHI M, 1980, J BIOL CHEM, V255, P5058; YAMAGUCHI M, 1982, J BIOL CHEM, V257, P2497; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598	67	63	65	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36719	36728		10.1074/jbc.M505334200	http://dx.doi.org/10.1074/jbc.M505334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150698	hybrid			2022-12-25	WOS:000232901800025
J	Sokolov, MV; Smilenov, LB; Hall, EJ; Panyutin, IG; Bonner, WM; Sedelnikova, OA				Sokolov, MV; Smilenov, LB; Hall, EJ; Panyutin, IG; Bonner, WM; Sedelnikova, OA			Ionizing radiation induces DNA double-strand breaks in bystander primary human fibroblasts	ONCOGENE			English	Article						bystander effect; DNA double-strand break; gamma-H2AX	MEDIATED INTERCELLULAR COMMUNICATION; TARGETED CYTOPLASMIC IRRADIATION; HISTONE H2AX PHOSPHORYLATION; C3H 10T(1)/(2) CELLS; ALPHA-PARTICLES; GENOMIC INSTABILITY; MAMMALIAN-CELLS; NONIRRADIATED CELLS; DAMAGE; INDUCTION	That irradiated cells affect their unirradiated 'bystander' neighbors is evidenced by reports of increased clonogenic mortality, genomic instability, and expression of DNA-repair genes in the bystander cell populations. The mechanisms underlying the bystander effect are obscure, but genomic instability suggests DNA double-strand breaks (DSBs) may be involved. Formation of DSBs induces the phosphorylation of the tumor suppressor protein, histone H2AX and this phosphorylated form, named gamma-H2AX, forms foci at DSB sites. Here we report that irradiation of target cells induces gamma-H2AX focus formation in bystander cell populations. The effect is manifested by increases in the fraction of cells in a population that contains multiple gamma-H2AX foci. After 18 h coculture with cells irradiated with 20 alpha-particles, the fraction of bystander cells with multiple foci increased 3.7-fold. Similar changes occurred in bystander populations mixed and grown with cells irradiated with gamma-rays, and in cultures containing media conditioned on gamma-irradiated cells. DNA DSB repair proteins accumulated at gamma-H2AX foci, indicating that they are sites of DNA DSB repair. Lindane, which blocks gap-junctions, prevented the bystander effect in mixing but not in media transfer protocols, while c-PTIO and aminoguanidine, which lower nitric oxide levels, prevented the bystander effect in both protocols. Thus, multiple mechanisms may be involved in transmitting bystander effects. These studies show that H2AX phosphorylation is an early step in the bystander effect and that the DNA DSBs underlying gamma-H2AX focus formation may be responsible for its downstream manifestations.	NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD 20892 USA; Inst Cell Biol & Genet Engn, Dept Radiat Biol & Biophys, UA-03143 Kiev, Ukraine; Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Academy of Sciences Ukraine; Institute of Cell Biology & Genetic Engineering of the National Academy of Sciences of Ukraine; Columbia University	Bonner, WM (corresponding author), NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH, Bldg 37 Room 5050,9000 Rockville Pike, Bethesda, MD 20892 USA.	bonnerw@mail.nih.gov; sedelnio@mail.nih.gov		Martin (nee Sedelnikova), Olga/0000-0003-3470-2935	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002033] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41-EB002033] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Azzam EI, 2004, CURR CANCER DRUG TAR, V4, P53, DOI 10.2174/1568009043481641; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bonner WM, 2004, MUTAT RES-FUND MOL M, V568, P33, DOI 10.1016/j.mrfmmm.2004.06.044; Brenner DJ, 2001, RADIAT RES, V155, P402, DOI 10.1667/0033-7587(2001)155[0402:TBEIRO]2.0.CO;2; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Hall EJ, 2003, ONCOGENE, V22, P7034, DOI 10.1038/sj.onc.1206900; Highfield D P, 1975, Methods Cell Biol, V9, P85, DOI 10.1016/S0091-679X(08)60070-9; Hill MA, 2005, RADIAT RES, V163, P36, DOI 10.1667/RR3282; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; MacPhail SH, 2003, RADIAT RES, V159, P759, DOI 10.1667/RR3003; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Marples B, 2003, RADIAT RES, V160, P38, DOI 10.1667/RR3013; Mitchell SA, 2004, INT J RADIAT BIOL, V80, P465, DOI 10.1080/09553000410001725116; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT RES, V157, P526, DOI 10.1667/0033-7587(2002)157[0526:RBRILD]2.0.CO;2; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; NAGASAWA H, 1992, CANCER RES, V52, P6394; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Ponnaiya B, 2004, RADIAT RES, V162, P426, DOI 10.1667/RR3236; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedelnikova OA, 2004, INT J RADIAT BIOL, V80, P927, DOI 10.1080/09553000400017648; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao C, 2003, CANCER RES, V63, P8437; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Suzuki M, 2004, RADIAT RES, V162, P264, DOI 10.1667/RR3226; Ward JF, 2000, COLD SPRING HARB SYM, V65, P377, DOI 10.1101/sqb.2000.65.377; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	46	184	191	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7257	7265		10.1038/sj.onc.1208886	http://dx.doi.org/10.1038/sj.onc.1208886			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16170376				2022-12-25	WOS:000233142100001
J	Ammosova, T; Jerebtsova, M; Beullens, M; Lesage, B; Jackson, A; Kashanchi, F; Southerland, W; Gordeuk, VR; Bollen, M; Nekhai, S				Ammosova, T; Jerebtsova, M; Beullens, M; Lesage, B; Jackson, A; Kashanchi, F; Southerland, W; Gordeuk, VR; Bollen, M; Nekhai, S			Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; C-TERMINAL DOMAIN; P-TEFB; TRANSCRIPTIONAL ACTIVITY; GAMMA(1)34.5 PROTEIN; STRUCTURAL BASIS; KINASE; ELONGATION; SUBUNIT	Transcription of human immunodeficiency virus (HIV)-1 genes is activated by HIV-1 Tat protein, which induces phosphorylation of the C-terminal domain of RNA polymerase-II by CDK9/cyclin T1. We previously showed that Tat-induced HIV-1 transcription is regulated by protein phosphatase-1 (PP1). In the present study we demonstrate that Tat interacts with PP1 and that disruption of this interaction prevents induction of HIV-1 transcription. We show that PP1 interacts with Tat in part through the binding of Val(36) and Phe(38) of Tat to PP1 and that Tat is involved in the nuclear and subnuclear targeting of PP1. The PP1 binding mutant Tat-V36A/ F38A displayed a decreased affinity for PP1 and was a poor activator of HIV-1 transcription. Surprisingly, Tat-Q35R mutant that had a higher affinity for PP1 was also a poor activator of HIV-1 transcription, because strong PP1 binding competed out binding of Tat to CDK9/ cyclin T1. Our results suggest that Tat might function as a nuclear regulator of PP1 and that interaction of Tat with PP1 is critical for activation of HIV-1 transcription by Tat.	Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Dept Biochem & Mol Biol, Washington, DC 20059 USA; Childrens Natl Med Ctr, CRI Ctr 3, Washington, DC 20010 USA; Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium; George Washington Univ, Dept Biochem & Mol Biol, Washington, DC 20037 USA	Howard University; Howard University; Children's National Health System; Universite Catholique Louvain; George Washington University	Nekhai, S (corresponding author), 2121 Georgia Ave NW, Washington, DC 20059 USA.	snekhai@howard.edu	Ammosova, Tatiana/J-7564-2018; , nekhai/AAW-3105-2021; Ammosova, Tatiana/HIA-0704-2022; Gordeuk, Victor/AAG-6577-2019; , nekhai/AFO-2652-2022	Ammosova, Tatiana/0000-0001-8777-1032; 	NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003048] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R21AI056973, R29AI044357] Funding Source: NIH RePORTER; NCRR NIH HHS [5G12RR03048] Funding Source: Medline; NHLBI NIH HHS [UH1 HL03679] Funding Source: Medline; NIAID NIH HHS [AI43894, AI44357, R21 AI056973, R21 AI056973-02, AI056973-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammosova T, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-47; Ammosova T, 2003, J BIOL CHEM, V278, P32189, DOI 10.1074/jbc.M300521200; Beullens M, 1998, METH MOL B, V93, P145; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Bharucha DC, 2002, VIROLOGY, V296, P6, DOI 10.1006/viro.2002.1438; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faulkner NE, 2003, J VIROL, V77, P2276, DOI 10.1128/JVI.77.3.2276-2281.2003; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1993, J BIOL CHEM, V268, P24940; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Lesage B, 2004, J BIOL CHEM, V279, P55978, DOI 10.1074/jbc.M411911200; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; Nekhai S, 1997, J VIROL, V71, P7436, DOI 10.1128/JVI.71.10.7436-7441.1997; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Raha T, 2005, PLOS BIOL, V3, P221, DOI 10.1371/journal.pbio.0030044; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Verhoef K, 1998, AIDS RES HUM RETROV, V14, P1553, DOI 10.1089/aid.1998.14.1553; Verhoef K, 1999, J VIROL, V73, P2781, DOI 10.1128/JVI.73.4.2781-2789.1999; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	43	46	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36364	36371		10.1074/jbc.M503673200	http://dx.doi.org/10.1074/jbc.M503673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131488	hybrid			2022-12-25	WOS:000232726900070
J	Jethanandani, P; Kramer, RH				Jethanandani, P; Kramer, RH			alpha 7 integrin expression is negatively regulated by delta EF1 during skeletal myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION; BINDING-PROTEINS; REPRESSOR; MYOD; ACTIVATION; CELLS; ZEB; MECHANISMS; JUNCTION; FOS	alpha 7 integrin levels increase dramatically as myoblasts differentiate to myotubes. A negative regulatory element with putative sites for delta EF1 is present in the alpha 7 proximal promoter region. To define the role of delta EF1 in regulating alpha 7 integrin expression, we overexpressed delta EF1 in C2C12 myoblasts. This resulted in a major downregulation of alpha 7 protein expression. Promoter assays revealed that C2C12 myoblasts transfected with delta EF1 showed a decrease in activity of the 2.8-kb alpha 7 promoter fragment, indicating regulation of alpha 7 integrin at the transcriptional level. We have identified two E-box-like sites for delta EF1 in the negative regulatory region. Mutation of these sites enhanced alpha 7 promoter activity, indicating that these sites function in repression. MYOD, an activator of alpha 7 integrin transcription, can compete with delta EF1 for binding at these sites in gel shift assay. By using chromatin immunoprecipitation, we demonstrated a reciprocal binding of delta EF1 and MYOD to this regulatory element depending on the stage of differentiation: delta EF1 is preferentially bound in myoblasts to this region, whereas MYOD is bound in myotubes. The N-terminal region of delta EF1 is necessary for alpha 7 repression, and this region also binds the co-activator p300/CBP. Importantly, we found that the p300/CBP co-activator can overcome repression by delta EF1, suggesting that delta EF1 can titrate limiting amounts of this co-activator. These findings suggest that delta EF1 has a role in suppressing integrin expression in myoblasts by displacing MYOD and competing for p300/CBP co-activator.	Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, Box 0640,C-640,521 Parnassus Ave, San Francisco, CA 94143 USA.	Randall.Kramer@ucsf.edu			NIDCR NIH HHS [DE015404] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015404] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOA ZZ, 1993, J CELL SCI, V106, P579; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Miosge N, 1999, LAB INVEST, V79, P1591; Pegoraro E, 2002, AM J PATHOL, V160, P2135, DOI 10.1016/S0002-9440(10)61162-5; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sekido R, 1997, GENES CELLS, V2, P771, DOI 10.1046/j.1365-2443.1997.1570355.x; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; VanderFlier A, 1997, DEV DYNAM, V210, P472, DOI 10.1002/(SICI)1097-0177(199712)210:4<472::AID-AJA10>3.0.CO;2-9; VANDROMME M, 1994, J CELL SCI, V107, P613; Xiao JQ, 2003, J BIOL CHEM, V278, P49780, DOI 10.1074/jbc.M308542200; Yao CC, 1997, J CELL SCI, V110, P1477; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457; Ziober BL, 1996, J BIOL CHEM, V271, P22915, DOI 10.1074/jbc.271.37.22915	28	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36037	36046		10.1074/jbc.M508698200	http://dx.doi.org/10.1074/jbc.M508698200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129691	hybrid			2022-12-25	WOS:000232726900033
J	Shao, BH; Fu, XY; McDonald, TO; Green, PS; Uchida, K; O'Brien, KD; Oram, JF; Heinecke, JW				Shao, BH; Fu, XY; McDonald, TO; Green, PS; Uchida, K; O'Brien, KD; Oram, JF; Heinecke, JW			Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; CELLULAR CHOLESTEROL; LIPID-PEROXIDATION; ALPHA,BETA-UNSATURATED ALDEHYDES; HDL APOLIPOPROTEINS; OXIDATIVE DAMAGE; LYSINE RESIDUES; MYELOPEROXIDASE; EFFLUX	Acrolein is a highly reactive alpha,beta-unsaturated aldehyde, but the factors that control its reactions with nucleophilic groups on proteins remain poorly understood. Lipid peroxidation and threonine oxidation by myeloperoxidase are potential sources of acrolein during inflammation. Because both pathways are implicated in atherogenesis and high density lipoprotein (HDL) is anti-atherogenic, we investigated the possibility that acrolein might target the major protein of HDL, apolipoprotein A-I (apoA-I), for modification. Tandem mass spectrometric analysis demonstrated that lysine 226, located near the center of helix 10 in apoA-I, was the major site modified by acrolein. Importantly, this region plays a critical role in the cellular interactions and ability of apoA-I to transport lipid. Indeed, we found that conversion of Lys-226 to N-epsilon-(3-methylpyridinium) lysine by acrolein associated quantitatively with decreased cholesterol efflux from cells via the ATP-binding cassette transporter A1 pathway. In the crystal structure of truncated apoA-I, Glu-234 lies adjacent to Lys-226, suggesting that negatively charged residues might direct the modification of specific lysine residues in proteins. Finally, immunohistochemical studies with a monoclonal antibody revealed co-localization of apoA-I with acrolein adducts in human atherosclerotic lesions. Our observations suggest that acrolein might interfere with normal reverse cholesterol transport by HDL by modifying specific sites in apoA-I. Thus, acrolein might contribute to atherogenesis by impairing cholesterol removal from the artery wall.	Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA; Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan	University of Washington; University of Washington Seattle; Nagoya University	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu	O'Brien, Kevin/CAH-4638-2022; O'Brien, Kevin Douglas/HDO-1461-2022	O'Brien, Kevin/0000-0002-2293-9196; O'Brien, Kevin Douglas/0000-0002-2293-9196; Uchida, Koji/0000-0003-3894-5299; Shao, Baohai/0000-0001-8832-2845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075340, R01HL039934, R01HL075381, P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047, P30DK035816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL075340, P01HL030086, HL39934, HL075381] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [DK02456, P30DK017047, P30DK35816] Funding Source: Medline; NIEHS NIH HHS [P30ES07033] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Bergt C, 2003, ARTERIOSCL THROM VAS, V23, P1488, DOI 10.1161/01.ATV.0000090570.99836.9C; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Chroni A, 2003, J BIOL CHEM, V278, P6719, DOI 10.1074/jbc.M205232200; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Davidson WS, 2005, CURR OPIN LIPIDOL, V16, P295, DOI 10.1097/01.mol.0000169349.38321.ad; Drapeau G R, 1977, Methods Enzymol, V47, P189; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; Frank PG, 2000, J LIPID RES, V41, P853; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Furuhata A, 2003, J BIOL CHEM, V278, P48658, DOI 10.1074/jbc.M309401200; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; Heinecke JW, 1997, CURR OPIN LIPIDOL, V8, P268, DOI 10.1097/00041433-199710000-00005; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; HOBERMAN HD, 1988, J BIOCHEM TOXICOL, V3, P105, DOI 10.1002/jbt.2570030205; Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c; MCCALL M, 1995, ARTERIOSCL THROM VAS, V15, P1599, DOI 10.1161/01.ATV.15.10.1599; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Mohamad N., 2004, J LIPID RES, V45, P993, DOI [10.1194/jlr.R400001-JLR200, DOI 10.1194/JLR.R400001-JLR200]; Natarajan P, 2004, J BIOL CHEM, V279, P24044, DOI 10.1074/jbc.M400561200; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Richter T, 2005, NEUROBIOL AGING, V26, P465, DOI 10.1016/j.neurobiolaging.2004.04.009; Sakata K, 2003, BIOCHEM BIOPH RES CO, V305, P143, DOI 10.1016/S0006-291X(03)00716-2; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Shao BH, 2005, ANN NY ACAD SCI, V1043, P396, DOI 10.1196/annals.1333.046; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Sorci-Thomas MG, 2002, TRENDS CARDIOVAS MED, V12, P121, DOI 10.1016/S1050-1738(01)00163-3; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; TU CK, 1989, J BIOL CHEM, V264, P12389; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; Uchida K, 1999, TRENDS CARDIOVAS MED, V9, P109, DOI 10.1016/S1050-1738(99)00016-X; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	55	97	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36386	36396		10.1074/jbc.M508169200	http://dx.doi.org/10.1074/jbc.M508169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126721	hybrid			2022-12-25	WOS:000232726900073
J	Yang, JS; Zhang, L; Erbel, PJA; Gardner, KH; Ding, K; Garcia, JA; Bruick, RK				Yang, JS; Zhang, L; Erbel, PJA; Gardner, KH; Ding, K; Garcia, JA; Bruick, RK			Functions of the Per/ARNT/Sim domains of the hypoxia-inducible factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN; STRUCTURAL BASIS; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; FACTOR 1-ALPHA; TARGET GENE; DNA-BINDING; HIF-ALPHA; FACTOR-I; OXYGEN	The heterodimeric transcription factor hypoxia-inducible factor (HIF) plays an important role in the progression of a number of processes in which O-2 availability is compromised and, as such, has become an increasingly attractive therapeutic target. Although tremendous progress has been made in recent years in unraveling the mechanisms underlying O-2-dependent regulation of HIF through its O-2-dependent degradation domain and C-terminal transactivation domain, our understanding of the contributions of other structural elements, particularly the Per/ARNT/Sim (PAS)-A and PAS-B domains, to the activity of HIF is incomplete. Using insights derived from the recently determined solution structures of the HIF PAS-B domains as a starting point, we have explored the function(s) of the HIF-2 alpha PAS domains via mutational analysis. In contrast to recent models, our data reveal that both PAS domains of the HIF-alpha subunit are necessary for heterodimer formation but are not required to mediate other HIF functions in which PAS domains have been implicated. Because disruption of individual PAS domains compromise HIF function independent of the mechanism of HIF induction, these data demonstrate the potential utility of targeting these domains for therapeutic applications.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bruick, RK (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Richard.Bruick@UTSouthwestern.edu	Gardner, Kevin/K-5493-2019; Gardner, Kevin H./K-7802-2012	Gardner, Kevin H./0000-0002-8671-2556; , Kan/0000-0003-3485-8200; Garcia, Joseph/0000-0002-5621-7538	NCI NIH HHS [CA95471, CA90601] Funding Source: Medline; NCRR NIH HHS [C06 RR-15437] Funding Source: Medline; NHLBI NIH HHS [K08 HL067154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095471, R01CA090601] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015437] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; CARD PB, 2005, IN PRESS J MOL BIOL; Chapman-Smith A, 2004, J BIOL CHEM, V279, P5353, DOI 10.1074/jbc.M310041200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Katschinski DM, 2004, CELL PHYSIOL BIOCHEM, V14, P351, DOI 10.1159/000080345; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Takahashi R, 2004, BIOCHEM BIOPH RES CO, V317, P84, DOI 10.1016/j.bbrc.2004.03.010; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG GL, 1996, METH MOL G, V8, P298; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	51	61	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36047	36054		10.1074/jbc.M501755200	http://dx.doi.org/10.1074/jbc.M501755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129688	hybrid			2022-12-25	WOS:000232726900034
J	Zhu, GZ; Fujii, K; Liu, Y; Codrea, V; Herrero, J; Shaw, S				Zhu, GZ; Fujii, K; Liu, Y; Codrea, V; Herrero, J; Shaw, S			A single pair of acidic residues in the kinase major groove mediates strong substrate preference for P-2 or P-5 arginine in the AGC, CAMK, and STE kinase families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SPECIFICITY DETERMINANTS; PHOSPHORYLATION SITE; RECOGNITION SEQUENCE; PEPTIDE SPECIFICITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; BASIC RESIDUES; MOTIFS; IDENTIFICATION	Most basophilic serine/threonine kinases preferentially phosphorylate substrates with Arg at P - 3 but vary greatly in additional strong preference for Arg at P - 2 or P - 5. The structural basis for P - 2 or P - 5 preference is known for two AGC kinases ( family of protein kinases A, G, and C) in which it is mediated by a single pair of acidic residues ( PEN + 1 and YEM + 1). We sought a general understanding of P - 2 and P - 5Arg preference. The strength of Arg preference at each position was assessed in 15 kinases using a new degenerate peptide library approach. Strong P - 2 or P - 5 Arg preference occurred not only in AGC kinases ( 7 of 8 studied) but also in calmodulin-dependent protein kinase (CAMK, 1 of 3) and Ste20 (STE) kinases ( 2 of 4). Analysis of sequence conservation demonstrated almost perfect correlation between ( a) strong P - 2 or P - 5 Arg preference and (b) acidic residues at both PEN + 1 and YEM + 1. Mutation of two kinases (PKC-theta and p21-activated kinase 1 (PAK1)) confirmed critical roles of both PEN + 1 and YEM + 1 residues in determining strong R-2 Arg preference. PAK kinases were unique in having exceptionally strong Arg preference at P - 2 but lacking strong Arg preference at P - 3. Preference for Arg at P - 2 was so critical to PAK recognition that PAK1 activity was virtually eliminated by mutating the PEN + 1 or YEM + 1 residues. The fact that this specific pair of acidic residues has been repeatedly and exclusively used by evolution for conferring strong Arg preference at two different substrate positions in three different kinase families implies it is uniquely well suited to mediate sufficiently good substrate binding without unduly restricting product release.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; AxCell Biosci, Newtown, PA 18940 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shaw, S (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.	sshaw@nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010272, ZIABC009257, ZIABC010272, Z01BC009257] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Batkin M, 2000, BIOCHEMISTRY-US, V39, P5366, DOI 10.1021/bi000153z; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Ebneth A, 1999, CELL MOTIL CYTOSKEL, V44, P209, DOI 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.0.CO;2-4; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Fujii K, 2004, P NATL ACAD SCI USA, V101, P13744, DOI 10.1073/pnas.0401881101; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; He XG, 2003, AM J PATHOL, V163, P243, DOI 10.1016/S0002-9440(10)63647-4; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Madhavan R, 1999, BBA-PROTEIN STRUCT M, V1434, P260, DOI 10.1016/S0167-4838(99)00193-4; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nolen B, 2003, BIOCHEMISTRY-US, V42, P9575, DOI 10.1021/bi0344331; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; Palaty CK, 1997, BIOCHEM CELL BIOL, V75, P153, DOI 10.1139/bcb-75-2-153; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; TURNER RS, 1985, J BIOL CHEM, V260, P1503; Velentza AV, 2001, J BIOL CHEM, V276, P38956, DOI 10.1074/jbc.M104273200; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu GZ, 2005, CELL CYCLE, V4, P52, DOI 10.4161/cc.4.1.1353	46	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36372	36379		10.1074/jbc.M505031200	http://dx.doi.org/10.1074/jbc.M505031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16131491	hybrid			2022-12-25	WOS:000232726900071
J	Boggs, K; Reisman, D				Boggs, K; Reisman, D			Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter	ONCOGENE			English	Article						p53; transcription; gene expression; cell cycle	BINDING-PROTEIN-BETA; NUCLEAR EXPORT SIGNAL; TUMOR-SUPPRESSOR GENE; LI-FRAUMENI-SYNDROME; KAPPA-B; POTENTIAL MEDIATOR; C/EBP-BETA; EXPRESSION; DAMAGE; MDM2	p53 mRNA levels are tightly regulated during the cell cycle with its transcription being induced prior to DNA synthesis. However, the mechanism controlling this regulation is not well defined. Through characterizing an additional 1000 bp of upstream DNA sequences of the murine p53 gene, we identified new positive and negative regulatory elements. Furthermore, we found a trans-acting factor(s) that binds within a positive cis-acting element (-972/-953) in a manner indicative of regulation during the cell cycle. When Swiss3T3 cells are arrested by serum depletion p53 mRNA levels decrease and binding of this regulatory factor( s) to the promoter is reduced. Upon serum stimulation, the regulatory factor( s) binds the promoter and p53 mRNA levels increase prior to the cells entering S phase. When the factors are experimentally sequestered from the promoter or when the regulatory element is deleted from the promoter, p53 promoter activity is reduced. There is no further reduction in p53 promoter activity upon serum depletion and the kinetics of induction upon serum stimulation is delayed by approximately 5 h. These findings indicate that a factor( s) binding within the -972/-953 regulatory element on the p53 promoter is important for the proper regulation of p53 mRNA expression in response to mitogen stimulation. Our initial findings indicate that a member of the C/EBP family of transcription factors may play a role in this regulation.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Coker Life Sci Bldg,Sumter St, Columbia, SC 29208 USA.	reisman@biol.sc.edu						Arnett Brenda, 2003, Mol Cancer, V2, P21, DOI 10.1186/1476-4598-2-21; Balint E, 1996, CANCER RES, V56, P1648; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CANCER RES, V59, P1; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GINSBERG D, 1990, ONCOGENE, V5, P1285; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu L, 1999, MOL CELL BIOL, V19, P1202; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; MIYASHITA T, 1995, CELL, V80, P293; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Reisman D, 2001, GENE, V274, P129, DOI 10.1016/S0378-1119(01)00623-0; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sigal A, 2000, CANCER RES, V60, P6788; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; VALEV LV, 2002, J BIOL CHEM, V2111, P42438; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WU HY, 1994, J BIOL CHEM, V269, P20067; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao RB, 2000, GENE DEV, V14, P981	46	22	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					555	565		10.1038/sj.onc.1209076	http://dx.doi.org/10.1038/sj.onc.1209076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158047				2022-12-25	WOS:000234897400007
J	Qiao, W; Li, AG; Owens, P; Xu, X; Wang, XJ; Deng, CX				Qiao, W; Li, AG; Owens, P; Xu, X; Wang, XJ; Deng, CX			Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin	ONCOGENE			English	Article						squamous cell carcinoma; hair follicle cycle; Pten; AKT; cyclin D1	TUMOR-SUPPRESSOR SMAD4/DPC4; TGF-BETA RECEPTOR; TRANSGENIC MICE; CHEMICAL CARCINOGENESIS; JUVENILE POLYPOSIS; CYCLE ARREST; EXPRESSION; GENE; DIFFERENTIATION; DELETION	Smad4 is the common mediator for TGF beta signals, which play important functions in many biological processes. To study the role of Smad4 in skin development and epidermal tumorigenesis, we disrupted this gene in skin using the Cre-loxP approach. We showed that absence of Smad4 blocked hair follicle differentiation and cycling, leading to a progressive hair loss of mutant (MT) mice. MT hair follicles exhibited diminished expression of Lef1, and increased proliferative cells in the outer root sheath. Additionally, the skin of MT mice exhibited increased proliferation of basal keratinocytes and epidermal hyperplasia. Furthermore, we provide evidence that the absence of Smad4 resulted in a block of both TGFb and bone morphogenetic protein (BMP) signaling pathways, including p21, a well-known cyclin-dependent kinase inhibitor. Consequently, all MT mice developed spontaneous malignant skin tumors from 3 months to 13 months of age. The majority of tumors are malignant squamous cell carcinomas. A most notable finding is that tumorigenesis is accompanied by inactivation of phosphatase and tensin homolog deleted on chromosome 10 (Pten), activation of AKT, fast proliferation and nuclear accumulation of cyclin D1. These observations revealed the essential functions of Smad4-mediated signals in repressing skin tumor formation through the TGF beta/BMP pathway, which interacts with the Pten signaling pathway.	Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wang, XJ (corresponding author), Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA.	wangxiao@ohsu.edu	deng, chuxia/N-6713-2016	Owens, Philip/0000-0002-1452-9285	NCI NIH HHS [CA87849] Funding Source: Medline; NIAMS NIH HHS [AR47898] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056012, ZIADK056012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.3.CO;2-G; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Go C, 1999, CANCER RES, V59, P2861; Hahn SA, 1996, CANCER RES, V56, P490; He W, 2001, ONCOGENE, V20, P471, DOI 10.1038/sj.onc.1204117; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Kobielak K, 2003, J CELL BIOL, V163, P609, DOI 10.1083/jcb.200309042; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Kwan KM, 2004, GENESIS, V39, P10, DOI 10.1002/gene.20021; Li AG, 2003, CYTOKINE GROWTH F R, V14, P99, DOI 10.1016/S1359-6101(03)00005-4; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Redman RS, 2005, J ORAL PATHOL MED, V34, P23, DOI 10.1111/j.1600-0714.2004.00246.x; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Takaku K, 1999, CANCER RES, V59, P6113; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wang XJ, 2001, MICROSC RES TECHNIQ, V52, P420, DOI 10.1002/1097-0029(20010215)52:4<420::AID-JEMT1027>3.3.CO;2-Z; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yuhki M, 2004, DEVELOPMENT, V131, P1825, DOI 10.1242/dev.01079	44	78	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					207	217		10.1038/sj.onc.1209029	http://dx.doi.org/10.1038/sj.onc.1209029			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170355				2022-12-25	WOS:000234583600005
J	Zalcenstein, A; Weisz, L; Stambolsky, P; Bar, J; Rotter, V; Oren, M				Zalcenstein, A; Weisz, L; Stambolsky, P; Bar, J; Rotter, V; Oren, M			Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53	ONCOGENE			English	Article						p53; MSP; MST-1; apoptosis; RON	RECEPTOR TYROSINE KINASE; MACROPHAGE-STIMULATING PROTEIN; WILD-TYPE P53; EXPRESSION PATTERNS; TUMOR-SUPPRESSOR; OF-FUNCTION; TRANSCRIPTIONAL REPRESSION; HUMAN MDR1; RON; CELLS	Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the MSP ( MST-1/HGFL) gene, encoding the ligand of the receptor tyrosine kinase RON, implicated in a variety of cellular responses. Mutant p53 associates with the MSP gene promoter and represses its transcriptional activity, leading to a decrease in mRNA levels and a subsequent decrease in the levels of secreted MSP protein. Forced downregulation of MSP expression in H1299 cells, derived from a large-cell lung carcinoma, confers increased resistance against etoposide-induced cell death. These antiapoptotic consequences of MSP downregulation seemingly conflict with the well-documented ability of the RON receptor to promote cell survival and tumor progression when aberrantly hyperactive. Yet, they are consistent with the fact that reduced MSP expression was observed in many types of human cancer, including large-cell lung carcinoma. Thus, repression of MSP gene expression by mutant p53 may contribute to oncogenesis in a cell type-specific manner.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, 300 Herzl St, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Bar, Jair/AAS-5743-2021	Bar, Jair/0000-0002-1224-3646; Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R37 CA40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albor A, 1998, CANCER RES, V58, P2091; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Camp ER, 2005, ANN SURG ONCOL, V12, P273, DOI 10.1245/ASO.2005.08.013; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Demidenko ZN, 2005, FEBS LETT, V579, P2231, DOI 10.1016/j.febslet.2005.03.012; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DIPPOLD W, 1993, Z GASTROENTEROL, V31, P24; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Gurova KV, 2003, CANCER RES, V63, P2905; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Miller AD, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-64; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sigal A, 2000, CANCER RES, V60, P6788; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Storz MN, 2003, J INVEST DERMATOL, V120, P865, DOI 10.1046/j.1523-1747.2003.12142.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang D, 2005, CARCINOGENESIS, V26, P27, DOI 10.1093/carcin/bgh284; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; WANG MH, 1994, J BIOL CHEM, V269, P3436; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	65	45	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					359	369		10.1038/sj.onc.1209061	http://dx.doi.org/10.1038/sj.onc.1209061			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170349				2022-12-25	WOS:000234714100004
J	Cerone, MA; Autexier, C; Londono-Vallejo, JA; Bacchetti, S				Cerone, MA; Autexier, C; Londono-Vallejo, JA; Bacchetti, S			A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT	ONCOGENE			English	Article						telomere; ALT; telomerase	IMMORTAL HUMAN-CELLS; MUTANT TELOMERASE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; RNA COMPONENT; RECOMBINATION; MAINTENANCE; RECONSTITUTION; EXPRESSION; MECHANISM	In human somatic cells proliferation results in telomere shortening due to the end replication problem and the absence of adequate levels of telomerase activity. The progressive loss of telomeric DNA has been associated with replicative senescence. Maintenance of telomere structure and function is, therefore, an essential requisite for cells that proliferate indefinitely. Human cells that have acquired the immortal phenotype mostly rely on telomerase to compensate for telomere shortening with cell division. However, a certain percentage of immortalized cell lines and human tumors maintain their telomeres by Alternative Lengthening of Telomeres (ALT), a mechanism not fully understood but apparently based on homologous recombination. Here, we report the isolation of an immortal human cell line that is derived from an ALT cell line but maintains telomeres in the absence of key features of ALT and of telomerase. The properties of these cells suggest that the identification of ALT cells may not be reliably based on known ALT markers. This finding is of relevance for discriminating between the mortal and immortal phenotype among telomerase-negative cells in vitro and in vivo, particularly in regard to the development of pharmacological approaches for cancer treatment based on telomerase inhibition.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B4, Canada; Jewish Gen Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; Inst Curie, Telomeres & Canc Lab, F-75248 Paris, France; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McGill University; Lady Davis Institute; McGill University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; McMaster University	Bacchetti, S (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	bacchett@mcmaster.ca	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bailey SM, 2004, CYTOGENET GENOME RES, V107, P14, DOI 10.1159/000079565; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Chute I, 1997, GENOMICS, V46, P51, DOI 10.1006/geno.1997.5007; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Cornforth MN, 2001, MUTAGENESIS, V16, P85, DOI 10.1093/mutage/16.1.85; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Henson JD, 2005, CLIN CANCER RES, V11, P217; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kurenova EV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1242; Lee SR, 2003, J BIOL CHEM, V278, P52531, DOI 10.1074/jbc.M311359200; Lin CY, 2005, EUKARYOT CELL, V4, P327, DOI 10.1128/EC.4.2.327-336.2005; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(05)00094-8; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Topcu Z, 2005, P NATL ACAD SCI USA, V102, P3348, DOI 10.1073/pnas.0408770102; Ulaner GA, 2003, CANCER RES, V63, P1759; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Yeager TR, 1999, CANCER RES, V59, P4175; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	57	53	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7893	7901		10.1038/sj.onc.1208934	http://dx.doi.org/10.1038/sj.onc.1208934			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116482				2022-12-25	WOS:000233463000008
J	Ijiri, K; Zerbini, LF; Peng, HB; Correa, RG; Lu, BF; Walsh, N; Zhao, YN; Taniguchi, N; Huang, XL; Otu, H; Wang, H; Wang, JF; Komiya, S; Ducy, P; Rahman, MU; Flavell, RA; Gravallese, EM; Oettgen, P; Libermann, TA; Goldring, MB				Ijiri, K; Zerbini, LF; Peng, HB; Correa, RG; Lu, BF; Walsh, N; Zhao, YN; Taniguchi, N; Huang, XL; Otu, H; Wang, H; Wang, JF; Komiya, S; Ducy, P; Rahman, MU; Flavell, RA; Gravallese, EM; Oettgen, P; Libermann, TA; Goldring, MB			A novel role for GADD45 beta as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; GROWTH-FACTOR-BETA; NF-KAPPA-B; X COLLAGEN GENE; TRANSCRIPTION FACTOR; IN-VIVO; HYPERTROPHIC CHONDROCYTES; ENDOCHONDRAL OSSIFICATION; SKELETAL MORPHOGENESIS; CBFA1-DEFICIENT MICE	The growth arrest and DNA damage-inducible 45 beta(GADD45 beta) gene product has been implicated in the stress response, cell cycle arrest, and apoptosis. Here we demonstrated the unexpected expression of GADD45 beta in the embryonic growth plate and uncovered its novel role as an essential mediator of matrix metalloproteinase-13 (MMP-13) expression during terminal chondrocyte differentiation. We identified GADD45 beta as a prominent early response gene induced by bone morphogenetic protein-2 (BMP-2) through a Smad1/Runx2-dependent pathway. Because this pathway is involved in skeletal development, we examined mouse embryonic growth plates, and we observed expression of Gadd45 beta mRNA coincident with Runx2 protein in pre-hypertrophic chondrocytes, whereas GADD45 beta protein was localized prominently in the nucleus in late stage hypertrophic chondrocytes where Mmp-13 mRNA was expressed. In Gadd45 beta(-/-) mouse embryos, defective mineralization and decreased bone growth accompanied deficient Mmp-13 and Col10a1 gene expression in the hypertrophic zone. Transduction of small interfering RNA-GADD45 beta in epiphyseal chondrocytes in vitro blocked terminal differentiation and the associated expression of Mmp-13 and Col10a1 mRNA in vitro. Finally, GADD45 beta stimulated MMP-13 promoter activity in chondrocytes through the JNK-mediated phosphorylation of JunD, partnered with Fra2, in synergy with Runx2. These observations indicated that GADD45 beta plays an essential role during chondrocyte terminal differentiation.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Genom Ctr, Boston, MA 02115 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA; Kagoshima Univ, Grad Sch Med & Dent, Dept Neuromusculoskeletal Disorders, Kagoshima 8908520, Japan; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Salk Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kagoshima University; Baylor College of Medicine; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Yale University	Goldring, MB (corresponding author), Harvard Univ, Sch Med, Inst Med, HIM 246,4 Blackfan Circle, Boston, MA 02115 USA.	mgoldrin@bidmc.harvard.edu	Oettgen, Peter/AAF-5026-2021; Correa, Ricardo G/G-7613-2012; Wang, Hong/H-6298-2012; Zerbini, Luiz/B-7720-2015; Zhao, Yani/A-1968-2013; Libermann, Towia/F-9866-2010	Correa, Ricardo G/0000-0001-6940-7034; Zerbini, Luiz/0000-0003-0736-9508; Libermann, Towia/0000-0002-4006-8179; Otu, Hasan/0000-0002-9253-8152	NIAID NIH HHS [R01 AI049527, R01-AI49527] Funding Source: Medline; NIAMS NIH HHS [R01-AR45378] Funding Source: Medline; NIA NIH HHS [R01 AG022021, R01-AG22021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258; Aigner T, 2001, ARTHRITIS RHEUM-US, V44, P2777, DOI 10.1002/1529-0131(200112)44:12<2777::AID-ART465>3.0.CO;2-H; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Balliet AG, 2003, DNA CELL BIOL, V22, P457, DOI 10.1089/104454903322247334; BALLOCK RT, 1994, J CELL BIOL, V126, P1311, DOI 10.1083/jcb.126.5.1311; Ballock RT, 2003, J BONE JOINT SURG AM, V85A, P715, DOI 10.2106/00004623-200304000-00021; Colnot C, 2005, J CELL BIOCHEM, V95, P688, DOI 10.1002/jcb.20449; Colnot C, 2004, DEV BIOL, V269, P55, DOI 10.1016/j.ydbio.2004.01.011; Colnot CI, 2001, MECH DEVELOP, V100, P245, DOI 10.1016/S0925-4773(00)00532-3; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 2004, KELLEYS TXB RHEUMATO, P203; Gress CJ, 2000, J CELL BIOL, V149, P983, DOI 10.1083/jcb.149.4.983; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Hess J, 2003, J CELL SCI, V116, P4587, DOI 10.1242/jcs.00772; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Jacenko O, 2001, AM J PATHOL, V159, P2257, DOI 10.1016/S0002-9440(10)63076-3; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414; Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756-3282(97)00180-4; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; MacLean HE, 2003, DEV BIOL, V262, P51, DOI 10.1016/S0012-1606(03)00324-5; Maeda Y, 2004, J CELL BIOCHEM, V93, P337, DOI 10.1002/jcb.20154; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ortega N, 2004, TRENDS CELL BIOL, V14, P86, DOI 10.1016/j.tcb.2003.12.003; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Pfeifer A, 2001, ANNU REV GENOM HUM G, V2, P177, DOI 10.1146/annurev.genom.2.1.177; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; Provot S, 2005, BIOCHEM BIOPH RES CO, V328, P658, DOI 10.1016/j.bbrc.2004.11.068; Qiao B, 2005, J BIOL CHEM, V280, P17562, DOI 10.1074/jbc.M500646200; Qiu WH, 2003, AM J PATHOL, V162, P1961, DOI 10.1016/S0002-9440(10)64329-5; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Seghatoleslami MR, 2003, J CELL BIOCHEM, V88, P1129, DOI 10.1002/jcb.10458; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Sironen RK, 2002, BBA-MOL CELL RES, V1591, P45, DOI 10.1016/S0167-4889(02)00247-1; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Thirunavukkarasu K, 2000, BIOTECHNIQUES, V28, P506, DOI 10.2144/00283st09; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Valcourt U, 2002, J BIOL CHEM, V277, P33545, DOI 10.1074/jbc.M202086200; Volk SW, 1998, J BONE MINER RES, V13, P1521, DOI 10.1359/jbmr.1998.13.10.1521; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wu CW, 2002, J BONE MINER RES, V17, P639, DOI 10.1359/jbmr.2002.17.4.639; Xu L, 2005, J BIOL CHEM, V280, P548, DOI 10.1074/jbc.M411036200; Xu SC, 2001, DNA CELL BIOL, V20, P359, DOI 10.1089/10445490152122479; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zerbini LF, 2003, CANCER RES, V63, P2206; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089	90	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38544	38555		10.1074/jbc.M504202200	http://dx.doi.org/10.1074/jbc.M504202200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144844	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000233239800053
J	Niedziela-Majka, A; Heyduk, T				Niedziela-Majka, A; Heyduk, T			Escherichia coli RNA polymerase contacts outside the -10 promoter element are not essential for promoter melting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; FORK JUNCTION DNA; NONTEMPLATE STRAND OLIGONUCLEOTIDE; TRANSCRIPTION INITIATION; ANGSTROM RESOLUTION; OPEN COMPLEX; SIGMA-70 HOLOENZYME; SIGMA(70) SUBUNIT; CRYSTAL-STRUCTURE; STRUCTURAL BASIS	We examined the relative affinity of model promoter constructs for binding Escherichia coli RNA polymerase (RNAP) holoenzyme. Model promoter constructs were designed to mimic DNA structures characteristic for different steps of transcription initiation. DNA duplexes in which a chemical cross-link was introduced just downstream from -10 hexamer to prevent DNA melting upon RNAP binding were used to mimic RNAP-promoter contacts in a closed complex. Fork junction DNA molecules with double-stranded/ single-stranded junction between -11 and -10 position were used to study interactions of RNA polymerase with DNA in open complex. The -35 and -10 promoter regions were found to be equally important for the initial RNAP binding. The recognition of -35 promoter region was independent of structural context of the model promoter fragment. In contrast, free energy of RNAP binding to -10 hexamer was highly dependent on DNA structure. The relative importance of -10 region for sequence-specific interaction with the polymerase was the lowest for constructs mimicking closed complex and the highest for the constructs mimicking open complex. The relative importance of region -10 was also dependent on the presence of -35 consensus element indicating a communication between different DNA binding determinants of polymerase during open complex formation. Short double-stranded promoter fragments comprising only -35 and -10 or only -10 consensus elements underwent melting in a complex with polymerase indicating that the core of promoter melting activity of the polymerase is localized to a very small subset of all promoter-polymerase contacts.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@slu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; Chan CL, 1996, STRUCTURE, V4, P1235, DOI 10.1016/S0969-2126(96)00131-1; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; Darst SA, 2002, P NATL ACAD SCI USA, V99, P4296, DOI 10.1073/pnas.052054099; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Fenton MS, 2001, P NATL ACAD SCI USA, V98, P9020, DOI 10.1073/pnas.161085798; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Fenton MS, 2003, J BIOL CHEM, V278, P39669, DOI 10.1074/jbc.M307412200; Fenton MS, 2003, NUCLEIC ACIDS RES, V31, P2745, DOI 10.1093/nar/gkg400; Fiedler U, 2000, BIOESSAYS, V22, P316, DOI 10.1002/(SICI)1521-1878(200004)22:4<316::AID-BIES2>3.0.CO;2-B; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Heyduk E, 1999, J BIOL CHEM, V274, P3315, DOI 10.1074/jbc.274.6.3315; Heyduk E, 2002, BIOCHEMISTRY-US, V41, P2876, DOI 10.1021/bi012133i; Heyduk T, 2001, METHODS, V25, P44, DOI 10.1006/meth.2001.1214; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; Lee SJ, 2003, J MOL BIOL, V329, P941, DOI 10.1016/S0022-2836(03)00369-3; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PRIBNOW D, 1975, P NATL ACAD SCI USA, V72, P784, DOI 10.1073/pnas.72.3.784; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; Selvin PR, 1996, IEEE J SEL TOP QUANT, V2, P1077, DOI 10.1109/2944.577339; Sun L, 2004, J MOL BIOL, V343, P1171, DOI 10.1016/j.jmb.2004.09.025; Tsujikawa L, 2002, P NATL ACAD SCI USA, V99, P3493, DOI 10.1073/pnas.062487299; Tsujikawa L, 2002, BIOCHEMISTRY-US, V41, P15334, DOI 10.1021/bi026539m; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Young BA, 2004, SCIENCE, V303, P1382, DOI 10.1126/science.1092462; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	42	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38219	38227		10.1074/jbc.M507984200	http://dx.doi.org/10.1074/jbc.M507984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169843	hybrid			2022-12-25	WOS:000233239800015
J	Talasz, H; Lindner, HH; Sarg, B; Helliger, W				Talasz, H; Lindner, HH; Sarg, B; Helliger, W			Histone H4-lysine 20 monomethylation is increased in promoter and coding regions of active genes and correlates with hyperacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE LYSINE METHYLATION; C-MYC; CHROMATIN; H4; DIFFERENTIATION; HETEROCHROMATIN; ACETYLATION; CELLS; H3; METHYLTRANSFERASE	Methylation and acetylation of position-specific lysine residues in the N-terminal tail of histones H3 and H4 play an important role in regulating chromatin structure and function. In the case of H3-Lys(4), H3-Lys(9), H3-Lys(27), and H4-Lys(20), the degree of methylation was variable from the mono- to the di- or trimethylated state, each of which was presumed to be involved in the organization of chromatin and the activation or repression of genes. Here we investigated the interplay between histone H4-Lys(20) mono- and trimethylation and H4 acetylation at induced (beta-major/beta-minor globin), repressed (c-myc), and silent ( embryonic beta-globin) genes during in vitro differentiation of mouse erythroleukemia cells. By using chromatin immunoprecipitation, we found that the beta-major and beta-minor promoter and the beta-globin coding regions as well as the promoter and the transcribed exon 2 regions of the highly expressed c-myc gene were hyperacetylated and monomethylated at H4-Lys(20). Although activation of the beta-globin gene resulted in an increase in hyperacetylated, monomethylated H4, down-regulation of the c-myc gene did not cause a decrease in hyperacetylated, monomethylated H4-Lys(20), thus showing a stable pattern of histone modifications. Immunofluorescence microscopy studies revealed that monomethylated H4-Lys(20) mainly overlaps with RNA pol II-stained euchromatic regions, thus indicating an association with transcriptionally engaged chromatin. Our chromatin immunoprecipitation results demonstrated that in contrast to trimethylated H4-Lys(20), which was found to inversely correlate with H4 hyperacetylation, H4-Lys(20) monomethylation is compatible with histone H4 hyperacetylation and correlates with the transcriptionally active or competent chromatin state.	Innsbruck Med Univ, Bioctr, Div Clin Biochem, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Talasz, H (corresponding author), Innsbruck Med Univ, Bioctr, Div Clin Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Heribert.Talasz@uibk.ac.at						Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Bernard P, 2002, TRENDS CELL BIOL, V12, P419, DOI 10.1016/S0962-8924(02)02344-9; Biron VL, 2004, DEV BIOL, V276, P337, DOI 10.1016/j.ydbio.2004.08.038; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; HENDZEL MJ, 1989, J BIOL CHEM, V264, P19208; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sarg B, 2004, J BIOL CHEM, V279, P53458, DOI 10.1074/jbc.M409099200; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735	38	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38814	38822		10.1074/jbc.M505563200	http://dx.doi.org/10.1074/jbc.M505563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166085	hybrid			2022-12-25	WOS:000233239800083
J	Zhang, L; Balcerzak, M; Radisson, J; Thouverey, C; Pikula, S; Azzar, G; Buchet, R				Zhang, L; Balcerzak, M; Radisson, J; Thouverey, C; Pikula, S; Azzar, G; Buchet, R			Phosphodiesterase activity of alkaline phosphatase in ATP-initiated Ca2+ and phosphate deposition in isolated chicken matrix vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANE GLYCOPROTEIN-1; NUCLEOTIDE PYROPHOSPHATASE; INORGANIC PYROPHOSPHATE; EPIPHYSEAL CARTILAGE; ENRICHED FRACTIONS; NUCLEATIONAL CORE; MINERALIZATION; CALCIFICATION; RELEASE; PROTEIN	Inorganic pyrophosphate is a potent inhibitor of bone mineralization by preventing the seeding of calcium-phosphate complexes. Plasma cell membrane glycoprotein-1 and tissue nonspecific alkaline phosphatase were reported to be antagonistic regulators of mineralization toward inorganic pyrophosphate formation (by plasma cell membrane glycoprotein-1) and degradation (by tissue nonspecific alkaline phosphatase) under physiological conditions. In addition, they possess broad overlapping enzymatic functions. Therefore, we examined the roles of tissue nonspecific alkaline phosphatase within matrix vesicles isolated from femurs of 17-day-old chick embryos, under conditions where these both antagonistic and overlapping functions could be evidenced. Addition of 25 mu M ATP significantly increased duration of mineralization process mediated by matrix vesicles, while supplementation of mineralization medium with levamisole, an alkaline phosphatase inhibitor, reduces the ATP-induced retardation of mineral formation. Phosphodiesterase activity of tissue nonspecific alkaline phosphatase for bis-p-nitrophenyl phosphate was confirmed, the rate of this phosphodiesterase activity is in the same range as that of phosphomonoesterase activity for p-nitrophenyl phosphate under physiological pH. In addition, tissue nonspecific alkaline phosphatase at pH 7.4 can hydrolyze ADPR. On the basis of these observations, it can be concluded that tissue nonspecific alkaline phosphatase, acting as a phosphomonoesterase, could hydrolyze free phosphate esters such as pyrophosphate and ATP, while as phosphodiesterase could contribute, together with plasma cell membrane glycoprotein-1, in the production of pyrophosphate from ATP.	Univ Lyon 1, CNRS, UMR 5013, UFR Chim Biochim, F-69622 Villeurbanne, France; Polish Acad Sci, M Nencki Inst Expt Biol, Warsaw, Poland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Zhang, L (corresponding author), Univ Lyon 1, CNRS, UMR 5013, UFR Chim Biochim, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	le_zhang@hotmail.com	Rene, Buchet/I-9781-2019	Rene, Buchet/0000-0002-7966-3856; Thouverey, Cyril/0000-0002-2741-1825; Pikula, Slawomir/0000-0003-4640-3094				ABNEY ER, 1976, BIOCHEM J, V159, P293, DOI 10.1042/bj1590293; Ali S.Y., 1992, BONE BIOL SKELETAL D, P19; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; Angrand M, 1997, EUR J BIOCHEM, V250, P168, DOI 10.1111/j.1432-1033.1997.t01-1-00168.x; BELLI SI, 1994, BIOCHEM J, V304, P75, DOI 10.1042/bj3040075; BELLI SI, 1995, EUR J BIOCHEM, V228, P669, DOI 10.1111/j.1432-1033.1995.tb20308.x; Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; BOWLER WB, 1998, J BONE MINER RES, V13, P524; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECEVIC L, 1972, CALC TISS RES, V10, P82, DOI 10.1007/BF02012538; BRENNER S, 1959, BIOCHIM BIOPHYS ACTA, V34, P103, DOI 10.1016/0006-3002(59)90237-9; Buckley KA, 2003, FASEB J, V17, P1401, DOI 10.1096/fj.02-0940com; Camolezi FL, 2002, INT J BIOCHEM CELL B, V34, P1091, DOI 10.1016/S1357-2725(02)00029-8; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; CYBORON GW, 1981, J BIOL CHEM, V256, P7262; Derfus B, 1998, CALCIFIED TISSUE INT, V63, P258, DOI 10.1007/s002239900523; Derfus BA, 1996, CONNECT TISSUE RES, V35, P337, DOI 10.3109/03008209609029209; EVANS WH, 1973, BIOCHEM J, V135, P819, DOI 10.1042/bj1350819; Galperin MY, 1998, PROTEIN SCI, V7, P1829, DOI 10.1002/pro.5560070819; Garimella Rama, 2004, Biol Proced Online, V6, P263, DOI 10.1251/bpo97; Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; Harmey D, 2004, AM J PATHOL, V164, P1199, DOI 10.1016/S0002-9440(10)63208-7; Harris PD, 1997, PARASITOL RES, V83, P533, DOI 10.1007/s004360050294; HATORI M, 1995, J CELL PHYSIOL, V165, P468, DOI 10.1002/jcp.1041650304; HEPPEL LA, 1962, J BIOL CHEM, V237, P841; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; HOWELL DS, 1968, J CLIN INVEST, V47, P1121, DOI 10.1172/JCI105801; Hsu HHT, 1996, J BIOL CHEM, V271, P26383, DOI 10.1074/jbc.271.42.26383; HSU HHT, 1994, INT J BIOCHEM, V26, P1351, DOI 10.1016/0020-711X(94)90177-5; HSU HHT, 1983, J BIOL CHEM, V258, P3463; HSU HHT, 1995, INT J BIOCHEM CELL B, V27, P1349, DOI 10.1016/1357-2725(95)00103-V; HULL WE, 1976, BIOCHEMISTRY-US, V15, P1547, DOI 10.1021/bi00652a028; HUNG CT, 1997, AM J PHYSIOL, V272, P1611; Johnson K, 1999, ARTHRITIS RHEUM-US, V42, P1986, DOI 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O; Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994; Johnson KA, 2000, AM J PHYSIOL-REG I, V279, pR1365, DOI 10.1152/ajpregu.2000.279.4.R1365; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD DK, 1999, CALCIFIED TISSUE INT, V64, P58; MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005-2744(75)90151-5; MEYER JL, 1984, ARCH BIOCHEM BIOPHYS, V231, P1, DOI 10.1016/0003-9861(84)90356-4; MONTESSUIT C, 1991, J BIOL CHEM, V266, P17791; Mornet E, 2001, J BIOL CHEM, V276, P31171, DOI 10.1074/jbc.M102788200; MOSS DW, 1967, BIOCHEM J, V102, P53, DOI 10.1042/bj1020053; MOSS DW, 1969, BIOCHIM BIOPHYS ACTA, V191, P476, DOI 10.1016/0005-2744(69)90269-1; MURPHY J, 1962, ANAL CHIM ACTA, V26, P31; O'Brien PJ, 2001, BIOCHEMISTRY-US, V40, P5691, DOI 10.1021/bi0028892; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; REGISTER TC, 1985, BONE, V6, P307, DOI 10.1016/8756-3282(85)90320-5; REGISTER TC, 1984, J BIOL CHEM, V259, P3511; REZENDE AA, 1994, BIOCHEM J, V301, P517, DOI 10.1042/bj3010517; Solan JL, 1996, J BONE MINER RES, V11, P183; Stefan C, 1996, EUR J BIOCHEM, V241, P338, DOI 10.1111/j.1432-1033.1996.00338.x; Strater N, 1996, ANGEW CHEM INT EDIT, V35, P2024, DOI 10.1002/anie.199620241; VAANANEN HK, 1979, CALCIFIED TISSUE INT, V28, P65, DOI 10.1007/BF02441219; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0; Wilcox DE, 1996, CHEM REV, V96, P2435, DOI 10.1021/cr950043b; Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200; WU LNY, 1993, J BIOL CHEM, V268, P25084; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; Zhang L, 2004, BIOPHYS J, V86, P3873, DOI 10.1529/biophysj.103.034116	67	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37289	37296		10.1074/jbc.M504260200	http://dx.doi.org/10.1074/jbc.M504260200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16147995	hybrid			2022-12-25	WOS:000232901800087
J	Interthal, H; Chen, HJ; Champoux, JJ				Interthal, H; Chen, HJ; Champoux, JJ			Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYL-DNA PHOSPHODIESTERASE; PHOSPHOLIPASE-D SUPERFAMILY; HUMAN TOPOISOMERASE-I; COVALENT COMPLEXES; CRYSTAL-STRUCTURE; HUMAN-CELLS; SPINOCEREBELLAR ATAXIA; CATALYTIC MECHANISM; DRUG CAMPTOTHECIN; D FAMILY	Human tyrosyl-DNA phosphodiesterase (Tdp1) hydrolyzes the phosphodiester bond between a DNA 3' end and a tyrosyl moiety. In eukaryotic cells, this type of linkage is found in stalled topoisomerase I-DNA covalent complexes, and Tdp1 has been implicated in the repair of such complexes in vivo. We confirm here that the Tdp1 catalytic cycle involves a covalent reaction intermediate in which a histidine residue is connected to a DNA 3'-phosphate through a phosphoamide linkage. Most surprisingly, this linkage can be hydrolyzed by Tdp1, and unlike a topoisomerase I-DNA complex, which requires modification to be an efficient substrate for Tdp1, the native form of Tdp1 can be removed from the DNA. The spinocerebellar ataxia with axonal neuropathy neurodegenerative disease is caused by the H493R mutant form of Tdp1, which shows reduced enzymatic activity and accumulates the Tdp1-DNA covalent intermediate. The ability of wild type Tdp1 to remove the stalled mutant protein from the DNA likely explains the recessive nature of spinocerebellar ataxia with axonal neuropathy. In addition to its activity on phosphotyrosine and phosphohistidine substrates, Tdp1 also possesses a limited DNA and RNA 3'-exonuclease activity in which a single nucleoside is removed from the 3'-hydroxyl end of the substrate. Furthermore, Tdp1 also removes a 3' abasic site and an artificial 3'-biotin adduct from the DNA. In combination with earlier data showing that Tdp1 can use 3'-phosphoglycolate as a substrate, these data suggest that Tdp1 may function to remove a variety of 3' adducts from DNA during DNA repair.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049156, GM49156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADICELLA JP, 1997, P NATL ACAD SCI USA, V94, P8010; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Barthelmes HU, 2004, J BIOL CHEM, V279, P55618, DOI 10.1074/jbc.M405042200; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Davies DR, 2004, J MED CHEM, V47, P829, DOI 10.1021/jm030487x; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; Davies DR, 2002, J MOL BIOL, V324, P917, DOI 10.1016/S0022-2836(02)01154-3; Davies DR, 2002, STRUCTURE, V10, P237, DOI 10.1016/S0969-2126(02)00707-4; Debethune L, 2002, NUCLEIC ACIDS RES, V30, P1198, DOI 10.1093/nar/30.5.1198; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; El-Khamisy SF, 2005, NATURE, V434, P108, DOI 10.1038/nature03314; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Interthal H, 2005, EMBO J, V24, P2224, DOI 10.1038/sj.emboj.7600694; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; Jiricny J, 2002, NATURE, V415, P593, DOI 10.1038/415593a; Klumpp S, 2002, EUR J BIOCHEM, V269, P1067, DOI 10.1046/j.1432-1033.2002.02755.x; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Leppard JB, 2005, CHROMOSOMA, V114, P75, DOI 10.1007/s00412-005-0345-5; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Liu CY, 2004, DNA REPAIR, V3, P593, DOI 10.1016/j.dnarep.2004.03.030; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nivens MC, 2004, CANCER CHEMOTH PHARM, V53, P107, DOI 10.1007/s00280-003-0717-6; Oh MK, 2003, BBA-PROTEINS PROTEOM, V1649, P146, DOI 10.1016/S1570-9639(03)00166-3; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Ponting CP, 1996, PROTEIN SCI, V5, P914; Poon HF, 2004, CLIN GERIATR MED, V20, P329, DOI 10.1016/j.cger.2004.02.005; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Raymond AC, 2004, J MOL BIOL, V338, P895, DOI 10.1016/j.jmb.2004.03.013; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rideout MC, 2004, NUCLEIC ACIDS RES, V32, P4657, DOI 10.1093/nar/gkh796; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; Schultz SJ, 2004, J MOL BIOL, V344, P635, DOI 10.1016/j.jmb.2004.09.081; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; Zhao Y, 1997, PROTEIN SCI, V6, P2655; Zhou T, 2005, NUCLEIC ACIDS RES, V33, P289, DOI 10.1093/nar/gki170	55	168	173	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36518	36528		10.1074/jbc.M508898200	http://dx.doi.org/10.1074/jbc.M508898200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141202	hybrid, Green Accepted			2022-12-25	WOS:000232726900086
J	Wigneshweraraj, SR; Burrows, PC; Severinov, K; Buck, M				Wigneshweraraj, SR; Burrows, PC; Severinov, K; Buck, M			Stable DNA opening within open promoter complexes is mediated by the RNA polymerase beta '-jaw domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATION; TERMINAL SEQUENCES; STRUCTURAL BASIS; SIGMA(54); SUBUNIT; PROTEIN; BINDING; HOLOENZYME; INITIATION	DNA opening for transcription-competent open promoter complex (OC) formation by the bacterial RNA polymerase ( RNAP) relies upon a complex network of interactions between the structurally conserved and flexible modules of the catalytic beta and beta'-subunits, RNAP-associated sigma-subunit, and the DNA. Here, we show that one such module, the beta'-jaw, functions to stabilize the OC. In OCs formed by the major sigma(70)-RNAP, the stabilizing role of the beta'-jaw is not restricted to any particular melted DNA segment. In contrast, in OCs formed by the major variant sigma(54)-RNAP, the beta'-jaw and a conserved sigma(54) regulatory domain co-operate to stabilize the melted DNA segment immediately upstream of the transcription start site. Clearly, regulated communication between the mobile modules of the RNAP and the functional domain(s) of the sigma subunit is required for stable DNA opening.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Biol, London SW7 2AZ, England; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Rutgers State University New Brunswick; Imperial College London; Rutgers State University New Brunswick; Russian Academy of Sciences	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.	severik@waksman.rutgers.edu; m.buck@imperial.ac.uk	Severinov, Konstantin/C-8545-2016	Wigneshweraraj, Sivaramesh/0000-0002-1418-4029	NIGMS NIH HHS [R01 GM64530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064530] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bordes P, 2004, MOL MICROBIOL, V54, P489, DOI 10.1111/j.1365-2958.2004.04280.x; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Burrows PC, 2004, EMBO J, V23, P4253, DOI 10.1038/sj.emboj.7600406; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Ederth J, 2002, J BIOL CHEM, V277, P37456, DOI 10.1074/jbc.M207038200; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; MAYER AN, 1995, GENE, V153, P1, DOI 10.1016/0378-1119(94)00752-E; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; MORRIS L, 1994, J BIOL CHEM, V269, P11563; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Nechaev S, 2000, J BIOL CHEM, V275, P25516, DOI 10.1074/jbc.M002511200; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; Sclavi B, 2005, P NATL ACAD SCI USA, V102, P4706, DOI 10.1073/pnas.0408218102; Tsujikawa L, 2002, P NATL ACAD SCI USA, V99, P3493, DOI 10.1073/pnas.062487299; Van Wynsberghe A, 2004, BIOCHEMISTRY-US, V43, P13083, DOI 10.1021/bi049738+; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Wigneshweraraj SR, 2000, EMBO J, V19, P3038, DOI 10.1093/emboj/19.12.3038; Wigneshweraraj SR, 2004, EMBO J, V23, P4264, DOI 10.1038/sj.emboj.7600407; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Wigneshweraraj SR, 2003, J BIOL CHEM, V278, P3455, DOI 10.1074/jbc.M209442200; Wigneshweraraj SR, 2002, J MOL BIOL, V319, P1067, DOI 10.1016/S0022-2836(02)00330-3; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Zenkin N, 2004, P NATL ACAD SCI USA, V101, P4396, DOI 10.1073/pnas.0400886101; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36176	36184		10.1074/jbc.M506416200	http://dx.doi.org/10.1074/jbc.M506416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123036	hybrid			2022-12-25	WOS:000232726900049
J	Musselmann, K; Alexandrou, B; Kane, B; Hassell, JR				Musselmann, K; Alexandrou, B; Kane, B; Hassell, JR			Maintenance of the keratocyte phenotype during cell proliferation stimulated by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; HUMAN DIABETIC CORNEAS; HUMAN OCULAR SURFACE; BOVINE KERATOCYTES; BASEMENT-MEMBRANE; GROWTH-FACTOR; IN-VITRO; INTEGRIN ALTERATIONS; KNOCKOUT MICE; LUMICAN	Keratocytes normally express high levels of aldehyde dehydrogenase and keratocan. They proliferate and lose their keratocyte markers when they become fibroblastic during corneal wound healing. Keratocytes cultured in fetal bovine serum also become fibroblastic, proliferate, and lose these markers. In this report, we studied the effects of three serum growth factors, fibroblast growth factor- 2, insulin, and platelet- derived growth factor- BB, on keratocyte proliferation and the maintenance of the keratocyte markers in 7- day cultures in cells plated at low ( 5,000 cells/ cm(2)) and high ( 20,000 cells/ cm(2)) density in serum- free medium. Keratocyte proliferation was measured by [ H-3] thymidine incorporation and by DNA content of the cultures. Cytosolic aldehyde dehydrogenase and keratocan accumulated in the medium were quantified by Western blot. The results showed that all the growth factors stimulated proliferation, but insulin stimulated proliferation more consistently. The keratocyte markers aldehyde dehydrogenase and keratocan were maintained after 7 days in culture in all growth factors, but keratocyte cell morphology was only maintained in medium containing insulin. Most of the proteoglycans were degraded in cultures of keratocytes plated at low density and cultured in the absence of growth factors. This degradation was prevented when keratocytes were cultured in the presence of the growth factors or when keratocytes were plated at high density. The results of this study show that insulin can expand keratocytes in vitro, maintain their phenotype, and prevent proteoglycan degradation.	Shriners Hosp Children, Mol Biol Res, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Hassell, JR (corresponding author), Shriners Hosp Children, Mol Biol Res, 12502 Pine Dr, Tampa, FL 33612 USA.	jhassell@shctampa.usf.edu			NATIONAL EYE INSTITUTE [R37EY008104, R01EY008104] Funding Source: NIH RePORTER; NEI NIH HHS [EY08104] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; Berryhill BL, 2002, INVEST OPHTH VIS SCI, V43, P3416; Berryhill BL, 2001, INVEST OPHTH VIS SCI, V42, P1201; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Carlson EC, 2003, MOL VIS, V9, P615; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Chakravarti S, 2002, GLYCOCONJUGATE J, V19, P287, DOI 10.1023/A:1025348417078; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chakravarti S, 2001, EXP EYE RES, V73, P411, DOI 10.1006/exer.2001.1055; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Dunlevy JR, 1998, J BIOL CHEM, V273, P9615, DOI 10.1074/jbc.273.16.9615; Fini ME, 1999, PROG RETIN EYE RES, V18, P529, DOI 10.1016/S1350-9462(98)00033-0; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; Jester JV, 1999, J CELL SCI, V112, P613; Jester JV, 2003, EXP EYE RES, V77, P581, DOI 10.1016/S0014-4835(03)00188-X; Kabosova A, 2003, EXP EYE RES, V77, P211, DOI 10.1016/S0014-4835(03)00111-8; Kao WWY, 2002, GLYCOCONJUGATE J, V19, P275, DOI 10.1023/A:1025396316169; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705; Lehmann OJ, 2001, INVEST OPHTH VIS SCI, V42, P3118; Liu CY, 2003, J BIOL CHEM, V278, P21672, DOI 10.1074/jbc.M301169200; Ljubimov AV, 1998, J HISTOCHEM CYTOCHEM, V46, P1033, DOI 10.1177/002215549804600907; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Moller-Pedersen T, 2004, EXP EYE RES, V78, P553, DOI 10.1016/S0014-4835(03)00208-2; Muller LJ, 2004, EXP EYE RES, V78, P493, DOI 10.1016/S0014-4835(03)00206-9; Musselmann K, 2003, EXP EYE RES, V77, P273, DOI 10.1016/S0014-4835(03)00160-X; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; Pedersen WA, 2004, NEUROBIOL DIS, V17, P500, DOI 10.1016/j.nbd.2004.08.003; Pellegata NS, 2000, NAT GENET, V25, P91, DOI 10.1038/75664; Rocha EM, 2002, ADV EXP MED BIOL, V506, P607; Rocha EM, 2002, INVEST OPHTH VIS SCI, V43, P963; ROSS R, 1990, PHILOS T ROY SOC B, V327, P155, DOI 10.1098/rstb.1990.0051; Saghizadeh M, 2001, AM J PATHOL, V158, P723, DOI 10.1016/S0002-9440(10)64015-1; Sanchez-Thorin JC, 1998, INT OPHTHALMOL CLIN, V38, P19, DOI 10.1097/00004397-199838020-00004; Serrero G, 1999, IN VITRO CELL DEV-AN, V35, P642; She HY, 2005, J BIOL CHEM, V280, P4959, DOI 10.1074/jbc.M410078200; Tasheva ES, 1998, GENE, V218, P63, DOI 10.1016/S0378-1119(98)00390-4; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WIGHT M, 2001, ART SCI, V20, P1	46	54	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32634	32639		10.1074/jbc.m504724200	http://dx.doi.org/10.1074/jbc.m504724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16169858	hybrid			2022-12-25	WOS:000231920300011
J	Enokido, Y; Suzuki, E; Iwasawa, K; Namekata, K; Okazawa, H; Kimura, H				Enokido, Y; Suzuki, E; Iwasawa, K; Namekata, K; Okazawa, H; Kimura, H			Cystathionine beta-synthase, a key enzyme for homocysteine metabolism, is preferentially expressed in the radial glia/astrocyte lineage of developing mouse CNS	FASEB JOURNAL			English	Article						homocystinuria; hippocampal dentate gyrus; glial cells; seizure; neural stem cells	ALPHA-B-CRYSTALLIN; FIBRILLARY ACIDIC PROTEIN; HEAT-SHOCK PROTEINS; GROWTH-FACTOR ALPHA; KAINIC ACID; REACTIVE ASTROCYTES; SEIZURE ACTIVITY; MICE DEFICIENT; DNA-DAMAGE; STEM-CELLS	Cystathionine beta-synthase (CBS; EC 4.2.1.22) is a key enzyme in the generation of cysteine from methionine. A deficiency of CBS leads to homocystinuria, an inherited human disease characterized by mental retardation, seizures, psychiatric disturbances, skeletal abnormalities, and vascular disorders; however, the underlying mechanisms remain largely unknown. Here, we show the regional and cellular distribution of CBS in the adult and developing mouse brain. In the adult mouse brain, CBS was expressed ubiquitously, but it is expressed most intensely in the cerebellar molecular layer and hippocampal dentate gyrus. Immunohistochemical analysis revealed that CBS is preferentially expressed in cerebellar Bergmann glia and in astrocytes throughout the brain. At early developmental stages, CBS was expressed in neuroepithelial cells in the ventricular zone, but its expression changed to radial glial cells and then to astrocytes during the late embryonic and neonatal periods. CBS was most highly expressed in juvenile brain, and a striking induction was observed in cultured astrocytes in response to EGF, TGF-alpha, cAMP, and dexamethasone. Moreover, CBS was significantly accumulated in reactive astrocytes in the hippocampus after kainic acid-induced seizures, and cerebellar morphological abnormalities were observed in CBS-deficient mice. Taken together, these results suggest that CBS plays a crucial role in the development and maintenance of the CNS and that radial glia/astrocyte dysfunction might be involved in the complex neuropathological features associated with abnormal homocysteine metabolism.	Tokyo Med & Dent Univ, Med Res Inst, Dept Neuropathol, Bunkyo Ku, Tokyo 1138510, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Genet, Tokyo, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Tokyo, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Enokido, Y (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Neuropathol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	enokido.npat@mri.tmd.ac.jp	Kimura, Hideo/AGK-0606-2022	Kimura, Hideo/0000-0002-6069-0475; Enokido, Yasushi/0000-0003-3252-504X				Altman J, 1997, DEV CEREBELLAR SYSTE; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Goffinet A., 2000, MOUSE BRAIN DEV; GOSS SJ, 1986, J CELL SCI, V82, P309; Ho PI, 2002, J NEUROSCI RES, V70, P694, DOI 10.1002/jnr.10416; Imura T, 1999, J NEUROSCI, V19, P9768; IWAKI T, 1992, AM J PATHOL, V140, P345; Jacobson M., 1991, DEV NEUROBIOLOGY; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Kruman II, 2004, J BIOL CHEM, V279, P43952, DOI 10.1074/jbc.M408025200; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Lisovoski F, 1997, J NEUROPATH EXP NEUR, V56, P459, DOI 10.1097/00005072-199705000-00001; Maclean KN, 2004, J BIOL CHEM, V279, P8558, DOI 10.1074/jbc.M310211200; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Maurel D, 2000, GLIA, V29, P212, DOI 10.1002/(SICI)1098-1136(20000201)29:3<212::AID-GLIA3>3.0.CO;2-6; Mudd S., 2001, METABOLIC MOL BASES, P2007; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; Namekata K, 2004, J BIOL CHEM, V279, P52961, DOI 10.1074/jbc.M406820200; Oikawa S, 2003, ONCOGENE, V22, P3530, DOI 10.1038/sj.onc.1206440; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; Plumier JCL, 1996, NEUROSCIENCE, V75, P849, DOI 10.1016/0306-4522(96)00317-X; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RAKIC P, 1988, PROG BRAIN RES, V73, P15; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; Rosenquist TH, 2001, P NUTR SOC, V60, P53; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; Sakai K, 2003, J NEUROSCI, V23, P550; Scott JM, 1999, P NUTR SOC, V58, P441, DOI 10.1017/S0029665199000580; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; Surtees R, 1997, PEDIATR RES, V42, P577, DOI 10.1203/00006450-199711000-00004; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Tanaka S, 1998, J NEUROSCI, V18, P6358; Volpe J., 1995, NEUROLOGY NEWBORN, P43; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Yamasaki M, 2001, J NEUROSCI, V21, P7691, DOI 10.1523/JNEUROSCI.21-19-07691.2001; Yap S, 2001, J INHERIT METAB DIS, V24, P437, DOI 10.1023/A:1010525528842; Yun SJ, 2002, NEUROSCI LETT, V324, P45, DOI 10.1016/S0304-3940(02)00173-8	51	170	185	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1854	+		10.1096/fj.05-3724fje	http://dx.doi.org/10.1096/fj.05-3724fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16160063				2022-12-25	WOS:000232315700017
J	Zeng, LX; Xu, HS; Chew, TL; Eng, E; Sadeghi, MM; Adler, S; Kanwar, YS; Danesh, FR				Zeng, LX; Xu, HS; Chew, TL; Eng, E; Sadeghi, MM; Adler, S; Kanwar, YS; Danesh, FR			HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation	FASEB JOURNAL			English	Article						endothelial dysfunction; statin; vascular endothelial growth factor; diabetic nephropathy	GROWTH-FACTOR; SIGNALING PATHWAY; STATINS; TRANSDUCTION; SIMVASTATIN; EXPRESSION; GTPASES; KINASE	The beneficial effects of statins are usually assumed to stem from their ability to reduce cholesterol biosynthesis. However, because statins are potent inhibitors of the mevalonate, which governs diverse cell signaling pathways, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may also result in pleiotropic effects. The present study describes a novel pleiotropic effect of statins on vascular endothelial growth factor (VEGF)-induced glomerular endothelial cell (GEnC) hyperpermeability. Using live cell imaging with green fluorescent protein-tagged myosin regulatory light chain (MLC) and correlative biochemical analyses, we investigated 1) VEGF signaling pathway leading to GEnC hyperpermeability and 2) the modulatory effects of statins on VEGF signaling. Our findings indicate that VEGF stimulation elicits a robust increase in GEnC permeability. The signaling pathway that mediates VEGF-induced GEnC hyperpermeability involves RhoA activation leading to actin cytoskeletal remodeling, MLC diphosphorylation, and enhanced paracellular gap formation. Remarkably, cotreatment of endothelial cells with simvastatin, a hydrophobic statin, reversed VEGF-induced GEnC hyperpermeability by preventing MLC diphosphorylation, and cytoskeletal remodeling. In summary, this study identifies RhoA and MLC phosphorylation as key mediators of VEGF-induced endothelial cell hyperpermeability and demonstrates the modulatory effects of statins on VEGF signaling pathway.	Northwestern Univ, Feinberg Sch Med, Div Nephrol Hypertens, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Yale Sch Med, Div Cardiovasc Med, New Haven, CT USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Yale University; New York Medical College; Northwestern University	Danesh, FR (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Nephrol Hypertens, 303 E Chicago Ave,Searle Bldg 10-563, Chicago, IL 60611 USA.	f-rahimi@northwestern.edu		Danesh, Farhad/0000-0001-6849-5239	PHS HHS [67604, 64106] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER S, 1992, AM J PHYSIOL, V262, pF697; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Athyros VG, 2003, CURR MED RES OPIN, V19, P615, DOI 10.1185/030079903125002315; Carbajal JM, 2000, AM J PHYSIOL-CELL PH, V279, pC195; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Chen J, 2002, AM J PHYSIOL-CELL PH, V282, pC1053, DOI 10.1152/ajpcell.00292.2001; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229; Danesh FR, 2004, FASEB J, V18, P805, DOI 10.1096/fj.03-0839rev; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Flyvbjerg A, 2002, DIABETES, V51, P3090, DOI 10.2337/diabetes.51.10.3090; GARCIA JGN, 1995, J INVEST MED, V43, P117; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kang DH, 2003, CURR OPIN NEPHROL HY, V12, P43, DOI 10.1097/00041552-200301000-00008; Kim SI, 2000, KIDNEY INT, V58, pS88, DOI 10.1046/j.1523-1755.2000.07714.x; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; McFarlane SI, 2002, J CLIN ENDOCR METAB, V87, P1451, DOI 10.1210/jc.87.4.1451; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Qin J, 2003, KIDNEY INT, V64, P565, DOI 10.1046/j.1523-1755.2003.00127.x; Sadeghi NM, 2000, J IMMUNOL, V165, P2712, DOI 10.4049/jimmunol.165.5.2712; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Sorensson J, 2002, J AM SOC NEPHROL, V13, P2639, DOI 10.1097/01.ASN.0000033277.32822.23; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; VAN AL, 1997, GENE DEV, V11, P2295; Vasile E, 1999, J HISTOCHEM CYTOCHEM, V47, P159, DOI 10.1177/002215549904700205; Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wolfrum S, 2003, ARTERIOSCL THROM VAS, V23, P729, DOI 10.1161/01.ATV.0000063385.12476.A7; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng LX, 2004, J AM SOC NEPHROL, V15, P1711, DOI 10.1097/01.ASN.0000129839.91567.68	38	61	71	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1845	+		10.1096/fj.05-4240fje	http://dx.doi.org/10.1096/fj.05-4240fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16160062				2022-12-25	WOS:000232315700016
J	Gartel, AL				Gartel, AL			A new mode of transcriptional repression by c-myc: methylation	ONCOGENE			English	Editorial Material							GROWTH ARREST; DNA; METHYLTRANSFERASES; RECRUITMENT; ASSOCIATION; MECHANISMS; EXPRESSION; MIZ-1; GENES		Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60612 USA.	agartel@uic.edu						Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vaque JP, 2005, J BIOL CHEM, V280, P1112, DOI 10.1074/jbc.M409503200; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	14	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	14					1989	1990		10.1038/sj.onc.1209101	http://dx.doi.org/10.1038/sj.onc.1209101			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16170342				2022-12-25	WOS:000236359700001
J	Bartholomeusz, C; Itamochi, H; Nitta, M; Saya, H; Ginsberg, MH; Ueno, NT				Bartholomeusz, C; Itamochi, H; Nitta, M; Saya, H; Ginsberg, MH; Ueno, NT			Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15	ONCOGENE			English	Article						adenovirus type 5 E1A; proliferation; ovarian neoplasms; PEA15; ERK	PROTEIN-KINASE-C; TUMOR SUPPRESSION; HUMAN BREAST; INDUCE APOPTOSIS; ADENOVIRUS-5 E1A; GENE-TRANSFER; CELL-GROWTH; PEA-15; EXPRESSION; TRANSFORMATION	The adenovirus type 5 gene E1A is known to suppress tumorigenicity by transcriptionally downregulating HER-2/neu (HER2) or by inducing apoptosis. We show here that E1A also suppressed the tumorigenicity of the low-HER2-expressing ovarian cancer cell line OVCAR- 3 by decreasing cell proliferation. We further found that the mechanism responsible for this reduced proliferation is the presence of PEA15 (phosphoprotein enriched in astro-cytes), which is upregulated by E1A in ovarian cancer; PEA15 promotes translocation of ERK from the nucleus to the cytoplasm, leading to inhibition of ERK-dependent transcription and proliferation. Indeed, siRNA-mediated knockdown of PEA15 expression in OVCAR-3 stable E1A transfectants resulted in a nuclear accumulation of the active form of ERK, followed by an increase in Elk-1 activity, DNA synthesis, and anchorage-independent growth. Finally, PEA15 by itself suppressed colony formation in breast and ovarian cancer cell lines, in which E1A is known to have antitumor activity. We conclude that part of the antitumor effect of E1A in ovarian cancer results from cytoplasmic sequestration of the activated form of ERK by PEA15.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Unit 448, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX USA; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto, Japan; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Kumamoto University; University of California System; University of California San Diego; University of Texas System; UTMD Anderson Cancer Center	Ueno, NT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Unit 448, 1515 Holcombe Blvd, Houston, TX 77030 USA.	nueno@mdanderson.org	Saya, Hideyuki/J-4325-2013		NCI NIH HHS [CA76450-1, CA16672-27, CA016672-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA076450, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BYRD PJ, 1988, ONCOGENE, V2, P477; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2004, CLIN CANCER RES, V10, P2905, DOI 10.1158/1078-0432.CCR-04-0644; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRISCH SM, 1990, ONCOGENE, V5, P75; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hao CH, 2001, CANCER RES, V61, P1162; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; Hwang S, 1997, GENOMICS, V42, P540, DOI 10.1006/geno.1997.4768; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Krueger J, 2005, MOL BIOL CELL, V16, P3552, DOI 10.1091/mbc.E04-11-1007; Kubes M, 1998, J NEUROCHEM, V71, P1307; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Mymryk JS, 1996, ONCOGENE, V13, P1581; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Renault F, 2003, BIOCHEM PHARMACOL, V66, P1581, DOI 10.1016/S0006-2952(03)00514-8; RENGANAHAN H, 2005, BIOCH J 0526; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shao RP, 2000, CANCER RES, V60, P3123; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; TEODORO JG, 1995, ONCOGENE, V11, P467; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Ueno NT, 2000, CLIN CANCER RES, V6, P250; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Xu FJ, 1999, CLIN CANCER RES, V5, P3653; YAN DH, 1991, ONCOGENE, V6, P343; Yoo GH, 2001, CLIN CANCER RES, V7, P1237; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; Zang RY, 2001, INT J GYNECOL CANCER, V11, P18, DOI 10.1046/j.1525-1438.2001.011001018.x; ZHANG YJ, 1995, ONCOGENE, V10, P1947	60	32	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					79	90		10.1038/sj.onc.1209014	http://dx.doi.org/10.1038/sj.onc.1209014			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170361				2022-12-25	WOS:000234406400009
J	Di-Poi, N; Desvergne, B; Michalik, L; Wahli, W				Di-Poi, N; Desvergne, B; Michalik, L; Wahli, W			Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; C/EBP-ALPHA; HAIR FOLLICLE; PPAR-BETA; PROMOTER ACTIVITY; CARCINOMA-CELLS; GROWTH ARREST; ONCOGENIC RAS; DNA-BINDING; DIFFERENTIATION	The roles of peroxisome proliferator-activated receptors (PPARs) and CCAAT/enhancer-binding proteins (C/EBPs) in keratinocyte and sebocyte differentiation suggest that both families of transcription factors closely interact in the skin. Initial characterization of the mouse PPAR beta promoter revealed an AP-1 site that is crucial for the regulation of PPAR beta expression in response to inflammatory cytokines in the skin. We now present evidence for a novel regulatory mechanism of the expression of the PPAR beta gene by which two members of the C/EBP family of transcription factors inhibit its basal promoter activity in mouse keratinocytes. We first demonstrate that C/EBP alpha and C/EBP beta, but not C/EBP delta, inhibit the expression of PPAR beta through the recruitment of a transcriptional repressor complex containing HDAC-1 to a specific C/EBP binding site on the PPAR beta promoter. Consistent with this repression, the expression patterns of PPAR beta and C/EBPs are mutually exclusive in keratinocytes of the interfollicular epidermis and hair follicles in mouse developing skin. This work reveals the importance of the regulatory interplay between PPAR beta and C/EBP transcription factors in the control of proliferation and differentiation in this organ. Such insights are crucial for the understanding of the molecular control regulating the balance between proliferation and differentiation in many cell types including keratinocytes.	Univ Lausanne, Ctr Integrat Genom, Natl Ctr Competence Res Frontiers Genet, CH-1015 Lausanne, Switzerland	University of Lausanne	Michalik, L (corresponding author), Univ Lausanne, Ctr Integrat Genom, Natl Ctr Competence Res Frontiers Genet, CH-1015 Lausanne, Switzerland.	liliane.michalik@unil.ch; walter.wahli@unil.ch	Di-Poi, Nicolas/O-2378-2015; Wahli, Walter/B-1398-2009; Di-Poi, Nicolas/O-6256-2019; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Di-Poi, Nicolas/0000-0002-3313-3016; Wahli, Walter/0000-0002-5966-9089; Di-Poi, Nicolas/0000-0002-3313-3016; Desvergne, Beatrice/0000-0001-5483-288X; Michalik, Liliane/0000-0003-2963-2100				Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Belsham DD, 2000, MOL ENDOCRINOL, V14, P212, DOI 10.1210/me.14.2.212; Bull JJ, 2002, J INVEST DERMATOL, V118, P17, DOI 10.1046/j.0022-202x.2001.01629.x; Burkart AD, 2005, ENDOCRINOLOGY, V146, P1909, DOI 10.1210/en.2004-0842; Chen WC, 2003, J INVEST DERMATOL, V121, P441, DOI 10.1046/j.1523-1747.2003.12411.x; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Cristiano L, 2005, NEUROSCIENCE, V131, P577, DOI 10.1016/j.neuroscience.2004.11.008; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Di-Poi N, 2004, LIPIDS, V39, P1093, DOI 10.1007/s11745-004-1335-y; Di-Poi N, 2005, MOL CELL BIOL, V25, P1696, DOI 10.1128/MCB.25.5.1696-1712.2005; Di-Poi N, 2003, J STEROID BIOCHEM, V85, P257, DOI 10.1016/S0960-0760(03)00215-2; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Grimaldi PA, 2001, PROG LIPID RES, V40, P269, DOI 10.1016/S0163-7827(01)00005-4; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Narayanan K, 2004, J BIOL CHEM, V279, P45423, DOI 10.1074/jbc.M405031200; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Osada S, 1996, J BIOL CHEM, V271, P3891; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014; Schuettengruber B, 2003, MOL CELL BIOL, V23, P6993, DOI 10.1128/MCB.23.19.6993-7004.2003; Shim M, 2005, CANCER RES, V65, P861; Smith C, 2004, BIOCHEM J, V380, P757, DOI 10.1042/BJ20040077; Steffensen KR, 2002, BIOCHEM BIOPH RES CO, V293, P1333, DOI 10.1016/S0006-291X(02)00390-X; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tan NS, 2004, EMBO J, V23, P4211, DOI 10.1038/sj.emboj.7600437; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	44	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38700	38710		10.1074/jbc.M507782200	http://dx.doi.org/10.1074/jbc.M507782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166081	hybrid			2022-12-25	WOS:000233239800072
J	Saouros, S; Edwards-Jones, B; Reiss, M; Sawmynaden, K; Cota, E; Simpson, P; Dowse, TJ; Jakle, U; Ramboarina, S; Shivarattan, T; Matthews, S; Soldati-Favre, D				Saouros, S; Edwards-Jones, B; Reiss, M; Sawmynaden, K; Cota, E; Simpson, P; Dowse, TJ; Jakle, U; Ramboarina, S; Shivarattan, T; Matthews, S; Soldati-Favre, D			A novel galectin-like domain from Toxoplasma gondii micronemal protein 1 assists the folding, assembly, and transport of a cell adhesion complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; MIC1	Immediately prior to invasion Toxoplasma gondii tachyzoites release a large number of micronemal proteins (TgMICs) that participate in host cell attachment and penetration. The TgMIC4-MIC1-MIC6 complex was the first to be identified in T. gondii and has been recently shown to be critical in invasion. This study establishes that the N-terminal throm- bospondin type I repeat-like domains (TSR1-like) from TgMIC1 function as an independent adhesin as well as promoting association with TgMIC4. Using the newly solved three-dimensional structure of the C-terminal domain of TgMIC1 we have identified a novel Galectin-like fold that does not possess carbohydrate binding properties and redefines the architecture of TgMIC1. Instead, the TgMIC1 Galectin-like domain interacts and stabilizes TgMIC6, which provides the basis for a highly specific quality control mechanism for successful exit from the early secretory compartments and for subsequent trafficking of the complex to the micronemes.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, London SW7 2AZ, England; Univ Geneva CMU, Fac Med, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland; Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany	Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK; University of Geneva; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Matthews, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, S Kensington Campus, London SW7 2AZ, England.	s.j.matthews@imperial.ac.uk	Soldati-Favre, Dominique/A-2999-2009; Cota, Ernesto/A-5292-2009	Matthews, Steve/0000-0003-0676-0927; Simpson, Pete/0000-0002-2679-9303	Medical Research Council [G0400423, MC_U117533887, G0400423(70972)] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400423, MC_U117533887] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Cerede O, 2005, J EXP MED, V201, P453, DOI 10.1084/jem.20041672; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Di Cristina M, 2000, MOL CELL BIOL, V20, P7332, DOI 10.1128/MCB.20.19.7332-7341.2000; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Lourenco EV, 2001, GLYCOBIOLOGY, V11, P541, DOI 10.1093/glycob/11.7.541; Meissner M, 2002, J CELL SCI, V115, P563; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; Saouros S, 2005, J BIOMOL NMR, V31, P177, DOI 10.1007/s10858-004-8237-1; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Soldati D, 2004, CURR OPIN CELL BIOL, V16, P32, DOI 10.1016/j.ceb.2003.11.013; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Stebbins CE, 2003, NAT REV MOL CELL BIO, V4, P738, DOI 10.1038/nrm1201; Tomley FM, 2001, TRENDS PARASITOL, V17, P81, DOI 10.1016/S1471-4922(00)01761-X; Umemoto K, 2003, BIOCHEMISTRY-US, V42, P3688, DOI 10.1021/bi026671m	25	59	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38583	38591		10.1074/jbc.C500365200	http://dx.doi.org/10.1074/jbc.C500365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166092	hybrid, Green Accepted			2022-12-25	WOS:000233239800058
J	Kumar, S; Roychowdhury, A; Ember, B; Wang, Q; Guan, RJ; Mariuzza, RA; Boons, GJ				Kumar, S; Roychowdhury, A; Ember, B; Wang, Q; Guan, RJ; Mariuzza, RA; Boons, GJ			Selective recognition of synthetic lysine and meso-diaminopimelic acid-type peptidoglycan fragments by human peptidoglycan recognition proteins I alpha and S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; GRAM-POSITIVE BACTERIA; L-ALANINE AMIDASE; INNATE IMMUNITY; DROSOPHILA; BINDING; NOD1; INFLAMMATION; TECHNOLOGY; ACTIVATION	The interactions of a range of synthetic peptidoglycan derivatives with PGRP-I alpha and PGRP-S have been studied in real-time using surface plasmon resonance. A dissociation constant of K-D = 62 mu M was obtained for the interaction of peptidoglycan recognition protein (PGRP)-I alpha with the lysine-containing muramyl pentapeptide ( compound 6). The normalized data for the lysine-containing muramyl tetra- ( compound 5) and pentapeptide ( compound 6) showed that these compounds have similar affinities, whereas a much lower affinity for muramyl tripeptide ( compound 3) was measured. Similar affinities were obtained when the lysine moiety of the muramyl peptides was replaced by meso-diaminopimelic acid (DAP). Furthermore, the compounds that contained only a stem peptide ( pentapeptide, compound 1) and (DAP-PP, compound 2) as well as muramyldipeptide ( compound 3) exhibited no binding indicating that the muramyltripeptide ( compound 4) is the smallest peptidoglycan fragment that can be recognized by PGRP-I alpha. Surprisingly, PGRP-S derived significantly higher affinities for the DAP-containing fragments to similar lysine-containing derivatives, and the following dissociation constants were measured: muramylpentapeptide-DAP, K-D = 104 nM; muramyltetrapeptide-DAP, 92.4 nM; and muramyltripeptide-DAP, 326 nM. The binding profiles were rationalized by using a recently reported x-ray crystal structure of PGRP-I alpha with the lysine-containing muramyltripeptide (4).	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, Rockville, MD 20850 USA	University System of Georgia; University of Georgia; University System of Maryland; University of Maryland Baltimore	Mariuzza, RA (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	mariuzza@carb.nist.gov; gjboons@ccrc.uga.edu	Boons, Geert-Jan P H/J-3211-2016	Boons, Geert-Jan P H/0000-0003-3111-5954	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047990, R01AI065612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065248] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47990, AI065612] Funding Source: Medline; NIGMS NIH HHS [GM065248] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Cannon MJ, 2004, ANAL BIOCHEM, V330, P98, DOI 10.1016/j.ab.2004.02.027; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Check W, 2004, ASM NEWS, V70, P317; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Chowdhury AR, 2005, TETRAHEDRON LETT, V46, P1675, DOI 10.1016/j.tetlet.2005.01.062; Chowdhury AR, 2002, TETRAHEDRON LETT, V43, P7805; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Guan RJ, 2004, J BIOL CHEM, V279, P31873, DOI 10.1074/jbc.M404920200; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Lien E., 2002, CRIT CARE MED, V30, P1; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; O'Neill LAJ, 2004, TRENDS IMMUNOL, V25, P687, DOI 10.1016/j.it.2004.10.005; O'Neill LAJ, 2004, SCIENCE, V303, P1481, DOI 10.1126/science.1096113; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schmitz F, 2004, EUR J IMMUNOL, V34, P2863, DOI 10.1002/eji.200425228; SIEBER P, 1987, TETRAHEDRON LETT, V28, P2107, DOI 10.1016/S0040-4039(00)96055-6; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; Van Amersfoort ES, 2003, CLIN MICROBIOL REV, V16, P379, DOI 10.1128/CMR.16.3.379-414.2003; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772	45	45	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37005	37012		10.1074/jbc.M506385200	http://dx.doi.org/10.1074/jbc.M506385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129677	hybrid			2022-12-25	WOS:000232901800058
J	Coblitz, B; Shikano, S; Wu, M; Gabelli, SB; Cockrell, LM; Spieker, M; Hanyu, Y; Fu, H; Amzel, LM; Li, M				Coblitz, B; Shikano, S; Wu, M; Gabelli, SB; Cockrell, LM; Spieker, M; Hanyu, Y; Fu, H; Amzel, LM; Li, M			C-terminal recognition by 14-3-3 proteins for surface expression of membrane receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; RAF-1 KINASE; POTASSIUM CHANNELS; CYTOPLASMIC DOMAIN; BINDING; PHOSPHORYLATION; TRAFFICKING; TRANSPORT	Diverse functions of 14-3-3proteins are directly coupled to their ability to interact with targeted peptide substrates. RSX(pS/pT) XP and RX Phi X(pS/pT) XP are two canonical consensus binding motifs for 14-3-3 proteins representing the two common binding modes, modes I and II, between 14-3-3 and internal peptides. Using a genetic selection, we have screened a random peptide library and identified a group of C-terminal motifs, termed SWTY, capable of overriding an endoplasmic reticulum localization signal and redirecting membrane proteins to cell surface. Here we report that the C-terminal SWTY motif, although different from mode I and II consensus, binds tightly to 14-3-3 proteins with a dissociation constant (K-D) of 0.17 mu M, comparable with that of internal canonical binding peptides. We show that all residues but proline in -SWTX-COOH are compatible for the interaction and surface expression. Because SWTY-like sequences have been found in native proteins, these results support a broad significance of 14-3-3 interaction with protein C termini. The C-terminal binding consensus, mode III, represents an expansion of the repertoire of 14-3-3-targeted sequences.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University; National Institute of Advanced Industrial Science & Technology (AIST)	Shikano, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, BRB311,733 N Broadway, Baltimore, MD 21205 USA.	minli@jhmi.edu	Gabelli, Sandra B/A-3705-2008; Wu, Meng/F-3958-2010; Hanyu, Yoshiro/M-2573-2018	Gabelli, Sandra B/0000-0003-1205-5204; Hanyu, Yoshiro/0000-0002-3718-1920; Wu, Meng/0000-0003-2222-0736; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM53165, GM70959, GM60033] Funding Source: Medline; NINDS NIH HHS [NS33324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060033, R29GM053165, R01GM053165, R01GM070959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033324, R55NS033324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 2003, J BIOL CHEM, V278, P42266, DOI 10.1074/jbc.M306707200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Ganguly S, 2005, P NATL ACAD SCI USA, V102, P1222, DOI 10.1073/pnas.0406871102; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Shikano S, 2003, P NATL ACAD SCI USA, V100, P5783, DOI 10.1073/pnas.1031748100; SHIKANO S, 2005, NAT CELL BIOL; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	32	71	73	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36263	36272		10.1074/jbc.M507559200	http://dx.doi.org/10.1074/jbc.M507559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16123035	hybrid			2022-12-25	WOS:000232726900059
J	Geddie, ML; O'Loughlin, TL; Woods, KK; Matsumura, I				Geddie, ML; O'Loughlin, TL; Woods, KK; Matsumura, I			Rational design of p53, an intrinsically unstructured protein, for the fabrication of novel molecular sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDASE; HIV-1 PROTEASE; LETHAL FACTOR; BINDING-SITE; DNA; COMPLEMENTATION; SPECIFICITY; COMPLEXES; PURIFICATION; RECOGNITION	The dominant paradigm of protein engineering is structure based site-directed mutagenesis. This rational approach is generally more effective for the engineering of local properties, such as substrate specificity, than global ones such as allostery. Previous workers have modified normally unregulated reporter enzymes, including beta-galactosidase, alkaline phosphatase, and beta-lactamase, so that the engineered versions are activated (up to 4-fold) by monoclonal antibodies. A reporter that could easily be "reprogrammed" for the facile detection of novel effectors (binding or modifying activities) would be useful in high throughput screens for directed evolution or drug discovery. Here we describe a straightforward and general solution to this potentially difficult design problem. The transcription factor p53 is normally regulated by a variety of post-translational modifications. The insertion of peptides into intrinsically unstructured domains of p53 generated variants that were activated up to 100-fold by novel effectors (proteases or antibodies). An engineered p53 was incorporated into an existing high throughput screen for the detection of human immunodeficiency virus protease, an arbitrarily chosen novel effector. These results suggest that the molecular recognition properties of intrinsically unstructured proteins are relatively easy to engineer and that the absence of crystal structures should not deter the rational engineering of this class of proteins.	Emory Univ, Sch Med, Ctr Fundamental & Appl Mol Evolut, Rollins Res Ctr,Dept Biochem, Atlanta, GA 30322 USA	Emory University	Matsumura, I (corresponding author), Emory Univ, Sch Med, Ctr Fundamental & Appl Mol Evolut, Rollins Res Ctr,Dept Biochem, Rm 4119,1510 Clifton Rd, Atlanta, GA 30322 USA.	imatsum@emory.edu	Matsumura, Ichiro/E-1985-2011		NIAID NIH HHS [R21 AI054602-02, 1 R21AI054602-01, R21 AI054602] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054602] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Baker K, 2002, P NATL ACAD SCI USA, V99, P16537, DOI 10.1073/pnas.262420099; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; BERG JM, 2002, BIOCHEMISTRY-US, P266; Brannigan JA, 2002, NAT REV MOL CELL BIO, V3, P964, DOI 10.1038/nrm975; BRENNAN CA, 1995, P NATL ACAD SCI USA, V92, P5783, DOI 10.1073/pnas.92.13.5783; Drees BL, 1999, CURR OPIN CHEM BIOL, V3, P64, DOI 10.1016/S1367-5931(99)80012-X; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feliu JX, 1998, FEBS LETT, V434, P23, DOI 10.1016/S0014-5793(98)00943-0; Feliu JX, 2002, BBA-PROTEIN STRUCT M, V1596, P212, DOI 10.1016/S0167-4838(02)00226-1; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Geddie ML, 2004, J BIOL CHEM, V279, P26462, DOI 10.1074/jbc.M401447200; HALL AR, 1995, ONCOGENE, V10, P561; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; Legendre D, 1999, NAT BIOTECHNOL, V17, P67, DOI 10.1038/5243; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Liu SH, 2005, NAT BIOTECHNOL, V23, P725, DOI 10.1038/nbt1091; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Matsumura I, 1999, PROTEIN SCI, V8, P731; Michnick SW, 2003, CURR OPIN BIOTECH, V14, P610, DOI 10.1016/j.copbio.2003.10.014; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Prabu-Jeyabalan M, 2002, STRUCTURE, V10, P369, DOI 10.1016/S0969-2126(02)00720-7; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Tompa P, 2003, BIOESSAYS, V25, P847, DOI 10.1002/bies.10324; Tompa P, 2005, FEBS LETT, V579, P3346, DOI 10.1016/j.febslet.2005.03.072; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vickrey JF, 2003, PROTEIN EXPRES PURIF, V28, P165, DOI 10.1016/S1046-5928(02)00650-2; Villaverde A, 2003, FEBS LETT, V554, P169, DOI 10.1016/S0014-5793(03)01160-8; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Vucetic S, 2005, BIOINFORMATICS, V21, P137, DOI 10.1093/bioinformatics/bth476; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Zhang WW, 2000, J BIOTECHNOL, V84, P79, DOI 10.1016/S0168-1656(00)00330-8	46	8	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35641	35646		10.1074/jbc.M508149200	http://dx.doi.org/10.1074/jbc.M508149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118206	Green Accepted, hybrid			2022-12-25	WOS:000232561200067
J	Kimple, ME; Nixon, AB; Kelly, P; Bailey, CL; Young, KH; Fields, TA; Casey, PJ				Kimple, ME; Nixon, AB; Kelly, P; Bailey, CL; Young, KH; Fields, TA; Casey, PJ			A role for G(z) in pancreatic islet beta-cell biology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; STIMULATED INSULIN-SECRETION; BINDING REGULATORY PROTEINS; HORMONAL INHIBITION; ACTIVATING PROTEIN; ADP-RIBOSYLATION; COFACTOR EYA2; EXPRESSION; G(I); PHOSPHORYLATION	Glucose-stimulated insulin secretion and beta-cell growth are important facets of pancreatic islet beta-cell biology. As a result, factors that modulate these processes are of great interest for the potential treatment of Type 2 diabetes. Here, we present evidence that the heterotrimeric G protein G(z) and its effectors, including some previously thought to be confined in expression to neuronal cells, are present in pancreatic beta-cells, the largest cellular constituent of the islets of Langerhans. Furthermore, signaling pathways upon which G alpha(z) impacts are intact in beta-cells, and G alpha(z) activation inhibits both cAMP production and glucose- stimulated insulin secretion in the Ins-1( 832/ 13) beta-cell-derived line. Inhibition of glucose- stimulated insulin secretion by prostaglandin E (PGE1) is pertussis-toxin insensitive, indicating that other G alpha(i) family members are not involved in this process in this beta-cell line. Indeed, overexpression of a selective deactivator of G alpha(z), the RGS domain of RGSZ1, blocks the inhibitory effect of PGE1 on glucose-stimulated insulin secretion. Finally, the inhibition of glucose- stimulated insulin secretion by PGE1 is substantially blunted by small interfering RNA-mediated knockdown of G alpha(z) expression. Taken together, these data strongly imply that the endogenous E prostanoid receptor in the Ins-1(832/13) beta-cell line couples to Gz predominantly and perhaps even exclusively. These data provide the first evidence for Gz signaling in pancreatic beta-cells, and identify an endogenous receptor-mediated signaling process in beta-cells that is dependent on G alpha(z) function.	Duke Univ, Dept Pharmacol & Canc Biol, Ctr Med, Durham, NC 27710 USA; Duke Univ, Dept Pathol, Ctr Med, Durham, NC 27710 USA	Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Ctr Med, Durham, NC 27710 USA.	casey006@mc.duke.edu	Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964; Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062833, F32DK067799, T32DK007568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM055717, R01GM055717] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK067799, F32 DK067799, DK62833, DK07568] Funding Source: Medline; NIGMS NIH HHS [GM55717, GM19663] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Cheng HY, 2003, AM J PHYSIOL-ENDOC M, V285, pE287, DOI 10.1152/ajpendo.00535.2002; Embry AC, 2004, MOL PHARMACOL, V66, P1325, DOI 10.1124/mol.104.004093; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HILLAIREBUYS D, 1992, EUR J PHARMACOL, V218, P359, DOI 10.1016/0014-2999(92)90193-8; Ho MKC, 2001, ONCOGENE, V20, P1615, DOI 10.1038/sj.onc.1204190; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; KABOURIDIS PS, 1995, MOL CELL BIOCHEM, V144, P45, DOI 10.1007/BF00926739; Kammermeier PJ, 2003, MOL PHARMACOL, V63, P183, DOI 10.1124/mol.63.1.183; KATADA T, 1979, J BIOL CHEM, V254, P469; Kozasa Tohru, 2003, V237, P153; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LAYCHOCK SG, 1987, FEBS LETT, V218, P7, DOI 10.1016/0014-5793(87)81007-4; Lingohr MK, 2002, TRENDS MOL MED, V8, P375, DOI 10.1016/S1471-4914(02)02377-8; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; Maghazachi AA, 1996, J IMMUNOL, V157, P5308; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Meng JW, 2002, J BIOL CHEM, V277, P43417, DOI 10.1074/jbc.M204074200; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; RIBALET B, 1995, J PHYSIOL-LONDON, V485, P73, DOI 10.1113/jphysiol.1995.sp020713; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; ROBERTSON RP, 1983, ANNU REV MED, V34, P1, DOI 10.1146/annurev.me.34.020183.000245; ROBERTSON RP, 1991, DIABETES, V40, P1, DOI 10.2337/diabetes.40.1.1; Rodriguez-Pena MS, 1997, ENDOCRINE, V7, P255, DOI 10.1007/BF02778148; Scheltdorf M, 2002, N-S ARCH PHARMACOL, V366, P204, DOI 10.1007/s00210-002-0612-4; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SEAQUIST ER, 1992, DIABETES, V41, P1390, DOI 10.2337/diabetes.41.11.1390; Sharp GWG, 1996, AM J PHYSIOL-CELL PH, V271, pC1781, DOI 10.1152/ajpcell.1996.271.6.C1781; Sjoholm A, 1996, BBA-MOL CELL RES, V1313, P106; Skoglund G, 1999, J ENDOCRINOL, V162, P31, DOI 10.1677/joe.0.1620031; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; Ulrich AB, 2002, PANCREAS, V24, P111, DOI 10.1097/00006676-200203000-00001; VARRAULT A, 1995, ENDOCRINOLOGY, V136, P4390, DOI 10.1210/en.136.10.4390; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Werner M, 1996, HISTOCHEM CELL BIOL, V105, P253, DOI 10.1007/BF01463928; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	48	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31708	31713		10.1074/jbc.M506700200	http://dx.doi.org/10.1074/jbc.M506700200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16157560	hybrid			2022-12-25	WOS:000231665200047
J	Hausel, P; Latado, H; Courjault-Gautier, F; Felley-Bosco, E				Hausel, P; Latado, H; Courjault-Gautier, F; Felley-Bosco, E			Src-mediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase	ONCOGENE			English	Article						inducible nitric oxide synthase; Src kinase; tyrosine phosphorylation	INTESTINAL EPITHELIAL-CELLS; ULCERATIVE-COLITIS; TYROSINE KINASES; CROHNS-DISEASE; PROTEIN-KINASE; EXPRESSION; ACTIVATION; PATHWAY; INDUCTION; CANCER	Inducible nitric oxide synthase ( iNOS) expression is regulated at both the transcriptional and post-transcriptional level in epithelial cells. The aim of this study was to characterize the effects of tyrosine phosphorylation on iNOS activity. In a human intestinal epithelial cell line stimulated with cytokines, tyrosine phosphorylation of human iNOS protein was observed after 30 min exposure to pervanadate (PV), an inhibitor of protein tyrosine phosphatases. 4-Amino-5-(4-chlorophenyl)7-(t-butyl) pyrazolo[3,4-d] pyrimidine, a specific inhibitor of Src tyrosine kinases, abolished the PV-induced iNOS tyrosine phosphorylation. Cotransfection of Src with iNOS cDNA in human embryonic kidney (HEK) 293 cells resulted in a threefold (P < 0.001) increase of iNOS protein levels and tyrosine phosphorylation of iNOS. In the presence of Src, 76% of wild-type (wt) iNOS was redistributed to detergent-insoluble domains and iNOS activity was decreased by 28% (P < 0.05) despite increased iNOS protein levels. Analysis of iNOS tyrosine mutants revealed decreased Src-induced effects in Y151F iNOS mutant. Using a GST-fusion protein containing a domain encompassing Y151, we show that Y151 is a direct substrate for active Src in vitro. These findings indicate a role for iNOS tyrosine phosphorylation in the regulation of iNOS activity and the implication of Src tyrosine kinases in this pathway.	Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland		Felley-Bosco, E (corresponding author), Dept Pharmacol & Toxicol, Rue Burgnon 27, CH-1005 Lausanne, Switzerland.	emanuela.felley-bosco@unil.ch	Felley-Bosco, Emanuela/E-7484-2017	Felley-Bosco, Emanuela/0000-0002-3408-0294				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Ambs S, 1998, CANCER RES, V58, P334; Andre M, 2005, BIOCHEM PHARMACOL, V69, P595, DOI 10.1016/j.bcp.2004.11.007; Andre M, 2003, FEBS LETT, V546, P223, DOI 10.1016/S0014-5793(03)00576-3; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Chiu T, 2002, AM J PHYSIOL-CELL PH, V282, pC434, DOI 10.1152/ajpcell.00240.2001; COBBS CS, 1995, CANCER RES, V55, P727; Espey MG, 2000, J BIOL CHEM, V275, P11341, DOI 10.1074/jbc.275.15.11341; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; FELLEYBOSCO E, 1994, AM J RESP CELL MOL, V11, P159, DOI 10.1165/ajrcmb.11.2.7519434; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kimura H, 1997, DIGEST DIS SCI, V42, P1047, DOI 10.1023/A:1018849405922; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lee J, 2003, P NATL ACAD SCI USA, V100, P4843, DOI 10.1073/pnas.0735876100; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Miller MJS, 1999, AM J PHYSIOL-GASTR L, V276, pG795, DOI 10.1152/ajpgi.1999.276.4.G795; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; Navarro-Lerida I, 2004, J BIOL CHEM, V279, P55682, DOI 10.1074/jbc.M406621200; Paccani SR, 2005, BLOOD, V105, P2042, DOI 10.1182/blood-2004-04-1299; Pan JM, 1996, BIOCHEM J, V314, P889, DOI 10.1042/bj3140889; POSNER BI, 1994, J BIOL CHEM, V269, P4596; RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Rumbo M, 2005, FEBS J, V272, P444, DOI 10.1111/j.1742-4658.2004.04484.x; Salh B, 1998, J IMMUNOL, V161, P6947; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Sondermann H, 2005, CELL, V121, P158, DOI 10.1016/j.cell.2005.04.001; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Vecchini F, 1997, CELL GROWTH DIFFER, V8, P261; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914	44	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					198	206		10.1038/sj.onc.1209030	http://dx.doi.org/10.1038/sj.onc.1209030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116474				2022-12-25	WOS:000234583600004
J	Hambleton, R; Krall, J; Tikishvili, E; Honeggar, M; Ahmad, F; Manganiello, VC; Movsesian, MA				Hambleton, R; Krall, J; Tikishvili, E; Honeggar, M; Ahmad, F; Manganiello, VC; Movsesian, MA			Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GUANYLYL CYCLASE-A; HUMAN VENTRICULAR MYOCARDIUM; RAT CARDIAC MYOCYTES; NITRIC-OXIDE; NATRIURETIC-PEPTIDE; HEART-FAILURE; SARCOPLASMIC-RETICULUM; CA2+ CURRENT; ROLIPRAM INHIBITION	Three isoforms of PDE3 (cGMP-inhibited) cyclic nucleotide phosphodiesterase regulate cAMP content in different intracellular compartments of cardiac myocytes in response to different signals. We characterized the catalytic activity and inhibitor sensitivity of these isoforms by using recombinant proteins. We determined their contribution to cAMP hydrolysis in cytosolic and microsomal fractions of human myocardium at 0.1 and 1.0 mu M cAMP in the absence and presence of Ca2+/calmodulin. We examined the effects of cGMP on cAMP hydrolysis in these fractions. PDE3A-136, PDE3A118, and PDE3A-94 have similar K-m and k(cat) values for cAMP and are equal in their sensitivities to inhibition by cGMP and cilostazol. In microsomes, PDE3A-136, PDE3A-118, and PDE3A-94 comprise the majority of cAMP hydrolytic activity under all conditions. In cytosolic fractions, PDE3A-118 and PDE3A-94 comprise > 50% of the cAMP hydrolytic activity at 0.1 mu M cAMP, in the absence of Ca2+/calmodulin. At 1.0 mu M cAMP, in the presence of Ca2+/calmodulin, activation of Ca2+/calmodulin-activated (PDE1) and other non-PDE3 phosphodiesterases reduces their contribution to < 20% of cAMP hydrolytic activity. cGMP inhibits cAMP hydrolysis in microsomal fractions by inhibiting PDE3 and in cytosolic fractions by inhibiting both PDE3 and PDE1. These findings indicate that the contribution of PDE3 isoforms to the regulation of cAMP hydrolysis in intracellular compartments of human myocardium and the effects of PDE3 inhibition on cAMP hydrolysis in these compartments are highly dependent on intracellular [Ca2+] and [cAMP], which are lower in failing hearts than in normal hearts. cGMP may amplify cAMP-mediated signaling in intracellular compartments of human myocardium by PDE3-dependent and PDE3-independent mechanisms.	Vet Affairs Salt Lake City Hlth Care Syst, Cardiol Sect, Salt Lake City, UT 84148 USA; Univ Utah, Sch Med, Dept Internal Med Cardiol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Pharmacol, Salt Lake City, UT 84132 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Movsesian, MA (corresponding author), Vet Affairs Salt Lake City Hlth Care Syst, Cardiol Sect, 500 Foothill Blvd, Salt Lake City, UT 84148 USA.	matthew.movsesian@hsc.utah.edu	Khan, Faiyaz Ahmad/AAW-7944-2021					Aizawa T, 2003, CIRC RES, V93, P406, DOI 10.1161/01.RES.0000091074.33584.F0; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BEAULIEU P, 1997, AM J PHYSIOL-HEART C, V273, pH1933; BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; BOHM M, 1994, CARDIOVASC RES, V28, P1713, DOI 10.1093/cvr/28.11.1713; Bolger GB, 1997, BIOCHEM J, V328, P539; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; Choi YH, 2001, BIOCHEM J, V353, P41, DOI 10.1042/0264-6021:3530041; Ding B, 2005, CIRCULATION, V111, P2469, DOI 10.1161/01.CIR.0000165128.39715.87; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Elbatarny HS, 2005, AM J PHYSIOL-ENDOC M, V289, pE695, DOI 10.1152/ajpendo.00125.2005; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Focaccio A, 1996, CIRCULATION, V93, P817, DOI 10.1161/01.CIR.93.4.817; Fung E, 2003, J CARDIOVASC PHARM, V41, P849, DOI 10.1097/00005344-200306000-00004; Georget M, 2003, FASEB J, V17, P1380, DOI 10.1096/fj.02-0784com; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Hassan Madiha A. H., 2005, BMC Pharmacology, V5, P10, DOI 10.1186/1471-2210-5-10; HAYES JS, 1982, BIOCHIM BIOPHYS ACTA, V714, P136, DOI 10.1016/0304-4165(82)90135-0; HAYES JS, 1980, J BIOL CHEM, V255, P5113; Hirose M, 1998, J PHARMACOL EXP THER, V286, P70; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Huston E, 2000, J BIOL CHEM, V275, P28063; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kuhn M, 2003, CIRC RES, V93, P700, DOI 10.1161/01.RES.0000094745.28948.4D; Kurtz A, 1998, P NATL ACAD SCI USA, V95, P4743, DOI 10.1073/pnas.95.8.4743; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Layland J, 2002, J PHYSIOL-LONDON, V540, P457, DOI 10.1113/jphysiol.2001.014126; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; LOHMANN SM, 1991, BASIC RES CARDIOL, V86, P503, DOI 10.1007/BF02190700; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MERY PF, 1993, J BIOL CHEM, V268, P26286; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Mongillo M, 2004, CIRC RES, V95, P67, DOI 10.1161/01.RES.0000134629.84732.11; Movsesian MA, 2003, J CARD FAIL, V9, P475, DOI 10.1016/S1071-9164(03)00135-0; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; Movsesian MA, 1998, ANN NY ACAD SCI, V853, P231, DOI 10.1111/j.1749-6632.1998.tb08271.x; Musialek P, 2000, J MOL CELL CARDIOL, V32, P1831, DOI 10.1006/jmcc.2000.1216; Padayatti PS, 2004, PHARMACOL THERAPEUT, V104, P83, DOI 10.1016/j.pharmthera.2004.08.003; Patel KN, 2001, BASIC RES CARDIOL, V96, P34, DOI 10.1007/s003950170075; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Pierkes M, 2002, CARDIOVASC RES, V53, P852, DOI 10.1016/S0008-6363(01)00543-0; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Saldou N, 1998, CELL SIGNAL, V10, P427, DOI 10.1016/S0898-6568(97)00169-1; SCHMITZ W, 1992, BASIC RES CARDIOL, V87, P65; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; Shakur Y, 2002, CARDIOVASC DRUG THER, V16, P417, DOI 10.1023/A:1022186402442; Sharma R.K., 1996, PHOSPHODIESTERASE IN, P65, DOI [10.1016/b978-012210720-7/50006-x, DOI 10.1016/B978-012210720-7/50006-X]; Shimizu K, 2002, BRIT J PHARMACOL, V137, P127, DOI 10.1038/sj.bjp.0704843; Takimoto E, 2005, NAT MED, V11, P214, DOI 10.1038/nm1175; TASKEN K, 1995, FACTSBOOK PROTEIN KI, P58; Vandecasteele G, 2001, J PHYSIOL-LONDON, V533, P329, DOI 10.1111/j.1469-7793.2001.0329a.x; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Wechsler J, 2002, J BIOL CHEM, V277, P38072, DOI 10.1074/jbc.M203647200; Wegener JW, 2002, CIRC RES, V90, P18, DOI 10.1161/hh0102.103222; Weiss HR, 2003, EUR J PHARMACOL, V481, P25, DOI 10.1016/j.ejphar.2003.09.006; Wen JF, 2004, CIRC RES, V94, P936, DOI 10.1161/01.RES.0000123826.70125.4D; Wollert KC, 2003, BRIT J PHARMACOL, V140, P1227, DOI 10.1038/sj.bjp.0705567; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zahabi A, 2003, J BIOL CHEM, V278, P47694, DOI 10.1074/jbc.M309661200	70	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39168	39174		10.1074/jbc.M506760200	http://dx.doi.org/10.1074/jbc.M506760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16172121	hybrid			2022-12-25	WOS:000233362200032
J	Sparr, E; Ash, WL; Nazarov, PV; Rijkers, DTS; Hemminga, MA; Tieleman, DP; Killian, JA				Sparr, E; Ash, WL; Nazarov, PV; Rijkers, DTS; Hemminga, MA; Tieleman, DP; Killian, JA			Self-association of transmembrane alpha-helices in model membranes - Importance of helix orientation and role of hydrophobic mismatch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-ORGANIZATION; LIPID RAFTS; PEPTIDES; PROTEINS; RESIDUES; BILAYERS; PACKING; SIMULATION; STABILITY; MECHANISM	Interactions between transmembrane helices play a key role in almost all cellular processes involving membrane proteins. We have investigated helix-helix interactions in lipid bilayers with synthetic tryptophan-flanked peptides that mimic the membrane spanning parts of membrane proteins. The peptides were functionalized with pyrene to allow the self-association of the helices to be monitored by pyrene fluorescence and Trp-pyrene fluorescence resonance energy transfer (FRET). Specific labeling of peptides at either their N or C terminus has shown that helix-helix association occurs almost exclusively between antiparallel helices. Furthermore, computer modeling suggested that antiparallel association arises primarily from the electrostatic interactions between alpha-helix backbone atoms. We propose that such interactions may provide a force for the preferentially antiparallel association of helices in polytopic membrane proteins. Helix-helix association was also found to depend on the lipid environment. In bilayers of dioleoylphosphatidylcholine, in which the hydrophobic length of the peptides approximately matched the bilayer thickness, association between the helices was found to require peptide/lipid ratios exceeding 1/25. Self-association of the helices was promoted by either increasing or decreasing the bilayer thickness, and by adding cholesterol. These results indicate that helix-helix association in membrane proteins can be promoted by unfavorable protein-lipid interactions.	Univ Utrecht, Dept Biochem Membranes, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Fac Pharmaceut Sci, Dept Med Chem, NL-3584 CH Utrecht, Netherlands; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Wageningen & Res Ctr, Biophys Lab, NL-6700 ET Wageningen, Netherlands	Utrecht University; Utrecht University; Utrecht University; University of Calgary; Wageningen University & Research	Sparr, E (corresponding author), Lund Univ, Ctr Chem & Chem Engn, Phys Chem 1,POB 124, SE-22100 Lund, Sweden.	emma.sparr@fkem1.lu.se; wlash@ucalgary.ca	Killian, J. Antoinette/I-3001-2016; Tieleman, D. Peter/A-4790-2011	Tieleman, D. Peter/0000-0001-5507-0688; Rijkers, Dirk T.S./0000-0002-8874-7576; Killian, J. Antoinette/0000-0001-8010-3816; Sparr, Emma/0000-0001-8343-9657; Nazarov, Petr/0000-0003-3443-0298				AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; Arkin IT, 2002, BBA-BIOMEMBRANES, V1565, P347, DOI 10.1016/S0005-2736(02)00580-1; Ash WL, 2004, BIOCHEMISTRY-US, V43, P9050, DOI 10.1021/bi0494572; BenTal N, 1996, BIOPHYS J, V71, P3046, DOI 10.1016/S0006-3495(96)79498-5; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Chamberlain AK, 2003, ADV PROTEIN CHEM, V63, P19; Choma C, 2000, NAT STRUCT BIOL, V7, P161; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; de Planque MRR, 1998, BIOCHEMISTRY-US, V37, P9333, DOI 10.1021/bi980233r; Demmers JAA, 2000, P NATL ACAD SCI USA, V97, P3189, DOI 10.1073/pnas.050444797; Engelman DM, 2003, FEBS LETT, V555, P122, DOI 10.1016/S0014-5793(03)01106-2; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; Johnson RM, 2004, BIOCHEMISTRY-US, V43, P14361, DOI 10.1021/bi0492760; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Killian JA, 2003, FEBS LETT, V555, P134, DOI 10.1016/S0014-5793(03)01154-2; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Langosch D, 2002, IUBMB LIFE, V54, P109, DOI 10.1080/15216540214538; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Lew S, 2003, BIOCHEMISTRY-US, V42, P10833, DOI 10.1021/bi034929i; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mall S, 2000, BIOCHEMISTRY-US, V39, P2071, DOI 10.1021/bi992205u; Mall S, 2001, BIOCHEMISTRY-US, V40, P12379, DOI 10.1021/bi011075y; Nazarov PV, 2004, J CHEM INF COMP SCI, V44, P568, DOI 10.1021/ci034149g; Nielsen RD, 2005, J AM CHEM SOC, V127, P6430, DOI 10.1021/ja042782s; NILGES M, 1993, PROTEINS, V15, P133, DOI 10.1002/prot.340150205; Orzaez M, 2005, FEBS LETT, V579, P1633, DOI 10.1016/j.febslet.2005.01.078; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Seo J, 2004, IEEE SYMPOSIUM ON INFORMATION VISUALIZATION 2004, PROCEEDINGS, P65; Sparr E, 2005, BIOCHEMISTRY-US, V44, P2, DOI 10.1021/bi048047a; Strelkov SV, 2002, J STRUCT BIOL, V137, P54, DOI 10.1006/jsbi.2002.4454; Subczynski WK, 1998, BIOCHEMISTRY-US, V37, P3156, DOI 10.1021/bi972148+; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021; Webb RJ, 1998, BIOCHEMISTRY-US, V37, P673, DOI 10.1021/bi972441+; Yano Y, 2002, BIOCHEMISTRY-US, V41, P3073, DOI 10.1021/bi011161y; Yatskou MM, 2001, CHEM PHYS LETT, V345, P141, DOI 10.1016/S0009-2614(01)00867-3; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	45	108	110	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39324	39331		10.1074/jbc.M502810200	http://dx.doi.org/10.1074/jbc.M502810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16169846	hybrid			2022-12-25	WOS:000233362200052
J	Michlig, S; Harris, M; Loffing, J; Rossier, BC; Firsov, D				Michlig, S; Harris, M; Loffing, J; Rossier, BC; Firsov, D			Progesterone down-regulates the open probability of the amiloride-sensitive epithelial sodium channel via a Nedd4-2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; DEPENDENT REGULATION; MOUSE MODEL; WW DOMAIN; ENAC; TRANSPORT; NEDD4; SGK1; ACTIVATION; ABSORPTION	Activation of the mitogen-activated protein (MAP) kinase cascade by progesterone in Xenopus oocytes leads to a marked down-regulation of activity of the amiloride-sensitive epithelial sodium channel (ENaC). Here we have studied the signaling pathways involved in progesterone effect on ENaC activity. We demonstrate that: (i) the truncation of the C termini of the alpha beta gamma ENaC subunits results in the loss of the progesterone effect on ENaC; (ii) the effect of progesterone was also suppressed by mutating conserved tyrosine residues in the Pro-X-X-Tyr (PY) motif of the C termini of the beta and gamma ENaC subunits (beta(Y618A) and gamma(Y628A)); (iii) the down-regulation of ENaC activity by progesterone was also suppressed by co-expression ENaC subunits with a catalytically inactive mutant of Nedd4-2, a ubiquitin ligase that has been previously demonstrated to decrease ENaC cell-surface expression via a ubiquitin-dependent internalization/degradation mechanism; (iv) the effect of progesterone was significantly reduced by suppression of consensus sites (beta(T613A) and gamma(T623A)) for ENaC phosphorylation by the extracellular-regulated kinase (ERK), a MAP kinase previously shown to facilitate the binding of Nedd4 ubiquitin ligases to ENaC; (v) the quantification of cell-surface-expressed ENaC subunits revealed that progesterone decreases ENaC open probability (whole cell P-o, wcP(o)) and not its cell-surface expression. Collectively, these results demonstrate that the binding of active Nedd4-2 to ENaC is a crucial step in the mechanism of ENaC inhibition by progesterone. Upon activation of ERK, the effect of Nedd4-2 on ENaC open probability can become more important than its effect on ENaC cell-surface expression.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Fribourg, Dept Med, Unite Anat, CH-1700 Fribourg, Switzerland	University of Lausanne; University of Fribourg	Firsov, D (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	dmitri.firsov@unil.ch	Loffing, Johannes/ABG-9973-2020	Loffing, Johannes/0000-0002-9415-6588				Dahlmann A, 2003, AM J PHYSIOL-RENAL, V285, pF310, DOI 10.1152/ajprenal.00016.2003; de la Rosa DA, 2004, J GEN PHYSIOL, V124, P395, DOI 10.1085/jgp.200409120; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Ilsley JL, 2002, CELL SIGNAL, V14, P183, DOI 10.1016/S0898-6568(01)00236-4; Kamynina E, 2002, AM J PHYSIOL-RENAL, V283, pF377, DOI 10.1152/ajprenal.00143.2002; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Nicod M, 2002, EMBO J, V21, P5109, DOI 10.1093/emboj/cdf509; Planes C, 2005, AM J PHYSIOL-LUNG C, V288, pL1099, DOI 10.1152/ajplung.00332.2004; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Pradervand S, 2003, J AM SOC NEPHROL, V14, P2219, DOI 10.1097/01.ASN.0000080204.65527.E6; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Rossier BC, 2002, J GEN PHYSIOL, V120, P67, DOI 10.1085/jgp.20028638; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Shen JP, 2003, AM J PHYSIOL-RENAL, V284, pF57, DOI 10.1152/ajprenal.00028.2002; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Veizis IE, 2005, AM J PHYSIOL-RENAL, V288, pF474, DOI 10.1152/ajprenal.00227.2004; Verrey F, 2003, CELL PHYSIOL BIOCHEM, V13, P21, DOI 10.1159/000070246; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600	31	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38264	38270		10.1074/jbc.M506308200	http://dx.doi.org/10.1074/jbc.M506308200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172119	hybrid, Green Submitted			2022-12-25	WOS:000233239800021
J	Vaughn, JP; Creacy, SD; Routh, ED; Joyner-Butt, C; Jenkins, GS; Pauli, S; Nagamine, Y; Akman, SA				Vaughn, JP; Creacy, SD; Routh, ED; Joyner-Butt, C; Jenkins, GS; Pauli, S; Nagamine, Y; Akman, SA			The DEXH protein product of the DHX36 gene is the major source of tetramolecular quadruplex G4-DNA resolving activity in HeLa cell lysates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA HELICASE-A; SMALL-MOLECULE; PROMOTER REGION; DNA-BINDING; IDENTIFICATION; TRANSCRIPTION; NUCLEOLIN; AFFINITY; ROLES	G4-DNA is a highly stable alternative DNA structure that can form spontaneously in guanine-rich regions of single-stranded DNA under physiological conditions. Since a number of biological processes create such single-stranded regions, G4-DNA occurrence must be regulated. To date, resolution of tetramolecular G4-DNA into single strands (G4-resolvase activity) has been observed only in recombinant RecQ DNA helicases. We previously reported that human cell lysates possess tetramolecular G4-DNA resolving activity (Harrington, C., Lan, Y., and Akman, S. (1997) J. Biol Chem. 272, 24631-24636). Here we report the first complete purification of a major non-RecQ, NTP-dependent G4-DNA resolving enzyme from human cell lysates. This enzyme is identified as the DEXH helicase product of gene DHX36 (also known as RHAU). G4-DNA resolving activity was captured from HeLa cell lysates on G4-DNA affinity beads and further purified by gel filtration chromatography. The DHX36 gene product was identified by mass spectrometric sequencing of a tryptic digest from the protein band on SDS-PAGE associated with activity. DHX36 was cloned within a His(6)-tagging vector, expressed, and purified from Escherichia coli. Inhibition and substrate resolution assays showed that recombinant DHX36 protein displayed robust, highly specific G4-DNA resolving activity. Immunodepletion of HeLa lysates by a monoclonal antibody to the DHX36 product removed ca. 77% of the enzyme from lysates and reduced G4-DNA resolving activity to 46.0 +/- 0.4% of control, demonstrating that DHX36 protein is responsible for the majority of tetramolecular G4-DNA resolvase activity.	Wake Forest Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Med Ctr, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University School of Medicine; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University School of Medicine; Friedrich Miescher Institute for Biomedical Research; Novartis	Akman, SA (corresponding author), Wake Forest Med Ctr, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	sakman@wfubmc.edu		Routh, Eric/0000-0002-7371-1802	NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [2-P30 CA12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Arthanari H, 2001, CHEM BIOL, V8, P221, DOI 10.1016/S1074-5521(01)00007-2; Chang CC, 2004, ANAL CHEM, V76, P4490, DOI 10.1021/ac049510s; Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; Ding H, 2004, CELL, V117, P873, DOI 10.1016/j.cell.2004.05.026; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Fu JJ, 2002, ACTA BIOCH BIOPH SIN, V34, P655; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Grand CL, 2004, P NATL ACAD SCI USA, V101, P6140, DOI 10.1073/pnas.0400460101; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Harrington C, 1997, J BIOL CHEM, V272, P24631, DOI 10.1074/jbc.272.39.24631; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Lew A, 2000, P NATL ACAD SCI USA, V97, P12508, DOI 10.1073/pnas.97.23.12508; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Patel SD, 2004, BIOCHEMISTRY-US, V43, P13452, DOI 10.1021/bi048892t; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rezler EM, 2003, CLIN CANCER RES, V9, p6124S; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; Sun DY, 2003, CLIN CANCER RES, V9, p6122S; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7	33	127	132	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38117	38120		10.1074/jbc.C500348200	http://dx.doi.org/10.1074/jbc.C500348200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16150737	hybrid			2022-12-25	WOS:000233239800002
J	Chen, SJ; Beaton, D; Nguyen, N; Senekeo-Effenberger, K; Brace-Sinnokrak, E; Argikar, U; Remmel, RP; Trottier, J; Barbier, O; Ritter, JK; Tukey, RH				Chen, SJ; Beaton, D; Nguyen, N; Senekeo-Effenberger, K; Brace-Sinnokrak, E; Argikar, U; Remmel, RP; Trottier, J; Barbier, O; Ritter, JK; Tukey, RH			Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN UDP-GLUCURONOSYLTRANSFERASES; PREGNANE-X-RECEPTOR; HUMAN BILIRUBIN; HUMAN LIVER; AH RECEPTOR; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; COMPLEX LOCUS; 1A LOCUS; GLUCURONIDATION	The human UDP-glucuronosyltransferase1(UGT1) locus spans nearly 200 kb on chromosome 2 and encodes nine UGT1A proteins that play a prominent role in drug and xenobiotic metabolism. Transgenic UGT1 (Tg-UGT1) mice have been created, and it has been demonstrated that tissue-specific and xenobiotic receptor control of the UGT1A genes is influenced through circulating humoral factors. In Tg-UGT1 mice, the UGT1A proteins are differentially expressed in the liver and gastrointestinal tract. Gene expression profiles confirmed that all of the UGT1A genes can be targeted for regulation by the pregnane X receptor activator pregnenolone-16 alpha-carbonitrile (PCN) or the Ah receptor ligand 2,3,7,8-tetrachlorodibenzop- dioxin ( TCDD). In addition, the selective induction of glucuronidation activity toward lamotrigine, ethinyl estradiol, chenodeoxycholic acid, and lithocholic acid by either PCN or TCDD in small intestine from Tg-UGT1 mice corresponded to expression of the locus in this tissue. Induction of UGT1A1 by PCN and TCDD is believed to be highly dependent upon glucocorticoids, because submicromolar concentrations of dexamethasone actively promote PCN and TCDD induction of UGT1A1 in Tg-UGT1 primary hepatocytes. The role of hormonal control of the UGT1 locus was further verified in pregnant and nursing Tg-UGT1 mice. Inmaternal 14-daypost-conception Tg-UGT1mice, liver UGT1A1, UGT1A4, and UGT1A6 were induced, with the levels returning to near normal by birth. However, maternal liver UGT1A4 and UGT1A6 were dramatically elevated and maintained after birth, indicating that these proteins may play a critical role in maternal metabolism during lactation. With expression of the UGT1 locus confirmed in a variety of mouse tissues, these results suggested that the Tg-UGT1 mice will be a useful model to examine the regulatory and functional properties of human glucuronidation.	Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Laval, Fac Pharm, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Ctr Hosp Univ Laval Res Ctr, Mol Endocrinol & Oncol Res Ctr, Quebec City, PQ G1K 7P4, Canada; Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN 55455 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Laval University; Laval University; University of Minnesota System; University of Minnesota Twin Cities; Virginia Commonwealth University	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, Leichtag Biomed Res Bldg, La Jolla, CA 92093 USA.	rtukey@ucsd.edu	Remmel, Rory/N-2453-2015	Argikar, Upendra/0000-0002-0939-0813; Chen, Shujuan/0000-0002-1068-195X; Barbier, Olivier/0000-0002-3067-1134	NIEHS NIH HHS [ES07762, ES10337] Funding Source: Medline; NIGMS NIH HHS [GM49135] Funding Source: Medline; NINDS NIH HHS [P50-NS16308] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES007762, P42ES010337, R01ES007762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Bock KW, 1998, ADV ENZYME REGUL, V38, P207, DOI 10.1016/S0065-2571(97)00013-7; Court MH, 2000, PHARMACOGENETICS, V10, P355, DOI 10.1097/00008571-200006000-00009; Dutton G.F., 1980, GLUCURONIDATION DRUG; EBNER T, 1993, MOL PHARMACOL, V43, P649; Gall WE, 1999, J STEROID BIOCHEM, V70, P101, DOI 10.1016/S0960-0760(99)00088-6; Gardner-Stephen D, 2004, DRUG METAB DISPOS, V32, P340, DOI 10.1124/dmd.32.3.340; Gentile S, 2005, ARCH WOMEN MENT HLTH, V8, P57, DOI 10.1007/s00737-005-0070-3; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Granvil CP, 2003, DRUG METAB DISPOS, V31, P548, DOI 10.1124/dmd.31.5.548; Green MD, 1998, DRUG METAB DISPOS, V26, P860; GREEN MD, 1995, DRUG METAB DISPOS, V23, P299; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Harden Cynthia L., 2002, Epilepsy Curr, V2, P183, DOI 10.1046/j.1535-7597.2002.00068.x; Inoue H, 2005, DRUG METAB DISPOS, V33, P55, DOI 10.1124/dmd.104.001537; Ishihara T, 2001, J GASTROEN HEPATOL, V16, P678, DOI 10.1046/j.1440-1746.2001.02495.x; King CD, 1999, ARCH BIOCHEM BIOPHYS, V365, P156, DOI 10.1006/abbi.1999.1155; King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171; Krasowski MD, 2005, MOL ENDOCRINOL, V19, P1720, DOI 10.1210/me.2004-0427; Krishnaswamy S, 2005, J PHARMACOL EXP THER, V313, P1340, DOI 10.1124/jpet.104.081968; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; LUQUITA MG, 1994, BIOCHEM PHARMACOL, V47, P1179, DOI 10.1016/0006-2952(94)90390-5; Luquita MG, 2001, J PHARMACOL EXP THER, V298, P49; Mackenzie PI, 2000, CLIN CHEM LAB MED, V38, P889, DOI 10.1515/CCLM.2000.129; MACKENZIE PI, 1995, REV BIOCHEM TOXICOL, V11, P29; MINERS JO, 1986, BRIT J CLIN PHARMACO, V22, P359, DOI 10.1111/j.1365-2125.1986.tb02901.x; Munzel PA, 2003, BIOCHEM PHARMACOL, V66, P841, DOI 10.1016/S0006-2952(03)00389-7; Munzel PA, 1999, DRUG METAB DISPOS, V27, P569; Munzel PA, 1998, ARCH BIOCHEM BIOPHYS, V350, P72, DOI 10.1006/abbi.1997.0485; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; REMMEL RP, 1991, DRUG METAB DISPOS, V19, P630; Ritter JK, 1999, HEPATOLOGY, V30, P476, DOI 10.1002/hep.510300205; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1997, CANCER RES, V57, P2979; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 1999, GASTROENTEROLOGY, V116, P149, DOI 10.1016/S0016-5085(99)70239-8; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Sugatani J, 2005, MOL PHARMACOL, V67, P845, DOI 10.1124/mol.104.007161; Tran TA, 2002, NEUROLOGY, V59, P251, DOI 10.1212/WNL.59.2.251; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Tukey RH, 2002, MOL PHARMACOL, V62, P446, DOI 10.1124/mol.62.3.446; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yueh MF, 2003, J BIOL CHEM, V278, P15001, DOI 10.1074/jbc.M300645200; Zheng Z, 2002, DRUG METAB DISPOS, V30, P397, DOI 10.1124/dmd.30.4.397; Zheng Z, 2001, JNCI-J NATL CANCER I, V93, P1411, DOI 10.1093/jnci/93.18.1411	50	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37547	37557		10.1074/jbc.M506683200	http://dx.doi.org/10.1074/jbc.M506683200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155002	hybrid			2022-12-25	WOS:000233044500031
J	Liu, Z; Wang, RW; Zhang, J; Chen, SRW; Wagenknecht, T				Liu, Z; Wang, RW; Zhang, J; Chen, SRW; Wagenknecht, T			Localization of a disease-associated mutation site in the three-dimensional structure of the cardiac muscle ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; FUNCTIONAL-CHARACTERIZATION; DIHYDROPYRIDINE RECEPTOR; VENTRICULAR-TACHYCARDIA; FK506-BINDING PROTEIN; ELECTRON-MICROSCOPY; SKELETAL-TYPE; PHOSPHORYLATION; IDENTIFICATION; FKBP12.6	The cardiac muscle ryanodine receptor (RyR2) functions as a calcium release channel in the heart. Up to 40 mutations in RyR2 have been linked to genetic forms of sudden cardiac death. These mutations are largely clustered in three regions of the sequence of the polypeptide: one near the N terminus, one in the central region, and the third in the C-terminal region. The central region includes 11 mutations, and an isoleucine-proline motif ( positions 2427 and 2428) in the same region is predicted to contribute to the binding of FKBP12.6 protein. We have mapped the central mutation site in the three-dimensional structure of RyR2 by green fluorescent protein insertion, cryoelectron microscopy, and single-particle image processing. The central mutation site was mapped to a "bridge" of density that connects cytoplasmic domains 5 and 6, which have been suggested to undergo conformational changes during channel gating. Moreover, the location of this central mutation site is not close to that of the FKBP12.6-binding site mapped previously by cryoelectron microscopy.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; Univ Calgary, Dept Physiol & Biochem, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; University of Calgary; University of Calgary; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Liu, Z (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza, Albany, NY 12201 USA.	liuz@wadsworth.org		Liu, Zheng/0000-0001-6952-3406	NCRR NIH HHS [RR01219, P41 RR001219] Funding Source: Medline; NIAMS NIH HHS [AR40615, R01 AR040615] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahern CA, 2003, BIOPHYS J, V84, P942, DOI 10.1016/S0006-3495(03)74911-X; American Heart Association, 2005, HEART DIS STROKE STA; ANDERSON K, 1989, J BIOL CHEM, V264, P1329; Bagattin A, 2004, CLIN CHEM, V50, P1148, DOI 10.1373/clinchem.2003.030734; Bauce B, 2002, J AM COLL CARDIOL, V40, P341, DOI 10.1016/S0735-1097(02)01946-0; Bers D.M., 2001, EXCITATION CONTRACTI, V2nd ed.; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Choi G, 2004, CIRCULATION, V110, P2119, DOI 10.1161/01.CIR.0000144471.98080.CA; Chugh SS, 2004, J AM COLL CARDIOL, V43, P1625, DOI 10.1016/j.jacc.2003.11.052; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; Francois G, 1996, J ETHNOPHARMACOL, V54, P125, DOI 10.1016/S0378-8741(96)01459-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; George CH, 2003, CIRC RES, V93, P531, DOI 10.1161/01.RES.0000091335.07574.86; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JEKAKUMAR LH, 2001, BIOCHEM BIOPH RES CO, V281, P979; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Laitinen PJ, 2003, EUR J HUM GENET, V11, P888, DOI 10.1038/sj.ejhg.5201061; Laitinen PJ, 2001, CIRCULATION, V103, P485, DOI 10.1161/01.CIR.103.4.485; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Liu Z, 2004, J MOL BIOL, V338, P533, DOI 10.1016/j.jmb.2004.03.011; Liu Z, 2002, J BIOL CHEM, V277, P46712, DOI 10.1074/jbc.M208124200; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Paolini C, 2004, J MOL BIOL, V342, P145, DOI 10.1016/j.jmb.2004.07.035; Perez CF, 2003, J BIOL CHEM, V278, P39644, DOI 10.1074/jbc.M305160200; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Priori SG, 2002, CIRCULATION, V106, P69, DOI 10.1161/01.CIR.0000020013.73106.D8; Priori SG, 2001, CIRCULATION, V103, P196; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; Protasi F, 2002, FRONT BIOSCI, V7, pD650, DOI 10.2741/protasi; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Serysheva I, 2005, J MOL BIOL, V345, P427, DOI 10.1016/j.jmb.2004.10.073; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; Stange M, 2003, J BIOL CHEM, V278, P51693, DOI 10.1074/jbc.M310406200; Tester DJ, 2004, MAYO CLIN PROC, V79, P1380, DOI 10.4065/79.11.1380; Tiso N, 2002, BIOCHEM BIOPH RES CO, V299, P594, DOI 10.1016/S0006-291X(02)02689-X; Tiso N, 2001, HUM MOL GENET, V10, P189, DOI 10.1093/hmg/10.3.189; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Xiao BL, 2004, CIRC RES, V94, P487, DOI 10.1161/01.RES.0000115945.89741.22; Zhang J, 2003, J BIOL CHEM, V278, P14211, DOI 10.1074/jbc.M213164200; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; Zissimopoulos S, 2005, J BIOL CHEM, V280, P5475, DOI 10.1074/jbc.M412954200	50	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37941	37947		10.1074/jbc.M505714200	http://dx.doi.org/10.1074/jbc.M505714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157601	Green Accepted, hybrid			2022-12-25	WOS:000233044500076
J	Madureira, PA; Matos, P; Soeiro, I; Dixon, LK; Simas, JP; Eric, WF				Madureira, PA; Matos, P; Soeiro, I; Dixon, LK; Simas, JP; Eric, WF			Murine gamma-herpesvirus 68 latency protein M2 binds to Vav signaling proteins and inhibits B-cell receptor-induced cell cycle arrest and apoptosis in WEHI-231 B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; ANTIGEN RECEPTOR; GAMMA; D2; HUMAN-HERPESVIRUS-8; EXPRESSION; GENE; GAMMAHERPESVIRUS-68; IDENTIFICATION; PROLIFERATION	The MHV-68 latent protein, M2, does not have homology to any known viral or cellular proteins, and its function is unclear. To define the role played by M2 during MHV-68 latency as well as the molecular mechanism involved, we used M2 as bait to screen a yeast two-hybrid mouse B-cell cDNA library. Vav1 was identified as an M2-interacting protein in two independent screenings. Subsequent yeast two-hybrid interaction studies showed that M2 also binds to Vav2, but not Vav3, and that three "PXXP" motifs located at the C terminus of M2 are important for this interaction. The interactions between M2 and Vav proteins were also confirmed in vivo in 293T and WEHI-231 B-cells by co-immunoprecipitation assays. Rac1/ GST-PAK "pull-down" experiments and Western blot analysis using a phospho-Vav antibody demonstrated that expression of M2 in WEHI-231 cells enhances Vav activity. We further showed in WEHI-231 cells that M2 expression promotes proliferation and survival and is associated with enhanced cyclin D2 and repressed p27(Kip1), p130, and Bim expression. Taken together, these experiments suggest that M2 might have an important role in disseminating the latent virus during the establishment and maintenance of latency by modulating B-cell receptor-mediated signaling events through Vav to promote B-cell activation, proliferation, and survival.	Hammersmith Hosp, Imperial Coll London, Dept Canc Med, Canc Res UK Labs, London W12 0NN, England; Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal; Univ Lisbon, Fac Med, Inst Microbiol, P-1699 Lisbon, Portugal; Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Inst Food Res, Inst Anim Hlth, Woking GU24 0NF, Surrey, England	Cancer Research UK; Imperial College London; Instituto Gulbenkian de Ciencia; Universidade de Lisboa; Instituto Nacional de Saude Dr. Ricardo Jorge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Quadram Institute	Madureira, PA (corresponding author), Hammersmith Hosp, Imperial Coll London, Dept Canc Med, Canc Res UK Labs, MRC Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.	p.madureira@imperial.ac.uk; jpsimas@igc.gulbenkian.pt	Madureira, Patricia/F-4656-2012; Simas, J Pedro/M-5157-2013; Lam, Eric W-F/AAW-8566-2020; Madureira, Patricia A/C-9666-2013; Matos, Paulo/F-5245-2012; Dixon, Linda K/B-9063-2019; Matos, Paulo/P-3012-2019	Madureira, Patricia/0000-0002-4856-3908; Simas, J Pedro/0000-0001-6982-9253; Lam, Eric W-F/0000-0003-1274-3576; Madureira, Patricia A/0000-0002-4856-3908; Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696; Dixon, Linda/0000-0003-3845-3016	Biotechnology and Biological Sciences Research Council [BBS/E/I/00001003, BBS/E/I/00001040] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Addlagatta A, 2005, BIOCHEMISTRY-US, V44, P7166, DOI 10.1021/bi0501176; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; Choi JK, 2000, J VIROL, V74, P436, DOI 10.1128/JVI.74.1.436-446.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Esteban M, 2003, J GEN VIROL, V84, P1463, DOI 10.1099/vir.0.19014-0; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Flano E, 2003, J IMMUNOL, V170, P3828, DOI 10.4049/jimmunol.170.7.3828; Flano E, 2002, J EXP MED, V196, P1363, DOI 10.1084/jem.20020890; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; Jacoby MA, 2002, J VIROL, V76, P1790, DOI 10.1128/JVI.76.4.1790-1801.2002; Jia CYH, 2005, MOL CELL PROTEOMICS, V4, P1155, DOI 10.1074/mcp.M500108-MCP200; Klein E, 1999, IMMUNOL LETT, V68, P147, DOI 10.1016/S0165-2478(99)00044-9; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Longnecker R, 2000, EXP CELL RES, V257, P332, DOI 10.1006/excr.2000.4900; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Marques S, 2003, J VIROL, V77, P7308, DOI 10.1128/JVI.77.13.7308-7318.2003; Muralidhar S, 2000, J CLIN VIROL, V16, P203, DOI 10.1016/S1386-6532(99)00081-5; Nash AA, 2001, PHILOS T R SOC B, V356, P569, DOI 10.1098/rstb.2000.0779; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Sharp TV, 2002, J VIROL, V76, P802, DOI 10.1128/JVI.76.2.802-816.2002; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Turner M, 2002, ADV EXP MED BIOL, V512, P29; Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1; Vigorito E, 2004, J IMMUNOL, V173, P3209, DOI 10.4049/jimmunol.173.5.3209; VIGORITO E, 2005, BLOOD; Willer DO, 2003, J VIROL, V77, P8310, DOI 10.1128/JVI.77.15.8310-8321.2003; Young LS, 2000, J CLIN PATHOL-MOL PA, V53, P238; Zimber-Strobl U, 2001, SEMIN CANCER BIOL, V11, P423, DOI 10.1006/scbi.2001.0409	48	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37310	37318		10.1074/jbc.M507478200	http://dx.doi.org/10.1074/jbc.M507478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150693	hybrid			2022-12-25	WOS:000233044500004
J	Abbasi, S; Su, B; Kellems, RE; Yang, JH; Xia, Y				Abbasi, S; Su, B; Kellems, RE; Yang, JH; Xia, Y			The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC HYPERTROPHIC RESPONSE; SYNDROME CRITICAL REGION; GENE-EXPRESSION; INHIBITION; PROTEIN; PHOSPHATASE; PATHWAYS; FAMILY; NFAT; DEPHOSPHORYLATION	Calcineurin is a serine/threonine protein phosphatase that plays a critical role in many physiologic processes, such as T-cell activation, apoptosis, skeletal myocyte differentiation, and cardiac hypertrophy. We determined that active MEKK3 was capable of activating calcineurin/nuclear factor of activated T-cells ( NFAT) signaling in cardiac myocytes and reprogramming cardiac gene expression. In contrast, small interference RNA directed against MEKK3 and a dominant negative form of MEKK3 caused the reduction of NFAT activation in response to angiotensin II in cardiac myocytes. Genetic studies showed that MEKK3-deficient mouse embryo fibroblasts failed to activate calcineurin/NFAT in response to angiotensin II, a potent NFAT activator. Conversely, restoring MEKK3 to the MEKK3-deficient cells restored angiotensin II-mediated calcineurin/NFAT activation. We determined that angiotensin II induced MEKK3 phosphorylation. Thus, MEKK3 functions downstream of the AT1 receptor and is essential for calcineurin/ NFAT activation. Finally, we determined that MEKK3-mediated activation of calcineurin/ NFAT signaling was associated with the phosphorylation of modulatory calcineurin-interacting protein 1 at Ser(108) and Ser(112). Taken together, our studies reveal a previously unrecognized novel essential regulatory role of MEKK3 signaling in calcineurin/ NFAT activation.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Texas Childrens Hosp, Baylor Coll Med, Ctr Canc, Dept Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Xia, Y (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.	Yang.Xia@uth.tmc.edu						Bueno OF, 2002, CARDIOVASC RES, V53, P806, DOI 10.1016/S0008-6363(01)00493-X; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Bushdid PB, 2003, CIRC RES, V92, P1305, DOI 10.1161/01.RES.0000077045.84609.9F; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Cheng JK, 2005, J BIOL CHEM, V280, P13477, DOI 10.1074/jbc.M414258200; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hilioti Z, 2003, BIOCHEM BIOPH RES CO, V311, P1089, DOI 10.1016/S0006-291X(03)01515-8; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Thway TM, 2004, CIRCULATION, V110, P1612, DOI 10.1161/01.CIR.0000142855.68398.3A; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xia Y, 2003, J BIOL CHEM, V278, P13143, DOI 10.1074/jbc.M208500200; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769	48	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36737	36746		10.1074/jbc.M506493200	http://dx.doi.org/10.1074/jbc.M506493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16126726	hybrid			2022-12-25	WOS:000232901800027
J	Al-Abed, Y; Dabideen, D; Aljabari, B; Valster, A; Messmer, D; Ochani, M; Tanovic, M; Ochani, K; Bacher, M; Nicoletti, F; Metz, C; Pavlov, VA; Miller, EJ; Tracey, KJ				Al-Abed, Y; Dabideen, D; Aljabari, B; Valster, A; Messmer, D; Ochani, M; Tanovic, M; Ochani, K; Bacher, M; Nicoletti, F; Metz, C; Pavlov, VA; Miller, EJ; Tracey, KJ			ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLPYRUVATE TAUTOMERASE; CRYSTAL-STRUCTURE; RAT-LIVER; EXPRESSION; DISCOVERY; CYTOKINE; MEDIATOR	MIF is a proinflammatory cytokine that has been implicated in the pathogenesis of sepsis, arthritis, and other inflammatory diseases. Antibodies against MIF are effective in experimental models of inflammation, and there is interest in strategies to inhibit its deleterious cytokine activities. Here we identify a mechanism of inhibiting MIF pro-inflammatory activities by targeting MIF tautomerase activity. We designed small molecules to inhibit this tautomerase activity; a lead molecule, "ISO-1 (( S, R)3-( 4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester)," significantly inhibits the cytokine activity in vitro. Moreover, ISO-1 inhibits tumor necrosis factor release from macrophages isolated from LPS-treated wild type mice but has no effect on cytokine release from MIF-deficient macrophages. The therapeutic importance of the MIF inhibition by ISO-1 is demonstrated by the significant protection from sepsis, induced by cecal ligation and puncture in a clinically relevant time frame. These results identify ISO-1 as the first small molecule inhibitor of MIF proinflammatory activities with therapeutic implications and indicate the potential of the MIF active site as a novel target for therapeutic interventions in human sepsis.	N Shore Long Isl Jewish Inst Med Res, Med Chem Lab, Manhasset, NY 11030 USA; New York Sch Med, New York, NY 10016 USA; N Shore Long Isl Jewish Inst Med Res, Ctr Oncol & Cell Biol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Inst Med Res, Expt Immunol Lab, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Inst Med Res, Lab Biomed Sci, Manhasset, NY 11030 USA; Univ Bonn, Dept Neurol, D-53105 Bonn, Germany; Univ Catania, Dept Biomed Sci, I-95021 Catania, Italy; N Shore Univ Hosp, N Shore Long Isl Jewish Inst Med Res, Med Biochem Lab, Manhasset, NY 11030 USA; N Shore Univ Hosp, N Shore Long Isl Jewish Inst Med Res, Dept Surg, Manhasset, NY 11030 USA	Northwell Health; Northwell Health; Northwell Health; Northwell Health; University of Bonn; University of Catania; Northwell Health; North Shore University Hospital; Northwell Health; North Shore University Hospital	Al-Abed, Y (corresponding author), N Shore Long Isl Jewish Inst Med Res, Med Chem Lab, 350 Community Dr, Manhasset, NY 11030 USA.	yalabed@nshs.edu	Nicoletti, Ferdinando/M-4428-2016	Nicoletti, Ferdinando/0000-0002-4570-8462; Tracey, Kevin J/0000-0003-1884-6314; Christine, Metz/0000-0002-1013-1691; Pavlov, Valentin/0000-0002-1994-2853	NIGMS NIH HHS [R01 GM062508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Cvetkovic I, 2005, ENDOCRINOLOGY, V146, P2942, DOI 10.1210/en.2004-1393; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Lan HY, 2000, KIDNEY INT, V57, P499, DOI 10.1046/j.1523-1755.2000.00869.x; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Murakami H, 2002, CLIN EXP IMMUNOL, V128, P504, DOI 10.1046/j.1365-2249.2002.01838.x; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; Rosengren E, 1997, MELANOMA RES, V7, P517, DOI 10.1097/00008390-199712000-00012; Senter PD, 2002, P NATL ACAD SCI USA, V99, P144, DOI 10.1073/pnas.011569399; Sugimoto H, 1995, J STRUCT BIOL, V115, P331, DOI 10.1006/jsbi.1995.1057; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Xue CB, 1997, J MED CHEM, V40, P2064, DOI 10.1021/jm960799i; Zang XX, 2002, J BIOL CHEM, V277, P44261, DOI 10.1074/jbc.M204655200	25	238	257	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36541	36544		10.1074/jbc.C500243200	http://dx.doi.org/10.1074/jbc.C500243200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115897	hybrid			2022-12-25	WOS:000232901800002
J	Chang, TC; Huang, CJ; Tam, K; Chen, SF; Tan, KT; Tsai, MS; Lin, TN; Shyue, SK				Chang, TC; Huang, CJ; Tam, K; Chen, SF; Tan, KT; Tsai, MS; Lin, TN; Shyue, SK			Stabilization of hypoxia-inducible factor-1 alpha by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; HUMAN ERYTHROPOIETIN GENE; PROSTAGLANDIN E-2; FACTOR 1-ALPHA; NADPH OXIDASE; HIF-ALPHA; ACTIVATION; EXPRESSION; PATHWAY; CYCLOOXYGENASE-2	Hypoxia-inducible factor-1 (HIF-1) takes part in the transcriptional activation of hypoxia-responsive genes. HIF-1 alpha, a subunit of HIF-1, is rapidly degraded under normoxic conditions by the ubiquitin-proteosome system. Hypoxia up-regulates HIF-1 alpha by inhibiting its degradation, thereby allowing it to accumulate to high levels with 3 - 6 h of hypoxia treatment and decreasing thereafter. In vascular tissues, prostacyclin ( prostaglandin I-2 (PGI(2))) is a potent vasodilator and inhibitor of platelet aggregation and is known as a vasoprotective molecule. However, the role of PGI(2) in HIF-1 activation has not been studied. In the present study, we investigated the effect of PGI(2) on HIF-1 regulation in human umbilical vein endothelial cells under prolonged hypoxia ( 12 h). Augmentation of PGI2 via adenovirus-mediated gene transfer of both cyclooxygenase-1 and PGI(2) synthase activated HIF-1 by stabilizing HIF-1 alpha in cells under prolonged hypoxia or the hypoxia-normoxia transition but not under normoxia. Exogenous H2O2 abolished PGI(2)- and catalase-induced HIF-1 alpha up-regulation, which suggests that degradation of HIF-1 alpha under prolonged hypoxia is through a reactive oxygen species-dependent pathway. Moreover, PGI(2) attenuated NADPH oxidase activity by suppressing Rac1 and p47(phox) expression under hypoxia. These data demonstrate a novel function of PGI(2) in down-regulating reactive oxygen species production by attenuating NADPH oxidase activity, which stabilizes HIF-1 alpha in human umbilical vein endothelial cells exposed to prolonged hypoxia.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 115, Taiwan; Cathay Gen Hosp, Dept Obstet & Gynecol, Prenatal Diag Ctr, Taipei 106, Taiwan	National Defense Medical Center; Academia Sinica - Taiwan; Cathay General Hospital	Shyue, SK (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sec 2, Taipei 11529, Taiwan.	skshyue@ibms.sinica.edu.tw	Shyue, Song-Kun/Q-2583-2018; Lin, Teng-nan/Q-4566-2018	Shyue, Song-Kun/0000-0002-1057-8696; Lin, Teng-nan/0000-0002-4009-0798				Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Frigola J, 2005, ONCOGENE; Fukuda R, 2003, CANCER RES, V63, P2330; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GOLDWASSER E, 1995, J BIOL CHEM, V270, P2628, DOI 10.1074/jbc.270.6.2628; Golpon HA, 2004, FASEB J, V18, P1716, DOI 10.1096/fj.04-1853fje; Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kluckow M, 1999, ARCH DIS CHILD-FETAL, V80, pF34, DOI 10.1136/fn.80.1.F34; Kolsut Piotr, 2003, Kardiol Pol, V59, P373; Kumar P, 2004, J BIOL CHEM, V279, P43352, DOI 10.1074/jbc.M405777200; Lin H, 2002, CIRCULATION, V105, P1962, DOI 10.1161/01.CIR.0000015365.49180.05; Lin SJ, 2004, J MOL CELL CARDIOL, V36, P129, DOI 10.1016/j.yjmcc.2003.10.011; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; MATSUMOTO M, 1992, ANESTH ANALG, V75, P773; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Muzaffar S, 2004, BRIT J PHARMACOL, V141, P488, DOI 10.1038/sj.bjp.0705626; OKUYAMA M, 1995, LIFE SCI, V57, P1051, DOI 10.1016/0024-3205(95)02050-S; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Shyue SK, 2001, CIRCULATION, V103, P2090; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; UMEKI S, 1994, INT J BIOCHEM, V26, P1003, DOI 10.1016/0020-711X(94)90071-X; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WU KK, 1995, AGENT ACTION SUPPL, V45, P11	42	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36567	36574		10.1074/jbc.M504280200	http://dx.doi.org/10.1074/jbc.M504280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115891	hybrid			2022-12-25	WOS:000232901800006
J	Chen, GC; Nomura, M; Morinaga, H; Matsubara, E; Okabe, T; Goto, K; Yanase, T; Zheng, H; Lu, J; Nawata, H				Chen, GC; Nomura, M; Morinaga, H; Matsubara, E; Okabe, T; Goto, K; Yanase, T; Zheng, H; Lu, J; Nawata, H			Modulation of androgen receptor transactivation by FoxH1 - A newly identified androgen receptor corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; ELEMENT-BINDING PROTEIN; PROSTATE-CANCER; ACTIVIN RECEPTOR; CROSS-TALK; TGF-BETA; TRANSCRIPTIONAL ACTIVITY; MEDIATED TRANSCRIPTION; SIGNAL TRANSDUCER; NUCLEAR RECEPTOR	Androgen signaling plays key roles in the development and progression of prostate cancer, and numerous ongoing studies focus on the regulation of androgen receptor (AR) transactivity to develop novel therapies for the treatment of androgen-independent prostate cancer. FoxH1, amember of the Forkhead-box ( FOX) gene family of transcription factors, takes part in mediating transforming growth factor-beta/activin signaling through its interaction with the Smad2 center dot Smad4 complex. Using a series of experiments, we found that FoxH1 repressed both ligand-dependent and - independent transactivation of the AR on androgen-induced promoters. This action of FoxH1 was independent of its transactivation capacity and activin A but relieved by Smad2 center dot Smad4. In addition, the repression of the AR by FoxH1 did not require deacetylase activity. A protein-protein interaction was identified between the AR and FoxH1 independently of dihydrotestosterone. Furthermore, a confocal microscopic analysis of LNCaP cells revealed that the interaction between the AR and FoxH1 occurred in the nucleus and that FoxH1 specifically blocked the foci formation of dihydrotestosterone-activated AR, which has been shown to be correlated with the AR transactivation potential. Taken together, our results indicate that FoxH1 functions as a new corepressor of the AR. Our observations not only strengthen the role of FoxH1 in AR-mediated transactivation but also suggest that therapeutic interventions based on AR-coregulator interactions could be designed to block both androgen-dependent and - independent growth of prostate cancer.	Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Fukuoka 8128582, Japan; Second Mil Med Univ, Dept Pathophysiol, Shanghai 200433, Peoples R China; Second Mil Med Univ, Lab Ctr Pharmacol, Shanghai 200433, Peoples R China	Kyushu University; Naval Medical University; Naval Medical University	Nomura, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	nomura@med.kyushu-u.ac.jp	Eri, MATSUBARA/AAJ-8405-2021; chen, guangchun/F-3910-2011	Eri, MATSUBARA/0000-0003-2385-0078; 				Abe Y, 2004, GROWTH FACTORS, V22, P105, DOI 10.1080/08977190410001704688; Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berrevoets CA, 2004, BIOCHEM J, V379, P731, DOI 10.1042/BJ20031456; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Carey JL, 2004, MOL ENDOCRINOL, V18, P696, DOI 10.1210/me.2003-0360; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen TS, 2000, CANCER RES, V60, P2132; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; Dalkin AC, 1996, ENDOCRINOLOGY, V137, P5230, DOI 10.1210/en.137.12.5230; Dehm SM, 2005, EXPERT REV ANTICANC, V5, P63, DOI 10.1586/14737140.5.1.63; Dotzlaw H, 2003, MOL CELL ENDOCRINOL, V213, P79, DOI 10.1016/j.mce.2003.10.036; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujii Y, 2004, AM J PHYSIOL-ENDOC M, V286, pE927, DOI 10.1152/ajpendo.00443.2003; Haendler B, 2002, BIOMED PHARMACOTHER, V56, P78, DOI 10.1016/S0753-3322(01)00159-7; Hayes SA, 2001, CANCER RES, V61, P2112; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hobisch A, 1998, CANCER RES, V58, P4640; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jeong BC, 2004, MOL ENDOCRINOL, V18, P13, DOI 10.1210/me.2003-0065; Jia L, 2004, CANCER RES, V64, P2619, DOI 10.1158/0008-5472.CAN-03-3486; Kawate H, 2005, MOL CELL ENDOCRINOL, V230, P77, DOI 10.1016/j.mce.2004.10.009; Kim J, 2005, J MOL ENDOCRINOL, V34, P107, DOI 10.1677/jme.1.01701; Kokontis J, 1991, Receptor, V1, P271; Lau KM, 2000, CANCER RES, V60, P3175; Lee ECY, 2004, J CELL BIOCHEM, V91, P662, DOI 10.1002/jcb.20040; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu B, 1999, MOL CELL BIOL, V19, P424; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Matsuda T, 2001, BIOCHEM BIOPH RES CO, V283, P179, DOI 10.1006/bbrc.2001.4758; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McPherson SJ, 1999, ENDOCRINOLOGY, V140, P5303, DOI 10.1210/en.140.11.5303; McPherson SJ, 1997, J ENDOCRINOL, V154, P535, DOI 10.1677/joe.0.1540535; Mellor SL, 2000, J CLIN ENDOCR METAB, V85, P4851, DOI 10.1210/jc.85.12.4851; Mukasa C, 2003, ENDOCRINOLOGY, V144, P1603, DOI 10.1210/en.2002-220978; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; Navarro D, 2002, J STEROID BIOCHEM, V81, P191, DOI 10.1016/S0960-0760(02)00064-X; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Santos AF, 2004, STEROIDS, V69, P79, DOI 10.1016/j.steroids.2003.10.005; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma M, 2001, MOL ENDOCRINOL, V15, P1918, DOI 10.1210/me.15.11.1918; Slagsvold T, 2000, MOL ENDOCRINOL, V14, P1603, DOI 10.1210/me.14.10.1603; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thomas TZ, 1998, PROSTATE, V34, P34, DOI 10.1002/(SICI)1097-0045(19980101)34:1<34::AID-PROS5>3.0.CO;2-K; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; van Schaik RHN, 2000, BRIT J CANCER, V82, P112; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang QF, 1996, ENDOCRINOLOGY, V137, P5476, DOI 10.1210/en.137.12.5476; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YING SY, 1989, J STEROID BIOCHEM, V33, P705; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang Z, 1997, BIOCHEM BIOPH RES CO, V234, P362, DOI 10.1006/bbrc.1997.6649; Zhao Y, 2002, J BIOL CHEM, V277, P30031, DOI 10.1074/jbc.M203811200; Zhou J, 2001, CANCER METAST REV, V20, P351, DOI 10.1023/A:1015504015302; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	79	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36355	36363		10.1074/jbc.M506147200	http://dx.doi.org/10.1074/jbc.M506147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120611	hybrid			2022-12-25	WOS:000232726900069
J	Cuomo, ME; Knebel, A; Platt, G; Morrice, N; Cohen, P; Mittnacht, S				Cuomo, ME; Knebel, A; Platt, G; Morrice, N; Cohen, P; Mittnacht, S			Regulation of microfilament organization by Kaposi sarcoma-associated herpes virus-cyclin center dot CDK6 phosphorylation of caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; CASEIN KINASE-II; CYCLIN-DEPENDENT KINASES; HUMAN ENDOTHELIAL-CELLS; ACTIN-BINDING; NONMUSCLE CALDESMON; CALMODULIN-BINDING; TRANSFORMED-CELLS; DNA-SEQUENCES; RETINOBLASTOMA PROTEIN	Kaposi sarcoma-associated herpes virus ( KSHV) encodes a D-like cyclin ( K-cyclin) that is thought to contribute to the viral oncogenicity. K-cyclin activates cellular cyclin-dependent kinases (CDK) 4 and 6, generating enzymes with a substrate selectivity deviant from CDK4 and CDK6 activated by D-type cyclins, suggesting different biochemical and biological functions. Here we report the identification of the actin- and calmodulin-binding protein caldesmon (CALD1) as a novel K-cyclin center dot CDK substrate, which is not phosphorylated by D center dot CDK. CALD1 plays a central role in the regulation of microfilament organization, consequently controlling cell shape, adhesion, cytokinesis and motility. K-cyclin center dot CDK6 specifically phosphorylates four Ser/Thr sites in the human CALD1 carboxyl terminus, abolishing CALD1 binding to its effector protein, actin, and its regulator protein, calmodulin. CALD1 is hyperphosphorylated in cells following K-cyclin expression and in KSHV-transformed lymphoma cells. Moreover, expression of exogenous K-cyclin results in microfilament loss and changes in cell morphology; both effects are reliant on CDK catalysis and can be reversed by the expression of a phosphorylation defective CALD1. Together, these data strongly suggest that K-cyclin expression modulates the activity of caldesmon and through this the microfilament functions in cells. These results establish a novel link between KSHV infection and the regulation of the actin cytoskeleton.	Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Kinasource, Lab 4 21, Dundee DD1 5EH, Scotland	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Dundee	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.	sibylle@icr.ac.uk		Knebel, Axel/0000-0002-9197-6054				ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bartegi A, 1998, EUR J BIOCHEM, V254, P571, DOI 10.1046/j.1432-1327.1998.2540571.x; Berwick DC, 2004, TRENDS BIOCHEM SCI, V29, P227, DOI 10.1016/j.tibs.2004.03.004; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; D'Angelo G, 1999, J BIOL CHEM, V274, P30115, DOI 10.1074/jbc.274.42.30115; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; Foster DB, 2004, J BIOL CHEM, V279, P53387, DOI 10.1074/jbc.M410109200; Franz CM, 2002, DEV CELL, V2, P153, DOI 10.1016/S1534-5807(02)00120-X; Fraser IDC, 1997, BIOCHEMISTRY-US, V36, P5483, DOI 10.1021/bi962969z; Gao SJ, 2003, J VIROL, V77, P9738, DOI 10.1128/JVI.77.18.9738-9749.2003; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hedges JC, 2000, AM J PHYSIOL-CELL PH, V278, pC718, DOI 10.1152/ajpcell.2000.278.4.C718; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HOSOYA N, 1993, J CELL BIOL, V121, P1075, DOI 10.1083/jcb.121.5.1075; Huang RJ, 2003, BIOCHEMISTRY-US, V42, P2513, DOI 10.1021/bi0268605; Huber PAJ, 1997, INT J BIOCHEM CELL B, V29, P1047, DOI 10.1016/S1357-2725(97)00004-6; Huber PAJ, 1998, BIOCHEMISTRY-US, V37, P2314, DOI 10.1021/bi971727b; IKEBE M, 1990, J BIOL CHEM, V265, P17607; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Laman H, 2001, EXP CELL RES, V271, P230, DOI 10.1006/excr.2001.5360; Laman H, 2001, MOL CELL BIOL, V21, P624, DOI 10.1128/MCB.21.2.624-635.2001; Li Y, 2004, J CELL SCI, V117, P3593, DOI 10.1242/jcs.01216; Li Y, 2003, CELL MOL LIFE SCI, V60, P198, DOI 10.1007/s000180300014; Li YH, 2000, J BIOL CHEM, V275, P10989, DOI 10.1074/jbc.275.15.10989; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; McNeill H, 2004, BIOCHEM J, V384, P391, DOI 10.1042/BJ20041498; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; Mirzapoiazova T, 2005, J CELL PHYSIOL, V203, P520, DOI 10.1002/jcp.20244; Mittnacht S, 2000, REV MED VIROL, V10, P175, DOI 10.1002/(SICI)1099-1654(200005/06)10:3<175::AID-RMV283>3.0.CO;2-F; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Murray JT, 2004, BIOCHEM J, V384, P489, DOI 10.1042/BJ20041058; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; NOVY RE, 1991, J BIOL CHEM, V266, P16917; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; Patchell VB, 2002, BBA-PROTEIN STRUCT M, V1596, P121, DOI 10.1016/S0167-4838(02)00210-8; Platt GM, 2000, VIROLOGY, V272, P257, DOI 10.1006/viro.2000.0343; Rao JY, 2004, CURR CANCER DRUG TAR, V4, P345, DOI 10.2174/1568009043332998; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sugaya M, 2005, BLOOD, V105, P2356, DOI 10.1182/blood-2004-08-3364; SUTHERLAND C, 1994, J MUSCLE RES CELL M, V15, P440, DOI 10.1007/BF00122118; TANAKA J, 1993, J CELL SCI, V104, P595; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; Van Dross R, 2005, JNCI-J NATL CANCER I, V97, P656, DOI 10.1093/jnci/dji113; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verschuren EW, 2004, CANCER RES, V64, P581, DOI 10.1158/0008-5472.CAN-03-1863; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; VOROTNIKOV AV, 1993, FEBS LETT, V334, P18, DOI 10.1016/0014-5793(93)81671-L; VOROTNIKOV AV, 1994, J MUSCLE RES CELL M, V15, P37, DOI 10.1007/BF00123831; WANG CLA, 1991, J BIOL CHEM, V266, P9166; Wang Z, 2000, BIOCHEMISTRY-US, V39, P11114, DOI 10.1021/bi0006767; WARREN KS, 1994, J CELL BIOL, V125, P359, DOI 10.1083/jcb.125.2.359; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Yamakita Y, 2003, J BIOL CHEM, V278, P17937, DOI 10.1074/jbc.M208739200; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamashiro S, 2001, MOL BIOL CELL, V12, P239, DOI 10.1091/mbc.12.1.239; YAMASHIRO S, 1995, J BIOL CHEM, V270, P4023, DOI 10.1074/jbc.270.8.4023; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zheng PP, 2004, AM J PATHOL, V164, P2217, DOI 10.1016/S0002-9440(10)63778-9	83	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35844	35858		10.1074/jbc.M503877200	http://dx.doi.org/10.1074/jbc.M503877200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115893	hybrid			2022-12-25	WOS:000232726900011
J	Kudo, M; Bao, M; D'Souza, A; Ying, F; Pan, HQ; Roe, BA; Canfield, WM				Kudo, M; Bao, M; D'Souza, A; Ying, F; Pan, HQ; Roe, BA; Canfield, WM			The alpha- and beta-subunits of the human UDP-N-acetylglucosamine : lysosomal enzyme phosphotransferase are encoded by a single cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-HURLER POLYDYSTROPHY; I-CELL DISEASE; RAPID INTERNALIZATION; N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; SEQUENCE; GENE; ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; PURIFICATION; SEROGROUP; DOMAIN	Lysosomal enzymes are targeted to the lysosome through binding to mannose 6-phosphate receptors because their glycans are modified with mannose 6-phosphate. This modification is catalyzed by UDP-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1- phosphotransferase (GlcNAc- phosphotransferase). Bovine GlcNAc- phosphotransferase was isolated using monoclonal antibody affinity chromatography, and an alpha(2)beta(2)gamma(2)-subunit structure was proposed. Although cDNA encoding the gamma-subunit has been described, cDNAs for the alpha- and beta-subunits have not. Using partial amino acid sequences from the bovine alpha-and beta-subunits, we have isolated a human cDNA that encodes both the alpha-and beta-subunits. Both subunits contain a single predicted membrane-spanning domain. The alpha- and beta-subunits appear to be generated by a proteolytic cleavage at the Lys(928)-Asp(929) bond. Transfection of 293T cells with the alpha/beta-subunits-precursor cDNA with or without the gamma-subunit cDNA results in a 3.6- or 17-fold increase in GlcNAc- phosphotransferase activity in cell lysates, suggesting that the precursor cDNA contains the catalytic domain. The sequence lacks significant similarity with any described vertebrate enzyme except for two Notch-like repeats in the alpha-subunit. However, a 112-amino acid sequence is highly similar to a group of bacterial capsular polymerases (46% identity). A BAC clone containing the gene that spanned 85.3 kb and was composed of 21 exons was sequenced and localized to chromosome 12q23. We now report the cloning of both the cDNA and genomic DNA of the precursor of GlcNAc- phosphotransferase. The completion of cloning all three subunits of GlcNAc- phosphotransferase allows expression of recombinant enzyme and dissection of lysosomal targeting disorders.	Genzyme Corp, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Berlex Biosci, Syst Biol, Richmond, CA 94804 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; N Carolina State Univ, Ctr Integrated Fungal Res, Raleigh, NC 27606 USA	Sanofi-Aventis; Genzyme Corporation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma - Norman; University of North Carolina; North Carolina State University	Canfield, WM (corresponding author), Genzyme Corp, 800 Res Pkwy,Suite 200, Oklahoma City, OK 73104 USA.	William.Canfield@genzyme.com			NHGRI NIH HHS [5 U54 HG02152] Funding Source: Medline; NICHD NIH HHS [HD31920] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031920] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG002152] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASHTON FE, 1983, J CLIN MICROBIOL, V17, P722, DOI 10.1128/JCM.17.5.722-727.1983; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; JADOT M, 1992, J BIOL CHEM, V267, P11069; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUELLER OT, 1987, CYTOGENET CELL GENET, V46, P664; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; Steet RA, 2005, AM J MED GENET A, V132A, P369, DOI 10.1002/ajmg.a.30498; Swartley JS, 1998, J BACTERIOL, V180, P1533, DOI 10.1128/JB.180.6.1533-1539.1998; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tzeng YL, 2003, INFECT IMMUN, V71, P6712, DOI 10.1128/IAI.71.12.6712-6720.2003; VARKI A, 1981, J BIOL CHEM, V256, P9937; VARKI A, 1982, AM J HUM GENET, V34, P717; VARKI AP, 1981, P NATL ACAD SCI-BIOL, V78, P7773, DOI 10.1073/pnas.78.12.7773; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717	43	92	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36141	36149		10.1074/jbc.m509008200	http://dx.doi.org/10.1074/jbc.m509008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120602	hybrid			2022-12-25	WOS:000232726900045
J	Wang, YT; Oram, JF				Wang, YT; Oram, JF			Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER 1; APOLIPOPROTEIN-A-I; PROTEIN-KINASE-C; CHOLESTEROL EFFLUX; TANGIER-DISEASE; MESSENGER-RNA; GENE; RECEPTOR; DEGRADATION	Abnormal high density lipoprotein (HDL) metabolism among patients with diabetes and insulin resistance may contribute to their increased risk of atherosclerosis. ATP-binding cassette transporter ABCA1 mediates the transport of cholesterol and phospholipids from cells to HDL apolipoproteins and thus modulates HDL levels and atherogenesis. Unsaturated fatty acids, which are elevated in diabetes, impair the ABCA1 pathway in cultured cells by destabilizing ABCA1 protein. Here we examined the cellular pathway that mediates the ABCA1 destabilizing effects of fatty acids. The long-chain acyl-CoA synthetase inhibitor triacsin C completely reversed fatty acid-induced ABCA1 destabilization, indicating that fatty acids need to be activated to their CoA derivatives to enhance ABCA1 degradation. Unsaturated but not saturated fatty acids stimulated phospholipase D(PLD) activity, the PLD inhibitor 1-butanol prevented the unsaturated fatty acid-induced reduction in ABCA1 levels, and the PLD2 activator mastoparan markedly reduced ABCA1 protein levels, implicating a role for PLD2 in the ABCA1 destabilizing effects of fatty acids. Unsaturated fatty acids and mastoparan increased phosphorylation of ABCA1 serines. PLD2 small interfering RNA abolished the ability of unsaturated fatty acids to inhibit lipid transport activity, to reduce protein levels, and to increase serine phosphorylation of ABCA1. The diacylglycerol analog oleoylacetylglycerol also reduced ABCA1 protein levels and increased its serine phosphorylation, suggesting that PLD2-generated diacylglycerols promote the destabilizing phosphorylation of ABCA1. These data provide evidence that intracellular unsaturated acyl-CoA derivatives destabilize ABCA1 by activating a PLD2 signaling pathway.	Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Oram, JF (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	joram@u.washington.edu			NHLBI NIH HHS [HL55362, HL18645] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; Ali H, 1996, J PHARMACOL EXP THER, V276, P837; ANGEL A, 1974, J LIPID RES, V15, P491; Askari B, 2002, J BIOL CHEM, V277, P36338, DOI 10.1074/jbc.M205112200; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chahdi A, 2003, J BIOL CHEM, V278, P12039, DOI 10.1074/jbc.M212084200; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Costet P, 2000, J BIOL CHEM, V275, P28240; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Kotter K, 1999, BRAIN RES, V830, P138, DOI 10.1016/S0006-8993(99)01416-X; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang Y, 2004, J LIPID RES, V45, P972, DOI 10.1194/jlr.M400011-JLR200; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	43	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35896	35903		10.1074/jbc.M506210200	http://dx.doi.org/10.1074/jbc.M506210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16118212	Green Submitted, hybrid			2022-12-25	WOS:000232726900016
J	Kichina, JV; Zeremski, M; Aris, L; Gurova, KV; Walker, E; Franks, R; Nikitin, AY; Kiyokawa, H; Gudkov, AV				Kichina, JV; Zeremski, M; Aris, L; Gurova, KV; Walker, E; Franks, R; Nikitin, AY; Kiyokawa, H; Gudkov, AV			Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas	ONCOGENE			English	Article						ING1; gene knockout; lymphoma; mouse; radiation sensitivity	CANDIDATE TUMOR-SUPPRESSOR; SQUAMOUS-CELL CARCINOMAS; PHD FINGER PROTEINS; GENE ING1; ALTERNATIVE TRANSCRIPTS; P53 EXPRESSION; MELANOMA-CELLS; MESSENGER-RNA; HUMAN HEAD; P33(ING1)	Ing1 belongs to the family of evolutionary conserved genes encoding nuclear PHD finger-containing proteins implicated in a variety of processes, including tumorigenesis, replicative senescence, excision repair and response to genotoxic stress. We have generated mice deficient in all the isoforms of Ing1 by targeted disruption of the exon that is common for all ing1 transcripts. Embryonic fibroblasts from ing1-knockout mice were similar to the wild-type cells in their growth characteristics, replicative lifespan in culture, p53 induction and sensitivity to various cytotoxic treatments with minor alterations in cell cycle distribution in response to genotoxic stress. ing1-deficient animals are characterized by reduced size with no obvious morphological, physiological or behavioral abnormalities, indicating that ing1 function is dispensable for the viability of mice under normal physiological conditions. Loss of ing1 was associated with earlier onset and higher incidence of lymphomas. Consistent with the possible involvement of Ing1 in DNA repair, ing1-deficient mice were more sensitive to total body gamma radiation. Our observations are well in line with the suggested role of ing1 as a candidate tumor suppressor gene involved in control of DNA damage response.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; Cleveland BioLabs Inc, Cleveland, OH USA; Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation; Cornell University	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.	gudkov@ccf.org		Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA 60730, CA 17579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Campos EI, 2004, INT J ONCOL, V25, P73; Campos EI, 2002, BRIT J DERMATOL, V146, P574, DOI 10.1046/j.1365-2133.2002.04641.x; Chen LS, 2001, CANCER RES, V61, P4345; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Cheung KJ, 2001, CANCER RES, V61, P4974; Cheung KJJ, 2000, BRIT J CANCER, V83, P1468, DOI 10.1054/bjoc.2000.1464; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gunduz M, 2000, CANCER RES, V60, P3143; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Helbing CC, 1997, CANCER RES, V57, P1255; Ito K, 2002, AM J HEMATOL, V69, P141, DOI 10.1002/ajh.10031; Kichina JV, 2003, ONCOGENE, V22, P4911, DOI 10.1038/sj.onc.1206741; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Maestro R, 1996, CANCER RES, V56, P1146; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Ohgi T, 2002, SCAND J GASTROENTERO, V37, P1440, DOI 10.1080/003655202762671332; Ohmori M, 1999, AM J HEMATOL, V62, P118; Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8; Ramirez-Solis Ramiro, 1994, Current Opinion in Biotechnology, V5, P528, DOI 10.1016/0958-1669(94)90069-8; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sanchez-Cespedes M, 2000, GENE CHROMOSOME CANC, V27, P319, DOI 10.1002/(SICI)1098-2264(200003)27:3<319::AID-GCC13>3.0.CO;2-P; Sarela AI, 1999, EUR J CANCER, V35, P1264, DOI 10.1016/S0959-8049(99)00104-5; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Scott M, 2001, J CELL SCI, V114, P3455; Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Ward JM, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P161; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zeremski M, 1997, SOMAT CELL MOLEC GEN, V23, P233, DOI 10.1007/BF02721376	48	60	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					857	866		10.1038/sj.onc.1209118	http://dx.doi.org/10.1038/sj.onc.1209118			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16170338				2022-12-25	WOS:000235212700005
J	Seiden-Long, IM; Brown, KR; Shih, W; Wigle, DA; Radulovich, N; Jurisica, I; Tsao, MS				Seiden-Long, IM; Brown, KR; Shih, W; Wigle, DA; Radulovich, N; Jurisica, I; Tsao, MS			Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer	ONCOGENE			English	Article						hepatocyte growth factor; protein-protein interaction; microarray; real-time RT-PCR; tumor markers; tissue array	FACTOR SCATTER FACTOR; FACTOR-RECEPTOR; C-MYC; MEDIATED APOPTOSIS; BETA-CATENIN; MET; CELLS; GENE; EXPRESSION; PATHWAY	Both Ki-ras mutation and hepatocyte growth factor (HGF) receptor Met overexpression occur at high frequency in colon cancer. This study investigates the transcriptional changes induced by Ki-ras oncogene and HGF/Met signaling activation in colon cancer cell lines in vitro and in vivo. The model system used in these studies included the DLD-1 colon cancer cell line with a mutated Ki-ras allele, and the DKO-4 cell line generated from DLD-1, with its mutant Ki-ras allele inactivated by targeted disruption. These cell lines were transduced with cDNAs of full-length Met receptor. Microarray transcriptional pro. ling was conducted on cell lines stimulated with HGF, as well as on tumor xenograft tissues. Overlapping genes between in vitro and in vivo microarray data sets were selected as a subset of HGF/Met and Ki-ras oncogene-regulated targets. Using the Online Predicted Human Interaction Database, novel HGF/Met and Ki-ras regulated proteins with putative functional linkage were identifi. ed. Novel proteins identified included histone acetyltransferase 1, phosphoribosyl pyrophosphate synthetase 2, chaperonin containing TCP1, subunit 8, CSE1 chromosome segregation 1-like (yeast)/cellular apoptosis susceptibility (mammals), CCR4-NOT transcription complex, subunit 8, and cyclin H. Transcript levels for these Met-signaling targets were correlated with Met expression levels, and were significantly elevated in both primary and metastatic human colorectal cancer samples compared to normal colorectal mucosa. These genes represent novel Met and/ or Ki-ras transcriptionally coregulated genes with a high degree of validation in human colorectal cancers.	Univ Toronto, Ontario Canc Inst, Dept Pathol, Princess Margaret Hosp,Univ Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Tsao, MS (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Pathol, Princess Margaret Hosp,Univ Hlth Network, Room 4-302,610 Univ Ave,9-610, Toronto, ON M5G 2M9, Canada.	ming.tsao@uhn.on.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Brown, Kevin/0000-0002-5514-2538				Balkovetz DF, 2004, AM J PHYSIOL-RENAL, V286, pF702, DOI 10.1152/ajprenal.00270.2003; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Behrens P, 2003, APOPTOSIS, V8, P39, DOI 10.1023/A:1021644918117; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Bhattacharjee RN, 2001, MOL CELL BIOL, V21, P5417, DOI 10.1128/MCB.21.16.5417-5425.2001; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; Conner EA, 1999, CARCINOGENESIS, V20, P583, DOI 10.1093/carcin/20.4.583; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fazekas K, 2001, CLIN EXP METASTAS, V18, P639, DOI 10.1023/A:1013136303880; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALABAN R, 1992, ONCOGENE, V7, P2195; Jiang MC, 2004, J EXP CLIN CANC RES, V23, P325; Jiang MC, 2002, BIOCHEM BIOPH RES CO, V294, P900, DOI 10.1016/S0006-291X(02)00551-X; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; LIU C, 1992, ONCOGENE, V7, P181; Liu J, 2004, ONCOGENE, V23, P6316, DOI 10.1038/sj.onc.1207795; Martinez-Garza SG, 1999, DIGEST DIS, V17, P225, DOI 10.1159/000016940; Monga SPS, 2002, CANCER RES, V62, P2064; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SEIDENLONG I, 2003, MOL CANCER RES, V1, P393; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sultan M, 2002, Bioinformatics, V18 Suppl 1, pS111; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098	42	63	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					91	102		10.1038/sj.onc.1209005	http://dx.doi.org/10.1038/sj.onc.1209005			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16158056				2022-12-25	WOS:000234406400010
J	Zhou, JM; Zhu, XF; Lu, YJ; Deng, R; Huang, ZS; Mei, YP; Wang, Y; Huang, WL; Liu, ZC; Gu, LQ; Zeng, YX				Zhou, JM; Zhu, XF; Lu, YJ; Deng, R; Huang, ZS; Mei, YP; Wang, Y; Huang, WL; Liu, ZC; Gu, LQ; Zeng, YX			Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines	ONCOGENE			English	Article						G-quadruplex; telomerase inhibition; senescence	INHIBITS TUMOR-GROWTH; DRUG DESIGN; IN-VIVO; DNA; MAINTENANCE; TARGET; COMPOUND; LIGANDS; BINDING; LENGTH	Agents stabilizing G-quadruplexes have the potential to interfere with telomere replication by blocking the elongation step catalysed by telomerase or telomerase-independent mechanism and could therefore act as antitumor agents. In this study, we found that quindoline derivatives interacted preferentially with intramolecular G-quadruplex structures and were novel potent telomerase inhibitors. Treatment with quindoline derivatives reproducibly inhibited telomerase activity in human leukemia K562 cells and colon cancer SW620 cells. N'-(10H-Indolo [3,2-b] quinolin-11-yl)- N, N-dimethylpropane- 1,3-diamine (SYUIQ-5), (one of quindoline derivatives), when added to K562 and SW620 cell culture at nonacute cytotoxic concentrations, increased time of population doublings of K562 and SW620 cells, induced a marked cessation in cell growth and cellular senescence phenotype after 35 and 18 days, respectively. Growth cessation was accompanied by a shortening of telomere length, and induction of p16, p21 and p27 protein expression. However, another compound SYUIQ-7 with greater IC50 for telomerase had no obvious cellular effect in nonacute cytotoxic concentrations. These results indicate that quindoline derivatives as novel potent G-quadruplex interactive agents induce senescence and telomere shortening in cancer cells and therefore are promising agents for cancer treatment.	Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510060, Peoples R China; Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510060, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, 651 Dongfeng Rd E, Guangzhou 510060, Peoples R China.	xfzhu70@public.guangzhou.gd.cn; yxzeng@gzsums.edu.cn	huang, wen/GXW-0661-2022					Bierer DE, 1998, J MED CHEM, V41, P2754, DOI 10.1021/jm970735n; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bonjean K, 1998, BIOCHEMISTRY-US, V37, P5136, DOI 10.1021/bi972927q; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Burger AM, 2005, CANCER RES, V65, P1489, DOI 10.1158/0008-5472.CAN-04-2910; Caprio V, 2000, BIOORG MED CHEM LETT, V10, P2063, DOI 10.1016/S0960-894X(00)00378-4; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Dixon IM, 2005, CHEMBIOCHEM, V6, P123, DOI 10.1002/cbic.200400113; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Grand CL, 2002, MOL CANCER THER, V1, P565; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; ISHIKAWA Y, 2001, NUCL ACIDS RES S, V1, P107; Izbicka E, 1999, CANCER RES, V59, P639; Keith WN, 2001, J PATHOL, V195, P404; Kelland LR, 2001, LANCET ONCOL, V2, P95, DOI 10.1016/S1470-2045(00)00226-6; Kerwin SM, 2000, CURR PHARM DESIGN, V6, P441, DOI 10.2174/1381612003400849; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lisgarten JN, 2002, NAT STRUCT BIOL, V9, P57, DOI 10.1038/nsb729; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Pennarun G, 2005, ONCOGENE, V24, P2917, DOI 10.1038/sj.onc.1208468; Perry PJ, 1999, ANTI-CANCER DRUG DES, V14, P373; Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q; Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Schultes CM, 2004, BIOORG MED CHEM LETT, V14, P4347, DOI 10.1016/j.bmcl.2004.05.090; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3	41	94	102	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					503	511		10.1038/sj.onc.1209067	http://dx.doi.org/10.1038/sj.onc.1209067			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170347				2022-12-25	WOS:000234897400002
J	Hirano, K; Miki, Y; Hirai, Y; Sato, R; Itoh, T; Hayashi, A; Yamanaka, M; Eda, S; Beppu, M				Hirano, K; Miki, Y; Hirai, Y; Sato, R; Itoh, T; Hayashi, A; Yamanaka, M; Eda, S; Beppu, M			A multifunctional shuttling protein nucleolin is a macrophage receptor for apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLLACTOSAMINYL SACCHARIDE CHAINS; DENSITY-LIPOPROTEIN RECEPTOR; SURFACE-EXPRESSED NUCLEOLIN; 3 AUTOANTIBODY BINDING; OXIDIZED ERYTHROCYTES; ENDOTHELIAL-CELLS; TARGET-CELLS; SUGAR CHAINS; THP-1 CELLS; RECOGNITION	Early apoptotic Jurkat T cells undergo capping of CD43, and its polylactosaminyl saccharide chains serve as ligands for phagocytosis by macrophages. This suggests the presence of a polylactosaminoglycan-binding receptor on macrophages. Here we show that this receptor is nucleolin, a multifunctional shuttling protein present in nucleus, cytoplasm, and on the surface of some types of cells. Nucleolin was detected at the surface of macrophages, and anti-nucleolin antibody inhibited the binding of the early apoptotic cells to macrophages. Nucleolin-transfected HEK293 cells expressed nucleolin on the cell surface and bound the early apoptotic cells but not phosphatidylserine-exposing late apoptotic cells. This binding was inhibited by anti-nucleolin antibody, by polylactosamine-containing oligosaccharides, and by anti-CD43 antibody. Deletion of the antibody binding region of nucleolin resulted in loss of the apoptotic cell-binding ability. Moreover, truncated recombinant nucleolin in solution containing this region blocked the apoptotic cell binding to macrophages, and the blocking effect was cancelled by the oligosaccharides. These results indicate that nucleolin is a macrophage receptor for apoptotic cells.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Beppu, M (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	beppum@ps.toyaku.ac.jp						Ando K, 1997, ARCH BIOCHEM BIOPHYS, V339, P250, DOI 10.1006/abbi.1996.9831; Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; BEPPU M, 1994, ARCH BIOCHEM BIOPHYS, V312, P189, DOI 10.1006/abbi.1994.1298; Beppu M, 2001, BIOL PHARM BULL, V24, P19, DOI 10.1248/bpb.24.19; Beppu M, 2000, ARCH BIOCHEM BIOPHYS, V384, P368, DOI 10.1006/abbi.2000.2122; Beppu M, 1996, BIOL PHARM BULL, V19, P188; Beppu M, 1996, CELL MOL BIOL, V42, P1007; Bose S, 2004, J VIROL, V78, P8146, DOI 10.1128/JVI.78.15.8146-8158.2004; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DUVALL E, 1985, IMMUNOLOGY, V56, P351; Eda S, 2004, J BIOL CHEM, V279, P5967, DOI 10.1074/jbc.M310805200; Eda S, 2001, ARCH BIOCHEM BIOPHYS, V385, P186, DOI 10.1006/abbi.2000.2142; Eda S, 1997, BIOL PHARM BULL, V20, P127, DOI 10.1248/bpb.20.127; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Falasca L, 1996, EXP CELL RES, V224, P152, DOI 10.1006/excr.1996.0123; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P107; Ginisty H, 1999, J CELL SCI, V112, P761; HALL SE, 1994, J IMMUNOL, V153, P3218; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Harms G, 2001, BIOCHEM J, V360, P531, DOI 10.1042/0264-6021:3600531; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x; Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004; MATSUMOTO A, 1982, J BIOCHEM-TOKYO, V91, P143, DOI 10.1093/oxfordjournals.jbchem.a133671; MEHES G, 1995, CELL PROLIFERAT, V28, P329, DOI 10.1111/j.1365-2184.1995.tb00074.x; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; MORRIS RG, 1984, AM J PATHOL, V115, P426; MURAKAMI T, 1991, J BIOCHEM-TOKYO, V110, P146, DOI 10.1093/oxfordjournals.jbchem.a123533; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nisole S, 2002, J BIOL CHEM, V277, P20877, DOI 10.1074/jbc.M110024200; Nisole S, 2002, EXP CELL RES, V276, P155, DOI 10.1006/excr.2002.5522; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Said EA, 2002, J BIOL CHEM, V277, P37492, DOI 10.1074/jbc.M201194200; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Sinclair JF, 2002, J BIOL CHEM, V277, P2876, DOI 10.1074/jbc.M110230200; Somersan S, 2001, J CELL BIOL, V155, P501, DOI 10.1083/jcb.200110066; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Yamanaka M, 2005, BIOCHEM BIOPH RES CO, V328, P273, DOI 10.1016/j.bbrc.2004.12.171	61	56	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39284	39293		10.1074/jbc.M505275200	http://dx.doi.org/10.1074/jbc.M505275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16135517	hybrid			2022-12-25	WOS:000233362200047
J	Bautista, JA; Tracewell, CA; Schlodder, E; Cunningham, FX; Brudvig, GW; Diner, BA				Bautista, JA; Tracewell, CA; Schlodder, E; Cunningham, FX; Brudvig, GW; Diner, BA			Construction and characterization of genetically modified Synechocystis sp. PCC 6803 Photosystem II core complexes containing carotenoids with shorter pi-conjugation than beta-carotene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CHARGE SEPARATION; CRYSTAL-STRUCTURE; REACTION CENTERS; RADICAL CATIONS; RHODOBACTER-SPHAEROIDES; PHYTOENE DESATURASE; ANGSTROM RESOLUTION; ABSORPTION-SPECTRA; LYCOPENE CYCLASE; WILD-TYPE	beta-Carotene has been identified as an intermediate in a secondary electron transfer pathway that oxidizes Chl(Z) and cytochrome b(559) in Photosystem II (PS II) when normal tyrosine oxidation is blocked. To test the redox function of carotenoids in this pathway, we replaced the zeta-carotene desaturase gene (zds) or both the zds and phytoene desaturase (pds) genes of Synechocystis sp. PCC 6803 with the phytoene desaturase gene ( crtI) of Rhodobacter capsulatus, producing carotenoids with shorter conjugated pi-electron systems and higher reduction potentials than beta-carotene. The PS II core complexes of both mutant strains contain approximately the same number of chlorophylls and carotenoids as the wild type but have replaced beta-carotene (11 double bonds), with neurosporene (9 conjugated double bonds) and beta-zeacarotene ( 9 conjugated double bonds and 1 beta-ionylidene ring). The presence of the ring appears necessary for PS II assembly. Visible and near-infrared spectroscopy were used to examine the light-induced formation of chlorophyll and carotenoid radical cations in the mutant PS II core complexes at temperatures from 20 to 160 K. At 20 K, a carotenoid cation radical is formed having an absorption maximum at 898 nm, an 85 nm blue shift relative to the beta-carotene radical cation peak in the WT, and consistent with the formation of the cation radical of a carotenoid with 9 conjugated double bonds. The ratio of Chl(+)/Car(+) is higher in the mutant core complexes, consistent with the higher reduction potential for Car(+). As the temperature increases, other carotenoids become accessible to oxidation by P-680(+).	DuPont Co Inc, Expt Stn, CR&D, Wilmington, DE 19880 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Tech Univ Berlin, D-10623 Berlin, Germany; Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA	DuPont; Yale University; Technical University of Berlin; University System of Maryland; University of Maryland College Park	Diner, BA (corresponding author), DuPont Co Inc, Expt Stn, CR&D, Wilmington, DE 19880 USA.	bruce.a.diner@usa.dupont.com	Schlodder, Eberhard/AAP-6766-2021		NIGMS NIH HHS [GM08283] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGALIDIS I, 1980, BIOCHIM BIOPHYS ACTA, V589, P264, DOI 10.1016/0005-2728(80)90043-2; Bautista JA, 2005, J BIOL CHEM, V280, P20030, DOI 10.1074/jbc.M500809200; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Britton G., 1995, SPECTROSCOPY-US, V1B, P13; Burke M, 2001, FEBS LETT, V500, P132, DOI 10.1016/S0014-5793(01)02601-1; CHAUVET JP, 1983, J PHYS CHEM-US, V87, P592, DOI 10.1021/j100227a016; COX RP, 1974, BIOCHIM BIOPHYS ACTA, V347, P49, DOI 10.1016/0005-2728(74)90199-6; Cuni A, 2004, PHYS CHEM CHEM PHYS, V6, P4825, DOI 10.1039/b407511k; CUNNINGHAM FX, 1994, PLANT CELL, V6, P1107, DOI 10.1105/tpc.6.8.1107; Cunningham FX, 1996, PLANT CELL, V8, P1613, DOI 10.2307/3870254; DAWE EA, 1975, J CHEM SOC FARAD T 1, V71, P2162, DOI 10.1039/f19757102162; Dekker JP, 2000, PHOTOSYNTH RES, V63, P195, DOI 10.1023/A:1006468024245; Deng Y, 2000, J PHYS CHEM B, V104, P5651, DOI 10.1021/jp994436g; Diner BA, 2002, ANNU REV PLANT BIOL, V53, P551, DOI 10.1146/annurev.arplant.53.100301.135238; Diner BA, 2001, BIOCHEMISTRY-US, V40, P9265, DOI 10.1021/bi010121r; Edge R, 2000, FEBS LETT, V471, P125, DOI 10.1016/S0014-5793(00)01366-1; EIJCKELHOFF C, 1995, BBA-BIOENERGETICS, V1231, P21, DOI 10.1016/0005-2728(95)00055-N; ERIXON K, 1971, BIOCHIM BIOPHYS ACTA, V234, P381, DOI 10.1016/0005-2728(71)90205-2; Farhoosh R, 1997, PHOTOCHEM PHOTOBIOL, V66, P97, DOI 10.1111/j.1751-1097.1997.tb03144.x; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Finazzi G, 2004, P NATL ACAD SCI USA, V101, P12375, DOI 10.1073/pnas.0404798101; Frank HA, 2004, BIOCHEMISTRY-US, V43, P8607, DOI 10.1021/bi0492096; Giorgi LB, 1996, J BIOL CHEM, V271, P2093, DOI 10.1074/jbc.271.4.2093; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; HILLMANN B, 1995, BBA-BIOENERGETICS, V1231, P76, DOI 10.1016/0005-2728(95)00068-T; Holt NE, 2005, SCIENCE, V307, P433, DOI 10.1126/science.1105833; Jeevarajan JA, 1996, J PHYS CHEM-US, V100, P5637, DOI 10.1021/jp9530663; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kawashima Y, 1997, CHEM PHYS LETT, V267, P82, DOI 10.1016/S0009-2614(97)00084-5; KLIMOV VV, 1981, PHOTOSYNTHETICA, V15, P592; KOBAYASHI M, 1990, FEBS LETT, V260, P138, DOI 10.1016/0014-5793(90)80086-X; Lakshmi KV, 2002, PHOTOSYNTH RES, V72, P175, DOI 10.1023/A:1016140902662; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Ma YZ, 2003, P NATL ACAD SCI USA, V100, P4377, DOI 10.1073/pnas.0736959100; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MOORE TA, 1984, NATURE, V307, P630, DOI 10.1038/307630a0; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; OMATA T, 1984, BIOCHIM BIOPHYS ACTA, V765, P403, DOI 10.1016/0005-2728(84)90182-8; Prokhorenko VI, 2000, J PHYS CHEM B, V104, P11563, DOI 10.1021/jp002323n; Rappaport F, 2002, BIOCHEMISTRY-US, V41, P8518, DOI 10.1021/bi025725p; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P216, DOI 10.1016/0005-2728(82)90014-7; SCHMIDT A, 1989, EUR J BIOCHEM, V184, P375, DOI 10.1111/j.1432-1033.1989.tb15029.x; Stewart DH, 1998, BIOCHEMISTRY-US, V37, P10040, DOI 10.1021/bi980668e; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Telfer A, 2003, BIOCHEMISTRY-US, V42, P1008, DOI 10.1021/bi026206p; Tomo T, 1997, BBA-BIOENERGETICS, V1321, P21, DOI 10.1016/S0005-2728(97)00037-6; Tracewell CA, 2003, BIOCHEMISTRY-US, V42, P9127, DOI 10.1021/bi0345844; Tracewell CA, 2001, ARCH BIOCHEM BIOPHYS, V385, P61, DOI 10.1006/abbi.2000.2150; Tracewell CA, 2001, BIOCHEMISTRY-US, V40, P193, DOI 10.1021/bi001992o; Trebst A, 1997, FEBS LETT, V400, P359, DOI 10.1016/S0014-5793(96)01419-6; Vasil'ev S, 2003, FEBS LETT, V543, P159, DOI 10.1016/S0014-5793(03)00442-3; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	55	22	23	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38839	38850		10.1074/jbc.M504953200	http://dx.doi.org/10.1074/jbc.M504953200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159754	hybrid			2022-12-25	WOS:000233239800086
J	Oberdorf, J; Pitonzo, D; Skach, WR				Oberdorf, J; Pitonzo, D; Skach, WR			An energy-dependent maturation step is required for release of the cystic fibrosis transmembrane conductance regulator from early endoplasmic reticulum biosynthetic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL SEQUENCE RECOGNITION; MEMBRANE-PROTEINS; P-GLYCOPROTEIN; CONFORMATIONAL MATURATION; INFLUENZA HEMAGGLUTININ; MOLECULAR CHAPERONES; CL-CHANNEL; WILD-TYPE; CFTR; ER	Polytopic proteins are synthesized in the endoplasmic reticulum (ER) by ribosomes docked at the Sec61 translocation channel. It is generally assumed that, upon termination of translation, polypeptides are spontaneously released into the ER membrane where final stages of folding and assembly are completed. Here we investigate early interactions between the ribosome-translocon complex and cystic fibrosis transmembrane conductance regulator (CFTR), a multidomain ABC transporter, and demonstrate that this is not always the case. Using in vitro and Xenopus oocyte expression systems we show that, during and immediately following synthesis, nascent CFTR polypeptides associate with large, heterogeneous, and dynamic protein complexes. Partial-length precursors were quantitatively isolated in a non-covalent, puromycin-sensitive complex (>3,500 kDa) that contained the Sec61 ER translocation machinery and the cytosolic chaperone Hsc70. Following the completion of synthesis, CFTR was gradually released into a smaller (600-800 kDa) ATP-sensitive complex. Surprisingly, release of full-length CFTR from the ribosome and translocon was significantly delayed after translation was completed. Moreover, this step required both nucleotide triphosphates and cytosol. Release of control proteins varied depending on their size and domain complexity. These studies thus identify a novel energy-dependent step early in the CFTR maturation pathway that is required to disengage nascent CFTR from ER biosynthetic machinery. We propose that, contrary to current models, the final stage of membrane integration is a regulated process that can be influenced by the state of nascent chain folding, and we speculate that this step is influenced by the complex multidomain structure of CFTR.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Skach, WR (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Mail Code L-224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	skachw@ohsu.edu		Oberdorf, Jon/0000-0002-0589-7115	NIDDK NIH HHS [DK51818, T32 DK07674] Funding Source: Medline; NIGMS NIH HHS [GM53457] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051818, T32DK007674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053457] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAR CE, 1991, J BIOL CHEM, V266, P19142; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Buck TM, 2004, AM J PHYSIOL-CELL PH, V287, pC1292, DOI 10.1152/ajpcell.00561.2003; Carveth K, 2002, J BIOL CHEM, V277, P39507, DOI 10.1074/jbc.M205759200; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen MG, 1999, BIOCHEMISTRY-US, V38, P5471, DOI 10.1021/bi982153t; Chen MG, 1996, MOL MEMBR BIOL, V13, P33, DOI 10.3109/09687689609160572; Chen W, 2000, MOL BIOL CELL, V11, P765, DOI 10.1091/mbc.11.2.765; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cotten JF, 1999, J BIOL CHEM, V274, P5429, DOI 10.1074/jbc.274.9.5429; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Fuller W, 2000, J BIOL CHEM, V275, P37462, DOI 10.1074/jbc.M006278200; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JIANG C, 1996, AM J PHYSIOL, V275, pC171; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KOWARIK M, 2003, MOL CELL, V10, P735; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meacock SL, 2002, MOL BIOL CELL, V13, P4114, DOI 10.1091/mbc.E02-04-0198; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Oberdorf J, 2001, BIOCHEMISTRY-US, V40, P13397, DOI 10.1021/bi011322y; Oberdorf Jon, 2002, Methods Mol Med, V70, P295; OHRUI T, 1994, AM J PHYSIOL, V266, pC1586; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; Ostedgaard LS, 1997, BIOCHEMISTRY-US, V36, P1287, DOI 10.1021/bi962174s; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PATRICK TD, 1989, DEVELOPMENT, V106, P1; PIND S, 1994, J BIOL CHEM, V269, P12784; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Rapoport TA, 1996, CURR OPIN CELL BIOL, V8, P499, DOI 10.1016/S0955-0674(96)80027-5; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sadlish H, 2005, NAT STRUCT MOL BIOL, V12, P870, DOI 10.1038/nsmb994; SADLISH H, 2004, J MEM BIOL, V202, P1; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; SHI LB, 1994, J BIOL CHEM, V269, P10417; Shibatani T, 2005, BIOCHEMISTRY-US, V44, P5982, DOI 10.1021/bi047328f; Skach WR, 1998, METHOD ENZYMOL, V292, P265; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P23552; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilson CM, 2005, J BIOL CHEM, V280, P4195, DOI 10.1074/jbc.M410329200; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	83	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38193	38202		10.1074/jbc.M504200200	http://dx.doi.org/10.1074/jbc.M504200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166089	hybrid			2022-12-25	WOS:000233239800012
J	Kim, H; Chan, R; Dankort, DL; Zuo, DM; Najoukas, M; Park, M; Muller, WJ				Kim, H; Chan, R; Dankort, DL; Zuo, DM; Najoukas, M; Park, M; Muller, WJ			The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation	ONCOGENE			English	Article						receptor; activation; kinase; transformation; tumorigenesis	EPIDERMAL-GROWTH-FACTOR; HUMAN BREAST-CANCER; FACTOR RECEPTOR; MAMMARY-TUMORS; TRANSGENIC MICE; NEU ONCOGENE; FAMILY KINASES; POINT MUTATION; ACTIVATION; PHOSPHORYLATION	c-Src associates with and is activated by the ErbB-2 receptor tyrosine kinase, but is unable to bind the EGFR. Although c-Src has been found to interact directly and specifically with the ErbB-2 receptor, the significance of this interaction is unclear. Using both chimeric receptor and site-directed mutagenesis approaches, the region of interaction of c-Src on ErbB-2 was identified. Significantly, EGFR could be converted into a receptor capable of binding c-Src by replacement of a catalytic domain of ErbB-2. We further demonstrated that MDCK cells that express mutant EGFR that are competent in c-Src recruitment lose epithelial polarity in organoid cultures, whereas cells overexpressing the wild-type EGFR retain a polarized phenotype. ErbB-2-dependent activation of c-Src results in disruption of epithelial cell-cell contacts leading to cell dispersal that correlates with the re-localization of phospho-MAPK to focal adhesions. Taken together, these observations suggest that recruitment of c-Src to these closely related EGFR family members plays a critical role in modulating cell polarity.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4L8, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4L8, Canada; McGill Univ, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ Calif San Francisco, Inst Canc Res, Ctr Comprehens Canc, San Francisco, CA 94115 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada	McGill University; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McMaster University; McGill University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; McMaster University	Muller, WJ (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Rm H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca		Dankort, David/0000-0002-5862-6829				Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Latta EK, 2002, MODERN PATHOL, V15, P1318, DOI 10.1097/01.MP.0000038462.62634.B1; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tapon N, 2003, CANCER CELL, V4, P333, DOI 10.1016/S1535-6108(03)00279-4; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Zhang HT, 1998, ONCOGENE, V16, P2835, DOI 10.1038/sj.onc.1201820	37	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7599	7607		10.1038/sj.onc.1208898	http://dx.doi.org/10.1038/sj.onc.1208898			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16170374				2022-12-25	WOS:000233333800009
J	Beinker, P; Schlee, S; Auvula, R; Reinstein, J				Beinker, P; Schlee, S; Auvula, R; Reinstein, J			Biochemical coupling of the two nucleotide binding domains of ClpB - Covalent linkage is not a prerequisite for chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; ATP-BINDING; CRYSTAL-STRUCTURE; TRANSFER-RNA; DNAK; HSP104; DISAGGREGATION; SYSTEM	ClpB cooperates with the DnaK chaperone system in the reactivation of protein from aggregates and is a member of the ATPases associated with a variety of cellular activities (AAA+) protein family. The underlying disaggregation reaction is dependent on ATP hydrolysis at both AAA cassettes of ClpB but the role of each AAA cassette in the reaction cycle is largely unknown. Here we analyze the activity of the separately expressed and purified nucleotide binding domains of ClpB from Thermus thermophilus. The two fragments show different biochemical properties: the first construct is inactive in ATPase activity assays and binds nucleotides weakly, the second construct has a very high ATPase activity and interacts tightly with nucleotides. Both individual fragments have lost their chaperone function and are not able to form large oligomers. When combined in solution, however, the two fragments form a stable heterodimer with oligomerization capacities equivalent to wildtype ClpB. This non-covalent complex regains activity in reactivating protein aggregates in cooperation with the DnaK chaperone system. Upon complex formation the ATPase activity of fragment 2 is reduced to a level similar to wild-type ClpB. Hence functional ClpB can be reassembled from its isolated AAA cassettes showing that covalent linkage of these domains is not a prerequisite for the chaperone activity. The observation that the intrinsically high ATPase activity of AAA2 is suppressed by AAA1 allows a hypothetical assignment of their mechanistic function. Whereas the energy gained upon ATP hydrolysis at the AAA2 is likely to drive a conformational change of the structure of ClpB, AAA1 might function as a regulator of the chaperone cycle.	Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany	Max Planck Society	Reinstein, J (corresponding author), Max Planck Inst Med Res, Dept Biomol Mech, Jahnstr 29, D-69120 Heidelberg, Germany.	jochen.reinstein@mpimf-heidelberg.mpg.de						Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; BERGMEYER HU, 1962, COLORIMETRIC ASSAYS, P573; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; Eriksson MJ, 2000, CELL STRESS CHAPERON, V5, P255, DOI 10.1379/1466-1268(2000)005<0255:TECHSP>2.0.CO;2; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Groemping Y, 2001, J MOL BIOL, V305, P1173, DOI 10.1006/jmbi.2000.4373; Halliwell CM, 2001, ANAL BIOCHEM, V295, P257, DOI 10.1006/abio.2001.5182; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Li JZ, 2003, STRUCTURE, V11, P323, DOI 10.1016/S0969-2126(03)00030-3; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Motojima F, 2004, P NATL ACAD SCI USA, V101, P15005, DOI 10.1073/pnas.0406132101; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; PARK SK, 1993, J BIOL CHEM, V268, P20170; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	39	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37965	37973		10.1074/jbc.M506672200	http://dx.doi.org/10.1074/jbc.M506672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16162497	Green Published, hybrid			2022-12-25	WOS:000233044500079
J	Lagor, WR; de Groh, ED; Ness, GC				Lagor, WR; de Groh, ED; Ness, GC			Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl-CoA reductase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-REGULATORY-ELEMENT; HMG-COA REDUCTASE; IN-VIVO; DIETARY-CHOLESTEROL; GENE-EXPRESSION; BINDING PROTEIN; HORMONAL-REGULATION; IDENTIFICATION; TRANSCRIPTION	Hepatic 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) protein and mRNA are substantially decreased in diabetic animals and rapidly restored by the administration of insulin. To begin to examine the underlying molecular mechanisms, measurements of transcription by nuclear run-on assays and an investigation of occupancy of the promoter were performed. The rate of transcription was substantially reduced in the diabetic rats and fully restored within 2 h after insulin treatment. In vivo footprinting revealed several areas of protein binding as shown by dimethyl sulfate protection or enhancement. The cAMP-response element was heavily protected in all conditions, including diabetes, feeding of dietary cholesterol, or statin treatment. Striking enhancements in footprints from diabetic animals were visible at - 142 and at - 161 ( in the sterol-response element). Protections at a newly identified NF-Y site at - 70/-71 were observed in normal animals and not in diabetics. This NF-Y site was found to be required for efficient HMGR transcription in luciferase assays. CREB-1 was able to bind the HMGR cAMP-response element in vitro and the promoter in vivo. This evidence supports an essential role for cAMP-response element-binding protein in transcription of hepatic HMGR and identifies at least two sites where in vivo occupancy is regulated by insulin.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Ness, GC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	gness@hsc.usf.edu		Lagor, William/0000-0002-1703-5125				Armitage J, 2004, CURR OPIN LIPIDOL, V15, P439, DOI 10.1097/01.mol.0000137219.31407.16; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; BIFULCO M, 1995, J BIOL CHEM, V270, P15231, DOI 10.1074/jbc.270.25.15231; Bossard P, 1997, METHODS, V11, P180, DOI 10.1006/meth.1996.0404; Chambers CM, 1997, BIOCHEM BIOPH RES CO, V232, P278, DOI 10.1006/bbrc.1997.6288; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; Latasa MJ, 2003, MOL CELL BIOL, V23, P5896, DOI 10.1128/MCB.23.16.5896-5907.2003; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; Lopez D, 1997, ARCH BIOCHEM BIOPHYS, V343, P118, DOI 10.1006/abbi.1997.0162; MANO H, 1994, J BIOL CHEM, V269, P1591; Miettinen TA, 2004, DIABETES CARE, V27, P53, DOI 10.2337/diacare.27.1.53; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Ness GC, 2004, EXP BIOL MED, V229, P407, DOI 10.1177/153537020422900508; Ness GC, 2004, EXP BIOL MED, V229, P412, DOI 10.1177/153537020422900509; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V309, P193, DOI 10.1006/abbi.1994.1102; Ness GC, 2000, P SOC EXP BIOL MED, V224, P8, DOI 10.1046/j.1525-1373.2000.22359.x; Ngo TT, 2002, J BIOL CHEM, V277, P33901, DOI 10.1074/jbc.M202135200; Osborne AR, 2004, BIOCHEM BIOPH RES CO, V318, P814, DOI 10.1016/j.bbrc.2004.04.105; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SINGER II, 1984, P NATL ACAD SCI-BIOL, V81, P5556, DOI 10.1073/pnas.81.17.5556; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang CK, 2005, BIOCHEM J, V386, P161, DOI 10.1042/BJ20041514	30	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36601	36608		10.1074/jbc.M504346200	http://dx.doi.org/10.1074/jbc.M504346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16127173	hybrid			2022-12-25	WOS:000232901800010
J	Matsui, T; Nakajima, A; Fujii, H; Matera, KM; Migita, CT; Yoshida, T; Ikeda-Saito, M				Matsui, T; Nakajima, A; Fujii, H; Matera, KM; Migita, CT; Yoshida, T; Ikeda-Saito, M			O-2- and H2O2-dependent verdoheme degradation by heme oxygenase - Reaction mechanisms and potential physiological roles of the dual pathway degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERROUS-NO FORMS; CARBON-MONOXIDE; CRYSTAL-STRUCTURE; CORYNEBACTERIUM-DIPHTHERIAE; CATALYTIC IMPLICATIONS; BILIVERDIN REDUCTASE; ACTIVATION; COMPLEX; DIOXYGEN; SYSTEM	Heme oxygenase (HO) catalyzes the catabolism of heme to biliverdin, CO, and a free iron through three successive oxygenation steps. The third oxygenation, oxidative degradation of verdoheme to biliverdin, has been the least understood step despite its importance in regulating HO activity. We have examined in detail the degradation of a synthetic verdoheme IX alpha complexed with rat HO-1. Our findings include: 1) HO degrades verdoheme through a dual pathway using either O-2 or H2O2; 2) the verdoheme reactivity with O-2 is the lowest among the three O-2 reactions in the HO catalysis, and the newly found H2O2 pathway is similar to 40-fold faster than the O-2-dependent verdoheme degradation; 3) both reactions are initiated by the binding of O-2 or H2O2 to allow the first direct observation of degradation intermediates of verdoheme; and 4) Asp(140) in HO-1 is critical for the verdoheme degradation regardless of the oxygen source. On the basis of these findings, we propose that the HO enzyme activates O-2 and H2O2 on the verdoheme iron with the aid of a nearby water molecule linked with Asp140. These mechanisms are similar to the well established mechanism of the first oxygenation, meso-hydroxylation of heme, and thus, HO can utilize a common architecture to promote the first and third oxygenation steps of the heme catabolism. In addition, our results infer the possible involvement of the H2O2-dependent verdoheme degradation in vivo, and potential roles of the dual pathway reaction of HO against oxidative stress are proposed.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Natl Inst Nat Sci, Inst Mol Sci, Okazaki, Aichi 4448787, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Baldwin Wallace Coll, Dept Chem, Berea, OH 44017 USA; Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan	Tohoku University; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Baldwin Wallace University; Yamaguchi University; Yamagata University	Matsui, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.	matsui@tagen.tohoku.ac.jp; mis2@tagen.tohoku.ac.jp	Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008; Matsui, Toshitaka/B-1570-2008	Matsui, Toshitaka/0000-0003-3865-8468				Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; Boehning D, 2004, J BIOL CHEM, V279, P30927, DOI 10.1074/jbc.C400222200; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Braun RD, 2001, AM J PHYSIOL-HEART C, V280, pH2533, DOI 10.1152/ajpheart.2001.280.6.H2533; Davis SJ, 1999, P NATL ACAD SCI USA, V96, P6541, DOI 10.1073/pnas.96.11.6541; Davydov R, 2004, J AM CHEM SOC, V126, P15960, DOI 10.1021/ja044646t; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; DOCHERTY JC, 1984, J BIOL CHEM, V259, P3066; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; HIROTA T, 1983, TETRAHEDRON LETT, V24, P995, DOI 10.1016/S0040-4039(00)81585-3; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; Jiang JJ, 1996, J APPL PHYSIOL, V80, P552, DOI 10.1152/jappl.1996.80.2.552; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Koerner R, 1998, J AM CHEM SOC, V120, P9246, DOI 10.1021/ja980558v; Kumar D, 2005, J AM CHEM SOC, V127, P8204, DOI 10.1021/ja0446956; Lad L, 2004, J INORG BIOCHEM, V98, P1686, DOI 10.1016/j.jinorgbio.2004.07.004; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; Matsui T, 2005, J BIOL CHEM, V280, P2981, DOI 10.1074/jbc.M410263200; Migita CT, 1998, J BIOL CHEM, V273, P945, DOI 10.1074/jbc.273.2.945; Nguyen KT, 2004, J AM CHEM SOC, V126, P6210, DOI 10.1021/ja049222d; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RAMETTE RW, 1965, J AM CHEM SOC, V87, P5001, DOI 10.1021/ja00950a005; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; Sakamoto H, 2002, EUR J BIOCHEM, V269, P5231, DOI 10.1046/j.1432-1033.2002.03230.x; Sakamoto H, 2000, J INORG BIOCHEM, V82, P113, DOI 10.1016/S0162-0134(00)00149-5; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Suematsu M, 2000, HEPATOLOGY, V31, P3, DOI 10.1002/hep.510310102; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sun D, 2000, ACTA CRYSTALLOGR D, V56, P1180, DOI 10.1107/S0907444900008520; Takahashi S, 1997, BIOCHEMISTRY-US, V36, P1402, DOI 10.1021/bi962361q; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; WILKS A, 1993, J BIOL CHEM, V268, P22357; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; Zhang XH, 2003, BIOCHEMISTRY-US, V42, P7418, DOI 10.1021/bi027173g	52	52	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36833	36840		10.1074/jbc.M503529200	http://dx.doi.org/10.1074/jbc.M503529200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115896	hybrid, Green Submitted			2022-12-25	WOS:000232901800038
J	Bhaskar, K; Yen, SH; Lee, G				Bhaskar, K; Yen, SH; Lee, G			Disease-related modifications in tau affect the interaction between Fyn and tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; SH3 DOMAINS; NEURODEGENERATIVE TAUOPATHIES; MICROTUBULE-BINDING; TYROSINE KINASE; PROLINE-RICH; IN-VITRO; PROTEIN; PHOSPHORYLATION	Microtubule-associated protein tau is the major component of the neurofibrillary tangles of Alzheimer disease (AD) and is genetically linked to frontotemporal dementias (FTDP-17). We have recently shown that tau interacts with the SH3 domain of Fyn, an Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18. Also, tyrosine-phosphorylated tau is present in the neuropathology of AD. To determine whether alterations in the tau-Fyn interaction might correlate with disease-related factors in AD and FTDP-17, we have performed real-time surface plasmon resonance studies on a panel of 21 tau constructs with Fyn SH3. We report that the interaction between Fyn SH3 and 3R-tau was 20-fold higher than that with 4R-tau. In addition, the affinity between 4R-tau and Fyn SH3 was increased 25-45-fold by phosphorylation-mimicking mutations or by FTDP-17 mutations. In vitro kinase reactions show that tau, with lower affinity SH3 interactions, exhibited a lower level of Tyr-18 phosphorylation under our reaction conditions. Lastly, we have demonstrated that tau is phosphorylated on Tyr-18 in the tau P301L mouse model for tauopathy (JNPL3). In summary, our results suggest that disease-related phosphorylation and missense mutations of tau increase association of tau with Fyn. Because these effects are mediated through the 4R component of the tau population, these results also have implications for the FTDP-17 diseases caused by increased expression of 4R-tau. Our data support a role for the Fyn-tau interaction in neurodegeneration.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA	University of Iowa; Mayo Clinic	Lee, G (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, 500 Newton Rd,MRC 17, Iowa City, IA 52242 USA.	gloria-lee@uiowa.edu	Lee, Gloria/F-5965-2011; Bhaskar, Kiran/AAF-2755-2020	Lee, Gloria/0000-0002-8633-1534	NATIONAL INSTITUTE ON AGING [R01AG017753] Funding Source: NIH RePORTER; NIA NIH HHS [AG17753] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abraha A, 2000, J CELL SCI, V113, P3737; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Barghorn S, 2004, BIOCHEMISTRY-US, V43, P1694, DOI 10.1021/bi0357006; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; Brandt R, 2005, BBA-MOL BASIS DIS, V1739, P331, DOI 10.1016/j.bbadis.2004.06.018; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Chin J, 2004, J NEUROSCI, V24, P4692, DOI 10.1523/JNEUROSCI.0277-04.2004; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Ho GJ, 2005, NEUROBIOL AGING, V26, P625, DOI 10.1016/j.neurobiolaging.2004.06.016; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kuret J, 2005, BBA-MOL BASIS DIS, V1739, P167, DOI 10.1016/j.bbadis.2004.06.016; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee G, 1998, J CELL SCI, V111, P3167; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Mayer BJ, 2001, J CELL SCI, V114, P1253; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Sergeant N, 2005, BBA-MOL BASIS DIS, V1739, P179, DOI 10.1016/j.bbadis.2004.06.020; SHIRAZI SK, 1993, NEUROREPORT, V4, P435, DOI 10.1097/00001756-199304000-00024; Singh TJ, 1997, MOL CELL BIOCHEM, V168, P141, DOI 10.1023/A:1006807105059; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Williams R, 2002, MATER WORLD, V10, P20; Zamora-Leon SP, 2001, J BIOL CHEM, V276, P39950, DOI 10.1074/jbc.M107807200; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	43	174	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35119	35125		10.1074/jbc.M505895200	http://dx.doi.org/10.1074/jbc.M505895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115884	hybrid			2022-12-25	WOS:000232561200008
J	Yoo, D; Fang, L; Mason, A; Kim, BY; Welling, PA				Yoo, D; Fang, L; Mason, A; Kim, BY; Welling, PA			A phosphorylation-dependent export structure in ROMK (Kir 1.1) channel overrides an endoplasmic reticulum localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CORTICAL COLLECTING TUBULE; CONDUCTANCE K+ CHANNEL; THICK ASCENDING LIMB; POTASSIUM CHANNEL; SURFACE EXPRESSION; CELL-SURFACE; MEMBRANE-PROTEINS; BARTTERS-SYNDROME; RETENTION SIGNAL	The cell surface density of functional Kir1.1 (ROMK, KCNJ1) channels in the renal collecting duct is precisely regulated to maintain potassium balance. Here, we explore the mechanism by which phosphorylation of Kir1.1a serine 44 controls plasmalemma expression. Studies in Xenopus oocytes, expressing wild-type, phosphorylation mimic (S44D), or phosphorylation null (S44A) Kir1.1a, revealed that phosphorylation of serine 44 is required to stimulate traffic of newly synthesized channels to the plasma membrane through a brefeldin A-sensitive pathway. ROMK channels were found to acquire mature glycosylation in a serine 44 phosphorylation-dependent manner, consistent with a phosphorylation- dependent trafficking step within the endoplasmic reticulum/Golgi. Serine 44 neighbors a string of three "RXR" motifs, reminiscent of basic trafficking signals involved in directing early transport steps within the secretory pathway. Replacement of the arginine residues with alanine (R35A, R37A, R39A, R41A, or all Arg to Ala) did not restore cell surface expression of the phospho-null S44A channel, making it unlikely that phosphorylation abrogates a nearby RXR-type endoplasmic reticulum (ER) localization signal. Instead, analysis of the compound S44D phospho-mimic mutants revealed that the neighboring arginine residues are also necessary for cell surface expression, identifying a structure that determines export in the biosynthetic pathway. Suppressor mutations in a putative dibasic ER retention signal, located within the cytoplasmic C terminus (K370A, R371A), restored cell surface expression of the phospho-null S44A channel to levels exhibited by the phospho-mimic S44D channel. Taken together, these studies indicate that phosphorylation of Ser(44) drives an export step within the secretory pathway to override an independent endoplasmic reticulum localization signal.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Welling, PA (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.	pwelling@umeryland.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054231, R01DK063049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK63049, DK54231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson HA, 1999, J IMMUNOL, V163, P5435; CASSOLA AC, 1993, AM J PHYSIOL, V264, pF502, DOI 10.1152/ajprenal.1993.264.3.F502; Ecelbarger CA, 2001, J AM SOC NEPHROL, V12, P10, DOI 10.1681/ASN.V12110; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Lin DH, 2005, P NATL ACAD SCI USA, V102, P4306, DOI 10.1073/pnas.0409767102; Lin DH, 2002, J BIOL CHEM, V277, P44278, DOI 10.1074/jbc.M203702200; Lorenz JN, 2002, J BIOL CHEM, V277, P37871, DOI 10.1074/jbc.M205627200; Lu M, 2002, J BIOL CHEM, V277, P37881, DOI 10.1074/jbc.M206644200; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; MacGregor GG, 1998, AM J PHYSIOL-RENAL, V275, pF415, DOI 10.1152/ajprenal.1998.275.3.F415; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; O'Connell AD, 2005, P NATL ACAD SCI USA, V102, P9954, DOI 10.1073/pnas.0504332102; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Palmer LG, 1999, AM J PHYSIOL-RENAL, V277, pF821, DOI 10.1152/ajprenal.1999.277.6.F821; Palmer LG, 2000, KIDNEY INT, V57, P1324, DOI 10.1046/j.1523-1755.2000.00970.x; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Scott DB, 2003, NEUROPHARMACOLOGY, V45, P755, DOI 10.1016/S0028-3908(03)00250-8; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; Wei Y, 2001, AM J PHYSIOL-RENAL, V281, pF206, DOI 10.1152/ajprenal.2001.281.2.F206; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Yoo D, 2004, J BIOL CHEM, V279, P6863, DOI 10.1074/jbc.M311599200; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Yun CC, 2002, J AM SOC NEPHROL, V13, P2823, DOI 10.1097/01.ASN.0000035085.54451.81; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V283, pF630, DOI 10.1152/ajprenal.00378.2001; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	53	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35281	35289		10.1074/jbc.M504836200	http://dx.doi.org/10.1074/jbc.M504836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118216	hybrid			2022-12-25	WOS:000232561200026
J	Liu, AMF; Wong, YH				Liu, AMF; Wong, YH			Activation of nuclear factor kappa B by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves G alpha(14) and multiple signaling components - A mechanism requiring protein kinase C, calmodulin-dependent kinase II, ERK, AND c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; COUPLED RECEPTOR; TYROSINE PHOSPHORYLATION; OPIOID RECEPTOR; PHOSPHOLIPASE-C; ALPHA; EXPRESSION; PATHWAY	Medications targeting the somatostatin type 2 receptor (SSTR2) have been employed for pancreatic inflammations and cancers, possibly via the regulation of the transcription factor nuclear factor kappa B (NF kappa B). Here we demonstrate that in tumoral pancreatic acinar AR42J cells, activation of SSTR2 leads to stimulation of the inhibitor kappa B kinase (IKK)/ NF kappa B signaling cascade via pertussis toxin-insensitive G proteins in a time- and dose-dependent manner. The inability of G(q/11) and G(12/13) proteins to activate IKK/NF kappa B by SSTR2 in transfected human embryonic kidney 293 cells and the lack of G alpha(16) in AR42J cells suggested a possible role of G alpha(14) in mediating SSTR2-induced responses. This regulatory role of G alpha(14) was further confirmed by the activation of IKK and NF kappa B in human embryonic kidney 293 cells expressing SSTR2 and G alpha(14) upon induction. The stimulatory effect of G beta(1)gamma(2) and the abrogation by overexpressing transducin confirmed the participation of G beta gamma in SSTR2-mediated IKK/NF kappa B activation. By the application of specific inhibitors and dominant negative mutants, phospholipase C beta, protein kinase C, and calmodulin-dependent kinase II were shown to be involved in SSTR2-induced responses. Inhibition of c-Src and numerous intermediates, including Ras, Raf-1 kinase, MEK1/2, along with the extracellular signal-regulated kinase cascade attenuated somatostatin-mediated IKK/NF kappa B activation. Although c-Jun N-terminal kinase and p38 mitogen-activated protein kinase ( MAPK) were also stimulated by SSTR2, suppression of these two MAPKs was ineffective in altering the somatostatin-mediated responses. Similar results were also obtained using AR42J cells. These data suggest that activation of the IKK/NF kappa B signaling cascade by SSTR2 requires a complicated network consisting of G alpha(14) and multiple intermediates.	Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	boyung@ust.hk		Wong, Yung Hou/0000-0002-0123-7697				Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chan ASL, 2000, J PHARMACOL EXP THER, V295, P1094; Chandrasekar B, 2004, J BIOL CHEM, V279, P3188, DOI 10.1074/jbc.M311660200; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Elberg G, 2002, MOL ENDOCRINOL, V16, P2502, DOI 10.1210/me.2002-0207; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ho MKC, 2001, BRIT J PHARMACOL, V132, P1431, DOI 10.1038/sj.bjp.0703933; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Illario M, 2003, J BIOL CHEM, V278, P45101, DOI 10.1074/jbc.M305355200; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kitagawa M, 1998, PANCREAS, V16, P427, DOI 10.1097/00006676-199804000-00035; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Liu AMF, 2005, NEUROSIGNALS, V14, P136, DOI 10.1159/000086296; Liu AMF, 2004, J BIOL CHEM, V279, P53196, DOI 10.1074/jbc.M410196200; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mody SM, 2000, MOL PHARMACOL, V57, P13; Paran Daphna, 2003, Curr Opin Investig Drugs, V4, P578; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; REUBI JC, 1994, CANCER RES, V54, P3455; Rosenberg L, 2003, EXPERT OPIN BIOL TH, V3, P319, DOI 10.1517/14712598.3.2.319; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; TAYLOR JE, 1995, BIOCHEM BIOPH RES CO, V214, P81, DOI 10.1006/bbrc.1995.2259; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang Y, 2003, J AM SOC NEPHROL, V14, P28, DOI 10.1097/01.ASN.0000043180.18456.47; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang M, 2003, MOL PHARMACOL, V64, P447, DOI 10.1124/mol.64.2.447; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Yule DI, 1999, AM J PHYSIOL-GASTR L, V276, pG271, DOI 10.1152/ajpgi.1999.276.1.G271; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	45	41	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34617	34625		10.1074/jbc.M504264200	http://dx.doi.org/10.1074/jbc.M504264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16115892	hybrid			2022-12-25	WOS:000232403900030
J	Maynard, MA; Evans, AJ; Hosomi, T; Hara, S; Jewett, MAS; Ohh, M				Maynard, MA; Evans, AJ; Hosomi, T; Hara, S; Jewett, MAS; Ohh, M			Human HIF-3 alpha 4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma	FASEB JOURNAL			English	Article						HIF-3 alpha 4; VHL; RCC; hypoxia	HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; HIPPEL-LINDAU PROTEIN; PAS DOMAIN PROTEIN; GENE-EXPRESSION; FACTOR 1-ALPHA; FACTOR-1; BINDING; TRANSCRIPTION; POLYCYTHEMIA	A universal response to changes in cellular oxygen tension is governed by a family of heterodimeric transcription factors called hypoxia-inducible factor (HIF). Tumor hypoxia, as well as various cancer-causing mutations, has been shown to elevate the level of HIF-1 alpha, signifying a critical role of the HIF pathway in cancer development. The recently identified third member of the human HIF-alpha family, HIF-3 alpha, produces multiple splice variants that contain extra DNA binding elements and protein-protein interaction motifs not found in HIF-1 alpha or HIF-2 alpha. Here we report the molecular cloning of the alternatively spliced human HIF-3 alpha variant HIF-3 alpha 4 and show that it attenuates the ability of HIF-1 to bind hypoxia-responsive elements located within the enhancer/promoter of HIF target genes. The overexpression of HIF-3 alpha 4 suppresses the transcriptional activity of HIF-1 and siRNA-mediated knockdown of the endogenous HIF-3 alpha 4 increases transcription by hypoxia-inducible genes. HIF3 alpha 4 itself is oxygen-regulated, suggesting a novel feedback mechanism of controlling HIF-1 activity. Furthermore, the expression of HIF-3 alpha 4 is dramatically down-regulated in the majority of primary renal carcinomas. These results demonstrate an important dominant-negative regulation of HIF-1-mediated gene transcription by HIF-3 alpha 4 in vivo and underscore its potential significance in renal epithelial oncogenesis.	Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Princess Margaret Hosp, Univ Hlth Network, Dept Pathol, Toronto, ON M4X 1K9, Canada; Kitasato Univ, Sch Pharmaceut Sci, Dept Publ Hlth & Mol Toxicol, Minato Ku, Tokyo 108, Japan; Univ Toronto, Dept Urol, Toronto, ON, Canada; Univ Toronto, Dept Surg Oncol, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Kitasato University; University of Toronto; University of Toronto	Ohh, M (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca						Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Bento JC, 2005, HAEMATOLOGICA, V90, P128; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cario H, 2005, HAEMATOLOGICA, V90, P19; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Eble J, 2004, WHO CLASSIFICATION T; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gorr TA, 2004, J BIOL CHEM, V279, P36048, DOI 10.1074/jbc.M405077200; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pastore Y, 2003, AM J HUM GENET, V73, P412, DOI 10.1086/377108; Ravi R, 2000, GENE DEV, V14, P34; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zimmer M, 2004, MOL CANCER RES, V2, P89; Zundel W, 2000, GENE DEV, V14, P391	31	137	144	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1396	1406		10.1096/fj.05-3788com	http://dx.doi.org/10.1096/fj.05-3788com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126907				2022-12-25	WOS:000232315700033
J	Zhang, YB; Kilroy, GE; Henagan, TM; Prpic-Uhing, V; Richards, WG; Bannon, AW; Mynatt, RL; Gettys, TW				Zhang, YB; Kilroy, GE; Henagan, TM; Prpic-Uhing, V; Richards, WG; Bannon, AW; Mynatt, RL; Gettys, TW			Targeted deletion of melanocortin receptor subtypes 3 and 4, but not CART, alters nutrient partitioning and compromises behavioral and metabolic responses to leptin	FASEB JOURNAL			English	Article						leptin; melanocortin receptors; uncoupling proteins; adipose tissue	AGOUTI-RELATED PROTEIN; WHITE ADIPOSE-TISSUE; MELANOCORTIN-4 RECEPTOR; FOOD-INTAKE; GENE-EXPRESSION; HYPOTHALAMIC PROOPIOMELANOCORTIN; C57BL/6J MICE; POMC NEURONS; OBESITY; BROWN	Mouse lines with targeted disruption of the cocaine amphetamine-related transcript (CART), melanocortin receptor 3 (MCR3), or melanocortin receptor 4 (MCR4) were used to assess the role of each component in mediating the anorectic and metabolic effects of leptin, and in regulating the partitioning of nutrient energy between fat and protein deposition. Leptin was administered over a 3 day period using either intraperitoneal or intracerebroventricular routes of injection. The absence of MCR4 blocked leptin's ability to increase UCP1 mRNA in both brown and white adipose tissue, but not its ability to reduce food consumption. In contrast, deletion of MCR3 compromised leptin's ability to reduce food consumption, but not its ability to reduce fat deposition or increase UCP1 expression in adipose tissue. Leptin-dependent effects on food consumption and adipocyte gene expression were unaffected by the absence of CART. Repeated measures of body composition over time indicate that the absence of either MCR3 or MCR4, but not CART, increased lipid deposition and produced comparable degrees of adiposity in both lines. Moreover, modest increases in fat content of the diet (4 to 11%) accentuated fat deposition and produced a rapid and comparable 10-12% increase in % body fat in both genotypes. The results indicate that nutrient partitioning, as well as the anorectic and metabolic responses to leptin, are dependent on integrated but separable inputs from the melanocortin 3 and 4 receptor subtypes.	Pennington Biomed Res Ctr, Div Expt Obes, Baton Rouge, LA 70808 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Amgen	Gettys, TW (corresponding author), Pennington Biomed Res Ctr, Div Expt Obes, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	gettystw@pbrc.edu	Mynatt, Randall L/N-1980-2017; Gettys, Thomas W/N-1964-2017	Mynatt, Randall L/0000-0003-4399-0019; Gettys, Thomas W/0000-0001-7125-7995; Henagan, Tara/0000-0001-5314-0128	NIDDK NIH HHS [DK 064156, DK 053872, DK60747] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060747, R01DK064156, R01DK053872] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott CR, 2000, BRAIN RES, V869, P203, DOI 10.1016/S0006-8993(00)02386-6; Albarado DC, 2004, ENDOCRINOLOGY, V145, P243, DOI 10.1210/en.2003-0452; Asnicar MA, 2001, ENDOCRINOLOGY, V142, P4394, DOI 10.1210/en.142.10.4394; Benoit SC, 2000, J NEUROSCI, V20, P3442, DOI 10.1523/JNEUROSCI.20-09-03442.2000; Berman Y, 2001, J BIOL CHEM, V276, P1466, DOI 10.1074/jbc.M008499200; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Chen AS, 2000, TRANSGENIC RES, V9, P145, DOI 10.1023/A:1008983615045; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; Commins SP, 1999, ENDOCRINOLOGY, V140, P4772, DOI 10.1210/en.140.10.4772; Cone RD, 1999, TRENDS ENDOCRIN MET, V10, P211, DOI 10.1016/S1043-2760(99)00153-8; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; da Silva AA, 2004, HYPERTENSION, V43, P1312, DOI 10.1161/01.HYP.0000128421.23499.b9; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GETTYS TW, 1986, AM J PHYSIOL, V251, pE357, DOI 10.1152/ajpendo.1986.251.3.E357; Gettys TW, 1997, ENDOCRINOLOGY, V138, P2697, DOI 10.1210/en.138.7.2697; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Haynes WG, 1997, HYPERTENSION, V30, P619, DOI 10.1161/01.HYP.30.3.619; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kask A, 1998, EUR J PHARMACOL, V360, P15, DOI 10.1016/S0014-2999(98)00699-2; Korner J, 1999, NEUROENDOCRINOLOGY, V70, P377, DOI 10.1159/000054499; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Li G, 2004, J ENDOCRINOL, V182, P123, DOI 10.1677/joe.0.1820123; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mountjoy KG, 1999, ENDOCRINOLOGY, V140, P2167, DOI 10.1210/en.140.5.2167; Nillni EA, 2000, J BIOL CHEM, V275, P36124, DOI 10.1074/jbc.M003549200; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Pelleymounter MA, 2000, J PHARMACOL EXP THER, V293, P799; Prpic V, 2003, ENDOCRINOLOGY, V144, P1155, DOI 10.1210/en.2002-220835; Prpic V, 2002, J NUTR, V132, P3325, DOI 10.1093/jn/132.11.3325; Rahmouni K, 2003, J NEUROSCI, V23, P5998, DOI 10.1523/JNEUROSCI.23-14-05998.2003; Satoh N, 1998, NEUROSCI LETT, V249, P107, DOI 10.1016/S0304-3940(98)00401-7; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Ste Marie L, 2000, P NATL ACAD SCI USA, V97, P12339, DOI 10.1073/pnas.220409497; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Watson PM, 2000, AM J PHYSIOL-ENDOC M, V279, pE356, DOI 10.1152/ajpendo.2000.279.2.E356; Williams DL, 2003, ENDOCRINOLOGY, V144, P4692, DOI 10.1210/en.2003-0440; Williams DL, 2000, ENDOCRINOLOGY, V141, P1332, DOI 10.1210/en.141.4.1332; Wilson BD, 1999, ENDOCRINOLOGY, V140, P2387, DOI 10.1210/en.140.5.2387	59	63	66	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1482	1491		10.1096/fj.05-3851com	http://dx.doi.org/10.1096/fj.05-3851com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126916				2022-12-25	WOS:000232315700042
J	Akekawatchai, C; Holland, JD; Kochetkova, M; Wallace, JC; McColl, SR				Akekawatchai, C; Holland, JD; Kochetkova, M; Wallace, JC; McColl, SR			Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PHOSPHOINOSITIDE 3-KINASES; SPHINGOSINE 1-PHOSPHATE; BETA RECEPTOR; T-CELLS; CHEMOKINE; MIGRATION; ACTIVATION; SURVIVAL; MICE	In the multimolecular environment in tissues and organs, crosstalk between growth factor and G protein-coupled receptors is likely to play an important role in both normal and pathological responses. In this report, we demonstrate transactivation of the chemokine receptor CXCR4 by the growth factor insulin-like growth factor ( IGF)-1 is required for IGF-1-induced cell migration in metastatic MDA-MB-231 cells. The induction of chemotaxis in MDA-MB-231 cells by IGF-1 was inhibited by pretreatment of the cells with pertussis toxin ( PTX) and by RNAi-mediated knockdown of CXCR4. Transactivation of the CXCR4 pathway by IGF-1 occurred independently of CXCL12, the chemokine ligand of CXCR4. Neither CXCR4 knockdown nor PTX had any effect on the ability of IGF-1 to activate IGF-1R, suggesting that CXCR4n and G proteins are activated subsequent to, or independently of, phosphorylation of IGF-1R by IGF-1. Coprecipitation studies revealed the presence of a constitutive complex containing IGF-1R, CXCR4, and the G protein subunits, G(i)alpha(2) and G beta, and stimulation of MDA-MB-231 cells with IGF-1 led to the release of G(i)alpha(2) and G beta from CXCR4. Based on our findings, we propose that CXCR4 constitutively forms a complex with IGF-1R in MDA-MB-231 cells, and that this interaction allows IGF-1 to activate migrational signaling pathways through CXCR4, G(i)alpha(2) and G beta.	Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	University of Adelaide	McColl, SR (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	shaun.mccoll@adelaide.edu.au	Akekawatchai, Chareeporn/K-7384-2019; , John/AAP-5150-2020; Kochetkova, Marina/ABE-9538-2021	Kochetkova, Marina/0000-0002-0599-7378				Adachi T, 2004, BIOCHEM BIOPH RES CO, V320, P292, DOI 10.1016/j.bbrc.2004.05.172; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Chen JW, 2003, AM J PHYSIOL-ENDOC M, V284, pE1149, DOI 10.1152/ajpendo.00410.2002; Curnock AP, 2003, J IMMUNOL, V170, P4021, DOI 10.4049/jimmunol.170.8.4021; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Denley A, 2004, MOL ENDOCRINOL, V18, P2502, DOI 10.1210/me.2004-0183; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Floridi F, 2003, J NEUROIMMUNOL, V135, P38, DOI 10.1016/S0165-5728(02)00432-0; Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kayali AG, 2003, J CELL BIOL, V163, P859, DOI 10.1083/jcb.200304153; Liao F, 1999, J IMMUNOL, V162, P186; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Marchesi F, 2004, CANCER RES, V64, P8420, DOI 10.1158/0008-5472.CAN-04-1343; Mira E, 2001, EMBO REP, V2, P151, DOI 10.1093/embo-reports/kve027; Mitra P, 2001, CELL SIGNAL, V13, P311, DOI 10.1016/S0898-6568(01)00156-5; Molyneaux KA, 2003, DEVELOPMENT, V130, P4279, DOI 10.1242/dev.00640; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Pennisi PA, 2002, CANCER RES, V62, P6529; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Procko E, 2005, BIOESSAYS, V27, P153, DOI 10.1002/bies.20157; Sadick MD, 1999, J PHARMACEUT BIOMED, V19, P883, DOI 10.1016/S0731-7085(98)00144-7; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Strieter RM, 2004, SEMIN CANCER BIOL, V14, P195, DOI 10.1016/j.semcancer.2003.10.006; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Trentin L, 2004, BLOOD, V104, P502, DOI 10.1182/blood-2003-09-3103; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Ward SG, 2004, TRENDS IMMUNOL, V25, P67, DOI 10.1016/j.it.2003.12.003; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	39	85	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39701	39708		10.1074/jbc.M509829200	http://dx.doi.org/10.1074/jbc.M509829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16172123	hybrid			2022-12-25	WOS:000233461300006
J	Kushner, JA; Simpson, L; Wartschow, LM; Guo, SD; Rankin, MM; Parsons, R; White, MF				Kushner, JA; Simpson, L; Wartschow, LM; Guo, SD; Rankin, MM; Parsons, R; White, MF			Phosphatase and tensin homolog regulation of islet growth and glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-2; BETA-CELLS; UP-REGULATION; PTEN; SUPPRESSION; DISRUPTION; RESISTANCE; DELETION; BRAIN; LIVER	The Irs2 branch of the insulin/insulin-like growth factor signaling cascade activates the phosphatidylinositol 3-kinase -> Akt -> Foxo1 cascade in many tissues, including hepatocytes and pancreatic beta-cells. The 3'-lipid phosphatase Pten ordinarily attenuates this cascade; however, its influence on beta-cell growth or function is unknown. To determine whether decreased Pten expression could restore beta-cell function and prevent diabetes in Irs2(-/-) mice, we generated wild type or Irs2 knock-out mice that were haploinsufficient for Pten ( Irs2(-/-):: Pten(-/-)). Irs2(-/-) mice develop diabetes by 3 months of age as beta-cell mass declined progressively until insulin production was lost. Pten insufficiency increased peripheral insulin sensitivity in wild type and Irs2(-/-) mice and increased Akt and Foxo1 phosphorylation in the islets. Glucose tolerance improved in the Pten(-/-) mice, although beta-cell mass and circulating insulin levels decreased. Compared with Irs2(-/-) mice, the Irs2(-/-):: Pten(-/-) mice displayed nearly normal glucose tolerance and survived without diabetes, because normal but small islets produced sufficient insulin until the mice died of lymphoproliferative disease at 12 months age. Thus, steps to enhance phosphatidylinositol 3-kinase signaling can promote beta-cell growth, function, and survival without the Irs2 branch of the insulin/insulin-like growth factor signaling cascade.	Harvard Univ, Sch Med, Childrens Hosp Boston,Dept Med, Div Endocrinol,Howard Hughes Med Inst, Boston, MA 02115 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Harvard Univ, Sch Med, Childrens Hosp Boston, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Columbia University; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	White, MF (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston,Dept Med, Div Endocrinol,Howard Hughes Med Inst, Karp Res Bldg,Rm 04210,300 Longwood Ave, Boston, MA 02115 USA.	morris.white@childrens.harvard.edu	Kushner, Jake A/AFJ-8198-2022; Kushner, Jake A/AAF-5049-2022	Kushner, Jake A/0000-0002-3646-1744; Kushner, Jake A/0000-0002-3646-1744; Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [R01 CA082783, R01 CA082783-06, CA82783] Funding Source: Medline; NIDDK NIH HHS [DK02024, DK38712, DK43808, DK55326, DK064101, K08 DK064101] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002024, K08DK064101, R01DK055326, R01DK043808, R29DK038712, R55DK038712, R01DK038712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Choudhury AI, 2005, J CLIN INVEST, V115, P940; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Komazawa N, 2004, NAT MED, V10, P1208, DOI 10.1038/nm1117; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kushner JA, 2004, DIABETES, V53, P61, DOI 10.2337/diabetes.53.1.61; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Nagle JA, 2004, MOL CELL BIOL, V24, P9726, DOI 10.1128/MCB.24.22.9726-9735.2004; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; O'Rahilly S, 2005, SCIENCE, V307, P370, DOI 10.1126/science.1104346; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yoon KH, 2003, J CLIN ENDOCR METAB, V88, P2300, DOI 10.1210/jc.2002-020735	32	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39388	39393		10.1074/jbc.M504155200	http://dx.doi.org/10.1074/jbc.M504155200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16170201	hybrid			2022-12-25	WOS:000233362200060
J	Nakata, D; Troy, FA				Nakata, D; Troy, FA			Degree of polymerization (DP) of polysialic acid (PolySia) on neural cell adhesion molecules (N-CAMs) - Development and application of a new strategy to accurately determine the DP of polySia chains on N-CAMs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ULTRASENSITIVE CHEMICAL METHOD; ANION-EXCHANGE CHROMATOGRAPHY; CENTRAL-NERVOUS-SYSTEM; ST8SIA II STX; DIFFERENTIAL BIOSYNTHESIS; GLYCOLYLNEURAMINIC ACIDS; 2 POLYSIALYLTRANSFERASES; CONTAINING GLYCOPROTEIN; CORE STRUCTURES	alpha 2,8-Linked polysialic acid (polySia) is a structurally unique anti-adhesive glycotope that covalently modifies N-linked glycans on neural cell adhesion molecules (N-CAMs). These sugar chains play a key role in modulating cell-cell interactions, principally during embryonic development, neural plasticity, and tumor metastasis. The degree of polymerization (DP) of polySia chains on N-CAM is postulated to be of critical importance in regulating N-CAM function. There are limitations, however, in the conventional methods to accurately determine the DP of polySia on N-CAM, the most serious being partial acid hydrolysis of internal alpha 2,8-ketosidic linkages that occur during fluorescent derivatization, a step necessary to enhance chromatographic detection. To circumvent this problem, we have developed a facile method that combines the use of Endo-beta-galactosidase to first release linear polySia chains from N-CAM, with high resolution high pressure liquid chromatography profiling. This strategy avoids acid hydrolysis prior to chromatographic profiling and thus provides an accurate determination of the DP and distribution of polySia on N-CAM. The potential of this new method was evaluated using a nonpolysialylated construct of N-CAM that was polysialylated in vitro using a soluble construct of ST8Sia II or ST8Sia IV. Whereas most of the oligosialic acid/polySia chains consisted of DPs similar to 50-60 or less, a subpopulation of chains with DPs similar to 150 to similar to 180 and extending to DP similar to 400 were detected. The DP of this subpopulation is considerably greater than reported previously for N-CAM. Endo-beta-galactosidase can also release polySia chains from polysialylated membranes expressed in the neuroblastoma cell line, Neuro2A, and native N-CAM from embryonic chick brains.	Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Davis, CA 95616 USA	University of California System; University of California Davis	Troy, FA (corresponding author), Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Tupper Hall, Davis, CA 95616 USA.	fatroy@ucdavis.edu		Nakata, Daisuke/0000-0001-7642-4836	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55703] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; BECKER CG, 1993, CELL TISSUE RES, V272, P289, DOI 10.1007/BF00302734; Close BE, 2001, GLYCOBIOLOGY, V11, P997, DOI 10.1093/glycob/11.11.997; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; FINNE J, 1982, J BIOL CHEM, V257, P1966; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; Geyer H, 2001, EUR J BIOCHEM, V268, P6587, DOI 10.1046/j.0014-2956.2001.02613.x; HALLENBECK PC, 1987, ANAL BIOCHEM, V161, P181, DOI 10.1016/0003-2697(87)90670-1; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; Hayrinen J, 2002, MOL IMMUNOL, V39, P399, DOI 10.1016/S0161-5890(02)00202-X; Hildebrandt H, 1998, CANCER RES, V58, P779; Inoue S, 2000, J BIOL CHEM, V275, P29968, DOI 10.1074/jbc.M004150200; Inoue S, 2003, J BIOL CHEM, V278, P8541, DOI 10.1074/jbc.M212799200; Inoue S, 2001, BIOCHIMIE, V83, P605, DOI 10.1016/S0300-9084(01)01307-4; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; Inoue S, 2001, GLYCOBIOLOGY, V11, P759, DOI 10.1093/glycob/11.9.759; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; Kurosawa N, 1997, J NEUROCHEM, V69, P494; LEHRMAN MA, 2003, GLYCOBIOLOGY, V13, P1; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; Lin SL, 1999, GLYCOBIOLOGY, V9, P807, DOI 10.1093/glycob/9.8.807; LIN SL, 1999, SIALOBIOLOGY OTHER N, P81; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANZI AE, 1994, J BIOL CHEM, V269, P23617; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mendiratta SS, 2005, J BIOL CHEM, V280, P32340, DOI 10.1074/jbc.M506217200; Miyata S, 2004, GLYCOBIOLOGY, V14, P827, DOI 10.1093/glycob/cwh100; Muhlenhoff M, 2001, J BIOL CHEM, V276, P34066, DOI 10.1074/jbc.M101022200; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; NAKAGAWA H, 1980, J BIOL CHEM, V255, P5955; Nakata D, 2004, GLYCOBIOLOGY, V14, P1055; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; REYNOSOPAZ S, 2001, GLYCOCONJ J, V18, P151; ROHR TE, 1980, J BIOL CHEM, V255, P2332; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; Seki T, 1998, J NEUROSCI, V18, P3757; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; Suzuki M, 2003, J BIOL CHEM, V278, P49459, DOI 10.1074/jbc.M308316200; Tanaka F, 2000, CANCER RES, V60, P3072; Troy F.A., 2004, ENCY BIOL CHEM, V3, P407; Troy F.A., 1995, BIOL SIALIC ACIDS, P95; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WUHRER M, 2000, BIOCHIMIE PARIS, V85, P207; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225; ZUBER C, 1992, J BIOL CHEM, V267, P9965	64	85	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38305	38316		10.1074/jbc.M508762200	http://dx.doi.org/10.1074/jbc.M508762200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16172115	hybrid			2022-12-25	WOS:000233239800026
J	Ruehl, M; Erben, U; Schuppan, D; Wagner, C; Zeller, A; Freise, C; Al-Hasani, H; Loesekann, M; Notter, M; Wittig, BM; Zeitz, M; Dieterich, W; Somasundaram, R				Ruehl, M; Erben, U; Schuppan, D; Wagner, C; Zeller, A; Freise, C; Al-Hasani, H; Loesekann, M; Notter, M; Wittig, BM; Zeitz, M; Dieterich, W; Somasundaram, R			The elongated first fibronectin type III domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; CELL-ADHESION; GROWTH; VI; EXPRESSION; UNDULIN; PROLIFERATION; LOCALIZATION; KINASE	Collagen XIV (CXIV) is a fibril-associated collagen that is mainly expressed in well differentiated tissues and in late embryonic development. Because CXIV is almost absent in proliferating and/or dedifferentiated tissues, a functional role in maintaining cell differentiation is suspected. We demonstrate antiproliferative, quiescence- and differentiation-inducing effects of human CXIV and its recombinant fragments on mesenchymal cells. In primary human fibroblasts, in mouse 3T3 fibroblasts and in 3T3-L1 preadipocytes, CXIV reduced de novo DNA synthesis by 75%, whereas cell numbers and viability remained unaltered. Cells showed no signs of apoptosis, and maximal proliferation was restored when serum was supplemented, thus indicating that CXIV induced reversible cellular quiescence. Exposure of fibroblasts to CXIV in vitro led to cellular bundles and clusters. CXIV also triggered trans-differentiation of 3T3-L1 preadipocytes into adipocytes, as could be shown by lipid accumulation and by expression of the glucose transporter Glut4. These effects were also observed with the amino-terminal recombinant fragment Gln(29)-Pro(154) that harbors the first fibronectin type III domain and a 39-amino-acid extension, whereas no activity was found for all other recombinant CXIV fragments. Based on these finding the development of small molecular analogs that modulate fibroblast cell growth and differentiation, e. g. in wound healing and fibrosis, seems feasible.	Dept Gastroenterol, D-12200 Berlin, Germany; Dept Hematol, D-12200 Berlin, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; German Inst Human Nutr, D-14558 Nuthetal, Germany; Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University of Erlangen Nuremberg	Somasundaram, R (corresponding author), Dept Gastroenterol, Charite Campus,Hindenburgdamm 30, D-12200 Berlin, Germany.	rajan.somasundaram@charite.de	Freise, Christian/P-4285-2019; Freise, Christian/H-9892-2012	Freise, Christian/0000-0003-2602-226X; Somasundaram, Rajan/0000-0003-3461-3326				Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; Bauer M, 1997, BBA-GENE STRUCT EXPR, V1354, P183, DOI 10.1016/S0167-4781(97)00131-0; BECKER J, 1987, VIRCHOWS ARCH A, V412, P161, DOI 10.1007/BF00716189; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; BROWN JC, 1994, MATRIX BIOL, V14, P287, DOI 10.1016/0945-053X(94)90194-5; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; Ehnis T, 1997, J BIOL CHEM, V272, P20414, DOI 10.1074/jbc.272.33.20414; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Ehnis T, 1998, EXP CELL RES, V239, P477, DOI 10.1006/excr.1997.3895; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gerecke DR, 2004, MATRIX BIOL, V22, P593, DOI 10.1016/j.matbio.2003.11.004; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Imhof M, 2001, J BIOL CHEM, V276, P9141, DOI 10.1074/jbc.M009148200; JUST M, 1991, J BIOL CHEM, V266, P17326; Klein G, 1998, MATRIX BIOL, V16, P307, DOI 10.1016/S0945-053X(98)90002-6; KNITTEL T, 1992, EXP CELL RES, V203, P312, DOI 10.1016/0014-4827(92)90004-R; Marhaba R, 2004, J MOL HISTOL, V35, P211; Nakagawa H, 1999, BIOCHEM BIOPH RES CO, V256, P642, DOI 10.1006/bbrc.1999.0393; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; RICARDBLUM S, 2000, UNCONVENTIONAL COLLA, P93; Ruhl M, 1999, EXP CELL RES, V250, P548, DOI 10.1006/excr.1999.4540; Ruhl M, 1999, J BIOL CHEM, V274, P34361, DOI 10.1074/jbc.274.48.34361; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0; Schuppan D, 2001, SEMIN LIVER DIS, V21, P351, DOI 10.1055/s-2001-17556; SCHUPPAN D, 2002, J GASTROENTEROL H S3, V17, P300; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Sohara N, 2002, J HEPATOL, V37, P214, DOI 10.1016/S0168-8278(02)00103-4; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; WALCHLI C, 1994, J CELL SCI, V107, P669; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; Young BB, 2000, DEV DYNAM, V217, P430, DOI 10.1002/(SICI)1097-0177(200004)217:4<430::AID-DVDY10>3.0.CO;2-5; Young BB, 2002, J CELL BIOCHEM, V87, P208, DOI 10.1002/jcb.10290	35	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38537	38543		10.1074/jbc.M502210200	http://dx.doi.org/10.1074/jbc.M502210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16129687	hybrid			2022-12-25	WOS:000233239800052
J	Sabbioneda, S; Minesinger, BK; Giannattasio, M; Plevani, P; Muzi-Falconi, M; Jinks-Robertson, S				Sabbioneda, S; Minesinger, BK; Giannattasio, M; Plevani, P; Muzi-Falconi, M; Jinks-Robertson, S			The 9-1-1 checkpoint clamp physically interacts with Pol zeta and is partially required for spontaneous Pol zeta-dependent mutagenesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST DNA-POLYMERASE; CELL NUCLEAR ANTIGEN; THYMINE-THYMINE DIMER; TRANSLESION SYNTHESIS; CHECKPOINT COMPLEX; IN-VIVO; EXCISION-REPAIR; REV1 PROTEIN; S-PHASE; REPLICATION	The use of translesion synthesis (TLS) polymerases to bypass DNA lesions during replication constitutes an important mechanism to restart blocked/stalled DNA replication forks. Because TLS polymerases generally have low fidelity on undamaged DNA, the cell must regulate the interaction of TLS polymerases with damaged versus undamaged DNA to maintain genome integrity. The Saccharomyces cerevisiae checkpoint proteins Ddc1, Rad17, and Mec3 form a clamp-like structure (the 9-1-1 clamp) that has physical similarity to the homotrimeric sliding clamp proliferating cell nuclear antigen, which interacts with and promotes the processivity of the replicative DNA polymerases. In this work, we demonstrate both an in vivo and in vitro physical interaction between the Mec3 and Ddc1 subunits of the 9-1-1 clamp and the Rev7 subunit of the Pol zeta TLS polymerase. In addition, we demonstrate that loss of Mec3, Ddc1, or Rad17 results in a decrease in Pol zeta-dependent spontaneous mutagenesis. These results suggest that, in addition to its checkpoint signaling role, the 9-1-1 clamp may physically regulate Pol zeta-dependent mutagenesis by controlling the access of Pol zeta to damaged DNA.	Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Emory Univ, Grad Div Biol & Biomed Sci, Biochem Cell & Dev Biol Program, Atlanta, GA 30322 USA	University of Milan; Emory University; Emory University	Muzi-Falconi, M (corresponding author), Via Celoria 26, I-20133 Milan, Italy.	marco.muzifalconi@unimi.it; sue.jinks-robertson@emory.edu	Muzi-Falconi, Marco/A-6035-2012; Giannattasio, Michele/M-8318-2019; Sabbioneda, Simone/N-7017-2015	Muzi-Falconi, Marco/0000-0001-7046-6090; Giannattasio, Michele/0000-0001-7099-5718; Sabbioneda, Simone/0000-0001-8551-5465; PLEVANI, PAOLO/0000-0003-1869-2626	NIGMS NIH HHS [GM064769] Funding Source: Medline; Telethon [GGP030406] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman D.G., 1990, PRACTICAL STAT MED R, DOI DOI 10.1201/9780429258589; Baynton K, 1999, MOL MICROBIOL, V34, P124, DOI 10.1046/j.1365-2958.1999.01583.x; Bellaoui M, 2003, EMBO J, V22, P4304, DOI 10.1093/emboj/cdg406; Ben-Aroya S, 2003, P NATL ACAD SCI USA, V100, P9906, DOI 10.1073/pnas.1633757100; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Chang DY, 2005, J BIOL CHEM, V280, P408, DOI 10.1074/jbc.M406800200; Dahm K, 2002, ONCOGENE, V21, P7710, DOI 10.1038/sj.onc.1205872; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Garg P, 2005, J BIOL CHEM, V280, P23446, DOI 10.1074/jbc.C500173200; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Giannattasio M, 2003, J BIOL CHEM, V278, P22303, DOI 10.1074/jbc.M301260200; Gibbs PEM, 2005, GENETICS, V169, P575, DOI 10.1534/genetics.104.034611; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanna JS, 2001, MOL CELL BIOL, V21, P3144, DOI 10.1128/MCB.21.9.3144-3158.2001; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Harfe BD, 1999, MOL CELL BIOL, V19, P4766; Harfe BD, 2000, MOL CELL, V6, P1491, DOI 10.1016/S1097-2765(00)00145-3; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Huang ME, 2002, GENETICS, V160, P1409; Huang ME, 2000, CURR GENET, V38, P178, DOI 10.1007/s002940000149; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kanellis P, 2003, CURR BIOL, V13, P1583, DOI 10.1016/S0960-9822(03)00578-5; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lucca C, 2004, ONCOGENE, V23, P1206, DOI 10.1038/sj.onc.1207199; Maga G, 2002, J BIOL CHEM, V277, P48434, DOI 10.1074/jbc.M206889200; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Minesinger BK, 2005, GENETICS, V169, P1939, DOI 10.1534/genetics.104.033894; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Pages V, 2002, ONCOGENE, V21, P8957, DOI 10.1038/sj.onc.1206006; Paulovich AG, 1998, GENETICS, V150, P75; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Plosky BS, 2004, CURR OPIN GENET DEV, V14, P113, DOI 10.1016/j.gde.2004.02.002; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; QUAH SK, 1980, GENETICS, V96, P819; Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shiomi Y, 2004, GENES CELLS, V9, P279, DOI 10.1111/j.1356-9597.2004.00724.x; Spell Rachelle Miller, 2004, Methods Mol Biol, V262, P3; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; TRAN HT, 1995, MOL CELL BIOL, V15, P5607; Ulrich HD, 2004, CELL CYCLE, V3, P15; Vidal AE, 2004, J BIOL CHEM, V279, P48360, DOI 10.1074/jbc.M406511200; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang WS, 2004, P NATL ACAD SCI USA, V101, P16762, DOI 10.1073/pnas.0407686101	66	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38657	38665		10.1074/jbc.M507638200	http://dx.doi.org/10.1074/jbc.M507638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169844	hybrid			2022-12-25	WOS:000233239800067
J	Vos, WL; Koehorst, RBM; Spruijt, RB; Hemminga, MA				Vos, WL; Koehorst, RBM; Spruijt, RB; Hemminga, MA			Membrane-bound conformation of M13 major coat protein - A structure validation through fret-derived constraints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE M13; ENERGY-TRANSFER; LIPID-BILAYERS; SPECTROSCOPY; TRYPTOPHAN; DOMAIN; MODEL; MODULATION; SIMULATION; MICELLES	M13 major coat protein, a 50-amino-acid-long protein, was incorporated into DOPC/DOPG (80/20 molar ratio) unilamellar vesicles. Over 60% of all amino acid residues was replaced with cysteine residues, and the single cysteine mutants were labeled with the fluorescent label I-AEDANS. The coat protein has a single tryptophan residue that is used as a donor in fluorescence ( or Forster) resonance energy transfer ( FRET) experiments, using AEDANS-labeled cysteines as acceptors. Based on FRET-derived constraints, a straight alpha-helix is proposed as the membrane-bound conformation of the coat protein. Different models were tested to represent the molecular conformations of the donor and acceptor moieties. The best model was used to make a quantitative comparison of the FRET data to the structures of M13 coat protein and related coat proteins in the Protein Data Bank. This shows that the membrane-bound conformation of the coat protein is similar to the structure of the coat protein in the bacteriophage that was obtained from x-ray diffraction. Coat protein embedded in stacked, oriented bilayers and in micelles turns out to be strongly affected by the environmental stress of these membrane-mimicking environments. Our findings emphasize the need to study membrane proteins in a suitable environment, such as in fully hydrated unilamellar vesicles. Although larger proteins than M13 major coat protein may be able to handle environmental stress in a different way, any membrane protein with water exposed parts in the C or N termini and hydrophilic loop regions should be treated with care.	Univ Wageningen & Res Ctr, Biophys Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Hemminga, MA (corresponding author), Univ Wageningen & Res Ctr, Biophys Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	marcus.hemminga@wur.nl						Anderluh G, 2003, J BIOL CHEM, V278, P21860, DOI 10.1074/jbc.M300411200; BAUDETNESSLER S, 1993, BIOCHEMISTRY-US, V32, P8457, DOI 10.1021/bi00084a010; Chou JJ, 2002, J AM CHEM SOC, V124, P2450, DOI 10.1021/ja017875d; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; CREIGHTON TE, 1983, PROTEINS; DATEMA KP, 1987, BIOCHEMISTRY-US, V26, P6145, DOI 10.1021/bi00393a030; EATON DF, 1988, PURE APPL CHEM, V60, P1107, DOI 10.1351/pac198860071107; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eisenhawer M, 2001, BIOCHEMISTRY-US, V40, P12321, DOI 10.1021/bi0107694; Fernandes F, 2003, BIOPHYS J, V85, P2430, DOI 10.1016/S0006-3495(03)74666-9; Fisher CA, 1999, J LIPID RES, V40, P93; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEMMINGA MA, 1992, PROG LIPID RES, V31, P301, DOI 10.1016/0163-7827(92)90011-7; HEMMINGA MA, 1993, NEW COMPREHENSIVE BI, P191; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; JOHNSON ID, 1989, BIOCHEMISTRY-US, V28, P6392, DOI 10.1021/bi00441a035; Koehorst RBM, 2004, BIOPHYS J, V87, P1445, DOI 10.1529/biophysj.104.043208; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lakshmikanth GS, 2001, NAT STRUCT BIOL, V8, P799, DOI 10.1038/nsb0901-799; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; Marassi FM, 2003, PROTEIN SCI, V12, P403, DOI 10.1110/ps.0211503; Marassi FM, 1997, P NATL ACAD SCI USA, V94, P8551, DOI 10.1073/pnas.94.16.8551; MARVIN DA, 1994, J MOL BIOL, V235, P260, DOI 10.1016/S0022-2836(05)80032-4; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; Meijer AB, 2001, BIOCHEMISTRY-US, V40, P8815, DOI 10.1021/bi002956s; Nazarov PV, 2004, J CHEM INF COMP SCI, V44, P568, DOI 10.1021/ci034149g; Papavoine CHM, 1998, J MOL BIOL, V282, P401, DOI 10.1006/jmbi.1998.1860; Salamon Z, 2000, BIOPHYS J, V78, P1400, DOI 10.1016/S0006-3495(00)76693-8; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; Spruijt RB, 2004, BIOCHEMISTRY-US, V43, P13972, DOI 10.1021/bi048437x; SPRUIJT RB, 1989, BIOCHEMISTRY-US, V28, P9158, DOI 10.1021/bi00449a030; Spruijt RB, 2000, BBA-BIOMEMBRANES, V1509, P311, DOI 10.1016/S0005-2736(00)00314-X; Stopar D, 2003, BBA-BIOMEMBRANES, V1611, P5, DOI 10.1016/S0005-2736(03)00047-6; Strancar J, 2005, J CHEM INF MODEL, V45, P394, DOI 10.1021/ci049748h; Torres J, 2003, TRENDS BIOCHEM SCI, V28, P137, DOI 10.1016/S0968-0004(03)00026-4; Tristram-Nagle S, 2004, CHEM PHYS LIPIDS, V127, P3, DOI 10.1016/j.chemphyslip.2003.09.002; WALL L, 1996, PROGRAMMING PERL	40	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38522	38527		10.1074/jbc.M505875200	http://dx.doi.org/10.1074/jbc.M505875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16150733	hybrid			2022-12-25	WOS:000233239800050
J	Abdulaev, NG; Ngo, T; Zhang, C; Dinh, A; Brabazon, DM; Ridge, KD; Marino, JP				Abdulaev, NG; Ngo, T; Zhang, C; Dinh, A; Brabazon, DM; Ridge, KD; Marino, JP			Heterotrimeric G-protein alpha-subunit adopts a "preactivated" conformation when associated with beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; LIGHT-ACTIVATED RHODOPSIN; PHOTORECEPTOR G-PROTEIN; X-RAY CRYSTALLOGRAPHY; EF-TS COMPLEX; CRYSTAL-STRUCTURE; STRUCTURAL DETERMINANTS; ANGSTROM RESOLUTION; CATALYTIC DOMAINS; ESCHERICHIA-COLI	Activation of a heterotrimeric G-protein by an agonist-stimulated G-protein-coupled receptor requires the propagation of structural signals from the receptor binding interface to the guanine nucleotide binding pocket of the G-protein. To probe the molecular basis of this signaling process, we are applying high resolution NMR to track structural changes in an isotope-labeled, full-length G-protein alpha-subunit (G(alpha)) chimera (ChiT) associated with G-protein beta gamma-subunit (G(beta gamma)) and activated receptor (R*) interactions. Here, we show that ChiT can be functionally reconstituted with G(beta gamma) as assessed by aluminum fluoride-dependent changes in intrinsic tryptophan fluorescence and light-activated rhodopsin-catalyzed guanine nucleotide exchange. We further show that N-15-ChiT can be titrated with G(beta gamma) to form stable heterotrimers at NMR concentrations. To assess structural changes in ChiT upon heterotrimer formation, HSQC spectra of the N-15-ChiT-reconstituted heterotrimer have been acquired and compared with spectra obtained for GDP/Mg2+-bound N-15-ChiT in the presence and absence of aluminum fluoride and guanosine 5'-3-O-(thio) triphosphate (GTP gamma S)/ Mg2+-bound N-15-ChiT. As anticipated, G(beta gamma) association with N-15-ChiT results in (HN)-H-1, N-15 chemical shift changes relative to the GDP/ Mg2+-bound state. Strikingly, however, most 1HN, 15N chemical shift changes associated with heterotrimer formation are the same as those observed upon formation of the GDP center dot AlF4-/Mg2+- and GTP gamma S/Mg2+-bound states. Based on these comparative analyses, assembly of the heterotrimer appears to induce structural changes in the switch II and carboxyl-terminal regions of G(alpha) ("preactivation") that may facilitate the interaction with R* and subsequent GDP/GTP exchange.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Rockville, MD 20850 USA; Loyola Coll, Dept Chem, Baltimore, MD 21210 USA	University of Texas System; University of Texas Health Science Center Houston; University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA; Loyola University Maryland	Ridge, KD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA.	Kevin.D.Ridge@uth.tmc.edu; john.marino@nist.gov			NCRR NIH HHS [RR015744] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015744] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abdulaev NG, 2005, J BIOMOL NMR, V32, P31, DOI 10.1007/s10858-005-3340-5; Abdulaev NG, 2000, J BIOL CHEM, V275, P39354, DOI 10.1074/jbc.M005642200; ANTONNY B, 1992, J BIOL CHEM, V267, P6710; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brabazon DM, 2003, BIOCHEMISTRY-US, V42, P302, DOI 10.1021/bi0268899; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Koenig BW, 2000, J BIOMOL NMR, V16, P121, DOI 10.1023/A:1008378523816; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Medkova M, 2002, BIOCHEMISTRY-US, V41, P9962, DOI 10.1021/bi0255726; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Preininger AM, 2003, BIOCHEMISTRY-US, V42, P7931, DOI 10.1021/bi0345438; PREININGER AM, 2004, SCI STKE, pRE3; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Ruan B, 2004, BIOCHEMISTRY-US, V43, P14539, DOI 10.1021/bi048177j; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 2000, METHOD ENZYMOL, V315, P502; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; YANG ZH, 1992, J BIOL CHEM, V267, P23197	63	23	25	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38071	38080		10.1074/jbc.M505259200	http://dx.doi.org/10.1074/jbc.M505259200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129667	hybrid			2022-12-25	WOS:000233044500090
J	Guo, ZY; Lin, S; Heinen, JA; Chang, CCY; Chang, TY				Guo, ZY; Lin, S; Heinen, JA; Chang, CCY; Chang, TY			The active site His-460 of human acyl-coenzyme A : cholesterol acyltransferase 1 resides in a hitherto undisclosed transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MEMBRANE TOPOLOGY; ACAT-1; EXPRESSION; MUTANT; COA; LOCALIZATION; PROTEIN	Human acyl-coenzyme A: cholesterol acyltransferase 1 (hACAT1) esterifies cholesterol at the endoplasmic reticulum ( ER). We had previously reported that hACAT1 contains seven transmembrane domains (TMD) (Lin, S., Cheng, D., Liu, M. S., Chen, J., and Chang, T. Y. ( 1999) J. Biol. Chem. 274, 23276 - 23285) and nine cysteines. The Cys near the N-terminal is located at the cytoplasm; the two cysteines near the C-terminal form a disulfide bond and are located in the ER lumen. The other six free cysteines are located in buried region(s) of the enzyme (Guo, Z.- Y., Chang, C. C. Y., Lu, X., Chen, J., Li, B.- L., and Chang, T.- Y. ( 2005) Biochemistry 44, 6537 6548). In the current study, we show that the conserved His-460 is a key active site residue for hACAT1. We next performed Cys-scanning mutagenesis within the region of amino acids 354 - 493, expressed these mutants in Chinese hamster ovary cells lacking ACAT1, and prepared microsomes from transfected cells. The microsomes are either left intact or permeabilized with detergent. The accessibility of the engineered cysteines of microsomal hACAT1 to various maleimide derivatives, including mPEG(5000)-maleimide ( large, hydrophilic, and membrane-impermeant), N-ethylmaleimide, 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid ( small, hydrophilic, and ER membrane-permeant), and N-phenylmaleimide ( small, hydrophobic, and ER membrane-permeant), were monitored by Western blot analysis. The results led us to construct a revised, nine-TMD model, with the active site His460 located within a hitherto undisclosed transmembrane domain, between Arg-443 and Tyr-462.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail,Room 304, Hanover, NH 03755 USA.	Ta.Yuan.Chang@dartmouth.edu		Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Chang CCY, 2000, J BIOL CHEM, V275, P28083; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; Chang TY, 2001, J LIPID RES, V42, P1933; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; GALL SL, 2004, MOL BIOL CELL, V15, P447; GOGL G, 2004, ANN NY ACAD SCI, V1033, P17; Guo ZY, 2005, BIOCHEMISTRY-US, V44, P6537, DOI 10.1021/bi047409b; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; Katzen F, 2003, P NATL ACAD SCI USA, V100, P10471, DOI 10.1073/pnas.1334136100; Kosolapov A, 2003, J BIOL CHEM, V278, P4305, DOI 10.1074/jbc.M209422200; Lee KA, 2003, J BIOL CHEM, V278, P44593, DOI 10.1074/jbc.M308312200; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Lin S, 2003, MOL BIOL CELL, V14, P2447, DOI 10.1091/mbc.E02-11-0725; LIU J, 2005, IN PRESS BIOCH J, V390; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Lu JL, 2001, BIOCHEMISTRY-US, V40, P13288, DOI 10.1021/bi0107647; LU X, 2002, 3 AHA NAT C ATH THRO; Lu XH, 2002, J BIOL CHEM, V277, P711, DOI 10.1074/jbc.M109427200; Miyazaki A, 1998, ARTERIOSCL THROM VAS, V18, P1568, DOI 10.1161/01.ATV.18.10.1568; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; Spady DK, 2000, J BIOL CHEM, V275, P27005; Yang L, 2004, J BIOL CHEM, V279, P46253, DOI 10.1074/jbc.M408155200; Yu CJ, 2002, BIOCHEMISTRY-US, V41, P3762, DOI 10.1021/bi0120188; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139; Zhang Y, 2003, J BIOL CHEM, V278, P11642, DOI 10.1074/jbc.M211559200	37	65	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37814	37826		10.1074/jbc.M508384200	http://dx.doi.org/10.1074/jbc.M508384200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154994	hybrid			2022-12-25	WOS:000233044500061
J	Landsman, T; Waxman, DJ				Landsman, T; Waxman, DJ			Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GENE-EXPRESSION; LIGAND-INDUCED INTERNALIZATION; UBIQUITIN-PROTEASOME PATHWAY; CLATHRIN-COATED PITS; SOCS-BOX MOTIF; GH RECEPTOR; C-CBL; SEXUAL-DIMORPHISM; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCER	The cytokine-inducible SH2 domain-containing protein CIS inhibits signaling from the growth hormone (GH) receptor (GHR) to STAT5b by a proteasome-dependent mechanism. Here, we used the GH-responsive rat liver cell line CWSV-1 to investigate the role of CIS and the proteasome in GH-induced GHR internalization. Cell-surface GHR localization and internalization were monitored in GH-stimulated cells by confocal immunofluorescence microscopy using an antibody directed against the GHR extracellular domain. In GH naive cells, GHR was detected in small, randomly distributed granules on the cell surface and in the cytoplasm, with accumulation in the perinuclear area. GH treatment induced a rapid ( within 5 min) internalization of GH center dot GHR complexes, which coincided with the onset of GHR tyrosine phosphorylation and the appearance in the cytosol of distinct granular structures containing internalized GH. GHR signaling to STAT5b continued for similar to 30 - 40 min, however, indicating that GHR signaling and deactivation of the GH center dot GHR complex both proceed from an intracellular compartment. The internalization of GH and GHR was inhibited by CIS-R107K, a dominant-negative SH2 domain mutant of CIS, and by the proteasome inhibitors MG132 and epoxomicin, which prolong GHR signaling to STAT5b. GH pulse-chase studies established that the internalized GH center dot GHR complexes did not recycle back to the cell surface in significant amounts under these conditions. Given the established specificity of CIS-R107K for blocking the GHR signaling inhibitory actions of CIS, but not those of other SOCS/CIS family members, these findings implicate CIS and the proteasome in the control of GHR internalization following receptor activation and suggest that CIS-dependent receptor internalization is a prerequisite for efficient termination of GHR signaling.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bu.edu		Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33765, R01 DK033765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Ahluwalia A, 2004, MOL ENDOCRINOL, V18, P747, DOI 10.1210/me.2003-0138; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Blesofsky WA, 2001, ONCOGENE, V20, P7326, DOI 10.1038/sj.onc.1204919; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Melker AA, 2004, J BIOL CHEM, V279, P55465, DOI 10.1074/jbc.M409765200; Du L, 2003, ENDOCRINOLOGY, V144, P868, DOI 10.1210/en.2002-220830; Frank SJ, 2002, ENDOCRINOLOGY, V143, P2, DOI 10.1210/en.143.1.2; FRICK GP, 1994, ENDOCRINOLOGY, V134, P307, DOI 10.1210/en.134.1.307; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Goh ELK, 2002, ENDOCRINOLOGY, V143, P3590, DOI 10.1210/en.2002-220374; Gonzalez L, 2002, ENDOCRINOLOGY, V143, P386, DOI 10.1210/en.143.2.386; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Greenhalgh CJ, 2004, GROWTH HORM IGF RES, V14, P200, DOI 10.1016/j.ghir.2003.12.011; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ilangumaran S, 2003, IMMUNOL REV, V192, P196, DOI 10.1034/j.1600-065X.2003.00020.x; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; KEMPE KC, 1995, BIOCHEM PHARMACOL, V49, P1091, DOI 10.1016/0006-2952(95)98506-5; Kuhn ER, 2002, COMP BIOCHEM PHYS B, V132, P299, DOI 10.1016/S1096-4959(02)00037-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lobie PE, 1999, EXP CELL RES, V246, P47, DOI 10.1006/excr.1998.4288; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miquet JG, 2004, ENDOCRINOLOGY, V145, P2824, DOI 10.1210/en.2003-1498; Moulin S, 2003, CELL SIGNAL, V15, P47, DOI 10.1016/S0898-6568(02)00054-2; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Nicola NA, 2000, EXP HEMATOL, V28, P1105, DOI 10.1016/S0301-472X(00)00525-7; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Piwien-Pilipuk G, 2002, J PEDIATR ENDOCR MET, V15, P771; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Sachse M, 2001, J CELL SCI, V114, P3943; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Takagi K, 2001, BIOL PHARM BULL, V24, P744, DOI 10.1248/bpb.24.744; Tannenbaum GS, 2001, ENDOCRINOLOGY, V142, P4599, DOI 10.1210/en.142.11.4599; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Wan Y, 2004, J BIOL CHEM, V279, P44775, DOI 10.1074/jbc.M406092200; Wan Y, 2003, MOL ENDOCRINOL, V17, P2240, DOI 10.1210/me.2003-0162; Wang L, 2002, ONCOGENE, V21, P5346, DOI 10.1038/sj.onc.1205670; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	71	54	57	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37471	37480		10.1074/jbc.M504125200	http://dx.doi.org/10.1074/jbc.M504125200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154995	hybrid			2022-12-25	WOS:000233044500023
J	Liu, F; Grundke-Iqbal, I; Iqbal, K; Oda, Y; Tomizawa, K; Gong, CX				Liu, F; Grundke-Iqbal, I; Iqbal, K; Oda, Y; Tomizawa, K; Gong, CX			Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMALLY PHOSPHORYLATED-TAU; PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE-2B CALCINEURIN; AUTOINHIBITORY DOMAIN; CLEAVAGE; P25; P35; DEPHOSPHORYLATION; NEUROTOXICITY; DEGRADATION	A disturbance of calcium homeostasis is believed to play an important role in the neurodegeneration of the brains of Alzheimer disease ( AD) patients, but the molecular pathways by which it contributes to the disease are not well understood. Here we studied the activation of two major Ca2+-regulated brain proteins, calpain and calcineurin, in AD brain. We found that calpain I is activated, which in turn cleaves and activates calcineurin in AD brain. Mass spectrometric analysis indicated that the cleavage of calcineurin by calpain I is at lysine 501, a position C-terminal to the autoinhibitory domain, which produces a 57-kDa truncated form. The 57-kDa calcineurin maintains its Ca2+/calmodulin dependence of the phosphatase activity, but the phosphatase activity is remarkably activated upon truncation. The cleavage and activation of calcineurin correlate to the number of neurofibrillary tangles in human brains. These findings suggest that the overactivation of calpain I and calcineurin may mediate the role of calcium homeostatic disturbance in the neurodegeneration of AD.	New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; Eisai & Co Ltd, Lab Seeds Finding Technol, Tsukuba, Ibaraki 3002635, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008585, Japan	Institute for Basic Research in Developmental Disabilities; Eisai Co Ltd; Okayama University	Liu, F (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	feiliu63@hotmail.com; cxgong@ultinet.net	Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627	NATIONAL INSTITUTE ON AGING [R01AG019158] Funding Source: NIH RePORTER; NIA NIH HHS [AG19158] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Bahl R, 2001, MOL BRAIN RES, V90, P101, DOI 10.1016/S0169-328X(01)00089-4; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gong CX, 1996, BRAIN RES, V741, P95, DOI 10.1016/S0006-8993(96)00904-3; Gong CX, 2005, J NEURAL TRANSM, V112, P813, DOI 10.1007/s00702-004-0221-0; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; Khachaturian Z S, 1989, Aging (Milano), V1, P17; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Ladner CJ, 1996, J NEUROPATH EXP NEUR, V55, P924, DOI 10.1097/00005072-199608000-00008; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lakshmikuttyamma A, 2004, NEUROCHEM RES, V29, P1913, DOI 10.1023/B:NERE.0000042218.27842.79; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lian QY, 2001, EXP NEUROL, V167, P158, DOI 10.1006/exnr.2000.7534; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Liu F, 2005, J BIOL CHEM, V280, P1790, DOI 10.1074/jbc.M410775200; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; LIU F, 2005, IN PRESS EUR J NEURO; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; MATTSON MP, 1992, NEUROBIOL AGING, V13, P617, DOI 10.1016/0197-4580(92)90068-9; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nixon RA, 2003, AGEING RES REV, V2, P407, DOI 10.1016/S1568-1637(03)00029-1; Pei JJ, 1998, J NEURAL TRANSM, V105, P69, DOI 10.1007/s007020050039; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Veeranna, 2004, AM J PATHOL, V165, P795, DOI 10.1016/S0002-9440(10)63342-1; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x	44	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37755	37762		10.1074/jbc.M507475200	http://dx.doi.org/10.1074/jbc.M507475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150694	hybrid			2022-12-25	WOS:000233044500054
J	Liu, ZP; Li, HB; Derouet, M; Filmus, J; LaCasse, EC; Korneluk, RG; Kerbel, RS; Rosen, KV				Liu, ZP; Li, HB; Derouet, M; Filmus, J; LaCasse, EC; Korneluk, RG; Kerbel, RS; Rosen, KV			ras oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells - Epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; BCL-2 PROTEIN FAMILY; HUMAN LUNG-CANCER; INDUCED APOPTOSIS; DOWN-REGULATION; CYTOCHROME-C; FACTOR-ALPHA; MITOCHONDRIAL PROTEIN; BCL-X(L) EXPRESSION; HUMAN KERATINOCYTES	Detachment of normal epithelial cells from the extracellular matrix (ECM) triggers apoptosis, a phenomenon called anoikis. Conversely, carcinomas ( cancers of epithelial origin) represent three-dimensional disorganized multicellular masses in which cells are deprived of adhesion to the ECM but remain viable. Resistance of cancer cells to anoikis is thought to be critical for tumor progression. However, the knowledge about molecular mechanisms of this type of resistance remains limited. Herein we report that ras oncogene, an established inhibitor of anoikis, triggers a significant upregulation of anti-apoptotic proteins cIAP2 and XIAP in intestinal epithelial cells. We also observed that the effect of ras on cIAP2 requires ras-induced autocrine production of transforming growth factor alpha (TGF-alpha), a ligand for epidermal growth factor receptor, whereas ras-triggered up-regulation of XIAP is TGF-alpha-independent. Moreover, overexpression of either cIAP2 or XIAP in nonmalignant intestinal epithelial cell was found to block anoikis. In addition, an established IAP antagonist Smac or Smac-derived cell-permeable peptide suppressed ras-induced anoikis resistance and subsequent anchorage-independent growth of ras-transformed cells. We conclude that ras-induced overexpression of cIAP2 and XIAP significantly contributes to the ability of ras-transformed intestinal epithelial cells to survive in the absence of adhesion to the ECM and grow in a three-dimensional manner.	Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, CRC, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Childrens Hosp Eastern Ontario, Res Inst, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	Dalhousie University; Dalhousie University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	Rosen, KV (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, CRC, Rm C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	Kirill.Rosen@Dal.Ca		Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Farahani R, 1997, GENOMICS, V42, P514, DOI 10.1006/geno.1997.4742; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; FILMUS J, 1993, ONCOGENE, V8, P1017; FILMUS J, 1994, ONCOGENE, V9, P3627; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARPER ME, 1993, PROSTATE, V23, P9, DOI 10.1002/pros.2990230103; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin LJ, 2003, WORLD J GASTROENTERO, V9, P974; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Miyazaki T, 2004, J BIOL CHEM, V279, P44667, DOI 10.1074/jbc.M408101200; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Park CM, 2005, BIOORG MED CHEM LETT, V15, P771, DOI 10.1016/j.bmcl.2004.11.010; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; REYNOLDS NJ, 1993, BIOCHEM J, V294, P535, DOI 10.1042/bj2940535; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590	73	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37383	37392		10.1074/jbc.M503724200	http://dx.doi.org/10.1074/jbc.M503724200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16115895	hybrid			2022-12-25	WOS:000233044500012
J	Wang, J; Devgan, V; Corrado, M; Prabhu, NS; El-Deiry, WS; Riccardi, C; Pandolfi, PP; Missero, C; Dotto, GP				Wang, J; Devgan, V; Corrado, M; Prabhu, NS; El-Deiry, WS; Riccardi, C; Pandolfi, PP; Missero, C; Dotto, GP			Glucocorticoid-induced tumor necrosis factor receptor is a p21(Cip1/WAF1) transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEATH RECEPTORS; P21(WAF1/CIP1); INDUCTION; GITR; ACTIVATION; LIGAND; GROWTH; TNF; DIFFERENTIATION	Glucocorticoid-induced tumor necrosis factor receptor ( GITR) is a member of the tumor necrosis factor receptor superfamily, is expressed in T lymphocytes, and exerts an anti-apoptotic function in these cells. We reported that GITR is also highly expressed in the skin, specifically in keratinocytes, and that it is under negative transcriptional control of p21(Cip1/WAF1), independently from the cell cycle. Although GITR expression is higher in p21-deficient keratinocytes and skin, it is down-modulated with differentiation and in response to UVB. The combined analysis of keratinocytes with increased GITR expression versus normal keratinocytes and skin of mice with a disruption of the GITR gene indicates that this protein protects keratinocytes from UVB-induced apoptosis both in vitro and in vivo.	Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Telethon Inst Genet & Med, I-80131 Naples, Italy; Univ Penn, Sch Med, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA; Univ Perugia, Sch Med, Pharmacol Sect, Dept Clin & Expt Med, I-06100 Perugia, Italy; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne; Harvard University; Massachusetts General Hospital; Harvard University; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Pennsylvania; Pennsylvania Medicine; University of Perugia; Memorial Sloan Kettering Cancer Center; University of Lausanne	Dotto, GP (corresponding author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	gdotto@partners.org	Riccardi, Carlo/N-4610-2014	Riccardi, Carlo/0000-0001-9257-3997; El-Deiry, Wafik/0000-0002-9577-8266; Missero, Caterina/0000-0003-0905-5123	NATIONAL CANCER INSTITUTE [R01CA073796, P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA73796, CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline; Telethon [TGM06S01, TGM03P14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Telethon(Fondazione Telethon)		Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Basile JR, 2003, MOL CANCER RES, V1, P262; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fritah A, 2005, MOL CELL BIOL, V25, P2419, DOI 10.1128/MCB.25.6.2419-2430.2005; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Kim JD, 2003, GENES IMMUN, V4, P564, DOI 10.1038/sj.gene.6364026; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Murphy M, 2002, J CLIN PATHOL, V55, P829, DOI 10.1136/jcp.55.11.829; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Nocentini G, 2000, DNA CELL BIOL, V19, P205, DOI 10.1089/104454900314474; Poole JC, 2004, CELL CYCLE, V3, P931; Reagan-Shaw S, 2004, ONCOGENE, V23, P5151, DOI 10.1038/sj.onc.1207666; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247	35	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37725	37731		10.1074/jbc.M507976200	http://dx.doi.org/10.1074/jbc.M507976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155000	hybrid			2022-12-25	WOS:000233044500050
J	Wingard, JN; Chan, J; Bosanac, I; Haeseleer, F; Palczewski, K; Ikura, M; Ames, JB				Wingard, JN; Chan, J; Bosanac, I; Haeseleer, F; Palczewski, K; Ikura, M; Ames, JB			Structural analysis of Mg2+ and Ca2+ binding to CaBP1, a neuron-specific regulator of calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION BINDING; CRYSTAL-STRUCTURE; TROPONIN-C; 3-DIMENSIONAL STRUCTURE; CA2+-BINDING PROTEIN-1; THERMAL-STABILITY; MAGNESIUM-BINDING; LIGAND-BINDING; CALMODULIN; CALDENDRIN	CaBP1 (calcium-binding protein 1) is a 19.4-kDa protein of the EF-hand superfamily that modulates the activity of Ca2+ channels in the brain and retina. Here we present data from NMR, microcalorimetry, and other biophysical studies that characterize Ca2+ binding, Mg2+ binding, and structural properties of recombinant CaBP1 purified from Escherichia coli. Mg2+ binds constitutively to CaBP1 at EF-1 with an apparent dissociation constant (K-d) of 300 mu M. Mg2+ binding to CaBP1 is enthalpic ( Delta H = - 3.725 kcal/mol) and promotes NMR spectral changes, indicative of a concerted Mg2+-induced conformational change. Ca2+ binding to CaBP1 induces NMR spectral changes assigned to residues in EF-3 and EF-4, indicating localized Ca2+-induced conformational changes at these sites. Ca2+ binds cooperatively to CaBP1 at EF-3 and EF-4 with an apparent K-d of 2.5 mu M and a Hill coefficient of 1.3. Ca2+ binds to EF-1 with low affinity (K-d > 100 mu M), and no Ca2+ binding was detected at EF-2. In the absence of Mg2+ and Ca2+, CaBP1 forms a flexible molten globule-like structure. Mg2+ and Ca2+ induce distinct conformational changes resulting in protein dimerization and markedly increased folding stability. The unfolding temperatures are 53, 74, and 76 degrees C for apo-, Mg2+-bound, and Ca2+-bound CaBP1, respectively. Together, our results suggest that CaBP1 switches between structurally distinct Mg2+-bound and Ca2+-bound states in response to Ca2+ signaling. Both conformational states may serve to modulate the activity of Ca2+ channel targets.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Ontario Canc Inst, Div Signaling Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University System of Maryland; University of Maryland Baltimore; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ames, JB (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.	james@carb.nist.gov		Ikura, Mitsuhiko/0000-0002-9524-1303	NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061, R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045909] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008061, EY08061, EY012347, R01 EY012347] Funding Source: Medline; NINDS NIH HHS [NS045909, R01 NS045909] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; Biekofsky RR, 2002, BIOCHEMISTRY-US, V41, P6850, DOI 10.1021/bi012187s; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Chakrabarti MC, 1999, NUCLEIC ACIDS RES, V27, P4801, DOI 10.1093/nar/27.24.4801; Clore GM, 1997, NAT STRUCT BIOL, V4, P849; COX JA, 1994, J BIOL CHEM, V269, P32807; DASILVA ACR, 1995, J BIOL CHEM, V270, P6773, DOI 10.1074/jbc.270.12.6773; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Gilli R, 1998, BIOCHEMISTRY-US, V37, P5450, DOI 10.1021/bi972083a; Gombos Z, 2003, BIOCHEMISTRY-US, V42, P5531, DOI 10.1021/bi034047j; Haeseleer F, 2004, NAT NEUROSCI, V7, P1079, DOI 10.1038/nn1320; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Haynes LP, 2004, J BIOL CHEM, V279, P547, DOI 10.1074/jbc.M309617200; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Henzl MT, 2003, ANAL BIOCHEM, V319, P216, DOI 10.1016/S0003-2697(03)00288-4; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Kinoshita-Kawada M, 2005, PFLUG ARCH EUR J PHY, V450, P345, DOI 10.1007/s00424-005-1419-1; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; LINSE S, 1991, J BIOL CHEM, V266, P8050; Masino L, 2000, PROTEIN SCI, V9, P1519, DOI 10.1110/ps.9.8.1519; MCCUBBIN WD, 1980, CAN J BIOCHEM CELL B, V58, P683, DOI 10.1139/o80-096; Menger N, 1999, CELL TISSUE RES, V298, P21, DOI 10.1007/s004419900060; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Osawa M, 2005, J BIOL CHEM, V280, P18008, DOI 10.1074/jbc.M500338200; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Papish AL, 2002, BIOPHYS J, V83, P1455, DOI 10.1016/S0006-3495(02)73916-7; PAULUS H, 1969, ANAL BIOCHEM, V32, P91, DOI 10.1016/0003-2697(69)90107-9; Peshenko IV, 2004, J BIOL CHEM, V279, P16903, DOI 10.1074/jbc.C400065200; Qi XF, 2001, EUR J BIOCHEM, V268, P4653, DOI 10.1046/j.1432-1327.2001.02388.x; RASHIN AA, 1985, J PHYS CHEM-US, V89, P5588, DOI 10.1021/j100272a006; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; Seidenbecher CI, 2002, ADV EXP MED BIOL, V514, P451; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; SNYDER EE, 1990, BIOCHEMISTRY-US, V29, P3937, DOI 10.1021/bi00468a021; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; STRYNADKA NCJ, 1988, PROTEINS, V3, P1, DOI 10.1002/prot.340030102; SUSSMAN F, 1989, P NATL ACAD SCI USA, V86, P7880, DOI 10.1073/pnas.86.20.7880; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; VIJAYKUMAR S, 1992, J MOL BIOL, V224, P413, DOI 10.1016/0022-2836(92)91004-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WNUK W, 1979, J BIOL CHEM, V254, P5284; Yamniuk AP, 2004, BIOCHEMISTRY-US, V43, P2558, DOI 10.1021/bi035432b; Yang C, 2001, J BIOMOL STRUCT DYN, V19, P247, DOI 10.1080/07391102.2001.10506736; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhou H, 2005, J BIOL CHEM, V280, P29612, DOI 10.1074/jbc.M504167200; Zhou H, 2004, J NEUROSCI, V24, P4698, DOI 10.1523/JNEUROSCI.5523-03.2004; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	63	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37461	37470		10.1074/jbc.M508541200	http://dx.doi.org/10.1074/jbc.M508541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16147998	Green Accepted, hybrid			2022-12-25	WOS:000233044500022
J	Essmann, F; Pohlmann, S; Gillissen, B; Daniel, PT; Schulze-Osthoff, K; Janicke, RU				Essmann, F; Pohlmann, S; Gillissen, B; Daniel, PT; Schulze-Osthoff, K; Janicke, RU			Irradiation-induced translocation of p53 to mitochondria in the absence of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-INDEPENDENT DEATH; CYTOCHROME-C RELEASE; STRESS-INDUCED P53; P53-DEPENDENT APOPTOSIS; IONIZING-RADIATION; DNA-DAMAGE; CELL-DEATH; IN-VIVO; ACTIVATION; BAX	The tumor suppressor protein p53 promotes apoptosis in response to death stimuli by transactivation of target genes and by transcription-independent mechanisms. Recently, it was shown that during apoptosis p53 can specifically translocate to mitochondria, where it physically interacts with and inactivates prosurvival Bcl-2 proteins. In the present study, we therefore investigated the role of mitochondrial translocation of p53 for the stress response of tumor cells. In various cell lines, DNA damage induced by either ionizing irradiation or topoisomerase inhibitors triggered a robust translocation of a fraction of p53 to mitochondria to a similar extent. Nevertheless, the cells succumbed to apoptosis only in response to topoisomerase inhibitors, but remained resistant to apoptosis induced by ionizing radiation. Irradiated cells became senescent, although irradiation triggered a functional p53 response and induced expression of p21, Bax, and Puma. Interestingly, even the targeted expression of p53 to mitochondria was insufficient to launch apoptosis, whereas overexpression of wild-type p53 induced Bax activation and apoptotic alterations. Together, these results suggest that, in contrast to previous reports, mitochondrial translocation of p53 does not per se lead to cell death and that this might constitute a mechanism that contributes to the resistance of tumor cells to ionizing radiation-induced apoptosis.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Janicke, RU (corresponding author), Univ Str 1, D-40225 Dusseldorf, Germany.	janicke@uniduesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456; Gillissen, Bernhard/0000-0002-1815-2091				Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nister M, 2005, ONCOGENE, V24, P3563, DOI 10.1038/sj.onc.1208354; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122	41	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37169	37177		10.1074/jbc.M502052200	http://dx.doi.org/10.1074/jbc.M502052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16148012	hybrid			2022-12-25	WOS:000232901800075
J	Francis, J; Chakrabarti, SK; Garmey, JC; Mirmira, RG				Francis, J; Chakrabarti, SK; Garmey, JC; Mirmira, RG			Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation during activation of insulin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL DIFFERENTIATION; GENE-TRANSCRIPTION; ACETYLTRANSFERASE COMPLEXES; METHYLTRANSFERASE; PHOSPHORYLATION; NKX6.1; HOMEODOMAIN; MECHANISM; PROMOTER; BINDING	Expression of the insulin gene is nearly exclusive to the beta cells of the pancreatic islets. Although the sequence-specific transcription factors that regulate insulin expression have been well studied, the interrelationship between these factors, chromatin structure, and transcriptional elongation by RNA polymerase II (pol II) has remained undefined. In this regard, recent studies have begun to establish a role for the methylation of histone H3 in the initiation or elongation of transcription by pol II. To determine a role for the transcriptional activator Pdx-1 in the maintenance of chromatin structure and pol II recruitment at the insulin gene, we performed small interfering RNA-mediated knockdown of Pdx-1 in beta TC3 cells and subsequently studied histone modifications and pol II recruitment by chromatin immunoprecipitation. We demonstrated here that the 50% fall in insulin transcription following knockdown of Pdx-1 is accompanied by a 60% fall in dimethylated histone H3-Lys-4 at the insulin promoter. H3-Lys-4 methylation at the insulin promoter may bemediated, at least partially, by the methyltransferase Set9. Immunohistochemical analysis revealed that Set9 is expressed in an islet-enriched pattern in the pancreas, similar to the pattern of Pdx-1 expression. The recruitment of Set9 to the insulin gene appears to be a consequence of its direct interaction with Pdx-1, and small interfering RNA-mediated knockdown of Set9 attenuates insulin transcription. Pdx-1 knockdown was also associated with an overall shift in the recruitment of pol II isoforms to the insulin gene, from an elongation isoform (Ser( P)-2) to an initiation isoform ( Ser( P)-5). Our findings therefore suggest a model whereby Pdx-1 plays a novel role in linking H3-Lys-4 dimethylation and pol II elongation to insulin transcription.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Diabet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Mirmira, RG (corresponding author), Univ Virginia Hlth Syst, 450 Ray C Hunt Dr,Box 801407, Charlottesville, VA 22908 USA.	mirmira@virginia.edu	Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075	NIDDK NIH HHS [R01 DK60581, R01 DK060581] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060581] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1991, J BIOL CHEM, V266, P11141; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Iype T, 2004, MOL ENDOCRINOL, V18, P1363, DOI 10.1210/me.2004-0006; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Melloul D, 2004, ANN NY ACAD SCI, V1014, P28, DOI 10.1196/annals.1294.003; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Weston RJ, 2004, J ESSENT OIL RES, V16, P453, DOI 10.1080/10412905.2004.9698770; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; YANG Z, 2003, PANCREAS, V26, P99; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09	37	77	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36244	36253		10.1074/jbc.M505741200	http://dx.doi.org/10.1074/jbc.M505741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141209	hybrid, Green Accepted			2022-12-25	WOS:000232726900057
J	Meng, Q; Wang, YF; Liu, XQ				Meng, Q; Wang, YF; Liu, XQ			An intron-encoded protein assists RNA splicing of multiple similar introns of different bacterial genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II INTRONS; ELEMENTS; DATABASE; PLANT; ORFS	Four group II introns were found in an unusually intron-rich dnaN gene (encoding the beta subunit of DNA polymerase III) of the cyanobacterium Trichodesmium erythraeum, and they have strong similarities to two introns of the RIR gene (encoding ribonucleotide reductase) of the same organism. Of these six introns, only the RIR-3 intron encodes a maturase protein and showed efficient RNA splicing when expressed in Escherichia coli cells. The other five introns do not encode a maturase protein and did not show RNA splicing in E. coli. But these maturase-less introns showed efficient RNA splicing when the RIR-3 intron-encoded maturase protein was co-expressed from a freestanding gene in the same cell. These findings demonstrated that an intron-encoded protein could function as a general maturase for multiple introns of different genes. Major implications may include an intron-mediated co-regulation of the different genes and a resemblance of the evolutionary origin of spliceosomal introns.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Liu, XQ (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.	pxqliu@dal.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Dai LX, 2003, RNA, V9, P14, DOI 10.1261/rna.2126203; Dai LX, 2003, NUCLEIC ACIDS RES, V31, P424, DOI 10.1093/nar/gkg049; Edgell DR, 2000, J BACTERIOL, V182, P5281, DOI 10.1128/JB.182.19.5281-5289.2000; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Huang HR, 2003, MOL CELL BIOL, V23, P8809, DOI 10.1128/MCB.23.23.8809-8819.2003; Lambowitz AM, 2004, ANNU REV GENET, V38, P1, DOI 10.1146/annurev.genet.38.072902.091600; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAMBOWITZ AM, 1999, RNA WORLD; Liu XQ, 2003, J BIOL CHEM, V278, P46826, DOI 10.1074/jbc.M309575200; Matsuura M, 2001, EMBO J, V20, P7259, DOI 10.1093/emboj/20.24.7259; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Mohr G, 2003, NUCLEIC ACIDS RES, V31, P647, DOI 10.1093/nar/gkg153; Toro N, 2003, ENVIRON MICROBIOL, V5, P143, DOI 10.1046/j.1462-2920.2003.00398.x; Vogel J, 1999, NUCLEIC ACIDS RES, V27, P3866, DOI 10.1093/nar/27.19.3866; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; Zimmerly S, 2001, NUCLEIC ACIDS RES, V29, P1238, DOI 10.1093/nar/29.5.1238; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	20	25	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35085	35088		10.1074/jbc.C500328200	http://dx.doi.org/10.1074/jbc.C500328200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16150738	hybrid			2022-12-25	WOS:000232561200004
J	Hahn, MA; Marsh, DJ				Hahn, MA; Marsh, DJ			Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin	ONCOGENE			English	Article						HRPT2; parafibromin; nuclear localization signal; hyperparathyroidism	EXPORT SIGNAL; PROTEIN; HRPT2; HYPERPARATHYROIDISM; MUTATIONS; EXPRESSION; SEQUENCE; COMPLEX; GENE	Parafibromin is a putative tumor suppressor encoded by HRPT2, mutations in which have been implicated in the familial tumor syndrome hyperparathyroidism jaw tumor syndrome (HPT-JT), and sporadic parathyroid carcinoma. Recently, parafibromin has been shown to be an accessory factor for RNA polymerase II as part of the human Paf1 complex, suggesting, as has been shown for its yeast homologue (Cdc73), that it may have a role as an important regulator of transcription. Parafibromin has also been shown to interact with a histone methyltransferase complex that methylates histone H3 and to inhibit proliferation when overexpressed in mammalian cell lines. Despite these findings, the cellular localization of parafibromin has been controversial, with reports of both nuclear and nucleocytoplasmic localization. We have expressed wild-type and mutant parafibromin tagged with enhanced green fluorescent protein and have identified a functional bipartite nuclear localization signal (NLS) at residues 125-139 (nucleotides 373-417), KRAADEV-LAEAKKPR, that is evolutionarily conserved and critical for the nuclear localization of parafibromin. We have also shown that the C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. In support of these findings, specific HRPT2 mutations identified in HPT-JT or sporadic parathyroid carcinoma predicted to truncate parafibromin upstream of or within this NLS disrupt nuclear localization.	Univ Sydney, Royal N Shore Hosp, Dept Mol Med, Kolling Inst Med Res, Sydney, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Marsh, DJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Dept Mol Med, Kolling Inst Med Res, Sydney, NSW 2065, Australia.	debbie_marsh@med.usyd.edu.au	Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931				Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Chen JD, 2003, J INTERN MED, V253, P634, DOI 10.1046/j.1365-2796.2003.01168.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Porter SE, 2005, EUKARYOT CELL, V4, P209, DOI 10.1128/EC.4.1.209-220.2005; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; van Koningsbruggen S, 2004, J MED GENET, V41, DOI 10.1136/jmg 2003.012781; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Zhang L, 2003, CANCER GENE THER, V10, P611, DOI 10.1038/sj.cgt.7700608	23	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6241	6248		10.1038/sj.onc.1208778	http://dx.doi.org/10.1038/sj.onc.1208778			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16116486				2022-12-25	WOS:000231877100005
J	Miharada, K; Hiroyama, T; Sudo, K; Nagasawa, T; Nakamura, Y				Miharada, K; Hiroyama, T; Sudo, K; Nagasawa, T; Nakamura, Y			Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion	FASEB JOURNAL			English	Article						erythropoiesis; apoptosis; homeostasis	TRUNCATED ERYTHROPOIETIN RECEPTOR; GELATINASE-ASSOCIATED LIPOCALIN; HUMAN NEUTROPHIL GELATINASE; ACUTE-PHASE PROTEIN; ERYTHROID-CELLS; SOCS PROTEINS; BONE-MARROW; EXPRESSION; DEATH; NGAL	Members of the lipocalin protein family are typically small, secreted proteins that possess a variety of functions. Although the physiological role of lipocalin 2 remains to be fully elucidated, a few pivotal functions have recently been reported, e. g., regulation of the apoptosis of leukocytes. Unexpectedly, lipocalin 2 is abundantly expressed in erythroid progenitor cells. An in vitro culture experiment demonstrated that lipocalin 2 induces apoptosis and inhibits differentiation of erythroid progenitor cells. During acute anemia the expression of lipocalin 2 was reduced in erythroid cells by a feedback system. Furthermore, injection of recombinant lipocalin 2 into mice suffering from acute anemia retarded the recovery of red blood cell (RBC) numbers, suggesting the importance of reduced expression of lipocalin 2 for the efficient recovery of RBC numbers. These results indicate that lipocalin 2 suppresses RBC production in an autocrine fashion. Hence, anemia arising from pathological conditions, such as chronic inflammation, might be partly due to increased levels of lipocalin 2 secreted from expanded leukocytes and/or macrophages. Also, anemia arising from malignancies might be partly due to the abundant secretion of lipocalin 2 from tumor cells. Thus, lipocalin 2 may represent an attractive therapeutic target for anemia under certain pathological conditions.	RIKEN, BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan	RIKEN; University of Tsukuba	Nakamura, Y (corresponding author), RIKEN, BioResource Ctr, Cell Engn Div, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	yukionak@brc.riken.jp	Miharada, Kenichi/C-1397-2014; Nakamura, Yukio/A-5263-2016	Miharada, Kenichi/0000-0001-8073-4001; Nakamura, Yukio/0000-0001-8056-4946				Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; BARTSCH S, 1995, FEBS LETT, V357, P255, DOI 10.1016/0014-5793(94)01303-I; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Flower DR, 1996, BIOCHEM J, V318, P1; Furutani M, 1998, CANCER LETT, V122, P209, DOI 10.1016/S0304-3835(97)00391-1; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Liu QS, 1997, MOL REPROD DEV, V46, P507, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;507::AID-MRD9&gt;3.0.CO;2-S; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Mishra J, 2004, J AM SOC NEPHROL, V15, P3073, DOI 10.1097/01.ASN.0000145013.44578.45; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; Nakamura Y, 1998, EXP HEMATOL, V26, P1105; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NVIDBERG V, 2005, FEBS LETT, V579, P773; Papadaki HA, 2002, BLOOD, V100, P474, DOI 10.1182/blood-2002-01-0136; Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zhang J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479; Zhu Y, 1994, Curr Opin Hematol, V1, P113	34	61	64	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1881	+		10.1096/fj.05-3809fje	http://dx.doi.org/10.1096/fj.05-3809fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16157692				2022-12-25	WOS:000232315700018
J	Rothman, S				Rothman, S			The constancy of the internal environment: proteins in plasma	FASEB JOURNAL			English	Article						proteins; peptides; blood; exocytosis; endocytosis; membrane transport; protein transport	MEMBRANE; TRANSPORT	The simple fact that there are normal concentrations of various proteins and peptides in blood has broad and surprising implications for how these molecules are released into and removed from the bloodstream by the cells of the body. If, as widely accepted, vesicle transport mechanisms such as exocytosis and endocytosis account for these events, then complex, presently unknown and seemingly unlikely mechanisms must exist to coordinate the rates of separate transport processes. The basis for this conclusion as well as the sole alternative method of transport, movement across permeable membranes, are discussed.	Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rothman, S (corresponding author), Univ Calif San Francisco, 98 Acacia Ave, Berkeley, CA 94708 USA.	rothman@itsa.ucsf.edu						Alberts B, 2002, MOL BIOL CELL; GOETZE H, 1978, Biochimica et Biophysica Acta, V512, P214; GONCZ KK, 1995, BBA-BIOMEMBRANES, V1238, P91, DOI 10.1016/0005-2736(95)00128-P; GONCZ KK, 1992, BIOCHIM BIOPHYS ACTA, V1109, P7, DOI 10.1016/0005-2736(92)90181-K; HENRY JB, 2001, CLIN DIAGNOSIS MANAG; Isenman L, 1995, BBA-REV BIOMEMBRANES, V1241, P341, DOI 10.1016/0304-4157(95)00009-7; ISENMAN LD, 1977, P NATL ACAD SCI USA, V74, P4068, DOI 10.1073/pnas.74.9.4068; JACOBS DS, 1996, LAB TEST HDB CONCISE; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; ROTHMAN S, 2001, LESSONS LIVING CELL; ROTHMAN SS, 1995, MEMBRANE PROTEIN TRA, V1; ROTHMAN SS, 1985, PROTEIN SECRETION CR; YOUNG DS, 1993, EFFECTS PREANALYTICA; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	14	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1383	1388		10.1096/fj.05-3922hyp	http://dx.doi.org/10.1096/fj.05-3922hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126905				2022-12-25	WOS:000232315700031
J	Korza, HJ; Bochtler, M				Korza, HJ; Bochtler, M			Pseudomonas aeruginosa LD-carboxypeptidase, a serine peptidase with a Ser-His-Glu triad and a nucleophilic elbow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; ALPHA/BETA-HYDROLASE FOLD; WALL-BOUND PEPTIDOGLYCAN; ESCHERICHIA-COLI K-12; BETA-SHEET BARRELS; GAFFKYA-HOMARI; GEOTRICHUM-CANDIDUM; DD-CARBOXYPEPTIDASE; CHEMICAL-STRUCTURE; PROTEIN STRUCTURES	LD- Carboxypeptidases ( EC 3.4.17.13) are named for their ability to cleave amide bonds between L- and D- amino acids, which occur naturally in bacterial peptidoglycan. They are specific for the link between meso- diaminopimelic acid and D- alanine and therefore degrade GlcNAc- MurNAc tetrapeptides to the corresponding tripeptides. As only the tripeptides can be reused as peptidoglycan building blocks, LD- carboxypeptidases are thought to play a role in peptidoglycan recycling. Despite the pharmaceutical interest in peptidoglycan biosynthesis, the fold and catalytic type of LD- carboxypeptidases are unknown. Here, we show that a previously uncharacterized open reading frame in Pseudomonas aeruginosa has LD- carboxypeptidase activity and present the crystal structure of this enzyme. The structure shows that the enzyme consists of an N-terminal beta-sheet and a C-terminal beta-barrel domain. At the interface of the two domains, Ser(115) adopts a highly strained conformation in the context of a strand-turn-helix motif that is similar to the "nucleophilic elbow" in alpha beta-hydrolases. Ser(115) is hydrogen- bonded to a histidine residue, which is oriented by a glutamate residue. All three residues, which occur in the order Ser-Glu-His in the amino acid sequence, are strictly conserved in naturally occurring LD- carboxypeptidases and cannot be mutated to alanines without loss of activity. We conclude that LD- carboxypeptidases are serine peptidases with Ser-His-Glu catalytic triads.	Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society	Bochtler, M (corresponding author), Int Inst Mol & Cell Biol, Ul Trojdena 4, PL-02109 Warsaw, Poland.	MBochtler@iimcb.gov.pl	Bochtler, Matthias/A-4514-2010; Korza, Henryk/H-9331-2012	Korza, Henryk/0000-0003-4434-3972; Bochtler, Matthias/0000-0001-7884-4463				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BECK BD, 1976, J BACTERIOL, V126, P1250, DOI 10.1128/JB.126.3.1250-1260.1976; BECK BD, 1977, J BACTERIOL, V130, P1292, DOI 10.1128/JB.130.3.1292-1302.1977; BEGG KJ, 1990, J BACTERIOL, V172, P6697, DOI 10.1128/jb.172.12.6697-6703.1990; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Chang CI, 2004, PLOS BIOL, V2, P1293, DOI 10.1371/journal.pbio.0020277; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GONZALEZPASTOR JE, 1995, J BACTERIOL, V177, P7131, DOI 10.1128/jb.177.24.7131-7140.1995; GUIJARRO JI, 1995, J BIOL CHEM, V270, P23520, DOI 10.1074/jbc.270.40.23520; Gunasekaran K, 1996, J MOL BIOL, V264, P191, DOI 10.1006/jmbi.1996.0633; Hakansson K, 2000, P NATL ACAD SCI USA, V97, P14097, DOI 10.1073/pnas.260376797; HAMMES WP, 1978, EUR J BIOCHEM, V91, P501, DOI 10.1111/j.1432-1033.1978.tb12703.x; HAMMES WP, 1978, EUR J BIOCHEM, V84, P141, DOI 10.1111/j.1432-1033.1978.tb12150.x; HAMMES WP, 1978, EUR J BIOCHEM, V91, P509, DOI 10.1111/j.1432-1033.1978.tb12704.x; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Knight SD, 2000, ACTA CRYSTALLOGR D, V56, P42, DOI 10.1107/S0907444999012913; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEGUINA JI, 1994, FEBS LETT, V339, P249, DOI 10.1016/0014-5793(94)80425-7; Li AJ, 1998, PROTEINS, V32, P111, DOI 10.1002/(SICI)1097-0134(19980701)32:1<111::AID-PROT12>3.0.CO;2-H; Li WZ, 2001, BIOINFORMATICS, V17, P282, DOI 10.1093/bioinformatics/17.3.282; Liu S, 2004, PROTEINS, V56, P93, DOI 10.1002/prot.20019; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MARKIEWICZ Z, 1983, J BACTERIOL, V156, P649, DOI 10.1128/JB.156.2.649-655.1983; Mathews MAA, 2001, EMBO J, V20, P5832, DOI 10.1093/emboj/20.21.5832; METZ R, 1986, ARCH MICROBIOL, V144, P175, DOI 10.1007/BF00414731; METZ R, 1986, ARCH MICROBIOL, V144, P181, DOI 10.1007/BF00414732; Miller ST, 2004, MOL CELL, V15, P677, DOI 10.1016/j.molcel.2004.07.020; Miranda JJL, 2003, PROTEIN SCI, V12, P73, DOI 10.1110/ps.0224203; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Muller-Dieckmann HJ, 1999, STRUCT FOLD DES, V7, P1547, DOI 10.1016/S0969-2126(00)88345-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Nicolet Y, 2003, J BIOL CHEM, V278, P41141, DOI 10.1074/jbc.M210241200; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Pal D, 2002, BIOPOLYMERS, V63, P195, DOI 10.1002/bip.10051; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Petock JM, 2003, PROTEINS, V53, P872, DOI 10.1002/prot.10484; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHARON N, 1967, PROC R SOC SER B-BIO, V167, P402, DOI 10.1098/rspb.1967.0037; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; URSINUS A, 1992, J BACTERIOL, V174, P441, DOI 10.1128/jb.174.2.441-446.1992; Vonrhein C, 1999, ACTA CRYSTALLOGR D, V55, P225, DOI 10.1107/S0907444998007914	59	41	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40802	40812		10.1074/jbc.M506328200	http://dx.doi.org/10.1074/jbc.M506328200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16162494	hybrid			2022-12-25	WOS:000233666600051
J	Bettoun, DJ; Scafonas, A; Rutledge, SJ; Hodor, P; Chen, O; Gambone, C; Vogel, R; McElwee-Witmer, S; Bai, C; Freedman, L; Schmidt, A				Bettoun, DJ; Scafonas, A; Rutledge, SJ; Hodor, P; Chen, O; Gambone, C; Vogel, R; McElwee-Witmer, S; Bai, C; Freedman, L; Schmidt, A			Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; BREAST-CANCER; EXPRESSION; ENDOCRINE; GENE; ACTIVATION; MUTATIONS; FAMILIES; SYSTEM; CELLS	Signaling by androgens and interferons (IFN) plays an important role in prostate cancer initiation and progression. Using microarray analysis, we describe here a functional cross-talk between dihydrotestosterone and interferon signaling. Glutathione S-transferase pull-down and co-immunoprecipitation experiments reveal that the androgen receptor and the interferon-activated RNase L interact with each other in a ligand-dependent manner. Furthermore, overexpression of wild type RNase L confers IFN sensitivity to a dihydrotestosterone-inducible reporter gene, whereas R462Q-mutated RNase L does not. Based on our data we hypothesize that in 22RV1 cells, activated androgen receptor (AR) contributes to the insensitivity to IFN of the cell. Accordingly, we show that AR knockdown restores responsiveness to IFN gamma. Our findings support a model in which both the activation of AR and the down-regulation of IFN signaling can synergize to promote cell survival and suppress apoptosis. This model provides the molecular basis to understand how mutated RNase L can lead to early onset PCa and illustrates how inflammatory cytokines and nuclear hormone signaling contribute to tumor development.	Dept Mol Endocrinol, Merck Res Lab, West Point, PA 19486 USA	Merck & Company	Bettoun, DJ (corresponding author), Dept Mol Endocrinol, Merck Res Lab, 770 Sumneytown Pike, West Point, PA 19486 USA.	david_bettoun@merck.com						Bettoun DJ, 2002, J BIOL CHEM, V277, P24847, DOI 10.1074/jbc.C200187200; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Carroll SS, 1997, J BIOL CHEM, V272, P19193, DOI 10.1074/jbc.272.31.19193; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen H, 2003, J Med Genet, V40, pe21, DOI 10.1136/jmg.40.3.e21; Cornwell PD, 2004, MUTAT RES-FUND MOL M, V549, P131, DOI 10.1016/j.mrfmmm.2003.12.019; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Green S, 1999, ENDOCR-RELAT CANCER, V6, P349, DOI 10.1677/erc.0.0060349; Hartig PC, 2002, TOXICOL SCI, V66, P82, DOI 10.1093/toxsci/66.1.82; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Nagano K, 2004, ONCOGENE, V23, P1693, DOI 10.1038/sj.onc.1207297; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; Sirotnak FM, 2002, CLIN CANCER RES, V8, P3870; Sirotnak FM, 2004, MOL CARCINOGEN, V41, P150, DOI 10.1002/mc.20051; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vaarala MH, 2000, LAB INVEST, V80, P1259, DOI 10.1038/labinvest.3780134; White JH, 2004, VITAM HORM, V68, P123; Xiang Y, 2003, CANCER RES, V63, P6795	30	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					38898	38901		10.1074/jbc.C500324200	http://dx.doi.org/10.1074/jbc.C500324200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16166078	hybrid			2022-12-25	WOS:000233362200002
J	Xiang, GS; Seki, T; Schuster, MD; Witkowski, P; Boyle, AJ; See, F; Martens, TP; Kocher, A; Sondermeijer, H; Krum, H; Itescu, S				Xiang, GS; Seki, T; Schuster, MD; Witkowski, P; Boyle, AJ; See, F; Martens, TP; Kocher, A; Sondermeijer, H; Krum, H; Itescu, S			Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVING DNA ENZYME; KINASE 1 ASK1; THIOREDOXIN FUNCTION; OXIDATIVE STRESS; REDOX REGULATION; APOPTOSIS; BINDING; ACTIVATION; EXPRESSION; CELLS	Vitamin D3 up-regulated protein 1 ( VDUP1) is a key mediator of oxidative stress on various cellular processes via downstream effects on apoptosis signaling kinase 1 ( ASK1) and p38 mitogen-activated protein kinase ( MAPK). Here, we report that VDUP1 expression is significantly increased in rat hearts following acute myocardial ischemia, suggesting it may have important regulatory effects on cardiac physiological processes during periods of oxidative stress. Transfection of H9C2 cardiomyoblasts with a sequence-specific VDUP1 DNA enzyme to down-regulate VDUP1 mRNA expression significantly reduced apoptosis and enhanced cell survival under conditions of H2O2 stress, and these effects involved inhibition of ASK1 activity. Direct intracardiac injection of the DNA enzyme at the time of acute myocardial infarction reduced myocardial VDUP1 mRNA expression and resulted in prolonged reduction in cardiomyocyte apoptosis and ASK1 activity. Moreover, down-regulation of VDUP1 was accompanied by significant reduction in cardiac expression of pro-collagen type I alpha 2 mRNA level, as well as marked reduction in myocardial scar formation. These features were accompanied by significant improvement in cardiac function. Together, these results suggest a direct role for VDUP1 in the adverse effects of ischemia and oxidative stress on cardiomyocyte survival, left ventricular collagen deposition, and cardiac function. Strategies to inhibit VDUP1 expression and/or function during acute ischemic events may be beneficial to cardiac functional recovery and prevention of left ventricular remodeling.	Columbia Univ, Med Ctr, Dept Surg, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Itescu, S (corresponding author), P&S 14-402,630 W 168th St, New York, NY 10032 USA.	si5@columbia.edu		Martens, Timothy/0000-0003-1559-7789; Boyle, Andrew/0000-0002-3919-5269	NHLBI NIH HHS [RFA-HL-02-017] Funding Source: Medline; NIA NIH HHS [RFA-AG-01-006] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Champliaud MF, 2003, J INVEST DERMATOL, V121, P781, DOI 10.1046/j.1523-1747.2003.12539.x; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; Goldberg SF, 2003, CANCER RES, V63, P432; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; He XG, 2003, AM J PATHOL, V163, P243, DOI 10.1016/S0002-9440(10)63647-4; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Izumi Y, 2003, CIRCULATION, V108, P2812, DOI 10.1161/01.CIR.0000096486.01652.FC; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kobayashi T, 2003, KIDNEY INT, V64, P1632, DOI 10.1046/j.1523-1755.2003.00263.x; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; See F, 2004, J AM COLL CARDIOL, V44, P1679, DOI 10.1016/j.jacc.2004.07.038; Shioji K, 2003, ANTIOXID REDOX SIGN, V5, P795, DOI 10.1089/152308603770380106; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Yamaguchi O, 2003, P NATL ACAD SCI USA, V100, P15883, DOI 10.1073/pnas.2136717100	30	69	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39394	39402		10.1074/jbc.M502966200	http://dx.doi.org/10.1074/jbc.M502966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16172122	hybrid			2022-12-25	WOS:000233362200061
J	Donier, E; Rugiero, F; Okuse, K; Wood, JN				Donier, E; Rugiero, F; Okuse, K; Wood, JN			Annexin II light chain p11 promotes functional expression of acid-sensing ion channel ASIC1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNELS; PROTEIN PICK1; PHOSPHOLIPASE A(2); GANGLION NEURONS; EPITHELIAL-CELLS; SODIUM-CHANNELS; SENSORY NEURONS; XENOPUS OOCYTES; P11; CONTRIBUTES	Acid-sensing ion channels (ASICs) have been implicated in a wide variety of physiological functions. We have used a rat dorsal root ganglion cDNA library in a yeast two-hybrid assay to identify sensory neuron proteins that interact with ASICs. We found that annexin II light chain p11 physically interacts with the N terminus of ASIC1a, but not other ASIC isoforms. Immunoprecipitation studies confirmed an interaction between p11 and ASIC1 in rat dorsal root ganglion neurons in vivo. Coexpression of p11 and ASIC1a in CHO-K1 cells led to a 2-fold increase in expression of the ion channel at the cell membrane as determined by membrane-associated immunoreactivity and cell-surface biotinylation. Consistent with these findings, peak ASIC1a currents in transfected CHO-K1 cells were up-regulated 2-fold in the presence of p11, whereas ASIC3-mediated currents were unaffected by p11 expression. Neither the pH dependence of activation nor the rates of desensitization were altered by p11, suggesting that its primary role in regulating ASIC1a activity is to enhance cell-surface expression of ASIC1a. These data demonstrate that p11, already known to traffic members of the voltage-gated sodium and potassium channel families as well as transient receptor potential and chloride channels, also plays a selective role in enhancing ASIC1a functional expression.	UCL, Dept Biol, Mol Nocicept Grp, London WC1E 6BT, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London Pain Consortium, London SW7 2AZ, England	University of London; University College London; Imperial College London	Wood, JN (corresponding author), UCL, Dept Biol, Mol Nocicept Grp, Gower St, London WC1E 6BT, England.	j.wood@ucl.ac.uk			MRC [G9717869] Funding Source: UKRI; Medical Research Council [G9717869] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benveniste M, 2005, NEW ENGL J MED, V352, P85, DOI 10.1056/NEJMcibr045010; Bianchi L, 2004, NAT NEUROSCI, V7, P1337, DOI 10.1038/nn1347; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chu XP, 2002, J NEUROPHYSIOL, V87, P2555, DOI 10.1152/jn.00741.2001; Deora AB, 2004, J BIOL CHEM, V279, P43411, DOI 10.1074/jbc.M408078200; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; Gonzalez-Martinez T, 2003, MICROSC RES TECHNIQ, V60, P633, DOI 10.1002/jemt.10304; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Hayes MJ, 2004, TRAFFIC, V5, P571, DOI 10.1111/j.1600-0854.2004.00210.x; Hruska-Hageman AM, 2004, J BIOL CHEM, V279, P46962, DOI 10.1074/jbc.M405874200; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Leonard AS, 2003, P NATL ACAD SCI USA, V100, P2029, DOI 10.1073/pnas.252782799; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Page AJ, 2004, GASTROENTEROLOGY, V127, P1739, DOI 10.1053/j.gastro.2004.08.061; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; Peng BG, 2004, J NEUROSCI, V24, P10167, DOI 10.1523/JNEUROSCI.3196-04.2004; Poon WYL, 2004, FEBS LETT, V558, P114, DOI 10.1016/S0014-5793(03)01512-6; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2004, J BIOL CHEM, V279, P53886, DOI 10.1074/jbc.M407708200; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Ugawa Shinya, 2003, Anatomical Science International, V78, P205, DOI 10.1046/j.0022-7722.2003.00062.x; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Voilley Nicolas, 2004, Current Drug Targets - Inflammation and Allergy, V3, P71, DOI 10.2174/1568010043483980; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zhang P, 2002, J GEN PHYSIOL, V120, P553, DOI 10.1085/jgp.20028574; Zhao WQ, 2004, J NEUROCHEM, V90, P609, DOI 10.1111/j.1471-4159.2004.02509.x; Zimmer DB, 2003, MICROSC RES TECHNIQ, V60, P552, DOI 10.1002/jemt.10297	52	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38666	38672		10.1074/jbc.M505981200	http://dx.doi.org/10.1074/jbc.M505981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169854	hybrid			2022-12-25	WOS:000233239800068
J	Fan, T; Varghese, G; Nguyen, T; Tse, R; O'Dowd, BF; George, SR				Fan, T; Varghese, G; Nguyen, T; Tse, R; O'Dowd, BF; George, SR			A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHINE-TOLERANCE; MICE LACKING; OLIGOMERIZATION; DESENSITIZATION; DEPENDENCE; AGONISTS; MOUSE; ANTINOCICEPTION; DIMERIZATION; EXPRESSION	Opioid receptor pharmacology in vivo has predicted a greater number of receptor subtypes than explained by the profiles of the three cloned opioid receptors, and the functional dependence of the receptors on each other shown in gene-deleted animal models remains unexplained. One mechanism for such findings is the generation of novel signaling complexes by receptor hetero-oligomerization, which we previously showed results in significantly different pharmacology for mu and delta receptor hetero-oligomers compared with the individual receptors. In the present study, we show that deltorphin-II is a fully functional agonist of the mu-delta heteromer, which induced desensitization and inhibited adenylyl cyclase through a pertussis toxin-insensitive G protein. Activation of the mu-delta receptor heteromer resulted in preferential activation of G alpha(z), illustrated by incorporation of GTP gamma(35)S, whereas activation of the individually expressed mu and delta receptors preferentially activated G alpha(i). The unique pharmacology of the mu-delta heteromer was dependent on the reciprocal involvement of the distal carboxyl tails of both receptors, so that truncation of the distal mu receptor carboxyl tail modified the delta-selective ligand-binding pocket, and truncation of the delta receptor distal carboxyl tail modified the mu-selective binding pocket. The distal carboxyl tails of both receptors also had a significant role in receptor interaction, as evidenced by the reduced ability to co-immunoprecipitate when the carboxyl tails were truncated. The interaction between mu and delta receptors occurred constitutively when the receptors were co-expressed, but did not occur when receptor expression was temporally separated, indicating that the hetero-oligomers were generated by a co-translational mechanism.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	George, SR (corresponding author), Med Sci Bldg,Rm 4358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	s.george@utoronto.ca	George, Susan R/P-9669-2018; George, Susan/W-7494-2019					ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Cahill CM, 2001, J NEUROSCI, V21, P7598, DOI 10.1523/JNEUROSCI.21-19-07598.2001; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; EGAN TM, 1981, SCIENCE, V214, P923, DOI 10.1126/science.6272393; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Garzon J, 1998, EUR J NEUROSCI, V10, P2557, DOI 10.1046/j.1460-9568.1998.t01-1-00267.x; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Hosohata Y, 2000, EUR J PHARMACOL, V388, P241, DOI 10.1016/S0014-2999(99)00897-3; Hutcheson DM, 2001, EUR J NEUROSCI, V13, P153, DOI 10.1046/j.1460-9568.2001.01363.x; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kitchen I, 1997, BRAIN RES, V778, P73, DOI 10.1016/S0006-8993(97)00988-8; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; LEVAC BA, 2001, CURR OPIN ENDOCRINOL, V8, P166; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Martin NA, 2001, MOL PHARMACOL, V59, P774, DOI 10.1124/mol.59.4.774; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pak Y, 1996, MOL PHARMACOL, V50, P1214; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; PORRECA F, 1992, J PHARMACOL EXP THER, V263, P147; Riba P, 2002, J PHARMACOL EXP THER, V300, P265, DOI 10.1124/jpet.300.1.265; SanchezBlazquez P, 1997, J PHARMACOL EXP THER, V280, P1423; Sora I, 1997, EUR J PHARMACOL, V324, pR1, DOI 10.1016/S0014-2999(97)10016-4; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; XU H, 1993, PEPTIDES, V14, P893, DOI 10.1016/0196-9781(93)90064-N; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3	36	84	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38478	38488		10.1074/jbc.M505644200	http://dx.doi.org/10.1074/jbc.M505644200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159882	hybrid			2022-12-25	WOS:000233239800045
J	Hohaus, A; Beyl, S; Kudrnac, M; Berjukow, S; Timin, EN; Marksteiner, R; Maw, MA; Hering, S				Hohaus, A; Beyl, S; Kudrnac, M; Berjukow, S; Timin, EN; Marksteiner, R; Maw, MA; Hering, S			Structural determinants of L-type channel activation in segment IIS6 revealed by a retinal disorder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; GATED CA2+ CHANNELS; BETA-SUBUNIT; MOLECULAR DETERMINANTS; TRANSMEMBRANE SEGMENT; VOLTAGE-DEPENDENCE; INACTIVATION; ALPHA(1C); EXPRESSION; MUTATION	The mechanism of channel opening for voltage-gated calcium channels is poorly understood. The importance of a conserved isoleucine residue in the pore-lining segment IIS6 has recently been highlighted by functional analyses of a mutation (I745T) in the Ca(V)1.4 channel causing severe visual impairment (Hemara-Wahanui, A., Berjukow, S., Hope, C. I., Dearden, P. K., Wu, S. B., Wilson-Wheeler, J., Sharp, D. M., Lundon-Treweek, P., Clover, G. M., Hoda, J. C., Striessnig, J., Marksteiner, R., Hering, S., and Maw, M. A. ( 2005) Proc. Natl. Acad. Sci. U. S. A. 102, 7553 - 7558). In the present study we analyzed the influence of amino acids in segment IIS6 on gating of the Ca(V)1.2 channel. Substitution of Ile-781, the Ca(V)1.2 residue corresponding to Ile-745 in Ca(V)1.4, by residues of different hydrophobicity, size and polarity shifted channel activation in the hyperpolarizing direction (I781P > I781T > I781N > I781A> I781L). As I781P caused the most dramatic shift ( - 37 mV), substitution with this amino acid was used to probe the role of other residues in IIS6 in the process of channel activation. Mutations revealed a high correlation between the midpoint voltages of activation and inactivation. A unique kinetic phenotype was observed for residues 779 - 782 (LAIA) located in the lower third of segment IIS6; a shift in the voltage dependence of activation was accompanied by a deceleration of activation at hyperpolarized potentials, a deceleration of deactivation at all potentials ( I781P and I781T), and decreased inactivation. These findings indicate that Ile-781 substitutions both destabilize the closed conformation and stabilize the open conformation of Ca(V)1.2. Moreover there may be a flexible center of helix bending at positions 779 - 782 of Ca(V)1.2. These four residues are completely conserved in high voltage-activated calcium channels suggesting that these channels may share a common mechanism of gating.	Univ Vienna, Inst Pharmacol & Toxicol, A-1090 Vienna, Austria; InnovaCell Biotechnol GmbH, A-6020 Innsbruck, Austria; Univ Otago, Dept Biochem, Aotearoa, New Zealand	University of Vienna; University of Otago	Hering, S (corresponding author), Univ Vienna, Inst Pharmacol & Toxicol, Althanstr 14, A-1090 Vienna, Austria.	steffen.hering@univie.ac.at			Austrian Science Fund FWF [P 15914] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Catterall WA, 2003, PHARMACOL REV, V55, P579, DOI 10.1124/pr.55.4.8; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hemara-Wahanui A, 2005, P NATL ACAD SCI USA, V102, P7553, DOI 10.1073/pnas.0501907102; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Hering S, 2002, TRENDS PHARMACOL SCI, V23, P509, DOI 10.1016/S0165-6147(02)02104-1; Hope CI, 2005, CLIN EXP OPHTHALMOL, V33, P129, DOI 10.1111/j.1442-9071.2005.00987.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Koschak A, 2003, J NEUROSCI, V23, P6041, DOI 10.1523/JNEUROSCI.23-14-06041.2003; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li JY, 2004, J BIOL CHEM, V279, P26858, DOI 10.1074/jbc.M313981200; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; Stotz SC, 2001, TRENDS NEUROSCI, V24, P176, DOI 10.1016/S0166-2236(00)01738-0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Yamaguchi H, 1999, P NATL ACAD SCI USA, V96, P1357, DOI 10.1073/pnas.96.4.1357; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Zhao Y, 2004, P NATL ACAD SCI USA, V101, P17873, DOI 10.1073/pnas.0408270101; Zhao Y, 2004, NEURON, V41, P859, DOI 10.1016/S0896-6273(04)00116-3	31	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38471	38477		10.1074/jbc.M507013200	http://dx.doi.org/10.1074/jbc.M507013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16157588	hybrid, Green Accepted			2022-12-25	WOS:000233239800044
J	Li, H; Frieden, C				Li, H; Frieden, C			Phenylalanine side chain behavior of the intestinal fatty acid-binding protein - The effect of urea on backbone and side chain stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; F-19 NMR; SPECTROSCOPY	The equilibrium unfolding behavior of the intestinal fatty acid-binding protein has been investigated by F-19-NMR after incorporation of 4-fluorophenylalanine and by pulsed field gradient diffusion H-1-NMR. At low urea concentrations (0-3 M) but prior to the global unfolding that begins at 4 M urea, the protein exhibits dynamic motion in the backbone and an expanded hydrodynamic radius with no major change in the side chain orientation. As monitored by two-dimensional F-19-F-19 nuclear Overhauser effect, the distance between two phenylalanine residues (Phe(68) and Phe(93)) located in the two different beta-sheets that enclose the internal cavity did not change up to 4 M urea. Additionally, the chemical shifts of these two residues changed almost identically as a function of denaturant. At all urea concentrations, as well as in the native protein, multiple conformations exist. These conformers interconvert at different rates under different conditions, ranging from slow exchange by showing separate peaks in the native state to intermediate exchange at intermediate urea concentrations. Residual structure persisted around Phe(62) even at very high concentrations of denaturant, suggesting that region as a nucleation site during folding. The results were compared with previous studies examining the backbone behavior (Hodsdon, M. E., and Frieden, C. (2001) Biochemistry 40, 732-742) and suggest that the side chains show more stability than the backbone prior to global unfolding of the protein.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Frieden, C (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	frieden@biochem.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013332, R01DK013332] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afrin R, 2005, PROTEIN SCI, V14, P1447, DOI 10.1110/ps.041282305; Bann JG, 2002, P NATL ACAD SCI USA, V99, P709, DOI 10.1073/pnas.022649599; Danielson MA, 1996, ANNU REV BIOPH BIOM, V25, P163, DOI 10.1146/annurev.bb.25.060196.001115; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gerig J. T., 2001, FLUORINE NMR, P1; Hodsdon ME, 2001, BIOCHEMISTRY-US, V40, P732, DOI 10.1021/bi001518i; Hoeltzli SD, 1998, BIOCHEMISTRY-US, V37, P387, DOI 10.1021/bi971962u; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; Kim K, 1997, PROTEIN SCI, V6, P364; Kim KY, 1998, PROTEIN SCI, V7, P1821, DOI 10.1002/pro.5560070818; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krishna MMG, 2004, METHODS, V34, P51, DOI 10.1016/j.ymeth.2004.03.005; Li H, 2005, BIOCHEMISTRY-US, V44, P2369, DOI 10.1021/bi047600l; Neuhaus D., 2000, NUCL OVERHAUSER EFFE; Pace C. N., 1997, PROTEIN STRUCTURE PR, P253; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; Rajabzadeh M, 2003, BIOCHEMISTRY-US, V42, P12192, DOI 10.1021/bi0301688; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; ROPSON IJ, 1992, P NATL ACAD SCI USA, V89, P7222, DOI 10.1073/pnas.89.15.7222; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176	25	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38556	38561		10.1074/jbc.M505435200	http://dx.doi.org/10.1074/jbc.M505435200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16162507	hybrid			2022-12-25	WOS:000233239800054
J	Skaff, DA; Kim, CS; Tsai, HJ; Honzatko, RB; Fromm, HJ				Skaff, DA; Kim, CS; Tsai, HJ; Honzatko, RB; Fromm, HJ			Glucose 6-phosphate release of wild-type and mutant human brain hexokinases from mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HALVES; INORGANIC-PHOSPHATE; RAT-TISSUES; MEMBRANE ASSOCIATION; MAMMALIAN HEXOKINASE; CRYSTAL-STRUCTURE; REGULATORY SITE; BINDING-SITES; I HEXOKINASE; PIG HEART	One molecule of glucose 6-phosphate inhibits brain hexokinase (HKI) with high affinity by binding to either one of two sites located in distinct halves of the enzyme. In addition to potent inhibition, glucose 6-phosphate releases HKI from the outer leaflet of mitochondria; however, the site of glucose 6-phosphate association responsible for the release of HKI is unclear. The incorporation of a C-terminal polyhistidine tag on HKI facilitates the rapid purification of recombinant enzyme from Escherichia coli. The tagged construct has N-formyl methionine as its first residue and has mitochondrial association properties comparable with native brain hexokinases. Release of wild-type and mutant hexokinases from mitochondria by glucose 6-phosphate follow equilibrium models, which explain the release phenomenon as the repartitioning of ligand-bound HKI between solution and the membrane. Mutations that block the binding of glucose 6-phosphate to the C-terminal half of HKI have little or no effect on the glucose 6-phosphate release. In contrast, mutations that block glucose 6-phosphate binding to the N-terminal half require similar to 7-fold higher concentrations of glucose 6-phosphate for the release of HKI. Results here implicate a primary role for the glucose 6-phosphate binding site at the N-terminal half of HKI in the release mechanism.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	hjfromm@iastate.edu			NINDS NIH HHS [NS10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleshin AE, 1999, BIOCHEMISTRY-US, V38, P8359, DOI 10.1021/bi990523n; Aleshin AE, 1998, FEBS LETT, V434, P42, DOI 10.1016/S0014-5793(98)00952-1; Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; ARORA KK, 1993, J BIOL CHEM, V268, P18259; AUBERTFOUCHER E, 1984, ARCH BIOCHEM BIOPHYS, V232, P391, DOI 10.1016/0003-9861(84)90554-X; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; BACHELARD HS, 1971, BIOCHEM J, V123, P707, DOI 10.1042/bj1230707; BAIJAL M, 1995, ARCH BIOCHEM BIOPHYS, V321, P413, DOI 10.1006/abbi.1995.1412; BEITNER R, 1984, INT J BIOCHEM, V16, P991, DOI 10.1016/0020-711X(84)90116-2; Birnbaum MJ, 2004, DEV CELL, V7, P781, DOI 10.1016/j.devcel.2004.11.016; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU AC, 1974, ARCH BIOCHEM BIOPHYS, V165, P628, DOI 10.1016/0003-9861(74)90290-2; CRANE RK, 1954, J BIOL CHEM, V210, P597; ELLISON WR, 1975, J BIOL CHEM, V250, P1864; ELLISON WR, 1974, BIOCHEM BIOPH RES CO, V57, P1214, DOI 10.1016/0006-291X(74)90826-2; Fang TY, 1998, J BIOL CHEM, V273, P19548, DOI 10.1074/jbc.273.31.19548; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FIECK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429; FONT B, 1975, FEBS LETT, V56, P24, DOI 10.1016/0014-5793(75)80103-7; FROMM HJ, 1962, J BIOL CHEM, V237, P1661; FROMM HJ, 1981, REGULATION CARBOHYDR, P45; GERBER G, 1974, EUR J BIOCHEM, V45, P39, DOI 10.1111/j.1432-1033.1974.tb03527.x; GONZALEZ C, 1964, BIOCHEM BIOPH RES CO, V16, P347, DOI 10.1016/0006-291X(64)90038-5; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Graham J M, 1993, Methods Mol Biol, V19, P29; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HABERMAN S, 1975, ISRAEL J MED SCI, V11, P1180; Hutny J, 2000, ACTA BIOCHIM POL, V47, P1045, DOI 10.18388/abp.2000_3958; KABIR F, 1993, ARCH BIOCHEM BIOPHYS, V300, P641, DOI 10.1006/abbi.1993.1089; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KOSOW DP, 1973, ARCH BIOCHEM BIOPHYS, V157, P114, DOI 10.1016/0003-9861(73)90396-2; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; Liu XF, 1999, J BIOL CHEM, V274, P31155, DOI 10.1074/jbc.274.44.31155; LOWRY OH, 1964, J BIOL CHEM, V239, P31; LOWRY OH, 1961, J BIOL CHEM, V236, P2813; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; REDKAR VD, 1972, J BIOL CHEM, V247, P7576; RIJKSEN G, 1977, BIOCHIM BIOPHYS ACTA, V485, P75, DOI 10.1016/0005-2744(77)90194-2; Rosano C, 1999, STRUCT FOLD DES, V7, P1427, DOI 10.1016/S0969-2126(00)80032-5; ROSE IA, 1967, J BIOL CHEM, V242, P1635; Sebastian S, 1999, ARCH BIOCHEM BIOPHYS, V362, P203, DOI 10.1006/abbi.1998.1043; TSUNASAWA S, 1993, METHODS PROTEIN SEQU, P43; VOWLES DT, 1979, BIOCHIM BIOPHYS ACTA, V566, P283, DOI 10.1016/0005-2744(79)90032-9; Vyssokikh MY, 2002, MOL BIOL REP, V29, P93, DOI 10.1023/A:1020383108620; WEILMALHERBE H, 1951, BIOCHEM J, V49, P339, DOI 10.1042/bj0490339; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WILSON JE, 1973, ARCH BIOCHEM BIOPHYS, V159, P543, DOI 10.1016/0003-9861(73)90486-4; WILSON JE, 1977, MOL CELL BIOCHEM, V18, P39, DOI 10.1007/BF00215278; XIE GC, 1990, ARCH BIOCHEM BIOPHYS, V276, P285, DOI 10.1016/0003-9861(90)90040-6; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509	55	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38403	38409		10.1074/jbc.M506943200	http://dx.doi.org/10.1074/jbc.M506943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166083	hybrid			2022-12-25	WOS:000233239800036
J	Fujita, K; Oura, F; Nagamine, N; Katayama, T; Hiratake, J; Sakata, K; Kumagai, H; Yamamoto, K				Fujita, K; Oura, F; Nagamine, N; Katayama, T; Hiratake, J; Sakata, K; Kumagai, H; Yamamoto, K			Identification and molecular cloning of a novel glycoside hydrolase family of core 1 type O-glycan-specific endo-alpha-N-acetylgalactosaminidase from Bifidobacterium longum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINIDASE; DIPLOCOCCUS-PNEUMONIAE; PARTIAL-PURIFICATION; TRANSGLYCOSYLATION ACTIVITY; MUCIN DEGRADATION; CULTURE-MEDIUM; OLIGOSACCHARIDES; GLYCOSYLATION; PHOSPHORYLASE; ANTIGENS	We found endo-alpha-N-acetylgalactosaminidase in most bifidobacterial strains, which are predominant bacteria in the human colon. This enzyme catalyzes the liberation of galactosyl beta 1,3-N-acetyl-D-galactosamine (Gal beta 1,3GalNAc) alpha-linked to serine or threonine residues from mucin-type glycoproteins. The gene (engBF) encoding the enzyme has been cloned from Bifidobacterium longum JCM 1217. The protein consisted of 1,966 amino acid residues, and the central domain ( 590 - 1381 amino acid residues) exhibited 31 - 53% identity to hypothetical proteins of several bacteria including Clostridium perfringens and Streptococcus pneumoniae. The recombinant protein expressed in Escherichia coli liberated Gal beta 1,3GalNAc disaccharide from Gal beta 1,3GalNAc alpha 1pNP and asialofetuin, but did not release GalNAc, Gal beta 1,3(GlcNAc beta 1,6) GalNAc, GlcNAc beta 1,3GalNAc, and Gal beta 1,3GlcNAc from each p-nitrophenyl (pNP) substrate, and also did not release sialo-oligosaccharides from fetuin, indicating its strict substrate specificity for the Core 1-type structure. The stereochemical course of hydrolysis was determined by H-1 NMR and was found to be retention. Site-directed mutagenesis of a total of 22 conserved Asp and Glu residues suggested that Asp-682 and Asp-789 are critical residues for the catalytic activity of the enzyme. The enzyme also exhibited transglycosylation activity toward various mono- and disaccharides and 1-alkanols, demonstrating its potential to synthesize neoglycoconjugates. This is the first report for the isolation of a gene encoding endo-alpha-N-acetylgalactosaminidase from any organisms and for the establishment of a new glycoside hydrolase family (GH family 101).	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; Ishikawa Prefectural Univ, Res Inst Bioresources & Biotechnol, Nonoichi, Ishikawa 9218836, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol Program, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Ishikawa Prefecture University; Kyoto University; Japan Science & Technology Agency (JST)	Fujita, K (corresponding author), Kagoshima Univ, Fac Agr, Dept Biochem Sci & Technol, Korimoto 1-21-24, Kagoshima 8900065, Japan.	kfujita@lif.kyoto.u.ac.jp		Fujita, Kiyotaka/0000-0002-3780-3750; Katayama, Takane/0000-0003-4009-7874				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashida H, 2000, ARCH BIOCHEM BIOPHYS, V373, P394, DOI 10.1006/abbi.1999.1565; Ashida H, 2001, CARBOHYD RES, V330, P487, DOI 10.1016/S0008-6215(01)00008-8; BAILEY RW, 1960, J CHROMATOGR, V4, P206, DOI 10.1016/S0021-9673(01)98394-3; BERNET MF, 1993, APPL ENVIRON MICROB, V59, P4121, DOI 10.1128/AEM.59.12.4121-4128.1993; BHAVANANDAN VP, 1976, BIOCHEM BIOPH RES CO, V70, P738, DOI 10.1016/0006-291X(76)90654-9; Brooks MM, 1997, GLYCOCONJUGATE J, V14, P183, DOI 10.1023/A:1018585604073; CARTRON JP, 1979, NATURE, V282, P621, DOI 10.1038/282621a0; Derensy-Dron D, 1999, BIOTECHNOL APPL BIOC, V29, P3; ENDO Y, 1976, J BIOCHEM-TOKYO, V80, P1; FAN JQ, 1988, AGR BIOL CHEM TOKYO, V52, P1715; Femia AP, 2002, CARCINOGENESIS, V23, P1953, DOI 10.1093/carcin/23.11.1953; GIBSON GR, 1994, J APPL BACTERIOL, V77, P412, DOI 10.1111/j.1365-2672.1994.tb03443.x; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GROSS V, 1989, FEBS LETT, V247, P323, DOI 10.1016/0014-5793(89)81361-4; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; HOSKINS LC, 1985, J CLIN INVEST, V75, P944, DOI 10.1172/JCI111795; HUANG CC, 1972, J BIOL CHEM, V247, P6737; IshiiKarakasa I, 1997, EUR J BIOCHEM, V247, P709, DOI 10.1111/j.1432-1033.1997.00709.x; ISHIIKARAKASA I, 1992, BIOCHEM J, V288, P475, DOI 10.1042/bj2880475; Katayama T, 2004, J BACTERIOL, V186, P4885, DOI 10.1128/JB.186.15.4885-4893.2004; Kitaoka M, 2005, APPL ENVIRON MICROB, V71, P3158, DOI 10.1128/AEM.71.6.3158-3162.2005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON G, 1988, J BIOL CHEM, V263, P10790; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; NAIM HY, 1992, J BIOL CHEM, V267, P25494; Novak J, 2001, J CLIN IMMUNOL, V21, P310, DOI 10.1023/A:1012284402054; Ouwehand A., 2002, European Journal of Nutrition, V41; Sambrook J., 1983, MOL CLONING LAB MANU; Schell MA, 2002, P NATL ACAD SCI USA, V99, P14422, DOI 10.1073/pnas.212527599; Sediva A, 1999, NEPHROL DIAL TRANSPL, V14, P2885, DOI 10.1093/ndt/14.12.2885; SIMON GL, 1986, DIG DIS SCI S, V31, P147; SPRINGER GF, 1995, CANCER DETECT PREV, V19, P173; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; Varki A., 1999, ESSENTIALS GLYCOBIOL	36	120	127	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37415	37422		10.1074/jbc.M506874200	http://dx.doi.org/10.1074/jbc.M506874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141207	hybrid			2022-12-25	WOS:000233044500016
J	Iguchi, H; Ikeda, Y; Okamura, M; Tanaka, T; Urashima, Y; Ohguchi, H; Takayasu, S; Kojima, N; Iwasaki, S; Ohashi, R; Jiang, SY; Hasegawa, G; Ioca, RX; Magoori, K; Sumi, K; Maejima, T; Uchida, A; Naito, M; Osborne, TF; Yanagisawa, M; Yamamoto, TT; Kodama, T; Sakai, J				Iguchi, H; Ikeda, Y; Okamura, M; Tanaka, T; Urashima, Y; Ohguchi, H; Takayasu, S; Kojima, N; Iwasaki, S; Ohashi, R; Jiang, SY; Hasegawa, G; Ioca, RX; Magoori, K; Sumi, K; Maejima, T; Uchida, A; Naito, M; Osborne, TF; Yanagisawa, M; Yamamoto, TT; Kodama, T; Sakai, J			SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional actvity and is down-regulated in hyperinsulinemic obese mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; GENE-TRANSCRIPTION; IDENTIFICATION; EXPRESSION; ACTIVATION; CELLS; METABOLISM; REQUIRES; CLEAVAGE; SREBPS	In obesity-related insulin resistance, pancreatic islets compensate for insulin resistance by increasing secretory capacity. Here, we report the identification of sex-determining region Y-box 6 (SOX6), a member of the high mobility group box superfamily of transcription factors, as a co-repressor for pancreatic-duodenal homeobox factor-1 (PDX1). SOX6 mRNA levels were profoundly reduced by both a long term high fat feeding protocol in normal mice and in genetically obese ob/ob mice on a normal chow diet. Interestingly, we show that SOX6 is expressed in adult pancreatic insulin-producing beta-cells and that overexpression of SOX6 decreased glucose-stimulated insulin secretion, which was accompanied by decreased ATP/ADP ratio, Ca2+ mobilization, proinsulin content, and insulin gene expression. In a complementary fashion, depletion of SOX6 by small interfering RNAs augmented glucose-stimulated insulin secretion in insulinoma mouse MIN6 and rat INS-1E cells. These effects can be explained by our mechanistic studies that show SOX6 acts to suppress PDX1 stimulation of the insulin II promoter through a direct protein/protein interaction. Furthermore, SOX6 retroviral expression decreased acetylation of histones H3 and H4 in chromatin from the promoter for the insulin II gene, suggesting that SOX6 may decrease PDX1 stimulation through changes in chromatin structure at specific promoters. These results suggest that perturbations in transcriptional regulation that are coordinated through SOX6 and PDX1 in beta-cells may contribute to the beta-cell adaptation in obesity-related insulin resistance.	Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan; Japan Sci & Technol Agcy, Yanagisawa Orphan Receptor Project, Tokyo 1350064, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Cellular Funct, Div Cellular & Mol Pathol, Niigata 9518510, Japan; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA; Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Tohoku Univ, Inst Dev Aging & Canc, Ctr Adv Genome Res, Sendai, Miyagi 9818555, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Niigata University; University of California System; University of California Irvine; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tohoku University	Sakai, J (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan.	jmsakai-tky@umin.ac.jp	Ohashi, Riuko/AAH-1415-2019	Ohashi, Riuko/0000-0001-5820-7870; Sakai, Juro/0000-0003-4043-1035				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dutta S, 2001, P NATL ACAD SCI USA, V98, P1065, DOI 10.1073/pnas.031561298; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hui HX, 2002, EUR J ENDOCRINOL, V146, P129, DOI 10.1530/eje.0.1460129; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; Ikeda Y, 2005, BIOCHEM BIOPH RES CO, V333, P778, DOI 10.1016/j.bbrc.2005.06.005; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; Kasimiotis H, 2000, DIABETES, V49, P555, DOI 10.2337/diabetes.49.4.555; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kulkarni RN, 2004, J CLIN INVEST, V114, P828, DOI 10.1172/JCI200421845; Laybutt DR, 2003, J BIOL CHEM, V278, P2997, DOI 10.1074/jbc.M210581200; Le Lay J, 2004, J BIOL CHEM, V279, P22228, DOI 10.1074/jbc.M312673200; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mosley AL, 2004, J BIOL CHEM, V279, P54241, DOI 10.1074/jbc.M410379200; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; Okita K, 1999, BIOCHEM BIOPH RES CO, V263, P566, DOI 10.1006/bbrc.1999.1412; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 2000, MOL ENDOCRINOL, V14, P1907, DOI 10.1210/me.14.12.1907; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200	53	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37669	37680		10.1074/jbc.M505392200	http://dx.doi.org/10.1074/jbc.M505392200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148004	hybrid			2022-12-25	WOS:000233044500044
J	Li, ZY; Agellon, LB; Vance, DE				Li, ZY; Agellon, LB; Vance, DE			Phosphatidylcholine homeostasis and liver failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; RAT HEPATOCYTES; ESSENTIAL NUTRIENT; CDP-CHOLINE; BIOSYNTHESIS; N-METHYLTRANSFERASE-2; PURIFICATION; METHYLATION; DISRUPTION; EXPRESSION	In mammals, the only endogenous pathway for choline biosynthesis is the methylation of phosphatidylethanolamine to phosphatidylcholine ( PC) by phosphatidylethanolamine N-methyltransferase ( PEMT) coupled to PC degradation. Complete choline deprivation in mice by feeding Pemt(-/-) mice a choline-deficient ( CD) diet decreases hepatic PC by 50% and is lethal within 5 days. PC secretion into bile is mediated by a PC-specific flippase, multiple drug-resistant protein 2 (MDR2). Here, we report that mice that lack both PEMT and MDR2 and are fed a CD diet survive for > 90 days. Unexpectedly, the amount of PC also decreases by 50% in the livers of Mdr2(-/-)/ Pemt(-/-) mice. The Mdr2(-/-)/ Pemt(-/-) mice adapt to the severe choline deprivation via choline recycling by induction of phospholipase A(2), choline kinase, and CTP: phosphocholine cytidylyltransferase activities and by a strikingly decreased expression of choline oxidase. The ability of Mdr2(-/-)/ Pemt(-/-) mice to survive complete choline deprivation suggests that acute lethality in CD-Pemt(-/-) mice results from rapid depletion of hepatic PC via biliary secretion.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Li, ZY (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Li, Zhaoyu/0000-0002-1136-2758				Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; Adibhatla R, 2005, NEUROCHEM RES, V30, P15, DOI 10.1007/s11064-004-9681-8; BEST CH, 1954, ANN NY ACAD SCI, V57, P646, DOI 10.1111/j.1749-6632.1954.tb36441.x; Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Borgstrom B., 1976, LIPID ABSORPTION BIO, P65; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; DATKO AH, 1988, PLANT PHYSIOL, V88, P854, DOI 10.1104/pp.88.3.854; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; Fioravanti M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000269.pub3; HISE MK, 1983, ANAL BIOCHEM, V135, P78, DOI 10.1016/0003-2697(83)90733-9; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KO KWS, 1986, J BIOL CHEM, V261, P7846; Krug E L, 1981, Methods Enzymol, V72, P347; Kuipers F, 1997, Subcell Biochem, V28, P295; MCCLUER RH, 1986, ADV CHROMATOGR, V25, P309; PELECH SL, 1981, J BIOL CHEM, V256, P8283; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; ROBINS SJ, 1975, AM J PHYSIOL, V229, P598, DOI 10.1152/ajplegacy.1975.229.3.598; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; WAITE M, 1990, ADV EXP MED BIOL, V279, P1; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Zeisel SH, 2000, NUTRITION, V16, P669, DOI 10.1016/S0899-9007(00)00349-X; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	37	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37798	37802		10.1074/jbc.M508575200	http://dx.doi.org/10.1074/jbc.M508575200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144842	hybrid			2022-12-25	WOS:000233044500059
J	Marjanovic, JA; Li, ZY; Stojanovic, A; Du, XP				Marjanovic, JA; Li, ZY; Stojanovic, A; Du, XP			Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-GMP; GUANOSINE 3',5'-MONOPHOSPHATE; INTEGRIN ALPHA(IIB)BETA(3); SODIUM-NITROPRUSSIDE; ENDOTHELIAL-CELLS; L-ARGININE; AGGREGATION; INHIBITION; MICE	Nitric oxide ( NO) stimulates soluble guanylyl cyclase and, thus, enhances cyclic guanosine monophosphate ( cGMP) levels. It is a currently prevailing concept that NO inhibits platelet activation. This concept, however, does not fully explain why platelet agonists stimulate NO production. Here we show that a major platelet NO synthase ( NOS) isoform, NOS3, plays a stimulatory role in platelet secretion and aggregation induced by low doses of platelet agonists. Furthermore, we show that NOS3 promotes thrombosis in vivo. The stimulatory role of NOS is mediated by soluble guanylyl cyclase and results from a cGMP-dependent stimulation of platelet granule secretion. These findings delineate a novel signaling pathway in which agonists sequentially activate NOS3, elevate cGMP, and induce platelet secretion and aggregation. Our data also suggest that NO plays a biphasic role in platelet activation, a stimulatory role at low NO concentrations and an inhibitory role at high NO concentrations.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Du, XP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,Rm E403, Chicago, IL 60612 USA.	xdu@uic.edu			NHLBI NIH HHS [R01 HL068819, HL68819, R01 HL062350, HL62350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068819, R01HL062350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONIADES HN, 1979, P NATL ACAD SCI USA, V76, P1809, DOI 10.1073/pnas.76.4.1809; Azula FJ, 1996, MOL PHARMACOL, V50, P367; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Day SM, 2004, THROMB HAEMOSTASIS, V92, P486, DOI 10.1055/s-0037-1613739; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Du X, 1997, THROMB HAEMOSTASIS, V78, P96; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; FUSTER V, 1999, LANCET S2, V353, P5; HAWRYLOWICZ CM, 1989, J IMMUNOL, V143, P4015; IGNARRO LJ, 1993, THROMB HAEMOSTASIS, V70, P148; Jang EK, 2002, BRIT J HAEMATOL, V117, P664, DOI 10.1046/j.1365-2141.2002.03479.x; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Li ZY, 2004, J BIOL CHEM, V279, P42469, DOI 10.1074/jbc.M401532200; Li ZY, 2003, J BIOL CHEM, V278, P30725, DOI 10.1074/jbc.M301838200; Li ZY, 2003, BLOOD, V101, P4423, DOI 10.1182/blood-2002-10-3210; Li ZY, 2003, CELL, V112, P77, DOI 10.1016/S0092-8674(02)01254-0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914; Marshall SJ, 2004, BLOOD, V103, P2601, DOI 10.1182/blood-2003-09-3319; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; MAURICE DH, 1990, MOL PHARMACOL, V37, P671; McDonald LJ, 1996, P SOC EXP BIOL MED, V211, P1; MELLION BT, 1981, BLOOD, V57, P946; MELLION BT, 1983, MOL PHARMACOL, V23, P653; Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; Randriamboavonjy V, 2004, J EXP MED, V199, P347, DOI 10.1084/jem.20030694; Reed GL, 2000, BLOOD, V96, P3334; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SASE K, 1995, LIFE SCI, V57, P2049, DOI 10.1016/0024-3205(95)02191-K; SAXON A, 1976, BLOOD, V47, P957; Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shi WB, 2002, CIRCULATION, V105, P2078, DOI 10.1161/01.CIR.0000015853.59427.32; SOMERVILLE B, 1975, CLIN CHIM ACTA, V65, P399, DOI 10.1016/0009-8981(75)90267-3; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	47	64	69	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37430	37438		10.1074/jbc.M506518200	http://dx.doi.org/10.1074/jbc.M506518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144836	hybrid			2022-12-25	WOS:000233044500018
J	Okamoto, K; Isohashi, F				Okamoto, K; Isohashi, F			Macromolecular translocation inhibitor II (Zn2+-binding protein, parathymosin) interacts with the glucocorticoid receptor and enhances transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHYMOSIN-ALPHA BINDS; NUCLEAR ANTIGEN 3C; HISTONE H1; RAT-LIVER; MESSENGER-RNA; C-MYC; PURIFICATION; CHROMATIN; LOCALIZATION; COACTIVATOR	Macromolecular translocation inhibitor II (MTI-II), which was first identified as an in vitro inhibitor of binding between the highly purified glucocorticoid receptor (GR) and isolated nuclei, is an 11.5-kDa Zn2+-binding protein that is also known as ZnBP or parathymosin. MTI-II is a small nuclear acidic protein that is highly conserved in rats, cows, and humans and widely distributed in mammalian tissues, yet its physiological function is unknown. To elucidate its in vivo function in relation to GR, we transiently transfected mammalian cells with an expression plasmid encoding MTI-II. Unexpectedly, we found that the expression of MTI-II enhances the transcriptional activity of GR. The magnitude of the transcriptional enhancement induced by MTI-II is comparable with that induced by the steroid receptor coactivator SRC-1. In contrast, MTI-II had little effect on the transcriptional activity of estrogen receptor. Immunoprecipitation analysis showed that in the presence of glucocorticoid hormone, GR coprecipitates with MTI-II, and, vice versa, MTI-II coprecipitates with GR. The expression of various deletion mutants of MTI-II revealed that the central acidic domain is essential for the enhancement of GR-dependent transcription. Microscopic analysis of MTI-II fused to green fluorescent protein and GR fused to red fluorescent protein in living HeLa cells showed that MTI-II colocalizes with GR in discrete subnuclear domains in a hormone-dependent manner. Coexpression of MTI-II with the coactivator SRC-1 or p300 further enhances GR-dependent transcription. Immunoprecipitation analysis showed that in the presence of glucocorticoid hormone, p300 and CREB-binding protein are coprecipitated with MTI-II. Furthermore, the knockdown of endogenous MTI-II by RNAi reduces the transcriptional activity of GR in cells. Moreover, expression of MTI-II enhances the glucocorticoid-dependent transcription of the endogenous glucocorticoid-inducible enzyme in cells. Taken together, these results indicate that MTI-II enhances GR-dependent transcription via a direct interaction with GR in vivo. Thus, MTI-II is a new member of the GR-coactivator complex.	St Marianna Univ, Sch Med, Dept Biochem, Miyamae Ku, Kanagawa 2168511, Japan	Saint Marianna University	Okamoto, K (corresponding author), St Marianna Univ, Sch Med, Dept Biochem, Miyamae Ku, Sugao 2-16-1, Kanagawa 2168511, Japan.	k2oka@marianna-u.ac.jp						Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BRAND IA, 1986, J BIOL CHEM, V261, P5892; BRAND IA, 1991, EUR J CELL BIOL, V54, P157; BRAND IA, 1991, J BIOL CHEM, V266, P20984; Castro JM, 1996, BIOCHEM BIOPH RES CO, V224, P140, DOI 10.1006/bbrc.1996.0997; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1989, BIOCHEM BIOPH RES CO, V158, P855, DOI 10.1016/0006-291X(89)92801-5; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Dion V, 2003, J BIOL CHEM, V278, P11495, DOI 10.1074/jbc.M211938200; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P1050, DOI 10.1073/pnas.82.4.1050; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; Hyodo M, 2001, J CHROMATOGR B, V765, P89, DOI 10.1016/S0378-4347(01)00408-X; ISOHASHI F, 1984, J STEROID BIOCHEM, V20, P1117; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Knight JS, 2003, J VIROL, V77, P4261, DOI 10.1128/JVI.77.7.4261-4272.2003; KOMIYAMA T, 1986, P NATL ACAD SCI USA, V83, P1242, DOI 10.1073/pnas.83.5.1242; Kondili K, 1996, EUR J BIOCHEM, V242, P67, DOI 10.1111/j.1432-1033.1996.0067r.x; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Martic G, 2005, J BIOL CHEM, V280, P16143, DOI 10.1074/jbc.M410175200; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Molenda HA, 2003, BIOL REPROD, V69, P1449, DOI 10.1095/biolreprod.103.019364; OKAMOTO K, 1983, ENDOCRINOLOGY, V112, P336, DOI 10.1210/endo-112-1-336; Okamoto K, 2003, J CHROMATOGR B, V790, P349, DOI 10.1016/S1570-0232(03)00166-1; Okamoto K, 1996, J BIOCHEM, V119, P920; OKAMOTO K, 1982, BIOCHEM BIOPH RES CO, V108, P1655, DOI 10.1016/S0006-291X(82)80100-9; Okamoto K, 2000, EUR J BIOCHEM, V267, P155, DOI 10.1046/j.1432-1327.2000.00987.x; Orre RS, 2001, J BIOL CHEM, V276, P1794, DOI 10.1074/jbc.M008560200; PANNEERSELVAM C, 1987, IMMUNOL METHODS, V104, P131; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Pineiro A, 2000, PEPTIDES, V21, P1433, DOI 10.1016/S0196-9781(00)00288-6; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; Subramanian C, 2002, J VIROL, V76, P4699, DOI 10.1128/JVI.76.10.4699-4708.2002; Trompeter HI, 1996, J BIOL CHEM, V271, P1187, DOI 10.1074/jbc.271.2.1187; TROMPETER HI, 1989, FEBS LETT, V253, P63, DOI 10.1016/0014-5793(89)80930-5; Trompeter HI, 1999, J CELL SCI, V112, P4113; VARELI K, 1995, FEBS LETT, V371, P337, DOI 10.1016/0014-5793(95)00938-6; Vareli K, 2000, EXP CELL RES, V257, P152, DOI 10.1006/excr.2000.4857; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WATTS JD, 1990, EUR J BIOCHEM, V192, P643, DOI 10.1111/j.1432-1033.1990.tb19271.x; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116	52	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36986	36993		10.1074/jbc.M506056200	http://dx.doi.org/10.1074/jbc.M506056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16150697	hybrid			2022-12-25	WOS:000232901800056
J	Rimessi, A; Coletto, L; Pinton, P; Rizzuto, R; Brini, M; Carafoli, E				Rimessi, A; Coletto, L; Pinton, P; Rizzuto, R; Brini, M; Carafoli, E			Inhibitory interaction of the 14-3-3 epsilon protein with isoform 4 of the plasma membrane Ca2+-ATPase pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ ATPASE; CALCIUM-PUMP; 4B; PURIFICATION; CALMODULIN; EXPRESSION; PEPTIDE; BINDS; 2B	The isoform-specific interaction of plasma membrane Ca2+-ATPase (PMCA) pumps with partner proteins has been explored using a yeast two-hybrid technique. The 90 N-terminal residues of two pump isoforms (PMCA2 and PMCA4), which have a low degree of sequence homology, have been used as baits. Screening of 5x10(6) clones of a human brain cDNA library yielded similar to 100 LEU2- and galactoside-positive clones for both pumps. A clone obtained with the PMCA4 bait specified the epsilon-isoform of the 14-3-3 protein, whereas no 14-3-3 epsilon clone was obtained with the PMCA2 bait. The 14-3-3 epsilon protein immunoprecipitated with PMCA4 (not with PMCA2) when expressed in HeLa cells. Overexpression of 14-3-3 epsilon in HeLa cells together with targeted aequorins showed that the ability of the cells to export Ca2+ was impaired; stimulation with histamine, an inositol 1,4,5-trisphosphate-producing agonist, generated higher cytosolic [Ca2+] transients, higher post-transient plateaus of the cytosolic [Ca2+], and higher Ca2+ levels in the endoplasmic reticulum lumen and in the subplasmalemmal domain. Thus, the interaction with 14-3-3 epsilon inhibited PMCA4. Silencing of the 14-3-3 epsilon gene by RNA interference significantly reduced the expression of 14-3-3 epsilon, substantially decreasing the height of the histamine-induced cytosolic [Ca2+] transient and of the post-transient cytosolic [Ca2+] plateau.	Univ Ferrara, Dept Expt & Diagnost Med, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Ferrara; Veneto Institute Molecular Medicine; University of Padua	Rizzuto, R (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Interdisciplinary Ctr Study Inflammat, Via Borsari 46, I-44100 Ferrara, Italy.	rzr@unife.it; ernesto.carafoli@unipd.it	Carafoli, Ernesto/K-5192-2016; Rizzuto, Rosario/B-6312-2008; Pinton, Paolo/J-8025-2012; Rimessi, Alessandro/K-5420-2016; Brini, Marisa/K-5189-2016; rimessi, alessandro/O-3335-2019	Carafoli, Ernesto/0000-0002-7826-0094; Pinton, Paolo/0000-0001-7108-6508; Rimessi, Alessandro/0000-0001-7091-5765; rimessi, alessandro/0000-0001-7091-5765; Rizzuto, Rosario/0000-0001-7044-5097; Brini, Marisa/0000-0001-5141-0243	Telethon [1285, GGP04169] Funding Source: Medline	Telethon(Fondazione Telethon)		Armesilla AL, 2004, J BIOL CHEM, V279, P31318, DOI 10.1074/jbc.M307557200; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 2003, J BIOL CHEM, V278, P24500, DOI 10.1074/jbc.M300784200; Buch MH, 2005, J BIOL CHEM, V280, P29479, DOI 10.1074/jbc.M501326200; Cardoso C, 2003, AM J HUM GENET, V72, P918, DOI 10.1086/374320; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; Guerini D, 2003, J BIOL CHEM, V278, P38141, DOI 10.1074/jbc.M302400200; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WANG KKW, 1991, J BIOL CHEM, V266, P9078	27	60	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37195	37203		10.1074/jbc.M504921200	http://dx.doi.org/10.1074/jbc.M504921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16126729	hybrid			2022-12-25	WOS:000232901800078
J	Das, A; Hazra, TK; Boldogh, I; Mitra, S; Bhakat, KK				Das, A; Hazra, TK; Boldogh, I; Mitra, S; Bhakat, KK			Induction of the human oxidized base-specific DNA glycosylase NEIL1 by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-III; OXIDATIVELY DAMAGED DNA; EXCISION-REPAIR; MAMMALIAN-CELLS; APURINIC/APYRIMIDINIC ENDONUCLEASE; TRANSCRIPTIONAL REGULATION; NTH1 GENE; STRESS; PROTEIN; LESIONS	NEIL1, a mammalian DNA glycosylase and ortholog of Escherichia coli Nei/Fpg, is involved in the repair of oxidatively damaged bases in mammalian cells. Exposure of HCT116 human colon carcinoma cells to reactive oxygen species, generated by glucose oxidase (GO), enhanced the levels of NEIL1 mRNA and polypeptide by 2-4-fold by 6 h after GO treatment. A similar oxidative stress-induced increase in human NEIL1 (hNEIL1) promoter-dependent luciferase expression in HCT116 cells indicates that reactive oxygen species activates NEIL1 transcription. The transcriptional start site of hNEIL1 was mapped, and the upstream promoter sequence was characterized via luciferase reporter assay. Two identical CRE/AP-1-binding sites were identified in the promoter that binds transcription factors c-Jun and CREB/ATF2. This binding was significantly enhanced in extracts of cells treated with GO. Furthermore, a simultaneous increase in the level of phosphorylated c-Jun suggests its involvement in up-regulating the NEIL1 promoter. Oxidative stress-induced activation of NEIL1 appears to be involved in the feedback regulation of cellular repair activity needed to handle an increase in the level of oxidative base damage.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-136 Med Res Bldg,Rte 1079, Galveston, TX 77555 USA.	samitra@utmb.edu	Classen, Scott/AAY-8176-2020; Bhakat, Kishor/C-8072-2012		NCI NIH HHS [P01 CA92584, R01 CA81063] Funding Source: Medline; NIA NIH HHS [P01 AG021830] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, ES06676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584, R01CA081063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021830] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Boldogh I, 1998, CANCER RES, V58, P3950; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Elder RH, 2002, J BIOL CHEM, V277, P50487, DOI 10.1074/jbc.M208153200; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; Grosch S, 1999, BIOCHEM BIOPH RES CO, V261, P859, DOI 10.1006/bbrc.1999.1125; Grosch S, 1998, CANCER RES, V58, P4410; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hailer MK, 2005, DNA REPAIR, V4, P41, DOI 10.1016/j.dnarep.2004.07.006; Hazra TK, 2003, CARCINOGENESIS, V24, P155, DOI 10.1093/carcin/24.2.155; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; He F, 2003, BIOL CHEM, V384, P19, DOI 10.1515/BC.2003.003; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katafuchi A, 2004, J BIOL CHEM, V279, P14464, DOI 10.1074/jbc.M400393200; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Lee MR, 2004, J BIOL CHEM, V279, P9857, DOI 10.1074/jbc.M311132200; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; NADA S, 1993, J BIOL CHEM, V268, P7660; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Ribardo DA, 2002, MICROB PATHOGENESIS, V32, P149, DOI 10.1006/mpat.2001.0490; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	40	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35272	35280		10.1074/jbc.M505526200	http://dx.doi.org/10.1074/jbc.M505526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118226	hybrid			2022-12-25	WOS:000232561200025
J	Imam, SZ; Jankovic, J; Ali, SF; Skinner, JT; Xie, WJ; Conneely, OM; Lee, WD				Imam, SZ; Jankovic, J; Ali, SF; Skinner, JT; Xie, WJ; Conneely, OM; Lee, WD			Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice	FASEB JOURNAL			English	Article						nitric oxide; dopamine; 3-NT; caspase; transcription; apoptosis	ORPHAN NUCLEAR RECEPTOR; ALPHA-SYNUCLEIN; EXPRESSION INCREASES; METHAMPHETAMINE; APOPTOSIS; DEATH; GENE; OVEREXPRESSION; PEROXYNITRITE; NEUROTOXICITY	Knocking out of Nurr1 gene, a member of nuclear receptor superfamily, causes selective agenesis of dopaminergic neurons in midbrain. Reduced expression of Nurr1 increases the vulnerability of mesencephalic dopamine neurons to dopaminergic toxins. We evaluated the role of nitric oxide as a possible mechanism for this increased susceptibility. Increased expression of neuronal nitric oxide synthase and increased 3-nitrotyrosine were observed in striatum of Nurr1 heterozygous (Nurr1 +/-) mice as compared with wild-type. Increased cytochrome C activation and consecutive release of Smac/DIABLO were also observed in Nurr1 +/- mice. An induction of active Caspase-3 and p53, cleavage of poly-ADP (RNase) polymerase and reduced expression of bcl-2 were observed in Nurr1 +/- mice. Methamphetamine significantly increased these markers in Nurr1 +/- mice as compared with wild-type. The present data therefore suggest that nitric oxide plays a role as a modulating factor for the increased susceptibility, but not the potentiation, of the dopaminergic terminals in Nurr1 +/- mice. We also report that this increased neuronal nitric oxide synthase expression and increased nitration in Nurr1 +/- mice led to the activation of apoptotic cascade via the differential alterations in the DNA binding activity of transcription factors responsible for the propagation of growth arrest as well as apoptosis.	Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; S Texas Vet Hlth Care Syst, San Antonio, TX USA; UT Hlth Sci, Dept Med, San Antonio, TX USA; US FDA, Neurochem Lab, Div Neurotoxicol, NCTR, Jefferson, AR USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; US Food & Drug Administration (FDA); Baylor College of Medicine	Lee, WD (corresponding author), Baylor Coll Med, Dept Neurol, NB 205,6501 Fannin St, Houston, TX 77030 USA.	simam@satx.rr.com; Weidongl@bcm.tmc.edu			NINDS NIH HHS [NS40370, NS043567] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040370, R01NS043567] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Backman C, 2003, BEHAV BRAIN RES, V143, P95, DOI 10.1016/S0166-4328(03)00029-9; Bannon MJ, 2002, P NATL ACAD SCI USA, V99, P6382, DOI 10.1073/pnas.092654299; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Catania MV, 1999, NEUROSCIENCE, V91, P1529, DOI 10.1016/S0306-4522(98)00544-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen W, 2002, CHINESE MED J-PEKING, V115, P446; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; Deng XL, 1999, BRAIN RES, V851, P254, DOI 10.1016/S0006-8993(99)02087-9; Deshmukh M, 1998, APOPTOSIS, V3, P387, DOI 10.1023/A:1009602401251; Elliott MJ, 2002, TUMOR BIOL, V23, P76, DOI 10.1159/000059708; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Greco C, 2001, ANTICANCER RES, V21, P3185; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hirata H, 1997, J NEUROCHEM, V69, P780; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Imam SZ, 2002, ANN NY ACAD SCI, V965, P204; Imam SZ, 2001, ANN NY ACAD SCI, V939, P366; Imam SZ, 2001, MOL BRAIN RES, V91, P174, DOI 10.1016/S0169-328X(01)00139-5; Imam SZ, 2001, J NEUROCHEM, V76, P745, DOI 10.1046/j.1471-4159.2001.00029.x; Itzhak Y, 1998, J PHARMACOL EXP THER, V284, P1040; Jayanthi S, 2005, P NATL ACAD SCI USA, V102, P868, DOI 10.1073/pnas.0404990102; Jiang CT, 2005, EXP NEUROL, V191, P154, DOI 10.1016/j.expneurol.2004.08.035; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Le W, 1999, J NEUROCHEM, V73, P2218; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MAGES HW, 1994, MOL ENDOCRINOL, V8, P1583, DOI 10.1210/me.8.11.1583; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Ojeda V, 2003, J NEUROSCI RES, V73, P686, DOI 10.1002/jnr.10705; Okano H, 2002, ANTI-CANCER DRUG, V13, P59, DOI 10.1097/00001813-200201000-00007; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perlmann T, 2004, CELL TISSUE RES, V318, P45, DOI 10.1007/s00441-004-0974-7; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445; Sugars KL, 2001, NUCLEIC ACIDS RES, V29, P4530, DOI 10.1093/nar/29.22.4530; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Yang YL, 2002, J BIOL CHEM, V277, P19482, DOI 10.1074/jbc.M201687200; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	48	24	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1441	1450		10.1096/fj.04-3362com	http://dx.doi.org/10.1096/fj.04-3362com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126911				2022-12-25	WOS:000232315700037
J	Park, HU; Jeong, SJ; Jeong, JH; Chung, JH; Brady, JN				Park, HU; Jeong, SJ; Jeong, JH; Chung, JH; Brady, JN			Human T-cell leukemia virus type 1 Tax attenuates gamma-irradiation-induced apoptosis through physical interaction with Chk2	ONCOGENE			English	Article						HTLV-1 Tax; Chk2; interaction; attenuation; apoptosis	NF-KAPPA-B; DNA-DAMAGE; CHECKPOINT KINASE; P53-MEDIATED TRANSACTIVATION; PHASE PROGRESSION; TUMOR-SUPPRESSOR; P53 INACTIVATION; GENE-EXPRESSION; PROTEIN; LYMPHOCYTES	Checkpoint kinase 2 (Chk2) is known to mediate diverse cellular responses to genotoxic stress. The fundamental role of Chk2 is to regulate the network of genomesurveillance pathways that coordinate cell-cycle progression withDN A repair and cell survival or death. Defects in Chk2 contribute to the development of both hereditary and sporadic human cancers. We now present evidence that the human T-cell leukemia virus type-1 (HTLV-1) Tax protein directly interacts with Chk2 and the kinase activity of Chk2 is inhibited by Tax. The physical interaction of Chk2 and Tax was observed by co-immunoprecipitation assays in HTLV-1-infected T cells (C81) as well as GST pull-down assays using purified proteins. Binding and kinase activity inhibition studies with Tax deletion mutants indicated that at least two domains of Tax mediate the interaction with Chk2. We have analysed the functional consequence of de novo expression of Tax upon the cellular DNA-damage-induced apoptosis, which is mediated by Chk2. Using transient transfection and TUNEL assay, we found that cirradiation-induced apoptosis was decreased in 293T and HCT-116 (p53 (-/-)) cells expressing HTLV-1 Tax. Our studies demonstrate an important potential target of Tax in cellular transformation.	NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bldg 41-B201,41 Medlars Dr,9000 Rockville Pike, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005691, ZIABC005691] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002243, ZIAHL002243] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; COOGAN TP, 1992, TOXICOL APPL PHARM, V113, P227, DOI 10.1016/0041-008X(92)90118-C; COOGAN TP, 1994, J TOXICOL ENV HEALTH, V41, P233, DOI 10.1080/15287399409531839; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Matsuda T, 2005, J VIROL, V79, P1367, DOI 10.1128/JVI.79.3.1367-1378.2005; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; SEGAWA K, 1993, ONCOGENE, V8, P543; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Sieburg M, 2004, J VIROL, V78, P10399, DOI 10.1128/JVI.78.19.10399-10409.2004; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	59	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					438	447		10.1038/sj.onc.1209059	http://dx.doi.org/10.1038/sj.onc.1209059			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158050				2022-12-25	WOS:000234714100012
J	Piu, F; Gauthier, NK; Wang, F				Piu, F; Gauthier, NK; Wang, F			beta-arrestin 2 modulates the activity of nuclear receptor RAR beta 2 through activation of ERK2 kinase	ONCOGENE			English	Article						nuclear receptor; arrestin; MAP kinase; activation	LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; BETA-ARRESTIN; CRYSTAL-STRUCTURE; RXR-ALPHA; DOWN-REGULATION; ACID; PATHWAY	The activity of retinoid receptors activity can be regulated by various extracellular stimuli. In an effort to understand the molecular basis for this phenomenon, the role of beta-arrestins was investigated. beta-Arrestins constitute a class of proteins involved in the internalization of agonist-activated receptors. They have also been linked to MAPK activation suggesting a direct involvement in signaling cascades. Here, we report that beta-arrestin 2 stimulates the transcriptional activation of the retinoid RAR and RXR receptors. Of all the retinoid receptors, the RAR beta 2 subtype showed the strongest sensitivity to beta-arrestin 2 action. Interestingly, this event requires the presence of the MAP kinase ERK2, but not that of JNK or P38. Site-directed mutagenesis showed that Ser 22 and Leu 217 are critical residues of the RAR b2 receptor through which b-arrestin 2 effects are mediated. More importantly, we demonstrate that the induction of PC12 growth inhibition by Nerve Growth Factor is indeed dependent upon RAR b2 transcriptional activation in a beta-arrestin 2- and ERK2-dependent manner.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA		Piu, F (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	fpiu@acadia-pharm.com						Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; Corcoran J, 1999, NAT NEUROSCI, V2, P307, DOI 10.1038/7214; Cosgaya JM, 2001, J NEUROCHEM, V76, P661, DOI 10.1046/j.1471-4159.2001.00078.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Harish S, 2000, BIOCHEM BIOPH RES CO, V279, P853, DOI 10.1006/bbrc.2000.4043; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199; Klaholz BP, 2000, J MOL BIOL, V302, P155, DOI 10.1006/jmbi.2000.4032; Koutsilieris M, 1997, ANTICANCER RES, V17, P1461; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KYRIAKIS JM, 2000, SCI STKE 2000, pE1; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MILLER LA, 1993, CANCER RES, V53, P2527; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Ostrowski J, 1998, J BIOL CHEM, V273, P3490, DOI 10.1074/jbc.273.6.3490; Piu F, 2002, ONCOGENE, V21, P3579, DOI 10.1038/sj.onc.1205444; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Schmidt P, 2001, MOL ENDOCRINOL, V15, P553, DOI 10.1210/me.15.4.553; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Vo HP, 1998, INT J ONCOL, V13, P1127; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	47	16	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					218	229		10.1038/sj.onc.1209024	http://dx.doi.org/10.1038/sj.onc.1209024			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170358				2022-12-25	WOS:000234583600006
J	Liu, YN; Lee, WW; Wang, CY; Chao, TH; Chen, Y; Chen, JH				Liu, YN; Lee, WW; Wang, CY; Chao, TH; Chen, Y; Chen, JH			Regulatory mechanisms controlling human E-cadherin gene expression	ONCOGENE			English	Article						E-cadherin; gene expression; HNF3 (Hepatocyte Nuclear Factor); metastasis	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; GASTRIC-CANCER; P-CADHERIN; PROMOTER; BINDING; REPRESSION; CELLS	In cancer cells, loss of E-cadherin gene expression caused dysfunction of the cell-cell junction system, triggering cancer invasion and metastasis. Therefore, E-cadherin is an important tumor-suppressor gene. To understand how E-cadherin gene expression is regulated in cancer cells, we have used E-cadherin-positive and -negative expressing cells to find out the possible up- or downregulating transcription factors in human E-cadherin regulatory sequences. Functional analysis of human E-cadherin regulatory sequences constructs indicated that AML1, Sp1, and p300 may play important roles in promoting E-cadherin expression. In addition, we found there are four HNF3-binding sites in human E-cadherin regulatory sequences. The exogenous HNF3 can enhance the E-cadherin promoter activity in metastatic breast cancer cells and the metastatic breast cancer cells stably transfected with HNF3 showed re-expression of E-cadherin. The HNF3 stable transfectants changed from mesenchymal-like into epithelial morphology. The transwell assays showed the re-expressed E-cadherin reduced cell motility of metastatic breast cancer cells. These results suggested HNF3 may play important roles in the upregulation of the E-cadherin promoter, with the consequent re-expression of E-cadherin, thus reducing the metastatic potential of breast cancer cells. These findings suggested HNF3 plays important roles in the upregulation of the E-cadherin gene and may be able to reduce the motility of metastatic breast cancer cells.	Tzu Chi Univ, Coll Life Sci, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Tzu Chi Univ, Grad Inst Med Sci, Hualien 970, Taiwan; Tzu Chi Univ, Dept Life Sci, Hualien 970, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Coll Life Sci, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd Sec 3, Hualien 970, Taiwan.	jhc@mail.tcu.edu.tw						Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1291, DOI 10.1006/bbrc.1994.2322; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHANG HW, 2000, CANCER, V94, P386; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Duband JL, 1995, ACTA ANAT, V154, P63; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; GRAFF JR, 1995, CANCER RES, V55, P5195; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SHIGEAKI L, 2002, FASEB J, V16, P1444; Si HX, 2001, CANCER LETT, V173, P71, DOI 10.1016/S0304-3835(01)00646-2; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Viebahn C, 1995, ACTA ANAT, V154, P79; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	53	156	169	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8277	8290		10.1038/sj.onc.1208991	http://dx.doi.org/10.1038/sj.onc.1208991			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16116478				2022-12-25	WOS:000233956500007
J	Datta, K; Mondal, S; Sinha, S; Li, JP; Wang, EF; Knebelmann, B; Karumanchi, SA; Mukhopadhyay, D				Datta, K; Mondal, S; Sinha, S; Li, JP; Wang, EF; Knebelmann, B; Karumanchi, SA; Mukhopadhyay, D			Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma	ONCOGENE			English	Article						VPF; VPF/VEGF; mRNA stability; angiogenesis; renal cell carcinoma; VHL; HuR	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; 3' UNTRANSLATED REGION; INDUCIBLE FACTOR-ALPHA; KINASE-C-ZETA; POSTTRANSCRIPTIONAL REGULATION; TUMOR ANGIOGENESIS; HIF-ALPHA; PROTEIN; HYPOXIA	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a key mediator of angiogenesis for both physiological and pathological conditions. It is well established that the hypoxic induction of VPF/VEGF is in large part an increase in the stability of its mRNA. A Hu family ubiquitously expressed RNA-binding protein HuR has recently been shown to be important for VPF/VEGF mRNA stabilization. In renal cancer cells, the inactivation of the tumor suppressor protein von Hippel Lindau (VHL) leads to an increase in VPF/VEGF expression. VHL not only inhibits the transcription of VPF/VEGF but also plays a significant role in decreasing its mRNA stability. Here we delineate a possible mechanism by which VHL can control the function of HuR in order to regulate the stability of VPF/VEGF mRNA. The experiments presented here suggest that the association of the elongin-binding domain of VHL with a specific RNA-binding domain of HuR (RRM1) is important for the destabilizing function of VHL on VPF/VEGF mRNA.	Mayo Clin Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hop Necker Enfants Malad, Paris, France	Mayo Clinic; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mukhopadhyay, D (corresponding author), Mayo Clin Fdn, Dept Biochem & Mol Biol, Gugg 1401A,200 1st St SW, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu	Karumanchi, Subbian Ananth/AAI-1694-2021		NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567] Funding Source: Medline; NIDDK NIH HHS [DK 02825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078383, R29CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chung J, 2004, CANCER RES, V64, P4711, DOI 10.1158/0008-5472.CAN-04-0347; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Datta K, 2004, CANCER RES, V64, P456, DOI 10.1158/0008-5472.CAN-03-2706; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1991, PRINCESS TAKAMATSU S, V11, P339; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, CANCER RES, V57, P5328; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1997, KIDNEY INT, V51, P575, DOI 10.1038/ki.1997.82; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pioli PA, 2001, J BIOL CHEM, V276, P40346, DOI 10.1074/jbc.M105391200; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shi W, 2002, BRIT J CANCER, V87, P119, DOI 10.1038/sj.bjc.6600416; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7850	7858		10.1038/sj.onc.1208912	http://dx.doi.org/10.1038/sj.onc.1208912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16170373				2022-12-25	WOS:000233463000004
J	Bordignon, E; Klare, JP; Doebber, M; Wegener, AA; Martell, S; Engelhard, M; Steinhoff, HJ				Bordignon, E; Klare, JP; Doebber, M; Wegener, AA; Martell, S; Engelhard, M; Steinhoff, HJ			Structural analysis of a HAMP domain - The linker region of the phototransducer in complex with sensory rhodopsin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL DOMAIN; E-F LOOP; PHARAONIS PHOBORHODOPSIN; TRANSDUCER; PROTEINS; RECEPTOR; HELICES; BACTERIORHODOPSIN; REVEALS; CHANNEL	Sensory rhodopsin II, the photophobic receptor from Natronomonas pharaonis ( NpSRII) 5, forms a 2: 2 complex with its cognate transducer (N. pharaonis halobacterial transducer of rhodopsins II ( NpHtrII)) in lipid membranes. Light activation of NpSRII leads to a displacement of helix F, which in turn triggers a rotation/screw-like motion of TM2 in NpHtrII. This conformational change is thought to be transmitted through the membrane adjacent conserved signal transduction domain in histidine kinases, adenylyl cyclases, methyl-accepting chemotaxis proteins, and phosphatases ( HAMP domain) to the cytoplasmic signaling domain of the transducer. The architecture and function of the HAMP domain are still unknown. In order to obtain information on the structure and dynamics of this region, EPR experiments on a truncated transducer (NpHtrII(157)) and NpSRII, site-directed spin-labeled and reconstituted into purple membrane lipids, have been carried out. A nitroxide scanning involving residues in the transducer helix TM2, in the predicted AS-1 region, and at selected positions in the following connector and AS-2 regions of the HAMP domain has been performed. Accessibility and dynamics data allowed us to identify a helical region up to residue Ala(94) in the AS-1 amphipathic sequence, followed by a highly dynamic domain protruding into the water phase. Additionally, transducer-transducer and transducer-receptor proximity relations revealed the overall architecture of the AS-1 sequences in the 2: 2 complex, which are suggested to form a molten globular type of a coiled-coil bundle.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Osnabruck, Fachbereich Phys, D-49069 Osnabruck, Germany	Max Planck Society; University Osnabruck	Engelhard, M (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	martin.engelhard@mpi-dortmund.mpg.de; hsteinho@uos.de	Steinhoff, Heinz-Juergen/H-3791-2014; Klare, Johann P./C-1428-2009	Steinhoff, Heinz-Juergen/0000-0002-5888-0157; Klare, Johann P./0000-0002-5761-5968; Bordignon, Enrica/0000-0003-2450-5161				ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Appleman JA, 2003, J BACTERIOL, V185, P89, DOI 10.1128/JB.185.1.89-97.2003; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; Chen XP, 2004, J BIOL CHEM, V279, P42964, DOI 10.1074/jbc.M406503200; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; FRIED JP, 1976, SPIN LABELING THEORY, P83; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; Hess JF, 2002, J BIOL CHEM, V277, P35516, DOI 10.1074/jbc.M206500200; Hippler-Mreyen S, 2003, J MOL BIOL, V330, P1203, DOI 10.1016/S0022-2836(03)00656-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hohenfeld IP, 1999, FEBS LETT, V442, P198, DOI 10.1016/S0014-5793(98)01659-7; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Jung KH, 2001, J BACTERIOL, V183, P6365, DOI 10.1128/JB.183.21.6365-6371.2001; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kim SH, 2002, P NATL ACAD SCI USA, V99, P11611, DOI 10.1073/pnas.132376499; Klare JP, 2004, FEBS LETT, V564, P219, DOI 10.1016/S0014-5793(04)00193-0; Klare JP, 2004, PHOTOCH PHOTOBIO SCI, V3, P543, DOI 10.1039/b402656j; LANYI JK, 1974, BACTERIOL REV, V38, P272, DOI 10.1128/MMBR.38.3.272-290.1974; Pfeiffer M, 1999, J MOL BIOL, V287, P163, DOI 10.1006/jmbi.1998.2593; Plato M, 2002, MOL PHYS, V100, P3711, DOI 10.1080/00268970210166246; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; Shimono K, 1997, FEBS LETT, V420, P54, DOI 10.1016/S0014-5793(97)01487-7; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Steinhoff HJ, 2000, BBA-BIOENERGETICS, V1457, P253, DOI 10.1016/S0005-2728(00)00106-7; Steinhoff HJ, 1997, BIOPHYS J, V73, P3287, DOI 10.1016/S0006-3495(97)78353-X; Sudo Y, 2001, BIOPHYS J, V80, P916, DOI 10.1016/S0006-3495(01)76070-5; TOMIOKA H, 1986, BIOCHEM BIOPH RES CO, V139, P389, DOI 10.1016/S0006-291X(86)80003-1; Trivedi VD, 2003, BIOCHEMISTRY-US, V42, P13887, DOI 10.1021/bi034399q; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Wegener AA, 2001, EMBO J, V20, P5312, DOI 10.1093/emboj/20.19.5312; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; Yang CS, 2004, J BIOL CHEM, V279, P42970, DOI 10.1074/jbc.M406504200; Yang CS, 2001, BIOCHEMISTRY-US, V40, P14207, DOI 10.1021/bi010985c	36	53	56	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38767	38775		10.1074/jbc.M509391200	http://dx.doi.org/10.1074/jbc.M509391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16157581	hybrid			2022-12-25	WOS:000233239800078
J	Dhar-Chowdhury, P; Harrell, MD; Han, SY; Jankowska, D; Parachuru, L; Morrissey, A; Srivastava, S; Liu, WX; Malester, B; Yoshida, H; Coetzee, WA				Dhar-Chowdhury, P; Harrell, MD; Han, SY; Jankowska, D; Parachuru, L; Morrissey, A; Srivastava, S; Liu, WX; Malester, B; Yoshida, H; Coetzee, WA			The glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase, triose-phosphate isomerase, and pyruvate kinase are components of the KATP channel macromolecular complex and regulate its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; PIG VENTRICULAR CELLS; SENSITIVE POTASSIUM CHANNELS; GUINEA-PIG; 3-PHOSPHOGLYCERATE KINASE; MEMBRANE PATCHES; PLASMA-MEMBRANE; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PREFERENTIAL REGULATION; SMOOTH-MUSCLE	The regulation of ATP-sensitive potassium (K-ATP) channel activity is complex and a multitude of factors determine their open probability. Physiologically and pathophysiologically, the most important of these are intracellular nucleotides, with a long-recognized role for glycolytically derived ATP in regulating channel activity. To identify novel regulatory subunits of the K-ATP channel complex, we performed a two-hybrid protein-protein interaction screen, using as bait the mouse Kir6.2 C terminus. Screening a rat heart cDNA library, we identified two potential interacting proteins to be the glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and triose-phosphate isomerase. The veracity of interaction was verified by co-immunoprecipitation techniques in transfected mammalian cells. We additionally demonstrated that pyruvate kinase also interacts with Kir6.2 subunits. The physiological relevance of these interactions is illustrated by the demonstration that native Kir6.2 protein similarly interact with GAPDH and pyruvate kinase in rat heart membrane fractions and that Kir6.2 protein co-localize with these glycolytic enzymes in rat ventricular myocytes. The functional relevance of our findings is demonstrated by the ability of GAPDH or pyruvate kinase substrates to directly block the K-ATP channel under patch clamp recording conditions. Taken together, our data provide direct evidence for the concept that key enzymes involved in glycolytic ATP production are part of a multi-subunit K-ATP channel protein complex. Our data are consistent with the concept that the activity of these enzymes ( possibly by ATP formation in the immediate intracellular microenvironment of this macromolecular K-ATP channel complex) causes channel closure.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University; New York University	Coetzee, WA (corresponding author), 560 1st Ave,TCH-407, New York, NY 10016 USA.	william.coetzee@med.nyu.edu		Coetzee, William/0000-0003-1522-8326; Srivastava, Shekhar/0000-0001-5165-7385	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085820, R01HL064838] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL064838, R01-HL064838, R01 HL085820] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHMARINA LI, 1984, BIOCHEM INT, V9, P511; Bers DM, 2004, J MOL CELL CARDIOL, V37, P417, DOI 10.1016/j.yjmcc.2004.05.026; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Crawford RM, 2002, EMBO J, V21, P3936, DOI 10.1093/emboj/cdf388; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Cui Y, 2001, P NATL ACAD SCI USA, V98, P729, DOI 10.1073/pnas.011370498; DAUM G, 1988, BIOCHIM BIOPHYS ACTA, V939, P277, DOI 10.1016/0005-2736(88)90071-5; Deeney JT, 2001, J BIOL CHEM, V276, P36946, DOI 10.1074/jbc.M105056200; Dizon J, 1998, AM J PHYSIOL-HEART C, V274, pH1082, DOI 10.1152/ajpheart.1998.274.4.H1082; Dubinsky WP, 1998, AM J PHYSIOL-CELL PH, V275, pC1653, DOI 10.1152/ajpcell.1998.275.6.C1653; GLITSCH HG, 1993, PFLUG ARCH EUR J PHY, V422, P380, DOI 10.1007/BF00374294; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; HURST AM, 1993, AM J PHYSIOL, V264, pF760, DOI 10.1152/ajprenal.1993.264.4.F760; Inagaki N, 1998, JPN J PHYSIOL, V48, P397, DOI 10.2170/jjphysiol.48.397; Jovanovic S, 2005, EMBO REP, V6, P848, DOI 10.1038/sj.embor.7400489; Kabakov AY, 1998, BIOPHYS J, V75, P2858, DOI 10.1016/S0006-3495(98)77728-8; KAKEI M, 1985, J PHYSIOL-LONDON, V363, P441, DOI 10.1113/jphysiol.1985.sp015721; KANTOR PF, 1990, CIRC RES, V66, P478, DOI 10.1161/01.RES.66.2.478; KHOROSHILOVA NA, 1992, FEBS LETT, V297, P247, DOI 10.1016/0014-5793(92)80548-U; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; Leonoudakis D, 2004, J BIOL CHEM, V279, P22331, DOI 10.1074/jbc.M400285200; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH987, DOI 10.1152/ajpheart.1997.272.2.H987; Losito VA, 1998, J PHYSIOL-LONDON, V511, P67, DOI 10.1111/j.1469-7793.1998.067bi.x; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; NAKAMURA S, 1989, CARDIOVASC RES, V23, P286, DOI 10.1093/cvr/23.4.286; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Nakamura TY, 1997, AM J PHYSIOL-HEART C, V273, pH1775, DOI 10.1152/ajpheart.1997.273.4.H1775; PASYK EA, 2003, J BIOL CHEM; PAUL RJ, 1989, FASEB J, V3, P2298, DOI 10.1096/fasebj.3.11.2528493; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; Pountney DJ, 2001, J MOL CELL CARDIOL, V33, P1541, DOI 10.1006/jmcc.2001.1407; Priebe L, 1996, J PHYSIOL-LONDON, V492, P405, DOI 10.1113/jphysiol.1996.sp021317; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Shibasaki T, 2004, J BIOL CHEM, V279, P7956, DOI 10.1074/jbc.M309068200; Shigematsu S, 1997, CARDIOVASC RES, V35, P273, DOI 10.1016/S0008-6363(97)00092-8; SUKHODOLETS MV, 1988, FEBS LETT, V238, P161, DOI 10.1016/0014-5793(88)80248-5; SUKHODOLETS MV, 1989, BIOCHEM BIOPH RES CO, V161, P187, DOI 10.1016/0006-291X(89)91579-9; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Tsuchiya K, 1997, CIRCULATION, V96, P3129, DOI 10.1161/01.CIR.96.9.3129; Tsuchiya K, 1998, J CARDIOVASC ELECTR, V9, P415, DOI 10.1111/j.1540-8167.1998.tb00929.x; Urbach V, 1996, J PHYSIOL-LONDON, V491, P99, DOI 10.1113/jphysiol.1996.sp021199; VLEUGELS A, 1980, CIRC RES, V47, P501, DOI 10.1161/01.RES.47.4.501; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; WERNSTEDT CO, 1975, CANCER RES, V35, P1536; Xu KY, 1998, J HISTOCHEM CYTOCHEM, V46, P419, DOI 10.1177/002215549804600401; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88; Yoshida H, 2004, J MOL CELL CARDIOL, V37, P857, DOI 10.1016/j.yjmcc.2004.05.022; Yuan F, 1997, J MOL CELL CARDIOL, V29, P2837, DOI 10.1006/jmcc.1997.0518; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	55	97	101	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38464	38470		10.1074/jbc.M508744200	http://dx.doi.org/10.1074/jbc.M508744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16170200	hybrid, Green Accepted			2022-12-25	WOS:000233239800043
J	Maiorino, M; Roveri, A; Benazzi, L; Bosello, V; Mauri, P; Toppo, S; Tosatto, SCE; Ursini, F				Maiorino, M; Roveri, A; Benazzi, L; Bosello, V; Mauri, P; Toppo, S; Tosatto, SCE; Ursini, F			Functional interaction of phospholipid hydroperoxide glutathione peroxidase with sperm mitochondrion-associated cysteine-rich protein discloses the adjacent cysteine motif as a new substrate of the selenoperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULE SELENOPROTEIN; MOUSE SPERM; CHROMOSOMAL LOCALIZATION; SELENOCYSTEINE CODONS; STRUCTURAL PROTEIN; RAT SPERM; GENE; SELENIUM; PHGPX; EXPRESSION	The mitochondrial capsule is a selenium- and disulfide-rich structure enchasing the outer mitochondrial membrane of mammalian spermatozoa. Among the proteins solubilized from the sperm mitochondrial capsule, we confirmed, by using a proteomic approach, the presence of phospholipid hydroperoxide glutathione peroxidase (PHGPx) as a major component, and we also identified the sperm mitochondrion-associated cysteine-rich protein ( SMCP) and fragments/aggregates of specific keratins that previously escaped detection (Ursini, F., Heim, S., Kiess, M., Maiorino, M., Roveri, A., Wissing, J., and Flohe ', L. ( 1999) Science 285, 1393 - 1396). The evidence for a functional association between PHGPx, SMCP, and keratins is further supported by the identification of a sequence motif of regularly spaced Cys-Cys doublets common to SMCP and high sulfur keratin-associated proteins, involved in bundling hair shaft keratin by disulfide cross-linking. Following the oxidative polymerization of mitochondrial capsule proteins, catalyzed by PHGPx, two-dimensional redox electrophoresis analysis showed homo- and heteropolymers of SMCP and PHGPx, together with other minor components. Adjacent cysteine residues in SMCP peptides are oxidized to cystine by PHGPx. This unusual disulfide is known to drive, by reshuffling oxidative protein folding. On this basis we propose that oxidative polymerization of the mitochondrial capsule is primed by the formation of cystine on SMCP, followed by reshuffling. Occurrence of reshuffling is further supported by the calculated thermodynamic gain of the process. This study suggests a new mechanism where selenium catalysis drives the cross-linking of structural elements of the cytoskeleton via the oxidation of a keratin-associated protein.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, Dept Biol, I-35121 Padua, Italy; Univ Padua, CRIBI Biotechnol Ctr, I-35121 Padua, Italy; CNR, Inst Biomed Technol, I-2090 Milan, Italy	University of Padua; University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Ursini, F (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	fulvio.ursini@unipd.it	benazzi, louise/AAW-2684-2020; Mauri, Pietro Luigi/AAC-3095-2019; Toppo, Stefano/Z-5479-2019; Roveri, Antonella/AAF-3669-2019; Tosatto, Silvio/B-2840-2009	Mauri, Pietro Luigi/0000-0003-4364-0393; Toppo, Stefano/0000-0002-0246-3119; Roveri, Antonella/0000-0002-3252-0559; Tosatto, Silvio/0000-0003-4525-7793; bosello travain, valentina/0000-0003-4659-1873				Adham IM, 1996, DNA CELL BIOL, V15, P159, DOI 10.1089/dna.1996.15.159; Aho H, 1996, GENOMICS, V32, P184, DOI 10.1006/geno.1996.0104; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; CALVIN HI, 1978, J EXP ZOOL, V204, P445, DOI 10.1002/jez.1402040315; CALVIN HI, 1981, GAMETE RES, V4, P139, DOI 10.1002/mrd.1120040208; CALVIN HI, 1979, SPERMATOZOON, P135; Cataldo L, 1996, MOL REPROD DEV, V45, P320, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;320::AID-MRD9&gt;3.0.CO;2-U; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Conrad M, 2005, MOL CELL BIOL, V25, P7637, DOI 10.1128/MCB.25.17.7637-7644.2005; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; Hinsch KD, 2004, J BIOL CHEM, V279, P15281, DOI 10.1074/jbc.M313433200; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; Imai H, 2003, BIOCHEM BIOPH RES CO, V305, P278, DOI 10.1016/S0006-291X(03)00734-4; KARIMPOUR I, 1992, DNA CELL BIOL, V11, P693, DOI 10.1089/dna.1992.11.693; KUHN R, 1991, MECH DEVELOP, V35, P143, DOI 10.1016/0925-4773(91)90064-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; Maiorino M, 2005, FEBS LETT, V579, P667, DOI 10.1016/j.febslet.2004.12.041; Maiorino M, 2003, J BIOL CHEM, V278, P34286, DOI 10.1074/jbc.M305327200; Maiorino M, 2002, BIOL CHEM, V383, P591, DOI 10.1515/BC.2002.061; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Mauri P, 2005, FASEB J, V19, P1125, DOI 10.1096/fj.04-3000fje; Mauri P, 2003, BIOL CHEM, V384, P575, DOI 10.1515/BC.2003.065; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Nayernia K, 2004, MOL REPROD DEV, V67, P458, DOI 10.1002/mrd.20039; Nayernia K, 2002, MOL CELL BIOL, V22, P3046, DOI 10.1128/MCB.22.9.3046-3052.2002; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; PALLINI V, 1979, J SUBMICR CYTOL PATH, V11, P165; Park C, 2001, PROTEIN ENG, V14, P939, DOI 10.1093/protein/14.11.939; Powell B C, 1997, EXS, V78, P59; Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111; Rogers MA, 2004, J INVEST DERMATOL, V122, P147, DOI 10.1046/j.0022-202X.2003.22128.x; ROVERI A, 1994, BBA-PROTEIN STRUCT M, V1208, P211, DOI 10.1016/0167-4838(94)90106-6; Roveri A, 2001, BIOFACTORS, V14, P213, DOI 10.1002/biof.5520140127; Su D, 2005, J BIOL CHEM, V280, P26491, DOI 10.1074/jbc.M503638200; Traut R., 1989, PROTEIN FUNCTION PRA, P101; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; WALLACE E, 1983, GAMETE RES, V7, P377, DOI 10.1002/mrd.1120070409; WALLACE E, 1983, GAMETE RES, V7, P389, DOI 10.1002/mrd.1120070410; WU ASH, 1979, BIOL REPROD, V20, P793, DOI 10.1095/biolreprod20.4.793; WU SH, 1973, BIOL REPROD, V8, P625, DOI 10.1093/biolreprod/8.5.625	50	60	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38395	38402		10.1074/jbc.M505983200	http://dx.doi.org/10.1074/jbc.M505983200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159880	hybrid, Green Published			2022-12-25	WOS:000233239800035
J	Zhao, ZY; Fang, L; Chen, NS; Johnsen, RC; Stein, L; Baillie, DL				Zhao, ZY; Fang, L; Chen, NS; Johnsen, RC; Stein, L; Baillie, DL			Distinct regulatory elements mediate similar expression patterns in the excretory cell of Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; IDENTIFICATION; TRANSCRIPTION; COREGULATION; SYSTEM; COEXPRESSION; EUKARYOTES; NETWORKS; BINDING; PROTEIN	Identification of cis-regulatory elements and their binding proteins constitutes an important part of understanding gene function and regulation. It is well accepted that co-expressed genes tend to share transcriptional elements. However, recent findings indicate that co-expression data show poor correlation with co-regulation data even in unicellular yeast. This motivates us to experimentally explore whether it is possible that co-expressed genes are subject to differential regulatory control using the excretory cell of Caenorhabditis elegans as an example. Excretory cell is a functional equivalent of human kidney. Transcriptional regulation of gene expression in the cell is largely unknown. We isolated a 10-bp excretory cell-specific cis-element, Ex-1, from a pgp-12 promoter. The significance of the element has been demonstrated by its capacity of converting an intestine-specific promoter into an excretory cell-specific one. We also isolated a cDNA encoding an Ex-1 binding transcription factor, DCP-66, using a yeast one-hybrid screen. Role of the factor in regulation of pgp-12 expression has been demonstrated both in vitro and in vivo. Search for occurrence of Ex-1 reveals that only a small portion of excretory cell-specific promoters contain Ex-1. Two other distinct cis-elements isolated from two different promoters can also dictate the excretory cell-specific expression but are independent of regulation by DCP-66. The results indicate that distinct regulatory elements are able to mediate the similar expression patterns.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Washington; University of Washington Seattle; Simon Fraser University; Cold Spring Harbor Laboratory	Zhao, ZY (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.	zhao@gs.washington.edu	Zhao, Zhongying/ABF-9458-2021; Zhao, Zhongying/C-3261-2015; Chen, Nansheng/E-6450-2012	Zhao, Zhongying/0000-0003-2743-9008; 				Allocco DJ, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-18; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; Burglin TR, 2001, DEVELOPMENT, V128, P779; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Cui MX, 2003, DEV BIOL, V257, P104, DOI 10.1016/S0012-1606(03)00033-2; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Elgar G, 2004, SEMIN CELL DEV BIOL, V15, P715, DOI 10.1016/j.semcdb.2004.10.001; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gilleard JS, 1999, DEV BIOL, V208, P265, DOI 10.1006/dbio.1999.9202; GuhaThakurta D, 2004, GENOME RES, V14, P2457, DOI 10.1101/gr.2961104; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; JONES SJM, 1995, MOL GEN GENET, V248, P719, DOI 10.1007/BF02191712; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lynch M, 2000, GENETICS, V154, P459; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; Mohrlen F, 2003, EUR J BIOCHEM, V270, P4909, DOI 10.1046/j.1432-1033.2003.03891.x; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; Qian J, 2003, BIOINFORMATICS, V19, P1917, DOI 10.1093/bioinformatics/btg347; Sheps JA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r15; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Snel B, 2004, NUCLEIC ACIDS RES, V32, P4725, DOI 10.1093/nar/gkh815; SPIETH J, 1988, DEV BIOL, V130, P285, DOI 10.1016/0012-1606(88)90434-4; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Stringham E, 2002, DEVELOPMENT, V129, P3367; Vilaboa N, 2004, NUCLEIC ACIDS RES, V32, P6454, DOI 10.1093/nar/gkh981; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang XD, 2004, NAT GENET, V36, P231, DOI 10.1038/ng1301; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yeung KY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r48; Zhao ZY, 2004, BIOCHEM BIOPH RES CO, V323, P104, DOI 10.1016/j.bbrc.2004.08.068; Zhao ZY, 2004, J MOL BIOL, V344, P409, DOI 10.1016/j.jmb.2004.09.052	36	26	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38787	38794		10.1074/jbc.M505701200	http://dx.doi.org/10.1074/jbc.M505701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16159881	hybrid			2022-12-25	WOS:000233239800080
J	Peric-Concha, N; Borovicka, B; Long, PF; Hranueli, D; Waterman, PG; Hunter, IS				Peric-Concha, N; Borovicka, B; Long, PF; Hranueli, D; Waterman, PG; Hunter, IS			Ablation of the otcC gene encoding a post-polyketide hydroxylase from the oxytetracyline biosynthetic pathway in Streptomyces rimosus results in novel polyketides with altered chain length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; AROMATIC POLYKETIDE; ENGINEERED BIOSYNTHESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; COELICOLOR A3(2); RATIONAL DESIGN; SYNTHASE; CLONING; TETRACYCLINES	Oxytetracycline (OTC) is a 19-carbon polyketide antibiotic made by Streptomyces rimosus. The otcC gene encodes an anhydrotetracycline oxygenase that catalyzes a hydroxylation of the anthracycline structure at position C-6 after biosynthesis of the polyketide backbone is completed. A recombinant strain of S. rimosus that was disrupted in the genomic copy of otcC synthesized a novel C-17 polyketide. This result indicates that the absence of the otcC gene product significantly influences the ability of the OTC "minimal" polyketide synthase to make a polyketide product of the correct chain length. A mutant copy of otcC was made by site-directed mutagenesis of three essential glycine codons located within the putative NADPH-binding domain. The mutant gene was expressed in Escherichia coli, and biochemical analysis confirmed that the gene product was catalytically inactive. When the mutant gene replaced the ablated gene in the chromosome of S. rimosus, the ability to make a 19-carbon backbone was restored, indicating that OtcC is an essential partner in the quaternary structure of the synthase complex.	Univ Strathclyde, Royal Coll, Dept Biosci, Glasgow G1 1QW, Lanark, Scotland; PLIVA Res & Dev Ltd, Biotechnol, Zagreb 10000, Croatia; Univ London, Sch Pharm, London WC1N 1AX, England	University of Strathclyde; Teva Pharmaceutical Industries; Pliva; University of London; University College London; University of London School of Pharmacy	Hunter, IS (corresponding author), Univ Strathclyde, Royal Coll, Dept Biosci, Glasgow G1 1QW, Lanark, Scotland.	i.s.hunter@strath.ac.uk		Hunter, Iain/0000-0003-2571-6016	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDEN TC, 1994, J MED CHEM, V37, P3205, DOI 10.1021/jm00046a003; BEHAL V, 1979, BIOTECHNOL LETT, V1, P177, DOI 10.1007/BF01388144; BINNIE C, 1989, J BACTERIOL, V171, P887, DOI 10.1128/jb.171.2.887-895.1989; Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER MJ, 1989, MOL GEN GENET, V215, P231, DOI 10.1007/BF00339722; BUTLER MJ, 1990, DEV IND MICROBIOL, V31, P41; Castaldo G, 2005, FOOD TECHNOL BIOTECH, V43, P109; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; DAIRI T, 1995, BIOSCI BIOTECH BIOCH, V59, P1099, DOI 10.1271/bbb.59.1099; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; Findlow SC, 2003, BIOCHEMISTRY-US, V42, P8423, DOI 10.1021/bi0342259; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; GIBSON T, 1984, THESIS U CAMBRIDGE U; GRAVIUS B, 1993, APPL ENVIRON MICROB, V59, P2220, DOI 10.1128/AEM.59.7.2220-2228.1993; Hadfield AT, 2004, STRUCTURE, V12, P1865, DOI 10.1016/j.str.2004.08.002; Hitchman TS, 1998, CHEM BIOL, V5, P35, DOI 10.1016/S1074-5521(98)90085-0; HRANUELI D, 1979, J GEN MICROBIOL, V114, P295, DOI 10.1099/00221287-114-2-295; Hranueli D, 1999, FOOD TECHNOL BIOTECH, V37, P117; Hunter I. S., 1997, BIOTECHNOLOGY ANTIBI, P659; Keatinge-Clay A, 2004, NAT STRUCT MOL BIOL, V11, P888, DOI 10.1038/nsmb808; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Q, 2003, BIOCHEMISTRY-US, V42, P4648, DOI 10.1021/bi0274120; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; McDowall KJ, 1999, J BACTERIOL, V181, P3025, DOI 10.1128/JB.181.10.3025-3032.1999; MCDOWALL KJ, 1991, FEMS SYMP, V55, P105; Moore BS, 2002, NAT PROD REP, V19, P70, DOI 10.1039/b003939j; Nicholson TP, 2003, CHEM COMMUN, P686, DOI 10.1039/b300847a; NOVOTNA J, 1989, FEMS MICROBIOL LETT, V59, P241; PALMER BR, 1994, GENE, V143, P1, DOI 10.1016/0378-1119(94)90597-5; Pan H, 2002, STRUCTURE, V10, P1559, DOI 10.1016/S0969-2126(02)00889-4; Pandza K, 1997, MICROBIOL-UK, V143, P1493, DOI 10.1099/00221287-143-5-1493; PARK W, 1994, BIOTECHNIQUES, V17, P657; Petkovic H, 1999, J BIOL CHEM, V274, P32829; PIGAC J, 1995, APPL ENVIRON MICROB, V61, P352, DOI 10.1128/AEM.61.1.352-356.1995; REVILL WP, 1995, J BACTERIOL, V177, P3946, DOI 10.1128/jb.177.14.3946-3952.1995; Ryan MJ, 1996, United States patent, Patent No. 5589385; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shen YM, 1999, P NATL ACAD SCI USA, V96, P3622, DOI 10.1073/pnas.96.7.3622; SKEGGS PA, 1987, J GEN MICROBIOL, V133, P915; Tang Y, 2004, PLOS BIOL, V2, P227, DOI 10.1371/journal.pbio.0020031; Tang Y, 2004, BIOCHEMISTRY-US, V43, P9546, DOI 10.1021/bi049157k; THOMAS R, 1983, J CHEM SOC CHEM COMM, P128, DOI 10.1039/c39830000128; THOMAS R, 1983, J CHEM SOC CHEM COMM, V7, P443; VASLIGAJ M, 1981, APPL ENVIRON MICROB, V41, P986; WARD JM, 1986, MOL GEN GENET, V203, P468, DOI 10.1007/BF00422072; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184	55	34	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37455	37460		10.1074/jbc.M503191200	http://dx.doi.org/10.1074/jbc.M503191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148009	hybrid			2022-12-25	WOS:000233044500021
J	Pochynyuk, O; Staruschenko, A; Tong, QS; Medina, J; Stockand, JD				Pochynyuk, O; Staruschenko, A; Tong, QS; Medina, J; Stockand, JD			Identification of a functional phosphatidylinositol 3,4,5-trisphosphate binding site in the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; K-ATP CHANNELS; SODIUM-CHANNEL; PIP2 REGULATION; KIR CHANNELS; ACTIVATION; ALDOSTERONE; TRANSPORT; ENAC; INHIBITION	Membrane phospholipids, such as phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5) P-3), are signaling molecules that can directly modulate the activity of ion channels, including the epithelial Na+ channel (ENaC). Whereas PI(3,4,5) P-3 directly activates ENaC, its binding site within the channel has not been identified. We identify here a region of gamma-mENaC just following the second trans-membrane domain ( residues 569 - 583) important to PI( 3,4,5) P3 binding and regulation. Deletion of this track decreases activity of ENaC heterologously expressed in Chinese hamster ovary cells. K-Ras and its first effector phosphoinositide 3-OH kinase (PI3-K), as well as RhoA and its effector phosphatidylinositol 4-phosphate 5-kinase increase ENaC activity. Whereas the former, via generation of PI( 3,4,5) P-3, increases ENaC open probability, the latter increases activity by increasing membrane levels of the channel. Deletion of the region just distal to the second trans-membrane domain disrupted regulation by K-Ras and PI3-K but not RhoA and phosphatidylinositol 4-phosphate 5-kinase. Moreover, PI( 3,4,5) P-3 binds ENaC with deletion of the region following the second transmembrane domain disrupting this interaction and disrupting direct activation of the channel by PI( 3,4,5) P-3. Mutation analysis revealed the importance of conserved positive and negative charged residues as well as bulky amino acids within this region to modulation of ENaC by PI3-K. The current results identify the region just distal to the second trans-membrane domain within gamma-mENaC as being part of a functional PI( 3,4,5) P-3 binding site that directly impacts ENaC activity. Phospholipid binding to this site is probably mediated by the positively charged amino acids within this track, with negatively charged and bulky residues also influencing specificity of interactions.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol 7756, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Staruschenko, Alexander/0000-0002-5190-8356; Stockand, James/0000-0002-3817-4319	NIDDK NIH HHS [R01-DK59594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; Bian JS, 2004, AM J PHYSIOL-HEART C, V287, pH2154, DOI 10.1152/ajpheart.00120.2004; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Blazer-Yost BL, 2004, AM J PHYSIOL-CELL PH, V287, pC1569, DOI 10.1152/ajpcell.00226.2004; Blazer-Yost BL, 2003, AM J PHYSIOL-CELL PH, V284, pC1645, DOI 10.1152/ajpcell.00372.2002; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Casamayor A, 2003, MOL CELL BIOL, V23, P2762, DOI 10.1128/MCB.23.8.2762-2777.2003; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Donaldson MR, 2003, NEUROLOGY, V60, P1811, DOI 10.1212/01.WNL.0000072261.14060.47; Dong K, 2002, J BIOL CHEM, V277, P49366, DOI 10.1074/jbc.M208679200; Du XO, 2004, J BIOL CHEM, V279, P37271, DOI 10.1074/jbc.M403413200; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gupta S, 2003, J BIOL CHEM, V278, P43541, DOI 10.1074/jbc.M308960200; Hendron E, 2002, J BIOL CHEM, V277, P34480, DOI 10.1074/jbc.M204615200; HILGEMANN DW, 2001, SCI STKE; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lopes CMB, 2005, J PHYSIOL-LONDON, V564, P117, DOI 10.1113/jphysiol.2004.081935; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Paunescu TG, 2000, AM J PHYSIOL-CELL PH, V279, pC236, DOI 10.1152/ajpcell.2000.279.1.C236; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Spehr M, 2002, NEURON, V33, P731, DOI 10.1016/S0896-6273(02)00610-4; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2005, BBA-BIOMEMBRANES, V1669, P108, DOI 10.1016/j.bbamem.2005.01.005; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Tong QS, 2005, AM J PHYSIOL-RENAL, V288, pF150, DOI 10.1152/ajprenal.00261.2004; Tong QS, 2004, AM J PHYSIOL-RENAL, V286, pF1232, DOI 10.1152/ajprenal.00345.2003; Xiao J, 2003, NAT NEUROSCI, V6, P811, DOI 10.1038/nn1090; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200; Zhainazarov AB, 2004, J MEMBRANE BIOL, V201, P51, DOI 10.1007/s00232-004-0707-4; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	55	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37565	37571		10.1074/jbc.M509071200	http://dx.doi.org/10.1074/jbc.M509071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154997	hybrid			2022-12-25	WOS:000233044500033
J	Valeva, A; Walev, I; Kemmer, H; Weis, S; Siegel, I; Boukhallouk, F; Wassenaar, TM; Chavakis, T; Bhakdi, S				Valeva, A; Walev, I; Kemmer, H; Weis, S; Siegel, I; Boukhallouk, F; Wassenaar, TM; Chavakis, T; Bhakdi, S			Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; ALPHA-HEMOLYSIN; RESPIRATORY BURST; RTX TOXINS; MEMBRANES; ACYLATION; INTEGRIN; ERYTHROCYTES; ASSOCIATION; INSERTION	Production of a single cysteine substitution mutant, S177C, allowed Escherichia coli hemolysin ( HlyA) to be radioactively labeled with tritiated N-ethylmaleimide without affecting biological activity. It thus became possible to study the binding characteristics of HlyA as well as of toxin mutants in which one or both acylation sites were deleted. All toxins bound to erythrocytes and granulocytes in a nonsaturable manner. Only wild-type toxin and the lytic monoacylated mutant stimulated production of superoxide anions in granulocytes. An oxidative burst coincided with elevation of intracellular Ca2+, which was likely because of passive influx of Ca2+ through the toxin pores. Competition experiments showed that binding to the cells was receptor-independent, and preloading of cells with a nonlytic HlyA mutant did not abrogate the respiratory burst provoked by a subsequent application of wild-type HlyA. In contrast to a previous report, expression or activation of the beta(2) integrin lymphocyte function-associated antigen-1 did not affect binding of HlyA. We conclude that HlyA binds nonspecifically to target cells and a receptor is involved neither in causing hemolysis nor in triggering cellular reactions.	Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Mol Microbiol & Genom Consultants, D-55576 Zotzenheim, Germany; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Valeva, A (corresponding author), Univ Mainz, Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany.	avaleva@uni-mainz.de	Chavakis, Triantafyllos/ABE-8845-2020	Wassenaar, Trudy/0000-0002-7024-1139	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Basar T, 2001, J BIOL CHEM, V276, P348, DOI 10.1074/jbc.M006463200; Bauer ME, 1996, INFECT IMMUN, V64, P4665, DOI 10.1128/IAI.64.11.4665-4672.1996; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BHAKDI S, 1989, J EXP MED, V169, P737, DOI 10.1084/jem.169.3.737; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; BHAKDI S, 1991, INFECT IMMUN, V59, P2955, DOI 10.1128/IAI.59.9.2955-2962.1991; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; EBERSPACHER B, 1989, INFECT IMMUN, V57, P983; GARNOTEL R, 1995, J BIOL CHEM, V270, P27495, DOI 10.1074/jbc.270.46.27495; GRIMMINGER F, 1991, J CLIN INVEST, V88, P1531, DOI 10.1172/JCI115463; GRIMMINGER F, 1991, J BIOL CHEM, V266, P14262; Herlax V, 2003, CHEM PHYS LIPIDS, V122, P185, DOI 10.1016/S0009-3084(02)00191-3; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; Jeyaseelan S, 2001, INFECT IMMUN, V69, P6131, DOI 10.1128/IAI.69.10.6131-6139.2001; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Soloaga A, 1996, EUR J BIOCHEM, V238, P418, DOI 10.1111/j.1432-1033.1996.0418z.x; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Valeva A, 2004, J BIOL CHEM, V279, P25143, DOI 10.1074/jbc.M313913200; VANEPPS DE, 1989, J IMMUNOL, V143, P3207; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x	28	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36657	36663		10.1074/jbc.M507690200	http://dx.doi.org/10.1074/jbc.M507690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131494	hybrid			2022-12-25	WOS:000232901800017
J	Huang, LY; Hwang, J; Sharma, SD; Hargittai, MRS; Chen, YF; Arnold, JJ; Raney, KD; Cameron, CE				Huang, LY; Hwang, J; Sharma, SD; Hargittai, MRS; Chen, YF; Arnold, JJ; Raney, KD; Cameron, CE			Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; NONTRANSLATED REGION; SECONDARY STRUCTURE; NS3 PROTEASE; CELL-LINES; LA PROTEIN; CDNA-CLONE; REPLICATION; POLYMERASE; DOMAIN	Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) has been shown to antagonize numerous cellular pathways, including the antiviral interferon-alpha response. However, the capacity of this protein to interact with the viral polymerase suggests a more direct role for NS5A in genome replication. In this study, we employed two bacterially expressed, soluble derivatives of NS5A to probe for novel functions of this protein. We find that NS5A has the capacity to bind to the 3'-ends of HCV plus and minus strand RNAs. The high affinity binding site for NS5A in the 3'-end of plus strand RNA maps to the polypyrimidine tract, an element known to be essential for genome replication and infectivity. NS5A has a preference for single-stranded RNA containing stretches of uridine or guanosine. Values for the equilibrium dissociation constants for high affinity binding sites were in the 10 nM range. Two-dimensional gel electrophoresis followed by Western blotting revealed the presence of unphosphorylated NS5A in Huh-7 cells stably expressing the subgenomic replicon. Moreover, RNA immunoprecipitation and NS5A pull-down experiments showed the capacity of replicon-derived NS5A to bind to synthetic RNA and the HCV genome, respectively. Deletion of all of the casein kinase II phosphorylation sites in NS5A supported stable replication of a subgenomic replicon in Huh-7. However, this derivative could not be labeled with inorganic phosphate, suggesting that extensive phosphorylation of NS5A is not required for the replication functions of NS5A. The discovery that NS5A is an RNA-binding protein defines a new functional target for development of agents to treat HCV infection and a new structural class of RNA-binding proteins.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Arkansas System; University of Arkansas Medical Sciences	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA.	cec9@psu.edu	SHARMA, Suresh/C-4431-2008; Hwang, Jungwook/P-1614-2015; SHARMA, Suresh D./AAD-7723-2022	SHARMA, Suresh/0000-0002-8633-4145; Hwang, Jungwook/0000-0002-2290-1649; SHARMA, Suresh D./0000-0002-8633-4145	NIAID NIH HHS [AI66919] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Allers J, 2001, J MOL BIOL, V311, P75, DOI 10.1006/jmbi.2001.4857; [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Canadillas JMP, 2003, EMBO J, V22, P2821, DOI 10.1093/emboj/cdg259; Chadalavada DM, 2000, J MOL BIOL, V301, P349, DOI 10.1006/jmbi.2000.3953; Chen L, 2003, NEUROSCIENCE, V120, P1005, DOI 10.1016/S0306-4522(03)00406-8; Collier AJ, 2002, NAT STRUCT BIOL, V9, P375, DOI 10.1038/nsb785; De Gaudenzi JG, 2003, J BIOL CHEM, V278, P18884, DOI 10.1074/jbc.M301756200; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Friebe P, 2002, J VIROL, V76, P5326, DOI 10.1128/JVI.76.11.5326-5338.2002; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; GUERON M, 1987, NATURE, V328, P89, DOI 10.1038/328089a0; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; Huang LY, 2004, PROTEIN EXPRES PURIF, V37, P144, DOI 10.1016/j.pep.2004.05.005; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; Ito T, 1997, J VIROL, V71, P8698, DOI 10.1128/JVI.71.11.8698-8706.1997; Kieft JS, 2002, NAT STRUCT BIOL, V9, P370, DOI 10.1038/nsb781; Koch JO, 1999, J VIROL, V73, P7138; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Konan KV, 2003, J VIROL, V77, P7843, DOI 10.1128/JVI.77.14.7843-7855.2003; LEROY JL, 1985, J BIOMOL STRUCT DYN, V2, P915, DOI 10.1080/07391102.1985.10507609; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lytle JR, 2002, RNA, V8, P1045, DOI 10.1017/S1355838202029965; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Ohndorf UM, 2001, J BIOL CHEM, V276, P27188, DOI 10.1074/jbc.M102891200; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Pathak HB, 2002, J BIOL CHEM, V277, P31551, DOI 10.1074/jbc.M204408200; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Reyes GR, 2002, J BIOMED SCI, V9, P187, DOI 10.1007/BF02256065; Schuster C, 2002, J VIROL, V76, P8058, DOI 10.1128/JVI.76.16.8058-8068.2002; Shimakami T, 2004, J VIROL, V78, P2738, DOI 10.1128/JVI.78.6.2738-2748.2004; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Spangberg K, 1999, J HUMAN VIROL, V2, P296; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; Tallet-Lopez B, 2003, NUCLEIC ACIDS RES, V31, P734, DOI 10.1093/nar/gkg139; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tellinghuisen TL, 2005, NATURE, V435, P374, DOI 10.1038/nature03580; Tellinghuisen TL, 2004, J BIOL CHEM, V279, P48576, DOI 10.1074/jbc.M407787200; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291; Yi MK, 2003, J VIROL, V77, P3557, DOI 10.1128/JVI.77.6.3557-3568.2003; You SY, 2004, J VIROL, V78, P1352, DOI 10.1128/JVI.78.3.1352-1366.2004	57	191	202	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36417	36428		10.1074/jbc.M508175200	http://dx.doi.org/10.1074/jbc.M508175200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126720	Green Published, hybrid			2022-12-25	WOS:000232726900076
J	Xu, HY; Yang, Q; Shen, MH; Huang, XM; Dembski, M; Gimeno, R; Tartaglia, LA; Kapeller, R; Wu, ZD				Xu, HY; Yang, Q; Shen, MH; Huang, XM; Dembski, M; Gimeno, R; Tartaglia, LA; Kapeller, R; Wu, ZD			Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYKINASE GTP GENE; PROTEIN-KINASE; INSULIN-RESISTANCE; EXPRESSION; ADIPOCYTES; PATHWAY; TARGETS; CLONING; MKP-3	Insulin is a key hormone that controls glucose homeostasis. In liver, insulin suppresses gluconeogenesis by inhibiting the transcriptions of phosphoenolpyruvate carboxylase ( PEPCK) and glucose-6-phosphatase (G6Pase) genes. In insulin resistance and type II diabetes there is an elevation of hepatic gluconeogenesis, which contributes to hyperglycemia. To search for novel genes that negatively regulate insulin signaling in controlling metabolic pathways, we screened a cDNA library derived from the white adipose tissue of ob/ob mice using a reporter system comprised of the PEPCK promoter placed upstream of the alkaline phosphatase gene. The mitogen-activated dual specificity protein kinase phosphatase 3 (MKP-3) was identified as a candidate gene that antagonized insulin suppression on PEPCK gene transcription from this screen. In this study, we showed that MKP-3 was expressed in insulin-responsive tissues and that its expression was markedly elevated in the livers of insulin-resistant obese mice. In addition, MKP-3 can activate PEPCK promoter in synergy with dexamethasone in hepatoma cells. Furthermore, ectopic expression of MKP-3 in hepatoma cells by adenoviral infection increased the expression of PEPCK and G6Pase genes and led to elevated glucose production. Taken together, our data strongly suggests that MKP-3 plays a role in regulating gluconeogenic gene expression and hepatic gluconeogenesis. Therefore, dysregulation of MKP-3 expression and/or function in liver may contribute to the pathogenesis of insulin resistance and type II diabetes.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Wu, ZD (corresponding author), Novartis Inst Biomed Res Inc, 100 Technol Sq, Cambridge, MA 02139 USA.	zhidan.wu@pharma.novartis.com		Wu, Zhidan/0000-0001-7289-9420	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080746] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK080746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barf T, 2004, MINI-REV MED CHEM, V4, P897, DOI 10.2174/1389557043403459; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Bazuine M, 2004, MOL ENDOCRINOL, V18, P1697, DOI 10.1210/me.2003-0213; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Dickinson RJ, 2002, MECH DEVELOP, V113, P193, DOI 10.1016/S0925-4773(02)00024-2; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Klock A, 2002, MECH DEVELOP, V116, P243, DOI 10.1016/S0925-4773(02)00153-3; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Muda M, 1996, J BIOL CHEM, V271, P4319; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/diacare.13.3.327; Olswang Y, 2003, J BIOL CHEM, V278, P12929, DOI 10.1074/jbc.M300263200; Sakaue H, 2004, J BIOL CHEM, V279, P39951, DOI 10.1074/jbc.M407353200; Sutherland C, 1996, PHILOS T ROY SOC B, V351, P191, DOI 10.1098/rstb.1996.0016; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Waltner-Law M, 2003, J BIOL CHEM, V278, P10427, DOI 10.1074/jbc.M211846200; Xu HY, 2003, J BIOL CHEM, V278, P30187, DOI 10.1074/jbc.M302010200	26	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36013	36018		10.1074/jbc.M508027200	http://dx.doi.org/10.1074/jbc.M508027200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126724	hybrid			2022-12-25	WOS:000232726900030
J	Dominguez, PL; Kolodney, MS				Dominguez, PL; Kolodney, MS			Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens	ONCOGENE			English	Article						polymerase chain reaction (PCR); locked nucleic acid (LNA); BRAF; melanoma	POINT MUTATIONS; DNA; PCR	Detection and sequencing of mutations from clinical specimens is often complicated by the presence of an excess of nonmutated cells. To facilitate the detection and sequencing of minority mutations from clinical specimens, we developed wild-type blocking polymerase chain reaction (WTB-PCR). This technique allows sensitive detection of minority mutations in a tissue sample containing excess wild-type DNA. In WTB-PCR, a nonextendable locked nucleic acid (LNA) oligonucleotide binds tightly to a region of wild-type DNA known to develop point mutations. This LNA sequence blocks amplification of wild-type DNA during PCR while permitting amplification of mutant exon 15. Our results show that the LNA blocking oligonucleotide inhibits amplification of wild-type DNA in a dose-dependent manner. WTB-PCR was able to detect mutant DNA in clinical samples of melanoma tissue containing an excess of nonmelanoma cells. This method was also able to detect small amounts of point mutated or tandem mutated DNA diluted with a much larger concentration of wild-type DNA. This rapid and simple assay overcomes the limitations of current methods to detect minority mutations. The potential applications of WTB-PCR include early diagnosis and prognosis of various cancers.	Harbor UCLA Med Ctr, Div Dermatol, Dept Med, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Kolodney, MS (corresponding author), Harbor UCLA Med Ctr, Div Dermatol, Dept Med, 1000 W Carson St,Box 459, Torrance, CA 90509 USA.	mkolodney@labiomed.org		kolodney, Michael/0000-0003-1931-8644				Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Kaur M, 2002, MUTAGENESIS, V17, P365, DOI 10.1093/mutage/17.5.365; Latorra D, 2003, MOL CELL PROBE, V17, P253, DOI 10.1016/S0890-8508(03)00062-8; Liu Q, 2002, BIOTECHNIQUES, V33, P129, DOI 10.2144/02331rr04; Makrigiorgos GM, 2004, HUM MUTAT, V23, P406, DOI 10.1002/humu.20024; Miller CJ, 2004, J INVEST DERMATOL, V123, P990, DOI 10.1111/j.0022-202X.2004.23468.x; Mouritzen P, 2003, EXPERT REV MOL DIAGN, V3, P27, DOI 10.1586/14737159.3.1.27; Oliver DH, 2000, J MOL DIAGN, V2, P202, DOI 10.1016/S1525-1578(10)60638-1; Parsons BL, 1997, MUTAT RES-REV MUTAT, V387, P97, DOI 10.1016/S1383-5742(97)00026-4; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Yu D, 1997, BIOTECHNIQUES, V23, P714, DOI 10.2144/97234st06; YU D, 1997, BIOTECHNIQUES, V23, P718	12	72	106	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6830	6834		10.1038/sj.onc.1208832	http://dx.doi.org/10.1038/sj.onc.1208832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16116485				2022-12-25	WOS:000232527800010
J	Collins, RF; Beis, K; Clarke, BR; Ford, RC; Hulley, M; Naismith, JH; Whitfield, C				Collins, RF; Beis, K; Clarke, BR; Ford, RC; Hulley, M; Naismith, JH; Whitfield, C			Periplasmic protein-protein contacts in the inner membrane protein Wzc form a tetrameric complex required for the assembly of Escherichia coli group 1 capsules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; TYROSINE AUTOKINASE; FUNCTIONAL-ANALYSIS; POLYSACCHARIDE; TRANSLOCATION; EXPRESSION; SURFACE; PHOSPHORYLATION; TRANSPORT; EXPORT	The K antigenic capsular polysaccharide forms a structural layer, the capsule, on the surfaces of Escherichia coli cells. The capsule provides an important protective covering that helps protect encapsulated bacteria from host immune defenses. The assembly and translocation of the capsule requires proteins in the inner and outer membranes. The inner membrane protein Wzc is a tyrosine autokinase that plays an essential role in what is believed to be a coordinated biosynthesis and secretion process. Mutants lacking Wzc can form K antigen oligosaccharides but are unable to polymerize high molecular weight capsular polymers. Wzc homologs have been identified in exopolymer biosynthesis systems in many different Gram-negative and -positive bacteria. Using single particle averaging on cryo-negatively stained samples, we have produced the first three-dimensional structure of this type of membrane protein in its phosphorylated state at similar to 14 angstrom resolution. Perfluoro-octanoate-PAGE analysis of detergent-solubilized oligomeric Wzc and symmetry analysis of the transmission electron microscopy data clearly demonstrated that Wzc forms a tetrameric complex with C4 rotational symmetry. Viewed from the top of the complex, the oligomer is square with a diameter of similar to 100 angstrom and can be divided into four separate densities. From the side, Wzc is similar to 110 angstrom high and has a distinctive appearance similar to an extracted molar tooth. The upper "crown" region is similar to 55 angstrom high and forms a continuous ring of density. Four unconnected "roots" (similar to 65 angstrom high) emerge from the underside of the crown. We propose that the crown is formed by protein-protein contacts from the four Wzc periplasmic domains, while each root represents an individual cytoplasmic tyrosine autokinase domain.	Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Manchester; University of St Andrews; University of Guelph	Collins, RF (corresponding author), Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England.	Richard.Collins@manchester.ac.uk; cwhitfie@uoguelph.ca	Naismith, James Henderson/H-3408-2012; Naismith, James Henderson/AAB-8614-2020	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Beis, Konstantinos/0000-0001-5727-4721; Ford, Robert/0000-0002-0958-1505	Wellcome Trust [067305, 081862] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beis K, 2004, J BIOL CHEM, V279, P28227, DOI 10.1074/jbc.M402913200; Bitter W, 2003, ARCH MICROBIOL, V179, P307, DOI 10.1007/s00203-003-0541-8; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; BURKHARD R, 2001, J STRUCT BIOL, V134, P204; Camberg JL, 2005, J BACTERIOL, V187, P249, DOI 10.1128/JB.187.1.249-256.2005; Collins RF, 2004, J BIOL CHEM, V279, P39750, DOI 10.1074/jbc.M405971200; Collins RF, 2001, J BACTERIOL, V183, P3825, DOI 10.1128/JB.183.13.3825-3832.2001; Cozzone AJ, 2004, ARCH MICROBIOL, V181, P171, DOI 10.1007/s00203-003-0640-6; Doublet P, 2002, J BIOL CHEM, V277, P37339, DOI 10.1074/jbc.M204465200; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Jann K., 1997, P113; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; Matias VRF, 2003, J BACTERIOL, V185, P6112, DOI 10.1128/JB.185.20.6112-6118.2003; Morona R, 2000, MICROBIOL-UK, V146, P1, DOI 10.1099/00221287-146-1-1; Nesper J, 2003, J BIOL CHEM, V278, P49763, DOI 10.1074/jbc.M308775200; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Paiment A, 2002, J BACTERIOL, V184, P6437, DOI 10.1128/JB.184.23.6437-6447.2002; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahn A, 2003, J BACTERIOL, V185, P5882, DOI 10.1128/JB.185.19.5882-5890.2003; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Reid AN, 2005, J BACTERIOL, V187, P5470, DOI 10.1128/JB.187.15.5470-5481.2005; Robien MA, 2003, J MOL BIOL, V333, P657, DOI 10.1016/j.jmb.2003.07.015; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Whitfield C, 2003, CARBOHYD RES, V338, P2491, DOI 10.1016/j.carres.2003.08.010; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200	34	62	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2144	2150		10.1074/jbc.M508078200	http://dx.doi.org/10.1074/jbc.M508078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16172129	hybrid, Green Accepted			2022-12-25	WOS:000234760400037
J	Kuphal, S; Wallner, S; Schimanski, CC; Bataille, F; Hofer, P; Strand, S; Strand, D; Bosserhoff, AK				Kuphal, S; Wallner, S; Schimanski, CC; Bataille, F; Hofer, P; Strand, S; Strand, D; Bosserhoff, AK			Expression of Hugl-1 is strongly reduced in malignant melanoma	ONCOGENE			English	Article						Lgl; Hugl; human; tumor; suppressor gene; malignant melanoma; cancer	TUMOR-SUPPRESSOR GENE; LETHAL-GIANT-LARVAE; II HEAVY-CHAIN; BREAST-CARCINOMA; CELL POLARITY; HUMAN HOMOLOG; IN-VIVO; DROSOPHILA; PROTEIN; CANCER	The human gene Hugl-1 (Llgl/Lgl1) has significant homology to the Drosophila tumor suppressor gene lethal(2) giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that is involved in maintaining cell polarity and epithelial integrity. We speculate that Hugl-1 might play a role in epithelial mesenchymal transition (EMT) and that loss of Hugl-1 expression plays a role in the development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of Hugl-1 transcription. We found that Hugl-1 was downregulated or lost in all cell lines and in most of the tumor samples analysed, and that these losses were associated with advanced stage of the disease. Redu ced Hugl-1 expression occurred as early as in primary tumors detected by both immunohistochemical and reverse transcription-polymerase chain reaction (RT-PCR) analysis. Fun ctional assays with stable Hugl-1-transfected cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Further, downregulation of MMP2 and MMP14 (MT1- MMP) and re-expression of E-cadherin was found in the Hugl-1-expressing cell clones supporting a role of Hugl-1 in EMT. Our studies thus indicate that loss of Hugl-1 expression contributes to melanoma progression.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany	University of Regensburg; Johannes Gutenberg University of Mainz	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Borg JP, 2004, PATHOL BIOL, V52, P328, DOI 10.1016/j.patbio.2003.09.015; DANEN EHJ, 1995, CANCER SURV, V24, P43; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Haass NK, 2004, J MOL HISTOL, V35, P309; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; JACOB K, 1995, INT J CANCER, V60, P668, DOI 10.1002/ijc.2910600517; Jankowski JA, 1997, J CLIN PATHOL-MOL PA, V50, P289; Justice N, 2003, CURR BIOL, V13, P778, DOI 10.1016/S0960-9822(03)00288-4; Kalmes A, 1996, J CELL SCI, V109, P1359; Kuphal S, 2005, MELANOMA RES, V15, P305, DOI 10.1097/00008390-200508000-00012; Li G, 2004, EXP CELL RES, V297, P142, DOI 10.1016/j.yexcr.2004.03.012; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	35	97	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					103	110		10.1038/sj.onc.1209008	http://dx.doi.org/10.1038/sj.onc.1209008			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170365				2022-12-25	WOS:000234406400011
J	Vera, J; Jaumot, M; Estanyol, JM; Brun, S; Agell, N; Bachs, O				Vera, J; Jaumot, M; Estanyol, JM; Brun, S; Agell, N; Bachs, O			Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor	ONCOGENE			English	Article						SET protein; hnRNPA2; PP2A; cell cycle	LUNG-CANCER DETECTION; ACTIVATING FACTOR-I; PHOSPHATASE 2A; GRANZYME-A; MESSENGER-RNA; FISSION YEAST; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; CELL-CYCLE; HNRNP A2	The oncoprotein SET participates in a diversity of cellular functions including cell proliferation. Its role on cell cycle progression is likely mediated by inhibiting cyclin B-cdk1 and the protein phosphatase 2A (PP2A). On identifying new SET cellular partners, we found that SET interacts in vitro and in vivo with the heterogeneous nuclear ribonucleoprotein A2(hnRNPA2); a protein involved in various aspects of mRNA biogenesis. The SET-binding region of hnRNPA2 is the RNP1 sequence that belongs to the RNA-binding domain (RBD) of this protein. We also found that hnRNPA2 has much higher affinity for single-standed DNA than for SET. On analysing the effect of hnRNPA2 on PP2A inhibition by SET, we observed that hnRNPA2 cooperates with SET on PP2A inhibition. This is because we found that hnRNPA2 is also a PP2A inhibitor. HnRNPA2 interacts with PP2A by the RNP1 sequence; however, to inhibit PP2A activity, the complete RBD is needed. We also observed that overexpression of hnRNPA2 inhibits PP2A activity and stimulates cell proliferation. Interestingly, the overexpression of the complete RBD is sufficient to stimulate proliferation. As hnRNPA2 is overexpressed in a variety of human tumors, our results suggest that hnRNPA2 might participate in oncogenesis by stimulating cell proliferation.	Univ Barcelona, Fac Med, Dept Cell Biol & Pathol, Barcelona, Spain	University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016; Jaumot, Montserrat/F-2640-2016; Brun, Sonia/AAA-4585-2019	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074; Brun, Sonia/0000-0002-2056-3180; Jaumot, Montserrat/0000-0003-2864-357X				Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; BOSSER R, 1995, MOL CELL BIOL, V15, P661; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fielding P, 1999, CLIN CANCER RES, V5, P4048; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moran-Jones K, 2005, NUCLEIC ACIDS RES, V33, P486, DOI 10.1093/nar/gki203; Mulshine JL, 2000, CANCER-AM CANCER SOC, V89, P2465; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Patry C, 2003, CANCER RES, V63, P7679; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Sanchez-Piris M, 2002, J BIOL CHEM, V277, P17722, DOI 10.1074/jbc.M200104200; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; VON LM, 1992, MOL CELL BIOL, V12, P3346; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yan-Sanders Y, 2002, CANCER LETT, V183, P215, DOI 10.1016/S0304-3835(02)00168-4; Zhou J, 2001, BREAST CANCER RES TR, V66, P217, DOI 10.1023/A:1010631915831	44	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					260	270		10.1038/sj.onc.1209050	http://dx.doi.org/10.1038/sj.onc.1209050			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170352				2022-12-25	WOS:000234583600010
J	Homer, C; Knight, DA; Hananeia, L; Sheard, P; Risk, J; Lasham, A; Royds, JA; Braithwaite, AW				Homer, C; Knight, DA; Hananeia, L; Sheard, P; Risk, J; Lasham, A; Royds, JA; Braithwaite, AW			Y-box factor YB1 controls p53 apoptotic function	ONCOGENE			English	Article						YB1; nuclear localization; p53 functions; apoptosis	BINDING-PROTEIN YB-1; MAMMARY EPITHELIAL-CELLS; MDR1 GENE-EXPRESSION; NUCLEAR EXPRESSION; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; P16(INK4) EXPRESSION; P-GLYCOPROTEIN; LOCALIZATION; DOMAIN	Nuclear localization and high levels of the Y-box-binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we have continued to explore YB1/p53 interactions. We report that transcriptionally active p53 is required for nuclear localization of YB1. We go on to show that nuclear YB1 regulates p53 function. Our data demonstrate that YB1 inhibits the ability of p53 to cause cell death and to transactivate cell death genes, but does not interfere with the ability of p53 to transactivate the CDKN1A gene, encoding the kinase p21(WAF1/CIP1) required for cell cycle arrest, nor the MDM2 gene. We also show that nuclear YB1 is associated with a failure to increase the level of the Bax protein in normal mammary epithelial cells after stress activation of p53. Together these data suggest that (nuclear) YB1 selectively alters p53 activity, which may in part provide an explanation for the correlation of nuclear YB1 with drug resistance and poor tumor prognosis.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin 9001, Otago, New Zealand; Univ Otago, Sch Med Sci, Dept Physiol, Dunedin, New Zealand; Genesis Res & Dev Corp Ltd, Auckland, New Zealand	University of Otago; University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin 9001, Otago, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz	Risk, Joanna/A-1998-2010					ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Chen CY, 2000, GENE DEV, V14, P1236; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Huschtscha LI, 1998, CANCER RES, V58, P3508; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Levenson VV, 2000, CANCER RES, V60, P5027; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Prives C, 1999, J PATHOL, V187, P112; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SAKURA H, 1988, GENE, V73, P499; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; SUTHERLAND BW, 2005, ADV ONLINE PUBLICATI; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	47	73	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8314	8325		10.1038/sj.onc.1208998	http://dx.doi.org/10.1038/sj.onc.1208998			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16158057				2022-12-25	WOS:000233956500010
J	Chernyavsky, AI; Arredondo, J; Karlsson, E; Wessler, I; Grando, SA				Chernyavsky, AI; Arredondo, J; Karlsson, E; Wessler, I; Grando, SA			The Ras/Raf-1/MEK1/ERK signaling pathway coupled to integrin expression mediates cholinergic regulation of keratinocyte directional migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; PULMONARY NEUROENDOCRINE CELLS; NERVE GROWTH CONES; ELECTRIC-FIELDS; MUSCARINIC RECEPTORS; CALCIUM INFLUX; KINASE PATHWAY; MUSCLE-CELLS; RAT; ACTIVATION	The physiologic mechanisms that determine directionality of lateral migration are a subject of intense research. Galvanotropism in a direct current ( DC) electric field represents a natural model of cell re-orientation toward the direction of future migration. Keratinocyte migration is regulated through both the nicotinic and muscarinic classes of acetylcholine (ACh) receptors. We sought to identify the signaling pathway mediating the cholinergic regulation of chemotaxis and galvanotropism. The pharmacologic and molecular modifiers of the Ras/Raf-1/MEK1/ERK signaling pathway altered both chemotaxis toward choline and galvanotropism toward the cathode in a similar way, indicating that the same signaling steps were involved. The galvanotropism was abrogated due to inhibition of ACh production by hemicholinium-3 and restored by exogenously added carbachol. The concentration gradients of ACh and choline toward the cathode in a DC field were established by high-performance liquid chromatographic measurements. This suggested that keratinocyte galvanotaxis is, in effect, chemotaxis toward the concentration gradient of ACh, which it creates in a DC field due to its highly positive charge. A time-course immunofluorescence study of the membrane redistribution of ACh receptors in keratinocytes exposed to a DC field revealed rapid relocation to and clustering at the leading edge of alpha 7 nicotinic and M-1 muscarinic receptors. Their inactivation with selective antagonists or small interfering RNAs inhibited galvanotropism, which could be prevented by transfecting the cells with constitutively active MEK1. The end-point effect of the cooperative signaling downstream from alpha 7 and M-1 through the MEK1/ERK was an up-regulated expression of alpha(2) and alpha(3) integrins, as judged from the results of real-time PCR and quantitative immunoblotting. Thus, alpha 7 works together with M-1 to orient a keratinocyte toward direction of its future migration. Both alpha 7 and M-1 apparently engage the Ras/Raf/MEK/ERK pathway to up-regulate expression of the "sedentary" integrins required for stabilization of the lamellipodium at the keratinocyte leading edge.	Univ Calif Davis, Sch Med, Dept Dermatol, Davis, CA 95616 USA; Karolinska Inst, Sect Expt Geriatr, NEUROTEC, S-14186 Huddinge, Sweden; Johannes Gutenberg Univ Mainz, Univ Hosp, Inst Pathol, D-55101 Mainz, Germany	University of California System; University of California Davis; Karolinska Institutet; Johannes Gutenberg University of Mainz; University Hospital Mainz	Grando, SA (corresponding author), Univ Calif Davis, Dept Dermatol, UC Davis Med Ctr, 4860 Y St,3400, Sacramento, CA 95817 USA.	sagrando@ucdavis.edu			NIDCR NIH HHS [DE14173] Funding Source: Medline; NIGMS NIH HHS [GM62136] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062136] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; BARKER AT, 1982, AM J PHYSIOL, V242, pR358, DOI 10.1152/ajpregu.1982.242.3.R358; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; Buchli R, 1999, J CELL BIOCHEM, V74, P264, DOI 10.1002/(SICI)1097-4644(19990801)74:2<264::AID-JCB11>3.0.CO;2-Z; BURR H. S., 1940, YALE JOUR BIOL AND MED, V12, P483; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Chernyavsky AI, 2004, J CELL SCI, V117, P5665, DOI 10.1242/jcs.01492; Chernyavsky AI, 2004, J CELL BIOL, V166, P261, DOI 10.1083/jcb.200401034; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; DIPALMA JR, 1994, BASIC PHARM MED; Elwary SMA, 2004, J INVEST DERMATOL, V123, P1206, DOI 10.1111/j.0022-202X.2004.23493.x; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; ERICKSON CA, 1984, J CELL BIOL, V98, P296, DOI 10.1083/jcb.98.1.296; Genersch E, 2000, J CELL SCI, V113, P4319; GRANDO SA, 1993, J INVEST DERMATOL, V101, P804, DOI 10.1111/1523-1747.ep12371699; Grando SA, 1996, J INVEST DERMATOL, V107, P412, DOI 10.1111/1523-1747.ep12363399; GRANDO SA, 1993, J INVEST DERMATOL, V101, P32, DOI 10.1111/1523-1747.ep12358588; GRANDO SA, 1997, CURR OPIN DERMATOL, V4, P262; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Jaffe L F, 1984, Clin Dermatol, V2, P34, DOI 10.1016/0738-081X(84)90025-7; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Karlsson E, 2000, BIOCHIMIE, V82, P793, DOI 10.1016/S0300-9084(00)01176-7; Kostouros GD, 1996, EUR J ORAL SCI, V104, P570, DOI 10.1111/j.1600-0722.1996.tb00143.x; Kuffler DP, 1996, MOL CHEM NEUROPATHOL, V28, P199, DOI 10.1007/BF02815223; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Li S, 2004, J PHARMACOL SCI, V94, P334, DOI 10.1254/jphs.94.334; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; LUTHER PW, 1985, J CELL BIOL, V100, P235, DOI 10.1083/jcb.100.1.235; Morris SJ, 1996, J PHYSIOL-LONDON, V496, P531, DOI 10.1113/jphysiol.1996.sp021704; Ndoye A, 1998, J INVEST DERMATOL, V111, P410, DOI 10.1046/j.1523-1747.1998.00299.x; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nguyen VT, 2000, J DENT RES, V79, P939; Nguyen VT, 2001, J CELL SCI, V114, P1189; Nishimura KY, 1996, J CELL SCI, V109, P199; NOWAK D, 1990, EXP PATHOL-JENA, V39, P37; Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070-2153(03)58001-2; Papke RL, 1996, NEUROSCI LETT, V213, P201; PENG HB, 1993, J CELL BIOL, V120, P197, DOI 10.1083/jcb.120.1.197; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; QIAN NX, 1995, LIFE SCI, V56, P945, DOI 10.1016/0024-3205(95)00032-2; Quik M, 1996, J NEUROCHEM, V67, P145; Reinheimer T, 1996, AM J PHYSIOL-LUNG C, V270, pL722, DOI 10.1152/ajplung.1996.270.5.L722; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; SLIWA L, 1995, ARCH ANDROLOGY, V35, P105, DOI 10.3109/01485019508987860; STOLLBERG J, 1990, J CELL BIOL, V111, P2029, DOI 10.1083/jcb.111.5.2029; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; TOTTI N, 1984, SCIENCE, V223, P169, DOI 10.1126/science.6318317; Trollinger DR, 2002, J CELL PHYSIOL, V193, P1, DOI 10.1002/jcp.10144; VANDERMEERS A, 1995, TOXICON, V33, P1171, DOI 10.1016/0041-0101(95)00057-S; VELDSEMACURRIE RD, 1984, BRAIN RES, V324, P305, DOI 10.1016/0006-8993(84)90041-6; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; VODOVNIK L, 1992, MED BIOL ENG COMPUT, V30, P257, DOI 10.1007/BF02446963; Wang ET, 2003, INVEST OPHTH VIS SCI, V44, P244, DOI 10.1167/iovs.02-0456; WEISS DS, 1990, ARCH DERMATOL, V126, P222, DOI 10.1001/archderm.126.2.222; WILSON WS, 1986, EXP EYE RES, V43, P235, DOI 10.1016/S0014-4835(86)80091-4; Wityak J, 2004, BIOORG MED CHEM LETT, V14, P1483, DOI 10.1016/j.bmcl.2004.01.012; Yassin L, 2001, MOL CELL NEUROSCI, V17, P589, DOI 10.1006/mcne.2000.0944; YOUNG SH, 1983, NATURE, V304, P161, DOI 10.1038/304161a0; Zheng JQ, 1996, PERSPECT DEV NEUROBI, V4, P205; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zia SH, 2000, J PHARMACOL EXP THER, V293, P973	64	70	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39220	39228		10.1074/jbc.M504407200	http://dx.doi.org/10.1074/jbc.M504407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16150734	hybrid			2022-12-25	WOS:000233362200038
J	Murakami, MT; Arni, RK				Murakami, MT; Arni, RK			Thrombomodulin-independent activation of protein C and specificity of hemostatically active snake venom serine proteinases - Crystal structures of native and inhibited Agkistrodon contortrix contortrix protein C activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; BLOOD-COAGULATION; FACTOR-V; INACTIVATION; PURIFICATION; MUTAGENESIS; REFINEMENT; PLASMA; SITE	Protein C activation initiated by the thrombin-thrombomodulin complex forms the major physiological anticoagulant pathway. Agkistrodon contortrix contortrix protein C activator, a glycosylated single-chain serine proteinase, activates protein C without relying on thrombomodulin. The crystal structures of native and inhibited Agkistrodon contortrix contortrix protein C activator determined at 1.65 and 1.54 angstrom resolutions, respectively, indicate the pivotal roles played by the positively charged belt and the strategic positioning of the three carbohydrate moieties surrounding the catalytic site in protein C recognition, binding, and activation. Structural changes in the benzamidine-inhibited enzyme suggest a probable function in allosteric regulation for the anion-binding site located in the C-terminal extension, which is fully conserved in snake venom serine proteinases, that preferentially binds Cl1- instead of SO42-.	UNESP, IBILCE, Dept Phys, Biochem & Struct Biol Grp, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil	Universidade Estadual Paulista	Arni, RK (corresponding author), UNESP, IBILCE, Dept Phys, Biochem & Struct Biol Grp, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.	arni@ibilce.unesp.br	Murakami, Mario T/F-5640-2016; Arni, Raghuvir K/N-9338-2018; Murakami, Mario T/C-2087-2012; Arni, Raghuvir K/B-2222-2013	Murakami, Mario T/0000-0002-0405-8010; Arni, Raghuvir K/0000-0003-2460-1145; Arni, Raghuvir K/0000-0003-2460-1145				ADLER M, 1995, J BIOL CHEM, V270, P23366, DOI 10.1074/jbc.270.40.23366; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1995, SEMIN CELL BIOL, V6, P259, DOI 10.1006/scel.1995.0035; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FULCHER CA, 1984, BLOOD, V63, P486; Gempeler-Messina PM, 2001, HAEMOSTASIS, V31, P266; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; HARLEY BS, 1971, ENZYMES, P323; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KISIEL W, 1987, J BIOL CHEM, V262, P12607; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marsh N, 2005, TOXICON, V45, P1171, DOI 10.1016/j.toxicon.2005.02.016; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MCMULLEN BA, 1989, BIOCHEMISTRY-US, V28, P674, DOI 10.1021/bi00428a039; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parry MAA, 1998, STRUCT FOLD DES, V6, P1195, DOI 10.1016/S0969-2126(98)00119-1; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; SCHWARZ HP, 1984, BLOOD, V64, P1297; STENFLO J, 1976, J BIOL CHEM, V251, P355; Stocker K., 1978, HDB EXPT PHARM, P451; STURZEBECHER J, 1991, TOXICON, V29, P151, DOI 10.1016/0041-0101(91)90099-D; Tu AT, 1991, HDB NATURAL TOXINS R, P827; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246; Zhang Y, 1997, J BIOL CHEM, V272, P20531, DOI 10.1074/jbc.272.33.20531; Zhu ZL, 2005, J BIOL CHEM, V280, P10524, DOI 10.1074/jbc.M412900200	32	36	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39309	39315		10.1074/jbc.M508502200	http://dx.doi.org/10.1074/jbc.M508502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16162508	hybrid			2022-12-25	WOS:000233362200050
J	Barran, PE; Roeseke, RW; Pawson, AJ; Sellar, R; Bowers, MT; Morgan, K; Lu, ZL; Tsuda, M; Kusakabe, T; Millar, RP				Barran, PE; Roeseke, RW; Pawson, AJ; Sellar, R; Bowers, MT; Morgan, K; Lu, ZL; Tsuda, M; Kusakabe, T; Millar, RP			Evolution of constrained gonadotropin-releasing hormone ligand conformation and receptor selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GNRH-II; AGONIST; PROTOCHORDATE; BINDING; STIMULATION; ANTAGONISTS; PITUITARY; PEPTIDES; AFFINITY; CHICKEN	Gonadotropin-releasing hormone (GnRH) is the central regulator of reproduction in vertebrates. GnRHs have recently been identified in protochordates and retain the conserved N- and C-terminal domains involved in receptor binding and activation. GnRHs of the jawed vertebrates have a central achiral amino acid (glycine) that favors a type II' beta-turn such that the N- and C-terminal domains are closely apposed in binding the GnRH receptor. However, protochordate GnRHs have a chiral amino acid in this position, suggesting that they bind their receptors in a more extended form. We demonstrate here that a protochordate GnRH receptor does not distinguish GnRHs with achiral or chiral amino acids, whereas GnRH receptors of jawed vertebrates are highly selective for GnRHs with the central achiral glycine. The poor activity of the protochordate GnRH was increased >10-fold at vertebrate receptors by replacement of the chiral amino acid with glycine or a D-amino acid, which favor the type II' beta-turn. Structural analysis of the GnRHs using ion mobility-mass spectrometry and molecular modeling showed a greater propensity for a type II' beta-turn in GnRHs with glycine or a D-amino acid, which correlates with binding affinity at vertebrate receptors. These findings indicate that the substitution of glycine for a chiral amino acid in GnRH during evolution allows a more constrained conformation for receptor binding and that this subtle single amino acid substitution in a site remote from the ligand functional domains has marked effects on its structure and activity.	Queens Med Res Inst, Ctr Reprod Biol, MRC, Human Reprod Sci Unit, Edinburgh EH16 4TJ, Midlothian, Scotland; Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Himeji Inst Technol, Dept Life Sci, Himeji, Hyogo 6781297, Japan; Univ Cape Town, Dept Biochem Med, ZA-7925 Cape Town, South Africa	University of Edinburgh; University of Edinburgh; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Santa Barbara; University of Hyogo; University of Cape Town	Millar, RP (corresponding author), Queens Med Res Inst, Ctr Reprod Biol, MRC, Human Reprod Sci Unit, Edinburgh EH16 4TJ, Midlothian, Scotland.	r.millar@hrsu.mrc.ac.uk	Kusakabe, Takehiro/H-7178-2012; Millar, Robert P/A-4853-2012; Barran, Perdita/AAY-6303-2021; Pawson, Adam J/Q-5678-2016	Kusakabe, Takehiro/0000-0002-8325-3665; Pawson, Adam J/0000-0003-2280-845X; Lu, Zhiliang/0000-0002-3442-1415; Millar, Robert P/0000-0003-3606-2708	Medical Research Council [MC_U127685846, U.1276.00.005.00001.01 (85846)] Funding Source: Medline; Engineering and Physical Sciences Research Council [GR/R76226/01] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Adams BA, 2003, ENDOCRINOLOGY, V144, P1907, DOI 10.1210/en.2002-0216; Bashford D, 2000, ANNU REV PHYS CHEM, V51, P129, DOI 10.1146/annurev.physchem.51.1.129; Bogerd J, 2002, ENDOCRINOLOGY, V143, P4673, DOI 10.1210/en.2002-220578; Cameron CB, 1999, GEN COMP ENDOCR, V114, P2, DOI 10.1006/gcen.1998.7218; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; Craig AG, 1997, FEBS LETT, V413, P215, DOI 10.1016/S0014-5793(97)00840-5; DALKIN AC, 1981, ENDOCRINOLOGY, V108, P1658, DOI 10.1210/endo-108-5-1658; Davidson JS, 1996, J BIOL CHEM, V271, P15510, DOI 10.1074/jbc.271.26.15510; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22636; Fromme BJ, 2001, MOL PHARMACOL, V60, P1280, DOI 10.1124/mol.60.6.1280; Gorbman A, 2003, GEN COMP ENDOCR, V131, P62, DOI 10.1016/S0016-6480(02)00647-0; Guarnieri F, 1996, J AM CHEM SOC, V118, P5580, DOI 10.1021/ja952745o; Harrison AG, 1997, MASS SPECTROM REV, V16, P201, DOI 10.1002/(SICI)1098-2787(1997)16:4<201::AID-MAS3>3.0.CO;2-L; Hoffmann SH, 2000, MOL ENDOCRINOL, V14, P1099, DOI 10.1210/me.14.7.1099; HSUEH AJW, 1985, J STEROID BIOCHEM, V23, P757, DOI 10.1016/S0022-4731(85)80011-X; Iwakoshi E, 2002, BIOCHEM BIOPH RES CO, V291, P1187, DOI 10.1006/bbrc.2002.6594; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; Kusakabe T, 2003, GENE, V322, P77, DOI 10.1016/j.gene.2003.08.013; Lu ZL, 2005, J BIOL CHEM, V280, P29796, DOI 10.1074/jbc.M413520200; Maliekal JC, 1997, S AFR J CHEM-S-AFR T, V50, P217; Mason E., 1988, TRANSPORT PROPERTIES; Millar RP, 2004, ENDOCR REV, V25, P235, DOI 10.1210/er.2003-0002; Millar RP, 1997, ADVANCES IN COMPARATIVE ENDOCRINOLOGY, TOMES 1 AND 2, P15; MONAHAN MW, 1973, BIOCHEMISTRY-US, V12, P4616, DOI 10.1021/bi00747a012; Oh DY, 2003, MOL CELL ENDOCRINOL, V205, P89, DOI 10.1016/S0303-7207(03)00204-1; Pawson AJ, 2003, ENDOCRINOLOGY, V144, P3860, DOI 10.1210/en.2003-0028; Pazos AJ, 1999, GEN COMP ENDOCR, V113, P112, DOI 10.1006/gcen.1998.7186; Pfleger KDG, 2002, MOL ENDOCRINOL, V16, P2155, DOI 10.1210/me.2002-0159; Polfer NC, 2005, MOL PHYS, V103, P1481, DOI 10.1080/00268970500095998; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; Powell JFF, 1996, P NATL ACAD SCI USA, V93, P10461, DOI 10.1073/pnas.93.19.10461; Sakuma, 1997, GNRH NEURONS GENE BE, P51; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Sun YM, 2001, J BIOL CHEM, V276, P7754, DOI 10.1074/jbc.M009020200; Tello JA, 2005, ENDOCRINOLOGY, V146, P4061, DOI 10.1210/en.2004-1558; Terakado K, 2001, GEN COMP ENDOCR, V124, P277, DOI 10.1006/gcen.2001.7728; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Wyttenbach T, 2003, TOP CURR CHEM, V225, P207, DOI 10.1007/b10470; Wyttenbach T, 2001, INT J MASS SPECTROM, V212, P13, DOI 10.1016/S1387-3806(01)00517-6; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHOU W, 1995, J BIOL CHEM, V270, P18853, DOI 10.1074/jbc.270.32.18853	41	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38569	38575		10.1074/jbc.M503086200	http://dx.doi.org/10.1074/jbc.M503086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16157590	hybrid			2022-12-25	WOS:000233239800056
J	de Bouteiller, O; Merck, E; Hasan, UA; Hubac, S; Benguigui, B; Trinchieri, G; Bates, EEM; Caux, C				de Bouteiller, O; Merck, E; Hasan, UA; Hubac, S; Benguigui, B; Trinchieri, G; Bates, EEM; Caux, C			Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN DENDRITIC CELLS; FC-RECEPTOR; CPG-DNA; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; ESSENTIAL COMPONENTS; IMMUNE-RESPONSES; APOPTOTIC CELLS; ACTIVATION	Studies involving Toll-like receptor 3 (TLR3)-deficient mice suggest that this receptor binds double-stranded RNA. In the present study, we analyzed ligand/receptor interactions and receptor-proximal events leading to TLR3 activation. The mutagenesis approach showed that certain cysteine residues and glycosylation in TLR3 amino-terminal leucine-rich repeats were necessary for ligand-induced signaling. Furthermore, inactive mutants had a dominant negative effect, suggesting that the signaling module is a multimer. We constructed a chimeric molecule fusing the amino-terminal ectodomain of TLR3 to the transmembrane and carboxyl terminal domains of CD32a containing an immunoreceptor tyrosine-based motif. Expression of TLR3-CD32 in HEK293T cells and the myeloid cell line U937 resulted in surface localization of the receptor, whereas the nonrecombinant molecule was intracellularly localized. The synthetic double-stranded RNAs poly(I-C) and poly(A-U) induced calcium mobilization in a TLR3-CD32 stably transfected U937 clone but not in control cells transfected with other constructs. An anti-TLR3 antibody also induced Ca2+ flux but only when cross-linked by a secondary anti-immunoglobulin antibody, confirming that multimerization by the ligand is a requirement for signaling. The inhibitors of lysosome maturation, bafilomycin and chloroquine, inhibited the poly(I-C)-induced biological response in immune cells, showing that TLR3 interacted with its ligand in acidic subcellular compartments. Furthermore, TLR3-CD32 activation with poly(I-C) was only observed within a narrow pH window (pH 5.7-6.7), whereas anti-TLR3-mediated Ca2+ flux was pH-insensitive. The importance of an acidic pH for TLR3-ligand interaction becomes critical when using oligomeric poly(I-C) (15-40-mers). These observations demonstrate that engagement of TLR3 by poly(I-C) at an acidic pH, probably in early phagolysosomes or endosomes, induces receptor aggregation leading to signaling.	Schering Plough Res Inst, Lab Immunol Res, F-69571 Dardilly, France	Merck & Company	Caux, C (corresponding author), INSERM, U590, Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon, France.	CAUXC@lyon.fnclcc.fr	Caux, Christophe/G-2851-2013; hasan, uzma A/G-3247-2013; Trinchieri, Giorgio/F-9369-2015	Caux, Christophe/0000-0003-2438-833X; Trinchieri, Giorgio/0000-0001-5892-7464; Hasan, Uzma/0000-0002-1770-5539				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aksoy E, 2005, J BIOL CHEM, V280, P277, DOI 10.1074/jbc.M411223200; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Albert ML, 2004, NAT REV IMMUNOL, V4, P223, DOI 10.1038/nri11308; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Garoff H, 2004, VIRUS RES, V106, P103, DOI 10.1016/j.virusres.2004.08.008; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942; Hasan UA, 2004, BIOCHEM BIOPH RES CO, V321, P124, DOI 10.1016/j.bbrc.2004.06.134; Hasan UA, 2005, J BIOL CHEM, V280, P20620, DOI 10.1074/jbc.M500877200; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hoebe K, 2004, J ENDOTOXIN RES, V10, P130, DOI 10.1179/096805104225004031; Kaisho T, 2003, CURR MOL MED, V3, P373, DOI 10.2174/1566524033479726; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee HK, 2004, J BIOL CHEM, V279, P10564, DOI 10.1074/jbc.M311564200; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Matsumoto M, 2001, Uirusu, V51, P209; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mukhopadhyay S, 2004, IMMUNOLOGY, V112, P521, DOI 10.1111/j.1365-2567.2004.01941.x; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Salio M, 2000, EUR J IMMUNOL, V30, P705, DOI 10.1002/1521-4141(200002)30:2<705::AID-IMMU705>3.0.CO;2-P; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Salonen A, 2003, J VIROL, V77, P1691, DOI 10.1128/JVI.77.3.1691-1702.2003; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; SHEN L, 1994, J IMMUNOL, V153, P5849; Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x; Shi XH, 2004, J VIROL, V78, P5414, DOI 10.1128/JVI.78.10.5414-5422.2004; Sugimoto N, 2001, BIOCHEMISTRY-US, V40, P9396, DOI 10.1021/bi010666l; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; VANDENHERIKOUDIJK IE, 1995, BLOOD, V86, P3302, DOI 10.1182/blood.V86.9.3302.bloodjournal8693302; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Weber SM, 2002, J IMMUNOL, V168, P5303, DOI 10.4049/jimmunol.168.10.5303; Wu CCN, 2004, J BIOL CHEM, V279, P33071, DOI 10.1074/jbc.M311662200; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	68	204	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38133	38145		10.1074/jbc.M507163200	http://dx.doi.org/10.1074/jbc.M507163200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144834	hybrid			2022-12-25	WOS:000233239800005
J	Hao, JJ; Zhu, JW; Zhou, K; Smith, N; Zhan, X				Hao, JJ; Zhu, JW; Zhou, K; Smith, N; Zhan, X			The coiled-coil domain is required for HS1 to bind to F-actin and activate Arp2/3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC PROTEIN-1; TYROSINE PHOSPHORYLATION; N-WASP; CORTACTIN; LOCALIZATION; SUBSTRATE; SRC	HS1 ( hematopoietic lineage cell-specific protein 1), a substrate of protein tyrosine kinases in lymphocytes, binds to F-actin, and promotes Arp2/3 complex-mediated actin polymerization. However, the mechanism for the interaction between HS1 and F-actin has not yet been fully characterized. HS1 contains 3.5 tandem repeats, a coiled-coil region, and an SH3 domain at the C terminus. Unlike cortactin, which is closely related to HS1 and requires absolutely the repeat domain for F-actin binding, an HS1 mutant with deletion of the repeat domain maintains a significant F-actin binding activity. On the other hand, deletion of the coiled-coil region abolished the ability of HS1 to bind to actin filaments and to activate the Arp2/3 complex for actin nucleation and actin branching. Furthermore, a peptide containing the coiled-coil sequence only was sufficient for F-actin binding. Within cells overexpressing green fluorescent protein-tagged HS1 proteins, wild type HS1 co-localizes with cortical F-actin at the cell leading edge, whereas mutants with deletion of either the coiled-coil region or the repeat domain diffuse in the cytoplasm. Immunoprecipitation analysis reveals that the coiled-coil deletion mutant binds poorly to F-actin, whereas the mutant without the repeat domain fails to bind to both Arp2/3 complex and F-actin. These data suggest that the HS1 coiled-coil region acts synergistically with the repeat domain in the modulation of the Arp2/3 complex-mediated actin polymerization.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Pathol, Baltimore, MD 20855 USA	University System of Maryland; University of Maryland Baltimore	Zhan, X (corresponding author), Univ Maryland, Dept Pathol, 800 W Baltimore St, Baltimore, MD 21201 USA.	xzhan@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA091984] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052753, R29HL052753] Funding Source: NIH RePORTER; NCI NIH HHS [CA91984] Funding Source: Medline; NHLBI NIH HHS [HL52753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Hao JJ, 2004, J BIOL CHEM, V279, P33413, DOI 10.1074/jbc.M313564200; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Katsube T, 2004, ARCH BIOCHEM BIOPHYS, V427, P79, DOI 10.1016/j.abb.2004.04.015; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Li YS, 2004, EXP CELL RES, V298, P107, DOI 10.1016/j.yexcr.2004.03.023; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Zhu JW, 2005, J CELL SCI, V118, P807, DOI 10.1242/jcs.01668	18	39	41	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37988	37994		10.1074/jbc.M504552200	http://dx.doi.org/10.1074/jbc.M504552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157603	hybrid			2022-12-25	WOS:000233044500081
J	Lubarski, I; Pihakaski-Maunsbach, K; Karlish, SJD; Maunsbach, AB; Garty, H				Lubarski, I; Pihakaski-Maunsbach, K; Karlish, SJD; Maunsbach, AB; Garty, H			Interaction with the Na, K-ATPase and tissue distribution of FXYD5 (related to ion channel)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLEMMAN-LIKE PROTEIN; NA,K-ATPASE GAMMA-SUBUNIT; IMMUNOCYTOCHEMICAL LOCALIZATION; FUNCTIONAL INTERACTION; XENOPUS OOCYTES; E-CADHERIN; EXPRESSION; DYSADHERIN; CHIF; FAMILY	FXYD5 ( related to ion channel, dysadherin) is a member of the FXYD family of single span type I membrane proteins. Five members of this group have been shown to interact with the Na, K-ATPase and to modulate its properties. However, FXYD5 is structurally different from other family members and has been suggested to play a role in regulating E-cadherin and promoting metastasis ( Ino, Y., Gotoh, M., Sakamoto, M., Tsukagoshi, K., and Hirohashi, S. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 365 - 370). The goal of this study was to determine whether FXYD5 can modulate the Na, KA-TPase activity, establish its cellular and tissue distribution, and characterize its biochemical properties. Anti-FXYD5 antibodies detected a 24-kDa polypeptide that was preferentially expressed in kidney, intestine, spleen, and lung. In kidney, FXYD5 resides in the basolateral membrane of the connecting tubule, the collecting tubule, and the intercalated cells of the collecting duct. However, there is also labeling of the apical membrane in long thin limb of Henle's loop. FXYD5 was effectively immunoprecipitated by antibodies to the alpha subunit of Na, K-ATPase and the anti-FXYD5 antibody immunoprecipitates alpha. Co-expressing FXYD5 with the alpha 1 and beta 1 subunits of the Na, K-ATPase in Xenopus oocytes elicited a more than 2-fold increase in pump activity, measured either as ouabain-blockable outward current or as ouabain-sensitive Rb-86(+) uptake. Thus, as found with other FXYD proteins, FXYD5 interacts with the Na, K-ATPase and modulates its properties.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Aarhus Univ, Water & Salt Res Ctr, DK-8000 Aarhus, Denmark	Weizmann Institute of Science; Aarhus University	Garty, H (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	h.garty@weizmann.ac.il						Ahlers BA, 2005, J BIOL CHEM, V280, P19875, DOI 10.1074/jbc.M414703200; Aoki S, 2003, BRIT J CANCER, V88, P726, DOI 10.1038/sj.bjc.6600778; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Crambert G, 2005, MOL BIOL CELL, V16, P2363, DOI 10.1091/mbc.E04-10-0878; CRAMBERT G, 2003, SCI STKE, pRE1; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Garty H, 2003, ANN NY ACAD SCI, V986, P395, DOI 10.1111/j.1749-6632.2003.tb07220.x; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GARTY H, 2005, IN PRESS ANN REV PHY; Ino Y, 2002, P NATL ACAD SCI USA, V99, P365, DOI 10.1073/pnas.012425299; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1992, J BIOL CHEM, V267, P577; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LUBARSKI L, 2005, J GEN PHYSIOL, V126, P51; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; Moorman JR, 1998, ADV EXP MED BIOL, V442, P219; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Omasa T, 2001, BBA-GENE STRUCT EXPR, V1517, P307, DOI 10.1016/S0167-4781(00)00251-7; Pihakaski-Maunsbach K, 2003, ANN NY ACAD SCI, V986, P401, DOI 10.1111/j.1749-6632.2003.tb07221.x; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Sato H, 2003, J CLIN ENDOCR METAB, V88, P4407, DOI 10.1210/jc.2002-021757; Shi HK, 2001, AM J PHYSIOL-RENAL, V280, pF505, DOI 10.1152/ajprenal.2001.280.3.F505; Shimamura T, 2003, J CLIN ONCOL, V21, P659, DOI 10.1200/JCO.2003.06.179; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Tsuiji H, 2003, GLYCOBIOLOGY, V13, P521, DOI 10.1093/glycob/cwg065; Wetzel RK, 2004, J BIOL CHEM, V279, P41750, DOI 10.1074/jbc.M405622200; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531	40	84	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37717	37724		10.1074/jbc.M506397200	http://dx.doi.org/10.1074/jbc.M506397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148001	hybrid			2022-12-25	WOS:000233044500049
J	Meyer, S; van Liempt, E; Imberty, A; van Kooyk, Y; Geyer, H; Geyer, R; van Die, I				Meyer, S; van Liempt, E; Imberty, A; van Kooyk, Y; Geyer, H; Geyer, R; van Die, I			DC-SIGN mediates binding of dendritic cells to authentic pseudo-Lewis(Y) glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; C-TYPE LECTINS; LEWIS-X; CARBOHYDRATE EPITOPES; STRUCTURAL BASIS; EGG ANTIGENS; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; IDENTIFICATION; EXPRESSION	During schistosomiasis, parasite-derived glycoconjugates play a key role in manipulation of the host immune response, associated with persistence of the parasite. Among the candidate host receptors that are triggered by glycoconjugates are C-type lectins (CLRs) on dendritic cells (DCs), which in concerted action with Toll-like receptors determine the balance in DCs between induction of immunity versus tolerance. Here we report that the CLR DC-SIGN mediates adhesion of DCs to authentic glycolipids derived from Schistosoma mansoni cercariae and their excretory/secretory products. Structural characterization of the glycolipids, in combination with solid phase and cellular binding studies revealed that DC-SIGN binds to the carbohydrate moieties of both glycosphingolipid species with Gal beta 1-4(Fuc alpha 1-3) GlcNAc (Lewis(X)) and Fuc alpha 1-3Gal beta 1-4( Fuc alpha 1-3) GlcNAc (pseudo-Lewis(Y)) determinants. Importantly, these data indicate that surveying DCs in the skin may encounter schistosome-derived glycolipids immediately after infection. Recent analysis of crystals of the carbohydrate binding domain of DC-SIGN bound to LewisX provided insight into the ability of DC-SIGN to bind fucosylated ligands. Using molecular modeling we showed that the observed binding of the schistosome-specific pseudo-Lewis(Y) to DC-SIGN is not directly compatible with the model described. To fit pseudo-Lewis(Y) into the model, the orientation of the side chain of Phe(313) in the secondary binding site of DC-SIGN was slightly changed, which results in a perfect stacking of Phe313 with the hydrophobic side of the galactose-linked fucose of pseudo-Lewis(Y). We propose that pathogens such as S. mansoni may use the observed flexibility in the secondary binding site of DC-SIGN to target DCs, which may contribute to immune escape.	Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France	Justus Liebig University Giessen; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	van Die, I (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Postbus 7057, NL-1007 MB Amsterdam, Netherlands.	im.vandie@vumc.nl	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Cummings RD, 1999, BBA-MOL BASIS DIS, V1455, P363, DOI 10.1016/S0925-4439(99)00063-0; DOMON B, 1988, BIOCHEMISTRY-US, V27, P1534, DOI 10.1021/bi00405a021; DYATLOVITSKAYA EV, 1987, BIOCHIM BIOPHYS ACTA, V907, P125, DOI 10.1016/0304-419X(87)90002-3; Ebner S, 2004, INT IMMUNOL, V16, P877, DOI 10.1093/intimm/dxh088; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hokke CH, 2001, GLYCOCONJUGATE J, V18, P573, DOI 10.1023/A:1020634602161; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Khoo KH, 1997, GLYCOBIOLOGY, V7, P653, DOI 10.1093/glycob/7.5.653; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Lochnit G, 1998, J BIOL CHEM, V273, P466, DOI 10.1074/jbc.273.1.466; MAKAARU CK, 1992, J BIOL CHEM, V267, P2251; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; NYAME K, 1989, J BIOL CHEM, V264, P3235; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Okano M, 1999, J IMMUNOL, V163, P6712; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SLUITERS JF, 1980, Z PARASITENKD, V63, P13, DOI 10.1007/BF00927722; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Sorme P, 2005, J AM CHEM SOC, V127, P1737, DOI 10.1021/ja043475p; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; van Kooyk Y, 2004, CURR OPIN IMMUNOL, V16, P488, DOI 10.1016/j.coi.2004.05.010; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Van Liempt E, 2004, J BIOL CHEM, V279, P33161, DOI 10.1074/jbc.M404988200; van Remoortere A, 2000, GLYCOBIOLOGY, V10, P601, DOI 10.1093/glycob/10.6.601; VANDAM GJ, 1994, EUR J BIOCHEM, V225, P467, DOI 10.1111/j.1432-1033.1994.00467.x; Velupillai P, 2000, HUM IMMUNOL, V61, P225, DOI 10.1016/S0198-8859(99)00136-6; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WEISS JB, 1986, J IMMUNOL, V136, P4275; Wuhrer M, 2002, EUR J BIOCHEM, V269, P481, DOI 10.1046/j.0014-2956.2001.02673.x; Wuhrer M, 2000, GLYCOBIOLOGY, V10, P89, DOI 10.1093/glycob/10.1.89; Wuhrer M, 1999, MOL BIOCHEM PARASIT, V103, P155, DOI 10.1016/S0166-6851(99)00123-1; Wuhrer M, 2000, BBA-GEN SUBJECTS, V1524, P155, DOI 10.1016/S0304-4165(00)00152-5; ZIEGLERHEITBROCK HWL, 1992, J IMMUNOL, V148, P1753	54	78	81	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37349	37359		10.1074/jbc.M507100200	http://dx.doi.org/10.1074/jbc.M507100200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155001	hybrid, Green Published			2022-12-25	WOS:000233044500008
J	Miller, PS; Da Silva, HMA; Smart, TG				Miller, PS; Da Silva, HMA; Smart, TG			Molecular basis for zinc potentiation at strychnine-sensitive glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT 5-HT3 RECEPTOR; SIGNATURE DISULFIDE LOOP; SPINAL-CORD NEURONS; CHLORIDE CHANNEL; STRUCTURAL BASIS; MODULATION; SUBUNIT; INHIBITION; BINDING; ZN2+	The divalent cation Zn2+ is a potent potentiator at the strychnine-sensitive glycine receptor (GlyR). This occurs at nanomolar concentrations, which are the predicted endogenous levels of extracellular neuronal Zn2+. Using structural modeling and functional mutagenesis, we have identified the molecular basis for the elusive Zn2+ potentiation site on GlyRs and account for the differential sensitivity of GlyR alpha(1) and GlyR alpha(2) to Zn2+ potentiation. In addition, juxtaposed to this Zn2+ site, which is located externally on the N-terminal domain of the alpha subunit, another residue was identified in the nearby Cys loop, a region that is critical for receptor gating in all Cys loop ligand-gated ion channels. This residue acted as a key control element in the allosteric transduction pathway for Zn2+ potentiation, enabling either potentiation or overt inhibition of receptor activation depending upon the moiety resident at this location. Overall, we propose that Zn2+ binds to a site on the extracellular outer face of the GlyR alpha subunit and exerts its positive allosteric effect via an interaction with the Cys loop to increase the efficacy of glycine receptor gating.	UCL, Dept Pharmacol, London WC1E 6BT, England	University of London; University College London	Smart, TG (corresponding author), UCL, Dept Pharmacol, Gower St, London WC1E 6BT, England.	t.smart@ucl.ac.uk		Miller, Paul/0000-0002-6512-9441	Medical Research Council [G9722520] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9722520] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Birinyi A, 2001, J COMP NEUROL, V433, P208, DOI 10.1002/cne.1136; BLOOMENTHAL AB, 1994, MOL PHARMACOL, V46, P1156; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brown CE, 2002, J NEUROSCI, V22, P2617, DOI 10.1523/JNEUROSCI.22-07-02617.2002; CELENTANO JJ, 1988, BRAIN RES, V455, P377, DOI 10.1016/0006-8993(88)90098-4; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; FREDERICKSON CJ, 1990, PROG BRAIN RES, V83, P71; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Hubbard PC, 2000, EUR J PHARMACOL, V394, P189, DOI 10.1016/S0014-2999(00)00143-6; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Laube B, 2000, J PHYSIOL-LONDON, V522, P215, DOI 10.1111/j.1469-7793.2000.t01-1-00215.x; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lynch JW, 1998, J NEUROCHEM, V71, P2159; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Miller PS, 2005, J PHYSIOL-LONDON, V566, P657, DOI 10.1113/jphysiol.2005.088575; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Morris KDW, 2004, MOL PHARMACOL, V66, P56, DOI 10.1124/mol.66.1.56; Nevin ST, 2003, J BIOL CHEM, V278, P28985, DOI 10.1074/jbc.M300097200; Paoletti P, 1997, J NEUROSCI, V17, P5711; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; RUIZ A, 2003, J NEUROPHYSIOL; Schofield CM, 2004, BIOCHEMISTRY-US, V43, P10058, DOI 10.1021/bi036159g; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; Suwa H, 2001, J NEUROPHYSIOL, V85, P912, DOI 10.1152/jn.2001.85.2.912; Wilkins ME, 2002, J NEUROSCI, V22, P5328; Wu FS, 1997, BRAIN RES, V750, P318, DOI 10.1016/S0006-8993(97)00053-X; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	40	71	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37877	37884		10.1074/jbc.M508303200	http://dx.doi.org/10.1074/jbc.M508303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16144831	hybrid			2022-12-25	WOS:000233044500068
J	To, KKW; Huang, LE				To, KKW; Huang, LE			Suppression of hypoxia-inducible factor 1 alpha (HIF-1 alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; FACTOR 1-ALPHA; ALPHA-SUBUNIT; DNA-BINDING; PROTEIN; OXYGEN; PATHWAY; VHL; DEGRADATION; ACTIVATION	The cellular response to hypoxia is, at least in part, mediated by the transcriptional regulation of hypoxia-responsive genes involved in balancing the intracellular ATP production and consumption. Recent evidence suggests that the transcription factor, HIF-1 alpha, functions as a master regulator of oxygen homeostasis by controlling a broad range of cellular events in hypoxia. In normoxia, HIF-1 alpha is targeted for destruction via prolyl hydroxylation, an oxygen-dependent modification that signals for recognition by the ubiquitin ligase complex containing the von Hippel-Lindau tumor suppressor. Three HIF prolyl hydroxylases (EGLN1, EGLN2, and EGLN3) have been identified in mammals, among which EGLN1 and EGLN3 are hypoxia-inducible at their mRNA levels in an HIF-1 alpha-dependent manner. In this study, we demonstrated that apart from promoting HIF-1 alpha proteolysis in normoxia, EGLN1 specifically represses HIF-1 alpha transcriptional activity in hypoxia. Ectopic expression of EGLN1 inhibited HIF-1 alpha transcriptional activity without altering its protein levels in a von Hippel-Lindau-deficient cell line, indicating a discrete activity of EGLN1 in transcriptional repression. Conversely, silencing of EGLN1 expression augmented HIF-1 alpha transcriptional activity and its target gene expression in hypoxia. Thus, we proposed that the accumulated EGLN1 in hypoxia acts as a negative-feedback mechanism to modulate HIF-1 alpha target gene expression. Our finding also provided new insight into the pharmacological manipulation of the HIF prolyl hydroxylase for ischemic diseases.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Huang, LE (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Rm 3044B,37 Convent Dr, Bethesda, MD 20892 USA.	huange@mail.nih.gov	To, Kenneth K W/M-4500-2013	To, Kenneth K W/0000-0003-2755-0283; Huang, Eric/0000-0002-6444-1708	DIVISION OF BASIC SCIENCES - NCI [Z01BC010424] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 BC010424-06] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hewitson KS, 2004, DRUG DISCOV TODAY, V9, P704, DOI 10.1016/S1359-6446(04)03202-7; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Huang LE, 2002, J BIOL CHEM, V277, P41750, DOI 10.1074/jbc.M207280200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kageyama Y, 2004, FASEB J, V18, P1028, DOI 10.1096/fj.03-1233fje; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Koshiji M, 2004, CELL CYCLE, V3, P853; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	51	75	79	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38102	38107		10.1074/jbc.M504342200	http://dx.doi.org/10.1074/jbc.M504342200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157596	Green Accepted, hybrid			2022-12-25	WOS:000233044500094
J	Infante-Duarte, C; Weber, A; Kratzschmar, K; Prozorovski, T; Pikol, S; Hamann, I; Bellmann-Strobl, J; Aktas, O; Dorr, J; Wuerfel, J; Sturzebecher, CS; Zipp, F				Infante-Duarte, C; Weber, A; Kratzschmar, K; Prozorovski, T; Pikol, S; Hamann, I; Bellmann-Strobl, J; Aktas, O; Dorr, J; Wuerfel, J; Sturzebecher, CS; Zipp, F			Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients	FASEB JOURNAL			English	Article						central nervous system; gene expression	GENE-EXPRESSION; FRACTALKINE CX3CL1; NK CELLS; RECEPTOR; ACTIVATION; CHEMOKINE; ADHESION; CX(3)CR1; BIOLOGY; BETA	Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by enormous variability in its clinical presentation and course, and for which clear diagnostic parameters are lacking. Here we performed an RNA screen in peripheral mononuclear cells from relapsing-remitting (RR) and primary progressive (PP) MS patients compared with healthy donors (HD) that indicated, among other findings, a role for the chemokine receptor CX(3)CR1 as a diagnostic marker. Gene expression and flow cytometric analyses demonstrated a significantly lower expression of CX(3)CR1 in MS patients compared with healthy individuals. The subpopulation of cells responsible for causing this reduced expression of CX(3)CR1 consisted exclusively of natural killer (NK) cells. Importantly, we found a correlation between disease activity and frequency of CX(3)CR1-positive NK cells in RRMS patients. These findings emphasize the role of NK cells in the development and course of MS and provide evidence for CX(3)CR1 expression as a marker for MS patients and disease activity.	Charite, Neurosci Res Ctr, Inst Neuroimmunol, D-10098 Berlin, Germany; Schering AG, Dept Genom, D-1000 Berlin, Germany; Schering AG, Dept Bioinformat, D-1000 Berlin, Germany; Schering AG, Dept Pharmacogenom, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; Schering AG; Schering AG	Zipp, F (corresponding author), Charite, Neurosci Res Ctr, Inst Neuroimmunol, D-10098 Berlin, Germany.	frauke.zipp@charite.de	Zipp, Frauke/C-9968-2015; Aktas, Orhan/B-7623-2009	Zipp, Frauke/0000-0002-1231-1928; Aktas, Orhan/0000-0002-2020-9210; Bellmann-Strobl, Judith/0000-0003-2615-1643; Infante Duarte, Carmen/0000-0003-3005-351X				Achiron A, 2004, ANN NEUROL, V55, P410, DOI 10.1002/ana.20008; Amoura Z, 2003, ARTHRITIS RHEUM-US, V48, P3487, DOI 10.1002/art.11350; Baxter AG, 2002, AUTOIMMUNITY, V35, P1, DOI 10.1080/08916930290005864; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENCZUR M, 1980, CLIN EXP IMMUNOL, V39, P657; Bomprezzi R, 2003, HUM MOL GENET, V12, P2191, DOI 10.1093/hmg/ddg221; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/S0091-6749(04)01061-9; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Hafler DA, 2004, J CLIN INVEST, V113, P788, DOI 10.1172/JCI200421357; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Hatori K, 2002, J NEUROSCI RES, V69, P418, DOI 10.1002/jnr.10304; Heusel JW, 2003, CURR OPIN PEDIATR, V15, P586, DOI 10.1097/00008480-200312000-00008; HIRSCH RL, 1985, CLIN IMMUNOL IMMUNOP, V37, P236, DOI 10.1016/0090-1229(85)90155-2; Horwitz DA, 1997, IMMUNOL TODAY, V18, P538, DOI 10.1016/S0167-5699(97)01149-3; Hughes PM, 2002, GLIA, V37, P314, DOI 10.1002/glia.10037; Iglesias AH, 2004, J NEUROIMMUNOL, V150, P163, DOI 10.1016/j.jneuroim.2004.01.017; Kastenbauer S, 2003, J NEUROIMMUNOL, V137, P210, DOI 10.1016/S0165-5728(03)00085-7; Kastrukoff LF, 1998, J NEUROIMMUNOL, V86, P123, DOI 10.1016/S0165-5728(98)00014-9; Kastrukoff LF, 2003, J NEUROIMMUNOL, V145, P103, DOI 10.1016/j.jneuroim.2003.10.001; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Maas K, 2002, J IMMUNOL, V169, P5, DOI 10.4049/jimmunol.169.1.5; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Nanki T, 2002, ARTHRITIS RHEUM, V46, P2878, DOI 10.1002/art.10622; NEIGHBOUR PA, 1982, CLIN EXP IMMUNOL, V49, P11; Neri S, 2001, CLIN DIAGN LAB IMMUN, V8, P1131, DOI 10.1128/CDLI.8.6.1131-1135.2001; Nishimura M, 2002, J IMMUNOL, V168, P6173, DOI 10.4049/jimmunol.168.12.6173; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; O'Connor P, 2002, NEUROLOGY, V59, P998; Ramanathan M, 2001, J NEUROIMMUNOL, V116, P213, DOI 10.1016/S0165-5728(01)00308-3; Ruth JH, 2001, ARTHRITIS RHEUM, V44, P2750, DOI 10.1002/1529-0131(200112)44:12<2750::AID-ART462>3.0.CO;2-C; Takahashi K, 2004, BRAIN, V127, P1917, DOI 10.1093/brain/awh219; Takahashi K, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-23; Umehara H, 2004, ARTERIOSCL THROM VAS, V24, P34, DOI 10.1161/01.ATV.0000095360.62479.1F; VRANES Z, 1989, J NEUROL SCI, V94, P115, DOI 10.1016/0022-510X(89)90222-0; Wandinger KP, 2001, ANN NEUROL, V50, P349, DOI 10.1002/ana.1096; Yoneda O, 2003, EUR J IMMUNOL, V33, P53, DOI 10.1002/immu.200390007	39	57	61	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1902	+		10.1096/fj.05-3832fje	http://dx.doi.org/10.1096/fj.05-3832fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16144955				2022-12-25	WOS:000232315700028
J	Okada, S; Ishii, K; Yamane, J; Iwanami, A; Ikegami, T; Katoh, H; Iwamoto, Y; Nakamura, M; Miyoshi, H; Okano, HJ; Contag, CH; Toyama, Y; Okano, H				Okada, S; Ishii, K; Yamane, J; Iwanami, A; Ikegami, T; Katoh, H; Iwamoto, Y; Nakamura, M; Miyoshi, H; Okano, HJ; Contag, CH; Toyama, Y; Okano, H			In vivo imaging of engrafted neural stem cells: its application in evaluating the optimal timing of transplantation for spinal cord injury	FASEB JOURNAL			English	Article						bioluminescence imaging; neural stem/progenitor cells; delayed transplantation	MAGNETIC-RESONANCE TRACKING; CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL RECOVERY; GENE-EXPRESSION; LENTIVIRAL VECTOR; CONTUSION INJURY; PROGENITOR CELLS; BRAIN; RATS; NANOPARTICLES	Neural stem/progenitor cells (NSPCs) hold promise in neural tissue replacement therapy after spinal cord injury. However, understanding the survival time of grafted NSPCs and determining the extent of migration away from transplantation sites are essential for optimizing treatment regimens. Here, we used in vivo bioluminescence imaging to noninvasively assess the survival and residence time of transplanted NSPCs at the injury sites in living animals, and we used histologic analyses to assess cell integration and morphology. Third-generation lentiviral vectors enabled efficient transduction and stable expression of both luciferase and a variant of green fluorescent protein in primary cultured NSPCs. Signals from these cells were detectable for up to 10 months or more after transplantation into the injured spinal cords of C57BL/6J mice. Histological and functional data supported the imaging data and suggest that the timing of NSPC transplantation may be a key determinant of the fates and function of integrated cells since cell survival and migration depended on the time of transplantation relative to injury. Optimization of cell therapies can be greatly accelerated and refined by imaging, and the methods in the present study can be widely applied to various research fields of regeneration medicine, including transplantation study.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan; RIKEN, Tsukuba Inst, Bioresource Ctr, Subteam Manipulat Cell Fate, Ibaraki 3050074, Japan; Stanford Univ, Sch Med, Dept Pediat, James H Clark Ctr,Bio X Program, Stanford, CA 94305 USA; Japan Sci & Technol, CREST, Saitama 3320012, Japan	Keio University; Keio University; Kyushu University; RIKEN; Stanford University; Japan Science & Technology Agency (JST)	Okano, H (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hidokano@sc.itc.keio.ac.jp	Okano, Hideyuki/I-7584-2019; Miyoshi, Hiroyuki/G-9808-2013; Nakamura, Masaya/K-4111-2013; Toyama, Yoshiaki/K-5743-2013	ISHII, KEN/0000-0003-0094-7918; Okada, Seiji/0000-0002-5107-8209; Okano, Hirotaka James/0000-0003-4611-7098; Contag, Christopher/0000-0002-1011-8278	NATIONAL CANCER INSTITUTE [R24CA092862] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA 92862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Bai Y, 2003, GENE THER, V10, P1446, DOI 10.1038/sj.gt.3302026; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bulte JWM, 2002, J CEREBR BLOOD F MET, V22, P899, DOI 10.1097/00004647-200208000-00001; Cao YA, 2004, P NATL ACAD SCI USA, V101, P221, DOI 10.1073/pnas.2637010100; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; De A, 2003, MOL THER, V7, P681, DOI 10.1016/S1525-0016(03)00070-4; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Graves EE, 2004, CURR MOL MED, V4, P419, DOI 10.2174/1566524043360555; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Iwanami A, 2005, J NEUROSCI RES, V80, P172, DOI 10.1002/jnr.20435; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Kim DE, 2004, STROKE, V35, P952, DOI 10.1161/01.STR.0000120308.21946.5D; Lee IH, 2004, EXP NEUROL, V187, P509, DOI 10.1016/j.expneurol.2004.02.007; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Mandl S, 2002, J CELL BIOCHEM, P239, DOI 10.1002/jcb.10454; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; Pirko I, 2004, FASEB J, V18, P179, DOI 10.1096/fj.02-1124fje; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Rice BW, 2001, J BIOMED OPT, V6, P432, DOI 10.1117/1.1413210; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Shah K, 2003, ONCOGENE, V22, P6865, DOI 10.1038/sj.onc.1206748; Wang XL, 2003, BLOOD, V102, P3478, DOI 10.1182/blood-2003-05-1432	41	180	192	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1839	+		10.1096/fj.05-4082fje	http://dx.doi.org/10.1096/fj.05-4082fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16141363				2022-12-25	WOS:000232315700030
J	Wada, Y; Otu, H; Wu, SQ; Abid, MR; Okada, H; Libermann, T; Kodama, T; Shih, SC; Minami, T; Aird, WC				Wada, Y; Otu, H; Wu, SQ; Abid, MR; Okada, H; Libermann, T; Kodama, T; Shih, SC; Minami, T; Aird, WC			Preconditioning of primary human endothelial cells with inflammatory mediators alters the "set point" of the cell	FASEB JOURNAL			English	Article						endothelium; NF-kappa B; sepsis; thrombin; HUVEC	THROMBIN STIMULATION; ADHESION MOLECULE-1; PROTEIN-KINASE; SEVERE SEPSIS; KAPPA-B; EXPRESSION; ACTIVATION; PROMOTER; THERAPY	Endothelial cells are highly sensitive to changes in the extracellular milieu. Sepsis results in activation of inflammatory and coagulation pathways. We hypothesized that sepsis-associated mediators may alter the response capacity (so-called "set point") of endothelial cells. Human umbilical vein endothelial cells (HUVEC) were preincubated in the presence or absence of tumor necrosis factor (TNF)-alpha, lipopolysaccharide (LPS), hypoxia, hyperthermia, and/or high glucose; treated with or without thrombin for 4 h; and then processed for RNase protection assays of selected activation markers. Priming with TNF-alpha and LPS significantly inhibited thrombin-mediated induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, tissue factor, and E-selectin, but not platelet-derived growth factor-A or CD44. In electrophoretic mobility shift assays, thrombin-treated HUVEC demonstrated inducible binding of p65 NF-kappa B, an effect that was significantly blunted by pretreatment of cells with TNF-alpha and LPS. Consistent with these results, TNF-alpha and LPS attenuated the effect of thrombin on I kappa B phosphorylation, total cytoplasmic I kappa B, and nuclear translocation of p65 NF-kappa B. The inhibitory effect of TNF-alpha on thrombin signaling persisted for up to 24 h following removal of the cytokine. Taken together, these data suggest that inflammatory mediators prime endothelial cells to modulate subsequent thrombin response.	Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Tokyo	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, RW-663,330 Brookline Ave, Boston, MA 02215 USA.	waird@bidmc.harvard.edu		Otu, Hasan/0000-0002-9253-8152; Libermann, Towia/0000-0002-4006-8179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060585] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL060585, HL 60585-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Ahmad S, 2003, AM J RESP CELL MOL, V28, P179, DOI 10.1165/rcmb.2002-0004OC; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Aird WC, 2004, BEST PRACT RES CL HA, V17, P161, DOI 10.1016/j.beha.2004.03.006; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Barash Y, 2004, BIOINFORMATICS, V20, P839, DOI 10.1093/bioinformatics/btg487; Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; Cines DB, 1998, BLOOD, V91, P3527; Delikouras A, 2003, EUR J IMMUNOL, V33, P3127, DOI 10.1002/eji.200323566; Ishida I, 2002, J IMMUNOL, V169, P2069, DOI 10.4049/jimmunol.169.4.2069; Kohn G, 2002, SHOCK, V17, P91, DOI 10.1097/00024382-200202000-00002; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minami T, 2003, ARTERIOSCL THROM VAS, V23, P2041, DOI 10.1161/01.ATV.0000089326.63053.9A; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16	25	22	25	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1914	+		10.1096/fj.05-4037fje	http://dx.doi.org/10.1096/fj.05-4037fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16172186	Green Accepted, Green Published			2022-12-25	WOS:000232315700010
J	Ivanova, IA; D'Souza, SJA; Dagnino, L				Ivanova, IA; D'Souza, SJA; Dagnino, L			E2F1 stability is regulated by a novel-PKC/p38 beta MAP kinase signaling pathway during keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation	ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; EPIDERMAL-KERATINOCYTES; MESSENGER-RNA; DEGRADATION; DELTA; RETINOBLASTOMA; GROWTH; PROLIFERATION; EXPRESSION	E2F transcription factors regulate proliferation, differentiation, DNA repair and apoptosis. Tight E2F regulation is crucial for epidermal formation and regeneration. However, virtually nothing is known about the molecular events modulating E2F during epidermal keratinocyte differentiation. Elucidation of these events is essential to understand epidermal morphogenesis, transformation and repair. Here we show that, in differentiating keratinocytes, Ca2(+) -induced protein kinase C (PKC) activation downregulates E2F1 protein levels. Further, we have identified PKC delta and eta as those isoforms specifically involved in induction of E2F1 proteasomal degradation. We also demonstrate that E2F1 downregulation by novel PKC isozymes requires activation of p38 beta mitogenactivated protein kinase ( MAPK). This is the first example of regulation in the E2F transcription factor family by activation of PKC and MAPK in the context of biologically significant differentiation stimuli in epithelia.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Alt A, 2001, CANCER RES, V61, P4591; Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; Cazzolli R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1204, DOI 10.1152/ajpendo.00487.2001; Chang WY, 2004, J BIOL CHEM, V279, P51343, DOI 10.1074/jbc.M408635200; Chida K, 2003, CANCER RES, V63, P2404; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Denning MF, 2004, INT J BIOCHEM CELL B, V36, P1141, DOI 10.1016/j.biocel.2003.12.004; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Koster MI, 2004, EUR J CELL BIOL, V83, P625, DOI 10.1078/0171-9335-00387; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Li LW, 1999, MOL CELL BIOL, V19, P8547; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Penuelas S, 2003, EUR J BIOCHEM, V270, P4809, DOI 10.1046/j.1432-1033.2003.03874.x; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; Romanova LY, 1998, BIOCHEMISTRY-US, V37, P5558, DOI 10.1021/bi9731807; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280	44	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					430	437		10.1038/sj.onc.1208999	http://dx.doi.org/10.1038/sj.onc.1208999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16116476				2022-12-25	WOS:000234714100011
J	Ota, H; Tokunaga, E; Chang, K; Hikasa, M; Iijima, K; Eto, M; Kozaki, K; Akishita, M; Ouchi, Y; Kaneki, M				Ota, H; Tokunaga, E; Chang, K; Hikasa, M; Iijima, K; Eto, M; Kozaki, K; Akishita, M; Ouchi, Y; Kaneki, M			Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells	ONCOGENE			English	Article						Sirt1; sirtinol; cellular senescence; Ras; MAPK; Akt/PKB	HISTONE DEACETYLASE INHIBITORS; TERMINAL PROLIFERATION ARREST; CELLULAR SENESCENCE; TUMOR-CELLS; HUMAN-FIBROBLASTS; IN-VIVO; DEPSIPEPTIDE FR901228; TRANSCRIPTION FACTORS; PROTEIN DEACETYLASES; PC12 CELLS	The induction of senescence-like growth arrest has emerged as a putative contributor to the anticancer effects of chemotherapeutic agents. Clinical trials are underway to evaluate the efficacy of inhibitors for class I and II histone deacetylases to treat malignancies. However, a potential antiproliferative effect of inhibitor for Sirt1, which is an NAD(+)-dependent deacetylase and belongs to class III histone deacetylases, has not yet been explored. Here, we show that Sirt1 inhibitor, Sirtinol, induced senescence-like growth arrest characterized by induction of senescence-associated beta-galactosidase activity and increased expression of plasminogen activator inhibitor 1 in human breast cancer MCF-7 cells and lung cancer H1299 cells. Sirtinol-induced senescence-like growth arrest was accompanied by impaired activation of mitogen-activated protein kinase ( MAPK) pathways, namely, extracellular-regulated protein kinase, c-jun N-terminal kinase and p38 MAPK, in response to epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I). Active Ras was reduced in Sirtinol-treated senescent cells compared with untreated cells. However, tyrosine phosphorylation of the receptors for EGF and IGF-I and Akt/PKB activation were unaltered by Sirtinol treatment. These results suggest that inhibitors for Sirt1 may have anticancer potential, and that impaired activation of Ras-MAPK pathway might take part in a senescence-like growth arrest program induced by Sirtinol.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan; Shriners Hosp Children, Boston, MA USA	Harvard University; Massachusetts General Hospital; University of Tokyo	Kaneki, M (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 149 13th St,Rm 6604, Charlestown, MA 02129 USA.	mkaneki@partners.org		Eto, Masato/0000-0002-6036-3431	NIDDK NIH HHS [R01DK058127] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058127] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Aviv H, 2001, ATHEROSCLEROSIS, V159, P281, DOI 10.1016/S0021-9150(01)00506-8; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Christov KT, 2003, EUR J CANCER, V39, P230, DOI 10.1016/S0959-8049(02)00497-5; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elegbede JA, 2002, LIFE SCI, V71, P421; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; Kahlem P, 2004, J CLIN INVEST, V113, P169, DOI 10.1172/JCI200420784; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Kim JH, 2003, BIOCHEM J, V373, P523, DOI 10.1042/BJ20030363; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; McLaughlin Fiona, 2004, Current Drug Targets - Inflammation and Allergy, V3, P213, DOI 10.2174/1568010043343859; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Munro J, 2004, EXP CELL RES, V295, P525, DOI 10.1016/j.yexcr.2004.01.017; Pelicci PG, 2004, J CLIN INVEST, V113, P4, DOI 10.1172/JCI200420750; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2002, DRUG RESIST UPDATE, V5, P204, DOI 10.1016/S1368764602001103; Rosato RR, 2004, EXPERT OPIN INV DRUG, V13, P21, DOI 10.1517/eoid.13.1.21.25283; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Sandor V, 2002, CLIN CANCER RES, V8, P718; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sugita H, 2005, J BIOL CHEM, V280, P14203, DOI 10.1074/jbc.M411226200; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; te Poele RH, 2002, CANCER RES, V62, P1876; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; Tresini M, 2001, EXP CELL RES, V269, P287, DOI 10.1006/excr.2001.5334; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vigushin DM, 2004, CURR CANCER DRUG TAR, V4, P205, DOI 10.2174/1568009043481560; Wagner M, 2001, EXP GERONTOL, V36, P1327, DOI 10.1016/S0531-5565(01)00105-X; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Wang XH, 2003, CURR CANCER DRUG TAR, V3, P153, DOI 10.2174/1568009033482001; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	67	348	369	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					176	185		10.1038/sj.onc.1209049	http://dx.doi.org/10.1038/sj.onc.1209049			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170353				2022-12-25	WOS:000234583600002
J	Taylor, JR; Brownlow, N; Domin, J; Dibb, NJ				Taylor, JR; Brownlow, N; Domin, J; Dibb, NJ			FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance	ONCOGENE			English	Article						imatinib; FMS; CSF-1; M-CSF; D802V; v-fms	PROTO-ONCOGENE PRODUCT; CELL-LINE FDC-P1; C-FMS; TYROSINE KINASE; GROWTH-FACTOR; ACTIVATING MUTATIONS; LUNG-CANCER; WILD-TYPE; IN-VITRO; STI-571 INHIBITION	The kinase inhibitor imatinib is used in the treatment of chronic myeloid leukaemia, where it targets the intracellular Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumours, where it targets either the KIT or PDGF tyrosine kinase receptors. Here, we report that imatinib is also an effective inhibitor of the closely related FMS receptor for macrophage colony stimulating factor and that mutation of Asp 802 of FMS to Val confers imatinib resistance. Imatinib readily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the oncogene v-fms and also inhibited the growth of the Bacl. 2F5 macrophage cell line. The cellular IC50 value of imatinib for FMS was similar to those for Bcr-Abl and KIT. Consequently, imatinib may also prove effective for the treatment of diseases whose progression is dependent upon macrophage-colony stimulating factor, this includes certain aspects of cancer and inflammation.	Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Div Med, London W12 0NN, England	Imperial College London; Imperial College London	Dibb, NJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	n.dibb@imperial.ac.uk	Taylor, James R/F-7960-2014; brownlow, nicola/H-6826-2015	brownlow, nicola/0000-0003-4733-9960				Aldskogius H., 2001, EXPER OPIN THER TAR, V5, P655; BAKER DA, 1994, LEUKEMIA, V8, P141; Bohmer FD, 2003, J BIOL CHEM, V278, P5148, DOI 10.1074/jbc.M209861200; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; CARUANA G, 1993, EXP HEMATOL, V21, P761; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood-2004-10-3967; Dewar AL, 2003, LEUKEMIA, V17, P1713, DOI 10.1038/sj.leu.2403071; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Frost MJ, 2002, MOL CANCER THER, V1, P1115; GLOVER HR, 1995, ONCOGENE, V11, P1347; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Morley GM, 1999, ONCOGENE, V18, P3076, DOI 10.1038/sj.onc.1202646; Mundy GR, 2002, ANNU REV MED, V53, P337, DOI 10.1146/annurev.med.53.082901.104047; Murray LJ, 2003, CLIN EXP METASTAS, V20, P757, DOI 10.1023/B:CLIN.0000006873.65590.68; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pollard JW, 1997, MOL REPROD DEV, V46, P54, DOI 10.1002/(SICI)1098-2795(199701)46:1&lt;54::AID-MRD9&gt;3.0.CO;2-Q; Pollard JW, 1997, MOL REPROD DEV, V46, P60; Reilly JT, 2002, BRIT J HAEMATOL, V116, P744, DOI 10.1046/j.0007-1048.2001.03294.x; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Sweet MJ, 2003, ARCH IMMUNOL THER EX, V51, P169; Uden M, 1999, ONCOGENE, V18, P3846, DOI 10.1038/sj.onc.1202743; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	44	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					147	151		10.1038/sj.onc.1209007	http://dx.doi.org/10.1038/sj.onc.1209007			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170366				2022-12-25	WOS:000234406400016
J	Bharadwaj, S; Thanawala, R; Bon, G; Falcioni, R; Prasad, GL				Bharadwaj, S; Thanawala, R; Bon, G; Falcioni, R; Prasad, GL			Resensitization of breast cancer cells to anoikis by Tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion	ONCOGENE			English	Article						cytoskeleton; breast cancer; anoikis; adhesion; integrins; Rho kinase signaling; tropomyosin	INTESTINAL EPITHELIAL-CELLS; ABL TYROSINE KINASE; FOCAL ADHESIONS; TRANSFORMED PHENOTYPE; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; ACTIN DYNAMICS; STRESS FIBERS; SUBCELLULAR-LOCALIZATION; HOST MICROENVIRONMENT	Two most common properties of malignant cells are the presence of aberrant actin cytoskeleton and resistance to anoikis. Suppression of several key cytoskeletal proteins, including tropomyosin-1 (TM1), during neoplastic transformation is hypothesized to contribute to the altered cytoskeleton and neoplastic phenotype. Using TM1 as a paradigm, we have shown that cytoskeletal proteins induce anoikis in breast cancer (MCF-7 and MDA MB 231) cells. Here, we have tested the hypothesis that TM1-mediated cytoskeletal changes regulate integrin activity and the sensitivity to anoikis. TM1 expression in MDA MB 231 cells promotes the assembly of stress fibers, induces rapid anoikis via caspase-dependent pathways involving the release of cytochrome c. Further, TM1 inhibits binding of MDA MB 231 cells to collagen I, but promotes adhesion to laminin. Inhibition of Rho kinase disrupts TM1-mediated cytoskeletal reorganization and adhesion to the extracellular matrix components, whereas the parental cells attach to collagen I, spread and form extensive actin meshwork in the presence of Rho kinase inhibitor, underscoring the differences in parental and TM1-transduced breast cancer cells. Further, treatment with the cytoskeletal disrupting drugs rescues the cells from TM1-induced anoikis. These new findings demonstrate that the aberrant cytoskeleton contributes to neoplastic transformation by conferring resistance to anoikis. Restoration of stress fiber network through enhanced expression of key cytoskeletal proteins may modulate the activity of focal adhesions and sensitize the neoplastic cells to anoikis.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	Wake Forest University; Wake Forest Baptist Medical Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	gprasad@wfubmc.edu	Falcioni, Rita/H-8869-2017; Bon, Giulia/ABH-6498-2020	Falcioni, Rita/0000-0002-3745-4327; Bon, Giulia/0000-0002-5409-5864	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alford D, 1998, BIOCHEM SOC SYMP, P245; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 2001, J CELL BIOL, V155, P187, DOI 10.1083/jcb.200107116; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Bharadwaj S, 2004, J BIOL CHEM, V279, P14039, DOI 10.1074/jbc.M310934200; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Braverman RH, 1996, ONCOGENE, V13, P537; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Caruso DA, 2001, CELL DEATH DIFFER, V8, P665, DOI 10.1038/sj.cdd.4400865; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; Chrenek MA, 2001, BREAST CANCER RES, V3, P224, DOI 10.1186/bcr300; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chung J, 2004, CANCER RES, V64, P4711, DOI 10.1158/0008-5472.CAN-04-0347; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Davies MA, 1998, CANCER RES, V58, P5285; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FALCIONI R, 1988, CANCER RES, V48, P816; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Janes SM, 2004, J CELL BIOL, V166, P419, DOI 10.1083/jcb.200312074; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MAEMURA M, 1995, CLIN EXP METASTAS, V13, P223, DOI 10.1007/BF00133478; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; Marco RAW, 2003, J CELL BIOCHEM, V88, P1038, DOI 10.1002/jcb.10465; Marston S, 1998, ACTA PHYSIOL SCAND, V164, P401, DOI 10.1111/j.1365-201X.1998.tb10696.x; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Normanno N, 2004, J CELL PHYSIOL, V198, P31, DOI 10.1002/jcp.10375; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Park HB, 2004, BIOCHEM J, V378, P559, DOI 10.1042/BJ20031392; Pawlak G, 2004, INT J CANCER, V110, P368, DOI 10.1002/ijc.20151; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Swan EA, 2003, ORAL ONCOL, V39, P648, DOI 10.1016/S1368-8375(03)00049-6; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	86	66	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8291	8303		10.1038/sj.onc.1208993	http://dx.doi.org/10.1038/sj.onc.1208993			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170368				2022-12-25	WOS:000233956500008
J	Dai, Q; Qian, SB; Li, HH; McDonough, H; Borchers, C; Huang, D; Takayama, S; Younger, JM; Ren, HY; Cyr, DM; Patterson, C				Dai, Q; Qian, SB; Li, HH; McDonough, H; Borchers, C; Huang, D; Takayama, S; Younger, JM; Ren, HY; Cyr, DM; Patterson, C			Regulation of the cytoplasmic quality control protein degradation pathway by BAG2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; HEAT-SHOCK PROTEINS; CHAPERONE ACTIVITY; MOLECULAR CHAPERONES; NUCLEOTIDE EXCHANGE; CHIP; IDENTIFICATION; HSP70; DOMAIN; HSC70	The cytoplasm is protected against the perils of protein misfolding by two mechanisms: molecular chaperones (which facilitate proper folding) and the ubiquitin-proteasome system, which regulates degradation of misfolded proteins. CHIP (carboxyl terminus of Hsp70-interacting protein) is an Hsp70-associated ubiquitin ligase that participates in this process by ubiquitylating misfolded proteins associated with cytoplasmic chaperones. Mechanisms that regulate the activity of CHIP are, at present, poorly understood. Using a proteomics approach, we have identified BAG2, a previously uncharacterized BAG domain-containing protein, as a common component of CHIP holocomplexes in vivo. Binding assays indicate that BAG2 associates with CHIP as part of a ternary complex with Hsc70, and BAG2 colocalizes with CHIP under both quiescent conditions and after heat shock. In vitro and in vivo ubiquitylation assays indicate that BAG2 is an efficient and specific inhibitor of CHIP-dependent ubiquitin ligase activity. This activity is due, in part, to inhibition of interactions between CHIP and its cognate ubiquitin-conjugating enzyme, UbcH5a, which may in turn be facilitated by ATP-dependent remodeling of the BAG2-Hsc70-CHIP heterocomplex. The association of BAG2 with CHIP provides a cochaperone-dependent regulatory mechanism for preventing unregulated ubiquitylation of misfolded proteins by CHIP.	Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Georgia; Augusta University	Cyr, DM (corresponding author), Univ N Carolina, Carolina Cardiovasc Biol Ctr, 8200 Med Biomol Res Bldg, Chapel Hill, NC 27599 USA.	cpatters@med.unc.edu	BORCHERS, Christoph/U-5964-2019	Huang, David/0000-0002-0658-8752; Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061728] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056981, GM61728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Borchers C, 2000, ANAL CHEM, V72, P1163, DOI 10.1021/ac990937m; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nikolay R, 2004, J BIOL CHEM, V279, P2673, DOI 10.1074/jbc.M311112200; Patterson Cam, 2002, Sci STKE, V2002, ppe4; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; Ueda K, 2004, J BIOL CHEM, V279, P41815, DOI 10.1074/jbc.M406049200; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065	30	111	117	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38673	38681		10.1074/jbc.M507986200	http://dx.doi.org/10.1074/jbc.M507986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169850	Green Published, hybrid			2022-12-25	WOS:000233239800069
J	Westin, MAK; Hunt, MC; Alexson, SEH				Westin, MAK; Hunt, MC; Alexson, SEH			The identification of a succinyl-CoA thioesterase suggests a novel pathway for succinate production in peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN DICARBOXYLIC-ACIDS; ACTIVATED-RECEPTOR-ALPHA; CLOFIBRATE-TREATED RATS; LONG-CHAIN; BETA-OXIDATION; LIPID-METABOLISM; MOLECULAR-CLONING; OMEGA-OXIDATION; FATTY-ACIDS; MALONYL-COA	Dicarboxylic acids are formed by omega-oxidation of fatty acids in the endoplasmic reticulum and degraded as the CoA ester via beta-oxidation in peroxisomes. Both synthesis and degradation of dicarboxylic acids occur mainly in kidney and liver, and the chain-shortened dicarboxylic acids are excreted in the urine as the free acids, implying that acyl-CoA thioesterases (ACOTs), which hydrolyze CoA esters to the free acid and CoASH, are needed for the release of the free acids. Recent studies show that peroxisomes contain several acyl-CoA thioesterases with different functions. We have now expressed a peroxisomal acyl-CoA thioesterase with a previously unknown function, ACOT4, which we show is active on dicarboxylyl-CoA esters. We also expressed ACOT8, another peroxisomal acyl-CoA thioesterase that was previously shown to hydrolyze a large variety of CoA esters. Acot4 and Acot8 are both strongly expressed in kidney and liver and are also target genes for the peroxisome proliferator-activated receptor alpha. Enzyme activity measurements with expressed ACOT4 and ACOT8 show that both enzymes hydrolyze CoA esters of dicarboxylic acids with high activity but with strikingly different specificities. Whereas ACOT4 mainly hydrolyzes succinyl-CoA, ACOT8 preferentially hydrolyzes longer dicarboxylyl-CoA esters (glutaryl-CoA, adipyl-CoA, suberyl-CoA, sebacyl-CoA, and dodecanedioyl-CoA). The identification of a highly specific succinyl-CoA thioesterase in peroxisomes strongly suggests that peroxisomal beta-oxidation of dicarboxylic acids leads to formation of succinate, at least under certain conditions, and that ACOT4 and ACOT8 are responsible for the termination of beta-oxidation of dicarboxylic acids of medium-chain length with the concomitant release of the corresponding free acids.	Karolinska Univ Hos Huddinge, Dept Lab Med, Div Clin Chem, SE-14186 Stockholm, Sweden		Alexson, SEH (corresponding author), Karolinska Univ Hos Huddinge, Dept Lab Med, Div Clin Chem, C1-74, SE-14186 Stockholm, Sweden.	stefan.alexson@ki.se		Hunt, Mary/0000-0001-6415-2992; Watter, Maria/0000-0001-9047-5517				ALEXSON SEH, 1989, BIOCHEM J, V262, P41, DOI 10.1042/bj2620041; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BERGSETH S, 1988, BIOCHIM BIOPHYS ACTA, V961, P103, DOI 10.1016/0005-2760(88)90135-X; Bian F, 2005, J BIOL CHEM, V280, P9265, DOI 10.1074/jbc.M412850200; BJORKHEM I, 1984, BIOCHIM BIOPHYS ACTA, V795, P15, DOI 10.1016/0005-2760(84)90099-7; BJORKHEM I, 1976, J BIOL CHEM, V251, P5259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CERDAN S, 1988, J BIOL CHEM, V263, P11664; CHASE JFA, 1967, BIOCHEM J, P510; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Ferdinandusse S, 2004, J LIPID RES, V45, P1104, DOI 10.1194/jlr.M300512-JLR200; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GREGERSEN N, 1982, SCAND J CLIN LAB INV, V42, P15; HORIE S, 1989, LIFE SCI, V44, P1141, DOI 10.1016/0024-3205(89)90342-1; Hunt MC, 2005, J LIPID RES, V46, P2029, DOI 10.1194/jlr.E500003-JLR200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; Kasumov T, 2005, BIOCHEM J, V389, P397, DOI 10.1042/BJ20050144; KOLVRAA S, 1986, BIOCHIM BIOPHYS ACTA, V876, P515, DOI 10.1016/0005-2760(86)90039-1; Korman SH, 2000, J INHERIT METAB DIS, V23, P425, DOI 10.1023/A:1005624523611; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Magnes C, 2005, ANAL CHEM, V77, P2889, DOI 10.1021/ac048314i; MORTENSEN PB, 1986, BIOCHIM BIOPHYS ACTA, V878, P14, DOI 10.1016/0005-2760(86)90338-3; MORTENSEN PB, 1982, BIOCHIM BIOPHYS ACTA, V713, P393, DOI 10.1016/0005-2760(82)90258-2; MORTENSEN PB, 1982, BIOCHIM BIOPHYS ACTA, V710, P477, DOI 10.1016/0005-2760(82)90132-1; MORTENSEN PB, 1980, CLIN CHIM ACTA, V103, P33, DOI 10.1016/0009-8981(80)90227-2; MORTENSEN PB, 1980, BIOCHIM BIOPHYS ACTA, V620, P177, DOI 10.1016/0005-2760(80)90199-X; Ofman R, 2002, BIOCHEM BIOPH RES CO, V290, P629, DOI 10.1006/bbrc.2001.6245; Okita RT, 2001, CURR DRUG METAB, V2, P265; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Reszko AE, 2004, J BIOL CHEM, V279, P19574, DOI 10.1074/jbc.M400162200; ROCCHICCIOLI F, 1986, PEDIATR RES, V20, P62, DOI 10.1203/00006450-198601000-00018; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Sanders RJ, 2005, J LIPID RES, V46, P1001, DOI 10.1194/jlr.M400510-JLR200; Singh I, 1997, MOL CELL BIOCHEM, V167, P1, DOI 10.1023/A:1006883229684; Suga Tetsuya, 2003, Drug Metab Pharmacokinet, V18, P155, DOI 10.2133/dmpk.18.155; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; VAMECQ J, 1985, BIOCHEM J, V230, P683, DOI 10.1042/bj2300683; VAMECQ J, 1985, EUR J BIOCHEM, V146, P663, DOI 10.1111/j.1432-1033.1985.tb08702.x; VAMECQ J, 1989, AM J PHYSIOL, V256, pG680, DOI 10.1152/ajpgi.1989.256.4.G680; VAMECQ J, 1989, J BIOCHEM-TOKYO, V106, P216, DOI 10.1093/oxfordjournals.jbchem.a122835; Verkade PE, 1934, BIOCHEM J, V28, P31, DOI 10.1042/bj0280031; WADA F, 1977, BIOCHIM BIOPHYS ACTA, V487, P261, DOI 10.1016/0005-2760(77)90002-9; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wanders RJA, 2004, AM J MED GENET A, V126A, P355, DOI 10.1002/ajmg.a.20661; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; Westin MAK, 2004, J BIOL CHEM, V279, P21841, DOI 10.1074/jbc.M313863200; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017; Yamada J, 1998, BIOCHEM BIOPH RES CO, V248, P608, DOI 10.1006/bbrc.1998.9048	58	63	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38125	38132		10.1074/jbc.M508479200	http://dx.doi.org/10.1074/jbc.M508479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16141203	hybrid			2022-12-25	WOS:000233239800004
J	Kang, SH; Li, HM; Rao, AJ; Hogan, PG				Kang, SH; Li, HM; Rao, AJ; Hogan, PG			Inhibition of the calcineurin-NFAT interaction by small organic molecules reflects binding at an allosteric site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOHEMOPROTEIN AMINE DEHYDROGENASE; TYROSINE-PHOSPHATASE 1B; S-TRANSFERASE P1-1; CYCLOSPORINE-A; T-CELLS; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; LYMPHOCYTE-ACTIVATION; SELECTIVE-INHIBITION; SULFUR NUCLEOPHILES	Transcriptional signaling from the Ca2+-calmodulin-activated phosphatase calcineurin to its substrate NFAT ( nuclear factor of activated T cells, also termed NFATc) is critically dependent on a protein-protein docking interaction between calcineurin and the PXIXIT motif in NFAT. Several inhibitors of NFAT-calcineurin association (INCA compounds) prevent binding of NFAT or the peptide ligand PVIVIT to calcineurin. Here we show that the binding site on calcineurin for INCA1, INCA2, and INCA6 is centered on cysteine 266 of calcineurin A alpha and does not coincide with the core PXIXIT-binding site. Although ample evidence indicates that INCA1 and INCA2 react covalently with cysteine 266, covalent derivatization alone is not sufficient for maximal inhibition of the calcineurin-PVIVIT interaction, because the maleimide INCA12 reacts with the same site and produces only very modest inhibition. Thus, inhibition arises through an allosteric change affecting the PXIXIT docking site, which may be assisted by covalent binding but depends on other specific features of the ligand. The spatial arrangement of the binding sites for PVIVIT and INCA makes it probable that the change in conformation involves the beta 11-beta 12 loop of calcineurin. The finding that an allosteric site controls NFAT binding opens new alternatives for inhibition of calcineurin-NFAT signaling.	CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Hogan, PG (corresponding author), CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	hogan@cbr.med.harvard.edu		Kang, Sunghyun/0000-0003-1542-9750	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040127, R21AI059940] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI059940, R01 AI40127] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Batiuk TD, 1997, J CLIN INVEST, V100, P1894, DOI 10.1172/JCI119719; BATIUK TD, 1995, J CLIN INVEST, V96, P1254, DOI 10.1172/JCI118159; Boatman RJ, 2000, CHEM RES TOXICOL, V13, P853, DOI 10.1021/tx000037x; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Chang MS, 2001, BIOCHEMISTRY-US, V40, P4811, DOI 10.1021/bi002513o; Chen G, 2003, J AM CHEM SOC, V125, P8130, DOI 10.1021/ja034287m; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen WQ, 1999, BIOCHEMISTRY-US, V38, P8159, DOI 10.1021/bi990125k; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; Erlanson DA, 2004, ANNU REV BIOPH BIOM, V33, P199, DOI 10.1146/annurev.biophys.33.110502.140409; FRUMAN DA, 1995, MOL CELL BIOL, V15, P3857; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; Fujii H, 2002, EUR J NEUROSCI, V16, P1777, DOI 10.1046/j.1460-9568.2002.02235.x; Furuke K, 1999, J IMMUNOL, V162, P1988; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HANZLIK RP, 1994, CHEM RES TOXICOL, V7, P177, DOI 10.1021/tx00038a010; HOFFMANN KJ, 1985, MOL PHARMACOL, V27, P566; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu J, 2001, J IMMUNOL, V167, P2677, DOI 10.4049/jimmunol.167.5.2677; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; Noguchi H, 2004, NAT MED, V10, P305, DOI 10.1038/nm994; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reiter TA, 2002, J BIOL INORG CHEM, V7, P823, DOI 10.1007/s00775-002-0367-x; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; Rusnak F, 2000, TRENDS BIOCHEM SCI, V25, P527, DOI 10.1016/S0968-0004(00)01659-5; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SLAUGHTER DE, 1993, ANAL BIOCHEM, V208, P288, DOI 10.1006/abio.1993.1048; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; TSUBOI A, 1994, MOL BIOL CELL, V5, P119, DOI 10.1091/mbc.5.1.119; van Zanden JJ, 2003, CHEM-BIOL INTERACT, V145, P139, DOI 10.1016/S0009-2797(02)00250-8; Venkatesh N, 2004, P NATL ACAD SCI USA, V101, P8969, DOI 10.1073/pnas.0402803101; Wang QP, 2004, BIOCHEMISTRY-US, V43, P4294, DOI 10.1021/bi035986e; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Way JC, 2000, CURR OPIN CHEM BIOL, V4, P40, DOI 10.1016/S1367-5931(99)00049-6; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Zheng J, 1997, CHEM RES TOXICOL, V10, P1008, DOI 10.1021/tx970061j	59	40	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37698	37706		10.1074/jbc.M502247200	http://dx.doi.org/10.1074/jbc.M502247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148011	hybrid			2022-12-25	WOS:000233044500047
J	Kim, DJ; Kim, KH; Lee, HH; Lee, SJ; Ha, JY; Yoon, HJ; Suh, SW				Kim, DJ; Kim, KH; Lee, HH; Lee, SJ; Ha, JY; Yoon, HJ; Suh, SW			Crystal structure of lipoate-protein ligase A bound with the activated intermediate - Insights into interaction with lipoyl domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POSTTRANSLATIONAL MODIFICATION; MULTIFUNCTIONAL ENZYMES; SWINGING ARMS; ACID; CLONING; LIPOYLTRANSFERASE; ALIGNMENT; BINDING; SYSTEM	Lipoic acid is the covalently attached cofactor of several multicomponent enzyme complexes that catalyze key metabolic reactions. Attachment of lipoic acid to the lipoyl-dependent enzymes is catalyzed by lipoate-protein ligases (LPLs). In Escherichia coli, two distinct enzymes lipoate-protein ligase A (LplA) and lipB-encoded lipoyltransferase ( LipB) catalyze independent pathways for lipoylation of the target proteins. The reaction catalyzed by LplA occurs in two steps. First, LplA activates exogenously supplied lipoic acid at the expense of ATP to lipoyl-AMP. Next, it transfers the enzyme-bound lipoyl-AMP to the epsilon-amino group of a specific lysine residue of the lipoyl domain to give an amide linkage. To gain insight into the mechanism of action by LplA, we have determined the crystal structure of Thermoplasma acidophilum LplA in three forms: (i) the apo form; (ii) the ATP complex; and (iii) the lipoyl-AMP complex. The overall fold of LplA bears some resemblance to that of the biotinyl protein ligase module of the E. coli biotin holoenzyme synthetase/ bio repressor (BirA). Lipoyl-AMP is bound deeply in the bifurcated pocket of LplA and adopts a U-shaped conformation. Only the phosphate group and part of the ribose sugar of lipoyl-AMP are accessible from the bulk solvent through a tunnel-like passage, whereas the rest of the activated intermediate is completely buried inside the active site pocket. This first view of the activated intermediate bound to LplA allowed us to propose a model of the complexes between Ta LplA and lipoyl domains, thus shedding light on the target protein/lysine residue specificity of LplA.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea	Seoul National University (SNU)	Suh, SW (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea.	sewonsuh@snu.ac.kr	Lee, Sang Jae/AAX-7611-2021; Kim, Do Jin/I-7675-2014; Suh, Won/H-8306-2013	Lee, Sang Jae/0000-0002-5366-2900; Suh, Won/0000-0002-1768-4635				Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fujiwara K, 1999, EUR J BIOCHEM, V260, P761, DOI 10.1046/j.1432-1327.1999.00204.x; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; Fujiwara K, 2005, J BIOL CHEM, V280, P33645, DOI 10.1074/jbc.M505010200; Fujiwara K, 2001, J BIOL CHEM, V276, P28819, DOI 10.1074/jbc.M101748200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan SW, 1997, METHOD ENZYMOL, V279, P176; Jordan SW, 2003, J BACTERIOL, V185, P1582, DOI 10.1128/JB.185.5.1582-1589.2003; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MORRIS TW, 1995, J BACTERIOL, V177, P1; Nakai T, 2003, ACTA CRYSTALLOGR D, V59, P1610, DOI 10.1107/S0907444903014975; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reche PA, 2000, PROTEIN SCI, V9, P1922, DOI 10.1110/ps.9.10.1922; Reddy DV, 1998, PROTEIN SCI, V7, P2156, DOI 10.1002/pro.5560071013; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; Zhao X, 2003, CHEM BIOL, V10, P1293, DOI 10.1016/j.chembiol.2003.11.016	28	40	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38081	38089		10.1074/jbc.M507284200	http://dx.doi.org/10.1074/jbc.M507284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141198	hybrid			2022-12-25	WOS:000233044500091
J	Orr, WC; Radyuk, SN; Prabhudesai, L; Toroser, D; Benes, JJ; Luchak, JM; Mockett, RJ; Rebrin, I; Hubbard, JG; Sohal, RS				Orr, WC; Radyuk, SN; Prabhudesai, L; Toroser, D; Benes, JJ; Luchak, JM; Mockett, RJ; Rebrin, I; Hubbard, JG; Sohal, RS			Overexpression of glutamate-cysteine ligase extends life span in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; GLUTATHIONE SYNTHESIS; OXIDATIVE STRESS; REDOX STATE; MODEL; CELL; RAT; DISULFIDES; EXPRESSION; SUBUNIT	The hypothesis that overexpression of glutamate-cysteine ligase (GCL), which catalyzes the rate-limiting reaction in de novo glutathione biosynthesis, could extend life span was tested in the fruit fly, Drosophila melanogaster. The GAL4-UAS binary transgenic system was used to generate flies overexpressing either the catalytic (GCLc) or modulatory (GCLm) subunit of this enzyme, in a global or neuronally targeted pattern. The GCL protein content of the central nervous system was elevated dramatically in the presence of either global or neuronal drivers. GCL activity was increased in the whole body or in heads, respectively, of GCLc transgenic flies containing global or neuronal drivers. The glutathione content of fly homogenates was increased by overexpression of GCLc or GCLm, particularly in flies overexpressing either subunit globally, or in the heads of GCLc flies possessing neuronal drivers. Neuronal overexpression of GCLc in a long-lived background extended mean and maximum life spans up to 50%, without affecting the rate of oxygen consumption by the flies. In contrast, global overexpression of GCLm extended the mean life span only up to 24%. These results demonstrate that enhancement of the glutathione biosynthetic capability, particularly in neuronal tissues, can extend the life span of flies, and thus support the oxidative stress hypothesis of aging.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	Southern Methodist University; University of Southern California	Orr, WC (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	borr@smu.edu	Toroser, Dikran/AAT-9352-2021	Radyuk, Svetlana/0000-0002-3467-5255	NATIONAL INSTITUTE ON AGING [R01AG015122] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG15122] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; HERMAN MM, 1971, ACTA NEUROPATHOL, V19, P167, DOI 10.1007/BF00684595; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Klichko VI, 1999, NEUROBIOL AGING, V20, P537, DOI 10.1016/S0197-4580(99)00090-1; MARTENSSON J, 1991, P NATL ACAD SCI USA, V88, P9360, DOI 10.1073/pnas.88.20.9360; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mockett RJ, 2002, METHOD ENZYMOL, V349, P213, DOI 10.1016/S0076-6879(02)49336-6; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; Pan ZH, 1996, INT J DEV NEUROSCI, V14, P559; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Radyuk SN, 2000, ARCH INSECT BIOCHEM, V45, P79, DOI 10.1002/1520-6327(200010)45:2&lt;79::AID-ARCH4&gt;3.0.CO;2-Y; Rebrin I, 2004, BIOCHEM J, V382, P131, DOI 10.1042/BJ20040506; ROBERTSON HM, 1988, GENETICS, V118, P461; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schuster Christoph M., 1993, Experientia Supplementum (Basel), V63, P234; SHI MM, 1994, J BIOL CHEM, V269, P26512; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; Toroser D, 2005, BIOCHEM BIOPH RES CO, V326, P586, DOI 10.1016/j.bbrc.2004.11.066; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	26	105	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37331	37338		10.1074/jbc.M508272200	http://dx.doi.org/10.1074/jbc.M508272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148000	hybrid			2022-12-25	WOS:000233044500006
J	Germann, M; Gallo, C; Donahue, T; Shirzadi, R; Stukey, J; Lang, S; Ruckenstuhl, C; Oliaro-Bosso, S; McDonough, V; Turnowsky, F; Balliano, G; Nickels, JT				Germann, M; Gallo, C; Donahue, T; Shirzadi, R; Stukey, J; Lang, S; Ruckenstuhl, C; Oliaro-Bosso, S; McDonough, V; Turnowsky, F; Balliano, G; Nickels, JT			Characterizing sterol defect suppressors uncovers a novel transcriptional signaling pathway regulating zymosterol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUALENE EPOXIDASE GENE; SACCHAROMYCES-CEREVISIAE; TERBINAFINE RESISTANCE; MOLECULAR-CLONING; CELL-SURFACE; YEAST; CHOLESTEROL; EXPRESSION; REDUCTASE; ERGOSTEROL	erg26-1(ts) cells harbor defects in the 4 alpha-carboxysterol-C3 dehydrogenase activity necessary for conversion of 4,4-dimethylzymosterol to zymosterol. Mutant cells accumulate toxic 4-carboxysterols and are inviable at high temperature. A genetic screen aimed at cloning recessive mutations remediating the temperature sensitive growth defect has resulted in the isolation of four complementation groups, ets1-4 (erg26-1(ts) temperature sensitive suppressor). We describe the characterization of ets1-1 and ets2-1. Gas chromatography/ mass spectrometry analyses demonstrate that erg26-1(ts) ets1-1 and erg26-1(ts) ets2-1 cells do not accumulate 4-carboxysterols, rather these cells have increased levels of squalene and squalene epoxide, respectively. ets1-1 and ets2-1 cells accumulate these same sterol intermediates. Chromosomal integration of ERG1 and ERG7 at their loci in erg26-1(ts) ets1-1 and erg26-1(ts) ets2-1 mutants, respectively, results in the loss of accumulation of squalene and squalene epoxide, re- accumulation of 4-carboxysterols and cell inviability at high temperature. Enzymatic assays demonstrate that mutants harboring the ets1-1 allele have decreased squalene epoxidase activity, while those containing the ets2-1 allele show weakened oxidosqualene cyclase activity. Thus, ETS1 and ETS2 are allelic to ERG1 and ERG7, respectively. We have mapped mutations within the erg1-1/ ets1-1 (G247D) and erg7-1/ets2-1 (D530N, V615E) alleles that suppress the inviability of erg26-1(ts) at high temperature, and cause accumulation of sterol intermediates and decreased enzymatic activities. Finally using erg1-1 and erg7-1 mutant strains, we demonstrate that the expression of the ERG25/26/27 genes required for zymosterol biosynthesis are coordinately transcriptionally regulated, along with ERG1 and ERG7, in response to blocks in sterol biosynthesis. Transcriptional regulation requires the transcription factors, Upc2p and Ecm22p.	Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; Hope Coll, Dept Biol, Holland, MI 49422 USA; Karl Franzens Univ Graz, Inst Mol Biol Biochem & Microbiol, A-8010 Graz, Austria; Univ Turin, Fac Farm, Dipartimento Sci & Tecnol Farmaco, I-10125 Turin, Italy	Drexel University; Hope College; University of Graz; University of Turin	Germann, M (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.			Gallo-Ebert, Christina/0000-0003-0985-3547; Ruckenstuhl, Christoph/0000-0002-4338-4679	NHLBI NIH HHS [HL67401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ArthingtonSkaggs BA, 1996, FEBS LETT, V392, P161, DOI 10.1016/0014-5793(96)00807-1; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALLIANO G, 1988, BIOCHIM BIOPHYS ACTA, V959, P9, DOI 10.1016/0005-2760(88)90144-0; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHAMBAZ EM, 1969, ANAL BIOCHEM, V30, P7, DOI 10.1016/0003-2697(69)90368-6; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DimsterDenk D, 1996, MOL CELL BIOL, V16, P3981; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; FAUST JR, 1988, BIOL CHOLESTEROL, P20; FIELD RB, 1979, LIPIDS, V14, P741, DOI 10.1007/BF02533900; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; Gachotte D, 2001, J LIPID RES, V42, P150; Grishin AV, 1998, GENETICS, V149, P879; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hinson DD, 1997, J LIPID RES, V38, P2216; Hongay C, 2002, EMBO J, V21, P4114, DOI 10.1093/emboj/cdf415; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; Kastaniotis AJ, 2000, MOL CELL BIOL, V20, P7088, DOI 10.1128/MCB.20.19.7088-7098.2000; Kennedy MA, 1999, BBA-GENE STRUCT EXPR, V1445, P110, DOI 10.1016/S0167-4781(99)00035-4; Klobucnikova V, 2003, BIOCHEM BIOPH RES CO, V309, P666, DOI 10.1016/j.bbrc.2003.08.051; Konig A, 2000, AM J MED GENET, V90, P339; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; Laden BP, 2000, ARCH BIOCHEM BIOPHYS, V374, P381, DOI 10.1006/abbi.1999.1629; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; Leber R, 2003, ANTIMICROB AGENTS CH, V47, P3890, DOI 10.1128/AAC.47.12.3890-3900.2003; Leber R, 2001, EUR J BIOCHEM, V268, P914, DOI 10.1046/j.1432-1327.2001.01940.x; Lechner M, 1999, J CHROMATOGR A, V857, P231, DOI 10.1016/S0021-9673(99)00751-7; Lees N., 1997, BIOCH FUNCTION STERO, P85; LEES ND, 1995, LIPIDS, V30, P221, DOI 10.1007/BF02537824; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; LISCUM L, 1992, J LIPID RES, V33, P1239; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; Marijanovic Z, 2003, MOL ENDOCRINOL, V17, P1715, DOI 10.1210/me.2002-0436; MBAYA B, 1989, LIPIDS, V24, P1020, DOI 10.1007/BF02544072; Mo C, 2003, BBA-MOL CELL BIOL L, V1633, P68, DOI 10.1016/S1388-1981(03)00088-X; Mo C, 2002, P NATL ACAD SCI USA, V99, P9739, DOI 10.1073/pnas.112202799; Mullner H, 2004, BBA-BIOMEMBRANES, V1663, P9, DOI 10.1016/S0005-2736(04)00079-3; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; Nagai M, 2002, BIOCHEM BIOPH RES CO, V295, P74, DOI 10.1016/S0006-291X(02)00623-X; Nagai M, 1997, GENOMICS, V44, P141, DOI 10.1006/geno.1997.4825; NES W D, 1989, Steroids, V53, P533, DOI 10.1016/0039-128X(89)90030-5; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; PARKS LW, 1995, LIPIDS, V30, P227, DOI 10.1007/BF02537825; PATTERSON GW, 1971, ANAL CHEM, V43, P1165, DOI 10.1021/ac60304a015; Phillips KM, 1999, J CHROMATOGR B, V732, P17, DOI 10.1016/S0378-4347(99)00257-1; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rodriguez C, 2003, CARDIOVASC RES, V58, P178, DOI 10.1016/S0008-6363(02)00856-8; RODRIGUEZ RJ, 1983, ARCH BIOCHEM BIOPHYS, V225, P861, DOI 10.1016/0003-9861(83)90099-1; Sato R, 1995, CELL STRUCT FUNCT, V20, P421, DOI 10.1247/csf.20.421; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; SUNG CK, 1995, BIOL PHARM BULL, V18, P1459; Swain E, 2002, J BIOL CHEM, V277, P36152, DOI 10.1074/jbc.M206624200; Thoma R, 2004, NATURE, V432, P118, DOI 10.1038/nature02993; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; WELIHINDA AA, 1994, BBA-BIOMEMBRANES, V1193, P107, DOI 10.1016/0005-2736(94)90339-5; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Wu WI, 2000, METHOD ENZYMOL, V312, P373; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X; Zweytick D, 2000, FEBS LETT, V470, P83, DOI 10.1016/S0014-5793(00)01290-4	77	25	26	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35904	35913		10.1074/jbc.M504978200	http://dx.doi.org/10.1074/jbc.M504978200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120615	hybrid			2022-12-25	WOS:000232726900017
J	Kray, AE; Carter, RS; Pennington, KN; Gomez, RJ; Sanders, LW; Llanes, JM; Khan, WN; Ballard, DW; Wadzinski, BE				Kray, AE; Carter, RS; Pennington, KN; Gomez, RJ; Sanders, LW; Llanes, JM; Khan, WN; Ballard, DW; Wadzinski, BE			Positive regulation of I kappa B kinase signaling by protein serine/threonine phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; OKADAIC ACID; IKK COMPLEX; AFFINITY-CHROMATOGRAPHY; CELL-GROWTH; HIGH-TITER; ACTIVATION; ALPHA; PHOSPHORYLATION; BETA	Transcription factor NF-kappa B plays a key regulatory role in the cellular response to pro-inflammatory cytokines such as tumor necrosis factor-alpha(TNF). In the absence of TNF, NF-kappa B is sequestered in the cytoplasm by inhibitory I kappa B proteins. Phosphorylation of I kappa B by the beta-catalytic subunit of IKK, a multicomponent I kappa B kinase, targets the inhibitor for proteolytic destruction and facilitates nuclear translocation of NF-kappa B. This pathway is initiated by TNF-dependent phosphorylation of T loop serines in IKK beta, which greatly stimulates I kappa B kinase activity. Prior in vitro mixing experiments indicate that protein serine/threonine phosphatase 2A (PP2A) can dephosphorylate these T loop serines and inactivate IKK, suggesting a negative regulatory role for PP2A in IKK signaling. Here we provided several in vivo lines of evidence indicating that PP2A plays a positive rather than a negative role in the regulation of IKK. First, TNF-induced degradation of I kappa B is attenuated in cells treated with okadaic acid or fostriecin, two potent inhibitors of PP2A. Second, PP2A forms stable complexes with IKK in untransfected mammalian cells. This interaction is critically dependent on amino acid residues 121 - 179 of the IKK gamma regulatory subunit. Third, deletion of the PP2A-binding site in IKK gamma attenuates T loop phosphorylation and catalytic activation of IKK beta in cells treated with TNF. Taken together, these data provide strong evidence that the formation of IKK center dot PP2A complexes is required for the proper induction of I kappa B kinase activity in vivo.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Wadzinski, BE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 424 RRB, Nashville, TN 37232 USA.	brian.wadzinski@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA082556, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050213, R01AI052379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366, T32GM007628, R01GM062265] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, CA082556] Funding Source: Medline; NIAID NIH HHS [AI052379, AI50213] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [GM51366, GM62265, 2-T32-GM07628] Funding Source: Medline; NIMH NIH HHS [MH19732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Bauman AL, 2000, J NEUROSCI, V20, P7571; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Carter RS, 2003, J BIOL CHEM, V278, P48903, DOI 10.1074/jbc.M310686200; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Fernandez PC, 1999, BIOCHEM BIOPH RES CO, V263, P63, DOI 10.1006/bbrc.1999.1312; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Fujita M, 2004, ORAL ONCOL, V40, P199, DOI 10.1016/S1368-8375(03)00152-0; Garcia A, 2000, MICROBES INFECT, V2, P401, DOI 10.1016/S1286-4579(00)00327-0; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krueger KM, 1997, J BIOL CHEM, V272, P5; Kupfer R, 2002, J IMMUNOL METHODS, V266, P155, DOI 10.1016/S0022-1759(02)00146-1; Lewy DS, 2002, CURR MED CHEM, V9, P2005, DOI 10.2174/0929867023368809; Mahboubi K, 1997, J PHARMACOL EXP THER, V282, P452; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Miskolci V, 2003, ARCH BIOCHEM BIOPHYS, V417, P44, DOI 10.1016/S0003-9861(03)00336-9; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Morimoto H, 2004, J BIOCHEM, V136, P433, DOI 10.1093/jb/mvh144; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Price NE, 1999, MOL BRAIN RES, V73, P68, DOI 10.1016/S0169-328X(99)00237-5; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Strack S, 1998, J COMP NEUROL, V392, P515; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	59	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35974	35982		10.1074/jbc.M506093200	http://dx.doi.org/10.1074/jbc.M506093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16126728	hybrid			2022-12-25	WOS:000232726900025
J	van der Westhuyzen, DR; Cai, L; de Beer, MC; de Beer, FC				van der Westhuyzen, DR; Cai, L; de Beer, MC; de Beer, FC			Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ACUTE-PHASE PROTEIN; CELLULAR CHOLESTEROL; MACROPHAGE CHOLESTEROL; MESSENGER-RNA; EXPRESSION; BINDING; IDENTIFICATION; METABOLISM; ISOFORM	Serum amyloid A (SAA) is an acute phase protein whose expression is markedly up-regulated during inflammation and infection. The physiological function of SAA is unclear. In this study, we reported that SAA promotes cellular cholesterol efflux mediated by scavenger receptor B-I (SR-BI). In Chinese hamster ovary cells, SAA promoted cellular cholesterol efflux in an SR-BI-dependent manner, whereas apoA-I did not. Similarly, SAA, but not apoA-I, promoted cholesterol efflux from HepG2 cells in an SR-BI-dependent manner as shown by using the SR-BI inhibitor BLT-1. When SAA was overexpressed in HepG2 cells using adenovirus-mediated gene transfer, the endogenously expressed SAA promoted SR-BI-dependent efflux. To assess the effect of SAA on SR-BI-mediated efflux to high density lipoprotein (HDL), we compared normal HDL, acute phase HDL(AP-HDL, prepared from mice injected with lipopolysaccharide), and AdSAA-HDL ( HDL prepared from mice overexpressing SAA). Both AP-HDL and AdSAA-HDL promoted 2-fold greater cholesterol efflux than normal HDL. Lipid-free SAA was shown to also stimulate ABCA1-dependent cholesterol efflux in fibroblasts, in line with an earlier report (Stonik, J. A., Remaley, A. T., Demosky, S. J., Neufeld, E. B., Bocharov, A., and Brewer, H. B. ( 2004) Biochem. Biophys. Res. Commun. 321, 936 - 941). When added to cells together, SAA and HDL exerted a synergistic effect in promoting ABCA1-dependent efflux, suggesting that SAA may remodel HDL in a manner that releases apoA-I or other efficient ABCA1 ligands from HDL. SAA also facilitated efflux by a process that was independent of SR-BI and ABCA1. We conclude that the acute phase protein SAA plays an important role in HDL cholesterol metabolism by promoting cellular cholesterol efflux through a number of different efflux pathways.	Univ Kentucky, Grad Ctr Nutr Sci, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Nutr Sci, Dept Physiol, Lexington, KY 40536 USA; Dept Vet Affairs Med Ctr, Lexington, KY 40511 USA	University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	van der Westhuyzen, DR (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, Dept Internal Med, Wethington Hlth Sci Bldg 541,900 S Limestone St, Lexington, KY 40536 USA.	dvwest1@uky.edu	Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [HL-65730, HL-63763] Funding Source: Medline; NIA NIH HHS [AG-17237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065730, R01HL063763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017237] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANKA CL, 1995, J LIPID RES, V36, P1058; Baranova IN, 2005, J BIOL CHEM, V280, P8031, DOI 10.1074/jbc.M405009200; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; CLIFTON PM, 1985, J LIPID RES, V26, P1389; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Hayat S, 1997, BIOCHEM SOC T, V25, pS348, DOI 10.1042/bst025348s; Hirano K, 1999, CIRC RES, V85, P108; Hosoai H, 1999, J LIPID RES, V40, P648; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Kisilevsky R, 2003, J LIPID RES, V44, P2257, DOI 10.1194/jlr.M300133-JLR200; Kisilevsky R, 2002, PEDIATR PATHOL MOL M, V21, P291, DOI 10.1080/02770930290056523; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LIANG JS, 1995, J LIPID RES, V36, P37; LY H, 1995, J LIPID RES, V36, P1254; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Rothblat GH, 1999, J LIPID RES, V40, P781; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; Stonik JA, 2004, BIOCHEM BIOPH RES CO, V321, P936, DOI 10.1016/j.bbrc.2004.07.052; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Tam SP, 2002, J LIPID RES, V43, P1410, DOI 10.1194/jlr.M100388-JLR200; Tsukamoto K, 1997, J LIPID RES, V38, P1869; TURNELL W, 1986, MOL BIOL MED, V3, P387; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Urieli-Shoval S, 2000, CURR OPIN HEMATOL, V7, P64, DOI 10.1097/00062752-200001000-00012; Wang LM, 2004, BIOCHEM BIOPH RES CO, V317, P157, DOI 10.1016/j.bbrc.2004.03.027; Webb NR, 1997, J LIPID RES, V38, P1583; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200	38	110	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35890	35895		10.1074/jbc.M505685200	http://dx.doi.org/10.1074/jbc.M505685200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120612	hybrid			2022-12-25	WOS:000232726900015
J	Van Kanegan, MJ; Adams, DG; Wadzinski, BE; Strack, S				Van Kanegan, MJ; Adams, DG; Wadzinski, BE; Strack, S			Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHORYLATION STATUS; CORE ENZYME; B56 SUBUNIT; B-SUBUNITS; ACTIVATION; PP2A; BINDING; CELLS; DEPHOSPHORYLATION	A key regulator of many kinase cascades, heterotrimeric protein serine/threonine phosphatase 2A (PP2A), is composed of catalytic ( C), scaffold ( A), and variable regulatory subunits (B, B', B '' gene families). In neuronal PC12 cells, PP2A acts predominantly as a gatekeeper of extracellular signal-regulated kinase (ERK) activity, as shown by inducible RNA interference of the A alpha scaffolding subunit and PP2A inhibition by okadaic acid. Although okadaic acid potentiates Akt/protein kinase B and ERK phosphorylation in response to epidermal, basic fibroblast, or nerve growth factor, silencing of A alpha paradoxically has the opposite effect. Epidermal growth factor receptor Tyr phosphorylation was unchanged following A alpha knockdown, suggesting that chronic Akt and ERK hyperphosphorylation leads to compensatory down-regulation of signaling molecules upstream of Ras and blunted growth factor responses. Inducible exchange of wild-type A alpha with a mutant with selective B' subunit binding deficiency implicated PP2A/B' heterotrimers as Akt modulators. Conversely, silencing of the B-family regulatory subunits B alpha and B delta led to hyperactivation of ERK stimulated by constitutively active MEK1. In vitro dephosphorylation assays further support a role for B alpha and B delta in targeting the PP2A heterotrimer to dephosphorylate and inactivate ERKs. Thus, receptor tyrosine kinase signaling cascades leading to Akt and ERK activation are modulated by PP2A holoenzymes with distinct regulatory properties.	Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	University of Iowa; Vanderbilt University	Strack, S (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, 2-432 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	stefan-strack@uiowa.edu		Strack, Stefan/0000-0002-6175-7280	NIDDK NIH HHS [5T32DK07563] Funding Source: Medline; NIGMS NIH HHS [GM62265, GM51366] Funding Source: Medline; NINDS NIH HHS [NS43254] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM051366, R01GM062265, R01GM051366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043254] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Berry M, 2000, EMBO J, V19, P2946, DOI 10.1093/emboj/19.12.2946; Borgatti P, 2003, J CELL PHYSIOL, V196, P79, DOI 10.1002/jcp.10279; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; CHANDLER LP, 1985, J BIOL CHEM, V260, P3360; Dagda RK, 2005, J BIOL CHEM, V280, P27375, DOI 10.1074/jbc.M503693200; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; Gual P, 2001, ONCOGENE, V20, P156, DOI 10.1038/sj.onc.1204047; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Hatakeyama M, 2004, ONCOGENE, V23, P5023, DOI 10.1038/sj.onc.1207664; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Hupfeld CJ, 2005, J BIOL CHEM, V280, P1016, DOI 10.1074/jbc.M403674200; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kao GT, 2004, DEVELOPMENT, V131, P755, DOI 10.1242/dev.00987; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Liu W, 2003, CELL DEATH DIFFER, V10, P772, DOI 10.1038/sj.cdd.4401238; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Spurney RF, 2001, J PHARMACOL EXP THER, V296, P592; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Usui H, 1998, FEBS LETT, V430, P312, DOI 10.1016/S0014-5793(98)00684-X; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yang J, 2003, DEVELOPMENT, V130, P5569, DOI 10.1242/dev.00762; Yu LG, 2004, J BIOL CHEM, V279, P41377, DOI 10.1074/jbc.M400017200; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	61	113	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36029	36036		10.1074/jbc.M506986200	http://dx.doi.org/10.1074/jbc.M506986200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129692	hybrid			2022-12-25	WOS:000232726900032
J	Chuang, LC; Yew, PR				Chuang, LC; Yew, PR			Proliferating cell nuclear antigen recruits cyclin-dependent kinase inhibitor Xic1 to DNA and couples its proteolysis to DNA polymerase switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							XENOPUS EGG EXTRACTS; REPLICATION LICENSING SYSTEM; ORIGIN RECOGNITION COMPLEX; S-PHASE; CDK INHIBITOR; PROTEIN-KINASE; IN-VITRO; PCNA; DEGRADATION; INITIATION	The Xenopus cyclin- dependent kinase ( CDK) inhibitor, p27(Xic1) ( Xic1), binds to CDK2- cyclins and proliferating cell nuclear antigen ( PCNA), inhibits DNA synthesis in Xenopus extracts, and is targeted for ubiquitin- mediated proteolysis. Previous studies suggest that Xic1 ubiquitination and degradation are coupled to the initiation of DNA replication, but the precise timing and molecular mechanism of Xic1 proteolysis has not been determined. Here we demonstrate that Xic1 proteolysis is temporally restricted to late replication initiation following the requirements for DNA polymerase alpha- primase, replication factor C, and PCNA. Our studies also indicate that Xic1 degradation is absolutely dependent upon the binding of Xic1 to PCNA in both Xenopus egg and gastrulation stage extracts. Additionally, extracts depleted of PCNA do not support Xic1 proteolysis. Importantly, while the addition of recombinant wild- type PCNA alone restores Xic1 degradation, the addition of a PCNA mutant defective for trimer formation does not restore Xic1 proteolysis in PCNA- depleted extracts, suggesting Xic1 proteolysis requires both PCNA binding to Xic1 and the ability of PCNA to be loaded onto primed DNA by replication factor C. Taken together, our studies suggest that Xic1 is targeted for ubiquitination and degradation during DNA polymerase switching through its interaction with PCNA at a site of initiation.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Yew, PR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA.	yew@uthscsa.edu			NIGMS NIH HHS [1R01-GM066226] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066226] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Bogan JA, 2000, J CELL PHYSIOL, V184, P139, DOI 10.1002/1097-4652(200008)184:2<139::AID-JCP1>3.0.CO;2-8; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chuang LC, 2005, J BIOL CHEM, V280, P35290, DOI 10.1074/jbc.M506430200; Chuang LC, 2001, J BIOL CHEM, V276, P1610, DOI 10.1074/jbc.M008896200; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coverley D, 2000, J CELL SCI, V113, P1929; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Daniels M, 2004, GENE, V342, P41, DOI 10.1016/j.gene.2004.07.038; DePamphilis ML, 2000, J STRUCT BIOL, V129, P186, DOI 10.1006/jsbi.2000.4219; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FUJITA M, 1999, FRONT BIOSCI, V4, P816; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Leatherwood J, 1998, CURR OPIN CELL BIOL, V10, P742, DOI 10.1016/S0955-0674(98)80117-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lei M, 2001, J CELL SCI, V114, P1447; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Mattock H, 2001, EXP CELL RES, V265, P242, DOI 10.1006/excr.2001.5181; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Sambrook J., 1989, MOL CLONING, pA1; Sclafani R A, 1998, Trends Genet, V14, P441, DOI 10.1016/S0168-9525(98)01610-2; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vernon AE, 2003, DEVELOPMENT, V130, P71, DOI 10.1242/dev.00180; Vernon AE, 2003, DEVELOPMENT, V130, P85, DOI 10.1242/dev.00193; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; You ZS, 2002, GENE DEV, V16, P1182, DOI 10.1101/gad.985302; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r	116	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35299	35309		10.1074/jbc.M506429200	http://dx.doi.org/10.1074/jbc.M506429200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118211	hybrid			2022-12-25	WOS:000232561200028
J	Samraj, AK; Stroh, C; Fischer, U; Schulze-Osthoff, K				Samraj, AK; Stroh, C; Fischer, U; Schulze-Osthoff, K			The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression	ONCOGENE			English	Article						apoptosis; Bak; Bax; Lck; mitochondria	SRC-FAMILY KINASES; INDUCED CELL-DEATH; NF-KAPPA-B; BCL-2 FAMILY; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; GENETIC-EVIDENCE; ALPHA-TOXIN; T-CELLS; RECEPTOR	Tyrosine kinases of the Src family have been implicated in key biological processes. Here, we provide evidence that p56(Lck), a lymphoid-specific Src kinase, is involved in the activation of the mitochondrial apoptosis pathway. Lck-deficient T cells were completely resistant to anticancer drugs. In contrast, apoptosis sensitivity to death receptors was not altered, indicating a specific interference of Lck with the mitochondrial pathway. Re-expression of Lck restored sensitivity to drug-induced apoptosis and triggered mitochondrial cytochrome c release and caspase activation. Further analysis identified that the sensitization by Lck was independent of classical mediators of T-cell signaling, but essentially involved the Bcl-2 protein Bak. Expression of Bak was completely absent in Lck-deficient cells, while re-expression of Lck transcriptionally triggered Bak expression and conferred sensitivity to apoptosis, associated with a proapoptotic conformational change of Bak. Furthermore, in vitro the truncated fragment of Bid specifically activated Bak and cytochrome c release only from mitochondria of Lck-expressing cells. These results do not only demonstrate a sentinel role of Lck in drug resistance but also delineate a hitherto unknown pathway of Src kinases in regulation of Bcl-2 proteins.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	KSO@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bantel H, 2001, J CELL BIOL, V155, P637, DOI 10.1083/jcb.200105081; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hernandez-Hansen V, 2004, J LEUKOCYTE BIOL, V75, P143, DOI 10.1189/jlb.0503224; Hur YG, 2004, J IMMUNOL, V172, P79, DOI 10.4049/jimmunol.172.1.79; Iwamoto KS, 1996, CANCER RES, V56, P3862; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Knudson CM, 2001, CANCER RES, V61, P659; Kondo S, 2000, CANCER RES, V60, P4328; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Melendez J, 2004, J BIOL CHEM, V279, P53516, DOI 10.1074/jbc.M408475200; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Seddon B, 2000, SCIENCE, V290, P127, DOI 10.1126/science.290.5489.127; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Singer AL, 2002, SCIENCE, V296, P1639, DOI 10.1126/science.1071551; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x	63	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					186	197		10.1038/sj.onc.1209034	http://dx.doi.org/10.1038/sj.onc.1209034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116473				2022-12-25	WOS:000234583600003
J	Bonaventura, C; Godette, G; Stevens, R; Brenowitz, M; Henkens, R				Bonaventura, C; Godette, G; Stevens, R; Brenowitz, M; Henkens, R			Overproduction of alpha chains provides a proton-insensitive component to the bluefish hemoglobin system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFHYDRYL GROUPS; STRUCTURAL BASIS; OXYGEN-AFFINITY; FISH	Expression of alpha and beta chains and their post-translational assembly into alpha(2)beta(2) tetramers is fundamental to the formation and function of most vertebrate hemoglobins. There is a strong evolutionary bias that favors expression of equal amounts of the two types of chains, because cooperativity, pH sensitivity, and anionic control of function occurs only for the alpha(2)beta(2) tetramers. Remarkably, an overproduction of alpha chains, as in the pathological condition known as beta thalassemia in humans, is adaptive rather than pathological in the bluefish hemoglobin system. The thalassemia of the bluefish is a novel means of providing for oxygen uptake and delivery when low pH conditions incapacitate the highly pH-sensitive Root effect hemoglobins of the fish. Although fish often have pH-insensitive along with highly pH-sensitive hemoglobins, having pH-insensitive alpha chain monomers in circulation is an unusual structural variation. The role of bluefish alpha chains in oxygen transport is enabled by their remarkably lower oxygen affinity relative to human alpha chains. This is the first reported case of a thalassemic condition that is maintained in a species as an adaptive advantage.	Duke Univ, Marine Lab, Nicholas Sch Environm & Earth Sci, Beaufort, NC 28516 USA; Duke Univ, Mass Spectrometry Facil, Dept Pediat, Res Triangle Pk, NC 27709 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Duke University; Duke University; Yeshiva University; Albert Einstein College of Medicine	Bonaventura, C (corresponding author), Duke Univ, Marine Lab, Nicholas Sch Environm & Earth Sci, Beaufort, NC 28516 USA.	bona@duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071064] Funding Source: NIH RePORTER; NHLBI NIH HHS [5PO1-HL-071064-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTOINI E, 1971, HEMOGLOBIN MYOGLOBIN, P195; BENTLEY TB, 1982, ENVIRON BIOL FISH, V7, P77, DOI 10.1007/BF00011828; Bonaventura C, 2004, ACTA PHYSIOL SCAND, V182, P245, DOI 10.1111/j.1365-201X.2004.01359.x; BONAVENTURA C, 1976, J BIOL CHEM, V251, P1871; Brunori M, 1975, Curr Top Cell Regul, V9, P1; GIARDINA B, 1975, NATURE, V256, P761, DOI 10.1038/256761a0; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; Mazzarella L, 1999, J MOL BIOL, V287, P897, DOI 10.1006/jmbi.1999.2632; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NOBLE RW, 1986, BIOCHIM BIOPHYS ACTA, V870, P552, DOI 10.1016/0167-4838(86)90265-7; OLIVER JD, 1989, US FISH WILDLIFE SER, V82; Pelster B., 1991, Advances in Comparative and Environmental Physiology, V8, P51; Perutz MF, 1996, NAT STRUCT BIOL, V3, P211, DOI 10.1038/nsb0396-211; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; POWERS DA, 1986, AM ZOOL, V26, P235; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; Root RW, 1931, BIOL BULL-US, V61, P427, DOI 10.2307/1536959; Salerno Daniel J., 2001, Journal of Northwest Atlantic Fishery Science, V29, P31; SCHOLANDER PF, 1954, BIOL BULL, V107, P247, DOI 10.2307/1538611; WEBER RE, 1976, J EXP BIOL, V64, P75; Weber RE, 2000, HEMOGLOBIN FUNCTION IN VERTEBRATES, P23; [No title captured]	24	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40509	40514		10.1074/jbc.M505353200	http://dx.doi.org/10.1074/jbc.M505353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16166086	hybrid			2022-12-25	WOS:000233666600017
J	Mueckler, M; Makepeace, C				Mueckler, M; Makepeace, C			Cysteine-scanning mutagenesis and substituted cysteine accessibility analysis of transmembrane segment 4 of the Glut1 glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PERMEATION PATHWAY; XENOPUS-OOCYTES; ESCHERICHIA-COLI; BINDING; MECHANISM; HELIX; DOMAINS; FAMILY; HEPG2	A low resolution model has been proposed for the exofacial conformation of the Glut1 glucose transporter in which eight transmembrane segments form an inner helical bundle stabilized by four outer helices. The role of transmembrane segment 4, predicted to be an inner helix in this structural model, was investigated by cysteine-scanning mutagenesis in conjunction with the substituted cysteine accessibility method using the membrane-impermeant, sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS). A functional, cysteine-less, parental Glut1 molecule was used to produce 21 Glut1 point mutants by individually changing each residue along transmembrane helix 4 to a cysteine. The single cysteine mutants were then expressed in Xenopus oocytes, and their expression levels, transport activities, and sensitivities to pCMBS were determined. In striking contrast to all of the other seven predicted inner helices, none of the 21 helix 4 single-cysteine mutants was demonstrably inhibited by pCMBS. However, cysteine substitution within helix 4 resulted in an unusually high number of severely transport-defective mutants. The low absolute transport activities of two of these mutants (G130C and G134C) were due to their extremely low levels of expression, presumably a result of structural instability and consequent degradation in oocytes, suggesting that these two residues play an important role in maintaining the native structure of Glut1. The other two transport-defective mutants (Y143C and E146C) exhibited low specific transport activities, implying that these two residues play an important role in the transport cycle. Based on these data, we conclude that the exoplasmic end of helix 4 lies outside the inner helical bundle in the exofacial configuration of Glut1.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Heinze M, 2004, BIOCHEMISTRY-US, V43, P931, DOI 10.1021/bi030175w; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KELLER K, 1989, J BIOL CHEM, V264, P18884; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; Mueckler M, 2004, J BIOL CHEM, V279, P46876, DOI 10.1074/jbc.M408632200; Mueckler M, 2004, J BIOL CHEM, V279, P10494, DOI 10.1074/jbc.M310786200; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6	26	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39562	39568		10.1074/jbc.M509050200	http://dx.doi.org/10.1074/jbc.M509050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16172126	hybrid			2022-12-25	WOS:000233362200079
J	Huang, CH; Lai, WL; Lee, MH; Chen, CJ; Vasella, A; Tsai, YC; Liaw, SH				Huang, CH; Lai, WL; Lee, MH; Chen, CJ; Vasella, A; Tsai, YC; Liaw, SH			Crystal structure of glucooligosaccharide oxidase from Acremonium strictum - A novel flavinylation of 6-S-cysteinyl, 8 alpha-N1-histidyl FAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE; ENZYME; RESOLUTION; PROTEIN; MONONUCLEOTIDE; MECHANISM; CRYSTALLOGRAPHY; COMPLEXES; CATALYSIS; DOMAIN	Glucooligosaccharide oxidase from Acremonium strictum has been screened for potential applications in oligosaccharide acid production and alternative carbohydrate detection, because it catalyzes the oxidation of glucose, maltose, lactose, cellobiose and cello- and maltooligosaccharides. We report the crystal structures of the enzyme and of its complex with an inhibitor, 5-amino-5-deoxycellobiono-1,5- lactam at 1.55- and 1.98-angstrom resolution, respectively. Unexpectedly, the protein structure demonstrates the first known double attachment flavinylation, 6-S-cysteinyl, 8 alpha-N1-histidyl FAD. The FAD cofactor is cross-linked to the enzyme via the C-6 atom and the 8 alpha-methyl group of the isoalloxazine ring with Cys(130) and His(70), respectively. This sugar oxidase possesses an open carbohydrate-binding groove, allowing the accommodation of higher oligosaccharides. The complex structure suggests that this enzyme may prefer a beta-D-glucosyl residue at the reducing end with the conserved Tyr(429) acting as a general base to abstract the OH1 proton in concert with the H-1 hydride transfer to the flavin N-5. Finally, a detailed comparison illustrates the structural conservation as well as the divergence between this protein and its related flavoenzymes.	Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Natl Yang Ming Univ, Struct Biol Program, Taipei 11221, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan; Natl Synchrotron Radiat Res Ctr, Div Res, Biol Grp, Hsinchu 30076, Taiwan; ETH Honggerberg, Organ Chem Lab, CH-8093 Zurich, Switzerland; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Synchrotron Radiation Research Center; Swiss Federal Institutes of Technology Domain; ETH Zurich	Tsai, YC (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan.	tasiyc@edu.tw; shliaw@ym.edu.tw	Chen, Chun-Jung/A-6880-2011	Chen, Chun-Jung/0000-0002-5157-4288				Aravind L, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r30; Benson TE, 1997, BIOCHEMISTRY-US, V36, P806, DOI 10.1021/bi962221g; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carter CJ, 2004, PLANT PHYSIOL, V134, P460, DOI 10.1104/pp.103.027482; Cunane LM, 2005, BIOCHEMISTRY-US, V44, P2963, DOI 10.1021/bi048020r; Custers JHHV, 2004, PLANT J, V39, P147, DOI 10.1111/j.1365-313X.2004.02117.x; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Dobbek H, 2002, P NATL ACAD SCI USA, V99, P15971, DOI 10.1073/pnas.212640899; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Dym O, 2000, P NATL ACAD SCI USA, V97, P9413, DOI 10.1073/pnas.97.17.9413; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Firbank SJ, 2001, P NATL ACAD SCI USA, V98, P12932, DOI 10.1073/pnas.231463798; Fitzpatrick PF, 2004, BIOORG CHEM, V32, P125, DOI 10.1016/j.bioorg.2003.02.001; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Fraaije MW, 2000, J BIOL CHEM, V275, P38654, DOI 10.1074/jbc.M004753200; Fujieda N, 2004, BIOCHEMISTRY-US, V43, P10800, DOI 10.1021/bi049061q; Groen BW, 1997, EUR J BIOCHEM, V244, P858, DOI 10.1111/j.1432-1033.1997.00858.x; Hallberg BM, 2004, J MOL BIOL, V341, P781, DOI 10.1016/j.jmb.2004.06.033; Hallberg BM, 2003, J BIOL CHEM, V278, P7160, DOI 10.1074/jbc.M210961200; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; LEE MH, 2005, IN PRESS APPL ENV MI; LIN SF, 1991, BIOCHIM BIOPHYS ACTA, V1118, P41, DOI 10.1016/0167-4838(91)90439-7; Malito E, 2004, J MOL BIOL, V341, P1237, DOI 10.1016/j.jmb.2004.06.083; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P2338; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Mewies M, 1997, BIOCHEMISTRY-US, V36, P7162, DOI 10.1021/bi970621d; MEYER AS, 1995, TRENDS FOOD SCI TECH, V6, P300, DOI 10.1016/S0924-2244(00)89140-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SCHOMBURG I, 2004, NUCLEIC ACIDS RES, V32, P431; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang JW, 2004, ACTA CRYSTALLOGR D, V60, P1244, DOI 10.1107/S0907444904010674; Wohlfahrt G, 1999, ACTA CRYSTALLOGR D, V55, P969, DOI 10.1107/S0907444999003431; [No title captured]	38	77	81	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38831	38838		10.1074/jbc.M506078200	http://dx.doi.org/10.1074/jbc.M506078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16154992	hybrid			2022-12-25	WOS:000233239800085
J	Mainardi, JL; Fourgeaud, M; Hugonnet, JE; Dubost, L; Brouard, JP; Ouazzani, J; Rice, LB; Gutmann, L; Arthur, M				Mainardi, JL; Fourgeaud, M; Hugonnet, JE; Dubost, L; Brouard, JP; Ouazzani, J; Rice, LB; Gutmann, L; Arthur, M			A novel peptidoglycan cross-linking enzyme for a beta-lactam-resistant transpeptidation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING-PROTEINS; GRAM-POSITIVE BACTERIA; ENTEROCOCCUS-FAECIUM; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; MECHANISMS; EXPRESSION; VANCOMYCIN; GROWTH	The beta-lactam antibiotics remain the most commonly used to treat severe infections. Because of structural similarity between the beta-lactam ring and the D-alanyl(4)-D-alanine(5) extremity of bacterial cell wall precursors, the drugs act as suicide substrates of the DD-transpeptidases that catalyze the last cross-linking step of cell wall assembly. Here, we show that this mechanism of action can be defeated by a novel type of transpeptidase identified for the first time by reverse genetics in a beta-lactam-resistant mutant of Enterococcus faecium. The enzyme, Ldt(fm), catalyzes in vitro the cross-linking of peptidoglycan subunits in a beta-lactam-insensitive LD-transpeptidation reaction. The specificity of Ldt(fm) for the L-lysyl(3)-D-alanine(4) peptide bond of tetrapeptide donors accounts for resistance because the substrate does not mimic beta-lactams in contrast to D-alanyl(4)-D-alanine(5) in the pentapeptide donors required for DD-transpeptidation. Ldt(fm) homologues are encountered sporadically among taxonomically distant bacteria, indicating that LD-transpeptidase-mediated resistance may emerge in various pathogens.	Univ Paris Descartes, Fac Med, INSERM, U655,Lab Rech Mol Antibiot, F-75270 Paris, France; Ctr Rech Biomed Cordeliers, F-75270 Paris, France; Univ Paris Descartes, Fac Med, Hop Europeen Georges Pompidou, AP HP, F-75908 Paris, France; Museum Natl Hist Nat, Dept Rech Dev & Divers Mol, Plateforme Spectrometrie Masse & Prote Museum, USM0502,CNRS,UMR8041, F-75005 Paris, France; CNRS, Inst Chim Subst Nat, Appl Microbiol Lab, F-91190 Gif Sur Yvette, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med & Res Serv, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Mainardi, JL (corresponding author), Univ Paris Descartes, Fac Med, INSERM, U655,Lab Rech Mol Antibiot, 15 Rue Ecole Med, F-75270 Paris, France.	jlmainar@bhdc.jussieu.fr	HUGONNET, Jean-Emmanuel/H-3581-2014; MAINARDI, Jean-Luc/E-2714-2014; Arthur, Michel/G-3680-2013; HUGONNET, Jean-Emmanuel/ABC-7914-2021	HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; MAINARDI, Jean-Luc/0000-0002-4159-0129; Arthur, Michel/0000-0003-1007-636X; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Ouazzani, Jamal/0000-0003-4483-6638	NIAID NIH HHS [R01 AI45626] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Anderson JW, 2003, BIOCHEM J, V373, P949, DOI 10.1042/BJ20030217; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; BillotKlein D, 1997, J BACTERIOL, V179, P4684, DOI 10.1128/jb.179.15.4684-4688.1997; BILLOTKLEIN D, 1992, ANTIMICROB AGENTS CH, V36, P1487, DOI 10.1128/AAC.36.7.1487; Chastanet A, 2003, MOL MICROBIOL, V47, P1061, DOI 10.1046/j.1365-2958.2003.03355.x; COYETTE J, 1974, EUR J BIOCHEM, V44, P459, DOI 10.1111/j.1432-1033.1974.tb03504.x; FONTANA R, 1983, J BACTERIOL, V155, P1343, DOI 10.1128/JB.155.3.1343-1350.1983; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Grohs P, 2000, J BACTERIOL, V182, P6228, DOI 10.1128/JB.182.21.6228-6232.2000; Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359; KELLY JA, 1982, SCIENCE, V218, P479, DOI 10.1126/science.7123246; KLARE I, 1992, ANTIMICROB AGENTS CH, V36, P783, DOI 10.1128/AAC.36.4.783; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; Messer M, 1997, COMP BIOCHEM PHYS B, V118, P403, DOI 10.1016/S0305-0491(97)00162-4; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PISABARRO AG, 1985, J BACTERIOL, V161, P238, DOI 10.1128/JB.161.1.238-242.1985; Rice LB, 2004, ANTIMICROB AGENTS CH, V48, P3028, DOI 10.1128/AAC.48.8.3028-3032.2004; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933	25	153	156	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38146	38152		10.1074/jbc.M507384200	http://dx.doi.org/10.1074/jbc.M507384200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16144833	hybrid			2022-12-25	WOS:000233239800006
J	Teng, MWL; Kershaw, MH; Hayakawa, Y; Cerutti, L; Jane, SM; Darcy, PK; Smyth, MJ				Teng, MWL; Kershaw, MH; Hayakawa, Y; Cerutti, L; Jane, SM; Darcy, PK; Smyth, MJ			T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NKG2D RECEPTOR; CD28 COSTIMULATION; COLON-CARCINOMA; TUMOR REJECTION; ACTIVATION; LIGAND; MEMORY; IMMUNORECEPTOR; ANTIBODY; MICE	NKG2D is an important activating/co-stimulatory receptor harnessed by NK and T cells in immune surveillance. In contrast to NK cells, T cells fail to express the activation-signaling molecule DAP12 even when activated and, therefore, ligation of NKG2D alone is insufficient to induce T cell cytolytic function. To test whether we could endow T cells with NK cell-like effector function, we have engineered DAP12 into T cells by retroviral transduction (T-DAP12). T-DAP12 cells were demonstrated to specifically secrete interferon-gamma following receptor ligation and to mediate potent and specific lysis of the NKG2D ligand (NKG2D-L) (Rae-1 beta) expressing MHC class I-deficient and class I-sufficient tumors. To circumvent the inability of T-DAP12 cells to proliferate following NKG2D ligation by Rae-1 beta expressing tumors, DAP12 was engineered into OT-1 cells with an endogenous T cell receptor specific for chicken ovalbumin peptide (amino acids 257-264). Importantly, following a period of proliferation through endogenous T cell receptor ligation, OT-1-DAP12 cells retained specificity against NKG2D-L expressing major histocompatibility complex class I-deficient tumor. In adoptive transfer experiments, T-DAP12 cells enhanced the survival of NK cell-depleted RAG-1-deficient mice inoculated with RMA-S-Rae-1 beta but not parental RMA-S tumors. Overall, this study demonstrated the significant potential of suppressing tumors and other cellular targets expressing NKG2D-L by endowing T cells with innate NK cell-like function.	Peter MacCallum Canc Ctr, Canc Immunol Program, Sir Donald & Lady Trescowthick Labs, Melbourne, Vic 8006, Australia; Royal Melbourne Hosp, Rotary Bone Marrow Res Lab, Parkville, Vic 3050, Australia	Peter Maccallum Cancer Center; Royal Melbourne Hospital	Smyth, MJ (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Program, Sir Donald & Lady Trescowthick Labs, Locked Bag 1,Abeckett St, Melbourne, Vic 8006, Australia.	mark.smyth@petermac.org	Smyth, Mark J/H-8709-2014; Jane, Stephen/D-6659-2011; Teng, Michele WL/S-5055-2016	Smyth, Mark J/0000-0001-7098-7240; Teng, Michele WL/0000-0003-1886-9145; Kershaw, Michael/0000-0002-2697-487X; Darcy, Phillip/0000-0002-5303-9561; Jane, Stephen Marsden/0000-0002-1045-0481				Billadeau DD, 2003, NAT IMMUNOL, V4, P557, DOI 10.1038/ni929; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Darcy PK, 1998, EUR J IMMUNOL, V28, P1663, DOI 10.1002/(SICI)1521-4141(199805)28:05<1663::AID-IMMU1663>3.0.CO;2-L; Dhanji S, 2004, BLOOD, V104, P2116, DOI 10.1182/blood-2004-01-0150; Dhanji S, 2003, J IMMUNOL, V171, P3442, DOI 10.4049/jimmunol.171.7.3442; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Ehrlich LIR, 2005, J IMMUNOL, V174, P1922, DOI 10.4049/jimmunol.174.4.1922; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Greenfield EA, 1998, CRIT REV IMMUNOL, V18, P389, DOI 10.1615/CritRevImmunol.v18.i5.10; Hayakawa Y, 2002, J IMMUNOL, V169, P5377, DOI 10.4049/jimmunol.169.10.5377; Haynes NM, 2002, BLOOD, V100, P3155, DOI 10.1182/blood-2002-04-1041; Haynes NM, 2002, J IMMUNOL, V169, P5780, DOI 10.4049/jimmunol.169.10.5780; Ho EL, 2002, J IMMUNOL, V169, P3667, DOI 10.4049/jimmunol.169.7.3667; Hombach A, 2001, J IMMUNOL, V167, P6123, DOI 10.4049/jimmunol.167.11.6123; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Kambayashi T, 2003, J IMMUNOL, V170, P2399, DOI 10.4049/jimmunol.170.5.2399; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kelly JM, 2002, NAT IMMUNOL, V3, P83, DOI 10.1038/ni746; Kershaw MH, 2002, NAT BIOTECHNOL, V20, P1221, DOI 10.1038/nbt756; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Rosen DB, 2004, J IMMUNOL, V173, P2470, DOI 10.4049/jimmunol.173.4.2470; Smyth MJ, 2004, IMMUNOL REV, V202, P275, DOI 10.1111/j.0105-2896.2004.00199.x; Smyth MJ, 1999, J IMMUNOL, V163, P1350; Snyder MR, 2002, J IMMUNOL, V168, P3839, DOI 10.4049/jimmunol.168.8.3839; Vivier E, 2002, CURR OPIN IMMUNOL, V14, P306, DOI 10.1016/S0952-7915(02)00337-0; Wilson MJ, 2000, IMMUNOL RES, V22, P21, DOI 10.1385/IR:22:1:21; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Yamada H, 2001, EUR J IMMUNOL, V31, P1917, DOI 10.1002/1521-4141(200106)31:6<1917::AID-IMMU1917>3.0.CO;2-F	32	9	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38235	38241		10.1074/jbc.M505331200	http://dx.doi.org/10.1074/jbc.M505331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169855	hybrid			2022-12-25	WOS:000233239800017
J	Yang, JQ; Croniger, CM; Lekstrom-Himes, J; Zhang, P; Fenyus, M; Tenen, DG; Darlington, GJ; Hanson, RW				Yang, JQ; Croniger, CM; Lekstrom-Himes, J; Zhang, P; Fenyus, M; Tenen, DG; Darlington, GJ; Hanson, RW			Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; C/EBP-ALPHA; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; CELL-PROLIFERATION; KNOCKOUT MICE; LIVER DEVELOPMENT; ADIPOSE-TISSUE; IN-VIVO; EXPRESSION	Although CCAAT/enhancer-binding protein alpha (C/EBP alpha) is essential for initiating or sustaining several metabolic processes during the perinatal period, the consequences of total ablation of C/EBP alpha during postnatal development have not been investigated. We have created a conditional knock-out model in which the administration of poly(I:C) caused a virtually total deletion of c/ebp alpha(C/EBP alpha(Delta/-) mice) in the liver, spleen, white and brown adipose tissues, pancreas, lung, and kidney of the mice. C/EBP alpha itself was completely ablated in the liver by day 4 after the injection of poly(I:C). There was no noticeable change in phenotype during the first 15 days after the injection. The mice maintained a normal level of fasting blood glucose and responded to the diabetogenic action of streptozotocin. From day 16 onward, the mice developed hypophagia, exhibited severe weight loss, lost triglyceride in white but not brown adipose tissue, became hypoglycemic and hypoinsulinemic, depleted their hepatic glycogen, and developed fatty liver. They also exhibited lowered plasma levels of free fatty acid, triglyceride, and cholesterol, as well as marked changes in hepatic mRNA for C/EBP delta, peroxisome proliferator-activated receptor alpha, sterol regulatory element-binding protein 1, hydroxymethylglutaryl-coenzyme A reductase, and apolipoproteins. Although basal levels of hepatic mRNA for the cytosolic isoform of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase were reduced, transcription of the genes for these enzymes was inducible by dibutyryl cyclic AMP in C/EBP alpha(Delta/-) mice. The animals died about 1 month after the injection of poly(I:C). These findings demonstrate that C/EBP alpha is essential for the survival of animals during postnatal life and that its ablation leads to distinct biphasic change in metabolic processes.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA	Case Western Reserve University; Case Western Reserve University; Harvard University; Harvard Medical School; Baylor College of Medicine	Yang, JQ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	jxy22@pop.cwru.edu		Tenen, Daniel/0000-0002-6423-3888	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541, R01DK053045, R01DK058620] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56745] Funding Source: Medline; NIDDK NIH HHS [DK53045, DK25541, DK58620] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; KUO CF, 1990, DEVELOPMENT, V109, P473; Lechner PS, 2001, J BIOL CHEM, V276, P22675, DOI 10.1074/jbc.M102422200; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; SCOTT LM, 1992, BLOOD, V80, P1725; Sugahara K, 2001, CELL TISSUE RES, V306, P57, DOI 10.1007/s004410100420; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Timchenko NA, 1998, NUCLEIC ACIDS RES, V26, P3293, DOI 10.1093/nar/26.13.3293; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006	42	61	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38689	38699		10.1074/jbc.M503486200	http://dx.doi.org/10.1074/jbc.M503486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166091	hybrid			2022-12-25	WOS:000233239800071
J	Bertsche, U; Breukink, E; Kast, T; Vollmer, W				Bertsche, U; Breukink, E; Kast, T; Vollmer, W			In vitro murein (peptidoglycan) synthesis by dimers of the bifunctional transglycosylase-transpeptidase PBP1B from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; CELL-WALL PEPTIDOGLYCAN; LIPID-II; 1B; GLYCOSYLTRANSFERASE; BIOSYNTHESIS; PURIFICATION; INHIBITORS; COMPONENT; MEMBRANE	PBP1B is a major bifunctional murein ( peptidoglycan) synthase catalyzing transglycosylation and transpeptidation reactions in Escherichia coli. PBP1B has been shown to form dimers in vivo. The K-D value for PBP1B dimerization was determined by surface plasmon resonance. The effect of the dimerization of PBP1B on its activities was studied with a newly developed in vitro murein synthesis assay with radioactively labeled lipid II precursor as substrate. Under conditions at which PBP1B dimerizes, the enzyme synthesized murein with long glycan strands (> 25 disaccharide units) and with almost 50% of the peptides being part of cross-links. PBP1B was also capable of synthesizing trimeric muropeptide structures. Tri-, tetra-, and pentapeptide compounds could serve as acceptors in the PBP1B-catalyzed transpeptidation reaction.	Univ Tubingen, D-72076 Tubingen, Germany; Univ Utrecht, Biomembrane Inst, Ctr Biomembranes & Lipid Enzymol, Dept Membrane Biochem, NL-3584 CH Utrecht, Netherlands; Max Planck Inst Entwicklungsbiol, Abt Biochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Utrecht University; Max Planck Society	Vollmer, W (corresponding author), Univ Tubingen, Morgenstelle 28, D-72076 Tubingen, Germany.	waldemar.vollmer@uni-tuebingen.de	Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660				Barrett DS, 2004, BIOCHEMISTRY-US, V43, P12375, DOI 10.1021/bi049142m; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Chalut C, 1999, J BACTERIOL, V181, P2970, DOI 10.1128/JB.181.9.2970-2972.1999; Chandrakala B, 2004, ANTIMICROB AGENTS CH, V48, P30, DOI 10.1128/AAC.48.1.30-40.2004; Charpentier X, 2002, J BACTERIOL, V184, P3749, DOI 10.1128/JB.184.13.3749-3752.2002; DARGIS M, 1994, ANTIMICROB AGENTS CH, V38, P973, DOI 10.1128/AAC.38.5.973; DiBerardino M, 1996, FEBS LETT, V392, P184, DOI 10.1016/0014-5793(96)00809-5; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Holtje JV, 1996, MICROB DRUG RESIST, V2, P99, DOI 10.1089/mdr.1996.2.99; HUBER G, 1968, BIOCHEM BIOPH RES CO, V30, P7, DOI 10.1016/0006-291X(68)90704-3; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KATO J, 1984, MOL GEN GENET, V196, P449, DOI 10.1007/BF00436192; KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253; Laan EVDD, 2003, J BACTERIOL, V185, P3773, DOI 10.1128/JB.185.3773.3779.2003; MATSUHASHI M, 1990, RES MICROBIOL, V141, P89, DOI 10.1016/0923-2508(90)90101-U; Meisel U, 2003, J BACTERIOL, V185, P5342, DOI 10.1128/JB.185.18.5342-5348.2003; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; NAKAGAWA J, 1982, BIOCHEM BIOPH RES CO, V105, P1546, DOI 10.1016/0006-291X(82)90964-0; ROJO F, 1984, EUR J BIOCHEM, V144, P571, DOI 10.1111/j.1432-1033.1984.tb08503.x; Schiffer G, 1999, J BIOL CHEM, V274, P32031, DOI 10.1074/jbc.274.45.32031; Schwartz B, 2001, J AM CHEM SOC, V123, P11638, DOI 10.1021/ja0166848; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; VANHEIJENOORT Y, 1978, FEBS LETT, V89, P141, DOI 10.1016/0014-5793(78)80540-7; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; Vollmer W, 2000, ANTIMICROB AGENTS CH, V44, P1181, DOI 10.1128/AAC.44.5.1181-1185.2000; Vollmer W, 2001, CURR OPIN MICROBIOL, V4, P625, DOI 10.1016/S1369-5274(01)00261-2; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; ZIJDERVELD CAL, 1995, J BACTERIOL, V177, P1860, DOI 10.1128/jb.177.7.1860-1863.1995; ZIJDERVELD CAL, 1991, J BACTERIOL, V173, P5740, DOI 10.1128/jb.173.18.5740-5746.1991	34	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38096	38101		10.1074/jbc.M508646200	http://dx.doi.org/10.1074/jbc.M508646200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16154998	Green Published, hybrid			2022-12-25	WOS:000233044500093
J	Riedel, CG; Mazza, M; Maier, P; Korner, R; Knop, M				Riedel, CG; Mazza, M; Maier, P; Korner, R; Knop, M			Differential requirement for phospholipase D/Spo14 and its novel interactor Sma1 for regulation of exocytotic vesicle fusion in yeast meiosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; MEMBRANE FORMATION; PROSPORE MEMBRANE; SPORULATION; PROTEIN; GENES; D1; LOCALIZATION; EXPRESSION	During sporulation and meiosis of budding yeast a developmental program determines the formation of the new plasma membranes of the spores. This process of prospore membrane (PSM) formation leads to the formation of meiotic daughter cells, the spores, within the lumen of the mother cell. It is initiated at the spindle pole bodies during meiosis II. Spore formation, but not meiotic cell cycle progression, requires the function of phospholipase D (PLD/Spo14). Here we show that PLD/Spo14 forms a complex with Sma1, ameiotically expressed protein essential for spore formation. Detailed analysis revealed that both proteins are required for early steps of prospore membrane assembly but with distinct defects in the respective mutants. In the Delta spo14 mutant the initiation of PSM formation is blocked and aggregated vesicles of homogenous size are detected at the spindle pole bodies. In contrast, initiation of PSM formation does occur in the Delta sma1 mutant, but the enlargement of the membrane is impaired. During PSM growth both Spo14 and Sma1 localize to the membrane, and localization of Spo14 is independent of Sma1. Biochemical analysis revealed that Sma1 is not necessary for PLD activity per se and that PLD present in a complex with Sma1 is highly active. Together, our results suggest that yeast PLD is involved in two distinct but essential steps during the regulated vesicle fusion necessary for the assembly of the membranous encapsulations of the spores.	European Mol Biol Lab, Cell Biol & Biophys Unit, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Knop, M (corresponding author), European Mol Biol Lab, Cell Biol & Biophys Unit, D-69117 Heidelberg, Germany.	knop@embl.de	Mazza, Massimiliano/AAA-4420-2021; Körner, Roman/G-8565-2011	Mazza, Massimiliano/0000-0001-9053-5743; Körner, Roman/0000-0001-9285-9290; Riedel, Christian/0000-0002-3689-8022				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Bajgier BK, 2001, MOL BIOL CELL, V12, P1611, DOI 10.1091/mbc.12.6.1611; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DAVIDOW LS, 1980, GENETICS, V94, P581; Davis L, 2001, GENETICS, V157, P1179; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Guthrie C., 1991, METHOD ENZYMOL, V194, P429; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; Jantti J, 2002, J CELL SCI, V115, P409; Knop M, 2000, EMBO J, V19, P3657, DOI 10.1093/emboj/19.14.3657; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KNOP M, 2005, MOL BIOL CELL   0719; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lynn R R, 1970, J Cell Biol, V44, P688, DOI 10.1083/jcb.44.3.688; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; Moreno-Borchart AC, 2001, EMBO J, V20, P6946, DOI 10.1093/emboj/20.24.6946; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; OKAMOTO S, 1982, J GEN MICROBIOL, V128, P1309; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Rudge SA, 1998, MOL BIOL CELL, V9, P2025, DOI 10.1091/mbc.9.8.2025; Rudge SA, 2002, GENETICS, V160, P1353; Sciorra VA, 2002, J CELL BIOL, V159, P1039, DOI 10.1083/jcb.200205056; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Zouwail S, 2005, BIOCHEM J, V389, P207, DOI 10.1042/BJ20050085	39	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37846	37852		10.1074/jbc.M504244200	http://dx.doi.org/10.1074/jbc.M504244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148007	hybrid			2022-12-25	WOS:000233044500065
J	Sander, P; Hamann, H; Drogemuller, C; Kashkevich, K; Schiebel, K; Leeb, T				Sander, P; Hamann, H; Drogemuller, C; Kashkevich, K; Schiebel, K; Leeb, T			Bovine prion protein gene (PRNP) promoter polymorphisms modulate PRNP expression and may be responsible for differences in bovine spongiform encephalopathy susceptibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; NATURAL SCRAPIE; DENDRITIC CELLS; FINGER PROTEIN; PRP GENE; SHEEP; MICE; VARIANTS; SPLEEN; TISSUE	The susceptibility of humans to the variant Creutzfeldt-Jakob disease is greatly influenced by polymorphisms within the human prion protein gene (PRNP). Similar genetic differences exist in sheep, in which PRNP polymorphisms modify the susceptibility to scrapie. However, the known coding polymorphisms within the bovine PRNP gene have little or no effect on bovine spongiform encephalopathy (BSE) susceptibility in cattle. We have recently found a tentative association between PRNP promoter polymorphisms and BSE susceptibility in German cattle ( Sander, P., Hamann, H., Pfeiffer, I., Wemheuer, W., Brenig, B., Groschup, M., Ziegler, U., Distl, O., and Leeb, T. ( 2004) Neurogenetics 5, 19 - 25). A plausible hypothesis explaining this observation could be that the bovine PRNP promoter polymorphisms cause changes in PRNP expression that might be responsible for differences in BSE incubation time and/or BSE susceptibility. To test this hypothesis, we performed a functional promoter analysis of the different bovine PRNP promoter alleles by reporter gene assays in vitro and by measuring PRNP mRNA levels in calves with different PRNP genotypes in vivo. Two variable sites, a 23-bp insertion/deletion (indel) polymorphism containing a RP58-binding site and a 12-bp indel polymorphism containing an SP1-binding site, were investigated. Band shift assays indicated differences in transcription factor binding to the different alleles at the two polymorphisms. Reporter gene assays demonstrated an interaction between the two postulated transcription factors and lower expression levels of the ins/ins allele compared with the del/del allele. The in vivo data revealed substantial individual variation of PRNP expression in different tissues. In intestinal lymph nodes, expression levels differed between the different PRNP genotypes.	Univ Vet Med, Inst Genet & Anim Breeding, D-30559 Hannover, Germany; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany	University of Veterinary Medicine Hannover, Foundation; University of Erlangen Nuremberg	Leeb, T (corresponding author), Inst Genet, Bremgartenstr 109A, CH-3001 Bern, Switzerland.	Tosso.Leeb@itz.unibe.ch	Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880; Drogemuller, Cord/0000-0001-9773-522X; Nicken, Petra/0000-0002-8535-1453				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; Becker KG, 1997, INT J DEV NEUROSCI, V15, P891, DOI 10.1016/S0736-5748(97)00034-8; BELT PBGM, 1995, J GEN VIROL, V76, P509, DOI 10.1099/0022-1317-76-3-509; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; Bossers A, 1996, J GEN VIROL, V77, P2669, DOI 10.1099/0022-1317-77-10-2669; Bossers A, 2000, J VIROL, V74, P1407, DOI 10.1128/JVI.74.3.1407-1414.2000; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; Daude N, 2004, VIRAL IMMUNOL, V17, P334, DOI 10.1089/vim.2004.17.334; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eddy RG, 1995, VET REC, V137, P648; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Huang FP, 2002, J GEN VIROL, V83, P267, DOI 10.1099/0022-1317-83-1-267; HUNTER N, 1992, VET REC, V130, P389, DOI 10.1136/vr.130.18.389; Inoue S, 1997, J VET MED SCI, V59, P175, DOI 10.1292/jvms.59.175; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LAPLANCHE JL, 1993, GENOMICS, V15, P30, DOI 10.1006/geno.1993.1006; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; Mabbott NA, 2003, J VIROL, V77, P6845, DOI 10.1128/JVI.77.12.6845-6854.2003; Maignien T, 1999, J GEN VIROL, V80, P3035, DOI 10.1099/0022-1317-80-11-3035; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Paltrinieri S, 2004, J HISTOCHEM CYTOCHEM, V52, P1639, DOI 10.1369/jhc.4A6441.2004; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sander P, 2004, NEUROGENETICS, V5, P19, DOI 10.1007/s10048-003-0171-y; SAS Institute Inc, 2003, SAS VERS 9 1; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	32	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37408	37414		10.1074/jbc.M506361200	http://dx.doi.org/10.1074/jbc.M506361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16141216	hybrid			2022-12-25	WOS:000233044500015
J	van den Akker, E; Ano, S; Shih, HM; Wang, LC; Pironin, M; Palvimo, JJ; Kotaja, N; Kirsh, O; Dejean, A; Ghysdael, J				van den Akker, E; Ano, S; Shih, HM; Wang, LC; Pironin, M; Palvimo, JJ; Kotaja, N; Kirsh, O; Dejean, A; Ghysdael, J			FLI-1 functionally interacts with PIASx alpha, a member of the PIAS E3 SUMO ligase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION PROPERTIES; GENE-TARGETED MICE; ANDROGEN RECEPTOR; DNA-BINDING; FLI-1-TRANSFORMED ERYTHROBLASTS; TRANSGENIC MICE; PROTEINS; NUCLEAR; REPRESSION; EXPRESSION	FLI-1 is a transcription factor of the ETS family that is involved in several developmental processes and that becomes oncogenic when overexpressed or mutated. As the functional regulators of FLI-1 are largely unknown, we performed a yeast two-hybrid screen with FLI-1 and identified the SUMO E3 ligase PIASx alpha/ARIP3 as a novel in vitro and in vivo binding partner of FLI-1. This interaction involved the ETS domain of FLI-1 and required the integrity of the SAP domain of PIASx alpha/ARIP3. SUMO-1 and Ubc9, the ubiquitin carrier protein component in the sumoylation pathway, were also identified as interactors of FLI-1. Both PIASx alpha/ARIP3 and the closely related PIASx beta isoform specifically enhanced sumoylation of FLI-1 at Lys(67), located in its N-terminal activation domain. PIASx alpha/ARIP3 relocalized the normally nuclear but diffusely distributed FLI-1 protein to PIASx alpha nuclear bodies and repressed FLI-1 transcriptional activation as assessed using different ETS-binding site-dependent promoters and different cell systems. PIASx alpha repressive activity was independent of sumoylation and did not result from inhibition of FLI-1 DNA-binding activity. Analysis of the properties of a series of ARIP3 mutants showed that the repressive properties of PIASx alpha/ARIP3 require its physical interaction with FLI-1, identifying PIASx alpha as a novel corepressor of FLI-1.	Inst Curie, Ctr Univ, CNRS, UMR 146, F-91405 Orsay, France; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Univ Kuopio, Dept Biochem Med, FIN-70211 Kuopio, Finland; Univ Helsinki, Biomedicum Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; Inst Pasteur, INSERM, U579, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Academia Sinica - Taiwan; University of Eastern Finland; University of Helsinki; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ghysdael, J (corresponding author), Inst Curie, Ctr Univ, CNRS, UMR 146, Bat 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	Shih, Hsiu-Ming/S-7023-2018; GHYSDAEL, Jacques/F-3377-2013; Dejean, Anne/L-5145-2018	Kotaja, Noora/0000-0003-1503-9170; Kirsh, Olivier/0000-0001-6200-5681; Palvimo, Jorma/0000-0003-2373-0578				Ano S, 2004, J BIOL CHEM, V279, P2993, DOI 10.1074/jbc.M303816200; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Arvand A, 2001, CANCER RES, V61, P5311; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Chun TH, 2003, CIRC RES, V92, P1201, DOI 10.1161/01.RES.0000076893.70898.36; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kawada H, 2001, INT J HEMATOL, V73, P463, DOI 10.1007/BF02994008; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Masuya M, 2005, BLOOD, V105, P95, DOI 10.1182/blood-2003-12-4345; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Roth W, 2004, J IMMUNOL, V173, P6189, DOI 10.4049/jimmunol.173.10.6189; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Santti H, 2005, J MOL ENDOCRINOL, V34, P645, DOI 10.1677/jme.1.01666; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Starck J, 1999, EXP HEMATOL, V27, P630, DOI 10.1016/S0301-472X(99)00006-5; Stein GS, 1998, J CELL BIOCHEM, P220; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; van den Akker E, 2004, BLOOD, V103, P4457, DOI 10.1182/blood-2003-08-2713; van Dijk TB, 2000, BLOOD, V96, P3406; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004	48	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38035	38046		10.1074/jbc.M502938200	http://dx.doi.org/10.1074/jbc.M502938200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16148010	Green Published, hybrid			2022-12-25	WOS:000233044500087
J	Hurne, AM; O'Brien, JJ; Wingrove, D; Cherednichenko, G; Allen, PD; Beam, KG; Pessah, IN				Hurne, AM; O'Brien, JJ; Wingrove, D; Cherednichenko, G; Allen, PD; Beam, KG; Pessah, IN			Ryanodine receptor type 1 (RyR1) mutations C4958S and C4961S reveal excitation-coupled calcium entry (ECCE) is independent of sarcoplasmic reticulum store depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; OPERATED CA2+ ENTRY; INOSITOL TRISPHOSPHATE RECEPTOR; GREEN FLUORESCENT PROTEIN; SKELETAL-MUSCLE; DIHYDROPYRIDINE-RECEPTOR; ENDOPLASMIC-RETICULUM; RELEASE CHANNEL; HYPERREACTIVE SULFHYDRYLS; REDOX SENSOR	Bi-directional signaling between ryanodine receptor type 1 (RyR1) and dihydropyridine receptor ( DHPR) in skeletal muscle serves as a prominent example of conformational coupling. Evidence for a physiological mechanism that upon depolarization of myotubes tightly couples three calcium channels, DHPR, RyR1, and a Ca2+ entry channel with SOCC-like properties, has recently been presented ( Cherednichenko, G., Hurne, A. M., Fessenden, J. D., Lee, E. H., Allen, P. D., Beam, K. G., and Pessah, I. N. ( 2004) Proc. Natl. Acad. Sci. U. S. A. 101, 15793 - 15798). This form of conformational coupling, termed excitation-coupled calcium entry (ECCE) is triggered by the alpha(1s)-DHPR voltage sensor and is highly dependent on RyR1 conformation. In this report, we substitute RyR1 cysteines 4958 or 4961 within the TXCFICG motif, common to all ER/SR Ca2+ channels, with serine. When expressed in skeletal myotubes, C4958S- and C4961S-RyR1 properly target and restore L-type current via the DHPR. However, these mutants do not respond to RyR activators and do not support skeletal type EC coupling. Nonetheless, depolarization of cells expressing C4958S- or C4961S-RyR1 triggers calcium entry via ECCE that resembles that for wild-type RyR1, except for substantially slowed inactivation and deactivation kinetics. ECCE in these cells is completely independent of store depletion, displays a cation selectivity of Ca2+> Sr2+ similar to Ba2+, and is fully inhibited by SKF-96365 or 2-APB. Mutation of other non-CXXC motif cysteines within the RyR1 transmembrane assembly (C3635S, C4876S, and C4882S) did not replicate the phenotype observed with C4958S- and C4961S-RyR1. This study demonstrates the essential role of Cys(4958) and Cys(4961) within an invariant CXXC motif for stabilizing conformations of RyR1 that influence both its function as a release channel and its interaction with ECCE channels.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA; Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; Colorado State University; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Dept VM Mol Biosci, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIAMS NIH HHS [2R01 AR43140, 2P0 AR17605] Funding Source: Medline; NIEHS NIH HHS [1P0ES11269] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AIREY JA, 1990, J BIOL CHEM, V265, P14187; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; Avila G, 2001, J BIOL CHEM, V276, P17732, DOI 10.1074/jbc.M009685200; Bakowski D, 2003, J PHYSIOL-LONDON, V553, P387, DOI 10.1113/jphysiol.2003.055335; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Chavis P, 1998, EUR J NEUROSCI, V10, P2322, DOI 10.1046/j.1460-9568.1998.00243.x; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; Cherednichenko G, 2004, P NATL ACAD SCI USA, V101, P15793, DOI 10.1073/pnas.0403485101; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; Dirksen RT, 1999, J GEN PHYSIOL, V114, P393, DOI 10.1085/jgp.114.3.393; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Hamilton SL, 2000, ANTIOXID REDOX SIGN, V2, P41, DOI 10.1089/ars.2000.2.1-41; Holmgren Arne, 2000, Biofactors, V11, P63; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Launikonis BS, 2003, P NATL ACAD SCI USA, V100, P2941, DOI 10.1073/pnas.0536227100; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; Lorenzon NM, 2001, ARCH BIOCHEM BIOPHYS, V388, P13, DOI 10.1006/abbi.2000.2263; Ma JJ, 2003, CELL CALCIUM, V33, P375, DOI 10.1016/S0143-4160(03)00050-2; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; O'Brien JJ, 2002, BIOPHYS J, V82, P2428, DOI 10.1016/S0006-3495(02)75586-0; Paolini C, 2004, P NATL ACAD SCI USA, V101, P12748, DOI 10.1073/pnas.0404836101; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Perez CF, 2003, J BIOL CHEM, V278, P39644, DOI 10.1074/jbc.M305160200; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Perez GJ, 1999, J GEN PHYSIOL, V113, P229, DOI 10.1085/jgp.113.2.229; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2001, J CELL SCI, V114, P2223; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Takekura H, 2004, MOL BIOL CELL, V15, P5408, DOI 10.1091/mbc.E04-05-0414; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; Voss AA, 2004, J BIOL CHEM, V279, P34514, DOI 10.1074/jbc.M404290200; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049	71	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36994	37004		10.1074/jbc.M506441200	http://dx.doi.org/10.1074/jbc.M506441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16120606	hybrid			2022-12-25	WOS:000232901800057
J	Jones, HM; Hamilton, KL; Devor, DC				Jones, HM; Hamilton, KL; Devor, DC			Role of an S4-S5 linker lysine in the trafficking of the Ca2+-activated K+ channels IK1 and SK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; LONG QT SYNDROME; INTERMEDIATE-CONDUCTANCE; ENDOPLASMIC-RETICULUM; CHLORIDE SECRETION; ARACHIDONIC-ACID; T84 CELLS; K(IR)1.1 CHANNELS; CYSTIC-FIBROSIS; GATING DOMAIN	We have investigated the role of the S4-S5 linker in the trafficking of the intermediate (human (h) IK1) and small (rat SK3) conductance K+ channels using a combination of patch-clamp, protein biochemical, and immunofluorescence-based techniques. We demonstrate that a lysine residue (Lys(197)) located on the intracellular loop between the S4 and S5 domains is necessary for the correct trafficking of hIK1 to the plasma membrane. Mutation of this residue to either alanine or methionine precluded trafficking of the channel to the membrane, whereas the charge-conserving arginine mutation had no effect on channel localization or function. Immunofluorescence localization demonstrated that the K197A mutation resulted in a channel that was primarily retained in the endoplasmic reticulum, and this could not be rescued by incubation at 27 degrees C. Furthermore, immunoblot analysis revealed that the K197A mutation was overexpressed compared with wild-type hIK1 and that this was due to a greatly diminished rate of channel degradation. Co-immunoprecipitation studies demonstrated that the K197A mutation did not preclude multimer formation. Indeed, the K197A mutation dramatically suppressed expression of wild-type hIK1 at the cell surface. Finally, mutation of this conserved lysine in rat SK3 similarly resulted in a channel that failed to correctly traffic to the plasma membrane. These results are the first to demonstrate a critical role for the S4-S5 linker in the trafficking and/or function of IK and SK channels.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Otago, Dept Physiol, Dunedin, New Zealand	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Otago	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S312 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	dd2@pitt.edu			NIDDK NIH HHS [DK54941, T32-DK061296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK054941] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adeagbo ASO, 1999, EUR J PHARMACOL, V379, P151, DOI 10.1016/S0014-2999(99)00489-6; Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Caprini M, 2005, J BIOL CHEM, V280, P18253, DOI 10.1074/jbc.M413389200; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; Clay JR, 2002, J NEUROSCI RES, V67, P745, DOI 10.1002/jnr.10182; Decher N, 2004, J BIOL CHEM, V279, P13859, DOI 10.1074/jbc.M313704200; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC149, DOI 10.1152/ajpcell.1998.274.1.C149; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC138, DOI 10.1152/ajpcell.1998.274.1.C138; DEVOR DC, 1993, AM J PHYSIOL, V265, pC1271, DOI 10.1152/ajpcell.1993.265.5.C1271; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Franqueza L, 1999, J BIOL CHEM, V274, P21063, DOI 10.1074/jbc.274.30.21063; Frenkel Z, 2004, MOL BIOL CELL, V15, P2133, DOI 10.1091/mbc.E03-12-0899; Hamilton KL, 2003, J BIOL CHEM, V278, P16690, DOI 10.1074/jbc.M212959200; Hanley PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/pnas.0400733101; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoffman JF, 2003, P NATL ACAD SCI USA, V100, P7366, DOI 10.1073/pnas.1232342100; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; HOPPNER CA, 2004, BIOPHYS J S, V86, pA288; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Jones HM, 2005, BIOPHYS J, V88, p469A; Jones HM, 2004, J BIOL CHEM, V279, P15531, DOI 10.1074/jbc.M400069200; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kohler R, 2000, CIRC RES, V87, P496; Kohler R, 2003, CIRCULATION, V108, P1119, DOI 10.1161/01.CIR.0000086464.04719.DD; Koster JC, 1998, BIOPHYS J, V74, P1821, DOI 10.1016/S0006-3495(98)77892-0; KRIJNSELOCKER J, 1995, MOL BIOL CELL, V6, P1315, DOI 10.1091/mbc.6.10.1315; Kubota T, 2000, J CARDIOVASC ELECTR, V11, P1048, DOI 10.1111/j.1540-8167.2000.tb00178.x; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Mauler F, 2004, EUR J NEUROSCI, V20, P1761, DOI 10.1111/j.1460-9568.2004.03615.x; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Pedersen KA, 2000, PFLUG ARCH EUR J PHY, V440, P153, DOI 10.1007/s004240051033; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Reich EP, 2005, EUR J IMMUNOL, V35, P1027, DOI 10.1002/eji.200425954; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Schnaider T, 1999, LIFE SCI, V65, P2417, DOI 10.1016/S0024-3205(99)00508-1; Schulte U, 2001, J PHYSIOL-LONDON, V534, P49, DOI 10.1111/j.1469-7793.2001.t01-1-00049.x; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schumacher MA, 2004, STRUCTURE, V12, P849, DOI 10.1016/S0969-2126(04)00112-1; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Syme CA, 2003, J BIOL CHEM, V278, P8476, DOI 10.1074/jbc.M210072200; Szkotak AJ, 2004, BRIT J PHARMACOL, V142, P531, DOI 10.1038/sj.bjp.0705846; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Ueda K, 2004, J BIOL CHEM, V279, P27194, DOI 10.1074/jbc.M311953200; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Wulff H, 2001, J BIOL CHEM, V276, P32040, DOI 10.1074/jbc.M105231200; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	63	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37257	37265		10.1074/jbc.M508601200	http://dx.doi.org/10.1074/jbc.M508601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16135513	hybrid			2022-12-25	WOS:000232901800084
J	Mare, L; Iatta, R; Montagna, MT; Luberto, C; Del Poeta, M				Mare, L; Iatta, R; Montagna, MT; Luberto, C; Del Poeta, M			APP1 transcription is regulated by inositolphosphorylceramide synthase 1-diacylglycerol pathway and is controlled by ATF2 transcription factor in Cryptococcus neoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID METABOLISM; GENE; YEAST; DIACYLGLYCEROL; PKC1; CERAMIDE; HOMOLOG; ENCODES	Inositol-phosphorylceramide synthase 1 (Ipc1) is a fungal-specific enzyme that regulates the level of two bioactive molecules, phytoceramide and diacylglycerol (DAG). In previous studies, we demonstrated that Ipc1 regulates the expression of the antiphagocytic protein 1 (App1), a novel fungal factor involved in pathogenicity of Cryptococcus neoformans. Here, we investigated the molecular mechanism by which Ipc1 regulates App1. To this end, the APP1 promoter was fused to the firefly luciferase gene in the C. neoformans GAL7: IPC1 strain, in which the Ipc1 expression can be modulated, and found that the luciferase activity was indeed regulated when Ipc1 was modulated. Next, using the luciferase reporter assay in both C. neoformans wild-type and GAL7: IPC1 strains, we investigated the role of DAG and sphingolipids in the activation of the APP1 promoter and found that treatment with 1,2-dioctanoylglycerol does increase APP1 transcription, whereas treatment with phytosphingosine or ceramides does not. Two putative consensus sequences were found in the APP1 promoter for ATF and AP-2 transcription factors. Mutagenesis analysis of these sequences revealed that they play a key role in the regulation of APP1 transcription: ATF is an activator, whereas AP-2 in a negative regulator. Finally, we identified a putative Atf2 transcription factor, which is required for APP1 transcription and under the control of Ipc1-DAG pathway. These studies provide novel regulatory mechanisms of the sphingolipid pathway involved in the regulation of gene transcription of C. neoformans.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Univ Bari, Dept Internal & Publ Med, I-70124 Bari, Italy	Medical University of South Carolina; Medical University of South Carolina; Universita degli Studi di Bari Aldo Moro	Del Poeta, M (corresponding author), 173 Ashley Ave,BSB 503, Charleston, SC 29425 USA.	delpoeta@musc.edu		Iatta, Roberta/0000-0003-2386-8542; Montagna, Maria Teresa/0000-0002-2958-5458	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056168] Funding Source: NIH RePORTER; NCRR NIH HHS [RR17677] Funding Source: Medline; NIAID NIH HHS [AI56168] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BELL R, 1992, ADV EXP MED BIOL, V318, P275; CASADEVALL A, 1998, CRYPTOCOCCUS NEOFORM, P381; Cerbon J, 2005, BIOCHEM J, V388, P169, DOI 10.1042/BJ20040475; Chung N, 2000, METHOD ENZYMOL, V311, P319; Costa M, 1996, EUR J BIOCHEM, V237, P532, DOI 10.1111/j.1432-1033.1996.00532.x; DHAWALE SS, 1993, NUCLEIC ACIDS RES, V21, P5537, DOI 10.1093/nar/21.24.5537; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Heidler SA, 2000, BBA-MOL BASIS DIS, V1500, P147, DOI 10.1016/S0925-4439(99)00097-6; Heung LJ, 2005, J BIOL CHEM, V280, P28547, DOI 10.1074/jbc.M503404200; Heung LJ, 2004, J BIOL CHEM, V279, P21144, DOI 10.1074/jbc.M312995200; Hirayoshi K, 1999, METHOD ENZYMOL, V304, P351; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jiang K, 1998, BIOCHEM BIOPH RES CO, V246, P192, DOI 10.1006/bbrc.1998.8591; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kuroda M, 1999, MOL GEN GENET, V261, P290, DOI 10.1007/s004380050969; Loftus BJ, 2005, SCIENCE, V307, P1321, DOI 10.1126/science.1103773; Luberto C, 1999, LIPIDS, V34, pS5, DOI 10.1007/BF02562221; Luberto C, 2003, J CLIN INVEST, V112, P1080, DOI 10.1172/JCI200318309; Luberto C, 2001, GENE DEV, V15, P201, DOI 10.1101/gad.856001; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Paravicini G, 1996, YEAST, V12, P741, DOI 10.1002/(SICI)1097-0061(19960630)12:8<741::AID-YEA967>3.0.CO;2-G; Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Spychala J, 1999, J BIOL CHEM, V274, P22705, DOI 10.1074/jbc.274.32.22705; Steinmuller L, 2003, BIOL CHEM, V384, P667, DOI 10.1515/BC.2003.074; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; WATANABE M, 1994, J BIOL CHEM, V269, P16829; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	32	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36055	36064		10.1074/jbc.M507285200	http://dx.doi.org/10.1074/jbc.M507285200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16129666	hybrid			2022-12-25	WOS:000232726900035
J	Hochstrasser, H; Tomiuk, J; Walter, U; Behnke, S; Spiegel, J; Kruger, R; Georg, B; Riess, O; Berg, D				Hochstrasser, H; Tomiuk, J; Walter, U; Behnke, S; Spiegel, J; Kruger, R; Georg, B; Riess, O; Berg, D			Functional relevance of ceruloplasmin mutations in Parkinson's Disease	FASEB JOURNAL			English	Article						functional analyses; neurodegenerative disease	CENTRAL-NERVOUS-SYSTEM; SUBSTANTIA-NIGRA; BASAL GANGLIA; IRON EFFLUX; IN-VITRO; NEURODEGENERATIVE DISORDERS; COPPER INCORPORATION; LIPID-PEROXIDATION; RAT CERULOPLASMIN; HYDROGEN-PEROXIDE	Increased iron levels of the substantia nigra and the discovery of ceruloplasmin mutations in patients with Parkinson's disease (PD) imply impaired iron metabolism in this neurodegenerative disorder. Ceruloplasmin has ferroxidase activity oxidizing iron(II) to iron(III). In the present study, we analyzed the amount of ceruloplasmin, iron, ferritin, and transferrin and the ceruloplasmin ferroxidase activity in serum of patients with the diagnosis of PD carrying the ceruloplasmin mutations I63T, D544E, and R793H. The impact of these missense mutations on the biosynthesis of holo-ceruloplasmin was investigated in cell culture experiments. Functional relevance was found for the ceruloplasmin mutations I63T and D544E. In vivo, the I63T mutation resulted in half the normal ceruloplasmin concentration and markedly reduced ferroxidase activity in serum from a heteroallelic PD patient. In cell culture, the I63T glycosylphosphatidylinositol (GPI)-linked ceruloplasmin isoform was retained in the endoplasmatic reticulum of human embryonic kidney cells. Furthermore, the D544E polymorphism resulted in significantly reduced serum ceruloplasmin levels and ferroxidase activity in heteroallelic patients and in expression of mainly apo-ceruloplasmin in cell culture. Our studies indicate that altered activity of ceruloplasmin may present a vulnerability factor for iron induced oxidative stress in PD.	Univ Tubingen, Dept Med Genet, D-72076 Tubingen, Germany; Univ Rostock, Dept Neurol, Rostock, Germany; Univ Homburg, Dept Neurol, D-6650 Homburg, Germany; Univ Tubingen, Ctr Neurol, Tubingen, Germany; Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Rostock; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Hochstrasser, H (corresponding author), Univ Tubingen, Dept Med Genet, Calwerstr 7, D-72076 Tubingen, Germany.	helmine.hochstrasser@med.uni-tuebingen.de	Berg, Daniela/A-8728-2019; Walter, Uwe/O-4591-2017	Berg, Daniela/0000-0001-5796-5442; Krueger, Rejko/0000-0003-4258-6241; Walter, Uwe/0000-0002-6280-785X				ALDRED AR, 1987, J BIOL CHEM, V262, P2875; Aouffen M, 2004, FREE RADICAL RES, V38, P19, DOI 10.1080/10715760310001624079; Berg D, 2002, NEUROTOX RES, V4, P637, DOI 10.1080/1029842021000045444; Berg D, 2001, J NEUROCHEM, V79, P225, DOI 10.1046/j.1471-4159.2001.00608.x; Bosio S, 2002, BLOOD, V100, P2246, DOI 10.1182/blood-2002-02-0584; Cochran W, 1950, EXPT DESIGNS; Daimon M, 2000, TOHOKU J EXP MED, V191, P119, DOI 10.1620/tjem.191.119; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Erel O, 1998, CLIN CHEM, V44, P2313; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Griffiths PD, 1999, BRAIN, V122, P667, DOI 10.1093/brain/122.4.667; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; Hochstrasser H, 2004, NEUROLOGY, V63, P1912, DOI 10.1212/01.WNL.0000144276.29988.C3; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2350; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2354; JACCARD J, 1996, LISREL APPROACHES IN; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; Ke Y, 2003, LANCET NEUROL, V2, P246, DOI 10.1016/S1474-4422(03)00353-3; Kim KS, 2002, BIOCHIMIE, V84, P625, DOI 10.1016/S0300-9084(02)01435-9; Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989; Kohno S, 2000, NEUROGENETICS, V2, P237; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; Lan J, 1997, J NEURAL TRANSM, V104, P649, DOI 10.1007/BF01291883; Lan J, 1997, J NEURAL TRANSM, V104, P469, DOI 10.1007/BF01277665; Lin AMY, 2002, EXP NEUROL, V176, P328, DOI 10.1006/exnr.2002.7938; Lockhart PJ, 1999, GENE, V236, P251, DOI 10.1016/S0378-1119(99)00276-0; MANN VM, 1994, ANN NEUROL, V36, P876, DOI 10.1002/ana.410360612; Miyajima H, 2001, NEUROLOGY, V57, P2205, DOI 10.1212/WNL.57.12.2205; Miyajima H, 2002, BLOOD CELL MOL DIS, V29, P433, DOI 10.1006/bcmd.2002.0561; Miyajima H, 2003, NEUROPATHOLOGY, V23, P345, DOI 10.1046/j.1440-1789.2003.00521.x; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; Molina-Arjona JA, 1999, REV NEUROLOGIA, V29, P12, DOI 10.33588/rn.2901.99073; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Patel BN, 2002, J NEUROSCI, V22, P6578; Ponka P, 2004, ANN NY ACAD SCI, V1012, P267, DOI 10.1196/annals.1306.022; Qian ZM, 2001, BRAIN RES REV, V35, P287, DOI 10.1016/S0165-0173(01)00056-X; Richardson DR, 1999, J LAB CLIN MED, V134, P454, DOI 10.1016/S0022-2143(99)90166-X; Santiago M, 1997, J NEUROCHEM, V68, P732; Sarkar J, 2003, J BIOL CHEM, V278, P44018, DOI 10.1074/jbc.M304926200; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Sudha K, 2003, NEUROL INDIA, V51, P60; Torsdottir G, 1999, PHARMACOL TOXICOL, V85, P239, DOI 10.1111/j.1600-0773.1999.tb02015.x; Yang F, 1996, AM J RESP CELL MOL, V14, P161, DOI 10.1165/ajrcmb.14.2.8630266; YANG F, 1986, P NATL ACAD SCI USA, V83, P3257, DOI 10.1073/pnas.83.10.3257; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Youdim MBH, 2004, ANN NY ACAD SCI, V1012, P306, DOI 10.1196/annals.1306.025; Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X	59	68	73	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1851	+		10.1096/fj.04-3486fje	http://dx.doi.org/10.1096/fj.04-3486fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150804				2022-12-25	WOS:000232315700021
J	Person, AM; Bills, KL; Liu, H; Botting, SK; Lindstrom, J; Wells, GB				Person, AM; Bills, KL; Liu, H; Botting, SK; Lindstrom, J; Wells, GB			Extracellular domain nicotinic acetylcholine receptors formed by alpha 4 and beta 2 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED UP-REGULATION; LIGAND-BINDING; ALPHA-BUNGAROTOXIN; AGONIST-BINDING; CHOLINERGIC-RECEPTORS; MONOCLONAL-ANTIBODIES; NONLINEAR-REGRESSION; MEMBRANE-PROTEINS; STRUCTURAL BASIS; NATIVE BRAIN	Models of the extracellular ligand-binding domain of nicotinic acetylcholine receptors ( nAChRs), which are pentameric integral membrane proteins, are attractive for structural studies because they potentially are water-soluble and better candidates for x-ray crystallography and because their smaller size is more amenable for NMRspectroscopy. The complete N-terminal extracellular domain is a promising foundation for such models, based on previous studies of alpha 7 and muscle-type subunits. Specific design requirements leading to high structural fidelity between extracellular domain nAChRs and full-length nAChRs, however, are not well understood. To study these requirements in heteromeric nAChRs, the extracellular domains of alpha 4 and 2 beta subunits with or without the first transmembrane domain ( M1) were expressed in Xenopus oocytes and compared with alpha 4 beta 2 nAChRs based on ligand binding and subunit assembly properties. Ligand affinities of detergent-solubilized, extracellular domain alpha 4 beta 2 nAChRs formed from subunits with M1 were nearly identical to affinities of alpha 4 beta 2 nAChRs when measured with [ H-3] epibatidine, cytisine, nicotine, and acetylcholine. Velocity sedimentation suggested that these extracellular domain nAChRs predominantly formed pentamers. The yield of these extracellular domain nAChRs was about half the yield of alpha 4 beta 2 nAChRs. In contrast, [ 3H] epibatidine binding was not detected from the extracellular domain alpha 4 and beta 2 subunits without M1, implying no detectable expression of extracellular domain nAChRs from these subunits. These results suggest that M1 domains on both alpha 4 and beta 2 play an important role for efficient expression of extracellular domain alpha 4 beta 2 nAChRs that are high fidelity structural models of full-length alpha 4 beta 2 nAChRs.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Pathol & Lab Med, Coll Med, College Stn, TX 77843 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Pennsylvania	Wells, GB (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Pathol & Lab Med, Coll Med, 208 Reynolds Med Bldg,1114 TAMU, College Stn, TX 77843 USA.	gbwells@tamu.edu	Wells, Gregg/AAU-7798-2021	theiler, shaleen/0000-0002-6881-6319	NINDS NIH HHS [NS01903, NS11323] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011323] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexeev T, 1999, EUR J BIOCHEM, V259, P310, DOI 10.1046/j.1432-1327.1999.00041.x; ANAND R, 1991, J BIOL CHEM, V266, P11192; ANAND R, 1993, BIOCHEMISTRY-US, V32, P9975, DOI 10.1021/bi00089a013; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P4272, DOI 10.1093/nar/18.14.4272; Avramopoulou V, 2004, J BIOL CHEM, V279, P38287, DOI 10.1074/jbc.M402533200; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Breitinger U, 2004, J BIOL CHEM, V279, P1627, DOI 10.1074/jbc.M303811200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BREW K, 1975, J BIOL CHEM, V250, P1434; Brown AM, 2001, COMPUT METH PROG BIO, V65, P191, DOI 10.1016/S0169-2607(00)00124-3; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CONROY WG, 1990, J BIOL CHEM, V265, P21642; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; DAS MK, 1991, BIOCHEMISTRY-US, V30, P2470, DOI 10.1021/bi00223a025; Eaton JB, 2003, MOL PHARMACOL, V64, P1283, DOI 10.1124/mol.64.6.1283; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Fiaux J, 2002, NATURE, V418, P207, DOI 10.1038/nature00860; Fischer M, 2001, P NATL ACAD SCI USA, V98, P3567, DOI 10.1073/pnas.041594798; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1; HOUGHTLING RA, 1995, MOL PHARMACOL, V48, P280; HOUGHTLING RA, 1994, MED CHEM RES, V4, P538; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kuryatov A, 1997, J NEUROSCI, V17, P9035; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; Lindstrom JM, 2003, ANN NY ACAD SCI, V998, P41, DOI 10.1196/annals.1254.007; Lopez-Hernandez GY, 2004, J BIOL CHEM, V279, P38007, DOI 10.1074/jbc.M403537200; Maksay G, 2003, J RECEPT SIG TRANSD, V23, P255, DOI 10.1081/RRS-120025568; Matthews GM, 1999, PRACT APPROACH SER, V202, P29; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Motulsky H., 2004, FITTING MODELS BIOL, P109; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Nelson ME, 2003, MOL PHARMACOL, V63, P332, DOI 10.1124/mol.63.2.332; Nevin ST, 2003, J BIOL CHEM, V278, P28985, DOI 10.1074/jbc.M300097200; Opella SJ, 2004, CHEM REV, V104, P3587, DOI 10.1021/cr0304121; PENG X, 1994, MOL PHARMACOL, V46, P523; Psaridi-Linardaki L, 2002, J BIOL CHEM, V277, P26980, DOI 10.1074/jbc.M110731200; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Sabey K, 1999, MOL PHARMACOL, V55, P58, DOI 10.1124/mol.55.1.58; Schrattenholz A, 1998, J BIOL CHEM, V273, P32393, DOI 10.1074/jbc.273.49.32393; Shafaee N, 1999, BRIT J PHARMACOL, V128, P1291, DOI 10.1038/sj.bjp.0702900; Sharma G, 2002, J NEUROBIOL, V53, P524, DOI 10.1002/neu.10114; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; Tierney ML, 2000, J MOL BIOL, V303, P185, DOI 10.1006/jmbi.2000.4137; Trudell JR, 2004, J MOL GRAPH MODEL, V23, P39, DOI 10.1016/j.jmgm.2004.03.004; Truong A, 2001, MOL BRAIN RES, V96, P68, DOI 10.1016/S0169-328X(01)00268-6; Tsetlin VI, 2002, EUR J BIOCHEM, V269, P2801, DOI 10.1046/j.1432-1033.2002.02961.x; Tugarinov V, 2005, P NATL ACAD SCI USA, V102, P622, DOI 10.1073/pnas.0407792102; Tugarinov V, 2004, ANNU REV BIOCHEM, V73, P107, DOI 10.1146/annurev.biochem.73.011303.074004; TZARTOS S, 1987, J NEUROIMMUNOL, V15, P185, DOI 10.1016/0165-5728(87)90092-0; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wang DX, 1996, J NEUROSCI RES, V44, P350, DOI 10.1002/(SICI)1097-4547(19960515)44:4<350::AID-JNR6>3.0.CO;2-B; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Wang ZX, 1996, FEBS LETT, V392, P245, DOI 10.1016/0014-5793(96)00818-6; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; Wang ZZ, 1996, J CELL BIOL, V135, P809, DOI 10.1083/jcb.135.3.809; Weber G., 1992, PROTEIN INTERACTIONS; Wells GB, 1998, J BIOL CHEM, V273, P964, DOI 10.1074/jbc.273.2.964; Wells J. W., 1992, RECEPTOR LIGAND INTE, P289; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; Whiteaker P, 1998, MOL PHARMACOL, V53, P950; WHITING PJ, 1988, J NEUROSCI, V8, P3395; Williamson PTF, 2004, EUR BIOPHYS J BIOPHY, V33, P247, DOI 10.1007/s00249-003-0380-1; Xue H, 2000, J MOL BIOL, V296, P739, DOI 10.1006/jmbi.2000.3502; Xue H, 2001, J MOL BIOL, V312, P915, DOI 10.1006/jmbi.2001.5022; Yao Y, 2002, J BIOL CHEM, V277, P12613, DOI 10.1074/jbc.M108845200; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200; Zhou Y, 2003, J NEUROSCI, V23, P9004; Zwart R, 1998, MOL PHARMACOL, V54, P1124, DOI 10.1124/mol.54.6.1124	83	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	2005	280	48					39990	40002		10.1074/jbc.M505087200	http://dx.doi.org/10.1074/jbc.M505087200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	986PD	16174636	hybrid			2022-12-25	WOS:000233461300037
J	Wang, M; Kirk, JS; Venkataraman, S; Domann, FE; Zhang, HJ; Schafer, FQ; Flanagan, SW; Weydert, CJ; Spitz, DR; Buettner, GR; Oberley, LW				Wang, M; Kirk, JS; Venkataraman, S; Domann, FE; Zhang, HJ; Schafer, FQ; Flanagan, SW; Weydert, CJ; Spitz, DR; Buettner, GR; Oberley, LW			Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor	ONCOGENE			English	Article						HIF-1; VEGF; angiogenesis; hypoxia; MnSOD	INDUCIBLE FACTOR-I; NF-KAPPA-B; LINDAU TUMOR-SUPPRESSOR; REDOX REGULATION; GLUTATHIONE-PEROXIDASE; INDUCED ANGIOGENESIS; ANTIOXIDANT ENZYMES; CELL PHENOTYPE; NITRIC-OXIDE; CANCER CELLS	Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that governs cellular responses to reduced O-2 availability by mediating crucial homeostatic processes. HIF-1 is composed of an HIF-1 alpha subunit and an HIF-1 beta subunit. HIF-1 alpha is degraded following enzyme-dependent hydroxylation of prolines of HIF-1 alpha in the presence of molecular oxygen, Fe2+, alpha-ketoglutarate, and ascorbate. These cofactors contribute to the redox environment of cells. The antioxidant enzyme manganese superoxide dismutase (MnSOD) also modulates the cellular redox environment. Here we show that MnSOD suppressed hypoxic accumulation of HIF-1 alpha protein in human breast carcinoma MCF-7 cells. This suppression was biphasic depending on MnSOD activity. At low levels of MnSOD activity, HIF-1 alpha protein accumulated under hypoxic conditions. At moderate levels of MnSOD activity (two-to six-fold increase compared to parent cells), these accumulations were blocked. However, at higher levels of MnSOD activity (> 6-fold increase), accumulation of HIF-1 alpha protein was again observed. This biphasic modulation was observed under both 1 and 4% O-2. Coexpression of mitochondrial hydrogen peroxide-removing proteins prevented the accumulation of HIF-1 alpha protein in cells with high levels of MnSOD; this effect demonstrates that the restabilization of HIF-1 alpha observed in high MnSOD overexpressors is probably due to hydrogen peroxide, most likely produced from MnSOD. Hypoxic induction of vascular endothelial growth factor ( VEGF) protein was also suppressed by elevated MnSOD activity and its levels reflected HIF-1 alpha protein levels. These observations demonstrated that HIF-1 alpha accumulation and VEGF expression could be modulated by the antioxidant enzyme MnSOD.	Univ Iowa, Holden Comprehens Canc Ctr, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa	Oberley, LW (corresponding author), Univ Iowa, Holden Comprehens Canc Ctr, Dept Radiat Oncol, Free Rad & Radiat Biol Program, B180 Med Labs, Iowa City, IA 52242 USA.	larry-oberley@uiowa.edu		Buettner, Garry/0000-0002-5594-1903; Domann, Frederick/0000-0002-0489-2179; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [CA66081, CA81090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081090, P01CA066081] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BROWN LF, 1997, EXS, V79, P233; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Collingridge DR, 1997, RADIAT RES, V147, P329, DOI 10.2307/3579340; DARR D, 1986, BIOCHEM PHARMACOL, V35, P3642, DOI 10.1016/0006-2952(86)90639-8; DEWHIRST MW, 1989, INT J RADIAT ONCOL, V17, P91, DOI 10.1016/0360-3016(89)90375-1; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hockel M, 1996, CANCER RES, V56, P4509; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kelley MR, 2001, ANTIOXID REDOX SIGN, V3, P671, DOI 10.1089/15230860152543014; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Li SJ, 2000, CANCER RES, V60, P3927; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; MOULDER JE, 1984, RADIAT RES, V98, P536, DOI 10.2307/3576486; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Park JH, 2003, CLIN CANCER RES, V9, P433; Powis G, 1997, Adv Pharmacol, V38, P329; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; Semenza GL, 1998, CHEST, V114, p40S, DOI 10.1378/chest.114.1_Supplement.40S; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI13374; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 1999, ANN NY ACAD SCI, V874, P262, DOI 10.1111/j.1749-6632.1999.tb09241.x; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SHAHYUKICH AA, 1988, LAB INVEST, V58, P236; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; TULCHIN N, 1976, ANAL BIOCHEM, V72, P485, DOI 10.1016/0003-2697(76)90558-3; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Wheeler MD, 2003, MOL CANCER RES, V1, P871; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 1999, CANCER RES, V59, P6276; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	68	96	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8154	8166		10.1038/sj.onc.1208986	http://dx.doi.org/10.1038/sj.onc.1208986			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16170370				2022-12-25	WOS:000233809400007
J	Liu, SQ; Alkema, PK; Tieche, C; Tefft, BJ; Liu, DZ; Li, YC; Sumpio, BE; Caprini, JA; Paniagua, M				Liu, SQ; Alkema, PK; Tieche, C; Tefft, BJ; Liu, DZ; Li, YC; Sumpio, BE; Caprini, JA; Paniagua, M			Negative regulation of monocyte adhesion to arterial elastic laminae by signal regulatory protein alpha and Src homology 2 domain-containing protein-tyrosine phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; SMOOTH-MUSCLE-CELLS; TRANSMEMBRANE GLYCOPROTEIN; VASCULAR MORPHOGENESIS; POINT MUTATIONS; VEIN GRAFTS; SIRP-ALPHA; BLOOD-FLOW; IN-VITRO; RECEPTOR	Elastic laminae are extracellular matrix constituents that not only contribute to the stability and elasticity of arteries but also play a role in regulating arterial morphogenesis and pathogenesis. We demonstrate here that an important function of arterial elastic laminae is to prevent monocyte adhesion, which is mediated by the inhibitory receptor signal regulatory protein (SIRP) alpha and Src homology 2 domain-containing protein-tyrosine phosphatase (SHP)-1. In a matrix-based arterial reconstruction model in vivo, elastic laminae were resistant to leukocyte adhesion and transmigration compared with the collagen-dominant arterial adventitia. The density of leukocytes within the elastic lamina-dominant media was about 58-70-fold lower than that within the adventitia from 1 to 30 days. An in vitro assay confirmed the inhibitory effect of elastic laminae on monocyte adhesion. The exposure of monocytes to elastic laminae induced activation of SIRP alpha, which in turn activated SHP-1. Elastic lamina degradation peptides extracted from arterial specimens could also activate SIRP alpha and SHP-1. The knockdown of SIRP alpha and SHP-1 by specific small interfering RNA diminished the inhibitory effect of elastic laminae, resulting in a significant increase in monocyte adhesion. These observations suggest that SIRP alpha and SHP-1 potentially mediate the inhibitory effect of elastic laminae on monocyte adhesion.	Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Yale Univ, Sch Med, Dept Surg, Cardiovasc Sect, New Haven, CT 06520 USA; Northwestern Univ, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; University of Chicago; Yale University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Liu, SQ (corresponding author), Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.	sliu@northwestern.edu	Liu, Shu Q/B-7626-2009; caprini, joseph/AAH-4750-2019					Adams S, 1998, J IMMUNOL, V161, P1853; Berg KL, 1998, ONCOGENE, V17, P2535, DOI 10.1038/sj.onc.1202203; BREWSTER DC, 2000, VASCULAR SURG, P492; Brooke BS, 2003, TRENDS CELL BIOL, V13, P51, DOI 10.1016/S0962-8924(02)00007-7; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Dong Q, 1999, J IMMUNOL, V162, P3220; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Grassl ED, 2002, J BIOMED MATER RES, V60, P607, DOI 10.1002/jbm.10107; Hance KA, 2002, J VASC SURG, V35, P254, DOI 10.1067/mva.2002.120382; Herring M B, 1991, Surg Annu, V23 Pt 2, P157; Hinek A, 1996, BIOL CHEM, V377, P471; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Hoerstrup SP, 2002, ANN THORAC SURG, V74, P46, DOI 10.1016/S0003-4975(02)03649-4; Huynh T, 1999, NAT BIOTECHNOL, V17, P1083, DOI 10.1038/15062; Ito S, 1997, Cardiovasc Surg, V5, P176, DOI 10.1016/S0967-2109(97)00004-5; Jensen N, 1996, ANN VASC SURG, V10, P530, DOI 10.1007/BF02000441; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Li DY, 1997, HUM MOL GENET, V6, P1021, DOI 10.1093/hmg/6.7.1021; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Lienard H, 1999, J BIOL CHEM, V274, P32493, DOI 10.1074/jbc.274.45.32493; Liu SQ, 2004, BIOMATERIALS, V25, P1869, DOI 10.1016/j.biomaterials.2003.08.044; Liu SQ, 2003, AM J PHYSIOL-HEART C, V285, pH1081, DOI 10.1152/ajpheart.00434.2003; Liu SQ, 1999, ARTERIOSCL THROM VAS, V19, P2630, DOI 10.1161/01.ATV.19.11.2630; Liu SQ, 1998, ATHEROSCLEROSIS, V140, P365, DOI 10.1016/S0021-9150(98)00143-9; Liu SQ, 1999, CRIT REV BIOMED ENG, V27, P75, DOI 10.1615/CritRevBiomedEng.v27.i1-2.30; Mayer JE, 1997, CURR OPIN CARDIOL, V12, P528, DOI 10.1097/00001573-199711000-00005; Mecham RP, 1995, CIBA F SYMP, V192, P172; MECHAM RP, 1982, METHOD ENZYMOL, V82, P744; Merrilees MJ, 2002, CIRC RES, V90, P481, DOI 10.1161/hh0402.105791; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; NEEL BG, 2004, HDB CELL SIGNALLING, V1, P707; Nerem RM, 2001, ANNU REV BIOMED ENG, V3, P225, DOI 10.1146/annurev.bioeng.3.1.225; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Nikolovski J, 2000, BIOMATERIALS, V21, P2025, DOI 10.1016/S0142-9612(00)00079-X; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Robert L, 1999, CONNECT TISSUE RES, V40, P75, DOI 10.3109/03008209909029103; Schoenemeyer A, 2005, J BIOL CHEM, V280, P17005, DOI 10.1074/jbc.M412584200; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Tassabehji M, 1997, HUM MOL GENET, V6, P1029, DOI 10.1093/hmg/6.7.1029; Thompson RW, 1996, ANN NY ACAD SCI, V800, P157, DOI 10.1111/j.1749-6632.1996.tb33307.x; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tran KT, 2003, EXP CELL RES, V289, P359, DOI 10.1016/S0014-4827(03)00287-8; Urban Z, 2002, AM J HUM GENET, V71, P30, DOI 10.1086/341035; Urry DW, 2002, PHILOS T R SOC B, V357, P169, DOI 10.1098/rstb.2001.1023; vanderGiessen WJ, 1996, CIRCULATION, V94, P1690, DOI 10.1161/01.CIR.94.7.1690; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Wong LCY, 1996, CIRC RES, V78, P799, DOI 10.1161/01.RES.78.5.799; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	59	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2005	280	47					39294	39301		10.1074/jbc.M503866200	http://dx.doi.org/10.1074/jbc.M503866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	985FL	16159885	hybrid			2022-12-25	WOS:000233362200048
J	Casteel, DE; Boss, GR; Pilz, RB				Casteel, DE; Boss, GR; Pilz, RB			Identification of the interface between cGMP-dependent protein kinase I beta and its interaction partners TFII-I and IRAG reveals a common interaction motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN PHOSPHATASE; SIGNALING COMPLEX; SMOOTH-MUSCLE; BINDING; ZIPPER; LOCALIZATION; DIMERIZATION; PREDICTION; REGULATOR; SUBSTRATE	Protein-protein interactions have emerged as an important mechanism providing for specificity in cellular signal transduction. Two splice variants of type I cGMP-dependent protein kinase (PKG I alpha and I beta) differ only in their N-terminal similar to 100 amino acids, which mediate binding to different target proteins. PKG I beta, but not I alpha, binds to the general transcriptional regulator TFII-I and the inositol 1,4,5-trisphosphate receptor-associated PKG substrate IRAG. Using a combination of site-directed mutagenesis and in vitro binding assays, we identified a group of acidic amino acids in the N-terminal leucine zipper dimerization domain of PKG I beta required for its binding to both TFII-I and IRAG. Small clusters of basic amino acids in possible alpha-helical regions in TFII-I and IRAG were found to mediate their interaction with PKG I beta. Mutation of two negatively charged residues in the PKG I beta leucine zipper (D26K/E31R) to positively charged residues, found in corresponding positions in PKG I alpha, completely abrogated binding to TFII-I and IRAG without disrupting PKG dimerization. Mutation of specific basic residues in TFII-I or IRAG abolished binding of the full-length proteins to PKG I beta in intact cells. Based on these results, we propose a model for specific PKG I beta interaction with target proteins.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rpilz@ucsd.edu		Boss, Gerry/0000-0002-9758-8714	NIAMS NIH HHS [AR051300] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline; PHS HHS [5T32 A107469] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051300] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; Borovkov AY, 1997, BIOTECHNIQUES, V22, P812, DOI 10.2144/97225bm04; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Koller A, 2003, BIOCHEM BIOPH RES CO, V300, P155, DOI 10.1016/S0006-291X(02)02799-7; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Richie-Jannetta R, 2003, J BIOL CHEM, V278, P50070, DOI 10.1074/jbc.M306796200; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Smith PJ, 2002, SIGHT SOUND, V12, P32; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Wen YD, 2003, J BIOL CHEM, V278, P1841, DOI 10.1074/jbc.M206528200; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897	28	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38211	38218		10.1074/jbc.M507021200	http://dx.doi.org/10.1074/jbc.M507021200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16166082	hybrid			2022-12-25	WOS:000233239800014
J	Chung, SK; Brown, JM; Provo, JN; Hopkins, R; McIntosh, MK				Chung, SK; Brown, JM; Provo, JN; Hopkins, R; McIntosh, MK			Conjugated linoleic acid promotes human adipocyte insulin resistance through NF kappa B-dependent cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACTIVATED-RECEPTOR-GAMMA; PROTEIN-KINASE-C; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; ADIPOSE-TISSUES; TNF-ALPHA; IKK-BETA; EXPRESSION; INTERLEUKIN-6	We previously demonstrated that trans-10,cis-12 conjugated linoleic acid (CLA) reduced the triglyceride content of human adipocytes by activating mitogen-activated protein kinase kinase/extracellular signal-related kinase (MEK/ERK) signaling via interleukins (IL) 6 and 8. However, the upstream mechanism is unknown. Here we show that CLA increased (>= 6 h) the secretion of IL-6 and IL-8 in cultures containing both differentiated adipocytes and stromal vascular (SV) cells, non-differentiated SV cells, and adipose tissue explants. CLA isomer-specific induction of IL-6 and tumor necrosis factor-alpha was associated with the activation of nuclear factor kappa B (NF kappa B) as evidenced by 1) phosphorylation of I kappa B alpha, I kappa B alpha kinase, and NF kappa B p65, 2) I kappa B alpha degradation, and 3) nuclear translocation of NF kappa B. Pretreatment with selective NF kappa B inhibitors and the MEK/ ERK inhibitor U0126 blocked CLA-mediated IL-6 gene expression. Trans-10, cis-12 CLA suppression of insulin-stimulated glucose uptake at 24 h was associated with decreased total and plasma membrane glucose transporter 4 proteins. Inhibition of NF kappa B activation or depletion of NF kappa B by RNA interference using small interfering NF kappa B p65 attenuated CLA suppression of glucose transporter 4 and peroxisome proliferator-activated receptor gamma proteins and glucose uptake. Collectively, these data demonstrate for the first time that trans-10, cis-12 CLA promotes NF kappa B activation and subsequent induction of IL-6, which are at least in part responsible for trans-10, cis-12 CLA-mediated suppression of peroxisome proliferator-activated receptor gamma target gene expression and insulin sensitivity in mature human adipocytes.	Univ N Carolina, Dept Nutr, Greensboro, NC 27402 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol & Comparat Med, Winston Salem, NC 27157 USA	University of North Carolina; University of North Carolina Greensboro; Wake Forest University; Wake Forest Baptist Medical Center	McIntosh, MK (corresponding author), Univ N Carolina, Dept Nutr, 318 Stone Bldg, Greensboro, NC 27402 USA.	mkmcinto@uncg.edu		Chung, Soonkyu/0000-0001-6279-7017	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL096166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063070] Funding Source: NIH RePORTER; NHLBI NIH HHS [R00 HL096166] Funding Source: Medline; NIDDK NIH HHS [R01DK-63070, R01 DK063070] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brown JM, 2004, J BIOL CHEM, V279, P26735, DOI 10.1074/jbc.M401766200; Brown JM, 2003, J LIPID RES, V44, P1287, DOI 10.1194/jlr.M300001-JLR200; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajpendo.00110.2003; Bruun JM, 2004, AM J PHYSIOL-ENDOC M, V286, pE8, DOI 10.1152/ajpendo.00269.2003; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Camp HS, 1997, J BIOL CHEM, V272, P10811; Carvalho E, 2004, J BIOL CHEM, V279, P21598, DOI 10.1074/jbc.M312269200; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chung SY, 2005, J LIPID RES, V46, P885, DOI 10.1194/jlr.M400476-JLR200; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Fain JN, 2004, INT J OBESITY, V28, P616, DOI 10.1038/sj.ijo.0802594; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; FRIED SK, 1993, J CLIN INVEST, V92, P2191, DOI 10.1172/JCI116821; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Harkins JM, 2004, J NUTR, V134, P2673, DOI 10.1093/jn/134.10.2673; House RL, 2005, OBES REV, V6, P247, DOI 10.1111/j.1467-789X.2005.00198.x; Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303; HU E, 1996, SCIENCE, V274, P31771; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Jove M, 2005, ENDOCRINOLOGY, V146, P3087, DOI 10.1210/en.2004-1560; Lagathu C, 2003, BIOCHEM BIOPH RES CO, V311, P372, DOI 10.1016/j.bbrc.2003.10.013; Lappas M, 2005, ENDOCRINOLOGY, V146, P1491, DOI 10.1210/en.2004-0809; Larsen TM, 2003, J LIPID RES, V44, P2234, DOI 10.1194/jlr.R300011-JLR200; Lau DCW, 2005, AM J PHYSIOL-HEART C, V288, pH2031, DOI 10.1152/ajpheart.01058.2004; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Nie M, 2005, J BIOL CHEM, V280, P2550, DOI 10.1074/jbc.M410616200; Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Riserus U, 2004, AM J CLIN NUTR, V79, p1146S; Riserus U, 2004, DIABETOLOGIA, V47, P1016, DOI 10.1007/s00125-004-1421-8; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; Sinha S, 2004, J BIOL CHEM, V279, P41294, DOI 10.1074/jbc.M406514200; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tsuboyama-Kasaoka N, 2003, J NUTR, V133, P1793, DOI 10.1093/jn/133.6.1793; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	54	128	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38445	38456		10.1074/jbc.M508159200	http://dx.doi.org/10.1074/jbc.M508159200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16155293	Green Accepted, hybrid			2022-12-25	WOS:000233239800041
J	Klaus, SMJ; Kunji, ERS; Bozzo, GG; Noiriel, A; de la Garza, RD; Basset, GJC; Ravanel, S; Rebeille, F; Gregory, JF; Hanson, AD				Klaus, SMJ; Kunji, ERS; Bozzo, GG; Noiriel, A; de la Garza, RD; Basset, GJC; Ravanel, S; Rebeille, F; Gregory, JF; Hanson, AD			Higher plant plastids and cyanobacteria have folate carriers related to those of trypanosomatids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; BIOPTERIN TRANSPORTER BT1; P-AMINOBENZOATE BRANCH; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; MEMBRANE-TRANSPORT; FOLIC-ACID; METHOTREXATE RESISTANCE; LEISHMANIA-DONOVANI; CHLOROPLASTS	Cyanobacterial and plant genomes encode proteins with some similarity to the folate and biopterin transporters of the trypanosomatid parasite Leishmania. The Synechocystis slr0642 gene product and its closest Arabidopsis homolog, the At2g32040 gene product, are representative examples. Both have 12 probable transmembrane domains, and the At2g32040 protein has a predicted chloroplast transit peptide. When expressed in Escherichia coli pabA pabB or folE, mutants, which are unable to produce or take up folates, the slr0642 protein and a modified At2g32040 protein ( truncated and fused to the N terminus of slr0642) enabled growth on 5-formyltetrahydrofolate or folic acid but not on 5-formyltetrahydrofolate triglutamate, demonstrating that both proteins mediate folate monoglutamate transport. Both proteins also mediate transport of the antifolate analogs methotrexate and aminopterin, as evidenced by their ability to greatly increase the sensitivity of E. coli to these inhibitors. The full-length At2g32040 polypeptide was translocated into isolated pea chloroplasts and, when fused to green fluorescent protein, directed the passenger protein to the envelope of Arabidopsis chloroplasts in transient expression experiments. At2g32040 transcripts were present at similar levels in roots and aerial organs, indicating that the protein occurs in non-green plastids as well as chloroplasts. Insertional inactivation of At2g32040 significantly raised the total folate content of chloroplasts and lowered the proportion of 5-methyltetrahydrofolate but did not discernibly affect growth. These findings establish conservation of function among folate and biopterin transporter family proteins from three kingdoms of life.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Grenoble 1, CEA Grenoble, Inst Natl Rech Agron, CNRS,Lab Physiol Cellulaire Vegetale, F-38054 Grenoble, France	State University System of Florida; University of Florida; State University System of Florida; University of Florida; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu	Kunji, Edmund/AAH-2362-2020; de la Garza, Rocío Isabel Diaz/B-7449-2011	Kunji, Edmund/0000-0002-0610-4500; de la Garza, Rocío Isabel Diaz/0000-0002-0006-5694; Ravanel, Stephane/0000-0001-9475-4222; Gregory, Jesse/0000-0002-9976-2085	MRC [MC_U105663139] Funding Source: UKRI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071382] Funding Source: NIH RePORTER; Medical Research Council [MC_U105663139] Funding Source: Medline; NIGMS NIH HHS [R01 GM071382-01] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; ARFMAN N, 1992, J BACTERIOL, V174, P7370, DOI 10.1128/jb.174.22.7370-7378.1992; Basset G, 2002, P NATL ACAD SCI USA, V99, P12489, DOI 10.1073/pnas.192278499; Basset GJC, 2004, PLANT J, V40, P453, DOI 10.1111/j.1365-313X.2004.02231.x; Basset GJC, 2004, P NATL ACAD SCI USA, V101, P1496, DOI 10.1073/pnas.0308331100; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; Bedhomme M, 2005, J BIOL CHEM, V280, P34823, DOI 10.1074/jbc.M506045200; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; Brzezinska A, 2000, ACTA BIOCHIM POL, V47, P735; Chan SY, 2003, PTERIDINES, V14, P67; Chang AB, 2004, MOL MEMBR BIOL, V21, P171, DOI 10.1080/09687680410001720830; Chen LF, 1997, PLANT PHYSIOL, V115, P299, DOI 10.1104/pp.115.1.299; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cossins EA, 1997, PHYTOCHEMISTRY, V45, P437, DOI 10.1016/S0031-9422(96)00833-3; Court DL, 2003, GENE, V315, P63, DOI 10.1016/S0378-1119(03)00728-5; deBree A, 1997, EUR J CLIN NUTR, V51, P643, DOI 10.1038/sj.ejcn.1600467; Dole VS, 2002, FEMS MICROBIOL LETT, V208, P89, DOI 10.1111/j.1574-6968.2002.tb11065.x; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Facey SJ, 2004, BBA-MOL CELL RES, V1694, P55, DOI 10.1016/j.bbamcr.2004.03.012; Gambonnet B, 2001, J SCI FOOD AGR, V81, P835, DOI 10.1002/jsfa.870; Gibeaut DM, 1997, PLANT PHYSIOL, V115, P317, DOI 10.1104/pp.115.2.317; Goyer A, 2005, J BIOL CHEM, V280, P26137, DOI 10.1074/jbc.M503106200; Goyer A, 2004, PLANT PHYSIOL, V135, P103, DOI 10.1104/pp.103.038430; Green JM, 1996, ESCHERICHIA COLI SAL, V1, P665; GREEN JM, 2002, CHEM BIOL PTERIDINES, P631; GRODZINSKI B, 1973, J BACTERIOL, V115, P456, DOI 10.1128/JB.115.1.456-458.1973; Hannaert V, 2003, P NATL ACAD SCI USA, V100, P1067, DOI 10.1073/pnas.0335769100; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; Hanson AD, 2000, TRENDS PLANT SCI, V5, P206, DOI 10.1016/S1360-1385(00)01599-5; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Hussein MJ, 1998, J BACTERIOL, V180, P6260; IWAI K, 1976, BIOCHIM BIOPHYS ACTA, V444, P618, DOI 10.1016/0304-4165(76)90406-2; Jabrin S, 2003, PLANT PHYSIOL, V131, P1431, DOI 10.1104/pp.016915; JANSZ ER, 1973, CAN J MICROBIOL, V19, P381, DOI 10.1139/m73-062; Klaus SMJ, 2005, J BIOL CHEM, V280, P5274, DOI 10.1074/jbc.M413759200; KUMAR HP, 1987, J BIOL CHEM, V262, P7171; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; Niwa Y., 2003, PLANT BIOTECHNOL-NAR, V20, P1, DOI [10.5511/plantbiotechnology.20.1, DOI 10.5511/PLANTBIOTECHNOLOGY.20.1]; Orsomando G, 2005, J BIOL CHEM, V280, P28877, DOI 10.1074/jbc.M504306200; Ouellette M, 2002, INT J PARASITOL, V32, P385, DOI 10.1016/S0020-7519(01)00346-0; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Quinlivan EP, 2003, J BIOL CHEM, V278, P20731, DOI 10.1074/jbc.M302894200; Ravanel S, 2004, J BIOL CHEM, V279, P22548, DOI 10.1074/jbc.M313250200; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Rebeille F, 1999, PR PHYT SOC, V42, P53; Richard D, 2004, J BIOL CHEM, V279, P54494, DOI 10.1074/jbc.M409264200; Richard D, 2002, J BIOL CHEM, V277, P29460, DOI 10.1074/jbc.M204796200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulz A, 2004, J HISTOCHEM CYTOCHEM, V52, P701, DOI 10.1177/002215540405200514; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; SHANE B, 1975, J BIOL CHEM, V250, P2243; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; Sybesma W, 2003, APPL ENVIRON MICROB, V69, P3069, DOI 10.1128/AEM.69.6.3069-3076.2003; Tamura T, 1997, MICROBIOL-UK, V143, P2639, DOI 10.1099/00221287-143-8-2639; Titus SA, 2000, J BIOL CHEM, V275, P36811, DOI 10.1074/jbc.M005163200; Waller RF, 2004, TRENDS PARASITOL, V20, P54, DOI 10.1016/j.pt.2003.10.018; WINTER H, 1994, PLANTA, V193, P530, DOI 10.1007/BF02411558; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	65	75	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38457	38463		10.1074/jbc.M507432200	http://dx.doi.org/10.1074/jbc.M507432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16162503	hybrid, Green Published			2022-12-25	WOS:000233239800042
J	Shapiro, MJ; Chen, YY; Shapiro, VS				Shapiro, MJ; Chen, YY; Shapiro, VS			The carboxyl-terminal segment of the adaptor protein ALX directs its nuclear export during T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATION; LOCALIZATION; DOMAIN; EXPRESSION; CLONING; TSAD; LAD	The adaptor protein ALX acts downstream of CD28 to regulate the interleukin-2 (IL-2) promoter during T cell activation. Whereas ALX is predominantly localized to the cytoplasm, ALX partially resides in the nucleus, and the nuclear pool is rapidly depleted in response to T cell receptor (TCR)/CD28 signaling. Here it is shown that this depletion occurs via nuclear export of ALX, which depends on a leucine-rich nuclear export signal (NES) in its carboxyl segment and on the CRM-1 transport protein. Nuclear import of ALX also depends on its carboxyl-terminal segment. Blocking nuclear export of ALX, either pharmacologically, by leptomycin B, or by site-directed mutation of the ALX NES, impairs CD28-mediated phosphorylation of ALX. Additionally, upon overexpression, the ALX NES mutant was found to be impaired in inhibiting TCR/CD28-induced transcriptional up-regulation of the RE/AP composite element from the IL-2 promoter, whereas a truncated form of ALX that is a potent inhibitor of RE/AP activation was found to reside entirely in the cytoplasm. Together, these results show that ALX exerts its effect on IL-2 up-regulation in the cytoplasm and suggest an intricate relationship between the nuclear localization/export, phosphorylation, and activity of ALX in response to TCR and CD28 signaling.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Shapiro, VS (corresponding author), Univ Penn, Dept Pathol & Lab Med, 288 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	shapirov@mail.med.upenn.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054974] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI054974] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Choi YB, 1999, J IMMUNOL, V163, P5242; Drappa J, 2003, J EXP MED, V198, P809, DOI 10.1084/jem.20021358; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Greene TA, 2003, J BIOL CHEM, V278, P45128, DOI 10.1074/jbc.M306283200; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Marti F, 2001, J EXP MED, V193, P1425, DOI 10.1084/jem.193.12.1425; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Rajagopal K, 1999, J EXP MED, V190, P1657, DOI 10.1084/jem.190.11.1657; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shapiro MJ, 2004, J BIOL CHEM, V279, P40647, DOI 10.1074/jbc.M404198200; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Spurkland A, 1998, J BIOL CHEM, V273, P4539, DOI 10.1074/jbc.273.8.4539; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Sundvold V, 2000, J IMMUNOL, V165, P2927, DOI 10.4049/jimmunol.165.6.2927; Vischioni B, 2004, EXP CELL RES, V298, P535, DOI 10.1016/j.yexcr.2004.04.040; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284	21	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38242	38246		10.1074/jbc.M507441200	http://dx.doi.org/10.1074/jbc.M507441200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16169852	hybrid			2022-12-25	WOS:000233239800018
J	Emoto, K; Inadome, H; Kanaho, Y; Narumiya, S; Umeda, M				Emoto, K; Inadome, H; Kanaho, Y; Narumiya, S; Umeda, M			Local change in phospholipid composition at the cleavage furrow is essential for completion of cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; SMALL GTPASE RHO; MEMBRANE TRAFFICKING; MAMMALIAN SEPTIN; CITRON KINASE; HUMAN HOMOLOG; PROTEIN; BINDING; PHOSPHORYLATION; CYTOSKELETAL	Cell division ends up with the membrane separation of two daughter cells, presumably by a membrane fusion that requires dynamic changes of the distribution and the composition of membrane lipids. We have previously shown that a membrane lipid phosphatidylethanolamine ( PE) is exposed on the cell surface of the cleavage furrow during late cytokinesis and that this PE movement is involved in regulation of the contractile ring disassembly. Here we show that immobilization of cell surface PE by a PE-binding peptide blocks the RhoA inactivation in the late stage of cytokinesis. Phosphatidylinositol 4-phosphate5-kinase (PIP5K), but not other RhoA effectors, is co-localized with RhoA in the peptide-treated cells. Indeed, PIP5K and its product phosphatidylinositol 4,5-bisphosphate (PI(4,5) P-2) are localized to the cleavage furrow of normally dividing cells. Both overexpression of a kinase-deficient PIP5K mutant and microinjection of anti-PI(4,5) P-2 antibodies compromise cytokinesis by preventing local accumulation of PI(4,5) P-2 in the cleavage furrow. These findings demonstrate that the localized production of PI(4,5) P-2 is required for the proper completion of cytokinesis and that the possible formation of a unique lipid domain in the cleavage furrow membrane may play a crucial role in coordinating the contractile rearrangement with the membrane remodeling during late cytokinesis.	Kyoto Univ, Inst Chem Res, Div Supramol Biol, Kyoto 6110011, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Umeda, M (corresponding author), Kyoto Univ, Inst Chem Res, Div Supramol Biol, Kyoto 6110011, Japan.	umeda@scl.kyoto-u.ac.jp	EMOTO, KAZUO/G-4992-2014					Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AOKI Y, 1994, J BIOCHEM-TOKYO, V116, P291, DOI 10.1093/oxfordjournals.jbchem.a124522; Brill JA, 2000, DEVELOPMENT, V127, P3855; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; DELAAT SW, 1980, P NATL ACAD SCI-BIOL, V77, P1526; Di Cunto F, 2000, NEURON, V28, P115, DOI 10.1016/S0896-6273(00)00090-8; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; Farkas RM, 2003, MOL BIOL CELL, V14, P190, DOI 10.1091/mbc.E02-06-0343; Finger FP, 2002, CELL, V108, P727, DOI 10.1016/S0092-8674(02)00668-2; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Glotzer M, 2003, CURR OPIN CELL BIOL, V15, P684, DOI 10.1016/j.ceb.2003.10.003; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Kato T, 2001, J CELL SCI, V114, P775; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Litvak V, 2002, MOL CELL BIOL, V22, P5064, DOI 10.1128/MCB.22.14.5064-5075.2002; Low SH, 2003, DEV CELL, V4, P753, DOI 10.1016/S1534-5807(03)00122-9; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; MIYAZAWA A, 1988, MOL IMMUNOL, V25, P1025; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Oegema K, 2000, J CELL BIOL, V150, P539, DOI 10.1083/jcb.150.3.539; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Schweitzer JK, 2004, EXP CELL RES, V295, P1, DOI 10.1016/j.yexcr.2003.12.023; Shuster CB, 2002, P NATL ACAD SCI USA, V99, P3633, DOI 10.1073/pnas.052342699; Skop AR, 2001, CURR BIOL, V11, P735, DOI 10.1016/S0960-9822(01)00231-7; Strickland LI, 2004, TRENDS CELL BIOL, V14, P115, DOI 10.1016/j.tcb.2004.01.006; Suetsugu S, 1999, FEBS LETT, V457, P470, DOI 10.1016/S0014-5793(99)01086-8; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; TETTEROO PAT, 1984, DEV BIOL, V104, P210, DOI 10.1016/0012-1606(84)90049-6; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Yamazaki M, 2002, J BIOL CHEM, V277, P17226, DOI 10.1074/jbc.M109795200; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3; Zhang YJ, 2000, J BIOL CHEM, V275, P35600, DOI 10.1074/jbc.M005575200	52	129	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37901	37907		10.1074/jbc.M504282200	http://dx.doi.org/10.1074/jbc.M504282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16162509	hybrid			2022-12-25	WOS:000233044500071
J	Eckerdt, F; Yuan, JP; Saxena, K; Martin, B; Kappel, S; Lindenau, C; Kramer, A; Naumann, S; Daum, S; Fischer, G; Dikic, I; Kaufmann, M; Strebhardt, K				Eckerdt, F; Yuan, JP; Saxena, K; Martin, B; Kappel, S; Lindenau, C; Kramer, A; Naumann, S; Daum, S; Fischer, G; Dikic, I; Kaufmann, M; Strebhardt, K			Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; DEPENDENT PROLINE ISOMERIZATION; SACCHAROMYCES-CEREVISIAE CDC5; DOWN-REGULATION; CANCER-CELLS; DROSOPHILA POLO; CYCLIN B1; MITOSIS; PLK1; DOMAIN	The Polo-like kinase 1 (Plk1) is a key regulator of mitosis. It is reported that the human peptidyl-prolyl cis/trans-isomerase Pin1 binds to Plk1 from mitotic cell extracts in vitro. Here we demonstrate that Ser-65 in Pin1 is the major site for Plk1-specific phosphorylation, and the polo-box domain of Plk1 is required for this phosphorylation. Interestingly, the phosphorylation of Pin1 by Plk1 does not affect its isomerase activity but rather is linked to its protein stability. Pin1 is ubiquitinated in HeLa S3 cells, and substitution of Glu for Ser-65 reduces the ubiquitination of Pin1. Furthermore, inhibition of Plk1 activity by expression of a dominant negative form of Plk1 or by transfection of small interfering RNA targeted to Plk1 enhances the ubiquitination of Pin1 and subsequently reduces the amount of Pin1 in human cancer cells. Since previous reports suggested that Plk1 is a substrate of Pin1, our work adds a new dimension to this interaction of two important mitotic regulators.	Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Organ Chem, D-60439 Frankfurt, Germany; Max Planck Res Unit, D-06120 Halle Saale, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; Max Planck Society	Eckerdt, F (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA.		Dikic, Ivan/O-4650-2015; Strebhardt, Klaus/E-8765-2011	Dikic, Ivan/0000-0001-8156-9511; Strebhardt, Klaus/0000-0003-2173-9763				Abrieu A, 1998, J CELL SCI, V111, P1751; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; DAI W, 2003, FRONT BIOSCI, V8, P1128; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DOCARMO AM, 2001, NAT CELL BIOL, V3, P421; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jacobs DM, 2002, J BIOMOL NMR, V23, P163, DOI 10.1023/A:1016364324096; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1999, P NATL ACAD SCI USA, V96, P14360, DOI 10.1073/pnas.96.25.14360; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Matthess Y, 2005, ONCOGENE, V24, P2973, DOI 10.1038/sj.onc.1208472; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YEH E, 2004, NAT CELL BIOL; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	60	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36575	36583		10.1074/jbc.M504548200	http://dx.doi.org/10.1074/jbc.M504548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16118204	hybrid			2022-12-25	WOS:000232901800007
J	Kamiya, Y; Yamaguchi, Y; Takahashi, N; Arata, Y; Kasai, K; Ihara, Y; Matsuo, I; Ito, Y; Yamamoto, K; Kato, K				Kamiya, Y; Yamaguchi, Y; Takahashi, N; Arata, Y; Kasai, K; Ihara, Y; Matsuo, I; Ito, Y; Yamamoto, K; Kato, K			Sugar-binding properties of VIP36, an intracellular animal lectin operating as a cargo receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTAL AFFINITY-CHROMATOGRAPHY; CARBOHYDRATE-RECOGNITION DOMAIN; MANNOSE TYPE GLYCANS; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS; LEGUMINOUS LECTINS; CRYSTAL-STRUCTURE	The vesicular integral protein of 36 kDa (VIP36) is an intracellular animal lectin that acts as a putative cargo receptor, which recycles between the Golgi and the endoplasmic reticulum. Although it is known that VIP36 interacts with glycoproteins carrying high mannose-type oligosaccharides, detailed analyses of the sugar-binding specificity that discriminates isomeric oligosaccharide structures have not yet been performed. In the present study, we have analyzed, using the frontal affinity chromatography (FAC) method, the sugar-binding properties of a recombinant carbohydrate recognition domain of VIP36 (VIP36-CRD). For this purpose, a pyridylaminated sugar library, consisting of 21 kinds of oligosaccharides, including isomeric structures, was prepared and subjected to FAC analyses. The FAC data have shown that glucosylation and trimming of the D1 mannosyl branch interfere with the binding of VIP36-CRD. VIP36-CRD exhibits a bell-shaped pH dependence of sugar binding with an optimal pH value of similar to 6.5. By inspection of the specificity and optimal pH value of the sugar binding of VIP36 and its subcellular localization, together with the organellar pH, we suggest that VIP36 binds glycoproteins that retain the intact D1 mannosyl branch in the cis-Golgi network and recycles to the endoplasmic reticulum where, due to higher pH, it releases its cargos, thereby contributing to the quality control of glycoproteins.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi 3321102, Japan; Okazaki Natl Res Inst, Inst Mol Sci, Aichi 4448787, Japan; GLYENCE Co Ltd, Naka Ku, Nagoya, Aichi 4608690, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Kanagawa 1990195, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Frontier Sci, Chiba 2778562, Japan	Nagoya City University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Teikyo University; Nagasaki University; RIKEN; University of Tokyo	Kato, K (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	kkato@phar.nagoya-cu.ac.jp	Yamaguchi, Yoshiki/N-5246-2015; Ito, Yukishige/ACL-6203-2022; Ito, Yukishige/M-5119-2014	Yamaguchi, Yoshiki/0000-0003-0100-5439; Ito, Yukishige/0000-0001-6251-7249; Ito, Yukishige/0000-0001-6251-7249; Kato, Koichi/0000-0001-7187-9612				Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; Arata Y, 2001, J BIOL CHEM, V276, P3068, DOI 10.1074/jbc.M008602200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; Fullekrug J, 1999, J CELL SCI, V112, P2813; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hara-Kuge S, 2004, GLYCOBIOLOGY, V14, P739, DOI 10.1093/glycob/cwh082; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Hauri HP, 2000, J CELL SCI, V113, P587; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hirabayashi J, 2003, METHOD ENZYMOL, V362, P353; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KASAI K, 1986, J CHROMATOGR, V376, P33, DOI 10.1016/S0378-4347(00)80822-1; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; Matsuo I, 2003, J AM CHEM SOC, V125, P3402, DOI 10.1021/ja021288q; Mizushima T, 2004, NAT STRUCT MOL BIOL, V11, P365, DOI 10.1038/nsmb732; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Moremen K. W., 2000, CARBOHYDRATES CHEM 2, V3, P81; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Nawa D, 2004, GLYCOBIOLOGY, V14, P1108; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Spiro RG, 2004, CELL MOL LIFE SCI, V61, P1025, DOI 10.1007/s00018-004-4037-8; Takabayashi M, 2003, ANTI-CANCER DRUG, V14, P251, DOI 10.1097/00001813-200303000-00010; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Weisz OA, 2003, INT REV CYTOL, V226, P259, DOI 10.1016/S0074-7696(03)01005-2; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890	44	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37178	37182		10.1074/jbc.M505757200	http://dx.doi.org/10.1074/jbc.M505757200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16129679	hybrid			2022-12-25	WOS:000232901800076
J	Barker, TH; Baneyx, G; Cardo-Vila, M; Workman, GA; Weaver, M; Menon, PM; Dedhar, S; Rempel, SA; Arap, W; Pasqualini, R; Vogel, V; Sage, EH				Barker, TH; Baneyx, G; Cardo-Vila, M; Workman, GA; Weaver, M; Menon, PM; Dedhar, S; Rempel, SA; Arap, W; Pasqualini, R; Vogel, V; Sage, EH			SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE TARGET SUBUNIT; RESONANCE ENERGY-TRANSFER; NULL MICE; MATRICELLULAR PROTEINS; CELL-MATRIX; ENDOTHELIAL-CELLS; SECRETED PROTEIN; CYSTEINE SPARC; FIBRONECTIN; BINDING	SPARC, a 32-kDa matricellular glycoprotein, mediates interactions between cells and their extracellular matrix, and targeted deletion of Sparc results in compromised extracellular matrix in mice. Fibronectin matrix provides provisional tissue scaffolding during development and wound healing and is essential for the stabilization of mature extracellular matrix. Herein, we report that SPARC expression does not significantly affect fibronectin-induced cell spreading but enhances fibronectin-induced stress fiber formation and cell-mediated partial unfolding of fibronectin molecules, an essential process in fibronectin matrix assembly. By phage display, we identify integrin-linked kinase as a potential binding partner of SPARC and verify the interaction by co-immunoprecipitation and colocalization in vitro. Cells lacking SPARC exhibit diminished fibronectin-induced integrin-linked kinase activation and integrin-linked kinase-dependent cell-contractile signaling. Furthermore, induced expression of SPARC in SPARC-null fibroblasts restores fibronectin-induced integrin-linked kinase activation, downstream signaling, and fibronectin unfolding. These data further confirm the function of SPARC in extracellular matrix organization and identify a novel mechanism by which SPARC regulates extracellular matrix assembly.	Virginia Mason, Benaroya Res Inst, Hope Heart Program, Seattle, WA 98101 USA; Univ Washington, Dept Bioengn, Seattle, WA 98101 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Henry Ford Hosp, Barbara Jane Levy Lab, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA; British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V5Z 1L3, Canada; ETH, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	Benaroya Research Institute; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; Henry Ford Health System; Henry Ford Hospital; British Columbia Cancer Agency; University of British Columbia; Swiss Federal Institutes of Technology Domain; ETH Zurich	Sage, EH (corresponding author), Virginia Mason, Benaroya Res Inst, Hope Heart Program, 1201 9th Ave, Seattle, WA 98101 USA.	hsage@benaroyaresearch.org	Vogel, Viola/O-8025-2015	Vogel, Viola/0000-0003-2898-7671; Dedhar, Shoukat/0000-0003-4355-1657	NATIONAL CANCER INSTITUTE [R01CA086997] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NCI NIH HHS [CA 086997, R01 CA086997] Funding Source: Medline; NEI NIH HHS [EY13180] Funding Source: Medline; NIGMS NIH HHS [GM40711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aycock RL, 2004, J INVEST DERMATOL, V123, P592, DOI 10.1111/j.0022-202X.2004.23316.x; Baneyx G, 2002, P NATL ACAD SCI USA, V99, P5139, DOI 10.1073/pnas.072650799; Baneyx G, 2001, P NATL ACAD SCI USA, V98, P14464, DOI 10.1073/pnas.251422998; Baugh L, 2004, J BIOMED MATER RES A, V69A, P525, DOI 10.1002/jbm.a.30026; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Bradshaw AD, 2001, WOUND REPAIR REGEN, V9, P522, DOI 10.1046/j.1524-475x.2001.00522.x; Bradshaw AD, 2002, J HISTOCHEM CYTOCHEM, V50, P1; Bradshaw Amy D., 2000, Molecular Cell Biology Research Communications, V3, P345, DOI 10.1006/mcbr.2000.0237; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brekken RA, 2004, J HISTOCHEM CYTOCHEM, V52, P735, DOI 10.1369/jhc.3A6245.2004; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2002, BIOCHEM J, V367, P517, DOI 10.1042/BJ20020522; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Gao M, 2003, P NATL ACAD SCI USA, V100, P14784, DOI 10.1073/pnas.2334390100; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Hagood JS, 1999, AM J PHYSIOL-LUNG C, V277, pL218, DOI 10.1152/ajplung.1999.277.1.L218; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Kiss E, 2002, BIOCHEM J, V365, P79, DOI 10.1042/BJ20011295; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MALAVAL L, 1987, J BONE MINER RES, V2, P457; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Puolakkainen P, 2003, AM J PATHOL, V162, P627, DOI 10.1016/S0002-9440(10)63856-4; Ran S, 2002, CANCER RES, V62, P6132; Robinson EE, 2004, MOL BIOL CELL, V15, P973, DOI 10.1091/mbc.E03-07-0528; SAGE EH, 1992, BIOCHEM CELL BIOL, V70, P56, DOI 10.1139/o92-008; SAGE EH, 2004, CURRENT PROTOCOLS CE; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1984, J BIOL CHEM, V259, P3993; Schmidt MHH, 2003, J CELL SCI, V116, P2845, DOI 10.1242/jcs.00522; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Sweetwyne MT, 2004, J HISTOCHEM CYTOCHEM, V52, P723, DOI 10.1369/jhc.3A6153.2004; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; WEAVER M, 2005, IN PRESS J CELL BIOC; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yan Q, 2002, J CELL SCI, V115, P2747; YAN Q, 2005, IN PRESS INVEST OPHT; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200	65	157	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36483	36493		10.1074/jbc.M504663200	http://dx.doi.org/10.1074/jbc.M504663200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115889	hybrid			2022-12-25	WOS:000232726900082
J	Marathe, GK; Johnson, C; Billings, SD; Southall, MD; Pei, Y; Spandau, D; Murphy, RC; Zimmerman, GA; McIntyre, TM; Travers, JB				Marathe, GK; Johnson, C; Billings, SD; Southall, MD; Pei, Y; Spandau, D; Murphy, RC; Zimmerman, GA; McIntyre, TM; Travers, JB			Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN-ENDOTHELIAL-CELLS; UVB-INDUCED APOPTOSIS; FACTOR-RECEPTOR; HUMAN KERATINOCYTES; OXIDIZED PHOSPHOLIPIDS; CIGARETTE-SMOKING; MASS-SPECTROMETRY; HUMAN-NEUTROPHILS; HUMAN SKIN	Ultraviolet B light ( UVB) causes cutaneous inflammation and cell death, but the agents responsible are not defined. These studies examined the role of the platelet- activating factor ( PAF) signaling system in UVB- mediated effects. Expression of the PAF receptor in the PAF receptor- negative epidermoid cell line KB augmented apoptosis in response to UVB irradiation. Overexpression of the PAF receptor in primary human keratinocytes also enhanced UVB- mediated apoptosis in vitro, and it enhanced apoptosis in an in vivo model of human keratinocytes grafted onto severe combined immune- deficient ( SCID) mice. To define the mechanism by which UVB activates the PAF receptor, we used mass spectrometry to demonstrate significant amounts of the C-4 PAF analogs 1- alkyl- 2( butanoyl and butenoyl)- sn- glycero- 3- phosphocholine, as well as native PAF in an epidermal cell line after UVB irradiation. Supplementing the cells with the precursor phospholipid 1- hexadecyl- 2-arachidonoyl- sn- glycero- 3- phosphocholine ( HAPC) increased the amount of C-4 PAF analogs recovered after UVB exposure. We irradiated HAPC directly and found, even in the absence of a photosensitizer, fragmentation to C-4- PAF receptor ligands. We conclude UVB photo- oxidizes cellular phospholipids, creating PAF analogs that stimulate the PAF receptor to induce further PAF synthesis and apoptosis. PAF signaling may participate in the cutaneous inflammation that occurs during photo- aggravated dermatoses.	Univ Utah, Human Mol Biol & Genet Program, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Jewish Health	Marathe, GK (corresponding author), Lerner Res Inst, Dept Cell Biol, NC-10,9500 Euclid Ave, Cleveland, OH 44195 USA.	marathg@ccf.org	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Marathe, Gopal/0000-0002-0025-6677; Travers, Jeffrey/0000-0001-7232-1039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044513, R01HL062996, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303, HL62996, HL44513] Funding Source: Medline; NIAMS NIH HHS [AR01993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; Baltas E, 2003, SKIN PHARMACOL APPL, V16, P259, DOI 10.1159/000070849; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Chen CH, 2003, CIRCULATION, V107, P2102, DOI 10.1161/01.CIR.0000065220.70220.F7; Countryman NB, 2000, J INVEST DERMATOL, V115, P267, DOI 10.1046/j.1523-1747.2000.00058.x; Dupre DJ, 2003, J BIOL CHEM, V278, P48228, DOI 10.1074/jbc.M304082200; Dy LC, 1999, J BIOL CHEM, V274, P26917, DOI 10.1074/jbc.274.38.26917; FRANKEL EN, 1984, PROG LIPID RES, V23, P197, DOI 10.1016/0163-7827(84)90011-0; Grundmann JU, 2004, SKIN PHARMACOL PHYS, V17, P37, DOI 10.1159/000074061; Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HELLER R, 1992, J IMMUNOL, V149, P3682; ILIOU JP, 1992, LIPIDS, V27, P959, DOI 10.1007/BF02535572; IMAIZUMI TA, 1991, ATHEROSCLEROSIS, V87, P47, DOI 10.1016/0021-9150(91)90231-Q; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; Lewis DA, 2003, EXP CELL RES, V284, P316, DOI 10.1016/S0014-4827(02)00043-5; Li T, 2003, J BIOL CHEM, V278, P16614, DOI 10.1074/jbc.M211287200; Marathe GK, 2001, J LIPID RES, V42, P1430; Marathe GK, 2001, J LIPID RES, V42, P587; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; Mass P, 2003, ARCH DERMATOL RES, V295, P71, DOI 10.1007/s00403-003-0403-x; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MUELLER HW, 1984, J LIPID RES, V25, P383; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; OGURA R, 1991, J INVEST DERMATOL, V97, P1044, DOI 10.1111/1523-1747.ep12492553; PATEL KD, 1992, J BIOL CHEM, V267, P15168; Pei Y, 1998, J IMMUNOL, V161, P1954; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; REKDAL K, 1995, CHEM PHYS LIPIDS, V75, P127, DOI 10.1016/0009-3084(94)02413-Y; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; Sato S, 1999, ARCH DERMATOL RES, V291, P614, DOI 10.1007/s004030050463; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; SIPES IG, 1991, ADV EXP MED BIOL, V283, P489; Spandau DF, 2000, EXP DERMATOL, V9, P252, DOI 10.1034/j.1600-0625.2000.009004252.x; Stewart MS, 1996, J INVEST DERMATOL, V106, P1086, DOI 10.1111/1523-1747.ep12339344; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TERAO J, 1984, ARCH BIOCHEM BIOPHYS, V235, P326, DOI 10.1016/0003-9861(84)90205-4; TOKUMURA A, 1989, J LIPID RES, V30, P219; Travers JB, 1999, J INVEST DERMATOL, V112, P279, DOI 10.1046/j.1523-1747.1999.00521.x; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	52	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35448	35457		10.1074/jbc.M503811200	http://dx.doi.org/10.1074/jbc.M503811200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115894	hybrid			2022-12-25	WOS:000232561200045
J	Astrakas, LG; Goljer, I; Yasuhara, S; Padfield, KE; Zhang, QH; Gopalan, S; Mindrinos, MN; Dai, G; Yu, YM; Martyn, JAJ; Tompkins, RG; Rahme, LG; Tzika, AA				Astrakas, LG; Goljer, I; Yasuhara, S; Padfield, KE; Zhang, QH; Gopalan, S; Mindrinos, MN; Dai, G; Yu, YM; Martyn, JAJ; Tompkins, RG; Rahme, LG; Tzika, AA			Proton NMR spectroscopy shows lipids accumulate in skeletal muscle in response to burn trauma-induced apoptosis	FASEB JOURNAL			English	Article						magnetic resonance spectroscopy; high-resolution magic angle spinning skeletal muscle; burn trauma; mitochondria; intramyocellular lipids	CONTROLLING MITOCHONDRIAL BIOGENESIS; MAGNETIC-RESONANCE-SPECTROSCOPY; IN-VIVO; INSULIN-RESISTANCE; CELL-DEATH; PROTEIN-TURNOVER; THERMAL-INJURY; BRAIN-TUMORS; GENE-THERAPY; EX-VIVO	Burn trauma triggers hypermetabolism and muscle wasting via increased cellular protein degradation and apoptosis. Proton nuclear magnetic resonance (H-1 NMR) spectroscopy can detect mobile lipids in vivo. To examine the local effects of burn in skeletal muscle, we performed in vivo H-1 NMR on mice 3 days after burn trauma; and ex vivo, high-resolution, magic angle spinning H-1 NMR on intact excised mouse muscle samples before and 1 and 3 days after burn. These samples were then analyzed for apoptotic nuclei using a terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. To confirm our NMR and cell biology results, we used transcriptome analysis to demonstrate that burn trauma alters the expression of genes involved in lipid metabolism and apoptosis. Our results demonstrate that burn injury results in a localized intramyocellular lipid accumulation, which in turn is accompanied by burn-induced apoptosis and mitochondrial dysfunction, as seen by the up-regulation of apoptotic genes and down-regulation of genes that encode lipid oxidation and the peroxisomal proliferator activator receptor gamma coactivator PGC-1 beta. Moreover, the increased levels of bisallylic methylene fatty acyl protons (2.8 ppm) and vinyl protons (5.4 ppm), in conjunction with the TUNEL assay results, further suggest that burn trauma results in apoptosis. Together, our results provide new insight into the local physiological changes that occur in skeletal muscle after severe burn trauma.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Burns Inst,Dept Surg,NMR Surg Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA; Varian NMR Syst, Columbia, MD USA; Massachusetts Gen Hosp, Shriners Burns Inst, Dept Anesthesiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Shriners Burns Inst, Dept Crit Care, Boston, MA 02114 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Stanford University	Tzika, AA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Burns Inst,Dept Surg,NMR Surg Lab, 51 Blossom St,Room 261, Boston, MA 02114 USA.	atzika@partners.org	Astrakas, Loukas G/F-5918-2011	Astrakas, Loukas G/0000-0002-4890-4805	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055082, P50GM021700] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055082, U54GM062119, P50GM021700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASTRAKAS LG, 2003, INT SOC MAGNETIC RES, V11, P1317; Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Boesch C, 1997, MAGN RESON MED, V37, P484, DOI 10.1002/mrm.1910370403; Bollard ME, 2000, MAGNET RESON MED, V44, P201, DOI 10.1002/1522-2594(200008)44:2<201::AID-MRM6>3.0.CO;2-5; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COHEN SM, 1979, P NATL ACAD SCI USA, V76, P1603, DOI 10.1073/pnas.76.4.1603; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; GALSTER AD, 1984, J TRAUMA, V24, P938, DOI 10.1097/00005373-198411000-00003; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GELFAND JA, 1983, ANN SURG, V198, P58, DOI 10.1097/00000658-198307000-00011; Griffin JL, 2003, CANCER RES, V63, P3195; Griffin JL, 2001, MAGNET RESON MED, V46, P249, DOI 10.1002/mrm.1185; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; Hakumaki JM, 2000, TRENDS BIOCHEM SCI, V25, P357, DOI 10.1016/S0968-0004(00)01614-5; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hasselgren PO, 2000, WORLD J SURG, V24, P1452, DOI 10.1007/s002680010262; HAVEL RJ, 1964, J APPL PHYSIOL, V19, P613, DOI 10.1152/jappl.1964.19.4.613; HELM PA, 1985, ARCH PHYS MED REHAB, V66, P451; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Ikezu T, 1997, J BIOL CHEM, V272, P25289, DOI 10.1074/jbc.272.40.25289; Jenkins GM, 2003, CELL MOL LIFE SCI, V60, P701, DOI 10.1007/s00018-003-2239-0; JOHNSON AB, 1992, CLIN SCI, V82, P219, DOI 10.1042/cs0820219; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P967, DOI 10.1111/j.1471-4159.1992.tb09350.x; KAUPPINEN RA, 1992, MAGNET RESON MED, V25, P398, DOI 10.1002/mrm.1910250221; KAYAR SR, 1986, EUR J APPL PHYSIOL O, V54, P578, DOI 10.1007/BF00943344; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; KIM MY, 1991, J BIOL CHEM, V266, P484; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Lee K, 2000, METAB ENG, V2, P312, DOI 10.1006/mben.2000.0160; Liu GL, 1999, CRIT REV CL LAB SCI, V36, P511, DOI 10.1080/10408369991239240; Lombardi V, 1997, CELL MOL NEUROBIOL, V17, P521, DOI 10.1023/A:1026362922549; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morvan D, 2002, CANCER RES, V62, P1890; MULLER MJ, 1994, LANCET, V343, P216, DOI 10.1016/S0140-6736(94)90995-4; Negendank W, 1996, ANTICANCER RES, V16, P1533; ODESSEY R, 1982, METABOLISM, V31, P82, DOI 10.1016/0026-0495(82)90049-X; Padfield KE, 2005, P NATL ACAD SCI USA, V102, P5368, DOI 10.1073/pnas.0501211102; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Pratt VC, 2001, LIPIDS, V36, P675, DOI 10.1007/s11745-001-0772-y; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; SHANGRAW RE, 1982, J SURG RES, V33, P345, DOI 10.1016/0022-4804(82)90048-8; St-Pierre DMM, 1998, ARCH PHYS MED REHAB, V79, P155, DOI 10.1016/S0003-9993(98)90292-1; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMERA JF, 1988, BURNS, V14, P210, DOI 10.1016/0305-4179(88)90040-X; TREDGET EE, 1992, WORLD J SURG, V16, P68, DOI 10.1007/BF02067117; Tzika AA, 2002, J NEUROSURG, V96, P1023, DOI 10.3171/jns.2002.96.6.1023; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; Veale MF, 1997, BIOCHEM BIOPH RES CO, V239, P868, DOI 10.1006/bbrc.1997.7566; Vermathen P, 2004, MAGNET RESON MED, V51, P253, DOI 10.1002/mrm.10721; Vit JP, 2003, ONCOGENE, V22, P8645, DOI 10.1038/sj.onc.1207087; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wiechert W, 2001, METAB ENG, V3, P195, DOI 10.1006/mben.2001.0187; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yasuhara S, 2000, AM J PHYSIOL-ENDOC M, V279, pE1114, DOI 10.1152/ajpendo.2000.279.5.E1114; Yu YM, 1999, JPEN-PARENTER ENTER, V23, P160, DOI 10.1177/0148607199023003160	73	27	30	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1431	1440		10.1096/fj.04-2005com	http://dx.doi.org/10.1096/fj.04-2005com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126910				2022-12-25	WOS:000232315700036
J	Bar-Am, O; Weinreb, O; Amit, T; Youdim, MBH				Bar-Am, O; Weinreb, O; Amit, T; Youdim, MBH			Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine	FASEB JOURNAL			English	Article						amyloid precursor protein; brain-derived neurotrophic factor; poly-ADP ribose polymerase	AMYLOID PRECURSOR PROTEIN; ANTI-PARKINSON DRUG; CEREBELLAR GRANULE NEURONS; MAO-B INHIBITOR; MESSENGER-RNA; ALZHEIMERS-DISEASE; KINASE-C; RESPONSIVE ELEMENT; OXIDATIVE STRESS; GENE-EXPRESSION	The anti-Parkinson drug, rasagiline (N-propargyl-(1R)-aminoindan) promotes neuronal survival, via neuroprotective activity related to its propargyl moiety (propargylamine). We have investigated the neurorescue effects of propargylamine, in a progressive neuronal death model, induced by long-term serum deprivation in human SH-SY5Y neuroblastoma cells. Propargylamine (0.1-10 mu M) dose-dependently reduced the levels of the early apoptosis-associated phosphorylated protein, H2A-X (ser 139), as well as decreased the cleavage of caspase-3 and its substrate poly-ADP ribose polymerase (PARP). In addition, the compound markedly reversed the apoptotic effects induced by long-term serum withdrawal, including down-regulation of the antiapoptotic protein, Bcl-2, as well as up-regulation of the proapoptotic proteins, Bax, Bad, and Bim. Real-time RT-PCR demonstrated that propargylamine elevated gene expression levels of Bcl-2, and the neurotrophic factors glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) and reduced Bax gene expression. Serum deprivation increased mRNA and protein levels of holo-amyloid precursor protein (APP), which was markedly decreased by propargylamine. This was accompanied by inducing the release of the nonamyloidogenic alpha-secretase form of soluble APP (sAPP alpha) into the medium. Similar effects on cell survival and APP regulation/processing were demonstrated for rasagiline. These results indicate that both rasagiline and propargylamine possess neurorescue activity, associated with regulation of Bcl-2 family proteins, neurotrophic factors, and APP metabolism.	Technion Israel Inst Technol, Fac Med, Rappaport Family Res Inst, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf & USA Natl Parkinson Fdn Ctr Excellence, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Family Res Inst, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Andoh T, 2000, FASEB J, V14, P2144; Atabay C, 1996, J NEUROSCI RES, V43, P465; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Ba F, 2003, J NEUROSCI METH, V123, P11, DOI 10.1016/S0165-0270(02)00324-2; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; Belzacq AS, 2003, CURR DRUG TARGETS, V4, P517, DOI 10.2174/1389450033490867; Belzacq AS, 2003, CANCER RES, V63, P541; Berry MD, 2003, PROG NEURO-PSYCHOPH, V27, P197, DOI 10.1016/S0278-5846(03)00015-0; Blandini F, 2004, EXP NEUROL, V187, P455, DOI 10.1016/j.expneurol.2004.03.005; Bonneh-Barkay D, 2005, NEUROPHARMACOLOGY, V48, P406, DOI 10.1016/j.neuropharm.2004.10.016; Charriaut-Marlangue C, 2004, THERAPIE, V59, P185, DOI 10.2515/therapie:2004035; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; Double KL, 2003, EXP NEUROL, V184, P530, DOI 10.1016/j.expneurol.2003.08.006; Finberg JPM, 1998, NEUROREPORT, V9, P703; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; Hoyer A, 2005, J NEURAL TRANSM, V112, P239, DOI 10.1007/s00702-004-0176-1; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; JENDROSKA K, 1995, ACTA NEUROPATHOL, V90, P461, DOI 10.1007/bf00294806; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lin L, 1998, NEUROREPORT, V9, P547, DOI 10.1097/00001756-199802160-00030; Mandel S, 2005, BRAIN RES REV, V48, P379, DOI 10.1016/j.brainresrev.2004.12.027; Maruyama W, 2004, NEUROCHEM INT, V44, P393, DOI 10.1016/j.neuint.2003.08.005; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; MARUYAMA W, 2005, IN PRESS J NEURAL TR; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ravina BM, 2003, NEUROLOGY, V60, P1234, DOI 10.1212/01.WNL.0000058760.13152.1A; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SAGI Y, 2001, NEURAL PLAST, V8, P197; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Shi J, 2000, NEUROBIOL AGING, V21, P357, DOI 10.1016/S0197-4580(00)00119-6; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; Shi J, 1997, BRAIN RES, V772, P247, DOI 10.1016/S0006-8993(97)00827-5; Shoji M, 2000, PSYCHIAT CLIN NEUROS, V54, P45, DOI 10.1046/j.1440-1819.2000.00636.x; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; Silva EFDE, 2003, NEUROCHEM RES, V28, P1553, DOI 10.1023/A:1025630627319; SIMONS M, 1995, FEBS LETT, V368, P363, DOI 10.1016/0014-5793(95)00654-R; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Speiser Z, 1999, J NEURAL TRANSM, V106, P593, DOI 10.1007/s007020050182; Sudoh S, 1996, MOL BRAIN RES, V39, P12, DOI 10.1016/0169-328X(95)00348-V; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; Tabakman R, 2004, BIOESSAYS, V26, P80, DOI 10.1002/bies.10378; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Wang L, 2002, GENE THER, V9, P381, DOI 10.1038/sj.gt.3301682; Weiner HL, 2002, NATURE, V420, P879, DOI 10.1038/nature01325; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Weinreb O, 2003, FASEB J, V17, P935, DOI 10.1096/fj.02-0712fje; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Yogev-Falach M, 2003, FASEB J, V17, P2325, DOI 10.1096/fj.03-0078fje; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Yokota M, 1996, J CEREBR BLOOD F MET, V16, P1219, DOI 10.1097/00004647-199611000-00016; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; Youdim MBH, 2005, J NEUROSCI RES, V79, P172, DOI 10.1002/jnr.20350; Youdim MBH, 2005, TRENDS PHARMACOL SCI, V26, P27, DOI 10.1016/j.tips.2004.11.007; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9	77	140	157	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1899	+		10.1096/fj.05-3794fje	http://dx.doi.org/10.1096/fj.05-3794fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148027				2022-12-25	WOS:000232315700027
J	Castello, L; Froio, T; Cavallini, G; Biasi, F; Sapino, A; Leonarduzzi, G; Bergamini, E; Poli, G; Chiarpotto, E				Castello, L; Froio, T; Cavallini, G; Biasi, F; Sapino, A; Leonarduzzi, G; Bergamini, E; Poli, G; Chiarpotto, E			Calorie restriction protects against age-related rat aorta sclerosis	FASEB JOURNAL			English	Article						TGF beta 1; ageing; MAPK; oxidative stress; aortic fibrosclerosis	FREE-RADICAL THEORY; GROWTH-FACTOR-BETA; TGF-BETA; AUTOPHAGIC PROTEOLYSIS; DIETARY RESTRICTION; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; PROMOTER-REGION; GENE-EXPRESSION; END-PRODUCT	Many theories have been advanced to account for the ageing process, among which the free radical theory deserves much attention. Numerous studies have also shown an association between tissue fibrosis and oxidative stress. Of note, fibrosis may be considered a significant index of tissue ageing. Calorie restriction (CR) has been demonstrated to maintain many physiological processes in a youthful state until a very advanced age. However the anti-ageing mechanisms of CR are still not fully understood. We thus evaluated the effect of CR on oxidative damage and its relationship with fibrosis during ageing. We found a significant increase of both oxidative stress and fibrosis parameters in the aortae from aged vs. young rats. CR reversed both phenomena. CR also protected against the age-associated increase of Jun-N-terminal kinase and p-38 activities, involved in TGF beta 1 expression and signaling. On the contrary, extracellular regulated kinases did not show any age-related change. CR similarly reversed the age-related increase of AP-1 DNA binding activity and the AP-1-dependent increase of vimentin gene expression. In parallel, CR reversed the age-related morphological alterations of the aorta wall cell composition. These data further support the relationship between oxidative stress and fibrosis in different diseases and during ageing. The protection exerted by CR against fibrosclerosis might be due to a decrease of oxidative stress, with consequent decreased MAPK activity and down-regulation of AP-1 activation and of TGF beta 1 expression and signaling.	Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy; Univ Pisa, Interdepartmental Res Ctr Biol & Pathol Ageing, I-56100 Pisa, Italy; Italian Natl Res Council, Turin, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy	University of Turin; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); University of Turin	Chiarpotto, E (corresponding author), Univ Turin, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Turin, Italy.	elena.chiarpotto@unito.it	Leonarduzzi, Gabriella/AAA-6575-2019; Sapino, Anna/AGY-9901-2022; Sapino, Anna/J-4113-2018	Sapino, Anna/0000-0003-3542-9571; Sapino, Anna/0000-0003-3542-9571; LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				Abrass CK, 2000, ADV RENAL REPLACE TH, V7, P4, DOI 10.1016/S1073-4449(00)70001-X; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burt DJ, 2003, DIABETOLOGIA, V46, P531, DOI 10.1007/s00125-003-1075-y; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; Cavallini G, 2001, EXP GERONTOL, V36, P497, DOI 10.1016/S0531-5565(00)00224-2; Cefalu WT, 1999, TOXICOL SCI, V52, P49, DOI 10.1093/toxsci/52.suppl_1.49; CHIARPOTTO E, 1995, BIOCHEM BIOPH RES CO, V207, P477, DOI 10.1006/bbrc.1995.1213; de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Donati A, 2001, J GERONTOL A-BIOL, V56, pB375, DOI 10.1093/gerona/56.9.B375; Duffy PH, 2001, AGING-CLIN EXP RES, V13, P263; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fornieri C, 1999, CONNECT TISSUE RES, V40, P131, DOI 10.3109/03008209909029109; Fulle S, 2004, EXP GERONTOL, V39, P17, DOI 10.1016/j.exger.2003.09.012; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hutter D, 2000, J GERONTOL A-BIOL, V55, pB125, DOI 10.1093/gerona/55.3.B125; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Kim HJ, 2002, MECH AGEING DEV, V123, P1589, DOI 10.1016/S0047-6374(02)00094-5; Kim JW, 2004, J GERONTOL A-BIOL, V59, P876; KIM SJ, 1989, J BIOL CHEM, V264, P402; Knapowski J, 2002, J PHYSIOL PHARMACOL, V53, P135; Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967; Lane MA, 1998, J ANTI-AGING MED, V1, P315, DOI DOI 10.1089/rej.1.1998.1.315; Lee J, 1999, FREE RADICAL BIO MED, V26, P260, DOI 10.1016/S0891-5849(98)00195-6; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; Li ZH, 1997, EXP MOL PATHOL, V64, P1, DOI 10.1006/exmp.1997.2204; Li ZH, 1999, HYPERTENSION, V33, P116, DOI 10.1161/01.HYP.33.1.116; Massague J, 2000, GENE DEV, V14, P627; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nitti M, 2002, BIOCHEM BIOPH RES CO, V294, P547, DOI 10.1016/S0006-291X(02)00512-0; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; Parola M, 1996, BIOCHEM BIOPH RES CO, V222, P261, DOI 10.1006/bbrc.1996.0732; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; POLI G, 2003, SIGNAL TRANSDUCTION, P180; Poli Giuseppe, 2000, Molecular Aspects of Medicine, V21, P49, DOI 10.1016/S0098-2997(00)00004-2; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raju J, 2003, CANCER RES, V63, P6595; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; Torrens C, 2003, J PHYSIOL-LONDON, V547, P77, DOI 10.1113/jphysiol.2002.026120; UCHIDA K, 1994, METHOD ENZYMOL, V233, P371; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang DS, 2003, BIOCHEM BIOPH RES CO, V310, P236, DOI 10.1016/j.bbrc.2003.09.003; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Weindruch R., 1988, RETARDATION AGING DI; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yu BP, 2002, J NUTR SCI VITAMINOL, V48, P257, DOI 10.3177/jnsv.48.257; Zanetti M, 2004, ATHEROSCLEROSIS, V175, P253, DOI 10.1016/j.atherosclerosis.2004.05.001	59	46	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1863	+		10.1096/fj.04-2864fje	http://dx.doi.org/10.1096/fj.04-2864fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150801				2022-12-25	WOS:000232315700023
J	Fukuyama, T; Ogita, H; Kawakatsu, T; Inagaki, M; Takai, Y				Fukuyama, T; Ogita, H; Kawakatsu, T; Inagaki, M; Takai, Y			Activation of Rac by cadherin through the c-Src-Rap1-phosphatidylinositol 3-kinase-Vav2 pathway	ONCOGENE			English	Article						cell protrusion; E-cadherin; signaling pathway	CELL-CELL-ADHESION; SMALL G-PROTEINS; NECTIN-LIKE MOLECULES; ADHERENS JUNCTIONS; TRANS-INTERACTIONS; TIGHT JUNCTIONS; FORCE MEASUREMENTS; C-SRC; CDC42; RAP1	Cadherin first forms homo-cis-dimerson the cell surface of the same cells, followed by formation of homo-trans-dimers(trans interactions) in a Ca2+ dependent manner, eventually causing adherens junctions. In addition, transinteracting cadherin induces activatio n of Rac small G protein, which stabilizes non-trans-interacting cadherin on the plasma membrane by inhibiting its endocytosis through the reorganization of the actin cytoskeleton. However, it has not fully been understood how cadherin induces the activation of Rac. We examined here the molecular mechanism of the activation of Rac by transinteracting cadherin in. fibroblasts and epithelial cells. Trans-interacting cadherin induced activation of c-Src locally at the cadherin-based cell-cell adhesion sites. c-Src then tyrosine- phosphorylated Vav2, one of the Rac-GDP/GTP exchange factors(GEFs), and induced activation of C3G, one of the Rap1-GEFs, through Crk adaptor protein, resulting in the activation of Rap1 locally at the cadherin-based cell-cell adhesion sites. The c-Src-catalysed tyrosine phosphorylation was not suf. cient for the activation of Vav2 and the c-Src-induced activation of Rap1 was additionally necessary for it, although activated Rap1 alone was not suf. cient for the activation of non-tyrosine-phosphorylated Vav2. This effect of Rap1 on Vav2 was mediated by phosphatidylinositol 3- kinase. We describe here the signaling pathway from trans-interacting cadherin to the activation of Rac.	Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ogita, Hisakazu/AAE-4416-2020	Ogita, Hisakazu/0000-0001-6750-1668				Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Martinez-Rico C, 2005, J BIOL CHEM, V280, P4753, DOI 10.1074/jbc.M412544200; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Yagi T, 2000, GENE DEV, V14, P1169; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	43	67	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					8	19		10.1038/sj.onc.1209010	http://dx.doi.org/10.1038/sj.onc.1209010			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170364				2022-12-25	WOS:000234406400002
J	Hu, YF; Ghosh, S; Amleh, A; Yue, W; Lu, YZ; Katz, A; Li, R				Hu, YF; Ghosh, S; Amleh, A; Yue, W; Lu, YZ; Katz, A; Li, R			Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression	ONCOGENE			English	Article						BRCA1; aromatase; ovarian granulosa cells; preadipocytes; tissue-specific tumor suppression; estrogen biosynthesis	BREAST; GENE; OVARIAN; DIFFERENTIATION; OOPHORECTOMY; PROMOTER; PARTNER; BARD1	Mutations in BRCA1 increase risks of familial breast and ovarian cancers, particularly among premenopausal women. While BRCA1 plays an active role in DNA repair, this function alone may not be sufficient to explain why BRCA1-associated tumors predominantly occur in estrogen-responsive tissues. Aromatase is the rate-limiting enzyme in estrogen biosynthesis and a key target in breast cancer treatment. Aromatase expression in ovarian granulosa cells dictates levels of circulating estrogen in premenopausal women, and its aberrant overexpression in breast adipose tissues promotes breast cancer growth. Here, we show that BRCA1 modulates aromatase expression in ovarian granulosa cells and primary preadipocytes. The cyclic AMP-dependent expression of aromatase in ovarian granulosa cells is inversely correlated with the protein level of BRCA1. Importantly, transient knockdown of BRCA1 enhances aromatase expression in both ovarian granulosa cells and primary preadipocytes. We propose that BRCA1 deficiency in epithelial and certain nonepithelial cells may result in combined effects of aberrant estrogen biosynthesis and compromised DNA repair capability, which in turn may lead to specific cancers in the breast and ovary.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Div Endocrinol, Charlottesville, VA 22908 USA; Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; Univ Virginia, Sch Med, Dept Plast & Reconstruct Surg, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; Fudan University; University of Virginia	Hu, YF (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	yh4b@virginia.edu; rl2t@virginia.edu		Amleh, Asma/0000-0003-3613-3182; Lu, Yunzhe/0000-0001-7542-6848	NCI NIH HHS [CA093506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Chen SU, 2001, J STEROID BIOCHEM, V79, P35, DOI 10.1016/S0960-0760(01)00132-7; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Ghosh S, 2005, ONCOGENE, V24, P2236, DOI 10.1038/sj.onc.1208415; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Huo ZM, 2002, RADIOLOGY, V225, P519, DOI 10.1148/radiol.2252010845; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Key T J, 1999, Breast Cancer Res, V1, P18, DOI 10.1186/bcr7; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Phillips KW, 1997, LAB INVEST, V76, P419; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Tekmal RR, 1999, ENDOCR-RELAT CANCER, V6, P307, DOI 10.1677/erc.0.0060307; Turner KJ, 2002, J ENDOCRINOL, V172, P21, DOI 10.1677/joe.0.1720021; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Yue W, 1997, J STEROID BIOCHEM, V63, P317, DOI 10.1016/S0960-0760(97)00072-1; Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454	29	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8343	8348		10.1038/sj.onc.1208985	http://dx.doi.org/10.1038/sj.onc.1208985			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170371				2022-12-25	WOS:000233956500013
J	Van Velkinburgh, JC; Samaras, SE; Gerrish, K; Artner, I; Stein, R				Van Velkinburgh, JC; Samaras, SE; Gerrish, K; Artner, I; Stein, R			Interactions between areas I and II direct pdx-1 expression specifically to islet cell types of the mature and developing pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; NUCLEAR FACTOR 3-BETA; BETA-CELLS; HOMEODOMAIN PROTEIN; MICE; ELEMENTS; DIFFERENTIATION; IDENTIFICATION; MORPHOGENESIS; EPITHELIUM	PDX-1 regulates transcription of genes involved in islet beta cell function and pancreas development. Islet-specific expression is controlled by 5'-flanking sequences from base pair (bp) - 2917 to - 1918 in transgenic experiments, which encompasses both conserved (i.e. Area I (bp - 2761/ - 2457), Area II (bp - 2153/ - 1923)) and non-conserved pdx-1 sequences. However, only an Area II-driven transgene is independently active in vivo, albeit in only a fraction of islet PDX-1-producing cells. Our objective was to identify the sequences within the - 2917/ - 1918-bp region that act in conjunction with Area II to allow comprehensive expression in islet PDX-1(+) cells. In cell line-based transfection assays, only Area I effectively potentiated Area II activity. Both Area I and Area II functioned in an orientation-independent manner, whereas synergistic, enhancer-like activation was uniquely found with duplicated Area II. Chimeras of Area II and the generally active SV40 enhancer or the beta cell-specific insulin enhancer suggested that islet cell-enriched activators were necessary for Area I activation, because Area II-mediated stimulation was reduced by the SV40 enhancer and activated by the insulin enhancer. Several conserved sites within Area I were important in Area I/Area II activation, with binding at bp - 2614/ - 2609 specifically controlled by Nkx2.2, an insulin gene regulator that is required for terminal beta cell differentiation. The ability of Area I to modulate Area II activation was also observed in vivo, as an Area I/Area II-driven transgene recapitulated the endogenous pdx-1 expression pattern in developing and adult islet cells. These results suggest that Area II is a central pdx-1 control region, whose islet cell activity is uniquely modified by Area I regulatory factors.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	Roland.Stein@vanderbilt.edu	van Velkinburgh, Jennifer/D-7205-2015	van Velkinburgh, Jennifer/0000-0002-4592-2397; Artner, Isabella/0000-0002-2895-5664	NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050203, P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, 5T32 CA09385-18] Funding Source: Medline; NIDDK NIH HHS [R01 DK-50203, DK20593, P60 DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Gannon M, 2001, DEV BIOL, V238, P185, DOI 10.1006/dbio.2001.0359; Gerrish K, 2004, MOL ENDOCRINOL, V18, P533, DOI 10.1210/me.2003-0371; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; Melloul D, 2004, ANN NY ACAD SCI, V1014, P28, DOI 10.1196/annals.1294.003; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Pictet R., 1972, HDB PHYSL; Samaras SE, 2003, J BIOL CHEM, V278, P12263, DOI 10.1074/jbc.M210801200; Samaras SE, 2002, MOL CELL BIOL, V22, P4702, DOI 10.1128/MCB.22.13.4702-4713.2002; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Servitja JM, 2004, DIABETOLOGIA, V47, P597, DOI 10.1007/s00125-004-1368-9; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1999, ENDOCRINOLOGY, V140, P5374, DOI 10.1210/en.140.11.5374; Sussel L, 1998, DEVELOPMENT, V125, P2213; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532; ZHAO LJ, 2005, J BIOL CHEM	44	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38438	38444		10.1074/jbc.M508594200	http://dx.doi.org/10.1074/jbc.M508594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16147997	hybrid			2022-12-25	WOS:000233239800040
J	Rogulski, K; Li, YJ; Rothermund, K; Pu, LX; Watkins, S; Yi, FH; Prochownik, EV				Rogulski, K; Li, YJ; Rothermund, K; Pu, LX; Watkins, S; Yi, FH; Prochownik, EV			Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway	ONCOGENE			English	Article						c-Myc; p53; Mdm2; Akt; PTEN; Max; apoptosis; green. fluorescent protein; PI-3 kinase; p19(ARF); shRNA	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; P53 STABILITY; DNA METHYLTRANSFERASES; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; CXXC MOTIF; IN-VITRO; MDM2	The c-Myc oncoprotein is a general transcription factor whose target genes dictate the c-Myc phenotype. One such target of c-Myc, 'onzin', is normally expressed at high levels in myeloid cells and is dramatically downregulated in response to c-Myc overexpression. We show here that short hairpin interfering RNA-mediated knockdown of endogenous onzin results in a reduced growth rate and a proapoptotic phenotype. In contrast, onzin overexpression in fibroblasts is associated with an increased growth rate, resistance to apoptotic stimuli, loss of the G2/M checkpoint, and tumorigenic conversion. Onzin-overexpressing cells fail to induce p53 in response to apoptotic stimuli and contain higher levels of the active, phosphorylated forms of Akt1 and, more strikingly, of Mdm2. Using yeast two-hybrid and coimmunoprecipitation assays, we show that onzin directly interacts with both proteins. Green fluorescent protein tagging also confirms directly that Akt1 and Mdm2 colocalize with onzin, although the precise subcellular distribution of each protein is dependent on its relative abundance. Collectively, our results identify onzin as a novel regulator of several p53-dependent aspects of the c-Myc phenotype via its dramatic effect on Mdm2. This is reminiscent of the c-Myc -> p19(ARF)-vertical bar Mdm2 pathway and might function as a complementary arm to ensure the proper cellular response to oncogenic and/or apoptotic stimuli.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Pittsburgh, PA 15213 USA; Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Braspenning J, 1998, ONCOGENE, V16, P1085, DOI 10.1038/sj.onc.1201617; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Collet JF, 2003, J BIOL CHEM, V278, P45325, DOI 10.1074/jbc.M307818200; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; Guo QM, 2000, CANCER RES, V60, P5922; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; KAUFMANN SH, 1998, BIOCHIM BIOPHYS ACTA, V400, P195; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 2001, Harvey Lect, V97, P57; Paez Juan, 2003, Cancer Treat Res, V115, P145; Page C, 2000, ANTICANCER RES, V20, P407; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Prescott JE, 2001, J BIOL CHEM, V276, P48276, DOI 10.1074/jbc.M107357200; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Willis AE, 1997, CURR TOP MICROBIOL, V224, P269; Wood LJ, 2000, CANCER RES, V60, P4256; Yang CW, 2003, MOL CARCINOGEN, V36, P15, DOI 10.1002/mc.10086; Yi FH, 2003, CANCER RES, V63, P2923; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	83	78	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7524	7541		10.1038/sj.onc.1208897	http://dx.doi.org/10.1038/sj.onc.1208897			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16170375				2022-12-25	WOS:000233333800003
J	Waas, WF; de Crecy-Lagard, V; Schimmel, P				Waas, WF; de Crecy-Lagard, V; Schimmel, P			Discovery of a gene family critical to wyosine base formation in a subset of phenylalanine-specific transfer RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; YEAST TRANSFER RNAPHE; PEROXY-Y BASE; MODIFIED NUCLEOSIDES; MASS-SPECTROMETRY; POSTTRANSCRIPTIONAL MODIFICATION; PANCREATIC RIBONUCLEASE; NUCLEOTIDE-SEQUENCE; MAGNETIC-RESONANCE; PARTIAL DIGESTION	A large number of post-transcriptional base modifications in transfer RNAs have been described (Sprinzl, M., Horn, C., Brown, M., Ioudovitch, A., and Steinberg, S. ( 1998) Nucleic Acids Res. 26, 148 - 153). These modifications enhance and expand tRNA function to increase cell viability. The intermediates and genes essential for base modifications in many instances remain unclear. An example is wyebutosine (yW), a fluorescent tricyclic modification of an invariant guanosine situated on the 3'-side of the tRNA(Phe) anticodon. Although biosynthesis of yW involves several reaction steps, only a single pathway-specific enzyme has been identified ( Kalhor, H. R., Penjwini, M., and Clarke, S. ( 2005) Biochem. Biophys. Res. Commun. 334, 433 - 440). We used comparative genomics analysis to identify a cluster of orthologous groups (COG0731) of wyosine family biosynthetic proteins. Gene knock-out and complementation studies in Saccharomyces cerevisiae established a role for YPL207w, a COG0731 ortholog that encodes an 810-amino acid polypeptide. Further analysis showed the accumulation of N-1-methylguanosine (m(1)G(37)) in tRNA from cells bearing a YPL207w deletion. A similar lack of wyosine base and build-up of m(1)G(37) is seen in certain mammalian tumor cell lines. We proposed that the 810-amino acid COG0731 polypeptide participates in converting tRNA(Phe)-m(1)G(37) to tRNA(Phe)-yW.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	Scripps Research Institute; Scripps Research Institute; State University System of Florida; University of Florida	de Crecy-Lagard, V (corresponding author), Scripps Res Inst, Dept Biol Mol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vcrecy@ufl.edu; schimmel@scripps.edu	de Crecy-Lagard, Valerie/AAN-8995-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R01GM023562, R37GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562, GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTWEGG M, 1979, NUCLEIC ACIDS RES, V7, P93, DOI 10.1093/nar/7.1.93; Armengaud J, 2004, J BIOL CHEM, V279, P37142, DOI 10.1074/jbc.M403845200; Bishop AC, 2002, J BIOL CHEM, V277, P25090, DOI 10.1074/jbc.M203208200; Bjork GR, 1999, FEBS LETT, V452, P47, DOI 10.1016/S0014-5793(99)00528-1; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; BLOBSTEIN SH, 1973, BIOCHEMISTRY-US, V12, P188, DOI 10.1021/bi00726a002; BOUADLOUN F, 1986, J BACTERIOL, V166, P1022, DOI 10.1128/jb.166.3.1022-1027.1986; Carlson BA, 2001, VIROLOGY, V279, P130, DOI 10.1006/viro.2000.0692; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; CHANG SH, 1968, J BIOL CHEM, V243, P592; Christian T, 2004, J MOL BIOL, V339, P707, DOI 10.1016/j.jmb.2004.04.025; Date SV, 2005, BIOINFORMATICS, V21, P2558, DOI 10.1093/bioinformatics/bti313; Datta D, 2002, J AM CHEM SOC, V124, P5652, DOI 10.1021/ja0177096; DROOGMANS L, 1987, EMBO J, V6, P477, DOI 10.1002/j.1460-2075.1987.tb04778.x; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; Gerlt JA, 2003, CHEM BIOL, V10, P1141, DOI 10.1016/j.chembiol.2003.12.008; GHOSH K, 1972, J BIOL CHEM, V247, P3369; GOLANKIEWICZ B, 1985, NUCLEIC ACIDS RES, V13, P2443, DOI 10.1093/nar/13.7.2443; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; GRUNBERGER D, 1975, NATURE, V253, P66, DOI 10.1038/253066a0; GUERRIERTAKADA C, 1975, FEBS LETT, V60, P286, DOI 10.1016/0014-5793(75)80732-0; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; Kalhor HR, 2005, BIOCHEM BIOPH RES CO, V334, P433, DOI 10.1016/j.bbrc.2005.06.111; KAN LS, 1975, BIOCHEMISTRY-US, V14, P3278, DOI 10.1021/bi00685a038; KEITH G, 1973, FEBS LETT, V31, P345, DOI 10.1016/0014-5793(73)80138-3; KEITH G, 1980, BIOCHEM BIOPH RES CO, V92, P109, DOI 10.1016/0006-291X(80)91526-0; KEITH G, 1974, FEBS LETT, V48, P50, DOI 10.1016/0014-5793(74)81059-8; KRZYZOSIAK WJ, 1983, NUCLEIC ACIDS RES, V11, P6913, DOI 10.1093/nar/11.19.6913; KUCHINO Y, 1979, BIOCHIM BIOPHYS ACTA, V565, P215, DOI 10.1016/0005-2787(79)90098-4; KUCHINO Y, 1982, NUCLEIC ACIDS RES, V10, P6421, DOI 10.1093/nar/10.20.6421; LI HJ, 1973, BIOCHEM BIOPH RES CO, V55, P818, DOI 10.1016/0006-291X(73)91217-5; MAELICKE A, 1973, BIOPOLYMERS, V12, P27, DOI 10.1002/bip.1973.360120104; MARTIN R, 1978, CR ACAD SCI D NAT, V287, P845; Matte-Tailliez O, 2000, TRENDS GENET, V16, P533, DOI 10.1016/S0168-9525(00)02137-5; MAZABRAUD A, 1979, FEBS LETT, V100, P235, DOI 10.1016/0014-5793(79)80341-5; McCloskey J A, 2000, Nucleic Acids Symp Ser, P267; McCloskey JA, 2001, NUCLEIC ACIDS RES, V29, P4699, DOI 10.1093/nar/29.22.4699; MUNCH HJ, 1975, FEBS LETT, V51, P257, DOI 10.1016/0014-5793(75)80900-8; NAKANISHI K, 1971, NATURE-NEW BIOL, V234, P107, DOI 10.1038/newbio234107b0; Noon KR, 2003, J BACTERIOL, V185, P5483, DOI 10.1128/JB.185.18.5483-5490.2003; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; PANG H, 1982, EUR J BIOCHEM, V127, P459; PERGOLIZZI RG, 1979, NUCLEIC ACIDS RES, V6, P2209, DOI 10.1093/nar/6.6.2209; PERSSON BC, 1993, MOL MICROBIOL, V8, P1011, DOI 10.1111/j.1365-2958.1993.tb01645.x; RAJBHAND.UL, 1968, J BIOL CHEM, V243, P584; RAJBHANDARY UL, 1968, J BIOL CHEM, V243, P598; RAJBHANDARY UL, 1968, J BIOL CHEM, V243, P565; RAJBHANDARY UL, 1968, J BIOL CHEM, V243, P575; Reader JS, 2004, J BIOL CHEM, V279, P6280, DOI 10.1074/jbc.M310858200; SCHMIDT J, 1971, BIOCHEMISTRY-US, V10, P3264; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHUGART L, 1972, EXP GERONTOL, V7, P251, DOI 10.1016/0531-5565(72)90015-0; SMITH C, 1985, BIOCHEMISTRY-US, V24, P1434, DOI 10.1021/bi00327a023; SMITH DWE, 1985, J BIOL CHEM, V260, P147; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; Stuart JW, 2003, J MOL BIOL, V334, P901, DOI 10.1016/j.jmb.2003.09.058; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; Taniguchi H, 1998, NUCLEIC ACIDS RES, V26, P1481, DOI 10.1093/nar/26.6.1481; VACHER J, 1984, J MOL BIOL, V177, P329, DOI 10.1016/0022-2836(84)90460-1; Van Lanen SG, 2005, P NATL ACAD SCI USA, V102, P4264, DOI 10.1073/pnas.0408056102; WIMMER E, 1968, BIOCHEMISTRY-US, V7, P2623, DOI 10.1021/bi00847a026; XUE H, 1993, J CHROMATOGR-BIOMED, V613, P247, DOI 10.1016/0378-4347(93)80139-U; Zhou SL, 2004, NUCLEOS NUCLEOT NUCL, V23, P41, DOI 10.1081/NCN-120027816; Zhou SL, 2004, BIOORG CHEM, V32, P82, DOI 10.1016/j.bioorg.2003.09.005	67	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37616	37622		10.1074/jbc.M506939200	http://dx.doi.org/10.1074/jbc.M506939200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16162496	hybrid			2022-12-25	WOS:000233044500038
J	Wei, QZ				Wei, QZ			Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated p53 degradation in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PITX2; ONCOPROTEIN; GENE; APOPTOSIS; TARGET; GROWTH; IMMORTALIZATION; UBIQUITINATION; IDENTIFICATION; SUPPRESSION	Binding of high risk human papillomavirus (HPV) E6 protein to E6-associated protein (E6AP), a cellular ubiquitin-protein ligase, enables E6AP to ubiquitinate p53, leading to p53 degradation in cervical cancer cells such as HeLa cells. Here we report that Pitx2a, a bicoid-type homeodomain transcription factor, can bind to HPV E6 protein and inhibit E6/E6AP-mediated p53 degradation. Deletion of the Pitx2a homeodomain abrogates its ability to bind to HPV E6 protein and to induce p53 accumulation in HeLa cells, suggesting that the homeodomain of Pitx2a is essential for inhibition of E6/E6AP-mediated p53 degradation. Recombinant Pitx2a can also block E6/E6AP-mediated p53 degradation in vitro, indicating that this function of Pitx2a is independent of its transcription activity. Pitx2a does not regulate Hdm2-mediated p53 degradation, because Pitx2a does not affect p53 protein levels in HPV-negative cells, such as HCT116, U2OS, and C33A cells. In addition, Pitx2a-induced p53 is transcriptionally active and maintains its specific DNA binding activity in HeLa cells. Taken together, these findings suggest that, by binding to E6, Pitx2a interferes with E6/E6AP-mediated p53 degradation, leading to the accumulation of functional p53 protein in HeLa cells.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	Kansas State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wei, QZ (corresponding author), Kansas State Univ, Dept Biochem, 103 Willard Hall, Manhattan, KS 66506 USA.	weiq@ksu.edu			NHLBI NIH HHS [K22 HL071542, K22 HL071542-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K22HL071542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez-Salas LM, 1999, ANTISENSE NUCLEIC A, V9, P441, DOI 10.1089/oli.1.1999.9.441; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Baek SH, 2003, P NATL ACAD SCI USA, V100, P3245, DOI 10.1073/pnas.0330217100; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cho CW, 2002, EXP MOL MED, V34, P159, DOI 10.1038/emm.2002.23; Clawson GA, 2004, GENE THER, V11, P1331, DOI 10.1038/sj.gt.3302303; Croce CM, 1999, CANCER RES, V59, p1778S; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gao QS, 1999, MOL CELL BIOL, V19, P733; Grm HS, 2004, J MOL BIOL, V335, P971, DOI 10.1016/j.jmb.2003.10.079; Hamada K, 1996, GYNECOL ONCOL, V63, P219, DOI 10.1006/gyno.1996.0310; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hjalt TA, 2000, DEV DYNAM, V218, P195, DOI 10.1002/(SICI)1097-0177(200005)218:1<195::AID-DVDY17>3.0.CO;2-C; Huibregtse JM, 1996, SEMIN CANCER BIOL, V7, P317, DOI 10.1006/scbi.1996.0041; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Martin DM, 2002, DEV BIOL, V252, P84, DOI 10.1006/dbio.2002.0835; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 2003, SEMIN CANCER BIOL, V13, P59, DOI 10.1016/S1044-579X(02)00100-1; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei Q, 2002, MOL BIOL CELL, V13, P683, DOI 10.1091/mbc.01-07-0358; Westmoreland JJ, 2001, J NEUROSCI, V21, P6810, DOI 10.1523/JNEUROSCI.21-17-06810.2001; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	50	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37790	37797		10.1074/jbc.M502974200	http://dx.doi.org/10.1074/jbc.M502974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16129685	hybrid, Green Accepted			2022-12-25	WOS:000233044500058
J	Regue, M; Izquierdo, L; Fresno, S; Jimenez, N; Pique, N; Corsaro, MM; Parrilli, M; Naldi, T; Merino, S; Tomas, JM				Regue, M; Izquierdo, L; Fresno, S; Jimenez, N; Pique, N; Corsaro, MM; Parrilli, M; Naldi, T; Merino, S; Tomas, JM			The incorporation of glucosamine into enterobacterial core lipopolysaccharide - Two enzymatic steps are required	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; STRUCTURAL-CHARACTERIZATION; REGION; GENE; OLIGOSACCHARIDE; POLYSACCHARIDE; IDENTIFICATION; BIOSYNTHESIS; EXPRESSION	The core lipopolysaccharide (LPS) of Klebsiella pneumoniae is characterized by the presence of disaccharide alpha GlcN-(1,4)- alpha GalA attached by an alpha 1,3 linkage to L-glycero-D-manno-heptopyranose II (LD-HeppII). Previously it has been shown that the WabH enzyme catalyzes the incorporation of GlcNAc from UDP-GlcNAc to outer core LPS. The presence of GlcNAc instead of GlcN and the lack of UDP-GlcN in bacteria indicate that an additional enzymatic step is required. In this work we identified a new gene (wabN) in the K. pneumoniae core LPS biosynthetic cluster. Chemical and structural analysis of K. pneumoniae non-polar wabN mutants showed truncated core LPS with GlcNAc instead of GlcN. In vitro assays using LPS truncated at the level of D-galacturonic acid ( GalA) and cell-free extract containing WabH and WabN together led to the incorporation of GlcN, whereas none of them alone were able to do it. This result suggests that the later enzyme ( WabN) catalyzes the deacetylation of the core LPS containing the GlcNAc residue. Thus, the incorporation of the GlcN residue to core LPS in K. pneumoniae requires two distinct enzymatic steps. WabN homologues are found in Serratia marcescens and some Proteus strains that show the same disaccharide alpha GlcN-( 1,4)-alpha GalA attached by an alpha 1,3 linkage to LD-HeppII.	Univ Barcelona, Fac Biol, Dept Microbiol, E-08071 Barcelona, Spain; Univ Barcelona, Fac Farm, Dept Microbiol & Parasitol Sanitarias, E-08028 Barcelona, Spain; Univ Naples Federico II, Complesso Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy	University of Barcelona; University of Barcelona; University of Naples Federico II	Tomas, JM (corresponding author), Univ Barcelona, Fac Biol, Dept Microbiol, Diagonal 645, E-08071 Barcelona, Spain.	jtomas@ub.edu	Merino, Susana/D-4342-2014; Tomas, Juan M/L-1398-2015; Corsaro, Maria Michela/T-6190-2019; Izquierdo, Luis/L-9291-2015	Merino, Susana/0000-0001-6040-4259; Tomas, Juan M/0000-0002-3575-7113; Corsaro, Maria Michela/0000-0002-6834-8682; Izquierdo, Luis/0000-0002-3704-9874; Pique, Nuria/0000-0002-7308-030X; Parrilli, Michelangelo/0000-0001-8858-3623; Jimenez, Natalia/0000-0002-7057-0426				CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Coderch N, 2004, J BACTERIOL, V186, P978, DOI 10.1128/JB.186.4.978-988.2004; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Frirdich E, 2004, J BIOL CHEM, V279, P27928, DOI 10.1074/jbc.M402549200; GABRIEL O, 1982, METHOD ENZYMOL, V83, P332; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hansen DS, 1998, J HOSP INFECT, V38, P119, DOI 10.1016/S0195-6701(98)90065-2; Hansen DS, 1999, J CLIN MICROBIOL, V37, P56, DOI 10.1128/JCM.37.1.56-62.1999; HERVAS JA, 1993, CLIN INFECT DIS, V16, P719, DOI 10.1093/clind/16.5.719; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Izquierdo L, 2003, J BACTERIOL, V185, P7213, DOI 10.1128/JB.185.24.7213-7221.2003; Izquierdo L, 2002, MICROBIOL-SGM, V148, P3485, DOI 10.1099/00221287-148-11-3485; Izquierdo L, 2002, FEMS MICROBIOL LETT, V216, P211, DOI 10.1016/S0378-1097(02)01027-3; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Long SR, 1996, PLANT CELL, V8, P1885, DOI 10.1105/tpc.8.10.1885; Miller J. H., 1972, EXPT MOL GENETICS, P433; NASSIF X, 1989, INFECT IMMUN, V57, P546, DOI 10.1128/IAI.57.2.546-552.1989; Olsthoorn MMA, 1999, J MASS SPECTROM, V34, P622, DOI 10.1002/(SICI)1096-9888(199906)34:6<622::AID-JMS814>3.3.CO;2-M; ORSKOV I, 1984, METHOD MICROBIOL, V14, P143, DOI 10.1016/S0580-9517(08)70449-5; PRADEL E, 1991, J BACTERIOL, V173, P6428, DOI 10.1128/jb.173.20.6428-6431.1991; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Regue M, 2005, J BACTERIOL, V187, P4198, DOI 10.1128/JB.187.12.4198-4206.2005; Regue M, 2001, J BACTERIOL, V183, P3564, DOI 10.1128/JB.183.12.3564-3573.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vinogradov E, 2002, AUST J CHEM, V55, P61, DOI 10.1071/CH01184; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Vinogradov E, 2001, EUR J BIOCHEM, V268, P1722; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030	36	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36648	36656		10.1074/jbc.M506278200	http://dx.doi.org/10.1074/jbc.M506278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16131489	hybrid			2022-12-25	WOS:000232901800016
J	Chuang, LC; Zhu, XN; Herrera, CR; Tseng, HM; Pfleger, CM; Block, K; Yew, PR				Chuang, LC; Zhu, XN; Herrera, CR; Tseng, HM; Pfleger, CM; Block, K; Yew, PR			The C-terminal domain of the Xenopus cyclin-dependent kinase inhibitor, p27(Xic1), is both necessary and sufficient for phosphorylation-independent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITOR; MEDIATED DEGRADATION; DNA-REPLICATION; S-PHASE; UBIQUITINATION; COMPLEX; P27(KIP1); CDC34; DIFFERENTIATION; PROMOTES	Cell cycle progression is regulated by cyclin-dependent kinases (CDKs), cyclins, and CDK inhibitors. In the frog, Xenopus laevis, the CDK inhibitor p27(Xic1) (Xic1) inhibits DNA synthesis by negatively regulating CDK2-cyclin E. Using the frog egg extract as a model system for the study of Xic1, studies have demonstrated that Xic1 protein levels are regulated by nuclear ubiquitination and proteolysis. To characterize the molecular mechanism that regulates Xic1 turnover, we have identified the minimal sequences of Xic1 that are necessary and sufficient for its nuclear ubiquitination and degradation. Using deletion mutagenesis, our studies indicated that the C-terminal 50 amino acids of Xic1 are critical for its proteolysis beyond a role in nuclear transport. Replacement of the Xic1 C terminus with the SV40 nuclear localization sequence resulted in the nuclear localization of Xic1 but not its ubiquitination or degradation. Our deletion studies also indicated that the CDK2-cyclin binding domain of Xic1 is important for its efficient retention in the nucleus. Further deletion analyses identified at least 3 lysine residues within the Xic1 C terminus that are targeted for specific ubiquitination. Importantly, our studies demonstrated that the Xic1 C-terminal 50 amino acids can serve as a nuclear degradation signal when fused to a stable heterologous nuclear protein. Moreover, a 30-amino-acid region within the C terminus of Xic1 can serve as a nuclear ubiquitination signal. To address the role of phosphorylation on Xic1 turnover, all the potential phosphorylation sites within the C-terminal 50 amino acids of Xic1 were mutated to alanine to prevent possible phosphorylation. This resulted in a Xic1 protein that was nevertheless degraded in a manner similar to wild-type Xic1, suggesting that phosphorylation of Xic1 is not critical for its nuclear ubiquitination or proteolysis.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Berkeley	Yew, PR (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.	yew@uthscsa.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066226] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01-GM066226] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Chuang LC, 2001, J BIOL CHEM, V276, P1610, DOI 10.1074/jbc.M008896200; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Leclerc V, 1996, Prog Cell Cycle Res, V2, P197; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vernon AE, 2003, DEVELOPMENT, V130, P71, DOI 10.1242/dev.00180; Vernon AE, 2003, DEVELOPMENT, V130, P85, DOI 10.1242/dev.00193; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; You ZS, 2002, GENE DEV, V16, P1182, DOI 10.1101/gad.985302; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	35	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35290	35298		10.1074/jbc.M506430200	http://dx.doi.org/10.1074/jbc.M506430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16118210	hybrid			2022-12-25	WOS:000232561200027
J	Roccio, M; Bos, JL; Zwartkruis, FJT				Roccio, M; Bos, JL; Zwartkruis, FJT			Regulation of the small GTPase Rheb by amino acids	ONCOGENE			English	Article						Rheb; mTOR; S6 kinase	TUBEROUS SCLEROSIS COMPLEX-1; TUMOR-SUPPRESSOR PROTEINS; TOP MESSENGER-RNAS; P70 S6 KINASE; CELL-GROWTH; MAMMALIAN TARGET; GENE-PRODUCTS; RPS6 PHOSPHORYLATION; RAPAMYCIN; MTOR	The mTOR/S6K/4E-BP1 pathway integrates extracellular signals derived from growth factors, and intracellular signals, determined by the availability of nutrients like amino acids and glucose. Activation of this pathway requires inhibition of the tumor suppressor complex TSC1/2. TSC2 is a GTPase-activating protein for the small GTPase Ras homologue enriched in brain ( Rheb), GTP loading of which activates mTOR by a yet unidentified mechanism. The level at which this pathway senses the availability of amino acids is unknown but is suggested to be at the level of TSC2. Here, we show that amino-acid depletion completely blocks insulin- and TPA-induced Rheb activation. This indicates that amino-acid sensing occurs upstream of Rheb. Despite this, amino-acid depletion can still inhibit mTOR/S6 kinase signaling in TSC2(-/-). broblasts. Since under these conditions Rheb-GTP levels remain high, a second level of amino-acid sensing exists, affecting mTOR activity in a Rhebin-dependent fashion.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University	Zwartkruis, FJT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	g.j.t.zwartkruis@med.uu.nl		Roccio, Marta/0000-0001-7568-9429				Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Grammer TC, 1996, CANCER SURV, V27, P271; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richardson CJ, 2004, CURR BIOL, V14, P1540, DOI 10.1016/j.cub.2004.08.061; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	39	114	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					657	664		10.1038/sj.onc.1209106	http://dx.doi.org/10.1038/sj.onc.1209106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16170341				2022-12-25	WOS:000235068800001
J	Li, X; Luwor, R; Lu, Y; Liang, K; Fan, Z				Li, X; Luwor, R; Lu, Y; Liang, K; Fan, Z			Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells	ONCOGENE			English	Article						EGF receptor inhibitors; alkylphospholipids; PTEN; Akt; targeted therapy	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; NEGATIVE REGULATION; PROSTATE-CANCER; SOLID TUMORS; PHASE-II; PATHWAY; MILTEFOSINE	Mutational inactivation or deletion of the phosphatase and tensin homologue deleted on chromosome 10 ( PTEN)/MMAC1/TEP gene in human cancer cells leads to a constitutively active status of the phosphatidylinositol 3-kinase/Akt pathway in the cells and has been linked to the lack of responses of the cells to the epidermal growth factor (EGF) receptor-targeted therapeutics. Akt is strongly inhibited by perifosine, an orally active alkyl-lysophospholipid currently being evaluated as an anticancer agent in phase 1 and 2 clinical trials. To determine whether perifosine may enhance the antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/ C225 in PTEN-deficient cancer cells, we exposed MDA468 breast cancer cells ( which contain mutated PTEN gene) and PC3 prostate cancer cells ( in which the PTEN gene is deleted) to perifosine and cetuximab, alone and in combination. Treatment of the cells with perifosine reduced baseline levels of phosphorylated Akt, phosphorylated p44/42 mitogen-activated protein kinase ( MAPK) and p38MAPK, and increased baseline levels of phosphorylated stress-activated protein kinase ( SAPK)/c-jun NH2-terminal kinase (JNK). A 72-h exposure of the MDA468 and PC3 cells to perifosine alone resulted in cell death in a dose-dependent manner, which was enhanced by cetuximab. Addition of subtoxic doses of perifosine to cetuximab treatment also enhanced the cetuximabinduced growth inhibition. The combination treatment enhanced the inhibition of phosphorylation of Akt, p44/ 42MAPK and p38MAPK, but offset the phosphorylation of SAPK/JNK that was activated by perifosine treatment alone. Taken together, the data showed that perifosine enhances the antitumor activity of cetuximab in PTEN deficient cancer cells. Further evaluation of the combination treatment in preclinical and clinical studies is warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zfan@mdanderson.org		Luwor, Rodney/0000-0002-3020-4245				Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Clive S, 1997, LANCET, V349, P621, DOI 10.1016/S0140-6736(05)61570-X; Clive S, 1999, CANCER CHEMOTH PHARM, V44, pS29, DOI 10.1007/s002800051114; Crul M, 2002, EUR J CANCER, V38, P1615, DOI 10.1016/S0959-8049(02)00127-2; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; DUMMER R, 1992, PROG EXP TUMOR RES, V34, P160; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; HILGARD P, 1993, CANCER CHEMOTH PHARM, V32, P90, DOI 10.1007/BF00685608; Hilgard P, 1997, EUR J CANCER, V33, P442; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kondapaka SB, 2003, MOL CANCER THER, V2, P1093; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liang K, 2003, MOL CANCER THER, V2, P1113; Liu B, 2000, BRIT J CANCER, V82, P1991; Lu Yiling, 2003, Rev Clin Exp Hematol, V7, P205; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011; Ruiter GA, 2002, INT J CANCER, V102, P343, DOI 10.1002/ijc.10741; Ruiter GA, 1999, CANCER RES, V59, P2457; She QB, 2003, CLIN CANCER RES, V9, P4340; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Teng DHF, 1997, CANCER RES, V57, P5221; Terwogt JMM, 1999, BRIT J CANCER, V79, P1158, DOI 10.1038/sj.bjc.6690184; UNGER C, 1992, PROG EXP TUMOR RES, V34, P153; Van Ummersen L, 2004, CLIN CANCER RES, V10, P7450, DOI 10.1158/1078-0432.CCR-03-0406; VERWEIJ J, 1992, J CANCER RES CLIN, V118, P606, DOI 10.1007/BF01211805; VERWEIJ J, 1993, EUR J CANCER, V29A, P778, DOI 10.1016/S0959-8049(05)80369-7; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhou X, 1996, J CLIN INVEST, V98, P937, DOI 10.1172/JCI118877	48	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					525	535		10.1038/sj.onc.1209075	http://dx.doi.org/10.1038/sj.onc.1209075			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170346				2022-12-25	WOS:000234897400004
J	Sakai, M; Shimokawa, T; Kobayashi, T; Matsushima, S; Yamada, Y; Nakamura, Y; Furukawa, Y				Sakai, M; Shimokawa, T; Kobayashi, T; Matsushima, S; Yamada, Y; Nakamura, Y; Furukawa, Y			Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor	ONCOGENE			English	Article						colon; cancer; C10orf3; TSG101	GENOME-WIDE ANALYSIS; METASTATIC COLORECTAL-CANCER; GENE-EXPRESSION; TSG101 PROTEIN; BREAST-CANCER; CDNA MICROARRAY; CELL-GROWTH; PROFILES; CARCINOGENESIS; IDENTIFICATION	After analysing gene-expression profiles of colon cancers on a cDNA microarray containing cDNAs corresponding to 23 040 human genes, we focused on a gene annotated as C10orf3 ( chromosome 10 open reading frame 3), whose expression was elevated in colorectal cancers (CRC) as well as in tumors arising in the stomach, lung, pancreas, and breast. The gene encodes a putative 464-amino-acid protein containing a domain known as AAA ( ATPases associated witha variety of cellular activities). Western blot analysis using an antibody to the gene product confirmed that the protein was overexpressed in nine of the 15 clinical cancer tissues examined, compared to corresponding noncancerous epithelial cells. A subsequent proteomics analysis revealed that C10orf3 product associated with the product of tumor susceptibility gene 101 (TSG101), and that C10orf3 downregulated TSG101 in a post-transcriptional manner. Expression of short interfering RNA in cells derived from CRC caused significant decreases in C10orf3 expression and inhibited growth of the transfected cells, which was associated with increased apoptotic cells. These data suggest that elevated C10orf3 expression might play an essential role in the growth of cancer cells, and that suppression of C10orf3-mediated signal transduction may be a novel therapeutic strategy to a wide range of human tumors.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, Tokyo 1088639, Japan; Yokohama City Univ, Sch Med, Dept Anesthesiol, Kanagawa, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,, Tokyo 1088639, Japan	University of Tokyo; Yokohama City University; University of Tokyo	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp	Sakai, Michihiro/B-8755-2011; Shimokawa, Takashi/AAA-5870-2020	Shimokawa, Takashi/0000-0001-6549-9277				Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gridelli C, 2003, ONCOGENE, V22, P6629, DOI 10.1038/sj.onc.1206957; Hasegawa S, 2002, CANCER RES, V62, P7012; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Molina MA, 2001, CANCER RES, V61, P4744; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Neuwald AF, 1999, GENOME RES, V9, P27; Nishidate T, 2004, INT J ONCOL, V25, P797; O'Dwyer ME, 2000, CURR OPIN ONCOL, V12, P594, DOI 10.1097/00001622-200011000-00013; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Okabe H, 2001, CANCER RES, V61, P2129; Okabe H, 2003, CANCER RES, V63, P3043; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Shimokawa T, 2003, CANCER RES, V63, P6116; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Walt G, 2004, BRIT MED J, V328, P6, DOI 10.1136/bmj.328.7430.6; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1998, CANCER RES, V58, P2699; Zhu G, 2004, INT J CANCER, V109, P541, DOI 10.1002/ijc.20014	27	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					480	486		10.1038/sj.onc.1209051	http://dx.doi.org/10.1038/sj.onc.1209051			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170351				2022-12-25	WOS:000234714100016
J	Coffa, G; Imber, AN; Maguire, BC; Laxmikanthan, G; Schneider, C; Gaffney, BJ; Brash, AR				Coffa, G; Imber, AN; Maguire, BC; Laxmikanthan, G; Schneider, C; Gaffney, BJ; Brash, AR			On the relationships of substrate orientation, hydrogen abstraction, and product stereochemistry in single and double dioxygenations by soybean lipoxygenase-1 and its Ala542Gly mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ARACHIDONIC-ACID; LINOLEIC-ACID; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; OXYGENATION; BINDING; CATALYSIS; 15-LIPOXYGENASE; CYCLOOXYGENASE	Recent findings associate the control of stereochemistry in lipoxygenase (LOX) catalysis with a conserved active site alanine for S configuration hydroperoxide products, or a corresponding glycine for R stereoconfiguration. To further elucidate the mechanistic basis for this stereocontrol we compared the stereoselectivity of the initiating hydrogen abstraction in soybean LOX-1 and an Ala542Gly mutant that converts linoleic acid to both 13S and 9R configuration hydroperoxide products. Using 11R- H-3-and 11S-H-3-labeled linoleic acid substrates to examine the initial hydrogen abstraction, we found that all the primary hydroperoxide products were formed with an identical and highly stereoselective pro-S hydrogen abstraction from C-11 of the substrate ( 97 - 99% pro-S-selective). This strongly suggests that 9R and 13S oxygenations occur with the same binding orientation of substrate in the active site, and as the equivalent 9R and 13S products were formed from a bulky ester derivative (1-palmitoyl-2-linoleoylphosphatidylcholine), one can infer that the orientation is tail-first. Both the EPR spectrum and the reaction kinetics were altered by the R product-inducing Ala-Gly mutation, indicating a substantial influence of this Ala-Gly substitution extending to the environment of the active site iron. To examine also the reversed orientation of substrate binding, we studied oxygenation of the 15S-hydroperoxide of arachidonic acid by the Ala542Gly mutant soybean LOX-1. In addition to the usual 5S, 15S- and 8S, 15S-dihydroperoxides, a new product was formed and identified by high-performance liquid chromatography, UV, gas chromatography-mass spectrometry, and NMR as 9R, 15S-dihydroperoxyeicosa5Z, 7E, 11Z, 13E-tetraenoic acid, the R configuration "partner" of the normal 5S, 15S product. This provides evidence that both tail-first and carboxylate end-first binding of substrate can be associated with S or R partnerships in product formation in the same active site.	Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Florida State Univ, Inst Mol Biophys, Dept Chem & Biochem, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; Vanderbilt University; State University System of Florida; Florida State University	Gaffney, BJ (corresponding author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.	gaffney@bio.fsu.edu; alan.brash@vanderbilt.edu	Gaffney, Betty J/C-9666-2015; Laxmikanthan, Gurunathan/D-1049-2012	Coffa, Gianguido/0000-0002-7959-3034	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065268, R01GM053638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65268, GM53638, R01 GM065268, R01 GM053638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILD GS, 1977, BIOCHEM BIOPH RES CO, V74, P949, DOI 10.1016/0006-291X(77)91610-2; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; Butovich IA, 2001, BBA-PROTEIN STRUCT M, V1546, P379, DOI 10.1016/S0167-4838(01)00162-5; Capdevila JH, 2002, PROSTAG OTH LIPID M, V68-9, P325, DOI 10.1016/S0090-6980(02)00038-2; Coffa G, 2004, P NATL ACAD SCI USA, V101, P15579, DOI 10.1073/pnas.0406727101; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; de Montellano PRO, 2002, NAT PROD REP, V19, P477, DOI 10.1039/b101297p; EGMOND MR, 1972, BIOCHEM BIOPH RES CO, V48, P1055, DOI 10.1016/0006-291X(72)90815-7; EGMOND MR, 1973, BIOCHEM BIOPH RES CO, V54, P1178, DOI 10.1016/0006-291X(73)90816-4; GAFFNEY BJ, 1993, BIOPHYS J, V64, P773, DOI 10.1016/S0006-3495(93)81438-3; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILMOR SA, 1997, NAT STRUCT BIOL, V4, P1003; Glickman MH, 1996, BIOCHEMISTRY-US, V35, P12882, DOI 10.1021/bi960985q; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1980, BIOCHIM BIOPHYS ACTA, V617, P545, DOI 10.1016/0005-2760(80)90022-3; Hughes RK, 2001, EUR J BIOCHEM, V268, P1030, DOI 10.1046/j.1432-1327.2001.01964.x; Knapp MJ, 2003, BIOCHEMISTRY-US, V42, P11466, DOI 10.1021/bi0300884; Knapp MJ, 2001, J AM CHEM SOC, V123, P2931, DOI 10.1021/ja003855k; Kurumbail RG, 2001, CURR OPIN STRUC BIOL, V11, P752, DOI 10.1016/S0959-440X(01)00277-9; MAGUIRE BC, 1999, THESIS J HOPKINS U B, P117; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Milne GL, 2001, LIPIDS, V36, P1265, DOI 10.1007/s11745-001-0841-2; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Prigge ST, 1996, PROTEINS, V24, P275; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; Ruddat VC, 2004, BIOCHEMISTRY-US, V43, P13063, DOI 10.1021/bi0489098; Schenk G, 2003, BIOCHEMISTRY-US, V42, P7294, DOI 10.1021/bi027380g; SCHILSTRA MJ, 1992, BIOCHEMISTRY-US, V31, P7692, DOI 10.1021/bi00148a033; Schneider C, 2000, ANAL BIOCHEM, V284, P125, DOI 10.1006/abio.2000.4670; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Schwarz K, 1998, BIOCHEMISTRY-US, V37, P15327, DOI 10.1021/bi9816204; Skrzypczak-Jankun E, 2001, J AM CHEM SOC, V123, P10814, DOI 10.1021/ja011759t; SMITH WL, 1972, J BIOL CHEM, V247, P1038; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tomchick DR, 2001, BIOCHEMISTRY-US, V40, P7509, DOI 10.1021/bi002893d; van Zadelhoff G, 1998, BIOCHEM BIOPH RES CO, V248, P33, DOI 10.1006/bbrc.1998.8910; VANDERHEIJDT LM, 1995, EUR J BIOCHEM, V231, P186, DOI 10.1111/j.1432-1033.1995.tb20685.x; VANOS CPA, 1979, BIOCHIM BIOPHYS ACTA, V575, P479, DOI 10.1016/0005-2760(79)90120-6; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; Walther M, 2001, CHEM BIOL, V8, P779, DOI 10.1016/S1074-5521(01)00050-3	46	54	57	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38756	38766		10.1074/jbc.M504870200	http://dx.doi.org/10.1074/jbc.M504870200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16157595	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000233239800077
J	Yagi, H; Kusaka, E; Hongo, K; Mizobata, T; Kawata, Y				Yagi, H; Kusaka, E; Hongo, K; Mizobata, T; Kawata, Y			Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins - Implications for the mechanism of transmissible conformational diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; PARKINSONS-DISEASE; IN-VITRO; NEURODEGENERATIVE DISORDERS; INHIBITS FIBRILLATION; ALZHEIMERS-DISEASE; PRION TRANSMISSION; LEWY BODIES; BETA; AGGREGATION	alpha-Synuclein is one of the causative proteins of familial Parkinson disease, which is characterized by neuronal inclusions named Lewy bodies. Lewy bodies include not only alpha-synuclein but also aggregates of other proteins. This fact raises a question as to whether the formation of alpha-synuclein amyloid fibrils in Lewy bodies may occur via interaction with fibrils derived from different proteins. To probe this hypothesis, we investigated in vitro fibril formation of human alpha-synuclein in the presence of preformed fibril seeds of various different proteins. We used three proteins, Escherichia coli chaperonin GroES, hen lysozyme, and bovine insulin, all of which have been shown to form amyloid fibrils. Very surprisingly, the formation of alpha-synuclein amyloid fibril was accelerated markedly in the presence of preformed seeds of GroES, lysozyme, and insulin fibrils. The structural characteristics of the natively unfolded state of alpha-synuclein may allow binding to various protein particles, which in turn triggers the formation (extension) of alpha-synuclein amyloid fibrils. This finding is very important for understanding the molecular mechanism of Parkinson disease and also provides interesting implications into the mechanism of transmissible conformational diseases.	Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6808552, Japan; Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct, Tottori 6808552, Japan	Tottori University; Tottori University	Kawata, Y (corresponding author), Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6808552, Japan.	kawata@bio.tottori-u.ac.jp	Kawata, Yasushi/ABA-9608-2021; Mizobata, Tomohiro/V-6672-2019	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				Ahmad A, 2004, J BIOL CHEM, V279, P14999, DOI 10.1074/jbc.M313134200; Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; Bernstein SL, 2004, J AM SOC MASS SPECTR, V15, P1435, DOI 10.1016/j.jasms.2004.05.003; Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Chatani E, 2005, J MOL BIOL, V352, P941, DOI 10.1016/j.jmb.2005.07.043; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Forman MS, 2002, AM J PATHOL, V160, P1725, DOI 10.1016/S0002-9440(10)61119-4; Fu XY, 2004, FEBS LETT, V563, P179, DOI 10.1016/S0014-5793(04)00295-9; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; Glatter O., 1982, SMALL ANGLE X RAY SC; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Hardy J, 2003, J MOL NEUROSCI, V20, P203, DOI 10.1385/JMN:20:2:203; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HIGUCHI K, 1986, J BIOL CHEM, V261, P2834; Higurashi T, 2005, J MOL BIOL, V351, P1057, DOI 10.1016/j.jmb.2005.07.006; Hoyer W, 2004, BIOCHEMISTRY-US, V43, P16233, DOI 10.1021/bi048453u; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Inoue Y, 2001, J BIOL CHEM, V276, P35227, DOI 10.1074/jbc.C100304200; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; Kihara M, 2005, J BIOL CHEM, V280, P12012, DOI 10.1074/jbc.M411949200; Krebs MRH, 2000, J MOL BIOL, V300, P541, DOI 10.1006/jmbi.2000.3862; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Li J, 2002, NEUROTOXICOLOGY, V23, P553, DOI 10.1016/S0161-813X(02)00066-9; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Lundmark K, 2005, P NATL ACAD SCI USA, V102, P6098, DOI 10.1073/pnas.0501814102; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; O'Nuallain B, 2004, J BIOL CHEM, V279, P17490, DOI 10.1074/jbc.M311300200; Ohnishi S, 2004, CELL MOL LIFE SCI, V61, P511, DOI 10.1007/s00018-003-3264-8; Pallitto MM, 2001, BIOPHYS J, V81, P1805, DOI 10.1016/S0006-3495(01)75831-6; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Shastry BS, 2003, NEUROCHEM INT, V43, P1, DOI 10.1016/S0197-0186(02)00196-1; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wirths O, 2003, PROG NEURO-PSYCHOPH, V27, P103, DOI 10.1016/S0278-5846(02)00339-1; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x	70	80	82	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38609	38616		10.1074/jbc.M508623200	http://dx.doi.org/10.1074/jbc.M508623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16162499	hybrid			2022-12-25	WOS:000233239800061
J	Buratti, E; Brindisi, A; Giombi, M; Tisminetzky, S; Ayala, YM; Baralle, FE				Buratti, E; Brindisi, A; Giombi, M; Tisminetzky, S; Ayala, YM; Baralle, FE			TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail - An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP A1; IN-VIVO; FUNCTIONAL IMPLICATIONS; RESPONSE ELEMENT; SR PROTEINS; GENE; SITES; SPECIFICITY; DIVERSITY	TDP-43 is a highly conserved nuclear factor of yet unknown function that binds to ug-repeated sequences and is responsible for cystic fibrosis transmembrane conductance regulator exon 9 splicing inhibition. We have analyzed TDP-43 interactions with other splicing factors and identified the critical regions for the protein/protein recognition events that determine this biological function. We show here that the C-terminal region of TDP-43 is capable of binding directly to several proteins of the heterogeneous nuclear ribonucleoprotein ( hnRNP) family with well known splicing inhibitory activity, in particular, hnRNPA2/ B1 and hnRNPA1. Mutational analysis showed that TDP-43 proteins lacking the C-terminal region could not inhibit splicing probably because they were unable to form the hnRNP-rich complex involved in splicing inhibition. Finally, through splicing complex analysis, we show that splicing inhibition mediated by TDP-43 occurs at the earliest stages of spliceosomal assembly.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	baralle@icgeb.org	Buratti, Emanuele/K-4691-2016	Buratti, Emanuele/0000-0002-1356-9074	Telethon [GGP02453] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams DJ, 2001, J CELL BIOL, V154, P25, DOI 10.1083/jcb.200010059; Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Anyanful A, 2004, J CELL BIOL, V167, P639, DOI 10.1083/jcb.200407085; Arrisi-Mercado P, 2004, J BIOL CHEM, V279, P39331, DOI 10.1074/jbc.M405566200; Ayala YM, 2005, J MOL BIOL, V348, P575, DOI 10.1016/j.jmb.2005.02.038; Bilbao D, 2003, NAT STRUCT BIOL, V10, P6, DOI 10.1038/nsb0103-6; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Boue S, 2003, BIOESSAYS, V25, P1031, DOI 10.1002/bies.10371; Bourgeois CF, 2004, PROG NUCLEIC ACID RE, V78, P37, DOI 10.1016/S0079-6603(04)78002-2; Brasier AR, 2004, J VIROL, V78, P11461, DOI 10.1128/JVI.78.21.11461-11476.2004; Buratti E, 2004, NUCLEIC ACIDS RES, V32, P4224, DOI 10.1093/nar/gkh752; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Buratti E, 2004, AM J HUM GENET, V74, P1322, DOI 10.1086/420978; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; Buratti E, 2004, MOL CELL BIOL, V24, P1387, DOI 10.1128/MCB.24.3.1387-1400.2004; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Burge CB, 1999, RNA WORLD, P525; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Canadillas JMP, 2003, EMBO J, V22, P2821, DOI 10.1093/emboj/cdg259; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Chabot B, 2003, Prog Mol Subcell Biol, V31, P59; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Disset A, 2005, HUM MUTAT, V25, P72, DOI 10.1002/humu.20115; Domsic JK, 2003, MOL CELL BIOL, V23, P8762, DOI 10.1128/MCB.23.23.8762-8772.2003; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; Faustino NA, 2005, MOL CELL BIOL, V25, P879, DOI 10.1128/MCB.25.3.879-887.2005; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Gabellini N, 2001, EUR J BIOCHEM, V268, P1076, DOI 10.1046/j.1432-1327.2001.01974.x; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Georgi AB, 2002, CURR BIOL, V12, P105, DOI 10.1016/S0960-9822(01)00662-5; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Groman JD, 2004, AM J HUM GENET, V74, P176, DOI 10.1086/381001; Hahm B, 1998, FEBS LETT, V425, P401, DOI 10.1016/S0014-5793(98)00269-5; Hefferon TW, 2004, P NATL ACAD SCI USA, V101, P3504, DOI 10.1073/pnas.0400182101; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; Hui JY, 2003, NAT STRUCT BIOL, V10, P33, DOI 10.1038/nsb875; Hutchison S, 2002, J BIOL CHEM, V277, P29745, DOI 10.1074/jbc.M203633200; Ibrahim EC, 2005, P NATL ACAD SCI USA, V102, P5002, DOI 10.1073/pnas.0500543102; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; KRAINER AR, 1997, FRONTIERS MOL BIOL E; Kreahling J, 2004, TRENDS GENET, V20, P1, DOI 10.1016/j.tig.2003.11.001; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Lareau LF, 2004, CURR OPIN STRUC BIOL, V14, P273, DOI 10.1016/j.sbi.2004.05.002; Ma ASW, 2002, J BIOL CHEM, V277, P18010, DOI 10.1074/jbc.M200050200; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Nasim FUH, 2002, RNA, V8, P1078, DOI 10.1017/S1355838202024056; Niedziela-Majka A, 1998, PROTEIN EXPRES PURIF, V14, P208, DOI 10.1006/prep.1998.0932; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Nissim-Rafinia M, 2000, HUM MOL GENET, V9, P1771, DOI 10.1093/hmg/9.12.1771; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Pagani F, 2004, NAT REV GENET, V5, P389, DOI 10.1038/nrg1327; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Shen HH, 2004, MOL CELL, V13, P367, DOI 10.1016/S1097-2765(04)00025-5; Shen HH, 2004, MOL CELL, V16, P363, DOI 10.1016/j.molcel.2004.10.021; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Takahashi N, 2000, BIOCHEM BIOPH RES CO, V277, P518, DOI 10.1006/bbrc.2000.3694; Tange TO, 2001, EMBO J, V20, P5748; Vandenbroucke I, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-13; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang HY, 2004, GENOMICS, V83, P130, DOI 10.1016/S0888-7543(03)00214-3; Wang IF, 2002, P NATL ACAD SCI USA, V99, P13583, DOI 10.1073/pnas.212483099; Yeo G, 2004, P NATL ACAD SCI USA, V101, P15700, DOI 10.1073/pnas.0404901101; Zhao B, 2004, EUKARYOT CELL, V3, P815, DOI 10.1128/EC.3.3.815-825.2004; Zheng ZM, 2004, J BIOMED SCI, V11, P278, DOI 10.1159/000077096; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; Zuccato E, 2004, J BIOL CHEM, V279, P16980, DOI 10.1074/jbc.M313439200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	86	347	354	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37572	37584		10.1074/jbc.M505557200	http://dx.doi.org/10.1074/jbc.M505557200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157593	hybrid			2022-12-25	WOS:000233044500034
J	Jank, T; Reinert, DJ; Giesemann, T; Schulz, GE; Aktories, K				Jank, T; Reinert, DJ; Giesemann, T; Schulz, GE; Aktories, K			Change of the donor substrate specificity of Clostridium difficile toxin B by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; NOVYI ALPHA-TOXIN; CATALYTIC DOMAIN; STRUCTURAL BASIS; RHO-PROTEINS; GLUCOSYLATION; GLYCOSYLTRANSFERASES; CYTOTOXINS; CELLS; RAS	The large cytotoxins of Clostridia species glycosylate and thereby inactivate small GTPases of the Rho family. Clostridium difficile toxins A and B and Clostridium sordellii lethal toxin use UDP-glucose as the donor for glucosylation of Rho/Ras GTPases. In contrast, alpha-toxin from Clostridium novyi N-acetylglucosaminylates Rho GTPases by using UDP-N-acetylglucosamine as a donor substrate. Based on the crystal structure of C. difficile toxin B, we studied the sugar donor specificity of the toxins by site-directed mutagenesis. The changing of Ile-383 and Gln-385 in toxin B to serine and alanine, respectively, largely increased the acceptance of UDP-N-acetylglucosamine as a sugar donor for modification of RhoA. The Km value was reduced from 960 to 26 mu M for the double mutant. Accordingly, the potential of the double mutant of toxin B to hydrolyze UDP-N-acetylglucosamine was higher than that for UDP-glucose. The changing of Ile-383 and Gln-385 in the lethal toxin of C. sordellii allowed modification of Ras in the presence of UDP-N-acetylglucosamine and reduced the acceptance of UDP-glucose as a donor for glycosylation. Vice versa, the changing of the equivalent residues in C. novyi alpha-toxin from Ser-385 and Ala-387 to isoleucine and glutamine, respectively, reversed the donor specificity of the toxin from UDP-N-acetylglucosamine to UDP-glucose. These data demonstrate that two amino acid residues are crucial for the co-substrate specificity of clostridial glycosylating toxins.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Otto Krayer Haus,Albertstr 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022; Jank, Thomas/R-9627-2017	Aktories, Klaus/0000-0002-5397-0436; 				Bartlett John G., 1995, P893; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busch C, 2000, INFECT IMMUN, V68, P6378, DOI 10.1128/IAI.68.11.6378-6383.2000; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Hofmann F, 1997, J BIOL CHEM, V272, P11074; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pfeifer G, 2003, J BIOL CHEM, V278, P44535, DOI 10.1074/jbc.M307540200; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Reinert DJ, 2005, J MOL BIOL, V351, P973, DOI 10.1016/j.jmb.2005.06.071; Rupnik M, 2005, MICROBIOL-SGM, V151, P199, DOI 10.1099/mic.0.27474-0; Schirmer J, 2004, BBA-GEN SUBJECTS, V1673, P66, DOI 10.1016/j.bbagen.2004.03.014; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VONEICHELSTREIBER C, 1992, J BACTERIOL, V174, P6707, DOI 10.1128/JB.174.20.6707-6710.1992; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5	22	32	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37833	37838		10.1074/jbc.M506836200	http://dx.doi.org/10.1074/jbc.M506836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16157585	hybrid			2022-12-25	WOS:000233044500063
J	Jeyaraj, S; Dakhlallah, D; Hill, SR; Lee, BS				Jeyaraj, S; Dakhlallah, D; Hill, SR; Lee, BS			HuR stabilizes vacuolar H+-translocating ATPase mRNA during cellular energy depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; ACTIVATED PROTEIN-KINASE; CYTOPLASMIC SHUTTLING PROTEIN; RENAL TUBULAR-ACIDOSIS; BINDING PROTEIN; YEAST VACUOLAR; ELAV PROTEIN; PROTON PUMP; IN-VIVO; 3'-UNTRANSLATED REGION	V-ATPases are multisubunit membrane proteins that use ATP binding and hydrolysis to transport protons across membranes against a concentration gradient. Although some cell types express plasma membrane forms of these transporters, all eukaryotes require V-ATPases to maintain an acidic pH in membrane-bound compartments of endocytic and secretory networks to facilitate protein trafficking and processing. Mammalian cells that completely lack V-ATPases are not viable; yet, the abundance of V-ATPases can differ among cell types by an order of magnitude or more, requiring precise control of their expression. We previously showed that mRNA stability appears to play a major role in regulating overall abundance of V-ATPases. In this report, we demonstrate that the stability of V-ATPase mRNA is regulated through AU-rich elements in 3'-untranslated regions. Unlike some mRNAs that are short-lived due to the presence of these elements, V-ATPase mRNAs have half-lives of hours to days. However, during stress induced by ATP depletion, AU-rich elements are necessary to maintain stability of these transcripts and their presence in the cytoplasm. HuR, an RNA-binding protein that interacts with and stabilizes AU-rich mRNAs, shows increased binding to some V-ATPase mRNAs during ATP depletion. siRNA-mediated knockdown of HuR results in diminished V-ATPase expression. These results indicate that AU-rich elements and associated proteins can play a role in regulation of even very stable mRNAs by protecting against loss during cellular stress.	Ohio State Univ, Dept Physiol & Cell Biol, Coll Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Lee, BS (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, Coll Med, 302 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	lee.2076@osu.edu	Lee, Beth S/E-9578-2010; dakhlallah, Duaa/C-1279-2014	Lee, Beth S/0000-0002-1468-6387; Dakhlallah, Duaa A/0000-0002-6288-4927	NIDDK NIH HHS [DK52131, R01 DK052131-10, R01 DK052131-08, R01 DK052131, R01 DK052131-09, R01 DK052131-07A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; Atasoy U, 1998, J CELL SCI, V111, P3145; Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Breton S, 1999, HISTOCHEM CELL BIOL, V111, P97, DOI 10.1007/s004180050339; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen J, 2001, AM J PHYSIOL-RENAL, V280, pF619, DOI 10.1152/ajprenal.2001.280.4.F619; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FISH EM, 1994, AM J PHYSIOL-RENAL, V267, pF566, DOI 10.1152/ajprenal.1994.267.4.F566; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Fraser S, 2005, AM J PHYSIOL-RENAL, V288, pF578, DOI 10.1152/ajprenal.00190.2004; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; Gouble A, 2000, ONCOGENE, V19, P5377, DOI 10.1038/sj.onc.1203910; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; Lee BS, 1997, J BIOL CHEM, V272, P174; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Meldrum KK, 2001, AM J PHYSIOL-REG I, V281, pR359, DOI 10.1152/ajpregu.2001.281.1.R359; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Padanilam BJ, 2003, AM J PHYSIOL-RENAL, V284, pF608, DOI 10.1152/ajprenal.00284.2002; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Smith AN, 2003, MOL CELL, V12, P801, DOI 10.1016/S1097-2765(03)00397-6; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; UNDERHILL DM, 1995, THESIS WASHINGTON U; Van Why SK, 1999, AM J PHYSIOL-RENAL, V277, pF227, DOI 10.1152/ajprenal.1999.277.2.F227; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang SP, 2002, J BIOL CHEM, V277, P8827, DOI 10.1074/jbc.M111959200; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Westmark CJ, 2005, ONCOGENE, V24, P502, DOI 10.1038/sj.onc.1208224; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Witzgall R, 1999, EXP NEPHROL, V7, P15; Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Zeng Q, 2000, J CELL SCI, V113, P471; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	66	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37957	37964		10.1074/jbc.M502883200	http://dx.doi.org/10.1074/jbc.M502883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155006	Green Accepted, hybrid			2022-12-25	WOS:000233044500078
J	Schmitz, C; Dorovkov, MV; Zhao, XY; Davenport, BJ; Ryazanov, AG; Perraud, AL				Schmitz, C; Dorovkov, MV; Zhao, XY; Davenport, BJ; Ryazanov, AG; Perraud, AL			The channel kinases TRPM6 and TRPM7 are functionally nonredundant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY HYPOCALCEMIA; ION CHANNELS; MG2+ HOMEOSTASIS; CATION CHANNELS; PROTEIN-KINASES; MAGNESIUM; HYPOMAGNESEMIA; TRANSPORT; MUTATION; FAMILY	TRPM7 and its closest homologue, TRPM6, are the only known fusions of an ion channel pore with a kinase domain. Deletion of TRPM7 in DT40 B-lymphocytes causes growth arrest, Mg2+ deficiency, and cell death within 24 - 48 h. Amazingly, in analogy to TRPM6-deficient patients who can live a normal life if provided with a Mg2+-rich diet, TRPM7-deficient DT40 B-lymphocytes show wild type cell growth if supplied with 5 - 10 mM Mg2+ concentrations in their extracellular medium. Here we have investigated the functional relationship between TRPM6 and TRPM7. We show that TRPM7 deficiency in DT40 cells cannot be complemented by heterologously expressed TRPM6. Nevertheless, both channels can influence each other's biological activity. Our data demonstrate that TRPM6 requires TRPM7 for surface expression in HEK-293 cells and also that TRPM6 is capable of cross-phosphorylating TRPM7 as assessed using a phosphothreonine-specific antibody but not vice versa. TRPM6 and TRPM7 coexpression studies in DT40 B-cells indicate that TRPM6 can modulate TRPM7 function. In conclusion, although TRPM6 and TRPM7 are closely related and deficiency in either one of these molecules severely affects Mg2+ homeostasis regulation, TRPM6 and TRPM7 do not appear to be functionally redundant but rather two unique and essential components of vertebrate ion homeostasis regulation.	Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Rutgers State University New Brunswick; Rutgers State University Medical Center	Perraud, AL (corresponding author), Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.	perrauda@njc.org	ryazanov, alexey/J-8081-2017		NIAID NIH HHS [K08AI060926] Funding Source: Medline; NIGMS NIH HHS [R01GM068801] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI060926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068801] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2002, SCIENCE, V295, P2228, DOI 10.1126/science.1070766; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; Hermosura MC, 2005, P NATL ACAD SCI USA, V102, P11510, DOI 10.1073/pnas.0505149102; Hoenderop JGJ, 2005, J AM SOC NEPHROL, V16, P15, DOI 10.1681/ASN.2004070523; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; Konrad M, 2004, AM J PHYSIOL-RENAL, V286, pF599, DOI 10.1152/ajprenal.00312.2003; Kraft R, 2005, PFLUG ARCH EUR J PHY, V451, P204, DOI 10.1007/s00424-005-1428-0; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; MILLA PJ, 1979, GUT, V20, P1028, DOI 10.1136/gut.20.11.1028; Montell C, 2003, CURR BIOL, V13, pR799, DOI 10.1016/j.cub.2003.09.048; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Perraud AL, 2004, MOL IMMUNOL, V41, P657, DOI 10.1016/j.molimm.2004.04.013; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanova LV, 2001, MOL BIOL+, V35, P271, DOI 10.1023/A:1010499720185; Schlingmann KP, 2005, J PHYSIOL-LONDON, V566, P301, DOI 10.1113/jphysiol.2004.080200; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Schmitz C, 2004, PEDIATR RES, V55, P734, DOI 10.1203/01.PDR.0000117848.37520.A2; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Ullrich ND, 2005, CELL CALCIUM, V37, P267, DOI 10.1016/j.ceca.2004.11.001; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; WOLF FI, 2004, SCI STKE, pPE23; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; YAMAMOTO T, 1985, Magnesium, V4, P153; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0	34	145	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37763	37771		10.1074/jbc.M509175200	http://dx.doi.org/10.1074/jbc.M509175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16150690	hybrid			2022-12-25	WOS:000233044500055
J	Szatmari, E; Habas, A; Peng, Y; Zheng, JJ; Hagg, T; Hetman, M				Szatmari, E; Habas, A; Peng, Y; Zheng, JJ; Hagg, T; Hetman, M			A positive feedback loop between glycogen synthase kinase 3 beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; SMALL-MOLECULE INHIBITORS; LONG-TERM DEPRESSION; CASEIN KINASE-II; HIPPOCAMPAL-NEURONS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-TRANSCRIPTION; SIGNALING PATHWAY; INTACT-CELLS	N-methyl-D-aspartate receptors (NMDARs) are critical for neuronal plasticity and survival, whereas their excessive activation produces excitotoxicity and may accelerate neurodegeneration. Here, we report that stimulation of NMDARs in cultured rat hippocampal or cortical neurons and in the adult mouse brain in vivo disinhibited glycogen synthase kinase 3 beta (GSK3 beta) by protein phosphatase 1(PP1)-mediated dephosphorylation of GSK3 beta at the serine 9 residue. NMDA-triggered GSK3 beta activation was mediated by NMDAR that contained the NR2B subunit. Interestingly, GSK3 beta inhibition reduced inhibitory phosphorylation of the PP1 inhibitor 2 (I2) and attenuated serine 9 dephosphorylation by PP1. These data suggest existence of a feedback loop between GSK3 beta and PP1 that results in amplification of PP1 activation by GSK3 beta. In addition, GSK3 beta inhibition decreased PP1-mediated dephosphorylation of the cAMP-response element-binding protein ( CREB) at the serine 133 residue in NMDA-stimulated neurons. Conversely, overexpression of GSK3 beta abolished non-NR2B-mediated activation of CRE-driven transcription. These data suggest that cross-talk between GSK3 beta and PP1 contributes to NR2B NMDAR-induced inhibition of CREB signaling by non-NR2BNMDAR. The excessive activation of NR2B-PP1-GSK3 beta-PP1 circuitry may contribute to the deficits of CREB-dependent neuronal plasticity in neurodegenerative diseases.	Univ Louisville, KY Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland	University of Louisville; University of Louisville; University of Louisville; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Hetman, M (corresponding author), Univ Louisville, KY Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR616, Louisville, KY 40292 USA.	michal.hetman@louisville.edu			NCRR NIH HHS [P20-RR15576] Funding Source: Medline; NINDS NIH HHS [NS047341] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047341] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamec E, 1997, BRAIN RES, V757, P93, DOI 10.1016/S0006-8993(97)00166-2; AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Carmichael J, 2002, J BIOL CHEM, V277, P33791, DOI 10.1074/jbc.m204861200; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLEMING LM, 1995, BIOCHEM J, V309, P41, DOI 10.1042/bj3090041; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2002, J BIOL CHEM, V277, P49577, DOI 10.1074/jbc.M111227200; Hetman M, 2000, J NEUROSCI, V20, P2567; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; Hughes JP, 2003, J NEUROCHEM, V86, P25, DOI 10.1046/j.1471-4159.2003.01830.x; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Jaworski J, 2003, J NEUROSCI, V23, P4519; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kopnisky KL, 2003, NEUROSCIENCE, V116, P425, DOI 10.1016/S0306-4522(02)00573-0; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; Leach C, 2003, J BIOL CHEM, V278, P26015, DOI 10.1074/jbc.M300782200; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Li XH, 2004, NEUROPSYCHOPHARMACOL, V29, P1426, DOI 10.1038/sj.npp.1300439; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Pei JJ, 1997, J NEUROPATH EXP NEUR, V56, P70, DOI 10.1097/00005072-199701000-00007; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; SCHWARCZ R, 1984, EXP NEUROL, V84, P1, DOI 10.1016/0014-4886(84)90001-3; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; Thiels E, 1998, NEUROSCIENCE, V86, P1023, DOI 10.1016/S0306-4522(98)00135-3; Vanhoutte P, 2003, CURR OPIN NEUROBIOL, V13, P366, DOI 10.1016/S0959-4388(03)00073-4; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	77	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					37526	37535		10.1074/jbc.M502699200	http://dx.doi.org/10.1074/jbc.M502699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16155008	hybrid			2022-12-25	WOS:000233044500029
J	Abell, AN; Johnson, GL				Abell, AN; Johnson, GL			MEKK4 is an effector of the embryonic TRAF4 for JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; FAMILY PROTEINS; RECEPTOR; EXPRESSION; INDUCTION; APOPTOSIS; INTERACT; COMMON	TRAF4 has previously been shown to activate JNK through an unknown mechanism. Here, we show that endogenous TRAF4 and MEKK4 associate in both human K562 cells and mouse E10.5 embryos. TRAF4 interacts with the kinase domain of MEKK4. However, this association does not require MEKK4 kinase activity. The interaction of MEKK4 and TRAF4 are further demonstrated by the colocalization of TRAF4 and MEKK4 in cells. Importantly, although TRAF4 has little or no ability to activate JNK independently, coexpression of TRAF4 and MEKK4 results in synergistic activation of JNK that is inhibited by a kinase-inactive mutant of MEKK4, MEKK4(K1361R). MEKK4 binds the TRAF domain of TRAF4 and MEKK4/ TRAF4 activation of JNK is inhibited by expression of the TRAF domain. Furthermore, TRAF4 stimulates MEKK4 kinase activity by promoting MEKK4 oligomerization and JNK activation can be stimulated by chemical induction of MEKK4 dimerization. The findings identify MEKK4 as the MAPK kinase kinase for TRAF4 regulation of the JNK pathway.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Johnson, GL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	gary_johnson@med.unc.edu			NIDDK NIH HHS [R01 DK037871, DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELL AN, 2005, IN PRESS MOL CELL BI, V25; Chi HB, 2005, P NATL ACAD SCI USA, V102, P3846, DOI 10.1073/pnas.0500026102; Chung JY, 2002, J CELL SCI, V115, P679; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Fleckenstein DS, 2003, LEUKEMIA RES, V27, P687, DOI 10.1016/S0145-2126(02)00325-9; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Krajewska M, 1998, AM J PATHOL, V152, P1549; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Masson R, 1998, MECH DEVELOP, V71, P187, DOI 10.1016/S0925-4773(97)00192-5; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; Vidal M, 2005, FEBS LETT, V579, P1834, DOI 10.1016/j.febslet.2005.02.030; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	20	33	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35793	35796		10.1074/jbc.C500260200	http://dx.doi.org/10.1074/jbc.C500260200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16157600	hybrid, Green Published			2022-12-25	WOS:000232726900004
J	Fisher, E; Almaguer, C; Holic, R; Griac, P; Patton-Vogt, J				Fisher, E; Almaguer, C; Holic, R; Griac, P; Patton-Vogt, J			Glycerophosphocholine-dependent growth requires Gde1p (YPL110c) and Git1p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IN-VITRO; PHOSPHOLIPID BIOSYNTHESIS; GENE DISRUPTIONS; BUDDING YEAST; PHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE; GLYCEROPHOSPHOINOSITOL; CHOLINE; METABOLISM	Glycerophosphocholine is formed via the deacylation of the phospholipid phosphatidylcholine. The protein encoded by Saccharomyces cerevisiae open reading frame YPL110c effects glycerophosphocholine metabolism in vivo, most likely by acting as a glycerophosphocholine phosphodiesterase. Deletion of YPL110c causes an accumulation of glycerophosphocholine in cells prelabeled with [C-14] choline. Correspondingly, overexpression of YPL110c results in reduced intracellular glycerophosphocholine in cells prelabeled with [C-14] choline. Glycerophospho[H-3] choline supplied in the growth medium accumulates to a much greater extent in the intracellular fraction of a YPL110 Delta strain than in a wild type strain. Furthermore, glycerophospho[H-3] choline accumulation requires the transporter encoded by GIT1, a known glycerophosphoinositol transporter. Growth on glycerophosphocholine as the sole phosphate source requires YPL110c and the Git1p permease. In contrast to glycerophosphocholine, glycerophosphoinositol metabolism is unaffected by deletion of YPL110c. The open reading frame YPL110c has been termed GDE1.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA; Slovak Acad Sci, Inst Anim Biochem & Genet, Ivanka Pri Dunaji 90028, Slovakia	Duquesne University; Slovak Academy of Sciences	Patton-Vogt, J (corresponding author), Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA.	pattonvogt@duq.edu	, Peter/ABA-9227-2020; Roman, Holic/X-7500-2018; Holic, Roman/AAC-8402-2019	, Peter/0000-0003-3538-0405; Roman, Holic/0000-0003-1347-4785; Holic, Roman/0000-0003-1347-4785	NIGMS NIH HHS [R01 GM059817, GM59817] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059817] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BAUERNSCHMITT HG, 1993, BIOCHIM BIOPHYS ACTA, V1150, P25; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Berrie CP, 1999, EUR J BIOCHEM, V266, P413, DOI 10.1046/j.1432-1327.1999.00870.x; BRZOSKA P, 1988, J BACTERIOL, V170, P4125, DOI 10.1128/jb.170.9.4125-4135.1988; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 2004, BIOCHEM CELL BIOL, V82, P62, DOI 10.1139/o03-064; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DAWSON RMC, 1977, BIOCHEM J, V162, P241, DOI 10.1042/bj1620241; DAWSON RMC, 1979, BIOCHEM J, V182, P39, DOI 10.1042/bj1820039; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; DWON ED, 1996, AM J PHYSIOL, V270, pC200; Fallbrook A, 1999, BRAIN RES, V834, P207, DOI 10.1016/S0006-8993(99)01570-X; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glunde K, 2004, CANCER RES, V64, P4270, DOI 10.1158/0008-5472.CAN-03-3829; Hama H, 2000, METHODS, V20, P465, DOI 10.1006/meth.2000.0959; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Komatsu H, 2003, BBA-MOL CELL BIOL L, V1635, P67, DOI 10.1016/j.bbalip.2003.10.007; LEE KS, 1994, J BIOL CHEM, V269, P19725; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Merkel O, 2005, BIOCHEM J, V387, P489, DOI 10.1042/BJ20041272; Mulder NJ, 2005, NUCLEIC ACIDS RES, V33, pD201, DOI 10.1093/nar/gki106; MUNSON RS, 1993, J BACTERIOL, V175, P4569, DOI 10.1128/JB.175.14.4569-4571.1993; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; Patton-Vogt JL, 1998, GENETICS, V149, P1707; Pinson B, 2004, J BIOL CHEM, V279, P35273, DOI 10.1074/jbc.M405398200; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sok DE, 1998, NEUROCHEM RES, V23, P1061, DOI 10.1023/A:1020755918632; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; TOMMASSEN J, 1991, MOL GEN GENET, V226, P321, DOI 10.1007/BF00273621; van der Rest B, 2004, BIOCHEM J, V379, P601, DOI 10.1042/BJ20031489; Voth WP, 2003, YEAST, V20, P985, DOI 10.1002/yea.1018; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Walter A, 2004, NEUROBIOL AGING, V25, P1299, DOI 10.1016/j.neurobiolaging.2004.02.016; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100	50	57	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36110	36117		10.1074/jbc.M507051200	http://dx.doi.org/10.1074/jbc.M507051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16141200	hybrid			2022-12-25	WOS:000232726900041
J	Jones, DC; Mehlert, A; Guther, MLS; Ferguson, MAJ				Jones, DC; Mehlert, A; Guther, MLS; Ferguson, MAJ			Deletion of the glucosidase II gene in Trypanosoma brucei reveals novel N-glycosylation mechanisms in the biosynthesis of variant surface glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLIPID MEMBRANE ANCHOR; BLOOD-STREAM FORM; PROTEIN GLYCOSYLATION; STRUCTURAL-CHARACTERIZATION; QUALITY-CONTROL; LINKED GLYCANS; OLIGOSACCHARIDES; PRECURSORS; PATHWAY; IDENTIFICATION	The trypanosomatids are generally aberrant in their protein N-glycosylation pathways. However, protein N-glycosylation in the African trypanosome Trypanosoma brucei, etiological agent of human African sleeping sickness, is not well understood. Here, we describe the creation of a bloodstream-form T. brucei mutant that is deficient in the endoplasmic reticulum enzyme glucosidase II. Characterization of the variant surface glycoprotein, the main glycoprotein synthesized by the parasite with two N-glycosylation sites, revealed unexpected changes in the N-glycosylation of this molecule. Structural characterization by mass spectrometry, nuclear magnetic resonance spectroscopy, and chemical and enzymatic treatments revealed that one of the two glycosylation sites was occupied by conventional oligomannose structures, whereas the other accumulated unusual structures in the form of Glc alpha 1-3Man alpha 1 - 2Man alpha 1 - 2Man alpha 1 - 3(Man alpha 1 - 6) Man beta 1 - 4GlcNAc beta 1-4GlcNAc, Glc alpha 1 - 3Man alpha 1 - 2Man alpha 1 - 2Man alpha 1 - 3(GlcNAc beta 1-2Man alpha 1 - 6) Man beta 1 - 4GlcNAc beta 1 - 4GlcNAc, and Glc alpha 1 - 3Man alpha 1-2Man alpha 1 - 2Man alpha 1 - 3(Gal beta 1 - 4GlcNAc beta 1 - 2Man alpha 1 - 6) Man beta 1-4GlcNAc beta 1-4GlcNAc. The possibility that these structures might arise from Glc(1)Man(9)GlcNAc(2) by unusually rapid alpha-mannosidase processing was ruled out using a mixture of alpha-mannosidase inhibitors. The results suggest that bloodstream-form T. brucei can transfer both Man(9)GlcNAc(2) and Man(5)GlcNAc(2) to the variant surface glycoprotein in a site-specific manner and that, unlike organisms that transfer exclusively Glc(3)Man(9)GlcNAc(2), the T. brucei UDP-Glc: glycoprotein glucosyltransferase and glucosidase II enzymes can use Man(5)GlcNAc(2) and Glc(1)Man(5)GlcNAc(2), respectively, as their substrates. The ability to transfer Man(5)GlcNAc(2) structures to N-glycosylation sites destined to become Man(4-3)GlcNAc(2) or complex structures may have evolved as a mechanism to conserve dolichol-phosphate-mannose donors for glycosylphosphatidylinositol anchor biosynthesis and points to fundamental differences in the specificities of host and parasite glycosyltransferases that initiate the synthesis of complex N-glycans.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acosta-Serrano A, 2004, EUKARYOT CELL, V3, P255, DOI 10.1128/EC.3.2.255-263.2004; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano N, 2003, GLYCOBIOLOGY, V13, p93R, DOI 10.1093/glycob/cwg090; BANGS JD, 1988, J BIOL CHEM, V263, P17697; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Conte L, 2003, MOL BIOL CELL, V14, P3529, DOI 10.1091/mbc.E03-04-0228; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DELACANAL L, 1987, J BIOL CHEM, V262, P11128; DOYLE P, 1986, MOL BIOCHEM PARASIT, V21, P93, DOI 10.1016/0166-6851(86)90083-6; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1994, GLYCOBIOLOGY PRACTIC, P349; Frenkel Z, 2003, J BIOL CHEM, V278, P34119, DOI 10.1074/jbc.M305929200; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hutchinson OC, 2003, MOL BIOCHEM PARASIT, V130, P127, DOI 10.1016/S0166-6851(03)00144-0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; LOW P, 1991, J BIOL CHEM, V266, P19250; MAYOR S, 1990, J BIOL CHEM, V265, P6164; Mehlert A, 2002, GLYCOBIOLOGY, V12, P607, DOI 10.1093/glycob/cwf079; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; Mehlert A, 1998, J MOL BIOL, V277, P379, DOI 10.1006/jmbi.1997.1600; MENON AK, 1990, J BIOL CHEM, V265, P9033; Milne KG, 2001, MOL BIOCHEM PARASIT, V112, P301, DOI 10.1016/S0166-6851(00)00369-8; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; PARODI AJ, 1982, J BIOL CHEM, V257, P7637; PARODI AJ, 1981, P NATL ACAD SCI-BIOL, V78, P6201, DOI 10.1073/pnas.78.10.6201; Petrescu AJ, 1997, EMBO J, V16, P4302, DOI 10.1093/emboj/16.14.4302; PREVIATO JO, 1986, MOL BIOCHEM PARASIT, V18, P343, DOI 10.1016/0166-6851(86)90091-5; RALTON JE, 1993, J BIOL CHEM, V268, P24183; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 2000, J BIOL CHEM, V275, P35657, DOI 10.1074/jbc.R000022200; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; TURCO SJ, 1982, J BIOL CHEM, V257, P8674; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; YAGODNIK C, 1987, BIOCHEMISTRY-US, V26, P5937, DOI 10.1021/bi00392a054; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	46	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35929	35942		10.1074/jbc.M509130200	http://dx.doi.org/10.1074/jbc.M509130200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16120601	hybrid			2022-12-25	WOS:000232726900020
J	Bao, XF; Muramatsu, T; Sugahara, K				Bao, XF; Muramatsu, T; Sugahara, K			Demonstration of the pleiotrophin-binding oligosaccharide sequences isolated from chondroitin sulfate/dermatan sulfate hybrid chains of embryonic pig brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVERSULFATED DERMATAN SULFATE; OUTGROWTH-PROMOTING ACTIVITY; PROTEIN LINKAGE REGION; NEURITE OUTGROWTH; GROWTH-FACTORS; CAENORHABDITIS-ELEGANS; HEXASACCHARIDE SEQUENCES; MOLECULAR-INTERACTIONS; NEURITOGENIC ACTIVITY; NEUROTROPHIC FACTORS	Mammalian brains contain significant amounts of chondroitin sulfate ( CS), dermatan sulfate ( DS), and CS/ DS hybrid chains. CS/ DS chains isolated from embryonic pig brains ( E- CS/ DS) promote the outgrowth of neurites in embryonic mouse hippocampal neurons in culture by interacting with pleiotrophin ( PTN), a heparin-binding growth factor. Here, we analyzed oligosaccharides isolated from E- CS/ DS, which showed that octasaccharides were the minimal size capable of interacting with PTN at a physiological salt concentration. Five and eight sequences were purified from fluorescently labeled PTN- bound and - unbound octasaccharide fractions, respectively, by enzymatic digestion followed by PTN- affinity chromatography. Their sequences were determined by enzymatic digestion in conjunction with high performance liquid chromatography, revealing a critical role for oversulfated D and/ or iD disaccharides in the low yet significant affinity for PTN, which is required for neuritogenesis. The critical D and iD units are GlcUA( 2- O- sulfate) beta 1 - 3GalNAc( 6- O- sulfate) and IdoUA( 2- O- sulfate) alpha 1 - 3GalNAc( 6- O- sulfate), respectively, where IdoUA represents L- iduronic acid. In contrast, high affinity interactions with PTN required decasaccharides with E units ( GlcUA beta 1 - 3GalNAc( 4, 6- O- disulfate)), B units ( GlcUA( 2- O- sulfate) beta 1 - 3GalNAc( 4- O- sulfate)), and/ or their IdoUA- containing counterparts ( iE and iB) in addition to D/ iD units, although the biological significance of such strong interactions remains to be investigated. Thus, chain size and composition are crucial to the interaction with PTN, and PTN binds to multiple sequences in E- CS/ DS chains with distinct affinity. Notably, not only heparan sulfate but also CS/ DS hybrid chain structures of mammalian brains contain a high degree of microheterogeneity with a cluster of oversulfated disaccharides and appear to play roles in regulating the functions of PTN.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4668550, Japan	Kobe Pharmaceutical University; Nagoya University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyama Kita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp						Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P23184, DOI 10.1074/jbc.M503036200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nadanaka S, 1999, FEBS LETT, V452, P185, DOI 10.1016/S0014-5793(99)00597-9; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; RHOMBERG AJ, 1997, LAB GUIDE GLYCOCONJU, P77; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Sakko AJ, 2003, CANCER RES, V63, P4786; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Takagi H, 2002, J CELL SCI, V115, P3309; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	43	58	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35318	35328		10.1074/jbc.M507304200	http://dx.doi.org/10.1074/jbc.M507304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16120610	hybrid			2022-12-25	WOS:000232561200030
J	Tzeng, SJ; Bolland, S; Inabe, K; Kurosaki, T; Pierce, SK				Tzeng, SJ; Bolland, S; Inabe, K; Kurosaki, T; Pierce, SK			The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNALS	The inhibitory Fc receptors function to regulate the antigen-driven activation and expansion of lymphocytes. In B cells, the Fc gamma RIIB1 is a potent inhibitor of B cell antigen receptor (BCR) signaling when coligated to the BCR by engagement of antigen-containing immune complexes. Inhibition is mediated by the recruitment of the inositol phosphatase, SHIP, to the Fc gamma RIIB1 phosphorylated tyrosine-based inhibitory motif (ITIM). Here we show that BCR-independent aggregation of the Fc gamma RIIB1 transduces an ITIM- and SHIP-independent proapoptotic signal that is dependent on members of the c-Abl tyrosine kinase family. These results define a novel Abl family kinase-dependent Fc gamma RIIB1 signaling pathway that functions independently of the BCR in controlling antigen-driven B cell responses.	NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Lymphocyte Differentiat, Tsurumi Ku, Kanagawa 2300045, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kansai Medical University; RIKEN	Pierce, SK (corresponding author), NIAID, Immunogenet Lab, NIH, Twinbrook 2,12441 Parklawn Dr,Rm 200B,MSC 8180, Rockville, MD 20852 USA.	spierce@nih.gov	Kurosaki, Tomohiro/D-1306-2009; Tzeng, Shiang-Jong/AED-3885-2022	Kurosaki, Tomohiro/0000-0002-6352-304X; Tzeng, Shiang-Jong/0000-0003-1633-020X	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000975, ZIAAI000975] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Davis RS, 2005, EUR J IMMUNOL, V35, P674, DOI 10.1002/eji.200425886; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fukuyama H, 2005, NAT IMMUNOL, V6, P99, DOI 10.1038/ni1151; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Muljo SA, 2003, NAT IMMUNOL, V4, P31, DOI 10.1038/ni870; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; Phee H, 2001, MOL CELL BIOL, V21, P8615, DOI 10.1128/MCB.21.24.8615-8625.2001; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622	20	61	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35247	35254		10.1074/jbc.M505308200	http://dx.doi.org/10.1074/jbc.M505308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115887	hybrid			2022-12-25	WOS:000232561200022
J	Mzali, R; Seguin, L; Liot, C; Auger, A; Pacaud, P; Loirand, G; Thibault, C; Pierre, J; Bertoglio, J				Mzali, R; Seguin, L; Liot, C; Auger, A; Pacaud, P; Loirand, G; Thibault, C; Pierre, J; Bertoglio, J			Regulation of Rho signaling pathways in interleukin-2-stimulated human T-lymphocytes	FASEB JOURNAL			English	Article						Rho; GTPases; exchange factors; GTPase activating proteins; cell cycle	GTP-BINDING-PROTEIN; NUCLEOTIDE EXCHANGE FACTOR; ACTIVATING PROTEIN; GTPASES; EXPRESSION; CDC42; RAS; FAMILY; RAC1; ECT2	Rho GTPases are key regulators of many cellular functions, including cytoskeleton organization which is important for cell morphology and mobility, gene expression, cell cycle progression, and cytokinesis. In addition, it has recently been recognized that Rho GTPase activity is required for development of the immune system, as well as for the specialized functions of the peripheral cells that act in the immune response such as antigen presenting cells and lymphocytes. Stimulation of T lymphocytes with interleukin-2 (IL-2) induces clonal expansion of antigen-specific populations and provides a model to study cell cycle entry and cell cycle progression. We have performed gene expression analysis in a model of human T lymphocytes, which proliferate in response to IL-2. In addition to changes in genes relevant to cell cycling and to the antiapoptotic effects of IL-2, we have analyzed expression and variations of more than 300 genes involved in Rho GTPase signaling pathways. We report here that IL-2 regulates the expression of a number of proteins, which participate in the Rho GTPase pathways, including some of the GTPases themselves, GDP/GTP exchange factors, GTPase activating proteins, as well as GDIs and effectors. Our results suggest that regulation of expression of components of the Rho GTPase pathways may be an important mechanism in assembling specific signal transduction cascades that need to be active at certain times during the cell cycle. Some of our findings may also be relevant to the roles of Rho GTPases in T lymphocyte functions and proliferation.	Fac Pharm Paris 11, INSERM, U461, F-92296 Chatenay Malabry, France; Fac Sci, INSERM, U533, Nantes, France; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bertoglio, J (corresponding author), Fac Pharm Paris 11, INSERM, U461, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	j.bertoglio@cep.u-psud.fr	Loirand, Gervaise/K-1834-2014; Pacaud, Pierre/D-6392-2015	Loirand, Gervaise/0000-0002-2306-3931; Thibault-Carpentier, Christelle/0000-0003-1562-1451; SEGUIN, Laetitia/0000-0003-2950-4766; Seguin, Laetitia/0000-0002-9610-7093				Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Beadling Carol, 2002, Med Immunol, V1, P2, DOI 10.1186/1476-9433-1-2; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Benvenuti F, 2004, SCIENCE, V305, P1150, DOI 10.1126/science.1099159; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Breslin EM, 2005, BRIT J PHARMACOL, V144, P791, DOI 10.1038/sj.bjp.0706061; Bustelo XR, 2002, BIOESSAYS, V24, P602, DOI 10.1002/bies.10107; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Chan AML, 1996, ONCOGENE, V12, P1259; Cherry LK, 2004, NAT IMMUNOL, V5, P961, DOI 10.1038/ni1103; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gesbert F, 1998, J CLIN IMMUNOL, V18, P307, DOI 10.1023/A:1023223614407; Groysman M, 2002, J BIOL CHEM, V277, P50121, DOI 10.1074/jbc.M204299200; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; HORI T, 1987, BLOOD, V70, P1069; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kitamura T, 2001, CELL STRUCT FUNCT, V26, P645, DOI 10.1247/csf.26.645; Kovanen PE, 2003, J BIOL CHEM, V278, P5205, DOI 10.1074/jbc.M209015200; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; LANG P, 1992, J BIOL CHEM, V267, P11677; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Lou ZK, 2001, J IMMUNOL, V167, P5749, DOI 10.4049/jimmunol.167.10.5749; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nikolaidou KK, 2004, CURR BIOL, V14, P1822, DOI 10.1016/j.cub.2004.09.080; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Oceguera-Yanez F, 2005, J CELL BIOL, V168, P221, DOI 10.1083/jcb.200408085; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Thompson PW, 2002, J IMMUNOL, V169, P1007, DOI 10.4049/jimmunol.169.2.1007; Toure A, 1998, J BIOL CHEM, V273, P6019, DOI 10.1074/jbc.273.11.6019; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Vicente-Manzanares M, 2003, J IMMUNOL, V171, P1023, DOI 10.4049/jimmunol.171.2.1023; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Yu H, 2001, J EXP MED, V194, P915, DOI 10.1084/jem.194.7.915; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zhang D, 2002, IEEE T CIRC SYST VID, V12, P331, DOI 10.1109/TCSVT.2002.1003472	58	15	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1911	+		10.1096/fj.05-4030fje	http://dx.doi.org/10.1096/fj.05-4030fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148026				2022-12-25	WOS:000232315700026
J	Shen, TY; Zong, CH; Hamelberg, D; McCammon, JA; Wolynes, PG				Shen, TY; Zong, CH; Hamelberg, D; McCammon, JA; Wolynes, PG			The folding energy landscape and phosphorylation: modeling the conformational switch of the NFAT regulatory domain	FASEB JOURNAL			English	Article						conformational switch; transcription factor; effective charge; multi-phosphorylation; contact-map PCA	ASSOCIATIVE MEMORY HAMILTONIANS; STRUCTURE-PREDICTION; DYNAMICS; CALCINEURIN; HOMOLOGY; BEHAVIOR	An energy landscape approach predicts the conformational changes of the configurations of the regulatory domain of the protein nuclear factor of activated T cells (NFAT) caused by phosphorylation of specific multiple sites. Structurally local effects and secondary structural changes are modeled using all-atom Brownian dynamics to investigate the changes of the backbone torsional distributions upon phosphorylation. For tertiary and global changes, we employ a coarse-grained model to sample ensembles of conformations both with and without phosphorylation. At the secondary structure level, phosphorylation moderately increases the helical propensity and gives a more rigid local backbone conformation. The tertiary effects of phosphorylation caused by the extensive charge modification are more pronounced and collectively change the conformation of the regulatory domain of NFAT from a flexible globular ensemble to a rather rigid helical bundle, blocking access to the nuclear localization sequence. These studies give computational support to one scenario conjectured from experiments.	Dept Chem & Biochem, La Jolla, CA USA; Ctr Theoret Biol Phys, La Jolla, CA USA; Univ Calif San Diego, Howard Hughes Med Inst, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Wolynes, PG (corresponding author), 9500 Gilman Dr,Mail Code 0371, La Jolla, CA 92093 USA.	pwolynes@chem.ucsd.edu	McCammon, J. Andrew/AAG-1832-2021; Zong, Chenghang/F-3243-2013; Shen, Tongye/A-9718-2008	Shen, Tongye/0000-0003-1495-3104; Zong, Chenghang/0000-0002-8337-8038; McCammon, J. Andrew/0000-0003-3065-1456				ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Buck M, 2001, SCIENCE, V291, P2329, DOI 10.1126/science.1060383; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; Eastwood MP, 2001, IBM J RES DEV, V45, P475, DOI 10.1147/rd.453.0475; FRIEDRICHS MS, 1989, SCIENCE, V246, P371, DOI 10.1126/science.246.4928.371; Hardin C, 2003, P NATL ACAD SCI USA, V100, P1679, DOI 10.1073/pnas.252753899; Hardin C, 2000, P NATL ACAD SCI USA, V97, P14235, DOI 10.1073/pnas.230432197; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Jolliffe I. T., 2002, PRINCIPAL COMPONENT, V2nd; Koretke KK, 1996, PROTEIN SCI, V5, P1043; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; MAKAROV AA, 1992, FEBS LETT, V306, P63, DOI 10.1016/0014-5793(92)80838-8; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Papoian GA, 2004, P NATL ACAD SCI USA, V101, P3352, DOI 10.1073/pnas.0307851100; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Qiu D, 1997, J PHYS CHEM A, V101, P3005, DOI 10.1021/jp961992r; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen TY, 2001, J AM CHEM SOC, V123, P9107, DOI 10.1021/ja010190t; Song JX, 2003, J BIOL CHEM, V278, P24714, DOI 10.1074/jbc.M210625200; Tholey A, 2001, BIOCHEMISTRY-US, V40, P225, DOI 10.1021/bi0021277; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429	27	44	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1389	1395		10.1096/fj.04-3590hyp	http://dx.doi.org/10.1096/fj.04-3590hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126906				2022-12-25	WOS:000232315700032
